{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "tKF4tEGbLdnp"
      },
      "source": [
        "# **1 Data Cleaning and Preprocessing**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "id": "BonhBIbnAEeD"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "import re\n",
        "from dateutil import parser"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 2,
      "metadata": {
        "id": "teHTP_mFDuHw",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "95952754-9217-4987-ad69-28531b5d63ff"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n"
          ]
        }
      ],
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "id": "Sqpz9uMiAUO9"
      },
      "outputs": [],
      "source": [
        "try:\n",
        "  df=pd.read_pickle(\"/content/drive/MyDrive/Earnings call prediction/motley-fool-data.pkl\")\n",
        "except Exception as e:\n",
        "  print(f\"Error : {e}\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 4,
      "metadata": {
        "id": "hh41-z_vFJGN",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "d8020ef8-3f47-4ec5-d397-6ae652d873d4"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['date', 'exchange', 'q', 'ticker', 'transcript'], dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 4
        }
      ],
      "source": [
        "df.columns"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 5,
      "metadata": {
        "id": "DRu3f7rmGvo8",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 223
        },
        "outputId": "4f786aaf-eddf-4211-b512-d0a856cd4287"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Data shape: (18755, 5)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript  \n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel...  \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta...  \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc...  \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon...  \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-373478b6-b4f1-464f-90f2-a51e6b58151e\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-373478b6-b4f1-464f-90f2-a51e6b58151e')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-373478b6-b4f1-464f-90f2-a51e6b58151e button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-373478b6-b4f1-464f-90f2-a51e6b58151e');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-dede9eb0-5fc3-46b5-a4db-96c0ac06239e\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-dede9eb0-5fc3-46b5-a4db-96c0ac06239e')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-dede9eb0-5fc3-46b5-a4db-96c0ac06239e button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 18755,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2879,\n        \"samples\": [\n          \"NASDAQ: VOXX\",\n          \"NYSE: AXE\",\n          \"NYSE: RBC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 25,\n        \"samples\": [\n          \"2022-Q3\",\n          \"2023-Q1\",\n          \"2020-Q2\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2876,\n        \"samples\": [\n          \"TFC\",\n          \"SNX\",\n          \"TMST\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17592,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nWelcome to the TFF Pharmaceuticals second quarter 2022 earnings conference call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator instructions] I would now like to turn the conference over to Corey Davis from LifeSci Advisors.\\nPlease go ahead.\\nCorey Davis -- Investor Relations\\nThank you, operator. Hello, everyone, and welcome to TFF Pharmaceuticals second quarter financial and business results conference call. With me on the line today is Glenn Mattes, president and CEO of TFF; Kirk Coleman, chief financial officer; Dr. Dale Christensen, TFF's director of clinical development; Dr.\\nBill Williams of the University of Texas at Austin; and Chris Cano, TFF's chief operating officer. The press release announcing our second quarter results is available on the TFF Pharmaceuticals website. Please take a moment to read the disclaimer about forward-looking statements in the release. The earnings release and this teleconference both include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made.\\nFactors that could cause actual results to differ are described in the disclaimer and in our filings with the U.S. Securities and Exchange Commission, including the Risk Factors section of our 2022 quarterly report on Form 10-Q filed with the SEC. And now, it's my pleasure to turn the call over to Mr. Glenn Mattes.\\nGo ahead, Glenn. \\nGlenn Mattes -- President and Chief Executive Officer\\nThank you, Corey. Good afternoon, and thank you for joining us today to review TFF's second quarter operations and recent highlights. During this call, I will provide an update on our overall financial progress, then ask our chief financial officer, Kirk Coleman, to review our second quarter financials. We appreciate all of the positive feedback from many of you on the format we used in our first quarter call.\\nSo we will take a similar approach today, Kirk and I will provide the formal commentary and then open up the call for questions to the entire team. Please note that we are joined by Bill Williams, Dale Christensen and Chris Cano, who will be available for the Q&A. The second quarter was another period of significant progress for the company. It is important to take a few minutes to focus on our Thin Film Freezing technology and how much we continue to learn about its potential.\\nAs we have discussed, TFF continues to increase the number of productive partnerships with pharma companies, academic institutions and the government. I am happy to say that the number of open material transfer agreements grew significantly in the second quarter, and we added three additional top 20 pharma companies through our portfolio of active collaborations. As we continue to advance these engagements beyond the initial formulation stage into advanced in vitro or animal testing, stability and production stages, the new data continues to support why we are so enthusiastic about the creation of shareholder value. There is absolutely no question that the growing demand for our technology reflects the versatility of Thin Film Freezing.\\nWe continue to successfully conduct numerous new feasibility studies across a broad range of experimental and approved drugs with an ever-increasing focus on biologics and complex macro molecules. These include monoclonal antibodies, fusion proteins, mRNA, bacteriophages, siRNA, peptides and peptoids, in addition to small molecules and others. The work we're doing in the vaccine space is particularly exciting and continues to expand. You have no doubt seen the recent news about the need to develop vaccines that can be administered directly to the nasal mucosa and the lung.\\nI've always said that a major opportunity for the TFF technology is in the second- and third-generation vaccines. The TFF technology is uniquely positioned to enable this to happen. These vaccines are not limited to providing alternatives for COVID-19 vaccines. We are doing work in flu and many other types of infections, including viral, bacterial and fungal.\\nLet me take a few minutes to remind everyone about the specific advantages of Thin Film Freezing and why it is highly differentiated over other technologies. Dr. Bill Williams, co-inventor of Thin Film Freezing, recently published an article in BioPharm International titled, Improved Formulations to Enable Stable Delivery of Biologics. The article provides a concise summary explaining the unique advantages of Thin Film Freezing of our other dry powder technologies, including freeze drying processes, differences that largely account for our success in forging partnerships at every level of the industry, academia and government.\\nMany of these statements of work start with a comparison of Thin Film Freezing to other dry powder technologies. It's essential that a manufacturing process has not changed the molecular structure or properties of a drug, so this therapeutic activity is maintained, and that is particularly true in creating a dry powder formulation for biologics. As noted in Dr. Williams review article, conventional dry powder formulation techniques such as shelf freeze drying, spray freeze drying and spray drying are not well suitable for many biologics due to their tendency to result in the protein clumping into larger or inactive structures, a process that's known as aggregation.\\nIn addition, many biologics are quite fragile and cannot withstand the harsh impact of sheer and stress. Aggregation can negatively impact the activity of the biologic. By contrast, Thin Film Freezing results in particles, which are highly porous with a large surface area and low-density, attributes that help reduce the tendency toward aggregation and ensure optimal bioactivity of the molecule. In addition to avoiding aggregation, Thin Film Freezing also doesn't rely on elevated temperatures during the drying process.\\nThat is a stark contrast to other dry powder techniques such as spray drying, which require high temperatures in the drying process. This can lead to denaturation of the biologic and does negatively impact the molecules activity. The BioPharma article further notes Thin Film Freezing's applicability in developing novel vaccine formulations, including positive results with mRNA-based vaccines. Our work with materials and specific compounds supplied by our partners show that after withstanding repeated freezing and falling of a dry powder vaccine containing aluminum salts, the Thin Film Freezing vaccine does not show aggregation following a reconstitution.\\nImportantly, the formulation also maintains drug activity after high temperature storage with immunogenicity of the dry powder vaccine preserved to temperatures as high as 40 degrees Celsius or 104 degrees Fahrenheit. So if the approach to immunization for COVID-19 continues to produce vaccines reliant on cold chain distribution and storage, it is clear that by demonstrating these results, we believe that TFF Thin Film Freezing technology will enable manufacturers to overcome this significant hurdle. The other day, I read that COVID-19 vaccine manufacturers had to destroy over $1 billion worth of product, which underscores the need to solve cold chain supply challenges. At this point in the call, you may be wondering why I'm reviewing these new data.\\nMy purpose is to answer the many questions I get about what work we are doing with partners as we move toward finalizing agreements. And to help let you all know why we're so very optimistic about the positive direction of the business. A bit more new data before reviewing our business progress. As I touched on earlier, many of our partners are evaluating Thin Film Freezing to improve other vaccine formulations for powder delivery to the lung or nasal mucosa.\\nThese include those formulations containing the well-known MF59 adjuvant. By way of brief background, MF59 is a liposomal-based adjuvant that enhances the patient's immune response to a vaccine through localized upregulation of cytokines, chemokines and promoting the recruitment of venous immune cells. First approved back in 1997, MF59 is commonly used in pandemic or seasonal flu vaccines. It is generally recognized as having an excellent safety profile and is now licensed in more than 30 countries.\\nHowever, vaccines containing MF59 must be stored at refrigerated temperatures and are sensitive to accidental slow freeze conditions. Dr. Williams and his team at the University of Texas at Austin, just published another paper in the International Journal of Pharmaceutics, demonstrating that vaccines containing MF59 or AddaVax, which is a preclinical nanoemulsion that has the same composition and droplet size as MF59 can be converted to dry powder form by Thin Film Freezing. By contrast, the research showed that subjecting the same AddaVax composition, the shelf freeze drying led to significant aggregation or fusion of the droplets and the aggregation fusion was mainly due to the slow freezing required by conventional shelf freeze drying.\\nThin Film Freezing avoids this step and therefore, is much less likely to cause aggregation. Thin Film Freezing also continues to show significant potential for nasal delivery, which, again, will have significant relevance for the mandated future vaccine development. Intranasal vaccination using vaccine dry powders and attractive noninvasive modality with better storage stability and added protection at the mucosal services. Thin Film Freezing has proven viable in enabling the production of dry powders of a larger variety of vaccines, adjuvanted or not adjuvanted, protein-based or nucleic acid-based, for example, the mRNA vaccines and DNA vaccines, as well as live attenuated virus-based and the vaccine powders have desirable properties for intranasal administration.\\nOne last example, data from Dr. Williams Labs of a recent preclinical study in a rat model using partners material show that it is feasible to induce specific mucosal and systemic antibody responses following intranasal administration of a thin film freeze-dried vaccine candidate. The dry powder was prepared by Thin Film Freezing of a model antigen absorbed on aluminum oxy-hydroxide as an adjuvant. This further demonstrated the ability of the technology to work in a variety of adjuvanted vaccines.\\nSpecial emphasis was placed on the characterization of the dry powder vaccine formulation that can be realistically used in humans with an intranasal dry powder delivery device. The TFF vaccine powder was found to have good aerosol properties and the vaccine was uniformly distributed within the dry powder. An in vitro nasal deposition study using a 3D printed human nose model showed that around 90% of the vaccine powder was deposited in the nasal cavity. Intranasal immunization in animal studies with the TFF powder vaccine elicited a specific serum-antibody response, as well as a specific IgA response in the nose and lung secretions of the animals.\\nThus, intranasally administered dry powder made by Thin Film Freezing or vaccines has been confirmed. I repeat, it has been confirmed. Indeed, one additional publication from Dr. Williams Group and the TFF collaborators he worked with, recently received second place for the Best Paper Award 2022 by the Journal of Pharmaceutics.\\nIn this paper, our team described the formulation of remdesivir and an active analog. I will stop here and say that I can share additional successful data we are producing and working with our partners. Thanks to Bill Williams and the entire team. TFF Pharmaceuticals has become a key partner for pharma and biotech companies evaluating dry powder formulations.\\nBut our superior technology is only a starting point and a long line of value creation that ultimately leads to medicines with the potential to create significant clinical benefit and outcomes. For each one of our programs, we start with a singular purpose to enable more efficient, targeted delivery of medicine to the patient while minimizing systemic exposure. To accommodate growing demand for our technology, we recently opened a new R&D facility in Austin, Texas, which will provide us with significantly more lab space to develop larger scale production for our numerous partnered preclinical programs. Dr.\\nDonald Owens, our director of product development, will supervise the facility supported by Dr. John Koleng, TFF's vice president of product development and manufacturing. We're also expanding the product development team in Austin, which will be based at the new facility to support the growing number of partnered preclinical projects. Two additional points.\\nFirst, we continue to fully partner with all of our colleagues at the University of Texas. Second, we are taking a very efficient approach to funding the new lab space. The costs will be managed within our existing budgets. In addition, we do receive funds from our partners to fund many of the experiments that are part of the expanding material transfer agreements and statements of work.\\nNow, on to key business updates. First, our two most advanced clinical stage programs, Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder, are currently in open label Phase 2 trials and we expect the initial valuable patient data by the end of the third quarter. As previously discussed, we intend to partner these programs and we're currently working with Torreya Partners to reach out broadly to potential interested companies. I'm happy to report that this process is going well with a number of companies under CDA and or in our product data rooms.\\nWe will release valuable patient data to those companies under CDA. Given each program's advanced stage of development, we seek partnerships that reflect our significant investment made to date and each product's potential to improve upon the current standard of care. In addition, we are working to build out the clinical supply materials so that prospective partners can remain focused on clinical development and registration strategy. We also expect both the VORI and TAC impact programs to gain more visibility in the very near term.\\nDr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia, has been selected to provide a podium presentation on the ongoing compassionate use study of our Voriconazole Inhalation Powder at the International Congress on Lung transplantation, taking place in Paris, France on September 8 and 9. Notably, in this lung transplant patient, we observed the expected lack of drug-drug interactions when administering voriconazole by inhalation, thus the patient did not require dose adjustment of their tacrolimus immunosuppressant, which is not possible with oral voriconazole and demonstrates one of the safety advantages we expect to further demonstrate in our ongoing Phase II study. We remain very excited about the value these two programs are created for TFF and look forward to providing further updates.\\nLet me now provide an update on the status of inhaled niclosamide powder. I'm happy to tell you that we very recently sent the niclosamide Phase I complete study report to UNION. We believe this study report provides meaningful information to our partners at UNION as they continue to evaluate all of the data and assess TFF's Niclosamide Inhalation Powder. I can tell you that UNION is an outstanding partner and are quite impressed with the results.\\nThe UNION is working diligently to provide TFF with feedback on their option to license Niclosamide Inhalation Powder and begin a Phase II clinical program in COVID-19 patients. In other updates, our partnership with Catalent is progressing well. Catalent has referred a number of their clients to TFF to begin feasibility work. In addition, we are working with multiple Catalent sites preparing to install TFF equipment for the purpose of developing and manufacturing product candidates.\\nWe also continue to think strategically about the future of Augmenta 3387. TFF and Augmenta believe there is a therapeutic opportunity for an effective monoclonal antibody potentially in combination with other antiviral therapeutic options. TFF also continues to be increasingly encouraged about the potential for our inhaled cannabinoid product opportunities. We recently produced additional product to be used in further consumer testing.\\nThe opportunity to partner with TFF on these opportunities has now been presented to Glass House and a broader base of cannabis companies, both in the U.S. and Canada is our goal to determine a specific path forward shortly. As I said earlier, the number of pharma companies with open MTAs has increased, and we added three new top 20 companies during the second quarter. Our datasets are reaching critical decision inflection points with many partners.\\nOn the legislative front, we are keenly focused on the opportunity Thin Film Freezing offers to the advanced development of therapeutics and vaccines. TFF is working directly with members of the Congressional Appropriations Committee and departments within health and human services. We expect that opportunities will be considered for funding TFF efforts under the language written in the 2022 omnibus budget bill. In addition, as our development projects increase and mature, we now have been able to file funding grants, which help us advance programs already moving forward as a part of our two creatives and our academic partnerships.\\nFinally, the work we are progressing with DARPA formulating topical and ocular preparations of countermeasures is now in year two, and the preliminary results are promising and the feedback from Leidos is excellent. With those updates, I'd like to turn the call over to our chief financial officer, Kirk Coleman, for a review of our financials. Kirk?\\nKirk Coleman -- Chief Financial Officer\\nThank you, Glenn. For the three months ended June 30, 2022, research and development expenses for the company were $5.1 million compared to $2.8 million for the same period in 2021. General and administrative expenses for the three months ended June 30, 2022, for the company were $3.7 million compared to $2.4 million for the same period in 2021. The company reported a net loss for the three months ended June 30, 2022, of $8.7 million compared to a net loss of $4.7 million for the same period in 2021.\\nWeighted average common shares outstanding basic and diluted for the three months ended June 30, 2022, were 25,373,706 compared with 25,369,144 for the same period of 2021. As of June 30, 2022, we had total assets of approximately $27.9 million and working capital of approximately $21.4 million. At the end of the second quarter, our liquidity included approximately $20.9 million of cash and cash equivalents. And with that, I'd like to turn the call back over to Glenn.\\nGlenn Mattes -- President and Chief Executive Officer\\nThank you, Kirk. The second half 2022 reported results promised to be a meaningful period for TFF Pharmaceuticals. I hope that I've given you a flavor for the data that further confirms the potential for our ubiquitous, unique and value-creating Thin Film Freezing platform technology. We are very well positioned to meet our needs, as well as the needs of our pharmaceutical, academic and government partners.\\nThe unmet needs of pharmaceutical development in this arena is perfectly set up for Thin Film Freezing. Please search out the comments by Dr. Fauci and other vaccine experts emphasizing the need to deliver vaccines directly to the nasal and lung mucosa. What a tremendous set of opportunities this is for TFF.\\nOur partnering activities continue to expand, we have in place both the personnel and facilities to accommodate this growth. As discussed, our inhaled voriconazole and tacrolimus programs are each slated to reach important clinical milestones, and we are also pleased with the pace of partnership discussions surrounding these two innovative products. Thanks to all of the TFF team for their hard work and positive outcomes and thanks, as always, to all of our investors. And with that, I will turn the call back to the operator and open it up to questions.\\nOperator?\\nQuestions & Answers:\\nOperator\\nThank you. Before going into Q&A, Glenn Mattes has an additional piece of information to add.\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. Thank you. I want to take this opportunity to inform our listeners both on the live wire here and on the website that I'm announcing that in our 10-Q today, we did announce that, unfortunately, Malcolm Fairbairn has resigned from the TFF board. I certainly want to thank Malcolm for his counsel, his service and wish him well in his future endeavors.\\nAnd with that, now, we will open it up to questions. Thank you, operator.\\nOperator\\n[Operator instructions] The first question comes from Jonathan Aschoff with ROTH Capital Partners. Please go ahead.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nThank you. Thank you, guys. Glenn, since TFF continues to test CBD formulations with consumers, what are your thoughts about entering the market formally?\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. Jonathan, it's been a really interesting six months. We certainly again want to acknowledge that PLUS did a great job in helping us get ready formulation-wise, and we really have now been able to take those samples and test them with consumers and also introduce the technology to other companies. Glad, Glass House has not confirmed their interest at this point.\\nSo we have been working to go out to different companies. They've been working with our samples. They've been also testing it on some consumers. So we now have a real opportunity to sit back a little bit, look at a strategy of either one or multiple multistate operators to take this into the marketplace.\\nAnd we're hopeful that that can still happen later in the year. We also have seen an uptick in interest from companies since the vaping is very moved from tobacco. And I think a lot of the companies feel that there is a real opportunity to look at Thin Film Freezing cannabinoid formulations as a healthy alternative. Now, of course, that hasn't seated in yet to the CBD market.\\nBut I've noted and the folks I work with that are helping to sort of help me map this out a real uptake in interest. So hopefully, by the next quarter's update, I'll have some more specifics there. But we're really seeing terrific response to the product. And I think that's the key here in order for us to take a look at this being a positive contribution to our revenue lines.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nOK. And regarding the compassionate use case report for the lung -- that will be presented in Paris at that lung transplant congress. Do those results from that patient support the treatment hypothesis for IPA and give you confidence for success in the Phase II trial?\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. Dale, could you answer that question? You're closest to that data.\\nDale Christensen -- Director of Clinical Development\\nYes. Thanks, Glenn and thanks Jonathan. It's a very good question. As we stated previously, we believe that by delivering voriconazole by inhalation directly to the lung, we can increase the local concentration in the lung where you would derive the best therapeutic benefit, and we can also reduce the systemic concentration that's associated with the toxicity and drug-drug interactions from the oral voriconazole.\\nAnd the patient that we have been treating could not take oral voriconazole or any other azole antifungal due to toxicity and tolerability issues. One of the toxicities was that they had a history of melanoma and there's kind of a black box warning on voriconazole for melanoma. And so, this patient couldn't take it. And so, this patient was having declining lung function.\\nWhat we were able to do is stabilize the lung function due to effective treatment of the fungal infection, and we were able to do so without the patient having to adjust the dose of their tacrolimus immunosuppression medication. So it showed that we can have efficacy and without the drug-drug interactions. And so, it really does reinforce that treatment hypothesis that we've been working on.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nMy next question is, with the dominant BA.5 COVID variant and data on Paxlovid rebound cases, what do you think that creates in terms of an opening for niclosamide?\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. Dale, can you answer that one as well, please?\\nDale Christensen -- Director of Clinical Development\\nSure. Thanks, again. Also, a very good question. So with the emergence of the BA.5 variant, it seems to be worse than the previous Omicron versions.\\nAnd really at 500 deaths a day -- nearly 500 deaths a day in the U.S. And basically, worldwide 65 deaths around the world from COVID in the last four weeks. It very clearly indicates COVID is not over and better treatments are needed. And so, that level of death really isn't acceptable.\\nAnd many of the patients that die are in high-risk categories, cancer patients, patients who can't take Paxlovid due to drug-drug interactions. And we think that those patients will benefit from inhaled niclosamide because they're -- again, like fluconazole, when we deliver to the lung, you can avoid drug-drug interactions. And we've also seen that from the Paxlovid rebound, it's very clear that BA.5 and potentially future variants will take longer. And so, we're planning to -- when we move forward dose longer in our studies because we can avoid the drug-drug interactions that have great safety, we think that we can prevent the rebound and we'll monitor that during the clinical trials.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nAnd sorry to hog the mic, but two more. Should partnering of VORI and TAC happen, will you bring in new internal development programs and how will you select them? And the last question is, you added three top 20 pharmas. What's that bring the total number to?\\nGlenn Mattes -- President and Chief Executive Officer\\nOK. So yes, our goal is always to have an active internal set of products that we're developing. We're not turning into a company that is going to take these things all the way to the finish line. But the goal is to -- just like we're doing with VORI and TAC, take them through meaningful clinical inflection points.\\nThe 505(b)(2) strategy certainly was the right way for us to go. But strategically, we're looking at potential arrangements that would include co-development and sharing of development like we did with Augmenta where we split development 50-50. Augmenta, we were going to take through Phase I and still naive and then split proceeds from that point on. So we have a number of different options available to us as we seek to -- we kind to refresh and serially look at taking products to the pipeline.\\nIn general, Jonathan, it takes about $7 million to $12 million depending on the cost of the API to get us to that inflection point. So we have some products that we've been -- and compounds we've been looking at. Jordan Kennedy, who's our lead analyst has been working with some folks on the outside to do some analysis on what the market opportunities might be and what the development programs might look like. So as soon as we created revenue and cleared out the expense for VORI and TAC, we will look to refresh that internal portfolio.\\nOn the top 20 question, I don't remember the exact number. We were at a majority. So we're somewhere now in the area of -- we'll come back to you on the exact number, I would say, between 12 and 15, probably on the higher side of that. But the good news there is, those companies, many of them are not one-trick ponies.\\nWe have multiple projects that we're working with them. And those programs are getting -- are quite detailed, some of them in the very last stages of producing data and others that are at the starting gate. And we're really excited about and wish we -- frankly, we wish we could share some of these with you. The big companies are very hesitant to let us disclose and you -- if you knew what we were working on, you can understand the competitive nature of what Thin Film Freezing could be doing for those companies and their compounds in their marketplaces.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nOK. Do you still see the VORI and TAC trials as pivotal? Or is that authentic?\\nGlenn Mattes -- President and Chief Executive Officer\\nWell, we certainly feel that the data will be meaningful. And Jonathan, you know that the FDA never says yes, and they never say no, it depends on the data. When we talk to the partner companies that we're already under CDA with and that are in the data room, we certainly talk about what potentially those latter -- those additional studies might look like. And believe me, as you know, those partners will be looking at those as well.\\nBut we'll start to see it pretty soon on what those data are showing us. And hopefully, we believe certainly that those data will be quite good, and we'll see where that lands us.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nThank you very much, guys.\\nGlenn Mattes -- President and Chief Executive Officer\\nBut one thing to note, Jonathan, we have not budgeted for additional trials. So the assumption here is that, the partner would take those -- if those trials needed to be done, would do those trials.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nUnderstood. Thank you.\\nGlenn Mattes -- President and Chief Executive Officer\\nThank you, Jonathan.\\nOperator\\nThe next question comes from Daniel Carlson with TW Research Group. Please go ahead.\\nDaniel Carlson -- TW Research Group -- Analyst\\nHey, Glenn. Thanks for taking the questions. First off, you're making great progress it appears and bringing in MTAs and potential partners there. But we're still looking at preclinical stuff.\\nAnd in the past, you've mentioned some pretty large numbers associated with getting these partners into full license agreement. So I'm just wondering, what is the big hurdle in getting from preclinical to in-human trials? And is it the terms or are they too tough? Or just trying to figure that one out?\\nGlenn Mattes -- President and Chief Executive Officer\\nNo, the terms are not an issue, Daniel. When we engage with a company, Chris is very clear what the expectations are and what the relationship would look like. So in discussions that we've had with companies that are closer to the finish line and terms are discussed, certainly, there's some negotiation there. But that -- we don't see that as a rate limiting step.\\nAnd we're -- that's really the bottom line. We're maturing the data before any company is willing to write a check and license it. They want to be sure that we've answered all their clinical questions, and that's where we're at. And sometimes it moves a little bit slower than we want, but the data are being seen in a very positive light.\\nAnd we don't see the financials as being an obstacle.\\nDaniel Carlson -- TW Research Group -- Analyst\\nGot you. That's good news then. The next question I have is like once again, in the past, you've mentioned that you've never lost a bake up, and I'm sure that a lot of these companies are looking at everything out there. And certainly, there has been a lot of stuff in the press about other people trying nasal vaccines, etc.\\nSo I'm just wondering, is it still the case that every one of the companies you're talking to has not moved forward with alternative technologies and do you guys are still in the running?\\nGlenn Mattes -- President and Chief Executive Officer\\nI can't say that they know of any company that informed us that they've moved forward with an alternative technology. There have been a few companies that have decided to stick with the base program before moving on to Thin Film Freezing. We've seen a little bit of an uptick in that, Daniel, in full transparency in these tough times in the capital markets where if things were better, I think these are the smaller- to medium-sized companies. They go into the capital markets to raise funding to do the project.\\nSo for a few of them we're on hold. But it's become pretty routine and it's almost predictable. Chris and I sit on these calls, you know they're comparing us to the standard lyophilization approaches. And that's why, frankly, I have Bill to do -- provide me with some of the specific data from his trials and publications to reassure the investor that we continue to produce outstanding data better than what you can see with the alternative modalities.\\nAnd that's now even going beyond, we will or even like three to six months ago looking at nasal delivery or a Dale is doing on the DARPA program. So that was a little bit of a different approach today, but those four papers that I cited and there are others where we're actually using partners' materials, I think give great evidence to that.\\nDaniel Carlson -- TW Research Group -- Analyst\\nYes. I was going to ask you about the papers that you published and just what they mean for your commercialization efforts.\\nGlenn Mattes -- President and Chief Executive Officer\\nBill, do you have a perspective on that?\\nBill Williams -- Scientific Consultant\\nI do. Yes. That's a great question. So our strategy has always been to -- and you can follow our papers is, we are -- our papers are the way that we teach our partners and potential partners about our technology and about potential uses that they can imagine with their compounds that they're working on, they can imagine it in our technology.\\nAnd so, we look for problems. We look for -- we're very aggressive in studying competing technologies and finding holes in competing technologies where our Thin Film Freezing sits in, and then our papers are a way that we leverage that with partners and potential partners. So it's a critical part of commercialization. And one last thing is, when we have our calls that Chris Cano and others set up, I mean, we're talking with the company's top scientists and they're all science-driven at the point we're talking to them.\\nAnd so, they want to see our data, they want to see it in publications and also publishing like this, it's a key part for our -- for the company.\\nDaniel Carlson -- TW Research Group -- Analyst\\nGot you. And then, Glenn, one last question for me. It looks like -- I think you put some new logos in your slide deck, and you've got three new MTAs or top 20, you mentioned. How does it -- is there a criteria for getting in there, you hitting a certain level of relationship? Or why are some companies in there and others not?\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. So Daniel, we certainly don't even approach the subject until we think we have on a meaningful path. The bigger companies are really, really reluctant to do that. We've had some breakthroughs there.\\nI think those are symbolic of sort of where we're at in terms of the work we're doing with them. We don't fight too hard as they say, no, look, we don't want to do anything to upset the Apple cards here. But when it's appropriate and when we think it's at a reasonable time, we will ask and -- but don't take it that if the logo isn't on there, it doesn't mean that we're in a pretty good place in terms of where we are in working with those companies. So it's -- we started that as a practice of where we can, putting companies or academic institutions on the slide.\\nWe'll continue to look for opportunities to do that. It just as an indication that we're moving forward. And in this quarter, I wish I can tell you who we signed up with and have new MTAs with, very exciting. But again, realize those three are starting from the starting line, and it won't happen in the next quarter, but hopefully soon enough.\\nDaniel Carlson -- TW Research Group -- Analyst\\nGreat. Thanks, guys. Looking forward to second half here. A lot of exciting stuff coming.\\nGlenn Mattes -- President and Chief Executive Officer\\nThank you. Operator, do we have any more questions?\\nOperator\\nWe do. The next question comes from Michael Okunewitch with Maxim Group. Please go ahead.\\nGlenn Mattes -- President and Chief Executive Officer\\nVery good. Thank you.\\nMichael Okunewitch -- Maxim Group -- Analyst\\nHey, guys. Thank you for taking my questions. So, I guess, my first question, I'd like to think a bit big picture and just see, given that you've had a lot more partner interaction in particular on the big pharma side, if you could talk about what kind of feedback you're getting on what specifically attracted them to the TFF platform as opposed to other inhalable technologies?\\nGlenn Mattes -- President and Chief Executive Officer\\nGood question. Chris, you probably have more of the initial calls. Can you answer that question, please?\\nChris Cano -- Chief Operating Officer\\nYes, sure. Thanks, Michael, for the question. So when we're dealing with a big pharma company, right, and engaging with them in discussions, there's usually a product that's been identified, usually a biologic that has a challenge. And so, we -- before we even engage with that partner, we do some diligence, we look at their pipeline and then we come to them with a solution to their problem.\\nAnd so, whether it is right for inhalation, whether it is for cold chain, now we're even exploring, as we've talked about, intranasal, it really depends on what the partners' program, what their challenge is, and that's where we really focus our efforts because our dry powder offers the solution to their problem.\\nMichael Okunewitch -- Maxim Group -- Analyst\\nYes, very much so. And then, just as a follow-up, in terms of that collaboration activity, I'd like to just ask where you see the partners looking to apply the technology. Is this -- are you more looking at reformulations of drugs that are already approved in life cycle management and just improving the profile of their existing products? Or is it more so novel drugs in their pipeline that would work better once you apply the tech?\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. So it's a good question. So when I started here almost five years ago and I recruited Chris, that come in shortly after. If you would ask this then, this question, I certainly would have said it would be more reformulation.\\nAnd -- but now as we sit here today, I'm going to -- I don't have an exact pie chart in front of me. I'd say it's about 80% NCEs and biologics and about 20% to 25% reformulation. Chris, you can -- if I'm way off, you can correct me, but I think that's a fair assessment of where we're at. It's come out much differently than I originally thought.\\nWe started to reach out to different kinds of companies when we started this. And then, slowly as we began to introduce the technology to companies as well, this is where this whole biologics set of opportunities really exploded for us. And what's unique about that, too, Michael is, we have seen some situations where we've gone as far as successfully formulating, getting into animals and then that new chemical entity isn't quite what the partner wants to see in terms of the outcome. And they'll give us another set of materials in a biologics space.\\nSo you do like it's kind of out of our hands there because we've done everything we need to do from a technology standpoint. And sometimes, it's come down to, wait a minute, their compound didn't really produce the kind of results that they needed. So it takes you back. They don't walk away from us, but it takes you back to the starting line again.\\nMichael Okunewitch -- Maxim Group -- Analyst\\nThank you. And I really appreciate the additional color and congrats in the progress over the quarter.\\nGlenn Mattes -- President and Chief Executive Officer\\nThanks, Michael. It's really -- again, I wish as I sit here today, I could tell you who these top 20s are and what we're working on because it's incredibly exciting. So I see that I think we have exhausted the list of questioners, and we're about at the end of the hour. I want to thank all of you for listening.\\nI want to hope -- I wish you all an enjoyable rest of the summer, and stay healthy. And we really do look forward to ongoing discussions with you. And before or if not, at least at the time we report our third quarter results. Thank you very much.\\nOperator\\n[Operator signoff]\\nDuration: 0 minutes\\nCall participants:\\nCorey Davis -- Investor Relations\\nGlenn Mattes -- President and Chief Executive Officer\\nKirk Coleman -- Chief Financial Officer\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nDale Christensen -- Director of Clinical Development\\nDaniel Carlson -- TW Research Group -- Analyst\\nBill Williams -- Scientific Consultant\\nMichael Okunewitch -- Maxim Group -- Analyst\\nChris Cano -- Chief Operating Officer\\nMore TFFP analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, and welcome to the VMware Third Quarter Fiscal Year 2022 Earnings Conference Call. Today's conference is being recorded.\\nAt this time, I'd like to turn the conference over to Mr. Paul Ziots, Vice President of Investor Relations. Please go ahead, sir.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you. Good afternoon, everyone, and welcome to VMware's third quarter fiscal year 2022 earnings conference call. On the call, we have Raghu Raghuram, Chief Executive Officer; and Zane Rowe, Executive Vice President and Chief Financial Officer. Following their prepared remarks, we will take questions.\\nOur press release was issued after close of market and is posted on our website where this call is being simultaneously webcast. Slides which accompany this webcast can be viewed in conjunction with live remarks and downloaded at the conclusion of the webcast from ir.vmware.com.\\nOn this call today, we will make forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially as a result of various risk factors described in the 10-Ks, 10-Qs and 8-Ks VMware files with the SEC. We assume no obligation to and do not currently intend to update any such forward-looking statements.\\nIn addition, during today's call, we will discuss certain non-GAAP financial measures. These non-GAAP financial measures, which are used as measures of VMware's performance, should be considered in addition to, not as a substitute for or in isolation from GAAP measures. Our non-GAAP measures exclude the effect on our GAAP results of stock-based compensation, employer payroll tax and employee stock transactions, amortization of acquired intangible assets, realignment charges, acquisition, disposition, certain litigation matters and other items, as well as discrete items impacting our GAAP tax rate. You can find additional disclosures regarding these non-GAAP measures, including reconciliations with comparable GAAP measures, in the press release and on our Investor Relations website.\\nThe webcast replay of this call will be available for the next 60 days on our Company website under the Investor Relations link. Our fourth quarter fiscal 2022 quiet period begins at the close of business, Thursday, January 13, 2022.\\nWith that, I'll turn it over to Raghu.\\nRaghu Raghuram -- Chief Executive Officer\\nThanks, Paul. I am pleased with the continued strong performance in Q3 fiscal year 2022 with revenue of $3.2 billion and non-GAAP earnings of $1.72 per diluted share. Earlier this month, we successfully completed our spin-off from Dell Technologies. As a stand-alone Company, we have more strategic and financial flexibility to deliver on our multi-cloud strategy. We are also able to partner even more deeply with all the cloud and on-premise infrastructure companies to create a better foundation that drives results for our customers.\\nCustomers continue to choose VMware as their trusted digital foundation to accelerate their innovation, and we continue to expand and advance our portfolio to meet their needs in these three ways: one, deliver a cloud-native app platform for building modern applications in a public cloud-first world; two, migrate enterprise applications to a cloud-agnostic infrastructure; and three, build out the secure edge to optimize across our workspace and edge-native applications. These three focus areas are built on a horizontal set of offerings across networking, security and management. It's clear that multi-cloud will be the model for digital business for the next 20 years and in this vibrant dynamic marketplace, the pace of innovation is relentless. VMware is at the center of it.\\nIn the modern app space, we recently provided the Department of Education for one of America's largest cities with application resiliency as part of their business continuity project. Leveraging VMware Tanzu, the customer now has improved ability to respond to ever-changing needs of students, their families and faculty while protecting student information and creating an environment to accelerate their innovation and automation. One of our new beta offerings in the space is the Tanzu Application Platform, which will make it easier and simpler for developers to drive productivity and velocity in a more secure fashion on any cloud. Our Tanzu portfolio is now one of the most comprehensive in the industry for both Kubernetes operations and developer experience. We also recently unveiled Tanzu Community Edition, a freely available, easy-to-manage Kubernetes platform for learners and users, and Tanzu Mission Control Starter, a multi-cloud, multi-cluster Kubernetes management solution available as a SaaS service.\\nWe are pleased to share some customer stories in support of our VMware Cloud services across the hyperscalers. PennyMac, a leading financial services firm is leveraging VMware Horizon on VMware Cloud on AWS to provide loan officers and call center agents a more secure work-from-anywhere virtual desktop in a fully automated and scalable cloud environment. We also worked with the University of Miami, who looked to the Azure VMware solution to support their VMware workloads on their preferred public cloud provider.\\nRecently, we announced new advancements for VMware Cloud, the industry's first and only cloud-agnostic computing infrastructure. Newly unveiled Project Arctic will bring the power of cloud to customers running VMware vSphere on-premises. It will enable cloud-based management for hundreds of thousands of vSphere customers and vSphere deployments around the world. Customers will be able to benefit from life cycle management, cloud disaster recovery and cloud burst capabilities as an extension of their vSphere deployments. We will bring Project Arctic to market next year as the next step in making our portfolio available in a subscription and SaaS form factor.\\nWe also announced VMware Sovereign Cloud initiative, where we are partnering across our VMware Cloud providers to deliver cloud services on a sovereign digital infrastructure to customers in regulated industries.\\nLastly, we introduced a tech preview of an exciting new management technology, Project Ensemble. It is designed to manage apps across multiple public clouds, bringing together a comprehensive set of costs, security, automation and performance capabilities for the public cloud environment.\\nVMware was once again ranked number one in the September 2021 IDC report titled Worldwide Cloud System and Service Management Software Market Shares, 2020: Growth Continues for the Top Vendors. In the area of Edge, we recently helped an international wholesaler with 800 stores across 30 countries to refresh its decade-old in-store platform. The VMware Edge Compute Stack is now serving as a single platform for both the customers existing and modern applications, offering a right-sized resilient solution that is providing ROI for their business. As a continued commitment to helping our customers at the Edge, we recently introduced VMware Edge, a product portfolio that will enable organizations to run, manage and better secure edge-native applications across multiple clouds anywhere. Together, VMware Cloud, Tanzu, VMware Edge and Anywhere Workspace offer our customers a solution for all of their applications across their multi-cloud environment.\\nIn the security space, VMware is delivering solutions built specifically for threats customers face today. We use the power of software, combined with a scaled-out distributed architecture, zero trust design principles and a cloud delivery model for better security that's easier to use. We are excited about our continuing innovation in SASE, Secure Access Services Edge, especially as many businesses are now working as a distributed workforce. We also announced the industry's first elastic application security edge, which enables the networking and security infrastructure at the data center or cloud edge to flex and adjust as app traffic changes. In the third quarter, VMware was positioned as a leader in The Forrester New Wave: Zero Trust Network Access Q3 2021.\\nOn the telco front, Vodafone recently selected VMware to deliver a single platform to automate and orchestrate all workloads running on its core networks across Europe, starting with 5G stand-alone. This recent work builds on Vodafone's previous selection of VMware Telco Cloud Infrastructure as its network functions virtualization platform.\\nIn the third quarter, VMware received additional recognition from leading industry analyst firms, once again being named as a leader in the August 2021 Gartner Magic Quadrant for Unified Endpoint Management Tools. Additionally, VMware was once again named a leader in the September 2021 Gartner Magic Quadrant for WAN Edge Infrastructure. Our innovation engine is thriving as we bought many of these new offerings, features, beta programs and partnerships to the forefront during VMworld 2021, which attracted approximately 116,000 registrants. We look forward to hosting VMworld China and VMworld Japan in the coming weeks.\\nOur environmental, social and governance agenda continues to be very important to us and core to our culture. VMware received recognition for our ESG leadership by being included in the Dow Jones Sustainability Indices, one of the world's leading ESG benchmarks for the second consecutive year.\\nIn summary, we strive to serve our customers in three unique ways: by being the trusted foundation for their most critical business operations; by offering a best-of-breed, innovative portfolio of best-in-class solutions to fulfill their multi-cloud vision; and by having a broad set of strategic partnerships required to unlock the full potential of multi-cloud.\\nI'll now turn it over to Zane for more detail on our business performance, as well as our forecast.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nThank you, Raghu. We are pleased with our Q3 financial performance, which exceeded our initial expectations and is a continuation of the good performance we've seen all year. We saw solid demand in the quarter and continued to execute on our multi-cloud strategy.\\nTotal revenue for Q3 was $3.2 billion. Combined subscription and SaaS and license revenue grew 16% year-over-year totaling $1.5 billion, ahead of our guidance. Subscription and SaaS revenue of $820 million was up 21% year-over-year, in line with our expectations, representing 26% of total revenue for the quarter. Subscription and SaaS ARR was $3.3 billion, up 25% year-over-year in Q3. Our largest contributors to subscription and SaaS were VCPP, Tanzu, EUC, Carbon Black and VMware Cloud on AWS, which saw strong double-digit year-over-year growth in revenue and ARR. License revenue in Q3 grew 11% year-over-year to $710 million. The strength we saw was due to good execution in the quarter and our broad installed base of customers that see us as the trusted ally for their mission-critical workloads. Our strategy is resonating with our customers who are confident that their investments can be leveraged over the longer-term in multi-cloud environments.\\nOur non-GAAP operating income for the quarter of $935 million was driven by our revenue performance and lower-than-expected growth in expenses. Non-GAAP operating margin for the quarter was 29.3% with non-GAAP earnings per share of $1.72 on a share count of 422 million diluted shares.\\nWe ended the quarter with $10.2 billion in unearned revenue and $12.5 billion in cash, cash equivalents and short-term investments, which includes proceeds from our $6 billion bond issuance. The bond issuance proceeds together with $4 billion of additional borrowings from term loan commitments, as well as other available cash on hand was used to fund a special dividend of $11.5 billion. The special dividend was paid on November 1 to all stockholders of record on October 29 in conjunction with our spin-off from Dell Technologies.\\nQ3 cash flow from operations was $1,090 million and free cash flow was $984 million. RPO was $11.1 billion, up 9% year-over-year, and current RPO was $6.2 billion, up 11% year-over-year. Total backlog was $124 million, substantially all of which consisted of orders received on the last three days of the quarter that were not shipped and orders held due to our export control process. License backlog at quarter end was $34 million.\\nWe are pleased with the overall bookings performance in Q3 as we continue to scale our subscription and SaaS offerings. We saw strong year-over-year product bookings growth in major product categories. Core SDDC product bookings increased over 20% year-over-year. Compute was up low-double digits, and Cloud Management was up strong double digits year-over-year. Both of these were helped by our multi-cloud subscription and SaaS offerings. We saw momentum in VMware Cloud, which includes hyperscalers such as Amazon, Microsoft, Google and Oracle. We also continue to drive innovation in new product offerings across our Carbon Black Cloud and Tanzu platforms.\\nNSX increased in the low double digits versus Q3 last year, and vSAN grew in the high-teens year-over-year. EUC product bookings, as well as sub and SaaS ACV bookings were up in the strong double digits year-over-year.\\nIn Q3, we repurchased approximately 1 million shares in the open market at an average price of $150 per share. In early October, our Board of Directors authorized up to $2 billion of stock repurchases through FY'24, which replaced the relatively small balance remaining on our prior authorization.\\nAs a part of our capital allocation framework, we plan to use our cash generation and balance sheet to invest in growing our business both organically and inorganically, paying down debt and returning excess capital to shareholders through share repurchases. In addition, we are committed to maintaining an investment-grade credit profile and rating.\\nTurning to guidance for fiscal 2022. We're increasing our expectation for total revenue to $12,830 million, a growth rate of approximately 9% year-over-year. We expect the combination of subscription and SaaS and license revenue to total $6,305 million, an increase of approximately 12% year-over-year. Approximately 50.5% of this amount is expected to be subscription and SaaS.\\nWe are increasing guidance for non-GAAP operating margin for the full-year to 30% and non-GAAP earnings per share to $7.19 on a diluted share count of 422 million shares. We're also increasing our cash flow from operations guidance to $4.1 billion and increasing free cash flow expectations to $3.7 billion. This reflects our performance in Q3 combined with our outlook for FY'22.\\nFor Q4, we expect total revenue of $3,510 million or a growth rate of approximately 7% year-over-year. We expect $1,875 million from subscription and SaaS and license revenue in Q4 or an increase of nearly 9% year-over-year with approximately $860 million from subscription and SaaS, reflecting the current pace of adoption of our subscription and SaaS offerings.\\nWe expect non-GAAP operating margin to be 30.4% for Q4 with non-GAAP earnings per share of $1.96 on a diluted share count of 422 million shares. Additional guidance details for Q4 and FY'22 are contained in the slide deck accompanying this call.\\nWe typically provide some color on our upcoming fiscal year at this time. We are driving innovation across the portfolio, scaling our subscription and SaaS offerings and progressively making our products available as subscription and SaaS. Consistent with the outlook framework we presented at the Financial Analyst Meeting last month, we currently expect total FY'23 revenue to grow in the high-single digits while we continue to build out our subscription and SaaS portfolio. We are planning on growing our sub and SaaS revenue to nearly 30% of total revenue with our FY'23 exiting ARR growth rate exceeding FY'22's. We expect non-GAAP operating margin of approximately 28%, which is similar to our initial outlook for FY'22, reflecting continued investments in subscription and SaaS and the resumption of more normalized level of T&E as we support our customers.\\nIn closing, we are pleased with the progress we are making on our multi-cloud strategy as reflected in our performance this quarter and in our outlook for FY'22 and FY'23. As a stand-alone Company, we are well positioned to enable our customers' multi-cloud journey and become the multi-cloud leader.\\nI'll now turn it back to Paul for Q&A.\\nPaul Ziots -- Vice President, Investor Relations\\nThanks, Zane. Before we begin the Q&A, I'll ask you to limit yourselves to one question consisting of one part so we can get to as many people as possible. Operator, let's get started.\\nQuestions and Answers:\\nOperator\\nThank you. [Operator Instructions] And we will take our first question from Matt Hedberg with RBC Capital Markets. Please go ahead.\\nMatthew Hedberg -- RBC Capital Markets -- Analyst\\nHey, guys. Thanks. Great. Perhaps [Phonetic] congrats on the results and completing the spin first of all. I don't know, maybe Zane for you. License revenue was a bit better than we thought. You sort of talked about that in your script, but subscription and SaaS was maybe a little lighter, just a tad lighter than we thought. I'm wondering, could you help us with a little bit more color on what drove that mix. And as we think about subscription and SaaS trends accelerating into fiscal 2023, are there things that you guys are doing, like sales incentives or partner incentives to drive subscription and SaaS?\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nYeah. Matt, thanks for the question. And I'll start and then, obviously, happy to hand over to Raghu to talk a little bit more about where we are looking into Q4, as well as next year. First off, I'd say, this was well within the framework that we discussed at the analyst meeting last month. So we're really pleased with the outperformance that we saw for the whole Company in Q3. As you highlighted, license came in much stronger. We had a number of deals over $10 million that exceeded our expectation in the quarter.\\nAnd our sub and SaaS performance came in, in line. So we're actually pleased with the increase that we've seen there. We had, as I mentioned, a nice healthy increase on a year-over-year basis, ARR 25% year-over-year. So everything was going according to plan for both the third quarter and the full-year as it relates to the sub and SaaS. We just continue to develop those products. We've highlighted the improvements and increases we've made in some of those segments that Raghu will get into. But generally, we're pleased. We're seeing some of the same trends that we highlighted in Q3, along the term of where we see the license in some of our products like Horizon, where customers are choosing the term license versus some of the sub and SaaS offerings, but nothing different from the trend that we saw in Q3 and our expectations heading into next year.\\nMaybe, Raghu, if you want to touch on how we think about the product development over the course of Q4?\\nRaghu Raghuram -- Chief Executive Officer\\nYeah, definitely. We are very excited about the product portfolio as it is laying out for us. So, as we have talked before that we look at our product portfolio on the SaaS and subscription side in three buckets. One is the pure SaaS and subscription offerings, 100% SaaS and subscription. We expect them to start to reach scale and start to impact our growth even in a much bigger fashion.\\nSecondly, we have a set of products that we call customer choice, basically meaning the customers can choose to get them in a perpetual or a term license form factor or in a subscription form factor. And this includes products like our Cloud Management, which are growing really well for us.\\nAnd then thirdly, products today that are primarily licensed, our core SDDC offerings that we'll be progressively making available as a subscription and SaaS next year. And we announced the first of those with the Project Arctic, and we believe they will start to contribute in the coming years as well. So the combination of these three will drive the product portfolio even more to subscription and SaaS and drive its growth.\\nAnd then last but not the least, we'll be tailoring our go-to-market programs, including our sales place and incentives and so on and so forth to drive all of these product shifts.\\nPaul Ziots -- Vice President, Investor Relations\\nThanks, Matt. Next question, please.\\nOperator\\nThank you. We'll hear next from Mark Murphy with J.P. Morgan.\\nMark Murphy -- J.P. Morgan -- Analyst\\nYes. Thank you. And I will add my congrats on a very nice performance. Raghu and Zane, so we've shown that your partner ecosystem is clearly positive and upbeat regarding the spin-off from Dell. I'm wondering, how is that excitement manifesting at this stage? And understanding it's very early stage, but can you sense partners perhaps mobilizing to staff up or bulk up on VMware-certified personnel? Maybe they're planning to lean in on co-marketing, co-selling next fiscal year. Just curious if there's any leading indicators that give you a sense of a tailwind that might be developing sometime during next fiscal year.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So, as you pointed out, it's pretty early. We're still in month one of the spin and being a stand-alone Company. Having said that, a lot of what you have said is exactly what we are seeing from the partners. We are seeing a sense of excitement and possibility from the partners. There are partners that are already planning to or starting to staff up on their VMware expertise. We are talking to other partners about what we could do to help them further in the markets where we could have joint solutions. So all these conversations have started happening, and these all have different timeline depending upon whether they are purely go-to-market or they involve technical collaboration and joint solutions, etc., etc. So I do expect that you will start to see some results over the course of the next year. Like I tell our internal employees, day one for us post-spin may not look very different, but day 365, you'll certainly start to see the benefits of it. And so, that's where we are.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Mark. Next question, please.\\nOperator\\nThank you. We'll hear next from Raimo Lenschow with Barclays.\\nRaimo Lenschow -- Barclays -- Analyst\\nHey. Thanks for taking my question, and congrats from me as well. Can I go back to Matt's question a little bit in terms of pragmatics? As you talk with your clients, but as you also think about the sales and incentives, the change in incentives next year a little bit, what do you see in terms of clients' understanding appreciation of your subscription, SaaS offering versus taking the choice around more of the license part? Because that's the one thing that everyone is focusing on, and it feels like you don't getting as much credit for the license part. So where are clients is coming out of the pandemic kind of their focus more to do more license again? Or how do we have to think about it? How can you influence that as well? Thank you.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. Thanks, Raimo. I'll start and then Sumit can add additional color as well. So, what I would say from our customers' point of view, it depends on a couple of factors. One is the product category that we are talking about. For example, if you think about Cloud Management, there is definite decided industry shift toward consuming management as a SaaS service. So we are seeing -- that's part of the reason why we are seeing our SaaS offerings and subscription offerings for management grow very nicely.\\nIf you think about our core universal offering, which is for the infrastructure, that is designed to help customers on their journey to the cloud. So very often, they are starting on-premise with licensed software. And then over a period of time, they intend to shift to the cloud. And then in terms of the third big bucket, which is the end-user computing, it depends on the customer segment.\\nAnd let me give it over to Sumit to add more color.\\nSumit Dhawan -- President\\nYeah. Hi, Raimo. How are you? First of all, I would say....\\nRaimo Lenschow -- Barclays -- Analyst\\nHey, Sumit.\\nSumit Dhawan -- President\\nHey. First of all, I would say that Q3 in addition to the results that Zane and Raghu talked about was a great quarter for us in terms of engaging with customers through our VMworld event, introducing all of our new offerings. And the momentum on that front with customer front is great because it's clear for customers as they're looking at their own strategies for cloud and multi-cloud, VMware becomes their key partner going forward. And on that, many of their -- how they build their multi-cloud control plane, whether it's through our Cloud Management software, Tanzu solutions, as well as cloud infrastructure to be served from multi-cloud, VMware gives them the right platform to do so.\\nSo, now to arrive at that solution, our universal programs gives them the best choice and flexibility to adopt subscription and SaaS and adopt cloud at their own pace. And we are continuing to see very, very strong interest and pull from customers and going toward multi-cloud using our universal offers, where they can start adopting our cloud solutions gradually as they're ready and they're not sort of having to spend double costs, if you may, where they have to run both on-premise and cloud and double pay. They can just transition to the cloud solutions and our subscription, SaaS offerings using our universal offers at their own pace and speed.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Raimo.\\nRaimo Lenschow -- Barclays -- Analyst\\nThank you.\\nPaul Ziots -- Vice President, Investor Relations\\nNext question, please.\\nOperator\\nThank you. We'll take our next question from Mark Moerdler with Bernstein Research.\\nMark Moerdler -- Sanford C. Bernstein & Co. -- Analyst\\nThank you very much, and congrats on both the spin-out in the quarter. As we've discussed before, VMware is using term licenses as a bridge to the cloud, but you're not including that revenue in subscription or SaaS. So, can -- to help us better understand the impact, can you give us some breakdown of how much of the revenue we're seeing in the quarter is from license and maintenance is coming from those term licenses that could convert over to subscription and SaaS? Thank you.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nYeah. Mark, I'm happy to start with that. As you alluded to, we see the term licenses, in particular with our Horizon offering to be that step for many, if not, all of our customers to sub and SaaS. So we're very pleased with the performance we've seen there in offering our customers flexibility and allowing them with that transition. If you were to think about quantifying the term license amount, it's roughly 13.5% of our license for the quarter. So it's just under $100 million in total that is sort of qualified as term. And as you point out, unlike a number of others, we included in our license bucket. We don't necessarily expect this to increase significantly over the years, at least as we've outlined our strategy today. So we think it will moderate around this number. And then ultimately, as we highlighted in many, if not, all of our products, will rotate to more sub and SaaS. And we see this as a natural step for our customers in their sub and SaaS journey as well.\\nHopefully, that adds some color for you, Mark.\\nMark Moerdler -- Sanford C. Bernstein & Co. -- Analyst\\nYes, it does. And I really do appreciate. Thank you very much and have a happy, healthy Thanksgiving and holidays to everyone.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nOf course, thank you. You too.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Mark. Next question, please.\\nOperator\\nThank you. We'll hear next from Phil Winslow with Credit Suisse.\\nPhilip Winslow -- Credit Suisse -- Analyst\\nHi. Thanks guys for taking my question, and congrats on a strong quarter. Just wanted to focus in on core vSphere and in particular, vSphere 7 with Tanzu. Obviously, with that release, vSphere 7, you had a native support within vSphere of Kubernetes and containers. Kind of two questions here together. Could you give us sort of an update of adoption of vSphere 7 with Tanzu? And what are you hearing from customers about why they're using VMware?\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So I'll start and Sumit, perhaps you can add more. Yeah. So vSphere 7 has been in the market for a while, and we have seen very successful adoption of it. And besides the customers moving to the latest and greatest, the ability to run containers through Tanzu is a key reason why they adopt it. What we are seeing on-premise especially, is that, as customers tend to build out their private cloud and make it as compelling as a public cloud in terms of developer agility and so on and so forth, containers become a necessary part of the core infrastructure platform offering or Infrastructure-as-a-Code offering. So that's what we are seeing happen with our customers. So -- and a lot of the workloads that traditionally were running on VMs that are these mission-critical workloads are now being converted into containers and run on vSphere.\\nThe other thing that you might have noticed as we published on our benchmark sites as well is that, customers are finding they can get 6 times the density of running containers on vSphere as compared to running it on bare metal using alternative products. So not only the manageability benefits are appealing to them, because we are now supporting containers natively on vSphere 7, you're getting a tremendous density benefit, which obviously results in significant cost savings as well. So these are some of the reasons why customers are excited about it.\\nAnd in terms of some customer adoption patterns, let me hand it over to Sumit.\\nSumit Dhawan -- President\\nYeah. Hey, Phil. Customers as they're looking at Kubernetes, first of all, high interest and containers high interest, but they're in the journey of kind of early innings of expanding the adoption. And they're excited about using vSphere 7 as this platform where they can manage both VMs and containers holistically. So, I would say, from a customer adoption perspective, huge interest, still early stage. But vSphere 7 adoption and how customers are using those two technologies, both containers and VMs together, really good.\\nIn addition, we introduced Tanzu Community Edition at VMworld, which also complements really well our entire stack and works also with customers wanting to use Tanzu full-stack solution with public cloud Kubernetes distribution. And the adoption of our Tanzu Kubernetes Edition that we introduced at VMworld has been stellar over the course of last six to eight weeks. So I'd say customer adoption, even though early stage, tons of interest in both vSphere 7, as well as Tanzu Community Edition, which gives us great promise for potential growth in the Tanzu portfolio over time.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Phil. Next question, please.\\nOperator\\nThank you. We'll hear next from Simon Leopold with Raymond James.\\nMauricio Munoz -- Raymond James -- Analyst\\nThank you for taking my question. This is Mauricio in for Simon. Can you please talk about the -- some of these industry supply shortages and how could this impact in VMware sales? I'm a bit curious about -- on the potential headwind from customers that are perhaps unable to get the systems that VMware runs on. So with the understanding that you sell software, are you seeing any impact from these hardware shortages that could be limiting your sales? Thank you.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So as you note, there are chip shortages that are impacting significant portions of the economy. We have not seen -- like you point out, we are in the software business, and we have not seen it significantly impact our business so far. And a lot of the customers run our software on their existing infrastructure. And even in the cases where they're -- as well as in the cloud, and this is, in fact, one of the benefits of our solution being available across all the clouds. And then even in those cases where they're putting our software on to new hardware, they have not reported on new shortages.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Maurice. Next question, please.\\nOperator\\nThank you. We'll take our next question from Brad Reback with Stifel.\\nBrad Reback -- Stifel -- Analyst\\nGreat. Thanks very much. Zane, I think last quarter, you talked about some of the hyperscaler-led business leading to longer rev rec. And I would assume that would be in the subscription and SaaS line. Did you see any of that this quarter?\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nHey, Brad. Yeah, this is Zane. We continue to see great growth in that area, not only on the bookings side, but now you're starting to see the traction. I mentioned in my prepared remarks, across all the hyperscalers, we're really pleased with the traction we're seeing. To your point, that does create a little bit of the delay between the bookings growth that we see and then ultimately when we see that consumption and recognize the revenue. So, I'd say, generally speaking, it's been consistent, but we're impressed with the demand we're seeing. And the interest, back to the earlier question on partnerships, that's another area where we see continued interest on partnerships and tremendous opportunity for us with our multi-cloud opportunities. So all good on that front.\\nThanks for the question, Brad.\\nBrad Reback -- Stifel -- Analyst\\nThanks.\\nPaul Ziots -- Vice President, Investor Relations\\nThanks, Brad. Next question, please.\\nOperator\\nSo we'll take our next question from Tyler Radke with Citi.\\nTyler Radke -- Citi -- Analyst\\nHey. Good afternoon. Thanks for taking my question. I wanted to ask you about the Q4 guidance. It looked like on the license side, the upside didn't fully flow through. Just curious if there was any type of kind of unusual activity you saw in Q3, whether pull-forward? And then just some comments overall, what you're expecting for fiscal year-end, just with budget flush and typical Q4 activity? Thank you.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nYeah. Sure, Tyler. It's a good question. As you point out, we increased the total guide, but we didn't obviously pull in -- take all of what we saw in Q3 into Q4. We're really pleased with our view of the second half of the year. And obviously, as you heard in our prepared remarks, as well as the commentary here, I mean, the macro is clearly supporting good growth across the Company, and we're quite encouraged with the momentum we're building across the portfolio. So, as we looked at it, we think our second half looks good. We were encouraged by our ability to execute in Q3. So there may have been a few deals that may have either landed in Q3 or Q4 that we saw in Q3, but we believe the demand is there. We're pleased with the execution across the Board and correspondingly with the guide.\\nSo I'll leave it at that, but obviously, we're encouraged by what we're seeing heading into Q4. And, obviously, with some of the high-level comments I provided for FY'23, we see that momentum continuing into the new fiscal year for us.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Tyler. Next question, please.\\nOperator\\nThank you. We'll hear next from Keith Weiss with Morgan Stanley.\\nKeith Weiss -- Morgan Stanley -- Analyst\\nExcellent. Thank you, guys, for taking the question and nice quarter. I was wondering if you could go back to the Project Arctic. And can you give us any guidelines in terms of how to think about the relative pricing for some of these SDDC solutions of what you're garnering from the customer in an on-premise environment and how that changes in a cloud environment when they start making that shift toward subscription and maybe not a cloud environment, but as they start making that transition to subscription? And relatedly, is that going to have any longer-term impacts on gross margins that we should be aware of when we're kind of forecasting out a couple of years?\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So, overall, with the Project Arctic, we are still in the very early days, and we don't have any pricing nor anything of that nature to disclose because we are not shipping the product yet -- shipping the cloud service yet. In general, because this is a cloud-delivered and cloud-managed service, usually, when we deliver something from the cloud managing some piece of software on-premise, there is a management premium that we had, and I would expect that to be present. The important aspect of Arctic is it also allows us to weave in things like disaster recovery and better security and so on and so forth. And those are additional capabilities that today are priced offerings that we would be able to as part of this upsell, as part of Project Arctic. So net-net, we expect this to be a win-win solution for the customer, helping them lower their management costs, also give them capabilities that they did not have before, lower their cost of insuring security, etc. And then from a VMware perspective, it will allow us to deliver more value to these existing customers.\\nAnd then the second aspect of your question around gross margin, again, we don't have operating -- actual operating experience because Arctic is not out yet, but we expect this to be a healthy gross margin business.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Keith. Next question, please.\\nOperator\\nThank you. We'll hear next from James Fish with Piper Sandler.\\nQuinton Gabrielli -- Piper Sandler -- Analyst\\nHey, guys. This is Quinton on for Jim. Thanks for taking our question. Maybe just for us, could we get an update on the team's appetite for acquisitions at this point? Are there opportunities to look at something a little bit larger, a little more transformational? Or do valuations today still push the team to more of a tech tuck-in type deal? Thank you.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So I'll start and Zane can add more. So from a VMware perspective, we've always had a fairly consistent philosophy with respect to acquisitions. By and large, the vast majority of what we do would be classified as tuck-ins or product-level acquisitions. And then occasionally, we do what we call platform level acquisitions, which we do when we enter into a new product segment, product category or expand significantly into a new adjacency. In fact, over the last, whatever, 15, 17 years of -- that we've been doing acquisitions, we have done only about four that were of that nature, over $1 billion. So I expect that pattern to continue. As you well know, we did two major acquisitions of that nature a couple of years ago, and we are still bringing them into the mainstream of our business and driving those product growth areas for us. So I expect the current pattern to continue going forward as well.\\nSo let me...\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nYeah. I would just add, as part of our capital allocation, obviously, we look at growing both organically and inorganically. And even with the debt that we've taken on and the special dividend, we believe we've got tremendous flexibility on the M&A front and continue to operate as we have in the past, as Raghu alluded to. So we're very comfortable with our positioning there.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Quin. Next question, please.\\nOperator\\nThank you. We'll hear next from Brad Sills with Bank of America Securities.\\nBradley Sills -- Bank of America -- Analyst\\nGreat. Thanks guys for taking the question here. I wanted to ask a question on some of the deliverables you outlined the launches at the Analyst Day for Tanzu Community Edition, Application Platform and Service Mesh Advanced Edition. I guess, in particular, there's a lot of innovation there. I guess, the Community Edition, should we think of that as a potential for driving some bottoms-up adoption here, where you see a real community develop here, open source users that you could see some upgrade activity from over time? Thank you.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah, for sure. A big goal for Tanzu Community Edition is for people that are coming new to Kubernetes, as well as developers that want to build on top of it. And in fact, over the first four to five weeks that we have had it available, we have had over 10,000 downloads. We've seen a nice community farming. And so, we are very encouraged by that, as well as the Tanzu Mission Control Starter Edition, which provides management capabilities at an entry level. So one aspect of VMware that is -- one aspect of our business that is critical when we get more and more developer and platform operator focus is product-led growth, and this would be the start of those initiatives.\\nBradley Sills -- Bank of America -- Analyst\\nThank you.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Brad. Next question, please.\\nOperator\\nThank you. We'll hear next from Brad Zelnick with Deutsche Bank.\\nBrad Zelnick -- Deutsche Bank -- Analyst\\nGreat. Thank you so much for fitting me in. My question is for Sumit. Sumit, it's now two quarters in a row where you've had more customers within EUC opt for term licenses versus subscription and SaaS. Is there something specific happening within VMware or within that particular product line that would explain for this? Or is there any reason to perhaps believe that customers are recommitting to self-managed infrastructure?\\nSumit Dhawan -- President\\nHi. Yeah. I think this is a little bit of a reflection of both timing, as well as choice. As with Horizon, we have given customers choice and flexibility for adopting the subscription and SaaS -- sorry, cloud products and cloud-based virtual desktops at their own timing and their own when they're ready. And they oftentimes start with term. And I think I've stated that in the past that each of these customers as we are signing them up with term-based license, they all have plans and intent to move their desktops to the cloud. And as the terms that they are signing up for come up for renewal is usually the time window when we get the opportunity to get them over to the cloud. And the window of the time when they sign up for term is just the duration it takes for them to plan moving their desktop to the cloud. So that's the best way for you to think about the business. There's really not sort of lack of intent or desire by customers to take their desktops to the cloud.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Brad.\\nBrad Zelnick -- Deutsche Bank -- Analyst\\nThank you.\\nPaul Ziots -- Vice President, Investor Relations\\nNext question, please.\\nOperator\\nThank you. We'll hear next from Brent Thill with Jefferies.\\nBill -- Jefferies -- Analyst\\nHey, guys. This is Bill [Phonetic] on for Brent. Thanks for taking our question. Just going off the previous question, given some of the noise recently around Citrix, just wanted to get a sense of what you're seeing on EUC and just in terms of win rates and if there has been any change at the margin there? Thanks.\\nSumit Dhawan -- President\\nYeah. I'll start and Raghu, you can add. First of all, we see tremendous interest in customers for our virtual desktop solution, and that's really the only category that we compete with Citrix. Our end user computing portfolio, first of all, is much broader than what Citrix offers. But oftentimes, customers who have had Citrix implementations and VMware's implementations for broader end user computing portfolio, not including virtual desktops. We are certainly seeing customers who, when they are looking at cloud-based desktop deployments, interest in standardizing on their broader workspace and end user computing portfolio with VMware. So we do see larger enterprises now looking at innovation from VMware and end user computing to be much stronger and more powerful. And we continue to see customers who have in the past used Citrix now looking at VMware Horizon solutions.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. Just to...\\nPaul Ziots -- Vice President, Investor Relations\\nThank you. Go ahead, Raghu.\\nRaghu Raghuram -- Chief Executive Officer\\nI have a couple of -- especially in this post-pandemic world that we live in, remote work has become a pretty significant part of the consideration when choosing these solutions. And we introduced an Anywhere Workspace solution that combines, obviously, the ability to run the desktops either in the data center or in the cloud, but also the ability to get network access and secure them through our SASE solutions, and of course, manage and provision applications. So it's a much more fuller solution with the cloud option that Sumit talked about. So that's very differentiated from Citrix.\\nPaul Ziots -- Vice President, Investor Relations\\nNext question, please.\\nOperator\\nThank you. We'll take our next question from Kash Rangan with Goldman Sachs.\\nKash Rangan -- Goldman Sachs -- Analyst\\nHi. Thank you very much. I'll add my congratulations as well. I wanted to just ask your perspective on the subscription and SaaS, and in particular, there are two important drivers strategically for the Company. One is the cloud provider partnership in particular. Wanted you to expand your comments, if you could? On AWS, what do you see in terms of the pipeline going ahead? Obviously, with re:Invent coming up the next week or so, how is that partnership with AWS progressing as far as the pipeline visibility is concerned? And also, if you could touch upon Tanzu, any big pivotal deals -- not pivotal, but pivotal Tanzu deals that are truly transformative that give you conviction that Tanzu is certainly headed strategically in the right path? Thank you so much and congrats.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So on the -- and let me start and Sumit can talk about the pipeline. So with AWS, as you know, Kash, they are our preferred partner, and we do some deep engineering collaboration with them. And we continue to do that, and we've got a number of items planned in our roadmap. Over the next months or so, that will further expand the addressable set of workloads that can be served using our joint solution. So the partnership is going very well, and the two teams have been working very well.\\nAnd before I turn it over to Sumit for the pipeline, let me briefly touch upon the Tanzu question. Yeah, we -- if you think about what we are trying to do with Tanzu, we're trying to do two sets of things. One is, we are trying to provide a modern application operations team that's in the public cloud or in the private cloud with a comprehensive set of solutions that help them manage their modern application environment, their cloud-native environment, secure them and connect them. So our products like Tanzu Service Mesh, Tanzu Observability, of course, Tanzu Mission Control, all of them put together serve as a very comprehensive portfolio. And we have seen customers buy into it. One of the key reasons they buy into it is this breadth of portfolio.\\nThe second reason they buy into it is the fact that this is available to them regardless of where their network cloud data application is running. And we have got a number of wins on Azure. We've got a number of wins on AWS. Of course, we've got wins on top of vSphere as well.\\nAnd then the second part of the portfolio is the Tanzu Application Platform, which accelerates developer productivity on the public cloud of their choice. That is still on beta, so we don't have transformative wins to announce there as yet. But we are super excited about the reception to both. Sumit?\\nSumit Dhawan -- President\\nKash, I'd add on -- I'll start off with cloud providers. First of all, I'm excited about the portfolio expansion that we did on the VMware Cloud front during last quarter. Certifications to expand us to target larger sort of federal customer base sort of expansion of services and sort of zones where the service is available across all hyperscalers, newer services that we have introduced on VMware Cloud on AWS such as Tanzu now integrated, as well as VMware Cloud on AWS Outposts. So tremendous opportunity and all of that leads to new use cases that we are able to serve.\\nNow, in terms of wins that give you -- a win that gives you a picture of how we are winning with cloud services, the best sort of story that I would provide is, our financial services firm where they're now looking at our cloud to provide all their loan officers, call center agents, a full sort of service that is fully automated and scaled out through our cloud environment. And now trying to do that modernization in their own infrastructure would have required them to have talent and time, neither of which were possible without our solution. And that's what we are seeing as a predominant reason why customers are looking at our cloud infrastructure across all of our -- all the cloud providers as a predominant use of going to VMware Cloud solution.\\nAnd then for Tanzu, I think Raghu already touched. For modern applications using Kubernetes across multi-cloud, we are seeing customers start with either one module or adopt our full platforms that Raghu talked about in a very, very easy-to-adopt fashion at this point of time from Tanzu.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Kash. Next question, please.\\nKash Rangan -- Goldman Sachs -- Analyst\\nThank you, Raghu and Sumit. Thanks so much.\\nOperator\\nThank you. We'll hear next from Karl Keirstead with UBS.\\nKarl Keirstead -- UBS -- Analyst\\nGreat. Zane, I wouldn't mind pressing a little bit on your guide for high-single-digit revenue growth for fiscal 2023. That's impressive, a little bit higher than I was modeling. It's actually an acceleration from your exit growth rate of 7% in 4Q this year despite larger scale, despite what I'm sure are some pressures as you transition from upfront license maintenance to subscription. So I just wanted to see if you might unpack a little bit where that confidence comes from and ask two secondary questions, whether it might be more second half weighted and whether if you could confirm that it's entirely organic? Thank you.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nSure, Karl. I'll tell you, first off, we obviously give it at a high level, so I appreciate the commentary on it. So I'm not going to get into detail on first or second half. I will tell you, as we look at next year, to your point, it is a balance of us continuing to drive that growth, not only on the product side, but the go-to-market side and the operating side of our sub and SaaS portfolio. And then in conjunction with that, continue to deliver on the license portion and the on-prem portion of the portfolio, which as you saw in the third quarter, had really strong performance. And it's a combination of that -- our message resonating in the marketplace, the confidence our sales teams, and as you've heard here across the portfolio that we have -- with the products we have, and in particular, the multi-cloud message that's resonating with our customers and the momentum we're seeing for the year.\\nI mentioned sort of the second half. And then, obviously, heading into FY'23, we're confident that we can continue to see that growth on the mix between the on-prem and then continue to drive the sub and SaaS growth at an ARR that we believe will be stronger than the ARR we expect to see this year for all the reasons that Raghu mentioned. When we breakout each element of that portfolio and we look at the bookings performance and the pipeline performance that we're already seeing, a lot of the deals that Sumit's team are negotiating right now will be recognized as revenue into the new year. So a lot of that gives us the backdrop to the outlook that we believe we'll execute against for the next fiscal year, and obviously, more to come on our next call. But thanks for the question.\\nKarl Keirstead -- UBS -- Analyst\\nOkay. Thank you, Zane.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nThanks.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Karl. We have time for one more question. So this would be the last question, please.\\nOperator\\nThank you. We'll take our next question from Keith Bachman with BMO.\\nKeith Bachman -- BMO Capital Markets -- Analyst\\nThank you very much. Good evening. Raghu, I wanted to see if I could direct this to you. In the past management, VMware management has talked about 80% of apps are running on the cloud -- running on-premise, 20% on cloud and over time that would invert. And I wanted to try to get a feedback on some of that growth is transitioning existing applications to the cloud, but a lot of it is the growth of new applications. And I want to hear your characterization of VMware's attach rates, ARR contribution and/or growth rates of new applications versus existing applications. What does that look like in terms of your ability to win for the new applications today in particular? And how would you think about that changing over the next year or two as Tanzu begins to -- or not begins to, but continues to mature?\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So as I've spoken about in the Financial Analyst Meeting, we are in an age of explosive growth with respect to applications. And we see applications growing, obviously, in the public cloud, in the data centers and private clouds and increasingly at the edge as well. I think by some industry analyst estimates, two out of three applications -- new applications are in the public cloud are a little higher, depending on which analysts you believe in. So for the applications that are going into the data center, given our preponderance in the data center and private cloud, they tend to invariably land on top of our platform -- the applications on top of our infrastructure platform. And then as we build out our Tanzu portfolio, they start to use Tanzu as well. Similarly, as applications go into the edge, we've got a pretty significant presence at the edge, and those applications tend to land on our platform as well.\\nThe applications on the public cloud, clearly, there's a large set of those applications landing on the Cloud Providers infrastructure. But as Tanzu gains more maturity and as we introduce new capabilities like Tanzu Application Platform, etc., we are seeing customers start to use that as well to make the task of building new applications on public clouds easier.\\nAnd then last, but not the least, with the VMware Cloud offerings on the public Cloud Providers, we are starting to see new applications land there as well because we just recently handed -- added Kubernetes capability to the VMware Cloud offerings. So as we build those out, we expect to see getting a good share of new applications on the public cloud as well. So on the whole, if you look at public cloud, data center, edge, we are well positioned to capture a good chunk of the new applications.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Keith. Before we conclude, Raghu, I think you had a concluding comment to make.\\nRaghu Raghuram -- Chief Executive Officer\\nAbsolutely. Thanks, Paul. So thanks for the Q&A, and thanks for spending the hour with us. What I wanted to say in summary, VMware is committed to providing an ubiquitous software platform for our customers as they navigate to the multi-cloud and distributed era. We have a fantastic team, and we have a great portfolio that serves our critical customer requirements. And last but not the least, especially post-spin, we have a strong and growing ecosystem. So we are really well positioned to succeed.\\nThanks for joining us today, and have a great Thanksgiving.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 61 minutes\\nCall participants:\\nPaul Ziots -- Vice President, Investor Relations\\nRaghu Raghuram -- Chief Executive Officer\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nSumit Dhawan -- President\\nMatthew Hedberg -- RBC Capital Markets -- Analyst\\nMark Murphy -- J.P. Morgan -- Analyst\\nRaimo Lenschow -- Barclays -- Analyst\\nMark Moerdler -- Sanford C. Bernstein & Co. -- Analyst\\nPhilip Winslow -- Credit Suisse -- Analyst\\nMauricio Munoz -- Raymond James -- Analyst\\nBrad Reback -- Stifel -- Analyst\\nTyler Radke -- Citi -- Analyst\\nKeith Weiss -- Morgan Stanley -- Analyst\\nQuinton Gabrielli -- Piper Sandler -- Analyst\\nBradley Sills -- Bank of America -- Analyst\\nBrad Zelnick -- Deutsche Bank -- Analyst\\nBill -- Jefferies -- Analyst\\nKash Rangan -- Goldman Sachs -- Analyst\\nKarl Keirstead -- UBS -- Analyst\\nKeith Bachman -- BMO Capital Markets -- Analyst\\nMore VMW analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nGood day and welcome to The Kroger Co. second-quarter earnings call. [Operator instructions] I would now like to turn the conference over to Rob Quast. Please go ahead.\\nRob Quast -- Director of Investor Relations\\nThank you, Sarah. Good morning. Thank you for joining us for Kroger's second-quarter 2021 earnings call. I am excited to be here today and look forward to working with all of you in my new role as head of investor relations.\\nI am joined today by Kroger's chairman and chief executive officer, Rodney McMullen; and chief financial officer, Gary Millerchip. Before we begin, I want to remind you that today's discussions will include forward-looking statements. We want to caution you that such statements are predictions and actual events or results can differ materially. A detailed discussion of the many factors that we believe may have a material effect on our business on an ongoing basis is contained in our SEC filings.\\nThe Kroger co. assumes no obligation to update that information. Our press release and supplemental information regarding the quarter can be found on our website at ir.kroger.com. After our prepared remarks, we look forward to taking your questions.\\nI will now turn the call over to Rodney. \\nRodney McMullen -- Chairman and Chief Executive Officer\\nThank you, Rob and congratulations on your new role. I would also like to take a minute to thank Rebekah Manis for her service to the IR team. We wish her continued success in her new role as head of new geographies for our customer fulfillment centers. Finally, I would like to thank you all for joining us today.\\nOur associates have done an incredible job operating our stores, pharmacies, supply chain and manufacturing facilities through the COVID environment. Their unending commitment to serving our customers and communities continues to make a difference in Kroger's second-quarter identical sales without fuel grew 14% on a two year stacked basis, ahead of our internal expectations. We saw triple digit growth in digital over the same time period and continue to drive costs out of the business through cost saving initiatives and operational efficiencies. We remain confident in our positioning and our ability to deliver consistently attractive total shareholder returns of 8% to 11% over time.\\nI'd like to spend the next few minutes discussing three key areas. First, customer behavior and how our seamless ecosystem is working. Second, I'll share examples of how we are leading with fresh and accelerating with digital and finally, I will highlight how we continue to live our purpose to feed the human spirit through the associate experience and our work to advance Kroger's ESG commitments. Our strategic focus on leading with fresh and accelerating with digital continues to build momentum across our businesses.\\nAs we've operated through the pandemic, we've recognized the structural shifts in our customers' eating and cooking habits. Customers are responding favorably to our value proposition and are enjoying the convenience of our seamless offerings. Early in the quarter, customers visited stores more frequently and many shifted from online to in store. This highlights the relevance and convenience of our easily accessible footprint.\\nTowards the end of the quarter, as COVID-19 cases increased in many geographies, customers began shifting back to our digital solutions. This further demonstrates the strength of our seamless ecosystem. Customers can choose how they want to shop. Our job is to be available in every channel, so the customer does not have to compromise.\\nRegardless of how they choose to shop, customers are eating more food at home because it's more affordable, convenient and healthier than other options. While some food and home trends may be transitory, our research suggests those I highlighted are structural and Kroger is uniquely positioned to address them. Through our assortment of fresh products, world-class digital platform and innovative meal solutions, we will continue to elevate our position as a food authority so that when customers think food, they think Kroger. We continue to advance our position as a leader in fresh during the second quarter.\\nWe saw positive identical sales in produce and floral and deli bakery, even as we lapped elevated sales in 2020. Our research shows how much our customers love our brands. Sales for both simple truth and private selection brands were strong as food-at-home trends remained sticky. We continue to innovate within fresh.\\nFor example, our expanded partnerships with ghost kitchens allow us to offer customers freshly prepared, on-demand restaurant food. This is especially relevant at a time when many customers are looking for inspiration and 70% of our customers say convenience is important when cooking. We also announced our 2021 Go Fresh & Local Supplier Accelerator cohort and are already bringing innovative, locally and regionally sourced products to stores across the country and helping many small entrepreneurs achieve their dreams. Earlier this week, Kroger announced our new brand icon.\\nThe fresh cart icon brings together the Kroger Family of Companies under one unifying visual and reinforces our brand promise, fresh for everyone. We are very proud of our growth in digital, which increased 114% over the last two years, similar to our first-quarter growth. We remain on track to deliver against our 2023 digital growth and profitability targets introduced at our 2021 IR Day. While digital sales decreased 13% during the quarter, almost all customers who reduced their online spend during the quarter continue to shop with us in store, highlighting the power of our ecosystem and our ability to create a meaningful customer experience across all channels.\\nAs a short reminder, Kroger has doubled our e-commerce household penetration, increasing the number of our brick-and-mortar customers that engage with our digital solutions since 2019. During the quarter, we added over 340,000 new customers to our digital platforms. We continue to expand capacity across our footprint and we reduced wait times for Kroger pickup. As we look ahead, our seamless ecosystem will remain a competitive advantage as we offer what customers need and want in a way that fits into their life, whether it's shopping in our stores, picking it up at our stores, or getting it delivered or shipped directly to their homes.\\nWe continue to enhance our seamless ecosystem. As we've shared last quarter, we currently have two customer fulfillment centers open, which are expanding our capabilities in Ohio and allowing us to expand into the new geographies within Florida. We are happy with the performance thus far and are energized by the volume and growth in both sheds. In Ohio, our focus has been on evolving the customer proposition to maximize opportunities alongside our existing digital solutions.\\nIn Florida, we launched delivery savings pass, offering customers unlimited deliveries for just $79 per year. We continue to see incredible Net Promoter Scores and our customers tell us they love our friendly, professionally trained drivers and the refrigerated delivery vans that bring the freshest food directly to their doorsteps. Looking ahead, we remain on track to open six customer fulfillment centers over 2022 and 2023, which will further expand our seamless ecosystem. Before I share some specifics on how we are using data and personalization to grow the business, I thought it would be helpful to remind you about our rewards program and how it works.\\nOur rewards program has been active for over two decades. It captures data from 60 million households and 96% of our sales. Customers clearly see the value of our program, which drives sales and builds loyalty. As an example, nearly 60% of all items in a digital basket were added through our personalization science, highlighting our ability to make meaningful suggestions that surprise and delight customers.\\nFurthermore, when we personalize recommendations for our customers, we can reduce their time to shop by nearly 70%. Overall, one in three people have noted that groceries have gotten more expensive in the past months. Kroger customers benefit from our personalization as we offer highly relevant savings at a household level, allowing them to further stretch their food dollars. Our associates continue to deliver a full, fresh and friendly customer experience every day, every time while also supporting our communities through the pandemic.\\nWe remain urgently focused on keeping people safe in our stores and facilities. Our teams were recently recognized with the gold award for excellence in human capital management from the Brandon Hall Group for our people-centered COVID-19 response. Obviously, we're especially proud of that recognition. During the quarter, we introduced new technology to elevate our associate experience.\\nKroger launched Fresh Start, a new, personalized training program to foster greater associate engagement and retention. We also launched our FEED app, which provides associates easy access to company communications and resources from their smartphones. We are incredibly proud that, during the quarter, we saw an improvement in retention as we strive to gain an employer where associates can come for a job and stay for a career. Now, turning now to the live our purpose.\\nWe continue to believe that customers, associates and investors are increasingly choosing where to shop, where to work and where to invest in companies that are taking meaningful steps to improve our communities and work to build a more sustainable planet. We've recently published our 2021 ESG report on thekrogerco.com. It outlines our progress over the last several years. It further outlines our aspiration to further integrate ESG performance into lines of business and our commitment to creating shared value that benefits all stakeholders.\\nWe imagine a world where everyone is thriving together and Kroger is helping millions of people live healthier, more sustainable lifestyles, protecting and restoring natural resources and contributing to more responsible and inclusive global systems. One of the many ways we bring our ESG vision to life is through our work that our Kroger Health team has been doing to serve and support our customers and communities through the pandemic. During the quarter, we worked with Lyft to provide rides to COVID-19 vaccine appointments, teamed up with local sports icon to drive awareness and access in the underserved communities and we concluded our #communityimmunity giveaway. To date, we have provided over 6.7 million doses of the vaccine and continue to drive availability and education.\\nAnd yesterday, president Biden noted that Kroger is one of three national partners who have agreed to make the rapid COVID test available to customers at cost for the next 100 days. Kroger is committed to helping people live healthier lives while safeguarding the communities we serve. Our ESG goals are ambitious. And with a team of almost 500,000 dedicated and driven associates, they are also achievable.\\nSince we first introduced our commitment to delivering strong and sustainable total shareholder return in 2019, our teams have been laser-focused on execution. This focus has resulted in tangible results, allowing us to deliver this quarter and for the long term. Now, I would like to turn it over to Gary to discuss our second-quarter financial results. Gary?\\nGary Millerchip -- Chief Financial Officer\\nThanks, Rodney and good morning, everyone. Kroger is delivering strong results and continues to build momentum as we execute on our priorities of leading with fresh and accelerating with digital. During the quarter, adjusted FIFO operating profit grew by a compounded annual growth rate of 23% over 2019 and adjusted EPS grew by a compounded annual growth rate of 35% over the same two year period. This reflects our disciplined approach to executing our strategy, balancing investments in our associates and customers with strong cost management and accelerating growth in our alternative profit business.\\nIt also provides a further proof point of how we are successfully navigating the pandemic and emerging stronger as a business. I will now provide additional details on our second-quarter results. Identical sales without fuel declined 0.6%. On a two year stack basis, identical sales without fuel increased 14%.\\nEach period during the quarter was stronger than the last and I'm delighted to say we returned to positive identical sales without fuel during the final period of the quarter. Our digital platform remains a key strength in our model and we were pleased with the triple digit growth achieved over 2019. We remain on track with our plans to double our digital business by 2023 and would expect continued investments in the customer experience, scaling of new fulfillment centers and several new innovations which we will announce throughout the year to drive future growth. As shared last quarter, we would not expect future digital growth to be linear, especially as we cycle COVID in 2021.\\nDuring the quarter, we also made further progress in improving digital profitability as we achieved a record low for the time taken to pick a digital order in store and continue to see growth in the media revenue generated on digital transactions. Gross margin was 21.4% of sales for the second quarter. The FIFO gross margin rate excluding fuel, decreased 60 basis points compared to the same period last year. This decrease was primarily related to price investments and higher shrink and supply chain costs, partially offset by sourcing benefits and growth in our alternative profit business.\\nOn a two year basis, our FIFO gross margin rate excluding fuel, decreased 55 basis points compared to 2019. Consistent with many retailers, we experienced supply chain constraints and increased warehouse and transportation costs during the quarter. We are actively managing this risk within our business by securing increased capacity and augmenting associate retention programs within our own facilities. We expect supply chain costs to remain elevated in the second half of the year and this is contemplated in our updated guidance.\\nIn the second half of the quarter, we also saw higher inflation in some categories. We are being disciplined in working with suppliers to manage these increases and are passing along higher cost to the customer where it makes sense to do so. While difficult to predict with precision, as we shared last quarter, we believe inflation for the full year will be higher than originally contemplated in our 2021 business plan. For the second half of 2021, our guidance now assumes inflation of between 2% and 3%.\\nRecognizing recent inflation trends and our outlook for the rest of the year, we recorded a higher LIFO charge for the quarter of $47 million compared to $23 million in the prior year. Further strong operational execution allowed us to leverage operating, general and administrative expenses by 76 basis points excluding fuel and adjustment items, in the second quarter. This reflects lower COVID-19-related costs and savings captured through our cost saving initiatives. On a two year basis, our OG&A rate excluding fuel and adjustment items, decreased by 137 basis points compared to 2019.\\nWe continue to see opportunities to streamline processes and leverage technology and remain on track to deliver $1 billion in cost savings during 2021. The traffic and data generated by our seamless ecosystem continues to create a strong flywheel effect for our alternative profit business, which again experienced significant profit growth in the quarter. Media and Kroger personal finance continued to lead the way and we remain on track to achieve the high end of our expected range of $100 million to $150 million of incremental operating profit in 2021. Fuel is also an important part of our overall value proposition for our customers.\\nGallons grew in the second quarter by 7% and outpaced market growth. The average retail price of fuel was $3.13 this quarter versus $2.14 in the same quarter last year. Our cents per gallon fuel margin was $0.39 compared to $0.37 in the same quarter in 2020 and fuel was a tailwind to operating profit of $33 million compared to prior year. Turning now to our financial strategy.\\nWe continue to generate strong free cash flow and remain committed to investing in the business to drive sustainable growth while also returning excess cash to shareholders. We are prioritizing capital investments that support our growth strategy, widen our competitive moats and deliver strong returns. Capital expenditures year-to-date were down compared to prior year as we carefully navigated the impact of higher project costs and longer project lead times due to a challenging labor market. As we confirmed in guidance today, we are maintaining our range for capital investments excluding mergers, acquisitions and purchases of leased facilities, of between $3.4 billion and $3.6 billion and would currently anticipate coming in at the low end of this range for the year.\\nDuring the quarter, Kroger repurchased $349 million of shares and year-to-date has repurchased $751 million of shares. As of the end of the second quarter, $779 million remains outstanding under the current board authorization announced on June 17, 2021. In June, Kroger also increased the dividend by 17%, marking the 15th consecutive year of dividend increases. Our proactive approach to investing in our associates over recent years is helping us navigate a challenging labor market.\\nOur strategy continues to focus on investing in compensation plans that reward our associates in ways that are meaningful to them. We are committing to investing $350 million in hourly wage increases for our associates during 2021, in addition to the $800 million we invested in associate wages between 2018 and 2020. Over the same period, we have also taken several opportunities to improve the security of our associates' pension benefits. Our average hourly rate is now in excess of $16 an hour.\\nAnd with comprehensive benefits factored in, we'll be approaching $21 by the end of 2021. We are committed to increasing retail hourly wages sustainably and our long-term financial model fully contemplates continued investments in associate hourly rates. During the second quarter, we ratified new labor agreements with the UFCW for associates in our Atlanta, Michigan, Food 4 Less and Mid-Atlantic divisions, covering over 34,000 associates. We continue to negotiate contracts with the UFCW for store associates in Houston, Little Rock, Memphis and Portland.\\nOur financial results continue to be pressured by inefficiencies in healthcare and pension costs, which most of our competitors do not face. We continue to communicate with our local and international unions, which represent many of our associates about the importance of growing our business in a profitable way, which will help us create more jobs and career opportunities and enhance job security for our associates. Turning now to our expectations for the second half of 2021. Driven by momentum in our results and sustained trends in food at home, we are raising our full-year guidance.\\nWe have also narrowed the range of our guidance as we are further into the year and the trends in our business and the broader food-at-home market become clearer. We now expect identical sales without fuel in the second half of 2021 to be flat to slightly positive, resulting in full-year results of negative 1.5% to negative 1% and a two year identical sales stack of between 12.6% to 13.1%. We expect our adjusted net earnings per diluted share to be in the range of $3.25 to $3.35. We expect our adjusted FIFO operating profit to be in the range of $3.9 billion to $4 billion, reflecting a two year compounded annual growth rate of between 14.1% and 15.6%.\\nIn conclusion, we are emerging stronger through the pandemic and remain confident in our ability to deliver total shareholder return of 8% to 11% by sustainably growing earnings and using our resilient free cash flow to return excess cash to investors. And now I'll turn it back to Rodney.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThank you, Gary. The environment we operate in is dynamic and I am so proud of our associates' ability to meet the challenge and serve our customers while building for the future. Kroger's seamless ecosystem is working. This was evident during the quarter as we saw customers seamlessly shift between channels and we continue to see strong digital engagement.\\nWe are leveraging technology, innovation and our competitive moats to deliver against the total shareholder return model we introduced in 2019 and reaffirmed in 2021. Kroger will continue to deliver for all stakeholders and position the business for long-term success. Now, we look forward to your questions.\\nQuestions & Answers:\\nOperator\\n[Operator instructions] Our first question comes from Greg Badishkanian with Wolfe Research. Please go ahead.\\nSpencer Hanus -- Wolfe Research -- Analyst\\nGood morning. This is Spencer Hanus on for Greg. Can you guys talk about the comps that you're seeing quarter to date? Because I think the guidance does imply somewhat of a slowdown on a two year basis in the second half. And then although it's early, how are you thinking about comps in 2022.\\nDo you guys get back to your long-term algo next year? Thanks.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYeah. As Gary mentioned in his prepared remarks, the last period of the second quarter, we returned to positive identicals. And so far, in the third quarter, we continue to see the trend of positive identicals and our guidance for the balance of the year is positive as well. So we're very pleased with where we are.\\nWe're pleased with the performance our teams are doing and we're making progress and substantially ahead of where we initially we thought we would be at this point in time on cycling the COVID peak from last year. As we look toward 2022, Gary, unless you want to get into more of the details, I think the key thing would be what we talked about at our investor day in 2021 and that's our commitment to a TSR model of 8% to 11%. And that's driven by a combination of sales growth, slight margin improvements and taking free cash flow and returning it to our shareholders via dividend and stock buyback. And the sum of those together is what will drive the 8% to 11% and we remain committed to that.\\nAnd obviously, since we put it in place in 2019, we've outperformed it. I don't know, Gary, if you want to add anything.\\nGary Millerchip -- Chief Financial Officer\\nThe only thing I would add, I think you said it very well, Rodney, is we feel really good about the trends in the business, obviously, as we shared on the prepared comments. As you look at the back half of the year, you asked some -- for additional color on how we're thinking about the trends that we're seeing there and the guidance, I would say we're obviously heading into the back half of the year, as Rodney mentioned, with momentum in the business. We did raise the guidance to now be in that sort of 0% to 1% for the back half of the year based on reversing into that from the year-to-date performance and the guidance that we gave for the year. Overall, we're feeling really good about how we're executing in the business and seeing that sustained trend in food at home as consumers continue to gravitate toward some of the trends that Rodney talked about.\\nAnd also, obviously, we are seeing some return to previous behavior with the Delta variant currently prevalent in the U.S. as well. That being said, we do still think there are some knowns in the market. If you look at different countries, how long the impact of the Delta variant lasts, if you like, on consumer behavior, we are seeing some consumers return to normal behavior, returning to offices in some cases.\\nAnd so while we feel really good about our trends and our ability to continue to win with the customer, the back half of the year would be more of an 11% to 12% two year stack based on still some of the uncertainties and unknowns around those elements that we're still looking to see how they play out. I think the only other thing that I would reinforce on Rodney's comment is that we do expect, as we shared at our investor day at the beginning of the year, that as we come through 2020 and 2021, we expect the overall food-at-home trends in the market but also specifically Kroger's overall sales to come out of 2021 in a much stronger position than we would have been had the pandemic not occurred. And so we believe that, that will still certainly be true as we head toward '22. And obviously, we look forward to sharing more details on 2022 when we get toward the end of the year.\\nSpencer Hanus -- Wolfe Research -- Analyst\\nThanks. That's really helpful color. And then could you guys comment on how rational your peers have been at passing through inflation? And are you expecting any gross margin headwinds from some of the elevated inflation in the perimeter of the store? Any additional color there would be helpful.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nIf you look at, during the quarter, about half of the gross margin impact was from higher shrink and higher supply chain costs and Gary, in his prepared remarks, talked a little bit about both of those. But if you look at shrink, a lot of that, about half of the half or 25% of it is driven within the shrink component and that's heavily driven by organized crime or at least it appears to be. And I know Congress and other groups are starting to spend more time on understanding what's driving that and what's behind it and what's the distribution channels for the stolen products as well and trying to manage that. And then on the supply chain costs, we are proactively investing there to minimize the effect.\\nOn both of those areas, the guidance that Gary shared for the balance of the year reflects the pressure in those areas. And from an inflationary standpoint, as you know, over time, we've been successful in operating in slow or negative inflation and high inflation and we would see this no different. And our business, the easiest place to operate is when inflation is between 3% or 4%, but you don't ever get what you -- it makes it the easiest. But so far, we're -- costs are being passed through in an organized way for the most part and as we would expect and following our strategy.\\nSpencer Hanus -- Wolfe Research -- Analyst\\nGreat. Thank you so much.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThanks, Greg. Sorry.\\nOperator\\nYour next question comes from Michael Lasser with UBS. Please go ahead.\\nMichael Lasser -- UBS -- Analyst\\nGood morning. Thanks a lot for taking my question. I wanted to drill down into your comments around the consumer embracing eating at home, coupled with targeting the total shareholder return formula for next year. We're still largely in the midst of this pandemic.\\nMany workers are still working from home. So is the strength this year just delaying the inevitable shift back to food away from home in calendar '22? And if that's the case, you're guiding to a 3% operating margin this year essentially. So how will you be able to maintain this operating margin rate in an environment where your sales are going to continue to be pressured, particularly as you have reduced a lot of your OG&A expenses this year?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThanks, Michael. I'll start and let Gary finish. If you look at all of our research on people eating at home, customers are telling us, they enjoy eating at home and eating with their families, which we believe is structural and sustainable. They're also telling us that eating at home, they're able to eat healthier, stretch their budget significantly further because it's not nearly as expensive as eating in a restaurant.\\nAnd they also like showing off their new skills on cooking. And all of those things, everything that our research would suggest are long-term trends and structural trends. The other thing that everybody on the call, your guess is as good as ours. But everything that we can tell, we believe that people will continue working from home more than the past.\\nAnd many companies and I know certainly we are, are supporting people in terms of different jobs, what jobs can be worked from what location. And in all of those cases, what we're finding is people are eating more meals at home, i.e., breakfast and lunch. So everything that we can see, a meaningful part of the trend change is really structural and sustainable and it's not just a onetime blip because of COVID. In terms of the margins and stuff Gary I'll let you drill into some of that detail.\\nGary Millerchip -- Chief Financial Officer\\nYeah. I think all I would add Rodney is maybe just -- Mike, we'll take you back to the journey we've been on for the last three years with our model. And if you think about how we teed it up at our investor days, we feel that over 2019, 2020 and now 2021, we're really demonstrating how we're able to manage the business more holistically as we think about delivering on our TSR model. So you think about the continued investments, even through the pandemic, that we are making in our customers to ensure that they see the value we're delivering, whether that's in the experience and some of the digital investments or through continuing to invest in price where it make sense and personalization to make sure positioned well with the customer, the investments that we're making in average hourly for our associates to ensure that we're continuing to improve the experience there.\\nAnd as you look at that and then think about the way in which we've managed costs, we're continuing to accelerate our alternative profit businesses and at the same time, continue to get stronger and more effective at sourcing and managing margins in that way. I think that gives us confidence in our ability to continue to manage the business overall and drive a strong TSR in line with our commitments as you think about over time what our commitments are to our shareholders. So we'll obviously get into more specifics around how we think about '22 later in the year. And at this point, I wouldn't want to get into specific details about next year, but that's certainly how we think about our model and how we get confident in our ability to maintain the trajectory over time and supported by Rodney's comment on how we think about continuing to see the customer spend dollars on food at home and how we can continue to grow our business within that context.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYes. As you look at cost, it's one of those things where we've been able to take cost out of the business without affecting the customer experience for years. And I know when we set out a goal, we always think that that's all we're going to find and then our great teams are able to find more areas for process change and cost opportunities. And when I watch our operations team, Gary mentioned the procurement team, our technology team, but more importantly, how our stores and technology and operations team are working as one, they continue to identify things to make our associates' job easier to reduce the number of touches of product and be able to take costs out, which our customers then benefit.\\nAnd some of that cost reduction is shared with our customers. Some of it is shared with our associates, but it's part of the overall flywheel that continues to accelerate and make our model sustainable. And Gary's point on alternative profit is an important component of that as well.\\nGary Millerchip -- Chief Financial Officer\\nActually, Rodney one other thing on the cost side Michael that I think is important too. We've mentioned this again at our investor day, but this -- the plan that we have to double digital profitability, that's obviously very important to the long-term strategy that Rodney outlined around how do we make sure that, from a customer perspective, they're not having to compromise between store and digital experiences but is also important from a business model point of view to continue to improve the profitability of the channel. So that from our perspective, we can be agnostic from whether the customer is buying online or buying in the store. As we grow that digital profitability rate, important to remember that just doesn't affect the growth in the future, it affects the $10 billion business that we have today.\\nSo that's also proving to be a tailwind in the financial modeling OG&A now but also will continue to be a tailwind because we're only partway through that journey as we take cost out of filling an order and continue to grow media revenue per transaction as well.\\nMichael Lasser -- UBS -- Analyst\\nAnd my follow-up is focusing on the media revenue per transaction, it seems like that's the area where you're really supporting the profitability of your digital business and subsequently, the overall gross margin for Kroger as a result. Where are you from an advertising perspective from a large CPG company perspective versus getting more advertisers on the platform? Can you frame out how big this advertising opportunity can be? And as an unrelated side note, to what extent was there a vaccine distribution benefit within the gross margin? One of your large competitors talked about that within the quarter.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nWell, several questions there. I'll briefly talk about the media. We still see retail media as a significant opportunity. And we shared at investor day, but Kroger's retail media team and our retail media offer in five different areas, we ranked No.\\n1 among our competitors in three of the five and we were tied for No. 1 on the other 2. So obviously, the value CPGs get from our offer and our ability to use our data to make sure the right customers are seeing offers is substantial and significant and we believe that it's a significant opportunity to continue to grow retail media. I won't get into specifics, other than we would say that we feel like we're just getting started.\\nGary Millerchip -- Chief Financial Officer\\nAnd then, Michael, I would just say on the health and wellness question, we would certainly have seen some benefit from COVID vaccines during the quarter. Having said that, we pivoted a lot of our efforts in the pharmacy business, which, as you know, is a big part of our operation and our little clinics. So I would say, net-net, if you look at the health and wellness business, I would think of it as largely being on plan. And so I wouldn't think of it as a headwind or a tailwind during the quarter or, for that matter, being a headwind for the rest of the year either.\\nI think we've got fully contemplated within our guidance the expectations around the health and wellness business going forward.\\nMichael Lasser -- UBS -- Analyst\\nThank you very much and good luck.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThank you.\\nOperator\\nYour next question comes from Chuck Cerankosky with Northcoast Research. Please go ahead.\\nChuck Cerankosky -- Northcoast Research -- Analyst\\nGood morning, everyone. Nice quarter. I want to talk a little bit about or ask a little bit about private label in this inflationary period. How do you see customers reacting to it? And is there a difference between a customer shopping in store and online?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYeah. If you look at our brands, simple truth and private selection continues to really gain share and grow. We're also finding big packs are growing significantly. If you look at -- for us, we find our brands -- if CPGs are passing through inflation that's not real, all -- every time when somebody does that, our brands even gain incremental share.\\nThe other thing that I've been really proud of our team is the innovation behind the product and we've introduced over 140 new products in the quarter and would continue to expect that going forward. I don't -- we're not seeing behavior changes. If you go back to prior times when you had inflation, the customer, a lot of times, would trade over to our brands as part of their -- structuring their budget. We're not seeing budget changes on our brands happening at this point but I'm sure if inflation continued.\\nOur customers are telling us they still feel pretty good where they are financially. And for the most part, people are still saving at record levels and things like that. Now at some point, if budgets got more constrained, you'd probably start seeing some of that behavior. But the business we're gaining right now is really being created because of the innovation in our product and the quality of the product and it's really standing on its own.\\nChuck Cerankosky -- Northcoast Research -- Analyst\\nAnd then secondly Rodney, are you seeing regional differences in the shifts in the way people moved in and out of e-commerce over the course of the quarter?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYes, we would. And it's really wherever COVID is higher, you would see the shift to more online and that's delivery and pickup. And as it moves north, you would see that within the company. And as I mentioned in my prepared remarks, the things that we're especially proud of is almost every customer that were shopping with us digitally early in the quarter that started -- that stopped shopping digitally, they started shopping in the stores.\\nAnd for us, that's really important as part of our overall strategy for seamless because what we find is, after the first year, an online shopper actually comes into the store more often than they did before they became an online shopper.\\nChuck Cerankosky -- Northcoast Research -- Analyst\\nAnd have you quantified what your total e-commerce did to the operating earnings during the quarter? Is there any way to put a number on that, whether a smaller loss or is it trending toward a positive number?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nWell, I'll let Gary -- I'll talk a little bit. If you look at within the quarter, obviously, we had the start-up costs of our sheds in Florida and Monroe. So that created a headwind. Obviously, that was reflected in our guidance that we gave for the year and our updated guidance.\\nI don't know, Gary, if there's any additional.\\nGary Millerchip -- Chief Financial Officer\\nWell, I think we talked about, Chuck, the profitability of digital in different ways. When we add in all the fixed costs, we're more on the journey toward profitability, as you are alluding to. We generally focus, though, on what's the pass-through rate on the transactions as we're growing customers because what we find with digital, as you know, is the customer becomes more loyal overall to Kroger and we see about 50% or so incrementality as the customer engages digitally. As we've talked about previously, we've kind of -- when you think back to last year, we're at mid-single-digit pass-through rate compared to a pass-through rate that will be closer to mid- to high teens on a store transaction.\\nAnd we're on the path to improving that profitability to drive toward doubling the profit rate on the digital transaction and ultimately targeting to get to parity. I would say we're making good progress on that journey. As I mentioned in my prepared comments, we continue to make solid improvements in the efficiency of picking a digital order. And over time, we'd expect Ocado to play a role in that as well, of course, with the automation they provide.\\nAnd with media revenue continuing to grow rapidly, that's also creating a tailwind. So I'd say we're seeing good momentum and on track with where we expected to be with that journey in the quarter.\\nChuck Cerankosky -- Northcoast Research -- Analyst\\nThank you very much. Good luck on the rest of the year.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThank you, Chuck.\\nOperator\\nYour next question comes from Edward Kelly with Wells Fargo. Please go ahead.\\nEdward Kelly -- Wells Fargo Securities -- Analyst\\nYeah. Hi, guys. Good morning. I wanted to ask about share repo and the cash balance.\\nSo you ended the quarter with a lot of cash. Again, you're well below your leverage target. Thoughts on the buyback. Is the stock attractive here, I guess, is a straightforward question? And what are your thoughts on taking out additional debt to buy back stock? Because with the dry powder that's there, I mean, it seems like you could probably take out north of 10% of the shares.\\nIs this a bigger part of delivering 8% to 11% next year? Just kind of curious as to how we should be thinking about all this.\\nGary Millerchip -- Chief Financial Officer\\nYeah. Thanks for the question, Ed. I would say, overall, we're not changing our overall financial strategy. As we think about our free cash flow, we continue to start with how can we invest in the business to grow it profitably and sustain growth and we still think there's lots of opportunity to accelerate the model.\\nAs we -- I think we alluded to a little bit of this at our last investor day, our goal over time would be to be stretching our top line growth and our overall earnings growth, so the focus for excess free cash flow is certainly looking for where the opportunities as we believe we can continue to lead with fresh and accelerate with digital to drive that growth. We're certainly going to look at any of those incremental investments against the bar of saying, is that going to drive a stronger return for investors versus buying back incremental stock? But within our overall framework today, as we obviously continue to invest in the business to grow, we are committed to continuing to return cash to shareholders at the level that we've shared in our current TSR model. As you've heard us say, we increased the dividend by 17% to reflect really our confidence that we expect to come out of COVID at a higher position from an operating profit perspective as we leave 2021. And and we continued to buy back stock during the quarter and would expect to continue to buy back stock at the current price.\\nWe do leverage a grid. I think I've referred to this before. So think about it as depending on where the share price is. That -- if the share price is lower, it buys back more stock during the quarter.\\nIf the share price is higher, it buys back less stock because we're not trying to time anything in the market. We're already trying to make sure that we're maximizing the return on the dollars as we go through the year to take advantage of fluctuations in the prices as it happens during a difficult trading period. But we certainly remain committed to returning cash to investors. We start with the excess cash from a point of view of saying where could we accelerate our growth.\\nAnd ultimately, we'll share more on that as we identify those opportunities. And we'll continue to flex, if we believe that there aren't those opportunities then obviously, we'll look to make sure we are dynamic in making sure we're deploying excess cash.\\nEdward Kelly -- Wells Fargo Securities -- Analyst\\nOK. Great. And just a quick follow-up on the gross margin. Is the two year number for Q2, is that a good way to think about the back half or with inflation accelerating and supply chain, does that headwind grow a little bit in the back half? Just curious as to how we should be thinking about that.\\nGary Millerchip -- Chief Financial Officer\\nYes. I think actually, Q2 is a pretty good sort of overall -- I'm going to -- again, we don't get into specific numbers. But I think, directionally, it's a helpful way to think about the back half of the year. As you think about overall earnings, we would think gross margin continued to be a headwind, part of that being warehouse and transportation, part of it being shrink.\\nWe're also continuing to invest in the business where we think it makes sense and give value to customers. OG&A will continue to be a tailwind, but we will see less COVID cycling, if you like, in the back half of the year. So that's why the overall impact on operating profit won't be as strong in the back half of the year. But I -- if you think about Q2 in general outside of that cycling of extra COVID costs last year in the first half of the year I think is a pretty good way to think about the back half of the half of the year, Ed.\\nEdward Kelly -- Wells Fargo Securities -- Analyst\\nGreat. Thank you.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThanks, Ed.\\nOperator\\nYour next question comes from Michael Montani with Evercore ISI. Please go ahead.\\nMichael Montani -- Evercore ISI -- Analyst\\nGreat. Thank you for taking the questions. I was just hoping to get a little bit of incremental color around the ID sales. Has the transaction count turned positive at this point? And then secondly, if you could provide some incremental color around how much inflation you were able to kind of pass through to consumers vis-\\u00e0-vis what you saw in COGS, just because at times, in the past, you have given some helpful context there?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYeah. If you look at transaction count, we would continue to have a slightly declining or kind of flat transaction count. It really depends on if you're looking at versus prior year or two years. If you look at basket size per purchase, it's significantly increased in terms of when customers come into the store, they buy significantly more; or if you look at our online shop customer, that customer's basket size is significantly higher than a basket when somebody comes into a store.\\nSo both from a digital standpoint and individual transaction standpoint, customers are significantly buying more. And it's all -- it's really three things. One, they're buying more. They're also buying premiumization of product where they've upgraded the products they buy and they also are buying bigger-sized products as well.\\nSo if you think about toilet paper, very few customers now can or will even buy a four pack of toilet paper, where most customers now are buying 24 pack or even bigger in some cases. In terms of the inflation, Gary, I'll let you answer Michael's question on that.\\nGary Millerchip -- Chief Financial Officer\\nThanks for the question, Michael. Yes, we've laid out before, I know, on the call, we have a very robust process for how we manage when we see inflationary costs flowing through from suppliers. And first of all, we challenge to make sure that we feel confident they're legitimate because, obviously, we want to make sure that they truly are structural cost changes. And then if they are, we absolutely have a process for passing them on to the customer.\\nI would say that, generally, we've been very comfortable with our ability to pass on the increases that we've seen at this point and we would expect that to continue to be the case looking into the back half of the year. As you saw during the quarter, we are, though, continuing to invest in price where we think it makes sense. Sometimes that might be in areas where we're seeing inflation. Sometimes it might be we're investing because we believe it's the right thing to do to grow customer long-term loyalty in other places through our personalization strategies.\\nSo overall, we feel good about the way in which we're able to manage the inflation within the business. At the same time, we are continuing to invest because we believe that's going to be important to grow share over the long term as well.\\nMichael Montani -- Evercore ISI -- Analyst\\nGot it. Thank you.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThank you.\\nOperator\\nYour next question comes from Karen Short with Barclays. Please go ahead.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nKaren, are you there?\\nKaren Short -- Barclays Investment Bank -- Analyst\\nOh, sorry. can You hear me now?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYes.\\nGary Millerchip -- Chief Financial Officer\\nYes.\\nKaren Short -- Barclays Investment Bank -- Analyst\\nSorry about that. Yes. So I had a couple of questions just related to guidance. Gary, you mentioned that the vaccine admin fee kind of netted out with respect to other initiatives that you had in, I guess, health and wellness in general.\\nI'm just wondering if you could give a little more color on that because it was very sizable and one of your competitors in terms of basis point contribution to gross margin. And then other model questions that I just wanted to clarify were what your actual LIFO expectations are for the year because that's obviously relevant for EPS and then what your COVID costs were in the quarter and what your expectations for COVID costs will be for the rest of the year. And then I had one other bigger-picture question.\\nGary Millerchip -- Chief Financial Officer\\nSure. Thanks, Karen. On the pharmacy side of things, yes, so essentially, as you know, we operate little clinics as well in a number of our stores and multiple of our stores have little clinic facilities. And in our pharmacy core business, we continue to support the COVID vaccines.\\nSo my comment earlier was, when you look at the total health and wellness business, as we pivoted resources to do more COVID vaccinations and as we provided that support, whether it be through off-site locations or through our own facilities and you look at the total impact of the pharmacy business as customers shifted to more COVID vaccines and less of the newer prescriptions, if you like, even though we grew script count overall during the quarter and continue to grow script count. If I look at the total impact on the health and wellness business for the quarter and the year-to-date, there wouldn't be a material overall outside of business plan performance. Although certainly, if you look to the COVID vaccines in isolation, they would have created an incremental value to the health and wellness business, but it was offset by lower revenue or lower margin impact on other parts of that business, so netted out to being on plan, if you like. And as we look at the back half of the year, I wouldn't expect it to be a reason that we have an incremental headwind in margin because of having less COVID vaccinations in the back half of the year as things start to return.\\nSo certainly, we expect some vaccines in the back half of the year, but things start to return a little bit more to normal and less of a spike in vaccines compared to what we saw in the first half of the year. From a LIFO perspective, as you -- I think you probably know, it's not really an easy thing to predict because LIFO was a charge, is one data point at the end of the year. As we looked at the data point so far this year, we're seeing an inflation. We use those spots to predict where it would be.\\nI think the best guidance we could give you is if you take the year-to-date performance in LIFO that we've charged to the P&L and then gross that up effectively for the full year, that would be essentially our full-year expectation based on the data points that we've seen to this point in the year in our outlook. But FIFO -- I'm sorry, LIFO, I beg your pardon, is notoriously difficult to predict, so we're giving you our best estimate. But at the end of the day, it will be driven by accounting rules and a data point toward the end of the year. But I think the best indication we can give you at this point is to use the year-to-date performance and gross that up for the year is our best estimate.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nIn essence, annualized. And so divided by seven times.\\nGary Millerchip -- Chief Financial Officer\\nExactly, exactly. Yes.\\nKaren Short -- Barclays Investment Bank -- Analyst\\nRight. And then just COVID?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nCosts for the quarter.\\nGary Millerchip -- Chief Financial Officer\\nYeah. So as I mentioned earlier, we certainly saw significantly greater costs in the first half of last year. As a company, we adapted and learned how to operate more efficiently. We would certainly see continued COVID costs in the back half of this year but cycling less costs from last year.\\nWe would expect it to be south of $100 million a quarter. But certainly, we're still seeing incremental costs. And some of the areas that you would probably expect when you think about how we're continuing to operate through COVID, we still have masks costs during the quarter. We still have cleaning costs.\\nWe still have extended leave of absence for any associates that are identified as having the COVID virus -- been diagnosed as a positive COVID case. So those would be the kind of costs that we would see and we'd expect it to be a little bit less than $100 million a year -- sorry, a quarter, I beg your pardon, as we look at the back half of the year and still being a slight tailwind year over year but nothing like what we have seen in the first half of 2020.\\nKaren Short -- Barclays Investment Bank -- Analyst\\nOK. And then just my bigger-picture question is on Florida, so with respect to Ocado. Curious, Rodney, on your early learnings from Florida and whether you think that you may want to emphasize opening sheds in markets where you actually don't have physical retail locations. Or any thoughts on where you're at on that philosophy in terms of markets where you have high market share, markets where you have middle market share or markets where you have no presence based on what you know so far?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYeah. It's a great question, but we're still early in the process of answering that. And if you look in Florida, we are tracking ahead of where we thought we would be at this point. And the thing that I'm especially proud of our teams in Florida is our Net Promoter Scores are incredibly strong.\\nI mean, mind-boggling strong and made up in the neighborhood of best-in-class across all industries. And as you know, food retail usually struggles with having Net Promoter Scores that are up in the Apple neighborhood and things like that. So I'm incredibly proud of what our teams are doing in terms of creating the experience for the customer. And I appreciate and like your question.\\nI would say we're still early in the process and we continue to learn every day on our ability to ramp up a facility in a new market. Certainly, it's easier communicating to the customer in new markets or markets where our share isn't as high. And that was one of the reasons why we picked Florida and picked Monroe here outside of Cincinnati was to learn how to integrate it within our existing infrastructure and then having something from the ground up. And I would expect, over time, we'll learn how to do both of them and we'll be really happy with the results.\\nKaren Short -- Barclays Investment Bank -- Analyst\\nGreat. Thanks very much. That's helpful.\\nOperator\\nYour last question comes from Rupesh Parikh with Oppenheimer. Please go ahead.\\nRupesh Parikh -- Oppenheimer & Co. Inc. -- Analyst\\nGood morning. Thanks for taking my question and fitting me in. So I guess just going back to the gross margin headwinds during the quarter that you saw. Today, you called out shrink in supply chain.\\nIt sounds like that may be half the pressure that you saw during the quarter. I was curious if you see those headwinds on the shrink and supply chain at all transitory.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nI think incrementally, yes. But if you look at shrink, I think shrink will remain higher. Now we will go through and do all kinds of process changes to try to minimize shrink, but we are being more aggressive. And Christine Wheatley, who's our General Counsel, is also working with some trade associations to try to start working on it in a broader group, not just Kroger-specific when you look at organized crime.\\nAnd I know I was reading Home Depot's earnings call and they talked about the same thing. So we do believe that will be important to partner with the government and the way products are able to be sold in the marketplace. So I do think there's things we will do to improve, but some of it will be a headwind until we're able to address that. On supply chain, I think an awful lot of that will be transitory, but you still have to manage through it.\\nRupesh Parikh -- Oppenheimer & Co. Inc. -- Analyst\\nOK. Great. And then maybe just one follow-up question. We're hearing more and more from suppliers lately of challenges in the supply chain and being able to fulfill all the consumer demand out there.\\nSo I was just curious how your out of stocks right now trending versus what you've seen in recent months?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYes. I would say that we're slightly higher. Now our teams had, going in, been continuing to aggressively forward buy inventory. Originally, it was because of the inflation pressures.\\nIt's ended up because of some of the supply chain issues. It's also one of the benefits of a lot of our own brands and we manufacture a lot of our own brands. So our plants are aggressively pushing capacity. So I would say that it is a headwind.\\nIt's slightly worse than it was, but we continue to work on minimizing and maximizing the in-stocks.\\u00a0\\nRupesh Parikh -- Oppenheimer & Co. Inc. -- Analyst\\nOK. Great. Thank you.\\nGary Millerchip -- Chief Financial Officer\\nBefore we conclude today's call, I'd like to take a moment to remember the tragic event that took place nearly 20 years ago tomorrow and to honor the lives lost on September 11, 2001. And as always, I'd like to take a moment to address our associates who are listening in. Thank you for delivering an outstanding performance this quarter and continuing to support our communities through the pandemic. As the number of COVID-19 cases continue to rise due to the rapid spread of the Delta variant, I want to affirm that health and safety of our associates and customers remain our top priority.\\nWe are doing everything we can do to make sure the vaccine is accessible and available to you and our customers wherever they are. I am so proud of our Kroger Health team who have already administrated 6.7 million doses of the COVID-19 vaccine. Thank you to our talented healthcare professionals for being there for our communities and for addressing questions for our customers about the vaccine and about getting the vaccine. I'm often reminded of the impact our associates have on the lives of our customers.\\nRecently, one of our pharmacy managers in Atlanta saved a life of a customer that was having an allergic reaction in one of our stores. This is just one of the many examples that in extraordinary ways our associates care for those around them. Thank you for inspiring me every day and thank you for all you do every day to be there for our customers, our communities and each other. That concludes today's call.\\nOperator\\n[Operator signoff]\\nDuration: 69 minutes\\nCall participants:\\nRob Quast -- Director of Investor Relations\\nRodney McMullen -- Chairman and Chief Executive Officer\\nGary Millerchip -- Chief Financial Officer\\nSpencer Hanus -- Wolfe Research -- Analyst\\nMichael Lasser -- UBS -- Analyst\\nChuck Cerankosky -- Northcoast Research -- Analyst\\nEdward Kelly -- Wells Fargo Securities -- Analyst\\nMichael Montani -- Evercore ISI -- Analyst\\nKaren Short -- Barclays Investment Bank -- Analyst\\nRupesh Parikh -- Oppenheimer & Co. Inc. -- Analyst\\nMore KR analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 5
        }
      ],
      "source": [
        "print(f\"Data shape: {df.shape}\")\n",
        "df.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 6,
      "metadata": {
        "id": "CU9xOA_rG008",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 363
        },
        "outputId": "e706b319-dd9d-4787-9460-a7ae97f3ecc1"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                          date      exchange        q ticker  \\\n",
              "0   Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1   Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2   Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3   Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4    Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "5    Nov 4, 2020, 5:00 p.m. ET    NYSE: GDOT  2020-Q3   GDOT   \n",
              "6    Aug 5, 2020, 8:30 a.m. ET     NYSE: KAR  2020-Q2    KAR   \n",
              "7  Mar 24, 2021, 11:00 a.m. ET    NYSE: EPAC  2021-Q2   EPAC   \n",
              "8    Jun 9, 2021, 8:30 a.m. ET     NYSE: ABM  2021-Q2    ABM   \n",
              "9   Aug 11, 2022, 8:30 a.m. ET    NYSE: SGHC  2022-Q2   SGHC   \n",
              "\n",
              "                                          transcript           Timestamp  \n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel... 2020-08-27 21:00:00  \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta... 2020-07-30 16:30:00  \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc... 2019-10-23 17:00:00  \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon... 2019-11-06 12:00:00  \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel... 2019-08-07 08:30:00  \n",
              "5  Prepared Remarks:\\nOperator\\nGood afternoon, a... 2020-11-04 17:00:00  \n",
              "6  Prepared Remarks:\\nOperator\\nLadies and gentle... 2020-08-05 08:30:00  \n",
              "7  Prepared Remarks:\\nOperator\\nLadies and gentle... 2021-03-24 11:00:00  \n",
              "8  Prepared Remarks:\\nOperator\\nGreetings and wel... 2021-06-09 08:30:00  \n",
              "9  Prepared Remarks:\\nOperator\\nGood morning and ... 2022-08-11 08:30:00  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-dcc4f2ee-87e3-4cdf-9984-2c4b53ca6815\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>Nov 4, 2020, 5:00 p.m. ET</td>\n",
              "      <td>NYSE: GDOT</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GDOT</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood afternoon, a...</td>\n",
              "      <td>2020-11-04 17:00:00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>Aug 5, 2020, 8:30 a.m. ET</td>\n",
              "      <td>NYSE: KAR</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>KAR</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nLadies and gentle...</td>\n",
              "      <td>2020-08-05 08:30:00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>Mar 24, 2021, 11:00 a.m. ET</td>\n",
              "      <td>NYSE: EPAC</td>\n",
              "      <td>2021-Q2</td>\n",
              "      <td>EPAC</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nLadies and gentle...</td>\n",
              "      <td>2021-03-24 11:00:00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>Jun 9, 2021, 8:30 a.m. ET</td>\n",
              "      <td>NYSE: ABM</td>\n",
              "      <td>2021-Q2</td>\n",
              "      <td>ABM</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2021-06-09 08:30:00</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>Aug 11, 2022, 8:30 a.m. ET</td>\n",
              "      <td>NYSE: SGHC</td>\n",
              "      <td>2022-Q2</td>\n",
              "      <td>SGHC</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood morning and ...</td>\n",
              "      <td>2022-08-11 08:30:00</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-dcc4f2ee-87e3-4cdf-9984-2c4b53ca6815')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-dcc4f2ee-87e3-4cdf-9984-2c4b53ca6815 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-dcc4f2ee-87e3-4cdf-9984-2c4b53ca6815');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-76ed3db3-e2bc-4971-873f-bb0843878a1b\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-76ed3db3-e2bc-4971-873f-bb0843878a1b')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-76ed3db3-e2bc-4971-873f-bb0843878a1b button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 18755,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2879,\n        \"samples\": [\n          \"NASDAQ: VOXX\",\n          \"NYSE: AXE\",\n          \"NYSE: RBC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 25,\n        \"samples\": [\n          \"2022-Q3\",\n          \"2023-Q1\",\n          \"2020-Q2\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2876,\n        \"samples\": [\n          \"TFC\",\n          \"SNX\",\n          \"TMST\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17592,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nWelcome to the TFF Pharmaceuticals second quarter 2022 earnings conference call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator instructions] I would now like to turn the conference over to Corey Davis from LifeSci Advisors.\\nPlease go ahead.\\nCorey Davis -- Investor Relations\\nThank you, operator. Hello, everyone, and welcome to TFF Pharmaceuticals second quarter financial and business results conference call. With me on the line today is Glenn Mattes, president and CEO of TFF; Kirk Coleman, chief financial officer; Dr. Dale Christensen, TFF's director of clinical development; Dr.\\nBill Williams of the University of Texas at Austin; and Chris Cano, TFF's chief operating officer. The press release announcing our second quarter results is available on the TFF Pharmaceuticals website. Please take a moment to read the disclaimer about forward-looking statements in the release. The earnings release and this teleconference both include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made.\\nFactors that could cause actual results to differ are described in the disclaimer and in our filings with the U.S. Securities and Exchange Commission, including the Risk Factors section of our 2022 quarterly report on Form 10-Q filed with the SEC. And now, it's my pleasure to turn the call over to Mr. Glenn Mattes.\\nGo ahead, Glenn. \\nGlenn Mattes -- President and Chief Executive Officer\\nThank you, Corey. Good afternoon, and thank you for joining us today to review TFF's second quarter operations and recent highlights. During this call, I will provide an update on our overall financial progress, then ask our chief financial officer, Kirk Coleman, to review our second quarter financials. We appreciate all of the positive feedback from many of you on the format we used in our first quarter call.\\nSo we will take a similar approach today, Kirk and I will provide the formal commentary and then open up the call for questions to the entire team. Please note that we are joined by Bill Williams, Dale Christensen and Chris Cano, who will be available for the Q&A. The second quarter was another period of significant progress for the company. It is important to take a few minutes to focus on our Thin Film Freezing technology and how much we continue to learn about its potential.\\nAs we have discussed, TFF continues to increase the number of productive partnerships with pharma companies, academic institutions and the government. I am happy to say that the number of open material transfer agreements grew significantly in the second quarter, and we added three additional top 20 pharma companies through our portfolio of active collaborations. As we continue to advance these engagements beyond the initial formulation stage into advanced in vitro or animal testing, stability and production stages, the new data continues to support why we are so enthusiastic about the creation of shareholder value. There is absolutely no question that the growing demand for our technology reflects the versatility of Thin Film Freezing.\\nWe continue to successfully conduct numerous new feasibility studies across a broad range of experimental and approved drugs with an ever-increasing focus on biologics and complex macro molecules. These include monoclonal antibodies, fusion proteins, mRNA, bacteriophages, siRNA, peptides and peptoids, in addition to small molecules and others. The work we're doing in the vaccine space is particularly exciting and continues to expand. You have no doubt seen the recent news about the need to develop vaccines that can be administered directly to the nasal mucosa and the lung.\\nI've always said that a major opportunity for the TFF technology is in the second- and third-generation vaccines. The TFF technology is uniquely positioned to enable this to happen. These vaccines are not limited to providing alternatives for COVID-19 vaccines. We are doing work in flu and many other types of infections, including viral, bacterial and fungal.\\nLet me take a few minutes to remind everyone about the specific advantages of Thin Film Freezing and why it is highly differentiated over other technologies. Dr. Bill Williams, co-inventor of Thin Film Freezing, recently published an article in BioPharm International titled, Improved Formulations to Enable Stable Delivery of Biologics. The article provides a concise summary explaining the unique advantages of Thin Film Freezing of our other dry powder technologies, including freeze drying processes, differences that largely account for our success in forging partnerships at every level of the industry, academia and government.\\nMany of these statements of work start with a comparison of Thin Film Freezing to other dry powder technologies. It's essential that a manufacturing process has not changed the molecular structure or properties of a drug, so this therapeutic activity is maintained, and that is particularly true in creating a dry powder formulation for biologics. As noted in Dr. Williams review article, conventional dry powder formulation techniques such as shelf freeze drying, spray freeze drying and spray drying are not well suitable for many biologics due to their tendency to result in the protein clumping into larger or inactive structures, a process that's known as aggregation.\\nIn addition, many biologics are quite fragile and cannot withstand the harsh impact of sheer and stress. Aggregation can negatively impact the activity of the biologic. By contrast, Thin Film Freezing results in particles, which are highly porous with a large surface area and low-density, attributes that help reduce the tendency toward aggregation and ensure optimal bioactivity of the molecule. In addition to avoiding aggregation, Thin Film Freezing also doesn't rely on elevated temperatures during the drying process.\\nThat is a stark contrast to other dry powder techniques such as spray drying, which require high temperatures in the drying process. This can lead to denaturation of the biologic and does negatively impact the molecules activity. The BioPharma article further notes Thin Film Freezing's applicability in developing novel vaccine formulations, including positive results with mRNA-based vaccines. Our work with materials and specific compounds supplied by our partners show that after withstanding repeated freezing and falling of a dry powder vaccine containing aluminum salts, the Thin Film Freezing vaccine does not show aggregation following a reconstitution.\\nImportantly, the formulation also maintains drug activity after high temperature storage with immunogenicity of the dry powder vaccine preserved to temperatures as high as 40 degrees Celsius or 104 degrees Fahrenheit. So if the approach to immunization for COVID-19 continues to produce vaccines reliant on cold chain distribution and storage, it is clear that by demonstrating these results, we believe that TFF Thin Film Freezing technology will enable manufacturers to overcome this significant hurdle. The other day, I read that COVID-19 vaccine manufacturers had to destroy over $1 billion worth of product, which underscores the need to solve cold chain supply challenges. At this point in the call, you may be wondering why I'm reviewing these new data.\\nMy purpose is to answer the many questions I get about what work we are doing with partners as we move toward finalizing agreements. And to help let you all know why we're so very optimistic about the positive direction of the business. A bit more new data before reviewing our business progress. As I touched on earlier, many of our partners are evaluating Thin Film Freezing to improve other vaccine formulations for powder delivery to the lung or nasal mucosa.\\nThese include those formulations containing the well-known MF59 adjuvant. By way of brief background, MF59 is a liposomal-based adjuvant that enhances the patient's immune response to a vaccine through localized upregulation of cytokines, chemokines and promoting the recruitment of venous immune cells. First approved back in 1997, MF59 is commonly used in pandemic or seasonal flu vaccines. It is generally recognized as having an excellent safety profile and is now licensed in more than 30 countries.\\nHowever, vaccines containing MF59 must be stored at refrigerated temperatures and are sensitive to accidental slow freeze conditions. Dr. Williams and his team at the University of Texas at Austin, just published another paper in the International Journal of Pharmaceutics, demonstrating that vaccines containing MF59 or AddaVax, which is a preclinical nanoemulsion that has the same composition and droplet size as MF59 can be converted to dry powder form by Thin Film Freezing. By contrast, the research showed that subjecting the same AddaVax composition, the shelf freeze drying led to significant aggregation or fusion of the droplets and the aggregation fusion was mainly due to the slow freezing required by conventional shelf freeze drying.\\nThin Film Freezing avoids this step and therefore, is much less likely to cause aggregation. Thin Film Freezing also continues to show significant potential for nasal delivery, which, again, will have significant relevance for the mandated future vaccine development. Intranasal vaccination using vaccine dry powders and attractive noninvasive modality with better storage stability and added protection at the mucosal services. Thin Film Freezing has proven viable in enabling the production of dry powders of a larger variety of vaccines, adjuvanted or not adjuvanted, protein-based or nucleic acid-based, for example, the mRNA vaccines and DNA vaccines, as well as live attenuated virus-based and the vaccine powders have desirable properties for intranasal administration.\\nOne last example, data from Dr. Williams Labs of a recent preclinical study in a rat model using partners material show that it is feasible to induce specific mucosal and systemic antibody responses following intranasal administration of a thin film freeze-dried vaccine candidate. The dry powder was prepared by Thin Film Freezing of a model antigen absorbed on aluminum oxy-hydroxide as an adjuvant. This further demonstrated the ability of the technology to work in a variety of adjuvanted vaccines.\\nSpecial emphasis was placed on the characterization of the dry powder vaccine formulation that can be realistically used in humans with an intranasal dry powder delivery device. The TFF vaccine powder was found to have good aerosol properties and the vaccine was uniformly distributed within the dry powder. An in vitro nasal deposition study using a 3D printed human nose model showed that around 90% of the vaccine powder was deposited in the nasal cavity. Intranasal immunization in animal studies with the TFF powder vaccine elicited a specific serum-antibody response, as well as a specific IgA response in the nose and lung secretions of the animals.\\nThus, intranasally administered dry powder made by Thin Film Freezing or vaccines has been confirmed. I repeat, it has been confirmed. Indeed, one additional publication from Dr. Williams Group and the TFF collaborators he worked with, recently received second place for the Best Paper Award 2022 by the Journal of Pharmaceutics.\\nIn this paper, our team described the formulation of remdesivir and an active analog. I will stop here and say that I can share additional successful data we are producing and working with our partners. Thanks to Bill Williams and the entire team. TFF Pharmaceuticals has become a key partner for pharma and biotech companies evaluating dry powder formulations.\\nBut our superior technology is only a starting point and a long line of value creation that ultimately leads to medicines with the potential to create significant clinical benefit and outcomes. For each one of our programs, we start with a singular purpose to enable more efficient, targeted delivery of medicine to the patient while minimizing systemic exposure. To accommodate growing demand for our technology, we recently opened a new R&D facility in Austin, Texas, which will provide us with significantly more lab space to develop larger scale production for our numerous partnered preclinical programs. Dr.\\nDonald Owens, our director of product development, will supervise the facility supported by Dr. John Koleng, TFF's vice president of product development and manufacturing. We're also expanding the product development team in Austin, which will be based at the new facility to support the growing number of partnered preclinical projects. Two additional points.\\nFirst, we continue to fully partner with all of our colleagues at the University of Texas. Second, we are taking a very efficient approach to funding the new lab space. The costs will be managed within our existing budgets. In addition, we do receive funds from our partners to fund many of the experiments that are part of the expanding material transfer agreements and statements of work.\\nNow, on to key business updates. First, our two most advanced clinical stage programs, Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder, are currently in open label Phase 2 trials and we expect the initial valuable patient data by the end of the third quarter. As previously discussed, we intend to partner these programs and we're currently working with Torreya Partners to reach out broadly to potential interested companies. I'm happy to report that this process is going well with a number of companies under CDA and or in our product data rooms.\\nWe will release valuable patient data to those companies under CDA. Given each program's advanced stage of development, we seek partnerships that reflect our significant investment made to date and each product's potential to improve upon the current standard of care. In addition, we are working to build out the clinical supply materials so that prospective partners can remain focused on clinical development and registration strategy. We also expect both the VORI and TAC impact programs to gain more visibility in the very near term.\\nDr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia, has been selected to provide a podium presentation on the ongoing compassionate use study of our Voriconazole Inhalation Powder at the International Congress on Lung transplantation, taking place in Paris, France on September 8 and 9. Notably, in this lung transplant patient, we observed the expected lack of drug-drug interactions when administering voriconazole by inhalation, thus the patient did not require dose adjustment of their tacrolimus immunosuppressant, which is not possible with oral voriconazole and demonstrates one of the safety advantages we expect to further demonstrate in our ongoing Phase II study. We remain very excited about the value these two programs are created for TFF and look forward to providing further updates.\\nLet me now provide an update on the status of inhaled niclosamide powder. I'm happy to tell you that we very recently sent the niclosamide Phase I complete study report to UNION. We believe this study report provides meaningful information to our partners at UNION as they continue to evaluate all of the data and assess TFF's Niclosamide Inhalation Powder. I can tell you that UNION is an outstanding partner and are quite impressed with the results.\\nThe UNION is working diligently to provide TFF with feedback on their option to license Niclosamide Inhalation Powder and begin a Phase II clinical program in COVID-19 patients. In other updates, our partnership with Catalent is progressing well. Catalent has referred a number of their clients to TFF to begin feasibility work. In addition, we are working with multiple Catalent sites preparing to install TFF equipment for the purpose of developing and manufacturing product candidates.\\nWe also continue to think strategically about the future of Augmenta 3387. TFF and Augmenta believe there is a therapeutic opportunity for an effective monoclonal antibody potentially in combination with other antiviral therapeutic options. TFF also continues to be increasingly encouraged about the potential for our inhaled cannabinoid product opportunities. We recently produced additional product to be used in further consumer testing.\\nThe opportunity to partner with TFF on these opportunities has now been presented to Glass House and a broader base of cannabis companies, both in the U.S. and Canada is our goal to determine a specific path forward shortly. As I said earlier, the number of pharma companies with open MTAs has increased, and we added three new top 20 companies during the second quarter. Our datasets are reaching critical decision inflection points with many partners.\\nOn the legislative front, we are keenly focused on the opportunity Thin Film Freezing offers to the advanced development of therapeutics and vaccines. TFF is working directly with members of the Congressional Appropriations Committee and departments within health and human services. We expect that opportunities will be considered for funding TFF efforts under the language written in the 2022 omnibus budget bill. In addition, as our development projects increase and mature, we now have been able to file funding grants, which help us advance programs already moving forward as a part of our two creatives and our academic partnerships.\\nFinally, the work we are progressing with DARPA formulating topical and ocular preparations of countermeasures is now in year two, and the preliminary results are promising and the feedback from Leidos is excellent. With those updates, I'd like to turn the call over to our chief financial officer, Kirk Coleman, for a review of our financials. Kirk?\\nKirk Coleman -- Chief Financial Officer\\nThank you, Glenn. For the three months ended June 30, 2022, research and development expenses for the company were $5.1 million compared to $2.8 million for the same period in 2021. General and administrative expenses for the three months ended June 30, 2022, for the company were $3.7 million compared to $2.4 million for the same period in 2021. The company reported a net loss for the three months ended June 30, 2022, of $8.7 million compared to a net loss of $4.7 million for the same period in 2021.\\nWeighted average common shares outstanding basic and diluted for the three months ended June 30, 2022, were 25,373,706 compared with 25,369,144 for the same period of 2021. As of June 30, 2022, we had total assets of approximately $27.9 million and working capital of approximately $21.4 million. At the end of the second quarter, our liquidity included approximately $20.9 million of cash and cash equivalents. And with that, I'd like to turn the call back over to Glenn.\\nGlenn Mattes -- President and Chief Executive Officer\\nThank you, Kirk. The second half 2022 reported results promised to be a meaningful period for TFF Pharmaceuticals. I hope that I've given you a flavor for the data that further confirms the potential for our ubiquitous, unique and value-creating Thin Film Freezing platform technology. We are very well positioned to meet our needs, as well as the needs of our pharmaceutical, academic and government partners.\\nThe unmet needs of pharmaceutical development in this arena is perfectly set up for Thin Film Freezing. Please search out the comments by Dr. Fauci and other vaccine experts emphasizing the need to deliver vaccines directly to the nasal and lung mucosa. What a tremendous set of opportunities this is for TFF.\\nOur partnering activities continue to expand, we have in place both the personnel and facilities to accommodate this growth. As discussed, our inhaled voriconazole and tacrolimus programs are each slated to reach important clinical milestones, and we are also pleased with the pace of partnership discussions surrounding these two innovative products. Thanks to all of the TFF team for their hard work and positive outcomes and thanks, as always, to all of our investors. And with that, I will turn the call back to the operator and open it up to questions.\\nOperator?\\nQuestions & Answers:\\nOperator\\nThank you. Before going into Q&A, Glenn Mattes has an additional piece of information to add.\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. Thank you. I want to take this opportunity to inform our listeners both on the live wire here and on the website that I'm announcing that in our 10-Q today, we did announce that, unfortunately, Malcolm Fairbairn has resigned from the TFF board. I certainly want to thank Malcolm for his counsel, his service and wish him well in his future endeavors.\\nAnd with that, now, we will open it up to questions. Thank you, operator.\\nOperator\\n[Operator instructions] The first question comes from Jonathan Aschoff with ROTH Capital Partners. Please go ahead.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nThank you. Thank you, guys. Glenn, since TFF continues to test CBD formulations with consumers, what are your thoughts about entering the market formally?\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. Jonathan, it's been a really interesting six months. We certainly again want to acknowledge that PLUS did a great job in helping us get ready formulation-wise, and we really have now been able to take those samples and test them with consumers and also introduce the technology to other companies. Glad, Glass House has not confirmed their interest at this point.\\nSo we have been working to go out to different companies. They've been working with our samples. They've been also testing it on some consumers. So we now have a real opportunity to sit back a little bit, look at a strategy of either one or multiple multistate operators to take this into the marketplace.\\nAnd we're hopeful that that can still happen later in the year. We also have seen an uptick in interest from companies since the vaping is very moved from tobacco. And I think a lot of the companies feel that there is a real opportunity to look at Thin Film Freezing cannabinoid formulations as a healthy alternative. Now, of course, that hasn't seated in yet to the CBD market.\\nBut I've noted and the folks I work with that are helping to sort of help me map this out a real uptake in interest. So hopefully, by the next quarter's update, I'll have some more specifics there. But we're really seeing terrific response to the product. And I think that's the key here in order for us to take a look at this being a positive contribution to our revenue lines.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nOK. And regarding the compassionate use case report for the lung -- that will be presented in Paris at that lung transplant congress. Do those results from that patient support the treatment hypothesis for IPA and give you confidence for success in the Phase II trial?\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. Dale, could you answer that question? You're closest to that data.\\nDale Christensen -- Director of Clinical Development\\nYes. Thanks, Glenn and thanks Jonathan. It's a very good question. As we stated previously, we believe that by delivering voriconazole by inhalation directly to the lung, we can increase the local concentration in the lung where you would derive the best therapeutic benefit, and we can also reduce the systemic concentration that's associated with the toxicity and drug-drug interactions from the oral voriconazole.\\nAnd the patient that we have been treating could not take oral voriconazole or any other azole antifungal due to toxicity and tolerability issues. One of the toxicities was that they had a history of melanoma and there's kind of a black box warning on voriconazole for melanoma. And so, this patient couldn't take it. And so, this patient was having declining lung function.\\nWhat we were able to do is stabilize the lung function due to effective treatment of the fungal infection, and we were able to do so without the patient having to adjust the dose of their tacrolimus immunosuppression medication. So it showed that we can have efficacy and without the drug-drug interactions. And so, it really does reinforce that treatment hypothesis that we've been working on.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nMy next question is, with the dominant BA.5 COVID variant and data on Paxlovid rebound cases, what do you think that creates in terms of an opening for niclosamide?\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. Dale, can you answer that one as well, please?\\nDale Christensen -- Director of Clinical Development\\nSure. Thanks, again. Also, a very good question. So with the emergence of the BA.5 variant, it seems to be worse than the previous Omicron versions.\\nAnd really at 500 deaths a day -- nearly 500 deaths a day in the U.S. And basically, worldwide 65 deaths around the world from COVID in the last four weeks. It very clearly indicates COVID is not over and better treatments are needed. And so, that level of death really isn't acceptable.\\nAnd many of the patients that die are in high-risk categories, cancer patients, patients who can't take Paxlovid due to drug-drug interactions. And we think that those patients will benefit from inhaled niclosamide because they're -- again, like fluconazole, when we deliver to the lung, you can avoid drug-drug interactions. And we've also seen that from the Paxlovid rebound, it's very clear that BA.5 and potentially future variants will take longer. And so, we're planning to -- when we move forward dose longer in our studies because we can avoid the drug-drug interactions that have great safety, we think that we can prevent the rebound and we'll monitor that during the clinical trials.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nAnd sorry to hog the mic, but two more. Should partnering of VORI and TAC happen, will you bring in new internal development programs and how will you select them? And the last question is, you added three top 20 pharmas. What's that bring the total number to?\\nGlenn Mattes -- President and Chief Executive Officer\\nOK. So yes, our goal is always to have an active internal set of products that we're developing. We're not turning into a company that is going to take these things all the way to the finish line. But the goal is to -- just like we're doing with VORI and TAC, take them through meaningful clinical inflection points.\\nThe 505(b)(2) strategy certainly was the right way for us to go. But strategically, we're looking at potential arrangements that would include co-development and sharing of development like we did with Augmenta where we split development 50-50. Augmenta, we were going to take through Phase I and still naive and then split proceeds from that point on. So we have a number of different options available to us as we seek to -- we kind to refresh and serially look at taking products to the pipeline.\\nIn general, Jonathan, it takes about $7 million to $12 million depending on the cost of the API to get us to that inflection point. So we have some products that we've been -- and compounds we've been looking at. Jordan Kennedy, who's our lead analyst has been working with some folks on the outside to do some analysis on what the market opportunities might be and what the development programs might look like. So as soon as we created revenue and cleared out the expense for VORI and TAC, we will look to refresh that internal portfolio.\\nOn the top 20 question, I don't remember the exact number. We were at a majority. So we're somewhere now in the area of -- we'll come back to you on the exact number, I would say, between 12 and 15, probably on the higher side of that. But the good news there is, those companies, many of them are not one-trick ponies.\\nWe have multiple projects that we're working with them. And those programs are getting -- are quite detailed, some of them in the very last stages of producing data and others that are at the starting gate. And we're really excited about and wish we -- frankly, we wish we could share some of these with you. The big companies are very hesitant to let us disclose and you -- if you knew what we were working on, you can understand the competitive nature of what Thin Film Freezing could be doing for those companies and their compounds in their marketplaces.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nOK. Do you still see the VORI and TAC trials as pivotal? Or is that authentic?\\nGlenn Mattes -- President and Chief Executive Officer\\nWell, we certainly feel that the data will be meaningful. And Jonathan, you know that the FDA never says yes, and they never say no, it depends on the data. When we talk to the partner companies that we're already under CDA with and that are in the data room, we certainly talk about what potentially those latter -- those additional studies might look like. And believe me, as you know, those partners will be looking at those as well.\\nBut we'll start to see it pretty soon on what those data are showing us. And hopefully, we believe certainly that those data will be quite good, and we'll see where that lands us.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nThank you very much, guys.\\nGlenn Mattes -- President and Chief Executive Officer\\nBut one thing to note, Jonathan, we have not budgeted for additional trials. So the assumption here is that, the partner would take those -- if those trials needed to be done, would do those trials.\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nUnderstood. Thank you.\\nGlenn Mattes -- President and Chief Executive Officer\\nThank you, Jonathan.\\nOperator\\nThe next question comes from Daniel Carlson with TW Research Group. Please go ahead.\\nDaniel Carlson -- TW Research Group -- Analyst\\nHey, Glenn. Thanks for taking the questions. First off, you're making great progress it appears and bringing in MTAs and potential partners there. But we're still looking at preclinical stuff.\\nAnd in the past, you've mentioned some pretty large numbers associated with getting these partners into full license agreement. So I'm just wondering, what is the big hurdle in getting from preclinical to in-human trials? And is it the terms or are they too tough? Or just trying to figure that one out?\\nGlenn Mattes -- President and Chief Executive Officer\\nNo, the terms are not an issue, Daniel. When we engage with a company, Chris is very clear what the expectations are and what the relationship would look like. So in discussions that we've had with companies that are closer to the finish line and terms are discussed, certainly, there's some negotiation there. But that -- we don't see that as a rate limiting step.\\nAnd we're -- that's really the bottom line. We're maturing the data before any company is willing to write a check and license it. They want to be sure that we've answered all their clinical questions, and that's where we're at. And sometimes it moves a little bit slower than we want, but the data are being seen in a very positive light.\\nAnd we don't see the financials as being an obstacle.\\nDaniel Carlson -- TW Research Group -- Analyst\\nGot you. That's good news then. The next question I have is like once again, in the past, you've mentioned that you've never lost a bake up, and I'm sure that a lot of these companies are looking at everything out there. And certainly, there has been a lot of stuff in the press about other people trying nasal vaccines, etc.\\nSo I'm just wondering, is it still the case that every one of the companies you're talking to has not moved forward with alternative technologies and do you guys are still in the running?\\nGlenn Mattes -- President and Chief Executive Officer\\nI can't say that they know of any company that informed us that they've moved forward with an alternative technology. There have been a few companies that have decided to stick with the base program before moving on to Thin Film Freezing. We've seen a little bit of an uptick in that, Daniel, in full transparency in these tough times in the capital markets where if things were better, I think these are the smaller- to medium-sized companies. They go into the capital markets to raise funding to do the project.\\nSo for a few of them we're on hold. But it's become pretty routine and it's almost predictable. Chris and I sit on these calls, you know they're comparing us to the standard lyophilization approaches. And that's why, frankly, I have Bill to do -- provide me with some of the specific data from his trials and publications to reassure the investor that we continue to produce outstanding data better than what you can see with the alternative modalities.\\nAnd that's now even going beyond, we will or even like three to six months ago looking at nasal delivery or a Dale is doing on the DARPA program. So that was a little bit of a different approach today, but those four papers that I cited and there are others where we're actually using partners' materials, I think give great evidence to that.\\nDaniel Carlson -- TW Research Group -- Analyst\\nYes. I was going to ask you about the papers that you published and just what they mean for your commercialization efforts.\\nGlenn Mattes -- President and Chief Executive Officer\\nBill, do you have a perspective on that?\\nBill Williams -- Scientific Consultant\\nI do. Yes. That's a great question. So our strategy has always been to -- and you can follow our papers is, we are -- our papers are the way that we teach our partners and potential partners about our technology and about potential uses that they can imagine with their compounds that they're working on, they can imagine it in our technology.\\nAnd so, we look for problems. We look for -- we're very aggressive in studying competing technologies and finding holes in competing technologies where our Thin Film Freezing sits in, and then our papers are a way that we leverage that with partners and potential partners. So it's a critical part of commercialization. And one last thing is, when we have our calls that Chris Cano and others set up, I mean, we're talking with the company's top scientists and they're all science-driven at the point we're talking to them.\\nAnd so, they want to see our data, they want to see it in publications and also publishing like this, it's a key part for our -- for the company.\\nDaniel Carlson -- TW Research Group -- Analyst\\nGot you. And then, Glenn, one last question for me. It looks like -- I think you put some new logos in your slide deck, and you've got three new MTAs or top 20, you mentioned. How does it -- is there a criteria for getting in there, you hitting a certain level of relationship? Or why are some companies in there and others not?\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. So Daniel, we certainly don't even approach the subject until we think we have on a meaningful path. The bigger companies are really, really reluctant to do that. We've had some breakthroughs there.\\nI think those are symbolic of sort of where we're at in terms of the work we're doing with them. We don't fight too hard as they say, no, look, we don't want to do anything to upset the Apple cards here. But when it's appropriate and when we think it's at a reasonable time, we will ask and -- but don't take it that if the logo isn't on there, it doesn't mean that we're in a pretty good place in terms of where we are in working with those companies. So it's -- we started that as a practice of where we can, putting companies or academic institutions on the slide.\\nWe'll continue to look for opportunities to do that. It just as an indication that we're moving forward. And in this quarter, I wish I can tell you who we signed up with and have new MTAs with, very exciting. But again, realize those three are starting from the starting line, and it won't happen in the next quarter, but hopefully soon enough.\\nDaniel Carlson -- TW Research Group -- Analyst\\nGreat. Thanks, guys. Looking forward to second half here. A lot of exciting stuff coming.\\nGlenn Mattes -- President and Chief Executive Officer\\nThank you. Operator, do we have any more questions?\\nOperator\\nWe do. The next question comes from Michael Okunewitch with Maxim Group. Please go ahead.\\nGlenn Mattes -- President and Chief Executive Officer\\nVery good. Thank you.\\nMichael Okunewitch -- Maxim Group -- Analyst\\nHey, guys. Thank you for taking my questions. So, I guess, my first question, I'd like to think a bit big picture and just see, given that you've had a lot more partner interaction in particular on the big pharma side, if you could talk about what kind of feedback you're getting on what specifically attracted them to the TFF platform as opposed to other inhalable technologies?\\nGlenn Mattes -- President and Chief Executive Officer\\nGood question. Chris, you probably have more of the initial calls. Can you answer that question, please?\\nChris Cano -- Chief Operating Officer\\nYes, sure. Thanks, Michael, for the question. So when we're dealing with a big pharma company, right, and engaging with them in discussions, there's usually a product that's been identified, usually a biologic that has a challenge. And so, we -- before we even engage with that partner, we do some diligence, we look at their pipeline and then we come to them with a solution to their problem.\\nAnd so, whether it is right for inhalation, whether it is for cold chain, now we're even exploring, as we've talked about, intranasal, it really depends on what the partners' program, what their challenge is, and that's where we really focus our efforts because our dry powder offers the solution to their problem.\\nMichael Okunewitch -- Maxim Group -- Analyst\\nYes, very much so. And then, just as a follow-up, in terms of that collaboration activity, I'd like to just ask where you see the partners looking to apply the technology. Is this -- are you more looking at reformulations of drugs that are already approved in life cycle management and just improving the profile of their existing products? Or is it more so novel drugs in their pipeline that would work better once you apply the tech?\\nGlenn Mattes -- President and Chief Executive Officer\\nYes. So it's a good question. So when I started here almost five years ago and I recruited Chris, that come in shortly after. If you would ask this then, this question, I certainly would have said it would be more reformulation.\\nAnd -- but now as we sit here today, I'm going to -- I don't have an exact pie chart in front of me. I'd say it's about 80% NCEs and biologics and about 20% to 25% reformulation. Chris, you can -- if I'm way off, you can correct me, but I think that's a fair assessment of where we're at. It's come out much differently than I originally thought.\\nWe started to reach out to different kinds of companies when we started this. And then, slowly as we began to introduce the technology to companies as well, this is where this whole biologics set of opportunities really exploded for us. And what's unique about that, too, Michael is, we have seen some situations where we've gone as far as successfully formulating, getting into animals and then that new chemical entity isn't quite what the partner wants to see in terms of the outcome. And they'll give us another set of materials in a biologics space.\\nSo you do like it's kind of out of our hands there because we've done everything we need to do from a technology standpoint. And sometimes, it's come down to, wait a minute, their compound didn't really produce the kind of results that they needed. So it takes you back. They don't walk away from us, but it takes you back to the starting line again.\\nMichael Okunewitch -- Maxim Group -- Analyst\\nThank you. And I really appreciate the additional color and congrats in the progress over the quarter.\\nGlenn Mattes -- President and Chief Executive Officer\\nThanks, Michael. It's really -- again, I wish as I sit here today, I could tell you who these top 20s are and what we're working on because it's incredibly exciting. So I see that I think we have exhausted the list of questioners, and we're about at the end of the hour. I want to thank all of you for listening.\\nI want to hope -- I wish you all an enjoyable rest of the summer, and stay healthy. And we really do look forward to ongoing discussions with you. And before or if not, at least at the time we report our third quarter results. Thank you very much.\\nOperator\\n[Operator signoff]\\nDuration: 0 minutes\\nCall participants:\\nCorey Davis -- Investor Relations\\nGlenn Mattes -- President and Chief Executive Officer\\nKirk Coleman -- Chief Financial Officer\\nJonathan Aschoff -- ROTH Capital Partners -- Analyst\\nDale Christensen -- Director of Clinical Development\\nDaniel Carlson -- TW Research Group -- Analyst\\nBill Williams -- Scientific Consultant\\nMichael Okunewitch -- Maxim Group -- Analyst\\nChris Cano -- Chief Operating Officer\\nMore TFFP analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, and welcome to the VMware Third Quarter Fiscal Year 2022 Earnings Conference Call. Today's conference is being recorded.\\nAt this time, I'd like to turn the conference over to Mr. Paul Ziots, Vice President of Investor Relations. Please go ahead, sir.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you. Good afternoon, everyone, and welcome to VMware's third quarter fiscal year 2022 earnings conference call. On the call, we have Raghu Raghuram, Chief Executive Officer; and Zane Rowe, Executive Vice President and Chief Financial Officer. Following their prepared remarks, we will take questions.\\nOur press release was issued after close of market and is posted on our website where this call is being simultaneously webcast. Slides which accompany this webcast can be viewed in conjunction with live remarks and downloaded at the conclusion of the webcast from ir.vmware.com.\\nOn this call today, we will make forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially as a result of various risk factors described in the 10-Ks, 10-Qs and 8-Ks VMware files with the SEC. We assume no obligation to and do not currently intend to update any such forward-looking statements.\\nIn addition, during today's call, we will discuss certain non-GAAP financial measures. These non-GAAP financial measures, which are used as measures of VMware's performance, should be considered in addition to, not as a substitute for or in isolation from GAAP measures. Our non-GAAP measures exclude the effect on our GAAP results of stock-based compensation, employer payroll tax and employee stock transactions, amortization of acquired intangible assets, realignment charges, acquisition, disposition, certain litigation matters and other items, as well as discrete items impacting our GAAP tax rate. You can find additional disclosures regarding these non-GAAP measures, including reconciliations with comparable GAAP measures, in the press release and on our Investor Relations website.\\nThe webcast replay of this call will be available for the next 60 days on our Company website under the Investor Relations link. Our fourth quarter fiscal 2022 quiet period begins at the close of business, Thursday, January 13, 2022.\\nWith that, I'll turn it over to Raghu.\\nRaghu Raghuram -- Chief Executive Officer\\nThanks, Paul. I am pleased with the continued strong performance in Q3 fiscal year 2022 with revenue of $3.2 billion and non-GAAP earnings of $1.72 per diluted share. Earlier this month, we successfully completed our spin-off from Dell Technologies. As a stand-alone Company, we have more strategic and financial flexibility to deliver on our multi-cloud strategy. We are also able to partner even more deeply with all the cloud and on-premise infrastructure companies to create a better foundation that drives results for our customers.\\nCustomers continue to choose VMware as their trusted digital foundation to accelerate their innovation, and we continue to expand and advance our portfolio to meet their needs in these three ways: one, deliver a cloud-native app platform for building modern applications in a public cloud-first world; two, migrate enterprise applications to a cloud-agnostic infrastructure; and three, build out the secure edge to optimize across our workspace and edge-native applications. These three focus areas are built on a horizontal set of offerings across networking, security and management. It's clear that multi-cloud will be the model for digital business for the next 20 years and in this vibrant dynamic marketplace, the pace of innovation is relentless. VMware is at the center of it.\\nIn the modern app space, we recently provided the Department of Education for one of America's largest cities with application resiliency as part of their business continuity project. Leveraging VMware Tanzu, the customer now has improved ability to respond to ever-changing needs of students, their families and faculty while protecting student information and creating an environment to accelerate their innovation and automation. One of our new beta offerings in the space is the Tanzu Application Platform, which will make it easier and simpler for developers to drive productivity and velocity in a more secure fashion on any cloud. Our Tanzu portfolio is now one of the most comprehensive in the industry for both Kubernetes operations and developer experience. We also recently unveiled Tanzu Community Edition, a freely available, easy-to-manage Kubernetes platform for learners and users, and Tanzu Mission Control Starter, a multi-cloud, multi-cluster Kubernetes management solution available as a SaaS service.\\nWe are pleased to share some customer stories in support of our VMware Cloud services across the hyperscalers. PennyMac, a leading financial services firm is leveraging VMware Horizon on VMware Cloud on AWS to provide loan officers and call center agents a more secure work-from-anywhere virtual desktop in a fully automated and scalable cloud environment. We also worked with the University of Miami, who looked to the Azure VMware solution to support their VMware workloads on their preferred public cloud provider.\\nRecently, we announced new advancements for VMware Cloud, the industry's first and only cloud-agnostic computing infrastructure. Newly unveiled Project Arctic will bring the power of cloud to customers running VMware vSphere on-premises. It will enable cloud-based management for hundreds of thousands of vSphere customers and vSphere deployments around the world. Customers will be able to benefit from life cycle management, cloud disaster recovery and cloud burst capabilities as an extension of their vSphere deployments. We will bring Project Arctic to market next year as the next step in making our portfolio available in a subscription and SaaS form factor.\\nWe also announced VMware Sovereign Cloud initiative, where we are partnering across our VMware Cloud providers to deliver cloud services on a sovereign digital infrastructure to customers in regulated industries.\\nLastly, we introduced a tech preview of an exciting new management technology, Project Ensemble. It is designed to manage apps across multiple public clouds, bringing together a comprehensive set of costs, security, automation and performance capabilities for the public cloud environment.\\nVMware was once again ranked number one in the September 2021 IDC report titled Worldwide Cloud System and Service Management Software Market Shares, 2020: Growth Continues for the Top Vendors. In the area of Edge, we recently helped an international wholesaler with 800 stores across 30 countries to refresh its decade-old in-store platform. The VMware Edge Compute Stack is now serving as a single platform for both the customers existing and modern applications, offering a right-sized resilient solution that is providing ROI for their business. As a continued commitment to helping our customers at the Edge, we recently introduced VMware Edge, a product portfolio that will enable organizations to run, manage and better secure edge-native applications across multiple clouds anywhere. Together, VMware Cloud, Tanzu, VMware Edge and Anywhere Workspace offer our customers a solution for all of their applications across their multi-cloud environment.\\nIn the security space, VMware is delivering solutions built specifically for threats customers face today. We use the power of software, combined with a scaled-out distributed architecture, zero trust design principles and a cloud delivery model for better security that's easier to use. We are excited about our continuing innovation in SASE, Secure Access Services Edge, especially as many businesses are now working as a distributed workforce. We also announced the industry's first elastic application security edge, which enables the networking and security infrastructure at the data center or cloud edge to flex and adjust as app traffic changes. In the third quarter, VMware was positioned as a leader in The Forrester New Wave: Zero Trust Network Access Q3 2021.\\nOn the telco front, Vodafone recently selected VMware to deliver a single platform to automate and orchestrate all workloads running on its core networks across Europe, starting with 5G stand-alone. This recent work builds on Vodafone's previous selection of VMware Telco Cloud Infrastructure as its network functions virtualization platform.\\nIn the third quarter, VMware received additional recognition from leading industry analyst firms, once again being named as a leader in the August 2021 Gartner Magic Quadrant for Unified Endpoint Management Tools. Additionally, VMware was once again named a leader in the September 2021 Gartner Magic Quadrant for WAN Edge Infrastructure. Our innovation engine is thriving as we bought many of these new offerings, features, beta programs and partnerships to the forefront during VMworld 2021, which attracted approximately 116,000 registrants. We look forward to hosting VMworld China and VMworld Japan in the coming weeks.\\nOur environmental, social and governance agenda continues to be very important to us and core to our culture. VMware received recognition for our ESG leadership by being included in the Dow Jones Sustainability Indices, one of the world's leading ESG benchmarks for the second consecutive year.\\nIn summary, we strive to serve our customers in three unique ways: by being the trusted foundation for their most critical business operations; by offering a best-of-breed, innovative portfolio of best-in-class solutions to fulfill their multi-cloud vision; and by having a broad set of strategic partnerships required to unlock the full potential of multi-cloud.\\nI'll now turn it over to Zane for more detail on our business performance, as well as our forecast.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nThank you, Raghu. We are pleased with our Q3 financial performance, which exceeded our initial expectations and is a continuation of the good performance we've seen all year. We saw solid demand in the quarter and continued to execute on our multi-cloud strategy.\\nTotal revenue for Q3 was $3.2 billion. Combined subscription and SaaS and license revenue grew 16% year-over-year totaling $1.5 billion, ahead of our guidance. Subscription and SaaS revenue of $820 million was up 21% year-over-year, in line with our expectations, representing 26% of total revenue for the quarter. Subscription and SaaS ARR was $3.3 billion, up 25% year-over-year in Q3. Our largest contributors to subscription and SaaS were VCPP, Tanzu, EUC, Carbon Black and VMware Cloud on AWS, which saw strong double-digit year-over-year growth in revenue and ARR. License revenue in Q3 grew 11% year-over-year to $710 million. The strength we saw was due to good execution in the quarter and our broad installed base of customers that see us as the trusted ally for their mission-critical workloads. Our strategy is resonating with our customers who are confident that their investments can be leveraged over the longer-term in multi-cloud environments.\\nOur non-GAAP operating income for the quarter of $935 million was driven by our revenue performance and lower-than-expected growth in expenses. Non-GAAP operating margin for the quarter was 29.3% with non-GAAP earnings per share of $1.72 on a share count of 422 million diluted shares.\\nWe ended the quarter with $10.2 billion in unearned revenue and $12.5 billion in cash, cash equivalents and short-term investments, which includes proceeds from our $6 billion bond issuance. The bond issuance proceeds together with $4 billion of additional borrowings from term loan commitments, as well as other available cash on hand was used to fund a special dividend of $11.5 billion. The special dividend was paid on November 1 to all stockholders of record on October 29 in conjunction with our spin-off from Dell Technologies.\\nQ3 cash flow from operations was $1,090 million and free cash flow was $984 million. RPO was $11.1 billion, up 9% year-over-year, and current RPO was $6.2 billion, up 11% year-over-year. Total backlog was $124 million, substantially all of which consisted of orders received on the last three days of the quarter that were not shipped and orders held due to our export control process. License backlog at quarter end was $34 million.\\nWe are pleased with the overall bookings performance in Q3 as we continue to scale our subscription and SaaS offerings. We saw strong year-over-year product bookings growth in major product categories. Core SDDC product bookings increased over 20% year-over-year. Compute was up low-double digits, and Cloud Management was up strong double digits year-over-year. Both of these were helped by our multi-cloud subscription and SaaS offerings. We saw momentum in VMware Cloud, which includes hyperscalers such as Amazon, Microsoft, Google and Oracle. We also continue to drive innovation in new product offerings across our Carbon Black Cloud and Tanzu platforms.\\nNSX increased in the low double digits versus Q3 last year, and vSAN grew in the high-teens year-over-year. EUC product bookings, as well as sub and SaaS ACV bookings were up in the strong double digits year-over-year.\\nIn Q3, we repurchased approximately 1 million shares in the open market at an average price of $150 per share. In early October, our Board of Directors authorized up to $2 billion of stock repurchases through FY'24, which replaced the relatively small balance remaining on our prior authorization.\\nAs a part of our capital allocation framework, we plan to use our cash generation and balance sheet to invest in growing our business both organically and inorganically, paying down debt and returning excess capital to shareholders through share repurchases. In addition, we are committed to maintaining an investment-grade credit profile and rating.\\nTurning to guidance for fiscal 2022. We're increasing our expectation for total revenue to $12,830 million, a growth rate of approximately 9% year-over-year. We expect the combination of subscription and SaaS and license revenue to total $6,305 million, an increase of approximately 12% year-over-year. Approximately 50.5% of this amount is expected to be subscription and SaaS.\\nWe are increasing guidance for non-GAAP operating margin for the full-year to 30% and non-GAAP earnings per share to $7.19 on a diluted share count of 422 million shares. We're also increasing our cash flow from operations guidance to $4.1 billion and increasing free cash flow expectations to $3.7 billion. This reflects our performance in Q3 combined with our outlook for FY'22.\\nFor Q4, we expect total revenue of $3,510 million or a growth rate of approximately 7% year-over-year. We expect $1,875 million from subscription and SaaS and license revenue in Q4 or an increase of nearly 9% year-over-year with approximately $860 million from subscription and SaaS, reflecting the current pace of adoption of our subscription and SaaS offerings.\\nWe expect non-GAAP operating margin to be 30.4% for Q4 with non-GAAP earnings per share of $1.96 on a diluted share count of 422 million shares. Additional guidance details for Q4 and FY'22 are contained in the slide deck accompanying this call.\\nWe typically provide some color on our upcoming fiscal year at this time. We are driving innovation across the portfolio, scaling our subscription and SaaS offerings and progressively making our products available as subscription and SaaS. Consistent with the outlook framework we presented at the Financial Analyst Meeting last month, we currently expect total FY'23 revenue to grow in the high-single digits while we continue to build out our subscription and SaaS portfolio. We are planning on growing our sub and SaaS revenue to nearly 30% of total revenue with our FY'23 exiting ARR growth rate exceeding FY'22's. We expect non-GAAP operating margin of approximately 28%, which is similar to our initial outlook for FY'22, reflecting continued investments in subscription and SaaS and the resumption of more normalized level of T&E as we support our customers.\\nIn closing, we are pleased with the progress we are making on our multi-cloud strategy as reflected in our performance this quarter and in our outlook for FY'22 and FY'23. As a stand-alone Company, we are well positioned to enable our customers' multi-cloud journey and become the multi-cloud leader.\\nI'll now turn it back to Paul for Q&A.\\nPaul Ziots -- Vice President, Investor Relations\\nThanks, Zane. Before we begin the Q&A, I'll ask you to limit yourselves to one question consisting of one part so we can get to as many people as possible. Operator, let's get started.\\nQuestions and Answers:\\nOperator\\nThank you. [Operator Instructions] And we will take our first question from Matt Hedberg with RBC Capital Markets. Please go ahead.\\nMatthew Hedberg -- RBC Capital Markets -- Analyst\\nHey, guys. Thanks. Great. Perhaps [Phonetic] congrats on the results and completing the spin first of all. I don't know, maybe Zane for you. License revenue was a bit better than we thought. You sort of talked about that in your script, but subscription and SaaS was maybe a little lighter, just a tad lighter than we thought. I'm wondering, could you help us with a little bit more color on what drove that mix. And as we think about subscription and SaaS trends accelerating into fiscal 2023, are there things that you guys are doing, like sales incentives or partner incentives to drive subscription and SaaS?\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nYeah. Matt, thanks for the question. And I'll start and then, obviously, happy to hand over to Raghu to talk a little bit more about where we are looking into Q4, as well as next year. First off, I'd say, this was well within the framework that we discussed at the analyst meeting last month. So we're really pleased with the outperformance that we saw for the whole Company in Q3. As you highlighted, license came in much stronger. We had a number of deals over $10 million that exceeded our expectation in the quarter.\\nAnd our sub and SaaS performance came in, in line. So we're actually pleased with the increase that we've seen there. We had, as I mentioned, a nice healthy increase on a year-over-year basis, ARR 25% year-over-year. So everything was going according to plan for both the third quarter and the full-year as it relates to the sub and SaaS. We just continue to develop those products. We've highlighted the improvements and increases we've made in some of those segments that Raghu will get into. But generally, we're pleased. We're seeing some of the same trends that we highlighted in Q3, along the term of where we see the license in some of our products like Horizon, where customers are choosing the term license versus some of the sub and SaaS offerings, but nothing different from the trend that we saw in Q3 and our expectations heading into next year.\\nMaybe, Raghu, if you want to touch on how we think about the product development over the course of Q4?\\nRaghu Raghuram -- Chief Executive Officer\\nYeah, definitely. We are very excited about the product portfolio as it is laying out for us. So, as we have talked before that we look at our product portfolio on the SaaS and subscription side in three buckets. One is the pure SaaS and subscription offerings, 100% SaaS and subscription. We expect them to start to reach scale and start to impact our growth even in a much bigger fashion.\\nSecondly, we have a set of products that we call customer choice, basically meaning the customers can choose to get them in a perpetual or a term license form factor or in a subscription form factor. And this includes products like our Cloud Management, which are growing really well for us.\\nAnd then thirdly, products today that are primarily licensed, our core SDDC offerings that we'll be progressively making available as a subscription and SaaS next year. And we announced the first of those with the Project Arctic, and we believe they will start to contribute in the coming years as well. So the combination of these three will drive the product portfolio even more to subscription and SaaS and drive its growth.\\nAnd then last but not the least, we'll be tailoring our go-to-market programs, including our sales place and incentives and so on and so forth to drive all of these product shifts.\\nPaul Ziots -- Vice President, Investor Relations\\nThanks, Matt. Next question, please.\\nOperator\\nThank you. We'll hear next from Mark Murphy with J.P. Morgan.\\nMark Murphy -- J.P. Morgan -- Analyst\\nYes. Thank you. And I will add my congrats on a very nice performance. Raghu and Zane, so we've shown that your partner ecosystem is clearly positive and upbeat regarding the spin-off from Dell. I'm wondering, how is that excitement manifesting at this stage? And understanding it's very early stage, but can you sense partners perhaps mobilizing to staff up or bulk up on VMware-certified personnel? Maybe they're planning to lean in on co-marketing, co-selling next fiscal year. Just curious if there's any leading indicators that give you a sense of a tailwind that might be developing sometime during next fiscal year.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So, as you pointed out, it's pretty early. We're still in month one of the spin and being a stand-alone Company. Having said that, a lot of what you have said is exactly what we are seeing from the partners. We are seeing a sense of excitement and possibility from the partners. There are partners that are already planning to or starting to staff up on their VMware expertise. We are talking to other partners about what we could do to help them further in the markets where we could have joint solutions. So all these conversations have started happening, and these all have different timeline depending upon whether they are purely go-to-market or they involve technical collaboration and joint solutions, etc., etc. So I do expect that you will start to see some results over the course of the next year. Like I tell our internal employees, day one for us post-spin may not look very different, but day 365, you'll certainly start to see the benefits of it. And so, that's where we are.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Mark. Next question, please.\\nOperator\\nThank you. We'll hear next from Raimo Lenschow with Barclays.\\nRaimo Lenschow -- Barclays -- Analyst\\nHey. Thanks for taking my question, and congrats from me as well. Can I go back to Matt's question a little bit in terms of pragmatics? As you talk with your clients, but as you also think about the sales and incentives, the change in incentives next year a little bit, what do you see in terms of clients' understanding appreciation of your subscription, SaaS offering versus taking the choice around more of the license part? Because that's the one thing that everyone is focusing on, and it feels like you don't getting as much credit for the license part. So where are clients is coming out of the pandemic kind of their focus more to do more license again? Or how do we have to think about it? How can you influence that as well? Thank you.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. Thanks, Raimo. I'll start and then Sumit can add additional color as well. So, what I would say from our customers' point of view, it depends on a couple of factors. One is the product category that we are talking about. For example, if you think about Cloud Management, there is definite decided industry shift toward consuming management as a SaaS service. So we are seeing -- that's part of the reason why we are seeing our SaaS offerings and subscription offerings for management grow very nicely.\\nIf you think about our core universal offering, which is for the infrastructure, that is designed to help customers on their journey to the cloud. So very often, they are starting on-premise with licensed software. And then over a period of time, they intend to shift to the cloud. And then in terms of the third big bucket, which is the end-user computing, it depends on the customer segment.\\nAnd let me give it over to Sumit to add more color.\\nSumit Dhawan -- President\\nYeah. Hi, Raimo. How are you? First of all, I would say....\\nRaimo Lenschow -- Barclays -- Analyst\\nHey, Sumit.\\nSumit Dhawan -- President\\nHey. First of all, I would say that Q3 in addition to the results that Zane and Raghu talked about was a great quarter for us in terms of engaging with customers through our VMworld event, introducing all of our new offerings. And the momentum on that front with customer front is great because it's clear for customers as they're looking at their own strategies for cloud and multi-cloud, VMware becomes their key partner going forward. And on that, many of their -- how they build their multi-cloud control plane, whether it's through our Cloud Management software, Tanzu solutions, as well as cloud infrastructure to be served from multi-cloud, VMware gives them the right platform to do so.\\nSo, now to arrive at that solution, our universal programs gives them the best choice and flexibility to adopt subscription and SaaS and adopt cloud at their own pace. And we are continuing to see very, very strong interest and pull from customers and going toward multi-cloud using our universal offers, where they can start adopting our cloud solutions gradually as they're ready and they're not sort of having to spend double costs, if you may, where they have to run both on-premise and cloud and double pay. They can just transition to the cloud solutions and our subscription, SaaS offerings using our universal offers at their own pace and speed.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Raimo.\\nRaimo Lenschow -- Barclays -- Analyst\\nThank you.\\nPaul Ziots -- Vice President, Investor Relations\\nNext question, please.\\nOperator\\nThank you. We'll take our next question from Mark Moerdler with Bernstein Research.\\nMark Moerdler -- Sanford C. Bernstein & Co. -- Analyst\\nThank you very much, and congrats on both the spin-out in the quarter. As we've discussed before, VMware is using term licenses as a bridge to the cloud, but you're not including that revenue in subscription or SaaS. So, can -- to help us better understand the impact, can you give us some breakdown of how much of the revenue we're seeing in the quarter is from license and maintenance is coming from those term licenses that could convert over to subscription and SaaS? Thank you.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nYeah. Mark, I'm happy to start with that. As you alluded to, we see the term licenses, in particular with our Horizon offering to be that step for many, if not, all of our customers to sub and SaaS. So we're very pleased with the performance we've seen there in offering our customers flexibility and allowing them with that transition. If you were to think about quantifying the term license amount, it's roughly 13.5% of our license for the quarter. So it's just under $100 million in total that is sort of qualified as term. And as you point out, unlike a number of others, we included in our license bucket. We don't necessarily expect this to increase significantly over the years, at least as we've outlined our strategy today. So we think it will moderate around this number. And then ultimately, as we highlighted in many, if not, all of our products, will rotate to more sub and SaaS. And we see this as a natural step for our customers in their sub and SaaS journey as well.\\nHopefully, that adds some color for you, Mark.\\nMark Moerdler -- Sanford C. Bernstein & Co. -- Analyst\\nYes, it does. And I really do appreciate. Thank you very much and have a happy, healthy Thanksgiving and holidays to everyone.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nOf course, thank you. You too.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Mark. Next question, please.\\nOperator\\nThank you. We'll hear next from Phil Winslow with Credit Suisse.\\nPhilip Winslow -- Credit Suisse -- Analyst\\nHi. Thanks guys for taking my question, and congrats on a strong quarter. Just wanted to focus in on core vSphere and in particular, vSphere 7 with Tanzu. Obviously, with that release, vSphere 7, you had a native support within vSphere of Kubernetes and containers. Kind of two questions here together. Could you give us sort of an update of adoption of vSphere 7 with Tanzu? And what are you hearing from customers about why they're using VMware?\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So I'll start and Sumit, perhaps you can add more. Yeah. So vSphere 7 has been in the market for a while, and we have seen very successful adoption of it. And besides the customers moving to the latest and greatest, the ability to run containers through Tanzu is a key reason why they adopt it. What we are seeing on-premise especially, is that, as customers tend to build out their private cloud and make it as compelling as a public cloud in terms of developer agility and so on and so forth, containers become a necessary part of the core infrastructure platform offering or Infrastructure-as-a-Code offering. So that's what we are seeing happen with our customers. So -- and a lot of the workloads that traditionally were running on VMs that are these mission-critical workloads are now being converted into containers and run on vSphere.\\nThe other thing that you might have noticed as we published on our benchmark sites as well is that, customers are finding they can get 6 times the density of running containers on vSphere as compared to running it on bare metal using alternative products. So not only the manageability benefits are appealing to them, because we are now supporting containers natively on vSphere 7, you're getting a tremendous density benefit, which obviously results in significant cost savings as well. So these are some of the reasons why customers are excited about it.\\nAnd in terms of some customer adoption patterns, let me hand it over to Sumit.\\nSumit Dhawan -- President\\nYeah. Hey, Phil. Customers as they're looking at Kubernetes, first of all, high interest and containers high interest, but they're in the journey of kind of early innings of expanding the adoption. And they're excited about using vSphere 7 as this platform where they can manage both VMs and containers holistically. So, I would say, from a customer adoption perspective, huge interest, still early stage. But vSphere 7 adoption and how customers are using those two technologies, both containers and VMs together, really good.\\nIn addition, we introduced Tanzu Community Edition at VMworld, which also complements really well our entire stack and works also with customers wanting to use Tanzu full-stack solution with public cloud Kubernetes distribution. And the adoption of our Tanzu Kubernetes Edition that we introduced at VMworld has been stellar over the course of last six to eight weeks. So I'd say customer adoption, even though early stage, tons of interest in both vSphere 7, as well as Tanzu Community Edition, which gives us great promise for potential growth in the Tanzu portfolio over time.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Phil. Next question, please.\\nOperator\\nThank you. We'll hear next from Simon Leopold with Raymond James.\\nMauricio Munoz -- Raymond James -- Analyst\\nThank you for taking my question. This is Mauricio in for Simon. Can you please talk about the -- some of these industry supply shortages and how could this impact in VMware sales? I'm a bit curious about -- on the potential headwind from customers that are perhaps unable to get the systems that VMware runs on. So with the understanding that you sell software, are you seeing any impact from these hardware shortages that could be limiting your sales? Thank you.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So as you note, there are chip shortages that are impacting significant portions of the economy. We have not seen -- like you point out, we are in the software business, and we have not seen it significantly impact our business so far. And a lot of the customers run our software on their existing infrastructure. And even in the cases where they're -- as well as in the cloud, and this is, in fact, one of the benefits of our solution being available across all the clouds. And then even in those cases where they're putting our software on to new hardware, they have not reported on new shortages.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Maurice. Next question, please.\\nOperator\\nThank you. We'll take our next question from Brad Reback with Stifel.\\nBrad Reback -- Stifel -- Analyst\\nGreat. Thanks very much. Zane, I think last quarter, you talked about some of the hyperscaler-led business leading to longer rev rec. And I would assume that would be in the subscription and SaaS line. Did you see any of that this quarter?\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nHey, Brad. Yeah, this is Zane. We continue to see great growth in that area, not only on the bookings side, but now you're starting to see the traction. I mentioned in my prepared remarks, across all the hyperscalers, we're really pleased with the traction we're seeing. To your point, that does create a little bit of the delay between the bookings growth that we see and then ultimately when we see that consumption and recognize the revenue. So, I'd say, generally speaking, it's been consistent, but we're impressed with the demand we're seeing. And the interest, back to the earlier question on partnerships, that's another area where we see continued interest on partnerships and tremendous opportunity for us with our multi-cloud opportunities. So all good on that front.\\nThanks for the question, Brad.\\nBrad Reback -- Stifel -- Analyst\\nThanks.\\nPaul Ziots -- Vice President, Investor Relations\\nThanks, Brad. Next question, please.\\nOperator\\nSo we'll take our next question from Tyler Radke with Citi.\\nTyler Radke -- Citi -- Analyst\\nHey. Good afternoon. Thanks for taking my question. I wanted to ask you about the Q4 guidance. It looked like on the license side, the upside didn't fully flow through. Just curious if there was any type of kind of unusual activity you saw in Q3, whether pull-forward? And then just some comments overall, what you're expecting for fiscal year-end, just with budget flush and typical Q4 activity? Thank you.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nYeah. Sure, Tyler. It's a good question. As you point out, we increased the total guide, but we didn't obviously pull in -- take all of what we saw in Q3 into Q4. We're really pleased with our view of the second half of the year. And obviously, as you heard in our prepared remarks, as well as the commentary here, I mean, the macro is clearly supporting good growth across the Company, and we're quite encouraged with the momentum we're building across the portfolio. So, as we looked at it, we think our second half looks good. We were encouraged by our ability to execute in Q3. So there may have been a few deals that may have either landed in Q3 or Q4 that we saw in Q3, but we believe the demand is there. We're pleased with the execution across the Board and correspondingly with the guide.\\nSo I'll leave it at that, but obviously, we're encouraged by what we're seeing heading into Q4. And, obviously, with some of the high-level comments I provided for FY'23, we see that momentum continuing into the new fiscal year for us.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Tyler. Next question, please.\\nOperator\\nThank you. We'll hear next from Keith Weiss with Morgan Stanley.\\nKeith Weiss -- Morgan Stanley -- Analyst\\nExcellent. Thank you, guys, for taking the question and nice quarter. I was wondering if you could go back to the Project Arctic. And can you give us any guidelines in terms of how to think about the relative pricing for some of these SDDC solutions of what you're garnering from the customer in an on-premise environment and how that changes in a cloud environment when they start making that shift toward subscription and maybe not a cloud environment, but as they start making that transition to subscription? And relatedly, is that going to have any longer-term impacts on gross margins that we should be aware of when we're kind of forecasting out a couple of years?\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So, overall, with the Project Arctic, we are still in the very early days, and we don't have any pricing nor anything of that nature to disclose because we are not shipping the product yet -- shipping the cloud service yet. In general, because this is a cloud-delivered and cloud-managed service, usually, when we deliver something from the cloud managing some piece of software on-premise, there is a management premium that we had, and I would expect that to be present. The important aspect of Arctic is it also allows us to weave in things like disaster recovery and better security and so on and so forth. And those are additional capabilities that today are priced offerings that we would be able to as part of this upsell, as part of Project Arctic. So net-net, we expect this to be a win-win solution for the customer, helping them lower their management costs, also give them capabilities that they did not have before, lower their cost of insuring security, etc. And then from a VMware perspective, it will allow us to deliver more value to these existing customers.\\nAnd then the second aspect of your question around gross margin, again, we don't have operating -- actual operating experience because Arctic is not out yet, but we expect this to be a healthy gross margin business.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Keith. Next question, please.\\nOperator\\nThank you. We'll hear next from James Fish with Piper Sandler.\\nQuinton Gabrielli -- Piper Sandler -- Analyst\\nHey, guys. This is Quinton on for Jim. Thanks for taking our question. Maybe just for us, could we get an update on the team's appetite for acquisitions at this point? Are there opportunities to look at something a little bit larger, a little more transformational? Or do valuations today still push the team to more of a tech tuck-in type deal? Thank you.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So I'll start and Zane can add more. So from a VMware perspective, we've always had a fairly consistent philosophy with respect to acquisitions. By and large, the vast majority of what we do would be classified as tuck-ins or product-level acquisitions. And then occasionally, we do what we call platform level acquisitions, which we do when we enter into a new product segment, product category or expand significantly into a new adjacency. In fact, over the last, whatever, 15, 17 years of -- that we've been doing acquisitions, we have done only about four that were of that nature, over $1 billion. So I expect that pattern to continue. As you well know, we did two major acquisitions of that nature a couple of years ago, and we are still bringing them into the mainstream of our business and driving those product growth areas for us. So I expect the current pattern to continue going forward as well.\\nSo let me...\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nYeah. I would just add, as part of our capital allocation, obviously, we look at growing both organically and inorganically. And even with the debt that we've taken on and the special dividend, we believe we've got tremendous flexibility on the M&A front and continue to operate as we have in the past, as Raghu alluded to. So we're very comfortable with our positioning there.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Quin. Next question, please.\\nOperator\\nThank you. We'll hear next from Brad Sills with Bank of America Securities.\\nBradley Sills -- Bank of America -- Analyst\\nGreat. Thanks guys for taking the question here. I wanted to ask a question on some of the deliverables you outlined the launches at the Analyst Day for Tanzu Community Edition, Application Platform and Service Mesh Advanced Edition. I guess, in particular, there's a lot of innovation there. I guess, the Community Edition, should we think of that as a potential for driving some bottoms-up adoption here, where you see a real community develop here, open source users that you could see some upgrade activity from over time? Thank you.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah, for sure. A big goal for Tanzu Community Edition is for people that are coming new to Kubernetes, as well as developers that want to build on top of it. And in fact, over the first four to five weeks that we have had it available, we have had over 10,000 downloads. We've seen a nice community farming. And so, we are very encouraged by that, as well as the Tanzu Mission Control Starter Edition, which provides management capabilities at an entry level. So one aspect of VMware that is -- one aspect of our business that is critical when we get more and more developer and platform operator focus is product-led growth, and this would be the start of those initiatives.\\nBradley Sills -- Bank of America -- Analyst\\nThank you.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Brad. Next question, please.\\nOperator\\nThank you. We'll hear next from Brad Zelnick with Deutsche Bank.\\nBrad Zelnick -- Deutsche Bank -- Analyst\\nGreat. Thank you so much for fitting me in. My question is for Sumit. Sumit, it's now two quarters in a row where you've had more customers within EUC opt for term licenses versus subscription and SaaS. Is there something specific happening within VMware or within that particular product line that would explain for this? Or is there any reason to perhaps believe that customers are recommitting to self-managed infrastructure?\\nSumit Dhawan -- President\\nHi. Yeah. I think this is a little bit of a reflection of both timing, as well as choice. As with Horizon, we have given customers choice and flexibility for adopting the subscription and SaaS -- sorry, cloud products and cloud-based virtual desktops at their own timing and their own when they're ready. And they oftentimes start with term. And I think I've stated that in the past that each of these customers as we are signing them up with term-based license, they all have plans and intent to move their desktops to the cloud. And as the terms that they are signing up for come up for renewal is usually the time window when we get the opportunity to get them over to the cloud. And the window of the time when they sign up for term is just the duration it takes for them to plan moving their desktop to the cloud. So that's the best way for you to think about the business. There's really not sort of lack of intent or desire by customers to take their desktops to the cloud.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Brad.\\nBrad Zelnick -- Deutsche Bank -- Analyst\\nThank you.\\nPaul Ziots -- Vice President, Investor Relations\\nNext question, please.\\nOperator\\nThank you. We'll hear next from Brent Thill with Jefferies.\\nBill -- Jefferies -- Analyst\\nHey, guys. This is Bill [Phonetic] on for Brent. Thanks for taking our question. Just going off the previous question, given some of the noise recently around Citrix, just wanted to get a sense of what you're seeing on EUC and just in terms of win rates and if there has been any change at the margin there? Thanks.\\nSumit Dhawan -- President\\nYeah. I'll start and Raghu, you can add. First of all, we see tremendous interest in customers for our virtual desktop solution, and that's really the only category that we compete with Citrix. Our end user computing portfolio, first of all, is much broader than what Citrix offers. But oftentimes, customers who have had Citrix implementations and VMware's implementations for broader end user computing portfolio, not including virtual desktops. We are certainly seeing customers who, when they are looking at cloud-based desktop deployments, interest in standardizing on their broader workspace and end user computing portfolio with VMware. So we do see larger enterprises now looking at innovation from VMware and end user computing to be much stronger and more powerful. And we continue to see customers who have in the past used Citrix now looking at VMware Horizon solutions.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. Just to...\\nPaul Ziots -- Vice President, Investor Relations\\nThank you. Go ahead, Raghu.\\nRaghu Raghuram -- Chief Executive Officer\\nI have a couple of -- especially in this post-pandemic world that we live in, remote work has become a pretty significant part of the consideration when choosing these solutions. And we introduced an Anywhere Workspace solution that combines, obviously, the ability to run the desktops either in the data center or in the cloud, but also the ability to get network access and secure them through our SASE solutions, and of course, manage and provision applications. So it's a much more fuller solution with the cloud option that Sumit talked about. So that's very differentiated from Citrix.\\nPaul Ziots -- Vice President, Investor Relations\\nNext question, please.\\nOperator\\nThank you. We'll take our next question from Kash Rangan with Goldman Sachs.\\nKash Rangan -- Goldman Sachs -- Analyst\\nHi. Thank you very much. I'll add my congratulations as well. I wanted to just ask your perspective on the subscription and SaaS, and in particular, there are two important drivers strategically for the Company. One is the cloud provider partnership in particular. Wanted you to expand your comments, if you could? On AWS, what do you see in terms of the pipeline going ahead? Obviously, with re:Invent coming up the next week or so, how is that partnership with AWS progressing as far as the pipeline visibility is concerned? And also, if you could touch upon Tanzu, any big pivotal deals -- not pivotal, but pivotal Tanzu deals that are truly transformative that give you conviction that Tanzu is certainly headed strategically in the right path? Thank you so much and congrats.\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So on the -- and let me start and Sumit can talk about the pipeline. So with AWS, as you know, Kash, they are our preferred partner, and we do some deep engineering collaboration with them. And we continue to do that, and we've got a number of items planned in our roadmap. Over the next months or so, that will further expand the addressable set of workloads that can be served using our joint solution. So the partnership is going very well, and the two teams have been working very well.\\nAnd before I turn it over to Sumit for the pipeline, let me briefly touch upon the Tanzu question. Yeah, we -- if you think about what we are trying to do with Tanzu, we're trying to do two sets of things. One is, we are trying to provide a modern application operations team that's in the public cloud or in the private cloud with a comprehensive set of solutions that help them manage their modern application environment, their cloud-native environment, secure them and connect them. So our products like Tanzu Service Mesh, Tanzu Observability, of course, Tanzu Mission Control, all of them put together serve as a very comprehensive portfolio. And we have seen customers buy into it. One of the key reasons they buy into it is this breadth of portfolio.\\nThe second reason they buy into it is the fact that this is available to them regardless of where their network cloud data application is running. And we have got a number of wins on Azure. We've got a number of wins on AWS. Of course, we've got wins on top of vSphere as well.\\nAnd then the second part of the portfolio is the Tanzu Application Platform, which accelerates developer productivity on the public cloud of their choice. That is still on beta, so we don't have transformative wins to announce there as yet. But we are super excited about the reception to both. Sumit?\\nSumit Dhawan -- President\\nKash, I'd add on -- I'll start off with cloud providers. First of all, I'm excited about the portfolio expansion that we did on the VMware Cloud front during last quarter. Certifications to expand us to target larger sort of federal customer base sort of expansion of services and sort of zones where the service is available across all hyperscalers, newer services that we have introduced on VMware Cloud on AWS such as Tanzu now integrated, as well as VMware Cloud on AWS Outposts. So tremendous opportunity and all of that leads to new use cases that we are able to serve.\\nNow, in terms of wins that give you -- a win that gives you a picture of how we are winning with cloud services, the best sort of story that I would provide is, our financial services firm where they're now looking at our cloud to provide all their loan officers, call center agents, a full sort of service that is fully automated and scaled out through our cloud environment. And now trying to do that modernization in their own infrastructure would have required them to have talent and time, neither of which were possible without our solution. And that's what we are seeing as a predominant reason why customers are looking at our cloud infrastructure across all of our -- all the cloud providers as a predominant use of going to VMware Cloud solution.\\nAnd then for Tanzu, I think Raghu already touched. For modern applications using Kubernetes across multi-cloud, we are seeing customers start with either one module or adopt our full platforms that Raghu talked about in a very, very easy-to-adopt fashion at this point of time from Tanzu.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Kash. Next question, please.\\nKash Rangan -- Goldman Sachs -- Analyst\\nThank you, Raghu and Sumit. Thanks so much.\\nOperator\\nThank you. We'll hear next from Karl Keirstead with UBS.\\nKarl Keirstead -- UBS -- Analyst\\nGreat. Zane, I wouldn't mind pressing a little bit on your guide for high-single-digit revenue growth for fiscal 2023. That's impressive, a little bit higher than I was modeling. It's actually an acceleration from your exit growth rate of 7% in 4Q this year despite larger scale, despite what I'm sure are some pressures as you transition from upfront license maintenance to subscription. So I just wanted to see if you might unpack a little bit where that confidence comes from and ask two secondary questions, whether it might be more second half weighted and whether if you could confirm that it's entirely organic? Thank you.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nSure, Karl. I'll tell you, first off, we obviously give it at a high level, so I appreciate the commentary on it. So I'm not going to get into detail on first or second half. I will tell you, as we look at next year, to your point, it is a balance of us continuing to drive that growth, not only on the product side, but the go-to-market side and the operating side of our sub and SaaS portfolio. And then in conjunction with that, continue to deliver on the license portion and the on-prem portion of the portfolio, which as you saw in the third quarter, had really strong performance. And it's a combination of that -- our message resonating in the marketplace, the confidence our sales teams, and as you've heard here across the portfolio that we have -- with the products we have, and in particular, the multi-cloud message that's resonating with our customers and the momentum we're seeing for the year.\\nI mentioned sort of the second half. And then, obviously, heading into FY'23, we're confident that we can continue to see that growth on the mix between the on-prem and then continue to drive the sub and SaaS growth at an ARR that we believe will be stronger than the ARR we expect to see this year for all the reasons that Raghu mentioned. When we breakout each element of that portfolio and we look at the bookings performance and the pipeline performance that we're already seeing, a lot of the deals that Sumit's team are negotiating right now will be recognized as revenue into the new year. So a lot of that gives us the backdrop to the outlook that we believe we'll execute against for the next fiscal year, and obviously, more to come on our next call. But thanks for the question.\\nKarl Keirstead -- UBS -- Analyst\\nOkay. Thank you, Zane.\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nThanks.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Karl. We have time for one more question. So this would be the last question, please.\\nOperator\\nThank you. We'll take our next question from Keith Bachman with BMO.\\nKeith Bachman -- BMO Capital Markets -- Analyst\\nThank you very much. Good evening. Raghu, I wanted to see if I could direct this to you. In the past management, VMware management has talked about 80% of apps are running on the cloud -- running on-premise, 20% on cloud and over time that would invert. And I wanted to try to get a feedback on some of that growth is transitioning existing applications to the cloud, but a lot of it is the growth of new applications. And I want to hear your characterization of VMware's attach rates, ARR contribution and/or growth rates of new applications versus existing applications. What does that look like in terms of your ability to win for the new applications today in particular? And how would you think about that changing over the next year or two as Tanzu begins to -- or not begins to, but continues to mature?\\nRaghu Raghuram -- Chief Executive Officer\\nYeah. So as I've spoken about in the Financial Analyst Meeting, we are in an age of explosive growth with respect to applications. And we see applications growing, obviously, in the public cloud, in the data centers and private clouds and increasingly at the edge as well. I think by some industry analyst estimates, two out of three applications -- new applications are in the public cloud are a little higher, depending on which analysts you believe in. So for the applications that are going into the data center, given our preponderance in the data center and private cloud, they tend to invariably land on top of our platform -- the applications on top of our infrastructure platform. And then as we build out our Tanzu portfolio, they start to use Tanzu as well. Similarly, as applications go into the edge, we've got a pretty significant presence at the edge, and those applications tend to land on our platform as well.\\nThe applications on the public cloud, clearly, there's a large set of those applications landing on the Cloud Providers infrastructure. But as Tanzu gains more maturity and as we introduce new capabilities like Tanzu Application Platform, etc., we are seeing customers start to use that as well to make the task of building new applications on public clouds easier.\\nAnd then last, but not the least, with the VMware Cloud offerings on the public Cloud Providers, we are starting to see new applications land there as well because we just recently handed -- added Kubernetes capability to the VMware Cloud offerings. So as we build those out, we expect to see getting a good share of new applications on the public cloud as well. So on the whole, if you look at public cloud, data center, edge, we are well positioned to capture a good chunk of the new applications.\\nPaul Ziots -- Vice President, Investor Relations\\nThank you, Keith. Before we conclude, Raghu, I think you had a concluding comment to make.\\nRaghu Raghuram -- Chief Executive Officer\\nAbsolutely. Thanks, Paul. So thanks for the Q&A, and thanks for spending the hour with us. What I wanted to say in summary, VMware is committed to providing an ubiquitous software platform for our customers as they navigate to the multi-cloud and distributed era. We have a fantastic team, and we have a great portfolio that serves our critical customer requirements. And last but not the least, especially post-spin, we have a strong and growing ecosystem. So we are really well positioned to succeed.\\nThanks for joining us today, and have a great Thanksgiving.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 61 minutes\\nCall participants:\\nPaul Ziots -- Vice President, Investor Relations\\nRaghu Raghuram -- Chief Executive Officer\\nZane Rowe -- Chief Financial Officer and Executive Vice President\\nSumit Dhawan -- President\\nMatthew Hedberg -- RBC Capital Markets -- Analyst\\nMark Murphy -- J.P. Morgan -- Analyst\\nRaimo Lenschow -- Barclays -- Analyst\\nMark Moerdler -- Sanford C. Bernstein & Co. -- Analyst\\nPhilip Winslow -- Credit Suisse -- Analyst\\nMauricio Munoz -- Raymond James -- Analyst\\nBrad Reback -- Stifel -- Analyst\\nTyler Radke -- Citi -- Analyst\\nKeith Weiss -- Morgan Stanley -- Analyst\\nQuinton Gabrielli -- Piper Sandler -- Analyst\\nBradley Sills -- Bank of America -- Analyst\\nBrad Zelnick -- Deutsche Bank -- Analyst\\nBill -- Jefferies -- Analyst\\nKash Rangan -- Goldman Sachs -- Analyst\\nKarl Keirstead -- UBS -- Analyst\\nKeith Bachman -- BMO Capital Markets -- Analyst\\nMore VMW analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nGood day and welcome to The Kroger Co. second-quarter earnings call. [Operator instructions] I would now like to turn the conference over to Rob Quast. Please go ahead.\\nRob Quast -- Director of Investor Relations\\nThank you, Sarah. Good morning. Thank you for joining us for Kroger's second-quarter 2021 earnings call. I am excited to be here today and look forward to working with all of you in my new role as head of investor relations.\\nI am joined today by Kroger's chairman and chief executive officer, Rodney McMullen; and chief financial officer, Gary Millerchip. Before we begin, I want to remind you that today's discussions will include forward-looking statements. We want to caution you that such statements are predictions and actual events or results can differ materially. A detailed discussion of the many factors that we believe may have a material effect on our business on an ongoing basis is contained in our SEC filings.\\nThe Kroger co. assumes no obligation to update that information. Our press release and supplemental information regarding the quarter can be found on our website at ir.kroger.com. After our prepared remarks, we look forward to taking your questions.\\nI will now turn the call over to Rodney. \\nRodney McMullen -- Chairman and Chief Executive Officer\\nThank you, Rob and congratulations on your new role. I would also like to take a minute to thank Rebekah Manis for her service to the IR team. We wish her continued success in her new role as head of new geographies for our customer fulfillment centers. Finally, I would like to thank you all for joining us today.\\nOur associates have done an incredible job operating our stores, pharmacies, supply chain and manufacturing facilities through the COVID environment. Their unending commitment to serving our customers and communities continues to make a difference in Kroger's second-quarter identical sales without fuel grew 14% on a two year stacked basis, ahead of our internal expectations. We saw triple digit growth in digital over the same time period and continue to drive costs out of the business through cost saving initiatives and operational efficiencies. We remain confident in our positioning and our ability to deliver consistently attractive total shareholder returns of 8% to 11% over time.\\nI'd like to spend the next few minutes discussing three key areas. First, customer behavior and how our seamless ecosystem is working. Second, I'll share examples of how we are leading with fresh and accelerating with digital and finally, I will highlight how we continue to live our purpose to feed the human spirit through the associate experience and our work to advance Kroger's ESG commitments. Our strategic focus on leading with fresh and accelerating with digital continues to build momentum across our businesses.\\nAs we've operated through the pandemic, we've recognized the structural shifts in our customers' eating and cooking habits. Customers are responding favorably to our value proposition and are enjoying the convenience of our seamless offerings. Early in the quarter, customers visited stores more frequently and many shifted from online to in store. This highlights the relevance and convenience of our easily accessible footprint.\\nTowards the end of the quarter, as COVID-19 cases increased in many geographies, customers began shifting back to our digital solutions. This further demonstrates the strength of our seamless ecosystem. Customers can choose how they want to shop. Our job is to be available in every channel, so the customer does not have to compromise.\\nRegardless of how they choose to shop, customers are eating more food at home because it's more affordable, convenient and healthier than other options. While some food and home trends may be transitory, our research suggests those I highlighted are structural and Kroger is uniquely positioned to address them. Through our assortment of fresh products, world-class digital platform and innovative meal solutions, we will continue to elevate our position as a food authority so that when customers think food, they think Kroger. We continue to advance our position as a leader in fresh during the second quarter.\\nWe saw positive identical sales in produce and floral and deli bakery, even as we lapped elevated sales in 2020. Our research shows how much our customers love our brands. Sales for both simple truth and private selection brands were strong as food-at-home trends remained sticky. We continue to innovate within fresh.\\nFor example, our expanded partnerships with ghost kitchens allow us to offer customers freshly prepared, on-demand restaurant food. This is especially relevant at a time when many customers are looking for inspiration and 70% of our customers say convenience is important when cooking. We also announced our 2021 Go Fresh & Local Supplier Accelerator cohort and are already bringing innovative, locally and regionally sourced products to stores across the country and helping many small entrepreneurs achieve their dreams. Earlier this week, Kroger announced our new brand icon.\\nThe fresh cart icon brings together the Kroger Family of Companies under one unifying visual and reinforces our brand promise, fresh for everyone. We are very proud of our growth in digital, which increased 114% over the last two years, similar to our first-quarter growth. We remain on track to deliver against our 2023 digital growth and profitability targets introduced at our 2021 IR Day. While digital sales decreased 13% during the quarter, almost all customers who reduced their online spend during the quarter continue to shop with us in store, highlighting the power of our ecosystem and our ability to create a meaningful customer experience across all channels.\\nAs a short reminder, Kroger has doubled our e-commerce household penetration, increasing the number of our brick-and-mortar customers that engage with our digital solutions since 2019. During the quarter, we added over 340,000 new customers to our digital platforms. We continue to expand capacity across our footprint and we reduced wait times for Kroger pickup. As we look ahead, our seamless ecosystem will remain a competitive advantage as we offer what customers need and want in a way that fits into their life, whether it's shopping in our stores, picking it up at our stores, or getting it delivered or shipped directly to their homes.\\nWe continue to enhance our seamless ecosystem. As we've shared last quarter, we currently have two customer fulfillment centers open, which are expanding our capabilities in Ohio and allowing us to expand into the new geographies within Florida. We are happy with the performance thus far and are energized by the volume and growth in both sheds. In Ohio, our focus has been on evolving the customer proposition to maximize opportunities alongside our existing digital solutions.\\nIn Florida, we launched delivery savings pass, offering customers unlimited deliveries for just $79 per year. We continue to see incredible Net Promoter Scores and our customers tell us they love our friendly, professionally trained drivers and the refrigerated delivery vans that bring the freshest food directly to their doorsteps. Looking ahead, we remain on track to open six customer fulfillment centers over 2022 and 2023, which will further expand our seamless ecosystem. Before I share some specifics on how we are using data and personalization to grow the business, I thought it would be helpful to remind you about our rewards program and how it works.\\nOur rewards program has been active for over two decades. It captures data from 60 million households and 96% of our sales. Customers clearly see the value of our program, which drives sales and builds loyalty. As an example, nearly 60% of all items in a digital basket were added through our personalization science, highlighting our ability to make meaningful suggestions that surprise and delight customers.\\nFurthermore, when we personalize recommendations for our customers, we can reduce their time to shop by nearly 70%. Overall, one in three people have noted that groceries have gotten more expensive in the past months. Kroger customers benefit from our personalization as we offer highly relevant savings at a household level, allowing them to further stretch their food dollars. Our associates continue to deliver a full, fresh and friendly customer experience every day, every time while also supporting our communities through the pandemic.\\nWe remain urgently focused on keeping people safe in our stores and facilities. Our teams were recently recognized with the gold award for excellence in human capital management from the Brandon Hall Group for our people-centered COVID-19 response. Obviously, we're especially proud of that recognition. During the quarter, we introduced new technology to elevate our associate experience.\\nKroger launched Fresh Start, a new, personalized training program to foster greater associate engagement and retention. We also launched our FEED app, which provides associates easy access to company communications and resources from their smartphones. We are incredibly proud that, during the quarter, we saw an improvement in retention as we strive to gain an employer where associates can come for a job and stay for a career. Now, turning now to the live our purpose.\\nWe continue to believe that customers, associates and investors are increasingly choosing where to shop, where to work and where to invest in companies that are taking meaningful steps to improve our communities and work to build a more sustainable planet. We've recently published our 2021 ESG report on thekrogerco.com. It outlines our progress over the last several years. It further outlines our aspiration to further integrate ESG performance into lines of business and our commitment to creating shared value that benefits all stakeholders.\\nWe imagine a world where everyone is thriving together and Kroger is helping millions of people live healthier, more sustainable lifestyles, protecting and restoring natural resources and contributing to more responsible and inclusive global systems. One of the many ways we bring our ESG vision to life is through our work that our Kroger Health team has been doing to serve and support our customers and communities through the pandemic. During the quarter, we worked with Lyft to provide rides to COVID-19 vaccine appointments, teamed up with local sports icon to drive awareness and access in the underserved communities and we concluded our #communityimmunity giveaway. To date, we have provided over 6.7 million doses of the vaccine and continue to drive availability and education.\\nAnd yesterday, president Biden noted that Kroger is one of three national partners who have agreed to make the rapid COVID test available to customers at cost for the next 100 days. Kroger is committed to helping people live healthier lives while safeguarding the communities we serve. Our ESG goals are ambitious. And with a team of almost 500,000 dedicated and driven associates, they are also achievable.\\nSince we first introduced our commitment to delivering strong and sustainable total shareholder return in 2019, our teams have been laser-focused on execution. This focus has resulted in tangible results, allowing us to deliver this quarter and for the long term. Now, I would like to turn it over to Gary to discuss our second-quarter financial results. Gary?\\nGary Millerchip -- Chief Financial Officer\\nThanks, Rodney and good morning, everyone. Kroger is delivering strong results and continues to build momentum as we execute on our priorities of leading with fresh and accelerating with digital. During the quarter, adjusted FIFO operating profit grew by a compounded annual growth rate of 23% over 2019 and adjusted EPS grew by a compounded annual growth rate of 35% over the same two year period. This reflects our disciplined approach to executing our strategy, balancing investments in our associates and customers with strong cost management and accelerating growth in our alternative profit business.\\nIt also provides a further proof point of how we are successfully navigating the pandemic and emerging stronger as a business. I will now provide additional details on our second-quarter results. Identical sales without fuel declined 0.6%. On a two year stack basis, identical sales without fuel increased 14%.\\nEach period during the quarter was stronger than the last and I'm delighted to say we returned to positive identical sales without fuel during the final period of the quarter. Our digital platform remains a key strength in our model and we were pleased with the triple digit growth achieved over 2019. We remain on track with our plans to double our digital business by 2023 and would expect continued investments in the customer experience, scaling of new fulfillment centers and several new innovations which we will announce throughout the year to drive future growth. As shared last quarter, we would not expect future digital growth to be linear, especially as we cycle COVID in 2021.\\nDuring the quarter, we also made further progress in improving digital profitability as we achieved a record low for the time taken to pick a digital order in store and continue to see growth in the media revenue generated on digital transactions. Gross margin was 21.4% of sales for the second quarter. The FIFO gross margin rate excluding fuel, decreased 60 basis points compared to the same period last year. This decrease was primarily related to price investments and higher shrink and supply chain costs, partially offset by sourcing benefits and growth in our alternative profit business.\\nOn a two year basis, our FIFO gross margin rate excluding fuel, decreased 55 basis points compared to 2019. Consistent with many retailers, we experienced supply chain constraints and increased warehouse and transportation costs during the quarter. We are actively managing this risk within our business by securing increased capacity and augmenting associate retention programs within our own facilities. We expect supply chain costs to remain elevated in the second half of the year and this is contemplated in our updated guidance.\\nIn the second half of the quarter, we also saw higher inflation in some categories. We are being disciplined in working with suppliers to manage these increases and are passing along higher cost to the customer where it makes sense to do so. While difficult to predict with precision, as we shared last quarter, we believe inflation for the full year will be higher than originally contemplated in our 2021 business plan. For the second half of 2021, our guidance now assumes inflation of between 2% and 3%.\\nRecognizing recent inflation trends and our outlook for the rest of the year, we recorded a higher LIFO charge for the quarter of $47 million compared to $23 million in the prior year. Further strong operational execution allowed us to leverage operating, general and administrative expenses by 76 basis points excluding fuel and adjustment items, in the second quarter. This reflects lower COVID-19-related costs and savings captured through our cost saving initiatives. On a two year basis, our OG&A rate excluding fuel and adjustment items, decreased by 137 basis points compared to 2019.\\nWe continue to see opportunities to streamline processes and leverage technology and remain on track to deliver $1 billion in cost savings during 2021. The traffic and data generated by our seamless ecosystem continues to create a strong flywheel effect for our alternative profit business, which again experienced significant profit growth in the quarter. Media and Kroger personal finance continued to lead the way and we remain on track to achieve the high end of our expected range of $100 million to $150 million of incremental operating profit in 2021. Fuel is also an important part of our overall value proposition for our customers.\\nGallons grew in the second quarter by 7% and outpaced market growth. The average retail price of fuel was $3.13 this quarter versus $2.14 in the same quarter last year. Our cents per gallon fuel margin was $0.39 compared to $0.37 in the same quarter in 2020 and fuel was a tailwind to operating profit of $33 million compared to prior year. Turning now to our financial strategy.\\nWe continue to generate strong free cash flow and remain committed to investing in the business to drive sustainable growth while also returning excess cash to shareholders. We are prioritizing capital investments that support our growth strategy, widen our competitive moats and deliver strong returns. Capital expenditures year-to-date were down compared to prior year as we carefully navigated the impact of higher project costs and longer project lead times due to a challenging labor market. As we confirmed in guidance today, we are maintaining our range for capital investments excluding mergers, acquisitions and purchases of leased facilities, of between $3.4 billion and $3.6 billion and would currently anticipate coming in at the low end of this range for the year.\\nDuring the quarter, Kroger repurchased $349 million of shares and year-to-date has repurchased $751 million of shares. As of the end of the second quarter, $779 million remains outstanding under the current board authorization announced on June 17, 2021. In June, Kroger also increased the dividend by 17%, marking the 15th consecutive year of dividend increases. Our proactive approach to investing in our associates over recent years is helping us navigate a challenging labor market.\\nOur strategy continues to focus on investing in compensation plans that reward our associates in ways that are meaningful to them. We are committing to investing $350 million in hourly wage increases for our associates during 2021, in addition to the $800 million we invested in associate wages between 2018 and 2020. Over the same period, we have also taken several opportunities to improve the security of our associates' pension benefits. Our average hourly rate is now in excess of $16 an hour.\\nAnd with comprehensive benefits factored in, we'll be approaching $21 by the end of 2021. We are committed to increasing retail hourly wages sustainably and our long-term financial model fully contemplates continued investments in associate hourly rates. During the second quarter, we ratified new labor agreements with the UFCW for associates in our Atlanta, Michigan, Food 4 Less and Mid-Atlantic divisions, covering over 34,000 associates. We continue to negotiate contracts with the UFCW for store associates in Houston, Little Rock, Memphis and Portland.\\nOur financial results continue to be pressured by inefficiencies in healthcare and pension costs, which most of our competitors do not face. We continue to communicate with our local and international unions, which represent many of our associates about the importance of growing our business in a profitable way, which will help us create more jobs and career opportunities and enhance job security for our associates. Turning now to our expectations for the second half of 2021. Driven by momentum in our results and sustained trends in food at home, we are raising our full-year guidance.\\nWe have also narrowed the range of our guidance as we are further into the year and the trends in our business and the broader food-at-home market become clearer. We now expect identical sales without fuel in the second half of 2021 to be flat to slightly positive, resulting in full-year results of negative 1.5% to negative 1% and a two year identical sales stack of between 12.6% to 13.1%. We expect our adjusted net earnings per diluted share to be in the range of $3.25 to $3.35. We expect our adjusted FIFO operating profit to be in the range of $3.9 billion to $4 billion, reflecting a two year compounded annual growth rate of between 14.1% and 15.6%.\\nIn conclusion, we are emerging stronger through the pandemic and remain confident in our ability to deliver total shareholder return of 8% to 11% by sustainably growing earnings and using our resilient free cash flow to return excess cash to investors. And now I'll turn it back to Rodney.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThank you, Gary. The environment we operate in is dynamic and I am so proud of our associates' ability to meet the challenge and serve our customers while building for the future. Kroger's seamless ecosystem is working. This was evident during the quarter as we saw customers seamlessly shift between channels and we continue to see strong digital engagement.\\nWe are leveraging technology, innovation and our competitive moats to deliver against the total shareholder return model we introduced in 2019 and reaffirmed in 2021. Kroger will continue to deliver for all stakeholders and position the business for long-term success. Now, we look forward to your questions.\\nQuestions & Answers:\\nOperator\\n[Operator instructions] Our first question comes from Greg Badishkanian with Wolfe Research. Please go ahead.\\nSpencer Hanus -- Wolfe Research -- Analyst\\nGood morning. This is Spencer Hanus on for Greg. Can you guys talk about the comps that you're seeing quarter to date? Because I think the guidance does imply somewhat of a slowdown on a two year basis in the second half. And then although it's early, how are you thinking about comps in 2022.\\nDo you guys get back to your long-term algo next year? Thanks.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYeah. As Gary mentioned in his prepared remarks, the last period of the second quarter, we returned to positive identicals. And so far, in the third quarter, we continue to see the trend of positive identicals and our guidance for the balance of the year is positive as well. So we're very pleased with where we are.\\nWe're pleased with the performance our teams are doing and we're making progress and substantially ahead of where we initially we thought we would be at this point in time on cycling the COVID peak from last year. As we look toward 2022, Gary, unless you want to get into more of the details, I think the key thing would be what we talked about at our investor day in 2021 and that's our commitment to a TSR model of 8% to 11%. And that's driven by a combination of sales growth, slight margin improvements and taking free cash flow and returning it to our shareholders via dividend and stock buyback. And the sum of those together is what will drive the 8% to 11% and we remain committed to that.\\nAnd obviously, since we put it in place in 2019, we've outperformed it. I don't know, Gary, if you want to add anything.\\nGary Millerchip -- Chief Financial Officer\\nThe only thing I would add, I think you said it very well, Rodney, is we feel really good about the trends in the business, obviously, as we shared on the prepared comments. As you look at the back half of the year, you asked some -- for additional color on how we're thinking about the trends that we're seeing there and the guidance, I would say we're obviously heading into the back half of the year, as Rodney mentioned, with momentum in the business. We did raise the guidance to now be in that sort of 0% to 1% for the back half of the year based on reversing into that from the year-to-date performance and the guidance that we gave for the year. Overall, we're feeling really good about how we're executing in the business and seeing that sustained trend in food at home as consumers continue to gravitate toward some of the trends that Rodney talked about.\\nAnd also, obviously, we are seeing some return to previous behavior with the Delta variant currently prevalent in the U.S. as well. That being said, we do still think there are some knowns in the market. If you look at different countries, how long the impact of the Delta variant lasts, if you like, on consumer behavior, we are seeing some consumers return to normal behavior, returning to offices in some cases.\\nAnd so while we feel really good about our trends and our ability to continue to win with the customer, the back half of the year would be more of an 11% to 12% two year stack based on still some of the uncertainties and unknowns around those elements that we're still looking to see how they play out. I think the only other thing that I would reinforce on Rodney's comment is that we do expect, as we shared at our investor day at the beginning of the year, that as we come through 2020 and 2021, we expect the overall food-at-home trends in the market but also specifically Kroger's overall sales to come out of 2021 in a much stronger position than we would have been had the pandemic not occurred. And so we believe that, that will still certainly be true as we head toward '22. And obviously, we look forward to sharing more details on 2022 when we get toward the end of the year.\\nSpencer Hanus -- Wolfe Research -- Analyst\\nThanks. That's really helpful color. And then could you guys comment on how rational your peers have been at passing through inflation? And are you expecting any gross margin headwinds from some of the elevated inflation in the perimeter of the store? Any additional color there would be helpful.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nIf you look at, during the quarter, about half of the gross margin impact was from higher shrink and higher supply chain costs and Gary, in his prepared remarks, talked a little bit about both of those. But if you look at shrink, a lot of that, about half of the half or 25% of it is driven within the shrink component and that's heavily driven by organized crime or at least it appears to be. And I know Congress and other groups are starting to spend more time on understanding what's driving that and what's behind it and what's the distribution channels for the stolen products as well and trying to manage that. And then on the supply chain costs, we are proactively investing there to minimize the effect.\\nOn both of those areas, the guidance that Gary shared for the balance of the year reflects the pressure in those areas. And from an inflationary standpoint, as you know, over time, we've been successful in operating in slow or negative inflation and high inflation and we would see this no different. And our business, the easiest place to operate is when inflation is between 3% or 4%, but you don't ever get what you -- it makes it the easiest. But so far, we're -- costs are being passed through in an organized way for the most part and as we would expect and following our strategy.\\nSpencer Hanus -- Wolfe Research -- Analyst\\nGreat. Thank you so much.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThanks, Greg. Sorry.\\nOperator\\nYour next question comes from Michael Lasser with UBS. Please go ahead.\\nMichael Lasser -- UBS -- Analyst\\nGood morning. Thanks a lot for taking my question. I wanted to drill down into your comments around the consumer embracing eating at home, coupled with targeting the total shareholder return formula for next year. We're still largely in the midst of this pandemic.\\nMany workers are still working from home. So is the strength this year just delaying the inevitable shift back to food away from home in calendar '22? And if that's the case, you're guiding to a 3% operating margin this year essentially. So how will you be able to maintain this operating margin rate in an environment where your sales are going to continue to be pressured, particularly as you have reduced a lot of your OG&A expenses this year?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThanks, Michael. I'll start and let Gary finish. If you look at all of our research on people eating at home, customers are telling us, they enjoy eating at home and eating with their families, which we believe is structural and sustainable. They're also telling us that eating at home, they're able to eat healthier, stretch their budget significantly further because it's not nearly as expensive as eating in a restaurant.\\nAnd they also like showing off their new skills on cooking. And all of those things, everything that our research would suggest are long-term trends and structural trends. The other thing that everybody on the call, your guess is as good as ours. But everything that we can tell, we believe that people will continue working from home more than the past.\\nAnd many companies and I know certainly we are, are supporting people in terms of different jobs, what jobs can be worked from what location. And in all of those cases, what we're finding is people are eating more meals at home, i.e., breakfast and lunch. So everything that we can see, a meaningful part of the trend change is really structural and sustainable and it's not just a onetime blip because of COVID. In terms of the margins and stuff Gary I'll let you drill into some of that detail.\\nGary Millerchip -- Chief Financial Officer\\nYeah. I think all I would add Rodney is maybe just -- Mike, we'll take you back to the journey we've been on for the last three years with our model. And if you think about how we teed it up at our investor days, we feel that over 2019, 2020 and now 2021, we're really demonstrating how we're able to manage the business more holistically as we think about delivering on our TSR model. So you think about the continued investments, even through the pandemic, that we are making in our customers to ensure that they see the value we're delivering, whether that's in the experience and some of the digital investments or through continuing to invest in price where it make sense and personalization to make sure positioned well with the customer, the investments that we're making in average hourly for our associates to ensure that we're continuing to improve the experience there.\\nAnd as you look at that and then think about the way in which we've managed costs, we're continuing to accelerate our alternative profit businesses and at the same time, continue to get stronger and more effective at sourcing and managing margins in that way. I think that gives us confidence in our ability to continue to manage the business overall and drive a strong TSR in line with our commitments as you think about over time what our commitments are to our shareholders. So we'll obviously get into more specifics around how we think about '22 later in the year. And at this point, I wouldn't want to get into specific details about next year, but that's certainly how we think about our model and how we get confident in our ability to maintain the trajectory over time and supported by Rodney's comment on how we think about continuing to see the customer spend dollars on food at home and how we can continue to grow our business within that context.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYes. As you look at cost, it's one of those things where we've been able to take cost out of the business without affecting the customer experience for years. And I know when we set out a goal, we always think that that's all we're going to find and then our great teams are able to find more areas for process change and cost opportunities. And when I watch our operations team, Gary mentioned the procurement team, our technology team, but more importantly, how our stores and technology and operations team are working as one, they continue to identify things to make our associates' job easier to reduce the number of touches of product and be able to take costs out, which our customers then benefit.\\nAnd some of that cost reduction is shared with our customers. Some of it is shared with our associates, but it's part of the overall flywheel that continues to accelerate and make our model sustainable. And Gary's point on alternative profit is an important component of that as well.\\nGary Millerchip -- Chief Financial Officer\\nActually, Rodney one other thing on the cost side Michael that I think is important too. We've mentioned this again at our investor day, but this -- the plan that we have to double digital profitability, that's obviously very important to the long-term strategy that Rodney outlined around how do we make sure that, from a customer perspective, they're not having to compromise between store and digital experiences but is also important from a business model point of view to continue to improve the profitability of the channel. So that from our perspective, we can be agnostic from whether the customer is buying online or buying in the store. As we grow that digital profitability rate, important to remember that just doesn't affect the growth in the future, it affects the $10 billion business that we have today.\\nSo that's also proving to be a tailwind in the financial modeling OG&A now but also will continue to be a tailwind because we're only partway through that journey as we take cost out of filling an order and continue to grow media revenue per transaction as well.\\nMichael Lasser -- UBS -- Analyst\\nAnd my follow-up is focusing on the media revenue per transaction, it seems like that's the area where you're really supporting the profitability of your digital business and subsequently, the overall gross margin for Kroger as a result. Where are you from an advertising perspective from a large CPG company perspective versus getting more advertisers on the platform? Can you frame out how big this advertising opportunity can be? And as an unrelated side note, to what extent was there a vaccine distribution benefit within the gross margin? One of your large competitors talked about that within the quarter.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nWell, several questions there. I'll briefly talk about the media. We still see retail media as a significant opportunity. And we shared at investor day, but Kroger's retail media team and our retail media offer in five different areas, we ranked No.\\n1 among our competitors in three of the five and we were tied for No. 1 on the other 2. So obviously, the value CPGs get from our offer and our ability to use our data to make sure the right customers are seeing offers is substantial and significant and we believe that it's a significant opportunity to continue to grow retail media. I won't get into specifics, other than we would say that we feel like we're just getting started.\\nGary Millerchip -- Chief Financial Officer\\nAnd then, Michael, I would just say on the health and wellness question, we would certainly have seen some benefit from COVID vaccines during the quarter. Having said that, we pivoted a lot of our efforts in the pharmacy business, which, as you know, is a big part of our operation and our little clinics. So I would say, net-net, if you look at the health and wellness business, I would think of it as largely being on plan. And so I wouldn't think of it as a headwind or a tailwind during the quarter or, for that matter, being a headwind for the rest of the year either.\\nI think we've got fully contemplated within our guidance the expectations around the health and wellness business going forward.\\nMichael Lasser -- UBS -- Analyst\\nThank you very much and good luck.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThank you.\\nOperator\\nYour next question comes from Chuck Cerankosky with Northcoast Research. Please go ahead.\\nChuck Cerankosky -- Northcoast Research -- Analyst\\nGood morning, everyone. Nice quarter. I want to talk a little bit about or ask a little bit about private label in this inflationary period. How do you see customers reacting to it? And is there a difference between a customer shopping in store and online?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYeah. If you look at our brands, simple truth and private selection continues to really gain share and grow. We're also finding big packs are growing significantly. If you look at -- for us, we find our brands -- if CPGs are passing through inflation that's not real, all -- every time when somebody does that, our brands even gain incremental share.\\nThe other thing that I've been really proud of our team is the innovation behind the product and we've introduced over 140 new products in the quarter and would continue to expect that going forward. I don't -- we're not seeing behavior changes. If you go back to prior times when you had inflation, the customer, a lot of times, would trade over to our brands as part of their -- structuring their budget. We're not seeing budget changes on our brands happening at this point but I'm sure if inflation continued.\\nOur customers are telling us they still feel pretty good where they are financially. And for the most part, people are still saving at record levels and things like that. Now at some point, if budgets got more constrained, you'd probably start seeing some of that behavior. But the business we're gaining right now is really being created because of the innovation in our product and the quality of the product and it's really standing on its own.\\nChuck Cerankosky -- Northcoast Research -- Analyst\\nAnd then secondly Rodney, are you seeing regional differences in the shifts in the way people moved in and out of e-commerce over the course of the quarter?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYes, we would. And it's really wherever COVID is higher, you would see the shift to more online and that's delivery and pickup. And as it moves north, you would see that within the company. And as I mentioned in my prepared remarks, the things that we're especially proud of is almost every customer that were shopping with us digitally early in the quarter that started -- that stopped shopping digitally, they started shopping in the stores.\\nAnd for us, that's really important as part of our overall strategy for seamless because what we find is, after the first year, an online shopper actually comes into the store more often than they did before they became an online shopper.\\nChuck Cerankosky -- Northcoast Research -- Analyst\\nAnd have you quantified what your total e-commerce did to the operating earnings during the quarter? Is there any way to put a number on that, whether a smaller loss or is it trending toward a positive number?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nWell, I'll let Gary -- I'll talk a little bit. If you look at within the quarter, obviously, we had the start-up costs of our sheds in Florida and Monroe. So that created a headwind. Obviously, that was reflected in our guidance that we gave for the year and our updated guidance.\\nI don't know, Gary, if there's any additional.\\nGary Millerchip -- Chief Financial Officer\\nWell, I think we talked about, Chuck, the profitability of digital in different ways. When we add in all the fixed costs, we're more on the journey toward profitability, as you are alluding to. We generally focus, though, on what's the pass-through rate on the transactions as we're growing customers because what we find with digital, as you know, is the customer becomes more loyal overall to Kroger and we see about 50% or so incrementality as the customer engages digitally. As we've talked about previously, we've kind of -- when you think back to last year, we're at mid-single-digit pass-through rate compared to a pass-through rate that will be closer to mid- to high teens on a store transaction.\\nAnd we're on the path to improving that profitability to drive toward doubling the profit rate on the digital transaction and ultimately targeting to get to parity. I would say we're making good progress on that journey. As I mentioned in my prepared comments, we continue to make solid improvements in the efficiency of picking a digital order. And over time, we'd expect Ocado to play a role in that as well, of course, with the automation they provide.\\nAnd with media revenue continuing to grow rapidly, that's also creating a tailwind. So I'd say we're seeing good momentum and on track with where we expected to be with that journey in the quarter.\\nChuck Cerankosky -- Northcoast Research -- Analyst\\nThank you very much. Good luck on the rest of the year.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThank you, Chuck.\\nOperator\\nYour next question comes from Edward Kelly with Wells Fargo. Please go ahead.\\nEdward Kelly -- Wells Fargo Securities -- Analyst\\nYeah. Hi, guys. Good morning. I wanted to ask about share repo and the cash balance.\\nSo you ended the quarter with a lot of cash. Again, you're well below your leverage target. Thoughts on the buyback. Is the stock attractive here, I guess, is a straightforward question? And what are your thoughts on taking out additional debt to buy back stock? Because with the dry powder that's there, I mean, it seems like you could probably take out north of 10% of the shares.\\nIs this a bigger part of delivering 8% to 11% next year? Just kind of curious as to how we should be thinking about all this.\\nGary Millerchip -- Chief Financial Officer\\nYeah. Thanks for the question, Ed. I would say, overall, we're not changing our overall financial strategy. As we think about our free cash flow, we continue to start with how can we invest in the business to grow it profitably and sustain growth and we still think there's lots of opportunity to accelerate the model.\\nAs we -- I think we alluded to a little bit of this at our last investor day, our goal over time would be to be stretching our top line growth and our overall earnings growth, so the focus for excess free cash flow is certainly looking for where the opportunities as we believe we can continue to lead with fresh and accelerate with digital to drive that growth. We're certainly going to look at any of those incremental investments against the bar of saying, is that going to drive a stronger return for investors versus buying back incremental stock? But within our overall framework today, as we obviously continue to invest in the business to grow, we are committed to continuing to return cash to shareholders at the level that we've shared in our current TSR model. As you've heard us say, we increased the dividend by 17% to reflect really our confidence that we expect to come out of COVID at a higher position from an operating profit perspective as we leave 2021. And and we continued to buy back stock during the quarter and would expect to continue to buy back stock at the current price.\\nWe do leverage a grid. I think I've referred to this before. So think about it as depending on where the share price is. That -- if the share price is lower, it buys back more stock during the quarter.\\nIf the share price is higher, it buys back less stock because we're not trying to time anything in the market. We're already trying to make sure that we're maximizing the return on the dollars as we go through the year to take advantage of fluctuations in the prices as it happens during a difficult trading period. But we certainly remain committed to returning cash to investors. We start with the excess cash from a point of view of saying where could we accelerate our growth.\\nAnd ultimately, we'll share more on that as we identify those opportunities. And we'll continue to flex, if we believe that there aren't those opportunities then obviously, we'll look to make sure we are dynamic in making sure we're deploying excess cash.\\nEdward Kelly -- Wells Fargo Securities -- Analyst\\nOK. Great. And just a quick follow-up on the gross margin. Is the two year number for Q2, is that a good way to think about the back half or with inflation accelerating and supply chain, does that headwind grow a little bit in the back half? Just curious as to how we should be thinking about that.\\nGary Millerchip -- Chief Financial Officer\\nYes. I think actually, Q2 is a pretty good sort of overall -- I'm going to -- again, we don't get into specific numbers. But I think, directionally, it's a helpful way to think about the back half of the year. As you think about overall earnings, we would think gross margin continued to be a headwind, part of that being warehouse and transportation, part of it being shrink.\\nWe're also continuing to invest in the business where we think it makes sense and give value to customers. OG&A will continue to be a tailwind, but we will see less COVID cycling, if you like, in the back half of the year. So that's why the overall impact on operating profit won't be as strong in the back half of the year. But I -- if you think about Q2 in general outside of that cycling of extra COVID costs last year in the first half of the year I think is a pretty good way to think about the back half of the half of the year, Ed.\\nEdward Kelly -- Wells Fargo Securities -- Analyst\\nGreat. Thank you.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThanks, Ed.\\nOperator\\nYour next question comes from Michael Montani with Evercore ISI. Please go ahead.\\nMichael Montani -- Evercore ISI -- Analyst\\nGreat. Thank you for taking the questions. I was just hoping to get a little bit of incremental color around the ID sales. Has the transaction count turned positive at this point? And then secondly, if you could provide some incremental color around how much inflation you were able to kind of pass through to consumers vis-\\u00e0-vis what you saw in COGS, just because at times, in the past, you have given some helpful context there?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYeah. If you look at transaction count, we would continue to have a slightly declining or kind of flat transaction count. It really depends on if you're looking at versus prior year or two years. If you look at basket size per purchase, it's significantly increased in terms of when customers come into the store, they buy significantly more; or if you look at our online shop customer, that customer's basket size is significantly higher than a basket when somebody comes into a store.\\nSo both from a digital standpoint and individual transaction standpoint, customers are significantly buying more. And it's all -- it's really three things. One, they're buying more. They're also buying premiumization of product where they've upgraded the products they buy and they also are buying bigger-sized products as well.\\nSo if you think about toilet paper, very few customers now can or will even buy a four pack of toilet paper, where most customers now are buying 24 pack or even bigger in some cases. In terms of the inflation, Gary, I'll let you answer Michael's question on that.\\nGary Millerchip -- Chief Financial Officer\\nThanks for the question, Michael. Yes, we've laid out before, I know, on the call, we have a very robust process for how we manage when we see inflationary costs flowing through from suppliers. And first of all, we challenge to make sure that we feel confident they're legitimate because, obviously, we want to make sure that they truly are structural cost changes. And then if they are, we absolutely have a process for passing them on to the customer.\\nI would say that, generally, we've been very comfortable with our ability to pass on the increases that we've seen at this point and we would expect that to continue to be the case looking into the back half of the year. As you saw during the quarter, we are, though, continuing to invest in price where we think it makes sense. Sometimes that might be in areas where we're seeing inflation. Sometimes it might be we're investing because we believe it's the right thing to do to grow customer long-term loyalty in other places through our personalization strategies.\\nSo overall, we feel good about the way in which we're able to manage the inflation within the business. At the same time, we are continuing to invest because we believe that's going to be important to grow share over the long term as well.\\nMichael Montani -- Evercore ISI -- Analyst\\nGot it. Thank you.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nThank you.\\nOperator\\nYour next question comes from Karen Short with Barclays. Please go ahead.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nKaren, are you there?\\nKaren Short -- Barclays Investment Bank -- Analyst\\nOh, sorry. can You hear me now?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYes.\\nGary Millerchip -- Chief Financial Officer\\nYes.\\nKaren Short -- Barclays Investment Bank -- Analyst\\nSorry about that. Yes. So I had a couple of questions just related to guidance. Gary, you mentioned that the vaccine admin fee kind of netted out with respect to other initiatives that you had in, I guess, health and wellness in general.\\nI'm just wondering if you could give a little more color on that because it was very sizable and one of your competitors in terms of basis point contribution to gross margin. And then other model questions that I just wanted to clarify were what your actual LIFO expectations are for the year because that's obviously relevant for EPS and then what your COVID costs were in the quarter and what your expectations for COVID costs will be for the rest of the year. And then I had one other bigger-picture question.\\nGary Millerchip -- Chief Financial Officer\\nSure. Thanks, Karen. On the pharmacy side of things, yes, so essentially, as you know, we operate little clinics as well in a number of our stores and multiple of our stores have little clinic facilities. And in our pharmacy core business, we continue to support the COVID vaccines.\\nSo my comment earlier was, when you look at the total health and wellness business, as we pivoted resources to do more COVID vaccinations and as we provided that support, whether it be through off-site locations or through our own facilities and you look at the total impact of the pharmacy business as customers shifted to more COVID vaccines and less of the newer prescriptions, if you like, even though we grew script count overall during the quarter and continue to grow script count. If I look at the total impact on the health and wellness business for the quarter and the year-to-date, there wouldn't be a material overall outside of business plan performance. Although certainly, if you look to the COVID vaccines in isolation, they would have created an incremental value to the health and wellness business, but it was offset by lower revenue or lower margin impact on other parts of that business, so netted out to being on plan, if you like. And as we look at the back half of the year, I wouldn't expect it to be a reason that we have an incremental headwind in margin because of having less COVID vaccinations in the back half of the year as things start to return.\\nSo certainly, we expect some vaccines in the back half of the year, but things start to return a little bit more to normal and less of a spike in vaccines compared to what we saw in the first half of the year. From a LIFO perspective, as you -- I think you probably know, it's not really an easy thing to predict because LIFO was a charge, is one data point at the end of the year. As we looked at the data point so far this year, we're seeing an inflation. We use those spots to predict where it would be.\\nI think the best guidance we could give you is if you take the year-to-date performance in LIFO that we've charged to the P&L and then gross that up effectively for the full year, that would be essentially our full-year expectation based on the data points that we've seen to this point in the year in our outlook. But FIFO -- I'm sorry, LIFO, I beg your pardon, is notoriously difficult to predict, so we're giving you our best estimate. But at the end of the day, it will be driven by accounting rules and a data point toward the end of the year. But I think the best indication we can give you at this point is to use the year-to-date performance and gross that up for the year is our best estimate.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nIn essence, annualized. And so divided by seven times.\\nGary Millerchip -- Chief Financial Officer\\nExactly, exactly. Yes.\\nKaren Short -- Barclays Investment Bank -- Analyst\\nRight. And then just COVID?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nCosts for the quarter.\\nGary Millerchip -- Chief Financial Officer\\nYeah. So as I mentioned earlier, we certainly saw significantly greater costs in the first half of last year. As a company, we adapted and learned how to operate more efficiently. We would certainly see continued COVID costs in the back half of this year but cycling less costs from last year.\\nWe would expect it to be south of $100 million a quarter. But certainly, we're still seeing incremental costs. And some of the areas that you would probably expect when you think about how we're continuing to operate through COVID, we still have masks costs during the quarter. We still have cleaning costs.\\nWe still have extended leave of absence for any associates that are identified as having the COVID virus -- been diagnosed as a positive COVID case. So those would be the kind of costs that we would see and we'd expect it to be a little bit less than $100 million a year -- sorry, a quarter, I beg your pardon, as we look at the back half of the year and still being a slight tailwind year over year but nothing like what we have seen in the first half of 2020.\\nKaren Short -- Barclays Investment Bank -- Analyst\\nOK. And then just my bigger-picture question is on Florida, so with respect to Ocado. Curious, Rodney, on your early learnings from Florida and whether you think that you may want to emphasize opening sheds in markets where you actually don't have physical retail locations. Or any thoughts on where you're at on that philosophy in terms of markets where you have high market share, markets where you have middle market share or markets where you have no presence based on what you know so far?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYeah. It's a great question, but we're still early in the process of answering that. And if you look in Florida, we are tracking ahead of where we thought we would be at this point. And the thing that I'm especially proud of our teams in Florida is our Net Promoter Scores are incredibly strong.\\nI mean, mind-boggling strong and made up in the neighborhood of best-in-class across all industries. And as you know, food retail usually struggles with having Net Promoter Scores that are up in the Apple neighborhood and things like that. So I'm incredibly proud of what our teams are doing in terms of creating the experience for the customer. And I appreciate and like your question.\\nI would say we're still early in the process and we continue to learn every day on our ability to ramp up a facility in a new market. Certainly, it's easier communicating to the customer in new markets or markets where our share isn't as high. And that was one of the reasons why we picked Florida and picked Monroe here outside of Cincinnati was to learn how to integrate it within our existing infrastructure and then having something from the ground up. And I would expect, over time, we'll learn how to do both of them and we'll be really happy with the results.\\nKaren Short -- Barclays Investment Bank -- Analyst\\nGreat. Thanks very much. That's helpful.\\nOperator\\nYour last question comes from Rupesh Parikh with Oppenheimer. Please go ahead.\\nRupesh Parikh -- Oppenheimer & Co. Inc. -- Analyst\\nGood morning. Thanks for taking my question and fitting me in. So I guess just going back to the gross margin headwinds during the quarter that you saw. Today, you called out shrink in supply chain.\\nIt sounds like that may be half the pressure that you saw during the quarter. I was curious if you see those headwinds on the shrink and supply chain at all transitory.\\nRodney McMullen -- Chairman and Chief Executive Officer\\nI think incrementally, yes. But if you look at shrink, I think shrink will remain higher. Now we will go through and do all kinds of process changes to try to minimize shrink, but we are being more aggressive. And Christine Wheatley, who's our General Counsel, is also working with some trade associations to try to start working on it in a broader group, not just Kroger-specific when you look at organized crime.\\nAnd I know I was reading Home Depot's earnings call and they talked about the same thing. So we do believe that will be important to partner with the government and the way products are able to be sold in the marketplace. So I do think there's things we will do to improve, but some of it will be a headwind until we're able to address that. On supply chain, I think an awful lot of that will be transitory, but you still have to manage through it.\\nRupesh Parikh -- Oppenheimer & Co. Inc. -- Analyst\\nOK. Great. And then maybe just one follow-up question. We're hearing more and more from suppliers lately of challenges in the supply chain and being able to fulfill all the consumer demand out there.\\nSo I was just curious how your out of stocks right now trending versus what you've seen in recent months?\\nRodney McMullen -- Chairman and Chief Executive Officer\\nYes. I would say that we're slightly higher. Now our teams had, going in, been continuing to aggressively forward buy inventory. Originally, it was because of the inflation pressures.\\nIt's ended up because of some of the supply chain issues. It's also one of the benefits of a lot of our own brands and we manufacture a lot of our own brands. So our plants are aggressively pushing capacity. So I would say that it is a headwind.\\nIt's slightly worse than it was, but we continue to work on minimizing and maximizing the in-stocks.\\u00a0\\nRupesh Parikh -- Oppenheimer & Co. Inc. -- Analyst\\nOK. Great. Thank you.\\nGary Millerchip -- Chief Financial Officer\\nBefore we conclude today's call, I'd like to take a moment to remember the tragic event that took place nearly 20 years ago tomorrow and to honor the lives lost on September 11, 2001. And as always, I'd like to take a moment to address our associates who are listening in. Thank you for delivering an outstanding performance this quarter and continuing to support our communities through the pandemic. As the number of COVID-19 cases continue to rise due to the rapid spread of the Delta variant, I want to affirm that health and safety of our associates and customers remain our top priority.\\nWe are doing everything we can do to make sure the vaccine is accessible and available to you and our customers wherever they are. I am so proud of our Kroger Health team who have already administrated 6.7 million doses of the COVID-19 vaccine. Thank you to our talented healthcare professionals for being there for our communities and for addressing questions for our customers about the vaccine and about getting the vaccine. I'm often reminded of the impact our associates have on the lives of our customers.\\nRecently, one of our pharmacy managers in Atlanta saved a life of a customer that was having an allergic reaction in one of our stores. This is just one of the many examples that in extraordinary ways our associates care for those around them. Thank you for inspiring me every day and thank you for all you do every day to be there for our customers, our communities and each other. That concludes today's call.\\nOperator\\n[Operator signoff]\\nDuration: 69 minutes\\nCall participants:\\nRob Quast -- Director of Investor Relations\\nRodney McMullen -- Chairman and Chief Executive Officer\\nGary Millerchip -- Chief Financial Officer\\nSpencer Hanus -- Wolfe Research -- Analyst\\nMichael Lasser -- UBS -- Analyst\\nChuck Cerankosky -- Northcoast Research -- Analyst\\nEdward Kelly -- Wells Fargo Securities -- Analyst\\nMichael Montani -- Evercore ISI -- Analyst\\nKaren Short -- Barclays Investment Bank -- Analyst\\nRupesh Parikh -- Oppenheimer & Co. Inc. -- Analyst\\nMore KR analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 10:00:00\",\n        \"max\": \"2023-02-23 11:00:00\",\n        \"num_unique_values\": 5201,\n        \"samples\": [\n          \"2020-08-13 07:30:00\",\n          \"2019-08-07 09:00:00\",\n          \"2020-05-04 12:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 6
        }
      ],
      "source": [
        "def parse_date(date_str):\n",
        "  try:\n",
        "    clean_str=re.sub(r\"\\sE[DS]?T\",\"\",str(date_str))\n",
        "    return parser.parse(clean_str)\n",
        "  except:\n",
        "    return None\n",
        "df[\"Timestamp\"]=df[\"date\"].apply(parse_date)\n",
        "df.head(10)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 7,
      "metadata": {
        "id": "q5z63aRaIRE4",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "3e4505aa-2fff-4669-f0a0-5d42c511b43b"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(18375, 6)"
            ]
          },
          "metadata": {},
          "execution_count": 7
        }
      ],
      "source": [
        "df=df.dropna(subset=[\"Timestamp\"])\n",
        "df.shape"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 8,
      "metadata": {
        "id": "3saAIqfnIf2O",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 293
        },
        "outputId": "6efd7020-e32c-4c99-890f-651a7aca14ed"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript           Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel... 2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta... 2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc... 2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon... 2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel... 2019-08-07 08:30:00   \n",
              "\n",
              "   Date_only  \n",
              "0 2020-08-27  \n",
              "1 2020-07-30  \n",
              "2 2019-10-23  \n",
              "3 2019-11-06  \n",
              "4 2019-08-07  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-712f6a4e-9d9f-45cd-95ca-a3fd6fa8d89c\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-712f6a4e-9d9f-45cd-95ca-a3fd6fa8d89c')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-712f6a4e-9d9f-45cd-95ca-a3fd6fa8d89c button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-712f6a4e-9d9f-45cd-95ca-a3fd6fa8d89c');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-c20be003-745e-43ad-9146-901c526112d0\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-c20be003-745e-43ad-9146-901c526112d0')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-c20be003-745e-43ad-9146-901c526112d0 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 18375,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5681,\n        \"samples\": [\n          \"May 10, 2022, 8:30 a.m. ET\",\n          \"Feb 16, 2021, 8:00 a.m. ET\",\n          \"Jun 01, 2022, 4:30 p.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2872,\n        \"samples\": [\n          \"NASDAQ: TTSH\",\n          \"NYSE: WDH\",\n          \"NASDAQ: HOPE\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q3\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2869,\n        \"samples\": [\n          \"CRWD\",\n          \"AME\",\n          \"WRLD\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17220,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nHello, and welcome to today's Expro Q2 2022 earnings presentation. My name is Elliot, and I will be coordinating your call today. [Operator instructions] I would now like to hand over to Karen David-Green. The floor is yours.\\nPlease go ahead.\\nKaren David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations\\nWelcome everyone, to Expro's second quarter 2022 conference call. I'm joined today by Mike Jardon, CEO; and Quinn Fanning, CFO. First, Mike and Quinn will share their prepared remarks, and then we will open it up for questions. We have an accompanying presentation on our second quarter results that is posted on the EXPRO website, expro.com under the investors section.\\nIn addition, the second quarter financials are downloadable on the Expro website under the Investors section. I'd like to remind everyone that some of today's comments may refer to or contain forward-looking statements. Such remarks are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such statements speak only as of today's date, and the company assumes no responsibility to update any forward-looking statements as of any future date.\\nThe company has included in its SEC filings, cautionary language identifying important factors that could cause actual results to be materially different from those set forth in any forward-looking statements. A more complete discussion of these risks is included in the company's SEC filings, which can be accessed on the SEC website or on our website at expro.com. Please note that any non-GAAP financial measures discussed during this call are defined and reconciled to the most directly comparable GAAP financial measure in our second quarter 2022 earnings release, which can be found on our website. With that, I'd like to turn the call over to Mike. \\nMike Jardon -- Chief Executive Officer\\nThank you, Karen. Good morning and good afternoon, everyone. I'm pleased to share with you that Expro delivered robust operational performance and financial results that exceeded the guidance we provided for the just completed second quarter. We are experiencing increase customer activity levels across all segments of our business, bolstered by a backdrop of strengthening industry fundamentals.\\nWe believe this positive momentum will not only continue, but will also accelerate going into 2023 and beyond. Expro is poised to capitalize on an expected increase in customer spending and activity. Today, Expro has a scope and financial profile required to compete and win in what we believe is the best outlook for energy services in at least a decade. Our results in the second quarter and our market outlook underscore the benefits of Expro's balanced portfolio of services and solutions with leading capabilities and a culture built around safety, service quality, organizational efficiency and risk management.\\nIn addition, we believe our through-cycle resilience is a significant advantage and competitive differentiator for Expro. Our current portfolio of services and solutions is paired with a global operating footprint with established positions in key growth markets and the combination provides Expro with good leverage to improving industry fundamentals and in particular, to the rebound that is beginning to take place in the international and offshore markets. We have never been better positioned to capture cyclical recovery upside. We also continue to have a best-in-class innovation platform and technology portfolio that enables us to support our customers' efficiency and emissions-related goals, grow market share and capitalize on longer-term industry trends.\\nFinally, our strong balance sheet and merger-related synergies provide us with significant financial, operational and strategic flexibility that will allow us to accelerate growth and create long-term stakeholder value. On today's call, I'll touch on three main topics. First, I'll walk you through our second quarter performance. Second, I'll give an update on our integration process.\\nAnd finally, I'll provide some perspective on trends we are seeing in the broader industry environment. For the second quarter, we delivered revenue of $314 million and an adjusted EBITDA of $51 million. Second quarter revenue increased 12% sequentially and on a Pro Forma basis, 10% year over year. Higher revenue during the quarter was driven by increased activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific regions.\\nAdjusted EBITDA increased 39% sequentially and on a Pro Forma basis, 33% year over year. Adjusted EBITDA was primarily driven by a more favorable activity mix during the second quarter and faster-than-anticipated realization of merger-related synergies. Well Construction revenue was up 9% quarter over quarter and well management, which includes our well flow management, subsea well access and well intervention integrity businesses was up 13% quarter over quarter. Second quarter results exceeded the prior guidance, primarily as a result of increased well flow management and well construction revenue within North and Latin America.\\nOur team continues to both capitalize on improving industry fundamentals and demonstrate the value of Expro's broad suite of cost-effective, innovative solutions to win new business and expand relationships with existing customers. During the quarter, we continued to secure contracts because of our exceptional service quality and technical delivery. We also continued the introduction of new technologies with both CoilHose and Octopoda, achieving market adoption at pace. The current commodity price environment puts a premium on maximizing production from existing well stock.\\nSo there is a strong customer interest in well intervention integrity solutions such as CoilHose and Octopoda. The significant under investment in energy supply over the last decade, coupled with growing demand, is also resulting in FID approvals. Importantly, for our company, nearly 60% of the new customer commitments are expected to be offshore. We achieved contract wins and extensions totaling approximately $300 million, which demonstrates the breadth and depth of our customer relationships and attraction that our solutions are gaining in the market.\\nOn a regional basis, in North and Latin America, our Well Construction team continues to demonstrate the position as the premier provider of casing and tubular running services with the award of contracts and successful operations delivered across the region. The team successfully completed a first casing running to a project in Brazil and carried out eight simultaneous TRS deepwater completions in the Gulf of Mexico, where activity continues to pick up. We also deployed our industry-leading 22-inch brotpackers in Mexico for the first time and have seen growing demand for this well integrity technology as operators across the region seek to protect their assets during storm season. This technology allows for quick and rely the well suspension when operators need it most.\\nWe want to influence contract for a major operator in Brazil. And in Alaska, our team was awarded and performed a well test for a strategically important new customer, further growing our presence in this region. Expro in MENA achieved contractor of the month from an international operator, demonstrating Expro's continued focus on delivering best-in-class safety, quality and customer service. In Europe and Sub-Saharan Africa, we saw good progress in securing new business in the second quarter, including the retention of the largest well flow management contract in the Norwegian continental shelf for an initial four-year term, highlighting the strength and depth of our relationship with this international operator.\\nA significant portion of this contract is directly linked to production optimization and enhancement as well as a demonstrable commitment to low carbon plan. The breadth of our portfolio, including market-leading technologies acquired in our July 2019 acquisition of Quality Intervention directly assisted us in expanding a core well intervention contract with a major international operator in the U.K. In addition, our service quality and portfolio of capabilities helped us secure an expanded contract to meet client needs for a nine-well plug and abandonment campaign in the U.K. Continental Shelf, where we also added well test and well intervention to an existing large board subsea services contract.\\nAs I noted earlier, CoilHose and Octopoda are gaining traction in the market to support clients' intervention and integrity needs. Octopoda is a truly unique service offering, which for the first time in our industry, allows direct access to well annualized in which we can ensure well integrity and production assurance. Octopoda was recently deployed in the Congo, the first deployment of this technology in Sub-Saharan Africa, and it continues to generate customer interest with its unique ability to investigate and remediate sustained casing pressure and other well annulus problems. Additionally, our CoilHose Light Well Circulation system is an innovative development, providing a lower cost more efficient alternative to traditional coiled tubing systems.\\nThis broadening of our portfolio and our depth of experience, combined with the ability to quickly mobilize assets and personnel to meet client requirements helped us secure a U.K. contract for well testing and exploration and appraisal services in support of a new offshore drilling campaign. Expro's superior quality and service performance as strong client partnerships led to the securing of multiple contract wins, including for our subsea team in the Ivory Coast and in Turkey, where we won well testing and CoilHose intervention work for a nine-well project on offshore gas storage project. In the second quarter, we also introduced Drill Stem testing into Angola, further broadening our comprehensive portfolio in this country and positioning us to take advantage of the increasing activity in deepwater operations in Angola.\\nWe have successfully started operations in Cabinda for a major operator, which will be our first deployment of hammering services as part of an Angolan Well Construction Service package. In May, we were also recognized as the safest service provider in Mozambique. Based on our recent performance, we are in discussions with the client regarding further expansion of our services, including the introduction of new technologies. In Chad, our work with the client is core to ensuring that our operations are conducted in an environmentally responsible way.\\nOur expertise and technologies are focused on having no environmental impact with testing and analysis carried out to ensure the appropriate purity of the regional freshwater system, underlining our status as a leading provider of on-site chemistry services with a strong environmental focus. In Norway, we completed our first operational campaign with our iTong Well Construction Technology, which provides a step change in safety and well construction operations. Operational performance exceeded client expectations, delivering significant rig efficiency improvements and cost savings to the customer overall. In the Middle East and North Africa, our Well Construction team has expanded into new territory to secure their first TRS contract in Algeria, which is planned to commence later this month.\\nThis opportunity reflects one of the many revenue synergies created by our October merger. We leverage expert relationships and well flow management to secure this new TRS award. In addition, the regional team was awarded two carbon boom contracts with Middle East drilling contractors, reflecting our market-leading capabilities and reputation in the market. In Egypt, our service offering and ability to deliver contributed to Expro being awarded significant well test contracts.\\nIn the Asia Pacific region, our well construction team in Brunei secured a major 5-year contract for TRS. Our outstanding track record of reliable performance in HSC and service quality were strong criteria for the contract award. In Thailand, the team secured additional TRS work covering 200 wells and in Malaysia and in offshore China, we were awarded three-year TRS contract extensions spanning development and exploration wells. Our subsea team's technical capability played a key part in securing a contract with a major international operator in Malaysia for the provision of our new vessel deployed Light Well Intervention package, with the team also securing significant additional work in Australia.\\nLike CoilHose and Octopoda, Expro's LWI capabilities are the result of investments we have made over the last several years, which should allow the company to offer differentiated production optimization solutions and thereby grow our top line faster than the overall market, while also improving profitability. Expro is strategically committed to continuing to invest in transforming our business portfolio and reducing greenhouse gas emissions. In April, we published our inaugural, environmental, social and governance review with a stated aim of achieving net 0 by 2050 with a 50% reduction in carbon intensity by 2030. As the energy industry embraces transition and the need to make real and visible headway toward a lower carbon world, we appreciate the key enablers to change will be those who can truly differentiate themselves as solutions providers.\\nAs recognized global well experts and a trusted partner, we believe Expro is well-positioned to play an important role in enabling our clients to achieve their carbon reduction goals in support of the energy transition. Expro remains committed to allocating roughly 50% of our research and development budget to carbon reduction initiatives. In doing so, we are developing and advancing solutions that will play a critical role in enabling our customers to achieve their own emission reduction goals while also allowing experts to achieve its goals. Expro's well expertise and range of well intervention, well integrity and wells measurement technologies and skills help operators cost-effectively develop oil and gas resources while minimizing both emissions and the required operating footprint.\\nAs our industry speaks to address tomorrow's challenges, we believe many of these technologies and skills are transferable. As a good example of adopting technologies to achieve more sustainable energy solutions, Expros supported geothermal well service projects since 1986. Most notably, in the second quarter, we were awarded our first integrated services geothermal contract to support a high-profile geothermal plant in Germany. The second topic I'd like to cover is to provide an update on our integration efforts.\\nDuring the quarter, we continued to make progress in bringing the legacy businesses together to capture the full potential of our combined platform. I am pleased to report that 9 months into our integration, we have identified an action more than 100% of the $55 million in annualized cost savings that we established with our target within the first 12 months following the closing of the merger. This comes a full quarter earlier than we had initially anticipated. As outlined previously, we are targeting cost and revenue synergies between $80 million to $100 million within 24 to 36 months post-merger.\\nWe remain confident that we will achieve $70 million in projected cost synergies during this time frame, if not earlier. Cost savings are primarily driven by the rationalization of support costs, consolidation of facilities and supply chain savings. In the second quarter, we consolidated additional facilities, including locations in Baku, either by John, St. John's, Canada; Lumpur, Malaysia; Mumbai, India; Corpus Christi and Midland, Texas.\\nWhile revenue synergies are more difficult to demonstrate, my sense is that our previous estimate of an incremental $10 million to $30 million in EBITDA for revenue synergies through our expanded customer relationships and operating footprint, increased time on rig and greater exposure to the full life of the field will likely prove to be conservative. I'd like to sincerely thank the entire expert team for their hard work and numerous contributions toward helping us realize our integration goals ahead of schedule. Without a doubt, we have a winning team that has proven the building to deliver on our commitments. Before I turn the call over to Quinn, I want to provide some perspective on trends we are observing in the market.\\nThe positive signs of a recovery we saw in Q1 continued to build, underpinned by a favorable supply demand dynamic. As I noted earlier, this is largely a result of limited upstream investment in recent years and a need for additional capacity to meet projected demand growth. With the more recent heightened focus on energy security, diversification of supply and the need to replace at least a portion of Russian oil and gas supply is expected to fully magnify what was already set up to be a favorable multi-year macro backdrop for OFS activity. Longer term, we believe the service sector will need to play an important role in facilitating the energy transition.\\nSo despite ongoing volatility in commodity prices, the fundamental backdrop for the energy services sector is quite constructive. In particular, after a strong recovery in the U.S. onshore market, we are seeing increasing demand for our services and solutions with international and offshore activity expected to accelerate through the second half of 2022 and into 2023 as operators look to increase production from existing assets and develop new fields. Notwithstanding near-term concerns of an economic slowdown, there seems to be a consensus that energy demand will trend back toward, if not through 100 million barrels of oil equivalent per day in 2023.\\nWe expect that increasing demand for energy services and capacity constraints in key service offerings, including high-end well construction equipment and subsea test trees should provide scope for improvement in net pricing beginning in late 2022 into early 2023. In Expro's view, expected growth will be broad-based geographically, span all phases of oil and gas development and include all operating environments. Geographically, we see strong potential in North and Latin America, the Middle East, North Africa, Sub-Saharan Africa, as well as Asia. And while many of our customers continue to focus on brownfield enhancement programs to maximize previous investments, we are also starting to see growth in exploration and development activity driven primarily by North and South America, with further activity expected in Norway, India and Sub-Saharan Africa.\\nThe brownfield focus will support steady growth in our well Intervention Integrity business as well as elements of our well flow management business, collectively, which represent about 35% of our business. The remaining circa 65% of our business is generally levered to drilling, well construction and well completions activity, which we believe is points for strong growth across several geographies and within which we generally capture very good faster on incremental revenue. Overall, the outlook for the remainder of '22 and into 2023 remains positive with sustained increases in E&P expenditures. After rather dramatic recovery in the North America onshore market, customer dialogue and tendering activity indicates to us that the outlook for offshore activity is strengthening.\\nThis should support sustained growth for Expro given our leading and differentiated portfolio capabilities and subsea well access services, complex well construction services and production optimization. This is particularly important as approximately 70% of our revenue today is generated from offshore activity. Before I close, I'm pleased to share that during the quarter, our board approved a new stock repurchase program under which the company is authorized to acquire up to $50 million of its outstanding common stock up to the November 2023 time frame. We view the repurchase of our shares as an attractive and prudent use of our capital that it is in the best interest of our shareholders.\\nWith a debt-free balance sheet, ample available liquidity and strong construction of an industry recovery, buybacks allow us to opportunistically increase shareholder value while maintaining sufficient cash resources to fund our business needs. In the second quarter, we repurchased $13 million in export stock, representing approximately 1% of our shares outstanding. From an operational standpoint, Expro is well positioned in the markets that we expect will continue to benefit from strengthening industry fundamentals. In particular, Expro has significant leverage to strengthen the international and offshore markets where experience, expertise and service quality can be in Expro's case are positive points of differentiation.\\nExecution is a traditional strength of Expro and when we plan to continue to deliver on both for our customers and our shareholders. With that, I will hand the call over to Quinn to discuss our financial results.\\nQuinn Fanning -- Chief Financial Officer\\nThank you, Mike. Good morning and good afternoon to everyone on the call. As Mike noted, I will cover the results for the quarter ended June 30th, 2022, and will primarily highlight our sequential performance compared to the quarter ended March 31st , 2022. To recap, we reported revenue of $314 million for the June quarter, which was up sequentially $34 million or approximately 12% relative to Q1 2022.\\nThe sequential increase in revenue was driven by higher activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific segments, partially offset by lower activities in the Middle East and North Africa segment. Adjusted EBITDA for Q2 2022 was approximately $51 million, representing a sequential increase of approximately $14 million or 39% relative to Q1 2022. Adjusted EBITDA margin in Q2 was 16% as compared to 13% in Q1. The sequential increase in revenue and adjusted EBITDA was driven by strong results for well flow management and well construction in North and Latin America.\\nAs highlighted in our press release, adjusted net income for the second quarter of 2022 was $0.02 per diluted share, compared to adjusted net income for the first quarter of 2022 of $0.01 per diluted share. As noted in our press release, adjusted net income for Q2 includes foreign exchange losses of $0.05 per diluted share as compared to foreign exchange gains of $0.03 per diluted share in Q1. Q2 contribution margin of 38% was up approximately one percentage point sequentially from Q1 2022, reflecting improved fall-through on higher revenue as a result of a more favorable activity mix. Q2 support costs of $70 million totaled 22% of group revenue and were down approximately $1 million sequentially or approximately 3 percentage points relate Q1 2022 and were down $8 million or approximately 9 percentage points relative to the combined support costs of Expro Frank's in Q4 2020, which was the last full quarter prior to the announcement of the merger.\\nThis represents approximately $30 million of annualized support cost savings achieved through the second quarter of 2022. In the near term, we expect to continue to manage total support costs to 22% of group revenue. With modest net pricing gains and/or incremental cost synergies, we believe we can manage overall support costs to about 20% of revenue. Total liquidity at quarter end was approximately $309 million.\\nCash and cash equivalents, including restricted cash, was $179 million as of June 30th. Total liquidity also includes $130 million that is available to the company for drawdowns as loans under our $200 million revolving credit facility. The balance of the facility is available for bonds and guarantees. Expro had no interest-bearing debt at quarter end Q2 2022, and the company has no interest-bearing debt today.\\nDuring the quarter ended June 30th, cash provided by operating activities was $2 million as compared to cash used in operating activities of $14 million in Q1. Q2 adjusted operating cash flow, reflecting cash used in operations before cash paid for interest, severance and other expenses and merger integration expenses, was positive $10 million compared to negative $1 million in Q1. Capital expenditures totaled $21 million in the second quarter compared to $11 million during the first quarter. For the second half of 2022, the company is planning for capital expenditures in the range of approximately $60 million to $70 million, implying total capex for 2022 of $90 million to $100 million or approximately 8% of expected revenue.\\nWe also continue to expect to be free cash flow generative for 2022, but as noted on our last earnings conference call, we expect that adjusted cash flow from operations and free cash flow will be heavily weighted to the second half of the year. Consistent with comments from several of our public peers, Expro's investment in working capital was up materially in the first half of 2022, with higher receivables reflecting higher activity levels and higher inventory reflecting both an expectation of continued momentum in the business and the procurement of long lead items, including critical spares. Consistent with historic patterns, we expect a reversal of the H1 build in working capital and a significant improvement in cash generation in H2 2022. As Mike previously discussed, under our recently announced stock repurchase program, during the second quarter, we opportunistically repurchased 1.1 million shares or approximately 1% of our shares outstanding for a total cost of $13 million.\\nThis program is a reflection of the long-term confidence we have in our business, which we believe is not reflected in the current market valuation. In due course, we will more formally articulate Expro's capital allocation priorities. For now, we expect that the small buyback will be completed in Q2 and for that matter, any additional buybacks will be funded by free cash flow. Now, moving into the details for reporting segment.\\nNorth and Latin America or NLA, revenue for the second quarter of 2022 was $130 million, a sequential increase of $26 million quarter over quarter. The increase was primarily due to higher revenues across all of our product lines during the current quarter with a significant increase in well flow management revenue in Mexico and higher well construction revenue in the U.S. and Guyana driven by higher customer activity levels during the just completed quarter. NLA segment EBITDA for the three months ended June 30th, 2022, was $39 million or approximately 30% of segment revenue.\\nIt was up sequentially by $17 million quarter over quarter. For Q1 2022, NLA segment EBITDA was 21% of segment revenue. The increase was attributable to higher activity and a more favorable product mix during the three months ended June 30th. For the Europe and Sub-Saharan Africa or ESA segment, revenue in Q2 was $90 million, which was up $8 million or approximately 10% quarter over quarter.\\nThe sequential increase was primarily driven by higher wealth flow management revenue in Angola and in the Congo and higher well construction revenue in the United Kingdom due to increased customer activities. The increase in revenues was partially offset by lower well intervention integrity revenue in Norway and Western Europe. ESA segment EBITDA for the second quarter was $15 million or approximately 16% of segment revenue, a sequential increase of $3 million quarter over quarter. The increase was primarily attributable to higher activity levels and a more favorable activity mix during the June quarter.\\nFor the Middle East and North Africa or MENA segment, revenue in the second quarter was $45 million, a decrease of $6 million or approximately 11% quarter over quarter. The sequential decrease was driven by lower equipment sales related to wealth management in Saudi Arabia and in the United Arab Emirates, partially offset by increased wall management activities in Algeria. MENA segment EBITDA for the June quarter was $14 million, a sequential decrease of $1 million quarter over quarter. Segment EBITDA margin was consistent with the prior quarter at 30%.\\nThe reduction in segment EBITDA was primarily due to lower activity. For Asia Pacific, or APAC, revenue for the second quarter was $48 million, which was an increase of $4 million or approximately 11% sequentially. The increase in revenue was primarily due to higher subsea well access revenue in Australia and Brunei and higher well construction revenue in Japan. The increase in revenue was partially offset by lower wealth flow management revenue in Thailand and in India.\\nAPAC segment EBITDA for the June quarter was $4 million or approximately 9% of segment revenue, a decrease of $1 million or about 3 percentage points quarter over quarter. The reduction in segment EBITDA in APAC, despite the increase in revenue was primarily due to additional mobilization and commissioning costs on a large subsea project that were incurred during the quarter as well as lower activity on higher-margin contracts. Additional commissioning costs on the Subsea projects, which totaled approximately $3 million and associated project start-up delays are in part COVID related and should be nonrecurring. As a result, we expect that revenue and segment EBITDA margin in APAC will trend positively in H2 2022 and into 2023.\\nAs Mike mentioned, our integration plans are progressing well, and we are already starting to realize significant synergy benefits we anticipated when we first announced our business combination in March of 2021. As Mike mentioned, through the second quarter of 2022, we have identified an action to approximately 100% of our synergies capture plan, both in regards to headcount and annualized value in dollars. We also completed the consolidation of several international facilities and made good progress on our ongoing migration to a single ERP platform, which should allow us to both to streamline a number of key business processes and begin to action additional cost synergies. As to our near-term outlook, we expect that Q3 2022 revenue will be up sequentially by plus or minus 8%, reflecting continued business momentum at NLA, the continuation of the seasonal rebound in ESA and the start-up of new contracts in MENA and APAC.\\nAdjusted EBITDA margin in Q3 should be in the area of 15% to 17% of consolidated revenue. Over the next couple of quarters, we continue to expect that our revenue run rate will approximate that of the pre-pandemic 2019 revenues of Legacy Expro and legacy Frank's on a combined basis. And we, therefore, reaffirm our guidance, the Q4 revenue should fall within a range of $325 million to $350 million. With the benefit of fall-through on incremental revenue and synergies, we expect that adjusted EBITDA margins will be in the area of 20% of revenue as we exit the year.\\nProvided our H1 build in working capital reverses in H2 2022 as is currently anticipated, absent additional M&A and/or share repurchases, we expect that our year-end cash position will be at or above where we started the year with cash generated from operating activities, funding integration costs, capex, the Q1 acquisition of SolaSense and the share buyback that was completed in Q2. By preserving and protecting our currently strong financial profile and by maintaining a disciplined approach to investment, we believe Expro will have sufficient financial flexibility to fund growth and increase returns to shareholders. As always, our objective is to enhance long-term value for our shareholders, employees, partners and the communities in which we operate. With that, I will turn the call back over to Mike for a few closing comments.\\nMike Jardon -- Chief Executive Officer\\nThank you, Quinn. We delivered exceptional operational performance that drove significant growth on a top and bottom line and is beginning to demonstrate the true capability of the company. Our broad portfolio of services and solutions continue to create opportunities in the growth markets that will be key to Expro's long-term success. Our innovative platform, next-generation technology and solutions and ESG applications are differentiators that continue to rapidly advance our reputation and outstanding track record with customers as a leading well expert.\\nWe continue to secure contracts and demonstrate the value of the breadth of our portfolio and the depth of our expertise can bring to clients across the life of their wells. Looking forward, the positive signs of a recovery we saw in the first quarter continued to gain momentum. We are seeing increased demand for our services and solutions as the recovery that began within the U.S. onshore market has begun to gain traction in the offshore international markets.\\nWe remain confident that the pipeline of projects we are seeing will support strong multi-year growth and firmly believe Expro is uniquely positioned to capitalize on this favorable outlook. We are incredibly excited about the strength and positioning of Expro. Our results could only have been achieved by the hard work and focus of our team. It's through their dedication that we continue to accelerate growth, improve profitability and enhance value for shareholders, employees, customers and partners.\\nThank you, again.\\nQuestions & Answers:\\nOperator\\n[Operator instructions] Our first question today comes from James West from Evercore ISI. Your line is open. Please go ahead.\\nJames West -- Evercore ISI -- Analyst\\nGood morning, guys.\\nMike Jardon -- Chief Executive Officer\\nGood morning James.\\nJames West -- Evercore ISI -- Analyst\\nSo one, Mike -- so curious, it seems like we've gone through a bit of acceleration in demand here over the last quarter, maybe two quarters in a sense of urgency has arisen within your customer base? I guess -- so first, is that -- am I getting that correct? And that this urgency is kicking in? And then second, are you seeing more of that urgency or increased demand on producing assets or new assets or interventions versus new well construction type work.\\nMike Jardon -- Chief Executive Officer\\nYes. So James, I can tell you one of the good things is we've really -- now that we're kind of more exited the pandemic. I've been able to spend an awful lot more time with customers, not only in the U.S., but in particular, Middle East and Asia. And what I'd say is the conversations particularly around new FIDs, new projects, new drilling and completion type activity, that's much more constructive, much more dialogue and discussion around that.\\nI'd say that the -- we've had continuing strong commentary and strong game with customers around producing assets. So that's -- I think that's ramping up, but not at the same rate as the positivity from the discussions around new well type -- new well drilling activity and new well completion activity.\\nJames West -- Evercore ISI -- Analyst\\nOK. Fair enough. And then on the pricing side, are you -- at this point, are we back to kind of -- or getting close to back to pre-pandemic type of levels? Admittedly, offshore wasn't as robust even then, but it's growing and robustness now. But are you achieving the returns on capital investments that you would like to see when you're allocating capital and what you're pricing new contracts?\\nMike Jardon -- Chief Executive Officer\\nSo I would -- and I tried to allude to it in my earlier comments, we're starting to see some spotty opportunities to push price, and we're pushing price every opportunity we can. It's more selective right now. I think we'll continue to gain more momentum around our ability to continue to press price as we exit '22 going into '23, but we are starting to have -- it hasn't quite turned the quarter, so to speak, like North America. U.S.\\nland has where there's lots of pricing leverage and pricing traction. But we are starting to see in some particular markets and some particular service lines, positive opportunity to continue to get that pricing. And I think we're all keen to make sure that we start to implement that absolutely as soon as we can.\\nQuinn Fanning -- Chief Financial Officer\\nJames, I think the only thing -- I could just point you back to Mike's prepared remarks, there are capacity constraints within certain solutions and certain product groups, complex well construction or to provide construction activity or TROs, as well as the subsea landing streams. It's obviously a market that is supported by just a handful of service providers ourselves being one of the two larger ones product lines. But obviously, everything about the supply and demand, there's less than a supply for those two equipment classes. The other thing I'd highlight is with the pickup in drilling and completion type activity.\\nIt's not necessarily how we present our supplemental disclosures. But what we consider to be our drilling completions over businesses, they were up 20% quarter-over-quarter revenue-wise and the thoughts for margins on the incremental activity is north of 50%. So that's really where you get the --\\nJames West -- Evercore ISI -- Analyst\\nOK. Got it. Yes, no doubt. That's going to be very helpful.\\nOperator\\nOur next question comes from David Anderson from Barclays. The line is open. Please go ahead.\\nDavid Anderson -- Barclays Capital -- Analyst\\nHey. Good morning, Mike. I was just curious which of your product lines showed the greatest margin improvement this quarter. And I think you maybe just touched on it just now here.\\nBut curious if there's been much of improvement in well construction, in particular, as a rental business in TRS with high offshore exposure. Just curious how we should be thinking about the margin expansion upside in that particular business and how that should contribute overall.\\nMike Jardon -- Chief Executive Officer\\nSure. We alluded to some of this in the prepared remarks. What kind of additional commentary I'd add to it, David, is we've really seen some increased mix, better mix of activity in North Latin America, in particular. So yes, particularly around TRS around well construction, we've been able to start to see some margin expansion there.\\nAnd then I think overall, what you're really seeing is starting to gain more traction with the cost synergies we're taking out the organization overall. We're in essence, we're a full quarter ahead of that. And I think one of the real positives of us being able to get the synergies implemented is if we're being to completely honest, anytime you're doing a consolidation, you're doing a merger, if there is a little too much internal focus that goes on. It's a necessary part of the eval as doing a merger as we can get more of that behind us, and we'll largely because we're a quarter ahead of it, that means going in exiting '22 and going into '23, we're really going to be much more externally focused.\\nAnd that's one of the reasons why I've been challenging the organization is so hard to make sure we get these things done sooner rather than later. But overall, we're seeing margin expansion across well construction and even in some of the well flow management and subsea access, we're getting some traction in all three of those right now.\\nDavid Anderson -- Barclays Capital -- Analyst\\nSo if I just stay on the well construction side, we're hearing a lot of talk about rigs coming back to work both on the jack-ups and the deepwater side. Are you getting inquiries for those? I'm just kind of curious, it's obviously only a couple of players in the TRS business. So I'm just kind of curious, are you starting to kind of roll out some additional equipment at been sidelined for a while. Can you help us give us a handle on what that looks like in terms of, I guess, your capacity type of equipment out there and how that's moved up?\\nMike Jardon -- Chief Executive Officer\\nYes. No, absolutely. We are seeing the same phenomenon that the drillers are seeing today with increased utilization, those kind of things. Because keep in mind, a drilling rig and TRS type equipment goes kind of hand in hand.\\nSo yes, we're able to start to put some of that equipment back to work. I referred to a casing running tool CRT opportunity we execute on in Brazil. That purely is taking assets and resources that were underutilized previously and putting those to work. So on the flip side of that, yes, we're seeing good traction with all construction.\\nThe other thing that we're seeing even more so than I had anticipated was it really becomes an early warning radar system for us, so to speak, because typically, with customers, they select the rig first almost in conjunction with that are certainly right behind it is selecting the TRS provider. And then you start moving into well completions and well testing, and those type of activities. So we're getting earlier customer engagement. And I think that we'll continue to see that allow us to more upholster revenue opportunities, those types of things.\\nDavid Anderson -- Barclays Capital -- Analyst\\nThat's interesting. So if I just -- on that on that well flow management, it was up 14% sequentially this quarter, I'm pretty sure what was pretty strong for business that I thought we would consider later cycle, more production focused. So I guess the question was, I think you had said in your remarks that MENA was a little bit weaker than expected. So where were the results? Was it more mix related this quarter? Was it regional? Was something else kind of picking up and offsetting what you said? I mean, because I would have thought MENA would have actually been a driver of that growth.\\nAnd it sounds like it wasn't --\\nMike Jardon -- Chief Executive Officer\\nSure. MENA for us was really -- we had kind of a quarter-on-quarter product sales that didn't reoccur in the second quarter. So that was what gave us a little bit of softness there. Our strong activity in the Middle East, Algeria, in particular, was actually up quarter on quarter.\\nWhat is important to recognize with well flow management is, in particular as well testing, we can utilize those assets in a well completions cleanup load or you can use those assets in a production optimization mode. And that allows us to kind of flex that equipment to deploy it into one or the other. And part of the growth we saw was starting to see some better activity from a new well completions, new well flowback, those type things within the quarter.\\nDavid Anderson -- Barclays Capital -- Analyst\\nOK. Thank you very much.\\nMike Jardon -- Chief Executive Officer\\nAbsolutely. Thanks for the questions.\\nOperator\\n[Operator signoff]\\nDuration: 0 minutes\\nCall participants:\\nKaren David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations\\nMike Jardon -- Chief Executive Officer\\nQuinn Fanning -- Chief Financial Officer\\nJames West -- Evercore ISI -- Analyst\\nDavid Anderson -- Barclays Capital -- Analyst\\nMore XPRO analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, and welcome to the Monster Beverage Company Second Quarter 2021 Conference Call. [Operator Instructions]\\nI would now like to turn the conference over to Rodney Sacks, Co-CEO, to begin the call. Please, go ahead.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nGood afternoon, ladies and gentlemen. Thank you for attending this call. I'm Rodney Sacks. Hilton Schlosberg, our Vice Chairman and Co-Chief Executive Officer, is on the call; as is Tom Kelly, our Chief Financial Officer.\\nTom Kelly will now read our cautionary statement.\\nThomas J. Kelly -- Chief Financial Officer\\nBefore we begin, I would like to remind listeners that certain statements made during this call may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and are based on currently available information regarding the expectations of management with respect to revenues, profitability, future business, future events, financial performance and trends, as well as the future impact of the COVID-19 pandemic on the company's business and operations.\\nManagement cautions that these statements are based on our current knowledge and expectations and are subject to certain risks and uncertainties, many of which are outside the control of the company that may cause actual results to differ materially from the forward-looking statements made during this call. Please refer to our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K filed on March 1, 2021, including the sections contained therein entitled Risk Factors and Forward-looking Statements, for a discussion on specific risks and uncertainties that may affect our performance. The company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events or otherwise.\\nI would now like to hand the call over to Rodney Sacks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThank you, Tom. The company's top priority remains the health, safety and well-being of its employees. The company's flavor manufacturing facilities, its co-packers, warehouses and shipment facilities have operated throughout the COVID-19 pandemic. The company's bottlers and distributors are operating, and the company's products remain generally available to consumers. In limited countries, the operations of the company's bottlers and distributors have, in part, been negatively affected for varying periods of time. Despite the ongoing impact of the COVID-19 pandemic, the company achieved record second quarter net sales. Currently, the company does not foresee a material impact on the ability of its co-packers to manufacture and its bottlers and distributors to distribute its products as a result of the COVID-19 pandemic.\\nThe company's supply chain remains largely intact. However, the company continues to experience shortages in its aluminum can requirements in the United States and EMEA, given the company's volume growth and the current supply constraints in the aluminum can industry. The company is also experiencing delays in procuring certain ingredients, both domestically and internationally. As a result, the company was unable to fully satisfy demand in the 2021 second quarter in the United States and EMEA. We expect such challenges to continue for the next few months. The company has taken steps to source additional quantities of aluminum cans from the United States, South America and Asia. The company has entered into new supply agreements with two new aluminum can suppliers in the United States, and which are expected to be operational in the 2021 fourth quarter. We expect deliveries of additional quantities of cans increasing sequentially during the latter part of the year.\\nLogistical issues, including shortages of shipping containers and port of entry congestion could delay ongoing international supply of aluminum cans. Separately, we are continuing to experiencing -- experience freight inefficiencies as well as significant increases in domestic and international freight costs and like other beverage companies are incurring increased aluminum can and other costs in the current environment, all of which in addition to other factors, will continue to adversely impact gross margin percentages. In the second quarter of 2021, net sales were $1.46 billion compared with $1.09 billion in the second quarter of 2020, an increase of 33.6%. Adjusting for foreign currency movements, net sales for the 2021 second quarter would have been up 30.1%. Gross profit as a percentage of net sales for the 2021 second quarter was 57.2% compared with 60.3% in the 2020 second quarter. The decrease in gross profit as a percentage of net sales for the three months ended June 30, 2021, was primarily the result of geographical sales mix and increased input costs, mainly increased raw material freight in costs and aluminum can costs.\\nOperating expenses for the 2021 second quarter were $310.9 million compared with $252.2 million in the 2020 second quarter. As a percentage of net sales, operating expenses for the 2021 second quarter were 21.3% compared with 23.1% in the 2020 second quarter. Operating income increased 29.1% to $526 million, up from $407.3 million in the second quarter of 2020. Net income increased to 29.7% and to $403.8 million compared to $311.4 million in the 2020 comparable quarter. Diluted earnings per share for the 2021 second quarter increased to 28.6% and to $0.75 from $0.59 in the second quarter of 2020. According to the Nielsen reports for the 13 weeks through July 24, 2021, for all outlets combined, namely convenience, grocery, drug, mass merchandisers, sales in dollars in the energy drink category, including energy shots, increased by 14.2% versus the same period a year ago. Sales of the company's energy brands, including Reign, were up 8.6% in the 13-week period. Sales of Monster were up 11.1%. Sales of Reign were down 6.1%. Sales of NOS decreased 4.1%, and sales of Full Throttle increased 7%. Sales of Red Bull increased 15.3%. Sales of Rockstar decreased by 15.7%, and sales of 5-Hour increased 8.5%. VPX Bang sales increased 20%.\\nAccording to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the energy drink category in the convenience and gas channel, including energy shots in dollars, increased 7.4% over the same period the previous year. Sales of the company's energy brands, which include Reign, increased 3.6% in the four-week period in the convenience and gas channel. Sales of Monster increased by 5.8% over the same period versus the previous year, Reign sales decreased 6.8%, NOS was down 10.7%, and Full Throttle was up 13.2%. Sales of Redbull were up 9%. Rockstar was down 18.6%, and 5-Hour was up 3.2%. VPX Bang sales increased 12.2%. According to Nielsen, for the four weeks ended July 24, 2021, the company's market share of the energy drink category in the convenience and gas channel, including energy shots, in dollars, decreased 1.3 points to 36.5%.\\nMonster share decreased 0.4 of a share point to 30.6% and. Reigns decreased 0.4 of a share point to two points -- sorry, 2.4%. NOS's share decreased 0.5 of a point to 2.7%, and Full Throttle share remained at 0.7%. Redbull's share increased point -- six points to 37.4%. Rockstar's share was down 1.2 points to 3.8%. 5-Hour share was lower by 0.2 points at 4.6%. VPX Bang share increased 0.3 points to 7.6%. As previously reported, Coca-Cola Energy is being discontinued in the United States and Canada by the end of 2021. According to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the coffee plus energy drink category, which includes our Java Monster line in the convenience and gas channel, increased 4.2% over the same period the previous year.\\nSales of Java Monster, including Java Monster 300, were 5.9% higher in the same period versus the previous year. Sales of Starbucks Energy were 0.4% higher. Java Monster share including Java Monster 300 of the coffee plus energy category, which primarily includes Java Monster, Java Monster 300, Starbucks Doubleshot and Tripleshot, Rockstar Roasted and Bang Keto Coffee for the four weeks ended July 24, 2021, was 51.9%, up 0.9 of a share point, while Starbucks' energy share was 45.5%, down 1.7 points. According to Stackline, which tracks energy drink sales by Amazon in the United States, in the four-week period ending July 3, 2021, sales in dollars in the energy category by Amazon, including energy shots, increased 104.5% over the same period the previous year.\\nSales of Monster increased 59.9%. And its share was 28.1%, down 7.8 share points versus the same period a year ago. Red Bull sales increased 109.4%, and its share was 16.6%, up 0.4 points. Celsius' sales increased 133.1%. And its share increased 1.8 points to 14.3% 5-hour sales increased 40.9%. And its share declined 1.3 points to 2.9%. VPX Bang sales increased 216.1%. And its share increased 1.8 share points to 5.2%. Reign's share decreased 0.1 of a share point to 5.3%. Rockstar's share increased 0.9 of a share point to 3.9%. According to Nielsen, in all measured channels in Canada, for the 12 weeks ended June 19, 2021, the energy drink category increased 17.9% in dollars.\\nSales of the company's energy drink brands increased 28.3% versus a year ago. The market share of the company's energy drink brands was 41.5%, up 3.4 points. Monster sales increased 18.3%, and its market share increased by 0.1 of a point to 35.4% -- sorry, 35.4%. NOS' sales increased 12.6%, and its market share decreased 0.3 of a point to 1.9%. Full Throttle sales decreased 2.1%, and its market share decreased 0.1 of a point to 0.6%. Red Bull sales increased 18.1%, and its market share increased 0.1 of a point to 38.7%. Rockstar sales decreased 8.6%, and its market share decreased 3.3 points to 11. 4%. GURU's sales increased 35.9%, and its share increased 0.5 of a share point to 4%.\\nAccording to Nielsen, for all outlets combined in Mexico, the energy drink category increased 45.2% for the month of June 2021. Monster sales increased 38.7%. Our market share in value decreased by 1.3 points to 27.2% and against the comparable period the previous year. Red Bull sales increased 41.4%, and its market share decreased by 0.2 of a point to 6.5%. Vive 100 sales increased 30.2%, and its market share decreased by 2.4 points to 20.5%. Volt's sales increased 41.1%, and its market share decreased 0.5 of a share point to 18.5%, while B:oost's sales increased 15.7%, and its market share decreased 1.3 points to 5.1%. Amp's sales increased 91.9%, and its market share increased 4.4 points to 17.9%. Predator, which was launched in March 2020, achieved a market share of 3.1%.\\nThe Nielsen statistics for Mexico cover single months, which is a short period that may often be materially influenced positively and/or negatively by sales in the OXXO convenience chain, which dominates the market. Sales in the OXXO convenience chain in turn can be materially influenced by promotions that may be undertaken in that chain by one or more energy drink brands during a particular month. Consequently, such activities could have a significant impact on the monthly Nielsen statistics for Mexico. According to Nielsen for the month of June 2021 compared to June 2020, Monster's retail market share in value increased in Argentina from 40.1% to 46.9% and in Brazil from 29.6% to 35.4%. In Chile, Monster's retail market share decreased from 45.7% to 41.9%. Monster Energy continues to be the leading energy brand in value in Argentina.\\nI would like to point out that the Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country-to-country and are reported on varying dates within the month referred to from country-to-country. According to Nielsen, in the 13-week period ending July 18, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 34.2% to 37.4% in Spain. According to Nielsen, in the 13-week period to the end of June 2021, Monster's retail market share in value as compared to the same period the previous year grew from 14.5% to 15.3% in Germany, from 18.4% to 19.4% in Poland and from 18.4% to 20.1% in South Africa. According to Nielsen, for the 13-week period ending June 20, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 12.5% to 16.2% in Belgium, from 24.2% to 25.3% in Denmark, from 25.8% to 28.2% in France, from 25% to 29% in Great Britain, from 6.7% to 8.4% in the Netherlands, from 27.1% to 31.2% in Norway, from 25.6% to 29.3% in the Republic of Ireland and from 13.4% to 14.5% in Sweden.\\nAccording to Nielsen, in the 13-week period until the end of May 2021, Monster's retail market share in value compared to the same period the previous year grew from 13.3% to 14.5% in the Czech Republic, from 35.1% to 37.9% in Greece and from 16.6% to 29% in Italy. According to Nielsen, in the 13-week period until the end of May 2021, Predator's retail market share in value as compared to the same period the previous year grew from 5.1% to 17.3% in Kenya and from 0% to 8.1% in Nigeria. The Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country to country.\\nAccording to IRI in Australia, Monster's market share in value for the month ending June 2021 increased from 11.6% to 14% as compared to the same period the previous year. Mother's market share in value decreased from 13.3% to 11.6% during the same period. The market share of the company's brands in Australia for the month ended June 2021 increased from 24.9% to 25.5%. According to IRI in New Zealand, Monster's market share in value for the four weeks ended July 11, 2021, increased from 9.9% to 12.4% as compared to the same period of the previous year. Live+ market share in value remained the same at 6.9%, and Mother's market share in value increased from 6.2% to 6.3%. The market share of the company's brands in New Zealand for the four weeks ended July 11, 2021, increased from 23.1% to 25.6%.\\nAccording to Nielsen, in South Korea, Monster's market share in value in all outlets combined for the month of June 2021 increased from 53.3% to 61.9% as compared to the same period in the previous year. According to INTAGE, in Japan, Monster's market share in value in the convenience store channel for the month of June 2021 was 50.6% as compared to 51% in the same period the previous year. Monster remains the market leader in Japan. We again point out that certain market statistics that cover single months or four week periods may often be materially influenced positively and/or negatively by promotions or other trading factors during those periods.\\nNet sales to customers outside of the US were $546.3 million, 37.4% of total net sales in the 2021 second quarter compared to $328.3 million or 30% of total net sales in the corresponding quarter in 2020. Foreign currency exchange rates had a positive impact on net sales in the US dollars by approximately $38.6 million in the 2021 second quarter. Included in reported geographic sales are our sales to the company's military customers, which are delivered in the US and transhipped to the military and their customers overseas.\\nIn EMEA, net sales in the 2021 second quarter increased to 105.7% in dollars and increased 86.5% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales for the second quarter was 39.8% compared to 38.1% in the same quarter in 2020, primarily due to a favorable country and product mix. We're also pleased that in the 2021 second quarter, Monster gained market share in Belgium, the Czech Republic, Denmark, France, Germany, Great Britain, Greece, Italy, the Netherlands, Norway, Poland, the Republic of Ireland, South Africa, Spain and Sweden.\\nIn Asia Pacific, net sales in the 2021 second quarter increased 5.2% in dollars and decreased 100% [Phonetic] in local currencies over the same period in 2020, largely due to sales in Japan and China. Gross profit in this region as a percentage of net sales was 44.4% versus 43.3% over the same period in 2020. In Japan, net sales in the 2021 second quarter decreased 15.1% in dollars and 13.9% in local currency, largely due to COVID-19 restrictions in Japan and distributor inventory adjustments. Depletions increased 7% during the quarter. Monster remains the market leader in Japan for the month of June 2021.\\nIn South Korea, net sales increased 63% in dollars and 50.4% in local currency as compared to the same quarter in 2020. In China, net sales decreased to 21.4% in dollars and 27.8% in local currency as compared to the same quarter in 2020. In this regard, we note that sales in the second quarter of 2020 included the initial launch of Dragon Tea. We are reevaluating the viability of this SKU and the optimal product range for China going forward. We remain optimistic about the prospects for the Monster brand in China. In Oceana, which includes Australia, New Zealand, Tahiti, French Polynesia, New Caledonia, Papua New Guinea and Guam, net sales increased to 146.5% in dollars and 98.2% in local currencies. Sales of the Monster brand in Oceana increased 210% in dollars and 155.6% in local currency as compared to the same quarter in 2020.\\nIn Latin America, including Mexico and the Caribbean, net sales in the 2021 second quarter increased to 19.7% in dollars and increased 117.6% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales was 40.7% compared to 41.2% in over the same period in 2020, primarily as a result of foreign exchange rates and certain raw materials and ingredients for products in this region are purchased in US dollars. In Brazil, net sales in the 2021 second quarter increased by 194.9% in dollars and 201.7% in local currency. Net sales in Chile increased 77.5% in dollars and 52% in local currency in the 2021 second quarter. Net sales in Argentina increased 291.4% in dollars and 458% in local currency in the 2021 second quarter.\\nIn March 2019, VPX, the maker of Bang Energy drinks, sued Monster, alleging that its Reign products infringed VPX's Bang trademarks and trade risk. A trial was held last year. And on August 3, 2021, the court issued an order denying all of VPX's claims and holding that VPX is entitled to no relief whatsoever. In fact, the court specifically found that VPX copied its bank trade risk from the original Monster Energy cans. The court's decision confirms that Monster and Poland retail partners are free to continue to sell our Reign products without any changes and without any restrictions. Monster always believed and maintained that VPX's claims were frivolous, and we are extremely pleased that the court rejected all of VPX's claims while vindicating Monster's rights. As other pending proceedings with VPX are subjudicate, we will not be answering any questions on this matter on today's call.\\nOur new product introductions in the United States in the first half of 2021 were primarily focused in the first quarter. In the United States, during the second quarter of 2021 we refreshed our can graphics on our Rehab Monster brand family as well as our Full Throttle line, also updating the name for Blue Agave to TrueBlue. Monster Energy Ultra Fiesta received a refresh and updated can graphics as well as the name change to Monster Energy Ultra Fiesta Manga. In May 2021, we launched Monster Ultra Fiesta in a 24-ounce option with an update to our Ultra Fiesta Manga plan for later this year. We are in the process of launching a new line of nonalcoholic pure energy sales under the True North brand name in 12-ounce sleek cans, which contained an organic plant-based energy blend and ingredients for immunity support. True North is being offered in six flavors, Cucumber Lime, Black Cherry, Grapefruit Lemonade, Water Mellon Mist, White Peach Pear and Mandarin Yuzu.\\nTrue North has a limited customer target in 2021 with plans for a full launch into mainstream channels in 2022. While cognizant of the can shortages, we believe that it is important to continue with our innovation plans. And to this end, we will be launching our new flavors reserve line of Monster Energy drinks in Water Mellon and White Pineapple in October 2021. We have deferred the launch of our new line of Java Monster Cold Brew Coffee + energy drinks until early 2022. In Canada, during the second quarter, we launched two new products: Monster Punch Papillon and Monster Punch Khaotic, both in a 473 ml can. In April 2021, we launched Reign Orange Dreamsicle in Puerto Rico and our second SKU in Bolivia with Monster Energy Zero Ultra. In El Salvador, we launched Fury Mean Green in May 2021.\\nIn the second quarter of 2021, we launched Juice Monster Pacific Punch and Monarch in a number of countries in EMEA. We also launched Ultra Paradise and Ultra Fiesta in a number of countries during the quarter. During the quarter, we also launched our strategic brand innovation and Predator in additional countries. In January 2021, we launched Ultra Rosa marketwide in Australia, following an exclusive lead launch with one chain in the fourth quarter of 2020. In March 2021 in New Zealand, we launched Monster Superfuel in both Purple Passion and sugar-free flavors. During the 2021 second quarter in Japan, we launched Monster Energy Super Cola with our distributor, Asahi Soft Drinks. Additionally, we effected the relaunch at retail of Ultra Paradise and began shipments in anticipation of the launch of Super Fuel early in the 2021 third quarter. Super Fuel has just gone on the shelves in Japan this week. We also launched Mango Loco in Korea in July 2021.\\nDuring the 2021 second quarter, we launched Pipeline Punch in Taiwan, Hong Kong and Macau. We also began distribution of Monster Energy Zero Sugar in the Philippines. As previously mentioned, in the second quarter of 2021, in China, we extended the national rollout of our new Monster Dragon Gold, which is non-carbonated. Our national summer on-pack promotion began in May with one of China's top consumer ambassadors. As a result of the COVID-19 pandemic, certain of our planned launches and innovation of new products in a number of Asia-Pacific markets have been deferred for a few months. However, we still anticipate such launches taking place toward the end of the 2021 calendar year. We are planning to launch a number of additional products and product lines in our domestic and international markets later this year.\\nWe estimate that July 2021 sales to be approximately 1.8% higher than in July 2020. On a foreign currency adjusted basis, July 2021 sales would have been comparable to the July 2020 sales. July 2021 had one less selling day than July 2020, which was 15.8% above July 2019, and which was 17.1% higher on a foreign currency adjusted basis. Certain production facilities, mainly from the Coke bottlers in EMEA, in particular, delayed production from July to August 2021. Furthermore, as mentioned earlier, the company has not been able to fully satisfy demand in the United States and EMEA due to a shortage of aluminum cans, which adversely impacted July sales. Such shortage was exacerbated in July as can availability did not keep pace with increased demand during the summer months. Additional cans have been sourced from domestic and overseas suppliers with expected deliveries increasing sequentially during the latter half of the year. We are working to replenish system inventories in order to meet customer demand as soon as possible.\\nAdditionally, the company also experienced delays in certain ingredients, which impacted supply. Our depletions remain solid as do our measured market data, as previously mentioned on this call. In this regard, we caution again that sales over a short period are often disproportionately impacted by various factors such as, for example, selling days, days of the week in which holidays for, timing of new product launches, and the timing of price increases and promotions in retail stores, distributor incentives as well as shifts in the timing of production in some instances where our bottlers are responsible for production and unilaterally determine their production schedules, which affects the dates on which we invoice such bottlers as well as inventory levels maintained by our distribution partners, which they alter unilaterally for their own business reasons.\\nWe reiterate that sales over a short period such as a single month should not necessarily be imputed to or regarded as indicative of results for a full quarter or any future period. If the COVID-19 pandemic and related unfavorable economic conditions continue in certain regions, our new product innovation launches in those regions could be delayed. In conclusion, I would like to summarize some recent positive points. Currently, the company's flavor manufacturing facilities, its co-packers, warehouses, and shipment facilities, and bottlers and distributors are all operating. We are continually addressing our aluminum can requirements, given our volume growth and the current supply constraints in the aluminum can industry.\\nWe are pleased with the new additions to the Monster Energy portfolio and are planning additional launches later in the year. We are planning to continue additional launches of our Reign Total Body Fuel high-performance energy drinks in additional international countries. We are pleased with the rollout of Predator and Fury and our affordable energy drink portfolio internationally. We are proceeding with plans to launch our affordable energy drinks in a number of international countries during the year.\\nI would like to open the floor to questions about the quarter. Thank you.\\nQuestions and Answers:\\nOperator\\nThank you. [Operator Instructions] The first question will come from Dara Mohsenian with Morgan Stanley. Please go ahead.\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nHey, guys.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nHey, Dara.\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nGreat top line growth in the quarter, but we have seen share losses in US track channel data worsened recently. A, just short-term, how much of that do you think is attributable to out of stocks and the supply constraints that you mentioned? Is that a material factor in retail sales?\\nAnd then maybe, b, from a longer-term standpoint, it has been a couple of quarters now where the share losses have reaccelerated year-over-year, just some progress in the beginning of the year. So, I was just hoping you could review some of the key factors that have been driving the share losses in the US? And how you think about those factors going forward in terms of continuing or dissipating and how you guys are positioned? Thanks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nHilton, if you take that, and I'll also say something once you've...\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nAll right. I think, Dara, what's important is that, that's not a result and not due to us not growing. We are not keeping up with our share, but our business is certainly growing. And you can track that from Nielsen. You can also track that from the non-measured channels, which are growing really very nicely. So while we're not keeping up necessarily with Red Bull in the major channels.\\nAs I've spoken on previous calls, Red Bull had a very large on-premise business, which has moved to off-premise and moved to off-premise during COVID. And that led to an acceleration in their share. However, we mentioned that we had and are continuing to sustain can issues and result in supply. And of course, that's having an impact on the share numbers that you are seeing.\\nSo I think on balance, the business is growing. You've seen the results. It's continuing to grow. And we are growing, but not at the extent of the market. I think with the full deck of cards, the situation may well be very different. But right now, we really are struggling with sufficient supplies of aluminum cans really to keep up with demand, which is, I suppose, a good position to be in. And on the other hand, is not such a good position to be in. The business is growing. And, that's the message I want to leave you with and other investors.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nI think in -- I'll just add two short points in that regard. I think what we've tried to do is to try and also basically focus on our faster selling and our larger SKUs, which has necessarily resulted in some of the smaller SKUs, which normally have their own traction and followers. So those haven't got on to shelf. And then the one additional thing that I think that has negatively affected our distribution sales and distribution levels in the US is labor shortages. And I think that what we've seen is that many of the bottlers, Coke bottlers are experiencing labor shortages. And while one would ordinarily say, well, everybody is going to have the same problem.\\nI think that where you have Red Bull is our main competitor, they have a dedicated system. I think they've been able to address their labor shortages just more effectively than the larger bottlers with large labor pools. And that has also, I think, detrimentally affected our distribution levels going forward. But again, I think those are things that once things start settling down and things will get back to normality, that's something that I think that will also, in due course, right itself.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nYes, I think we should also -- Dara, I think we should also add that what we're seeing with cans is something that will persist through this year. I'm a bit more optimistic about the fourth quarter because we have two new can suppliers coming on board. But the situation will persist. And then next year, we should be in -- we believe we'll be in very good shape. But again, it all depends on consumer demand, which is growing, and you've seen that month-by-month and quarter-by-quarter.\\nOperator\\nAnd the next question today will come from Bonnie Herzog with Goldman Sachs. Please go ahead.\\nBonnie Herzog -- Goldman Sachs -- Analyst\\nThank you. Hi, everyone. I just wanted to ask about your gross margins. Clearly, they continue to be pressured as broadly expected, which you guys have been discussing with us. But just want to get your outlook for these pressures in the back half of the year? Hilton, you just mentioned that you're optimistic. So just wanted to verify that you still expect some of these pressures to ease by Q4? Or do you think it's going to take a little bit longer, especially in light of the recent spike in aluminum prices. So trying to understand how that factors in? And then just a clarification on the can shortages that you mentioned that you're still experiencing, I guess, it sounds like it's getting worse, but I really did want to clarify that. And is there any way that you guys could quantify how big of an impact the supply shortages had on your top-line either in the quarter or in July? Just trying to understand how much you think your shipments would have been up in July without these shortages, for instance? Thanks.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nOkay. So let me deal with the first issue first, if I may. I spoke about optimistic about can supplies. I really didn't talk about margins. You'll recall on the last call, I spoke about the issues that we were confronting with margin pressures like most other beverage companies. And where we are right now with aluminum, I mean, nobody knows. So you can talk to the leading banks in the field, which we do on a regular basis, and they really are pulls apart about their projections for aluminum in 2022, let alone 2021.\\nSo the last couple of days, you've seen a spike in the Midwest premium from this tax that is expected to be imposed on Russian aluminum. And as, you know, the Midwest premium is strongly factors the last ton of aluminum to enter the US and the cost of that. And so we've seen a spike in the Midwest premium. And we continue to see spikes in aluminum. So from that score, I think we just are in uncharted territory. I've been in this business for a long time, as you know, and I've never seen aluminum where it's at right now. And I've never seen the Midwest premium at these kind of levels. So aluminum, I really cannot talk about. And also when you look at our business and you look at the factors that really have affected gross margin, number one, the fact that we're selling a lot more internationally. So I talked earlier about 37.4% of our sales in the quarter outside of the US 30% last year, that obviously impacts margins. We are importing cans from a number of [Technical Issues] that obviously impacts margins.\\nIn fact, the China and India cans that we are using in the United States and in EMEA will only be filed in August in July, and they will be filled this month. So that in itself, the imputation will impact gross margins. And then to cap everything else, we have ingredient issues. We had ingredient issues, as we mentioned, in July, which again reduced the amount that we would actually sell because we didn't have sufficient ingredients to meet themselves, particularly with NOS. And so there are a number of factors that are increasing that are increasing our cost of goods.\\nAnd last quarter, I said I didn't think that margins would get better in the second and third quarters. I read they will not -- I think margins will deteriorate in the third quarter. In the fourth quarter, we're getting some relief in terms of supplies from the US on cans that are -- have been contracted for and they were contracted for two years ago. And we saw the opportunity to work with two major suppliers to get additional cans produced in the US, and that's why we have two new supplies opening, and we are an important and an anchor customer of both those facilities. But even that, you're still dependent on aluminum. We have some hedges in place, but obviously not enough to take into consideration the amount of sales and the amount of consumer demand that is out there. So that's a long-winded way of saying, I think, answering your question as best as I can.\\nAnd then just getting to your second question because you're really only allowed one. But to get to your second question, we have quantified or try to quantify the impact on can shortages in July and in this quarter and in the -- potentially in the third quarter, but I really don't want to -- I'm not comfortable with those numbers yet. A lot of detailed work is being done on them. And I just -- I can't in good contents give those numbers because we still are in the throes of kind of finalizing what we think is probably correct. Rodney mentioned in his script earlier that a number of the bottlers, he mentioned particularly in EMEA, but there were cases in the US as well, and there was a substantial case in the US where the bottlers were obviously focused on other things in the quarter and were producing Coca-Cola brands. And as a result, I think we -- our production got moved from July to August. So, when I look at July, it doesn't -- I don't get overly concerned because I know the sales are going into August.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nPerhaps, if I just on the shortage level, just to add that when we buy cans in contracted for our annual amount, they usually are sort of reasonably flat line across the year. And we used the first half of the year to build up can inventories and finished product inventories with ourselves and our bottlers. Earlier this year, obviously, demand sort of was strong, and so we really didn't have that opportunity. So what has happened is that in June and July, which is your normal peak months, the demand has been higher, but our supply has been more level until we can get more can inventories into the market. So what happened is just that we have had a sort of a heartened increased shortage in the last month and July and probably will be a little bit in August. And then obviously, as we start increasing our -- the cans we're getting in, and then we're able to balance it more and our demand balances more, we'll start to have less of a different delta between these demand and supplier and eventually be able to -- we're hoping to able to build up our inventories and supply back to normal by the end of the fourth quarter or during or by the end of the fourth quarter.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nNo one's comfortable with the level of finished goods inventories that we're running at, but it's a sign of the times. I mean, we're doing everything we can to supply our customers. And that's why we spoke about freights. Freight is a big issue, not only getting raw material ingredients into co-packing system and into our bottling system and -- but also distributing from our co-packers. And obviously, the one goes into cost of sales and freight out goes into operating expenses. So that's why you'll see freight really hitting both of those line items.\\nOperator\\nThe next question will come from Andrea Teixeira with JPMorgan. Please go ahead.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nHi. Thank you. Hi. Good afternoon.\\nThomas J. Kelly -- Chief Financial Officer\\nHi.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nHi, Andrea.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nHow are you Hilton? Hi.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nI'm good.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nYes. Just on the gross margin, because your gross margin comments were very helpful and given this deterioration obviously that its probably here to stay in the next few quarters. How are you thinking about pricing? Obviously, you can't supply the service levels that are used to with the retailers. So is that is something that takes -- obviously, you have to take into account? Or perhaps as you get more informed on how the aluminum cost will evolve, you may contemplate it again?\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nYes. With regard to pricing, we continue to evaluate pricing, honestly, on a very, very regular basis, if not weekly. So we continue to evaluate it, and we want to make a good decision. Last time around, as I mentioned on previous calls, we went out alone, and we would like to have been in a situation this time where we followed our competitor, but we have to evaluate, obviously, the business as we see it and the impact for us. What we've done is we're reducing our promotional allowances. So we're taking a price increase the other way, through reducing promotional allowances, but the impact of that reduction in the second quarter was not as we would have liked. So we are -- we really put the accelerator down and are more aggressive in reducing our promotional allowances. But we are continuing to evaluate the pricing and price increases.\\nAnd then I have to leave this call with my favorite saying, and that is, we don't bank gross profit margins, we bank gross profit dollars. And to me, the fact that we're doing everything we can to satisfy our customers as best as we can is impacting gross profit margins. But at the end of the day, we don't want to lose gross profit dollars, which is really important to ensure the sustainability of the brand. And that's the most important thing for us right now.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nThank you. Thanks fair. Thank you both.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nYeah. Basically, just make it clear, at this point, we are watching and we're not planning a price increase. We we're not adverse to a price, but we'll wait and see what the market does and what our competitors do.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nThank you, Rodney.\\nOperator\\nThis will conclude today's question-and-answer session. I would now like to turn the conference back over to management for any closing remarks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThanks very much. Thank you, everyone, for your continued interest and support of the company. We continue to believe in the company and our growth strategy to remain committed to continuing to innovate, develop and differentiate our brands and to expand the company, both domestically and abroad. And in particular, expand distribution of our products through the Coca-Cola bottler system internationally.\\nWe believe that we will be able to navigate through the challenges ahead as a result of the COVID-19 pandemic and hope that this unfortunate situation will resolve itself in the near future. We believe that we are well positioned in the energy drink category and will continue to be and are optimistic about our total portfolio of energy drink brands. We hope that you will stay safe and healthy. Thank you very much for your attendance.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 50 minutes\\nCall participants:\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThomas J. Kelly -- Chief Financial Officer\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nBonnie Herzog -- Goldman Sachs -- Analyst\\nAndrea Teixeira -- JPMorgan -- Analyst\\nMore MNST analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nGood evening, and welcome to Oyster Point Pharma's fourth quarter 2021 earnings conference call. My name is Valerie, and I will be your operator today. [Operator instructions] At this time, I would like to turn the call over to Mr. Daniel Lochner, Oyster Point Pharma's chief financial officer.\\nPlease go ahead.\\nDan Lochner -- Chief Financial Officer\\nGood evening, everyone. And welcome to Oyster Point Pharma's fourth quarter earnings conference call for the three months ended December 31, 2021. This evening, we issued a press release containing our fourth quarter and full year ended December 31, 2021, financial results and recent business highlights. In addition, our earnings press release and our Form 10-K, which were filed with the SEC after the close of market today, are available on our website under the investors and news section at www.oysterpointrx.com.\\nJoining us on our call today are Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma; and John Snisarenko, chief commercial officer. Following Dr. Nau and Mr.\\nSnisarenko and my prepared remarks, we will open up the line for questions. During the call today, we will be making forward-looking statements regarding potential future events, including statements regarding Oyster Point Pharma's potential future financial status and results of operations and our plans and potential for success relating to commercializing TYRVAYA. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. For a description of these factors, please see our annual report on Form 10-K for the year ended December 31, 2021, filed with the SEC after the close of market today.\\nI will now turn the call over to Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma. \\nJeff Nau -- President and Chief Executive Officer\\nThank you, Dan. Good evening, everyone. And thank you for joining us on our call today to discuss our fourth quarter 2021 financial results and recent business highlights. This is a particularly exciting time for Oyster Point.\\nThis is our very first earnings call where we are pleased to be reporting partial revenues from the commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease in the United States marketplace. Today, you will learn more about how we are delivering these encouraging commercial results on the launch of TYRVAYA Nasal Spray. But first, let me provide the company's 2021 business highlights. In October of 2021, we received FDA approval of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease.\\nDry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence. The dry eye market is now being introduced to the first nasally delivered, pharmaceutical dry eye therapy, and we believe that given the high level of patient and physician satisfaction that we are seeing in the field with TYRVAYA, that significant growth remains ahead. You will be hearing more shortly from John Snisarenko, our chief commercial officer, about the details of the launch of TYRVAYA Nasal Spray, but I'm happy to state that we had great partial fourth quarter commercial performance in 2021.\\nWe are happy to report that TYRVAYA Nasal Spray had a net product revenue of $1.2 million in Q4 of 2021. In addition, we recognized $5.4 million from our license agreement with Ji Xing Pharmaceuticals. We are now entering 2022, having demonstrated the ability to achieve the successful commercialization of TYRVAYA, as well as drive strong execution across multiple areas of our business, including our exclusive license agreement with Ji Xing to develop and commercialize OC-01 and OC-02 in Greater China, securing nondilutive funding and pursuing additional treatment advancements in the clinic, as well as in the R&D laboratory for patients with ophthalmic diseases. This week, we publicly announced an early commercial win with one of the largest commercial payers.\\nOur press release from Tuesday announced that TYRVAYA Nasal Spray is now covered by Express Scripts effective on February 19. This is a fantastic accomplishment for our market access team in achieving the addition of 26 million covered lives and more importantly, this early in our first full quarter since launch. Patients are increasingly gaining access to TYRVAYA in the U.S. for a disease state that, up until 2021, we believe, experienced very little innovation for the current large unmet need in dry eye disease.\\nTYRVAYA is a first-in-class cholinergic agonist nasal spray that is highly differentiated from the other pharmaceutical products in the dry eye space and includes the following potential advantages. TYRVAYA Nasal Spray has a differentiated mechanism of action as it is believed to activate the trigeminal parasympathetic pathway via the nose, resulting in increased production of basal tear film as a treatment for dry eye disease. Basal tear film is responsible for lubricating, nourishing and protecting the cornea. TYRVAYA is the only ocular surface-sparing pharmaceutical therapy for dry eye patients.\\nFor those patients with a compromised ocular surface, increasing tear production without the burden of administering a topical medication may provide a welcome method to treat their disease. For the first time, dry eye disease patients have an FDA-approved, pharmaceutical treatment option that is not administered as a topical eye drop to an already irritated ocular surface. Although we are focused on the critical launch of TYRVAYA Nasal Spray and continue to execute plans for the life cycle development of the TYRVAYA franchise, our R&D team remains committed to multiple exciting pipeline projects aimed at bringing additional innovative therapies to address diseases like neurotrophic keratopathy and severe allergic or vernal keratoconjunctivitis. In 2022, we will continue to advance our enriched tear film gene therapy platform, as well as our research and development collaboration with companies like Adaptive Phage Therapeutics.\\nWe remain excited about the ongoing OLYMPIA Phase 2 study of OC-01 nasal spray in Stage 1 neurotrophic keratopathy. We are expecting a readout in the second half of this year. NK is a disease that is currently underdiagnosed or misdiagnosed in many patients with ocular surface disease. We feel that Stage 1 neurotrophic keratopathy could represent a meaningful indication for OC-01 nasal spray.\\nOur vision and focus is clear. The world needs an innovative leader that can bring innovative and transformative ophthalmic disease treatments, and we aim to be that leader. We believe that we're building Oyster Point into a best-in-class eye care company. I would now like to turn the call over to John Snisarenko, Oyster Point's chief commercial officer, to discuss our ongoing commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease.\\nJohn Snisarenko -- Chief Commercial Officer\\nThank you, Jeff. As we have previously communicated, the dry eye disease segment is a large market with over 17 million people diagnosed in the United States alone. Only a small proportion of these patients, approximately 2 million, are currently being treated with a branded therapeutic. And over 7 million people diagnosed with dry eye disease have tried and abandoned the other available options.\\nWe believe that TYRVAYA Nasal Spray is a new treatment option for the large patient population that exists in the dry eye disease marketplace, including the refractory patients, as well as those who are newly diagnosed. As Jeff highlighted previously, we are incredibly excited to have initiated the U.S. launch of TYRVAYA Nasal Spray on November 1. We are pleased to report that as of the quarter ending December 31, 2021, data indicates that approximately 5,500 prescriptions for TYRVAYA have been filled, written by over 1,900 unique prescribers.\\nThese encouraging metrics were achieved in less than nine weeks from the launch, including holiday periods. In this short time, TYRVAYA is quickly establishing itself in the market as an exciting new option for dry eye patients. Regarding market access, a core part of our commercial strategy is to promote accelerated payer adoption of TYRVAYA to the top payer organizations. Our market access team has done a great job in securing coverage for TYRVAYA with Express Scripts National Preferred, Basic and High Performance Formularies effective February 19.\\nWith this latest formulary addition, we now have coverage for a total of 43% of U.S. commercial lives for an aggregate total of approximately 84 million lives. We are incredibly pleased with this level of coverage so early in our launch, and we look forward to further growing our market access coverage in 2022. Oyster Point remains very committed to offering comprehensive patient services that help provide access to TYRVAYA for appropriate patients.\\nWe have launched a comprehensive set of technology-driven patient services offerings aimed at enabling patients to successfully navigate the patient journey and procure TYRVAYA. Our patient support program is called TEAMTyrvaya. And for more information on this program and how to enroll, please visit the website, tyrvaya-pro.com. We have been quite diligent with the sizing of our field force, which enables us to target 20,750 eye care practitioners, covering both optometrists and ophthalmologists and representing approximately 94% of the dry eye prescriptions in the market today, helping us in our efforts to achieve the full commercial potential of TYRVAYA.\\nIn the first nine weeks of launch, our sales force was able to introduce TYRVAYA to more than 50% of the targeted prescriber base. On the marketing side, we're leveraging the latest technology, including sophisticated analytics, in-person, as well as virtual detailing, best-in-class digital and social media efforts and partners, as well as utilizing a digital online pharmacy to enhance communication and delivery of TYRVAYA to patients. We will continue to adopt the latest media and technology-driven marketing approaches to maximize TYRVAYA's share of voice and impact in the market. Our focus continues to be on broad eye care provider and patient education and marketing efforts, with targeted direct-to-patient digital campaigns leveraging TYRVAYA's differentiated MOA and nasal spray route of administration to drive a positive patient marketing experience.\\nI am so proud of our commercial team's collective efforts during this early phase of our launch, especially in these challenging times with the pandemic. I will now turn the call back over to Dan Lochner, Oyster Point's chief financial officer, to discuss our fourth quarter financial results.\\nDan Lochner -- Chief Financial Officer\\nThank you, John. I will now provide a brief overview of Oyster Point Pharma's fourth quarter financial results. Additional detail about our fourth quarter, as well as our annual financial results can be found in our Form 10-K that was filed with the SEC this evening. For the fourth quarter of 2021, Oyster Point Pharma reported a net loss of $42.1 million, compared to a net loss of $22.2 million for the same period in 2020.\\nAs of December 31, 2021, cash and cash equivalents were $193.4 million, compared to $192.6 million as of December 31, 2020. Based on our current business plan, we believe the company's available cash and cash equivalents will be sufficient to fund the company's planned operation for at least 12 months from our 10-K filing this evening. Net product revenues for the fourth quarter of 2021 were approximately $1.2 million, following the FDA approval of TYRVAYA Nasal Spray on October 15, 2021, and our subsequent commercial launch in the U.S. in November 2021.\\nApproximately half of the TYRVAYA net product revenue was attributable to channel building by distributors upon launch of the product. In addition, pursuant to our license agreement with Ji Xing, the company also recognized $5.4 million in milestone and license revenue following the FDA approval of TYRVAYA Nasal Spray, which includes the noncash consideration of Ji Xing senior common shares. The company did not generate any revenues during the third -- three months ended December 31, 2020. Cost of product revenue for the three months ended December 31, 2021, was $1.5 million and consisted mainly of third-party manufacturing costs, which included pre-approval costs, reserves for inventory obsolescence and damaged goods and product royalty expense related to Pfizer.\\nThe cost of product revenue included a reserve for inventory obsolescence of $0.9 million. The inventory manufactured prior to FDA approval of TYRVAYA Nasal Spray was charged to R&D expense. And as a result, the company expects the unit cost of product revenue will be lower until the company fully utilizes this product that was manufactured pre-FDA approval. The company started expensing pre-approval inventory in 2020 and recorded an R&D expense of approximately $4.3 million for pre-approval inventory during the year ended December 31, 2021.\\nThe company anticipates selling the remaining pre-approval inventory by the end of 2022. The company's sales and marketing expense increased by $21.8 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase was primarily due to higher payroll-related expenses of $11.7 million, inclusive of sales commission expense, as well as an increase in stock-based compensation expense of $0.5 million, both of which were primarily driven by onboarding a commercial field force in the second half of 2021. The company also incurred higher marketing -- market access, commercial and other expenses of $10.1 million in anticipation of, and in connection with, the U.S.\\nlaunch of TYRVAYA Nasal Spray. The company's general and administrative expenses increased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase is primarily due to higher G&A expense of $3.8 million related to accounting, consulting, legal and other professional expenses incurred in connection with the credit agreement, as well as the company's transition from a clinical stage to a commercial-stage company. The company also incurred higher payroll-related expenses of $2.4 million, including recruiting expense due to an increase in headcount to support an ongoing efforts to commercialize TYRVAYA.\\nThe company's research and development expenses decreased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The company's decrease in R&D expense is primarily due to the company receiving FDA approval of TYRVAYA Nasal Spray in October 2021. The company expensed inventory prior to receiving FDA approval and expensed approximately $3.5 million as R&D during the three months ended December 31, 2020. The company also incurred a fee of $2.9 million in connection with the New Drug Application submitted to the FDA in December 2020.\\nThe company incurred interest expense of $2.6 million during the three months ended December 31, 2021, primarily related to the credit agreement with OrbiMed. Interest expense included contractual interest of $1.7 million, as well as noncash expense of $0.9 million related to the amortization of loan commitment fees and accretion of other long-term debt-related costs. The company had no interest expense during the three months ended December 31, 2020. Now as we turn to our outlook, for 2022, our goal is to continue to achieve broad ECP and patient experience with TYRVAYA, including both optometry and ophthalmology offices, in order to reach the total addressable dry eye market opportunity of TYRVAYA Nasal Spray.\\nWe anticipate the three large national commercial plans will make their coverage determinations by the midpoint of the year. While we await such coverage determinations, we will continue to provide patient-assisted programs to support eligible commercial patients in gaining access to TYRVAYA. With that overview of our financials, I will now turn the call back over to the operator to open up the line for questions.\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] Our first question comes from the line of Ken Cacciatore with Cowen. Your line is open.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nHey, team, looks like a really good and clean initial launch. I was wondering if you would wanna help us a little bit with maybe the revenue pacing. I know consensus, I believe, is around $30 million. And I know there's only a few of us analysts that are formally involved in the consensus, but I think it's around $30 million.\\nSo I was wondering if you could just kind of hold hands with that number, how we should be thinking about it. And then also, we've been doing clinician checks and getting very good feedback. But I guess, you could help us, as you would have a better sense of the early retention metrics, maybe the -- be able to definitively let us know how you're seeing some of the retention numbers and patients returning. So those are my first two.\\nI'm going to ask one more, if I could, though. Could you talk, John, a little bit about any refinements or learnings of your patient support system? Obviously, early days, but wondering if you're already tweaking it a bit. Anything that seems to be working very well or you've needed to change? And with that, I'll go back in the queue. Thanks so much.\\nJeff Nau -- President and Chief Executive Officer\\nGreat. Thanks, Ken, for the questions and very thoughtful. So maybe what we could do is we'll just take those in order. So I'll turn it over to Dan to just talk about the numbers for the year.\\nAnd then, we'll go into retention and have a discussion about John's experience with the bridge programs and the different patient services.\\nDan Lochner -- Chief Financial Officer\\nYeah. Great. I would say on revenues, while we haven't really provided official revenue guidance, I would say we think about it very operationally, focus in terms of our sales reps that are out in the field doing a great job. And I would say the focus very early on and throughout 2022 will really be about growing that eye care practitioner count, and we have goals internally for what we expect to achieve on a weekly and monthly basis.\\nAnd so, I think, it really starts with getting those ECPs onboard on a monthly sequential basis and then starting to look at what the right pattern is on an NRx basis per month and then what we then start observing on that pull-through on resell rate. And so, to kind of wrap that all up, we see it sequentially building through the quarters for the entire year as we start working through that total target population that we've identified, which is roughly 20,750 targets. And I think, it would be great to have John kind of speak about how we're really going after that target base and how that's been building through the quarters. And I think, what you'll see, at least for Q4, we've hit about 1,900 of those ECPs in respect to the 20,750.\\nAnd we'll continue to really work through that population of ECPs and really build that NRx and resell rate, the TRx, and then really playing out on revenue. The other dynamic, of course, is always on gross to net. And while we're not providing official guidance on gross to net because our focus really is on that volume and share component throughout 2022, I would say there is that first-half component related to the majority of patients in the first half expecting to be on that bridge program, which has a discrete impact to gross to net. And then, with our guidance, which is focusing on coverage determinations for the big three PBMs by the midpoint of the year, that transition from bridge over to commercial insurance will have a positive benefit discretely on that line in relation to gross to net, which would kind of tie up to your question on kind of how revenues would flow from a price and volume perspective through the year.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, thank you, Dan. This is John. You asked a question around retention rates and then refill rates. We've been very, very pleased to date with the metrics we've been seeing in that space.\\nEven patients that had been prescribed in early November, we started seeing early refill rates. I could quote that if you look at our blended refill rates with retail pharmacy and our digital online pharmacy, they're hovering around 64%, 65%. So we're very pleased with patients that are coming back and getting the refills. We are getting very, very nice position, as well as patient feedback, and we are hoping to continue that trend throughout 2022.\\nI think, part of that as well is your third part of your question around patient support programs, we out of the gate wanted to really employ a lot of technology around our patient services to TYRVAYA. So we're trying to make it very easy for that patient to navigate that journey through the prior auth and benefit investigations to get them to enroll into the program through QR codes in the offices, online, as well as other digital means. So because of that, we've been getting very, very good high enrollment rates and good fill rates that come through that program. So in terms of tweaking, we're continuing to put out more patient materials to surround sound the patient with different ways to enroll into the program.\\nBut overall, we're very, very pleased with how the program has been going. If the patient is deemed insured, but not covered, they automatically popped into our bridge program that they were appropriate patients and are able to get that script fulfilled and get experience with TYRVAYA. So we'll keep monitoring the patient services program, but so far, we've been very, very pleased.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nGreat. Thanks so much. Appreciate it.\\nJeff Nau -- President and Chief Executive Officer\\nOne thing I will add on, Ken, comment there is as we think about TYRVAYA as a product, when we think about the current marketplace and what it offers to patients, from an immunomodulator perspective, patients will go on a course of an immunomodulator. If they're not happy with the outcome at the end of that course, they're transitioning off, and they're likely either going on to another product or another device or another modality, but very rarely are they coming back. So we see a very low number of patients come back to the original therapy. I think, that the one thing to really keep in mind with TYRVAYA is it works so quickly to provide the patient relief, and it has such a differentiated mechanism of action that we are excited to look forward into the future to see how patients interact with the product.\\nIt's going to be a very different interaction than you would see with an immunomodulator because I do think not only will we have solid refill rates, but we will have people coming back to the product in those later years. And so, we're excited about that. And then, I would -- I'll just throw one comment out there for my team back at the office. Our patient services program is, bar none, one of the best I've ever seen.\\nAnd it is going very well in the field. And so, kudos to the team for putting together such a great program.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nGreat. Thanks so much.\\nOperator\\nThank you. Our next question comes from Joe Catanzaro with Piper Sandler. Your line is open.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nHey, guys, thanks so much for taking my questions, and congrats on the progress here. So maybe just to follow up, I think, Dan, you mentioned you guys had some internal benchmarks, I'm sure, on a bunch of things. But I'm wondering if you can maybe help put into context the early penetration in terms of the number of unique prescribers you've seen relative to your target ECP pool and where your early expectations were there. And then, I'm wondering what aspect -- and maybe it's something you just alluded to, Jeff, what aspect of the product profile do you see as resonating the most? And how do you go about fully leveraging that? And maybe I have a follow-up as well.\\nDan Lochner -- Chief Financial Officer\\nYeah. Maybe I'll start with it on my end. As you saw in the press release, we had achieved 1,900 unique writers in the quarter, which is just under about 10% of the targets that we are going after with our sales force of 162 sales reps. And so, I think, we had great progress in the quarter just under about nine weeks.\\nAnd so, as we look at benchmarks of prior therapies that have come to market more recently, I think we're in a great place for where we had expected us to land. Of course, we also understood that this is a new way of treating dry eye disease. So really communicating the benefits with the nasal spray. And so, I think, we're quite pleased with where we landed and continue to work toward that 21,000 target count as we progress throughout the year.\\nJeff Nau -- President and Chief Executive Officer\\nAnd maybe what I'll add on to -- the second part of the question there is some of the things that are resonating. I think, one of the things that's really been exciting about the launch of this product is patient feedback has been really great. And so, we've been excited to not only hear stories from the field, see posts on social media of patients going out on their own and talking about the product. And just really, it's a great product to launch where you're having that patient feedback come back to the teams and to those folks that have put such hard work into getting the product out there into the marketplace because it's really why we do this and it really drives the team.\\nSo I think, one of the things that we hear that is something that's really encouraging is just the patients stating that they really like the profile. They like the way it's making their eyes feel, and it's just differentiated in the way that it's able to be used. So we do hear stories back of people who are unable to deliver a topical eye drop. And this is another option for them because maybe they don't have the dexterity or they're elderly and they're just not able to put a drop into their eye, and so they're able to use nasal sprays.\\nAnd the other thing that we hear in the field often is the physicians are not getting patients calling back and complaining. And so, that's also really important for us. But again, we're very early in the launch. So we have many patients that haven't been on the product for more than a few months.\\nSo we're excited to see how the long-term feedback is. But for the moment, we are really encouraged by the feedback or sometimes lack of negative feedback coming back from the patients.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nGreat. And if I maybe just squeeze in a quick follow-up. I think, you said you guys have maybe covered about 50% of your target ECPs. Can you maybe speak to what percent of those have been given a sample? And how soon after sampling are you seeing ECPs write a script? Thanks.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, no, thank you, Joe. Great question. Part of our strategy is really to introduce TYRVAYA into the office practice with the prescriber base, the technicians, the staff that are involved with training, the patients and so on prior to actually sampling because we want to make sure that the product is taken appropriately and the patient gets the best possible experience they can with the nasal spray. So we handed out quite a few samples, probably over 100,000 samples since launch.\\nBut we want to make sure that we hand them out appropriately and that installation with that office has actually taken place before that sampling is initiated. So so far, that's worked well for us because we've seen a higher proportion of patients that tried a sample, see if it works for them before they're getting into our patient hub and actually getting that prescription filled. So that kind of connection has been very, very positive with that approach.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nOK, that's helpful. Thanks, again, for taking questions.\\nOperator\\nThank you. Our next question comes from Patrick Dolezal with LifeSci Capital. Your line is open.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nGreat. I'm just curious how the availability of generic cyclosporine has impacted discussions with payers, if at all. Were there any modifications to negotiations with Express Scripts as that approval came to light? I'm just curious if you expect any impacts going forward as you onboard other payers. And then, I have a follow-up as well.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Patrick, thanks for your question. We've seen kind of early mixed reactions from the payer community on how they're going to manage the generic entry of cyclosporine. And with the early listing with ESI, they're actually covering TYRVAYA across their formularies with only a traditional step, sort of an artificial tear. So that's what I mean by mix.\\nSome of the payers are kind of waiting until more than one generic comes out, and they'll take a look at the dry eye space or they're not really managing the dry eye space as closely. And others are going to evolve a little quicker. So we're able to modify our approach. We are ready for a generic to be on the market or not with.\\nAnd that's the way our negotiations are going with the major PBMs. And our goal is to get access for TYRVAYA on a level playing field with the branded therapeutics. And our differentiation along with our strategic contracting will help us get there.\\nJeff Nau -- President and Chief Executive Officer\\nAnd one other comment, Patrick. As you well know, generic entry into the marketplace doesn't change the dynamic that exists where patients cycle off many of these drugs, whether it be for lack of effect or side effects or whatnot. And so, that certainly will not change. So we were planning on generic entry coming.\\nI think, we've been planning for a long time, but it's been always in the back of our mind, and so the team is ready.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nThat's helpful. Thanks. And as it relates to just drug launch surrogates, there's not a ton in the dry eye space really, but obviously, we do have these eye drops. Just curious to hear any similarities and differences that might be worth pointing out.\\nAnd just if you could comment on the role of coverage and driving drug adoption in the dry eye space generally, that would be helpful. I'm curious if there's a tipping point where you feel that the amount of coverage really will drive adoption, 50% if it's a bit more. I would love to hear your thoughts there. Thanks.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Patrick, in regards to the Xiidra launch, we did see very quick uptake. Well, this was back in 2016. They had very early access to the commercial insurers, and they launched with 280-plus reps. We are very pleased with the number of reps we have and the trajectory we're seeing with TYRVAYA.\\nWe are on track in regards to the payer negotiations. And in fact, the ESI listing was an early listing for us. So we will get to that point that we're expecting in terms of broad base of writers, the eye care professionals prescribing TYRVAYA. We just won't be out of the gate as quickly as you saw with the Xiidra launch.\\nI could tell you, versus the latest two launches, we're very pleased with how our trajectory is going versus kind of the more recent entries. But it was a different space back in 2016, less managed, and also they were second entry at the time after Restasis.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nThat makes sense. Thanks for taking the questions.\\nOperator\\nThank you. Our next question comes from Chris Neyor with J.P. Morgan. Your line is open.\\nChris Neyor -- J.P. Morgan -- Analyst\\nGreat. Thanks for taking the questions. So first one is on me -- for me is just wanted to get a bit more details on the Express Scripts contract. So really just thinking about what's the mix between preferred and non-preferred coverage within those 26 million lives that you had estimated.\\nAnd within the Express Scripts plan, are there -- is there potential for additional pickup of patients and additional contracting that would either add additional patients or move more patients toward preferred access? And when talking about that kind of mix -- the mix of customers, what type of co-pay should we be thinking about for most of these patients? I think, I have a couple of follow-ups after that.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Chris. No, thanks. In regards to ESI, whether preferred or non-preferred, in terms of access whether you're listed preferred or non-preferred, the key criteria is you have to have tried and failed on an artificial tear for all of the branded products here. So as you mentioned in the last part of your question, the out-of-pocket is a difference between the Tier 3 and a Tier 2.\\nAnd pretty appropriate patients, commercial patients, we definitely buy down that out-of-pocket to be very competitive with the leading branded product out there. So we feel our 26 million lives that are covered are on a level playing field with regard to the leaders out there. And that -- those are the majority of the larger plans within ESI, but we will continue to work with signing on some of the downstream plans that ESI covers -- sorry, that Ascent covers as well and through ESI. So the tiering for us is not a disadvantage.\\nWe feel we're going to be very competitive with the two major brand leaders out there.\\nChris Neyor -- J.P. Morgan -- Analyst\\nGreat. That's helpful. And then, you kind of touched on the refill rates and also maybe you could just discuss your confidence in being able to hit that commercial coverage for CVS Caremark and UnitedHealth by the middle of this year. And then, aside from maybe overall script trends, any other KPIs that we should be watching for the launch in the coming weeks and quarters?\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, no, Chris, in regards to the refill rates, we've been very pleased with the kind of 60%, 65% rate of refills we've been seeing. We feel that based on the product profile, as well as the services we offer to make sure that both the prescriber base, as well as the patients are supported through the clinical experience with TYRVAYA. In regards to some of the other PBMs, we are in the middle of negotiations with them. We are still on track to have coverage determinations by midyear.\\nAnd we are ready to negotiate whether they're going to be managing the generic space or not. We feel we're going to be very, very competitive to be able to get TYRVAYA listed and get the majority of those commercial lives covered by midyear of '22.\\nChris Neyor -- J.P. Morgan -- Analyst\\nPerfect. Appreciate the questions.\\nOperator\\nThank you. And I'm currently showing no further questions at this time. I would like to hand the conference back over to Dr. Nau for any closing comments.\\nJeff Nau -- President and Chief Executive Officer\\nThank you, operator, and thanks to everyone for joining the call with us today. As I mentioned in my opening remarks, we are extremely pleased to announce that TYRVAYA Nasal Spray, indicated for the treatment of the signs and symptoms of dry eye disease, is currently in its first full quarter of launch for patients and eye care providers in the U.S. We are extremely excited for the potential of significant growth that remains ahead. Our vision and focus on bringing innovative and transformative ophthalmic disease treatments to patients and building Oyster Point Pharma into a best-in-class eye care company remains our primary goal as a company.\\nIn closing, I want to thank everybody for joining us tonight and to have a great evening.\\nOperator\\n[Operator signoff]\\nDuration: 41 minutes\\nCall participants:\\nDan Lochner -- Chief Financial Officer\\nJeff Nau -- President and Chief Executive Officer\\nJohn Snisarenko -- Chief Commercial Officer\\nKen Cacciatore -- Cowen and Company -- Analyst\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nChris Neyor -- J.P. Morgan -- Analyst\\nMore OYST analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 10:00:00\",\n        \"max\": \"2023-02-23 11:00:00\",\n        \"num_unique_values\": 5201,\n        \"samples\": [\n          \"2020-08-13 07:30:00\",\n          \"2019-08-07 09:00:00\",\n          \"2020-05-04 12:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 00:00:00\",\n        \"max\": \"2023-02-23 00:00:00\",\n        \"num_unique_values\": 835,\n        \"samples\": [\n          \"2020-03-11 00:00:00\",\n          \"2023-01-10 00:00:00\",\n          \"2022-03-29 00:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 8
        }
      ],
      "source": [
        "df[\"Date_only\"]=df[\"Timestamp\"].dt.normalize()\n",
        "df.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 9,
      "metadata": {
        "id": "9I_YLNvEIyiB",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 414
        },
        "outputId": "d0cc03aa-3401-4b2a-c7d3-4d485e5147eb"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "(18375, 9)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript           Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel... 2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta... 2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc... 2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon... 2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel... 2019-08-07 08:30:00   \n",
              "\n",
              "   Date_only                                         Clean_Text  word_count  \n",
              "0 2020-08-27  At this time, I would like to turn the confere...        5623  \n",
              "1 2020-07-30  Brian G. Harris -- Senior Vice President and C...        4755  \n",
              "2 2019-10-23  Tina Correia -- Vice President, Investor Relat...        8917  \n",
              "3 2019-11-06  Joining us today are BBSIs President and CEO, ...        8286  \n",
              "4 2019-08-07  I would now like to turn the conference over t...        4611  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-f6e9a360-e1a6-4658-b4bf-c1256ed11f73\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>Clean_Text</th>\n",
              "      <th>word_count</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>At this time, I would like to turn the confere...</td>\n",
              "      <td>5623</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>Brian G. Harris -- Senior Vice President and C...</td>\n",
              "      <td>4755</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>Tina Correia -- Vice President, Investor Relat...</td>\n",
              "      <td>8917</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>Joining us today are BBSIs President and CEO, ...</td>\n",
              "      <td>8286</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>I would now like to turn the conference over t...</td>\n",
              "      <td>4611</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-f6e9a360-e1a6-4658-b4bf-c1256ed11f73')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-f6e9a360-e1a6-4658-b4bf-c1256ed11f73 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-f6e9a360-e1a6-4658-b4bf-c1256ed11f73');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-da3ce29e-9dd3-4a86-8aa4-d0524102db4a\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-da3ce29e-9dd3-4a86-8aa4-d0524102db4a')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-da3ce29e-9dd3-4a86-8aa4-d0524102db4a button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 18375,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5681,\n        \"samples\": [\n          \"May 10, 2022, 8:30 a.m. ET\",\n          \"Feb 16, 2021, 8:00 a.m. ET\",\n          \"Jun 01, 2022, 4:30 p.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2872,\n        \"samples\": [\n          \"NASDAQ: TTSH\",\n          \"NYSE: WDH\",\n          \"NASDAQ: HOPE\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q3\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2869,\n        \"samples\": [\n          \"CRWD\",\n          \"AME\",\n          \"WRLD\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17220,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nHello, and welcome to today's Expro Q2 2022 earnings presentation. My name is Elliot, and I will be coordinating your call today. [Operator instructions] I would now like to hand over to Karen David-Green. The floor is yours.\\nPlease go ahead.\\nKaren David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations\\nWelcome everyone, to Expro's second quarter 2022 conference call. I'm joined today by Mike Jardon, CEO; and Quinn Fanning, CFO. First, Mike and Quinn will share their prepared remarks, and then we will open it up for questions. We have an accompanying presentation on our second quarter results that is posted on the EXPRO website, expro.com under the investors section.\\nIn addition, the second quarter financials are downloadable on the Expro website under the Investors section. I'd like to remind everyone that some of today's comments may refer to or contain forward-looking statements. Such remarks are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such statements speak only as of today's date, and the company assumes no responsibility to update any forward-looking statements as of any future date.\\nThe company has included in its SEC filings, cautionary language identifying important factors that could cause actual results to be materially different from those set forth in any forward-looking statements. A more complete discussion of these risks is included in the company's SEC filings, which can be accessed on the SEC website or on our website at expro.com. Please note that any non-GAAP financial measures discussed during this call are defined and reconciled to the most directly comparable GAAP financial measure in our second quarter 2022 earnings release, which can be found on our website. With that, I'd like to turn the call over to Mike. \\nMike Jardon -- Chief Executive Officer\\nThank you, Karen. Good morning and good afternoon, everyone. I'm pleased to share with you that Expro delivered robust operational performance and financial results that exceeded the guidance we provided for the just completed second quarter. We are experiencing increase customer activity levels across all segments of our business, bolstered by a backdrop of strengthening industry fundamentals.\\nWe believe this positive momentum will not only continue, but will also accelerate going into 2023 and beyond. Expro is poised to capitalize on an expected increase in customer spending and activity. Today, Expro has a scope and financial profile required to compete and win in what we believe is the best outlook for energy services in at least a decade. Our results in the second quarter and our market outlook underscore the benefits of Expro's balanced portfolio of services and solutions with leading capabilities and a culture built around safety, service quality, organizational efficiency and risk management.\\nIn addition, we believe our through-cycle resilience is a significant advantage and competitive differentiator for Expro. Our current portfolio of services and solutions is paired with a global operating footprint with established positions in key growth markets and the combination provides Expro with good leverage to improving industry fundamentals and in particular, to the rebound that is beginning to take place in the international and offshore markets. We have never been better positioned to capture cyclical recovery upside. We also continue to have a best-in-class innovation platform and technology portfolio that enables us to support our customers' efficiency and emissions-related goals, grow market share and capitalize on longer-term industry trends.\\nFinally, our strong balance sheet and merger-related synergies provide us with significant financial, operational and strategic flexibility that will allow us to accelerate growth and create long-term stakeholder value. On today's call, I'll touch on three main topics. First, I'll walk you through our second quarter performance. Second, I'll give an update on our integration process.\\nAnd finally, I'll provide some perspective on trends we are seeing in the broader industry environment. For the second quarter, we delivered revenue of $314 million and an adjusted EBITDA of $51 million. Second quarter revenue increased 12% sequentially and on a Pro Forma basis, 10% year over year. Higher revenue during the quarter was driven by increased activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific regions.\\nAdjusted EBITDA increased 39% sequentially and on a Pro Forma basis, 33% year over year. Adjusted EBITDA was primarily driven by a more favorable activity mix during the second quarter and faster-than-anticipated realization of merger-related synergies. Well Construction revenue was up 9% quarter over quarter and well management, which includes our well flow management, subsea well access and well intervention integrity businesses was up 13% quarter over quarter. Second quarter results exceeded the prior guidance, primarily as a result of increased well flow management and well construction revenue within North and Latin America.\\nOur team continues to both capitalize on improving industry fundamentals and demonstrate the value of Expro's broad suite of cost-effective, innovative solutions to win new business and expand relationships with existing customers. During the quarter, we continued to secure contracts because of our exceptional service quality and technical delivery. We also continued the introduction of new technologies with both CoilHose and Octopoda, achieving market adoption at pace. The current commodity price environment puts a premium on maximizing production from existing well stock.\\nSo there is a strong customer interest in well intervention integrity solutions such as CoilHose and Octopoda. The significant under investment in energy supply over the last decade, coupled with growing demand, is also resulting in FID approvals. Importantly, for our company, nearly 60% of the new customer commitments are expected to be offshore. We achieved contract wins and extensions totaling approximately $300 million, which demonstrates the breadth and depth of our customer relationships and attraction that our solutions are gaining in the market.\\nOn a regional basis, in North and Latin America, our Well Construction team continues to demonstrate the position as the premier provider of casing and tubular running services with the award of contracts and successful operations delivered across the region. The team successfully completed a first casing running to a project in Brazil and carried out eight simultaneous TRS deepwater completions in the Gulf of Mexico, where activity continues to pick up. We also deployed our industry-leading 22-inch brotpackers in Mexico for the first time and have seen growing demand for this well integrity technology as operators across the region seek to protect their assets during storm season. This technology allows for quick and rely the well suspension when operators need it most.\\nWe want to influence contract for a major operator in Brazil. And in Alaska, our team was awarded and performed a well test for a strategically important new customer, further growing our presence in this region. Expro in MENA achieved contractor of the month from an international operator, demonstrating Expro's continued focus on delivering best-in-class safety, quality and customer service. In Europe and Sub-Saharan Africa, we saw good progress in securing new business in the second quarter, including the retention of the largest well flow management contract in the Norwegian continental shelf for an initial four-year term, highlighting the strength and depth of our relationship with this international operator.\\nA significant portion of this contract is directly linked to production optimization and enhancement as well as a demonstrable commitment to low carbon plan. The breadth of our portfolio, including market-leading technologies acquired in our July 2019 acquisition of Quality Intervention directly assisted us in expanding a core well intervention contract with a major international operator in the U.K. In addition, our service quality and portfolio of capabilities helped us secure an expanded contract to meet client needs for a nine-well plug and abandonment campaign in the U.K. Continental Shelf, where we also added well test and well intervention to an existing large board subsea services contract.\\nAs I noted earlier, CoilHose and Octopoda are gaining traction in the market to support clients' intervention and integrity needs. Octopoda is a truly unique service offering, which for the first time in our industry, allows direct access to well annualized in which we can ensure well integrity and production assurance. Octopoda was recently deployed in the Congo, the first deployment of this technology in Sub-Saharan Africa, and it continues to generate customer interest with its unique ability to investigate and remediate sustained casing pressure and other well annulus problems. Additionally, our CoilHose Light Well Circulation system is an innovative development, providing a lower cost more efficient alternative to traditional coiled tubing systems.\\nThis broadening of our portfolio and our depth of experience, combined with the ability to quickly mobilize assets and personnel to meet client requirements helped us secure a U.K. contract for well testing and exploration and appraisal services in support of a new offshore drilling campaign. Expro's superior quality and service performance as strong client partnerships led to the securing of multiple contract wins, including for our subsea team in the Ivory Coast and in Turkey, where we won well testing and CoilHose intervention work for a nine-well project on offshore gas storage project. In the second quarter, we also introduced Drill Stem testing into Angola, further broadening our comprehensive portfolio in this country and positioning us to take advantage of the increasing activity in deepwater operations in Angola.\\nWe have successfully started operations in Cabinda for a major operator, which will be our first deployment of hammering services as part of an Angolan Well Construction Service package. In May, we were also recognized as the safest service provider in Mozambique. Based on our recent performance, we are in discussions with the client regarding further expansion of our services, including the introduction of new technologies. In Chad, our work with the client is core to ensuring that our operations are conducted in an environmentally responsible way.\\nOur expertise and technologies are focused on having no environmental impact with testing and analysis carried out to ensure the appropriate purity of the regional freshwater system, underlining our status as a leading provider of on-site chemistry services with a strong environmental focus. In Norway, we completed our first operational campaign with our iTong Well Construction Technology, which provides a step change in safety and well construction operations. Operational performance exceeded client expectations, delivering significant rig efficiency improvements and cost savings to the customer overall. In the Middle East and North Africa, our Well Construction team has expanded into new territory to secure their first TRS contract in Algeria, which is planned to commence later this month.\\nThis opportunity reflects one of the many revenue synergies created by our October merger. We leverage expert relationships and well flow management to secure this new TRS award. In addition, the regional team was awarded two carbon boom contracts with Middle East drilling contractors, reflecting our market-leading capabilities and reputation in the market. In Egypt, our service offering and ability to deliver contributed to Expro being awarded significant well test contracts.\\nIn the Asia Pacific region, our well construction team in Brunei secured a major 5-year contract for TRS. Our outstanding track record of reliable performance in HSC and service quality were strong criteria for the contract award. In Thailand, the team secured additional TRS work covering 200 wells and in Malaysia and in offshore China, we were awarded three-year TRS contract extensions spanning development and exploration wells. Our subsea team's technical capability played a key part in securing a contract with a major international operator in Malaysia for the provision of our new vessel deployed Light Well Intervention package, with the team also securing significant additional work in Australia.\\nLike CoilHose and Octopoda, Expro's LWI capabilities are the result of investments we have made over the last several years, which should allow the company to offer differentiated production optimization solutions and thereby grow our top line faster than the overall market, while also improving profitability. Expro is strategically committed to continuing to invest in transforming our business portfolio and reducing greenhouse gas emissions. In April, we published our inaugural, environmental, social and governance review with a stated aim of achieving net 0 by 2050 with a 50% reduction in carbon intensity by 2030. As the energy industry embraces transition and the need to make real and visible headway toward a lower carbon world, we appreciate the key enablers to change will be those who can truly differentiate themselves as solutions providers.\\nAs recognized global well experts and a trusted partner, we believe Expro is well-positioned to play an important role in enabling our clients to achieve their carbon reduction goals in support of the energy transition. Expro remains committed to allocating roughly 50% of our research and development budget to carbon reduction initiatives. In doing so, we are developing and advancing solutions that will play a critical role in enabling our customers to achieve their own emission reduction goals while also allowing experts to achieve its goals. Expro's well expertise and range of well intervention, well integrity and wells measurement technologies and skills help operators cost-effectively develop oil and gas resources while minimizing both emissions and the required operating footprint.\\nAs our industry speaks to address tomorrow's challenges, we believe many of these technologies and skills are transferable. As a good example of adopting technologies to achieve more sustainable energy solutions, Expros supported geothermal well service projects since 1986. Most notably, in the second quarter, we were awarded our first integrated services geothermal contract to support a high-profile geothermal plant in Germany. The second topic I'd like to cover is to provide an update on our integration efforts.\\nDuring the quarter, we continued to make progress in bringing the legacy businesses together to capture the full potential of our combined platform. I am pleased to report that 9 months into our integration, we have identified an action more than 100% of the $55 million in annualized cost savings that we established with our target within the first 12 months following the closing of the merger. This comes a full quarter earlier than we had initially anticipated. As outlined previously, we are targeting cost and revenue synergies between $80 million to $100 million within 24 to 36 months post-merger.\\nWe remain confident that we will achieve $70 million in projected cost synergies during this time frame, if not earlier. Cost savings are primarily driven by the rationalization of support costs, consolidation of facilities and supply chain savings. In the second quarter, we consolidated additional facilities, including locations in Baku, either by John, St. John's, Canada; Lumpur, Malaysia; Mumbai, India; Corpus Christi and Midland, Texas.\\nWhile revenue synergies are more difficult to demonstrate, my sense is that our previous estimate of an incremental $10 million to $30 million in EBITDA for revenue synergies through our expanded customer relationships and operating footprint, increased time on rig and greater exposure to the full life of the field will likely prove to be conservative. I'd like to sincerely thank the entire expert team for their hard work and numerous contributions toward helping us realize our integration goals ahead of schedule. Without a doubt, we have a winning team that has proven the building to deliver on our commitments. Before I turn the call over to Quinn, I want to provide some perspective on trends we are observing in the market.\\nThe positive signs of a recovery we saw in Q1 continued to build, underpinned by a favorable supply demand dynamic. As I noted earlier, this is largely a result of limited upstream investment in recent years and a need for additional capacity to meet projected demand growth. With the more recent heightened focus on energy security, diversification of supply and the need to replace at least a portion of Russian oil and gas supply is expected to fully magnify what was already set up to be a favorable multi-year macro backdrop for OFS activity. Longer term, we believe the service sector will need to play an important role in facilitating the energy transition.\\nSo despite ongoing volatility in commodity prices, the fundamental backdrop for the energy services sector is quite constructive. In particular, after a strong recovery in the U.S. onshore market, we are seeing increasing demand for our services and solutions with international and offshore activity expected to accelerate through the second half of 2022 and into 2023 as operators look to increase production from existing assets and develop new fields. Notwithstanding near-term concerns of an economic slowdown, there seems to be a consensus that energy demand will trend back toward, if not through 100 million barrels of oil equivalent per day in 2023.\\nWe expect that increasing demand for energy services and capacity constraints in key service offerings, including high-end well construction equipment and subsea test trees should provide scope for improvement in net pricing beginning in late 2022 into early 2023. In Expro's view, expected growth will be broad-based geographically, span all phases of oil and gas development and include all operating environments. Geographically, we see strong potential in North and Latin America, the Middle East, North Africa, Sub-Saharan Africa, as well as Asia. And while many of our customers continue to focus on brownfield enhancement programs to maximize previous investments, we are also starting to see growth in exploration and development activity driven primarily by North and South America, with further activity expected in Norway, India and Sub-Saharan Africa.\\nThe brownfield focus will support steady growth in our well Intervention Integrity business as well as elements of our well flow management business, collectively, which represent about 35% of our business. The remaining circa 65% of our business is generally levered to drilling, well construction and well completions activity, which we believe is points for strong growth across several geographies and within which we generally capture very good faster on incremental revenue. Overall, the outlook for the remainder of '22 and into 2023 remains positive with sustained increases in E&P expenditures. After rather dramatic recovery in the North America onshore market, customer dialogue and tendering activity indicates to us that the outlook for offshore activity is strengthening.\\nThis should support sustained growth for Expro given our leading and differentiated portfolio capabilities and subsea well access services, complex well construction services and production optimization. This is particularly important as approximately 70% of our revenue today is generated from offshore activity. Before I close, I'm pleased to share that during the quarter, our board approved a new stock repurchase program under which the company is authorized to acquire up to $50 million of its outstanding common stock up to the November 2023 time frame. We view the repurchase of our shares as an attractive and prudent use of our capital that it is in the best interest of our shareholders.\\nWith a debt-free balance sheet, ample available liquidity and strong construction of an industry recovery, buybacks allow us to opportunistically increase shareholder value while maintaining sufficient cash resources to fund our business needs. In the second quarter, we repurchased $13 million in export stock, representing approximately 1% of our shares outstanding. From an operational standpoint, Expro is well positioned in the markets that we expect will continue to benefit from strengthening industry fundamentals. In particular, Expro has significant leverage to strengthen the international and offshore markets where experience, expertise and service quality can be in Expro's case are positive points of differentiation.\\nExecution is a traditional strength of Expro and when we plan to continue to deliver on both for our customers and our shareholders. With that, I will hand the call over to Quinn to discuss our financial results.\\nQuinn Fanning -- Chief Financial Officer\\nThank you, Mike. Good morning and good afternoon to everyone on the call. As Mike noted, I will cover the results for the quarter ended June 30th, 2022, and will primarily highlight our sequential performance compared to the quarter ended March 31st , 2022. To recap, we reported revenue of $314 million for the June quarter, which was up sequentially $34 million or approximately 12% relative to Q1 2022.\\nThe sequential increase in revenue was driven by higher activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific segments, partially offset by lower activities in the Middle East and North Africa segment. Adjusted EBITDA for Q2 2022 was approximately $51 million, representing a sequential increase of approximately $14 million or 39% relative to Q1 2022. Adjusted EBITDA margin in Q2 was 16% as compared to 13% in Q1. The sequential increase in revenue and adjusted EBITDA was driven by strong results for well flow management and well construction in North and Latin America.\\nAs highlighted in our press release, adjusted net income for the second quarter of 2022 was $0.02 per diluted share, compared to adjusted net income for the first quarter of 2022 of $0.01 per diluted share. As noted in our press release, adjusted net income for Q2 includes foreign exchange losses of $0.05 per diluted share as compared to foreign exchange gains of $0.03 per diluted share in Q1. Q2 contribution margin of 38% was up approximately one percentage point sequentially from Q1 2022, reflecting improved fall-through on higher revenue as a result of a more favorable activity mix. Q2 support costs of $70 million totaled 22% of group revenue and were down approximately $1 million sequentially or approximately 3 percentage points relate Q1 2022 and were down $8 million or approximately 9 percentage points relative to the combined support costs of Expro Frank's in Q4 2020, which was the last full quarter prior to the announcement of the merger.\\nThis represents approximately $30 million of annualized support cost savings achieved through the second quarter of 2022. In the near term, we expect to continue to manage total support costs to 22% of group revenue. With modest net pricing gains and/or incremental cost synergies, we believe we can manage overall support costs to about 20% of revenue. Total liquidity at quarter end was approximately $309 million.\\nCash and cash equivalents, including restricted cash, was $179 million as of June 30th. Total liquidity also includes $130 million that is available to the company for drawdowns as loans under our $200 million revolving credit facility. The balance of the facility is available for bonds and guarantees. Expro had no interest-bearing debt at quarter end Q2 2022, and the company has no interest-bearing debt today.\\nDuring the quarter ended June 30th, cash provided by operating activities was $2 million as compared to cash used in operating activities of $14 million in Q1. Q2 adjusted operating cash flow, reflecting cash used in operations before cash paid for interest, severance and other expenses and merger integration expenses, was positive $10 million compared to negative $1 million in Q1. Capital expenditures totaled $21 million in the second quarter compared to $11 million during the first quarter. For the second half of 2022, the company is planning for capital expenditures in the range of approximately $60 million to $70 million, implying total capex for 2022 of $90 million to $100 million or approximately 8% of expected revenue.\\nWe also continue to expect to be free cash flow generative for 2022, but as noted on our last earnings conference call, we expect that adjusted cash flow from operations and free cash flow will be heavily weighted to the second half of the year. Consistent with comments from several of our public peers, Expro's investment in working capital was up materially in the first half of 2022, with higher receivables reflecting higher activity levels and higher inventory reflecting both an expectation of continued momentum in the business and the procurement of long lead items, including critical spares. Consistent with historic patterns, we expect a reversal of the H1 build in working capital and a significant improvement in cash generation in H2 2022. As Mike previously discussed, under our recently announced stock repurchase program, during the second quarter, we opportunistically repurchased 1.1 million shares or approximately 1% of our shares outstanding for a total cost of $13 million.\\nThis program is a reflection of the long-term confidence we have in our business, which we believe is not reflected in the current market valuation. In due course, we will more formally articulate Expro's capital allocation priorities. For now, we expect that the small buyback will be completed in Q2 and for that matter, any additional buybacks will be funded by free cash flow. Now, moving into the details for reporting segment.\\nNorth and Latin America or NLA, revenue for the second quarter of 2022 was $130 million, a sequential increase of $26 million quarter over quarter. The increase was primarily due to higher revenues across all of our product lines during the current quarter with a significant increase in well flow management revenue in Mexico and higher well construction revenue in the U.S. and Guyana driven by higher customer activity levels during the just completed quarter. NLA segment EBITDA for the three months ended June 30th, 2022, was $39 million or approximately 30% of segment revenue.\\nIt was up sequentially by $17 million quarter over quarter. For Q1 2022, NLA segment EBITDA was 21% of segment revenue. The increase was attributable to higher activity and a more favorable product mix during the three months ended June 30th. For the Europe and Sub-Saharan Africa or ESA segment, revenue in Q2 was $90 million, which was up $8 million or approximately 10% quarter over quarter.\\nThe sequential increase was primarily driven by higher wealth flow management revenue in Angola and in the Congo and higher well construction revenue in the United Kingdom due to increased customer activities. The increase in revenues was partially offset by lower well intervention integrity revenue in Norway and Western Europe. ESA segment EBITDA for the second quarter was $15 million or approximately 16% of segment revenue, a sequential increase of $3 million quarter over quarter. The increase was primarily attributable to higher activity levels and a more favorable activity mix during the June quarter.\\nFor the Middle East and North Africa or MENA segment, revenue in the second quarter was $45 million, a decrease of $6 million or approximately 11% quarter over quarter. The sequential decrease was driven by lower equipment sales related to wealth management in Saudi Arabia and in the United Arab Emirates, partially offset by increased wall management activities in Algeria. MENA segment EBITDA for the June quarter was $14 million, a sequential decrease of $1 million quarter over quarter. Segment EBITDA margin was consistent with the prior quarter at 30%.\\nThe reduction in segment EBITDA was primarily due to lower activity. For Asia Pacific, or APAC, revenue for the second quarter was $48 million, which was an increase of $4 million or approximately 11% sequentially. The increase in revenue was primarily due to higher subsea well access revenue in Australia and Brunei and higher well construction revenue in Japan. The increase in revenue was partially offset by lower wealth flow management revenue in Thailand and in India.\\nAPAC segment EBITDA for the June quarter was $4 million or approximately 9% of segment revenue, a decrease of $1 million or about 3 percentage points quarter over quarter. The reduction in segment EBITDA in APAC, despite the increase in revenue was primarily due to additional mobilization and commissioning costs on a large subsea project that were incurred during the quarter as well as lower activity on higher-margin contracts. Additional commissioning costs on the Subsea projects, which totaled approximately $3 million and associated project start-up delays are in part COVID related and should be nonrecurring. As a result, we expect that revenue and segment EBITDA margin in APAC will trend positively in H2 2022 and into 2023.\\nAs Mike mentioned, our integration plans are progressing well, and we are already starting to realize significant synergy benefits we anticipated when we first announced our business combination in March of 2021. As Mike mentioned, through the second quarter of 2022, we have identified an action to approximately 100% of our synergies capture plan, both in regards to headcount and annualized value in dollars. We also completed the consolidation of several international facilities and made good progress on our ongoing migration to a single ERP platform, which should allow us to both to streamline a number of key business processes and begin to action additional cost synergies. As to our near-term outlook, we expect that Q3 2022 revenue will be up sequentially by plus or minus 8%, reflecting continued business momentum at NLA, the continuation of the seasonal rebound in ESA and the start-up of new contracts in MENA and APAC.\\nAdjusted EBITDA margin in Q3 should be in the area of 15% to 17% of consolidated revenue. Over the next couple of quarters, we continue to expect that our revenue run rate will approximate that of the pre-pandemic 2019 revenues of Legacy Expro and legacy Frank's on a combined basis. And we, therefore, reaffirm our guidance, the Q4 revenue should fall within a range of $325 million to $350 million. With the benefit of fall-through on incremental revenue and synergies, we expect that adjusted EBITDA margins will be in the area of 20% of revenue as we exit the year.\\nProvided our H1 build in working capital reverses in H2 2022 as is currently anticipated, absent additional M&A and/or share repurchases, we expect that our year-end cash position will be at or above where we started the year with cash generated from operating activities, funding integration costs, capex, the Q1 acquisition of SolaSense and the share buyback that was completed in Q2. By preserving and protecting our currently strong financial profile and by maintaining a disciplined approach to investment, we believe Expro will have sufficient financial flexibility to fund growth and increase returns to shareholders. As always, our objective is to enhance long-term value for our shareholders, employees, partners and the communities in which we operate. With that, I will turn the call back over to Mike for a few closing comments.\\nMike Jardon -- Chief Executive Officer\\nThank you, Quinn. We delivered exceptional operational performance that drove significant growth on a top and bottom line and is beginning to demonstrate the true capability of the company. Our broad portfolio of services and solutions continue to create opportunities in the growth markets that will be key to Expro's long-term success. Our innovative platform, next-generation technology and solutions and ESG applications are differentiators that continue to rapidly advance our reputation and outstanding track record with customers as a leading well expert.\\nWe continue to secure contracts and demonstrate the value of the breadth of our portfolio and the depth of our expertise can bring to clients across the life of their wells. Looking forward, the positive signs of a recovery we saw in the first quarter continued to gain momentum. We are seeing increased demand for our services and solutions as the recovery that began within the U.S. onshore market has begun to gain traction in the offshore international markets.\\nWe remain confident that the pipeline of projects we are seeing will support strong multi-year growth and firmly believe Expro is uniquely positioned to capitalize on this favorable outlook. We are incredibly excited about the strength and positioning of Expro. Our results could only have been achieved by the hard work and focus of our team. It's through their dedication that we continue to accelerate growth, improve profitability and enhance value for shareholders, employees, customers and partners.\\nThank you, again.\\nQuestions & Answers:\\nOperator\\n[Operator instructions] Our first question today comes from James West from Evercore ISI. Your line is open. Please go ahead.\\nJames West -- Evercore ISI -- Analyst\\nGood morning, guys.\\nMike Jardon -- Chief Executive Officer\\nGood morning James.\\nJames West -- Evercore ISI -- Analyst\\nSo one, Mike -- so curious, it seems like we've gone through a bit of acceleration in demand here over the last quarter, maybe two quarters in a sense of urgency has arisen within your customer base? I guess -- so first, is that -- am I getting that correct? And that this urgency is kicking in? And then second, are you seeing more of that urgency or increased demand on producing assets or new assets or interventions versus new well construction type work.\\nMike Jardon -- Chief Executive Officer\\nYes. So James, I can tell you one of the good things is we've really -- now that we're kind of more exited the pandemic. I've been able to spend an awful lot more time with customers, not only in the U.S., but in particular, Middle East and Asia. And what I'd say is the conversations particularly around new FIDs, new projects, new drilling and completion type activity, that's much more constructive, much more dialogue and discussion around that.\\nI'd say that the -- we've had continuing strong commentary and strong game with customers around producing assets. So that's -- I think that's ramping up, but not at the same rate as the positivity from the discussions around new well type -- new well drilling activity and new well completion activity.\\nJames West -- Evercore ISI -- Analyst\\nOK. Fair enough. And then on the pricing side, are you -- at this point, are we back to kind of -- or getting close to back to pre-pandemic type of levels? Admittedly, offshore wasn't as robust even then, but it's growing and robustness now. But are you achieving the returns on capital investments that you would like to see when you're allocating capital and what you're pricing new contracts?\\nMike Jardon -- Chief Executive Officer\\nSo I would -- and I tried to allude to it in my earlier comments, we're starting to see some spotty opportunities to push price, and we're pushing price every opportunity we can. It's more selective right now. I think we'll continue to gain more momentum around our ability to continue to press price as we exit '22 going into '23, but we are starting to have -- it hasn't quite turned the quarter, so to speak, like North America. U.S.\\nland has where there's lots of pricing leverage and pricing traction. But we are starting to see in some particular markets and some particular service lines, positive opportunity to continue to get that pricing. And I think we're all keen to make sure that we start to implement that absolutely as soon as we can.\\nQuinn Fanning -- Chief Financial Officer\\nJames, I think the only thing -- I could just point you back to Mike's prepared remarks, there are capacity constraints within certain solutions and certain product groups, complex well construction or to provide construction activity or TROs, as well as the subsea landing streams. It's obviously a market that is supported by just a handful of service providers ourselves being one of the two larger ones product lines. But obviously, everything about the supply and demand, there's less than a supply for those two equipment classes. The other thing I'd highlight is with the pickup in drilling and completion type activity.\\nIt's not necessarily how we present our supplemental disclosures. But what we consider to be our drilling completions over businesses, they were up 20% quarter-over-quarter revenue-wise and the thoughts for margins on the incremental activity is north of 50%. So that's really where you get the --\\nJames West -- Evercore ISI -- Analyst\\nOK. Got it. Yes, no doubt. That's going to be very helpful.\\nOperator\\nOur next question comes from David Anderson from Barclays. The line is open. Please go ahead.\\nDavid Anderson -- Barclays Capital -- Analyst\\nHey. Good morning, Mike. I was just curious which of your product lines showed the greatest margin improvement this quarter. And I think you maybe just touched on it just now here.\\nBut curious if there's been much of improvement in well construction, in particular, as a rental business in TRS with high offshore exposure. Just curious how we should be thinking about the margin expansion upside in that particular business and how that should contribute overall.\\nMike Jardon -- Chief Executive Officer\\nSure. We alluded to some of this in the prepared remarks. What kind of additional commentary I'd add to it, David, is we've really seen some increased mix, better mix of activity in North Latin America, in particular. So yes, particularly around TRS around well construction, we've been able to start to see some margin expansion there.\\nAnd then I think overall, what you're really seeing is starting to gain more traction with the cost synergies we're taking out the organization overall. We're in essence, we're a full quarter ahead of that. And I think one of the real positives of us being able to get the synergies implemented is if we're being to completely honest, anytime you're doing a consolidation, you're doing a merger, if there is a little too much internal focus that goes on. It's a necessary part of the eval as doing a merger as we can get more of that behind us, and we'll largely because we're a quarter ahead of it, that means going in exiting '22 and going into '23, we're really going to be much more externally focused.\\nAnd that's one of the reasons why I've been challenging the organization is so hard to make sure we get these things done sooner rather than later. But overall, we're seeing margin expansion across well construction and even in some of the well flow management and subsea access, we're getting some traction in all three of those right now.\\nDavid Anderson -- Barclays Capital -- Analyst\\nSo if I just stay on the well construction side, we're hearing a lot of talk about rigs coming back to work both on the jack-ups and the deepwater side. Are you getting inquiries for those? I'm just kind of curious, it's obviously only a couple of players in the TRS business. So I'm just kind of curious, are you starting to kind of roll out some additional equipment at been sidelined for a while. Can you help us give us a handle on what that looks like in terms of, I guess, your capacity type of equipment out there and how that's moved up?\\nMike Jardon -- Chief Executive Officer\\nYes. No, absolutely. We are seeing the same phenomenon that the drillers are seeing today with increased utilization, those kind of things. Because keep in mind, a drilling rig and TRS type equipment goes kind of hand in hand.\\nSo yes, we're able to start to put some of that equipment back to work. I referred to a casing running tool CRT opportunity we execute on in Brazil. That purely is taking assets and resources that were underutilized previously and putting those to work. So on the flip side of that, yes, we're seeing good traction with all construction.\\nThe other thing that we're seeing even more so than I had anticipated was it really becomes an early warning radar system for us, so to speak, because typically, with customers, they select the rig first almost in conjunction with that are certainly right behind it is selecting the TRS provider. And then you start moving into well completions and well testing, and those type of activities. So we're getting earlier customer engagement. And I think that we'll continue to see that allow us to more upholster revenue opportunities, those types of things.\\nDavid Anderson -- Barclays Capital -- Analyst\\nThat's interesting. So if I just -- on that on that well flow management, it was up 14% sequentially this quarter, I'm pretty sure what was pretty strong for business that I thought we would consider later cycle, more production focused. So I guess the question was, I think you had said in your remarks that MENA was a little bit weaker than expected. So where were the results? Was it more mix related this quarter? Was it regional? Was something else kind of picking up and offsetting what you said? I mean, because I would have thought MENA would have actually been a driver of that growth.\\nAnd it sounds like it wasn't --\\nMike Jardon -- Chief Executive Officer\\nSure. MENA for us was really -- we had kind of a quarter-on-quarter product sales that didn't reoccur in the second quarter. So that was what gave us a little bit of softness there. Our strong activity in the Middle East, Algeria, in particular, was actually up quarter on quarter.\\nWhat is important to recognize with well flow management is, in particular as well testing, we can utilize those assets in a well completions cleanup load or you can use those assets in a production optimization mode. And that allows us to kind of flex that equipment to deploy it into one or the other. And part of the growth we saw was starting to see some better activity from a new well completions, new well flowback, those type things within the quarter.\\nDavid Anderson -- Barclays Capital -- Analyst\\nOK. Thank you very much.\\nMike Jardon -- Chief Executive Officer\\nAbsolutely. Thanks for the questions.\\nOperator\\n[Operator signoff]\\nDuration: 0 minutes\\nCall participants:\\nKaren David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations\\nMike Jardon -- Chief Executive Officer\\nQuinn Fanning -- Chief Financial Officer\\nJames West -- Evercore ISI -- Analyst\\nDavid Anderson -- Barclays Capital -- Analyst\\nMore XPRO analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, and welcome to the Monster Beverage Company Second Quarter 2021 Conference Call. [Operator Instructions]\\nI would now like to turn the conference over to Rodney Sacks, Co-CEO, to begin the call. Please, go ahead.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nGood afternoon, ladies and gentlemen. Thank you for attending this call. I'm Rodney Sacks. Hilton Schlosberg, our Vice Chairman and Co-Chief Executive Officer, is on the call; as is Tom Kelly, our Chief Financial Officer.\\nTom Kelly will now read our cautionary statement.\\nThomas J. Kelly -- Chief Financial Officer\\nBefore we begin, I would like to remind listeners that certain statements made during this call may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and are based on currently available information regarding the expectations of management with respect to revenues, profitability, future business, future events, financial performance and trends, as well as the future impact of the COVID-19 pandemic on the company's business and operations.\\nManagement cautions that these statements are based on our current knowledge and expectations and are subject to certain risks and uncertainties, many of which are outside the control of the company that may cause actual results to differ materially from the forward-looking statements made during this call. Please refer to our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K filed on March 1, 2021, including the sections contained therein entitled Risk Factors and Forward-looking Statements, for a discussion on specific risks and uncertainties that may affect our performance. The company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events or otherwise.\\nI would now like to hand the call over to Rodney Sacks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThank you, Tom. The company's top priority remains the health, safety and well-being of its employees. The company's flavor manufacturing facilities, its co-packers, warehouses and shipment facilities have operated throughout the COVID-19 pandemic. The company's bottlers and distributors are operating, and the company's products remain generally available to consumers. In limited countries, the operations of the company's bottlers and distributors have, in part, been negatively affected for varying periods of time. Despite the ongoing impact of the COVID-19 pandemic, the company achieved record second quarter net sales. Currently, the company does not foresee a material impact on the ability of its co-packers to manufacture and its bottlers and distributors to distribute its products as a result of the COVID-19 pandemic.\\nThe company's supply chain remains largely intact. However, the company continues to experience shortages in its aluminum can requirements in the United States and EMEA, given the company's volume growth and the current supply constraints in the aluminum can industry. The company is also experiencing delays in procuring certain ingredients, both domestically and internationally. As a result, the company was unable to fully satisfy demand in the 2021 second quarter in the United States and EMEA. We expect such challenges to continue for the next few months. The company has taken steps to source additional quantities of aluminum cans from the United States, South America and Asia. The company has entered into new supply agreements with two new aluminum can suppliers in the United States, and which are expected to be operational in the 2021 fourth quarter. We expect deliveries of additional quantities of cans increasing sequentially during the latter part of the year.\\nLogistical issues, including shortages of shipping containers and port of entry congestion could delay ongoing international supply of aluminum cans. Separately, we are continuing to experiencing -- experience freight inefficiencies as well as significant increases in domestic and international freight costs and like other beverage companies are incurring increased aluminum can and other costs in the current environment, all of which in addition to other factors, will continue to adversely impact gross margin percentages. In the second quarter of 2021, net sales were $1.46 billion compared with $1.09 billion in the second quarter of 2020, an increase of 33.6%. Adjusting for foreign currency movements, net sales for the 2021 second quarter would have been up 30.1%. Gross profit as a percentage of net sales for the 2021 second quarter was 57.2% compared with 60.3% in the 2020 second quarter. The decrease in gross profit as a percentage of net sales for the three months ended June 30, 2021, was primarily the result of geographical sales mix and increased input costs, mainly increased raw material freight in costs and aluminum can costs.\\nOperating expenses for the 2021 second quarter were $310.9 million compared with $252.2 million in the 2020 second quarter. As a percentage of net sales, operating expenses for the 2021 second quarter were 21.3% compared with 23.1% in the 2020 second quarter. Operating income increased 29.1% to $526 million, up from $407.3 million in the second quarter of 2020. Net income increased to 29.7% and to $403.8 million compared to $311.4 million in the 2020 comparable quarter. Diluted earnings per share for the 2021 second quarter increased to 28.6% and to $0.75 from $0.59 in the second quarter of 2020. According to the Nielsen reports for the 13 weeks through July 24, 2021, for all outlets combined, namely convenience, grocery, drug, mass merchandisers, sales in dollars in the energy drink category, including energy shots, increased by 14.2% versus the same period a year ago. Sales of the company's energy brands, including Reign, were up 8.6% in the 13-week period. Sales of Monster were up 11.1%. Sales of Reign were down 6.1%. Sales of NOS decreased 4.1%, and sales of Full Throttle increased 7%. Sales of Red Bull increased 15.3%. Sales of Rockstar decreased by 15.7%, and sales of 5-Hour increased 8.5%. VPX Bang sales increased 20%.\\nAccording to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the energy drink category in the convenience and gas channel, including energy shots in dollars, increased 7.4% over the same period the previous year. Sales of the company's energy brands, which include Reign, increased 3.6% in the four-week period in the convenience and gas channel. Sales of Monster increased by 5.8% over the same period versus the previous year, Reign sales decreased 6.8%, NOS was down 10.7%, and Full Throttle was up 13.2%. Sales of Redbull were up 9%. Rockstar was down 18.6%, and 5-Hour was up 3.2%. VPX Bang sales increased 12.2%. According to Nielsen, for the four weeks ended July 24, 2021, the company's market share of the energy drink category in the convenience and gas channel, including energy shots, in dollars, decreased 1.3 points to 36.5%.\\nMonster share decreased 0.4 of a share point to 30.6% and. Reigns decreased 0.4 of a share point to two points -- sorry, 2.4%. NOS's share decreased 0.5 of a point to 2.7%, and Full Throttle share remained at 0.7%. Redbull's share increased point -- six points to 37.4%. Rockstar's share was down 1.2 points to 3.8%. 5-Hour share was lower by 0.2 points at 4.6%. VPX Bang share increased 0.3 points to 7.6%. As previously reported, Coca-Cola Energy is being discontinued in the United States and Canada by the end of 2021. According to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the coffee plus energy drink category, which includes our Java Monster line in the convenience and gas channel, increased 4.2% over the same period the previous year.\\nSales of Java Monster, including Java Monster 300, were 5.9% higher in the same period versus the previous year. Sales of Starbucks Energy were 0.4% higher. Java Monster share including Java Monster 300 of the coffee plus energy category, which primarily includes Java Monster, Java Monster 300, Starbucks Doubleshot and Tripleshot, Rockstar Roasted and Bang Keto Coffee for the four weeks ended July 24, 2021, was 51.9%, up 0.9 of a share point, while Starbucks' energy share was 45.5%, down 1.7 points. According to Stackline, which tracks energy drink sales by Amazon in the United States, in the four-week period ending July 3, 2021, sales in dollars in the energy category by Amazon, including energy shots, increased 104.5% over the same period the previous year.\\nSales of Monster increased 59.9%. And its share was 28.1%, down 7.8 share points versus the same period a year ago. Red Bull sales increased 109.4%, and its share was 16.6%, up 0.4 points. Celsius' sales increased 133.1%. And its share increased 1.8 points to 14.3% 5-hour sales increased 40.9%. And its share declined 1.3 points to 2.9%. VPX Bang sales increased 216.1%. And its share increased 1.8 share points to 5.2%. Reign's share decreased 0.1 of a share point to 5.3%. Rockstar's share increased 0.9 of a share point to 3.9%. According to Nielsen, in all measured channels in Canada, for the 12 weeks ended June 19, 2021, the energy drink category increased 17.9% in dollars.\\nSales of the company's energy drink brands increased 28.3% versus a year ago. The market share of the company's energy drink brands was 41.5%, up 3.4 points. Monster sales increased 18.3%, and its market share increased by 0.1 of a point to 35.4% -- sorry, 35.4%. NOS' sales increased 12.6%, and its market share decreased 0.3 of a point to 1.9%. Full Throttle sales decreased 2.1%, and its market share decreased 0.1 of a point to 0.6%. Red Bull sales increased 18.1%, and its market share increased 0.1 of a point to 38.7%. Rockstar sales decreased 8.6%, and its market share decreased 3.3 points to 11. 4%. GURU's sales increased 35.9%, and its share increased 0.5 of a share point to 4%.\\nAccording to Nielsen, for all outlets combined in Mexico, the energy drink category increased 45.2% for the month of June 2021. Monster sales increased 38.7%. Our market share in value decreased by 1.3 points to 27.2% and against the comparable period the previous year. Red Bull sales increased 41.4%, and its market share decreased by 0.2 of a point to 6.5%. Vive 100 sales increased 30.2%, and its market share decreased by 2.4 points to 20.5%. Volt's sales increased 41.1%, and its market share decreased 0.5 of a share point to 18.5%, while B:oost's sales increased 15.7%, and its market share decreased 1.3 points to 5.1%. Amp's sales increased 91.9%, and its market share increased 4.4 points to 17.9%. Predator, which was launched in March 2020, achieved a market share of 3.1%.\\nThe Nielsen statistics for Mexico cover single months, which is a short period that may often be materially influenced positively and/or negatively by sales in the OXXO convenience chain, which dominates the market. Sales in the OXXO convenience chain in turn can be materially influenced by promotions that may be undertaken in that chain by one or more energy drink brands during a particular month. Consequently, such activities could have a significant impact on the monthly Nielsen statistics for Mexico. According to Nielsen for the month of June 2021 compared to June 2020, Monster's retail market share in value increased in Argentina from 40.1% to 46.9% and in Brazil from 29.6% to 35.4%. In Chile, Monster's retail market share decreased from 45.7% to 41.9%. Monster Energy continues to be the leading energy brand in value in Argentina.\\nI would like to point out that the Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country-to-country and are reported on varying dates within the month referred to from country-to-country. According to Nielsen, in the 13-week period ending July 18, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 34.2% to 37.4% in Spain. According to Nielsen, in the 13-week period to the end of June 2021, Monster's retail market share in value as compared to the same period the previous year grew from 14.5% to 15.3% in Germany, from 18.4% to 19.4% in Poland and from 18.4% to 20.1% in South Africa. According to Nielsen, for the 13-week period ending June 20, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 12.5% to 16.2% in Belgium, from 24.2% to 25.3% in Denmark, from 25.8% to 28.2% in France, from 25% to 29% in Great Britain, from 6.7% to 8.4% in the Netherlands, from 27.1% to 31.2% in Norway, from 25.6% to 29.3% in the Republic of Ireland and from 13.4% to 14.5% in Sweden.\\nAccording to Nielsen, in the 13-week period until the end of May 2021, Monster's retail market share in value compared to the same period the previous year grew from 13.3% to 14.5% in the Czech Republic, from 35.1% to 37.9% in Greece and from 16.6% to 29% in Italy. According to Nielsen, in the 13-week period until the end of May 2021, Predator's retail market share in value as compared to the same period the previous year grew from 5.1% to 17.3% in Kenya and from 0% to 8.1% in Nigeria. The Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country to country.\\nAccording to IRI in Australia, Monster's market share in value for the month ending June 2021 increased from 11.6% to 14% as compared to the same period the previous year. Mother's market share in value decreased from 13.3% to 11.6% during the same period. The market share of the company's brands in Australia for the month ended June 2021 increased from 24.9% to 25.5%. According to IRI in New Zealand, Monster's market share in value for the four weeks ended July 11, 2021, increased from 9.9% to 12.4% as compared to the same period of the previous year. Live+ market share in value remained the same at 6.9%, and Mother's market share in value increased from 6.2% to 6.3%. The market share of the company's brands in New Zealand for the four weeks ended July 11, 2021, increased from 23.1% to 25.6%.\\nAccording to Nielsen, in South Korea, Monster's market share in value in all outlets combined for the month of June 2021 increased from 53.3% to 61.9% as compared to the same period in the previous year. According to INTAGE, in Japan, Monster's market share in value in the convenience store channel for the month of June 2021 was 50.6% as compared to 51% in the same period the previous year. Monster remains the market leader in Japan. We again point out that certain market statistics that cover single months or four week periods may often be materially influenced positively and/or negatively by promotions or other trading factors during those periods.\\nNet sales to customers outside of the US were $546.3 million, 37.4% of total net sales in the 2021 second quarter compared to $328.3 million or 30% of total net sales in the corresponding quarter in 2020. Foreign currency exchange rates had a positive impact on net sales in the US dollars by approximately $38.6 million in the 2021 second quarter. Included in reported geographic sales are our sales to the company's military customers, which are delivered in the US and transhipped to the military and their customers overseas.\\nIn EMEA, net sales in the 2021 second quarter increased to 105.7% in dollars and increased 86.5% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales for the second quarter was 39.8% compared to 38.1% in the same quarter in 2020, primarily due to a favorable country and product mix. We're also pleased that in the 2021 second quarter, Monster gained market share in Belgium, the Czech Republic, Denmark, France, Germany, Great Britain, Greece, Italy, the Netherlands, Norway, Poland, the Republic of Ireland, South Africa, Spain and Sweden.\\nIn Asia Pacific, net sales in the 2021 second quarter increased 5.2% in dollars and decreased 100% [Phonetic] in local currencies over the same period in 2020, largely due to sales in Japan and China. Gross profit in this region as a percentage of net sales was 44.4% versus 43.3% over the same period in 2020. In Japan, net sales in the 2021 second quarter decreased 15.1% in dollars and 13.9% in local currency, largely due to COVID-19 restrictions in Japan and distributor inventory adjustments. Depletions increased 7% during the quarter. Monster remains the market leader in Japan for the month of June 2021.\\nIn South Korea, net sales increased 63% in dollars and 50.4% in local currency as compared to the same quarter in 2020. In China, net sales decreased to 21.4% in dollars and 27.8% in local currency as compared to the same quarter in 2020. In this regard, we note that sales in the second quarter of 2020 included the initial launch of Dragon Tea. We are reevaluating the viability of this SKU and the optimal product range for China going forward. We remain optimistic about the prospects for the Monster brand in China. In Oceana, which includes Australia, New Zealand, Tahiti, French Polynesia, New Caledonia, Papua New Guinea and Guam, net sales increased to 146.5% in dollars and 98.2% in local currencies. Sales of the Monster brand in Oceana increased 210% in dollars and 155.6% in local currency as compared to the same quarter in 2020.\\nIn Latin America, including Mexico and the Caribbean, net sales in the 2021 second quarter increased to 19.7% in dollars and increased 117.6% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales was 40.7% compared to 41.2% in over the same period in 2020, primarily as a result of foreign exchange rates and certain raw materials and ingredients for products in this region are purchased in US dollars. In Brazil, net sales in the 2021 second quarter increased by 194.9% in dollars and 201.7% in local currency. Net sales in Chile increased 77.5% in dollars and 52% in local currency in the 2021 second quarter. Net sales in Argentina increased 291.4% in dollars and 458% in local currency in the 2021 second quarter.\\nIn March 2019, VPX, the maker of Bang Energy drinks, sued Monster, alleging that its Reign products infringed VPX's Bang trademarks and trade risk. A trial was held last year. And on August 3, 2021, the court issued an order denying all of VPX's claims and holding that VPX is entitled to no relief whatsoever. In fact, the court specifically found that VPX copied its bank trade risk from the original Monster Energy cans. The court's decision confirms that Monster and Poland retail partners are free to continue to sell our Reign products without any changes and without any restrictions. Monster always believed and maintained that VPX's claims were frivolous, and we are extremely pleased that the court rejected all of VPX's claims while vindicating Monster's rights. As other pending proceedings with VPX are subjudicate, we will not be answering any questions on this matter on today's call.\\nOur new product introductions in the United States in the first half of 2021 were primarily focused in the first quarter. In the United States, during the second quarter of 2021 we refreshed our can graphics on our Rehab Monster brand family as well as our Full Throttle line, also updating the name for Blue Agave to TrueBlue. Monster Energy Ultra Fiesta received a refresh and updated can graphics as well as the name change to Monster Energy Ultra Fiesta Manga. In May 2021, we launched Monster Ultra Fiesta in a 24-ounce option with an update to our Ultra Fiesta Manga plan for later this year. We are in the process of launching a new line of nonalcoholic pure energy sales under the True North brand name in 12-ounce sleek cans, which contained an organic plant-based energy blend and ingredients for immunity support. True North is being offered in six flavors, Cucumber Lime, Black Cherry, Grapefruit Lemonade, Water Mellon Mist, White Peach Pear and Mandarin Yuzu.\\nTrue North has a limited customer target in 2021 with plans for a full launch into mainstream channels in 2022. While cognizant of the can shortages, we believe that it is important to continue with our innovation plans. And to this end, we will be launching our new flavors reserve line of Monster Energy drinks in Water Mellon and White Pineapple in October 2021. We have deferred the launch of our new line of Java Monster Cold Brew Coffee + energy drinks until early 2022. In Canada, during the second quarter, we launched two new products: Monster Punch Papillon and Monster Punch Khaotic, both in a 473 ml can. In April 2021, we launched Reign Orange Dreamsicle in Puerto Rico and our second SKU in Bolivia with Monster Energy Zero Ultra. In El Salvador, we launched Fury Mean Green in May 2021.\\nIn the second quarter of 2021, we launched Juice Monster Pacific Punch and Monarch in a number of countries in EMEA. We also launched Ultra Paradise and Ultra Fiesta in a number of countries during the quarter. During the quarter, we also launched our strategic brand innovation and Predator in additional countries. In January 2021, we launched Ultra Rosa marketwide in Australia, following an exclusive lead launch with one chain in the fourth quarter of 2020. In March 2021 in New Zealand, we launched Monster Superfuel in both Purple Passion and sugar-free flavors. During the 2021 second quarter in Japan, we launched Monster Energy Super Cola with our distributor, Asahi Soft Drinks. Additionally, we effected the relaunch at retail of Ultra Paradise and began shipments in anticipation of the launch of Super Fuel early in the 2021 third quarter. Super Fuel has just gone on the shelves in Japan this week. We also launched Mango Loco in Korea in July 2021.\\nDuring the 2021 second quarter, we launched Pipeline Punch in Taiwan, Hong Kong and Macau. We also began distribution of Monster Energy Zero Sugar in the Philippines. As previously mentioned, in the second quarter of 2021, in China, we extended the national rollout of our new Monster Dragon Gold, which is non-carbonated. Our national summer on-pack promotion began in May with one of China's top consumer ambassadors. As a result of the COVID-19 pandemic, certain of our planned launches and innovation of new products in a number of Asia-Pacific markets have been deferred for a few months. However, we still anticipate such launches taking place toward the end of the 2021 calendar year. We are planning to launch a number of additional products and product lines in our domestic and international markets later this year.\\nWe estimate that July 2021 sales to be approximately 1.8% higher than in July 2020. On a foreign currency adjusted basis, July 2021 sales would have been comparable to the July 2020 sales. July 2021 had one less selling day than July 2020, which was 15.8% above July 2019, and which was 17.1% higher on a foreign currency adjusted basis. Certain production facilities, mainly from the Coke bottlers in EMEA, in particular, delayed production from July to August 2021. Furthermore, as mentioned earlier, the company has not been able to fully satisfy demand in the United States and EMEA due to a shortage of aluminum cans, which adversely impacted July sales. Such shortage was exacerbated in July as can availability did not keep pace with increased demand during the summer months. Additional cans have been sourced from domestic and overseas suppliers with expected deliveries increasing sequentially during the latter half of the year. We are working to replenish system inventories in order to meet customer demand as soon as possible.\\nAdditionally, the company also experienced delays in certain ingredients, which impacted supply. Our depletions remain solid as do our measured market data, as previously mentioned on this call. In this regard, we caution again that sales over a short period are often disproportionately impacted by various factors such as, for example, selling days, days of the week in which holidays for, timing of new product launches, and the timing of price increases and promotions in retail stores, distributor incentives as well as shifts in the timing of production in some instances where our bottlers are responsible for production and unilaterally determine their production schedules, which affects the dates on which we invoice such bottlers as well as inventory levels maintained by our distribution partners, which they alter unilaterally for their own business reasons.\\nWe reiterate that sales over a short period such as a single month should not necessarily be imputed to or regarded as indicative of results for a full quarter or any future period. If the COVID-19 pandemic and related unfavorable economic conditions continue in certain regions, our new product innovation launches in those regions could be delayed. In conclusion, I would like to summarize some recent positive points. Currently, the company's flavor manufacturing facilities, its co-packers, warehouses, and shipment facilities, and bottlers and distributors are all operating. We are continually addressing our aluminum can requirements, given our volume growth and the current supply constraints in the aluminum can industry.\\nWe are pleased with the new additions to the Monster Energy portfolio and are planning additional launches later in the year. We are planning to continue additional launches of our Reign Total Body Fuel high-performance energy drinks in additional international countries. We are pleased with the rollout of Predator and Fury and our affordable energy drink portfolio internationally. We are proceeding with plans to launch our affordable energy drinks in a number of international countries during the year.\\nI would like to open the floor to questions about the quarter. Thank you.\\nQuestions and Answers:\\nOperator\\nThank you. [Operator Instructions] The first question will come from Dara Mohsenian with Morgan Stanley. Please go ahead.\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nHey, guys.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nHey, Dara.\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nGreat top line growth in the quarter, but we have seen share losses in US track channel data worsened recently. A, just short-term, how much of that do you think is attributable to out of stocks and the supply constraints that you mentioned? Is that a material factor in retail sales?\\nAnd then maybe, b, from a longer-term standpoint, it has been a couple of quarters now where the share losses have reaccelerated year-over-year, just some progress in the beginning of the year. So, I was just hoping you could review some of the key factors that have been driving the share losses in the US? And how you think about those factors going forward in terms of continuing or dissipating and how you guys are positioned? Thanks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nHilton, if you take that, and I'll also say something once you've...\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nAll right. I think, Dara, what's important is that, that's not a result and not due to us not growing. We are not keeping up with our share, but our business is certainly growing. And you can track that from Nielsen. You can also track that from the non-measured channels, which are growing really very nicely. So while we're not keeping up necessarily with Red Bull in the major channels.\\nAs I've spoken on previous calls, Red Bull had a very large on-premise business, which has moved to off-premise and moved to off-premise during COVID. And that led to an acceleration in their share. However, we mentioned that we had and are continuing to sustain can issues and result in supply. And of course, that's having an impact on the share numbers that you are seeing.\\nSo I think on balance, the business is growing. You've seen the results. It's continuing to grow. And we are growing, but not at the extent of the market. I think with the full deck of cards, the situation may well be very different. But right now, we really are struggling with sufficient supplies of aluminum cans really to keep up with demand, which is, I suppose, a good position to be in. And on the other hand, is not such a good position to be in. The business is growing. And, that's the message I want to leave you with and other investors.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nI think in -- I'll just add two short points in that regard. I think what we've tried to do is to try and also basically focus on our faster selling and our larger SKUs, which has necessarily resulted in some of the smaller SKUs, which normally have their own traction and followers. So those haven't got on to shelf. And then the one additional thing that I think that has negatively affected our distribution sales and distribution levels in the US is labor shortages. And I think that what we've seen is that many of the bottlers, Coke bottlers are experiencing labor shortages. And while one would ordinarily say, well, everybody is going to have the same problem.\\nI think that where you have Red Bull is our main competitor, they have a dedicated system. I think they've been able to address their labor shortages just more effectively than the larger bottlers with large labor pools. And that has also, I think, detrimentally affected our distribution levels going forward. But again, I think those are things that once things start settling down and things will get back to normality, that's something that I think that will also, in due course, right itself.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nYes, I think we should also -- Dara, I think we should also add that what we're seeing with cans is something that will persist through this year. I'm a bit more optimistic about the fourth quarter because we have two new can suppliers coming on board. But the situation will persist. And then next year, we should be in -- we believe we'll be in very good shape. But again, it all depends on consumer demand, which is growing, and you've seen that month-by-month and quarter-by-quarter.\\nOperator\\nAnd the next question today will come from Bonnie Herzog with Goldman Sachs. Please go ahead.\\nBonnie Herzog -- Goldman Sachs -- Analyst\\nThank you. Hi, everyone. I just wanted to ask about your gross margins. Clearly, they continue to be pressured as broadly expected, which you guys have been discussing with us. But just want to get your outlook for these pressures in the back half of the year? Hilton, you just mentioned that you're optimistic. So just wanted to verify that you still expect some of these pressures to ease by Q4? Or do you think it's going to take a little bit longer, especially in light of the recent spike in aluminum prices. So trying to understand how that factors in? And then just a clarification on the can shortages that you mentioned that you're still experiencing, I guess, it sounds like it's getting worse, but I really did want to clarify that. And is there any way that you guys could quantify how big of an impact the supply shortages had on your top-line either in the quarter or in July? Just trying to understand how much you think your shipments would have been up in July without these shortages, for instance? Thanks.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nOkay. So let me deal with the first issue first, if I may. I spoke about optimistic about can supplies. I really didn't talk about margins. You'll recall on the last call, I spoke about the issues that we were confronting with margin pressures like most other beverage companies. And where we are right now with aluminum, I mean, nobody knows. So you can talk to the leading banks in the field, which we do on a regular basis, and they really are pulls apart about their projections for aluminum in 2022, let alone 2021.\\nSo the last couple of days, you've seen a spike in the Midwest premium from this tax that is expected to be imposed on Russian aluminum. And as, you know, the Midwest premium is strongly factors the last ton of aluminum to enter the US and the cost of that. And so we've seen a spike in the Midwest premium. And we continue to see spikes in aluminum. So from that score, I think we just are in uncharted territory. I've been in this business for a long time, as you know, and I've never seen aluminum where it's at right now. And I've never seen the Midwest premium at these kind of levels. So aluminum, I really cannot talk about. And also when you look at our business and you look at the factors that really have affected gross margin, number one, the fact that we're selling a lot more internationally. So I talked earlier about 37.4% of our sales in the quarter outside of the US 30% last year, that obviously impacts margins. We are importing cans from a number of [Technical Issues] that obviously impacts margins.\\nIn fact, the China and India cans that we are using in the United States and in EMEA will only be filed in August in July, and they will be filled this month. So that in itself, the imputation will impact gross margins. And then to cap everything else, we have ingredient issues. We had ingredient issues, as we mentioned, in July, which again reduced the amount that we would actually sell because we didn't have sufficient ingredients to meet themselves, particularly with NOS. And so there are a number of factors that are increasing that are increasing our cost of goods.\\nAnd last quarter, I said I didn't think that margins would get better in the second and third quarters. I read they will not -- I think margins will deteriorate in the third quarter. In the fourth quarter, we're getting some relief in terms of supplies from the US on cans that are -- have been contracted for and they were contracted for two years ago. And we saw the opportunity to work with two major suppliers to get additional cans produced in the US, and that's why we have two new supplies opening, and we are an important and an anchor customer of both those facilities. But even that, you're still dependent on aluminum. We have some hedges in place, but obviously not enough to take into consideration the amount of sales and the amount of consumer demand that is out there. So that's a long-winded way of saying, I think, answering your question as best as I can.\\nAnd then just getting to your second question because you're really only allowed one. But to get to your second question, we have quantified or try to quantify the impact on can shortages in July and in this quarter and in the -- potentially in the third quarter, but I really don't want to -- I'm not comfortable with those numbers yet. A lot of detailed work is being done on them. And I just -- I can't in good contents give those numbers because we still are in the throes of kind of finalizing what we think is probably correct. Rodney mentioned in his script earlier that a number of the bottlers, he mentioned particularly in EMEA, but there were cases in the US as well, and there was a substantial case in the US where the bottlers were obviously focused on other things in the quarter and were producing Coca-Cola brands. And as a result, I think we -- our production got moved from July to August. So, when I look at July, it doesn't -- I don't get overly concerned because I know the sales are going into August.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nPerhaps, if I just on the shortage level, just to add that when we buy cans in contracted for our annual amount, they usually are sort of reasonably flat line across the year. And we used the first half of the year to build up can inventories and finished product inventories with ourselves and our bottlers. Earlier this year, obviously, demand sort of was strong, and so we really didn't have that opportunity. So what has happened is that in June and July, which is your normal peak months, the demand has been higher, but our supply has been more level until we can get more can inventories into the market. So what happened is just that we have had a sort of a heartened increased shortage in the last month and July and probably will be a little bit in August. And then obviously, as we start increasing our -- the cans we're getting in, and then we're able to balance it more and our demand balances more, we'll start to have less of a different delta between these demand and supplier and eventually be able to -- we're hoping to able to build up our inventories and supply back to normal by the end of the fourth quarter or during or by the end of the fourth quarter.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nNo one's comfortable with the level of finished goods inventories that we're running at, but it's a sign of the times. I mean, we're doing everything we can to supply our customers. And that's why we spoke about freights. Freight is a big issue, not only getting raw material ingredients into co-packing system and into our bottling system and -- but also distributing from our co-packers. And obviously, the one goes into cost of sales and freight out goes into operating expenses. So that's why you'll see freight really hitting both of those line items.\\nOperator\\nThe next question will come from Andrea Teixeira with JPMorgan. Please go ahead.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nHi. Thank you. Hi. Good afternoon.\\nThomas J. Kelly -- Chief Financial Officer\\nHi.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nHi, Andrea.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nHow are you Hilton? Hi.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nI'm good.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nYes. Just on the gross margin, because your gross margin comments were very helpful and given this deterioration obviously that its probably here to stay in the next few quarters. How are you thinking about pricing? Obviously, you can't supply the service levels that are used to with the retailers. So is that is something that takes -- obviously, you have to take into account? Or perhaps as you get more informed on how the aluminum cost will evolve, you may contemplate it again?\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nYes. With regard to pricing, we continue to evaluate pricing, honestly, on a very, very regular basis, if not weekly. So we continue to evaluate it, and we want to make a good decision. Last time around, as I mentioned on previous calls, we went out alone, and we would like to have been in a situation this time where we followed our competitor, but we have to evaluate, obviously, the business as we see it and the impact for us. What we've done is we're reducing our promotional allowances. So we're taking a price increase the other way, through reducing promotional allowances, but the impact of that reduction in the second quarter was not as we would have liked. So we are -- we really put the accelerator down and are more aggressive in reducing our promotional allowances. But we are continuing to evaluate the pricing and price increases.\\nAnd then I have to leave this call with my favorite saying, and that is, we don't bank gross profit margins, we bank gross profit dollars. And to me, the fact that we're doing everything we can to satisfy our customers as best as we can is impacting gross profit margins. But at the end of the day, we don't want to lose gross profit dollars, which is really important to ensure the sustainability of the brand. And that's the most important thing for us right now.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nThank you. Thanks fair. Thank you both.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nYeah. Basically, just make it clear, at this point, we are watching and we're not planning a price increase. We we're not adverse to a price, but we'll wait and see what the market does and what our competitors do.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nThank you, Rodney.\\nOperator\\nThis will conclude today's question-and-answer session. I would now like to turn the conference back over to management for any closing remarks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThanks very much. Thank you, everyone, for your continued interest and support of the company. We continue to believe in the company and our growth strategy to remain committed to continuing to innovate, develop and differentiate our brands and to expand the company, both domestically and abroad. And in particular, expand distribution of our products through the Coca-Cola bottler system internationally.\\nWe believe that we will be able to navigate through the challenges ahead as a result of the COVID-19 pandemic and hope that this unfortunate situation will resolve itself in the near future. We believe that we are well positioned in the energy drink category and will continue to be and are optimistic about our total portfolio of energy drink brands. We hope that you will stay safe and healthy. Thank you very much for your attendance.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 50 minutes\\nCall participants:\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThomas J. Kelly -- Chief Financial Officer\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nBonnie Herzog -- Goldman Sachs -- Analyst\\nAndrea Teixeira -- JPMorgan -- Analyst\\nMore MNST analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nGood evening, and welcome to Oyster Point Pharma's fourth quarter 2021 earnings conference call. My name is Valerie, and I will be your operator today. [Operator instructions] At this time, I would like to turn the call over to Mr. Daniel Lochner, Oyster Point Pharma's chief financial officer.\\nPlease go ahead.\\nDan Lochner -- Chief Financial Officer\\nGood evening, everyone. And welcome to Oyster Point Pharma's fourth quarter earnings conference call for the three months ended December 31, 2021. This evening, we issued a press release containing our fourth quarter and full year ended December 31, 2021, financial results and recent business highlights. In addition, our earnings press release and our Form 10-K, which were filed with the SEC after the close of market today, are available on our website under the investors and news section at www.oysterpointrx.com.\\nJoining us on our call today are Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma; and John Snisarenko, chief commercial officer. Following Dr. Nau and Mr.\\nSnisarenko and my prepared remarks, we will open up the line for questions. During the call today, we will be making forward-looking statements regarding potential future events, including statements regarding Oyster Point Pharma's potential future financial status and results of operations and our plans and potential for success relating to commercializing TYRVAYA. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. For a description of these factors, please see our annual report on Form 10-K for the year ended December 31, 2021, filed with the SEC after the close of market today.\\nI will now turn the call over to Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma. \\nJeff Nau -- President and Chief Executive Officer\\nThank you, Dan. Good evening, everyone. And thank you for joining us on our call today to discuss our fourth quarter 2021 financial results and recent business highlights. This is a particularly exciting time for Oyster Point.\\nThis is our very first earnings call where we are pleased to be reporting partial revenues from the commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease in the United States marketplace. Today, you will learn more about how we are delivering these encouraging commercial results on the launch of TYRVAYA Nasal Spray. But first, let me provide the company's 2021 business highlights. In October of 2021, we received FDA approval of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease.\\nDry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence. The dry eye market is now being introduced to the first nasally delivered, pharmaceutical dry eye therapy, and we believe that given the high level of patient and physician satisfaction that we are seeing in the field with TYRVAYA, that significant growth remains ahead. You will be hearing more shortly from John Snisarenko, our chief commercial officer, about the details of the launch of TYRVAYA Nasal Spray, but I'm happy to state that we had great partial fourth quarter commercial performance in 2021.\\nWe are happy to report that TYRVAYA Nasal Spray had a net product revenue of $1.2 million in Q4 of 2021. In addition, we recognized $5.4 million from our license agreement with Ji Xing Pharmaceuticals. We are now entering 2022, having demonstrated the ability to achieve the successful commercialization of TYRVAYA, as well as drive strong execution across multiple areas of our business, including our exclusive license agreement with Ji Xing to develop and commercialize OC-01 and OC-02 in Greater China, securing nondilutive funding and pursuing additional treatment advancements in the clinic, as well as in the R&D laboratory for patients with ophthalmic diseases. This week, we publicly announced an early commercial win with one of the largest commercial payers.\\nOur press release from Tuesday announced that TYRVAYA Nasal Spray is now covered by Express Scripts effective on February 19. This is a fantastic accomplishment for our market access team in achieving the addition of 26 million covered lives and more importantly, this early in our first full quarter since launch. Patients are increasingly gaining access to TYRVAYA in the U.S. for a disease state that, up until 2021, we believe, experienced very little innovation for the current large unmet need in dry eye disease.\\nTYRVAYA is a first-in-class cholinergic agonist nasal spray that is highly differentiated from the other pharmaceutical products in the dry eye space and includes the following potential advantages. TYRVAYA Nasal Spray has a differentiated mechanism of action as it is believed to activate the trigeminal parasympathetic pathway via the nose, resulting in increased production of basal tear film as a treatment for dry eye disease. Basal tear film is responsible for lubricating, nourishing and protecting the cornea. TYRVAYA is the only ocular surface-sparing pharmaceutical therapy for dry eye patients.\\nFor those patients with a compromised ocular surface, increasing tear production without the burden of administering a topical medication may provide a welcome method to treat their disease. For the first time, dry eye disease patients have an FDA-approved, pharmaceutical treatment option that is not administered as a topical eye drop to an already irritated ocular surface. Although we are focused on the critical launch of TYRVAYA Nasal Spray and continue to execute plans for the life cycle development of the TYRVAYA franchise, our R&D team remains committed to multiple exciting pipeline projects aimed at bringing additional innovative therapies to address diseases like neurotrophic keratopathy and severe allergic or vernal keratoconjunctivitis. In 2022, we will continue to advance our enriched tear film gene therapy platform, as well as our research and development collaboration with companies like Adaptive Phage Therapeutics.\\nWe remain excited about the ongoing OLYMPIA Phase 2 study of OC-01 nasal spray in Stage 1 neurotrophic keratopathy. We are expecting a readout in the second half of this year. NK is a disease that is currently underdiagnosed or misdiagnosed in many patients with ocular surface disease. We feel that Stage 1 neurotrophic keratopathy could represent a meaningful indication for OC-01 nasal spray.\\nOur vision and focus is clear. The world needs an innovative leader that can bring innovative and transformative ophthalmic disease treatments, and we aim to be that leader. We believe that we're building Oyster Point into a best-in-class eye care company. I would now like to turn the call over to John Snisarenko, Oyster Point's chief commercial officer, to discuss our ongoing commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease.\\nJohn Snisarenko -- Chief Commercial Officer\\nThank you, Jeff. As we have previously communicated, the dry eye disease segment is a large market with over 17 million people diagnosed in the United States alone. Only a small proportion of these patients, approximately 2 million, are currently being treated with a branded therapeutic. And over 7 million people diagnosed with dry eye disease have tried and abandoned the other available options.\\nWe believe that TYRVAYA Nasal Spray is a new treatment option for the large patient population that exists in the dry eye disease marketplace, including the refractory patients, as well as those who are newly diagnosed. As Jeff highlighted previously, we are incredibly excited to have initiated the U.S. launch of TYRVAYA Nasal Spray on November 1. We are pleased to report that as of the quarter ending December 31, 2021, data indicates that approximately 5,500 prescriptions for TYRVAYA have been filled, written by over 1,900 unique prescribers.\\nThese encouraging metrics were achieved in less than nine weeks from the launch, including holiday periods. In this short time, TYRVAYA is quickly establishing itself in the market as an exciting new option for dry eye patients. Regarding market access, a core part of our commercial strategy is to promote accelerated payer adoption of TYRVAYA to the top payer organizations. Our market access team has done a great job in securing coverage for TYRVAYA with Express Scripts National Preferred, Basic and High Performance Formularies effective February 19.\\nWith this latest formulary addition, we now have coverage for a total of 43% of U.S. commercial lives for an aggregate total of approximately 84 million lives. We are incredibly pleased with this level of coverage so early in our launch, and we look forward to further growing our market access coverage in 2022. Oyster Point remains very committed to offering comprehensive patient services that help provide access to TYRVAYA for appropriate patients.\\nWe have launched a comprehensive set of technology-driven patient services offerings aimed at enabling patients to successfully navigate the patient journey and procure TYRVAYA. Our patient support program is called TEAMTyrvaya. And for more information on this program and how to enroll, please visit the website, tyrvaya-pro.com. We have been quite diligent with the sizing of our field force, which enables us to target 20,750 eye care practitioners, covering both optometrists and ophthalmologists and representing approximately 94% of the dry eye prescriptions in the market today, helping us in our efforts to achieve the full commercial potential of TYRVAYA.\\nIn the first nine weeks of launch, our sales force was able to introduce TYRVAYA to more than 50% of the targeted prescriber base. On the marketing side, we're leveraging the latest technology, including sophisticated analytics, in-person, as well as virtual detailing, best-in-class digital and social media efforts and partners, as well as utilizing a digital online pharmacy to enhance communication and delivery of TYRVAYA to patients. We will continue to adopt the latest media and technology-driven marketing approaches to maximize TYRVAYA's share of voice and impact in the market. Our focus continues to be on broad eye care provider and patient education and marketing efforts, with targeted direct-to-patient digital campaigns leveraging TYRVAYA's differentiated MOA and nasal spray route of administration to drive a positive patient marketing experience.\\nI am so proud of our commercial team's collective efforts during this early phase of our launch, especially in these challenging times with the pandemic. I will now turn the call back over to Dan Lochner, Oyster Point's chief financial officer, to discuss our fourth quarter financial results.\\nDan Lochner -- Chief Financial Officer\\nThank you, John. I will now provide a brief overview of Oyster Point Pharma's fourth quarter financial results. Additional detail about our fourth quarter, as well as our annual financial results can be found in our Form 10-K that was filed with the SEC this evening. For the fourth quarter of 2021, Oyster Point Pharma reported a net loss of $42.1 million, compared to a net loss of $22.2 million for the same period in 2020.\\nAs of December 31, 2021, cash and cash equivalents were $193.4 million, compared to $192.6 million as of December 31, 2020. Based on our current business plan, we believe the company's available cash and cash equivalents will be sufficient to fund the company's planned operation for at least 12 months from our 10-K filing this evening. Net product revenues for the fourth quarter of 2021 were approximately $1.2 million, following the FDA approval of TYRVAYA Nasal Spray on October 15, 2021, and our subsequent commercial launch in the U.S. in November 2021.\\nApproximately half of the TYRVAYA net product revenue was attributable to channel building by distributors upon launch of the product. In addition, pursuant to our license agreement with Ji Xing, the company also recognized $5.4 million in milestone and license revenue following the FDA approval of TYRVAYA Nasal Spray, which includes the noncash consideration of Ji Xing senior common shares. The company did not generate any revenues during the third -- three months ended December 31, 2020. Cost of product revenue for the three months ended December 31, 2021, was $1.5 million and consisted mainly of third-party manufacturing costs, which included pre-approval costs, reserves for inventory obsolescence and damaged goods and product royalty expense related to Pfizer.\\nThe cost of product revenue included a reserve for inventory obsolescence of $0.9 million. The inventory manufactured prior to FDA approval of TYRVAYA Nasal Spray was charged to R&D expense. And as a result, the company expects the unit cost of product revenue will be lower until the company fully utilizes this product that was manufactured pre-FDA approval. The company started expensing pre-approval inventory in 2020 and recorded an R&D expense of approximately $4.3 million for pre-approval inventory during the year ended December 31, 2021.\\nThe company anticipates selling the remaining pre-approval inventory by the end of 2022. The company's sales and marketing expense increased by $21.8 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase was primarily due to higher payroll-related expenses of $11.7 million, inclusive of sales commission expense, as well as an increase in stock-based compensation expense of $0.5 million, both of which were primarily driven by onboarding a commercial field force in the second half of 2021. The company also incurred higher marketing -- market access, commercial and other expenses of $10.1 million in anticipation of, and in connection with, the U.S.\\nlaunch of TYRVAYA Nasal Spray. The company's general and administrative expenses increased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase is primarily due to higher G&A expense of $3.8 million related to accounting, consulting, legal and other professional expenses incurred in connection with the credit agreement, as well as the company's transition from a clinical stage to a commercial-stage company. The company also incurred higher payroll-related expenses of $2.4 million, including recruiting expense due to an increase in headcount to support an ongoing efforts to commercialize TYRVAYA.\\nThe company's research and development expenses decreased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The company's decrease in R&D expense is primarily due to the company receiving FDA approval of TYRVAYA Nasal Spray in October 2021. The company expensed inventory prior to receiving FDA approval and expensed approximately $3.5 million as R&D during the three months ended December 31, 2020. The company also incurred a fee of $2.9 million in connection with the New Drug Application submitted to the FDA in December 2020.\\nThe company incurred interest expense of $2.6 million during the three months ended December 31, 2021, primarily related to the credit agreement with OrbiMed. Interest expense included contractual interest of $1.7 million, as well as noncash expense of $0.9 million related to the amortization of loan commitment fees and accretion of other long-term debt-related costs. The company had no interest expense during the three months ended December 31, 2020. Now as we turn to our outlook, for 2022, our goal is to continue to achieve broad ECP and patient experience with TYRVAYA, including both optometry and ophthalmology offices, in order to reach the total addressable dry eye market opportunity of TYRVAYA Nasal Spray.\\nWe anticipate the three large national commercial plans will make their coverage determinations by the midpoint of the year. While we await such coverage determinations, we will continue to provide patient-assisted programs to support eligible commercial patients in gaining access to TYRVAYA. With that overview of our financials, I will now turn the call back over to the operator to open up the line for questions.\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] Our first question comes from the line of Ken Cacciatore with Cowen. Your line is open.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nHey, team, looks like a really good and clean initial launch. I was wondering if you would wanna help us a little bit with maybe the revenue pacing. I know consensus, I believe, is around $30 million. And I know there's only a few of us analysts that are formally involved in the consensus, but I think it's around $30 million.\\nSo I was wondering if you could just kind of hold hands with that number, how we should be thinking about it. And then also, we've been doing clinician checks and getting very good feedback. But I guess, you could help us, as you would have a better sense of the early retention metrics, maybe the -- be able to definitively let us know how you're seeing some of the retention numbers and patients returning. So those are my first two.\\nI'm going to ask one more, if I could, though. Could you talk, John, a little bit about any refinements or learnings of your patient support system? Obviously, early days, but wondering if you're already tweaking it a bit. Anything that seems to be working very well or you've needed to change? And with that, I'll go back in the queue. Thanks so much.\\nJeff Nau -- President and Chief Executive Officer\\nGreat. Thanks, Ken, for the questions and very thoughtful. So maybe what we could do is we'll just take those in order. So I'll turn it over to Dan to just talk about the numbers for the year.\\nAnd then, we'll go into retention and have a discussion about John's experience with the bridge programs and the different patient services.\\nDan Lochner -- Chief Financial Officer\\nYeah. Great. I would say on revenues, while we haven't really provided official revenue guidance, I would say we think about it very operationally, focus in terms of our sales reps that are out in the field doing a great job. And I would say the focus very early on and throughout 2022 will really be about growing that eye care practitioner count, and we have goals internally for what we expect to achieve on a weekly and monthly basis.\\nAnd so, I think, it really starts with getting those ECPs onboard on a monthly sequential basis and then starting to look at what the right pattern is on an NRx basis per month and then what we then start observing on that pull-through on resell rate. And so, to kind of wrap that all up, we see it sequentially building through the quarters for the entire year as we start working through that total target population that we've identified, which is roughly 20,750 targets. And I think, it would be great to have John kind of speak about how we're really going after that target base and how that's been building through the quarters. And I think, what you'll see, at least for Q4, we've hit about 1,900 of those ECPs in respect to the 20,750.\\nAnd we'll continue to really work through that population of ECPs and really build that NRx and resell rate, the TRx, and then really playing out on revenue. The other dynamic, of course, is always on gross to net. And while we're not providing official guidance on gross to net because our focus really is on that volume and share component throughout 2022, I would say there is that first-half component related to the majority of patients in the first half expecting to be on that bridge program, which has a discrete impact to gross to net. And then, with our guidance, which is focusing on coverage determinations for the big three PBMs by the midpoint of the year, that transition from bridge over to commercial insurance will have a positive benefit discretely on that line in relation to gross to net, which would kind of tie up to your question on kind of how revenues would flow from a price and volume perspective through the year.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, thank you, Dan. This is John. You asked a question around retention rates and then refill rates. We've been very, very pleased to date with the metrics we've been seeing in that space.\\nEven patients that had been prescribed in early November, we started seeing early refill rates. I could quote that if you look at our blended refill rates with retail pharmacy and our digital online pharmacy, they're hovering around 64%, 65%. So we're very pleased with patients that are coming back and getting the refills. We are getting very, very nice position, as well as patient feedback, and we are hoping to continue that trend throughout 2022.\\nI think, part of that as well is your third part of your question around patient support programs, we out of the gate wanted to really employ a lot of technology around our patient services to TYRVAYA. So we're trying to make it very easy for that patient to navigate that journey through the prior auth and benefit investigations to get them to enroll into the program through QR codes in the offices, online, as well as other digital means. So because of that, we've been getting very, very good high enrollment rates and good fill rates that come through that program. So in terms of tweaking, we're continuing to put out more patient materials to surround sound the patient with different ways to enroll into the program.\\nBut overall, we're very, very pleased with how the program has been going. If the patient is deemed insured, but not covered, they automatically popped into our bridge program that they were appropriate patients and are able to get that script fulfilled and get experience with TYRVAYA. So we'll keep monitoring the patient services program, but so far, we've been very, very pleased.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nGreat. Thanks so much. Appreciate it.\\nJeff Nau -- President and Chief Executive Officer\\nOne thing I will add on, Ken, comment there is as we think about TYRVAYA as a product, when we think about the current marketplace and what it offers to patients, from an immunomodulator perspective, patients will go on a course of an immunomodulator. If they're not happy with the outcome at the end of that course, they're transitioning off, and they're likely either going on to another product or another device or another modality, but very rarely are they coming back. So we see a very low number of patients come back to the original therapy. I think, that the one thing to really keep in mind with TYRVAYA is it works so quickly to provide the patient relief, and it has such a differentiated mechanism of action that we are excited to look forward into the future to see how patients interact with the product.\\nIt's going to be a very different interaction than you would see with an immunomodulator because I do think not only will we have solid refill rates, but we will have people coming back to the product in those later years. And so, we're excited about that. And then, I would -- I'll just throw one comment out there for my team back at the office. Our patient services program is, bar none, one of the best I've ever seen.\\nAnd it is going very well in the field. And so, kudos to the team for putting together such a great program.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nGreat. Thanks so much.\\nOperator\\nThank you. Our next question comes from Joe Catanzaro with Piper Sandler. Your line is open.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nHey, guys, thanks so much for taking my questions, and congrats on the progress here. So maybe just to follow up, I think, Dan, you mentioned you guys had some internal benchmarks, I'm sure, on a bunch of things. But I'm wondering if you can maybe help put into context the early penetration in terms of the number of unique prescribers you've seen relative to your target ECP pool and where your early expectations were there. And then, I'm wondering what aspect -- and maybe it's something you just alluded to, Jeff, what aspect of the product profile do you see as resonating the most? And how do you go about fully leveraging that? And maybe I have a follow-up as well.\\nDan Lochner -- Chief Financial Officer\\nYeah. Maybe I'll start with it on my end. As you saw in the press release, we had achieved 1,900 unique writers in the quarter, which is just under about 10% of the targets that we are going after with our sales force of 162 sales reps. And so, I think, we had great progress in the quarter just under about nine weeks.\\nAnd so, as we look at benchmarks of prior therapies that have come to market more recently, I think we're in a great place for where we had expected us to land. Of course, we also understood that this is a new way of treating dry eye disease. So really communicating the benefits with the nasal spray. And so, I think, we're quite pleased with where we landed and continue to work toward that 21,000 target count as we progress throughout the year.\\nJeff Nau -- President and Chief Executive Officer\\nAnd maybe what I'll add on to -- the second part of the question there is some of the things that are resonating. I think, one of the things that's really been exciting about the launch of this product is patient feedback has been really great. And so, we've been excited to not only hear stories from the field, see posts on social media of patients going out on their own and talking about the product. And just really, it's a great product to launch where you're having that patient feedback come back to the teams and to those folks that have put such hard work into getting the product out there into the marketplace because it's really why we do this and it really drives the team.\\nSo I think, one of the things that we hear that is something that's really encouraging is just the patients stating that they really like the profile. They like the way it's making their eyes feel, and it's just differentiated in the way that it's able to be used. So we do hear stories back of people who are unable to deliver a topical eye drop. And this is another option for them because maybe they don't have the dexterity or they're elderly and they're just not able to put a drop into their eye, and so they're able to use nasal sprays.\\nAnd the other thing that we hear in the field often is the physicians are not getting patients calling back and complaining. And so, that's also really important for us. But again, we're very early in the launch. So we have many patients that haven't been on the product for more than a few months.\\nSo we're excited to see how the long-term feedback is. But for the moment, we are really encouraged by the feedback or sometimes lack of negative feedback coming back from the patients.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nGreat. And if I maybe just squeeze in a quick follow-up. I think, you said you guys have maybe covered about 50% of your target ECPs. Can you maybe speak to what percent of those have been given a sample? And how soon after sampling are you seeing ECPs write a script? Thanks.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, no, thank you, Joe. Great question. Part of our strategy is really to introduce TYRVAYA into the office practice with the prescriber base, the technicians, the staff that are involved with training, the patients and so on prior to actually sampling because we want to make sure that the product is taken appropriately and the patient gets the best possible experience they can with the nasal spray. So we handed out quite a few samples, probably over 100,000 samples since launch.\\nBut we want to make sure that we hand them out appropriately and that installation with that office has actually taken place before that sampling is initiated. So so far, that's worked well for us because we've seen a higher proportion of patients that tried a sample, see if it works for them before they're getting into our patient hub and actually getting that prescription filled. So that kind of connection has been very, very positive with that approach.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nOK, that's helpful. Thanks, again, for taking questions.\\nOperator\\nThank you. Our next question comes from Patrick Dolezal with LifeSci Capital. Your line is open.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nGreat. I'm just curious how the availability of generic cyclosporine has impacted discussions with payers, if at all. Were there any modifications to negotiations with Express Scripts as that approval came to light? I'm just curious if you expect any impacts going forward as you onboard other payers. And then, I have a follow-up as well.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Patrick, thanks for your question. We've seen kind of early mixed reactions from the payer community on how they're going to manage the generic entry of cyclosporine. And with the early listing with ESI, they're actually covering TYRVAYA across their formularies with only a traditional step, sort of an artificial tear. So that's what I mean by mix.\\nSome of the payers are kind of waiting until more than one generic comes out, and they'll take a look at the dry eye space or they're not really managing the dry eye space as closely. And others are going to evolve a little quicker. So we're able to modify our approach. We are ready for a generic to be on the market or not with.\\nAnd that's the way our negotiations are going with the major PBMs. And our goal is to get access for TYRVAYA on a level playing field with the branded therapeutics. And our differentiation along with our strategic contracting will help us get there.\\nJeff Nau -- President and Chief Executive Officer\\nAnd one other comment, Patrick. As you well know, generic entry into the marketplace doesn't change the dynamic that exists where patients cycle off many of these drugs, whether it be for lack of effect or side effects or whatnot. And so, that certainly will not change. So we were planning on generic entry coming.\\nI think, we've been planning for a long time, but it's been always in the back of our mind, and so the team is ready.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nThat's helpful. Thanks. And as it relates to just drug launch surrogates, there's not a ton in the dry eye space really, but obviously, we do have these eye drops. Just curious to hear any similarities and differences that might be worth pointing out.\\nAnd just if you could comment on the role of coverage and driving drug adoption in the dry eye space generally, that would be helpful. I'm curious if there's a tipping point where you feel that the amount of coverage really will drive adoption, 50% if it's a bit more. I would love to hear your thoughts there. Thanks.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Patrick, in regards to the Xiidra launch, we did see very quick uptake. Well, this was back in 2016. They had very early access to the commercial insurers, and they launched with 280-plus reps. We are very pleased with the number of reps we have and the trajectory we're seeing with TYRVAYA.\\nWe are on track in regards to the payer negotiations. And in fact, the ESI listing was an early listing for us. So we will get to that point that we're expecting in terms of broad base of writers, the eye care professionals prescribing TYRVAYA. We just won't be out of the gate as quickly as you saw with the Xiidra launch.\\nI could tell you, versus the latest two launches, we're very pleased with how our trajectory is going versus kind of the more recent entries. But it was a different space back in 2016, less managed, and also they were second entry at the time after Restasis.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nThat makes sense. Thanks for taking the questions.\\nOperator\\nThank you. Our next question comes from Chris Neyor with J.P. Morgan. Your line is open.\\nChris Neyor -- J.P. Morgan -- Analyst\\nGreat. Thanks for taking the questions. So first one is on me -- for me is just wanted to get a bit more details on the Express Scripts contract. So really just thinking about what's the mix between preferred and non-preferred coverage within those 26 million lives that you had estimated.\\nAnd within the Express Scripts plan, are there -- is there potential for additional pickup of patients and additional contracting that would either add additional patients or move more patients toward preferred access? And when talking about that kind of mix -- the mix of customers, what type of co-pay should we be thinking about for most of these patients? I think, I have a couple of follow-ups after that.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Chris. No, thanks. In regards to ESI, whether preferred or non-preferred, in terms of access whether you're listed preferred or non-preferred, the key criteria is you have to have tried and failed on an artificial tear for all of the branded products here. So as you mentioned in the last part of your question, the out-of-pocket is a difference between the Tier 3 and a Tier 2.\\nAnd pretty appropriate patients, commercial patients, we definitely buy down that out-of-pocket to be very competitive with the leading branded product out there. So we feel our 26 million lives that are covered are on a level playing field with regard to the leaders out there. And that -- those are the majority of the larger plans within ESI, but we will continue to work with signing on some of the downstream plans that ESI covers -- sorry, that Ascent covers as well and through ESI. So the tiering for us is not a disadvantage.\\nWe feel we're going to be very competitive with the two major brand leaders out there.\\nChris Neyor -- J.P. Morgan -- Analyst\\nGreat. That's helpful. And then, you kind of touched on the refill rates and also maybe you could just discuss your confidence in being able to hit that commercial coverage for CVS Caremark and UnitedHealth by the middle of this year. And then, aside from maybe overall script trends, any other KPIs that we should be watching for the launch in the coming weeks and quarters?\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, no, Chris, in regards to the refill rates, we've been very pleased with the kind of 60%, 65% rate of refills we've been seeing. We feel that based on the product profile, as well as the services we offer to make sure that both the prescriber base, as well as the patients are supported through the clinical experience with TYRVAYA. In regards to some of the other PBMs, we are in the middle of negotiations with them. We are still on track to have coverage determinations by midyear.\\nAnd we are ready to negotiate whether they're going to be managing the generic space or not. We feel we're going to be very, very competitive to be able to get TYRVAYA listed and get the majority of those commercial lives covered by midyear of '22.\\nChris Neyor -- J.P. Morgan -- Analyst\\nPerfect. Appreciate the questions.\\nOperator\\nThank you. And I'm currently showing no further questions at this time. I would like to hand the conference back over to Dr. Nau for any closing comments.\\nJeff Nau -- President and Chief Executive Officer\\nThank you, operator, and thanks to everyone for joining the call with us today. As I mentioned in my opening remarks, we are extremely pleased to announce that TYRVAYA Nasal Spray, indicated for the treatment of the signs and symptoms of dry eye disease, is currently in its first full quarter of launch for patients and eye care providers in the U.S. We are extremely excited for the potential of significant growth that remains ahead. Our vision and focus on bringing innovative and transformative ophthalmic disease treatments to patients and building Oyster Point Pharma into a best-in-class eye care company remains our primary goal as a company.\\nIn closing, I want to thank everybody for joining us tonight and to have a great evening.\\nOperator\\n[Operator signoff]\\nDuration: 41 minutes\\nCall participants:\\nDan Lochner -- Chief Financial Officer\\nJeff Nau -- President and Chief Executive Officer\\nJohn Snisarenko -- Chief Commercial Officer\\nKen Cacciatore -- Cowen and Company -- Analyst\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nChris Neyor -- J.P. Morgan -- Analyst\\nMore OYST analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 10:00:00\",\n        \"max\": \"2023-02-23 11:00:00\",\n        \"num_unique_values\": 5201,\n        \"samples\": [\n          \"2020-08-13 07:30:00\",\n          \"2019-08-07 09:00:00\",\n          \"2020-05-04 12:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 00:00:00\",\n        \"max\": \"2023-02-23 00:00:00\",\n        \"num_unique_values\": 835,\n        \"samples\": [\n          \"2020-03-11 00:00:00\",\n          \"2023-01-10 00:00:00\",\n          \"2022-03-29 00:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Clean_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17220,\n        \"samples\": [\n          \"Please go ahead. Karen David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations Welcome everyone, to Expro's second quarter 2022 conference call. I'm joined today by Mike Jardon, CEO; and Quinn Fanning, CFO. First, Mike and Quinn will share their prepared remarks, and then we will open it up for questions. We have an accompanying presentation on our second quarter results that is posted on the EXPRO website, expro.com under the investors section. In addition, the second quarter financials are downloadable on the Expro website under the Investors section. I'd like to remind everyone that some of today's comments may refer to or contain forward-looking statements. Such remarks are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such statements speak only as of today's date, and the company assumes no responsibility to update any forward-looking statements as of any future date. The company has included in its SEC filings, cautionary language identifying important factors that could cause actual results to be materially different from those set forth in any forward-looking statements. A more complete discussion of these risks is included in the company's SEC filings, which can be accessed on the SEC website or on our website at expro.com. Please note that any non-GAAP financial measures discussed during this call are defined and reconciled to the most directly comparable GAAP financial measure in our second quarter 2022 earnings release, which can be found on our website. With that, I'd like to turn the call over to Mike. Mike Jardon -- Chief Executive Officer Thank you, Karen. Good morning and good afternoon, everyone. I'm pleased to share with you that Expro delivered robust operational performance and financial results that exceeded the guidance we provided for the just completed second quarter. We are experiencing increase customer activity levels across all segments of our business, bolstered by a backdrop of strengthening industry fundamentals. We believe this positive momentum will not only continue, but will also accelerate going into 2023 and beyond. Expro is poised to capitalize on an expected increase in customer spending and activity. Today, Expro has a scope and financial profile required to compete and win in what we believe is the best outlook for energy services in at least a decade. Our results in the second quarter and our market outlook underscore the benefits of Expro's balanced portfolio of services and solutions with leading capabilities and a culture built around safety, service quality, organizational efficiency and risk management. In addition, we believe our through-cycle resilience is a significant advantage and competitive differentiator for Expro. Our current portfolio of services and solutions is paired with a global operating footprint with established positions in key growth markets and the combination provides Expro with good leverage to improving industry fundamentals and in particular, to the rebound that is beginning to take place in the international and offshore markets. We have never been better positioned to capture cyclical recovery upside. We also continue to have a best-in-class innovation platform and technology portfolio that enables us to support our customers' efficiency and emissions-related goals, grow market share and capitalize on longer-term industry trends. Finally, our strong balance sheet and merger-related synergies provide us with significant financial, operational and strategic flexibility that will allow us to accelerate growth and create long-term stakeholder value. On today's call, I'll touch on three main topics. First, I'll walk you through our second quarter performance. Second, I'll give an update on our integration process. And finally, I'll provide some perspective on trends we are seeing in the broader industry environment. For the second quarter, we delivered revenue of $314 million and an adjusted EBITDA of $51 million. Second quarter revenue increased 12% sequentially and on a Pro Forma basis, 10% year over year. Higher revenue during the quarter was driven by increased activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific regions. Adjusted EBITDA increased 39% sequentially and on a Pro Forma basis, 33% year over year. Adjusted EBITDA was primarily driven by a more favorable activity mix during the second quarter and faster-than-anticipated realization of merger-related synergies. Well Construction revenue was up 9% quarter over quarter and well management, which includes our well flow management, subsea well access and well intervention integrity businesses was up 13% quarter over quarter. Second quarter results exceeded the prior guidance, primarily as a result of increased well flow management and well construction revenue within North and Latin America. Our team continues to both capitalize on improving industry fundamentals and demonstrate the value of Expro's broad suite of cost-effective, innovative solutions to win new business and expand relationships with existing customers. During the quarter, we continued to secure contracts because of our exceptional service quality and technical delivery. We also continued the introduction of new technologies with both CoilHose and Octopoda, achieving market adoption at pace. The current commodity price environment puts a premium on maximizing production from existing well stock. So there is a strong customer interest in well intervention integrity solutions such as CoilHose and Octopoda. The significant under investment in energy supply over the last decade, coupled with growing demand, is also resulting in FID approvals. Importantly, for our company, nearly 60% of the new customer commitments are expected to be offshore. We achieved contract wins and extensions totaling approximately $300 million, which demonstrates the breadth and depth of our customer relationships and attraction that our solutions are gaining in the market. On a regional basis, in North and Latin America, our Well Construction team continues to demonstrate the position as the premier provider of casing and tubular running services with the award of contracts and successful operations delivered across the region. The team successfully completed a first casing running to a project in Brazil and carried out eight simultaneous TRS deepwater completions in the Gulf of Mexico, where activity continues to pick up. We also deployed our industry-leading 22-inch brotpackers in Mexico for the first time and have seen growing demand for this well integrity technology as operators across the region seek to protect their assets during storm season. This technology allows for quick and rely the well suspension when operators need it most. We want to influence contract for a major operator in Brazil. And in Alaska, our team was awarded and performed a well test for a strategically important new customer, further growing our presence in this region. Expro in MENA achieved contractor of the month from an international operator, demonstrating Expro's continued focus on delivering best-in-class safety, quality and customer service. In Europe and Sub-Saharan Africa, we saw good progress in securing new business in the second quarter, including the retention of the largest well flow management contract in the Norwegian continental shelf for an initial four-year term, highlighting the strength and depth of our relationship with this international operator. A significant portion of this contract is directly linked to production optimization and enhancement as well as a demonstrable commitment to low carbon plan. The breadth of our portfolio, including market-leading technologies acquired in our July 2019 acquisition of Quality Intervention directly assisted us in expanding a core well intervention contract with a major international operator in the U.K. In addition, our service quality and portfolio of capabilities helped us secure an expanded contract to meet client needs for a nine-well plug and abandonment campaign in the U.K. Continental Shelf, where we also added well test and well intervention to an existing large board subsea services contract. As I noted earlier, CoilHose and Octopoda are gaining traction in the market to support clients' intervention and integrity needs. Octopoda is a truly unique service offering, which for the first time in our industry, allows direct access to well annualized in which we can ensure well integrity and production assurance. Octopoda was recently deployed in the Congo, the first deployment of this technology in Sub-Saharan Africa, and it continues to generate customer interest with its unique ability to investigate and remediate sustained casing pressure and other well annulus problems. Additionally, our CoilHose Light Well Circulation system is an innovative development, providing a lower cost more efficient alternative to traditional coiled tubing systems. This broadening of our portfolio and our depth of experience, combined with the ability to quickly mobilize assets and personnel to meet client requirements helped us secure a U.K. contract for well testing and exploration and appraisal services in support of a new offshore drilling campaign. Expro's superior quality and service performance as strong client partnerships led to the securing of multiple contract wins, including for our subsea team in the Ivory Coast and in Turkey, where we won well testing and CoilHose intervention work for a nine-well project on offshore gas storage project. In the second quarter, we also introduced Drill Stem testing into Angola, further broadening our comprehensive portfolio in this country and positioning us to take advantage of the increasing activity in deepwater operations in Angola. We have successfully started operations in Cabinda for a major operator, which will be our first deployment of hammering services as part of an Angolan Well Construction Service package. In May, we were also recognized as the safest service provider in Mozambique. Based on our recent performance, we are in discussions with the client regarding further expansion of our services, including the introduction of new technologies. In Chad, our work with the client is core to ensuring that our operations are conducted in an environmentally responsible way. Our expertise and technologies are focused on having no environmental impact with testing and analysis carried out to ensure the appropriate purity of the regional freshwater system, underlining our status as a leading provider of on-site chemistry services with a strong environmental focus. In Norway, we completed our first operational campaign with our iTong Well Construction Technology, which provides a step change in safety and well construction operations. Operational performance exceeded client expectations, delivering significant rig efficiency improvements and cost savings to the customer overall. In the Middle East and North Africa, our Well Construction team has expanded into new territory to secure their first TRS contract in Algeria, which is planned to commence later this month. This opportunity reflects one of the many revenue synergies created by our October merger. We leverage expert relationships and well flow management to secure this new TRS award. In addition, the regional team was awarded two carbon boom contracts with Middle East drilling contractors, reflecting our market-leading capabilities and reputation in the market. In Egypt, our service offering and ability to deliver contributed to Expro being awarded significant well test contracts. In the Asia Pacific region, our well construction team in Brunei secured a major 5-year contract for TRS. Our outstanding track record of reliable performance in HSC and service quality were strong criteria for the contract award. In Thailand, the team secured additional TRS work covering 200 wells and in Malaysia and in offshore China, we were awarded three-year TRS contract extensions spanning development and exploration wells. Our subsea team's technical capability played a key part in securing a contract with a major international operator in Malaysia for the provision of our new vessel deployed Light Well Intervention package, with the team also securing significant additional work in Australia. Like CoilHose and Octopoda, Expro's LWI capabilities are the result of investments we have made over the last several years, which should allow the company to offer differentiated production optimization solutions and thereby grow our top line faster than the overall market, while also improving profitability. Expro is strategically committed to continuing to invest in transforming our business portfolio and reducing greenhouse gas emissions. In April, we published our inaugural, environmental, social and governance review with a stated aim of achieving net 0 by 2050 with a 50% reduction in carbon intensity by 2030. As the energy industry embraces transition and the need to make real and visible headway toward a lower carbon world, we appreciate the key enablers to change will be those who can truly differentiate themselves as solutions providers. As recognized global well experts and a trusted partner, we believe Expro is well-positioned to play an important role in enabling our clients to achieve their carbon reduction goals in support of the energy transition. Expro remains committed to allocating roughly 50% of our research and development budget to carbon reduction initiatives. In doing so, we are developing and advancing solutions that will play a critical role in enabling our customers to achieve their own emission reduction goals while also allowing experts to achieve its goals. Expro's well expertise and range of well intervention, well integrity and wells measurement technologies and skills help operators cost-effectively develop oil and gas resources while minimizing both emissions and the required operating footprint. As our industry speaks to address tomorrow's challenges, we believe many of these technologies and skills are transferable. As a good example of adopting technologies to achieve more sustainable energy solutions, Expros supported geothermal well service projects since 1986. Most notably, in the second quarter, we were awarded our first integrated services geothermal contract to support a high-profile geothermal plant in Germany. The second topic I'd like to cover is to provide an update on our integration efforts. During the quarter, we continued to make progress in bringing the legacy businesses together to capture the full potential of our combined platform. I am pleased to report that 9 months into our integration, we have identified an action more than 100% of the $55 million in annualized cost savings that we established with our target within the first 12 months following the closing of the merger. This comes a full quarter earlier than we had initially anticipated. As outlined previously, we are targeting cost and revenue synergies between $80 million to $100 million within 24 to 36 months post-merger. We remain confident that we will achieve $70 million in projected cost synergies during this time frame, if not earlier. Cost savings are primarily driven by the rationalization of support costs, consolidation of facilities and supply chain savings. In the second quarter, we consolidated additional facilities, including locations in Baku, either by John, St. John's, Canada; Lumpur, Malaysia; Mumbai, India; Corpus Christi and Midland, Texas. While revenue synergies are more difficult to demonstrate, my sense is that our previous estimate of an incremental $10 million to $30 million in EBITDA for revenue synergies through our expanded customer relationships and operating footprint, increased time on rig and greater exposure to the full life of the field will likely prove to be conservative. I'd like to sincerely thank the entire expert team for their hard work and numerous contributions toward helping us realize our integration goals ahead of schedule. Without a doubt, we have a winning team that has proven the building to deliver on our commitments. Before I turn the call over to Quinn, I want to provide some perspective on trends we are observing in the market. The positive signs of a recovery we saw in Q1 continued to build, underpinned by a favorable supply demand dynamic. As I noted earlier, this is largely a result of limited upstream investment in recent years and a need for additional capacity to meet projected demand growth. With the more recent heightened focus on energy security, diversification of supply and the need to replace at least a portion of Russian oil and gas supply is expected to fully magnify what was already set up to be a favorable multi-year macro backdrop for OFS activity. Longer term, we believe the service sector will need to play an important role in facilitating the energy transition. So despite ongoing volatility in commodity prices, the fundamental backdrop for the energy services sector is quite constructive. In particular, after a strong recovery in the U.S. onshore market, we are seeing increasing demand for our services and solutions with international and offshore activity expected to accelerate through the second half of 2022 and into 2023 as operators look to increase production from existing assets and develop new fields. Notwithstanding near-term concerns of an economic slowdown, there seems to be a consensus that energy demand will trend back toward, if not through 100 million barrels of oil equivalent per day in 2023. We expect that increasing demand for energy services and capacity constraints in key service offerings, including high-end well construction equipment and subsea test trees should provide scope for improvement in net pricing beginning in late 2022 into early 2023. In Expro's view, expected growth will be broad-based geographically, span all phases of oil and gas development and include all operating environments. Geographically, we see strong potential in North and Latin America, the Middle East, North Africa, Sub-Saharan Africa, as well as Asia. And while many of our customers continue to focus on brownfield enhancement programs to maximize previous investments, we are also starting to see growth in exploration and development activity driven primarily by North and South America, with further activity expected in Norway, India and Sub-Saharan Africa. The brownfield focus will support steady growth in our well Intervention Integrity business as well as elements of our well flow management business, collectively, which represent about 35% of our business. The remaining circa 65% of our business is generally levered to drilling, well construction and well completions activity, which we believe is points for strong growth across several geographies and within which we generally capture very good faster on incremental revenue. Overall, the outlook for the remainder of '22 and into 2023 remains positive with sustained increases in E&P expenditures. After rather dramatic recovery in the North America onshore market, customer dialogue and tendering activity indicates to us that the outlook for offshore activity is strengthening. This should support sustained growth for Expro given our leading and differentiated portfolio capabilities and subsea well access services, complex well construction services and production optimization. This is particularly important as approximately 70% of our revenue today is generated from offshore activity. Before I close, I'm pleased to share that during the quarter, our board approved a new stock repurchase program under which the company is authorized to acquire up to $50 million of its outstanding common stock up to the November 2023 time frame. We view the repurchase of our shares as an attractive and prudent use of our capital that it is in the best interest of our shareholders. With a debt-free balance sheet, ample available liquidity and strong construction of an industry recovery, buybacks allow us to opportunistically increase shareholder value while maintaining sufficient cash resources to fund our business needs. In the second quarter, we repurchased $13 million in export stock, representing approximately 1% of our shares outstanding. From an operational standpoint, Expro is well positioned in the markets that we expect will continue to benefit from strengthening industry fundamentals. In particular, Expro has significant leverage to strengthen the international and offshore markets where experience, expertise and service quality can be in Expro's case are positive points of differentiation. Execution is a traditional strength of Expro and when we plan to continue to deliver on both for our customers and our shareholders. With that, I will hand the call over to Quinn to discuss our financial results. Quinn Fanning -- Chief Financial Officer Thank you, Mike. Good morning and good afternoon to everyone on the call. As Mike noted, I will cover the results for the quarter ended June 30th, 2022, and will primarily highlight our sequential performance compared to the quarter ended March 31st , 2022. To recap, we reported revenue of $314 million for the June quarter, which was up sequentially $34 million or approximately 12% relative to Q1 2022. The sequential increase in revenue was driven by higher activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific segments, partially offset by lower activities in the Middle East and North Africa segment. Adjusted EBITDA for Q2 2022 was approximately $51 million, representing a sequential increase of approximately $14 million or 39% relative to Q1 2022. Adjusted EBITDA margin in Q2 was 16% as compared to 13% in Q1. The sequential increase in revenue and adjusted EBITDA was driven by strong results for well flow management and well construction in North and Latin America. As highlighted in our press release, adjusted net income for the second quarter of 2022 was $0.02 per diluted share, compared to adjusted net income for the first quarter of 2022 of $0.01 per diluted share. As noted in our press release, adjusted net income for Q2 includes foreign exchange losses of $0.05 per diluted share as compared to foreign exchange gains of $0.03 per diluted share in Q1. Q2 contribution margin of 38% was up approximately one percentage point sequentially from Q1 2022, reflecting improved fall-through on higher revenue as a result of a more favorable activity mix. Q2 support costs of $70 million totaled 22% of group revenue and were down approximately $1 million sequentially or approximately 3 percentage points relate Q1 2022 and were down $8 million or approximately 9 percentage points relative to the combined support costs of Expro Frank's in Q4 2020, which was the last full quarter prior to the announcement of the merger. This represents approximately $30 million of annualized support cost savings achieved through the second quarter of 2022. In the near term, we expect to continue to manage total support costs to 22% of group revenue. With modest net pricing gains and/or incremental cost synergies, we believe we can manage overall support costs to about 20% of revenue. Total liquidity at quarter end was approximately $309 million. Cash and cash equivalents, including restricted cash, was $179 million as of June 30th. Total liquidity also includes $130 million that is available to the company for drawdowns as loans under our $200 million revolving credit facility. The balance of the facility is available for bonds and guarantees. Expro had no interest-bearing debt at quarter end Q2 2022, and the company has no interest-bearing debt today. During the quarter ended June 30th, cash provided by operating activities was $2 million as compared to cash used in operating activities of $14 million in Q1. Q2 adjusted operating cash flow, reflecting cash used in operations before cash paid for interest, severance and other expenses and merger integration expenses, was positive $10 million compared to negative $1 million in Q1. Capital expenditures totaled $21 million in the second quarter compared to $11 million during the first quarter. For the second half of 2022, the company is planning for capital expenditures in the range of approximately $60 million to $70 million, implying total capex for 2022 of $90 million to $100 million or approximately 8% of expected revenue. We also continue to expect to be free cash flow generative for 2022, but as noted on our last earnings conference call, we expect that adjusted cash flow from operations and free cash flow will be heavily weighted to the second half of the year. Consistent with comments from several of our public peers, Expro's investment in working capital was up materially in the first half of 2022, with higher receivables reflecting higher activity levels and higher inventory reflecting both an expectation of continued momentum in the business and the procurement of long lead items, including critical spares. Consistent with historic patterns, we expect a reversal of the H1 build in working capital and a significant improvement in cash generation in H2 2022. As Mike previously discussed, under our recently announced stock repurchase program, during the second quarter, we opportunistically repurchased 1.1 million shares or approximately 1% of our shares outstanding for a total cost of $13 million. This program is a reflection of the long-term confidence we have in our business, which we believe is not reflected in the current market valuation. In due course, we will more formally articulate Expro's capital allocation priorities. For now, we expect that the small buyback will be completed in Q2 and for that matter, any additional buybacks will be funded by free cash flow. Now, moving into the details for reporting segment. North and Latin America or NLA, revenue for the second quarter of 2022 was $130 million, a sequential increase of $26 million quarter over quarter. The increase was primarily due to higher revenues across all of our product lines during the current quarter with a significant increase in well flow management revenue in Mexico and higher well construction revenue in the U.S. and Guyana driven by higher customer activity levels during the just completed quarter. NLA segment EBITDA for the three months ended June 30th, 2022, was $39 million or approximately 30% of segment revenue. It was up sequentially by $17 million quarter over quarter. For Q1 2022, NLA segment EBITDA was 21% of segment revenue. The increase was attributable to higher activity and a more favorable product mix during the three months ended June 30th. For the Europe and Sub-Saharan Africa or ESA segment, revenue in Q2 was $90 million, which was up $8 million or approximately 10% quarter over quarter. The sequential increase was primarily driven by higher wealth flow management revenue in Angola and in the Congo and higher well construction revenue in the United Kingdom due to increased customer activities. The increase in revenues was partially offset by lower well intervention integrity revenue in Norway and Western Europe. ESA segment EBITDA for the second quarter was $15 million or approximately 16% of segment revenue, a sequential increase of $3 million quarter over quarter. The increase was primarily attributable to higher activity levels and a more favorable activity mix during the June quarter. For the Middle East and North Africa or MENA segment, revenue in the second quarter was $45 million, a decrease of $6 million or approximately 11% quarter over quarter. The sequential decrease was driven by lower equipment sales related to wealth management in Saudi Arabia and in the United Arab Emirates, partially offset by increased wall management activities in Algeria. MENA segment EBITDA for the June quarter was $14 million, a sequential decrease of $1 million quarter over quarter. Segment EBITDA margin was consistent with the prior quarter at 30%. The reduction in segment EBITDA was primarily due to lower activity. For Asia Pacific, or APAC, revenue for the second quarter was $48 million, which was an increase of $4 million or approximately 11% sequentially. The increase in revenue was primarily due to higher subsea well access revenue in Australia and Brunei and higher well construction revenue in Japan. The increase in revenue was partially offset by lower wealth flow management revenue in Thailand and in India. APAC segment EBITDA for the June quarter was $4 million or approximately 9% of segment revenue, a decrease of $1 million or about 3 percentage points quarter over quarter. The reduction in segment EBITDA in APAC, despite the increase in revenue was primarily due to additional mobilization and commissioning costs on a large subsea project that were incurred during the quarter as well as lower activity on higher-margin contracts. Additional commissioning costs on the Subsea projects, which totaled approximately $3 million and associated project start-up delays are in part COVID related and should be nonrecurring. As a result, we expect that revenue and segment EBITDA margin in APAC will trend positively in H2 2022 and into 2023. As Mike mentioned, our integration plans are progressing well, and we are already starting to realize significant synergy benefits we anticipated when we first announced our business combination in March of 2021. As Mike mentioned, through the second quarter of 2022, we have identified an action to approximately 100% of our synergies capture plan, both in regards to headcount and annualized value in dollars. We also completed the consolidation of several international facilities and made good progress on our ongoing migration to a single ERP platform, which should allow us to both to streamline a number of key business processes and begin to action additional cost synergies. As to our near-term outlook, we expect that Q3 2022 revenue will be up sequentially by plus or minus 8%, reflecting continued business momentum at NLA, the continuation of the seasonal rebound in ESA and the start-up of new contracts in MENA and APAC. Adjusted EBITDA margin in Q3 should be in the area of 15% to 17% of consolidated revenue. Over the next couple of quarters, we continue to expect that our revenue run rate will approximate that of the pre-pandemic 2019 revenues of Legacy Expro and legacy Frank's on a combined basis. And we, therefore, reaffirm our guidance, the Q4 revenue should fall within a range of $325 million to $350 million. With the benefit of fall-through on incremental revenue and synergies, we expect that adjusted EBITDA margins will be in the area of 20% of revenue as we exit the year. Provided our H1 build in working capital reverses in H2 2022 as is currently anticipated, absent additional M&A and/or share repurchases, we expect that our year-end cash position will be at or above where we started the year with cash generated from operating activities, funding integration costs, capex, the Q1 acquisition of SolaSense and the share buyback that was completed in Q2. By preserving and protecting our currently strong financial profile and by maintaining a disciplined approach to investment, we believe Expro will have sufficient financial flexibility to fund growth and increase returns to shareholders. As always, our objective is to enhance long-term value for our shareholders, employees, partners and the communities in which we operate. With that, I will turn the call back over to Mike for a few closing comments. Mike Jardon -- Chief Executive Officer Thank you, Quinn. We delivered exceptional operational performance that drove significant growth on a top and bottom line and is beginning to demonstrate the true capability of the company. Our broad portfolio of services and solutions continue to create opportunities in the growth markets that will be key to Expro's long-term success. Our innovative platform, next-generation technology and solutions and ESG applications are differentiators that continue to rapidly advance our reputation and outstanding track record with customers as a leading well expert. We continue to secure contracts and demonstrate the value of the breadth of our portfolio and the depth of our expertise can bring to clients across the life of their wells. Looking forward, the positive signs of a recovery we saw in the first quarter continued to gain momentum. We are seeing increased demand for our services and solutions as the recovery that began within the U.S. onshore market has begun to gain traction in the offshore international markets. We remain confident that the pipeline of projects we are seeing will support strong multi-year growth and firmly believe Expro is uniquely positioned to capitalize on this favorable outlook. We are incredibly excited about the strength and positioning of Expro. Our results could only have been achieved by the hard work and focus of our team. It's through their dedication that we continue to accelerate growth, improve profitability and enhance value for shareholders, employees, customers and partners. Thank you, again. Questions & Answers: James West -- Evercore ISI -- Analyst Good morning, guys. Mike Jardon -- Chief Executive Officer Good morning James. James West -- Evercore ISI -- Analyst So one, Mike -- so curious, it seems like we've gone through a bit of acceleration in demand here over the last quarter, maybe two quarters in a sense of urgency has arisen within your customer base? I guess -- so first, is that -- am I getting that correct? And that this urgency is kicking in? And then second, are you seeing more of that urgency or increased demand on producing assets or new assets or interventions versus new well construction type work. Mike Jardon -- Chief Executive Officer Yes. So James, I can tell you one of the good things is we've really -- now that we're kind of more exited the pandemic. I've been able to spend an awful lot more time with customers, not only in the U.S., but in particular, Middle East and Asia. And what I'd say is the conversations particularly around new FIDs, new projects, new drilling and completion type activity, that's much more constructive, much more dialogue and discussion around that. I'd say that the -- we've had continuing strong commentary and strong game with customers around producing assets. So that's -- I think that's ramping up, but not at the same rate as the positivity from the discussions around new well type -- new well drilling activity and new well completion activity. James West -- Evercore ISI -- Analyst OK. Fair enough. And then on the pricing side, are you -- at this point, are we back to kind of -- or getting close to back to pre-pandemic type of levels? Admittedly, offshore wasn't as robust even then, but it's growing and robustness now. But are you achieving the returns on capital investments that you would like to see when you're allocating capital and what you're pricing new contracts? Mike Jardon -- Chief Executive Officer So I would -- and I tried to allude to it in my earlier comments, we're starting to see some spotty opportunities to push price, and we're pushing price every opportunity we can. It's more selective right now. I think we'll continue to gain more momentum around our ability to continue to press price as we exit '22 going into '23, but we are starting to have -- it hasn't quite turned the quarter, so to speak, like North America. U.S. land has where there's lots of pricing leverage and pricing traction. But we are starting to see in some particular markets and some particular service lines, positive opportunity to continue to get that pricing. And I think we're all keen to make sure that we start to implement that absolutely as soon as we can. Quinn Fanning -- Chief Financial Officer James, I think the only thing -- I could just point you back to Mike's prepared remarks, there are capacity constraints within certain solutions and certain product groups, complex well construction or to provide construction activity or TROs, as well as the subsea landing streams. It's obviously a market that is supported by just a handful of service providers ourselves being one of the two larger ones product lines. But obviously, everything about the supply and demand, there's less than a supply for those two equipment classes. The other thing I'd highlight is with the pickup in drilling and completion type activity. It's not necessarily how we present our supplemental disclosures. But what we consider to be our drilling completions over businesses, they were up 20% quarter-over-quarter revenue-wise and the thoughts for margins on the incremental activity is north of 50%. So that's really where you get the -- James West -- Evercore ISI -- Analyst OK. Got it. Yes, no doubt. That's going to be very helpful. David Anderson -- Barclays Capital -- Analyst Hey. Good morning, Mike. I was just curious which of your product lines showed the greatest margin improvement this quarter. And I think you maybe just touched on it just now here. But curious if there's been much of improvement in well construction, in particular, as a rental business in TRS with high offshore exposure. Just curious how we should be thinking about the margin expansion upside in that particular business and how that should contribute overall. Mike Jardon -- Chief Executive Officer Sure. We alluded to some of this in the prepared remarks. What kind of additional commentary I'd add to it, David, is we've really seen some increased mix, better mix of activity in North Latin America, in particular. So yes, particularly around TRS around well construction, we've been able to start to see some margin expansion there. And then I think overall, what you're really seeing is starting to gain more traction with the cost synergies we're taking out the organization overall. We're in essence, we're a full quarter ahead of that. And I think one of the real positives of us being able to get the synergies implemented is if we're being to completely honest, anytime you're doing a consolidation, you're doing a merger, if there is a little too much internal focus that goes on. It's a necessary part of the eval as doing a merger as we can get more of that behind us, and we'll largely because we're a quarter ahead of it, that means going in exiting '22 and going into '23, we're really going to be much more externally focused. And that's one of the reasons why I've been challenging the organization is so hard to make sure we get these things done sooner rather than later. But overall, we're seeing margin expansion across well construction and even in some of the well flow management and subsea access, we're getting some traction in all three of those right now. David Anderson -- Barclays Capital -- Analyst So if I just stay on the well construction side, we're hearing a lot of talk about rigs coming back to work both on the jack-ups and the deepwater side. Are you getting inquiries for those? I'm just kind of curious, it's obviously only a couple of players in the TRS business. So I'm just kind of curious, are you starting to kind of roll out some additional equipment at been sidelined for a while. Can you help us give us a handle on what that looks like in terms of, I guess, your capacity type of equipment out there and how that's moved up? Mike Jardon -- Chief Executive Officer Yes. No, absolutely. We are seeing the same phenomenon that the drillers are seeing today with increased utilization, those kind of things. Because keep in mind, a drilling rig and TRS type equipment goes kind of hand in hand. So yes, we're able to start to put some of that equipment back to work. I referred to a casing running tool CRT opportunity we execute on in Brazil. That purely is taking assets and resources that were underutilized previously and putting those to work. So on the flip side of that, yes, we're seeing good traction with all construction. The other thing that we're seeing even more so than I had anticipated was it really becomes an early warning radar system for us, so to speak, because typically, with customers, they select the rig first almost in conjunction with that are certainly right behind it is selecting the TRS provider. And then you start moving into well completions and well testing, and those type of activities. So we're getting earlier customer engagement. And I think that we'll continue to see that allow us to more upholster revenue opportunities, those types of things. David Anderson -- Barclays Capital -- Analyst That's interesting. So if I just -- on that on that well flow management, it was up 14% sequentially this quarter, I'm pretty sure what was pretty strong for business that I thought we would consider later cycle, more production focused. So I guess the question was, I think you had said in your remarks that MENA was a little bit weaker than expected. So where were the results? Was it more mix related this quarter? Was it regional? Was something else kind of picking up and offsetting what you said? I mean, because I would have thought MENA would have actually been a driver of that growth. And it sounds like it wasn't -- Mike Jardon -- Chief Executive Officer Sure. MENA for us was really -- we had kind of a quarter-on-quarter product sales that didn't reoccur in the second quarter. So that was what gave us a little bit of softness there. Our strong activity in the Middle East, Algeria, in particular, was actually up quarter on quarter. What is important to recognize with well flow management is, in particular as well testing, we can utilize those assets in a well completions cleanup load or you can use those assets in a production optimization mode. And that allows us to kind of flex that equipment to deploy it into one or the other. And part of the growth we saw was starting to see some better activity from a new well completions, new well flowback, those type things within the quarter. David Anderson -- Barclays Capital -- Analyst OK. Thank you very much. Mike Jardon -- Chief Executive Officer Absolutely. Thanks for the questions. Duration: 0 minutes Call participants: Karen David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations Mike Jardon -- Chief Executive Officer Quinn Fanning -- Chief Financial Officer James West -- Evercore ISI -- Analyst David Anderson -- Barclays Capital -- Analyst More XPRO analysis All earnings call transcripts\",\n          \"I would now like to turn the conference over to Rodney Sacks, Co-CEO, to begin the call. Please, go ahead. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Good afternoon, ladies and gentlemen. Thank you for attending this call. I'm Rodney Sacks. Hilton Schlosberg, our Vice Chairman and Co-Chief Executive Officer, is on the call; as is Tom Kelly, our Chief Financial Officer. Tom Kelly will now read our cautionary statement. Thomas J. Kelly -- Chief Financial Officer Before we begin, I would like to remind listeners that certain statements made during this call may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and are based on currently available information regarding the expectations of management with respect to revenues, profitability, future business, future events, financial performance and trends, as well as the future impact of the COVID-19 pandemic on the company's business and operations. Management cautions that these statements are based on our current knowledge and expectations and are subject to certain risks and uncertainties, many of which are outside the control of the company that may cause actual results to differ materially from the forward-looking statements made during this call. Please refer to our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K filed on March 1, 2021, including the sections contained therein entitled Risk Factors and Forward-looking Statements, for a discussion on specific risks and uncertainties that may affect our performance. The company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events or otherwise. I would now like to hand the call over to Rodney Sacks. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Thank you, Tom. The company's top priority remains the health, safety and well-being of its employees. The company's flavor manufacturing facilities, its co-packers, warehouses and shipment facilities have operated throughout the COVID-19 pandemic. The company's bottlers and distributors are operating, and the company's products remain generally available to consumers. In limited countries, the operations of the company's bottlers and distributors have, in part, been negatively affected for varying periods of time. Despite the ongoing impact of the COVID-19 pandemic, the company achieved record second quarter net sales. Currently, the company does not foresee a material impact on the ability of its co-packers to manufacture and its bottlers and distributors to distribute its products as a result of the COVID-19 pandemic. The company's supply chain remains largely intact. However, the company continues to experience shortages in its aluminum can requirements in the United States and EMEA, given the company's volume growth and the current supply constraints in the aluminum can industry. The company is also experiencing delays in procuring certain ingredients, both domestically and internationally. As a result, the company was unable to fully satisfy demand in the 2021 second quarter in the United States and EMEA. We expect such challenges to continue for the next few months. The company has taken steps to source additional quantities of aluminum cans from the United States, South America and Asia. The company has entered into new supply agreements with two new aluminum can suppliers in the United States, and which are expected to be operational in the 2021 fourth quarter. We expect deliveries of additional quantities of cans increasing sequentially during the latter part of the year. Logistical issues, including shortages of shipping containers and port of entry congestion could delay ongoing international supply of aluminum cans. Separately, we are continuing to experiencing -- experience freight inefficiencies as well as significant increases in domestic and international freight costs and like other beverage companies are incurring increased aluminum can and other costs in the current environment, all of which in addition to other factors, will continue to adversely impact gross margin percentages. In the second quarter of 2021, net sales were $1.46 billion compared with $1.09 billion in the second quarter of 2020, an increase of 33.6%. Adjusting for foreign currency movements, net sales for the 2021 second quarter would have been up 30.1%. Gross profit as a percentage of net sales for the 2021 second quarter was 57.2% compared with 60.3% in the 2020 second quarter. The decrease in gross profit as a percentage of net sales for the three months ended June 30, 2021, was primarily the result of geographical sales mix and increased input costs, mainly increased raw material freight in costs and aluminum can costs. Operating expenses for the 2021 second quarter were $310.9 million compared with $252.2 million in the 2020 second quarter. As a percentage of net sales, operating expenses for the 2021 second quarter were 21.3% compared with 23.1% in the 2020 second quarter. Operating income increased 29.1% to $526 million, up from $407.3 million in the second quarter of 2020. Net income increased to 29.7% and to $403.8 million compared to $311.4 million in the 2020 comparable quarter. Diluted earnings per share for the 2021 second quarter increased to 28.6% and to $0.75 from $0.59 in the second quarter of 2020. According to the Nielsen reports for the 13 weeks through July 24, 2021, for all outlets combined, namely convenience, grocery, drug, mass merchandisers, sales in dollars in the energy drink category, including energy shots, increased by 14.2% versus the same period a year ago. Sales of the company's energy brands, including Reign, were up 8.6% in the 13-week period. Sales of Monster were up 11.1%. Sales of Reign were down 6.1%. Sales of NOS decreased 4.1%, and sales of Full Throttle increased 7%. Sales of Red Bull increased 15.3%. Sales of Rockstar decreased by 15.7%, and sales of 5-Hour increased 8.5%. VPX Bang sales increased 20%. According to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the energy drink category in the convenience and gas channel, including energy shots in dollars, increased 7.4% over the same period the previous year. Sales of the company's energy brands, which include Reign, increased 3.6% in the four-week period in the convenience and gas channel. Sales of Monster increased by 5.8% over the same period versus the previous year, Reign sales decreased 6.8%, NOS was down 10.7%, and Full Throttle was up 13.2%. Sales of Redbull were up 9%. Rockstar was down 18.6%, and 5-Hour was up 3.2%. VPX Bang sales increased 12.2%. According to Nielsen, for the four weeks ended July 24, 2021, the company's market share of the energy drink category in the convenience and gas channel, including energy shots, in dollars, decreased 1.3 points to 36.5%. Monster share decreased 0.4 of a share point to 30.6% and. Reigns decreased 0.4 of a share point to two points -- sorry, 2.4%. NOS's share decreased 0.5 of a point to 2.7%, and Full Throttle share remained at 0.7%. Redbull's share increased point -- six points to 37.4%. Rockstar's share was down 1.2 points to 3.8%. 5-Hour share was lower by 0.2 points at 4.6%. VPX Bang share increased 0.3 points to 7.6%. As previously reported, Coca-Cola Energy is being discontinued in the United States and Canada by the end of 2021. According to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the coffee plus energy drink category, which includes our Java Monster line in the convenience and gas channel, increased 4.2% over the same period the previous year. Sales of Java Monster, including Java Monster 300, were 5.9% higher in the same period versus the previous year. Sales of Starbucks Energy were 0.4% higher. Java Monster share including Java Monster 300 of the coffee plus energy category, which primarily includes Java Monster, Java Monster 300, Starbucks Doubleshot and Tripleshot, Rockstar Roasted and Bang Keto Coffee for the four weeks ended July 24, 2021, was 51.9%, up 0.9 of a share point, while Starbucks' energy share was 45.5%, down 1.7 points. According to Stackline, which tracks energy drink sales by Amazon in the United States, in the four-week period ending July 3, 2021, sales in dollars in the energy category by Amazon, including energy shots, increased 104.5% over the same period the previous year. Sales of Monster increased 59.9%. And its share was 28.1%, down 7.8 share points versus the same period a year ago. Red Bull sales increased 109.4%, and its share was 16.6%, up 0.4 points. Celsius' sales increased 133.1%. And its share increased 1.8 points to 14.3% 5-hour sales increased 40.9%. And its share declined 1.3 points to 2.9%. VPX Bang sales increased 216.1%. And its share increased 1.8 share points to 5.2%. Reign's share decreased 0.1 of a share point to 5.3%. Rockstar's share increased 0.9 of a share point to 3.9%. According to Nielsen, in all measured channels in Canada, for the 12 weeks ended June 19, 2021, the energy drink category increased 17.9% in dollars. Sales of the company's energy drink brands increased 28.3% versus a year ago. The market share of the company's energy drink brands was 41.5%, up 3.4 points. Monster sales increased 18.3%, and its market share increased by 0.1 of a point to 35.4% -- sorry, 35.4%. NOS' sales increased 12.6%, and its market share decreased 0.3 of a point to 1.9%. Full Throttle sales decreased 2.1%, and its market share decreased 0.1 of a point to 0.6%. Red Bull sales increased 18.1%, and its market share increased 0.1 of a point to 38.7%. Rockstar sales decreased 8.6%, and its market share decreased 3.3 points to 11. 4%. GURU's sales increased 35.9%, and its share increased 0.5 of a share point to 4%. According to Nielsen, for all outlets combined in Mexico, the energy drink category increased 45.2% for the month of June 2021. Monster sales increased 38.7%. Our market share in value decreased by 1.3 points to 27.2% and against the comparable period the previous year. Red Bull sales increased 41.4%, and its market share decreased by 0.2 of a point to 6.5%. Vive 100 sales increased 30.2%, and its market share decreased by 2.4 points to 20.5%. Volt's sales increased 41.1%, and its market share decreased 0.5 of a share point to 18.5%, while B:oost's sales increased 15.7%, and its market share decreased 1.3 points to 5.1%. Amp's sales increased 91.9%, and its market share increased 4.4 points to 17.9%. Predator, which was launched in March 2020, achieved a market share of 3.1%. The Nielsen statistics for Mexico cover single months, which is a short period that may often be materially influenced positively and/or negatively by sales in the OXXO convenience chain, which dominates the market. Sales in the OXXO convenience chain in turn can be materially influenced by promotions that may be undertaken in that chain by one or more energy drink brands during a particular month. Consequently, such activities could have a significant impact on the monthly Nielsen statistics for Mexico. According to Nielsen for the month of June 2021 compared to June 2020, Monster's retail market share in value increased in Argentina from 40.1% to 46.9% and in Brazil from 29.6% to 35.4%. In Chile, Monster's retail market share decreased from 45.7% to 41.9%. Monster Energy continues to be the leading energy brand in value in Argentina. I would like to point out that the Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country-to-country and are reported on varying dates within the month referred to from country-to-country. According to Nielsen, in the 13-week period ending July 18, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 34.2% to 37.4% in Spain. According to Nielsen, in the 13-week period to the end of June 2021, Monster's retail market share in value as compared to the same period the previous year grew from 14.5% to 15.3% in Germany, from 18.4% to 19.4% in Poland and from 18.4% to 20.1% in South Africa. According to Nielsen, for the 13-week period ending June 20, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 12.5% to 16.2% in Belgium, from 24.2% to 25.3% in Denmark, from 25.8% to 28.2% in France, from 25% to 29% in Great Britain, from 6.7% to 8.4% in the Netherlands, from 27.1% to 31.2% in Norway, from 25.6% to 29.3% in the Republic of Ireland and from 13.4% to 14.5% in Sweden. According to Nielsen, in the 13-week period until the end of May 2021, Monster's retail market share in value compared to the same period the previous year grew from 13.3% to 14.5% in the Czech Republic, from 35.1% to 37.9% in Greece and from 16.6% to 29% in Italy. According to Nielsen, in the 13-week period until the end of May 2021, Predator's retail market share in value as compared to the same period the previous year grew from 5.1% to 17.3% in Kenya and from 0% to 8.1% in Nigeria. The Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country to country. According to IRI in Australia, Monster's market share in value for the month ending June 2021 increased from 11.6% to 14% as compared to the same period the previous year. Mother's market share in value decreased from 13.3% to 11.6% during the same period. The market share of the company's brands in Australia for the month ended June 2021 increased from 24.9% to 25.5%. According to IRI in New Zealand, Monster's market share in value for the four weeks ended July 11, 2021, increased from 9.9% to 12.4% as compared to the same period of the previous year. Live+ market share in value remained the same at 6.9%, and Mother's market share in value increased from 6.2% to 6.3%. The market share of the company's brands in New Zealand for the four weeks ended July 11, 2021, increased from 23.1% to 25.6%. According to Nielsen, in South Korea, Monster's market share in value in all outlets combined for the month of June 2021 increased from 53.3% to 61.9% as compared to the same period in the previous year. According to INTAGE, in Japan, Monster's market share in value in the convenience store channel for the month of June 2021 was 50.6% as compared to 51% in the same period the previous year. Monster remains the market leader in Japan. We again point out that certain market statistics that cover single months or four week periods may often be materially influenced positively and/or negatively by promotions or other trading factors during those periods. Net sales to customers outside of the US were $546.3 million, 37.4% of total net sales in the 2021 second quarter compared to $328.3 million or 30% of total net sales in the corresponding quarter in 2020. Foreign currency exchange rates had a positive impact on net sales in the US dollars by approximately $38.6 million in the 2021 second quarter. Included in reported geographic sales are our sales to the company's military customers, which are delivered in the US and transhipped to the military and their customers overseas. In EMEA, net sales in the 2021 second quarter increased to 105.7% in dollars and increased 86.5% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales for the second quarter was 39.8% compared to 38.1% in the same quarter in 2020, primarily due to a favorable country and product mix. We're also pleased that in the 2021 second quarter, Monster gained market share in Belgium, the Czech Republic, Denmark, France, Germany, Great Britain, Greece, Italy, the Netherlands, Norway, Poland, the Republic of Ireland, South Africa, Spain and Sweden. In Asia Pacific, net sales in the 2021 second quarter increased 5.2% in dollars and decreased 100% [Phonetic] in local currencies over the same period in 2020, largely due to sales in Japan and China. Gross profit in this region as a percentage of net sales was 44.4% versus 43.3% over the same period in 2020. In Japan, net sales in the 2021 second quarter decreased 15.1% in dollars and 13.9% in local currency, largely due to COVID-19 restrictions in Japan and distributor inventory adjustments. Depletions increased 7% during the quarter. Monster remains the market leader in Japan for the month of June 2021. In South Korea, net sales increased 63% in dollars and 50.4% in local currency as compared to the same quarter in 2020. In China, net sales decreased to 21.4% in dollars and 27.8% in local currency as compared to the same quarter in 2020. In this regard, we note that sales in the second quarter of 2020 included the initial launch of Dragon Tea. We are reevaluating the viability of this SKU and the optimal product range for China going forward. We remain optimistic about the prospects for the Monster brand in China. In Oceana, which includes Australia, New Zealand, Tahiti, French Polynesia, New Caledonia, Papua New Guinea and Guam, net sales increased to 146.5% in dollars and 98.2% in local currencies. Sales of the Monster brand in Oceana increased 210% in dollars and 155.6% in local currency as compared to the same quarter in 2020. In Latin America, including Mexico and the Caribbean, net sales in the 2021 second quarter increased to 19.7% in dollars and increased 117.6% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales was 40.7% compared to 41.2% in over the same period in 2020, primarily as a result of foreign exchange rates and certain raw materials and ingredients for products in this region are purchased in US dollars. In Brazil, net sales in the 2021 second quarter increased by 194.9% in dollars and 201.7% in local currency. Net sales in Chile increased 77.5% in dollars and 52% in local currency in the 2021 second quarter. Net sales in Argentina increased 291.4% in dollars and 458% in local currency in the 2021 second quarter. In March 2019, VPX, the maker of Bang Energy drinks, sued Monster, alleging that its Reign products infringed VPX's Bang trademarks and trade risk. A trial was held last year. And on August 3, 2021, the court issued an order denying all of VPX's claims and holding that VPX is entitled to no relief whatsoever. In fact, the court specifically found that VPX copied its bank trade risk from the original Monster Energy cans. The court's decision confirms that Monster and Poland retail partners are free to continue to sell our Reign products without any changes and without any restrictions. Monster always believed and maintained that VPX's claims were frivolous, and we are extremely pleased that the court rejected all of VPX's claims while vindicating Monster's rights. As other pending proceedings with VPX are subjudicate, we will not be answering any questions on this matter on today's call. Our new product introductions in the United States in the first half of 2021 were primarily focused in the first quarter. In the United States, during the second quarter of 2021 we refreshed our can graphics on our Rehab Monster brand family as well as our Full Throttle line, also updating the name for Blue Agave to TrueBlue. Monster Energy Ultra Fiesta received a refresh and updated can graphics as well as the name change to Monster Energy Ultra Fiesta Manga. In May 2021, we launched Monster Ultra Fiesta in a 24-ounce option with an update to our Ultra Fiesta Manga plan for later this year. We are in the process of launching a new line of nonalcoholic pure energy sales under the True North brand name in 12-ounce sleek cans, which contained an organic plant-based energy blend and ingredients for immunity support. True North is being offered in six flavors, Cucumber Lime, Black Cherry, Grapefruit Lemonade, Water Mellon Mist, White Peach Pear and Mandarin Yuzu. True North has a limited customer target in 2021 with plans for a full launch into mainstream channels in 2022. While cognizant of the can shortages, we believe that it is important to continue with our innovation plans. And to this end, we will be launching our new flavors reserve line of Monster Energy drinks in Water Mellon and White Pineapple in October 2021. We have deferred the launch of our new line of Java Monster Cold Brew Coffee + energy drinks until early 2022. In Canada, during the second quarter, we launched two new products: Monster Punch Papillon and Monster Punch Khaotic, both in a 473 ml can. In April 2021, we launched Reign Orange Dreamsicle in Puerto Rico and our second SKU in Bolivia with Monster Energy Zero Ultra. In El Salvador, we launched Fury Mean Green in May 2021. In the second quarter of 2021, we launched Juice Monster Pacific Punch and Monarch in a number of countries in EMEA. We also launched Ultra Paradise and Ultra Fiesta in a number of countries during the quarter. During the quarter, we also launched our strategic brand innovation and Predator in additional countries. In January 2021, we launched Ultra Rosa marketwide in Australia, following an exclusive lead launch with one chain in the fourth quarter of 2020. In March 2021 in New Zealand, we launched Monster Superfuel in both Purple Passion and sugar-free flavors. During the 2021 second quarter in Japan, we launched Monster Energy Super Cola with our distributor, Asahi Soft Drinks. Additionally, we effected the relaunch at retail of Ultra Paradise and began shipments in anticipation of the launch of Super Fuel early in the 2021 third quarter. Super Fuel has just gone on the shelves in Japan this week. We also launched Mango Loco in Korea in July 2021. During the 2021 second quarter, we launched Pipeline Punch in Taiwan, Hong Kong and Macau. We also began distribution of Monster Energy Zero Sugar in the Philippines. As previously mentioned, in the second quarter of 2021, in China, we extended the national rollout of our new Monster Dragon Gold, which is non-carbonated. Our national summer on-pack promotion began in May with one of China's top consumer ambassadors. As a result of the COVID-19 pandemic, certain of our planned launches and innovation of new products in a number of Asia-Pacific markets have been deferred for a few months. However, we still anticipate such launches taking place toward the end of the 2021 calendar year. We are planning to launch a number of additional products and product lines in our domestic and international markets later this year. We estimate that July 2021 sales to be approximately 1.8% higher than in July 2020. On a foreign currency adjusted basis, July 2021 sales would have been comparable to the July 2020 sales. July 2021 had one less selling day than July 2020, which was 15.8% above July 2019, and which was 17.1% higher on a foreign currency adjusted basis. Certain production facilities, mainly from the Coke bottlers in EMEA, in particular, delayed production from July to August 2021. Furthermore, as mentioned earlier, the company has not been able to fully satisfy demand in the United States and EMEA due to a shortage of aluminum cans, which adversely impacted July sales. Such shortage was exacerbated in July as can availability did not keep pace with increased demand during the summer months. Additional cans have been sourced from domestic and overseas suppliers with expected deliveries increasing sequentially during the latter half of the year. We are working to replenish system inventories in order to meet customer demand as soon as possible. Additionally, the company also experienced delays in certain ingredients, which impacted supply. Our depletions remain solid as do our measured market data, as previously mentioned on this call. In this regard, we caution again that sales over a short period are often disproportionately impacted by various factors such as, for example, selling days, days of the week in which holidays for, timing of new product launches, and the timing of price increases and promotions in retail stores, distributor incentives as well as shifts in the timing of production in some instances where our bottlers are responsible for production and unilaterally determine their production schedules, which affects the dates on which we invoice such bottlers as well as inventory levels maintained by our distribution partners, which they alter unilaterally for their own business reasons. We reiterate that sales over a short period such as a single month should not necessarily be imputed to or regarded as indicative of results for a full quarter or any future period. If the COVID-19 pandemic and related unfavorable economic conditions continue in certain regions, our new product innovation launches in those regions could be delayed. In conclusion, I would like to summarize some recent positive points. Currently, the company's flavor manufacturing facilities, its co-packers, warehouses, and shipment facilities, and bottlers and distributors are all operating. We are continually addressing our aluminum can requirements, given our volume growth and the current supply constraints in the aluminum can industry. We are pleased with the new additions to the Monster Energy portfolio and are planning additional launches later in the year. We are planning to continue additional launches of our Reign Total Body Fuel high-performance energy drinks in additional international countries. We are pleased with the rollout of Predator and Fury and our affordable energy drink portfolio internationally. We are proceeding with plans to launch our affordable energy drinks in a number of international countries during the year. I would like to open the floor to questions about the quarter. Thank you. Dara Mohsenian -- Morgan Stanley -- Analyst Hey, guys. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Hey, Dara. Dara Mohsenian -- Morgan Stanley -- Analyst Great top line growth in the quarter, but we have seen share losses in US track channel data worsened recently. A, just short-term, how much of that do you think is attributable to out of stocks and the supply constraints that you mentioned? Is that a material factor in retail sales? And then maybe, b, from a longer-term standpoint, it has been a couple of quarters now where the share losses have reaccelerated year-over-year, just some progress in the beginning of the year. So, I was just hoping you could review some of the key factors that have been driving the share losses in the US? And how you think about those factors going forward in terms of continuing or dissipating and how you guys are positioned? Thanks. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Hilton, if you take that, and I'll also say something once you've... Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board All right. I think, Dara, what's important is that, that's not a result and not due to us not growing. We are not keeping up with our share, but our business is certainly growing. And you can track that from Nielsen. You can also track that from the non-measured channels, which are growing really very nicely. So while we're not keeping up necessarily with Red Bull in the major channels. As I've spoken on previous calls, Red Bull had a very large on-premise business, which has moved to off-premise and moved to off-premise during COVID. And that led to an acceleration in their share. However, we mentioned that we had and are continuing to sustain can issues and result in supply. And of course, that's having an impact on the share numbers that you are seeing. So I think on balance, the business is growing. You've seen the results. It's continuing to grow. And we are growing, but not at the extent of the market. I think with the full deck of cards, the situation may well be very different. But right now, we really are struggling with sufficient supplies of aluminum cans really to keep up with demand, which is, I suppose, a good position to be in. And on the other hand, is not such a good position to be in. The business is growing. And, that's the message I want to leave you with and other investors. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer I think in -- I'll just add two short points in that regard. I think what we've tried to do is to try and also basically focus on our faster selling and our larger SKUs, which has necessarily resulted in some of the smaller SKUs, which normally have their own traction and followers. So those haven't got on to shelf. And then the one additional thing that I think that has negatively affected our distribution sales and distribution levels in the US is labor shortages. And I think that what we've seen is that many of the bottlers, Coke bottlers are experiencing labor shortages. And while one would ordinarily say, well, everybody is going to have the same problem. I think that where you have Red Bull is our main competitor, they have a dedicated system. I think they've been able to address their labor shortages just more effectively than the larger bottlers with large labor pools. And that has also, I think, detrimentally affected our distribution levels going forward. But again, I think those are things that once things start settling down and things will get back to normality, that's something that I think that will also, in due course, right itself. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Yes, I think we should also -- Dara, I think we should also add that what we're seeing with cans is something that will persist through this year. I'm a bit more optimistic about the fourth quarter because we have two new can suppliers coming on board. But the situation will persist. And then next year, we should be in -- we believe we'll be in very good shape. But again, it all depends on consumer demand, which is growing, and you've seen that month-by-month and quarter-by-quarter. Bonnie Herzog -- Goldman Sachs -- Analyst Thank you. Hi, everyone. I just wanted to ask about your gross margins. Clearly, they continue to be pressured as broadly expected, which you guys have been discussing with us. But just want to get your outlook for these pressures in the back half of the year? Hilton, you just mentioned that you're optimistic. So just wanted to verify that you still expect some of these pressures to ease by Q4? Or do you think it's going to take a little bit longer, especially in light of the recent spike in aluminum prices. So trying to understand how that factors in? And then just a clarification on the can shortages that you mentioned that you're still experiencing, I guess, it sounds like it's getting worse, but I really did want to clarify that. And is there any way that you guys could quantify how big of an impact the supply shortages had on your top-line either in the quarter or in July? Just trying to understand how much you think your shipments would have been up in July without these shortages, for instance? Thanks. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Okay. So let me deal with the first issue first, if I may. I spoke about optimistic about can supplies. I really didn't talk about margins. You'll recall on the last call, I spoke about the issues that we were confronting with margin pressures like most other beverage companies. And where we are right now with aluminum, I mean, nobody knows. So you can talk to the leading banks in the field, which we do on a regular basis, and they really are pulls apart about their projections for aluminum in 2022, let alone 2021. So the last couple of days, you've seen a spike in the Midwest premium from this tax that is expected to be imposed on Russian aluminum. And as, you know, the Midwest premium is strongly factors the last ton of aluminum to enter the US and the cost of that. And so we've seen a spike in the Midwest premium. And we continue to see spikes in aluminum. So from that score, I think we just are in uncharted territory. I've been in this business for a long time, as you know, and I've never seen aluminum where it's at right now. And I've never seen the Midwest premium at these kind of levels. So aluminum, I really cannot talk about. And also when you look at our business and you look at the factors that really have affected gross margin, number one, the fact that we're selling a lot more internationally. So I talked earlier about 37.4% of our sales in the quarter outside of the US 30% last year, that obviously impacts margins. We are importing cans from a number of [Technical Issues] that obviously impacts margins. In fact, the China and India cans that we are using in the United States and in EMEA will only be filed in August in July, and they will be filled this month. So that in itself, the imputation will impact gross margins. And then to cap everything else, we have ingredient issues. We had ingredient issues, as we mentioned, in July, which again reduced the amount that we would actually sell because we didn't have sufficient ingredients to meet themselves, particularly with NOS. And so there are a number of factors that are increasing that are increasing our cost of goods. And last quarter, I said I didn't think that margins would get better in the second and third quarters. I read they will not -- I think margins will deteriorate in the third quarter. In the fourth quarter, we're getting some relief in terms of supplies from the US on cans that are -- have been contracted for and they were contracted for two years ago. And we saw the opportunity to work with two major suppliers to get additional cans produced in the US, and that's why we have two new supplies opening, and we are an important and an anchor customer of both those facilities. But even that, you're still dependent on aluminum. We have some hedges in place, but obviously not enough to take into consideration the amount of sales and the amount of consumer demand that is out there. So that's a long-winded way of saying, I think, answering your question as best as I can. And then just getting to your second question because you're really only allowed one. But to get to your second question, we have quantified or try to quantify the impact on can shortages in July and in this quarter and in the -- potentially in the third quarter, but I really don't want to -- I'm not comfortable with those numbers yet. A lot of detailed work is being done on them. And I just -- I can't in good contents give those numbers because we still are in the throes of kind of finalizing what we think is probably correct. Rodney mentioned in his script earlier that a number of the bottlers, he mentioned particularly in EMEA, but there were cases in the US as well, and there was a substantial case in the US where the bottlers were obviously focused on other things in the quarter and were producing Coca-Cola brands. And as a result, I think we -- our production got moved from July to August. So, when I look at July, it doesn't -- I don't get overly concerned because I know the sales are going into August. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Perhaps, if I just on the shortage level, just to add that when we buy cans in contracted for our annual amount, they usually are sort of reasonably flat line across the year. And we used the first half of the year to build up can inventories and finished product inventories with ourselves and our bottlers. Earlier this year, obviously, demand sort of was strong, and so we really didn't have that opportunity. So what has happened is that in June and July, which is your normal peak months, the demand has been higher, but our supply has been more level until we can get more can inventories into the market. So what happened is just that we have had a sort of a heartened increased shortage in the last month and July and probably will be a little bit in August. And then obviously, as we start increasing our -- the cans we're getting in, and then we're able to balance it more and our demand balances more, we'll start to have less of a different delta between these demand and supplier and eventually be able to -- we're hoping to able to build up our inventories and supply back to normal by the end of the fourth quarter or during or by the end of the fourth quarter. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board No one's comfortable with the level of finished goods inventories that we're running at, but it's a sign of the times. I mean, we're doing everything we can to supply our customers. And that's why we spoke about freights. Freight is a big issue, not only getting raw material ingredients into co-packing system and into our bottling system and -- but also distributing from our co-packers. And obviously, the one goes into cost of sales and freight out goes into operating expenses. So that's why you'll see freight really hitting both of those line items. Andrea Teixeira -- JPMorgan -- Analyst Hi. Thank you. Hi. Good afternoon. Thomas J. Kelly -- Chief Financial Officer Hi. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Hi, Andrea. Andrea Teixeira -- JPMorgan -- Analyst How are you Hilton? Hi. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board I'm good. Andrea Teixeira -- JPMorgan -- Analyst Yes. Just on the gross margin, because your gross margin comments were very helpful and given this deterioration obviously that its probably here to stay in the next few quarters. How are you thinking about pricing? Obviously, you can't supply the service levels that are used to with the retailers. So is that is something that takes -- obviously, you have to take into account? Or perhaps as you get more informed on how the aluminum cost will evolve, you may contemplate it again? Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Yes. With regard to pricing, we continue to evaluate pricing, honestly, on a very, very regular basis, if not weekly. So we continue to evaluate it, and we want to make a good decision. Last time around, as I mentioned on previous calls, we went out alone, and we would like to have been in a situation this time where we followed our competitor, but we have to evaluate, obviously, the business as we see it and the impact for us. What we've done is we're reducing our promotional allowances. So we're taking a price increase the other way, through reducing promotional allowances, but the impact of that reduction in the second quarter was not as we would have liked. So we are -- we really put the accelerator down and are more aggressive in reducing our promotional allowances. But we are continuing to evaluate the pricing and price increases. And then I have to leave this call with my favorite saying, and that is, we don't bank gross profit margins, we bank gross profit dollars. And to me, the fact that we're doing everything we can to satisfy our customers as best as we can is impacting gross profit margins. But at the end of the day, we don't want to lose gross profit dollars, which is really important to ensure the sustainability of the brand. And that's the most important thing for us right now. Andrea Teixeira -- JPMorgan -- Analyst Thank you. Thanks fair. Thank you both. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Yeah. Basically, just make it clear, at this point, we are watching and we're not planning a price increase. We we're not adverse to a price, but we'll wait and see what the market does and what our competitors do. Andrea Teixeira -- JPMorgan -- Analyst Thank you, Rodney. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Thanks very much. Thank you, everyone, for your continued interest and support of the company. We continue to believe in the company and our growth strategy to remain committed to continuing to innovate, develop and differentiate our brands and to expand the company, both domestically and abroad. And in particular, expand distribution of our products through the Coca-Cola bottler system internationally. We believe that we will be able to navigate through the challenges ahead as a result of the COVID-19 pandemic and hope that this unfortunate situation will resolve itself in the near future. We believe that we are well positioned in the energy drink category and will continue to be and are optimistic about our total portfolio of energy drink brands. We hope that you will stay safe and healthy. Thank you very much for your attendance. Duration: 50 minutes Call participants: Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Thomas J. Kelly -- Chief Financial Officer Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Dara Mohsenian -- Morgan Stanley -- Analyst Bonnie Herzog -- Goldman Sachs -- Analyst Andrea Teixeira -- JPMorgan -- Analyst More MNST analysis All earnings call transcripts\",\n          \"Please go ahead. Dan Lochner -- Chief Financial Officer Good evening, everyone. And welcome to Oyster Point Pharma's fourth quarter earnings conference call for the three months ended December 31, 2021. This evening, we issued a press release containing our fourth quarter and full year ended December 31, 2021, financial results and recent business highlights. In addition, our earnings press release and our Form 10-K, which were filed with the SEC after the close of market today, are available on our website under the investors and news section at www.oysterpointrx.com. Joining us on our call today are Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma; and John Snisarenko, chief commercial officer. Following Dr. Nau and Mr. Snisarenko and my prepared remarks, we will open up the line for questions. During the call today, we will be making forward-looking statements regarding potential future events, including statements regarding Oyster Point Pharma's potential future financial status and results of operations and our plans and potential for success relating to commercializing TYRVAYA. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. For a description of these factors, please see our annual report on Form 10-K for the year ended December 31, 2021, filed with the SEC after the close of market today. I will now turn the call over to Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma. Jeff Nau -- President and Chief Executive Officer Thank you, Dan. Good evening, everyone. And thank you for joining us on our call today to discuss our fourth quarter 2021 financial results and recent business highlights. This is a particularly exciting time for Oyster Point. This is our very first earnings call where we are pleased to be reporting partial revenues from the commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease in the United States marketplace. Today, you will learn more about how we are delivering these encouraging commercial results on the launch of TYRVAYA Nasal Spray. But first, let me provide the company's 2021 business highlights. In October of 2021, we received FDA approval of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Dry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence. The dry eye market is now being introduced to the first nasally delivered, pharmaceutical dry eye therapy, and we believe that given the high level of patient and physician satisfaction that we are seeing in the field with TYRVAYA, that significant growth remains ahead. You will be hearing more shortly from John Snisarenko, our chief commercial officer, about the details of the launch of TYRVAYA Nasal Spray, but I'm happy to state that we had great partial fourth quarter commercial performance in 2021. We are happy to report that TYRVAYA Nasal Spray had a net product revenue of $1.2 million in Q4 of 2021. In addition, we recognized $5.4 million from our license agreement with Ji Xing Pharmaceuticals. We are now entering 2022, having demonstrated the ability to achieve the successful commercialization of TYRVAYA, as well as drive strong execution across multiple areas of our business, including our exclusive license agreement with Ji Xing to develop and commercialize OC-01 and OC-02 in Greater China, securing nondilutive funding and pursuing additional treatment advancements in the clinic, as well as in the R&D laboratory for patients with ophthalmic diseases. This week, we publicly announced an early commercial win with one of the largest commercial payers. Our press release from Tuesday announced that TYRVAYA Nasal Spray is now covered by Express Scripts effective on February 19. This is a fantastic accomplishment for our market access team in achieving the addition of 26 million covered lives and more importantly, this early in our first full quarter since launch. Patients are increasingly gaining access to TYRVAYA in the U.S. for a disease state that, up until 2021, we believe, experienced very little innovation for the current large unmet need in dry eye disease. TYRVAYA is a first-in-class cholinergic agonist nasal spray that is highly differentiated from the other pharmaceutical products in the dry eye space and includes the following potential advantages. TYRVAYA Nasal Spray has a differentiated mechanism of action as it is believed to activate the trigeminal parasympathetic pathway via the nose, resulting in increased production of basal tear film as a treatment for dry eye disease. Basal tear film is responsible for lubricating, nourishing and protecting the cornea. TYRVAYA is the only ocular surface-sparing pharmaceutical therapy for dry eye patients. For those patients with a compromised ocular surface, increasing tear production without the burden of administering a topical medication may provide a welcome method to treat their disease. For the first time, dry eye disease patients have an FDA-approved, pharmaceutical treatment option that is not administered as a topical eye drop to an already irritated ocular surface. Although we are focused on the critical launch of TYRVAYA Nasal Spray and continue to execute plans for the life cycle development of the TYRVAYA franchise, our R&D team remains committed to multiple exciting pipeline projects aimed at bringing additional innovative therapies to address diseases like neurotrophic keratopathy and severe allergic or vernal keratoconjunctivitis. In 2022, we will continue to advance our enriched tear film gene therapy platform, as well as our research and development collaboration with companies like Adaptive Phage Therapeutics. We remain excited about the ongoing OLYMPIA Phase 2 study of OC-01 nasal spray in Stage 1 neurotrophic keratopathy. We are expecting a readout in the second half of this year. NK is a disease that is currently underdiagnosed or misdiagnosed in many patients with ocular surface disease. We feel that Stage 1 neurotrophic keratopathy could represent a meaningful indication for OC-01 nasal spray. Our vision and focus is clear. The world needs an innovative leader that can bring innovative and transformative ophthalmic disease treatments, and we aim to be that leader. We believe that we're building Oyster Point into a best-in-class eye care company. I would now like to turn the call over to John Snisarenko, Oyster Point's chief commercial officer, to discuss our ongoing commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease. John Snisarenko -- Chief Commercial Officer Thank you, Jeff. As we have previously communicated, the dry eye disease segment is a large market with over 17 million people diagnosed in the United States alone. Only a small proportion of these patients, approximately 2 million, are currently being treated with a branded therapeutic. And over 7 million people diagnosed with dry eye disease have tried and abandoned the other available options. We believe that TYRVAYA Nasal Spray is a new treatment option for the large patient population that exists in the dry eye disease marketplace, including the refractory patients, as well as those who are newly diagnosed. As Jeff highlighted previously, we are incredibly excited to have initiated the U.S. launch of TYRVAYA Nasal Spray on November 1. We are pleased to report that as of the quarter ending December 31, 2021, data indicates that approximately 5,500 prescriptions for TYRVAYA have been filled, written by over 1,900 unique prescribers. These encouraging metrics were achieved in less than nine weeks from the launch, including holiday periods. In this short time, TYRVAYA is quickly establishing itself in the market as an exciting new option for dry eye patients. Regarding market access, a core part of our commercial strategy is to promote accelerated payer adoption of TYRVAYA to the top payer organizations. Our market access team has done a great job in securing coverage for TYRVAYA with Express Scripts National Preferred, Basic and High Performance Formularies effective February 19. With this latest formulary addition, we now have coverage for a total of 43% of U.S. commercial lives for an aggregate total of approximately 84 million lives. We are incredibly pleased with this level of coverage so early in our launch, and we look forward to further growing our market access coverage in 2022. Oyster Point remains very committed to offering comprehensive patient services that help provide access to TYRVAYA for appropriate patients. We have launched a comprehensive set of technology-driven patient services offerings aimed at enabling patients to successfully navigate the patient journey and procure TYRVAYA. Our patient support program is called TEAMTyrvaya. And for more information on this program and how to enroll, please visit the website, tyrvaya-pro.com. We have been quite diligent with the sizing of our field force, which enables us to target 20,750 eye care practitioners, covering both optometrists and ophthalmologists and representing approximately 94% of the dry eye prescriptions in the market today, helping us in our efforts to achieve the full commercial potential of TYRVAYA. In the first nine weeks of launch, our sales force was able to introduce TYRVAYA to more than 50% of the targeted prescriber base. On the marketing side, we're leveraging the latest technology, including sophisticated analytics, in-person, as well as virtual detailing, best-in-class digital and social media efforts and partners, as well as utilizing a digital online pharmacy to enhance communication and delivery of TYRVAYA to patients. We will continue to adopt the latest media and technology-driven marketing approaches to maximize TYRVAYA's share of voice and impact in the market. Our focus continues to be on broad eye care provider and patient education and marketing efforts, with targeted direct-to-patient digital campaigns leveraging TYRVAYA's differentiated MOA and nasal spray route of administration to drive a positive patient marketing experience. I am so proud of our commercial team's collective efforts during this early phase of our launch, especially in these challenging times with the pandemic. I will now turn the call back over to Dan Lochner, Oyster Point's chief financial officer, to discuss our fourth quarter financial results. Dan Lochner -- Chief Financial Officer Thank you, John. I will now provide a brief overview of Oyster Point Pharma's fourth quarter financial results. Additional detail about our fourth quarter, as well as our annual financial results can be found in our Form 10-K that was filed with the SEC this evening. For the fourth quarter of 2021, Oyster Point Pharma reported a net loss of $42.1 million, compared to a net loss of $22.2 million for the same period in 2020. As of December 31, 2021, cash and cash equivalents were $193.4 million, compared to $192.6 million as of December 31, 2020. Based on our current business plan, we believe the company's available cash and cash equivalents will be sufficient to fund the company's planned operation for at least 12 months from our 10-K filing this evening. Net product revenues for the fourth quarter of 2021 were approximately $1.2 million, following the FDA approval of TYRVAYA Nasal Spray on October 15, 2021, and our subsequent commercial launch in the U.S. in November 2021. Approximately half of the TYRVAYA net product revenue was attributable to channel building by distributors upon launch of the product. In addition, pursuant to our license agreement with Ji Xing, the company also recognized $5.4 million in milestone and license revenue following the FDA approval of TYRVAYA Nasal Spray, which includes the noncash consideration of Ji Xing senior common shares. The company did not generate any revenues during the third -- three months ended December 31, 2020. Cost of product revenue for the three months ended December 31, 2021, was $1.5 million and consisted mainly of third-party manufacturing costs, which included pre-approval costs, reserves for inventory obsolescence and damaged goods and product royalty expense related to Pfizer. The cost of product revenue included a reserve for inventory obsolescence of $0.9 million. The inventory manufactured prior to FDA approval of TYRVAYA Nasal Spray was charged to R&D expense. And as a result, the company expects the unit cost of product revenue will be lower until the company fully utilizes this product that was manufactured pre-FDA approval. The company started expensing pre-approval inventory in 2020 and recorded an R&D expense of approximately $4.3 million for pre-approval inventory during the year ended December 31, 2021. The company anticipates selling the remaining pre-approval inventory by the end of 2022. The company's sales and marketing expense increased by $21.8 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase was primarily due to higher payroll-related expenses of $11.7 million, inclusive of sales commission expense, as well as an increase in stock-based compensation expense of $0.5 million, both of which were primarily driven by onboarding a commercial field force in the second half of 2021. The company also incurred higher marketing -- market access, commercial and other expenses of $10.1 million in anticipation of, and in connection with, the U.S. launch of TYRVAYA Nasal Spray. The company's general and administrative expenses increased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase is primarily due to higher G&A expense of $3.8 million related to accounting, consulting, legal and other professional expenses incurred in connection with the credit agreement, as well as the company's transition from a clinical stage to a commercial-stage company. The company also incurred higher payroll-related expenses of $2.4 million, including recruiting expense due to an increase in headcount to support an ongoing efforts to commercialize TYRVAYA. The company's research and development expenses decreased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The company's decrease in R&D expense is primarily due to the company receiving FDA approval of TYRVAYA Nasal Spray in October 2021. The company expensed inventory prior to receiving FDA approval and expensed approximately $3.5 million as R&D during the three months ended December 31, 2020. The company also incurred a fee of $2.9 million in connection with the New Drug Application submitted to the FDA in December 2020. The company incurred interest expense of $2.6 million during the three months ended December 31, 2021, primarily related to the credit agreement with OrbiMed. Interest expense included contractual interest of $1.7 million, as well as noncash expense of $0.9 million related to the amortization of loan commitment fees and accretion of other long-term debt-related costs. The company had no interest expense during the three months ended December 31, 2020. Now as we turn to our outlook, for 2022, our goal is to continue to achieve broad ECP and patient experience with TYRVAYA, including both optometry and ophthalmology offices, in order to reach the total addressable dry eye market opportunity of TYRVAYA Nasal Spray. We anticipate the three large national commercial plans will make their coverage determinations by the midpoint of the year. While we await such coverage determinations, we will continue to provide patient-assisted programs to support eligible commercial patients in gaining access to TYRVAYA. With that overview of our financials, I will now turn the call back over to the operator to open up the line for questions. Questions & Answers: Ken Cacciatore -- Cowen and Company -- Analyst Hey, team, looks like a really good and clean initial launch. I was wondering if you would wanna help us a little bit with maybe the revenue pacing. I know consensus, I believe, is around $30 million. And I know there's only a few of us analysts that are formally involved in the consensus, but I think it's around $30 million. So I was wondering if you could just kind of hold hands with that number, how we should be thinking about it. And then also, we've been doing clinician checks and getting very good feedback. But I guess, you could help us, as you would have a better sense of the early retention metrics, maybe the -- be able to definitively let us know how you're seeing some of the retention numbers and patients returning. So those are my first two. I'm going to ask one more, if I could, though. Could you talk, John, a little bit about any refinements or learnings of your patient support system? Obviously, early days, but wondering if you're already tweaking it a bit. Anything that seems to be working very well or you've needed to change? And with that, I'll go back in the queue. Thanks so much. Jeff Nau -- President and Chief Executive Officer Great. Thanks, Ken, for the questions and very thoughtful. So maybe what we could do is we'll just take those in order. So I'll turn it over to Dan to just talk about the numbers for the year. And then, we'll go into retention and have a discussion about John's experience with the bridge programs and the different patient services. Dan Lochner -- Chief Financial Officer Yeah. Great. I would say on revenues, while we haven't really provided official revenue guidance, I would say we think about it very operationally, focus in terms of our sales reps that are out in the field doing a great job. And I would say the focus very early on and throughout 2022 will really be about growing that eye care practitioner count, and we have goals internally for what we expect to achieve on a weekly and monthly basis. And so, I think, it really starts with getting those ECPs onboard on a monthly sequential basis and then starting to look at what the right pattern is on an NRx basis per month and then what we then start observing on that pull-through on resell rate. And so, to kind of wrap that all up, we see it sequentially building through the quarters for the entire year as we start working through that total target population that we've identified, which is roughly 20,750 targets. And I think, it would be great to have John kind of speak about how we're really going after that target base and how that's been building through the quarters. And I think, what you'll see, at least for Q4, we've hit about 1,900 of those ECPs in respect to the 20,750. And we'll continue to really work through that population of ECPs and really build that NRx and resell rate, the TRx, and then really playing out on revenue. The other dynamic, of course, is always on gross to net. And while we're not providing official guidance on gross to net because our focus really is on that volume and share component throughout 2022, I would say there is that first-half component related to the majority of patients in the first half expecting to be on that bridge program, which has a discrete impact to gross to net. And then, with our guidance, which is focusing on coverage determinations for the big three PBMs by the midpoint of the year, that transition from bridge over to commercial insurance will have a positive benefit discretely on that line in relation to gross to net, which would kind of tie up to your question on kind of how revenues would flow from a price and volume perspective through the year. John Snisarenko -- Chief Commercial Officer Yeah, thank you, Dan. This is John. You asked a question around retention rates and then refill rates. We've been very, very pleased to date with the metrics we've been seeing in that space. Even patients that had been prescribed in early November, we started seeing early refill rates. I could quote that if you look at our blended refill rates with retail pharmacy and our digital online pharmacy, they're hovering around 64%, 65%. So we're very pleased with patients that are coming back and getting the refills. We are getting very, very nice position, as well as patient feedback, and we are hoping to continue that trend throughout 2022. I think, part of that as well is your third part of your question around patient support programs, we out of the gate wanted to really employ a lot of technology around our patient services to TYRVAYA. So we're trying to make it very easy for that patient to navigate that journey through the prior auth and benefit investigations to get them to enroll into the program through QR codes in the offices, online, as well as other digital means. So because of that, we've been getting very, very good high enrollment rates and good fill rates that come through that program. So in terms of tweaking, we're continuing to put out more patient materials to surround sound the patient with different ways to enroll into the program. But overall, we're very, very pleased with how the program has been going. If the patient is deemed insured, but not covered, they automatically popped into our bridge program that they were appropriate patients and are able to get that script fulfilled and get experience with TYRVAYA. So we'll keep monitoring the patient services program, but so far, we've been very, very pleased. Ken Cacciatore -- Cowen and Company -- Analyst Great. Thanks so much. Appreciate it. Jeff Nau -- President and Chief Executive Officer One thing I will add on, Ken, comment there is as we think about TYRVAYA as a product, when we think about the current marketplace and what it offers to patients, from an immunomodulator perspective, patients will go on a course of an immunomodulator. If they're not happy with the outcome at the end of that course, they're transitioning off, and they're likely either going on to another product or another device or another modality, but very rarely are they coming back. So we see a very low number of patients come back to the original therapy. I think, that the one thing to really keep in mind with TYRVAYA is it works so quickly to provide the patient relief, and it has such a differentiated mechanism of action that we are excited to look forward into the future to see how patients interact with the product. It's going to be a very different interaction than you would see with an immunomodulator because I do think not only will we have solid refill rates, but we will have people coming back to the product in those later years. And so, we're excited about that. And then, I would -- I'll just throw one comment out there for my team back at the office. Our patient services program is, bar none, one of the best I've ever seen. And it is going very well in the field. And so, kudos to the team for putting together such a great program. Ken Cacciatore -- Cowen and Company -- Analyst Great. Thanks so much. Joe Catanzaro -- Piper Sandler -- Analyst Hey, guys, thanks so much for taking my questions, and congrats on the progress here. So maybe just to follow up, I think, Dan, you mentioned you guys had some internal benchmarks, I'm sure, on a bunch of things. But I'm wondering if you can maybe help put into context the early penetration in terms of the number of unique prescribers you've seen relative to your target ECP pool and where your early expectations were there. And then, I'm wondering what aspect -- and maybe it's something you just alluded to, Jeff, what aspect of the product profile do you see as resonating the most? And how do you go about fully leveraging that? And maybe I have a follow-up as well. Dan Lochner -- Chief Financial Officer Yeah. Maybe I'll start with it on my end. As you saw in the press release, we had achieved 1,900 unique writers in the quarter, which is just under about 10% of the targets that we are going after with our sales force of 162 sales reps. And so, I think, we had great progress in the quarter just under about nine weeks. And so, as we look at benchmarks of prior therapies that have come to market more recently, I think we're in a great place for where we had expected us to land. Of course, we also understood that this is a new way of treating dry eye disease. So really communicating the benefits with the nasal spray. And so, I think, we're quite pleased with where we landed and continue to work toward that 21,000 target count as we progress throughout the year. Jeff Nau -- President and Chief Executive Officer And maybe what I'll add on to -- the second part of the question there is some of the things that are resonating. I think, one of the things that's really been exciting about the launch of this product is patient feedback has been really great. And so, we've been excited to not only hear stories from the field, see posts on social media of patients going out on their own and talking about the product. And just really, it's a great product to launch where you're having that patient feedback come back to the teams and to those folks that have put such hard work into getting the product out there into the marketplace because it's really why we do this and it really drives the team. So I think, one of the things that we hear that is something that's really encouraging is just the patients stating that they really like the profile. They like the way it's making their eyes feel, and it's just differentiated in the way that it's able to be used. So we do hear stories back of people who are unable to deliver a topical eye drop. And this is another option for them because maybe they don't have the dexterity or they're elderly and they're just not able to put a drop into their eye, and so they're able to use nasal sprays. And the other thing that we hear in the field often is the physicians are not getting patients calling back and complaining. And so, that's also really important for us. But again, we're very early in the launch. So we have many patients that haven't been on the product for more than a few months. So we're excited to see how the long-term feedback is. But for the moment, we are really encouraged by the feedback or sometimes lack of negative feedback coming back from the patients. Joe Catanzaro -- Piper Sandler -- Analyst Great. And if I maybe just squeeze in a quick follow-up. I think, you said you guys have maybe covered about 50% of your target ECPs. Can you maybe speak to what percent of those have been given a sample? And how soon after sampling are you seeing ECPs write a script? Thanks. John Snisarenko -- Chief Commercial Officer Yeah, no, thank you, Joe. Great question. Part of our strategy is really to introduce TYRVAYA into the office practice with the prescriber base, the technicians, the staff that are involved with training, the patients and so on prior to actually sampling because we want to make sure that the product is taken appropriately and the patient gets the best possible experience they can with the nasal spray. So we handed out quite a few samples, probably over 100,000 samples since launch. But we want to make sure that we hand them out appropriately and that installation with that office has actually taken place before that sampling is initiated. So so far, that's worked well for us because we've seen a higher proportion of patients that tried a sample, see if it works for them before they're getting into our patient hub and actually getting that prescription filled. So that kind of connection has been very, very positive with that approach. Joe Catanzaro -- Piper Sandler -- Analyst OK, that's helpful. Thanks, again, for taking questions. Patrick Dolezal -- LifeSci Capital -- Analyst Great. I'm just curious how the availability of generic cyclosporine has impacted discussions with payers, if at all. Were there any modifications to negotiations with Express Scripts as that approval came to light? I'm just curious if you expect any impacts going forward as you onboard other payers. And then, I have a follow-up as well. John Snisarenko -- Chief Commercial Officer Yeah, Patrick, thanks for your question. We've seen kind of early mixed reactions from the payer community on how they're going to manage the generic entry of cyclosporine. And with the early listing with ESI, they're actually covering TYRVAYA across their formularies with only a traditional step, sort of an artificial tear. So that's what I mean by mix. Some of the payers are kind of waiting until more than one generic comes out, and they'll take a look at the dry eye space or they're not really managing the dry eye space as closely. And others are going to evolve a little quicker. So we're able to modify our approach. We are ready for a generic to be on the market or not with. And that's the way our negotiations are going with the major PBMs. And our goal is to get access for TYRVAYA on a level playing field with the branded therapeutics. And our differentiation along with our strategic contracting will help us get there. Jeff Nau -- President and Chief Executive Officer And one other comment, Patrick. As you well know, generic entry into the marketplace doesn't change the dynamic that exists where patients cycle off many of these drugs, whether it be for lack of effect or side effects or whatnot. And so, that certainly will not change. So we were planning on generic entry coming. I think, we've been planning for a long time, but it's been always in the back of our mind, and so the team is ready. Patrick Dolezal -- LifeSci Capital -- Analyst That's helpful. Thanks. And as it relates to just drug launch surrogates, there's not a ton in the dry eye space really, but obviously, we do have these eye drops. Just curious to hear any similarities and differences that might be worth pointing out. And just if you could comment on the role of coverage and driving drug adoption in the dry eye space generally, that would be helpful. I'm curious if there's a tipping point where you feel that the amount of coverage really will drive adoption, 50% if it's a bit more. I would love to hear your thoughts there. Thanks. John Snisarenko -- Chief Commercial Officer Yeah, Patrick, in regards to the Xiidra launch, we did see very quick uptake. Well, this was back in 2016. They had very early access to the commercial insurers, and they launched with 280-plus reps. We are very pleased with the number of reps we have and the trajectory we're seeing with TYRVAYA. We are on track in regards to the payer negotiations. And in fact, the ESI listing was an early listing for us. So we will get to that point that we're expecting in terms of broad base of writers, the eye care professionals prescribing TYRVAYA. We just won't be out of the gate as quickly as you saw with the Xiidra launch. I could tell you, versus the latest two launches, we're very pleased with how our trajectory is going versus kind of the more recent entries. But it was a different space back in 2016, less managed, and also they were second entry at the time after Restasis. Patrick Dolezal -- LifeSci Capital -- Analyst That makes sense. Thanks for taking the questions. Chris Neyor -- J.P. Morgan -- Analyst Great. Thanks for taking the questions. So first one is on me -- for me is just wanted to get a bit more details on the Express Scripts contract. So really just thinking about what's the mix between preferred and non-preferred coverage within those 26 million lives that you had estimated. And within the Express Scripts plan, are there -- is there potential for additional pickup of patients and additional contracting that would either add additional patients or move more patients toward preferred access? And when talking about that kind of mix -- the mix of customers, what type of co-pay should we be thinking about for most of these patients? I think, I have a couple of follow-ups after that. John Snisarenko -- Chief Commercial Officer Yeah, Chris. No, thanks. In regards to ESI, whether preferred or non-preferred, in terms of access whether you're listed preferred or non-preferred, the key criteria is you have to have tried and failed on an artificial tear for all of the branded products here. So as you mentioned in the last part of your question, the out-of-pocket is a difference between the Tier 3 and a Tier 2. And pretty appropriate patients, commercial patients, we definitely buy down that out-of-pocket to be very competitive with the leading branded product out there. So we feel our 26 million lives that are covered are on a level playing field with regard to the leaders out there. And that -- those are the majority of the larger plans within ESI, but we will continue to work with signing on some of the downstream plans that ESI covers -- sorry, that Ascent covers as well and through ESI. So the tiering for us is not a disadvantage. We feel we're going to be very competitive with the two major brand leaders out there. Chris Neyor -- J.P. Morgan -- Analyst Great. That's helpful. And then, you kind of touched on the refill rates and also maybe you could just discuss your confidence in being able to hit that commercial coverage for CVS Caremark and UnitedHealth by the middle of this year. And then, aside from maybe overall script trends, any other KPIs that we should be watching for the launch in the coming weeks and quarters? John Snisarenko -- Chief Commercial Officer Yeah, no, Chris, in regards to the refill rates, we've been very pleased with the kind of 60%, 65% rate of refills we've been seeing. We feel that based on the product profile, as well as the services we offer to make sure that both the prescriber base, as well as the patients are supported through the clinical experience with TYRVAYA. In regards to some of the other PBMs, we are in the middle of negotiations with them. We are still on track to have coverage determinations by midyear. And we are ready to negotiate whether they're going to be managing the generic space or not. We feel we're going to be very, very competitive to be able to get TYRVAYA listed and get the majority of those commercial lives covered by midyear of '22. Chris Neyor -- J.P. Morgan -- Analyst Perfect. Appreciate the questions. Jeff Nau -- President and Chief Executive Officer Thank you, operator, and thanks to everyone for joining the call with us today. As I mentioned in my opening remarks, we are extremely pleased to announce that TYRVAYA Nasal Spray, indicated for the treatment of the signs and symptoms of dry eye disease, is currently in its first full quarter of launch for patients and eye care providers in the U.S. We are extremely excited for the potential of significant growth that remains ahead. Our vision and focus on bringing innovative and transformative ophthalmic disease treatments to patients and building Oyster Point Pharma into a best-in-class eye care company remains our primary goal as a company. In closing, I want to thank everybody for joining us tonight and to have a great evening. Duration: 41 minutes Call participants: Dan Lochner -- Chief Financial Officer Jeff Nau -- President and Chief Executive Officer John Snisarenko -- Chief Commercial Officer Ken Cacciatore -- Cowen and Company -- Analyst Joe Catanzaro -- Piper Sandler -- Analyst Patrick Dolezal -- LifeSci Capital -- Analyst Chris Neyor -- J.P. Morgan -- Analyst More OYST analysis All earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2523,\n        \"min\": 525,\n        \"max\": 32540,\n        \"num_unique_values\": 7950,\n        \"samples\": [\n          7952,\n          6261,\n          8233\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 9
        }
      ],
      "source": [
        "def clean_transcript(text):\n",
        "  if not isinstance(text,str):\n",
        "    return \"\"\n",
        "  text = re.sub(r'(Prepared Remarks:|Questions and Answers:)', '', text, flags=re.IGNORECASE)   #headers-Prepared remarks, Q&A\n",
        "  text = re.sub(r'Operator\\n.*?\\n', '', text, flags=re.IGNORECASE)   #operator word\n",
        "  text = re.sub(r'\\s+', ' ', text).strip()  #extra whitespace\n",
        "  return text\n",
        "df[\"Clean_Text\"]=df['transcript'].apply(clean_transcript)\n",
        "df[\"word_count\"]=df[\"Clean_Text\"].apply(lambda x: len(str(x).split()))\n",
        "df=df[df[\"word_count\"]>100]      #keeping text word count >100, deleting short or cancelled calls\n",
        "output_path=\"/content/drive/MyDrive/Earnings call prediction/cleaned_transcripts.pkl\"\n",
        "df.to_pickle(output_path)\n",
        "print(df.shape)\n",
        "df.head(5)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "LFUiIBdcNCXQ"
      },
      "source": [
        "# **2 Stock Price Reaction**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 10,
      "metadata": {
        "id": "NpU16VIlNpcj",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "35670f63-d736-4b12-d48d-c1e360c54823"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting yfinance\n",
            "  Downloading yfinance-0.2.66-py2.py3-none-any.whl.metadata (6.0 kB)\n",
            "Requirement already satisfied: pandas>=1.3.0 in /usr/local/lib/python3.12/dist-packages (from yfinance) (2.2.2)\n",
            "Requirement already satisfied: numpy>=1.16.5 in /usr/local/lib/python3.12/dist-packages (from yfinance) (2.0.2)\n",
            "Requirement already satisfied: requests>=2.31 in /usr/local/lib/python3.12/dist-packages (from yfinance) (2.32.4)\n",
            "Collecting multitasking>=0.0.7 (from yfinance)\n",
            "  Downloading multitasking-0.0.12.tar.gz (19 kB)\n",
            "  Installing build dependencies ... \u001b[?25l\u001b[?25hdone\n",
            "  Getting requirements to build wheel ... \u001b[?25l\u001b[?25hdone\n",
            "  Preparing metadata (pyproject.toml) ... \u001b[?25l\u001b[?25hdone\n",
            "Requirement already satisfied: platformdirs>=2.0.0 in /usr/local/lib/python3.12/dist-packages (from yfinance) (4.5.1)\n",
            "Requirement already satisfied: pytz>=2022.5 in /usr/local/lib/python3.12/dist-packages (from yfinance) (2025.2)\n",
            "Collecting frozendict>=2.3.4 (from yfinance)\n",
            "  Downloading frozendict-2.4.7-py3-none-any.whl.metadata (23 kB)\n",
            "Collecting peewee>=3.16.2 (from yfinance)\n",
            "  Downloading peewee-3.18.3.tar.gz (3.0 MB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m3.0/3.0 MB\u001b[0m \u001b[31m49.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25h  Installing build dependencies ... \u001b[?25l\u001b[?25hdone\n",
            "  Getting requirements to build wheel ... \u001b[?25l\u001b[?25hdone\n",
            "  Preparing metadata (pyproject.toml) ... \u001b[?25l\u001b[?25hdone\n",
            "Requirement already satisfied: beautifulsoup4>=4.11.1 in /usr/local/lib/python3.12/dist-packages (from yfinance) (4.13.5)\n",
            "Collecting curl_cffi>=0.7 (from yfinance)\n",
            "  Downloading curl_cffi-0.13.0-cp39-abi3-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (13 kB)\n",
            "Requirement already satisfied: protobuf>=3.19.0 in /usr/local/lib/python3.12/dist-packages (from yfinance) (6.33.2)\n",
            "Requirement already satisfied: websockets>=13.0 in /usr/local/lib/python3.12/dist-packages (from yfinance) (15.0.1)\n",
            "Requirement already satisfied: soupsieve>1.2 in /usr/local/lib/python3.12/dist-packages (from beautifulsoup4>=4.11.1->yfinance) (2.8)\n",
            "Requirement already satisfied: typing-extensions>=4.0.0 in /usr/local/lib/python3.12/dist-packages (from beautifulsoup4>=4.11.1->yfinance) (4.15.0)\n",
            "Requirement already satisfied: cffi>=1.12.0 in /usr/local/lib/python3.12/dist-packages (from curl_cffi>=0.7->yfinance) (2.0.0)\n",
            "Requirement already satisfied: certifi>=2024.2.2 in /usr/local/lib/python3.12/dist-packages (from curl_cffi>=0.7->yfinance) (2025.11.12)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.3.0->yfinance) (2.9.0.post0)\n",
            "Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.3.0->yfinance) (2025.2)\n",
            "Requirement already satisfied: charset_normalizer<4,>=2 in /usr/local/lib/python3.12/dist-packages (from requests>=2.31->yfinance) (3.4.4)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.12/dist-packages (from requests>=2.31->yfinance) (3.11)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.12/dist-packages (from requests>=2.31->yfinance) (2.5.0)\n",
            "Requirement already satisfied: pycparser in /usr/local/lib/python3.12/dist-packages (from cffi>=1.12.0->curl_cffi>=0.7->yfinance) (2.23)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.12/dist-packages (from python-dateutil>=2.8.2->pandas>=1.3.0->yfinance) (1.17.0)\n",
            "Downloading yfinance-0.2.66-py2.py3-none-any.whl (123 kB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m123.4/123.4 kB\u001b[0m \u001b[31m10.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading curl_cffi-0.13.0-cp39-abi3-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (8.3 MB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m8.3/8.3 MB\u001b[0m \u001b[31m125.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading frozendict-2.4.7-py3-none-any.whl (16 kB)\n",
            "Building wheels for collected packages: multitasking, peewee\n",
            "  Building wheel for multitasking (pyproject.toml) ... \u001b[?25l\u001b[?25hdone\n",
            "  Created wheel for multitasking: filename=multitasking-0.0.12-py3-none-any.whl size=15636 sha256=5ed785509250307598cf0cde54dfecdeaa15fddd9c677bfba243e87e5d6eddf6\n",
            "  Stored in directory: /root/.cache/pip/wheels/cc/bd/6f/664d62c99327abeef7d86489e6631cbf45b56fbf7ef1d6ef00\n",
            "  Building wheel for peewee (pyproject.toml) ... \u001b[?25l\u001b[?25hdone\n",
            "  Created wheel for peewee: filename=peewee-3.18.3-cp312-cp312-linux_x86_64.whl size=936697 sha256=4de07e9bdc0988ea19cd4e33f1b2a74820d0fb355f8da567711b3b912bba3c0a\n",
            "  Stored in directory: /root/.cache/pip/wheels/e2/48/b6/675a31c56e50b8b343e1ffbb1d9209f0d95025e2cfa0bbeeed\n",
            "Successfully built multitasking peewee\n",
            "Installing collected packages: peewee, multitasking, frozendict, curl_cffi, yfinance\n",
            "Successfully installed curl_cffi-0.13.0 frozendict-2.4.7 multitasking-0.0.12 peewee-3.18.3 yfinance-0.2.66\n"
          ]
        }
      ],
      "source": [
        "!pip install yfinance"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 11,
      "metadata": {
        "id": "ik9M46w5NAmD"
      },
      "outputs": [],
      "source": [
        "import yfinance as yf\n",
        "from datetime import timedelta\n",
        "import time\n",
        "import pandas as pd"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 12,
      "metadata": {
        "id": "mv3giUuqgFuF"
      },
      "outputs": [],
      "source": [
        "df=pd.read_pickle(\"/content/drive/MyDrive/Earnings call prediction/cleaned_transcripts.pkl\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 13,
      "metadata": {
        "id": "e-rNu-aBSSOK",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "82cd5579-39eb-49fa-a065-889a8e9a6143"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Earliest Transcript Date found: 2019-04-11 00:00:00\n",
            "Fetching stock history from: 2019-03-12\n"
          ]
        }
      ],
      "source": [
        "earliest_date = df['Date_only'].min()\n",
        "print(f\"Earliest Transcript Date found: {earliest_date}\")\n",
        "start_date_dynamic=(earliest_date-pd.Timedelta(days=30)).strftime(\"%Y-%m-%d\")\n",
        "print(f\"Fetching stock history from: {start_date_dynamic}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 14,
      "metadata": {
        "id": "R9aBoDk8pyWv",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "b085a866-c38f-4446-f03b-ed95c5f5ff00"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "unique tickers: ['BILI', 'GFF', 'LRCX', 'BBSI', 'CSTE', 'GDOT', 'KAR', 'EPAC', 'ABM', 'SGHC', 'WDR', 'SJM', 'URBN', 'HESM', 'SPOK', 'TSM', 'MYOV', 'GNW', 'WPP', 'DXCM', 'EME', 'EEFT', 'COUP', 'ARAY', 'WBA', 'ZBRA', 'ROST', 'FL', 'STZ', 'NET', 'HZO', 'LZB', 'USPH', 'MRNA', 'MELI', 'CDNS', 'VIV', 'NTCT', 'U', 'RUSHA', 'DTM', 'VCEL', 'MSTR', 'CSIQ', 'AAPL', 'CENT', 'BCOV', 'FLNT', 'ACLS', 'GEO', 'DFIN', 'GOTU', 'MT', 'SHOP', 'EL', 'LGIH', 'EBS', 'REGN', 'EAF', 'META', 'HRB', 'STRS', 'TTE', 'FCNCA', 'OTIS', 'DHI', 'AIMC', 'HLT', 'TLRY', 'ALGN', 'SGEN', 'F', 'ADNT', 'PPG', 'AL', 'MKL', 'INBK', 'AAWW', 'CARA', 'LILAK', 'SXC', 'CNI', 'BX', 'CMC', 'SIVB', 'GNRC', 'BABA', 'CTIC', 'OPRX', 'XLNX', 'MOD', 'LAMR', 'TRV', 'LOPE', 'OCFT', 'AYX', 'HUN', 'TGT', 'SBSW', 'STNG)', 'WWE', 'DB', 'CHS', 'MRCY', 'AI', 'FCN', 'PSMT', 'LITE', 'HCAT', 'KO', 'CMLS', 'ATC)', 'CTK', 'ZUO', 'OOMA', 'MVIS', 'BJRI', 'AGNC', 'LHCG', 'TTWO', 'AMZN', 'IMOS', 'ROKU', 'CGEN', 'ONTO', 'MNKD', 'HR', 'CLF', 'SIX', 'SITM', 'OLED', 'COHR', 'ABR', 'WGO', 'APAM', 'CASH', 'MSA', 'GPI', 'CYD', 'ICPT', 'ZEUS', 'VLDR', 'WFC', 'NGD', 'PRI', 'CB', 'ANET', 'ARRY', 'ITCB', 'SEER', 'KMB', 'GMLP', 'GPRO', 'VVV', 'SNAP', 'OKTA', 'TIG', 'NCR', 'NUE', 'DIS', 'MED', 'UNM', 'CRTO', 'CCK', 'PODD', 'SBNY', 'SPOT', 'PAYS', 'APPS', 'CHDN', 'VIRT', 'SYK', 'IHG', 'SE', 'AMWL', 'IRS', 'SIRI', 'SQ', 'EQIX', 'CARS', 'CACI', 'FOSL', 'GOGO', 'SABR', 'SDGR', 'HGV', 'TWO', 'MAX', 'TPIC', 'LULU', 'CWBHF', 'TGNA', 'OGI', 'CF', 'CCO', 'RTX', 'TSLA', 'ONCT', 'BGFV', 'PLNT', 'PFGC', 'PLD', 'KMX', 'QRVO', 'BNGO', 'NSA', 'DOV', 'SBRA', 'PRGO', 'BZUN', 'CRVL', 'MTSI', 'PBYI', 'UPS', 'ETSY', 'SCL', 'ESS', 'INTC', 'LLY', 'CBT', 'EGRX', 'NSTG', 'VUZI', 'CPE', 'SBH', 'DADA', 'FOXF', 'NKE', 'ACM', 'CDMO', 'AON', 'TCS', 'PBR', 'CDXS', 'CVLG', 'LBTYA', 'CVGW', 'PINS', 'EBIX', 'PAG', 'SUI', 'PTC', 'ATVI', 'IBM', 'AKTS', 'PM', 'TFFP', 'MODG', 'KOS', 'ERIE', 'SYF', 'LVS', 'ICUI', 'MAN', 'XGN', 'APTX', 'OMC', 'NOW', 'VLO', 'OLO', 'DISC.A', 'MASI', 'EOG', 'PLTR', 'C', 'PARA', 'BOX', 'BCRX', 'BLND', 'USB', 'MNST', 'CCXI', 'GRPN', 'PKE', 'WIX', 'XPO', 'BAC', 'JOUT', 'SNDL', 'BALL', 'IDXX', 'LX', 'BWXT', 'CHD', 'GOOGL', 'MAIN', 'RC', 'PCH', 'NVO', 'MSCI', 'GERN', 'TNDM', 'ATTO', 'FRO', 'CHE', 'GWW', 'OCFC', 'KEX', 'MAT', 'TCEHY', 'LHDX', 'NDAQ', 'GLYC', 'NAVI', 'ARGX', 'ATHM', 'NMIH', 'MSM', 'K', 'IGT', 'FSM', 'PRFT', 'DOMO', 'CLX', 'GVA', 'KWR', 'COST', 'VRNT', 'RETA', 'ANGI', 'CSGP', 'RDS.A', 'REYN', 'UAA', 'TRMK', 'BFH', 'GTY', 'ESE', 'CNA', 'BP', 'VRS', 'GEOS', 'BZH', 'ENB', 'UFS', 'ISRG', 'TTD', 'RDWR', 'BUD', 'OII', 'UBER', 'IEA', 'STAG', 'HLX', 'CLDT', 'BCS', 'ADM', 'RAIN', 'CLFD', 'SO', 'BEST', 'TPX', 'ADPT', 'ING', 'ATI', 'VNET', 'OCGN', 'GEF', 'REX', 'FCAU', 'APO', 'TXT', 'IDSY', 'GEL', 'DFS', 'IT', 'TENB', 'HMC', 'SIFY', 'JCI', 'EEX', 'GE', 'HCA', 'FTHM', 'GSHD', 'TWOU', 'RACE', 'TREX', 'ILPT', 'ORGO', 'PTON', 'ATOM', 'ALTR', 'FROG', 'X', 'GFI', 'ONTF', 'HST', 'SWBI', 'AAP', 'LILA', 'NVDA', 'CNX', 'SNY', 'EVC', 'AIR', 'TK', 'EZPW', 'CCEP', 'GIS', 'CBRL', 'MIDD', 'CORT', 'ORCL', 'LOW', 'FCEL', 'INCY', 'RTN', 'NOC', 'DLB', 'NYT', 'OCSL', 'PGNY', 'ALNY', 'WKME', 'MGPI', 'ICL', 'EQC', 'UCTT', 'BKCC', 'WMS', 'CLNE', 'MTZ', 'YY', 'NOK', 'COTY', 'CC', 'CHKP', 'ACMR', 'EXPI', 'NGVT', 'HLIT', 'UEIC', 'ACEL', 'NJR', 'KTB', 'SPB', 'RERE', 'T', 'NKTR', 'SFT', 'BKI', 'LFUS', 'CRWD', 'SJW', 'DCOM', 'AZPN', 'REGI', 'HZNP', 'MCD', 'NIO', 'HIMX', 'AVT', 'TXRH', 'UL', 'TX', 'LASR', 'PNC', 'WM', 'DOCU', 'AQN', 'DOW', 'FANG', 'AR', 'MTDR', 'VOXX', 'SCHL', 'CYRX', 'CPSI', 'UPWK', 'PTEN', 'BB', 'MTH', 'SWKS', 'LPI', 'HA', 'AMSC', 'VVNT', 'RKT', 'GCO', 'GPS', 'AER', 'GRWG', 'WPC', 'AFYA)', 'AIT', 'STON', 'SBAC', 'EGBN', 'IPG', 'SSRM', 'HD', 'ABTX', 'TCOM', 'ALE', 'CVNA', 'HNI', 'BIG', 'AINV', 'PGTI', 'RLX', 'KRC', 'IR', 'HAS', 'KR', 'GBDC', 'VVI', 'PLAY', 'KEY', 'BIO', 'SITC', 'RRC', 'HMSY', 'OTEX', 'CAMP', 'ALL', 'TMCI', 'ZVIA', 'MIME', 'SLM', 'BMRN', 'NTCO', 'HL', 'AMBC', 'FTCH', 'CIR', 'BGCP', 'NEWR', 'AMRC', 'ECL', 'TRMB', 'RY', 'KSU', 'RDN', 'TDCX', 'PLAB', 'NVT', 'TWNK', 'BSIG', 'EXTR', 'ALV', 'TPRE', 'SFBS', 'INTU', 'DAR', 'ARCE', 'EQNR', 'EXEL', 'MFGP', 'MNTV', 'CLB', 'OZK', 'CYH', 'VRAY', 'ASR', 'AMRX', 'HUBS', 'MRVL', 'JBL', 'SJI', 'TILE', 'GS', 'VNE', 'CTSH', 'GAIN', 'CMRE)', 'OCSI', 'NVCR', 'GPL', 'GCP', 'FUTU', 'AEM', 'HEAR', 'A', 'NLS', 'MGRC', 'WETF', 'INO', 'AVB', 'CXW', 'NWN', 'MMM', 'STX', 'BAX', 'AGIO', 'LMT', 'FSLY', 'ESTA)', 'TIGO', 'LCII', 'STNG', 'SMTS', 'RITM', 'NEE', 'DGICA', 'NEO', 'CHCT', 'OTRK', 'TSE', 'LII', 'LGND', 'BYND', 'GLNG', 'CINF', 'IMXI', 'TFC', 'VSTO', 'GHL', 'SPNS', 'PCYO', 'RGS', 'PBI', 'ALKS', 'VOD', 'CPS', 'JBSS', 'DRNA', 'SYY', 'MLCO', 'RAD', 'NTR', 'GOLD', 'JLL', 'NDLS', 'MTCH', 'JNJ', 'CVS', 'FLXN', 'UPLD', 'CAH', 'FHB', 'DQ', 'UHAL', 'HSY', 'FUV', 'LAD', 'STER', 'CANG', 'EQX', 'WW', 'PHG', 'PANW', 'FIBK', 'NEM', 'IIPR', 'CMTL', 'VECO', 'FDS', 'MYOK', 'BJ', 'DT', 'FIVE', 'FE', 'RUN', 'ASML', 'SBS', 'NFLX', 'FLGT', 'TBI', 'CEIX', 'FRPT', 'VST', 'RF', 'CRIS', 'UNH', 'ZS', 'ITW', 'CNSL', 'OIS', 'AVGO', 'DSKE', 'VNOM', 'DAL', 'CLAR', 'GD', 'OPRA', 'SXT', 'OI', 'GL', 'QDEL', 'CVET', 'EPZM', 'XM', 'UROV', 'XXII', 'AMTB', 'SSD', 'CDK', 'AMRN', 'LOVE', 'TWTR', 'WYNN', 'SOVO', 'BNED', 'AAOI', 'AZUL', 'QTRX', 'KAI', 'NWSA', 'ACCD', 'MESA', 'JG', 'DPZ', 'XP', 'MGNI', 'AXP', 'CCRN', 'CRC', 'TXN', 'TMUS', 'MO', 'WPRT', 'PAC', 'LEN', 'BLK', 'EM', 'MEI', 'NBR', 'EVBG', 'CMG', 'SQNS', 'CIGI', 'ETD', 'AQUA', 'CNS', 'ALLE', 'FTV', 'NVTA', 'GBT', 'TTSH', 'PATK', 'FARO', 'CARR', 'BDSX', 'NKLA', 'JAZZ', 'CSSE', 'SF', 'HII', 'HAL', 'DCT', 'ERF', 'KNDI', 'SU', 'INSG', 'GSK', 'GLT', 'CEQP', 'HSBC', 'NCLH', 'AMD', 'MPC', 'WDAY', 'LPLA', 'DSGX', 'SPG', 'TISI', 'PFC', 'TSEM', 'NTGR', 'FBHS', 'WRLD', 'VIPS', 'MSGS', 'EURN', 'ETM', 'BLDP', 'VIAV', 'AEIS', 'VERU', 'ONDK', 'HRC', 'DVN', 'BIRD', 'WSM', 'AMPL', 'DKNG', 'CRY', 'LQDT', 'TRUP', 'AIRG', 'LCTX', 'ACIW', 'TXMD', 'DG', 'RTLR', 'KPTI', 'CVEO', 'MYRG', 'BLMN', 'EXLS', 'PDM', 'ESI', 'FNF', 'DNAY', 'OSTK', 'INMB', 'RELY', 'DUK', 'ICE', 'BIOX', 'ET', 'MKTX', 'HNGR', 'SON', 'SUMO', 'VERX', 'EIG', 'CCL', 'BIGC', 'XRAY', 'HIW', 'SHEN', 'PRVB', 'BG', 'GBX', 'BKR', 'GATX', 'BMBL', 'EVLO', 'CIM', 'WSBC', 'JELD', 'BOOM', 'CHRS', 'SSSS', 'AROC', 'FUN', 'AWK', 'HDB', 'SKYW', 'G', 'CMP', 'RADA', 'EGO', 'NXPI', 'VZ', 'GWGH)', 'PSTG', 'RPAY', 'MAC', 'FOUR', 'GLOB', 'ASC', 'OXM', 'PDD', 'VGR', 'SMSI', 'PACB', 'EXK', 'BCOR', 'DBX', 'DCPH', 'MSI', 'TDS', 'JAGX', 'GM', 'LMAT', 'FCPT', 'LSTR', 'COMP', 'HCC', 'PRTS', 'DVA', 'STM', 'RCII', 'NXST', 'ACGL', 'BIIB', 'SPCE', 'TLYS', 'ANF', 'STNE', 'OHI', 'CDNA', 'TELA', 'IPHA', 'HAE', 'SBLK', 'WDFC', 'HIBB', 'FOLD', 'NTST', 'SERA', 'LRN', 'TT', 'SGU', 'SCI', 'CNR', 'OGE', 'AHCO', 'IRM', 'JWN', 'MUR', 'BCH', 'FLR', 'ST', 'SIG', 'RDHL', 'EBAY', 'PHR', 'VNO', 'JE', 'MDU', 'TEX', 'FPI', 'DAC', 'SONY', 'TGH', 'LAW', 'AJX', 'WRB', 'ENR', 'WB', 'VSH', 'GKOS', 'AGCO', 'GOL', 'PEN', 'PAA', 'JPM', 'NX', 'PLUG', 'AMAT', 'SAIL', 'PRLB', 'JACK', 'GDRX', 'CNHI', 'WST', 'UNFI', 'ENPH', 'BPMC', 'SM', 'LYTS', 'DASTY', 'SLG', 'SNEX', 'EH', 'AXTI', 'FRC', 'DBRG', 'NATI', 'PERI', 'LBRD.A', 'NRP', 'RMD', 'VITL', 'AXTA', 'JMIA', 'ALK', 'HUBB', 'LIND', 'COO', 'VOYA', 'LOB', 'JOAN', 'ABT', 'VRSK', 'HPQ', 'LXP', 'BDC', 'APPN', 'LNG', 'MKC', 'PGR', 'NYMT', 'SNOW', 'RBLX', 'ON', 'TCBI', 'KAMN', 'CTRN', 'VFF', 'APEI', 'MDP', 'ULTA', 'CS', 'EPAM', 'PRTY', 'VMW', 'AX', 'FWONA', 'VRSN', 'AYI', 'OSPN', 'SHYF', 'ARMK', 'IPGP', 'HQY', 'GPP', 'ALSN', 'AVD', 'SPH', 'OMCL', 'CTS', 'OPK', 'AZN', 'PR', 'MSGE', 'GPRE', 'IPI', 'BEP', 'OYST', 'WEN', 'MTB', 'ZNGA', 'TW', 'APOG', 'AUY', 'ASIX', 'GES', 'BALY', 'ABMD', 'L', 'AMGN', 'CRMD', 'MANH', 'SND', 'AMT', 'STN', 'MTOR', 'KALU', 'QSR', 'LGF-A', 'KOP', 'WOR', 'AGS', 'NYCB', 'MCK', 'IQV', 'ZI', 'CVX', 'PCG', 'FC', 'E', 'IONS', 'EVRI', 'MMP', 'ZEN', 'URI', 'USM', 'ALGM', 'EVER', 'RNG', 'BNR', 'STIM', 'AMBA', 'MPLX', 'RMR', 'TEAM', 'OTTR', 'BIDU', 'EW', 'VRA', 'LNC', 'HBM', 'CWT', 'CARG', 'ALLY', 'SCU', 'SRPT', 'DLR', 'REPH', 'ABB', 'RRGB', 'LAND', 'KMI', 'AJG', 'ITCI', 'DBI', 'ADSK', 'GLIBA', 'TRQ', 'IMGN', 'PXD', 'PRTK', 'MDT', 'NFH', 'BYSI', 'TTC', 'MPWR', 'CGNX', 'RIG', 'IQ', 'VRNS', 'MYGN', 'DRH', 'WPM', 'VERI', 'MRLN', 'SSYS', 'CPT', 'WMT', 'HRZN', 'BA', 'CAAS', 'BSX', 'SKX', 'SLP', 'PARR', 'SHW', 'LDI', 'LBRT', 'AXL', 'TWLO', 'EXAS', 'TRUE', 'AVYA', 'AMG', 'COP', 'RDUS', 'PAR', 'HUYA', 'ECHO', 'OFC', 'HRI', 'NTLA', 'NPO', 'EGLE', 'HON', 'BEN', 'HT', 'UTZ', 'BERY', 'GMED', 'LUV', 'BCPC', 'NLY', 'TUP', 'ALT', 'NTES', 'SNV', 'ESRT', 'SEDG', 'SCWX', 'ENTG', 'ATUS', 'EA', 'SLCA', 'WAL', 'TFII', 'GLW', 'DECK', 'HELE', 'NBN', 'BRG', 'CWEN', 'DDOG', 'VALE', 'RS', 'RRR', 'WAT', 'SONO', 'ENLC', 'WOLF', 'CROX', 'MATX', 'JBLU', 'HOLX', 'CSGS', 'BOH', 'TDG', 'SKT', 'NOAH', 'WSO', 'CHTR', 'CBZ', 'OXY', 'CODI', 'H', 'CL', 'TASK', 'AUDC', 'DHC', 'RCL', 'GTN', 'CNP', 'JD', 'GLPI', 'ESLT', 'RBA', 'MCO', 'CHWY', 'CME', 'GMDA', 'ZM', 'IDCC', 'ARCO', 'INFN', 'ARNA', 'RM', 'TMO', 'ESTC', 'TPH', 'SDC', 'SRT', 'ORCC', 'MBUU', 'WHD', 'AZEK', 'DKL', 'TSU', 'CPRX', 'LIN', 'XHR', 'IVR', 'VIAO', 'NTNX', 'XERS', 'CTAS', 'PSB', 'FNV', 'SFM', 'ABNB', 'NDSN', 'SIMO', 'MTRN', 'BBBY', 'POOL', 'RRD', 'BCO', 'QCOM', 'MCHP', 'MDC', 'HTGC', 'PETS', 'TEF', 'CNTG', 'ADCT', 'LECO', 'AN', 'FSLR', 'LOCO', 'ZUMZ', 'ACN', 'SBGI', 'HTA', 'SAM', 'UTL', 'LEA', 'SQM', 'FIVN', 'KLAC', 'DOX', 'CYBR', 'HEES', 'ICHR', 'DLTR', 'MFA', 'AMSWA', 'ANSS', 'D', 'TRN', 'NVGS', 'ALB', 'MRO', 'MOH', 'MGM', 'APG', 'AUPH', 'GHG', 'TIGR', 'RL', 'ORLY', 'CNO', 'EHTH', 'ZD', 'CAG', 'TDC', 'FLEX', 'AZO', 'AXNX', 'YEXT', 'PNR', 'BRC', 'VEON', 'WDC', 'LSPD', 'CDAY', 'ZTS', 'IBKR', 'ETRN', 'WELL', 'CNDT', 'GEVO', 'ICLR', 'NBIX', 'SPPI', 'HOPE', 'DKS', 'BHE', 'APA', 'CLPT', 'GILD', 'CUBE', 'GME', 'STAA', 'LSCC', 'PMT', 'IRBT', 'TRGP', 'FOXA', 'FG', 'TRMR', 'AHH', 'CE', 'FN', 'MXIM', 'COHU', 'ISEE', 'SSP', 'VMI', 'TECH', 'LH', 'PRGS', 'PPL', 'AFIB', 'GDS', 'RAAS', 'CRUS', 'IMAX', 'BDSI', 'URGN', 'HBAN', 'TITN', 'WEX', 'AVID', 'V', 'WVE', 'YETI', 'LMND', 'SMAR', 'VRE', 'AXGN', 'EXPE', 'CM', 'POWL', 'RCM', 'ASPN', 'TMST', 'IOSP', 'MDB', 'ENS', 'SMP', 'OKE', 'CPB', 'ENSG', 'ACCO', 'BFAM', 'BMY', 'SCHN', 'JJSF', 'IDT', 'CLS', 'GMS', 'COF', 'GCI', 'ENV', 'KBR', 'COIN', 'SBT', 'BECN', 'VICI', 'ERJ', 'NOV', 'BR', 'FGEN', 'TRIP', 'CRI', 'BRKR', 'AGYS', 'DCI', 'SWAV', 'ZLND.Y', 'ROG', 'TTEC', 'VFC', 'NNBR', 'TWST', 'XPEV', 'QFIN', 'LNN', 'ECVT', 'OTIC', 'SPTN', 'HFC', 'GBCI', 'LW', 'PFE', 'INT', 'LYFT', 'NSC', 'MTX', 'DAO', 'DDD', 'BBY', 'FCX', 'AXSM', 'CASY', 'ELF', 'PEP', 'SBUX', 'CRON', 'MNSO', 'FDP', 'MA', 'AFL', 'MEDP', 'HTH', 'PG', 'ARCC', 'CAE', 'RVLV', 'ASO', 'ARCB', 'ARWR', 'PWR', 'PHM', 'DHT', 'CPLG', 'STWD', 'TNET', 'VIAB', 'MOS', 'GTLS', 'CACC', 'PSO', 'CFLT', 'EXTN', 'ASTE', 'AAL', 'CMA', 'HRMY', 'CUTR', 'SAFE', 'BDN', 'EPD', 'AXE', 'LTRPA', 'BKNG', 'BRY', 'DGX', 'ORA', 'VNT', 'STOR', 'ABBV', 'NRG', 'APTV)', 'DVAX', 'MRCC', 'PYPL', 'RCI', 'QRTEA', 'ZEAL', 'TJX', 'DLTH', 'CABO', 'FATE', 'LE', 'SII', 'GNSS', 'PENN', 'RMNI', 'COOP', 'WWW', 'KOPN', 'PAYX', 'HHC', 'ABEV', 'MMC', 'DRI', 'VSTA', 'EVH', 'CCI', 'XYL', 'ATAX', 'AA', 'SMG', 'NVS', 'KEYS', 'MMS', 'TSN', 'UNP', 'COLM', 'BWA', 'WTFC', 'IEP', 'TBBK', 'HRL', 'CONN', 'RUTH', 'GOCO', 'MGNX', 'WSC', 'EPM', 'BMO', 'SLAB', 'YUM', 'KMPR', 'ESPR', 'RHP', 'JAMF', 'SAGE', 'CRS', 'VRM', 'ANDE', 'NATR', 'HSTM', 'TDOC', 'VRTX', 'RDFN', 'HUD', 'AMC', 'EXP', 'RH', 'BBDC', 'AERI', 'ARLP', 'HOOD', 'OB', 'BDX', 'CEVA', 'ADP', 'CBOE', 'CNC', 'IRT', 'TD', 'SUN', 'CFG', 'LFST', 'JBT', 'PSX', 'EVCM', 'PEG', 'ALDX', 'MITK', 'AIV', 'DOC', 'CMRX', 'WLK', 'BEDU', 'EXPR', 'SSTK', 'ODFL', 'WING', 'PLXS', 'AKAM', 'DXC', 'INMD', 'YOU', 'TPR', 'AOS', 'QLYS', 'KBH', 'ALIM', 'ADC', 'KIRK', 'SPLK', 'PRCT', 'NLTX', 'SLGN', 'MTN', 'CLR', 'AGEN', 'CRNT', 'NTRS', 'TERP', 'CW', 'RGP', 'DMS', 'LEVI', 'VEEV', 'ZENV', 'PRU', 'CAMT', 'CRH', 'KTOS', 'ACB', 'OMI', 'FLXS', 'FTCI', 'ELAN', 'WIRE', 'NXGN', 'CWAN', 'QGEN', 'RBBN', 'NEU', 'CRM', 'HAIN', 'NMFC', 'AVAV', 'YQ', 'GSL', 'SIGI', 'HUBG', 'DV', 'CBD', 'HLNE', 'BELFB', 'PII', 'NTB', 'STAR', 'XOM', 'SLB', 'WEC', 'SPWR', 'CCAP', 'JKHY', 'IEX', 'PAYC', 'NWE', 'ATO', 'BZ', 'HY', 'TECK', 'ABUS', 'SGH', 'MITT', 'DAN', 'MAR', 'HUM', 'FDX', 'MDLZ', 'SEE', 'TRU', 'THRM', 'GGB', 'PBF', 'W', 'SPGI', 'CSCO', 'CHX', 'KSS', 'TEVA', 'ENVA', 'CZR', 'SWI', 'EYE', 'VREX', 'AEO', 'VTR', 'PING', 'LSI', 'CPLP', 'BRBR', 'EPR', 'LI', 'ABCL', 'CHMA', 'PLYM', 'LUNG', 'BBVA', 'ABG', 'PNW', 'USNA', 'CTVA', 'GPN', 'AQST', 'HSIC', 'MRK', 'LPSN', 'HBI', 'CUBI', 'HOG', 'EWBC', 'UNF', 'VSAT', 'JW.A', 'SRDX', 'JKS', 'CHH', 'ARR', 'UXIN', 'OPI', 'AHT', 'SAP', 'MGY', 'ITI', 'GNL', 'EAT', 'SNN', 'ADAP', 'AIG', 'CALA', 'DSP', 'JNCE', 'IBEX', 'PCRX', 'BILL', 'ACI', 'INNV', 'RARE', 'CCMP', 'TGP', 'EVTC', 'BXMT', 'QIWI', 'MTW', 'FRME', 'PWFL', 'FOCS', 'IVC', 'TTI', 'HEP', 'GIII', 'FINV', 'YI', 'ARD', 'BAP', 'NCNO', 'BRFS', 'CBRE', 'CBAY', 'JRVR', 'DLX', 'NIU', 'FFIV', 'CRMT', 'NNN', 'DISH', 'CVBF', 'ALRS', 'AMED', 'AVO', 'REKR', 'SNA', 'ATRO', 'HPE', 'SHG', 'SNBR', 'HMLP', 'EXR', 'MSFT', 'KRT', 'ROCK', 'GPX', 'AMWD', 'UAL', 'CHUY', 'CENX', 'SUZ', 'PRAA', 'GLPG', 'KN', 'CPL', 'NOMD', 'AMRS', 'CMCM', 'FSS', 'DSSI', 'CX', 'FITB', 'AFG', 'KVHI', 'TXG', 'CSTM', 'UFI', 'FSV', 'HTLF', 'SVC', 'LAZ', 'AZZ', 'RJF', 'AIN', 'ELV', 'RUSHB', 'COMM', 'BIO.B', 'CPNG', 'ZION', 'ARNC', 'ATCO', 'SEM', 'ECOL', 'MCFE', 'COLB', 'PAAS', 'ATSG', 'CDLX', 'IAC', 'BMA', 'EBR', 'CMRE', 'PHX', 'CUB', 'RIO', 'HZN', 'CHEF', 'OCN', 'MRVI', 'ODC', 'HE', 'APTO', 'BHF', 'CELH', 'SGC', 'SNCR', 'CERS', 'HALO', 'UTHR', 'CP', 'PAGS', 'RPM', 'LKQ', 'HCRS.Q', 'KRG', 'HMST', 'FIGS', 'GHM', 'REVG', 'CSX', 'OVV', 'GFL', 'PDS', 'MCRB', 'RYN', 'MTD', 'CRK', 'CTO', 'INGR', 'ADI', 'SMWB', 'BAK', 'ITGR', 'ULCC', 'TRI', 'AVNT', 'WNC', 'DISCA', 'PFBC', 'VIE', 'VTRU', 'AKBA', 'LCUT', 'AGFY', 'AFYA', 'TIPT', 'TER', 'JHX', 'TPC', 'PWFL)', 'SATS', 'KMT', 'WES', 'JT', 'FAF', 'BHC', 'LAKE', 'MHO', 'SCOR', 'RYAM', 'CFX', 'PBA', 'AVDL', 'MQ', 'FTI', 'UIS', 'STKL', 'POSH', 'OPB', 'UMPQ', 'SNX', 'TEL', 'SWCH', 'BCE', 'TFX', 'SMCI', 'HAYW', 'UVSP', 'IBA', 'BLI', 'FORR', 'SOPH', 'KODK', 'AZTA', 'CMCSA', 'YELP', 'BXP', 'RGEN', 'BC', 'CYTK', 'INN', 'CSWC', 'SFIX', 'ALGT', 'SAIC', 'LESL', 'XEL', 'EQT', 'SUPV', 'XNET', 'TUSK', 'YSG', 'FNB', 'AGO', 'ATR', 'AMH', 'PTVE', 'SRE', 'NH', 'ROAD', 'ADMS', 'EMN', 'LTC', 'LNTH', 'ARGO', 'CMD', 'COR', 'IFF', 'NWG', 'RMBS', 'GLOP', 'SNDR', 'CNXN', 'DYNC)', 'RAMP', 'SMTC', 'REDU', 'MPW', 'AXS', 'NARI', 'GPK', 'AAIC', 'MEG', 'WAB', 'OPCH', 'CIEN', 'GT', 'ROP', 'TBPH', 'MYTE', 'WU', 'RXT', 'BNS', 'MAS', 'CWCO', 'HASI', 'GAMB', 'EQH', 'CSLT', 'FTNT', 'RELX', 'BYD', 'TWI', 'CSL', 'MTRX', 'PRDO', 'SHSP', 'ACC', 'MPAA', 'NUVA', 'YELL', 'KGC', 'KOF', 'TOL', 'RPRX', 'LTHM', 'CTXS', 'CSII', 'MXL', 'LNT', 'SFL', 'ASGN', 'NP', 'IVZ', 'CGC', 'CRSR', 'FIS', 'ACRX', 'FLY', 'WMG', 'CNNE', 'KFY', 'AMKR', 'PKG', 'TREE', 'MGIC', 'HYFM', 'BL', 'OC', 'TS', 'WUBA', 'UPST', 'CXP', 'CPRT', 'MSP', 'GMAB', 'KHC', 'GSM', 'BANR', 'MR', 'GTE', 'WCC', 'COWN', 'GDDY', 'AY', 'CIO', 'VC', 'DEI', 'FISV', 'NGL', 'GTES', 'ANGO', 'VALN)', 'TM', 'ADT', 'WBT', 'PLYA', 'CATY', 'CNF', 'SOHU', 'DEA', 'CEL', 'CI', 'DAKT', 'PNNT', 'PDFS', 'USFD', 'TGS', 'ICAD', 'SPSC', 'DRE', 'RTL', 'UCL', 'CNK', 'GGG', 'HEI', 'KELYA', 'ATRA', 'WRBY', 'MWA', 'MSGM', 'TKC', 'BVN)', 'TTPH', 'VKTX', 'SLQT', 'AMK', 'KL', 'GAN', 'EDIT', 'CPF', 'POWI', 'SLF', 'FPH', 'ATNX', 'FELE', 'ATHX', 'FOE', 'MYE', 'PLTK', 'KB', 'DNOW', 'AVIR', 'CWST', 'GRBK', 'AWR', 'NS', 'ARLO', 'CMI', 'SWIM', 'NVST', 'ECPG', 'GORO', 'ALEX', 'IDN', 'FRT', 'AMCR', 'DNUT', 'KUKE', 'ICFI', 'FLWS', 'SEAS', 'CTSO', 'DIN', 'YMM', 'LHX', 'SUPN', 'KRA', 'RVNC', 'DD', 'MNDY', 'NVRO', 'RLI', 'SMLP', 'CDE', 'APD', 'AWH', 'WCN', 'DOOO', 'WRK', 'BBCP', 'STC', 'SGHT', 'FSP', 'SNPS', 'MERC', 'INSM', 'XPOF', 'DOLE', 'HLI', 'ACTG', 'KLIC', 'SAR', 'IP', 'ROOT', 'OSH', 'ORI', 'CLW', 'CVAC', 'ANH', 'UGP', 'RDNT', 'TSCO', 'NTAP', 'PCAR', 'BRX', 'AX.DL', 'INFY', 'AVXL', 'LPRO', 'IHRT', 'SWIR', 'XPER', 'LPX', 'BSY', 'SAMG', 'PDCO', 'GLUU', 'CULP', 'RWT', 'FWRD', 'YRD', 'POST', 'FTDR', 'ARCH', 'NWL', 'GTHX', 'HWC', 'WBK', 'CERT', 'INSW', 'BCC', 'FMS', 'CWK', 'RGNX', 'ONEW', 'AEGN', 'BBU', 'FBP', 'CNTY', 'UNVR', 'SIEN', 'MUSA', 'FBK', 'TCMD', 'M', 'VIOT', 'DZSI', 'CHRW', 'PK', 'IIIN', 'BRKL', 'VAPO', 'MOR', 'WMB', 'LMNR', 'ALX', 'MAA', 'QTNT', 'DXPE', 'BGS', 'RNST', 'WSR', 'HAFC', 'ATNI', 'AEYE', 'AUB', 'SAIA', 'CCOI', 'VRTS', 'R', 'SPT', 'MATW', 'AMCX', 'TRTN', 'INSP', 'VICR', 'WY', 'EXC', 'SXI', 'HCM', 'QNST', 'NSP', 'MGI', 'DIOD', 'WD', 'VRRM', 'BBD', 'SR', 'HP', 'EPRT', 'VG', 'CVLT', 'ZYXI', 'BXS', 'CPA', 'MKSI', 'SGMO', 'SWX', 'GIB', 'WWD', 'WERN', 'CMCO', 'TA', 'WH', 'UGI', 'DGII', 'IAA', 'CPRI', 'SHAK', 'BCEI', 'KIM', 'JHG', 'PYCR', 'NI', 'RPD', 'PFS', 'SITE', 'IRWD', 'WIT', 'PNTG', 'AVA', 'AM', 'NVMI', 'TRHC', 'SHOO', 'PEB', 'GWB', 'GOLF', 'REG', 'LU', 'MTLS', 'ASB', 'PPC', 'AGRX', 'ALG', 'AGRO', 'ACHC', 'OMF', 'OMP', 'MFC', 'STXB', 'FRGI', 'SPR', 'DENN', 'USAC', 'VLY', 'UVE', 'BV', 'CHMI', 'DESP', 'ITUB', 'ANIK', 'CSWI', 'PPD', 'AEP', 'SMPL', 'UCBI', 'CONE', 'WLTW', 'GPC', 'ALBO', 'DX', 'UIHC', 'APPF', 'BKH', 'INGN', 'SFNC', 'IRTC', 'PLMR', 'LIVN', 'LANC', 'VAC', 'NFG', 'AKR', 'GSBC', 'IIIV', 'EAR', 'OSIS', 'NR', 'FTAI', 'FIX', 'ABCB', 'RSG', 'POR', 'FLS', 'CAL', 'FDUS', 'TNC', 'VBTX', 'AGR', 'EQR', 'STRA', 'FULT', 'ASPS', 'NEXA', 'FANH', 'RESN', 'OFG', 'CUZ', 'PUMP', 'PBH', 'AMN', 'RNR', 'TTGT', 'CIVB', 'RHI', 'MMSI', 'FLT', 'UFCS', 'DTE', 'KREF', 'HCI', 'THS', 'SHLX', 'ASND', 'WLL', 'GWRE', 'BAH', 'COLL', 'YUMC', 'MHK', 'HVT', 'AMPH', 'HIG', 'SUM', 'BANC', 'JBHT', 'GIL', 'FORM', 'CHNG', 'AAT', 'BPOP', 'PSA', 'VNDA', 'IART', 'ATRC', 'AZRE', 'CNQ', 'THG', 'ARW', 'APH', 'FCF', 'EB', 'INVH', 'TDY', 'ITRI', 'RPT', 'CCR', 'TV', 'HES', 'MMYT', 'TTMI', 'SHO', 'RBC', 'AVNS', 'BSM', 'LPG', 'API', 'CVCO', 'OGS', 'ONB', 'CSPR', 'PTCT', 'CVI', 'EVOP', 'PSXP', 'FMC', 'UMBF', 'CHT', 'TMHC', 'FUL', 'EVRG', 'ZIXI', 'KURA', 'ITT', 'PEAK', 'ENTA', 'FLO', 'HSII', 'CLLS', 'AME', 'AGI', 'PRA', 'MEOH', 'GPMT', 'TALO', 'WPX', 'CNCE', 'BOKF', 'CDXC', 'PH', 'HFWA', 'XLRN', 'EFSC', 'BOOT', 'SLN', 'CALX', 'SKY', 'GEN', 'ELP', 'ROCC', 'SASR', 'AAN', 'ZIM', 'HPP', 'ACA', 'TRS', 'AIZ', 'MET', 'FR', 'TAC', 'ODP', 'CRL', 'ACRE', 'ARES', 'MLM', 'EVA', 'TSLX', 'MTG', 'SRC', 'NMRK', 'NBEV', 'CTMX', 'AVY', 'J', 'TLS', 'ROIC', 'SANM', 'HCCI', 'SWN', 'MOG.A', 'ROLL', 'STXS', 'LDOS', 'CVGI', 'XNCR', 'IBP', 'WOOF', 'AFRM', 'RMAX', 'CCJ', 'SEIC', 'ANIP', 'NXRT', 'EPAY', 'NGMS', 'CDW', 'FTS', 'CFR', 'OSUR', 'AAON', 'NUS', 'CR', 'THRY', 'BLFS', 'PROG', 'IDEX', 'EIX', 'LNDC', 'DY', 'PAHC', 'WHR', 'OFIX', 'WTRG', 'CNMD', 'TEN', 'AEE', 'SSNC', 'OSCR', 'MGP', 'OXLC', 'CTRE', 'IPAR', 'LEG', 'RGLD', 'THC', 'IBTX', 'FLOW', 'PGEN', 'NBHC', 'SPXC', 'EPC', 'PKI', 'ESNT', 'REXR', 'LYV', 'LIVX', 'CG', 'PCTY', 'SYNA', 'AVTR', 'REZI', 'PEGA', 'NHI', 'EFC', 'SAND', 'BLKB', 'TCPC', 'CBU', 'MMI', 'RES', 'NLSN', 'PNFP', 'NICE', 'MCS', 'LYG', 'ASPU', 'DUO', 'HMN', 'FHN', 'OSK', 'UHS', 'HOUS', 'ARI', 'STL', 'HMTV', 'OR', 'PHI', 'ADTN', 'ZBH', 'LCI', 'WSFS', 'IMMR', 'B', 'EXPO', 'SID', 'NMR', 'OMAB', 'SYX', 'SAH', 'PRMW', 'TVTY', 'NEPT', 'ATGE', 'IRDM', 'AEG', 'HWM', 'VCTR', 'BLD', 'SYNH', 'CAC', 'CCS', 'LYB', 'UVV', 'KKR', 'SBCF', 'HSC', 'PINC', 'CDEV', 'MNRL', 'AEL', 'DBD', 'EGP', 'FHI', 'PDCE', 'VCRA', 'ABC', 'MNRO', 'BSAC', 'AVLR', 'NVEC', 'KDP', 'NBTB', 'EFX', 'MANT', 'UDR', 'AXU', 'CEPU', 'CPK', 'FMX', 'RE', 'FRBA', 'BKD', 'ATEC', 'PB', 'EHC', 'NTUS', 'SGRY', 'OLN', 'MD', 'BE', 'SAN', 'IDA', 'BHLB', 'VIVO', 'ADMA', 'ALC', 'APP', 'TYL', 'FICO', 'FND', 'TNL', 'AMSF', 'ES', 'EVR', 'UMC', 'OUT', 'GNE', 'SRCL', 'HAYN', 'SAVE', 'CLH', 'DSPG', 'WRE', 'EMR', 'EC', 'ROL', 'ADUS', 'LNW', 'MESO', 'XEC', 'CVE', 'JNPR', 'ASX', 'VRTV', 'ETR', 'APTV', 'BPMP', 'NEOG', 'DNB', 'CTLT', 'SCSC', 'INDB', 'IAG', 'AIRC', 'CO', 'RGR', 'MDRX', 'ETN', 'SSL', 'DRQ', 'PFG', 'PTR', 'PZZA', 'EGIO', 'VYNE', 'SI', 'ADBE', 'HSKA', 'CERN', 'PJT', 'BRO', 'FRG', 'VMC', 'IMAB', 'KT', 'HMPT', 'NSIT', 'GP', 'DCP', 'HLF', 'GHLD', 'UNIT', 'GATO', 'OCDX', 'APLE', 'LBRDK', 'NWS', 'RGA', 'BF.B', 'DRVN', 'IMV', 'MC', 'TIXT', 'QMCO', 'DEN', 'TSHA', 'HI', 'AES', 'MATV', 'OESX', 'PD', 'CIG', 'KNBE', 'SKYT', 'IOVA', 'OM', 'AKYA', 'S', 'NOTE', 'PAY', 'ADV', 'O', 'PUBM', 'KLTR', 'AXON', 'TGI', 'NNOX', 'VALN', 'BVS', 'EBET', 'PACK', 'DIBS', 'OMIC', 'PCOR', 'LZ', 'FUBO', 'PAX', 'CXM', 'XMTR', 'ESMT', 'TUYA', 'GO', 'ERIC', 'MASS', 'SRAD', 'WEBR', 'TPG', 'ZIMV', 'CAR', 'DLO', 'EWCZ', 'NVAX', 'PRVA', 'ABOS', 'PEIX)', 'EE', 'BFLY', 'ALTO', 'MXCT', 'TLIS)', 'RDY', 'BLNK', 'ZETA', 'GSX', 'PLTK)', 'FORG', 'HLMN)', 'DUOL', 'EBC', 'FSBC', 'WKME)', 'AFCG', 'KARO', 'AGTI', 'VTOL)', 'AVAH', 'PROF', 'CSAN', 'APR', 'CENTA', 'DASH', 'SHLS', 'SHC', 'GLBE', 'INTA', 'MCW', 'IAS', 'AOMR', 'PRG', 'ABSI', 'FRSH', 'PATH', 'RXST', 'RSKD', 'HNST', 'CEG', 'BLFY', 'SNCY', 'STVN', 'CRDO', 'OTLY', 'NEP', 'LUMN', 'TFIN', 'TLIS', 'XPRO', 'SQSP', 'DCFC', 'CMPS', 'SGFY', 'BRLT', 'EDR', 'BASE', 'PRO', 'ZIP', 'MLNK', 'COUR', 'ZY', 'ALHC', 'BHG', 'MCG', 'ALKT', 'TTEK', 'FYBR', 'PSN', 'HEPS', 'QS', 'PFHC', 'FLYW', 'ADN', 'IGIC)', 'AGL)', 'SKLZ', 'DOCS', 'MPLN', 'EGHT', 'EDU', 'NPCE', 'ACAD', 'VTOL', 'NTRA', 'VTRS', 'RPID', 'COOK', 'LL', 'AKYA)', 'SGFY)', 'THRN', 'AXAHY', 'PECO', 'VTEX', 'TMX', 'BNL', 'WDH', 'TPL', 'SWIM)', 'TCRT', 'TOST', 'BROS', 'ACVA', 'NYXH', 'KW', 'ESTA', 'GLS', 'AMEH', 'DH', 'AKA', 'ARE', 'AEVA', 'MF', 'LC', 'TIMB', 'FSR', 'BLCO', 'DDI', 'CPG', 'AGL', 'FAST', 'ALLO', 'STE', 'KRT)', 'DE', 'MP', 'RAIN)', 'ADV)', 'BAND', 'TSP', 'CRGY', 'AFMD', 'BBL', 'MOLN', 'NRGV', 'POLY', 'CIB)']\n"
          ]
        }
      ],
      "source": [
        "def clean_ticker(ticker_str):\n",
        "  t=str(ticker_str).upper().strip()\n",
        "  if \":\" in t:    #if ticker is NASDAQ:AAPL\n",
        "    t=t.split(\":\")[1].strip()\n",
        "  t=t.replace(\"$\",\"\")\n",
        "  return t\n",
        "df[\"ticker_clean\"]=df['ticker'].apply(clean_ticker)\n",
        "print(f\"unique tickers: {df[\"ticker_clean\"].unique().tolist()}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 15,
      "metadata": {
        "id": "Fw9ZdtZDgjGQ",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "f366efce-ce4b-4395-a801-9396dfad5d62"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Number of rows in 'ticker_clean' still containing '$': 0\n"
          ]
        }
      ],
      "source": [
        "# This uses 'regex=False' to search for the literal '$' character\n",
        "print(f\"Number of rows in 'ticker_clean' still containing '$': {df['ticker_clean'].str.contains('$', regex=False).sum()}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 16,
      "metadata": {
        "id": "6pSH-mDVLZ69",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "87586a98-51db-4965-d2ac-0ccc41da289e"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Fetching data\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "ERROR:yfinance:$WDR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MYOV: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$COUP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$WBA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$FL: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BCOV: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AIMC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SGEN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AAWW: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CARA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SIVB: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CTIC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$XLNX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AYX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$STNG): possibly delisted; no timezone found\n",
            "ERROR:yfinance:$WWE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CHS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ATC): possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CTK: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ZUO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$LHCG: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SIX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ICPT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VLDR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ITCB: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GMLP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TIG: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NCR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SQ: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ONCT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BGFV: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NSTG: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CPE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DADA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CDMO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TCS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$EBIX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ATVI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TFFP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$APTX: possibly delisted; no price data found  (1d 2019-03-12 -> 2025-12-15)\n",
            "ERROR:yfinance:$OLO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DISC.A: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PARA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CCXI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ATTO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$LHDX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GLYC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$IGT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PRFT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RETA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RDS.A: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VRS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$UFS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$IEA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BEST: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TPX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$FCAU: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$IDSY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DFS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ALTR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$X: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RTN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$WKME: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$EQC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BKCC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$YY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SFT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BKI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SJW: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AZPN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$REGI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HZNP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VOXX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CPSI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$LPI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VVNT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GPS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AFYA): possibly delisted; no timezone found\n",
            "ERROR:yfinance:$STON: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ABTX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BIG: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AINV: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PGTI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VVI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HMSY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MIME: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NTCO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$FTCH: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CIR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BGCP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NEWR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$KSU: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TDCX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TWNK: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BSIG: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TPRE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ARCE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MFGP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MNTV: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VRAY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SJI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VNE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CMRE): possibly delisted; no timezone found\n",
            "ERROR:yfinance:$OCSI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GPL: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GCP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HEAR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NLS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$WETF: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ESTA): possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SMTS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VSTO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GHL: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DRNA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RAD: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$FUV: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MYOK: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CEIX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CNSL: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DSKE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CVET: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$EPZM: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$XM: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$UROV: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CDK: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TWTR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SOVO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AZUL: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ACCD: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$EVBG: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AQUA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NVTA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GBT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$FARO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DCT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ERF: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GLT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CEQP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PFC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$FBHS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$EURN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ETM: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ONDK: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HRC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CRY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RTLR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DNAY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$OSTK: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HNGR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SUMO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BIGC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PRVB: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RADA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GWGH): possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VGR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DCPH: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RCII: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HIBB: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$JWN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$JE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TGH: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AJX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GOL: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CNHI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BPMC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$FRC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NATI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$LBRD.A: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$JOAN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NYMT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$KAMN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MDP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PRTY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VMW: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SHYF: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GPP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$OYST: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ZNGA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AUY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ABMD: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MTOR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$LGF-A: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AGS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NYCB: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ZI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$EVRI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MMP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ZEN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$USM: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SCU: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$REPH: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ABB: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ITCI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TRQ: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$IMGN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PXD: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PRTK: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NFH: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MRLN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SKX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AVYA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RDUS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ECHO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$OFC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BERY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TUP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SCWX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SLCA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BRG: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ENLC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GMDA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$INFN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ARNA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SDC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SRT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ORCC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AZEK: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TSU: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VIAO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PSB: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RRD: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MDC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HTA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HEES: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AMSWA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ANSS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MRO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AXNX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CDAY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ETRN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SPPI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TRMR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MXIM: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ISEE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RAAS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BDSI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AVID: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SMAR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RCM: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TMST: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SCHN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GMS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ENV: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SBT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BECN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SWAV: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ZLND.Y: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$OTIC: possibly delisted; no price data found  (1d 2019-03-12 -> 2025-12-15)\n",
            "ERROR:yfinance:$SPTN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HFC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$INT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CPLG: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VIAB: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$EXTN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AXE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$LTRPA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$STOR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$APTV): possibly delisted; no timezone found\n",
            "ERROR:yfinance:$QRTEA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ZEAL: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$COOP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HHC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ATAX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RUTH: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SAGE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$RDFN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HUD: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AERI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$OB: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$JBT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CMRX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$EXPR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ALIM: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$KIRK: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SPLK: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NLTX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CLR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TERP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DMS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$WIRE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$NXGN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CBD: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$STAR: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SGH: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CHX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SWI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PING: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$LSI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CPLP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CHMA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$JW.A: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$OPI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ITI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$JNCE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CCMP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$TGP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PWFL: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$FOCS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$IVC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HEP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ARD: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BRFS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CBAY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DISH: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AMED: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HMLP: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$GPX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CHUY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CPL: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AMRS: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DSSI: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HTLF: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BIO.B: possibly delisted; no price data found  (1d 2019-03-12 -> 2025-12-15)\n",
            "ERROR:yfinance:$ARNC: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ATCO: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ECOL: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$MCFE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$ATSG: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PHX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HZN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$OCN: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HCRS.Q: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$HMST: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$DISCA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VIE: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$VTRU: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$AGFY: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$PWFL): possibly delisted; no timezone found\n",
            "ERROR:yfinance:$JT: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$CFX: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$POSH: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$OPB: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$UMPQ: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$SWCH: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$IBA: possibly delisted; no timezone found\n",
            "ERROR:yfinance:$BLI: possibly delisted; no timezone found\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Error on: SAIC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LESL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: XEL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EQT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SUPV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: XNET Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TUSK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: YSG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FNB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AGO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ATR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AMH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PTVE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SRE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ROAD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ADMS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EMN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LTC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LNTH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ARGO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CMD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: COR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IFF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NWG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RMBS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GLOP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SNDR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CNXN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DYNC) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RAMP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SMTC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: REDU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MPW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AXS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NARI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GPK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AAIC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MEG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WAB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OPCH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CIEN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ROP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TBPH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MYTE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RXT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BNS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MAS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CWCO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HASI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GAMB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EQH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CSLT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FTNT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RELX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BYD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TWI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CSL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MTRX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PRDO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SHSP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ACC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MPAA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NUVA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: YELL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KGC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KOF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TOL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RPRX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LTHM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CTXS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CSII Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MXL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LNT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SFL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ASGN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IVZ Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CGC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CRSR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FIS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ACRX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FLY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WMG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CNNE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KFY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AMKR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PKG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TREE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MGIC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HYFM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WUBA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UPST Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CXP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CPRT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MSP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GMAB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GSM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BANR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GTE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WCC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: COWN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GDDY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CIO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DEI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FISV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NGL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GTES Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ANGO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VALN) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ADT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WBT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PLYA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CATY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CNF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SOHU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DEA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CEL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DAKT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PNNT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PDFS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: USFD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TGS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ICAD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SPSC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DRE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RTL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UCL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CNK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GGG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HEI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KELYA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ATRA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WRBY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MWA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MSGM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TKC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BVN) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TTPH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VKTX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SLQT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AMK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GAN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EDIT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CPF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: POWI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SLF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FPH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ATNX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FELE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ATHX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FOE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MYE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PLTK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DNOW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AVIR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CWST Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GRBK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AWR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ARLO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CMI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SWIM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NVST Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ECPG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GORO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ALEX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IDN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FRT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AMCR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DNUT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KUKE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ICFI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FLWS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SEAS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CTSO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DIN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: YMM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LHX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SUPN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KRA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RVNC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MNDY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NVRO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RLI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SMLP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CDE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: APD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AWH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WCN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DOOO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WRK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BBCP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: STC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SGHT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FSP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SNPS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MERC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: INSM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: XPOF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DOLE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HLI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ACTG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KLIC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SAR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ROOT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OSH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ORI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CLW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CVAC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ANH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UGP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RDNT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TSCO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NTAP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PCAR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BRX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AX.DL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: INFY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AVXL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LPRO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IHRT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SWIR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: XPER Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LPX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BSY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SAMG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PDCO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GLUU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CULP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RWT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FWRD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: YRD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: POST Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FTDR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ARCH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NWL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GTHX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HWC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WBK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CERT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: INSW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BCC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FMS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CWK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RGNX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ONEW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AEGN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BBU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FBP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CNTY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UNVR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SIEN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MUSA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FBK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TCMD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: M Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VIOT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DZSI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CHRW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IIIN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BRKL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VAPO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MOR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WMB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LMNR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ALX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MAA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: QTNT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DXPE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BGS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RNST Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WSR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HAFC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ATNI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AEYE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AUB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SAIA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CCOI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VRTS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: R Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SPT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MATW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AMCX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TRTN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: INSP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VICR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EXC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SXI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HCM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: QNST Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NSP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MGI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DIOD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VRRM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BBD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EPRT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CVLT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ZYXI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BXS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CPA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MKSI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SGMO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SWX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GIB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WWD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WERN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CMCO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UGI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DGII Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IAA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CPRI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SHAK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BCEI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KIM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: JHG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PYCR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RPD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PFS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SITE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IRWD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WIT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PNTG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AVA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NVMI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TRHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SHOO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PEB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GWB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GOLF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: REG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MTLS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ASB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PPC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AGRX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ALG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AGRO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ACHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OMF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OMP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MFC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: STXB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FRGI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SPR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DENN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: USAC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VLY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UVE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CHMI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DESP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ITUB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ANIK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CSWI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PPD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AEP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SMPL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UCBI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CONE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WLTW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GPC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ALBO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UIHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: APPF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BKH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: INGN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SFNC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IRTC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PLMR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LIVN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LANC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VAC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NFG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AKR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GSBC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IIIV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EAR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OSIS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FTAI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FIX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ABCB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RSG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: POR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FLS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CAL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FDUS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TNC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VBTX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AGR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EQR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: STRA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FULT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ASPS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NEXA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FANH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RESN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OFG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CUZ Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PUMP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PBH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AMN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RNR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TTGT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CIVB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RHI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MMSI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FLT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UFCS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DTE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KREF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HCI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: THS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SHLX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ASND Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WLL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GWRE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BAH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: COLL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: YUMC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MHK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HVT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AMPH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HIG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SUM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BANC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: JBHT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GIL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FORM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CHNG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AAT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BPOP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PSA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VNDA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IART Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ATRC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AZRE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CNQ Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: THG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ARW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: APH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FCF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: INVH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TDY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ITRI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RPT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CCR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HES Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MMYT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TTMI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SHO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RBC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AVNS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BSM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LPG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: API Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CVCO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OGS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ONB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CSPR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PTCT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CVI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EVOP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PSXP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FMC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UMBF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CHT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TMHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FUL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EVRG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ZIXI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KURA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ITT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PEAK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ENTA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FLO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HSII Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CLLS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AME Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AGI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PRA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MEOH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GPMT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TALO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WPX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CNCE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BOKF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CDXC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HFWA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: XLRN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EFSC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BOOT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SLN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CALX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SKY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GEN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ELP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ROCC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SASR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AAN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ZIM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HPP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ACA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TRS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AIZ Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MET Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TAC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ODP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CRL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ACRE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ARES Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MLM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EVA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TSLX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MTG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SRC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NMRK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NBEV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CTMX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AVY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: J Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TLS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ROIC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SANM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HCCI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SWN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MOG.A Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ROLL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: STXS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LDOS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CVGI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: XNCR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IBP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WOOF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AFRM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RMAX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CCJ Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SEIC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ANIP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NXRT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EPAY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NGMS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CDW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FTS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CFR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OSUR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AAON Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NUS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: THRY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BLFS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PROG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IDEX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EIX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LNDC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PAHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WHR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OFIX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WTRG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CNMD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TEN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AEE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SSNC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OSCR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MGP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OXLC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CTRE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IPAR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LEG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RGLD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: THC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IBTX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FLOW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PGEN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NBHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SPXC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EPC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PKI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ESNT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: REXR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LYV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LIVX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PCTY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SYNA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AVTR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: REZI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PEGA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NHI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EFC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SAND Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BLKB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TCPC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CBU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MMI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RES Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NLSN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PNFP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NICE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MCS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LYG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ASPU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DUO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HMN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FHN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OSK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UHS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HOUS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ARI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: STL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HMTV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PHI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ADTN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ZBH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LCI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WSFS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IMMR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: B Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EXPO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SID Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NMR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OMAB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SYX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SAH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PRMW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TVTY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NEPT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ATGE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IRDM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AEG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HWM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VCTR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BLD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SYNH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CAC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CCS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LYB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UVV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KKR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SBCF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HSC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PINC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CDEV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MNRL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AEL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DBD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EGP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FHI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PDCE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VCRA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ABC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MNRO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BSAC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AVLR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NVEC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KDP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NBTB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EFX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MANT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UDR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AXU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CEPU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CPK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FMX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FRBA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BKD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ATEC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NTUS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SGRY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OLN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SAN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IDA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BHLB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VIVO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ADMA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ALC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: APP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TYL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FICO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FND Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TNL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AMSF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ES Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EVR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UMC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OUT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GNE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SRCL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HAYN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SAVE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CLH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DSPG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WRE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EMR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ROL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ADUS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LNW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MESO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: XEC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CVE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: JNPR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ASX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VRTV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ETR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: APTV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BPMP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NEOG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DNB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CTLT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SCSC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: INDB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IAG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AIRC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RGR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MDRX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ETN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SSL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DRQ Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PFG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PTR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PZZA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EGIO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VYNE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ADBE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HSKA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CERN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PJT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BRO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FRG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VMC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IMAB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HMPT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NSIT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DCP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HLF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GHLD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: UNIT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GATO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OCDX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: APLE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LBRDK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NWS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RGA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BF.B Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DRVN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IMV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TIXT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: QMCO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DEN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TSHA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AES Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MATV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OESX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CIG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KNBE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SKYT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IOVA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AKYA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: S Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NOTE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PAY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ADV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: O Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PUBM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KLTR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AXON Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TGI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NNOX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VALN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BVS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EBET Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PACK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DIBS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OMIC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PCOR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LZ Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FUBO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PAX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CXM Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: XMTR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ESMT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TUYA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ERIC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MASS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SRAD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WEBR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TPG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ZIMV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CAR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DLO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EWCZ Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NVAX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PRVA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ABOS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PEIX) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BFLY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ALTO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MXCT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TLIS) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RDY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BLNK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ZETA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GSX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PLTK) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FORG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HLMN) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DUOL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EBC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FSBC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WKME) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AFCG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KARO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AGTI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VTOL) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AVAH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PROF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CSAN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: APR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CENTA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DASH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SHLS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GLBE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: INTA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MCW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IAS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AOMR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PRG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ABSI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FRSH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PATH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RXST Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RSKD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HNST Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CEG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BLFY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SNCY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: STVN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CRDO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: OTLY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NEP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LUMN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TFIN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TLIS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: XPRO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SQSP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DCFC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CMPS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SGFY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BRLT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EDR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BASE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PRO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ZIP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MLNK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: COUR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ZY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ALHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BHG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MCG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ALKT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TTEK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FYBR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PSN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: HEPS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: QS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PFHC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FLYW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ADN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: IGIC) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AGL) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SKLZ Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DOCS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MPLN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EGHT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: EDU Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NPCE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ACAD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VTOL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NTRA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VTRS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RPID Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: COOK Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AKYA) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SGFY) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: THRN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AXAHY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: PECO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: VTEX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TMX Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BNL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: WDH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TPL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: SWIM) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TCRT Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TOST Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BROS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ACVA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NYXH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KW Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ESTA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: GLS Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AMEH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DH Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AKA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ARE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AEVA Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MF Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: LC Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TIMB Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FSR Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BLCO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DDI Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CPG Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AGL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: FAST Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ALLO Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: STE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: KRT) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: DE Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: RAIN) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: ADV) Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BAND Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: TSP Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CRGY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: AFMD Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: BBL Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: MOLN Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: NRGV Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: POLY Error:Too Many Requests. Rate limited. Try after a while.\n",
            "Error on: CIB) Error:Too Many Requests. Rate limited. Try after a while.\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript           Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel... 2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta... 2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc... 2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon... 2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel... 2019-08-07 08:30:00   \n",
              "\n",
              "   Date_only                                         Clean_Text  word_count  \\\n",
              "0 2020-08-27  At this time, I would like to turn the confere...        5623   \n",
              "1 2020-07-30  Brian G. Harris -- Senior Vice President and C...        4755   \n",
              "2 2019-10-23  Tina Correia -- Vice President, Investor Relat...        8917   \n",
              "3 2019-11-06  Joining us today are BBSIs President and CEO, ...        8286   \n",
              "4 2019-08-07  I would now like to turn the conference over t...        4611   \n",
              "\n",
              "  ticker_clean  Price_change  \n",
              "0         BILI      0.035078  \n",
              "1          GFF      0.116154  \n",
              "2         LRCX      0.142022  \n",
              "3         BBSI      0.029891  \n",
              "4         CSTE      0.249623  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-92a087f8-ab2f-4f8b-814a-42b69b80f0d1\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>Clean_Text</th>\n",
              "      <th>word_count</th>\n",
              "      <th>ticker_clean</th>\n",
              "      <th>Price_change</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>At this time, I would like to turn the confere...</td>\n",
              "      <td>5623</td>\n",
              "      <td>BILI</td>\n",
              "      <td>0.035078</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>Brian G. Harris -- Senior Vice President and C...</td>\n",
              "      <td>4755</td>\n",
              "      <td>GFF</td>\n",
              "      <td>0.116154</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>Tina Correia -- Vice President, Investor Relat...</td>\n",
              "      <td>8917</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>0.142022</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>Joining us today are BBSIs President and CEO, ...</td>\n",
              "      <td>8286</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>0.029891</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>I would now like to turn the conference over t...</td>\n",
              "      <td>4611</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>0.249623</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-92a087f8-ab2f-4f8b-814a-42b69b80f0d1')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-92a087f8-ab2f-4f8b-814a-42b69b80f0d1 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-92a087f8-ab2f-4f8b-814a-42b69b80f0d1');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-07fd6d82-476c-41eb-aa60-bbadbc4ea5e2\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-07fd6d82-476c-41eb-aa60-bbadbc4ea5e2')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-07fd6d82-476c-41eb-aa60-bbadbc4ea5e2 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 18375,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5681,\n        \"samples\": [\n          \"May 10, 2022, 8:30 a.m. ET\",\n          \"Feb 16, 2021, 8:00 a.m. ET\",\n          \"Jun 01, 2022, 4:30 p.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2872,\n        \"samples\": [\n          \"NASDAQ: TTSH\",\n          \"NYSE: WDH\",\n          \"NASDAQ: HOPE\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q3\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2869,\n        \"samples\": [\n          \"CRWD\",\n          \"AME\",\n          \"WRLD\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17220,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nHello, and welcome to today's Expro Q2 2022 earnings presentation. My name is Elliot, and I will be coordinating your call today. [Operator instructions] I would now like to hand over to Karen David-Green. The floor is yours.\\nPlease go ahead.\\nKaren David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations\\nWelcome everyone, to Expro's second quarter 2022 conference call. I'm joined today by Mike Jardon, CEO; and Quinn Fanning, CFO. First, Mike and Quinn will share their prepared remarks, and then we will open it up for questions. We have an accompanying presentation on our second quarter results that is posted on the EXPRO website, expro.com under the investors section.\\nIn addition, the second quarter financials are downloadable on the Expro website under the Investors section. I'd like to remind everyone that some of today's comments may refer to or contain forward-looking statements. Such remarks are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such statements speak only as of today's date, and the company assumes no responsibility to update any forward-looking statements as of any future date.\\nThe company has included in its SEC filings, cautionary language identifying important factors that could cause actual results to be materially different from those set forth in any forward-looking statements. A more complete discussion of these risks is included in the company's SEC filings, which can be accessed on the SEC website or on our website at expro.com. Please note that any non-GAAP financial measures discussed during this call are defined and reconciled to the most directly comparable GAAP financial measure in our second quarter 2022 earnings release, which can be found on our website. With that, I'd like to turn the call over to Mike. \\nMike Jardon -- Chief Executive Officer\\nThank you, Karen. Good morning and good afternoon, everyone. I'm pleased to share with you that Expro delivered robust operational performance and financial results that exceeded the guidance we provided for the just completed second quarter. We are experiencing increase customer activity levels across all segments of our business, bolstered by a backdrop of strengthening industry fundamentals.\\nWe believe this positive momentum will not only continue, but will also accelerate going into 2023 and beyond. Expro is poised to capitalize on an expected increase in customer spending and activity. Today, Expro has a scope and financial profile required to compete and win in what we believe is the best outlook for energy services in at least a decade. Our results in the second quarter and our market outlook underscore the benefits of Expro's balanced portfolio of services and solutions with leading capabilities and a culture built around safety, service quality, organizational efficiency and risk management.\\nIn addition, we believe our through-cycle resilience is a significant advantage and competitive differentiator for Expro. Our current portfolio of services and solutions is paired with a global operating footprint with established positions in key growth markets and the combination provides Expro with good leverage to improving industry fundamentals and in particular, to the rebound that is beginning to take place in the international and offshore markets. We have never been better positioned to capture cyclical recovery upside. We also continue to have a best-in-class innovation platform and technology portfolio that enables us to support our customers' efficiency and emissions-related goals, grow market share and capitalize on longer-term industry trends.\\nFinally, our strong balance sheet and merger-related synergies provide us with significant financial, operational and strategic flexibility that will allow us to accelerate growth and create long-term stakeholder value. On today's call, I'll touch on three main topics. First, I'll walk you through our second quarter performance. Second, I'll give an update on our integration process.\\nAnd finally, I'll provide some perspective on trends we are seeing in the broader industry environment. For the second quarter, we delivered revenue of $314 million and an adjusted EBITDA of $51 million. Second quarter revenue increased 12% sequentially and on a Pro Forma basis, 10% year over year. Higher revenue during the quarter was driven by increased activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific regions.\\nAdjusted EBITDA increased 39% sequentially and on a Pro Forma basis, 33% year over year. Adjusted EBITDA was primarily driven by a more favorable activity mix during the second quarter and faster-than-anticipated realization of merger-related synergies. Well Construction revenue was up 9% quarter over quarter and well management, which includes our well flow management, subsea well access and well intervention integrity businesses was up 13% quarter over quarter. Second quarter results exceeded the prior guidance, primarily as a result of increased well flow management and well construction revenue within North and Latin America.\\nOur team continues to both capitalize on improving industry fundamentals and demonstrate the value of Expro's broad suite of cost-effective, innovative solutions to win new business and expand relationships with existing customers. During the quarter, we continued to secure contracts because of our exceptional service quality and technical delivery. We also continued the introduction of new technologies with both CoilHose and Octopoda, achieving market adoption at pace. The current commodity price environment puts a premium on maximizing production from existing well stock.\\nSo there is a strong customer interest in well intervention integrity solutions such as CoilHose and Octopoda. The significant under investment in energy supply over the last decade, coupled with growing demand, is also resulting in FID approvals. Importantly, for our company, nearly 60% of the new customer commitments are expected to be offshore. We achieved contract wins and extensions totaling approximately $300 million, which demonstrates the breadth and depth of our customer relationships and attraction that our solutions are gaining in the market.\\nOn a regional basis, in North and Latin America, our Well Construction team continues to demonstrate the position as the premier provider of casing and tubular running services with the award of contracts and successful operations delivered across the region. The team successfully completed a first casing running to a project in Brazil and carried out eight simultaneous TRS deepwater completions in the Gulf of Mexico, where activity continues to pick up. We also deployed our industry-leading 22-inch brotpackers in Mexico for the first time and have seen growing demand for this well integrity technology as operators across the region seek to protect their assets during storm season. This technology allows for quick and rely the well suspension when operators need it most.\\nWe want to influence contract for a major operator in Brazil. And in Alaska, our team was awarded and performed a well test for a strategically important new customer, further growing our presence in this region. Expro in MENA achieved contractor of the month from an international operator, demonstrating Expro's continued focus on delivering best-in-class safety, quality and customer service. In Europe and Sub-Saharan Africa, we saw good progress in securing new business in the second quarter, including the retention of the largest well flow management contract in the Norwegian continental shelf for an initial four-year term, highlighting the strength and depth of our relationship with this international operator.\\nA significant portion of this contract is directly linked to production optimization and enhancement as well as a demonstrable commitment to low carbon plan. The breadth of our portfolio, including market-leading technologies acquired in our July 2019 acquisition of Quality Intervention directly assisted us in expanding a core well intervention contract with a major international operator in the U.K. In addition, our service quality and portfolio of capabilities helped us secure an expanded contract to meet client needs for a nine-well plug and abandonment campaign in the U.K. Continental Shelf, where we also added well test and well intervention to an existing large board subsea services contract.\\nAs I noted earlier, CoilHose and Octopoda are gaining traction in the market to support clients' intervention and integrity needs. Octopoda is a truly unique service offering, which for the first time in our industry, allows direct access to well annualized in which we can ensure well integrity and production assurance. Octopoda was recently deployed in the Congo, the first deployment of this technology in Sub-Saharan Africa, and it continues to generate customer interest with its unique ability to investigate and remediate sustained casing pressure and other well annulus problems. Additionally, our CoilHose Light Well Circulation system is an innovative development, providing a lower cost more efficient alternative to traditional coiled tubing systems.\\nThis broadening of our portfolio and our depth of experience, combined with the ability to quickly mobilize assets and personnel to meet client requirements helped us secure a U.K. contract for well testing and exploration and appraisal services in support of a new offshore drilling campaign. Expro's superior quality and service performance as strong client partnerships led to the securing of multiple contract wins, including for our subsea team in the Ivory Coast and in Turkey, where we won well testing and CoilHose intervention work for a nine-well project on offshore gas storage project. In the second quarter, we also introduced Drill Stem testing into Angola, further broadening our comprehensive portfolio in this country and positioning us to take advantage of the increasing activity in deepwater operations in Angola.\\nWe have successfully started operations in Cabinda for a major operator, which will be our first deployment of hammering services as part of an Angolan Well Construction Service package. In May, we were also recognized as the safest service provider in Mozambique. Based on our recent performance, we are in discussions with the client regarding further expansion of our services, including the introduction of new technologies. In Chad, our work with the client is core to ensuring that our operations are conducted in an environmentally responsible way.\\nOur expertise and technologies are focused on having no environmental impact with testing and analysis carried out to ensure the appropriate purity of the regional freshwater system, underlining our status as a leading provider of on-site chemistry services with a strong environmental focus. In Norway, we completed our first operational campaign with our iTong Well Construction Technology, which provides a step change in safety and well construction operations. Operational performance exceeded client expectations, delivering significant rig efficiency improvements and cost savings to the customer overall. In the Middle East and North Africa, our Well Construction team has expanded into new territory to secure their first TRS contract in Algeria, which is planned to commence later this month.\\nThis opportunity reflects one of the many revenue synergies created by our October merger. We leverage expert relationships and well flow management to secure this new TRS award. In addition, the regional team was awarded two carbon boom contracts with Middle East drilling contractors, reflecting our market-leading capabilities and reputation in the market. In Egypt, our service offering and ability to deliver contributed to Expro being awarded significant well test contracts.\\nIn the Asia Pacific region, our well construction team in Brunei secured a major 5-year contract for TRS. Our outstanding track record of reliable performance in HSC and service quality were strong criteria for the contract award. In Thailand, the team secured additional TRS work covering 200 wells and in Malaysia and in offshore China, we were awarded three-year TRS contract extensions spanning development and exploration wells. Our subsea team's technical capability played a key part in securing a contract with a major international operator in Malaysia for the provision of our new vessel deployed Light Well Intervention package, with the team also securing significant additional work in Australia.\\nLike CoilHose and Octopoda, Expro's LWI capabilities are the result of investments we have made over the last several years, which should allow the company to offer differentiated production optimization solutions and thereby grow our top line faster than the overall market, while also improving profitability. Expro is strategically committed to continuing to invest in transforming our business portfolio and reducing greenhouse gas emissions. In April, we published our inaugural, environmental, social and governance review with a stated aim of achieving net 0 by 2050 with a 50% reduction in carbon intensity by 2030. As the energy industry embraces transition and the need to make real and visible headway toward a lower carbon world, we appreciate the key enablers to change will be those who can truly differentiate themselves as solutions providers.\\nAs recognized global well experts and a trusted partner, we believe Expro is well-positioned to play an important role in enabling our clients to achieve their carbon reduction goals in support of the energy transition. Expro remains committed to allocating roughly 50% of our research and development budget to carbon reduction initiatives. In doing so, we are developing and advancing solutions that will play a critical role in enabling our customers to achieve their own emission reduction goals while also allowing experts to achieve its goals. Expro's well expertise and range of well intervention, well integrity and wells measurement technologies and skills help operators cost-effectively develop oil and gas resources while minimizing both emissions and the required operating footprint.\\nAs our industry speaks to address tomorrow's challenges, we believe many of these technologies and skills are transferable. As a good example of adopting technologies to achieve more sustainable energy solutions, Expros supported geothermal well service projects since 1986. Most notably, in the second quarter, we were awarded our first integrated services geothermal contract to support a high-profile geothermal plant in Germany. The second topic I'd like to cover is to provide an update on our integration efforts.\\nDuring the quarter, we continued to make progress in bringing the legacy businesses together to capture the full potential of our combined platform. I am pleased to report that 9 months into our integration, we have identified an action more than 100% of the $55 million in annualized cost savings that we established with our target within the first 12 months following the closing of the merger. This comes a full quarter earlier than we had initially anticipated. As outlined previously, we are targeting cost and revenue synergies between $80 million to $100 million within 24 to 36 months post-merger.\\nWe remain confident that we will achieve $70 million in projected cost synergies during this time frame, if not earlier. Cost savings are primarily driven by the rationalization of support costs, consolidation of facilities and supply chain savings. In the second quarter, we consolidated additional facilities, including locations in Baku, either by John, St. John's, Canada; Lumpur, Malaysia; Mumbai, India; Corpus Christi and Midland, Texas.\\nWhile revenue synergies are more difficult to demonstrate, my sense is that our previous estimate of an incremental $10 million to $30 million in EBITDA for revenue synergies through our expanded customer relationships and operating footprint, increased time on rig and greater exposure to the full life of the field will likely prove to be conservative. I'd like to sincerely thank the entire expert team for their hard work and numerous contributions toward helping us realize our integration goals ahead of schedule. Without a doubt, we have a winning team that has proven the building to deliver on our commitments. Before I turn the call over to Quinn, I want to provide some perspective on trends we are observing in the market.\\nThe positive signs of a recovery we saw in Q1 continued to build, underpinned by a favorable supply demand dynamic. As I noted earlier, this is largely a result of limited upstream investment in recent years and a need for additional capacity to meet projected demand growth. With the more recent heightened focus on energy security, diversification of supply and the need to replace at least a portion of Russian oil and gas supply is expected to fully magnify what was already set up to be a favorable multi-year macro backdrop for OFS activity. Longer term, we believe the service sector will need to play an important role in facilitating the energy transition.\\nSo despite ongoing volatility in commodity prices, the fundamental backdrop for the energy services sector is quite constructive. In particular, after a strong recovery in the U.S. onshore market, we are seeing increasing demand for our services and solutions with international and offshore activity expected to accelerate through the second half of 2022 and into 2023 as operators look to increase production from existing assets and develop new fields. Notwithstanding near-term concerns of an economic slowdown, there seems to be a consensus that energy demand will trend back toward, if not through 100 million barrels of oil equivalent per day in 2023.\\nWe expect that increasing demand for energy services and capacity constraints in key service offerings, including high-end well construction equipment and subsea test trees should provide scope for improvement in net pricing beginning in late 2022 into early 2023. In Expro's view, expected growth will be broad-based geographically, span all phases of oil and gas development and include all operating environments. Geographically, we see strong potential in North and Latin America, the Middle East, North Africa, Sub-Saharan Africa, as well as Asia. And while many of our customers continue to focus on brownfield enhancement programs to maximize previous investments, we are also starting to see growth in exploration and development activity driven primarily by North and South America, with further activity expected in Norway, India and Sub-Saharan Africa.\\nThe brownfield focus will support steady growth in our well Intervention Integrity business as well as elements of our well flow management business, collectively, which represent about 35% of our business. The remaining circa 65% of our business is generally levered to drilling, well construction and well completions activity, which we believe is points for strong growth across several geographies and within which we generally capture very good faster on incremental revenue. Overall, the outlook for the remainder of '22 and into 2023 remains positive with sustained increases in E&P expenditures. After rather dramatic recovery in the North America onshore market, customer dialogue and tendering activity indicates to us that the outlook for offshore activity is strengthening.\\nThis should support sustained growth for Expro given our leading and differentiated portfolio capabilities and subsea well access services, complex well construction services and production optimization. This is particularly important as approximately 70% of our revenue today is generated from offshore activity. Before I close, I'm pleased to share that during the quarter, our board approved a new stock repurchase program under which the company is authorized to acquire up to $50 million of its outstanding common stock up to the November 2023 time frame. We view the repurchase of our shares as an attractive and prudent use of our capital that it is in the best interest of our shareholders.\\nWith a debt-free balance sheet, ample available liquidity and strong construction of an industry recovery, buybacks allow us to opportunistically increase shareholder value while maintaining sufficient cash resources to fund our business needs. In the second quarter, we repurchased $13 million in export stock, representing approximately 1% of our shares outstanding. From an operational standpoint, Expro is well positioned in the markets that we expect will continue to benefit from strengthening industry fundamentals. In particular, Expro has significant leverage to strengthen the international and offshore markets where experience, expertise and service quality can be in Expro's case are positive points of differentiation.\\nExecution is a traditional strength of Expro and when we plan to continue to deliver on both for our customers and our shareholders. With that, I will hand the call over to Quinn to discuss our financial results.\\nQuinn Fanning -- Chief Financial Officer\\nThank you, Mike. Good morning and good afternoon to everyone on the call. As Mike noted, I will cover the results for the quarter ended June 30th, 2022, and will primarily highlight our sequential performance compared to the quarter ended March 31st , 2022. To recap, we reported revenue of $314 million for the June quarter, which was up sequentially $34 million or approximately 12% relative to Q1 2022.\\nThe sequential increase in revenue was driven by higher activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific segments, partially offset by lower activities in the Middle East and North Africa segment. Adjusted EBITDA for Q2 2022 was approximately $51 million, representing a sequential increase of approximately $14 million or 39% relative to Q1 2022. Adjusted EBITDA margin in Q2 was 16% as compared to 13% in Q1. The sequential increase in revenue and adjusted EBITDA was driven by strong results for well flow management and well construction in North and Latin America.\\nAs highlighted in our press release, adjusted net income for the second quarter of 2022 was $0.02 per diluted share, compared to adjusted net income for the first quarter of 2022 of $0.01 per diluted share. As noted in our press release, adjusted net income for Q2 includes foreign exchange losses of $0.05 per diluted share as compared to foreign exchange gains of $0.03 per diluted share in Q1. Q2 contribution margin of 38% was up approximately one percentage point sequentially from Q1 2022, reflecting improved fall-through on higher revenue as a result of a more favorable activity mix. Q2 support costs of $70 million totaled 22% of group revenue and were down approximately $1 million sequentially or approximately 3 percentage points relate Q1 2022 and were down $8 million or approximately 9 percentage points relative to the combined support costs of Expro Frank's in Q4 2020, which was the last full quarter prior to the announcement of the merger.\\nThis represents approximately $30 million of annualized support cost savings achieved through the second quarter of 2022. In the near term, we expect to continue to manage total support costs to 22% of group revenue. With modest net pricing gains and/or incremental cost synergies, we believe we can manage overall support costs to about 20% of revenue. Total liquidity at quarter end was approximately $309 million.\\nCash and cash equivalents, including restricted cash, was $179 million as of June 30th. Total liquidity also includes $130 million that is available to the company for drawdowns as loans under our $200 million revolving credit facility. The balance of the facility is available for bonds and guarantees. Expro had no interest-bearing debt at quarter end Q2 2022, and the company has no interest-bearing debt today.\\nDuring the quarter ended June 30th, cash provided by operating activities was $2 million as compared to cash used in operating activities of $14 million in Q1. Q2 adjusted operating cash flow, reflecting cash used in operations before cash paid for interest, severance and other expenses and merger integration expenses, was positive $10 million compared to negative $1 million in Q1. Capital expenditures totaled $21 million in the second quarter compared to $11 million during the first quarter. For the second half of 2022, the company is planning for capital expenditures in the range of approximately $60 million to $70 million, implying total capex for 2022 of $90 million to $100 million or approximately 8% of expected revenue.\\nWe also continue to expect to be free cash flow generative for 2022, but as noted on our last earnings conference call, we expect that adjusted cash flow from operations and free cash flow will be heavily weighted to the second half of the year. Consistent with comments from several of our public peers, Expro's investment in working capital was up materially in the first half of 2022, with higher receivables reflecting higher activity levels and higher inventory reflecting both an expectation of continued momentum in the business and the procurement of long lead items, including critical spares. Consistent with historic patterns, we expect a reversal of the H1 build in working capital and a significant improvement in cash generation in H2 2022. As Mike previously discussed, under our recently announced stock repurchase program, during the second quarter, we opportunistically repurchased 1.1 million shares or approximately 1% of our shares outstanding for a total cost of $13 million.\\nThis program is a reflection of the long-term confidence we have in our business, which we believe is not reflected in the current market valuation. In due course, we will more formally articulate Expro's capital allocation priorities. For now, we expect that the small buyback will be completed in Q2 and for that matter, any additional buybacks will be funded by free cash flow. Now, moving into the details for reporting segment.\\nNorth and Latin America or NLA, revenue for the second quarter of 2022 was $130 million, a sequential increase of $26 million quarter over quarter. The increase was primarily due to higher revenues across all of our product lines during the current quarter with a significant increase in well flow management revenue in Mexico and higher well construction revenue in the U.S. and Guyana driven by higher customer activity levels during the just completed quarter. NLA segment EBITDA for the three months ended June 30th, 2022, was $39 million or approximately 30% of segment revenue.\\nIt was up sequentially by $17 million quarter over quarter. For Q1 2022, NLA segment EBITDA was 21% of segment revenue. The increase was attributable to higher activity and a more favorable product mix during the three months ended June 30th. For the Europe and Sub-Saharan Africa or ESA segment, revenue in Q2 was $90 million, which was up $8 million or approximately 10% quarter over quarter.\\nThe sequential increase was primarily driven by higher wealth flow management revenue in Angola and in the Congo and higher well construction revenue in the United Kingdom due to increased customer activities. The increase in revenues was partially offset by lower well intervention integrity revenue in Norway and Western Europe. ESA segment EBITDA for the second quarter was $15 million or approximately 16% of segment revenue, a sequential increase of $3 million quarter over quarter. The increase was primarily attributable to higher activity levels and a more favorable activity mix during the June quarter.\\nFor the Middle East and North Africa or MENA segment, revenue in the second quarter was $45 million, a decrease of $6 million or approximately 11% quarter over quarter. The sequential decrease was driven by lower equipment sales related to wealth management in Saudi Arabia and in the United Arab Emirates, partially offset by increased wall management activities in Algeria. MENA segment EBITDA for the June quarter was $14 million, a sequential decrease of $1 million quarter over quarter. Segment EBITDA margin was consistent with the prior quarter at 30%.\\nThe reduction in segment EBITDA was primarily due to lower activity. For Asia Pacific, or APAC, revenue for the second quarter was $48 million, which was an increase of $4 million or approximately 11% sequentially. The increase in revenue was primarily due to higher subsea well access revenue in Australia and Brunei and higher well construction revenue in Japan. The increase in revenue was partially offset by lower wealth flow management revenue in Thailand and in India.\\nAPAC segment EBITDA for the June quarter was $4 million or approximately 9% of segment revenue, a decrease of $1 million or about 3 percentage points quarter over quarter. The reduction in segment EBITDA in APAC, despite the increase in revenue was primarily due to additional mobilization and commissioning costs on a large subsea project that were incurred during the quarter as well as lower activity on higher-margin contracts. Additional commissioning costs on the Subsea projects, which totaled approximately $3 million and associated project start-up delays are in part COVID related and should be nonrecurring. As a result, we expect that revenue and segment EBITDA margin in APAC will trend positively in H2 2022 and into 2023.\\nAs Mike mentioned, our integration plans are progressing well, and we are already starting to realize significant synergy benefits we anticipated when we first announced our business combination in March of 2021. As Mike mentioned, through the second quarter of 2022, we have identified an action to approximately 100% of our synergies capture plan, both in regards to headcount and annualized value in dollars. We also completed the consolidation of several international facilities and made good progress on our ongoing migration to a single ERP platform, which should allow us to both to streamline a number of key business processes and begin to action additional cost synergies. As to our near-term outlook, we expect that Q3 2022 revenue will be up sequentially by plus or minus 8%, reflecting continued business momentum at NLA, the continuation of the seasonal rebound in ESA and the start-up of new contracts in MENA and APAC.\\nAdjusted EBITDA margin in Q3 should be in the area of 15% to 17% of consolidated revenue. Over the next couple of quarters, we continue to expect that our revenue run rate will approximate that of the pre-pandemic 2019 revenues of Legacy Expro and legacy Frank's on a combined basis. And we, therefore, reaffirm our guidance, the Q4 revenue should fall within a range of $325 million to $350 million. With the benefit of fall-through on incremental revenue and synergies, we expect that adjusted EBITDA margins will be in the area of 20% of revenue as we exit the year.\\nProvided our H1 build in working capital reverses in H2 2022 as is currently anticipated, absent additional M&A and/or share repurchases, we expect that our year-end cash position will be at or above where we started the year with cash generated from operating activities, funding integration costs, capex, the Q1 acquisition of SolaSense and the share buyback that was completed in Q2. By preserving and protecting our currently strong financial profile and by maintaining a disciplined approach to investment, we believe Expro will have sufficient financial flexibility to fund growth and increase returns to shareholders. As always, our objective is to enhance long-term value for our shareholders, employees, partners and the communities in which we operate. With that, I will turn the call back over to Mike for a few closing comments.\\nMike Jardon -- Chief Executive Officer\\nThank you, Quinn. We delivered exceptional operational performance that drove significant growth on a top and bottom line and is beginning to demonstrate the true capability of the company. Our broad portfolio of services and solutions continue to create opportunities in the growth markets that will be key to Expro's long-term success. Our innovative platform, next-generation technology and solutions and ESG applications are differentiators that continue to rapidly advance our reputation and outstanding track record with customers as a leading well expert.\\nWe continue to secure contracts and demonstrate the value of the breadth of our portfolio and the depth of our expertise can bring to clients across the life of their wells. Looking forward, the positive signs of a recovery we saw in the first quarter continued to gain momentum. We are seeing increased demand for our services and solutions as the recovery that began within the U.S. onshore market has begun to gain traction in the offshore international markets.\\nWe remain confident that the pipeline of projects we are seeing will support strong multi-year growth and firmly believe Expro is uniquely positioned to capitalize on this favorable outlook. We are incredibly excited about the strength and positioning of Expro. Our results could only have been achieved by the hard work and focus of our team. It's through their dedication that we continue to accelerate growth, improve profitability and enhance value for shareholders, employees, customers and partners.\\nThank you, again.\\nQuestions & Answers:\\nOperator\\n[Operator instructions] Our first question today comes from James West from Evercore ISI. Your line is open. Please go ahead.\\nJames West -- Evercore ISI -- Analyst\\nGood morning, guys.\\nMike Jardon -- Chief Executive Officer\\nGood morning James.\\nJames West -- Evercore ISI -- Analyst\\nSo one, Mike -- so curious, it seems like we've gone through a bit of acceleration in demand here over the last quarter, maybe two quarters in a sense of urgency has arisen within your customer base? I guess -- so first, is that -- am I getting that correct? And that this urgency is kicking in? And then second, are you seeing more of that urgency or increased demand on producing assets or new assets or interventions versus new well construction type work.\\nMike Jardon -- Chief Executive Officer\\nYes. So James, I can tell you one of the good things is we've really -- now that we're kind of more exited the pandemic. I've been able to spend an awful lot more time with customers, not only in the U.S., but in particular, Middle East and Asia. And what I'd say is the conversations particularly around new FIDs, new projects, new drilling and completion type activity, that's much more constructive, much more dialogue and discussion around that.\\nI'd say that the -- we've had continuing strong commentary and strong game with customers around producing assets. So that's -- I think that's ramping up, but not at the same rate as the positivity from the discussions around new well type -- new well drilling activity and new well completion activity.\\nJames West -- Evercore ISI -- Analyst\\nOK. Fair enough. And then on the pricing side, are you -- at this point, are we back to kind of -- or getting close to back to pre-pandemic type of levels? Admittedly, offshore wasn't as robust even then, but it's growing and robustness now. But are you achieving the returns on capital investments that you would like to see when you're allocating capital and what you're pricing new contracts?\\nMike Jardon -- Chief Executive Officer\\nSo I would -- and I tried to allude to it in my earlier comments, we're starting to see some spotty opportunities to push price, and we're pushing price every opportunity we can. It's more selective right now. I think we'll continue to gain more momentum around our ability to continue to press price as we exit '22 going into '23, but we are starting to have -- it hasn't quite turned the quarter, so to speak, like North America. U.S.\\nland has where there's lots of pricing leverage and pricing traction. But we are starting to see in some particular markets and some particular service lines, positive opportunity to continue to get that pricing. And I think we're all keen to make sure that we start to implement that absolutely as soon as we can.\\nQuinn Fanning -- Chief Financial Officer\\nJames, I think the only thing -- I could just point you back to Mike's prepared remarks, there are capacity constraints within certain solutions and certain product groups, complex well construction or to provide construction activity or TROs, as well as the subsea landing streams. It's obviously a market that is supported by just a handful of service providers ourselves being one of the two larger ones product lines. But obviously, everything about the supply and demand, there's less than a supply for those two equipment classes. The other thing I'd highlight is with the pickup in drilling and completion type activity.\\nIt's not necessarily how we present our supplemental disclosures. But what we consider to be our drilling completions over businesses, they were up 20% quarter-over-quarter revenue-wise and the thoughts for margins on the incremental activity is north of 50%. So that's really where you get the --\\nJames West -- Evercore ISI -- Analyst\\nOK. Got it. Yes, no doubt. That's going to be very helpful.\\nOperator\\nOur next question comes from David Anderson from Barclays. The line is open. Please go ahead.\\nDavid Anderson -- Barclays Capital -- Analyst\\nHey. Good morning, Mike. I was just curious which of your product lines showed the greatest margin improvement this quarter. And I think you maybe just touched on it just now here.\\nBut curious if there's been much of improvement in well construction, in particular, as a rental business in TRS with high offshore exposure. Just curious how we should be thinking about the margin expansion upside in that particular business and how that should contribute overall.\\nMike Jardon -- Chief Executive Officer\\nSure. We alluded to some of this in the prepared remarks. What kind of additional commentary I'd add to it, David, is we've really seen some increased mix, better mix of activity in North Latin America, in particular. So yes, particularly around TRS around well construction, we've been able to start to see some margin expansion there.\\nAnd then I think overall, what you're really seeing is starting to gain more traction with the cost synergies we're taking out the organization overall. We're in essence, we're a full quarter ahead of that. And I think one of the real positives of us being able to get the synergies implemented is if we're being to completely honest, anytime you're doing a consolidation, you're doing a merger, if there is a little too much internal focus that goes on. It's a necessary part of the eval as doing a merger as we can get more of that behind us, and we'll largely because we're a quarter ahead of it, that means going in exiting '22 and going into '23, we're really going to be much more externally focused.\\nAnd that's one of the reasons why I've been challenging the organization is so hard to make sure we get these things done sooner rather than later. But overall, we're seeing margin expansion across well construction and even in some of the well flow management and subsea access, we're getting some traction in all three of those right now.\\nDavid Anderson -- Barclays Capital -- Analyst\\nSo if I just stay on the well construction side, we're hearing a lot of talk about rigs coming back to work both on the jack-ups and the deepwater side. Are you getting inquiries for those? I'm just kind of curious, it's obviously only a couple of players in the TRS business. So I'm just kind of curious, are you starting to kind of roll out some additional equipment at been sidelined for a while. Can you help us give us a handle on what that looks like in terms of, I guess, your capacity type of equipment out there and how that's moved up?\\nMike Jardon -- Chief Executive Officer\\nYes. No, absolutely. We are seeing the same phenomenon that the drillers are seeing today with increased utilization, those kind of things. Because keep in mind, a drilling rig and TRS type equipment goes kind of hand in hand.\\nSo yes, we're able to start to put some of that equipment back to work. I referred to a casing running tool CRT opportunity we execute on in Brazil. That purely is taking assets and resources that were underutilized previously and putting those to work. So on the flip side of that, yes, we're seeing good traction with all construction.\\nThe other thing that we're seeing even more so than I had anticipated was it really becomes an early warning radar system for us, so to speak, because typically, with customers, they select the rig first almost in conjunction with that are certainly right behind it is selecting the TRS provider. And then you start moving into well completions and well testing, and those type of activities. So we're getting earlier customer engagement. And I think that we'll continue to see that allow us to more upholster revenue opportunities, those types of things.\\nDavid Anderson -- Barclays Capital -- Analyst\\nThat's interesting. So if I just -- on that on that well flow management, it was up 14% sequentially this quarter, I'm pretty sure what was pretty strong for business that I thought we would consider later cycle, more production focused. So I guess the question was, I think you had said in your remarks that MENA was a little bit weaker than expected. So where were the results? Was it more mix related this quarter? Was it regional? Was something else kind of picking up and offsetting what you said? I mean, because I would have thought MENA would have actually been a driver of that growth.\\nAnd it sounds like it wasn't --\\nMike Jardon -- Chief Executive Officer\\nSure. MENA for us was really -- we had kind of a quarter-on-quarter product sales that didn't reoccur in the second quarter. So that was what gave us a little bit of softness there. Our strong activity in the Middle East, Algeria, in particular, was actually up quarter on quarter.\\nWhat is important to recognize with well flow management is, in particular as well testing, we can utilize those assets in a well completions cleanup load or you can use those assets in a production optimization mode. And that allows us to kind of flex that equipment to deploy it into one or the other. And part of the growth we saw was starting to see some better activity from a new well completions, new well flowback, those type things within the quarter.\\nDavid Anderson -- Barclays Capital -- Analyst\\nOK. Thank you very much.\\nMike Jardon -- Chief Executive Officer\\nAbsolutely. Thanks for the questions.\\nOperator\\n[Operator signoff]\\nDuration: 0 minutes\\nCall participants:\\nKaren David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations\\nMike Jardon -- Chief Executive Officer\\nQuinn Fanning -- Chief Financial Officer\\nJames West -- Evercore ISI -- Analyst\\nDavid Anderson -- Barclays Capital -- Analyst\\nMore XPRO analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, and welcome to the Monster Beverage Company Second Quarter 2021 Conference Call. [Operator Instructions]\\nI would now like to turn the conference over to Rodney Sacks, Co-CEO, to begin the call. Please, go ahead.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nGood afternoon, ladies and gentlemen. Thank you for attending this call. I'm Rodney Sacks. Hilton Schlosberg, our Vice Chairman and Co-Chief Executive Officer, is on the call; as is Tom Kelly, our Chief Financial Officer.\\nTom Kelly will now read our cautionary statement.\\nThomas J. Kelly -- Chief Financial Officer\\nBefore we begin, I would like to remind listeners that certain statements made during this call may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and are based on currently available information regarding the expectations of management with respect to revenues, profitability, future business, future events, financial performance and trends, as well as the future impact of the COVID-19 pandemic on the company's business and operations.\\nManagement cautions that these statements are based on our current knowledge and expectations and are subject to certain risks and uncertainties, many of which are outside the control of the company that may cause actual results to differ materially from the forward-looking statements made during this call. Please refer to our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K filed on March 1, 2021, including the sections contained therein entitled Risk Factors and Forward-looking Statements, for a discussion on specific risks and uncertainties that may affect our performance. The company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events or otherwise.\\nI would now like to hand the call over to Rodney Sacks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThank you, Tom. The company's top priority remains the health, safety and well-being of its employees. The company's flavor manufacturing facilities, its co-packers, warehouses and shipment facilities have operated throughout the COVID-19 pandemic. The company's bottlers and distributors are operating, and the company's products remain generally available to consumers. In limited countries, the operations of the company's bottlers and distributors have, in part, been negatively affected for varying periods of time. Despite the ongoing impact of the COVID-19 pandemic, the company achieved record second quarter net sales. Currently, the company does not foresee a material impact on the ability of its co-packers to manufacture and its bottlers and distributors to distribute its products as a result of the COVID-19 pandemic.\\nThe company's supply chain remains largely intact. However, the company continues to experience shortages in its aluminum can requirements in the United States and EMEA, given the company's volume growth and the current supply constraints in the aluminum can industry. The company is also experiencing delays in procuring certain ingredients, both domestically and internationally. As a result, the company was unable to fully satisfy demand in the 2021 second quarter in the United States and EMEA. We expect such challenges to continue for the next few months. The company has taken steps to source additional quantities of aluminum cans from the United States, South America and Asia. The company has entered into new supply agreements with two new aluminum can suppliers in the United States, and which are expected to be operational in the 2021 fourth quarter. We expect deliveries of additional quantities of cans increasing sequentially during the latter part of the year.\\nLogistical issues, including shortages of shipping containers and port of entry congestion could delay ongoing international supply of aluminum cans. Separately, we are continuing to experiencing -- experience freight inefficiencies as well as significant increases in domestic and international freight costs and like other beverage companies are incurring increased aluminum can and other costs in the current environment, all of which in addition to other factors, will continue to adversely impact gross margin percentages. In the second quarter of 2021, net sales were $1.46 billion compared with $1.09 billion in the second quarter of 2020, an increase of 33.6%. Adjusting for foreign currency movements, net sales for the 2021 second quarter would have been up 30.1%. Gross profit as a percentage of net sales for the 2021 second quarter was 57.2% compared with 60.3% in the 2020 second quarter. The decrease in gross profit as a percentage of net sales for the three months ended June 30, 2021, was primarily the result of geographical sales mix and increased input costs, mainly increased raw material freight in costs and aluminum can costs.\\nOperating expenses for the 2021 second quarter were $310.9 million compared with $252.2 million in the 2020 second quarter. As a percentage of net sales, operating expenses for the 2021 second quarter were 21.3% compared with 23.1% in the 2020 second quarter. Operating income increased 29.1% to $526 million, up from $407.3 million in the second quarter of 2020. Net income increased to 29.7% and to $403.8 million compared to $311.4 million in the 2020 comparable quarter. Diluted earnings per share for the 2021 second quarter increased to 28.6% and to $0.75 from $0.59 in the second quarter of 2020. According to the Nielsen reports for the 13 weeks through July 24, 2021, for all outlets combined, namely convenience, grocery, drug, mass merchandisers, sales in dollars in the energy drink category, including energy shots, increased by 14.2% versus the same period a year ago. Sales of the company's energy brands, including Reign, were up 8.6% in the 13-week period. Sales of Monster were up 11.1%. Sales of Reign were down 6.1%. Sales of NOS decreased 4.1%, and sales of Full Throttle increased 7%. Sales of Red Bull increased 15.3%. Sales of Rockstar decreased by 15.7%, and sales of 5-Hour increased 8.5%. VPX Bang sales increased 20%.\\nAccording to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the energy drink category in the convenience and gas channel, including energy shots in dollars, increased 7.4% over the same period the previous year. Sales of the company's energy brands, which include Reign, increased 3.6% in the four-week period in the convenience and gas channel. Sales of Monster increased by 5.8% over the same period versus the previous year, Reign sales decreased 6.8%, NOS was down 10.7%, and Full Throttle was up 13.2%. Sales of Redbull were up 9%. Rockstar was down 18.6%, and 5-Hour was up 3.2%. VPX Bang sales increased 12.2%. According to Nielsen, for the four weeks ended July 24, 2021, the company's market share of the energy drink category in the convenience and gas channel, including energy shots, in dollars, decreased 1.3 points to 36.5%.\\nMonster share decreased 0.4 of a share point to 30.6% and. Reigns decreased 0.4 of a share point to two points -- sorry, 2.4%. NOS's share decreased 0.5 of a point to 2.7%, and Full Throttle share remained at 0.7%. Redbull's share increased point -- six points to 37.4%. Rockstar's share was down 1.2 points to 3.8%. 5-Hour share was lower by 0.2 points at 4.6%. VPX Bang share increased 0.3 points to 7.6%. As previously reported, Coca-Cola Energy is being discontinued in the United States and Canada by the end of 2021. According to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the coffee plus energy drink category, which includes our Java Monster line in the convenience and gas channel, increased 4.2% over the same period the previous year.\\nSales of Java Monster, including Java Monster 300, were 5.9% higher in the same period versus the previous year. Sales of Starbucks Energy were 0.4% higher. Java Monster share including Java Monster 300 of the coffee plus energy category, which primarily includes Java Monster, Java Monster 300, Starbucks Doubleshot and Tripleshot, Rockstar Roasted and Bang Keto Coffee for the four weeks ended July 24, 2021, was 51.9%, up 0.9 of a share point, while Starbucks' energy share was 45.5%, down 1.7 points. According to Stackline, which tracks energy drink sales by Amazon in the United States, in the four-week period ending July 3, 2021, sales in dollars in the energy category by Amazon, including energy shots, increased 104.5% over the same period the previous year.\\nSales of Monster increased 59.9%. And its share was 28.1%, down 7.8 share points versus the same period a year ago. Red Bull sales increased 109.4%, and its share was 16.6%, up 0.4 points. Celsius' sales increased 133.1%. And its share increased 1.8 points to 14.3% 5-hour sales increased 40.9%. And its share declined 1.3 points to 2.9%. VPX Bang sales increased 216.1%. And its share increased 1.8 share points to 5.2%. Reign's share decreased 0.1 of a share point to 5.3%. Rockstar's share increased 0.9 of a share point to 3.9%. According to Nielsen, in all measured channels in Canada, for the 12 weeks ended June 19, 2021, the energy drink category increased 17.9% in dollars.\\nSales of the company's energy drink brands increased 28.3% versus a year ago. The market share of the company's energy drink brands was 41.5%, up 3.4 points. Monster sales increased 18.3%, and its market share increased by 0.1 of a point to 35.4% -- sorry, 35.4%. NOS' sales increased 12.6%, and its market share decreased 0.3 of a point to 1.9%. Full Throttle sales decreased 2.1%, and its market share decreased 0.1 of a point to 0.6%. Red Bull sales increased 18.1%, and its market share increased 0.1 of a point to 38.7%. Rockstar sales decreased 8.6%, and its market share decreased 3.3 points to 11. 4%. GURU's sales increased 35.9%, and its share increased 0.5 of a share point to 4%.\\nAccording to Nielsen, for all outlets combined in Mexico, the energy drink category increased 45.2% for the month of June 2021. Monster sales increased 38.7%. Our market share in value decreased by 1.3 points to 27.2% and against the comparable period the previous year. Red Bull sales increased 41.4%, and its market share decreased by 0.2 of a point to 6.5%. Vive 100 sales increased 30.2%, and its market share decreased by 2.4 points to 20.5%. Volt's sales increased 41.1%, and its market share decreased 0.5 of a share point to 18.5%, while B:oost's sales increased 15.7%, and its market share decreased 1.3 points to 5.1%. Amp's sales increased 91.9%, and its market share increased 4.4 points to 17.9%. Predator, which was launched in March 2020, achieved a market share of 3.1%.\\nThe Nielsen statistics for Mexico cover single months, which is a short period that may often be materially influenced positively and/or negatively by sales in the OXXO convenience chain, which dominates the market. Sales in the OXXO convenience chain in turn can be materially influenced by promotions that may be undertaken in that chain by one or more energy drink brands during a particular month. Consequently, such activities could have a significant impact on the monthly Nielsen statistics for Mexico. According to Nielsen for the month of June 2021 compared to June 2020, Monster's retail market share in value increased in Argentina from 40.1% to 46.9% and in Brazil from 29.6% to 35.4%. In Chile, Monster's retail market share decreased from 45.7% to 41.9%. Monster Energy continues to be the leading energy brand in value in Argentina.\\nI would like to point out that the Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country-to-country and are reported on varying dates within the month referred to from country-to-country. According to Nielsen, in the 13-week period ending July 18, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 34.2% to 37.4% in Spain. According to Nielsen, in the 13-week period to the end of June 2021, Monster's retail market share in value as compared to the same period the previous year grew from 14.5% to 15.3% in Germany, from 18.4% to 19.4% in Poland and from 18.4% to 20.1% in South Africa. According to Nielsen, for the 13-week period ending June 20, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 12.5% to 16.2% in Belgium, from 24.2% to 25.3% in Denmark, from 25.8% to 28.2% in France, from 25% to 29% in Great Britain, from 6.7% to 8.4% in the Netherlands, from 27.1% to 31.2% in Norway, from 25.6% to 29.3% in the Republic of Ireland and from 13.4% to 14.5% in Sweden.\\nAccording to Nielsen, in the 13-week period until the end of May 2021, Monster's retail market share in value compared to the same period the previous year grew from 13.3% to 14.5% in the Czech Republic, from 35.1% to 37.9% in Greece and from 16.6% to 29% in Italy. According to Nielsen, in the 13-week period until the end of May 2021, Predator's retail market share in value as compared to the same period the previous year grew from 5.1% to 17.3% in Kenya and from 0% to 8.1% in Nigeria. The Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country to country.\\nAccording to IRI in Australia, Monster's market share in value for the month ending June 2021 increased from 11.6% to 14% as compared to the same period the previous year. Mother's market share in value decreased from 13.3% to 11.6% during the same period. The market share of the company's brands in Australia for the month ended June 2021 increased from 24.9% to 25.5%. According to IRI in New Zealand, Monster's market share in value for the four weeks ended July 11, 2021, increased from 9.9% to 12.4% as compared to the same period of the previous year. Live+ market share in value remained the same at 6.9%, and Mother's market share in value increased from 6.2% to 6.3%. The market share of the company's brands in New Zealand for the four weeks ended July 11, 2021, increased from 23.1% to 25.6%.\\nAccording to Nielsen, in South Korea, Monster's market share in value in all outlets combined for the month of June 2021 increased from 53.3% to 61.9% as compared to the same period in the previous year. According to INTAGE, in Japan, Monster's market share in value in the convenience store channel for the month of June 2021 was 50.6% as compared to 51% in the same period the previous year. Monster remains the market leader in Japan. We again point out that certain market statistics that cover single months or four week periods may often be materially influenced positively and/or negatively by promotions or other trading factors during those periods.\\nNet sales to customers outside of the US were $546.3 million, 37.4% of total net sales in the 2021 second quarter compared to $328.3 million or 30% of total net sales in the corresponding quarter in 2020. Foreign currency exchange rates had a positive impact on net sales in the US dollars by approximately $38.6 million in the 2021 second quarter. Included in reported geographic sales are our sales to the company's military customers, which are delivered in the US and transhipped to the military and their customers overseas.\\nIn EMEA, net sales in the 2021 second quarter increased to 105.7% in dollars and increased 86.5% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales for the second quarter was 39.8% compared to 38.1% in the same quarter in 2020, primarily due to a favorable country and product mix. We're also pleased that in the 2021 second quarter, Monster gained market share in Belgium, the Czech Republic, Denmark, France, Germany, Great Britain, Greece, Italy, the Netherlands, Norway, Poland, the Republic of Ireland, South Africa, Spain and Sweden.\\nIn Asia Pacific, net sales in the 2021 second quarter increased 5.2% in dollars and decreased 100% [Phonetic] in local currencies over the same period in 2020, largely due to sales in Japan and China. Gross profit in this region as a percentage of net sales was 44.4% versus 43.3% over the same period in 2020. In Japan, net sales in the 2021 second quarter decreased 15.1% in dollars and 13.9% in local currency, largely due to COVID-19 restrictions in Japan and distributor inventory adjustments. Depletions increased 7% during the quarter. Monster remains the market leader in Japan for the month of June 2021.\\nIn South Korea, net sales increased 63% in dollars and 50.4% in local currency as compared to the same quarter in 2020. In China, net sales decreased to 21.4% in dollars and 27.8% in local currency as compared to the same quarter in 2020. In this regard, we note that sales in the second quarter of 2020 included the initial launch of Dragon Tea. We are reevaluating the viability of this SKU and the optimal product range for China going forward. We remain optimistic about the prospects for the Monster brand in China. In Oceana, which includes Australia, New Zealand, Tahiti, French Polynesia, New Caledonia, Papua New Guinea and Guam, net sales increased to 146.5% in dollars and 98.2% in local currencies. Sales of the Monster brand in Oceana increased 210% in dollars and 155.6% in local currency as compared to the same quarter in 2020.\\nIn Latin America, including Mexico and the Caribbean, net sales in the 2021 second quarter increased to 19.7% in dollars and increased 117.6% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales was 40.7% compared to 41.2% in over the same period in 2020, primarily as a result of foreign exchange rates and certain raw materials and ingredients for products in this region are purchased in US dollars. In Brazil, net sales in the 2021 second quarter increased by 194.9% in dollars and 201.7% in local currency. Net sales in Chile increased 77.5% in dollars and 52% in local currency in the 2021 second quarter. Net sales in Argentina increased 291.4% in dollars and 458% in local currency in the 2021 second quarter.\\nIn March 2019, VPX, the maker of Bang Energy drinks, sued Monster, alleging that its Reign products infringed VPX's Bang trademarks and trade risk. A trial was held last year. And on August 3, 2021, the court issued an order denying all of VPX's claims and holding that VPX is entitled to no relief whatsoever. In fact, the court specifically found that VPX copied its bank trade risk from the original Monster Energy cans. The court's decision confirms that Monster and Poland retail partners are free to continue to sell our Reign products without any changes and without any restrictions. Monster always believed and maintained that VPX's claims were frivolous, and we are extremely pleased that the court rejected all of VPX's claims while vindicating Monster's rights. As other pending proceedings with VPX are subjudicate, we will not be answering any questions on this matter on today's call.\\nOur new product introductions in the United States in the first half of 2021 were primarily focused in the first quarter. In the United States, during the second quarter of 2021 we refreshed our can graphics on our Rehab Monster brand family as well as our Full Throttle line, also updating the name for Blue Agave to TrueBlue. Monster Energy Ultra Fiesta received a refresh and updated can graphics as well as the name change to Monster Energy Ultra Fiesta Manga. In May 2021, we launched Monster Ultra Fiesta in a 24-ounce option with an update to our Ultra Fiesta Manga plan for later this year. We are in the process of launching a new line of nonalcoholic pure energy sales under the True North brand name in 12-ounce sleek cans, which contained an organic plant-based energy blend and ingredients for immunity support. True North is being offered in six flavors, Cucumber Lime, Black Cherry, Grapefruit Lemonade, Water Mellon Mist, White Peach Pear and Mandarin Yuzu.\\nTrue North has a limited customer target in 2021 with plans for a full launch into mainstream channels in 2022. While cognizant of the can shortages, we believe that it is important to continue with our innovation plans. And to this end, we will be launching our new flavors reserve line of Monster Energy drinks in Water Mellon and White Pineapple in October 2021. We have deferred the launch of our new line of Java Monster Cold Brew Coffee + energy drinks until early 2022. In Canada, during the second quarter, we launched two new products: Monster Punch Papillon and Monster Punch Khaotic, both in a 473 ml can. In April 2021, we launched Reign Orange Dreamsicle in Puerto Rico and our second SKU in Bolivia with Monster Energy Zero Ultra. In El Salvador, we launched Fury Mean Green in May 2021.\\nIn the second quarter of 2021, we launched Juice Monster Pacific Punch and Monarch in a number of countries in EMEA. We also launched Ultra Paradise and Ultra Fiesta in a number of countries during the quarter. During the quarter, we also launched our strategic brand innovation and Predator in additional countries. In January 2021, we launched Ultra Rosa marketwide in Australia, following an exclusive lead launch with one chain in the fourth quarter of 2020. In March 2021 in New Zealand, we launched Monster Superfuel in both Purple Passion and sugar-free flavors. During the 2021 second quarter in Japan, we launched Monster Energy Super Cola with our distributor, Asahi Soft Drinks. Additionally, we effected the relaunch at retail of Ultra Paradise and began shipments in anticipation of the launch of Super Fuel early in the 2021 third quarter. Super Fuel has just gone on the shelves in Japan this week. We also launched Mango Loco in Korea in July 2021.\\nDuring the 2021 second quarter, we launched Pipeline Punch in Taiwan, Hong Kong and Macau. We also began distribution of Monster Energy Zero Sugar in the Philippines. As previously mentioned, in the second quarter of 2021, in China, we extended the national rollout of our new Monster Dragon Gold, which is non-carbonated. Our national summer on-pack promotion began in May with one of China's top consumer ambassadors. As a result of the COVID-19 pandemic, certain of our planned launches and innovation of new products in a number of Asia-Pacific markets have been deferred for a few months. However, we still anticipate such launches taking place toward the end of the 2021 calendar year. We are planning to launch a number of additional products and product lines in our domestic and international markets later this year.\\nWe estimate that July 2021 sales to be approximately 1.8% higher than in July 2020. On a foreign currency adjusted basis, July 2021 sales would have been comparable to the July 2020 sales. July 2021 had one less selling day than July 2020, which was 15.8% above July 2019, and which was 17.1% higher on a foreign currency adjusted basis. Certain production facilities, mainly from the Coke bottlers in EMEA, in particular, delayed production from July to August 2021. Furthermore, as mentioned earlier, the company has not been able to fully satisfy demand in the United States and EMEA due to a shortage of aluminum cans, which adversely impacted July sales. Such shortage was exacerbated in July as can availability did not keep pace with increased demand during the summer months. Additional cans have been sourced from domestic and overseas suppliers with expected deliveries increasing sequentially during the latter half of the year. We are working to replenish system inventories in order to meet customer demand as soon as possible.\\nAdditionally, the company also experienced delays in certain ingredients, which impacted supply. Our depletions remain solid as do our measured market data, as previously mentioned on this call. In this regard, we caution again that sales over a short period are often disproportionately impacted by various factors such as, for example, selling days, days of the week in which holidays for, timing of new product launches, and the timing of price increases and promotions in retail stores, distributor incentives as well as shifts in the timing of production in some instances where our bottlers are responsible for production and unilaterally determine their production schedules, which affects the dates on which we invoice such bottlers as well as inventory levels maintained by our distribution partners, which they alter unilaterally for their own business reasons.\\nWe reiterate that sales over a short period such as a single month should not necessarily be imputed to or regarded as indicative of results for a full quarter or any future period. If the COVID-19 pandemic and related unfavorable economic conditions continue in certain regions, our new product innovation launches in those regions could be delayed. In conclusion, I would like to summarize some recent positive points. Currently, the company's flavor manufacturing facilities, its co-packers, warehouses, and shipment facilities, and bottlers and distributors are all operating. We are continually addressing our aluminum can requirements, given our volume growth and the current supply constraints in the aluminum can industry.\\nWe are pleased with the new additions to the Monster Energy portfolio and are planning additional launches later in the year. We are planning to continue additional launches of our Reign Total Body Fuel high-performance energy drinks in additional international countries. We are pleased with the rollout of Predator and Fury and our affordable energy drink portfolio internationally. We are proceeding with plans to launch our affordable energy drinks in a number of international countries during the year.\\nI would like to open the floor to questions about the quarter. Thank you.\\nQuestions and Answers:\\nOperator\\nThank you. [Operator Instructions] The first question will come from Dara Mohsenian with Morgan Stanley. Please go ahead.\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nHey, guys.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nHey, Dara.\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nGreat top line growth in the quarter, but we have seen share losses in US track channel data worsened recently. A, just short-term, how much of that do you think is attributable to out of stocks and the supply constraints that you mentioned? Is that a material factor in retail sales?\\nAnd then maybe, b, from a longer-term standpoint, it has been a couple of quarters now where the share losses have reaccelerated year-over-year, just some progress in the beginning of the year. So, I was just hoping you could review some of the key factors that have been driving the share losses in the US? And how you think about those factors going forward in terms of continuing or dissipating and how you guys are positioned? Thanks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nHilton, if you take that, and I'll also say something once you've...\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nAll right. I think, Dara, what's important is that, that's not a result and not due to us not growing. We are not keeping up with our share, but our business is certainly growing. And you can track that from Nielsen. You can also track that from the non-measured channels, which are growing really very nicely. So while we're not keeping up necessarily with Red Bull in the major channels.\\nAs I've spoken on previous calls, Red Bull had a very large on-premise business, which has moved to off-premise and moved to off-premise during COVID. And that led to an acceleration in their share. However, we mentioned that we had and are continuing to sustain can issues and result in supply. And of course, that's having an impact on the share numbers that you are seeing.\\nSo I think on balance, the business is growing. You've seen the results. It's continuing to grow. And we are growing, but not at the extent of the market. I think with the full deck of cards, the situation may well be very different. But right now, we really are struggling with sufficient supplies of aluminum cans really to keep up with demand, which is, I suppose, a good position to be in. And on the other hand, is not such a good position to be in. The business is growing. And, that's the message I want to leave you with and other investors.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nI think in -- I'll just add two short points in that regard. I think what we've tried to do is to try and also basically focus on our faster selling and our larger SKUs, which has necessarily resulted in some of the smaller SKUs, which normally have their own traction and followers. So those haven't got on to shelf. And then the one additional thing that I think that has negatively affected our distribution sales and distribution levels in the US is labor shortages. And I think that what we've seen is that many of the bottlers, Coke bottlers are experiencing labor shortages. And while one would ordinarily say, well, everybody is going to have the same problem.\\nI think that where you have Red Bull is our main competitor, they have a dedicated system. I think they've been able to address their labor shortages just more effectively than the larger bottlers with large labor pools. And that has also, I think, detrimentally affected our distribution levels going forward. But again, I think those are things that once things start settling down and things will get back to normality, that's something that I think that will also, in due course, right itself.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nYes, I think we should also -- Dara, I think we should also add that what we're seeing with cans is something that will persist through this year. I'm a bit more optimistic about the fourth quarter because we have two new can suppliers coming on board. But the situation will persist. And then next year, we should be in -- we believe we'll be in very good shape. But again, it all depends on consumer demand, which is growing, and you've seen that month-by-month and quarter-by-quarter.\\nOperator\\nAnd the next question today will come from Bonnie Herzog with Goldman Sachs. Please go ahead.\\nBonnie Herzog -- Goldman Sachs -- Analyst\\nThank you. Hi, everyone. I just wanted to ask about your gross margins. Clearly, they continue to be pressured as broadly expected, which you guys have been discussing with us. But just want to get your outlook for these pressures in the back half of the year? Hilton, you just mentioned that you're optimistic. So just wanted to verify that you still expect some of these pressures to ease by Q4? Or do you think it's going to take a little bit longer, especially in light of the recent spike in aluminum prices. So trying to understand how that factors in? And then just a clarification on the can shortages that you mentioned that you're still experiencing, I guess, it sounds like it's getting worse, but I really did want to clarify that. And is there any way that you guys could quantify how big of an impact the supply shortages had on your top-line either in the quarter or in July? Just trying to understand how much you think your shipments would have been up in July without these shortages, for instance? Thanks.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nOkay. So let me deal with the first issue first, if I may. I spoke about optimistic about can supplies. I really didn't talk about margins. You'll recall on the last call, I spoke about the issues that we were confronting with margin pressures like most other beverage companies. And where we are right now with aluminum, I mean, nobody knows. So you can talk to the leading banks in the field, which we do on a regular basis, and they really are pulls apart about their projections for aluminum in 2022, let alone 2021.\\nSo the last couple of days, you've seen a spike in the Midwest premium from this tax that is expected to be imposed on Russian aluminum. And as, you know, the Midwest premium is strongly factors the last ton of aluminum to enter the US and the cost of that. And so we've seen a spike in the Midwest premium. And we continue to see spikes in aluminum. So from that score, I think we just are in uncharted territory. I've been in this business for a long time, as you know, and I've never seen aluminum where it's at right now. And I've never seen the Midwest premium at these kind of levels. So aluminum, I really cannot talk about. And also when you look at our business and you look at the factors that really have affected gross margin, number one, the fact that we're selling a lot more internationally. So I talked earlier about 37.4% of our sales in the quarter outside of the US 30% last year, that obviously impacts margins. We are importing cans from a number of [Technical Issues] that obviously impacts margins.\\nIn fact, the China and India cans that we are using in the United States and in EMEA will only be filed in August in July, and they will be filled this month. So that in itself, the imputation will impact gross margins. And then to cap everything else, we have ingredient issues. We had ingredient issues, as we mentioned, in July, which again reduced the amount that we would actually sell because we didn't have sufficient ingredients to meet themselves, particularly with NOS. And so there are a number of factors that are increasing that are increasing our cost of goods.\\nAnd last quarter, I said I didn't think that margins would get better in the second and third quarters. I read they will not -- I think margins will deteriorate in the third quarter. In the fourth quarter, we're getting some relief in terms of supplies from the US on cans that are -- have been contracted for and they were contracted for two years ago. And we saw the opportunity to work with two major suppliers to get additional cans produced in the US, and that's why we have two new supplies opening, and we are an important and an anchor customer of both those facilities. But even that, you're still dependent on aluminum. We have some hedges in place, but obviously not enough to take into consideration the amount of sales and the amount of consumer demand that is out there. So that's a long-winded way of saying, I think, answering your question as best as I can.\\nAnd then just getting to your second question because you're really only allowed one. But to get to your second question, we have quantified or try to quantify the impact on can shortages in July and in this quarter and in the -- potentially in the third quarter, but I really don't want to -- I'm not comfortable with those numbers yet. A lot of detailed work is being done on them. And I just -- I can't in good contents give those numbers because we still are in the throes of kind of finalizing what we think is probably correct. Rodney mentioned in his script earlier that a number of the bottlers, he mentioned particularly in EMEA, but there were cases in the US as well, and there was a substantial case in the US where the bottlers were obviously focused on other things in the quarter and were producing Coca-Cola brands. And as a result, I think we -- our production got moved from July to August. So, when I look at July, it doesn't -- I don't get overly concerned because I know the sales are going into August.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nPerhaps, if I just on the shortage level, just to add that when we buy cans in contracted for our annual amount, they usually are sort of reasonably flat line across the year. And we used the first half of the year to build up can inventories and finished product inventories with ourselves and our bottlers. Earlier this year, obviously, demand sort of was strong, and so we really didn't have that opportunity. So what has happened is that in June and July, which is your normal peak months, the demand has been higher, but our supply has been more level until we can get more can inventories into the market. So what happened is just that we have had a sort of a heartened increased shortage in the last month and July and probably will be a little bit in August. And then obviously, as we start increasing our -- the cans we're getting in, and then we're able to balance it more and our demand balances more, we'll start to have less of a different delta between these demand and supplier and eventually be able to -- we're hoping to able to build up our inventories and supply back to normal by the end of the fourth quarter or during or by the end of the fourth quarter.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nNo one's comfortable with the level of finished goods inventories that we're running at, but it's a sign of the times. I mean, we're doing everything we can to supply our customers. And that's why we spoke about freights. Freight is a big issue, not only getting raw material ingredients into co-packing system and into our bottling system and -- but also distributing from our co-packers. And obviously, the one goes into cost of sales and freight out goes into operating expenses. So that's why you'll see freight really hitting both of those line items.\\nOperator\\nThe next question will come from Andrea Teixeira with JPMorgan. Please go ahead.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nHi. Thank you. Hi. Good afternoon.\\nThomas J. Kelly -- Chief Financial Officer\\nHi.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nHi, Andrea.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nHow are you Hilton? Hi.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nI'm good.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nYes. Just on the gross margin, because your gross margin comments were very helpful and given this deterioration obviously that its probably here to stay in the next few quarters. How are you thinking about pricing? Obviously, you can't supply the service levels that are used to with the retailers. So is that is something that takes -- obviously, you have to take into account? Or perhaps as you get more informed on how the aluminum cost will evolve, you may contemplate it again?\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nYes. With regard to pricing, we continue to evaluate pricing, honestly, on a very, very regular basis, if not weekly. So we continue to evaluate it, and we want to make a good decision. Last time around, as I mentioned on previous calls, we went out alone, and we would like to have been in a situation this time where we followed our competitor, but we have to evaluate, obviously, the business as we see it and the impact for us. What we've done is we're reducing our promotional allowances. So we're taking a price increase the other way, through reducing promotional allowances, but the impact of that reduction in the second quarter was not as we would have liked. So we are -- we really put the accelerator down and are more aggressive in reducing our promotional allowances. But we are continuing to evaluate the pricing and price increases.\\nAnd then I have to leave this call with my favorite saying, and that is, we don't bank gross profit margins, we bank gross profit dollars. And to me, the fact that we're doing everything we can to satisfy our customers as best as we can is impacting gross profit margins. But at the end of the day, we don't want to lose gross profit dollars, which is really important to ensure the sustainability of the brand. And that's the most important thing for us right now.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nThank you. Thanks fair. Thank you both.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nYeah. Basically, just make it clear, at this point, we are watching and we're not planning a price increase. We we're not adverse to a price, but we'll wait and see what the market does and what our competitors do.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nThank you, Rodney.\\nOperator\\nThis will conclude today's question-and-answer session. I would now like to turn the conference back over to management for any closing remarks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThanks very much. Thank you, everyone, for your continued interest and support of the company. We continue to believe in the company and our growth strategy to remain committed to continuing to innovate, develop and differentiate our brands and to expand the company, both domestically and abroad. And in particular, expand distribution of our products through the Coca-Cola bottler system internationally.\\nWe believe that we will be able to navigate through the challenges ahead as a result of the COVID-19 pandemic and hope that this unfortunate situation will resolve itself in the near future. We believe that we are well positioned in the energy drink category and will continue to be and are optimistic about our total portfolio of energy drink brands. We hope that you will stay safe and healthy. Thank you very much for your attendance.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 50 minutes\\nCall participants:\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThomas J. Kelly -- Chief Financial Officer\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nBonnie Herzog -- Goldman Sachs -- Analyst\\nAndrea Teixeira -- JPMorgan -- Analyst\\nMore MNST analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nGood evening, and welcome to Oyster Point Pharma's fourth quarter 2021 earnings conference call. My name is Valerie, and I will be your operator today. [Operator instructions] At this time, I would like to turn the call over to Mr. Daniel Lochner, Oyster Point Pharma's chief financial officer.\\nPlease go ahead.\\nDan Lochner -- Chief Financial Officer\\nGood evening, everyone. And welcome to Oyster Point Pharma's fourth quarter earnings conference call for the three months ended December 31, 2021. This evening, we issued a press release containing our fourth quarter and full year ended December 31, 2021, financial results and recent business highlights. In addition, our earnings press release and our Form 10-K, which were filed with the SEC after the close of market today, are available on our website under the investors and news section at www.oysterpointrx.com.\\nJoining us on our call today are Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma; and John Snisarenko, chief commercial officer. Following Dr. Nau and Mr.\\nSnisarenko and my prepared remarks, we will open up the line for questions. During the call today, we will be making forward-looking statements regarding potential future events, including statements regarding Oyster Point Pharma's potential future financial status and results of operations and our plans and potential for success relating to commercializing TYRVAYA. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. For a description of these factors, please see our annual report on Form 10-K for the year ended December 31, 2021, filed with the SEC after the close of market today.\\nI will now turn the call over to Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma. \\nJeff Nau -- President and Chief Executive Officer\\nThank you, Dan. Good evening, everyone. And thank you for joining us on our call today to discuss our fourth quarter 2021 financial results and recent business highlights. This is a particularly exciting time for Oyster Point.\\nThis is our very first earnings call where we are pleased to be reporting partial revenues from the commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease in the United States marketplace. Today, you will learn more about how we are delivering these encouraging commercial results on the launch of TYRVAYA Nasal Spray. But first, let me provide the company's 2021 business highlights. In October of 2021, we received FDA approval of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease.\\nDry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence. The dry eye market is now being introduced to the first nasally delivered, pharmaceutical dry eye therapy, and we believe that given the high level of patient and physician satisfaction that we are seeing in the field with TYRVAYA, that significant growth remains ahead. You will be hearing more shortly from John Snisarenko, our chief commercial officer, about the details of the launch of TYRVAYA Nasal Spray, but I'm happy to state that we had great partial fourth quarter commercial performance in 2021.\\nWe are happy to report that TYRVAYA Nasal Spray had a net product revenue of $1.2 million in Q4 of 2021. In addition, we recognized $5.4 million from our license agreement with Ji Xing Pharmaceuticals. We are now entering 2022, having demonstrated the ability to achieve the successful commercialization of TYRVAYA, as well as drive strong execution across multiple areas of our business, including our exclusive license agreement with Ji Xing to develop and commercialize OC-01 and OC-02 in Greater China, securing nondilutive funding and pursuing additional treatment advancements in the clinic, as well as in the R&D laboratory for patients with ophthalmic diseases. This week, we publicly announced an early commercial win with one of the largest commercial payers.\\nOur press release from Tuesday announced that TYRVAYA Nasal Spray is now covered by Express Scripts effective on February 19. This is a fantastic accomplishment for our market access team in achieving the addition of 26 million covered lives and more importantly, this early in our first full quarter since launch. Patients are increasingly gaining access to TYRVAYA in the U.S. for a disease state that, up until 2021, we believe, experienced very little innovation for the current large unmet need in dry eye disease.\\nTYRVAYA is a first-in-class cholinergic agonist nasal spray that is highly differentiated from the other pharmaceutical products in the dry eye space and includes the following potential advantages. TYRVAYA Nasal Spray has a differentiated mechanism of action as it is believed to activate the trigeminal parasympathetic pathway via the nose, resulting in increased production of basal tear film as a treatment for dry eye disease. Basal tear film is responsible for lubricating, nourishing and protecting the cornea. TYRVAYA is the only ocular surface-sparing pharmaceutical therapy for dry eye patients.\\nFor those patients with a compromised ocular surface, increasing tear production without the burden of administering a topical medication may provide a welcome method to treat their disease. For the first time, dry eye disease patients have an FDA-approved, pharmaceutical treatment option that is not administered as a topical eye drop to an already irritated ocular surface. Although we are focused on the critical launch of TYRVAYA Nasal Spray and continue to execute plans for the life cycle development of the TYRVAYA franchise, our R&D team remains committed to multiple exciting pipeline projects aimed at bringing additional innovative therapies to address diseases like neurotrophic keratopathy and severe allergic or vernal keratoconjunctivitis. In 2022, we will continue to advance our enriched tear film gene therapy platform, as well as our research and development collaboration with companies like Adaptive Phage Therapeutics.\\nWe remain excited about the ongoing OLYMPIA Phase 2 study of OC-01 nasal spray in Stage 1 neurotrophic keratopathy. We are expecting a readout in the second half of this year. NK is a disease that is currently underdiagnosed or misdiagnosed in many patients with ocular surface disease. We feel that Stage 1 neurotrophic keratopathy could represent a meaningful indication for OC-01 nasal spray.\\nOur vision and focus is clear. The world needs an innovative leader that can bring innovative and transformative ophthalmic disease treatments, and we aim to be that leader. We believe that we're building Oyster Point into a best-in-class eye care company. I would now like to turn the call over to John Snisarenko, Oyster Point's chief commercial officer, to discuss our ongoing commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease.\\nJohn Snisarenko -- Chief Commercial Officer\\nThank you, Jeff. As we have previously communicated, the dry eye disease segment is a large market with over 17 million people diagnosed in the United States alone. Only a small proportion of these patients, approximately 2 million, are currently being treated with a branded therapeutic. And over 7 million people diagnosed with dry eye disease have tried and abandoned the other available options.\\nWe believe that TYRVAYA Nasal Spray is a new treatment option for the large patient population that exists in the dry eye disease marketplace, including the refractory patients, as well as those who are newly diagnosed. As Jeff highlighted previously, we are incredibly excited to have initiated the U.S. launch of TYRVAYA Nasal Spray on November 1. We are pleased to report that as of the quarter ending December 31, 2021, data indicates that approximately 5,500 prescriptions for TYRVAYA have been filled, written by over 1,900 unique prescribers.\\nThese encouraging metrics were achieved in less than nine weeks from the launch, including holiday periods. In this short time, TYRVAYA is quickly establishing itself in the market as an exciting new option for dry eye patients. Regarding market access, a core part of our commercial strategy is to promote accelerated payer adoption of TYRVAYA to the top payer organizations. Our market access team has done a great job in securing coverage for TYRVAYA with Express Scripts National Preferred, Basic and High Performance Formularies effective February 19.\\nWith this latest formulary addition, we now have coverage for a total of 43% of U.S. commercial lives for an aggregate total of approximately 84 million lives. We are incredibly pleased with this level of coverage so early in our launch, and we look forward to further growing our market access coverage in 2022. Oyster Point remains very committed to offering comprehensive patient services that help provide access to TYRVAYA for appropriate patients.\\nWe have launched a comprehensive set of technology-driven patient services offerings aimed at enabling patients to successfully navigate the patient journey and procure TYRVAYA. Our patient support program is called TEAMTyrvaya. And for more information on this program and how to enroll, please visit the website, tyrvaya-pro.com. We have been quite diligent with the sizing of our field force, which enables us to target 20,750 eye care practitioners, covering both optometrists and ophthalmologists and representing approximately 94% of the dry eye prescriptions in the market today, helping us in our efforts to achieve the full commercial potential of TYRVAYA.\\nIn the first nine weeks of launch, our sales force was able to introduce TYRVAYA to more than 50% of the targeted prescriber base. On the marketing side, we're leveraging the latest technology, including sophisticated analytics, in-person, as well as virtual detailing, best-in-class digital and social media efforts and partners, as well as utilizing a digital online pharmacy to enhance communication and delivery of TYRVAYA to patients. We will continue to adopt the latest media and technology-driven marketing approaches to maximize TYRVAYA's share of voice and impact in the market. Our focus continues to be on broad eye care provider and patient education and marketing efforts, with targeted direct-to-patient digital campaigns leveraging TYRVAYA's differentiated MOA and nasal spray route of administration to drive a positive patient marketing experience.\\nI am so proud of our commercial team's collective efforts during this early phase of our launch, especially in these challenging times with the pandemic. I will now turn the call back over to Dan Lochner, Oyster Point's chief financial officer, to discuss our fourth quarter financial results.\\nDan Lochner -- Chief Financial Officer\\nThank you, John. I will now provide a brief overview of Oyster Point Pharma's fourth quarter financial results. Additional detail about our fourth quarter, as well as our annual financial results can be found in our Form 10-K that was filed with the SEC this evening. For the fourth quarter of 2021, Oyster Point Pharma reported a net loss of $42.1 million, compared to a net loss of $22.2 million for the same period in 2020.\\nAs of December 31, 2021, cash and cash equivalents were $193.4 million, compared to $192.6 million as of December 31, 2020. Based on our current business plan, we believe the company's available cash and cash equivalents will be sufficient to fund the company's planned operation for at least 12 months from our 10-K filing this evening. Net product revenues for the fourth quarter of 2021 were approximately $1.2 million, following the FDA approval of TYRVAYA Nasal Spray on October 15, 2021, and our subsequent commercial launch in the U.S. in November 2021.\\nApproximately half of the TYRVAYA net product revenue was attributable to channel building by distributors upon launch of the product. In addition, pursuant to our license agreement with Ji Xing, the company also recognized $5.4 million in milestone and license revenue following the FDA approval of TYRVAYA Nasal Spray, which includes the noncash consideration of Ji Xing senior common shares. The company did not generate any revenues during the third -- three months ended December 31, 2020. Cost of product revenue for the three months ended December 31, 2021, was $1.5 million and consisted mainly of third-party manufacturing costs, which included pre-approval costs, reserves for inventory obsolescence and damaged goods and product royalty expense related to Pfizer.\\nThe cost of product revenue included a reserve for inventory obsolescence of $0.9 million. The inventory manufactured prior to FDA approval of TYRVAYA Nasal Spray was charged to R&D expense. And as a result, the company expects the unit cost of product revenue will be lower until the company fully utilizes this product that was manufactured pre-FDA approval. The company started expensing pre-approval inventory in 2020 and recorded an R&D expense of approximately $4.3 million for pre-approval inventory during the year ended December 31, 2021.\\nThe company anticipates selling the remaining pre-approval inventory by the end of 2022. The company's sales and marketing expense increased by $21.8 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase was primarily due to higher payroll-related expenses of $11.7 million, inclusive of sales commission expense, as well as an increase in stock-based compensation expense of $0.5 million, both of which were primarily driven by onboarding a commercial field force in the second half of 2021. The company also incurred higher marketing -- market access, commercial and other expenses of $10.1 million in anticipation of, and in connection with, the U.S.\\nlaunch of TYRVAYA Nasal Spray. The company's general and administrative expenses increased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase is primarily due to higher G&A expense of $3.8 million related to accounting, consulting, legal and other professional expenses incurred in connection with the credit agreement, as well as the company's transition from a clinical stage to a commercial-stage company. The company also incurred higher payroll-related expenses of $2.4 million, including recruiting expense due to an increase in headcount to support an ongoing efforts to commercialize TYRVAYA.\\nThe company's research and development expenses decreased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The company's decrease in R&D expense is primarily due to the company receiving FDA approval of TYRVAYA Nasal Spray in October 2021. The company expensed inventory prior to receiving FDA approval and expensed approximately $3.5 million as R&D during the three months ended December 31, 2020. The company also incurred a fee of $2.9 million in connection with the New Drug Application submitted to the FDA in December 2020.\\nThe company incurred interest expense of $2.6 million during the three months ended December 31, 2021, primarily related to the credit agreement with OrbiMed. Interest expense included contractual interest of $1.7 million, as well as noncash expense of $0.9 million related to the amortization of loan commitment fees and accretion of other long-term debt-related costs. The company had no interest expense during the three months ended December 31, 2020. Now as we turn to our outlook, for 2022, our goal is to continue to achieve broad ECP and patient experience with TYRVAYA, including both optometry and ophthalmology offices, in order to reach the total addressable dry eye market opportunity of TYRVAYA Nasal Spray.\\nWe anticipate the three large national commercial plans will make their coverage determinations by the midpoint of the year. While we await such coverage determinations, we will continue to provide patient-assisted programs to support eligible commercial patients in gaining access to TYRVAYA. With that overview of our financials, I will now turn the call back over to the operator to open up the line for questions.\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] Our first question comes from the line of Ken Cacciatore with Cowen. Your line is open.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nHey, team, looks like a really good and clean initial launch. I was wondering if you would wanna help us a little bit with maybe the revenue pacing. I know consensus, I believe, is around $30 million. And I know there's only a few of us analysts that are formally involved in the consensus, but I think it's around $30 million.\\nSo I was wondering if you could just kind of hold hands with that number, how we should be thinking about it. And then also, we've been doing clinician checks and getting very good feedback. But I guess, you could help us, as you would have a better sense of the early retention metrics, maybe the -- be able to definitively let us know how you're seeing some of the retention numbers and patients returning. So those are my first two.\\nI'm going to ask one more, if I could, though. Could you talk, John, a little bit about any refinements or learnings of your patient support system? Obviously, early days, but wondering if you're already tweaking it a bit. Anything that seems to be working very well or you've needed to change? And with that, I'll go back in the queue. Thanks so much.\\nJeff Nau -- President and Chief Executive Officer\\nGreat. Thanks, Ken, for the questions and very thoughtful. So maybe what we could do is we'll just take those in order. So I'll turn it over to Dan to just talk about the numbers for the year.\\nAnd then, we'll go into retention and have a discussion about John's experience with the bridge programs and the different patient services.\\nDan Lochner -- Chief Financial Officer\\nYeah. Great. I would say on revenues, while we haven't really provided official revenue guidance, I would say we think about it very operationally, focus in terms of our sales reps that are out in the field doing a great job. And I would say the focus very early on and throughout 2022 will really be about growing that eye care practitioner count, and we have goals internally for what we expect to achieve on a weekly and monthly basis.\\nAnd so, I think, it really starts with getting those ECPs onboard on a monthly sequential basis and then starting to look at what the right pattern is on an NRx basis per month and then what we then start observing on that pull-through on resell rate. And so, to kind of wrap that all up, we see it sequentially building through the quarters for the entire year as we start working through that total target population that we've identified, which is roughly 20,750 targets. And I think, it would be great to have John kind of speak about how we're really going after that target base and how that's been building through the quarters. And I think, what you'll see, at least for Q4, we've hit about 1,900 of those ECPs in respect to the 20,750.\\nAnd we'll continue to really work through that population of ECPs and really build that NRx and resell rate, the TRx, and then really playing out on revenue. The other dynamic, of course, is always on gross to net. And while we're not providing official guidance on gross to net because our focus really is on that volume and share component throughout 2022, I would say there is that first-half component related to the majority of patients in the first half expecting to be on that bridge program, which has a discrete impact to gross to net. And then, with our guidance, which is focusing on coverage determinations for the big three PBMs by the midpoint of the year, that transition from bridge over to commercial insurance will have a positive benefit discretely on that line in relation to gross to net, which would kind of tie up to your question on kind of how revenues would flow from a price and volume perspective through the year.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, thank you, Dan. This is John. You asked a question around retention rates and then refill rates. We've been very, very pleased to date with the metrics we've been seeing in that space.\\nEven patients that had been prescribed in early November, we started seeing early refill rates. I could quote that if you look at our blended refill rates with retail pharmacy and our digital online pharmacy, they're hovering around 64%, 65%. So we're very pleased with patients that are coming back and getting the refills. We are getting very, very nice position, as well as patient feedback, and we are hoping to continue that trend throughout 2022.\\nI think, part of that as well is your third part of your question around patient support programs, we out of the gate wanted to really employ a lot of technology around our patient services to TYRVAYA. So we're trying to make it very easy for that patient to navigate that journey through the prior auth and benefit investigations to get them to enroll into the program through QR codes in the offices, online, as well as other digital means. So because of that, we've been getting very, very good high enrollment rates and good fill rates that come through that program. So in terms of tweaking, we're continuing to put out more patient materials to surround sound the patient with different ways to enroll into the program.\\nBut overall, we're very, very pleased with how the program has been going. If the patient is deemed insured, but not covered, they automatically popped into our bridge program that they were appropriate patients and are able to get that script fulfilled and get experience with TYRVAYA. So we'll keep monitoring the patient services program, but so far, we've been very, very pleased.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nGreat. Thanks so much. Appreciate it.\\nJeff Nau -- President and Chief Executive Officer\\nOne thing I will add on, Ken, comment there is as we think about TYRVAYA as a product, when we think about the current marketplace and what it offers to patients, from an immunomodulator perspective, patients will go on a course of an immunomodulator. If they're not happy with the outcome at the end of that course, they're transitioning off, and they're likely either going on to another product or another device or another modality, but very rarely are they coming back. So we see a very low number of patients come back to the original therapy. I think, that the one thing to really keep in mind with TYRVAYA is it works so quickly to provide the patient relief, and it has such a differentiated mechanism of action that we are excited to look forward into the future to see how patients interact with the product.\\nIt's going to be a very different interaction than you would see with an immunomodulator because I do think not only will we have solid refill rates, but we will have people coming back to the product in those later years. And so, we're excited about that. And then, I would -- I'll just throw one comment out there for my team back at the office. Our patient services program is, bar none, one of the best I've ever seen.\\nAnd it is going very well in the field. And so, kudos to the team for putting together such a great program.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nGreat. Thanks so much.\\nOperator\\nThank you. Our next question comes from Joe Catanzaro with Piper Sandler. Your line is open.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nHey, guys, thanks so much for taking my questions, and congrats on the progress here. So maybe just to follow up, I think, Dan, you mentioned you guys had some internal benchmarks, I'm sure, on a bunch of things. But I'm wondering if you can maybe help put into context the early penetration in terms of the number of unique prescribers you've seen relative to your target ECP pool and where your early expectations were there. And then, I'm wondering what aspect -- and maybe it's something you just alluded to, Jeff, what aspect of the product profile do you see as resonating the most? And how do you go about fully leveraging that? And maybe I have a follow-up as well.\\nDan Lochner -- Chief Financial Officer\\nYeah. Maybe I'll start with it on my end. As you saw in the press release, we had achieved 1,900 unique writers in the quarter, which is just under about 10% of the targets that we are going after with our sales force of 162 sales reps. And so, I think, we had great progress in the quarter just under about nine weeks.\\nAnd so, as we look at benchmarks of prior therapies that have come to market more recently, I think we're in a great place for where we had expected us to land. Of course, we also understood that this is a new way of treating dry eye disease. So really communicating the benefits with the nasal spray. And so, I think, we're quite pleased with where we landed and continue to work toward that 21,000 target count as we progress throughout the year.\\nJeff Nau -- President and Chief Executive Officer\\nAnd maybe what I'll add on to -- the second part of the question there is some of the things that are resonating. I think, one of the things that's really been exciting about the launch of this product is patient feedback has been really great. And so, we've been excited to not only hear stories from the field, see posts on social media of patients going out on their own and talking about the product. And just really, it's a great product to launch where you're having that patient feedback come back to the teams and to those folks that have put such hard work into getting the product out there into the marketplace because it's really why we do this and it really drives the team.\\nSo I think, one of the things that we hear that is something that's really encouraging is just the patients stating that they really like the profile. They like the way it's making their eyes feel, and it's just differentiated in the way that it's able to be used. So we do hear stories back of people who are unable to deliver a topical eye drop. And this is another option for them because maybe they don't have the dexterity or they're elderly and they're just not able to put a drop into their eye, and so they're able to use nasal sprays.\\nAnd the other thing that we hear in the field often is the physicians are not getting patients calling back and complaining. And so, that's also really important for us. But again, we're very early in the launch. So we have many patients that haven't been on the product for more than a few months.\\nSo we're excited to see how the long-term feedback is. But for the moment, we are really encouraged by the feedback or sometimes lack of negative feedback coming back from the patients.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nGreat. And if I maybe just squeeze in a quick follow-up. I think, you said you guys have maybe covered about 50% of your target ECPs. Can you maybe speak to what percent of those have been given a sample? And how soon after sampling are you seeing ECPs write a script? Thanks.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, no, thank you, Joe. Great question. Part of our strategy is really to introduce TYRVAYA into the office practice with the prescriber base, the technicians, the staff that are involved with training, the patients and so on prior to actually sampling because we want to make sure that the product is taken appropriately and the patient gets the best possible experience they can with the nasal spray. So we handed out quite a few samples, probably over 100,000 samples since launch.\\nBut we want to make sure that we hand them out appropriately and that installation with that office has actually taken place before that sampling is initiated. So so far, that's worked well for us because we've seen a higher proportion of patients that tried a sample, see if it works for them before they're getting into our patient hub and actually getting that prescription filled. So that kind of connection has been very, very positive with that approach.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nOK, that's helpful. Thanks, again, for taking questions.\\nOperator\\nThank you. Our next question comes from Patrick Dolezal with LifeSci Capital. Your line is open.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nGreat. I'm just curious how the availability of generic cyclosporine has impacted discussions with payers, if at all. Were there any modifications to negotiations with Express Scripts as that approval came to light? I'm just curious if you expect any impacts going forward as you onboard other payers. And then, I have a follow-up as well.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Patrick, thanks for your question. We've seen kind of early mixed reactions from the payer community on how they're going to manage the generic entry of cyclosporine. And with the early listing with ESI, they're actually covering TYRVAYA across their formularies with only a traditional step, sort of an artificial tear. So that's what I mean by mix.\\nSome of the payers are kind of waiting until more than one generic comes out, and they'll take a look at the dry eye space or they're not really managing the dry eye space as closely. And others are going to evolve a little quicker. So we're able to modify our approach. We are ready for a generic to be on the market or not with.\\nAnd that's the way our negotiations are going with the major PBMs. And our goal is to get access for TYRVAYA on a level playing field with the branded therapeutics. And our differentiation along with our strategic contracting will help us get there.\\nJeff Nau -- President and Chief Executive Officer\\nAnd one other comment, Patrick. As you well know, generic entry into the marketplace doesn't change the dynamic that exists where patients cycle off many of these drugs, whether it be for lack of effect or side effects or whatnot. And so, that certainly will not change. So we were planning on generic entry coming.\\nI think, we've been planning for a long time, but it's been always in the back of our mind, and so the team is ready.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nThat's helpful. Thanks. And as it relates to just drug launch surrogates, there's not a ton in the dry eye space really, but obviously, we do have these eye drops. Just curious to hear any similarities and differences that might be worth pointing out.\\nAnd just if you could comment on the role of coverage and driving drug adoption in the dry eye space generally, that would be helpful. I'm curious if there's a tipping point where you feel that the amount of coverage really will drive adoption, 50% if it's a bit more. I would love to hear your thoughts there. Thanks.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Patrick, in regards to the Xiidra launch, we did see very quick uptake. Well, this was back in 2016. They had very early access to the commercial insurers, and they launched with 280-plus reps. We are very pleased with the number of reps we have and the trajectory we're seeing with TYRVAYA.\\nWe are on track in regards to the payer negotiations. And in fact, the ESI listing was an early listing for us. So we will get to that point that we're expecting in terms of broad base of writers, the eye care professionals prescribing TYRVAYA. We just won't be out of the gate as quickly as you saw with the Xiidra launch.\\nI could tell you, versus the latest two launches, we're very pleased with how our trajectory is going versus kind of the more recent entries. But it was a different space back in 2016, less managed, and also they were second entry at the time after Restasis.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nThat makes sense. Thanks for taking the questions.\\nOperator\\nThank you. Our next question comes from Chris Neyor with J.P. Morgan. Your line is open.\\nChris Neyor -- J.P. Morgan -- Analyst\\nGreat. Thanks for taking the questions. So first one is on me -- for me is just wanted to get a bit more details on the Express Scripts contract. So really just thinking about what's the mix between preferred and non-preferred coverage within those 26 million lives that you had estimated.\\nAnd within the Express Scripts plan, are there -- is there potential for additional pickup of patients and additional contracting that would either add additional patients or move more patients toward preferred access? And when talking about that kind of mix -- the mix of customers, what type of co-pay should we be thinking about for most of these patients? I think, I have a couple of follow-ups after that.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Chris. No, thanks. In regards to ESI, whether preferred or non-preferred, in terms of access whether you're listed preferred or non-preferred, the key criteria is you have to have tried and failed on an artificial tear for all of the branded products here. So as you mentioned in the last part of your question, the out-of-pocket is a difference between the Tier 3 and a Tier 2.\\nAnd pretty appropriate patients, commercial patients, we definitely buy down that out-of-pocket to be very competitive with the leading branded product out there. So we feel our 26 million lives that are covered are on a level playing field with regard to the leaders out there. And that -- those are the majority of the larger plans within ESI, but we will continue to work with signing on some of the downstream plans that ESI covers -- sorry, that Ascent covers as well and through ESI. So the tiering for us is not a disadvantage.\\nWe feel we're going to be very competitive with the two major brand leaders out there.\\nChris Neyor -- J.P. Morgan -- Analyst\\nGreat. That's helpful. And then, you kind of touched on the refill rates and also maybe you could just discuss your confidence in being able to hit that commercial coverage for CVS Caremark and UnitedHealth by the middle of this year. And then, aside from maybe overall script trends, any other KPIs that we should be watching for the launch in the coming weeks and quarters?\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, no, Chris, in regards to the refill rates, we've been very pleased with the kind of 60%, 65% rate of refills we've been seeing. We feel that based on the product profile, as well as the services we offer to make sure that both the prescriber base, as well as the patients are supported through the clinical experience with TYRVAYA. In regards to some of the other PBMs, we are in the middle of negotiations with them. We are still on track to have coverage determinations by midyear.\\nAnd we are ready to negotiate whether they're going to be managing the generic space or not. We feel we're going to be very, very competitive to be able to get TYRVAYA listed and get the majority of those commercial lives covered by midyear of '22.\\nChris Neyor -- J.P. Morgan -- Analyst\\nPerfect. Appreciate the questions.\\nOperator\\nThank you. And I'm currently showing no further questions at this time. I would like to hand the conference back over to Dr. Nau for any closing comments.\\nJeff Nau -- President and Chief Executive Officer\\nThank you, operator, and thanks to everyone for joining the call with us today. As I mentioned in my opening remarks, we are extremely pleased to announce that TYRVAYA Nasal Spray, indicated for the treatment of the signs and symptoms of dry eye disease, is currently in its first full quarter of launch for patients and eye care providers in the U.S. We are extremely excited for the potential of significant growth that remains ahead. Our vision and focus on bringing innovative and transformative ophthalmic disease treatments to patients and building Oyster Point Pharma into a best-in-class eye care company remains our primary goal as a company.\\nIn closing, I want to thank everybody for joining us tonight and to have a great evening.\\nOperator\\n[Operator signoff]\\nDuration: 41 minutes\\nCall participants:\\nDan Lochner -- Chief Financial Officer\\nJeff Nau -- President and Chief Executive Officer\\nJohn Snisarenko -- Chief Commercial Officer\\nKen Cacciatore -- Cowen and Company -- Analyst\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nChris Neyor -- J.P. Morgan -- Analyst\\nMore OYST analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 10:00:00\",\n        \"max\": \"2023-02-23 11:00:00\",\n        \"num_unique_values\": 5201,\n        \"samples\": [\n          \"2020-08-13 07:30:00\",\n          \"2019-08-07 09:00:00\",\n          \"2020-05-04 12:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 00:00:00\",\n        \"max\": \"2023-02-23 00:00:00\",\n        \"num_unique_values\": 835,\n        \"samples\": [\n          \"2020-03-11 00:00:00\",\n          \"2023-01-10 00:00:00\",\n          \"2022-03-29 00:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Clean_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17220,\n        \"samples\": [\n          \"Please go ahead. Karen David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations Welcome everyone, to Expro's second quarter 2022 conference call. I'm joined today by Mike Jardon, CEO; and Quinn Fanning, CFO. First, Mike and Quinn will share their prepared remarks, and then we will open it up for questions. We have an accompanying presentation on our second quarter results that is posted on the EXPRO website, expro.com under the investors section. In addition, the second quarter financials are downloadable on the Expro website under the Investors section. I'd like to remind everyone that some of today's comments may refer to or contain forward-looking statements. Such remarks are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such statements speak only as of today's date, and the company assumes no responsibility to update any forward-looking statements as of any future date. The company has included in its SEC filings, cautionary language identifying important factors that could cause actual results to be materially different from those set forth in any forward-looking statements. A more complete discussion of these risks is included in the company's SEC filings, which can be accessed on the SEC website or on our website at expro.com. Please note that any non-GAAP financial measures discussed during this call are defined and reconciled to the most directly comparable GAAP financial measure in our second quarter 2022 earnings release, which can be found on our website. With that, I'd like to turn the call over to Mike. Mike Jardon -- Chief Executive Officer Thank you, Karen. Good morning and good afternoon, everyone. I'm pleased to share with you that Expro delivered robust operational performance and financial results that exceeded the guidance we provided for the just completed second quarter. We are experiencing increase customer activity levels across all segments of our business, bolstered by a backdrop of strengthening industry fundamentals. We believe this positive momentum will not only continue, but will also accelerate going into 2023 and beyond. Expro is poised to capitalize on an expected increase in customer spending and activity. Today, Expro has a scope and financial profile required to compete and win in what we believe is the best outlook for energy services in at least a decade. Our results in the second quarter and our market outlook underscore the benefits of Expro's balanced portfolio of services and solutions with leading capabilities and a culture built around safety, service quality, organizational efficiency and risk management. In addition, we believe our through-cycle resilience is a significant advantage and competitive differentiator for Expro. Our current portfolio of services and solutions is paired with a global operating footprint with established positions in key growth markets and the combination provides Expro with good leverage to improving industry fundamentals and in particular, to the rebound that is beginning to take place in the international and offshore markets. We have never been better positioned to capture cyclical recovery upside. We also continue to have a best-in-class innovation platform and technology portfolio that enables us to support our customers' efficiency and emissions-related goals, grow market share and capitalize on longer-term industry trends. Finally, our strong balance sheet and merger-related synergies provide us with significant financial, operational and strategic flexibility that will allow us to accelerate growth and create long-term stakeholder value. On today's call, I'll touch on three main topics. First, I'll walk you through our second quarter performance. Second, I'll give an update on our integration process. And finally, I'll provide some perspective on trends we are seeing in the broader industry environment. For the second quarter, we delivered revenue of $314 million and an adjusted EBITDA of $51 million. Second quarter revenue increased 12% sequentially and on a Pro Forma basis, 10% year over year. Higher revenue during the quarter was driven by increased activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific regions. Adjusted EBITDA increased 39% sequentially and on a Pro Forma basis, 33% year over year. Adjusted EBITDA was primarily driven by a more favorable activity mix during the second quarter and faster-than-anticipated realization of merger-related synergies. Well Construction revenue was up 9% quarter over quarter and well management, which includes our well flow management, subsea well access and well intervention integrity businesses was up 13% quarter over quarter. Second quarter results exceeded the prior guidance, primarily as a result of increased well flow management and well construction revenue within North and Latin America. Our team continues to both capitalize on improving industry fundamentals and demonstrate the value of Expro's broad suite of cost-effective, innovative solutions to win new business and expand relationships with existing customers. During the quarter, we continued to secure contracts because of our exceptional service quality and technical delivery. We also continued the introduction of new technologies with both CoilHose and Octopoda, achieving market adoption at pace. The current commodity price environment puts a premium on maximizing production from existing well stock. So there is a strong customer interest in well intervention integrity solutions such as CoilHose and Octopoda. The significant under investment in energy supply over the last decade, coupled with growing demand, is also resulting in FID approvals. Importantly, for our company, nearly 60% of the new customer commitments are expected to be offshore. We achieved contract wins and extensions totaling approximately $300 million, which demonstrates the breadth and depth of our customer relationships and attraction that our solutions are gaining in the market. On a regional basis, in North and Latin America, our Well Construction team continues to demonstrate the position as the premier provider of casing and tubular running services with the award of contracts and successful operations delivered across the region. The team successfully completed a first casing running to a project in Brazil and carried out eight simultaneous TRS deepwater completions in the Gulf of Mexico, where activity continues to pick up. We also deployed our industry-leading 22-inch brotpackers in Mexico for the first time and have seen growing demand for this well integrity technology as operators across the region seek to protect their assets during storm season. This technology allows for quick and rely the well suspension when operators need it most. We want to influence contract for a major operator in Brazil. And in Alaska, our team was awarded and performed a well test for a strategically important new customer, further growing our presence in this region. Expro in MENA achieved contractor of the month from an international operator, demonstrating Expro's continued focus on delivering best-in-class safety, quality and customer service. In Europe and Sub-Saharan Africa, we saw good progress in securing new business in the second quarter, including the retention of the largest well flow management contract in the Norwegian continental shelf for an initial four-year term, highlighting the strength and depth of our relationship with this international operator. A significant portion of this contract is directly linked to production optimization and enhancement as well as a demonstrable commitment to low carbon plan. The breadth of our portfolio, including market-leading technologies acquired in our July 2019 acquisition of Quality Intervention directly assisted us in expanding a core well intervention contract with a major international operator in the U.K. In addition, our service quality and portfolio of capabilities helped us secure an expanded contract to meet client needs for a nine-well plug and abandonment campaign in the U.K. Continental Shelf, where we also added well test and well intervention to an existing large board subsea services contract. As I noted earlier, CoilHose and Octopoda are gaining traction in the market to support clients' intervention and integrity needs. Octopoda is a truly unique service offering, which for the first time in our industry, allows direct access to well annualized in which we can ensure well integrity and production assurance. Octopoda was recently deployed in the Congo, the first deployment of this technology in Sub-Saharan Africa, and it continues to generate customer interest with its unique ability to investigate and remediate sustained casing pressure and other well annulus problems. Additionally, our CoilHose Light Well Circulation system is an innovative development, providing a lower cost more efficient alternative to traditional coiled tubing systems. This broadening of our portfolio and our depth of experience, combined with the ability to quickly mobilize assets and personnel to meet client requirements helped us secure a U.K. contract for well testing and exploration and appraisal services in support of a new offshore drilling campaign. Expro's superior quality and service performance as strong client partnerships led to the securing of multiple contract wins, including for our subsea team in the Ivory Coast and in Turkey, where we won well testing and CoilHose intervention work for a nine-well project on offshore gas storage project. In the second quarter, we also introduced Drill Stem testing into Angola, further broadening our comprehensive portfolio in this country and positioning us to take advantage of the increasing activity in deepwater operations in Angola. We have successfully started operations in Cabinda for a major operator, which will be our first deployment of hammering services as part of an Angolan Well Construction Service package. In May, we were also recognized as the safest service provider in Mozambique. Based on our recent performance, we are in discussions with the client regarding further expansion of our services, including the introduction of new technologies. In Chad, our work with the client is core to ensuring that our operations are conducted in an environmentally responsible way. Our expertise and technologies are focused on having no environmental impact with testing and analysis carried out to ensure the appropriate purity of the regional freshwater system, underlining our status as a leading provider of on-site chemistry services with a strong environmental focus. In Norway, we completed our first operational campaign with our iTong Well Construction Technology, which provides a step change in safety and well construction operations. Operational performance exceeded client expectations, delivering significant rig efficiency improvements and cost savings to the customer overall. In the Middle East and North Africa, our Well Construction team has expanded into new territory to secure their first TRS contract in Algeria, which is planned to commence later this month. This opportunity reflects one of the many revenue synergies created by our October merger. We leverage expert relationships and well flow management to secure this new TRS award. In addition, the regional team was awarded two carbon boom contracts with Middle East drilling contractors, reflecting our market-leading capabilities and reputation in the market. In Egypt, our service offering and ability to deliver contributed to Expro being awarded significant well test contracts. In the Asia Pacific region, our well construction team in Brunei secured a major 5-year contract for TRS. Our outstanding track record of reliable performance in HSC and service quality were strong criteria for the contract award. In Thailand, the team secured additional TRS work covering 200 wells and in Malaysia and in offshore China, we were awarded three-year TRS contract extensions spanning development and exploration wells. Our subsea team's technical capability played a key part in securing a contract with a major international operator in Malaysia for the provision of our new vessel deployed Light Well Intervention package, with the team also securing significant additional work in Australia. Like CoilHose and Octopoda, Expro's LWI capabilities are the result of investments we have made over the last several years, which should allow the company to offer differentiated production optimization solutions and thereby grow our top line faster than the overall market, while also improving profitability. Expro is strategically committed to continuing to invest in transforming our business portfolio and reducing greenhouse gas emissions. In April, we published our inaugural, environmental, social and governance review with a stated aim of achieving net 0 by 2050 with a 50% reduction in carbon intensity by 2030. As the energy industry embraces transition and the need to make real and visible headway toward a lower carbon world, we appreciate the key enablers to change will be those who can truly differentiate themselves as solutions providers. As recognized global well experts and a trusted partner, we believe Expro is well-positioned to play an important role in enabling our clients to achieve their carbon reduction goals in support of the energy transition. Expro remains committed to allocating roughly 50% of our research and development budget to carbon reduction initiatives. In doing so, we are developing and advancing solutions that will play a critical role in enabling our customers to achieve their own emission reduction goals while also allowing experts to achieve its goals. Expro's well expertise and range of well intervention, well integrity and wells measurement technologies and skills help operators cost-effectively develop oil and gas resources while minimizing both emissions and the required operating footprint. As our industry speaks to address tomorrow's challenges, we believe many of these technologies and skills are transferable. As a good example of adopting technologies to achieve more sustainable energy solutions, Expros supported geothermal well service projects since 1986. Most notably, in the second quarter, we were awarded our first integrated services geothermal contract to support a high-profile geothermal plant in Germany. The second topic I'd like to cover is to provide an update on our integration efforts. During the quarter, we continued to make progress in bringing the legacy businesses together to capture the full potential of our combined platform. I am pleased to report that 9 months into our integration, we have identified an action more than 100% of the $55 million in annualized cost savings that we established with our target within the first 12 months following the closing of the merger. This comes a full quarter earlier than we had initially anticipated. As outlined previously, we are targeting cost and revenue synergies between $80 million to $100 million within 24 to 36 months post-merger. We remain confident that we will achieve $70 million in projected cost synergies during this time frame, if not earlier. Cost savings are primarily driven by the rationalization of support costs, consolidation of facilities and supply chain savings. In the second quarter, we consolidated additional facilities, including locations in Baku, either by John, St. John's, Canada; Lumpur, Malaysia; Mumbai, India; Corpus Christi and Midland, Texas. While revenue synergies are more difficult to demonstrate, my sense is that our previous estimate of an incremental $10 million to $30 million in EBITDA for revenue synergies through our expanded customer relationships and operating footprint, increased time on rig and greater exposure to the full life of the field will likely prove to be conservative. I'd like to sincerely thank the entire expert team for their hard work and numerous contributions toward helping us realize our integration goals ahead of schedule. Without a doubt, we have a winning team that has proven the building to deliver on our commitments. Before I turn the call over to Quinn, I want to provide some perspective on trends we are observing in the market. The positive signs of a recovery we saw in Q1 continued to build, underpinned by a favorable supply demand dynamic. As I noted earlier, this is largely a result of limited upstream investment in recent years and a need for additional capacity to meet projected demand growth. With the more recent heightened focus on energy security, diversification of supply and the need to replace at least a portion of Russian oil and gas supply is expected to fully magnify what was already set up to be a favorable multi-year macro backdrop for OFS activity. Longer term, we believe the service sector will need to play an important role in facilitating the energy transition. So despite ongoing volatility in commodity prices, the fundamental backdrop for the energy services sector is quite constructive. In particular, after a strong recovery in the U.S. onshore market, we are seeing increasing demand for our services and solutions with international and offshore activity expected to accelerate through the second half of 2022 and into 2023 as operators look to increase production from existing assets and develop new fields. Notwithstanding near-term concerns of an economic slowdown, there seems to be a consensus that energy demand will trend back toward, if not through 100 million barrels of oil equivalent per day in 2023. We expect that increasing demand for energy services and capacity constraints in key service offerings, including high-end well construction equipment and subsea test trees should provide scope for improvement in net pricing beginning in late 2022 into early 2023. In Expro's view, expected growth will be broad-based geographically, span all phases of oil and gas development and include all operating environments. Geographically, we see strong potential in North and Latin America, the Middle East, North Africa, Sub-Saharan Africa, as well as Asia. And while many of our customers continue to focus on brownfield enhancement programs to maximize previous investments, we are also starting to see growth in exploration and development activity driven primarily by North and South America, with further activity expected in Norway, India and Sub-Saharan Africa. The brownfield focus will support steady growth in our well Intervention Integrity business as well as elements of our well flow management business, collectively, which represent about 35% of our business. The remaining circa 65% of our business is generally levered to drilling, well construction and well completions activity, which we believe is points for strong growth across several geographies and within which we generally capture very good faster on incremental revenue. Overall, the outlook for the remainder of '22 and into 2023 remains positive with sustained increases in E&P expenditures. After rather dramatic recovery in the North America onshore market, customer dialogue and tendering activity indicates to us that the outlook for offshore activity is strengthening. This should support sustained growth for Expro given our leading and differentiated portfolio capabilities and subsea well access services, complex well construction services and production optimization. This is particularly important as approximately 70% of our revenue today is generated from offshore activity. Before I close, I'm pleased to share that during the quarter, our board approved a new stock repurchase program under which the company is authorized to acquire up to $50 million of its outstanding common stock up to the November 2023 time frame. We view the repurchase of our shares as an attractive and prudent use of our capital that it is in the best interest of our shareholders. With a debt-free balance sheet, ample available liquidity and strong construction of an industry recovery, buybacks allow us to opportunistically increase shareholder value while maintaining sufficient cash resources to fund our business needs. In the second quarter, we repurchased $13 million in export stock, representing approximately 1% of our shares outstanding. From an operational standpoint, Expro is well positioned in the markets that we expect will continue to benefit from strengthening industry fundamentals. In particular, Expro has significant leverage to strengthen the international and offshore markets where experience, expertise and service quality can be in Expro's case are positive points of differentiation. Execution is a traditional strength of Expro and when we plan to continue to deliver on both for our customers and our shareholders. With that, I will hand the call over to Quinn to discuss our financial results. Quinn Fanning -- Chief Financial Officer Thank you, Mike. Good morning and good afternoon to everyone on the call. As Mike noted, I will cover the results for the quarter ended June 30th, 2022, and will primarily highlight our sequential performance compared to the quarter ended March 31st , 2022. To recap, we reported revenue of $314 million for the June quarter, which was up sequentially $34 million or approximately 12% relative to Q1 2022. The sequential increase in revenue was driven by higher activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific segments, partially offset by lower activities in the Middle East and North Africa segment. Adjusted EBITDA for Q2 2022 was approximately $51 million, representing a sequential increase of approximately $14 million or 39% relative to Q1 2022. Adjusted EBITDA margin in Q2 was 16% as compared to 13% in Q1. The sequential increase in revenue and adjusted EBITDA was driven by strong results for well flow management and well construction in North and Latin America. As highlighted in our press release, adjusted net income for the second quarter of 2022 was $0.02 per diluted share, compared to adjusted net income for the first quarter of 2022 of $0.01 per diluted share. As noted in our press release, adjusted net income for Q2 includes foreign exchange losses of $0.05 per diluted share as compared to foreign exchange gains of $0.03 per diluted share in Q1. Q2 contribution margin of 38% was up approximately one percentage point sequentially from Q1 2022, reflecting improved fall-through on higher revenue as a result of a more favorable activity mix. Q2 support costs of $70 million totaled 22% of group revenue and were down approximately $1 million sequentially or approximately 3 percentage points relate Q1 2022 and were down $8 million or approximately 9 percentage points relative to the combined support costs of Expro Frank's in Q4 2020, which was the last full quarter prior to the announcement of the merger. This represents approximately $30 million of annualized support cost savings achieved through the second quarter of 2022. In the near term, we expect to continue to manage total support costs to 22% of group revenue. With modest net pricing gains and/or incremental cost synergies, we believe we can manage overall support costs to about 20% of revenue. Total liquidity at quarter end was approximately $309 million. Cash and cash equivalents, including restricted cash, was $179 million as of June 30th. Total liquidity also includes $130 million that is available to the company for drawdowns as loans under our $200 million revolving credit facility. The balance of the facility is available for bonds and guarantees. Expro had no interest-bearing debt at quarter end Q2 2022, and the company has no interest-bearing debt today. During the quarter ended June 30th, cash provided by operating activities was $2 million as compared to cash used in operating activities of $14 million in Q1. Q2 adjusted operating cash flow, reflecting cash used in operations before cash paid for interest, severance and other expenses and merger integration expenses, was positive $10 million compared to negative $1 million in Q1. Capital expenditures totaled $21 million in the second quarter compared to $11 million during the first quarter. For the second half of 2022, the company is planning for capital expenditures in the range of approximately $60 million to $70 million, implying total capex for 2022 of $90 million to $100 million or approximately 8% of expected revenue. We also continue to expect to be free cash flow generative for 2022, but as noted on our last earnings conference call, we expect that adjusted cash flow from operations and free cash flow will be heavily weighted to the second half of the year. Consistent with comments from several of our public peers, Expro's investment in working capital was up materially in the first half of 2022, with higher receivables reflecting higher activity levels and higher inventory reflecting both an expectation of continued momentum in the business and the procurement of long lead items, including critical spares. Consistent with historic patterns, we expect a reversal of the H1 build in working capital and a significant improvement in cash generation in H2 2022. As Mike previously discussed, under our recently announced stock repurchase program, during the second quarter, we opportunistically repurchased 1.1 million shares or approximately 1% of our shares outstanding for a total cost of $13 million. This program is a reflection of the long-term confidence we have in our business, which we believe is not reflected in the current market valuation. In due course, we will more formally articulate Expro's capital allocation priorities. For now, we expect that the small buyback will be completed in Q2 and for that matter, any additional buybacks will be funded by free cash flow. Now, moving into the details for reporting segment. North and Latin America or NLA, revenue for the second quarter of 2022 was $130 million, a sequential increase of $26 million quarter over quarter. The increase was primarily due to higher revenues across all of our product lines during the current quarter with a significant increase in well flow management revenue in Mexico and higher well construction revenue in the U.S. and Guyana driven by higher customer activity levels during the just completed quarter. NLA segment EBITDA for the three months ended June 30th, 2022, was $39 million or approximately 30% of segment revenue. It was up sequentially by $17 million quarter over quarter. For Q1 2022, NLA segment EBITDA was 21% of segment revenue. The increase was attributable to higher activity and a more favorable product mix during the three months ended June 30th. For the Europe and Sub-Saharan Africa or ESA segment, revenue in Q2 was $90 million, which was up $8 million or approximately 10% quarter over quarter. The sequential increase was primarily driven by higher wealth flow management revenue in Angola and in the Congo and higher well construction revenue in the United Kingdom due to increased customer activities. The increase in revenues was partially offset by lower well intervention integrity revenue in Norway and Western Europe. ESA segment EBITDA for the second quarter was $15 million or approximately 16% of segment revenue, a sequential increase of $3 million quarter over quarter. The increase was primarily attributable to higher activity levels and a more favorable activity mix during the June quarter. For the Middle East and North Africa or MENA segment, revenue in the second quarter was $45 million, a decrease of $6 million or approximately 11% quarter over quarter. The sequential decrease was driven by lower equipment sales related to wealth management in Saudi Arabia and in the United Arab Emirates, partially offset by increased wall management activities in Algeria. MENA segment EBITDA for the June quarter was $14 million, a sequential decrease of $1 million quarter over quarter. Segment EBITDA margin was consistent with the prior quarter at 30%. The reduction in segment EBITDA was primarily due to lower activity. For Asia Pacific, or APAC, revenue for the second quarter was $48 million, which was an increase of $4 million or approximately 11% sequentially. The increase in revenue was primarily due to higher subsea well access revenue in Australia and Brunei and higher well construction revenue in Japan. The increase in revenue was partially offset by lower wealth flow management revenue in Thailand and in India. APAC segment EBITDA for the June quarter was $4 million or approximately 9% of segment revenue, a decrease of $1 million or about 3 percentage points quarter over quarter. The reduction in segment EBITDA in APAC, despite the increase in revenue was primarily due to additional mobilization and commissioning costs on a large subsea project that were incurred during the quarter as well as lower activity on higher-margin contracts. Additional commissioning costs on the Subsea projects, which totaled approximately $3 million and associated project start-up delays are in part COVID related and should be nonrecurring. As a result, we expect that revenue and segment EBITDA margin in APAC will trend positively in H2 2022 and into 2023. As Mike mentioned, our integration plans are progressing well, and we are already starting to realize significant synergy benefits we anticipated when we first announced our business combination in March of 2021. As Mike mentioned, through the second quarter of 2022, we have identified an action to approximately 100% of our synergies capture plan, both in regards to headcount and annualized value in dollars. We also completed the consolidation of several international facilities and made good progress on our ongoing migration to a single ERP platform, which should allow us to both to streamline a number of key business processes and begin to action additional cost synergies. As to our near-term outlook, we expect that Q3 2022 revenue will be up sequentially by plus or minus 8%, reflecting continued business momentum at NLA, the continuation of the seasonal rebound in ESA and the start-up of new contracts in MENA and APAC. Adjusted EBITDA margin in Q3 should be in the area of 15% to 17% of consolidated revenue. Over the next couple of quarters, we continue to expect that our revenue run rate will approximate that of the pre-pandemic 2019 revenues of Legacy Expro and legacy Frank's on a combined basis. And we, therefore, reaffirm our guidance, the Q4 revenue should fall within a range of $325 million to $350 million. With the benefit of fall-through on incremental revenue and synergies, we expect that adjusted EBITDA margins will be in the area of 20% of revenue as we exit the year. Provided our H1 build in working capital reverses in H2 2022 as is currently anticipated, absent additional M&A and/or share repurchases, we expect that our year-end cash position will be at or above where we started the year with cash generated from operating activities, funding integration costs, capex, the Q1 acquisition of SolaSense and the share buyback that was completed in Q2. By preserving and protecting our currently strong financial profile and by maintaining a disciplined approach to investment, we believe Expro will have sufficient financial flexibility to fund growth and increase returns to shareholders. As always, our objective is to enhance long-term value for our shareholders, employees, partners and the communities in which we operate. With that, I will turn the call back over to Mike for a few closing comments. Mike Jardon -- Chief Executive Officer Thank you, Quinn. We delivered exceptional operational performance that drove significant growth on a top and bottom line and is beginning to demonstrate the true capability of the company. Our broad portfolio of services and solutions continue to create opportunities in the growth markets that will be key to Expro's long-term success. Our innovative platform, next-generation technology and solutions and ESG applications are differentiators that continue to rapidly advance our reputation and outstanding track record with customers as a leading well expert. We continue to secure contracts and demonstrate the value of the breadth of our portfolio and the depth of our expertise can bring to clients across the life of their wells. Looking forward, the positive signs of a recovery we saw in the first quarter continued to gain momentum. We are seeing increased demand for our services and solutions as the recovery that began within the U.S. onshore market has begun to gain traction in the offshore international markets. We remain confident that the pipeline of projects we are seeing will support strong multi-year growth and firmly believe Expro is uniquely positioned to capitalize on this favorable outlook. We are incredibly excited about the strength and positioning of Expro. Our results could only have been achieved by the hard work and focus of our team. It's through their dedication that we continue to accelerate growth, improve profitability and enhance value for shareholders, employees, customers and partners. Thank you, again. Questions & Answers: James West -- Evercore ISI -- Analyst Good morning, guys. Mike Jardon -- Chief Executive Officer Good morning James. James West -- Evercore ISI -- Analyst So one, Mike -- so curious, it seems like we've gone through a bit of acceleration in demand here over the last quarter, maybe two quarters in a sense of urgency has arisen within your customer base? I guess -- so first, is that -- am I getting that correct? And that this urgency is kicking in? And then second, are you seeing more of that urgency or increased demand on producing assets or new assets or interventions versus new well construction type work. Mike Jardon -- Chief Executive Officer Yes. So James, I can tell you one of the good things is we've really -- now that we're kind of more exited the pandemic. I've been able to spend an awful lot more time with customers, not only in the U.S., but in particular, Middle East and Asia. And what I'd say is the conversations particularly around new FIDs, new projects, new drilling and completion type activity, that's much more constructive, much more dialogue and discussion around that. I'd say that the -- we've had continuing strong commentary and strong game with customers around producing assets. So that's -- I think that's ramping up, but not at the same rate as the positivity from the discussions around new well type -- new well drilling activity and new well completion activity. James West -- Evercore ISI -- Analyst OK. Fair enough. And then on the pricing side, are you -- at this point, are we back to kind of -- or getting close to back to pre-pandemic type of levels? Admittedly, offshore wasn't as robust even then, but it's growing and robustness now. But are you achieving the returns on capital investments that you would like to see when you're allocating capital and what you're pricing new contracts? Mike Jardon -- Chief Executive Officer So I would -- and I tried to allude to it in my earlier comments, we're starting to see some spotty opportunities to push price, and we're pushing price every opportunity we can. It's more selective right now. I think we'll continue to gain more momentum around our ability to continue to press price as we exit '22 going into '23, but we are starting to have -- it hasn't quite turned the quarter, so to speak, like North America. U.S. land has where there's lots of pricing leverage and pricing traction. But we are starting to see in some particular markets and some particular service lines, positive opportunity to continue to get that pricing. And I think we're all keen to make sure that we start to implement that absolutely as soon as we can. Quinn Fanning -- Chief Financial Officer James, I think the only thing -- I could just point you back to Mike's prepared remarks, there are capacity constraints within certain solutions and certain product groups, complex well construction or to provide construction activity or TROs, as well as the subsea landing streams. It's obviously a market that is supported by just a handful of service providers ourselves being one of the two larger ones product lines. But obviously, everything about the supply and demand, there's less than a supply for those two equipment classes. The other thing I'd highlight is with the pickup in drilling and completion type activity. It's not necessarily how we present our supplemental disclosures. But what we consider to be our drilling completions over businesses, they were up 20% quarter-over-quarter revenue-wise and the thoughts for margins on the incremental activity is north of 50%. So that's really where you get the -- James West -- Evercore ISI -- Analyst OK. Got it. Yes, no doubt. That's going to be very helpful. David Anderson -- Barclays Capital -- Analyst Hey. Good morning, Mike. I was just curious which of your product lines showed the greatest margin improvement this quarter. And I think you maybe just touched on it just now here. But curious if there's been much of improvement in well construction, in particular, as a rental business in TRS with high offshore exposure. Just curious how we should be thinking about the margin expansion upside in that particular business and how that should contribute overall. Mike Jardon -- Chief Executive Officer Sure. We alluded to some of this in the prepared remarks. What kind of additional commentary I'd add to it, David, is we've really seen some increased mix, better mix of activity in North Latin America, in particular. So yes, particularly around TRS around well construction, we've been able to start to see some margin expansion there. And then I think overall, what you're really seeing is starting to gain more traction with the cost synergies we're taking out the organization overall. We're in essence, we're a full quarter ahead of that. And I think one of the real positives of us being able to get the synergies implemented is if we're being to completely honest, anytime you're doing a consolidation, you're doing a merger, if there is a little too much internal focus that goes on. It's a necessary part of the eval as doing a merger as we can get more of that behind us, and we'll largely because we're a quarter ahead of it, that means going in exiting '22 and going into '23, we're really going to be much more externally focused. And that's one of the reasons why I've been challenging the organization is so hard to make sure we get these things done sooner rather than later. But overall, we're seeing margin expansion across well construction and even in some of the well flow management and subsea access, we're getting some traction in all three of those right now. David Anderson -- Barclays Capital -- Analyst So if I just stay on the well construction side, we're hearing a lot of talk about rigs coming back to work both on the jack-ups and the deepwater side. Are you getting inquiries for those? I'm just kind of curious, it's obviously only a couple of players in the TRS business. So I'm just kind of curious, are you starting to kind of roll out some additional equipment at been sidelined for a while. Can you help us give us a handle on what that looks like in terms of, I guess, your capacity type of equipment out there and how that's moved up? Mike Jardon -- Chief Executive Officer Yes. No, absolutely. We are seeing the same phenomenon that the drillers are seeing today with increased utilization, those kind of things. Because keep in mind, a drilling rig and TRS type equipment goes kind of hand in hand. So yes, we're able to start to put some of that equipment back to work. I referred to a casing running tool CRT opportunity we execute on in Brazil. That purely is taking assets and resources that were underutilized previously and putting those to work. So on the flip side of that, yes, we're seeing good traction with all construction. The other thing that we're seeing even more so than I had anticipated was it really becomes an early warning radar system for us, so to speak, because typically, with customers, they select the rig first almost in conjunction with that are certainly right behind it is selecting the TRS provider. And then you start moving into well completions and well testing, and those type of activities. So we're getting earlier customer engagement. And I think that we'll continue to see that allow us to more upholster revenue opportunities, those types of things. David Anderson -- Barclays Capital -- Analyst That's interesting. So if I just -- on that on that well flow management, it was up 14% sequentially this quarter, I'm pretty sure what was pretty strong for business that I thought we would consider later cycle, more production focused. So I guess the question was, I think you had said in your remarks that MENA was a little bit weaker than expected. So where were the results? Was it more mix related this quarter? Was it regional? Was something else kind of picking up and offsetting what you said? I mean, because I would have thought MENA would have actually been a driver of that growth. And it sounds like it wasn't -- Mike Jardon -- Chief Executive Officer Sure. MENA for us was really -- we had kind of a quarter-on-quarter product sales that didn't reoccur in the second quarter. So that was what gave us a little bit of softness there. Our strong activity in the Middle East, Algeria, in particular, was actually up quarter on quarter. What is important to recognize with well flow management is, in particular as well testing, we can utilize those assets in a well completions cleanup load or you can use those assets in a production optimization mode. And that allows us to kind of flex that equipment to deploy it into one or the other. And part of the growth we saw was starting to see some better activity from a new well completions, new well flowback, those type things within the quarter. David Anderson -- Barclays Capital -- Analyst OK. Thank you very much. Mike Jardon -- Chief Executive Officer Absolutely. Thanks for the questions. Duration: 0 minutes Call participants: Karen David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations Mike Jardon -- Chief Executive Officer Quinn Fanning -- Chief Financial Officer James West -- Evercore ISI -- Analyst David Anderson -- Barclays Capital -- Analyst More XPRO analysis All earnings call transcripts\",\n          \"I would now like to turn the conference over to Rodney Sacks, Co-CEO, to begin the call. Please, go ahead. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Good afternoon, ladies and gentlemen. Thank you for attending this call. I'm Rodney Sacks. Hilton Schlosberg, our Vice Chairman and Co-Chief Executive Officer, is on the call; as is Tom Kelly, our Chief Financial Officer. Tom Kelly will now read our cautionary statement. Thomas J. Kelly -- Chief Financial Officer Before we begin, I would like to remind listeners that certain statements made during this call may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and are based on currently available information regarding the expectations of management with respect to revenues, profitability, future business, future events, financial performance and trends, as well as the future impact of the COVID-19 pandemic on the company's business and operations. Management cautions that these statements are based on our current knowledge and expectations and are subject to certain risks and uncertainties, many of which are outside the control of the company that may cause actual results to differ materially from the forward-looking statements made during this call. Please refer to our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K filed on March 1, 2021, including the sections contained therein entitled Risk Factors and Forward-looking Statements, for a discussion on specific risks and uncertainties that may affect our performance. The company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events or otherwise. I would now like to hand the call over to Rodney Sacks. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Thank you, Tom. The company's top priority remains the health, safety and well-being of its employees. The company's flavor manufacturing facilities, its co-packers, warehouses and shipment facilities have operated throughout the COVID-19 pandemic. The company's bottlers and distributors are operating, and the company's products remain generally available to consumers. In limited countries, the operations of the company's bottlers and distributors have, in part, been negatively affected for varying periods of time. Despite the ongoing impact of the COVID-19 pandemic, the company achieved record second quarter net sales. Currently, the company does not foresee a material impact on the ability of its co-packers to manufacture and its bottlers and distributors to distribute its products as a result of the COVID-19 pandemic. The company's supply chain remains largely intact. However, the company continues to experience shortages in its aluminum can requirements in the United States and EMEA, given the company's volume growth and the current supply constraints in the aluminum can industry. The company is also experiencing delays in procuring certain ingredients, both domestically and internationally. As a result, the company was unable to fully satisfy demand in the 2021 second quarter in the United States and EMEA. We expect such challenges to continue for the next few months. The company has taken steps to source additional quantities of aluminum cans from the United States, South America and Asia. The company has entered into new supply agreements with two new aluminum can suppliers in the United States, and which are expected to be operational in the 2021 fourth quarter. We expect deliveries of additional quantities of cans increasing sequentially during the latter part of the year. Logistical issues, including shortages of shipping containers and port of entry congestion could delay ongoing international supply of aluminum cans. Separately, we are continuing to experiencing -- experience freight inefficiencies as well as significant increases in domestic and international freight costs and like other beverage companies are incurring increased aluminum can and other costs in the current environment, all of which in addition to other factors, will continue to adversely impact gross margin percentages. In the second quarter of 2021, net sales were $1.46 billion compared with $1.09 billion in the second quarter of 2020, an increase of 33.6%. Adjusting for foreign currency movements, net sales for the 2021 second quarter would have been up 30.1%. Gross profit as a percentage of net sales for the 2021 second quarter was 57.2% compared with 60.3% in the 2020 second quarter. The decrease in gross profit as a percentage of net sales for the three months ended June 30, 2021, was primarily the result of geographical sales mix and increased input costs, mainly increased raw material freight in costs and aluminum can costs. Operating expenses for the 2021 second quarter were $310.9 million compared with $252.2 million in the 2020 second quarter. As a percentage of net sales, operating expenses for the 2021 second quarter were 21.3% compared with 23.1% in the 2020 second quarter. Operating income increased 29.1% to $526 million, up from $407.3 million in the second quarter of 2020. Net income increased to 29.7% and to $403.8 million compared to $311.4 million in the 2020 comparable quarter. Diluted earnings per share for the 2021 second quarter increased to 28.6% and to $0.75 from $0.59 in the second quarter of 2020. According to the Nielsen reports for the 13 weeks through July 24, 2021, for all outlets combined, namely convenience, grocery, drug, mass merchandisers, sales in dollars in the energy drink category, including energy shots, increased by 14.2% versus the same period a year ago. Sales of the company's energy brands, including Reign, were up 8.6% in the 13-week period. Sales of Monster were up 11.1%. Sales of Reign were down 6.1%. Sales of NOS decreased 4.1%, and sales of Full Throttle increased 7%. Sales of Red Bull increased 15.3%. Sales of Rockstar decreased by 15.7%, and sales of 5-Hour increased 8.5%. VPX Bang sales increased 20%. According to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the energy drink category in the convenience and gas channel, including energy shots in dollars, increased 7.4% over the same period the previous year. Sales of the company's energy brands, which include Reign, increased 3.6% in the four-week period in the convenience and gas channel. Sales of Monster increased by 5.8% over the same period versus the previous year, Reign sales decreased 6.8%, NOS was down 10.7%, and Full Throttle was up 13.2%. Sales of Redbull were up 9%. Rockstar was down 18.6%, and 5-Hour was up 3.2%. VPX Bang sales increased 12.2%. According to Nielsen, for the four weeks ended July 24, 2021, the company's market share of the energy drink category in the convenience and gas channel, including energy shots, in dollars, decreased 1.3 points to 36.5%. Monster share decreased 0.4 of a share point to 30.6% and. Reigns decreased 0.4 of a share point to two points -- sorry, 2.4%. NOS's share decreased 0.5 of a point to 2.7%, and Full Throttle share remained at 0.7%. Redbull's share increased point -- six points to 37.4%. Rockstar's share was down 1.2 points to 3.8%. 5-Hour share was lower by 0.2 points at 4.6%. VPX Bang share increased 0.3 points to 7.6%. As previously reported, Coca-Cola Energy is being discontinued in the United States and Canada by the end of 2021. According to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the coffee plus energy drink category, which includes our Java Monster line in the convenience and gas channel, increased 4.2% over the same period the previous year. Sales of Java Monster, including Java Monster 300, were 5.9% higher in the same period versus the previous year. Sales of Starbucks Energy were 0.4% higher. Java Monster share including Java Monster 300 of the coffee plus energy category, which primarily includes Java Monster, Java Monster 300, Starbucks Doubleshot and Tripleshot, Rockstar Roasted and Bang Keto Coffee for the four weeks ended July 24, 2021, was 51.9%, up 0.9 of a share point, while Starbucks' energy share was 45.5%, down 1.7 points. According to Stackline, which tracks energy drink sales by Amazon in the United States, in the four-week period ending July 3, 2021, sales in dollars in the energy category by Amazon, including energy shots, increased 104.5% over the same period the previous year. Sales of Monster increased 59.9%. And its share was 28.1%, down 7.8 share points versus the same period a year ago. Red Bull sales increased 109.4%, and its share was 16.6%, up 0.4 points. Celsius' sales increased 133.1%. And its share increased 1.8 points to 14.3% 5-hour sales increased 40.9%. And its share declined 1.3 points to 2.9%. VPX Bang sales increased 216.1%. And its share increased 1.8 share points to 5.2%. Reign's share decreased 0.1 of a share point to 5.3%. Rockstar's share increased 0.9 of a share point to 3.9%. According to Nielsen, in all measured channels in Canada, for the 12 weeks ended June 19, 2021, the energy drink category increased 17.9% in dollars. Sales of the company's energy drink brands increased 28.3% versus a year ago. The market share of the company's energy drink brands was 41.5%, up 3.4 points. Monster sales increased 18.3%, and its market share increased by 0.1 of a point to 35.4% -- sorry, 35.4%. NOS' sales increased 12.6%, and its market share decreased 0.3 of a point to 1.9%. Full Throttle sales decreased 2.1%, and its market share decreased 0.1 of a point to 0.6%. Red Bull sales increased 18.1%, and its market share increased 0.1 of a point to 38.7%. Rockstar sales decreased 8.6%, and its market share decreased 3.3 points to 11. 4%. GURU's sales increased 35.9%, and its share increased 0.5 of a share point to 4%. According to Nielsen, for all outlets combined in Mexico, the energy drink category increased 45.2% for the month of June 2021. Monster sales increased 38.7%. Our market share in value decreased by 1.3 points to 27.2% and against the comparable period the previous year. Red Bull sales increased 41.4%, and its market share decreased by 0.2 of a point to 6.5%. Vive 100 sales increased 30.2%, and its market share decreased by 2.4 points to 20.5%. Volt's sales increased 41.1%, and its market share decreased 0.5 of a share point to 18.5%, while B:oost's sales increased 15.7%, and its market share decreased 1.3 points to 5.1%. Amp's sales increased 91.9%, and its market share increased 4.4 points to 17.9%. Predator, which was launched in March 2020, achieved a market share of 3.1%. The Nielsen statistics for Mexico cover single months, which is a short period that may often be materially influenced positively and/or negatively by sales in the OXXO convenience chain, which dominates the market. Sales in the OXXO convenience chain in turn can be materially influenced by promotions that may be undertaken in that chain by one or more energy drink brands during a particular month. Consequently, such activities could have a significant impact on the monthly Nielsen statistics for Mexico. According to Nielsen for the month of June 2021 compared to June 2020, Monster's retail market share in value increased in Argentina from 40.1% to 46.9% and in Brazil from 29.6% to 35.4%. In Chile, Monster's retail market share decreased from 45.7% to 41.9%. Monster Energy continues to be the leading energy brand in value in Argentina. I would like to point out that the Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country-to-country and are reported on varying dates within the month referred to from country-to-country. According to Nielsen, in the 13-week period ending July 18, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 34.2% to 37.4% in Spain. According to Nielsen, in the 13-week period to the end of June 2021, Monster's retail market share in value as compared to the same period the previous year grew from 14.5% to 15.3% in Germany, from 18.4% to 19.4% in Poland and from 18.4% to 20.1% in South Africa. According to Nielsen, for the 13-week period ending June 20, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 12.5% to 16.2% in Belgium, from 24.2% to 25.3% in Denmark, from 25.8% to 28.2% in France, from 25% to 29% in Great Britain, from 6.7% to 8.4% in the Netherlands, from 27.1% to 31.2% in Norway, from 25.6% to 29.3% in the Republic of Ireland and from 13.4% to 14.5% in Sweden. According to Nielsen, in the 13-week period until the end of May 2021, Monster's retail market share in value compared to the same period the previous year grew from 13.3% to 14.5% in the Czech Republic, from 35.1% to 37.9% in Greece and from 16.6% to 29% in Italy. According to Nielsen, in the 13-week period until the end of May 2021, Predator's retail market share in value as compared to the same period the previous year grew from 5.1% to 17.3% in Kenya and from 0% to 8.1% in Nigeria. The Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country to country. According to IRI in Australia, Monster's market share in value for the month ending June 2021 increased from 11.6% to 14% as compared to the same period the previous year. Mother's market share in value decreased from 13.3% to 11.6% during the same period. The market share of the company's brands in Australia for the month ended June 2021 increased from 24.9% to 25.5%. According to IRI in New Zealand, Monster's market share in value for the four weeks ended July 11, 2021, increased from 9.9% to 12.4% as compared to the same period of the previous year. Live+ market share in value remained the same at 6.9%, and Mother's market share in value increased from 6.2% to 6.3%. The market share of the company's brands in New Zealand for the four weeks ended July 11, 2021, increased from 23.1% to 25.6%. According to Nielsen, in South Korea, Monster's market share in value in all outlets combined for the month of June 2021 increased from 53.3% to 61.9% as compared to the same period in the previous year. According to INTAGE, in Japan, Monster's market share in value in the convenience store channel for the month of June 2021 was 50.6% as compared to 51% in the same period the previous year. Monster remains the market leader in Japan. We again point out that certain market statistics that cover single months or four week periods may often be materially influenced positively and/or negatively by promotions or other trading factors during those periods. Net sales to customers outside of the US were $546.3 million, 37.4% of total net sales in the 2021 second quarter compared to $328.3 million or 30% of total net sales in the corresponding quarter in 2020. Foreign currency exchange rates had a positive impact on net sales in the US dollars by approximately $38.6 million in the 2021 second quarter. Included in reported geographic sales are our sales to the company's military customers, which are delivered in the US and transhipped to the military and their customers overseas. In EMEA, net sales in the 2021 second quarter increased to 105.7% in dollars and increased 86.5% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales for the second quarter was 39.8% compared to 38.1% in the same quarter in 2020, primarily due to a favorable country and product mix. We're also pleased that in the 2021 second quarter, Monster gained market share in Belgium, the Czech Republic, Denmark, France, Germany, Great Britain, Greece, Italy, the Netherlands, Norway, Poland, the Republic of Ireland, South Africa, Spain and Sweden. In Asia Pacific, net sales in the 2021 second quarter increased 5.2% in dollars and decreased 100% [Phonetic] in local currencies over the same period in 2020, largely due to sales in Japan and China. Gross profit in this region as a percentage of net sales was 44.4% versus 43.3% over the same period in 2020. In Japan, net sales in the 2021 second quarter decreased 15.1% in dollars and 13.9% in local currency, largely due to COVID-19 restrictions in Japan and distributor inventory adjustments. Depletions increased 7% during the quarter. Monster remains the market leader in Japan for the month of June 2021. In South Korea, net sales increased 63% in dollars and 50.4% in local currency as compared to the same quarter in 2020. In China, net sales decreased to 21.4% in dollars and 27.8% in local currency as compared to the same quarter in 2020. In this regard, we note that sales in the second quarter of 2020 included the initial launch of Dragon Tea. We are reevaluating the viability of this SKU and the optimal product range for China going forward. We remain optimistic about the prospects for the Monster brand in China. In Oceana, which includes Australia, New Zealand, Tahiti, French Polynesia, New Caledonia, Papua New Guinea and Guam, net sales increased to 146.5% in dollars and 98.2% in local currencies. Sales of the Monster brand in Oceana increased 210% in dollars and 155.6% in local currency as compared to the same quarter in 2020. In Latin America, including Mexico and the Caribbean, net sales in the 2021 second quarter increased to 19.7% in dollars and increased 117.6% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales was 40.7% compared to 41.2% in over the same period in 2020, primarily as a result of foreign exchange rates and certain raw materials and ingredients for products in this region are purchased in US dollars. In Brazil, net sales in the 2021 second quarter increased by 194.9% in dollars and 201.7% in local currency. Net sales in Chile increased 77.5% in dollars and 52% in local currency in the 2021 second quarter. Net sales in Argentina increased 291.4% in dollars and 458% in local currency in the 2021 second quarter. In March 2019, VPX, the maker of Bang Energy drinks, sued Monster, alleging that its Reign products infringed VPX's Bang trademarks and trade risk. A trial was held last year. And on August 3, 2021, the court issued an order denying all of VPX's claims and holding that VPX is entitled to no relief whatsoever. In fact, the court specifically found that VPX copied its bank trade risk from the original Monster Energy cans. The court's decision confirms that Monster and Poland retail partners are free to continue to sell our Reign products without any changes and without any restrictions. Monster always believed and maintained that VPX's claims were frivolous, and we are extremely pleased that the court rejected all of VPX's claims while vindicating Monster's rights. As other pending proceedings with VPX are subjudicate, we will not be answering any questions on this matter on today's call. Our new product introductions in the United States in the first half of 2021 were primarily focused in the first quarter. In the United States, during the second quarter of 2021 we refreshed our can graphics on our Rehab Monster brand family as well as our Full Throttle line, also updating the name for Blue Agave to TrueBlue. Monster Energy Ultra Fiesta received a refresh and updated can graphics as well as the name change to Monster Energy Ultra Fiesta Manga. In May 2021, we launched Monster Ultra Fiesta in a 24-ounce option with an update to our Ultra Fiesta Manga plan for later this year. We are in the process of launching a new line of nonalcoholic pure energy sales under the True North brand name in 12-ounce sleek cans, which contained an organic plant-based energy blend and ingredients for immunity support. True North is being offered in six flavors, Cucumber Lime, Black Cherry, Grapefruit Lemonade, Water Mellon Mist, White Peach Pear and Mandarin Yuzu. True North has a limited customer target in 2021 with plans for a full launch into mainstream channels in 2022. While cognizant of the can shortages, we believe that it is important to continue with our innovation plans. And to this end, we will be launching our new flavors reserve line of Monster Energy drinks in Water Mellon and White Pineapple in October 2021. We have deferred the launch of our new line of Java Monster Cold Brew Coffee + energy drinks until early 2022. In Canada, during the second quarter, we launched two new products: Monster Punch Papillon and Monster Punch Khaotic, both in a 473 ml can. In April 2021, we launched Reign Orange Dreamsicle in Puerto Rico and our second SKU in Bolivia with Monster Energy Zero Ultra. In El Salvador, we launched Fury Mean Green in May 2021. In the second quarter of 2021, we launched Juice Monster Pacific Punch and Monarch in a number of countries in EMEA. We also launched Ultra Paradise and Ultra Fiesta in a number of countries during the quarter. During the quarter, we also launched our strategic brand innovation and Predator in additional countries. In January 2021, we launched Ultra Rosa marketwide in Australia, following an exclusive lead launch with one chain in the fourth quarter of 2020. In March 2021 in New Zealand, we launched Monster Superfuel in both Purple Passion and sugar-free flavors. During the 2021 second quarter in Japan, we launched Monster Energy Super Cola with our distributor, Asahi Soft Drinks. Additionally, we effected the relaunch at retail of Ultra Paradise and began shipments in anticipation of the launch of Super Fuel early in the 2021 third quarter. Super Fuel has just gone on the shelves in Japan this week. We also launched Mango Loco in Korea in July 2021. During the 2021 second quarter, we launched Pipeline Punch in Taiwan, Hong Kong and Macau. We also began distribution of Monster Energy Zero Sugar in the Philippines. As previously mentioned, in the second quarter of 2021, in China, we extended the national rollout of our new Monster Dragon Gold, which is non-carbonated. Our national summer on-pack promotion began in May with one of China's top consumer ambassadors. As a result of the COVID-19 pandemic, certain of our planned launches and innovation of new products in a number of Asia-Pacific markets have been deferred for a few months. However, we still anticipate such launches taking place toward the end of the 2021 calendar year. We are planning to launch a number of additional products and product lines in our domestic and international markets later this year. We estimate that July 2021 sales to be approximately 1.8% higher than in July 2020. On a foreign currency adjusted basis, July 2021 sales would have been comparable to the July 2020 sales. July 2021 had one less selling day than July 2020, which was 15.8% above July 2019, and which was 17.1% higher on a foreign currency adjusted basis. Certain production facilities, mainly from the Coke bottlers in EMEA, in particular, delayed production from July to August 2021. Furthermore, as mentioned earlier, the company has not been able to fully satisfy demand in the United States and EMEA due to a shortage of aluminum cans, which adversely impacted July sales. Such shortage was exacerbated in July as can availability did not keep pace with increased demand during the summer months. Additional cans have been sourced from domestic and overseas suppliers with expected deliveries increasing sequentially during the latter half of the year. We are working to replenish system inventories in order to meet customer demand as soon as possible. Additionally, the company also experienced delays in certain ingredients, which impacted supply. Our depletions remain solid as do our measured market data, as previously mentioned on this call. In this regard, we caution again that sales over a short period are often disproportionately impacted by various factors such as, for example, selling days, days of the week in which holidays for, timing of new product launches, and the timing of price increases and promotions in retail stores, distributor incentives as well as shifts in the timing of production in some instances where our bottlers are responsible for production and unilaterally determine their production schedules, which affects the dates on which we invoice such bottlers as well as inventory levels maintained by our distribution partners, which they alter unilaterally for their own business reasons. We reiterate that sales over a short period such as a single month should not necessarily be imputed to or regarded as indicative of results for a full quarter or any future period. If the COVID-19 pandemic and related unfavorable economic conditions continue in certain regions, our new product innovation launches in those regions could be delayed. In conclusion, I would like to summarize some recent positive points. Currently, the company's flavor manufacturing facilities, its co-packers, warehouses, and shipment facilities, and bottlers and distributors are all operating. We are continually addressing our aluminum can requirements, given our volume growth and the current supply constraints in the aluminum can industry. We are pleased with the new additions to the Monster Energy portfolio and are planning additional launches later in the year. We are planning to continue additional launches of our Reign Total Body Fuel high-performance energy drinks in additional international countries. We are pleased with the rollout of Predator and Fury and our affordable energy drink portfolio internationally. We are proceeding with plans to launch our affordable energy drinks in a number of international countries during the year. I would like to open the floor to questions about the quarter. Thank you. Dara Mohsenian -- Morgan Stanley -- Analyst Hey, guys. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Hey, Dara. Dara Mohsenian -- Morgan Stanley -- Analyst Great top line growth in the quarter, but we have seen share losses in US track channel data worsened recently. A, just short-term, how much of that do you think is attributable to out of stocks and the supply constraints that you mentioned? Is that a material factor in retail sales? And then maybe, b, from a longer-term standpoint, it has been a couple of quarters now where the share losses have reaccelerated year-over-year, just some progress in the beginning of the year. So, I was just hoping you could review some of the key factors that have been driving the share losses in the US? And how you think about those factors going forward in terms of continuing or dissipating and how you guys are positioned? Thanks. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Hilton, if you take that, and I'll also say something once you've... Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board All right. I think, Dara, what's important is that, that's not a result and not due to us not growing. We are not keeping up with our share, but our business is certainly growing. And you can track that from Nielsen. You can also track that from the non-measured channels, which are growing really very nicely. So while we're not keeping up necessarily with Red Bull in the major channels. As I've spoken on previous calls, Red Bull had a very large on-premise business, which has moved to off-premise and moved to off-premise during COVID. And that led to an acceleration in their share. However, we mentioned that we had and are continuing to sustain can issues and result in supply. And of course, that's having an impact on the share numbers that you are seeing. So I think on balance, the business is growing. You've seen the results. It's continuing to grow. And we are growing, but not at the extent of the market. I think with the full deck of cards, the situation may well be very different. But right now, we really are struggling with sufficient supplies of aluminum cans really to keep up with demand, which is, I suppose, a good position to be in. And on the other hand, is not such a good position to be in. The business is growing. And, that's the message I want to leave you with and other investors. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer I think in -- I'll just add two short points in that regard. I think what we've tried to do is to try and also basically focus on our faster selling and our larger SKUs, which has necessarily resulted in some of the smaller SKUs, which normally have their own traction and followers. So those haven't got on to shelf. And then the one additional thing that I think that has negatively affected our distribution sales and distribution levels in the US is labor shortages. And I think that what we've seen is that many of the bottlers, Coke bottlers are experiencing labor shortages. And while one would ordinarily say, well, everybody is going to have the same problem. I think that where you have Red Bull is our main competitor, they have a dedicated system. I think they've been able to address their labor shortages just more effectively than the larger bottlers with large labor pools. And that has also, I think, detrimentally affected our distribution levels going forward. But again, I think those are things that once things start settling down and things will get back to normality, that's something that I think that will also, in due course, right itself. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Yes, I think we should also -- Dara, I think we should also add that what we're seeing with cans is something that will persist through this year. I'm a bit more optimistic about the fourth quarter because we have two new can suppliers coming on board. But the situation will persist. And then next year, we should be in -- we believe we'll be in very good shape. But again, it all depends on consumer demand, which is growing, and you've seen that month-by-month and quarter-by-quarter. Bonnie Herzog -- Goldman Sachs -- Analyst Thank you. Hi, everyone. I just wanted to ask about your gross margins. Clearly, they continue to be pressured as broadly expected, which you guys have been discussing with us. But just want to get your outlook for these pressures in the back half of the year? Hilton, you just mentioned that you're optimistic. So just wanted to verify that you still expect some of these pressures to ease by Q4? Or do you think it's going to take a little bit longer, especially in light of the recent spike in aluminum prices. So trying to understand how that factors in? And then just a clarification on the can shortages that you mentioned that you're still experiencing, I guess, it sounds like it's getting worse, but I really did want to clarify that. And is there any way that you guys could quantify how big of an impact the supply shortages had on your top-line either in the quarter or in July? Just trying to understand how much you think your shipments would have been up in July without these shortages, for instance? Thanks. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Okay. So let me deal with the first issue first, if I may. I spoke about optimistic about can supplies. I really didn't talk about margins. You'll recall on the last call, I spoke about the issues that we were confronting with margin pressures like most other beverage companies. And where we are right now with aluminum, I mean, nobody knows. So you can talk to the leading banks in the field, which we do on a regular basis, and they really are pulls apart about their projections for aluminum in 2022, let alone 2021. So the last couple of days, you've seen a spike in the Midwest premium from this tax that is expected to be imposed on Russian aluminum. And as, you know, the Midwest premium is strongly factors the last ton of aluminum to enter the US and the cost of that. And so we've seen a spike in the Midwest premium. And we continue to see spikes in aluminum. So from that score, I think we just are in uncharted territory. I've been in this business for a long time, as you know, and I've never seen aluminum where it's at right now. And I've never seen the Midwest premium at these kind of levels. So aluminum, I really cannot talk about. And also when you look at our business and you look at the factors that really have affected gross margin, number one, the fact that we're selling a lot more internationally. So I talked earlier about 37.4% of our sales in the quarter outside of the US 30% last year, that obviously impacts margins. We are importing cans from a number of [Technical Issues] that obviously impacts margins. In fact, the China and India cans that we are using in the United States and in EMEA will only be filed in August in July, and they will be filled this month. So that in itself, the imputation will impact gross margins. And then to cap everything else, we have ingredient issues. We had ingredient issues, as we mentioned, in July, which again reduced the amount that we would actually sell because we didn't have sufficient ingredients to meet themselves, particularly with NOS. And so there are a number of factors that are increasing that are increasing our cost of goods. And last quarter, I said I didn't think that margins would get better in the second and third quarters. I read they will not -- I think margins will deteriorate in the third quarter. In the fourth quarter, we're getting some relief in terms of supplies from the US on cans that are -- have been contracted for and they were contracted for two years ago. And we saw the opportunity to work with two major suppliers to get additional cans produced in the US, and that's why we have two new supplies opening, and we are an important and an anchor customer of both those facilities. But even that, you're still dependent on aluminum. We have some hedges in place, but obviously not enough to take into consideration the amount of sales and the amount of consumer demand that is out there. So that's a long-winded way of saying, I think, answering your question as best as I can. And then just getting to your second question because you're really only allowed one. But to get to your second question, we have quantified or try to quantify the impact on can shortages in July and in this quarter and in the -- potentially in the third quarter, but I really don't want to -- I'm not comfortable with those numbers yet. A lot of detailed work is being done on them. And I just -- I can't in good contents give those numbers because we still are in the throes of kind of finalizing what we think is probably correct. Rodney mentioned in his script earlier that a number of the bottlers, he mentioned particularly in EMEA, but there were cases in the US as well, and there was a substantial case in the US where the bottlers were obviously focused on other things in the quarter and were producing Coca-Cola brands. And as a result, I think we -- our production got moved from July to August. So, when I look at July, it doesn't -- I don't get overly concerned because I know the sales are going into August. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Perhaps, if I just on the shortage level, just to add that when we buy cans in contracted for our annual amount, they usually are sort of reasonably flat line across the year. And we used the first half of the year to build up can inventories and finished product inventories with ourselves and our bottlers. Earlier this year, obviously, demand sort of was strong, and so we really didn't have that opportunity. So what has happened is that in June and July, which is your normal peak months, the demand has been higher, but our supply has been more level until we can get more can inventories into the market. So what happened is just that we have had a sort of a heartened increased shortage in the last month and July and probably will be a little bit in August. And then obviously, as we start increasing our -- the cans we're getting in, and then we're able to balance it more and our demand balances more, we'll start to have less of a different delta between these demand and supplier and eventually be able to -- we're hoping to able to build up our inventories and supply back to normal by the end of the fourth quarter or during or by the end of the fourth quarter. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board No one's comfortable with the level of finished goods inventories that we're running at, but it's a sign of the times. I mean, we're doing everything we can to supply our customers. And that's why we spoke about freights. Freight is a big issue, not only getting raw material ingredients into co-packing system and into our bottling system and -- but also distributing from our co-packers. And obviously, the one goes into cost of sales and freight out goes into operating expenses. So that's why you'll see freight really hitting both of those line items. Andrea Teixeira -- JPMorgan -- Analyst Hi. Thank you. Hi. Good afternoon. Thomas J. Kelly -- Chief Financial Officer Hi. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Hi, Andrea. Andrea Teixeira -- JPMorgan -- Analyst How are you Hilton? Hi. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board I'm good. Andrea Teixeira -- JPMorgan -- Analyst Yes. Just on the gross margin, because your gross margin comments were very helpful and given this deterioration obviously that its probably here to stay in the next few quarters. How are you thinking about pricing? Obviously, you can't supply the service levels that are used to with the retailers. So is that is something that takes -- obviously, you have to take into account? Or perhaps as you get more informed on how the aluminum cost will evolve, you may contemplate it again? Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Yes. With regard to pricing, we continue to evaluate pricing, honestly, on a very, very regular basis, if not weekly. So we continue to evaluate it, and we want to make a good decision. Last time around, as I mentioned on previous calls, we went out alone, and we would like to have been in a situation this time where we followed our competitor, but we have to evaluate, obviously, the business as we see it and the impact for us. What we've done is we're reducing our promotional allowances. So we're taking a price increase the other way, through reducing promotional allowances, but the impact of that reduction in the second quarter was not as we would have liked. So we are -- we really put the accelerator down and are more aggressive in reducing our promotional allowances. But we are continuing to evaluate the pricing and price increases. And then I have to leave this call with my favorite saying, and that is, we don't bank gross profit margins, we bank gross profit dollars. And to me, the fact that we're doing everything we can to satisfy our customers as best as we can is impacting gross profit margins. But at the end of the day, we don't want to lose gross profit dollars, which is really important to ensure the sustainability of the brand. And that's the most important thing for us right now. Andrea Teixeira -- JPMorgan -- Analyst Thank you. Thanks fair. Thank you both. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Yeah. Basically, just make it clear, at this point, we are watching and we're not planning a price increase. We we're not adverse to a price, but we'll wait and see what the market does and what our competitors do. Andrea Teixeira -- JPMorgan -- Analyst Thank you, Rodney. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Thanks very much. Thank you, everyone, for your continued interest and support of the company. We continue to believe in the company and our growth strategy to remain committed to continuing to innovate, develop and differentiate our brands and to expand the company, both domestically and abroad. And in particular, expand distribution of our products through the Coca-Cola bottler system internationally. We believe that we will be able to navigate through the challenges ahead as a result of the COVID-19 pandemic and hope that this unfortunate situation will resolve itself in the near future. We believe that we are well positioned in the energy drink category and will continue to be and are optimistic about our total portfolio of energy drink brands. We hope that you will stay safe and healthy. Thank you very much for your attendance. Duration: 50 minutes Call participants: Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Thomas J. Kelly -- Chief Financial Officer Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Dara Mohsenian -- Morgan Stanley -- Analyst Bonnie Herzog -- Goldman Sachs -- Analyst Andrea Teixeira -- JPMorgan -- Analyst More MNST analysis All earnings call transcripts\",\n          \"Please go ahead. Dan Lochner -- Chief Financial Officer Good evening, everyone. And welcome to Oyster Point Pharma's fourth quarter earnings conference call for the three months ended December 31, 2021. This evening, we issued a press release containing our fourth quarter and full year ended December 31, 2021, financial results and recent business highlights. In addition, our earnings press release and our Form 10-K, which were filed with the SEC after the close of market today, are available on our website under the investors and news section at www.oysterpointrx.com. Joining us on our call today are Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma; and John Snisarenko, chief commercial officer. Following Dr. Nau and Mr. Snisarenko and my prepared remarks, we will open up the line for questions. During the call today, we will be making forward-looking statements regarding potential future events, including statements regarding Oyster Point Pharma's potential future financial status and results of operations and our plans and potential for success relating to commercializing TYRVAYA. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. For a description of these factors, please see our annual report on Form 10-K for the year ended December 31, 2021, filed with the SEC after the close of market today. I will now turn the call over to Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma. Jeff Nau -- President and Chief Executive Officer Thank you, Dan. Good evening, everyone. And thank you for joining us on our call today to discuss our fourth quarter 2021 financial results and recent business highlights. This is a particularly exciting time for Oyster Point. This is our very first earnings call where we are pleased to be reporting partial revenues from the commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease in the United States marketplace. Today, you will learn more about how we are delivering these encouraging commercial results on the launch of TYRVAYA Nasal Spray. But first, let me provide the company's 2021 business highlights. In October of 2021, we received FDA approval of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Dry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence. The dry eye market is now being introduced to the first nasally delivered, pharmaceutical dry eye therapy, and we believe that given the high level of patient and physician satisfaction that we are seeing in the field with TYRVAYA, that significant growth remains ahead. You will be hearing more shortly from John Snisarenko, our chief commercial officer, about the details of the launch of TYRVAYA Nasal Spray, but I'm happy to state that we had great partial fourth quarter commercial performance in 2021. We are happy to report that TYRVAYA Nasal Spray had a net product revenue of $1.2 million in Q4 of 2021. In addition, we recognized $5.4 million from our license agreement with Ji Xing Pharmaceuticals. We are now entering 2022, having demonstrated the ability to achieve the successful commercialization of TYRVAYA, as well as drive strong execution across multiple areas of our business, including our exclusive license agreement with Ji Xing to develop and commercialize OC-01 and OC-02 in Greater China, securing nondilutive funding and pursuing additional treatment advancements in the clinic, as well as in the R&D laboratory for patients with ophthalmic diseases. This week, we publicly announced an early commercial win with one of the largest commercial payers. Our press release from Tuesday announced that TYRVAYA Nasal Spray is now covered by Express Scripts effective on February 19. This is a fantastic accomplishment for our market access team in achieving the addition of 26 million covered lives and more importantly, this early in our first full quarter since launch. Patients are increasingly gaining access to TYRVAYA in the U.S. for a disease state that, up until 2021, we believe, experienced very little innovation for the current large unmet need in dry eye disease. TYRVAYA is a first-in-class cholinergic agonist nasal spray that is highly differentiated from the other pharmaceutical products in the dry eye space and includes the following potential advantages. TYRVAYA Nasal Spray has a differentiated mechanism of action as it is believed to activate the trigeminal parasympathetic pathway via the nose, resulting in increased production of basal tear film as a treatment for dry eye disease. Basal tear film is responsible for lubricating, nourishing and protecting the cornea. TYRVAYA is the only ocular surface-sparing pharmaceutical therapy for dry eye patients. For those patients with a compromised ocular surface, increasing tear production without the burden of administering a topical medication may provide a welcome method to treat their disease. For the first time, dry eye disease patients have an FDA-approved, pharmaceutical treatment option that is not administered as a topical eye drop to an already irritated ocular surface. Although we are focused on the critical launch of TYRVAYA Nasal Spray and continue to execute plans for the life cycle development of the TYRVAYA franchise, our R&D team remains committed to multiple exciting pipeline projects aimed at bringing additional innovative therapies to address diseases like neurotrophic keratopathy and severe allergic or vernal keratoconjunctivitis. In 2022, we will continue to advance our enriched tear film gene therapy platform, as well as our research and development collaboration with companies like Adaptive Phage Therapeutics. We remain excited about the ongoing OLYMPIA Phase 2 study of OC-01 nasal spray in Stage 1 neurotrophic keratopathy. We are expecting a readout in the second half of this year. NK is a disease that is currently underdiagnosed or misdiagnosed in many patients with ocular surface disease. We feel that Stage 1 neurotrophic keratopathy could represent a meaningful indication for OC-01 nasal spray. Our vision and focus is clear. The world needs an innovative leader that can bring innovative and transformative ophthalmic disease treatments, and we aim to be that leader. We believe that we're building Oyster Point into a best-in-class eye care company. I would now like to turn the call over to John Snisarenko, Oyster Point's chief commercial officer, to discuss our ongoing commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease. John Snisarenko -- Chief Commercial Officer Thank you, Jeff. As we have previously communicated, the dry eye disease segment is a large market with over 17 million people diagnosed in the United States alone. Only a small proportion of these patients, approximately 2 million, are currently being treated with a branded therapeutic. And over 7 million people diagnosed with dry eye disease have tried and abandoned the other available options. We believe that TYRVAYA Nasal Spray is a new treatment option for the large patient population that exists in the dry eye disease marketplace, including the refractory patients, as well as those who are newly diagnosed. As Jeff highlighted previously, we are incredibly excited to have initiated the U.S. launch of TYRVAYA Nasal Spray on November 1. We are pleased to report that as of the quarter ending December 31, 2021, data indicates that approximately 5,500 prescriptions for TYRVAYA have been filled, written by over 1,900 unique prescribers. These encouraging metrics were achieved in less than nine weeks from the launch, including holiday periods. In this short time, TYRVAYA is quickly establishing itself in the market as an exciting new option for dry eye patients. Regarding market access, a core part of our commercial strategy is to promote accelerated payer adoption of TYRVAYA to the top payer organizations. Our market access team has done a great job in securing coverage for TYRVAYA with Express Scripts National Preferred, Basic and High Performance Formularies effective February 19. With this latest formulary addition, we now have coverage for a total of 43% of U.S. commercial lives for an aggregate total of approximately 84 million lives. We are incredibly pleased with this level of coverage so early in our launch, and we look forward to further growing our market access coverage in 2022. Oyster Point remains very committed to offering comprehensive patient services that help provide access to TYRVAYA for appropriate patients. We have launched a comprehensive set of technology-driven patient services offerings aimed at enabling patients to successfully navigate the patient journey and procure TYRVAYA. Our patient support program is called TEAMTyrvaya. And for more information on this program and how to enroll, please visit the website, tyrvaya-pro.com. We have been quite diligent with the sizing of our field force, which enables us to target 20,750 eye care practitioners, covering both optometrists and ophthalmologists and representing approximately 94% of the dry eye prescriptions in the market today, helping us in our efforts to achieve the full commercial potential of TYRVAYA. In the first nine weeks of launch, our sales force was able to introduce TYRVAYA to more than 50% of the targeted prescriber base. On the marketing side, we're leveraging the latest technology, including sophisticated analytics, in-person, as well as virtual detailing, best-in-class digital and social media efforts and partners, as well as utilizing a digital online pharmacy to enhance communication and delivery of TYRVAYA to patients. We will continue to adopt the latest media and technology-driven marketing approaches to maximize TYRVAYA's share of voice and impact in the market. Our focus continues to be on broad eye care provider and patient education and marketing efforts, with targeted direct-to-patient digital campaigns leveraging TYRVAYA's differentiated MOA and nasal spray route of administration to drive a positive patient marketing experience. I am so proud of our commercial team's collective efforts during this early phase of our launch, especially in these challenging times with the pandemic. I will now turn the call back over to Dan Lochner, Oyster Point's chief financial officer, to discuss our fourth quarter financial results. Dan Lochner -- Chief Financial Officer Thank you, John. I will now provide a brief overview of Oyster Point Pharma's fourth quarter financial results. Additional detail about our fourth quarter, as well as our annual financial results can be found in our Form 10-K that was filed with the SEC this evening. For the fourth quarter of 2021, Oyster Point Pharma reported a net loss of $42.1 million, compared to a net loss of $22.2 million for the same period in 2020. As of December 31, 2021, cash and cash equivalents were $193.4 million, compared to $192.6 million as of December 31, 2020. Based on our current business plan, we believe the company's available cash and cash equivalents will be sufficient to fund the company's planned operation for at least 12 months from our 10-K filing this evening. Net product revenues for the fourth quarter of 2021 were approximately $1.2 million, following the FDA approval of TYRVAYA Nasal Spray on October 15, 2021, and our subsequent commercial launch in the U.S. in November 2021. Approximately half of the TYRVAYA net product revenue was attributable to channel building by distributors upon launch of the product. In addition, pursuant to our license agreement with Ji Xing, the company also recognized $5.4 million in milestone and license revenue following the FDA approval of TYRVAYA Nasal Spray, which includes the noncash consideration of Ji Xing senior common shares. The company did not generate any revenues during the third -- three months ended December 31, 2020. Cost of product revenue for the three months ended December 31, 2021, was $1.5 million and consisted mainly of third-party manufacturing costs, which included pre-approval costs, reserves for inventory obsolescence and damaged goods and product royalty expense related to Pfizer. The cost of product revenue included a reserve for inventory obsolescence of $0.9 million. The inventory manufactured prior to FDA approval of TYRVAYA Nasal Spray was charged to R&D expense. And as a result, the company expects the unit cost of product revenue will be lower until the company fully utilizes this product that was manufactured pre-FDA approval. The company started expensing pre-approval inventory in 2020 and recorded an R&D expense of approximately $4.3 million for pre-approval inventory during the year ended December 31, 2021. The company anticipates selling the remaining pre-approval inventory by the end of 2022. The company's sales and marketing expense increased by $21.8 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase was primarily due to higher payroll-related expenses of $11.7 million, inclusive of sales commission expense, as well as an increase in stock-based compensation expense of $0.5 million, both of which were primarily driven by onboarding a commercial field force in the second half of 2021. The company also incurred higher marketing -- market access, commercial and other expenses of $10.1 million in anticipation of, and in connection with, the U.S. launch of TYRVAYA Nasal Spray. The company's general and administrative expenses increased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase is primarily due to higher G&A expense of $3.8 million related to accounting, consulting, legal and other professional expenses incurred in connection with the credit agreement, as well as the company's transition from a clinical stage to a commercial-stage company. The company also incurred higher payroll-related expenses of $2.4 million, including recruiting expense due to an increase in headcount to support an ongoing efforts to commercialize TYRVAYA. The company's research and development expenses decreased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The company's decrease in R&D expense is primarily due to the company receiving FDA approval of TYRVAYA Nasal Spray in October 2021. The company expensed inventory prior to receiving FDA approval and expensed approximately $3.5 million as R&D during the three months ended December 31, 2020. The company also incurred a fee of $2.9 million in connection with the New Drug Application submitted to the FDA in December 2020. The company incurred interest expense of $2.6 million during the three months ended December 31, 2021, primarily related to the credit agreement with OrbiMed. Interest expense included contractual interest of $1.7 million, as well as noncash expense of $0.9 million related to the amortization of loan commitment fees and accretion of other long-term debt-related costs. The company had no interest expense during the three months ended December 31, 2020. Now as we turn to our outlook, for 2022, our goal is to continue to achieve broad ECP and patient experience with TYRVAYA, including both optometry and ophthalmology offices, in order to reach the total addressable dry eye market opportunity of TYRVAYA Nasal Spray. We anticipate the three large national commercial plans will make their coverage determinations by the midpoint of the year. While we await such coverage determinations, we will continue to provide patient-assisted programs to support eligible commercial patients in gaining access to TYRVAYA. With that overview of our financials, I will now turn the call back over to the operator to open up the line for questions. Questions & Answers: Ken Cacciatore -- Cowen and Company -- Analyst Hey, team, looks like a really good and clean initial launch. I was wondering if you would wanna help us a little bit with maybe the revenue pacing. I know consensus, I believe, is around $30 million. And I know there's only a few of us analysts that are formally involved in the consensus, but I think it's around $30 million. So I was wondering if you could just kind of hold hands with that number, how we should be thinking about it. And then also, we've been doing clinician checks and getting very good feedback. But I guess, you could help us, as you would have a better sense of the early retention metrics, maybe the -- be able to definitively let us know how you're seeing some of the retention numbers and patients returning. So those are my first two. I'm going to ask one more, if I could, though. Could you talk, John, a little bit about any refinements or learnings of your patient support system? Obviously, early days, but wondering if you're already tweaking it a bit. Anything that seems to be working very well or you've needed to change? And with that, I'll go back in the queue. Thanks so much. Jeff Nau -- President and Chief Executive Officer Great. Thanks, Ken, for the questions and very thoughtful. So maybe what we could do is we'll just take those in order. So I'll turn it over to Dan to just talk about the numbers for the year. And then, we'll go into retention and have a discussion about John's experience with the bridge programs and the different patient services. Dan Lochner -- Chief Financial Officer Yeah. Great. I would say on revenues, while we haven't really provided official revenue guidance, I would say we think about it very operationally, focus in terms of our sales reps that are out in the field doing a great job. And I would say the focus very early on and throughout 2022 will really be about growing that eye care practitioner count, and we have goals internally for what we expect to achieve on a weekly and monthly basis. And so, I think, it really starts with getting those ECPs onboard on a monthly sequential basis and then starting to look at what the right pattern is on an NRx basis per month and then what we then start observing on that pull-through on resell rate. And so, to kind of wrap that all up, we see it sequentially building through the quarters for the entire year as we start working through that total target population that we've identified, which is roughly 20,750 targets. And I think, it would be great to have John kind of speak about how we're really going after that target base and how that's been building through the quarters. And I think, what you'll see, at least for Q4, we've hit about 1,900 of those ECPs in respect to the 20,750. And we'll continue to really work through that population of ECPs and really build that NRx and resell rate, the TRx, and then really playing out on revenue. The other dynamic, of course, is always on gross to net. And while we're not providing official guidance on gross to net because our focus really is on that volume and share component throughout 2022, I would say there is that first-half component related to the majority of patients in the first half expecting to be on that bridge program, which has a discrete impact to gross to net. And then, with our guidance, which is focusing on coverage determinations for the big three PBMs by the midpoint of the year, that transition from bridge over to commercial insurance will have a positive benefit discretely on that line in relation to gross to net, which would kind of tie up to your question on kind of how revenues would flow from a price and volume perspective through the year. John Snisarenko -- Chief Commercial Officer Yeah, thank you, Dan. This is John. You asked a question around retention rates and then refill rates. We've been very, very pleased to date with the metrics we've been seeing in that space. Even patients that had been prescribed in early November, we started seeing early refill rates. I could quote that if you look at our blended refill rates with retail pharmacy and our digital online pharmacy, they're hovering around 64%, 65%. So we're very pleased with patients that are coming back and getting the refills. We are getting very, very nice position, as well as patient feedback, and we are hoping to continue that trend throughout 2022. I think, part of that as well is your third part of your question around patient support programs, we out of the gate wanted to really employ a lot of technology around our patient services to TYRVAYA. So we're trying to make it very easy for that patient to navigate that journey through the prior auth and benefit investigations to get them to enroll into the program through QR codes in the offices, online, as well as other digital means. So because of that, we've been getting very, very good high enrollment rates and good fill rates that come through that program. So in terms of tweaking, we're continuing to put out more patient materials to surround sound the patient with different ways to enroll into the program. But overall, we're very, very pleased with how the program has been going. If the patient is deemed insured, but not covered, they automatically popped into our bridge program that they were appropriate patients and are able to get that script fulfilled and get experience with TYRVAYA. So we'll keep monitoring the patient services program, but so far, we've been very, very pleased. Ken Cacciatore -- Cowen and Company -- Analyst Great. Thanks so much. Appreciate it. Jeff Nau -- President and Chief Executive Officer One thing I will add on, Ken, comment there is as we think about TYRVAYA as a product, when we think about the current marketplace and what it offers to patients, from an immunomodulator perspective, patients will go on a course of an immunomodulator. If they're not happy with the outcome at the end of that course, they're transitioning off, and they're likely either going on to another product or another device or another modality, but very rarely are they coming back. So we see a very low number of patients come back to the original therapy. I think, that the one thing to really keep in mind with TYRVAYA is it works so quickly to provide the patient relief, and it has such a differentiated mechanism of action that we are excited to look forward into the future to see how patients interact with the product. It's going to be a very different interaction than you would see with an immunomodulator because I do think not only will we have solid refill rates, but we will have people coming back to the product in those later years. And so, we're excited about that. And then, I would -- I'll just throw one comment out there for my team back at the office. Our patient services program is, bar none, one of the best I've ever seen. And it is going very well in the field. And so, kudos to the team for putting together such a great program. Ken Cacciatore -- Cowen and Company -- Analyst Great. Thanks so much. Joe Catanzaro -- Piper Sandler -- Analyst Hey, guys, thanks so much for taking my questions, and congrats on the progress here. So maybe just to follow up, I think, Dan, you mentioned you guys had some internal benchmarks, I'm sure, on a bunch of things. But I'm wondering if you can maybe help put into context the early penetration in terms of the number of unique prescribers you've seen relative to your target ECP pool and where your early expectations were there. And then, I'm wondering what aspect -- and maybe it's something you just alluded to, Jeff, what aspect of the product profile do you see as resonating the most? And how do you go about fully leveraging that? And maybe I have a follow-up as well. Dan Lochner -- Chief Financial Officer Yeah. Maybe I'll start with it on my end. As you saw in the press release, we had achieved 1,900 unique writers in the quarter, which is just under about 10% of the targets that we are going after with our sales force of 162 sales reps. And so, I think, we had great progress in the quarter just under about nine weeks. And so, as we look at benchmarks of prior therapies that have come to market more recently, I think we're in a great place for where we had expected us to land. Of course, we also understood that this is a new way of treating dry eye disease. So really communicating the benefits with the nasal spray. And so, I think, we're quite pleased with where we landed and continue to work toward that 21,000 target count as we progress throughout the year. Jeff Nau -- President and Chief Executive Officer And maybe what I'll add on to -- the second part of the question there is some of the things that are resonating. I think, one of the things that's really been exciting about the launch of this product is patient feedback has been really great. And so, we've been excited to not only hear stories from the field, see posts on social media of patients going out on their own and talking about the product. And just really, it's a great product to launch where you're having that patient feedback come back to the teams and to those folks that have put such hard work into getting the product out there into the marketplace because it's really why we do this and it really drives the team. So I think, one of the things that we hear that is something that's really encouraging is just the patients stating that they really like the profile. They like the way it's making their eyes feel, and it's just differentiated in the way that it's able to be used. So we do hear stories back of people who are unable to deliver a topical eye drop. And this is another option for them because maybe they don't have the dexterity or they're elderly and they're just not able to put a drop into their eye, and so they're able to use nasal sprays. And the other thing that we hear in the field often is the physicians are not getting patients calling back and complaining. And so, that's also really important for us. But again, we're very early in the launch. So we have many patients that haven't been on the product for more than a few months. So we're excited to see how the long-term feedback is. But for the moment, we are really encouraged by the feedback or sometimes lack of negative feedback coming back from the patients. Joe Catanzaro -- Piper Sandler -- Analyst Great. And if I maybe just squeeze in a quick follow-up. I think, you said you guys have maybe covered about 50% of your target ECPs. Can you maybe speak to what percent of those have been given a sample? And how soon after sampling are you seeing ECPs write a script? Thanks. John Snisarenko -- Chief Commercial Officer Yeah, no, thank you, Joe. Great question. Part of our strategy is really to introduce TYRVAYA into the office practice with the prescriber base, the technicians, the staff that are involved with training, the patients and so on prior to actually sampling because we want to make sure that the product is taken appropriately and the patient gets the best possible experience they can with the nasal spray. So we handed out quite a few samples, probably over 100,000 samples since launch. But we want to make sure that we hand them out appropriately and that installation with that office has actually taken place before that sampling is initiated. So so far, that's worked well for us because we've seen a higher proportion of patients that tried a sample, see if it works for them before they're getting into our patient hub and actually getting that prescription filled. So that kind of connection has been very, very positive with that approach. Joe Catanzaro -- Piper Sandler -- Analyst OK, that's helpful. Thanks, again, for taking questions. Patrick Dolezal -- LifeSci Capital -- Analyst Great. I'm just curious how the availability of generic cyclosporine has impacted discussions with payers, if at all. Were there any modifications to negotiations with Express Scripts as that approval came to light? I'm just curious if you expect any impacts going forward as you onboard other payers. And then, I have a follow-up as well. John Snisarenko -- Chief Commercial Officer Yeah, Patrick, thanks for your question. We've seen kind of early mixed reactions from the payer community on how they're going to manage the generic entry of cyclosporine. And with the early listing with ESI, they're actually covering TYRVAYA across their formularies with only a traditional step, sort of an artificial tear. So that's what I mean by mix. Some of the payers are kind of waiting until more than one generic comes out, and they'll take a look at the dry eye space or they're not really managing the dry eye space as closely. And others are going to evolve a little quicker. So we're able to modify our approach. We are ready for a generic to be on the market or not with. And that's the way our negotiations are going with the major PBMs. And our goal is to get access for TYRVAYA on a level playing field with the branded therapeutics. And our differentiation along with our strategic contracting will help us get there. Jeff Nau -- President and Chief Executive Officer And one other comment, Patrick. As you well know, generic entry into the marketplace doesn't change the dynamic that exists where patients cycle off many of these drugs, whether it be for lack of effect or side effects or whatnot. And so, that certainly will not change. So we were planning on generic entry coming. I think, we've been planning for a long time, but it's been always in the back of our mind, and so the team is ready. Patrick Dolezal -- LifeSci Capital -- Analyst That's helpful. Thanks. And as it relates to just drug launch surrogates, there's not a ton in the dry eye space really, but obviously, we do have these eye drops. Just curious to hear any similarities and differences that might be worth pointing out. And just if you could comment on the role of coverage and driving drug adoption in the dry eye space generally, that would be helpful. I'm curious if there's a tipping point where you feel that the amount of coverage really will drive adoption, 50% if it's a bit more. I would love to hear your thoughts there. Thanks. John Snisarenko -- Chief Commercial Officer Yeah, Patrick, in regards to the Xiidra launch, we did see very quick uptake. Well, this was back in 2016. They had very early access to the commercial insurers, and they launched with 280-plus reps. We are very pleased with the number of reps we have and the trajectory we're seeing with TYRVAYA. We are on track in regards to the payer negotiations. And in fact, the ESI listing was an early listing for us. So we will get to that point that we're expecting in terms of broad base of writers, the eye care professionals prescribing TYRVAYA. We just won't be out of the gate as quickly as you saw with the Xiidra launch. I could tell you, versus the latest two launches, we're very pleased with how our trajectory is going versus kind of the more recent entries. But it was a different space back in 2016, less managed, and also they were second entry at the time after Restasis. Patrick Dolezal -- LifeSci Capital -- Analyst That makes sense. Thanks for taking the questions. Chris Neyor -- J.P. Morgan -- Analyst Great. Thanks for taking the questions. So first one is on me -- for me is just wanted to get a bit more details on the Express Scripts contract. So really just thinking about what's the mix between preferred and non-preferred coverage within those 26 million lives that you had estimated. And within the Express Scripts plan, are there -- is there potential for additional pickup of patients and additional contracting that would either add additional patients or move more patients toward preferred access? And when talking about that kind of mix -- the mix of customers, what type of co-pay should we be thinking about for most of these patients? I think, I have a couple of follow-ups after that. John Snisarenko -- Chief Commercial Officer Yeah, Chris. No, thanks. In regards to ESI, whether preferred or non-preferred, in terms of access whether you're listed preferred or non-preferred, the key criteria is you have to have tried and failed on an artificial tear for all of the branded products here. So as you mentioned in the last part of your question, the out-of-pocket is a difference between the Tier 3 and a Tier 2. And pretty appropriate patients, commercial patients, we definitely buy down that out-of-pocket to be very competitive with the leading branded product out there. So we feel our 26 million lives that are covered are on a level playing field with regard to the leaders out there. And that -- those are the majority of the larger plans within ESI, but we will continue to work with signing on some of the downstream plans that ESI covers -- sorry, that Ascent covers as well and through ESI. So the tiering for us is not a disadvantage. We feel we're going to be very competitive with the two major brand leaders out there. Chris Neyor -- J.P. Morgan -- Analyst Great. That's helpful. And then, you kind of touched on the refill rates and also maybe you could just discuss your confidence in being able to hit that commercial coverage for CVS Caremark and UnitedHealth by the middle of this year. And then, aside from maybe overall script trends, any other KPIs that we should be watching for the launch in the coming weeks and quarters? John Snisarenko -- Chief Commercial Officer Yeah, no, Chris, in regards to the refill rates, we've been very pleased with the kind of 60%, 65% rate of refills we've been seeing. We feel that based on the product profile, as well as the services we offer to make sure that both the prescriber base, as well as the patients are supported through the clinical experience with TYRVAYA. In regards to some of the other PBMs, we are in the middle of negotiations with them. We are still on track to have coverage determinations by midyear. And we are ready to negotiate whether they're going to be managing the generic space or not. We feel we're going to be very, very competitive to be able to get TYRVAYA listed and get the majority of those commercial lives covered by midyear of '22. Chris Neyor -- J.P. Morgan -- Analyst Perfect. Appreciate the questions. Jeff Nau -- President and Chief Executive Officer Thank you, operator, and thanks to everyone for joining the call with us today. As I mentioned in my opening remarks, we are extremely pleased to announce that TYRVAYA Nasal Spray, indicated for the treatment of the signs and symptoms of dry eye disease, is currently in its first full quarter of launch for patients and eye care providers in the U.S. We are extremely excited for the potential of significant growth that remains ahead. Our vision and focus on bringing innovative and transformative ophthalmic disease treatments to patients and building Oyster Point Pharma into a best-in-class eye care company remains our primary goal as a company. In closing, I want to thank everybody for joining us tonight and to have a great evening. Duration: 41 minutes Call participants: Dan Lochner -- Chief Financial Officer Jeff Nau -- President and Chief Executive Officer John Snisarenko -- Chief Commercial Officer Ken Cacciatore -- Cowen and Company -- Analyst Joe Catanzaro -- Piper Sandler -- Analyst Patrick Dolezal -- LifeSci Capital -- Analyst Chris Neyor -- J.P. Morgan -- Analyst More OYST analysis All earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2523,\n        \"min\": 525,\n        \"max\": 32540,\n        \"num_unique_values\": 7950,\n        \"samples\": [\n          7952,\n          6261,\n          8233\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker_clean\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2869,\n        \"samples\": [\n          \"CRWD\",\n          \"AME\",\n          \"WRLD\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08086309609059461,\n        \"min\": -0.6091428484235492,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 9985,\n        \"samples\": [\n          0.011530214945978869,\n          0.10530232274255087,\n          -0.07811321228005444\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 16
        }
      ],
      "source": [
        "price_data={}\n",
        "def get_price_reaction(row):\n",
        "  ticker=row[\"ticker_clean\"]\n",
        "  call_date=row[\"Date_only\"]\n",
        "  if not ticker or not isinstance(ticker, str): return None\n",
        "  if ticker not in price_data:\n",
        "    try:\n",
        "      stock=yf.Ticker(ticker)\n",
        "      hist=stock.history(start=start_date_dynamic,end=None)\n",
        "      if hist.empty:\n",
        "        price_data[ticker] = None\n",
        "        return None\n",
        "      hist.index=hist.index.tz_localize(None)\n",
        "      price_data[ticker]=hist\n",
        "    except Exception as e:\n",
        "      print(f\"Error on: {ticker} Error:{e}\")\n",
        "      price_data[ticker]=None\n",
        "      return None\n",
        "  hist=price_data[ticker]\n",
        "  if hist is None or hist.empty:\n",
        "    return None\n",
        "  try:\n",
        "    if call_date<hist.index.min() or call_date>hist.index.max():\n",
        "      return None\n",
        "    idx=hist.index.get_indexer([call_date],method=\"nearest\")[0]\n",
        "    if idx+1>=len(hist):\n",
        "      return None\n",
        "    day_0=hist.iloc[idx]\n",
        "    day_1=hist.iloc[idx+1]\n",
        "    price_change=(day_1[\"Close\"]-day_0[\"Open\"])/day_0[\"Open\"]\n",
        "    return price_change\n",
        "  except Exception:\n",
        "    return None\n",
        "\n",
        "print(f\"Fetching data\")\n",
        "df[\"Price_change\"]=df.apply(get_price_reaction,axis=1)\n",
        "df.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 17,
      "metadata": {
        "id": "2bde119b",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "4b155387-c899-4c98-a897-9fba1010a253"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Number of rows where Price_change could not be fetched: 7462\n"
          ]
        }
      ],
      "source": [
        "num_failed_fetches = df['Price_change'].isnull().sum()\n",
        "print(f\"Number of rows where Price_change could not be fetched: {num_failed_fetches}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 18,
      "metadata": {
        "id": "b9f02dba",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "7b85baf5-0132-437b-a95d-d9cfc35c86fe"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "New DataFrame shape after dropping rows: (10913, 11)\n"
          ]
        }
      ],
      "source": [
        "df_cleaned = df.dropna(subset=['Price_change']).copy()\n",
        "print(f\"New DataFrame shape after dropping rows: {df_cleaned.shape}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 19,
      "metadata": {
        "id": "ACqmM85FXOoQ",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 660
        },
        "outputId": "b82b7290-9651-4476-e28a-86096d897462"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript           Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel... 2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta... 2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc... 2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon... 2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel... 2019-08-07 08:30:00   \n",
              "\n",
              "   Date_only                                         Clean_Text  word_count  \\\n",
              "0 2020-08-27  At this time, I would like to turn the confere...        5623   \n",
              "1 2020-07-30  Brian G. Harris -- Senior Vice President and C...        4755   \n",
              "2 2019-10-23  Tina Correia -- Vice President, Investor Relat...        8917   \n",
              "3 2019-11-06  Joining us today are BBSIs President and CEO, ...        8286   \n",
              "4 2019-08-07  I would now like to turn the conference over t...        4611   \n",
              "\n",
              "  ticker_clean  Price_change  \n",
              "0         BILI      0.035078  \n",
              "1          GFF      0.116154  \n",
              "2         LRCX      0.142022  \n",
              "3         BBSI      0.029891  \n",
              "4         CSTE      0.249623  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-13a3095c-40e9-41aa-b39e-1f9cca7ae7c3\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>Clean_Text</th>\n",
              "      <th>word_count</th>\n",
              "      <th>ticker_clean</th>\n",
              "      <th>Price_change</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>At this time, I would like to turn the confere...</td>\n",
              "      <td>5623</td>\n",
              "      <td>BILI</td>\n",
              "      <td>0.035078</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>Brian G. Harris -- Senior Vice President and C...</td>\n",
              "      <td>4755</td>\n",
              "      <td>GFF</td>\n",
              "      <td>0.116154</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>Tina Correia -- Vice President, Investor Relat...</td>\n",
              "      <td>8917</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>0.142022</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>Joining us today are BBSIs President and CEO, ...</td>\n",
              "      <td>8286</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>0.029891</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>I would now like to turn the conference over t...</td>\n",
              "      <td>4611</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>0.249623</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-13a3095c-40e9-41aa-b39e-1f9cca7ae7c3')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-13a3095c-40e9-41aa-b39e-1f9cca7ae7c3 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-13a3095c-40e9-41aa-b39e-1f9cca7ae7c3');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-882619f9-4589-44f6-863e-58926037dffd\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-882619f9-4589-44f6-863e-58926037dffd')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-882619f9-4589-44f6-863e-58926037dffd button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df",
              "summary": "{\n  \"name\": \"df\",\n  \"rows\": 18375,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5681,\n        \"samples\": [\n          \"May 10, 2022, 8:30 a.m. ET\",\n          \"Feb 16, 2021, 8:00 a.m. ET\",\n          \"Jun 01, 2022, 4:30 p.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2872,\n        \"samples\": [\n          \"NASDAQ: TTSH\",\n          \"NYSE: WDH\",\n          \"NASDAQ: HOPE\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q3\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2869,\n        \"samples\": [\n          \"CRWD\",\n          \"AME\",\n          \"WRLD\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17220,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nHello, and welcome to today's Expro Q2 2022 earnings presentation. My name is Elliot, and I will be coordinating your call today. [Operator instructions] I would now like to hand over to Karen David-Green. The floor is yours.\\nPlease go ahead.\\nKaren David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations\\nWelcome everyone, to Expro's second quarter 2022 conference call. I'm joined today by Mike Jardon, CEO; and Quinn Fanning, CFO. First, Mike and Quinn will share their prepared remarks, and then we will open it up for questions. We have an accompanying presentation on our second quarter results that is posted on the EXPRO website, expro.com under the investors section.\\nIn addition, the second quarter financials are downloadable on the Expro website under the Investors section. I'd like to remind everyone that some of today's comments may refer to or contain forward-looking statements. Such remarks are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such statements speak only as of today's date, and the company assumes no responsibility to update any forward-looking statements as of any future date.\\nThe company has included in its SEC filings, cautionary language identifying important factors that could cause actual results to be materially different from those set forth in any forward-looking statements. A more complete discussion of these risks is included in the company's SEC filings, which can be accessed on the SEC website or on our website at expro.com. Please note that any non-GAAP financial measures discussed during this call are defined and reconciled to the most directly comparable GAAP financial measure in our second quarter 2022 earnings release, which can be found on our website. With that, I'd like to turn the call over to Mike. \\nMike Jardon -- Chief Executive Officer\\nThank you, Karen. Good morning and good afternoon, everyone. I'm pleased to share with you that Expro delivered robust operational performance and financial results that exceeded the guidance we provided for the just completed second quarter. We are experiencing increase customer activity levels across all segments of our business, bolstered by a backdrop of strengthening industry fundamentals.\\nWe believe this positive momentum will not only continue, but will also accelerate going into 2023 and beyond. Expro is poised to capitalize on an expected increase in customer spending and activity. Today, Expro has a scope and financial profile required to compete and win in what we believe is the best outlook for energy services in at least a decade. Our results in the second quarter and our market outlook underscore the benefits of Expro's balanced portfolio of services and solutions with leading capabilities and a culture built around safety, service quality, organizational efficiency and risk management.\\nIn addition, we believe our through-cycle resilience is a significant advantage and competitive differentiator for Expro. Our current portfolio of services and solutions is paired with a global operating footprint with established positions in key growth markets and the combination provides Expro with good leverage to improving industry fundamentals and in particular, to the rebound that is beginning to take place in the international and offshore markets. We have never been better positioned to capture cyclical recovery upside. We also continue to have a best-in-class innovation platform and technology portfolio that enables us to support our customers' efficiency and emissions-related goals, grow market share and capitalize on longer-term industry trends.\\nFinally, our strong balance sheet and merger-related synergies provide us with significant financial, operational and strategic flexibility that will allow us to accelerate growth and create long-term stakeholder value. On today's call, I'll touch on three main topics. First, I'll walk you through our second quarter performance. Second, I'll give an update on our integration process.\\nAnd finally, I'll provide some perspective on trends we are seeing in the broader industry environment. For the second quarter, we delivered revenue of $314 million and an adjusted EBITDA of $51 million. Second quarter revenue increased 12% sequentially and on a Pro Forma basis, 10% year over year. Higher revenue during the quarter was driven by increased activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific regions.\\nAdjusted EBITDA increased 39% sequentially and on a Pro Forma basis, 33% year over year. Adjusted EBITDA was primarily driven by a more favorable activity mix during the second quarter and faster-than-anticipated realization of merger-related synergies. Well Construction revenue was up 9% quarter over quarter and well management, which includes our well flow management, subsea well access and well intervention integrity businesses was up 13% quarter over quarter. Second quarter results exceeded the prior guidance, primarily as a result of increased well flow management and well construction revenue within North and Latin America.\\nOur team continues to both capitalize on improving industry fundamentals and demonstrate the value of Expro's broad suite of cost-effective, innovative solutions to win new business and expand relationships with existing customers. During the quarter, we continued to secure contracts because of our exceptional service quality and technical delivery. We also continued the introduction of new technologies with both CoilHose and Octopoda, achieving market adoption at pace. The current commodity price environment puts a premium on maximizing production from existing well stock.\\nSo there is a strong customer interest in well intervention integrity solutions such as CoilHose and Octopoda. The significant under investment in energy supply over the last decade, coupled with growing demand, is also resulting in FID approvals. Importantly, for our company, nearly 60% of the new customer commitments are expected to be offshore. We achieved contract wins and extensions totaling approximately $300 million, which demonstrates the breadth and depth of our customer relationships and attraction that our solutions are gaining in the market.\\nOn a regional basis, in North and Latin America, our Well Construction team continues to demonstrate the position as the premier provider of casing and tubular running services with the award of contracts and successful operations delivered across the region. The team successfully completed a first casing running to a project in Brazil and carried out eight simultaneous TRS deepwater completions in the Gulf of Mexico, where activity continues to pick up. We also deployed our industry-leading 22-inch brotpackers in Mexico for the first time and have seen growing demand for this well integrity technology as operators across the region seek to protect their assets during storm season. This technology allows for quick and rely the well suspension when operators need it most.\\nWe want to influence contract for a major operator in Brazil. And in Alaska, our team was awarded and performed a well test for a strategically important new customer, further growing our presence in this region. Expro in MENA achieved contractor of the month from an international operator, demonstrating Expro's continued focus on delivering best-in-class safety, quality and customer service. In Europe and Sub-Saharan Africa, we saw good progress in securing new business in the second quarter, including the retention of the largest well flow management contract in the Norwegian continental shelf for an initial four-year term, highlighting the strength and depth of our relationship with this international operator.\\nA significant portion of this contract is directly linked to production optimization and enhancement as well as a demonstrable commitment to low carbon plan. The breadth of our portfolio, including market-leading technologies acquired in our July 2019 acquisition of Quality Intervention directly assisted us in expanding a core well intervention contract with a major international operator in the U.K. In addition, our service quality and portfolio of capabilities helped us secure an expanded contract to meet client needs for a nine-well plug and abandonment campaign in the U.K. Continental Shelf, where we also added well test and well intervention to an existing large board subsea services contract.\\nAs I noted earlier, CoilHose and Octopoda are gaining traction in the market to support clients' intervention and integrity needs. Octopoda is a truly unique service offering, which for the first time in our industry, allows direct access to well annualized in which we can ensure well integrity and production assurance. Octopoda was recently deployed in the Congo, the first deployment of this technology in Sub-Saharan Africa, and it continues to generate customer interest with its unique ability to investigate and remediate sustained casing pressure and other well annulus problems. Additionally, our CoilHose Light Well Circulation system is an innovative development, providing a lower cost more efficient alternative to traditional coiled tubing systems.\\nThis broadening of our portfolio and our depth of experience, combined with the ability to quickly mobilize assets and personnel to meet client requirements helped us secure a U.K. contract for well testing and exploration and appraisal services in support of a new offshore drilling campaign. Expro's superior quality and service performance as strong client partnerships led to the securing of multiple contract wins, including for our subsea team in the Ivory Coast and in Turkey, where we won well testing and CoilHose intervention work for a nine-well project on offshore gas storage project. In the second quarter, we also introduced Drill Stem testing into Angola, further broadening our comprehensive portfolio in this country and positioning us to take advantage of the increasing activity in deepwater operations in Angola.\\nWe have successfully started operations in Cabinda for a major operator, which will be our first deployment of hammering services as part of an Angolan Well Construction Service package. In May, we were also recognized as the safest service provider in Mozambique. Based on our recent performance, we are in discussions with the client regarding further expansion of our services, including the introduction of new technologies. In Chad, our work with the client is core to ensuring that our operations are conducted in an environmentally responsible way.\\nOur expertise and technologies are focused on having no environmental impact with testing and analysis carried out to ensure the appropriate purity of the regional freshwater system, underlining our status as a leading provider of on-site chemistry services with a strong environmental focus. In Norway, we completed our first operational campaign with our iTong Well Construction Technology, which provides a step change in safety and well construction operations. Operational performance exceeded client expectations, delivering significant rig efficiency improvements and cost savings to the customer overall. In the Middle East and North Africa, our Well Construction team has expanded into new territory to secure their first TRS contract in Algeria, which is planned to commence later this month.\\nThis opportunity reflects one of the many revenue synergies created by our October merger. We leverage expert relationships and well flow management to secure this new TRS award. In addition, the regional team was awarded two carbon boom contracts with Middle East drilling contractors, reflecting our market-leading capabilities and reputation in the market. In Egypt, our service offering and ability to deliver contributed to Expro being awarded significant well test contracts.\\nIn the Asia Pacific region, our well construction team in Brunei secured a major 5-year contract for TRS. Our outstanding track record of reliable performance in HSC and service quality were strong criteria for the contract award. In Thailand, the team secured additional TRS work covering 200 wells and in Malaysia and in offshore China, we were awarded three-year TRS contract extensions spanning development and exploration wells. Our subsea team's technical capability played a key part in securing a contract with a major international operator in Malaysia for the provision of our new vessel deployed Light Well Intervention package, with the team also securing significant additional work in Australia.\\nLike CoilHose and Octopoda, Expro's LWI capabilities are the result of investments we have made over the last several years, which should allow the company to offer differentiated production optimization solutions and thereby grow our top line faster than the overall market, while also improving profitability. Expro is strategically committed to continuing to invest in transforming our business portfolio and reducing greenhouse gas emissions. In April, we published our inaugural, environmental, social and governance review with a stated aim of achieving net 0 by 2050 with a 50% reduction in carbon intensity by 2030. As the energy industry embraces transition and the need to make real and visible headway toward a lower carbon world, we appreciate the key enablers to change will be those who can truly differentiate themselves as solutions providers.\\nAs recognized global well experts and a trusted partner, we believe Expro is well-positioned to play an important role in enabling our clients to achieve their carbon reduction goals in support of the energy transition. Expro remains committed to allocating roughly 50% of our research and development budget to carbon reduction initiatives. In doing so, we are developing and advancing solutions that will play a critical role in enabling our customers to achieve their own emission reduction goals while also allowing experts to achieve its goals. Expro's well expertise and range of well intervention, well integrity and wells measurement technologies and skills help operators cost-effectively develop oil and gas resources while minimizing both emissions and the required operating footprint.\\nAs our industry speaks to address tomorrow's challenges, we believe many of these technologies and skills are transferable. As a good example of adopting technologies to achieve more sustainable energy solutions, Expros supported geothermal well service projects since 1986. Most notably, in the second quarter, we were awarded our first integrated services geothermal contract to support a high-profile geothermal plant in Germany. The second topic I'd like to cover is to provide an update on our integration efforts.\\nDuring the quarter, we continued to make progress in bringing the legacy businesses together to capture the full potential of our combined platform. I am pleased to report that 9 months into our integration, we have identified an action more than 100% of the $55 million in annualized cost savings that we established with our target within the first 12 months following the closing of the merger. This comes a full quarter earlier than we had initially anticipated. As outlined previously, we are targeting cost and revenue synergies between $80 million to $100 million within 24 to 36 months post-merger.\\nWe remain confident that we will achieve $70 million in projected cost synergies during this time frame, if not earlier. Cost savings are primarily driven by the rationalization of support costs, consolidation of facilities and supply chain savings. In the second quarter, we consolidated additional facilities, including locations in Baku, either by John, St. John's, Canada; Lumpur, Malaysia; Mumbai, India; Corpus Christi and Midland, Texas.\\nWhile revenue synergies are more difficult to demonstrate, my sense is that our previous estimate of an incremental $10 million to $30 million in EBITDA for revenue synergies through our expanded customer relationships and operating footprint, increased time on rig and greater exposure to the full life of the field will likely prove to be conservative. I'd like to sincerely thank the entire expert team for their hard work and numerous contributions toward helping us realize our integration goals ahead of schedule. Without a doubt, we have a winning team that has proven the building to deliver on our commitments. Before I turn the call over to Quinn, I want to provide some perspective on trends we are observing in the market.\\nThe positive signs of a recovery we saw in Q1 continued to build, underpinned by a favorable supply demand dynamic. As I noted earlier, this is largely a result of limited upstream investment in recent years and a need for additional capacity to meet projected demand growth. With the more recent heightened focus on energy security, diversification of supply and the need to replace at least a portion of Russian oil and gas supply is expected to fully magnify what was already set up to be a favorable multi-year macro backdrop for OFS activity. Longer term, we believe the service sector will need to play an important role in facilitating the energy transition.\\nSo despite ongoing volatility in commodity prices, the fundamental backdrop for the energy services sector is quite constructive. In particular, after a strong recovery in the U.S. onshore market, we are seeing increasing demand for our services and solutions with international and offshore activity expected to accelerate through the second half of 2022 and into 2023 as operators look to increase production from existing assets and develop new fields. Notwithstanding near-term concerns of an economic slowdown, there seems to be a consensus that energy demand will trend back toward, if not through 100 million barrels of oil equivalent per day in 2023.\\nWe expect that increasing demand for energy services and capacity constraints in key service offerings, including high-end well construction equipment and subsea test trees should provide scope for improvement in net pricing beginning in late 2022 into early 2023. In Expro's view, expected growth will be broad-based geographically, span all phases of oil and gas development and include all operating environments. Geographically, we see strong potential in North and Latin America, the Middle East, North Africa, Sub-Saharan Africa, as well as Asia. And while many of our customers continue to focus on brownfield enhancement programs to maximize previous investments, we are also starting to see growth in exploration and development activity driven primarily by North and South America, with further activity expected in Norway, India and Sub-Saharan Africa.\\nThe brownfield focus will support steady growth in our well Intervention Integrity business as well as elements of our well flow management business, collectively, which represent about 35% of our business. The remaining circa 65% of our business is generally levered to drilling, well construction and well completions activity, which we believe is points for strong growth across several geographies and within which we generally capture very good faster on incremental revenue. Overall, the outlook for the remainder of '22 and into 2023 remains positive with sustained increases in E&P expenditures. After rather dramatic recovery in the North America onshore market, customer dialogue and tendering activity indicates to us that the outlook for offshore activity is strengthening.\\nThis should support sustained growth for Expro given our leading and differentiated portfolio capabilities and subsea well access services, complex well construction services and production optimization. This is particularly important as approximately 70% of our revenue today is generated from offshore activity. Before I close, I'm pleased to share that during the quarter, our board approved a new stock repurchase program under which the company is authorized to acquire up to $50 million of its outstanding common stock up to the November 2023 time frame. We view the repurchase of our shares as an attractive and prudent use of our capital that it is in the best interest of our shareholders.\\nWith a debt-free balance sheet, ample available liquidity and strong construction of an industry recovery, buybacks allow us to opportunistically increase shareholder value while maintaining sufficient cash resources to fund our business needs. In the second quarter, we repurchased $13 million in export stock, representing approximately 1% of our shares outstanding. From an operational standpoint, Expro is well positioned in the markets that we expect will continue to benefit from strengthening industry fundamentals. In particular, Expro has significant leverage to strengthen the international and offshore markets where experience, expertise and service quality can be in Expro's case are positive points of differentiation.\\nExecution is a traditional strength of Expro and when we plan to continue to deliver on both for our customers and our shareholders. With that, I will hand the call over to Quinn to discuss our financial results.\\nQuinn Fanning -- Chief Financial Officer\\nThank you, Mike. Good morning and good afternoon to everyone on the call. As Mike noted, I will cover the results for the quarter ended June 30th, 2022, and will primarily highlight our sequential performance compared to the quarter ended March 31st , 2022. To recap, we reported revenue of $314 million for the June quarter, which was up sequentially $34 million or approximately 12% relative to Q1 2022.\\nThe sequential increase in revenue was driven by higher activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific segments, partially offset by lower activities in the Middle East and North Africa segment. Adjusted EBITDA for Q2 2022 was approximately $51 million, representing a sequential increase of approximately $14 million or 39% relative to Q1 2022. Adjusted EBITDA margin in Q2 was 16% as compared to 13% in Q1. The sequential increase in revenue and adjusted EBITDA was driven by strong results for well flow management and well construction in North and Latin America.\\nAs highlighted in our press release, adjusted net income for the second quarter of 2022 was $0.02 per diluted share, compared to adjusted net income for the first quarter of 2022 of $0.01 per diluted share. As noted in our press release, adjusted net income for Q2 includes foreign exchange losses of $0.05 per diluted share as compared to foreign exchange gains of $0.03 per diluted share in Q1. Q2 contribution margin of 38% was up approximately one percentage point sequentially from Q1 2022, reflecting improved fall-through on higher revenue as a result of a more favorable activity mix. Q2 support costs of $70 million totaled 22% of group revenue and were down approximately $1 million sequentially or approximately 3 percentage points relate Q1 2022 and were down $8 million or approximately 9 percentage points relative to the combined support costs of Expro Frank's in Q4 2020, which was the last full quarter prior to the announcement of the merger.\\nThis represents approximately $30 million of annualized support cost savings achieved through the second quarter of 2022. In the near term, we expect to continue to manage total support costs to 22% of group revenue. With modest net pricing gains and/or incremental cost synergies, we believe we can manage overall support costs to about 20% of revenue. Total liquidity at quarter end was approximately $309 million.\\nCash and cash equivalents, including restricted cash, was $179 million as of June 30th. Total liquidity also includes $130 million that is available to the company for drawdowns as loans under our $200 million revolving credit facility. The balance of the facility is available for bonds and guarantees. Expro had no interest-bearing debt at quarter end Q2 2022, and the company has no interest-bearing debt today.\\nDuring the quarter ended June 30th, cash provided by operating activities was $2 million as compared to cash used in operating activities of $14 million in Q1. Q2 adjusted operating cash flow, reflecting cash used in operations before cash paid for interest, severance and other expenses and merger integration expenses, was positive $10 million compared to negative $1 million in Q1. Capital expenditures totaled $21 million in the second quarter compared to $11 million during the first quarter. For the second half of 2022, the company is planning for capital expenditures in the range of approximately $60 million to $70 million, implying total capex for 2022 of $90 million to $100 million or approximately 8% of expected revenue.\\nWe also continue to expect to be free cash flow generative for 2022, but as noted on our last earnings conference call, we expect that adjusted cash flow from operations and free cash flow will be heavily weighted to the second half of the year. Consistent with comments from several of our public peers, Expro's investment in working capital was up materially in the first half of 2022, with higher receivables reflecting higher activity levels and higher inventory reflecting both an expectation of continued momentum in the business and the procurement of long lead items, including critical spares. Consistent with historic patterns, we expect a reversal of the H1 build in working capital and a significant improvement in cash generation in H2 2022. As Mike previously discussed, under our recently announced stock repurchase program, during the second quarter, we opportunistically repurchased 1.1 million shares or approximately 1% of our shares outstanding for a total cost of $13 million.\\nThis program is a reflection of the long-term confidence we have in our business, which we believe is not reflected in the current market valuation. In due course, we will more formally articulate Expro's capital allocation priorities. For now, we expect that the small buyback will be completed in Q2 and for that matter, any additional buybacks will be funded by free cash flow. Now, moving into the details for reporting segment.\\nNorth and Latin America or NLA, revenue for the second quarter of 2022 was $130 million, a sequential increase of $26 million quarter over quarter. The increase was primarily due to higher revenues across all of our product lines during the current quarter with a significant increase in well flow management revenue in Mexico and higher well construction revenue in the U.S. and Guyana driven by higher customer activity levels during the just completed quarter. NLA segment EBITDA for the three months ended June 30th, 2022, was $39 million or approximately 30% of segment revenue.\\nIt was up sequentially by $17 million quarter over quarter. For Q1 2022, NLA segment EBITDA was 21% of segment revenue. The increase was attributable to higher activity and a more favorable product mix during the three months ended June 30th. For the Europe and Sub-Saharan Africa or ESA segment, revenue in Q2 was $90 million, which was up $8 million or approximately 10% quarter over quarter.\\nThe sequential increase was primarily driven by higher wealth flow management revenue in Angola and in the Congo and higher well construction revenue in the United Kingdom due to increased customer activities. The increase in revenues was partially offset by lower well intervention integrity revenue in Norway and Western Europe. ESA segment EBITDA for the second quarter was $15 million or approximately 16% of segment revenue, a sequential increase of $3 million quarter over quarter. The increase was primarily attributable to higher activity levels and a more favorable activity mix during the June quarter.\\nFor the Middle East and North Africa or MENA segment, revenue in the second quarter was $45 million, a decrease of $6 million or approximately 11% quarter over quarter. The sequential decrease was driven by lower equipment sales related to wealth management in Saudi Arabia and in the United Arab Emirates, partially offset by increased wall management activities in Algeria. MENA segment EBITDA for the June quarter was $14 million, a sequential decrease of $1 million quarter over quarter. Segment EBITDA margin was consistent with the prior quarter at 30%.\\nThe reduction in segment EBITDA was primarily due to lower activity. For Asia Pacific, or APAC, revenue for the second quarter was $48 million, which was an increase of $4 million or approximately 11% sequentially. The increase in revenue was primarily due to higher subsea well access revenue in Australia and Brunei and higher well construction revenue in Japan. The increase in revenue was partially offset by lower wealth flow management revenue in Thailand and in India.\\nAPAC segment EBITDA for the June quarter was $4 million or approximately 9% of segment revenue, a decrease of $1 million or about 3 percentage points quarter over quarter. The reduction in segment EBITDA in APAC, despite the increase in revenue was primarily due to additional mobilization and commissioning costs on a large subsea project that were incurred during the quarter as well as lower activity on higher-margin contracts. Additional commissioning costs on the Subsea projects, which totaled approximately $3 million and associated project start-up delays are in part COVID related and should be nonrecurring. As a result, we expect that revenue and segment EBITDA margin in APAC will trend positively in H2 2022 and into 2023.\\nAs Mike mentioned, our integration plans are progressing well, and we are already starting to realize significant synergy benefits we anticipated when we first announced our business combination in March of 2021. As Mike mentioned, through the second quarter of 2022, we have identified an action to approximately 100% of our synergies capture plan, both in regards to headcount and annualized value in dollars. We also completed the consolidation of several international facilities and made good progress on our ongoing migration to a single ERP platform, which should allow us to both to streamline a number of key business processes and begin to action additional cost synergies. As to our near-term outlook, we expect that Q3 2022 revenue will be up sequentially by plus or minus 8%, reflecting continued business momentum at NLA, the continuation of the seasonal rebound in ESA and the start-up of new contracts in MENA and APAC.\\nAdjusted EBITDA margin in Q3 should be in the area of 15% to 17% of consolidated revenue. Over the next couple of quarters, we continue to expect that our revenue run rate will approximate that of the pre-pandemic 2019 revenues of Legacy Expro and legacy Frank's on a combined basis. And we, therefore, reaffirm our guidance, the Q4 revenue should fall within a range of $325 million to $350 million. With the benefit of fall-through on incremental revenue and synergies, we expect that adjusted EBITDA margins will be in the area of 20% of revenue as we exit the year.\\nProvided our H1 build in working capital reverses in H2 2022 as is currently anticipated, absent additional M&A and/or share repurchases, we expect that our year-end cash position will be at or above where we started the year with cash generated from operating activities, funding integration costs, capex, the Q1 acquisition of SolaSense and the share buyback that was completed in Q2. By preserving and protecting our currently strong financial profile and by maintaining a disciplined approach to investment, we believe Expro will have sufficient financial flexibility to fund growth and increase returns to shareholders. As always, our objective is to enhance long-term value for our shareholders, employees, partners and the communities in which we operate. With that, I will turn the call back over to Mike for a few closing comments.\\nMike Jardon -- Chief Executive Officer\\nThank you, Quinn. We delivered exceptional operational performance that drove significant growth on a top and bottom line and is beginning to demonstrate the true capability of the company. Our broad portfolio of services and solutions continue to create opportunities in the growth markets that will be key to Expro's long-term success. Our innovative platform, next-generation technology and solutions and ESG applications are differentiators that continue to rapidly advance our reputation and outstanding track record with customers as a leading well expert.\\nWe continue to secure contracts and demonstrate the value of the breadth of our portfolio and the depth of our expertise can bring to clients across the life of their wells. Looking forward, the positive signs of a recovery we saw in the first quarter continued to gain momentum. We are seeing increased demand for our services and solutions as the recovery that began within the U.S. onshore market has begun to gain traction in the offshore international markets.\\nWe remain confident that the pipeline of projects we are seeing will support strong multi-year growth and firmly believe Expro is uniquely positioned to capitalize on this favorable outlook. We are incredibly excited about the strength and positioning of Expro. Our results could only have been achieved by the hard work and focus of our team. It's through their dedication that we continue to accelerate growth, improve profitability and enhance value for shareholders, employees, customers and partners.\\nThank you, again.\\nQuestions & Answers:\\nOperator\\n[Operator instructions] Our first question today comes from James West from Evercore ISI. Your line is open. Please go ahead.\\nJames West -- Evercore ISI -- Analyst\\nGood morning, guys.\\nMike Jardon -- Chief Executive Officer\\nGood morning James.\\nJames West -- Evercore ISI -- Analyst\\nSo one, Mike -- so curious, it seems like we've gone through a bit of acceleration in demand here over the last quarter, maybe two quarters in a sense of urgency has arisen within your customer base? I guess -- so first, is that -- am I getting that correct? And that this urgency is kicking in? And then second, are you seeing more of that urgency or increased demand on producing assets or new assets or interventions versus new well construction type work.\\nMike Jardon -- Chief Executive Officer\\nYes. So James, I can tell you one of the good things is we've really -- now that we're kind of more exited the pandemic. I've been able to spend an awful lot more time with customers, not only in the U.S., but in particular, Middle East and Asia. And what I'd say is the conversations particularly around new FIDs, new projects, new drilling and completion type activity, that's much more constructive, much more dialogue and discussion around that.\\nI'd say that the -- we've had continuing strong commentary and strong game with customers around producing assets. So that's -- I think that's ramping up, but not at the same rate as the positivity from the discussions around new well type -- new well drilling activity and new well completion activity.\\nJames West -- Evercore ISI -- Analyst\\nOK. Fair enough. And then on the pricing side, are you -- at this point, are we back to kind of -- or getting close to back to pre-pandemic type of levels? Admittedly, offshore wasn't as robust even then, but it's growing and robustness now. But are you achieving the returns on capital investments that you would like to see when you're allocating capital and what you're pricing new contracts?\\nMike Jardon -- Chief Executive Officer\\nSo I would -- and I tried to allude to it in my earlier comments, we're starting to see some spotty opportunities to push price, and we're pushing price every opportunity we can. It's more selective right now. I think we'll continue to gain more momentum around our ability to continue to press price as we exit '22 going into '23, but we are starting to have -- it hasn't quite turned the quarter, so to speak, like North America. U.S.\\nland has where there's lots of pricing leverage and pricing traction. But we are starting to see in some particular markets and some particular service lines, positive opportunity to continue to get that pricing. And I think we're all keen to make sure that we start to implement that absolutely as soon as we can.\\nQuinn Fanning -- Chief Financial Officer\\nJames, I think the only thing -- I could just point you back to Mike's prepared remarks, there are capacity constraints within certain solutions and certain product groups, complex well construction or to provide construction activity or TROs, as well as the subsea landing streams. It's obviously a market that is supported by just a handful of service providers ourselves being one of the two larger ones product lines. But obviously, everything about the supply and demand, there's less than a supply for those two equipment classes. The other thing I'd highlight is with the pickup in drilling and completion type activity.\\nIt's not necessarily how we present our supplemental disclosures. But what we consider to be our drilling completions over businesses, they were up 20% quarter-over-quarter revenue-wise and the thoughts for margins on the incremental activity is north of 50%. So that's really where you get the --\\nJames West -- Evercore ISI -- Analyst\\nOK. Got it. Yes, no doubt. That's going to be very helpful.\\nOperator\\nOur next question comes from David Anderson from Barclays. The line is open. Please go ahead.\\nDavid Anderson -- Barclays Capital -- Analyst\\nHey. Good morning, Mike. I was just curious which of your product lines showed the greatest margin improvement this quarter. And I think you maybe just touched on it just now here.\\nBut curious if there's been much of improvement in well construction, in particular, as a rental business in TRS with high offshore exposure. Just curious how we should be thinking about the margin expansion upside in that particular business and how that should contribute overall.\\nMike Jardon -- Chief Executive Officer\\nSure. We alluded to some of this in the prepared remarks. What kind of additional commentary I'd add to it, David, is we've really seen some increased mix, better mix of activity in North Latin America, in particular. So yes, particularly around TRS around well construction, we've been able to start to see some margin expansion there.\\nAnd then I think overall, what you're really seeing is starting to gain more traction with the cost synergies we're taking out the organization overall. We're in essence, we're a full quarter ahead of that. And I think one of the real positives of us being able to get the synergies implemented is if we're being to completely honest, anytime you're doing a consolidation, you're doing a merger, if there is a little too much internal focus that goes on. It's a necessary part of the eval as doing a merger as we can get more of that behind us, and we'll largely because we're a quarter ahead of it, that means going in exiting '22 and going into '23, we're really going to be much more externally focused.\\nAnd that's one of the reasons why I've been challenging the organization is so hard to make sure we get these things done sooner rather than later. But overall, we're seeing margin expansion across well construction and even in some of the well flow management and subsea access, we're getting some traction in all three of those right now.\\nDavid Anderson -- Barclays Capital -- Analyst\\nSo if I just stay on the well construction side, we're hearing a lot of talk about rigs coming back to work both on the jack-ups and the deepwater side. Are you getting inquiries for those? I'm just kind of curious, it's obviously only a couple of players in the TRS business. So I'm just kind of curious, are you starting to kind of roll out some additional equipment at been sidelined for a while. Can you help us give us a handle on what that looks like in terms of, I guess, your capacity type of equipment out there and how that's moved up?\\nMike Jardon -- Chief Executive Officer\\nYes. No, absolutely. We are seeing the same phenomenon that the drillers are seeing today with increased utilization, those kind of things. Because keep in mind, a drilling rig and TRS type equipment goes kind of hand in hand.\\nSo yes, we're able to start to put some of that equipment back to work. I referred to a casing running tool CRT opportunity we execute on in Brazil. That purely is taking assets and resources that were underutilized previously and putting those to work. So on the flip side of that, yes, we're seeing good traction with all construction.\\nThe other thing that we're seeing even more so than I had anticipated was it really becomes an early warning radar system for us, so to speak, because typically, with customers, they select the rig first almost in conjunction with that are certainly right behind it is selecting the TRS provider. And then you start moving into well completions and well testing, and those type of activities. So we're getting earlier customer engagement. And I think that we'll continue to see that allow us to more upholster revenue opportunities, those types of things.\\nDavid Anderson -- Barclays Capital -- Analyst\\nThat's interesting. So if I just -- on that on that well flow management, it was up 14% sequentially this quarter, I'm pretty sure what was pretty strong for business that I thought we would consider later cycle, more production focused. So I guess the question was, I think you had said in your remarks that MENA was a little bit weaker than expected. So where were the results? Was it more mix related this quarter? Was it regional? Was something else kind of picking up and offsetting what you said? I mean, because I would have thought MENA would have actually been a driver of that growth.\\nAnd it sounds like it wasn't --\\nMike Jardon -- Chief Executive Officer\\nSure. MENA for us was really -- we had kind of a quarter-on-quarter product sales that didn't reoccur in the second quarter. So that was what gave us a little bit of softness there. Our strong activity in the Middle East, Algeria, in particular, was actually up quarter on quarter.\\nWhat is important to recognize with well flow management is, in particular as well testing, we can utilize those assets in a well completions cleanup load or you can use those assets in a production optimization mode. And that allows us to kind of flex that equipment to deploy it into one or the other. And part of the growth we saw was starting to see some better activity from a new well completions, new well flowback, those type things within the quarter.\\nDavid Anderson -- Barclays Capital -- Analyst\\nOK. Thank you very much.\\nMike Jardon -- Chief Executive Officer\\nAbsolutely. Thanks for the questions.\\nOperator\\n[Operator signoff]\\nDuration: 0 minutes\\nCall participants:\\nKaren David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations\\nMike Jardon -- Chief Executive Officer\\nQuinn Fanning -- Chief Financial Officer\\nJames West -- Evercore ISI -- Analyst\\nDavid Anderson -- Barclays Capital -- Analyst\\nMore XPRO analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, and welcome to the Monster Beverage Company Second Quarter 2021 Conference Call. [Operator Instructions]\\nI would now like to turn the conference over to Rodney Sacks, Co-CEO, to begin the call. Please, go ahead.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nGood afternoon, ladies and gentlemen. Thank you for attending this call. I'm Rodney Sacks. Hilton Schlosberg, our Vice Chairman and Co-Chief Executive Officer, is on the call; as is Tom Kelly, our Chief Financial Officer.\\nTom Kelly will now read our cautionary statement.\\nThomas J. Kelly -- Chief Financial Officer\\nBefore we begin, I would like to remind listeners that certain statements made during this call may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and are based on currently available information regarding the expectations of management with respect to revenues, profitability, future business, future events, financial performance and trends, as well as the future impact of the COVID-19 pandemic on the company's business and operations.\\nManagement cautions that these statements are based on our current knowledge and expectations and are subject to certain risks and uncertainties, many of which are outside the control of the company that may cause actual results to differ materially from the forward-looking statements made during this call. Please refer to our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K filed on March 1, 2021, including the sections contained therein entitled Risk Factors and Forward-looking Statements, for a discussion on specific risks and uncertainties that may affect our performance. The company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events or otherwise.\\nI would now like to hand the call over to Rodney Sacks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThank you, Tom. The company's top priority remains the health, safety and well-being of its employees. The company's flavor manufacturing facilities, its co-packers, warehouses and shipment facilities have operated throughout the COVID-19 pandemic. The company's bottlers and distributors are operating, and the company's products remain generally available to consumers. In limited countries, the operations of the company's bottlers and distributors have, in part, been negatively affected for varying periods of time. Despite the ongoing impact of the COVID-19 pandemic, the company achieved record second quarter net sales. Currently, the company does not foresee a material impact on the ability of its co-packers to manufacture and its bottlers and distributors to distribute its products as a result of the COVID-19 pandemic.\\nThe company's supply chain remains largely intact. However, the company continues to experience shortages in its aluminum can requirements in the United States and EMEA, given the company's volume growth and the current supply constraints in the aluminum can industry. The company is also experiencing delays in procuring certain ingredients, both domestically and internationally. As a result, the company was unable to fully satisfy demand in the 2021 second quarter in the United States and EMEA. We expect such challenges to continue for the next few months. The company has taken steps to source additional quantities of aluminum cans from the United States, South America and Asia. The company has entered into new supply agreements with two new aluminum can suppliers in the United States, and which are expected to be operational in the 2021 fourth quarter. We expect deliveries of additional quantities of cans increasing sequentially during the latter part of the year.\\nLogistical issues, including shortages of shipping containers and port of entry congestion could delay ongoing international supply of aluminum cans. Separately, we are continuing to experiencing -- experience freight inefficiencies as well as significant increases in domestic and international freight costs and like other beverage companies are incurring increased aluminum can and other costs in the current environment, all of which in addition to other factors, will continue to adversely impact gross margin percentages. In the second quarter of 2021, net sales were $1.46 billion compared with $1.09 billion in the second quarter of 2020, an increase of 33.6%. Adjusting for foreign currency movements, net sales for the 2021 second quarter would have been up 30.1%. Gross profit as a percentage of net sales for the 2021 second quarter was 57.2% compared with 60.3% in the 2020 second quarter. The decrease in gross profit as a percentage of net sales for the three months ended June 30, 2021, was primarily the result of geographical sales mix and increased input costs, mainly increased raw material freight in costs and aluminum can costs.\\nOperating expenses for the 2021 second quarter were $310.9 million compared with $252.2 million in the 2020 second quarter. As a percentage of net sales, operating expenses for the 2021 second quarter were 21.3% compared with 23.1% in the 2020 second quarter. Operating income increased 29.1% to $526 million, up from $407.3 million in the second quarter of 2020. Net income increased to 29.7% and to $403.8 million compared to $311.4 million in the 2020 comparable quarter. Diluted earnings per share for the 2021 second quarter increased to 28.6% and to $0.75 from $0.59 in the second quarter of 2020. According to the Nielsen reports for the 13 weeks through July 24, 2021, for all outlets combined, namely convenience, grocery, drug, mass merchandisers, sales in dollars in the energy drink category, including energy shots, increased by 14.2% versus the same period a year ago. Sales of the company's energy brands, including Reign, were up 8.6% in the 13-week period. Sales of Monster were up 11.1%. Sales of Reign were down 6.1%. Sales of NOS decreased 4.1%, and sales of Full Throttle increased 7%. Sales of Red Bull increased 15.3%. Sales of Rockstar decreased by 15.7%, and sales of 5-Hour increased 8.5%. VPX Bang sales increased 20%.\\nAccording to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the energy drink category in the convenience and gas channel, including energy shots in dollars, increased 7.4% over the same period the previous year. Sales of the company's energy brands, which include Reign, increased 3.6% in the four-week period in the convenience and gas channel. Sales of Monster increased by 5.8% over the same period versus the previous year, Reign sales decreased 6.8%, NOS was down 10.7%, and Full Throttle was up 13.2%. Sales of Redbull were up 9%. Rockstar was down 18.6%, and 5-Hour was up 3.2%. VPX Bang sales increased 12.2%. According to Nielsen, for the four weeks ended July 24, 2021, the company's market share of the energy drink category in the convenience and gas channel, including energy shots, in dollars, decreased 1.3 points to 36.5%.\\nMonster share decreased 0.4 of a share point to 30.6% and. Reigns decreased 0.4 of a share point to two points -- sorry, 2.4%. NOS's share decreased 0.5 of a point to 2.7%, and Full Throttle share remained at 0.7%. Redbull's share increased point -- six points to 37.4%. Rockstar's share was down 1.2 points to 3.8%. 5-Hour share was lower by 0.2 points at 4.6%. VPX Bang share increased 0.3 points to 7.6%. As previously reported, Coca-Cola Energy is being discontinued in the United States and Canada by the end of 2021. According to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the coffee plus energy drink category, which includes our Java Monster line in the convenience and gas channel, increased 4.2% over the same period the previous year.\\nSales of Java Monster, including Java Monster 300, were 5.9% higher in the same period versus the previous year. Sales of Starbucks Energy were 0.4% higher. Java Monster share including Java Monster 300 of the coffee plus energy category, which primarily includes Java Monster, Java Monster 300, Starbucks Doubleshot and Tripleshot, Rockstar Roasted and Bang Keto Coffee for the four weeks ended July 24, 2021, was 51.9%, up 0.9 of a share point, while Starbucks' energy share was 45.5%, down 1.7 points. According to Stackline, which tracks energy drink sales by Amazon in the United States, in the four-week period ending July 3, 2021, sales in dollars in the energy category by Amazon, including energy shots, increased 104.5% over the same period the previous year.\\nSales of Monster increased 59.9%. And its share was 28.1%, down 7.8 share points versus the same period a year ago. Red Bull sales increased 109.4%, and its share was 16.6%, up 0.4 points. Celsius' sales increased 133.1%. And its share increased 1.8 points to 14.3% 5-hour sales increased 40.9%. And its share declined 1.3 points to 2.9%. VPX Bang sales increased 216.1%. And its share increased 1.8 share points to 5.2%. Reign's share decreased 0.1 of a share point to 5.3%. Rockstar's share increased 0.9 of a share point to 3.9%. According to Nielsen, in all measured channels in Canada, for the 12 weeks ended June 19, 2021, the energy drink category increased 17.9% in dollars.\\nSales of the company's energy drink brands increased 28.3% versus a year ago. The market share of the company's energy drink brands was 41.5%, up 3.4 points. Monster sales increased 18.3%, and its market share increased by 0.1 of a point to 35.4% -- sorry, 35.4%. NOS' sales increased 12.6%, and its market share decreased 0.3 of a point to 1.9%. Full Throttle sales decreased 2.1%, and its market share decreased 0.1 of a point to 0.6%. Red Bull sales increased 18.1%, and its market share increased 0.1 of a point to 38.7%. Rockstar sales decreased 8.6%, and its market share decreased 3.3 points to 11. 4%. GURU's sales increased 35.9%, and its share increased 0.5 of a share point to 4%.\\nAccording to Nielsen, for all outlets combined in Mexico, the energy drink category increased 45.2% for the month of June 2021. Monster sales increased 38.7%. Our market share in value decreased by 1.3 points to 27.2% and against the comparable period the previous year. Red Bull sales increased 41.4%, and its market share decreased by 0.2 of a point to 6.5%. Vive 100 sales increased 30.2%, and its market share decreased by 2.4 points to 20.5%. Volt's sales increased 41.1%, and its market share decreased 0.5 of a share point to 18.5%, while B:oost's sales increased 15.7%, and its market share decreased 1.3 points to 5.1%. Amp's sales increased 91.9%, and its market share increased 4.4 points to 17.9%. Predator, which was launched in March 2020, achieved a market share of 3.1%.\\nThe Nielsen statistics for Mexico cover single months, which is a short period that may often be materially influenced positively and/or negatively by sales in the OXXO convenience chain, which dominates the market. Sales in the OXXO convenience chain in turn can be materially influenced by promotions that may be undertaken in that chain by one or more energy drink brands during a particular month. Consequently, such activities could have a significant impact on the monthly Nielsen statistics for Mexico. According to Nielsen for the month of June 2021 compared to June 2020, Monster's retail market share in value increased in Argentina from 40.1% to 46.9% and in Brazil from 29.6% to 35.4%. In Chile, Monster's retail market share decreased from 45.7% to 41.9%. Monster Energy continues to be the leading energy brand in value in Argentina.\\nI would like to point out that the Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country-to-country and are reported on varying dates within the month referred to from country-to-country. According to Nielsen, in the 13-week period ending July 18, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 34.2% to 37.4% in Spain. According to Nielsen, in the 13-week period to the end of June 2021, Monster's retail market share in value as compared to the same period the previous year grew from 14.5% to 15.3% in Germany, from 18.4% to 19.4% in Poland and from 18.4% to 20.1% in South Africa. According to Nielsen, for the 13-week period ending June 20, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 12.5% to 16.2% in Belgium, from 24.2% to 25.3% in Denmark, from 25.8% to 28.2% in France, from 25% to 29% in Great Britain, from 6.7% to 8.4% in the Netherlands, from 27.1% to 31.2% in Norway, from 25.6% to 29.3% in the Republic of Ireland and from 13.4% to 14.5% in Sweden.\\nAccording to Nielsen, in the 13-week period until the end of May 2021, Monster's retail market share in value compared to the same period the previous year grew from 13.3% to 14.5% in the Czech Republic, from 35.1% to 37.9% in Greece and from 16.6% to 29% in Italy. According to Nielsen, in the 13-week period until the end of May 2021, Predator's retail market share in value as compared to the same period the previous year grew from 5.1% to 17.3% in Kenya and from 0% to 8.1% in Nigeria. The Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country to country.\\nAccording to IRI in Australia, Monster's market share in value for the month ending June 2021 increased from 11.6% to 14% as compared to the same period the previous year. Mother's market share in value decreased from 13.3% to 11.6% during the same period. The market share of the company's brands in Australia for the month ended June 2021 increased from 24.9% to 25.5%. According to IRI in New Zealand, Monster's market share in value for the four weeks ended July 11, 2021, increased from 9.9% to 12.4% as compared to the same period of the previous year. Live+ market share in value remained the same at 6.9%, and Mother's market share in value increased from 6.2% to 6.3%. The market share of the company's brands in New Zealand for the four weeks ended July 11, 2021, increased from 23.1% to 25.6%.\\nAccording to Nielsen, in South Korea, Monster's market share in value in all outlets combined for the month of June 2021 increased from 53.3% to 61.9% as compared to the same period in the previous year. According to INTAGE, in Japan, Monster's market share in value in the convenience store channel for the month of June 2021 was 50.6% as compared to 51% in the same period the previous year. Monster remains the market leader in Japan. We again point out that certain market statistics that cover single months or four week periods may often be materially influenced positively and/or negatively by promotions or other trading factors during those periods.\\nNet sales to customers outside of the US were $546.3 million, 37.4% of total net sales in the 2021 second quarter compared to $328.3 million or 30% of total net sales in the corresponding quarter in 2020. Foreign currency exchange rates had a positive impact on net sales in the US dollars by approximately $38.6 million in the 2021 second quarter. Included in reported geographic sales are our sales to the company's military customers, which are delivered in the US and transhipped to the military and their customers overseas.\\nIn EMEA, net sales in the 2021 second quarter increased to 105.7% in dollars and increased 86.5% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales for the second quarter was 39.8% compared to 38.1% in the same quarter in 2020, primarily due to a favorable country and product mix. We're also pleased that in the 2021 second quarter, Monster gained market share in Belgium, the Czech Republic, Denmark, France, Germany, Great Britain, Greece, Italy, the Netherlands, Norway, Poland, the Republic of Ireland, South Africa, Spain and Sweden.\\nIn Asia Pacific, net sales in the 2021 second quarter increased 5.2% in dollars and decreased 100% [Phonetic] in local currencies over the same period in 2020, largely due to sales in Japan and China. Gross profit in this region as a percentage of net sales was 44.4% versus 43.3% over the same period in 2020. In Japan, net sales in the 2021 second quarter decreased 15.1% in dollars and 13.9% in local currency, largely due to COVID-19 restrictions in Japan and distributor inventory adjustments. Depletions increased 7% during the quarter. Monster remains the market leader in Japan for the month of June 2021.\\nIn South Korea, net sales increased 63% in dollars and 50.4% in local currency as compared to the same quarter in 2020. In China, net sales decreased to 21.4% in dollars and 27.8% in local currency as compared to the same quarter in 2020. In this regard, we note that sales in the second quarter of 2020 included the initial launch of Dragon Tea. We are reevaluating the viability of this SKU and the optimal product range for China going forward. We remain optimistic about the prospects for the Monster brand in China. In Oceana, which includes Australia, New Zealand, Tahiti, French Polynesia, New Caledonia, Papua New Guinea and Guam, net sales increased to 146.5% in dollars and 98.2% in local currencies. Sales of the Monster brand in Oceana increased 210% in dollars and 155.6% in local currency as compared to the same quarter in 2020.\\nIn Latin America, including Mexico and the Caribbean, net sales in the 2021 second quarter increased to 19.7% in dollars and increased 117.6% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales was 40.7% compared to 41.2% in over the same period in 2020, primarily as a result of foreign exchange rates and certain raw materials and ingredients for products in this region are purchased in US dollars. In Brazil, net sales in the 2021 second quarter increased by 194.9% in dollars and 201.7% in local currency. Net sales in Chile increased 77.5% in dollars and 52% in local currency in the 2021 second quarter. Net sales in Argentina increased 291.4% in dollars and 458% in local currency in the 2021 second quarter.\\nIn March 2019, VPX, the maker of Bang Energy drinks, sued Monster, alleging that its Reign products infringed VPX's Bang trademarks and trade risk. A trial was held last year. And on August 3, 2021, the court issued an order denying all of VPX's claims and holding that VPX is entitled to no relief whatsoever. In fact, the court specifically found that VPX copied its bank trade risk from the original Monster Energy cans. The court's decision confirms that Monster and Poland retail partners are free to continue to sell our Reign products without any changes and without any restrictions. Monster always believed and maintained that VPX's claims were frivolous, and we are extremely pleased that the court rejected all of VPX's claims while vindicating Monster's rights. As other pending proceedings with VPX are subjudicate, we will not be answering any questions on this matter on today's call.\\nOur new product introductions in the United States in the first half of 2021 were primarily focused in the first quarter. In the United States, during the second quarter of 2021 we refreshed our can graphics on our Rehab Monster brand family as well as our Full Throttle line, also updating the name for Blue Agave to TrueBlue. Monster Energy Ultra Fiesta received a refresh and updated can graphics as well as the name change to Monster Energy Ultra Fiesta Manga. In May 2021, we launched Monster Ultra Fiesta in a 24-ounce option with an update to our Ultra Fiesta Manga plan for later this year. We are in the process of launching a new line of nonalcoholic pure energy sales under the True North brand name in 12-ounce sleek cans, which contained an organic plant-based energy blend and ingredients for immunity support. True North is being offered in six flavors, Cucumber Lime, Black Cherry, Grapefruit Lemonade, Water Mellon Mist, White Peach Pear and Mandarin Yuzu.\\nTrue North has a limited customer target in 2021 with plans for a full launch into mainstream channels in 2022. While cognizant of the can shortages, we believe that it is important to continue with our innovation plans. And to this end, we will be launching our new flavors reserve line of Monster Energy drinks in Water Mellon and White Pineapple in October 2021. We have deferred the launch of our new line of Java Monster Cold Brew Coffee + energy drinks until early 2022. In Canada, during the second quarter, we launched two new products: Monster Punch Papillon and Monster Punch Khaotic, both in a 473 ml can. In April 2021, we launched Reign Orange Dreamsicle in Puerto Rico and our second SKU in Bolivia with Monster Energy Zero Ultra. In El Salvador, we launched Fury Mean Green in May 2021.\\nIn the second quarter of 2021, we launched Juice Monster Pacific Punch and Monarch in a number of countries in EMEA. We also launched Ultra Paradise and Ultra Fiesta in a number of countries during the quarter. During the quarter, we also launched our strategic brand innovation and Predator in additional countries. In January 2021, we launched Ultra Rosa marketwide in Australia, following an exclusive lead launch with one chain in the fourth quarter of 2020. In March 2021 in New Zealand, we launched Monster Superfuel in both Purple Passion and sugar-free flavors. During the 2021 second quarter in Japan, we launched Monster Energy Super Cola with our distributor, Asahi Soft Drinks. Additionally, we effected the relaunch at retail of Ultra Paradise and began shipments in anticipation of the launch of Super Fuel early in the 2021 third quarter. Super Fuel has just gone on the shelves in Japan this week. We also launched Mango Loco in Korea in July 2021.\\nDuring the 2021 second quarter, we launched Pipeline Punch in Taiwan, Hong Kong and Macau. We also began distribution of Monster Energy Zero Sugar in the Philippines. As previously mentioned, in the second quarter of 2021, in China, we extended the national rollout of our new Monster Dragon Gold, which is non-carbonated. Our national summer on-pack promotion began in May with one of China's top consumer ambassadors. As a result of the COVID-19 pandemic, certain of our planned launches and innovation of new products in a number of Asia-Pacific markets have been deferred for a few months. However, we still anticipate such launches taking place toward the end of the 2021 calendar year. We are planning to launch a number of additional products and product lines in our domestic and international markets later this year.\\nWe estimate that July 2021 sales to be approximately 1.8% higher than in July 2020. On a foreign currency adjusted basis, July 2021 sales would have been comparable to the July 2020 sales. July 2021 had one less selling day than July 2020, which was 15.8% above July 2019, and which was 17.1% higher on a foreign currency adjusted basis. Certain production facilities, mainly from the Coke bottlers in EMEA, in particular, delayed production from July to August 2021. Furthermore, as mentioned earlier, the company has not been able to fully satisfy demand in the United States and EMEA due to a shortage of aluminum cans, which adversely impacted July sales. Such shortage was exacerbated in July as can availability did not keep pace with increased demand during the summer months. Additional cans have been sourced from domestic and overseas suppliers with expected deliveries increasing sequentially during the latter half of the year. We are working to replenish system inventories in order to meet customer demand as soon as possible.\\nAdditionally, the company also experienced delays in certain ingredients, which impacted supply. Our depletions remain solid as do our measured market data, as previously mentioned on this call. In this regard, we caution again that sales over a short period are often disproportionately impacted by various factors such as, for example, selling days, days of the week in which holidays for, timing of new product launches, and the timing of price increases and promotions in retail stores, distributor incentives as well as shifts in the timing of production in some instances where our bottlers are responsible for production and unilaterally determine their production schedules, which affects the dates on which we invoice such bottlers as well as inventory levels maintained by our distribution partners, which they alter unilaterally for their own business reasons.\\nWe reiterate that sales over a short period such as a single month should not necessarily be imputed to or regarded as indicative of results for a full quarter or any future period. If the COVID-19 pandemic and related unfavorable economic conditions continue in certain regions, our new product innovation launches in those regions could be delayed. In conclusion, I would like to summarize some recent positive points. Currently, the company's flavor manufacturing facilities, its co-packers, warehouses, and shipment facilities, and bottlers and distributors are all operating. We are continually addressing our aluminum can requirements, given our volume growth and the current supply constraints in the aluminum can industry.\\nWe are pleased with the new additions to the Monster Energy portfolio and are planning additional launches later in the year. We are planning to continue additional launches of our Reign Total Body Fuel high-performance energy drinks in additional international countries. We are pleased with the rollout of Predator and Fury and our affordable energy drink portfolio internationally. We are proceeding with plans to launch our affordable energy drinks in a number of international countries during the year.\\nI would like to open the floor to questions about the quarter. Thank you.\\nQuestions and Answers:\\nOperator\\nThank you. [Operator Instructions] The first question will come from Dara Mohsenian with Morgan Stanley. Please go ahead.\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nHey, guys.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nHey, Dara.\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nGreat top line growth in the quarter, but we have seen share losses in US track channel data worsened recently. A, just short-term, how much of that do you think is attributable to out of stocks and the supply constraints that you mentioned? Is that a material factor in retail sales?\\nAnd then maybe, b, from a longer-term standpoint, it has been a couple of quarters now where the share losses have reaccelerated year-over-year, just some progress in the beginning of the year. So, I was just hoping you could review some of the key factors that have been driving the share losses in the US? And how you think about those factors going forward in terms of continuing or dissipating and how you guys are positioned? Thanks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nHilton, if you take that, and I'll also say something once you've...\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nAll right. I think, Dara, what's important is that, that's not a result and not due to us not growing. We are not keeping up with our share, but our business is certainly growing. And you can track that from Nielsen. You can also track that from the non-measured channels, which are growing really very nicely. So while we're not keeping up necessarily with Red Bull in the major channels.\\nAs I've spoken on previous calls, Red Bull had a very large on-premise business, which has moved to off-premise and moved to off-premise during COVID. And that led to an acceleration in their share. However, we mentioned that we had and are continuing to sustain can issues and result in supply. And of course, that's having an impact on the share numbers that you are seeing.\\nSo I think on balance, the business is growing. You've seen the results. It's continuing to grow. And we are growing, but not at the extent of the market. I think with the full deck of cards, the situation may well be very different. But right now, we really are struggling with sufficient supplies of aluminum cans really to keep up with demand, which is, I suppose, a good position to be in. And on the other hand, is not such a good position to be in. The business is growing. And, that's the message I want to leave you with and other investors.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nI think in -- I'll just add two short points in that regard. I think what we've tried to do is to try and also basically focus on our faster selling and our larger SKUs, which has necessarily resulted in some of the smaller SKUs, which normally have their own traction and followers. So those haven't got on to shelf. And then the one additional thing that I think that has negatively affected our distribution sales and distribution levels in the US is labor shortages. And I think that what we've seen is that many of the bottlers, Coke bottlers are experiencing labor shortages. And while one would ordinarily say, well, everybody is going to have the same problem.\\nI think that where you have Red Bull is our main competitor, they have a dedicated system. I think they've been able to address their labor shortages just more effectively than the larger bottlers with large labor pools. And that has also, I think, detrimentally affected our distribution levels going forward. But again, I think those are things that once things start settling down and things will get back to normality, that's something that I think that will also, in due course, right itself.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nYes, I think we should also -- Dara, I think we should also add that what we're seeing with cans is something that will persist through this year. I'm a bit more optimistic about the fourth quarter because we have two new can suppliers coming on board. But the situation will persist. And then next year, we should be in -- we believe we'll be in very good shape. But again, it all depends on consumer demand, which is growing, and you've seen that month-by-month and quarter-by-quarter.\\nOperator\\nAnd the next question today will come from Bonnie Herzog with Goldman Sachs. Please go ahead.\\nBonnie Herzog -- Goldman Sachs -- Analyst\\nThank you. Hi, everyone. I just wanted to ask about your gross margins. Clearly, they continue to be pressured as broadly expected, which you guys have been discussing with us. But just want to get your outlook for these pressures in the back half of the year? Hilton, you just mentioned that you're optimistic. So just wanted to verify that you still expect some of these pressures to ease by Q4? Or do you think it's going to take a little bit longer, especially in light of the recent spike in aluminum prices. So trying to understand how that factors in? And then just a clarification on the can shortages that you mentioned that you're still experiencing, I guess, it sounds like it's getting worse, but I really did want to clarify that. And is there any way that you guys could quantify how big of an impact the supply shortages had on your top-line either in the quarter or in July? Just trying to understand how much you think your shipments would have been up in July without these shortages, for instance? Thanks.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nOkay. So let me deal with the first issue first, if I may. I spoke about optimistic about can supplies. I really didn't talk about margins. You'll recall on the last call, I spoke about the issues that we were confronting with margin pressures like most other beverage companies. And where we are right now with aluminum, I mean, nobody knows. So you can talk to the leading banks in the field, which we do on a regular basis, and they really are pulls apart about their projections for aluminum in 2022, let alone 2021.\\nSo the last couple of days, you've seen a spike in the Midwest premium from this tax that is expected to be imposed on Russian aluminum. And as, you know, the Midwest premium is strongly factors the last ton of aluminum to enter the US and the cost of that. And so we've seen a spike in the Midwest premium. And we continue to see spikes in aluminum. So from that score, I think we just are in uncharted territory. I've been in this business for a long time, as you know, and I've never seen aluminum where it's at right now. And I've never seen the Midwest premium at these kind of levels. So aluminum, I really cannot talk about. And also when you look at our business and you look at the factors that really have affected gross margin, number one, the fact that we're selling a lot more internationally. So I talked earlier about 37.4% of our sales in the quarter outside of the US 30% last year, that obviously impacts margins. We are importing cans from a number of [Technical Issues] that obviously impacts margins.\\nIn fact, the China and India cans that we are using in the United States and in EMEA will only be filed in August in July, and they will be filled this month. So that in itself, the imputation will impact gross margins. And then to cap everything else, we have ingredient issues. We had ingredient issues, as we mentioned, in July, which again reduced the amount that we would actually sell because we didn't have sufficient ingredients to meet themselves, particularly with NOS. And so there are a number of factors that are increasing that are increasing our cost of goods.\\nAnd last quarter, I said I didn't think that margins would get better in the second and third quarters. I read they will not -- I think margins will deteriorate in the third quarter. In the fourth quarter, we're getting some relief in terms of supplies from the US on cans that are -- have been contracted for and they were contracted for two years ago. And we saw the opportunity to work with two major suppliers to get additional cans produced in the US, and that's why we have two new supplies opening, and we are an important and an anchor customer of both those facilities. But even that, you're still dependent on aluminum. We have some hedges in place, but obviously not enough to take into consideration the amount of sales and the amount of consumer demand that is out there. So that's a long-winded way of saying, I think, answering your question as best as I can.\\nAnd then just getting to your second question because you're really only allowed one. But to get to your second question, we have quantified or try to quantify the impact on can shortages in July and in this quarter and in the -- potentially in the third quarter, but I really don't want to -- I'm not comfortable with those numbers yet. A lot of detailed work is being done on them. And I just -- I can't in good contents give those numbers because we still are in the throes of kind of finalizing what we think is probably correct. Rodney mentioned in his script earlier that a number of the bottlers, he mentioned particularly in EMEA, but there were cases in the US as well, and there was a substantial case in the US where the bottlers were obviously focused on other things in the quarter and were producing Coca-Cola brands. And as a result, I think we -- our production got moved from July to August. So, when I look at July, it doesn't -- I don't get overly concerned because I know the sales are going into August.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nPerhaps, if I just on the shortage level, just to add that when we buy cans in contracted for our annual amount, they usually are sort of reasonably flat line across the year. And we used the first half of the year to build up can inventories and finished product inventories with ourselves and our bottlers. Earlier this year, obviously, demand sort of was strong, and so we really didn't have that opportunity. So what has happened is that in June and July, which is your normal peak months, the demand has been higher, but our supply has been more level until we can get more can inventories into the market. So what happened is just that we have had a sort of a heartened increased shortage in the last month and July and probably will be a little bit in August. And then obviously, as we start increasing our -- the cans we're getting in, and then we're able to balance it more and our demand balances more, we'll start to have less of a different delta between these demand and supplier and eventually be able to -- we're hoping to able to build up our inventories and supply back to normal by the end of the fourth quarter or during or by the end of the fourth quarter.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nNo one's comfortable with the level of finished goods inventories that we're running at, but it's a sign of the times. I mean, we're doing everything we can to supply our customers. And that's why we spoke about freights. Freight is a big issue, not only getting raw material ingredients into co-packing system and into our bottling system and -- but also distributing from our co-packers. And obviously, the one goes into cost of sales and freight out goes into operating expenses. So that's why you'll see freight really hitting both of those line items.\\nOperator\\nThe next question will come from Andrea Teixeira with JPMorgan. Please go ahead.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nHi. Thank you. Hi. Good afternoon.\\nThomas J. Kelly -- Chief Financial Officer\\nHi.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nHi, Andrea.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nHow are you Hilton? Hi.\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nI'm good.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nYes. Just on the gross margin, because your gross margin comments were very helpful and given this deterioration obviously that its probably here to stay in the next few quarters. How are you thinking about pricing? Obviously, you can't supply the service levels that are used to with the retailers. So is that is something that takes -- obviously, you have to take into account? Or perhaps as you get more informed on how the aluminum cost will evolve, you may contemplate it again?\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nYes. With regard to pricing, we continue to evaluate pricing, honestly, on a very, very regular basis, if not weekly. So we continue to evaluate it, and we want to make a good decision. Last time around, as I mentioned on previous calls, we went out alone, and we would like to have been in a situation this time where we followed our competitor, but we have to evaluate, obviously, the business as we see it and the impact for us. What we've done is we're reducing our promotional allowances. So we're taking a price increase the other way, through reducing promotional allowances, but the impact of that reduction in the second quarter was not as we would have liked. So we are -- we really put the accelerator down and are more aggressive in reducing our promotional allowances. But we are continuing to evaluate the pricing and price increases.\\nAnd then I have to leave this call with my favorite saying, and that is, we don't bank gross profit margins, we bank gross profit dollars. And to me, the fact that we're doing everything we can to satisfy our customers as best as we can is impacting gross profit margins. But at the end of the day, we don't want to lose gross profit dollars, which is really important to ensure the sustainability of the brand. And that's the most important thing for us right now.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nThank you. Thanks fair. Thank you both.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nYeah. Basically, just make it clear, at this point, we are watching and we're not planning a price increase. We we're not adverse to a price, but we'll wait and see what the market does and what our competitors do.\\nAndrea Teixeira -- JPMorgan -- Analyst\\nThank you, Rodney.\\nOperator\\nThis will conclude today's question-and-answer session. I would now like to turn the conference back over to management for any closing remarks.\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThanks very much. Thank you, everyone, for your continued interest and support of the company. We continue to believe in the company and our growth strategy to remain committed to continuing to innovate, develop and differentiate our brands and to expand the company, both domestically and abroad. And in particular, expand distribution of our products through the Coca-Cola bottler system internationally.\\nWe believe that we will be able to navigate through the challenges ahead as a result of the COVID-19 pandemic and hope that this unfortunate situation will resolve itself in the near future. We believe that we are well positioned in the energy drink category and will continue to be and are optimistic about our total portfolio of energy drink brands. We hope that you will stay safe and healthy. Thank you very much for your attendance.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 50 minutes\\nCall participants:\\nRodney C. Sacks -- Chairman and Co-Chief Executive Officer\\nThomas J. Kelly -- Chief Financial Officer\\nHilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board\\nDara Mohsenian -- Morgan Stanley -- Analyst\\nBonnie Herzog -- Goldman Sachs -- Analyst\\nAndrea Teixeira -- JPMorgan -- Analyst\\nMore MNST analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nGood evening, and welcome to Oyster Point Pharma's fourth quarter 2021 earnings conference call. My name is Valerie, and I will be your operator today. [Operator instructions] At this time, I would like to turn the call over to Mr. Daniel Lochner, Oyster Point Pharma's chief financial officer.\\nPlease go ahead.\\nDan Lochner -- Chief Financial Officer\\nGood evening, everyone. And welcome to Oyster Point Pharma's fourth quarter earnings conference call for the three months ended December 31, 2021. This evening, we issued a press release containing our fourth quarter and full year ended December 31, 2021, financial results and recent business highlights. In addition, our earnings press release and our Form 10-K, which were filed with the SEC after the close of market today, are available on our website under the investors and news section at www.oysterpointrx.com.\\nJoining us on our call today are Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma; and John Snisarenko, chief commercial officer. Following Dr. Nau and Mr.\\nSnisarenko and my prepared remarks, we will open up the line for questions. During the call today, we will be making forward-looking statements regarding potential future events, including statements regarding Oyster Point Pharma's potential future financial status and results of operations and our plans and potential for success relating to commercializing TYRVAYA. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. For a description of these factors, please see our annual report on Form 10-K for the year ended December 31, 2021, filed with the SEC after the close of market today.\\nI will now turn the call over to Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma. \\nJeff Nau -- President and Chief Executive Officer\\nThank you, Dan. Good evening, everyone. And thank you for joining us on our call today to discuss our fourth quarter 2021 financial results and recent business highlights. This is a particularly exciting time for Oyster Point.\\nThis is our very first earnings call where we are pleased to be reporting partial revenues from the commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease in the United States marketplace. Today, you will learn more about how we are delivering these encouraging commercial results on the launch of TYRVAYA Nasal Spray. But first, let me provide the company's 2021 business highlights. In October of 2021, we received FDA approval of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease.\\nDry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence. The dry eye market is now being introduced to the first nasally delivered, pharmaceutical dry eye therapy, and we believe that given the high level of patient and physician satisfaction that we are seeing in the field with TYRVAYA, that significant growth remains ahead. You will be hearing more shortly from John Snisarenko, our chief commercial officer, about the details of the launch of TYRVAYA Nasal Spray, but I'm happy to state that we had great partial fourth quarter commercial performance in 2021.\\nWe are happy to report that TYRVAYA Nasal Spray had a net product revenue of $1.2 million in Q4 of 2021. In addition, we recognized $5.4 million from our license agreement with Ji Xing Pharmaceuticals. We are now entering 2022, having demonstrated the ability to achieve the successful commercialization of TYRVAYA, as well as drive strong execution across multiple areas of our business, including our exclusive license agreement with Ji Xing to develop and commercialize OC-01 and OC-02 in Greater China, securing nondilutive funding and pursuing additional treatment advancements in the clinic, as well as in the R&D laboratory for patients with ophthalmic diseases. This week, we publicly announced an early commercial win with one of the largest commercial payers.\\nOur press release from Tuesday announced that TYRVAYA Nasal Spray is now covered by Express Scripts effective on February 19. This is a fantastic accomplishment for our market access team in achieving the addition of 26 million covered lives and more importantly, this early in our first full quarter since launch. Patients are increasingly gaining access to TYRVAYA in the U.S. for a disease state that, up until 2021, we believe, experienced very little innovation for the current large unmet need in dry eye disease.\\nTYRVAYA is a first-in-class cholinergic agonist nasal spray that is highly differentiated from the other pharmaceutical products in the dry eye space and includes the following potential advantages. TYRVAYA Nasal Spray has a differentiated mechanism of action as it is believed to activate the trigeminal parasympathetic pathway via the nose, resulting in increased production of basal tear film as a treatment for dry eye disease. Basal tear film is responsible for lubricating, nourishing and protecting the cornea. TYRVAYA is the only ocular surface-sparing pharmaceutical therapy for dry eye patients.\\nFor those patients with a compromised ocular surface, increasing tear production without the burden of administering a topical medication may provide a welcome method to treat their disease. For the first time, dry eye disease patients have an FDA-approved, pharmaceutical treatment option that is not administered as a topical eye drop to an already irritated ocular surface. Although we are focused on the critical launch of TYRVAYA Nasal Spray and continue to execute plans for the life cycle development of the TYRVAYA franchise, our R&D team remains committed to multiple exciting pipeline projects aimed at bringing additional innovative therapies to address diseases like neurotrophic keratopathy and severe allergic or vernal keratoconjunctivitis. In 2022, we will continue to advance our enriched tear film gene therapy platform, as well as our research and development collaboration with companies like Adaptive Phage Therapeutics.\\nWe remain excited about the ongoing OLYMPIA Phase 2 study of OC-01 nasal spray in Stage 1 neurotrophic keratopathy. We are expecting a readout in the second half of this year. NK is a disease that is currently underdiagnosed or misdiagnosed in many patients with ocular surface disease. We feel that Stage 1 neurotrophic keratopathy could represent a meaningful indication for OC-01 nasal spray.\\nOur vision and focus is clear. The world needs an innovative leader that can bring innovative and transformative ophthalmic disease treatments, and we aim to be that leader. We believe that we're building Oyster Point into a best-in-class eye care company. I would now like to turn the call over to John Snisarenko, Oyster Point's chief commercial officer, to discuss our ongoing commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease.\\nJohn Snisarenko -- Chief Commercial Officer\\nThank you, Jeff. As we have previously communicated, the dry eye disease segment is a large market with over 17 million people diagnosed in the United States alone. Only a small proportion of these patients, approximately 2 million, are currently being treated with a branded therapeutic. And over 7 million people diagnosed with dry eye disease have tried and abandoned the other available options.\\nWe believe that TYRVAYA Nasal Spray is a new treatment option for the large patient population that exists in the dry eye disease marketplace, including the refractory patients, as well as those who are newly diagnosed. As Jeff highlighted previously, we are incredibly excited to have initiated the U.S. launch of TYRVAYA Nasal Spray on November 1. We are pleased to report that as of the quarter ending December 31, 2021, data indicates that approximately 5,500 prescriptions for TYRVAYA have been filled, written by over 1,900 unique prescribers.\\nThese encouraging metrics were achieved in less than nine weeks from the launch, including holiday periods. In this short time, TYRVAYA is quickly establishing itself in the market as an exciting new option for dry eye patients. Regarding market access, a core part of our commercial strategy is to promote accelerated payer adoption of TYRVAYA to the top payer organizations. Our market access team has done a great job in securing coverage for TYRVAYA with Express Scripts National Preferred, Basic and High Performance Formularies effective February 19.\\nWith this latest formulary addition, we now have coverage for a total of 43% of U.S. commercial lives for an aggregate total of approximately 84 million lives. We are incredibly pleased with this level of coverage so early in our launch, and we look forward to further growing our market access coverage in 2022. Oyster Point remains very committed to offering comprehensive patient services that help provide access to TYRVAYA for appropriate patients.\\nWe have launched a comprehensive set of technology-driven patient services offerings aimed at enabling patients to successfully navigate the patient journey and procure TYRVAYA. Our patient support program is called TEAMTyrvaya. And for more information on this program and how to enroll, please visit the website, tyrvaya-pro.com. We have been quite diligent with the sizing of our field force, which enables us to target 20,750 eye care practitioners, covering both optometrists and ophthalmologists and representing approximately 94% of the dry eye prescriptions in the market today, helping us in our efforts to achieve the full commercial potential of TYRVAYA.\\nIn the first nine weeks of launch, our sales force was able to introduce TYRVAYA to more than 50% of the targeted prescriber base. On the marketing side, we're leveraging the latest technology, including sophisticated analytics, in-person, as well as virtual detailing, best-in-class digital and social media efforts and partners, as well as utilizing a digital online pharmacy to enhance communication and delivery of TYRVAYA to patients. We will continue to adopt the latest media and technology-driven marketing approaches to maximize TYRVAYA's share of voice and impact in the market. Our focus continues to be on broad eye care provider and patient education and marketing efforts, with targeted direct-to-patient digital campaigns leveraging TYRVAYA's differentiated MOA and nasal spray route of administration to drive a positive patient marketing experience.\\nI am so proud of our commercial team's collective efforts during this early phase of our launch, especially in these challenging times with the pandemic. I will now turn the call back over to Dan Lochner, Oyster Point's chief financial officer, to discuss our fourth quarter financial results.\\nDan Lochner -- Chief Financial Officer\\nThank you, John. I will now provide a brief overview of Oyster Point Pharma's fourth quarter financial results. Additional detail about our fourth quarter, as well as our annual financial results can be found in our Form 10-K that was filed with the SEC this evening. For the fourth quarter of 2021, Oyster Point Pharma reported a net loss of $42.1 million, compared to a net loss of $22.2 million for the same period in 2020.\\nAs of December 31, 2021, cash and cash equivalents were $193.4 million, compared to $192.6 million as of December 31, 2020. Based on our current business plan, we believe the company's available cash and cash equivalents will be sufficient to fund the company's planned operation for at least 12 months from our 10-K filing this evening. Net product revenues for the fourth quarter of 2021 were approximately $1.2 million, following the FDA approval of TYRVAYA Nasal Spray on October 15, 2021, and our subsequent commercial launch in the U.S. in November 2021.\\nApproximately half of the TYRVAYA net product revenue was attributable to channel building by distributors upon launch of the product. In addition, pursuant to our license agreement with Ji Xing, the company also recognized $5.4 million in milestone and license revenue following the FDA approval of TYRVAYA Nasal Spray, which includes the noncash consideration of Ji Xing senior common shares. The company did not generate any revenues during the third -- three months ended December 31, 2020. Cost of product revenue for the three months ended December 31, 2021, was $1.5 million and consisted mainly of third-party manufacturing costs, which included pre-approval costs, reserves for inventory obsolescence and damaged goods and product royalty expense related to Pfizer.\\nThe cost of product revenue included a reserve for inventory obsolescence of $0.9 million. The inventory manufactured prior to FDA approval of TYRVAYA Nasal Spray was charged to R&D expense. And as a result, the company expects the unit cost of product revenue will be lower until the company fully utilizes this product that was manufactured pre-FDA approval. The company started expensing pre-approval inventory in 2020 and recorded an R&D expense of approximately $4.3 million for pre-approval inventory during the year ended December 31, 2021.\\nThe company anticipates selling the remaining pre-approval inventory by the end of 2022. The company's sales and marketing expense increased by $21.8 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase was primarily due to higher payroll-related expenses of $11.7 million, inclusive of sales commission expense, as well as an increase in stock-based compensation expense of $0.5 million, both of which were primarily driven by onboarding a commercial field force in the second half of 2021. The company also incurred higher marketing -- market access, commercial and other expenses of $10.1 million in anticipation of, and in connection with, the U.S.\\nlaunch of TYRVAYA Nasal Spray. The company's general and administrative expenses increased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase is primarily due to higher G&A expense of $3.8 million related to accounting, consulting, legal and other professional expenses incurred in connection with the credit agreement, as well as the company's transition from a clinical stage to a commercial-stage company. The company also incurred higher payroll-related expenses of $2.4 million, including recruiting expense due to an increase in headcount to support an ongoing efforts to commercialize TYRVAYA.\\nThe company's research and development expenses decreased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The company's decrease in R&D expense is primarily due to the company receiving FDA approval of TYRVAYA Nasal Spray in October 2021. The company expensed inventory prior to receiving FDA approval and expensed approximately $3.5 million as R&D during the three months ended December 31, 2020. The company also incurred a fee of $2.9 million in connection with the New Drug Application submitted to the FDA in December 2020.\\nThe company incurred interest expense of $2.6 million during the three months ended December 31, 2021, primarily related to the credit agreement with OrbiMed. Interest expense included contractual interest of $1.7 million, as well as noncash expense of $0.9 million related to the amortization of loan commitment fees and accretion of other long-term debt-related costs. The company had no interest expense during the three months ended December 31, 2020. Now as we turn to our outlook, for 2022, our goal is to continue to achieve broad ECP and patient experience with TYRVAYA, including both optometry and ophthalmology offices, in order to reach the total addressable dry eye market opportunity of TYRVAYA Nasal Spray.\\nWe anticipate the three large national commercial plans will make their coverage determinations by the midpoint of the year. While we await such coverage determinations, we will continue to provide patient-assisted programs to support eligible commercial patients in gaining access to TYRVAYA. With that overview of our financials, I will now turn the call back over to the operator to open up the line for questions.\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] Our first question comes from the line of Ken Cacciatore with Cowen. Your line is open.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nHey, team, looks like a really good and clean initial launch. I was wondering if you would wanna help us a little bit with maybe the revenue pacing. I know consensus, I believe, is around $30 million. And I know there's only a few of us analysts that are formally involved in the consensus, but I think it's around $30 million.\\nSo I was wondering if you could just kind of hold hands with that number, how we should be thinking about it. And then also, we've been doing clinician checks and getting very good feedback. But I guess, you could help us, as you would have a better sense of the early retention metrics, maybe the -- be able to definitively let us know how you're seeing some of the retention numbers and patients returning. So those are my first two.\\nI'm going to ask one more, if I could, though. Could you talk, John, a little bit about any refinements or learnings of your patient support system? Obviously, early days, but wondering if you're already tweaking it a bit. Anything that seems to be working very well or you've needed to change? And with that, I'll go back in the queue. Thanks so much.\\nJeff Nau -- President and Chief Executive Officer\\nGreat. Thanks, Ken, for the questions and very thoughtful. So maybe what we could do is we'll just take those in order. So I'll turn it over to Dan to just talk about the numbers for the year.\\nAnd then, we'll go into retention and have a discussion about John's experience with the bridge programs and the different patient services.\\nDan Lochner -- Chief Financial Officer\\nYeah. Great. I would say on revenues, while we haven't really provided official revenue guidance, I would say we think about it very operationally, focus in terms of our sales reps that are out in the field doing a great job. And I would say the focus very early on and throughout 2022 will really be about growing that eye care practitioner count, and we have goals internally for what we expect to achieve on a weekly and monthly basis.\\nAnd so, I think, it really starts with getting those ECPs onboard on a monthly sequential basis and then starting to look at what the right pattern is on an NRx basis per month and then what we then start observing on that pull-through on resell rate. And so, to kind of wrap that all up, we see it sequentially building through the quarters for the entire year as we start working through that total target population that we've identified, which is roughly 20,750 targets. And I think, it would be great to have John kind of speak about how we're really going after that target base and how that's been building through the quarters. And I think, what you'll see, at least for Q4, we've hit about 1,900 of those ECPs in respect to the 20,750.\\nAnd we'll continue to really work through that population of ECPs and really build that NRx and resell rate, the TRx, and then really playing out on revenue. The other dynamic, of course, is always on gross to net. And while we're not providing official guidance on gross to net because our focus really is on that volume and share component throughout 2022, I would say there is that first-half component related to the majority of patients in the first half expecting to be on that bridge program, which has a discrete impact to gross to net. And then, with our guidance, which is focusing on coverage determinations for the big three PBMs by the midpoint of the year, that transition from bridge over to commercial insurance will have a positive benefit discretely on that line in relation to gross to net, which would kind of tie up to your question on kind of how revenues would flow from a price and volume perspective through the year.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, thank you, Dan. This is John. You asked a question around retention rates and then refill rates. We've been very, very pleased to date with the metrics we've been seeing in that space.\\nEven patients that had been prescribed in early November, we started seeing early refill rates. I could quote that if you look at our blended refill rates with retail pharmacy and our digital online pharmacy, they're hovering around 64%, 65%. So we're very pleased with patients that are coming back and getting the refills. We are getting very, very nice position, as well as patient feedback, and we are hoping to continue that trend throughout 2022.\\nI think, part of that as well is your third part of your question around patient support programs, we out of the gate wanted to really employ a lot of technology around our patient services to TYRVAYA. So we're trying to make it very easy for that patient to navigate that journey through the prior auth and benefit investigations to get them to enroll into the program through QR codes in the offices, online, as well as other digital means. So because of that, we've been getting very, very good high enrollment rates and good fill rates that come through that program. So in terms of tweaking, we're continuing to put out more patient materials to surround sound the patient with different ways to enroll into the program.\\nBut overall, we're very, very pleased with how the program has been going. If the patient is deemed insured, but not covered, they automatically popped into our bridge program that they were appropriate patients and are able to get that script fulfilled and get experience with TYRVAYA. So we'll keep monitoring the patient services program, but so far, we've been very, very pleased.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nGreat. Thanks so much. Appreciate it.\\nJeff Nau -- President and Chief Executive Officer\\nOne thing I will add on, Ken, comment there is as we think about TYRVAYA as a product, when we think about the current marketplace and what it offers to patients, from an immunomodulator perspective, patients will go on a course of an immunomodulator. If they're not happy with the outcome at the end of that course, they're transitioning off, and they're likely either going on to another product or another device or another modality, but very rarely are they coming back. So we see a very low number of patients come back to the original therapy. I think, that the one thing to really keep in mind with TYRVAYA is it works so quickly to provide the patient relief, and it has such a differentiated mechanism of action that we are excited to look forward into the future to see how patients interact with the product.\\nIt's going to be a very different interaction than you would see with an immunomodulator because I do think not only will we have solid refill rates, but we will have people coming back to the product in those later years. And so, we're excited about that. And then, I would -- I'll just throw one comment out there for my team back at the office. Our patient services program is, bar none, one of the best I've ever seen.\\nAnd it is going very well in the field. And so, kudos to the team for putting together such a great program.\\nKen Cacciatore -- Cowen and Company -- Analyst\\nGreat. Thanks so much.\\nOperator\\nThank you. Our next question comes from Joe Catanzaro with Piper Sandler. Your line is open.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nHey, guys, thanks so much for taking my questions, and congrats on the progress here. So maybe just to follow up, I think, Dan, you mentioned you guys had some internal benchmarks, I'm sure, on a bunch of things. But I'm wondering if you can maybe help put into context the early penetration in terms of the number of unique prescribers you've seen relative to your target ECP pool and where your early expectations were there. And then, I'm wondering what aspect -- and maybe it's something you just alluded to, Jeff, what aspect of the product profile do you see as resonating the most? And how do you go about fully leveraging that? And maybe I have a follow-up as well.\\nDan Lochner -- Chief Financial Officer\\nYeah. Maybe I'll start with it on my end. As you saw in the press release, we had achieved 1,900 unique writers in the quarter, which is just under about 10% of the targets that we are going after with our sales force of 162 sales reps. And so, I think, we had great progress in the quarter just under about nine weeks.\\nAnd so, as we look at benchmarks of prior therapies that have come to market more recently, I think we're in a great place for where we had expected us to land. Of course, we also understood that this is a new way of treating dry eye disease. So really communicating the benefits with the nasal spray. And so, I think, we're quite pleased with where we landed and continue to work toward that 21,000 target count as we progress throughout the year.\\nJeff Nau -- President and Chief Executive Officer\\nAnd maybe what I'll add on to -- the second part of the question there is some of the things that are resonating. I think, one of the things that's really been exciting about the launch of this product is patient feedback has been really great. And so, we've been excited to not only hear stories from the field, see posts on social media of patients going out on their own and talking about the product. And just really, it's a great product to launch where you're having that patient feedback come back to the teams and to those folks that have put such hard work into getting the product out there into the marketplace because it's really why we do this and it really drives the team.\\nSo I think, one of the things that we hear that is something that's really encouraging is just the patients stating that they really like the profile. They like the way it's making their eyes feel, and it's just differentiated in the way that it's able to be used. So we do hear stories back of people who are unable to deliver a topical eye drop. And this is another option for them because maybe they don't have the dexterity or they're elderly and they're just not able to put a drop into their eye, and so they're able to use nasal sprays.\\nAnd the other thing that we hear in the field often is the physicians are not getting patients calling back and complaining. And so, that's also really important for us. But again, we're very early in the launch. So we have many patients that haven't been on the product for more than a few months.\\nSo we're excited to see how the long-term feedback is. But for the moment, we are really encouraged by the feedback or sometimes lack of negative feedback coming back from the patients.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nGreat. And if I maybe just squeeze in a quick follow-up. I think, you said you guys have maybe covered about 50% of your target ECPs. Can you maybe speak to what percent of those have been given a sample? And how soon after sampling are you seeing ECPs write a script? Thanks.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, no, thank you, Joe. Great question. Part of our strategy is really to introduce TYRVAYA into the office practice with the prescriber base, the technicians, the staff that are involved with training, the patients and so on prior to actually sampling because we want to make sure that the product is taken appropriately and the patient gets the best possible experience they can with the nasal spray. So we handed out quite a few samples, probably over 100,000 samples since launch.\\nBut we want to make sure that we hand them out appropriately and that installation with that office has actually taken place before that sampling is initiated. So so far, that's worked well for us because we've seen a higher proportion of patients that tried a sample, see if it works for them before they're getting into our patient hub and actually getting that prescription filled. So that kind of connection has been very, very positive with that approach.\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nOK, that's helpful. Thanks, again, for taking questions.\\nOperator\\nThank you. Our next question comes from Patrick Dolezal with LifeSci Capital. Your line is open.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nGreat. I'm just curious how the availability of generic cyclosporine has impacted discussions with payers, if at all. Were there any modifications to negotiations with Express Scripts as that approval came to light? I'm just curious if you expect any impacts going forward as you onboard other payers. And then, I have a follow-up as well.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Patrick, thanks for your question. We've seen kind of early mixed reactions from the payer community on how they're going to manage the generic entry of cyclosporine. And with the early listing with ESI, they're actually covering TYRVAYA across their formularies with only a traditional step, sort of an artificial tear. So that's what I mean by mix.\\nSome of the payers are kind of waiting until more than one generic comes out, and they'll take a look at the dry eye space or they're not really managing the dry eye space as closely. And others are going to evolve a little quicker. So we're able to modify our approach. We are ready for a generic to be on the market or not with.\\nAnd that's the way our negotiations are going with the major PBMs. And our goal is to get access for TYRVAYA on a level playing field with the branded therapeutics. And our differentiation along with our strategic contracting will help us get there.\\nJeff Nau -- President and Chief Executive Officer\\nAnd one other comment, Patrick. As you well know, generic entry into the marketplace doesn't change the dynamic that exists where patients cycle off many of these drugs, whether it be for lack of effect or side effects or whatnot. And so, that certainly will not change. So we were planning on generic entry coming.\\nI think, we've been planning for a long time, but it's been always in the back of our mind, and so the team is ready.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nThat's helpful. Thanks. And as it relates to just drug launch surrogates, there's not a ton in the dry eye space really, but obviously, we do have these eye drops. Just curious to hear any similarities and differences that might be worth pointing out.\\nAnd just if you could comment on the role of coverage and driving drug adoption in the dry eye space generally, that would be helpful. I'm curious if there's a tipping point where you feel that the amount of coverage really will drive adoption, 50% if it's a bit more. I would love to hear your thoughts there. Thanks.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Patrick, in regards to the Xiidra launch, we did see very quick uptake. Well, this was back in 2016. They had very early access to the commercial insurers, and they launched with 280-plus reps. We are very pleased with the number of reps we have and the trajectory we're seeing with TYRVAYA.\\nWe are on track in regards to the payer negotiations. And in fact, the ESI listing was an early listing for us. So we will get to that point that we're expecting in terms of broad base of writers, the eye care professionals prescribing TYRVAYA. We just won't be out of the gate as quickly as you saw with the Xiidra launch.\\nI could tell you, versus the latest two launches, we're very pleased with how our trajectory is going versus kind of the more recent entries. But it was a different space back in 2016, less managed, and also they were second entry at the time after Restasis.\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nThat makes sense. Thanks for taking the questions.\\nOperator\\nThank you. Our next question comes from Chris Neyor with J.P. Morgan. Your line is open.\\nChris Neyor -- J.P. Morgan -- Analyst\\nGreat. Thanks for taking the questions. So first one is on me -- for me is just wanted to get a bit more details on the Express Scripts contract. So really just thinking about what's the mix between preferred and non-preferred coverage within those 26 million lives that you had estimated.\\nAnd within the Express Scripts plan, are there -- is there potential for additional pickup of patients and additional contracting that would either add additional patients or move more patients toward preferred access? And when talking about that kind of mix -- the mix of customers, what type of co-pay should we be thinking about for most of these patients? I think, I have a couple of follow-ups after that.\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, Chris. No, thanks. In regards to ESI, whether preferred or non-preferred, in terms of access whether you're listed preferred or non-preferred, the key criteria is you have to have tried and failed on an artificial tear for all of the branded products here. So as you mentioned in the last part of your question, the out-of-pocket is a difference between the Tier 3 and a Tier 2.\\nAnd pretty appropriate patients, commercial patients, we definitely buy down that out-of-pocket to be very competitive with the leading branded product out there. So we feel our 26 million lives that are covered are on a level playing field with regard to the leaders out there. And that -- those are the majority of the larger plans within ESI, but we will continue to work with signing on some of the downstream plans that ESI covers -- sorry, that Ascent covers as well and through ESI. So the tiering for us is not a disadvantage.\\nWe feel we're going to be very competitive with the two major brand leaders out there.\\nChris Neyor -- J.P. Morgan -- Analyst\\nGreat. That's helpful. And then, you kind of touched on the refill rates and also maybe you could just discuss your confidence in being able to hit that commercial coverage for CVS Caremark and UnitedHealth by the middle of this year. And then, aside from maybe overall script trends, any other KPIs that we should be watching for the launch in the coming weeks and quarters?\\nJohn Snisarenko -- Chief Commercial Officer\\nYeah, no, Chris, in regards to the refill rates, we've been very pleased with the kind of 60%, 65% rate of refills we've been seeing. We feel that based on the product profile, as well as the services we offer to make sure that both the prescriber base, as well as the patients are supported through the clinical experience with TYRVAYA. In regards to some of the other PBMs, we are in the middle of negotiations with them. We are still on track to have coverage determinations by midyear.\\nAnd we are ready to negotiate whether they're going to be managing the generic space or not. We feel we're going to be very, very competitive to be able to get TYRVAYA listed and get the majority of those commercial lives covered by midyear of '22.\\nChris Neyor -- J.P. Morgan -- Analyst\\nPerfect. Appreciate the questions.\\nOperator\\nThank you. And I'm currently showing no further questions at this time. I would like to hand the conference back over to Dr. Nau for any closing comments.\\nJeff Nau -- President and Chief Executive Officer\\nThank you, operator, and thanks to everyone for joining the call with us today. As I mentioned in my opening remarks, we are extremely pleased to announce that TYRVAYA Nasal Spray, indicated for the treatment of the signs and symptoms of dry eye disease, is currently in its first full quarter of launch for patients and eye care providers in the U.S. We are extremely excited for the potential of significant growth that remains ahead. Our vision and focus on bringing innovative and transformative ophthalmic disease treatments to patients and building Oyster Point Pharma into a best-in-class eye care company remains our primary goal as a company.\\nIn closing, I want to thank everybody for joining us tonight and to have a great evening.\\nOperator\\n[Operator signoff]\\nDuration: 41 minutes\\nCall participants:\\nDan Lochner -- Chief Financial Officer\\nJeff Nau -- President and Chief Executive Officer\\nJohn Snisarenko -- Chief Commercial Officer\\nKen Cacciatore -- Cowen and Company -- Analyst\\nJoe Catanzaro -- Piper Sandler -- Analyst\\nPatrick Dolezal -- LifeSci Capital -- Analyst\\nChris Neyor -- J.P. Morgan -- Analyst\\nMore OYST analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 10:00:00\",\n        \"max\": \"2023-02-23 11:00:00\",\n        \"num_unique_values\": 5201,\n        \"samples\": [\n          \"2020-08-13 07:30:00\",\n          \"2019-08-07 09:00:00\",\n          \"2020-05-04 12:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 00:00:00\",\n        \"max\": \"2023-02-23 00:00:00\",\n        \"num_unique_values\": 835,\n        \"samples\": [\n          \"2020-03-11 00:00:00\",\n          \"2023-01-10 00:00:00\",\n          \"2022-03-29 00:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Clean_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17220,\n        \"samples\": [\n          \"Please go ahead. Karen David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations Welcome everyone, to Expro's second quarter 2022 conference call. I'm joined today by Mike Jardon, CEO; and Quinn Fanning, CFO. First, Mike and Quinn will share their prepared remarks, and then we will open it up for questions. We have an accompanying presentation on our second quarter results that is posted on the EXPRO website, expro.com under the investors section. In addition, the second quarter financials are downloadable on the Expro website under the Investors section. I'd like to remind everyone that some of today's comments may refer to or contain forward-looking statements. Such remarks are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such statements speak only as of today's date, and the company assumes no responsibility to update any forward-looking statements as of any future date. The company has included in its SEC filings, cautionary language identifying important factors that could cause actual results to be materially different from those set forth in any forward-looking statements. A more complete discussion of these risks is included in the company's SEC filings, which can be accessed on the SEC website or on our website at expro.com. Please note that any non-GAAP financial measures discussed during this call are defined and reconciled to the most directly comparable GAAP financial measure in our second quarter 2022 earnings release, which can be found on our website. With that, I'd like to turn the call over to Mike. Mike Jardon -- Chief Executive Officer Thank you, Karen. Good morning and good afternoon, everyone. I'm pleased to share with you that Expro delivered robust operational performance and financial results that exceeded the guidance we provided for the just completed second quarter. We are experiencing increase customer activity levels across all segments of our business, bolstered by a backdrop of strengthening industry fundamentals. We believe this positive momentum will not only continue, but will also accelerate going into 2023 and beyond. Expro is poised to capitalize on an expected increase in customer spending and activity. Today, Expro has a scope and financial profile required to compete and win in what we believe is the best outlook for energy services in at least a decade. Our results in the second quarter and our market outlook underscore the benefits of Expro's balanced portfolio of services and solutions with leading capabilities and a culture built around safety, service quality, organizational efficiency and risk management. In addition, we believe our through-cycle resilience is a significant advantage and competitive differentiator for Expro. Our current portfolio of services and solutions is paired with a global operating footprint with established positions in key growth markets and the combination provides Expro with good leverage to improving industry fundamentals and in particular, to the rebound that is beginning to take place in the international and offshore markets. We have never been better positioned to capture cyclical recovery upside. We also continue to have a best-in-class innovation platform and technology portfolio that enables us to support our customers' efficiency and emissions-related goals, grow market share and capitalize on longer-term industry trends. Finally, our strong balance sheet and merger-related synergies provide us with significant financial, operational and strategic flexibility that will allow us to accelerate growth and create long-term stakeholder value. On today's call, I'll touch on three main topics. First, I'll walk you through our second quarter performance. Second, I'll give an update on our integration process. And finally, I'll provide some perspective on trends we are seeing in the broader industry environment. For the second quarter, we delivered revenue of $314 million and an adjusted EBITDA of $51 million. Second quarter revenue increased 12% sequentially and on a Pro Forma basis, 10% year over year. Higher revenue during the quarter was driven by increased activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific regions. Adjusted EBITDA increased 39% sequentially and on a Pro Forma basis, 33% year over year. Adjusted EBITDA was primarily driven by a more favorable activity mix during the second quarter and faster-than-anticipated realization of merger-related synergies. Well Construction revenue was up 9% quarter over quarter and well management, which includes our well flow management, subsea well access and well intervention integrity businesses was up 13% quarter over quarter. Second quarter results exceeded the prior guidance, primarily as a result of increased well flow management and well construction revenue within North and Latin America. Our team continues to both capitalize on improving industry fundamentals and demonstrate the value of Expro's broad suite of cost-effective, innovative solutions to win new business and expand relationships with existing customers. During the quarter, we continued to secure contracts because of our exceptional service quality and technical delivery. We also continued the introduction of new technologies with both CoilHose and Octopoda, achieving market adoption at pace. The current commodity price environment puts a premium on maximizing production from existing well stock. So there is a strong customer interest in well intervention integrity solutions such as CoilHose and Octopoda. The significant under investment in energy supply over the last decade, coupled with growing demand, is also resulting in FID approvals. Importantly, for our company, nearly 60% of the new customer commitments are expected to be offshore. We achieved contract wins and extensions totaling approximately $300 million, which demonstrates the breadth and depth of our customer relationships and attraction that our solutions are gaining in the market. On a regional basis, in North and Latin America, our Well Construction team continues to demonstrate the position as the premier provider of casing and tubular running services with the award of contracts and successful operations delivered across the region. The team successfully completed a first casing running to a project in Brazil and carried out eight simultaneous TRS deepwater completions in the Gulf of Mexico, where activity continues to pick up. We also deployed our industry-leading 22-inch brotpackers in Mexico for the first time and have seen growing demand for this well integrity technology as operators across the region seek to protect their assets during storm season. This technology allows for quick and rely the well suspension when operators need it most. We want to influence contract for a major operator in Brazil. And in Alaska, our team was awarded and performed a well test for a strategically important new customer, further growing our presence in this region. Expro in MENA achieved contractor of the month from an international operator, demonstrating Expro's continued focus on delivering best-in-class safety, quality and customer service. In Europe and Sub-Saharan Africa, we saw good progress in securing new business in the second quarter, including the retention of the largest well flow management contract in the Norwegian continental shelf for an initial four-year term, highlighting the strength and depth of our relationship with this international operator. A significant portion of this contract is directly linked to production optimization and enhancement as well as a demonstrable commitment to low carbon plan. The breadth of our portfolio, including market-leading technologies acquired in our July 2019 acquisition of Quality Intervention directly assisted us in expanding a core well intervention contract with a major international operator in the U.K. In addition, our service quality and portfolio of capabilities helped us secure an expanded contract to meet client needs for a nine-well plug and abandonment campaign in the U.K. Continental Shelf, where we also added well test and well intervention to an existing large board subsea services contract. As I noted earlier, CoilHose and Octopoda are gaining traction in the market to support clients' intervention and integrity needs. Octopoda is a truly unique service offering, which for the first time in our industry, allows direct access to well annualized in which we can ensure well integrity and production assurance. Octopoda was recently deployed in the Congo, the first deployment of this technology in Sub-Saharan Africa, and it continues to generate customer interest with its unique ability to investigate and remediate sustained casing pressure and other well annulus problems. Additionally, our CoilHose Light Well Circulation system is an innovative development, providing a lower cost more efficient alternative to traditional coiled tubing systems. This broadening of our portfolio and our depth of experience, combined with the ability to quickly mobilize assets and personnel to meet client requirements helped us secure a U.K. contract for well testing and exploration and appraisal services in support of a new offshore drilling campaign. Expro's superior quality and service performance as strong client partnerships led to the securing of multiple contract wins, including for our subsea team in the Ivory Coast and in Turkey, where we won well testing and CoilHose intervention work for a nine-well project on offshore gas storage project. In the second quarter, we also introduced Drill Stem testing into Angola, further broadening our comprehensive portfolio in this country and positioning us to take advantage of the increasing activity in deepwater operations in Angola. We have successfully started operations in Cabinda for a major operator, which will be our first deployment of hammering services as part of an Angolan Well Construction Service package. In May, we were also recognized as the safest service provider in Mozambique. Based on our recent performance, we are in discussions with the client regarding further expansion of our services, including the introduction of new technologies. In Chad, our work with the client is core to ensuring that our operations are conducted in an environmentally responsible way. Our expertise and technologies are focused on having no environmental impact with testing and analysis carried out to ensure the appropriate purity of the regional freshwater system, underlining our status as a leading provider of on-site chemistry services with a strong environmental focus. In Norway, we completed our first operational campaign with our iTong Well Construction Technology, which provides a step change in safety and well construction operations. Operational performance exceeded client expectations, delivering significant rig efficiency improvements and cost savings to the customer overall. In the Middle East and North Africa, our Well Construction team has expanded into new territory to secure their first TRS contract in Algeria, which is planned to commence later this month. This opportunity reflects one of the many revenue synergies created by our October merger. We leverage expert relationships and well flow management to secure this new TRS award. In addition, the regional team was awarded two carbon boom contracts with Middle East drilling contractors, reflecting our market-leading capabilities and reputation in the market. In Egypt, our service offering and ability to deliver contributed to Expro being awarded significant well test contracts. In the Asia Pacific region, our well construction team in Brunei secured a major 5-year contract for TRS. Our outstanding track record of reliable performance in HSC and service quality were strong criteria for the contract award. In Thailand, the team secured additional TRS work covering 200 wells and in Malaysia and in offshore China, we were awarded three-year TRS contract extensions spanning development and exploration wells. Our subsea team's technical capability played a key part in securing a contract with a major international operator in Malaysia for the provision of our new vessel deployed Light Well Intervention package, with the team also securing significant additional work in Australia. Like CoilHose and Octopoda, Expro's LWI capabilities are the result of investments we have made over the last several years, which should allow the company to offer differentiated production optimization solutions and thereby grow our top line faster than the overall market, while also improving profitability. Expro is strategically committed to continuing to invest in transforming our business portfolio and reducing greenhouse gas emissions. In April, we published our inaugural, environmental, social and governance review with a stated aim of achieving net 0 by 2050 with a 50% reduction in carbon intensity by 2030. As the energy industry embraces transition and the need to make real and visible headway toward a lower carbon world, we appreciate the key enablers to change will be those who can truly differentiate themselves as solutions providers. As recognized global well experts and a trusted partner, we believe Expro is well-positioned to play an important role in enabling our clients to achieve their carbon reduction goals in support of the energy transition. Expro remains committed to allocating roughly 50% of our research and development budget to carbon reduction initiatives. In doing so, we are developing and advancing solutions that will play a critical role in enabling our customers to achieve their own emission reduction goals while also allowing experts to achieve its goals. Expro's well expertise and range of well intervention, well integrity and wells measurement technologies and skills help operators cost-effectively develop oil and gas resources while minimizing both emissions and the required operating footprint. As our industry speaks to address tomorrow's challenges, we believe many of these technologies and skills are transferable. As a good example of adopting technologies to achieve more sustainable energy solutions, Expros supported geothermal well service projects since 1986. Most notably, in the second quarter, we were awarded our first integrated services geothermal contract to support a high-profile geothermal plant in Germany. The second topic I'd like to cover is to provide an update on our integration efforts. During the quarter, we continued to make progress in bringing the legacy businesses together to capture the full potential of our combined platform. I am pleased to report that 9 months into our integration, we have identified an action more than 100% of the $55 million in annualized cost savings that we established with our target within the first 12 months following the closing of the merger. This comes a full quarter earlier than we had initially anticipated. As outlined previously, we are targeting cost and revenue synergies between $80 million to $100 million within 24 to 36 months post-merger. We remain confident that we will achieve $70 million in projected cost synergies during this time frame, if not earlier. Cost savings are primarily driven by the rationalization of support costs, consolidation of facilities and supply chain savings. In the second quarter, we consolidated additional facilities, including locations in Baku, either by John, St. John's, Canada; Lumpur, Malaysia; Mumbai, India; Corpus Christi and Midland, Texas. While revenue synergies are more difficult to demonstrate, my sense is that our previous estimate of an incremental $10 million to $30 million in EBITDA for revenue synergies through our expanded customer relationships and operating footprint, increased time on rig and greater exposure to the full life of the field will likely prove to be conservative. I'd like to sincerely thank the entire expert team for their hard work and numerous contributions toward helping us realize our integration goals ahead of schedule. Without a doubt, we have a winning team that has proven the building to deliver on our commitments. Before I turn the call over to Quinn, I want to provide some perspective on trends we are observing in the market. The positive signs of a recovery we saw in Q1 continued to build, underpinned by a favorable supply demand dynamic. As I noted earlier, this is largely a result of limited upstream investment in recent years and a need for additional capacity to meet projected demand growth. With the more recent heightened focus on energy security, diversification of supply and the need to replace at least a portion of Russian oil and gas supply is expected to fully magnify what was already set up to be a favorable multi-year macro backdrop for OFS activity. Longer term, we believe the service sector will need to play an important role in facilitating the energy transition. So despite ongoing volatility in commodity prices, the fundamental backdrop for the energy services sector is quite constructive. In particular, after a strong recovery in the U.S. onshore market, we are seeing increasing demand for our services and solutions with international and offshore activity expected to accelerate through the second half of 2022 and into 2023 as operators look to increase production from existing assets and develop new fields. Notwithstanding near-term concerns of an economic slowdown, there seems to be a consensus that energy demand will trend back toward, if not through 100 million barrels of oil equivalent per day in 2023. We expect that increasing demand for energy services and capacity constraints in key service offerings, including high-end well construction equipment and subsea test trees should provide scope for improvement in net pricing beginning in late 2022 into early 2023. In Expro's view, expected growth will be broad-based geographically, span all phases of oil and gas development and include all operating environments. Geographically, we see strong potential in North and Latin America, the Middle East, North Africa, Sub-Saharan Africa, as well as Asia. And while many of our customers continue to focus on brownfield enhancement programs to maximize previous investments, we are also starting to see growth in exploration and development activity driven primarily by North and South America, with further activity expected in Norway, India and Sub-Saharan Africa. The brownfield focus will support steady growth in our well Intervention Integrity business as well as elements of our well flow management business, collectively, which represent about 35% of our business. The remaining circa 65% of our business is generally levered to drilling, well construction and well completions activity, which we believe is points for strong growth across several geographies and within which we generally capture very good faster on incremental revenue. Overall, the outlook for the remainder of '22 and into 2023 remains positive with sustained increases in E&P expenditures. After rather dramatic recovery in the North America onshore market, customer dialogue and tendering activity indicates to us that the outlook for offshore activity is strengthening. This should support sustained growth for Expro given our leading and differentiated portfolio capabilities and subsea well access services, complex well construction services and production optimization. This is particularly important as approximately 70% of our revenue today is generated from offshore activity. Before I close, I'm pleased to share that during the quarter, our board approved a new stock repurchase program under which the company is authorized to acquire up to $50 million of its outstanding common stock up to the November 2023 time frame. We view the repurchase of our shares as an attractive and prudent use of our capital that it is in the best interest of our shareholders. With a debt-free balance sheet, ample available liquidity and strong construction of an industry recovery, buybacks allow us to opportunistically increase shareholder value while maintaining sufficient cash resources to fund our business needs. In the second quarter, we repurchased $13 million in export stock, representing approximately 1% of our shares outstanding. From an operational standpoint, Expro is well positioned in the markets that we expect will continue to benefit from strengthening industry fundamentals. In particular, Expro has significant leverage to strengthen the international and offshore markets where experience, expertise and service quality can be in Expro's case are positive points of differentiation. Execution is a traditional strength of Expro and when we plan to continue to deliver on both for our customers and our shareholders. With that, I will hand the call over to Quinn to discuss our financial results. Quinn Fanning -- Chief Financial Officer Thank you, Mike. Good morning and good afternoon to everyone on the call. As Mike noted, I will cover the results for the quarter ended June 30th, 2022, and will primarily highlight our sequential performance compared to the quarter ended March 31st , 2022. To recap, we reported revenue of $314 million for the June quarter, which was up sequentially $34 million or approximately 12% relative to Q1 2022. The sequential increase in revenue was driven by higher activity across the North and Latin America, Europe and Sub-Saharan Africa and Asia Pacific segments, partially offset by lower activities in the Middle East and North Africa segment. Adjusted EBITDA for Q2 2022 was approximately $51 million, representing a sequential increase of approximately $14 million or 39% relative to Q1 2022. Adjusted EBITDA margin in Q2 was 16% as compared to 13% in Q1. The sequential increase in revenue and adjusted EBITDA was driven by strong results for well flow management and well construction in North and Latin America. As highlighted in our press release, adjusted net income for the second quarter of 2022 was $0.02 per diluted share, compared to adjusted net income for the first quarter of 2022 of $0.01 per diluted share. As noted in our press release, adjusted net income for Q2 includes foreign exchange losses of $0.05 per diluted share as compared to foreign exchange gains of $0.03 per diluted share in Q1. Q2 contribution margin of 38% was up approximately one percentage point sequentially from Q1 2022, reflecting improved fall-through on higher revenue as a result of a more favorable activity mix. Q2 support costs of $70 million totaled 22% of group revenue and were down approximately $1 million sequentially or approximately 3 percentage points relate Q1 2022 and were down $8 million or approximately 9 percentage points relative to the combined support costs of Expro Frank's in Q4 2020, which was the last full quarter prior to the announcement of the merger. This represents approximately $30 million of annualized support cost savings achieved through the second quarter of 2022. In the near term, we expect to continue to manage total support costs to 22% of group revenue. With modest net pricing gains and/or incremental cost synergies, we believe we can manage overall support costs to about 20% of revenue. Total liquidity at quarter end was approximately $309 million. Cash and cash equivalents, including restricted cash, was $179 million as of June 30th. Total liquidity also includes $130 million that is available to the company for drawdowns as loans under our $200 million revolving credit facility. The balance of the facility is available for bonds and guarantees. Expro had no interest-bearing debt at quarter end Q2 2022, and the company has no interest-bearing debt today. During the quarter ended June 30th, cash provided by operating activities was $2 million as compared to cash used in operating activities of $14 million in Q1. Q2 adjusted operating cash flow, reflecting cash used in operations before cash paid for interest, severance and other expenses and merger integration expenses, was positive $10 million compared to negative $1 million in Q1. Capital expenditures totaled $21 million in the second quarter compared to $11 million during the first quarter. For the second half of 2022, the company is planning for capital expenditures in the range of approximately $60 million to $70 million, implying total capex for 2022 of $90 million to $100 million or approximately 8% of expected revenue. We also continue to expect to be free cash flow generative for 2022, but as noted on our last earnings conference call, we expect that adjusted cash flow from operations and free cash flow will be heavily weighted to the second half of the year. Consistent with comments from several of our public peers, Expro's investment in working capital was up materially in the first half of 2022, with higher receivables reflecting higher activity levels and higher inventory reflecting both an expectation of continued momentum in the business and the procurement of long lead items, including critical spares. Consistent with historic patterns, we expect a reversal of the H1 build in working capital and a significant improvement in cash generation in H2 2022. As Mike previously discussed, under our recently announced stock repurchase program, during the second quarter, we opportunistically repurchased 1.1 million shares or approximately 1% of our shares outstanding for a total cost of $13 million. This program is a reflection of the long-term confidence we have in our business, which we believe is not reflected in the current market valuation. In due course, we will more formally articulate Expro's capital allocation priorities. For now, we expect that the small buyback will be completed in Q2 and for that matter, any additional buybacks will be funded by free cash flow. Now, moving into the details for reporting segment. North and Latin America or NLA, revenue for the second quarter of 2022 was $130 million, a sequential increase of $26 million quarter over quarter. The increase was primarily due to higher revenues across all of our product lines during the current quarter with a significant increase in well flow management revenue in Mexico and higher well construction revenue in the U.S. and Guyana driven by higher customer activity levels during the just completed quarter. NLA segment EBITDA for the three months ended June 30th, 2022, was $39 million or approximately 30% of segment revenue. It was up sequentially by $17 million quarter over quarter. For Q1 2022, NLA segment EBITDA was 21% of segment revenue. The increase was attributable to higher activity and a more favorable product mix during the three months ended June 30th. For the Europe and Sub-Saharan Africa or ESA segment, revenue in Q2 was $90 million, which was up $8 million or approximately 10% quarter over quarter. The sequential increase was primarily driven by higher wealth flow management revenue in Angola and in the Congo and higher well construction revenue in the United Kingdom due to increased customer activities. The increase in revenues was partially offset by lower well intervention integrity revenue in Norway and Western Europe. ESA segment EBITDA for the second quarter was $15 million or approximately 16% of segment revenue, a sequential increase of $3 million quarter over quarter. The increase was primarily attributable to higher activity levels and a more favorable activity mix during the June quarter. For the Middle East and North Africa or MENA segment, revenue in the second quarter was $45 million, a decrease of $6 million or approximately 11% quarter over quarter. The sequential decrease was driven by lower equipment sales related to wealth management in Saudi Arabia and in the United Arab Emirates, partially offset by increased wall management activities in Algeria. MENA segment EBITDA for the June quarter was $14 million, a sequential decrease of $1 million quarter over quarter. Segment EBITDA margin was consistent with the prior quarter at 30%. The reduction in segment EBITDA was primarily due to lower activity. For Asia Pacific, or APAC, revenue for the second quarter was $48 million, which was an increase of $4 million or approximately 11% sequentially. The increase in revenue was primarily due to higher subsea well access revenue in Australia and Brunei and higher well construction revenue in Japan. The increase in revenue was partially offset by lower wealth flow management revenue in Thailand and in India. APAC segment EBITDA for the June quarter was $4 million or approximately 9% of segment revenue, a decrease of $1 million or about 3 percentage points quarter over quarter. The reduction in segment EBITDA in APAC, despite the increase in revenue was primarily due to additional mobilization and commissioning costs on a large subsea project that were incurred during the quarter as well as lower activity on higher-margin contracts. Additional commissioning costs on the Subsea projects, which totaled approximately $3 million and associated project start-up delays are in part COVID related and should be nonrecurring. As a result, we expect that revenue and segment EBITDA margin in APAC will trend positively in H2 2022 and into 2023. As Mike mentioned, our integration plans are progressing well, and we are already starting to realize significant synergy benefits we anticipated when we first announced our business combination in March of 2021. As Mike mentioned, through the second quarter of 2022, we have identified an action to approximately 100% of our synergies capture plan, both in regards to headcount and annualized value in dollars. We also completed the consolidation of several international facilities and made good progress on our ongoing migration to a single ERP platform, which should allow us to both to streamline a number of key business processes and begin to action additional cost synergies. As to our near-term outlook, we expect that Q3 2022 revenue will be up sequentially by plus or minus 8%, reflecting continued business momentum at NLA, the continuation of the seasonal rebound in ESA and the start-up of new contracts in MENA and APAC. Adjusted EBITDA margin in Q3 should be in the area of 15% to 17% of consolidated revenue. Over the next couple of quarters, we continue to expect that our revenue run rate will approximate that of the pre-pandemic 2019 revenues of Legacy Expro and legacy Frank's on a combined basis. And we, therefore, reaffirm our guidance, the Q4 revenue should fall within a range of $325 million to $350 million. With the benefit of fall-through on incremental revenue and synergies, we expect that adjusted EBITDA margins will be in the area of 20% of revenue as we exit the year. Provided our H1 build in working capital reverses in H2 2022 as is currently anticipated, absent additional M&A and/or share repurchases, we expect that our year-end cash position will be at or above where we started the year with cash generated from operating activities, funding integration costs, capex, the Q1 acquisition of SolaSense and the share buyback that was completed in Q2. By preserving and protecting our currently strong financial profile and by maintaining a disciplined approach to investment, we believe Expro will have sufficient financial flexibility to fund growth and increase returns to shareholders. As always, our objective is to enhance long-term value for our shareholders, employees, partners and the communities in which we operate. With that, I will turn the call back over to Mike for a few closing comments. Mike Jardon -- Chief Executive Officer Thank you, Quinn. We delivered exceptional operational performance that drove significant growth on a top and bottom line and is beginning to demonstrate the true capability of the company. Our broad portfolio of services and solutions continue to create opportunities in the growth markets that will be key to Expro's long-term success. Our innovative platform, next-generation technology and solutions and ESG applications are differentiators that continue to rapidly advance our reputation and outstanding track record with customers as a leading well expert. We continue to secure contracts and demonstrate the value of the breadth of our portfolio and the depth of our expertise can bring to clients across the life of their wells. Looking forward, the positive signs of a recovery we saw in the first quarter continued to gain momentum. We are seeing increased demand for our services and solutions as the recovery that began within the U.S. onshore market has begun to gain traction in the offshore international markets. We remain confident that the pipeline of projects we are seeing will support strong multi-year growth and firmly believe Expro is uniquely positioned to capitalize on this favorable outlook. We are incredibly excited about the strength and positioning of Expro. Our results could only have been achieved by the hard work and focus of our team. It's through their dedication that we continue to accelerate growth, improve profitability and enhance value for shareholders, employees, customers and partners. Thank you, again. Questions & Answers: James West -- Evercore ISI -- Analyst Good morning, guys. Mike Jardon -- Chief Executive Officer Good morning James. James West -- Evercore ISI -- Analyst So one, Mike -- so curious, it seems like we've gone through a bit of acceleration in demand here over the last quarter, maybe two quarters in a sense of urgency has arisen within your customer base? I guess -- so first, is that -- am I getting that correct? And that this urgency is kicking in? And then second, are you seeing more of that urgency or increased demand on producing assets or new assets or interventions versus new well construction type work. Mike Jardon -- Chief Executive Officer Yes. So James, I can tell you one of the good things is we've really -- now that we're kind of more exited the pandemic. I've been able to spend an awful lot more time with customers, not only in the U.S., but in particular, Middle East and Asia. And what I'd say is the conversations particularly around new FIDs, new projects, new drilling and completion type activity, that's much more constructive, much more dialogue and discussion around that. I'd say that the -- we've had continuing strong commentary and strong game with customers around producing assets. So that's -- I think that's ramping up, but not at the same rate as the positivity from the discussions around new well type -- new well drilling activity and new well completion activity. James West -- Evercore ISI -- Analyst OK. Fair enough. And then on the pricing side, are you -- at this point, are we back to kind of -- or getting close to back to pre-pandemic type of levels? Admittedly, offshore wasn't as robust even then, but it's growing and robustness now. But are you achieving the returns on capital investments that you would like to see when you're allocating capital and what you're pricing new contracts? Mike Jardon -- Chief Executive Officer So I would -- and I tried to allude to it in my earlier comments, we're starting to see some spotty opportunities to push price, and we're pushing price every opportunity we can. It's more selective right now. I think we'll continue to gain more momentum around our ability to continue to press price as we exit '22 going into '23, but we are starting to have -- it hasn't quite turned the quarter, so to speak, like North America. U.S. land has where there's lots of pricing leverage and pricing traction. But we are starting to see in some particular markets and some particular service lines, positive opportunity to continue to get that pricing. And I think we're all keen to make sure that we start to implement that absolutely as soon as we can. Quinn Fanning -- Chief Financial Officer James, I think the only thing -- I could just point you back to Mike's prepared remarks, there are capacity constraints within certain solutions and certain product groups, complex well construction or to provide construction activity or TROs, as well as the subsea landing streams. It's obviously a market that is supported by just a handful of service providers ourselves being one of the two larger ones product lines. But obviously, everything about the supply and demand, there's less than a supply for those two equipment classes. The other thing I'd highlight is with the pickup in drilling and completion type activity. It's not necessarily how we present our supplemental disclosures. But what we consider to be our drilling completions over businesses, they were up 20% quarter-over-quarter revenue-wise and the thoughts for margins on the incremental activity is north of 50%. So that's really where you get the -- James West -- Evercore ISI -- Analyst OK. Got it. Yes, no doubt. That's going to be very helpful. David Anderson -- Barclays Capital -- Analyst Hey. Good morning, Mike. I was just curious which of your product lines showed the greatest margin improvement this quarter. And I think you maybe just touched on it just now here. But curious if there's been much of improvement in well construction, in particular, as a rental business in TRS with high offshore exposure. Just curious how we should be thinking about the margin expansion upside in that particular business and how that should contribute overall. Mike Jardon -- Chief Executive Officer Sure. We alluded to some of this in the prepared remarks. What kind of additional commentary I'd add to it, David, is we've really seen some increased mix, better mix of activity in North Latin America, in particular. So yes, particularly around TRS around well construction, we've been able to start to see some margin expansion there. And then I think overall, what you're really seeing is starting to gain more traction with the cost synergies we're taking out the organization overall. We're in essence, we're a full quarter ahead of that. And I think one of the real positives of us being able to get the synergies implemented is if we're being to completely honest, anytime you're doing a consolidation, you're doing a merger, if there is a little too much internal focus that goes on. It's a necessary part of the eval as doing a merger as we can get more of that behind us, and we'll largely because we're a quarter ahead of it, that means going in exiting '22 and going into '23, we're really going to be much more externally focused. And that's one of the reasons why I've been challenging the organization is so hard to make sure we get these things done sooner rather than later. But overall, we're seeing margin expansion across well construction and even in some of the well flow management and subsea access, we're getting some traction in all three of those right now. David Anderson -- Barclays Capital -- Analyst So if I just stay on the well construction side, we're hearing a lot of talk about rigs coming back to work both on the jack-ups and the deepwater side. Are you getting inquiries for those? I'm just kind of curious, it's obviously only a couple of players in the TRS business. So I'm just kind of curious, are you starting to kind of roll out some additional equipment at been sidelined for a while. Can you help us give us a handle on what that looks like in terms of, I guess, your capacity type of equipment out there and how that's moved up? Mike Jardon -- Chief Executive Officer Yes. No, absolutely. We are seeing the same phenomenon that the drillers are seeing today with increased utilization, those kind of things. Because keep in mind, a drilling rig and TRS type equipment goes kind of hand in hand. So yes, we're able to start to put some of that equipment back to work. I referred to a casing running tool CRT opportunity we execute on in Brazil. That purely is taking assets and resources that were underutilized previously and putting those to work. So on the flip side of that, yes, we're seeing good traction with all construction. The other thing that we're seeing even more so than I had anticipated was it really becomes an early warning radar system for us, so to speak, because typically, with customers, they select the rig first almost in conjunction with that are certainly right behind it is selecting the TRS provider. And then you start moving into well completions and well testing, and those type of activities. So we're getting earlier customer engagement. And I think that we'll continue to see that allow us to more upholster revenue opportunities, those types of things. David Anderson -- Barclays Capital -- Analyst That's interesting. So if I just -- on that on that well flow management, it was up 14% sequentially this quarter, I'm pretty sure what was pretty strong for business that I thought we would consider later cycle, more production focused. So I guess the question was, I think you had said in your remarks that MENA was a little bit weaker than expected. So where were the results? Was it more mix related this quarter? Was it regional? Was something else kind of picking up and offsetting what you said? I mean, because I would have thought MENA would have actually been a driver of that growth. And it sounds like it wasn't -- Mike Jardon -- Chief Executive Officer Sure. MENA for us was really -- we had kind of a quarter-on-quarter product sales that didn't reoccur in the second quarter. So that was what gave us a little bit of softness there. Our strong activity in the Middle East, Algeria, in particular, was actually up quarter on quarter. What is important to recognize with well flow management is, in particular as well testing, we can utilize those assets in a well completions cleanup load or you can use those assets in a production optimization mode. And that allows us to kind of flex that equipment to deploy it into one or the other. And part of the growth we saw was starting to see some better activity from a new well completions, new well flowback, those type things within the quarter. David Anderson -- Barclays Capital -- Analyst OK. Thank you very much. Mike Jardon -- Chief Executive Officer Absolutely. Thanks for the questions. Duration: 0 minutes Call participants: Karen David-Green -- Chief Communications, Stakeholder and Sustainability Officer, Investor Relations Mike Jardon -- Chief Executive Officer Quinn Fanning -- Chief Financial Officer James West -- Evercore ISI -- Analyst David Anderson -- Barclays Capital -- Analyst More XPRO analysis All earnings call transcripts\",\n          \"I would now like to turn the conference over to Rodney Sacks, Co-CEO, to begin the call. Please, go ahead. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Good afternoon, ladies and gentlemen. Thank you for attending this call. I'm Rodney Sacks. Hilton Schlosberg, our Vice Chairman and Co-Chief Executive Officer, is on the call; as is Tom Kelly, our Chief Financial Officer. Tom Kelly will now read our cautionary statement. Thomas J. Kelly -- Chief Financial Officer Before we begin, I would like to remind listeners that certain statements made during this call may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and are based on currently available information regarding the expectations of management with respect to revenues, profitability, future business, future events, financial performance and trends, as well as the future impact of the COVID-19 pandemic on the company's business and operations. Management cautions that these statements are based on our current knowledge and expectations and are subject to certain risks and uncertainties, many of which are outside the control of the company that may cause actual results to differ materially from the forward-looking statements made during this call. Please refer to our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K filed on March 1, 2021, including the sections contained therein entitled Risk Factors and Forward-looking Statements, for a discussion on specific risks and uncertainties that may affect our performance. The company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events or otherwise. I would now like to hand the call over to Rodney Sacks. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Thank you, Tom. The company's top priority remains the health, safety and well-being of its employees. The company's flavor manufacturing facilities, its co-packers, warehouses and shipment facilities have operated throughout the COVID-19 pandemic. The company's bottlers and distributors are operating, and the company's products remain generally available to consumers. In limited countries, the operations of the company's bottlers and distributors have, in part, been negatively affected for varying periods of time. Despite the ongoing impact of the COVID-19 pandemic, the company achieved record second quarter net sales. Currently, the company does not foresee a material impact on the ability of its co-packers to manufacture and its bottlers and distributors to distribute its products as a result of the COVID-19 pandemic. The company's supply chain remains largely intact. However, the company continues to experience shortages in its aluminum can requirements in the United States and EMEA, given the company's volume growth and the current supply constraints in the aluminum can industry. The company is also experiencing delays in procuring certain ingredients, both domestically and internationally. As a result, the company was unable to fully satisfy demand in the 2021 second quarter in the United States and EMEA. We expect such challenges to continue for the next few months. The company has taken steps to source additional quantities of aluminum cans from the United States, South America and Asia. The company has entered into new supply agreements with two new aluminum can suppliers in the United States, and which are expected to be operational in the 2021 fourth quarter. We expect deliveries of additional quantities of cans increasing sequentially during the latter part of the year. Logistical issues, including shortages of shipping containers and port of entry congestion could delay ongoing international supply of aluminum cans. Separately, we are continuing to experiencing -- experience freight inefficiencies as well as significant increases in domestic and international freight costs and like other beverage companies are incurring increased aluminum can and other costs in the current environment, all of which in addition to other factors, will continue to adversely impact gross margin percentages. In the second quarter of 2021, net sales were $1.46 billion compared with $1.09 billion in the second quarter of 2020, an increase of 33.6%. Adjusting for foreign currency movements, net sales for the 2021 second quarter would have been up 30.1%. Gross profit as a percentage of net sales for the 2021 second quarter was 57.2% compared with 60.3% in the 2020 second quarter. The decrease in gross profit as a percentage of net sales for the three months ended June 30, 2021, was primarily the result of geographical sales mix and increased input costs, mainly increased raw material freight in costs and aluminum can costs. Operating expenses for the 2021 second quarter were $310.9 million compared with $252.2 million in the 2020 second quarter. As a percentage of net sales, operating expenses for the 2021 second quarter were 21.3% compared with 23.1% in the 2020 second quarter. Operating income increased 29.1% to $526 million, up from $407.3 million in the second quarter of 2020. Net income increased to 29.7% and to $403.8 million compared to $311.4 million in the 2020 comparable quarter. Diluted earnings per share for the 2021 second quarter increased to 28.6% and to $0.75 from $0.59 in the second quarter of 2020. According to the Nielsen reports for the 13 weeks through July 24, 2021, for all outlets combined, namely convenience, grocery, drug, mass merchandisers, sales in dollars in the energy drink category, including energy shots, increased by 14.2% versus the same period a year ago. Sales of the company's energy brands, including Reign, were up 8.6% in the 13-week period. Sales of Monster were up 11.1%. Sales of Reign were down 6.1%. Sales of NOS decreased 4.1%, and sales of Full Throttle increased 7%. Sales of Red Bull increased 15.3%. Sales of Rockstar decreased by 15.7%, and sales of 5-Hour increased 8.5%. VPX Bang sales increased 20%. According to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the energy drink category in the convenience and gas channel, including energy shots in dollars, increased 7.4% over the same period the previous year. Sales of the company's energy brands, which include Reign, increased 3.6% in the four-week period in the convenience and gas channel. Sales of Monster increased by 5.8% over the same period versus the previous year, Reign sales decreased 6.8%, NOS was down 10.7%, and Full Throttle was up 13.2%. Sales of Redbull were up 9%. Rockstar was down 18.6%, and 5-Hour was up 3.2%. VPX Bang sales increased 12.2%. According to Nielsen, for the four weeks ended July 24, 2021, the company's market share of the energy drink category in the convenience and gas channel, including energy shots, in dollars, decreased 1.3 points to 36.5%. Monster share decreased 0.4 of a share point to 30.6% and. Reigns decreased 0.4 of a share point to two points -- sorry, 2.4%. NOS's share decreased 0.5 of a point to 2.7%, and Full Throttle share remained at 0.7%. Redbull's share increased point -- six points to 37.4%. Rockstar's share was down 1.2 points to 3.8%. 5-Hour share was lower by 0.2 points at 4.6%. VPX Bang share increased 0.3 points to 7.6%. As previously reported, Coca-Cola Energy is being discontinued in the United States and Canada by the end of 2021. According to Nielsen, for the four weeks ended July 24, 2021, sales in dollars in the coffee plus energy drink category, which includes our Java Monster line in the convenience and gas channel, increased 4.2% over the same period the previous year. Sales of Java Monster, including Java Monster 300, were 5.9% higher in the same period versus the previous year. Sales of Starbucks Energy were 0.4% higher. Java Monster share including Java Monster 300 of the coffee plus energy category, which primarily includes Java Monster, Java Monster 300, Starbucks Doubleshot and Tripleshot, Rockstar Roasted and Bang Keto Coffee for the four weeks ended July 24, 2021, was 51.9%, up 0.9 of a share point, while Starbucks' energy share was 45.5%, down 1.7 points. According to Stackline, which tracks energy drink sales by Amazon in the United States, in the four-week period ending July 3, 2021, sales in dollars in the energy category by Amazon, including energy shots, increased 104.5% over the same period the previous year. Sales of Monster increased 59.9%. And its share was 28.1%, down 7.8 share points versus the same period a year ago. Red Bull sales increased 109.4%, and its share was 16.6%, up 0.4 points. Celsius' sales increased 133.1%. And its share increased 1.8 points to 14.3% 5-hour sales increased 40.9%. And its share declined 1.3 points to 2.9%. VPX Bang sales increased 216.1%. And its share increased 1.8 share points to 5.2%. Reign's share decreased 0.1 of a share point to 5.3%. Rockstar's share increased 0.9 of a share point to 3.9%. According to Nielsen, in all measured channels in Canada, for the 12 weeks ended June 19, 2021, the energy drink category increased 17.9% in dollars. Sales of the company's energy drink brands increased 28.3% versus a year ago. The market share of the company's energy drink brands was 41.5%, up 3.4 points. Monster sales increased 18.3%, and its market share increased by 0.1 of a point to 35.4% -- sorry, 35.4%. NOS' sales increased 12.6%, and its market share decreased 0.3 of a point to 1.9%. Full Throttle sales decreased 2.1%, and its market share decreased 0.1 of a point to 0.6%. Red Bull sales increased 18.1%, and its market share increased 0.1 of a point to 38.7%. Rockstar sales decreased 8.6%, and its market share decreased 3.3 points to 11. 4%. GURU's sales increased 35.9%, and its share increased 0.5 of a share point to 4%. According to Nielsen, for all outlets combined in Mexico, the energy drink category increased 45.2% for the month of June 2021. Monster sales increased 38.7%. Our market share in value decreased by 1.3 points to 27.2% and against the comparable period the previous year. Red Bull sales increased 41.4%, and its market share decreased by 0.2 of a point to 6.5%. Vive 100 sales increased 30.2%, and its market share decreased by 2.4 points to 20.5%. Volt's sales increased 41.1%, and its market share decreased 0.5 of a share point to 18.5%, while B:oost's sales increased 15.7%, and its market share decreased 1.3 points to 5.1%. Amp's sales increased 91.9%, and its market share increased 4.4 points to 17.9%. Predator, which was launched in March 2020, achieved a market share of 3.1%. The Nielsen statistics for Mexico cover single months, which is a short period that may often be materially influenced positively and/or negatively by sales in the OXXO convenience chain, which dominates the market. Sales in the OXXO convenience chain in turn can be materially influenced by promotions that may be undertaken in that chain by one or more energy drink brands during a particular month. Consequently, such activities could have a significant impact on the monthly Nielsen statistics for Mexico. According to Nielsen for the month of June 2021 compared to June 2020, Monster's retail market share in value increased in Argentina from 40.1% to 46.9% and in Brazil from 29.6% to 35.4%. In Chile, Monster's retail market share decreased from 45.7% to 41.9%. Monster Energy continues to be the leading energy brand in value in Argentina. I would like to point out that the Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country-to-country and are reported on varying dates within the month referred to from country-to-country. According to Nielsen, in the 13-week period ending July 18, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 34.2% to 37.4% in Spain. According to Nielsen, in the 13-week period to the end of June 2021, Monster's retail market share in value as compared to the same period the previous year grew from 14.5% to 15.3% in Germany, from 18.4% to 19.4% in Poland and from 18.4% to 20.1% in South Africa. According to Nielsen, for the 13-week period ending June 20, 2021, Monster's retail market share in value as compared to the same period the previous year grew from 12.5% to 16.2% in Belgium, from 24.2% to 25.3% in Denmark, from 25.8% to 28.2% in France, from 25% to 29% in Great Britain, from 6.7% to 8.4% in the Netherlands, from 27.1% to 31.2% in Norway, from 25.6% to 29.3% in the Republic of Ireland and from 13.4% to 14.5% in Sweden. According to Nielsen, in the 13-week period until the end of May 2021, Monster's retail market share in value compared to the same period the previous year grew from 13.3% to 14.5% in the Czech Republic, from 35.1% to 37.9% in Greece and from 16.6% to 29% in Italy. According to Nielsen, in the 13-week period until the end of May 2021, Predator's retail market share in value as compared to the same period the previous year grew from 5.1% to 17.3% in Kenya and from 0% to 8.1% in Nigeria. The Nielsen numbers in EMEA should only be used as a guide because the channels read by Nielsen in EMEA vary from country to country. According to IRI in Australia, Monster's market share in value for the month ending June 2021 increased from 11.6% to 14% as compared to the same period the previous year. Mother's market share in value decreased from 13.3% to 11.6% during the same period. The market share of the company's brands in Australia for the month ended June 2021 increased from 24.9% to 25.5%. According to IRI in New Zealand, Monster's market share in value for the four weeks ended July 11, 2021, increased from 9.9% to 12.4% as compared to the same period of the previous year. Live+ market share in value remained the same at 6.9%, and Mother's market share in value increased from 6.2% to 6.3%. The market share of the company's brands in New Zealand for the four weeks ended July 11, 2021, increased from 23.1% to 25.6%. According to Nielsen, in South Korea, Monster's market share in value in all outlets combined for the month of June 2021 increased from 53.3% to 61.9% as compared to the same period in the previous year. According to INTAGE, in Japan, Monster's market share in value in the convenience store channel for the month of June 2021 was 50.6% as compared to 51% in the same period the previous year. Monster remains the market leader in Japan. We again point out that certain market statistics that cover single months or four week periods may often be materially influenced positively and/or negatively by promotions or other trading factors during those periods. Net sales to customers outside of the US were $546.3 million, 37.4% of total net sales in the 2021 second quarter compared to $328.3 million or 30% of total net sales in the corresponding quarter in 2020. Foreign currency exchange rates had a positive impact on net sales in the US dollars by approximately $38.6 million in the 2021 second quarter. Included in reported geographic sales are our sales to the company's military customers, which are delivered in the US and transhipped to the military and their customers overseas. In EMEA, net sales in the 2021 second quarter increased to 105.7% in dollars and increased 86.5% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales for the second quarter was 39.8% compared to 38.1% in the same quarter in 2020, primarily due to a favorable country and product mix. We're also pleased that in the 2021 second quarter, Monster gained market share in Belgium, the Czech Republic, Denmark, France, Germany, Great Britain, Greece, Italy, the Netherlands, Norway, Poland, the Republic of Ireland, South Africa, Spain and Sweden. In Asia Pacific, net sales in the 2021 second quarter increased 5.2% in dollars and decreased 100% [Phonetic] in local currencies over the same period in 2020, largely due to sales in Japan and China. Gross profit in this region as a percentage of net sales was 44.4% versus 43.3% over the same period in 2020. In Japan, net sales in the 2021 second quarter decreased 15.1% in dollars and 13.9% in local currency, largely due to COVID-19 restrictions in Japan and distributor inventory adjustments. Depletions increased 7% during the quarter. Monster remains the market leader in Japan for the month of June 2021. In South Korea, net sales increased 63% in dollars and 50.4% in local currency as compared to the same quarter in 2020. In China, net sales decreased to 21.4% in dollars and 27.8% in local currency as compared to the same quarter in 2020. In this regard, we note that sales in the second quarter of 2020 included the initial launch of Dragon Tea. We are reevaluating the viability of this SKU and the optimal product range for China going forward. We remain optimistic about the prospects for the Monster brand in China. In Oceana, which includes Australia, New Zealand, Tahiti, French Polynesia, New Caledonia, Papua New Guinea and Guam, net sales increased to 146.5% in dollars and 98.2% in local currencies. Sales of the Monster brand in Oceana increased 210% in dollars and 155.6% in local currency as compared to the same quarter in 2020. In Latin America, including Mexico and the Caribbean, net sales in the 2021 second quarter increased to 19.7% in dollars and increased 117.6% in local currencies over the same period in 2020. Gross profit in this region as a percentage of net sales was 40.7% compared to 41.2% in over the same period in 2020, primarily as a result of foreign exchange rates and certain raw materials and ingredients for products in this region are purchased in US dollars. In Brazil, net sales in the 2021 second quarter increased by 194.9% in dollars and 201.7% in local currency. Net sales in Chile increased 77.5% in dollars and 52% in local currency in the 2021 second quarter. Net sales in Argentina increased 291.4% in dollars and 458% in local currency in the 2021 second quarter. In March 2019, VPX, the maker of Bang Energy drinks, sued Monster, alleging that its Reign products infringed VPX's Bang trademarks and trade risk. A trial was held last year. And on August 3, 2021, the court issued an order denying all of VPX's claims and holding that VPX is entitled to no relief whatsoever. In fact, the court specifically found that VPX copied its bank trade risk from the original Monster Energy cans. The court's decision confirms that Monster and Poland retail partners are free to continue to sell our Reign products without any changes and without any restrictions. Monster always believed and maintained that VPX's claims were frivolous, and we are extremely pleased that the court rejected all of VPX's claims while vindicating Monster's rights. As other pending proceedings with VPX are subjudicate, we will not be answering any questions on this matter on today's call. Our new product introductions in the United States in the first half of 2021 were primarily focused in the first quarter. In the United States, during the second quarter of 2021 we refreshed our can graphics on our Rehab Monster brand family as well as our Full Throttle line, also updating the name for Blue Agave to TrueBlue. Monster Energy Ultra Fiesta received a refresh and updated can graphics as well as the name change to Monster Energy Ultra Fiesta Manga. In May 2021, we launched Monster Ultra Fiesta in a 24-ounce option with an update to our Ultra Fiesta Manga plan for later this year. We are in the process of launching a new line of nonalcoholic pure energy sales under the True North brand name in 12-ounce sleek cans, which contained an organic plant-based energy blend and ingredients for immunity support. True North is being offered in six flavors, Cucumber Lime, Black Cherry, Grapefruit Lemonade, Water Mellon Mist, White Peach Pear and Mandarin Yuzu. True North has a limited customer target in 2021 with plans for a full launch into mainstream channels in 2022. While cognizant of the can shortages, we believe that it is important to continue with our innovation plans. And to this end, we will be launching our new flavors reserve line of Monster Energy drinks in Water Mellon and White Pineapple in October 2021. We have deferred the launch of our new line of Java Monster Cold Brew Coffee + energy drinks until early 2022. In Canada, during the second quarter, we launched two new products: Monster Punch Papillon and Monster Punch Khaotic, both in a 473 ml can. In April 2021, we launched Reign Orange Dreamsicle in Puerto Rico and our second SKU in Bolivia with Monster Energy Zero Ultra. In El Salvador, we launched Fury Mean Green in May 2021. In the second quarter of 2021, we launched Juice Monster Pacific Punch and Monarch in a number of countries in EMEA. We also launched Ultra Paradise and Ultra Fiesta in a number of countries during the quarter. During the quarter, we also launched our strategic brand innovation and Predator in additional countries. In January 2021, we launched Ultra Rosa marketwide in Australia, following an exclusive lead launch with one chain in the fourth quarter of 2020. In March 2021 in New Zealand, we launched Monster Superfuel in both Purple Passion and sugar-free flavors. During the 2021 second quarter in Japan, we launched Monster Energy Super Cola with our distributor, Asahi Soft Drinks. Additionally, we effected the relaunch at retail of Ultra Paradise and began shipments in anticipation of the launch of Super Fuel early in the 2021 third quarter. Super Fuel has just gone on the shelves in Japan this week. We also launched Mango Loco in Korea in July 2021. During the 2021 second quarter, we launched Pipeline Punch in Taiwan, Hong Kong and Macau. We also began distribution of Monster Energy Zero Sugar in the Philippines. As previously mentioned, in the second quarter of 2021, in China, we extended the national rollout of our new Monster Dragon Gold, which is non-carbonated. Our national summer on-pack promotion began in May with one of China's top consumer ambassadors. As a result of the COVID-19 pandemic, certain of our planned launches and innovation of new products in a number of Asia-Pacific markets have been deferred for a few months. However, we still anticipate such launches taking place toward the end of the 2021 calendar year. We are planning to launch a number of additional products and product lines in our domestic and international markets later this year. We estimate that July 2021 sales to be approximately 1.8% higher than in July 2020. On a foreign currency adjusted basis, July 2021 sales would have been comparable to the July 2020 sales. July 2021 had one less selling day than July 2020, which was 15.8% above July 2019, and which was 17.1% higher on a foreign currency adjusted basis. Certain production facilities, mainly from the Coke bottlers in EMEA, in particular, delayed production from July to August 2021. Furthermore, as mentioned earlier, the company has not been able to fully satisfy demand in the United States and EMEA due to a shortage of aluminum cans, which adversely impacted July sales. Such shortage was exacerbated in July as can availability did not keep pace with increased demand during the summer months. Additional cans have been sourced from domestic and overseas suppliers with expected deliveries increasing sequentially during the latter half of the year. We are working to replenish system inventories in order to meet customer demand as soon as possible. Additionally, the company also experienced delays in certain ingredients, which impacted supply. Our depletions remain solid as do our measured market data, as previously mentioned on this call. In this regard, we caution again that sales over a short period are often disproportionately impacted by various factors such as, for example, selling days, days of the week in which holidays for, timing of new product launches, and the timing of price increases and promotions in retail stores, distributor incentives as well as shifts in the timing of production in some instances where our bottlers are responsible for production and unilaterally determine their production schedules, which affects the dates on which we invoice such bottlers as well as inventory levels maintained by our distribution partners, which they alter unilaterally for their own business reasons. We reiterate that sales over a short period such as a single month should not necessarily be imputed to or regarded as indicative of results for a full quarter or any future period. If the COVID-19 pandemic and related unfavorable economic conditions continue in certain regions, our new product innovation launches in those regions could be delayed. In conclusion, I would like to summarize some recent positive points. Currently, the company's flavor manufacturing facilities, its co-packers, warehouses, and shipment facilities, and bottlers and distributors are all operating. We are continually addressing our aluminum can requirements, given our volume growth and the current supply constraints in the aluminum can industry. We are pleased with the new additions to the Monster Energy portfolio and are planning additional launches later in the year. We are planning to continue additional launches of our Reign Total Body Fuel high-performance energy drinks in additional international countries. We are pleased with the rollout of Predator and Fury and our affordable energy drink portfolio internationally. We are proceeding with plans to launch our affordable energy drinks in a number of international countries during the year. I would like to open the floor to questions about the quarter. Thank you. Dara Mohsenian -- Morgan Stanley -- Analyst Hey, guys. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Hey, Dara. Dara Mohsenian -- Morgan Stanley -- Analyst Great top line growth in the quarter, but we have seen share losses in US track channel data worsened recently. A, just short-term, how much of that do you think is attributable to out of stocks and the supply constraints that you mentioned? Is that a material factor in retail sales? And then maybe, b, from a longer-term standpoint, it has been a couple of quarters now where the share losses have reaccelerated year-over-year, just some progress in the beginning of the year. So, I was just hoping you could review some of the key factors that have been driving the share losses in the US? And how you think about those factors going forward in terms of continuing or dissipating and how you guys are positioned? Thanks. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Hilton, if you take that, and I'll also say something once you've... Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board All right. I think, Dara, what's important is that, that's not a result and not due to us not growing. We are not keeping up with our share, but our business is certainly growing. And you can track that from Nielsen. You can also track that from the non-measured channels, which are growing really very nicely. So while we're not keeping up necessarily with Red Bull in the major channels. As I've spoken on previous calls, Red Bull had a very large on-premise business, which has moved to off-premise and moved to off-premise during COVID. And that led to an acceleration in their share. However, we mentioned that we had and are continuing to sustain can issues and result in supply. And of course, that's having an impact on the share numbers that you are seeing. So I think on balance, the business is growing. You've seen the results. It's continuing to grow. And we are growing, but not at the extent of the market. I think with the full deck of cards, the situation may well be very different. But right now, we really are struggling with sufficient supplies of aluminum cans really to keep up with demand, which is, I suppose, a good position to be in. And on the other hand, is not such a good position to be in. The business is growing. And, that's the message I want to leave you with and other investors. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer I think in -- I'll just add two short points in that regard. I think what we've tried to do is to try and also basically focus on our faster selling and our larger SKUs, which has necessarily resulted in some of the smaller SKUs, which normally have their own traction and followers. So those haven't got on to shelf. And then the one additional thing that I think that has negatively affected our distribution sales and distribution levels in the US is labor shortages. And I think that what we've seen is that many of the bottlers, Coke bottlers are experiencing labor shortages. And while one would ordinarily say, well, everybody is going to have the same problem. I think that where you have Red Bull is our main competitor, they have a dedicated system. I think they've been able to address their labor shortages just more effectively than the larger bottlers with large labor pools. And that has also, I think, detrimentally affected our distribution levels going forward. But again, I think those are things that once things start settling down and things will get back to normality, that's something that I think that will also, in due course, right itself. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Yes, I think we should also -- Dara, I think we should also add that what we're seeing with cans is something that will persist through this year. I'm a bit more optimistic about the fourth quarter because we have two new can suppliers coming on board. But the situation will persist. And then next year, we should be in -- we believe we'll be in very good shape. But again, it all depends on consumer demand, which is growing, and you've seen that month-by-month and quarter-by-quarter. Bonnie Herzog -- Goldman Sachs -- Analyst Thank you. Hi, everyone. I just wanted to ask about your gross margins. Clearly, they continue to be pressured as broadly expected, which you guys have been discussing with us. But just want to get your outlook for these pressures in the back half of the year? Hilton, you just mentioned that you're optimistic. So just wanted to verify that you still expect some of these pressures to ease by Q4? Or do you think it's going to take a little bit longer, especially in light of the recent spike in aluminum prices. So trying to understand how that factors in? And then just a clarification on the can shortages that you mentioned that you're still experiencing, I guess, it sounds like it's getting worse, but I really did want to clarify that. And is there any way that you guys could quantify how big of an impact the supply shortages had on your top-line either in the quarter or in July? Just trying to understand how much you think your shipments would have been up in July without these shortages, for instance? Thanks. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Okay. So let me deal with the first issue first, if I may. I spoke about optimistic about can supplies. I really didn't talk about margins. You'll recall on the last call, I spoke about the issues that we were confronting with margin pressures like most other beverage companies. And where we are right now with aluminum, I mean, nobody knows. So you can talk to the leading banks in the field, which we do on a regular basis, and they really are pulls apart about their projections for aluminum in 2022, let alone 2021. So the last couple of days, you've seen a spike in the Midwest premium from this tax that is expected to be imposed on Russian aluminum. And as, you know, the Midwest premium is strongly factors the last ton of aluminum to enter the US and the cost of that. And so we've seen a spike in the Midwest premium. And we continue to see spikes in aluminum. So from that score, I think we just are in uncharted territory. I've been in this business for a long time, as you know, and I've never seen aluminum where it's at right now. And I've never seen the Midwest premium at these kind of levels. So aluminum, I really cannot talk about. And also when you look at our business and you look at the factors that really have affected gross margin, number one, the fact that we're selling a lot more internationally. So I talked earlier about 37.4% of our sales in the quarter outside of the US 30% last year, that obviously impacts margins. We are importing cans from a number of [Technical Issues] that obviously impacts margins. In fact, the China and India cans that we are using in the United States and in EMEA will only be filed in August in July, and they will be filled this month. So that in itself, the imputation will impact gross margins. And then to cap everything else, we have ingredient issues. We had ingredient issues, as we mentioned, in July, which again reduced the amount that we would actually sell because we didn't have sufficient ingredients to meet themselves, particularly with NOS. And so there are a number of factors that are increasing that are increasing our cost of goods. And last quarter, I said I didn't think that margins would get better in the second and third quarters. I read they will not -- I think margins will deteriorate in the third quarter. In the fourth quarter, we're getting some relief in terms of supplies from the US on cans that are -- have been contracted for and they were contracted for two years ago. And we saw the opportunity to work with two major suppliers to get additional cans produced in the US, and that's why we have two new supplies opening, and we are an important and an anchor customer of both those facilities. But even that, you're still dependent on aluminum. We have some hedges in place, but obviously not enough to take into consideration the amount of sales and the amount of consumer demand that is out there. So that's a long-winded way of saying, I think, answering your question as best as I can. And then just getting to your second question because you're really only allowed one. But to get to your second question, we have quantified or try to quantify the impact on can shortages in July and in this quarter and in the -- potentially in the third quarter, but I really don't want to -- I'm not comfortable with those numbers yet. A lot of detailed work is being done on them. And I just -- I can't in good contents give those numbers because we still are in the throes of kind of finalizing what we think is probably correct. Rodney mentioned in his script earlier that a number of the bottlers, he mentioned particularly in EMEA, but there were cases in the US as well, and there was a substantial case in the US where the bottlers were obviously focused on other things in the quarter and were producing Coca-Cola brands. And as a result, I think we -- our production got moved from July to August. So, when I look at July, it doesn't -- I don't get overly concerned because I know the sales are going into August. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Perhaps, if I just on the shortage level, just to add that when we buy cans in contracted for our annual amount, they usually are sort of reasonably flat line across the year. And we used the first half of the year to build up can inventories and finished product inventories with ourselves and our bottlers. Earlier this year, obviously, demand sort of was strong, and so we really didn't have that opportunity. So what has happened is that in June and July, which is your normal peak months, the demand has been higher, but our supply has been more level until we can get more can inventories into the market. So what happened is just that we have had a sort of a heartened increased shortage in the last month and July and probably will be a little bit in August. And then obviously, as we start increasing our -- the cans we're getting in, and then we're able to balance it more and our demand balances more, we'll start to have less of a different delta between these demand and supplier and eventually be able to -- we're hoping to able to build up our inventories and supply back to normal by the end of the fourth quarter or during or by the end of the fourth quarter. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board No one's comfortable with the level of finished goods inventories that we're running at, but it's a sign of the times. I mean, we're doing everything we can to supply our customers. And that's why we spoke about freights. Freight is a big issue, not only getting raw material ingredients into co-packing system and into our bottling system and -- but also distributing from our co-packers. And obviously, the one goes into cost of sales and freight out goes into operating expenses. So that's why you'll see freight really hitting both of those line items. Andrea Teixeira -- JPMorgan -- Analyst Hi. Thank you. Hi. Good afternoon. Thomas J. Kelly -- Chief Financial Officer Hi. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Hi, Andrea. Andrea Teixeira -- JPMorgan -- Analyst How are you Hilton? Hi. Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board I'm good. Andrea Teixeira -- JPMorgan -- Analyst Yes. Just on the gross margin, because your gross margin comments were very helpful and given this deterioration obviously that its probably here to stay in the next few quarters. How are you thinking about pricing? Obviously, you can't supply the service levels that are used to with the retailers. So is that is something that takes -- obviously, you have to take into account? Or perhaps as you get more informed on how the aluminum cost will evolve, you may contemplate it again? Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Yes. With regard to pricing, we continue to evaluate pricing, honestly, on a very, very regular basis, if not weekly. So we continue to evaluate it, and we want to make a good decision. Last time around, as I mentioned on previous calls, we went out alone, and we would like to have been in a situation this time where we followed our competitor, but we have to evaluate, obviously, the business as we see it and the impact for us. What we've done is we're reducing our promotional allowances. So we're taking a price increase the other way, through reducing promotional allowances, but the impact of that reduction in the second quarter was not as we would have liked. So we are -- we really put the accelerator down and are more aggressive in reducing our promotional allowances. But we are continuing to evaluate the pricing and price increases. And then I have to leave this call with my favorite saying, and that is, we don't bank gross profit margins, we bank gross profit dollars. And to me, the fact that we're doing everything we can to satisfy our customers as best as we can is impacting gross profit margins. But at the end of the day, we don't want to lose gross profit dollars, which is really important to ensure the sustainability of the brand. And that's the most important thing for us right now. Andrea Teixeira -- JPMorgan -- Analyst Thank you. Thanks fair. Thank you both. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Yeah. Basically, just make it clear, at this point, we are watching and we're not planning a price increase. We we're not adverse to a price, but we'll wait and see what the market does and what our competitors do. Andrea Teixeira -- JPMorgan -- Analyst Thank you, Rodney. Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Thanks very much. Thank you, everyone, for your continued interest and support of the company. We continue to believe in the company and our growth strategy to remain committed to continuing to innovate, develop and differentiate our brands and to expand the company, both domestically and abroad. And in particular, expand distribution of our products through the Coca-Cola bottler system internationally. We believe that we will be able to navigate through the challenges ahead as a result of the COVID-19 pandemic and hope that this unfortunate situation will resolve itself in the near future. We believe that we are well positioned in the energy drink category and will continue to be and are optimistic about our total portfolio of energy drink brands. We hope that you will stay safe and healthy. Thank you very much for your attendance. Duration: 50 minutes Call participants: Rodney C. Sacks -- Chairman and Co-Chief Executive Officer Thomas J. Kelly -- Chief Financial Officer Hilton H. Schlosberg -- Co-Chief Executive Officer, Vice Chairman of The Board Dara Mohsenian -- Morgan Stanley -- Analyst Bonnie Herzog -- Goldman Sachs -- Analyst Andrea Teixeira -- JPMorgan -- Analyst More MNST analysis All earnings call transcripts\",\n          \"Please go ahead. Dan Lochner -- Chief Financial Officer Good evening, everyone. And welcome to Oyster Point Pharma's fourth quarter earnings conference call for the three months ended December 31, 2021. This evening, we issued a press release containing our fourth quarter and full year ended December 31, 2021, financial results and recent business highlights. In addition, our earnings press release and our Form 10-K, which were filed with the SEC after the close of market today, are available on our website under the investors and news section at www.oysterpointrx.com. Joining us on our call today are Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma; and John Snisarenko, chief commercial officer. Following Dr. Nau and Mr. Snisarenko and my prepared remarks, we will open up the line for questions. During the call today, we will be making forward-looking statements regarding potential future events, including statements regarding Oyster Point Pharma's potential future financial status and results of operations and our plans and potential for success relating to commercializing TYRVAYA. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. For a description of these factors, please see our annual report on Form 10-K for the year ended December 31, 2021, filed with the SEC after the close of market today. I will now turn the call over to Dr. Jeffrey Nau, president and chief executive officer of Oyster Point Pharma. Jeff Nau -- President and Chief Executive Officer Thank you, Dan. Good evening, everyone. And thank you for joining us on our call today to discuss our fourth quarter 2021 financial results and recent business highlights. This is a particularly exciting time for Oyster Point. This is our very first earnings call where we are pleased to be reporting partial revenues from the commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease in the United States marketplace. Today, you will learn more about how we are delivering these encouraging commercial results on the launch of TYRVAYA Nasal Spray. But first, let me provide the company's 2021 business highlights. In October of 2021, we received FDA approval of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Dry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence. The dry eye market is now being introduced to the first nasally delivered, pharmaceutical dry eye therapy, and we believe that given the high level of patient and physician satisfaction that we are seeing in the field with TYRVAYA, that significant growth remains ahead. You will be hearing more shortly from John Snisarenko, our chief commercial officer, about the details of the launch of TYRVAYA Nasal Spray, but I'm happy to state that we had great partial fourth quarter commercial performance in 2021. We are happy to report that TYRVAYA Nasal Spray had a net product revenue of $1.2 million in Q4 of 2021. In addition, we recognized $5.4 million from our license agreement with Ji Xing Pharmaceuticals. We are now entering 2022, having demonstrated the ability to achieve the successful commercialization of TYRVAYA, as well as drive strong execution across multiple areas of our business, including our exclusive license agreement with Ji Xing to develop and commercialize OC-01 and OC-02 in Greater China, securing nondilutive funding and pursuing additional treatment advancements in the clinic, as well as in the R&D laboratory for patients with ophthalmic diseases. This week, we publicly announced an early commercial win with one of the largest commercial payers. Our press release from Tuesday announced that TYRVAYA Nasal Spray is now covered by Express Scripts effective on February 19. This is a fantastic accomplishment for our market access team in achieving the addition of 26 million covered lives and more importantly, this early in our first full quarter since launch. Patients are increasingly gaining access to TYRVAYA in the U.S. for a disease state that, up until 2021, we believe, experienced very little innovation for the current large unmet need in dry eye disease. TYRVAYA is a first-in-class cholinergic agonist nasal spray that is highly differentiated from the other pharmaceutical products in the dry eye space and includes the following potential advantages. TYRVAYA Nasal Spray has a differentiated mechanism of action as it is believed to activate the trigeminal parasympathetic pathway via the nose, resulting in increased production of basal tear film as a treatment for dry eye disease. Basal tear film is responsible for lubricating, nourishing and protecting the cornea. TYRVAYA is the only ocular surface-sparing pharmaceutical therapy for dry eye patients. For those patients with a compromised ocular surface, increasing tear production without the burden of administering a topical medication may provide a welcome method to treat their disease. For the first time, dry eye disease patients have an FDA-approved, pharmaceutical treatment option that is not administered as a topical eye drop to an already irritated ocular surface. Although we are focused on the critical launch of TYRVAYA Nasal Spray and continue to execute plans for the life cycle development of the TYRVAYA franchise, our R&D team remains committed to multiple exciting pipeline projects aimed at bringing additional innovative therapies to address diseases like neurotrophic keratopathy and severe allergic or vernal keratoconjunctivitis. In 2022, we will continue to advance our enriched tear film gene therapy platform, as well as our research and development collaboration with companies like Adaptive Phage Therapeutics. We remain excited about the ongoing OLYMPIA Phase 2 study of OC-01 nasal spray in Stage 1 neurotrophic keratopathy. We are expecting a readout in the second half of this year. NK is a disease that is currently underdiagnosed or misdiagnosed in many patients with ocular surface disease. We feel that Stage 1 neurotrophic keratopathy could represent a meaningful indication for OC-01 nasal spray. Our vision and focus is clear. The world needs an innovative leader that can bring innovative and transformative ophthalmic disease treatments, and we aim to be that leader. We believe that we're building Oyster Point into a best-in-class eye care company. I would now like to turn the call over to John Snisarenko, Oyster Point's chief commercial officer, to discuss our ongoing commercial launch of TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease. John Snisarenko -- Chief Commercial Officer Thank you, Jeff. As we have previously communicated, the dry eye disease segment is a large market with over 17 million people diagnosed in the United States alone. Only a small proportion of these patients, approximately 2 million, are currently being treated with a branded therapeutic. And over 7 million people diagnosed with dry eye disease have tried and abandoned the other available options. We believe that TYRVAYA Nasal Spray is a new treatment option for the large patient population that exists in the dry eye disease marketplace, including the refractory patients, as well as those who are newly diagnosed. As Jeff highlighted previously, we are incredibly excited to have initiated the U.S. launch of TYRVAYA Nasal Spray on November 1. We are pleased to report that as of the quarter ending December 31, 2021, data indicates that approximately 5,500 prescriptions for TYRVAYA have been filled, written by over 1,900 unique prescribers. These encouraging metrics were achieved in less than nine weeks from the launch, including holiday periods. In this short time, TYRVAYA is quickly establishing itself in the market as an exciting new option for dry eye patients. Regarding market access, a core part of our commercial strategy is to promote accelerated payer adoption of TYRVAYA to the top payer organizations. Our market access team has done a great job in securing coverage for TYRVAYA with Express Scripts National Preferred, Basic and High Performance Formularies effective February 19. With this latest formulary addition, we now have coverage for a total of 43% of U.S. commercial lives for an aggregate total of approximately 84 million lives. We are incredibly pleased with this level of coverage so early in our launch, and we look forward to further growing our market access coverage in 2022. Oyster Point remains very committed to offering comprehensive patient services that help provide access to TYRVAYA for appropriate patients. We have launched a comprehensive set of technology-driven patient services offerings aimed at enabling patients to successfully navigate the patient journey and procure TYRVAYA. Our patient support program is called TEAMTyrvaya. And for more information on this program and how to enroll, please visit the website, tyrvaya-pro.com. We have been quite diligent with the sizing of our field force, which enables us to target 20,750 eye care practitioners, covering both optometrists and ophthalmologists and representing approximately 94% of the dry eye prescriptions in the market today, helping us in our efforts to achieve the full commercial potential of TYRVAYA. In the first nine weeks of launch, our sales force was able to introduce TYRVAYA to more than 50% of the targeted prescriber base. On the marketing side, we're leveraging the latest technology, including sophisticated analytics, in-person, as well as virtual detailing, best-in-class digital and social media efforts and partners, as well as utilizing a digital online pharmacy to enhance communication and delivery of TYRVAYA to patients. We will continue to adopt the latest media and technology-driven marketing approaches to maximize TYRVAYA's share of voice and impact in the market. Our focus continues to be on broad eye care provider and patient education and marketing efforts, with targeted direct-to-patient digital campaigns leveraging TYRVAYA's differentiated MOA and nasal spray route of administration to drive a positive patient marketing experience. I am so proud of our commercial team's collective efforts during this early phase of our launch, especially in these challenging times with the pandemic. I will now turn the call back over to Dan Lochner, Oyster Point's chief financial officer, to discuss our fourth quarter financial results. Dan Lochner -- Chief Financial Officer Thank you, John. I will now provide a brief overview of Oyster Point Pharma's fourth quarter financial results. Additional detail about our fourth quarter, as well as our annual financial results can be found in our Form 10-K that was filed with the SEC this evening. For the fourth quarter of 2021, Oyster Point Pharma reported a net loss of $42.1 million, compared to a net loss of $22.2 million for the same period in 2020. As of December 31, 2021, cash and cash equivalents were $193.4 million, compared to $192.6 million as of December 31, 2020. Based on our current business plan, we believe the company's available cash and cash equivalents will be sufficient to fund the company's planned operation for at least 12 months from our 10-K filing this evening. Net product revenues for the fourth quarter of 2021 were approximately $1.2 million, following the FDA approval of TYRVAYA Nasal Spray on October 15, 2021, and our subsequent commercial launch in the U.S. in November 2021. Approximately half of the TYRVAYA net product revenue was attributable to channel building by distributors upon launch of the product. In addition, pursuant to our license agreement with Ji Xing, the company also recognized $5.4 million in milestone and license revenue following the FDA approval of TYRVAYA Nasal Spray, which includes the noncash consideration of Ji Xing senior common shares. The company did not generate any revenues during the third -- three months ended December 31, 2020. Cost of product revenue for the three months ended December 31, 2021, was $1.5 million and consisted mainly of third-party manufacturing costs, which included pre-approval costs, reserves for inventory obsolescence and damaged goods and product royalty expense related to Pfizer. The cost of product revenue included a reserve for inventory obsolescence of $0.9 million. The inventory manufactured prior to FDA approval of TYRVAYA Nasal Spray was charged to R&D expense. And as a result, the company expects the unit cost of product revenue will be lower until the company fully utilizes this product that was manufactured pre-FDA approval. The company started expensing pre-approval inventory in 2020 and recorded an R&D expense of approximately $4.3 million for pre-approval inventory during the year ended December 31, 2021. The company anticipates selling the remaining pre-approval inventory by the end of 2022. The company's sales and marketing expense increased by $21.8 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase was primarily due to higher payroll-related expenses of $11.7 million, inclusive of sales commission expense, as well as an increase in stock-based compensation expense of $0.5 million, both of which were primarily driven by onboarding a commercial field force in the second half of 2021. The company also incurred higher marketing -- market access, commercial and other expenses of $10.1 million in anticipation of, and in connection with, the U.S. launch of TYRVAYA Nasal Spray. The company's general and administrative expenses increased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The increase is primarily due to higher G&A expense of $3.8 million related to accounting, consulting, legal and other professional expenses incurred in connection with the credit agreement, as well as the company's transition from a clinical stage to a commercial-stage company. The company also incurred higher payroll-related expenses of $2.4 million, including recruiting expense due to an increase in headcount to support an ongoing efforts to commercialize TYRVAYA. The company's research and development expenses decreased by $6.2 million during the three months ended December 31, 2021, compared to the same period in 2020. The company's decrease in R&D expense is primarily due to the company receiving FDA approval of TYRVAYA Nasal Spray in October 2021. The company expensed inventory prior to receiving FDA approval and expensed approximately $3.5 million as R&D during the three months ended December 31, 2020. The company also incurred a fee of $2.9 million in connection with the New Drug Application submitted to the FDA in December 2020. The company incurred interest expense of $2.6 million during the three months ended December 31, 2021, primarily related to the credit agreement with OrbiMed. Interest expense included contractual interest of $1.7 million, as well as noncash expense of $0.9 million related to the amortization of loan commitment fees and accretion of other long-term debt-related costs. The company had no interest expense during the three months ended December 31, 2020. Now as we turn to our outlook, for 2022, our goal is to continue to achieve broad ECP and patient experience with TYRVAYA, including both optometry and ophthalmology offices, in order to reach the total addressable dry eye market opportunity of TYRVAYA Nasal Spray. We anticipate the three large national commercial plans will make their coverage determinations by the midpoint of the year. While we await such coverage determinations, we will continue to provide patient-assisted programs to support eligible commercial patients in gaining access to TYRVAYA. With that overview of our financials, I will now turn the call back over to the operator to open up the line for questions. Questions & Answers: Ken Cacciatore -- Cowen and Company -- Analyst Hey, team, looks like a really good and clean initial launch. I was wondering if you would wanna help us a little bit with maybe the revenue pacing. I know consensus, I believe, is around $30 million. And I know there's only a few of us analysts that are formally involved in the consensus, but I think it's around $30 million. So I was wondering if you could just kind of hold hands with that number, how we should be thinking about it. And then also, we've been doing clinician checks and getting very good feedback. But I guess, you could help us, as you would have a better sense of the early retention metrics, maybe the -- be able to definitively let us know how you're seeing some of the retention numbers and patients returning. So those are my first two. I'm going to ask one more, if I could, though. Could you talk, John, a little bit about any refinements or learnings of your patient support system? Obviously, early days, but wondering if you're already tweaking it a bit. Anything that seems to be working very well or you've needed to change? And with that, I'll go back in the queue. Thanks so much. Jeff Nau -- President and Chief Executive Officer Great. Thanks, Ken, for the questions and very thoughtful. So maybe what we could do is we'll just take those in order. So I'll turn it over to Dan to just talk about the numbers for the year. And then, we'll go into retention and have a discussion about John's experience with the bridge programs and the different patient services. Dan Lochner -- Chief Financial Officer Yeah. Great. I would say on revenues, while we haven't really provided official revenue guidance, I would say we think about it very operationally, focus in terms of our sales reps that are out in the field doing a great job. And I would say the focus very early on and throughout 2022 will really be about growing that eye care practitioner count, and we have goals internally for what we expect to achieve on a weekly and monthly basis. And so, I think, it really starts with getting those ECPs onboard on a monthly sequential basis and then starting to look at what the right pattern is on an NRx basis per month and then what we then start observing on that pull-through on resell rate. And so, to kind of wrap that all up, we see it sequentially building through the quarters for the entire year as we start working through that total target population that we've identified, which is roughly 20,750 targets. And I think, it would be great to have John kind of speak about how we're really going after that target base and how that's been building through the quarters. And I think, what you'll see, at least for Q4, we've hit about 1,900 of those ECPs in respect to the 20,750. And we'll continue to really work through that population of ECPs and really build that NRx and resell rate, the TRx, and then really playing out on revenue. The other dynamic, of course, is always on gross to net. And while we're not providing official guidance on gross to net because our focus really is on that volume and share component throughout 2022, I would say there is that first-half component related to the majority of patients in the first half expecting to be on that bridge program, which has a discrete impact to gross to net. And then, with our guidance, which is focusing on coverage determinations for the big three PBMs by the midpoint of the year, that transition from bridge over to commercial insurance will have a positive benefit discretely on that line in relation to gross to net, which would kind of tie up to your question on kind of how revenues would flow from a price and volume perspective through the year. John Snisarenko -- Chief Commercial Officer Yeah, thank you, Dan. This is John. You asked a question around retention rates and then refill rates. We've been very, very pleased to date with the metrics we've been seeing in that space. Even patients that had been prescribed in early November, we started seeing early refill rates. I could quote that if you look at our blended refill rates with retail pharmacy and our digital online pharmacy, they're hovering around 64%, 65%. So we're very pleased with patients that are coming back and getting the refills. We are getting very, very nice position, as well as patient feedback, and we are hoping to continue that trend throughout 2022. I think, part of that as well is your third part of your question around patient support programs, we out of the gate wanted to really employ a lot of technology around our patient services to TYRVAYA. So we're trying to make it very easy for that patient to navigate that journey through the prior auth and benefit investigations to get them to enroll into the program through QR codes in the offices, online, as well as other digital means. So because of that, we've been getting very, very good high enrollment rates and good fill rates that come through that program. So in terms of tweaking, we're continuing to put out more patient materials to surround sound the patient with different ways to enroll into the program. But overall, we're very, very pleased with how the program has been going. If the patient is deemed insured, but not covered, they automatically popped into our bridge program that they were appropriate patients and are able to get that script fulfilled and get experience with TYRVAYA. So we'll keep monitoring the patient services program, but so far, we've been very, very pleased. Ken Cacciatore -- Cowen and Company -- Analyst Great. Thanks so much. Appreciate it. Jeff Nau -- President and Chief Executive Officer One thing I will add on, Ken, comment there is as we think about TYRVAYA as a product, when we think about the current marketplace and what it offers to patients, from an immunomodulator perspective, patients will go on a course of an immunomodulator. If they're not happy with the outcome at the end of that course, they're transitioning off, and they're likely either going on to another product or another device or another modality, but very rarely are they coming back. So we see a very low number of patients come back to the original therapy. I think, that the one thing to really keep in mind with TYRVAYA is it works so quickly to provide the patient relief, and it has such a differentiated mechanism of action that we are excited to look forward into the future to see how patients interact with the product. It's going to be a very different interaction than you would see with an immunomodulator because I do think not only will we have solid refill rates, but we will have people coming back to the product in those later years. And so, we're excited about that. And then, I would -- I'll just throw one comment out there for my team back at the office. Our patient services program is, bar none, one of the best I've ever seen. And it is going very well in the field. And so, kudos to the team for putting together such a great program. Ken Cacciatore -- Cowen and Company -- Analyst Great. Thanks so much. Joe Catanzaro -- Piper Sandler -- Analyst Hey, guys, thanks so much for taking my questions, and congrats on the progress here. So maybe just to follow up, I think, Dan, you mentioned you guys had some internal benchmarks, I'm sure, on a bunch of things. But I'm wondering if you can maybe help put into context the early penetration in terms of the number of unique prescribers you've seen relative to your target ECP pool and where your early expectations were there. And then, I'm wondering what aspect -- and maybe it's something you just alluded to, Jeff, what aspect of the product profile do you see as resonating the most? And how do you go about fully leveraging that? And maybe I have a follow-up as well. Dan Lochner -- Chief Financial Officer Yeah. Maybe I'll start with it on my end. As you saw in the press release, we had achieved 1,900 unique writers in the quarter, which is just under about 10% of the targets that we are going after with our sales force of 162 sales reps. And so, I think, we had great progress in the quarter just under about nine weeks. And so, as we look at benchmarks of prior therapies that have come to market more recently, I think we're in a great place for where we had expected us to land. Of course, we also understood that this is a new way of treating dry eye disease. So really communicating the benefits with the nasal spray. And so, I think, we're quite pleased with where we landed and continue to work toward that 21,000 target count as we progress throughout the year. Jeff Nau -- President and Chief Executive Officer And maybe what I'll add on to -- the second part of the question there is some of the things that are resonating. I think, one of the things that's really been exciting about the launch of this product is patient feedback has been really great. And so, we've been excited to not only hear stories from the field, see posts on social media of patients going out on their own and talking about the product. And just really, it's a great product to launch where you're having that patient feedback come back to the teams and to those folks that have put such hard work into getting the product out there into the marketplace because it's really why we do this and it really drives the team. So I think, one of the things that we hear that is something that's really encouraging is just the patients stating that they really like the profile. They like the way it's making their eyes feel, and it's just differentiated in the way that it's able to be used. So we do hear stories back of people who are unable to deliver a topical eye drop. And this is another option for them because maybe they don't have the dexterity or they're elderly and they're just not able to put a drop into their eye, and so they're able to use nasal sprays. And the other thing that we hear in the field often is the physicians are not getting patients calling back and complaining. And so, that's also really important for us. But again, we're very early in the launch. So we have many patients that haven't been on the product for more than a few months. So we're excited to see how the long-term feedback is. But for the moment, we are really encouraged by the feedback or sometimes lack of negative feedback coming back from the patients. Joe Catanzaro -- Piper Sandler -- Analyst Great. And if I maybe just squeeze in a quick follow-up. I think, you said you guys have maybe covered about 50% of your target ECPs. Can you maybe speak to what percent of those have been given a sample? And how soon after sampling are you seeing ECPs write a script? Thanks. John Snisarenko -- Chief Commercial Officer Yeah, no, thank you, Joe. Great question. Part of our strategy is really to introduce TYRVAYA into the office practice with the prescriber base, the technicians, the staff that are involved with training, the patients and so on prior to actually sampling because we want to make sure that the product is taken appropriately and the patient gets the best possible experience they can with the nasal spray. So we handed out quite a few samples, probably over 100,000 samples since launch. But we want to make sure that we hand them out appropriately and that installation with that office has actually taken place before that sampling is initiated. So so far, that's worked well for us because we've seen a higher proportion of patients that tried a sample, see if it works for them before they're getting into our patient hub and actually getting that prescription filled. So that kind of connection has been very, very positive with that approach. Joe Catanzaro -- Piper Sandler -- Analyst OK, that's helpful. Thanks, again, for taking questions. Patrick Dolezal -- LifeSci Capital -- Analyst Great. I'm just curious how the availability of generic cyclosporine has impacted discussions with payers, if at all. Were there any modifications to negotiations with Express Scripts as that approval came to light? I'm just curious if you expect any impacts going forward as you onboard other payers. And then, I have a follow-up as well. John Snisarenko -- Chief Commercial Officer Yeah, Patrick, thanks for your question. We've seen kind of early mixed reactions from the payer community on how they're going to manage the generic entry of cyclosporine. And with the early listing with ESI, they're actually covering TYRVAYA across their formularies with only a traditional step, sort of an artificial tear. So that's what I mean by mix. Some of the payers are kind of waiting until more than one generic comes out, and they'll take a look at the dry eye space or they're not really managing the dry eye space as closely. And others are going to evolve a little quicker. So we're able to modify our approach. We are ready for a generic to be on the market or not with. And that's the way our negotiations are going with the major PBMs. And our goal is to get access for TYRVAYA on a level playing field with the branded therapeutics. And our differentiation along with our strategic contracting will help us get there. Jeff Nau -- President and Chief Executive Officer And one other comment, Patrick. As you well know, generic entry into the marketplace doesn't change the dynamic that exists where patients cycle off many of these drugs, whether it be for lack of effect or side effects or whatnot. And so, that certainly will not change. So we were planning on generic entry coming. I think, we've been planning for a long time, but it's been always in the back of our mind, and so the team is ready. Patrick Dolezal -- LifeSci Capital -- Analyst That's helpful. Thanks. And as it relates to just drug launch surrogates, there's not a ton in the dry eye space really, but obviously, we do have these eye drops. Just curious to hear any similarities and differences that might be worth pointing out. And just if you could comment on the role of coverage and driving drug adoption in the dry eye space generally, that would be helpful. I'm curious if there's a tipping point where you feel that the amount of coverage really will drive adoption, 50% if it's a bit more. I would love to hear your thoughts there. Thanks. John Snisarenko -- Chief Commercial Officer Yeah, Patrick, in regards to the Xiidra launch, we did see very quick uptake. Well, this was back in 2016. They had very early access to the commercial insurers, and they launched with 280-plus reps. We are very pleased with the number of reps we have and the trajectory we're seeing with TYRVAYA. We are on track in regards to the payer negotiations. And in fact, the ESI listing was an early listing for us. So we will get to that point that we're expecting in terms of broad base of writers, the eye care professionals prescribing TYRVAYA. We just won't be out of the gate as quickly as you saw with the Xiidra launch. I could tell you, versus the latest two launches, we're very pleased with how our trajectory is going versus kind of the more recent entries. But it was a different space back in 2016, less managed, and also they were second entry at the time after Restasis. Patrick Dolezal -- LifeSci Capital -- Analyst That makes sense. Thanks for taking the questions. Chris Neyor -- J.P. Morgan -- Analyst Great. Thanks for taking the questions. So first one is on me -- for me is just wanted to get a bit more details on the Express Scripts contract. So really just thinking about what's the mix between preferred and non-preferred coverage within those 26 million lives that you had estimated. And within the Express Scripts plan, are there -- is there potential for additional pickup of patients and additional contracting that would either add additional patients or move more patients toward preferred access? And when talking about that kind of mix -- the mix of customers, what type of co-pay should we be thinking about for most of these patients? I think, I have a couple of follow-ups after that. John Snisarenko -- Chief Commercial Officer Yeah, Chris. No, thanks. In regards to ESI, whether preferred or non-preferred, in terms of access whether you're listed preferred or non-preferred, the key criteria is you have to have tried and failed on an artificial tear for all of the branded products here. So as you mentioned in the last part of your question, the out-of-pocket is a difference between the Tier 3 and a Tier 2. And pretty appropriate patients, commercial patients, we definitely buy down that out-of-pocket to be very competitive with the leading branded product out there. So we feel our 26 million lives that are covered are on a level playing field with regard to the leaders out there. And that -- those are the majority of the larger plans within ESI, but we will continue to work with signing on some of the downstream plans that ESI covers -- sorry, that Ascent covers as well and through ESI. So the tiering for us is not a disadvantage. We feel we're going to be very competitive with the two major brand leaders out there. Chris Neyor -- J.P. Morgan -- Analyst Great. That's helpful. And then, you kind of touched on the refill rates and also maybe you could just discuss your confidence in being able to hit that commercial coverage for CVS Caremark and UnitedHealth by the middle of this year. And then, aside from maybe overall script trends, any other KPIs that we should be watching for the launch in the coming weeks and quarters? John Snisarenko -- Chief Commercial Officer Yeah, no, Chris, in regards to the refill rates, we've been very pleased with the kind of 60%, 65% rate of refills we've been seeing. We feel that based on the product profile, as well as the services we offer to make sure that both the prescriber base, as well as the patients are supported through the clinical experience with TYRVAYA. In regards to some of the other PBMs, we are in the middle of negotiations with them. We are still on track to have coverage determinations by midyear. And we are ready to negotiate whether they're going to be managing the generic space or not. We feel we're going to be very, very competitive to be able to get TYRVAYA listed and get the majority of those commercial lives covered by midyear of '22. Chris Neyor -- J.P. Morgan -- Analyst Perfect. Appreciate the questions. Jeff Nau -- President and Chief Executive Officer Thank you, operator, and thanks to everyone for joining the call with us today. As I mentioned in my opening remarks, we are extremely pleased to announce that TYRVAYA Nasal Spray, indicated for the treatment of the signs and symptoms of dry eye disease, is currently in its first full quarter of launch for patients and eye care providers in the U.S. We are extremely excited for the potential of significant growth that remains ahead. Our vision and focus on bringing innovative and transformative ophthalmic disease treatments to patients and building Oyster Point Pharma into a best-in-class eye care company remains our primary goal as a company. In closing, I want to thank everybody for joining us tonight and to have a great evening. Duration: 41 minutes Call participants: Dan Lochner -- Chief Financial Officer Jeff Nau -- President and Chief Executive Officer John Snisarenko -- Chief Commercial Officer Ken Cacciatore -- Cowen and Company -- Analyst Joe Catanzaro -- Piper Sandler -- Analyst Patrick Dolezal -- LifeSci Capital -- Analyst Chris Neyor -- J.P. Morgan -- Analyst More OYST analysis All earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2523,\n        \"min\": 525,\n        \"max\": 32540,\n        \"num_unique_values\": 7950,\n        \"samples\": [\n          7952,\n          6261,\n          8233\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker_clean\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2869,\n        \"samples\": [\n          \"CRWD\",\n          \"AME\",\n          \"WRLD\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08086309609059461,\n        \"min\": -0.6091428484235492,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 9985,\n        \"samples\": [\n          0.011530214945978869,\n          0.10530232274255087,\n          -0.07811321228005444\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 19
        }
      ],
      "source": [
        "df.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 20,
      "metadata": {
        "id": "mMhRZ6YSj7ZB"
      },
      "outputs": [],
      "source": [
        "original_df_path=\"/content/drive/MyDrive/Earnings call prediction/original_stock_price_reaction.csv\"\n",
        "final_df_path=\"/content/drive/MyDrive/Earnings call prediction/cleaned_stock_price_reaction.csv\"   #for model training\n",
        "df.to_csv(original_df_path,index=False)\n",
        "df_cleaned.to_csv(final_df_path,index=False)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "zuS6wSXGmeEO"
      },
      "source": [
        "# **3 Exploratory Data Analysis**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 21,
      "metadata": {
        "id": "nzQlDQ3MmRUJ"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "import numpy as np"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 22,
      "metadata": {
        "id": "IEAO02orm_er",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 660
        },
        "outputId": "5391381e-b293-4c60-d2d6-d1b88c769f32"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript            Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel...  2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta...  2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc...  2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon...  2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel...  2019-08-07 08:30:00   \n",
              "\n",
              "    Date_only                                         Clean_Text  word_count  \\\n",
              "0  2020-08-27  At this time, I would like to turn the confere...        5623   \n",
              "1  2020-07-30  Brian G. Harris -- Senior Vice President and C...        4755   \n",
              "2  2019-10-23  Tina Correia -- Vice President, Investor Relat...        8917   \n",
              "3  2019-11-06  Joining us today are BBSIs President and CEO, ...        8286   \n",
              "4  2019-08-07  I would now like to turn the conference over t...        4611   \n",
              "\n",
              "  ticker_clean  Price_change  \n",
              "0         BILI      0.035078  \n",
              "1          GFF      0.116154  \n",
              "2         LRCX      0.142022  \n",
              "3         BBSI      0.029891  \n",
              "4         CSTE      0.249623  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-f8e59c8e-b7d8-4fee-b763-e0b9a76366f4\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>Clean_Text</th>\n",
              "      <th>word_count</th>\n",
              "      <th>ticker_clean</th>\n",
              "      <th>Price_change</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>At this time, I would like to turn the confere...</td>\n",
              "      <td>5623</td>\n",
              "      <td>BILI</td>\n",
              "      <td>0.035078</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>Brian G. Harris -- Senior Vice President and C...</td>\n",
              "      <td>4755</td>\n",
              "      <td>GFF</td>\n",
              "      <td>0.116154</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>Tina Correia -- Vice President, Investor Relat...</td>\n",
              "      <td>8917</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>0.142022</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>Joining us today are BBSIs President and CEO, ...</td>\n",
              "      <td>8286</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>0.029891</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>I would now like to turn the conference over t...</td>\n",
              "      <td>4611</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>0.249623</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-f8e59c8e-b7d8-4fee-b763-e0b9a76366f4')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-f8e59c8e-b7d8-4fee-b763-e0b9a76366f4 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-f8e59c8e-b7d8-4fee-b763-e0b9a76366f4');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-35fb1b2e-9693-4f5e-a157-555c862d4fe5\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-35fb1b2e-9693-4f5e-a157-555c862d4fe5')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-35fb1b2e-9693-4f5e-a157-555c862d4fe5 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_analysis",
              "summary": "{\n  \"name\": \"df_analysis\",\n  \"rows\": 10913,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4311,\n        \"samples\": [\n          \"Jul 8, 2021, 11:00 a.m. ET\",\n          \"Feb 13, 2020, 9:00 a.m. ET\",\n          \"May 18, 2022, 9:00 a.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"NYSE: AVB\",\n          \"NASDAQ: THRM\",\n          \"NASDAQ: ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q4\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"AVB\",\n          \"THRM\",\n          \"ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10031,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nGood afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the PTC's 2022 first quarter conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open for questions.\\nI'd now like to turn the call over to Matt Shimao, PTC's head of investor relations. Please go ahead.\\nMatthew Shimao -- Head of Investor Relations\\nHello. Thank you, Julian, and welcome to PTC's results call for Q1 of fiscal '22. On the call today are Jim Heppelmann, chief executive officer; and Kristian Talvitie, chief financial officer. During this call, PTC will make forward-looking statements, including guidance on future operating results.\\nBecause such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in PTC's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission, as well as in today's press release. The forward-looking statements, including guidance provided during today's call are valid only as of today's date, January 26, 2022, and PTC assumes no obligation to update these forward-looking statements.\\nDuring the call, PTC will also discuss non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures can be found in today's press release made available on our website. With that, I'd like to turn the call over to PTC's chief executive officer, Jim Heppelmann.\\u00a0 \\nJim Heppelmann -- Chief Executive Officer\\nThanks, Matt. Good afternoon, everyone, and thank you for joining us. Turning to Slide 3, I'm pleased to share that PTC delivered another strong financial performance in fiscal Q1. We executed very well, building on the momentum we saw in Q4.\\nTo simplify things, please note that throughout my prepared commentary, I will only discuss growth rates in constant currency. ARR came in at $1.507 billion, which was better than the $1.5 billion we had guided to at the recent Investor Day. That represents 16% growth, 11% of which was organic. Adjusted free cash flow was also strong at $145 million, which was up 20% year over year and better than the $140 million expectation we said at the Investor Day.\\nWe're off to a very strong start in fiscal 2022. Turning to Slide 4. Of particular note was our bookings strength. Bookings were up double digits organically and high teens overall against the very strong COVID bounce back quarter we saw in Q1 of fiscal '21 when bookings grew more than 30% over the prior year.\\nTo put it in perspective, given the tough comparison against Q1 of last year, we had planned bookings to actually be down slightly, inclusive of Arena. So this performance was more than 20% above plan. I know that some analysts and investors had voice concerned that the restructuring work we did in late Q4 and throughout Q1 would distract us, but obviously, we didn't see that. The strength was broad-based across direct sales and resellers and was achieved with no megadeals.\\nRockwell came in ahead of their part of our plan, too, which was great to see and suggest my concerns of them being distracted and may prove overstated. Arena contributed the inorganic element of bookings growth, with another strong bookings quarter, coming in above plan as well. With the Arena acquisition getting round tripped here in Q2, Arena becomes part of the organic results going forward and their low 20s growth rate will then add another tailwind to the organic results. Arena has been a great acquisition.\\nBookings growth was particularly strong in PLM, and in both Europe and Americas. From a macro perspective, global PMIs remain an expansion territory, while digital transformation and SaaS continue to grow in importance as secular drivers. The interest in digital transformation in SaaS has been driving strong bookings for what is very sticky software, which when layered into a recurring revenue model that is atypical of industry peers, has allowed PTC to deliver performance in excess of market growth rates. This happened right through the pandemic, especially in the large core business that represents about 70% of our ARR, and we fully expect it to continue going forward.\\nThese factors gave us confidence to raise the lower end of our ARR guidance range, which at the new midpoint basically means we've rolled our Q1 beat forward. Now let's take a look at the ARR performance by geography on Slide 5 before turning to business units. In Q1, we saw a strong ARR performance across all geographies. Our ARR growth in the Americas was 19%.\\nAll product segments grew with key growth drivers being the acquired Arena contribution and the velocity business unit overall, layered on top of another strong quarter in the core CAD and PLM business. In Europe, our ARR growth was 13%. We saw strong results across the board in Europe, with the strongest drivers of the growth being our digital thread growth and core businesses. Europe has the largest mix of channel versus direct and the resellers continue to perform well.\\nOur ARR growth in APAC was 14%, with growth primarily driven by our digital thread core business. Next, let's take a look at the ARR performance of our various business units, starting with the digital thread group on Slide 6. In our largest product segment, digital thread core, we delivered yet another double-digit performance in Q1 with 11% growth. Within this, CAD and PLM, both grew double digits, with strong growth across all three geographies.\\nThis is the 17th consecutive quarter of double-digit ARR growth in the core business. And as we roll out our more aggressive SaaS strategy, I expect we'll see many more. In the digital thread growth, which is IoT and AR, we saw ARR growth of about 14%, consistent across both elements. This was in line with our plan and the mid-teens near-term growth expectation we set at the recent Investor Day.\\nWhile this level of growth remains accretive to company growth, we continue to expect an acceleration of growth into the 20s as we get into the back half of the year. The biggest driver of growth in Q1 was from expansions, especially in Europe and APAC. We believe market conditions in IoT are improving, and we like the way the pipeline for our new DPM offering is developing through both PTC and Rockwell channels. For AR, we continue to see a tremendous level of interest, but the market remains nascent.\\nPerhaps most importantly, the formation of the digital thread business unit at the start of FY '22 has driven important initiatives to increase our focus on cross-selling of IoT and AR into the core CAD and PLM customer base. FSG had a great Q1 with 6% ARR growth. The expansion deal we recently announced with the U.S. Air Force, both increases and extends this key relationship for up to five more years.\\nContracts like this demonstrate the value that our customers are realizing from Servigistics and other FSG products such as retail PLM and ALM. You may remember, I noted at our Investor Day that having FSG grow in the mid-single digits rather than flat would be a helpful upside growth driver. So I'm pleased to see FSG post another strong quarter. Let me run through a couple of quick customer anecdotes to give you a sense for our digital thread customers and how they rely on us.\\nOn Slide 7, MAN Energy Solutions is the world's top provider of large-bore engines in turbomachinery for the maritime and energy industries. The company manufactures complex parts in nearly every engine they make must meet unique customer requirements. Before implementing Creo, they relied on manual outdated processes that slowed design and production. With Creo, they've been able to transition from 2D to a full 3D model-based approach.\\nCreo's broad range of tool path automation capabilities enable them to save time in the programming of the tool pass used to machine the large complex engine parts, greatly increasing efficiency in transitioning from design to production. Turning to Slide 8. You may have noticed we announced a deal with -- we announced that the German company, Scheffler, has expanded its relationship with PTC, and I'd like to share a bit of the back story. Scheffler has been a longtime Creo customer and has successfully deployed Windchill within engineering.\\nBut back in 2017, one of our PLM competitors announced a large PLM deal with Scheffler that appeared to cap PTC's expansion opportunity. But that system didn't ultimately stick as Scheffler has now decided to consolidate on PTC systems with Windchill being the backbone and is broadly deploying our solutions in their standard out-of-the-box fashion so that Scheffler can participate in the full power of our digital thread portfolio. I'm very excited about this collaboration and the further expansion that Scheffler is exploring with our IoT and AR offerings. On Slide 9, you'll see how IMA Group, our global business that delivers packaging machines, services, and solutions to a wide variety of industries, was looking for a way to expand their control room offering to help their customers improve overall equipment effectiveness and reduce downtime.\\nAs longtime users of PTC's Creo and Windchill, IMA decided that ThingWorx was the ideal IoT solution for their initiative and that Kepware could provide connectivity not only to their machines, but to the other vendors' machines deployed alongside them. IMA has successfully launched new revenue streams by enabling 24/7 monitoring of customer production lines and improved OEE by up to 16%. The Vuforia integrated with ThingWorx is the platform of choice for the U.S. Air Force training initiatives.\\nSlide 10 highlights the work that PTC partner, Vectrona has done with the U.S. Air Force. With finite training resources and limited capacity, the U.S. Air Force set out to incorporate augmented reality into their maintenance and munitions training.\\nVectrona using Vuforia Studio worked with the U.S. Air Force to create immersive 3D AR experiences for phones, tablets, and the HoloLens 2 that are designed to accelerate learning, improve work performance and facilitate remote training. The improved training shows better engagement and information retention with continuous and repeatable task training available regardless of the system or aircraft type. Turning to Slide 11, the velocity business ARR growth in Q1 was more than 650% due to the inclusion of Arena and 53% organically, which would be Onshape.\\nIf you were to add Arena's pre-acquisition results into the prior year to get a better pro forma comparison, then you'd have the velocity business unit growing at 28% in Q1. That 28% is a mix of Onshape growing at 53% and the larger Arena business growing in the low 20s. Growth of both Onshape and Arena is multiple times higher than market rates, clearly demonstrating that industrial companies see the benefits of SaaS. We continue to ramp investments to expand technology leadership and to broaden the geographic presence of our velocity businesses.\\nOn Slide 12, Beta Technologies, a leading developer of next-generation electric aircraft for the cargo and logistics market, sought a cloud-native product development platform where everyone would be working with one single source of truth without the workflow restrictions of traditional file-based design systems. Beta turned to Onshape because of how it enables real-time collaboration, allowing the engineering team to work from any location while streamlining their communications during the design process. To profile Arena customer, Potrero Medical, on Slide 13, is a predictive health company developing the next generation of medical devices, leveraging smart sensors and artificial intelligence. Potrero needed a scalable quality management system to support its growing product development and compliance needs, including satisfying FDA audit requirements.\\nArena was the right solution, offering a cloud-native QMS with a quick implementation, leading to ECO cycle time reduction of 30% and nonconformance improvement of 20%. As a final topic, I'd like to give you a quick update on our SaaS acceleration initiative on Slide 14. We've made tremendous progress in the past 90 days since we announced the more aggressive strategy. We've launched our SaaS program management office, which was modeled after the very successful approach we used to drive our subscription transition several years back.\\nOur field organizations transition to the new two-in-a-box customer success organization model without missing a beat. We converged our cloud and tech support organizations with product development to deploy the DevOps type of approach you see in virtually all SaaS companies. We've made good progress advancing our offerings, especially the Windchill multi-tenant version, which will go into production shortly this quarter, and we made good progress preparing the SaaS conversion offerings that will power the hundreds of lifts and shifts that will happen in the coming quarters and years. We have more work to do, but we're certainly up and running.\\nThe time for SaaS has arrived in our industry and PTC is very well positioned. We're already the SaaS leader in our space with continued strong SaaS growth in Windchill and FSG and high levels of growth in our cloud-native velocity business unit. Sharing the Atlas SaaS platform, we have a dual strategy to win with Onshape and Arena powering a new agile product development approach, while we transition our digital thread portfolio and existing customer base to SaaS to elevate the platform strategies that so many larger companies have. To wrap up on Slide 15, I'm pleased with PTC's position and the opportunity that lies ahead.\\nQ1 gave us a strong start to what we expect to be our fifth consecutive year of double-digit ARR growth. Our portfolio of products is unique and compelling and obviously aligns well to customer demand. Our results have been consistently strong for many quarters, but we're poised to accelerate growth as the SaaS tailwind blows harder in coming quarters and as we gain more momentum with our IoT and AR initiatives in the back half of the year. We're poised to drive higher levels of profitability, too, following the organizational changes we've already implemented and as our start-up businesses continue to mature up their J curves.\\nThe company has never been in a better position to create shareholder value. With that, I'll turn it over to Kristian for more details on the financial results.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nThanks, Jim, and good afternoon, everyone. Before I review our results, I'd like to note that I'll be discussing non-GAAP results and guidance, and growth rate references will be in both constant currency and as-reported rates. So turning to Slide 17, we delivered constant currency ARR of $1.507 billion, which is 16% growth year over year and slightly exceeded our Q1 guidance of $1.5 billion. On an organic constant currency basis, this is 11% growth.\\nFX was an approximate $11 million headwind in Q1, so our as reported ARR was $1.496 billion. Our SaaS products in both the digital thread and velocity business units saw a continued strong growth in Q1, with growth rates similar to what we discussed at our recent Investor Day. This is in combination with continued strong growth of our software-only sales. As of Q1, our SaaS portfolio is now 15% of our total ARR on a constant currency basis.\\nQ1 free cash flow of $134 million grew 21% year over year and includes $11 million in restructuring and other related payments. Adjusted free cash flow was $145 million and was slightly ahead of the $140 million we discussed at our Investor Day. Q1 revenue of $458 million increased 7% year over year. As we've discussed previously, revenue is impacted by ASC 606, so we do not believe that revenue growth rates are indicative of our underlying business performance but would rather guide you to ARR as the best metric to understand our top-line performance and cash collection.\\nFX only impacted revenue by about $1 million in Q1. So our revenue on a constant currency basis was $459 million. Q1 non-GAAP operating margin of 35%, compared to 36% in Q1 of 2021. While this is a strong result, it's still worth pointing out that because revenue was impacted by ASC 606, other derivative metrics such as gross margin, operating margin, and EPS are all also impacted.\\nSuffice it to say that our COGS and opex came in in line with our expectations in Q1, and we continue to maintain good discipline on our operating expense structure. I would like to point out that our GAAP results reflect a gain of $9.8 million related to our investment in Matterport. And we're also slightly reducing the range for expected P&L charges from approximately $45 million to $50 million, down to $40 million to $45 million for the full year. And coincidentally, we're also reducing the range of expected cash payments for the restructuring and other from what was previously $50 million to $55 million, down to $45 million to $50 million for the full year.\\nFor guidance purposes, we will continue to show $50 million as the cash payments and the adjusted free cash flow reconciliation. But as payments come in lower, then we would just expect actual free cash flow to come in higher. There's no change to the $450 million adjusted free cash flow target. Moving to Slide 18, I'll begin with our balance sheet.\\nWe ended Q1 with cash and cash equivalents of $296 million. In addition, at the end of Q1, we had medium-term investments of $87 million, primarily related to our investment in Matterport. Our gross debt was $1.45 billion with an aggregate interest rate of about 3.2%. In Q1, we used $120 million of cash to repurchase shares.\\nWe also had an additional $5 million of repurchases, which settled early in Q2. For the remainder of fiscal '22, we will focus on delevering and looking forward to FY '23 in an ongoing go-forward basis, assuming our debt-to-EBITDA ratio is below three times, we will continue to target to return approximately 50% of our free cash flow to shareholders via share repurchases. Turning to Slide 19. We post a data table to our IR website that has our financial statements, as well as ARR detail by segment.\\nIn that file, we share both constant currency and as-reported ARR. As a reminder, when we calculate constant currency, we use our current year plan FX rates and restate history to the same rates. So here, for example, on this slide, you can see our Q1 constant currency ARR of $1.507 billion and the actual as reported ARR of $1.496 billion. This is important to remember in the context of our guidance because we provide guidance at the planned rate.\\nWe believe this is the best way to evaluate the top-line performance of our business because it removes FX fluctuations from the analysis, positive or negative. With that, I'll move on to guidance on Slide 20. As Jim mentioned, we're raising the low end of our full year constant currency ARR guidance by $10 million. The new range is now $1.625 billion to $1.660 billion.\\nThis essentially reflects rolling our Q1 overperformance through the remainder of the year. We're now expecting constant currency ARR growth of 11% to 13% in fiscal '22. It's worth pointing out that based on FX rates at the end of Q1, we would expect a $13 million headwind against that full year ARR guidance. For Q2, we're setting constant currency ARR guidance of $1.540 billion to $1.550 billion.\\nThis is 12% organic constant currency growth at the midpoint. On an as-reported basis, the FX impact we're calculating based on the FX rates at the end of Q1 is a $12 million headwind in Q2 compared to the constant currency guidance. Moving to free cash flow. We're maintaining our full year free cash flow target of $400 million.\\nThis includes approximately $50 million of restructuring and acquisition-related payments. The majority of these payments are related to the reorganization we announced in Q1 with some residual payments primarily related to our Seaport move for which we took the accounting charge in prior periods. So our adjusted free cash flow target for fiscal '22 remains $450 million. Fiscal Q2 adjusted free cash flow is expected to be approximately $155 million.\\nWe expect to make approximately $20 million in restructuring and other related payments in Q2, bringing our free cash flow to approximately $135 million. Moving to revenue. We're also taking the low end of the full year revenue guidance up by $20 million. This reflects both the strength in software and strength in the professional services business that we saw in Q1 and the related forecasts for the full year.\\nSo for fiscal '22, our net revenue guidance range is $1.870 billion to $1.975 billion. The year-over-year growth rate range is now 3% to 9%. Our ASC 606 makes revenue very difficult to predict for on-premise subscription companies, hence the wide range. Note that revenue variability has -- this is from 606, has no impact on ARR or its related cash generation as we continue to primarily bill customers annually upfront regardless of term length.\\nWe continue to expect more than 60% of our annual free cash flow generation to occur in the first half of the year. Collections are stronger in the first half, and we expect expenses to increase as we ramp hiring in our SaaS investments throughout the year. We're wrapping up on Slide 21 with the free cash flow model that we use and went into some depth on at our recent Investor Day that you can see here. I know many of you use model free cash flow using the indirect method.\\nHowever, given the complexities related to revenue recognition due to 606, this is difficult to do. The model we show here has proven quite effective. The table shows fiscal '21 actuals compared to the model we shared at Investor Day compared to our current guidance. Let me take you through the model focusing on the non-GAAP column on the right and starting at the top.\\nFirst, we're showing the midpoint of our as reported ARR guidance of $1.630 billion, which is different from the constant currency guidance that we gave due to the $13 million FX headwind and is also $5 million lower than what we showed at the Investor Day. We use it as reported here because it's a better reflection of the cash we expect to generate. You can also see that we have increased the perpetual license revenue forecast slightly and also the professional services revenue increase that we mentioned earlier. COGS is slightly higher, reflecting the increased costs to deliver the incremental professional services revenue and the rest of the assumptions remain the same, and we still end up with our target adjusted free cash flow of $450 million.\\nObviously, this is a model based on assumptions such as the midpoint of the ARR range, the impact of FX, the pace of hiring, etc. So if some of those variables change, which they invariably will, the model will have to be adjusted accordingly. And as I mentioned earlier, if cash payments related to the restructuring coming at the low end of the range, we would see a flip from the restructuring line to the free cash flow line, but the adjusted free cash flow target would remain unchanged. But as we sit here today, we think this is a reasonable view of how we expect the year to shape up.\\nSo with that, I'll turn the call over to the operator, and we can begin Q&A.\\u00a0\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] We ask the analysts to please limit themselves to one question only. If you have any additional questions, please return to the queue. Thank you.\\nYour first question will come from Andrew Obin from Bank of America. Please go ahead. Your line is open.\\u00a0\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nHi, yes. Good afternoon.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Andrew.\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nJust a bigger picture question. I apologize, I missed the first couple of minutes. You know, we hear a lot about supply chain constraints. And frankly, we're hearing that this might extend the run-in terms of PMI expansion.\\nSo what are you hearing in terms of sort of as you have conversations about PLM and in terms of adoption? What kind of conversations are you having with your customers? And do customers have awareness of sort of supply chains being gummed up for longer? And are you seeing this having any discernible impact on what kind of conversations you're having with people?\\nJim Heppelmann -- Chief Executive Officer\\nAndrew, it's Jim. No, actually, it's not really a frequent topic in our conversations because -- well, first of all, since you said you missed the first minute, one of the things I pointed out is that our bookings came in very, very strong, and I explained about 20% higher than planned. So we had a very, very strong bookings quarter. And notable in that was PLM, although, frankly, the strength was broad-based.\\nI think the key thing to remember is that PLM is really associated with preparing product data in engineering that will then subsequently be used in manufacturing and perhaps in aftermarket service. And it's collecting data from supply chain partners and so forth. But production problems in a supply chain don't necessarily impede the collaboration during the engineering and the preparation for production process. So I think people are saying like, maybe I can't get chips to complete the product, but that doesn't mean I should stop designing the next one because if it does, then I'll fall behind.\\nSo I think that our view would be that the product development process has largely been unaffected by the supply chain process. Now some other things, we talked about how perhaps COVID had an impact on IoT, perhaps the supply chain a little bit, although I think muted compared to COVID. So to me, the supply chain thing is a fairly small factor in our results. We just see very little correlation between what's happening out there with supply chain problems and what's happening with our pipeline and frankly, with our bookings.\\nOperator\\nYour next question comes from Yun Kim from Loop Capital. Please go ahead. Your line is open.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nHey, Yun.\\nYun Kim -- Loop Capital -- Analyst\\nThank you. Hi, Jim. Can you just talk about the IoT business, you know, in terms of the large deal activity? What kind of trends are you seeing there? Obviously, you are expecting that business to accelerate in the back half -- second half of the year. If you can talk about whether that confidence is coming from the, you know, improvement in the large deal activity? Or is it just the overall volume of the activity around IoT? And then also, if you can just comment around deal size activity around the AR business as well.\\nThanks.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I think deal sizes are sort of unchanged from previous trends. If you think -- what are we looking at when we project forward how IoT and AR will perform. Well, we're looking at the bookings, let me say, at the pipeline that will drive bookings, and for IoT and AR was quite strong.\\nWe're looking at the backlog. Last year, bookings actually had improved over the prior year. And bookings that went into backlog or -- I'm sorry, what we call deferred ARR, were quite high. We were well ahead of our deferred planned number as we actually did last year.\\nSo you could imagine we've got more, and if you want to call it, backlog waiting for us. And then what other initiatives are we doing? So for example, our DPM launch, I think, will be materially positive for our IoT results. It will drive bigger deals. It will drive better value propositions.\\nIt's really software that's ready to turn on and get value from as opposed to a platform. And then the other thing is, Troy Richardson talked at our Investor Day about organizing better for cross-sell. And I think if we look backwards, maybe we had pivoted too much toward new logos, which are great. I mean, new logos are a wonderful thing.\\nBut we probably have low-hanging fruit yet to pick within our installed base of CAD and PLM accounts. So I think it's really this combination of a strong-looking pipeline, good-looking trends, awaiting us in the deferred backlog and then these other initiatives kicking into place, DPM and cross-sell that I think will all be very helpful as we proceed through the year. And again, I want to remind everybody, we set the expectation that the two handle would materialize in the back half of the year and that you wouldn't see it in Q1 and Q2. So we sort of feel like this was as we had predicted just mid-December a couple of weeks ago.\\nOperator\\nYour next question comes from Jason Celino from KeyBanc Capital Markets. Please go ahead. Your line is open.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nHey. Hi, Jim. Hi, Kristian.\\nJim Heppelmann -- Chief Executive Officer\\nHi, Jason.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nSo one question on maybe the SaaS Windchill, you know, launch. It seems like it's coming along, you know, nicely, and we could see something maybe go GA this quarter. Have you had a chance to maybe, you know, discuss this with customers? How is the pipeline shaping? Or is it maybe better to think that the pipeline might start to form once we do go live?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nNo, we have, for sure, started talking about it with customers. I mean, ramping up that process. We've got to educate a lot of people and they, in turn, have to educate customers. But we've certainly made some progress, and I can tell you the customer interest is actually quite high.\\nYou should know that actually, customers were pushing us a little bit to get going with such initiatives -- so I feel like the demand is there. And in fact, again, just reflecting on what we told you, that business has been growing about 30%. And Kristian mentioned we posted another quarter just like that, without us really invoking the new strategy yet. So there's lots of demand.\\nWe're just looking for a model where we can promote the demand because we like the margin profile better. And that's what's coming into place here in Q2.\\nOperator\\nYour next question comes from Adam Borg from Stifel. Please go ahead. Your line is open.\\u00a0\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nGreat. Thanks so much. And maybe just two quick ones. Just on the Scheffler win that you announced yesterday and highlighted on the call earlier.\\nOne of the things I thought was really interesting in the press release was this opportunity around some more vertical-specific or market-specific solutions targeting either automotive or industrial companies. So maybe, Jim, if you could just talk about that. And maybe just as a quick follow-up, just maybe for Kristian. Any way you could talk about this transition, it's great to get the early feedback on the SaaSification efforts, but any way to comment on, you know, how much this has contributed to bookings or the pipeline, at least qualitatively? Thanks so much.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I'll get the first part of the question. Kristian, you can take the second part. Yeah.\\nSo Scheffler is a great account. And as I mentioned back in 2017, it appeared they were going in a different direction, and now they've decided to come back into the fold. And honestly, they did that for two main reasons. One is that they really want off-the-shelf technology.\\nThe other competitor had told them this low-code, no-code story, and they tried that out and decided that's not really what they want. They don't want to develop their own solutions. They want to deploy standard out-of-the-box software that all works together. And then they want to engage in partnerships with the vendor, in this case, PTC to talk about how those solutions should evolve to be more and more powerful to meet their needs.\\nSo yeah, I'm very excited. I'm in the middle of that relationship myself. And yes, what's going to come out of that is technology that fits better and better, for example, for the automotive supply chain, which is a place where we have a lot of customers. So it's a great win or win back, maybe I should say, and a great partnership going forward that's going to produce a lot more business for us in years to come.\\nAnd sorry, the second part of the question was around the transition to SaaS and how that's manifesting itself in terms of pipeline and activity? Is that right, just making sure I got that right.\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nExactly. Any way to qualitatively comment from, you know, either bookings or a pipeline perspective?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, remember, I mean, the bookings that we just reported were for Q1, and Q1 is really when we actually just announced the acceleration of it. So I would say there's actually a limited impact in the actual bookings result here in Q1. That said, as I mentioned, we continue to see strong demand for the SaaS properties that we have.\\nThat's both in velocity and the digital thread. And so those products continue to grow at a rate higher than our software-only products. And now as the program is pushing ahead, we expect to see demand and pipeline generate, especially with the new Windchill launch coming out here and the program continuing to pick up speed internally.\\nKristian Talvitie -- Chief Financial Officer\\nMaybe, Adam, I could just add. We launched this phase 3 strategy 90 days ago on the earnings call. And there's nothing we've seen since that makes us any less bullish than we were back then. I mean it looks like a really nice opportunity for PTC, and we're pushing forward ahead as aggressively as we can because we'd like to bring that very promising upside growth driver, you know, closer in.\\nSo it has a bigger impact on '23 and '24 and so forth than it would otherwise have had.\\u00a0\\nOperator\\nYour next question comes from Jay Vleeschhouwer from Griffin Securities. Please go ahead. Your line is open.\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nThank you. Hello. Hi, Jim. Hi, Kristian.\\nA couple of things. With regard to the strength you noted for PLM, at your partner conference six months ago, back in the summer, management presented to the channel, your concept that PLM was no longer just an engineering vault that it was becoming memorial, what you call, multisystem, multidiscipline concept. And the question is, to what extent is that broader, more diverse view of PLM a current part of new business or in the pipeline for new business as compared to the more conventional historical way of thinking about PLM? By our calculation, we are already the second-largest brand by revenue in PLM, and maybe talk about what some of the drivers are to that? And then just a quick clarification you referred earlier to cross-sell. At the Analyst Meeting last month, in the slide deck, you referred to cross-sell 10 times and relatedly account-based selling.\\nPTC is often over the years, talked about cross-sell, but maybe talk about what's different this time in terms of resources and programs across your various segments and your new customer segmentation model.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, on your first question, Jay, you know, you are always very pressy on, you've been watching this industry for a long time. When we say multisystem, multidiscipline, what we're really talking about is an enterprise system. And so what's happened in the last couple of years is PLM has graduated from being an engineering data management system to being an enterprise system that contains the system of record for the product definition.\\nAnd so if you're in manufacturing, well, you need to know the product definition. If you're in procurement, you need to know the product definition. If you're all on an installation or a support call, you probably need to know the product definition. So definitely what's happened is that the enterprise deployments of Windchill are multiple times larger than the engineering deployments of Windchill.\\nSo something that's been driving growth for some years now is that the new deals we're taking are more and more frequently enterprise deals and they're larger. You may remember, last quarter, I told you we took the largest deal we had taken to date from a med device company. And the second thing that's happening is, we're circling back to those companies who had deployed the engineering solution like say, Scheffler, and we're upselling them to the enterprise solution and turning that into a much bigger opportunity for us. So definitely, that's a real thing, and it's been driving the momentum we've seen in Windchill for years.\\nAnd frankly, there's a lot of it out ahead of us even before we start talking about SaaS. The upsell from a departmental solution to an enterprise solution is a driver, taking that whole enterprise solution to SaaS is a whole another growth driver that's on top of that and sort of orthogonal to it. And then on the account-based selling, there's two ways to look at that. Cross-selling into your accounts is a great thing.\\nYou have established relationships. It's much easier to sell another product to an existing customer than to sell a new product to a new customer or a first product to a new customer. At the same time, we like new logos. So it's really always about the balance of how much do you invest in new logos pursuits versus how much do you invest in selling more to the companies who know and trust you.\\nAnd I think perhaps with IoT and AR, we realized we had over pivoted toward new logo, which is just generally speaking, less productive selling, you might imagine. And so the reason we formed this digital thread group, which brought CAD and PLM and IoT and AR together under Troy Richardson, was to really lubricate how these products work together and how we position them together and to be able to start anywhere and sell up and down that chain. So it's a good strategy. It's one that we -- it's a muscle we've developed well over the years.\\nWe really built the Windchill business, largely by cross-selling to the Creo base. And I think this is going to be something that will help us a lot to kind of get the right balance of new logo pursuits in cross-sell.\\nOperator\\nYour next question comes from Ken Wong from Guggenheim Securities. Please go ahead. Your line is open.\\u00a0\\nKen Wong -- Guggenheim Securities -- Analyst\\nThank you so much for taking my question. Jim or Kristian, I wanted to perhaps dive into the double-digit organic bookings growth. You know, I couldn't help and notice you guys also had a very large Servigistics expansion deal with the Air Force. I mean how much of that was already in expectations? Or did you get some boost there from timing shifts or anything of that nature?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Let me tell you, none of that actually contributed to the double-digit growth because that was a Q4 deal. You know, we released it when we had approval to release it, and I commented on it because it was, you know, an important customer and so forth. And let me say that deal, again, that was closed in Q4, both represented five years of extension, but also about a 50% growth in a ramp that happens over -- I think it's three years.\\nSo it roughly goes from a $10 million run rate to a $15 million run rate over three years and stays there for a couple more. That's what the contract contemplates. So some of that will come into ARR in Q4 of this year, but the bookings actually were in Q4 last year. So that strength -- the strength we saw in Q1 was exclusive of that Air Force deal, which just means it was really great strength.\\nSo anyway, it was hard to pin down where the strength comes from because it came from CAD. It came from PLM. The IoT number was actually pretty decent. It didn't all go into ARR.\\nAnd then, of course, the velocity numbers and the FSG numbers. So it was broad-based in all geographies and really in all product lines.\\nOperator\\nYour next question comes from Matt Broome from Mizuho Securities. Please go ahead. Your line is open.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Matt.\\nMatt Broome -- Mizuho Securities -- Analyst\\nThanks, man. So Jim, I mean, I guess, just on that -- sorry, just deal that I can just mention. Given the importance of supply chain management right now, are you seeing like ramping demand to the solution elsewhere? And sort of following on from that, is there a chance that FSG ARR could actually accelerate on the back of that demand beyond the sort of the mid-single-digit level and actually become sort of more strategic in a way?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean that's one of the points, Matt, that I brought up at the recent Investor Day is that we've generally modeled FSG to be roughly flat, flat about plus 1% to 2%. But it's actually been performing. I think last year, Kristian, wasn't up 7%, FSG.\\nIt was up 6% here again in Q1. So yes, we're overperforming and Servigistics is one of the key drivers. And then the second one probably is retail PLM, which has also been doing fairly well. So definitely, there's some -- I think we'll be conservative and leave the FSG sort of guidance where it is in the near term, but I do like overperforming it because it's a growth driver.\\nThe FSG business is about the same size as the IoT and AR business. So every point of growth we get there is pretty meaningful.\\nOperator\\nYour next question comes from Matt Hedberg from RBC Capital Markets. Please go ahead. Your line is open.\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nYeah. Thanks. This is Matt Swanson on for Matt. I'll kind of follow up on a piece of both Adam and Jay's questions.\\nSo looking at the Scheffler announcement, I think the thing I was really interested in was the idea around standardization and the idea around end-to-end. So could you talk a little bit about your customers' desire around standardization? And clearly, this product road map has really expanded your TAM, but I think one of the upside areas something we -- you know, maybe the holy grail of the transition would be more competitive displacements. And I'm just curious if you're starting to hear, you know, any early or more talk around that because you're building something so differentiated.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean, for sure. So the standard thing, I think maybe over the last couple of years, industrial companies have realized that they should be using software, not developing it. And so we saw this in our IoT business, and it's been why we've been heading up the stack with solutions like DPM is, customers would like to buy the software and use it, not buy some kind of a platform and create it because they just don't really know how to create it if I'm frank.\\nSo Scheffler had gone down the path of kind of like I said, low-code sort of environments and came back to standard products. And then the end-to-end thing, for sure, the CAD data that's created in Creo and managed in Windchill gets used, for example, in augmented reality, manufacturing, and service instructions much later and in a different part of the company if it's all well managed. And that connectivity from IoT, well, let's say, from CAD to PLM to IoT to AR is what we call the digital thread. And so we actually see so much interest in this that we kind of organized around that principle.\\nLet's stop presenting these products as kind of independent things and let's shine the light on how well they work together in an end-to-end solution. And by the way, how they're all ready to go. That this is something that turn on and use. And that's really what one Scheffler over, but I can tell you, Scheffler is not unique at all.\\nAnd it's really -- we're organizing to respond to that. SaaS is helpful, by the way, because if you want a lot of technology working end to end, it'd be better not to ship at all to the customer side because it gets complicated. The customer would like to just use it, not set it all up and care and feed for it on-premise.\\nOperator\\nYour next question comes from Saket Kalia from Barclays Capital. Please go ahead. Your line is open.\\nSaket Kalia -- Barclays -- Analyst\\nOK, great. Hey, guys. Thanks for taking my question here. Hi, Jim.\\nHey, Jim, maybe -- hey, Kristian. Jim, maybe for you, it was great to hear the PLM strength this quarter in bookings. With other companies that have done shifts like this, there's always a risk, I guess, of customers behaving differently, right, whether that's slowing purchases to see what's coming or maybe pulling forward purchases before something new comes out. Now just to be clear, it doesn't sound like that happened here.\\nBut can you just stress test that for us a little bit? And what you sort of look at to sort of manage what is, you know, more choices for our customer to make. Does that make sense?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Are you referring -- just let me clarify, are you referring to like SaaS choices being new choices or more broad --\\u00a0\\nSaket Kalia -- Barclays -- Analyst\\nYeah, that's right, yeah, Windchill. No, Windchill specifically.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So keep in mind, Saket, we have been selling Windchill as SaaS for some time. Remember, the phase 1, phase 2, phase 3 thing. So since phase 1, we've been selling Windchill, and we showed you, it's got a three-year growth CAGR of 30% in SaaS.\\nSo the customer demand is strong. It's just -- on the PTC side, we need to pivot to multi-tenant because in the single-tenant model we just don't have the profitability we like. So the demand is strong. The customers are buying it.\\nKristian mentioned we had another strong quarter. So it really is, we'd like to meet that demand with a solution that's more efficient for us to operate on behalf of the customer. And that's what phase 3 multitenant really is all about. Now when it becomes more efficient for us, we can then lean in on the promotion and marketing of it, because we haven't really done that.\\nSo we've been servicing demand, not driving it. And with phase 3, we think there's an opportunity to drive demand and, you know, the preliminary data we've seen this quarter suggest customers are very responsive, both to buying new systems that way, but also to lifting and shifting the previous systems they bought and giving them to us to operate and serve back to them in a SaaS model.\\nOperator\\nYour next question comes from Joe Vruwink from Baird. Please go ahead. Your line is open.\\nJoe Vruwink -- Robert W. Baird and Company\\nGreat. Hi, everyone. Just to go back to bookings, does the strength this quarter absent mega deals suggest anything about either the demand environments or maybe just the health of your mid-market and SMB customers? And looking ahead, are there going to be certain things you think about or track when contemplating, you know, the probability of more mega deals or maybe the larger ARR contributors for PTC, maybe, you know, being a bit more represented in future bookings?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nKristian, let me again take a stab at that and maybe you'll find things to add. So I think if you look at the bookings, again, they were phenomenal, and it's hard to pin down. It wasn't one geography. It wasn't one product.\\nIt was all geographies, all products. So I think it tells us that the end market is very healthy. And I would say, for two different reasons. On one hand, the PMIs are in good shape.\\nThat's helpful. On the other hand, the interest they have in the digital thread, digital transformation story, and the interest they have in SaaS is secular. That interest is not related to the PMIs, it's kind of independent of them. And so I think that we're just in a very healthy situation where industrial companies are leaning in on trying to get more digital.\\nThey see PTC as having a fairly unique and compelling portfolio, and they're interested in engaging and trying to make their companies more efficient. I can tell you, at Scheffler, for example, it's one of the top initiatives in the company is to get more digital. And as it relates to the whole product life cycle, the partners PTC. And we see that kind of phenomenon happening in a lot of places in the industrial world.\\nSo I think it's just good, strong, secular and as well macro-environment out there right now. But I'll remind you that we've had good performance even when the macro environment wasn't so strong. So all things being equal, I like the strong macro. But we're 17 quarters in with double-digit growth in the core business, and there were a lot of bad macro quarters over the course of those 17.\\nSo I think it really is the secular driver. Kristian, anything?\\nKristian Talvitie -- Chief Financial Officer\\nYeah. I mean I agree with all that. I mean, actually, just on the big deal dynamic, you know, what we used to call mega deals. We haven't -- I think we've had four in the past four years.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, keep in mind, perpetual drove bigger upfront purchases and subscription or SaaS tends not to.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYeah, which is my point that we've been seeing good strong bookings performance and bookings growth, you know, even with the absence of what used to be a fairly regular occurrence back in the perpetual days, like we really don't see a lot of those.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah, it's a good healthy business. OK. Next question.\\nOperator\\nYour next question comes from Blair Abernethy from Rosenblatt Securities. Please go ahead. Your line is open.\\u00a0\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nThanks very much. Guys, just maybe a quick question on -- around partnerships, in particular. I wonder if you could just give us a little deeper dive into how things are going with Rockwell and as well on the simulation side with Ansys?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So the state of the partner economy is good and, you know, Microsoft, I could put on that list, is also strong. With Rockwell, you'll remember in the past quarters, I had said we should take a bit of a conservative posture as it relates to what Rockwell would contribute to PTC's numbers here in fiscal '22. And we did that because Rockwell had made a big acquisition.\\nYou know, Rockwell never completely agreed with me on that. Their own public commentary kind of indicated they didn't worry too much about that. And in Q1, they were right. So we're pleased to see that Rockwell's contribution was solid in Q1 and starting to feel pretty good about the year.\\nI'll tell you one thing is this DPM solution appears to be a very good fit with Rockwell. And in fact, their Calypso alarm is probably lined up to be our strongest partner in promoting DPM. So we're very happy with that. Calypso has a long-term relationship with PTC that even predates their acquisition by Rockwell.\\nSo great alignment around DPM. Again, DPM is a high-value up-to-stack solution that drives bigger deal sizes, and we think will be a very sticky solution. So lots of optimism around that. With Ansys, we continue to differentiate now with best-in-class simulation.\\nSo whereas simulation some years back would have been viewed as a soft spot for PTC. Now it's a strength. If we're competing against Autodesk or Siemens or Dassault, nobody is going to have a better simulation story than PTC because nobody has a better simulation story than Ansys, and Ansys products are built into PTC products. So that's been going well.\\nAnd then, of course, with Microsoft, that partnership is performing well and poised to get a lot bigger because as we bring more stuff aggressively to SaaS, a whole lot of that is going to land on Azure. So I think all three partnerships are alive and well and as important as ever and helping us achieve the kind of results that we're achieving.\\u00a0\\nOperator\\nYour last question comes from Sterling Auty from J.P. Morgan. Please go ahead. Your line is open.\\nSterling Auty -- J.P. Morgan -- Analyst\\nYeah. Thanks. Hi, guys. Just wondering if you could characterize with the headcount changes that you pointed out are necessary to facilitate the acceleration to SaaS.\\nWhere are you in that process? What's left to go? And kind of what's the time frame that you expect to complete that over?\\nJim Heppelmann -- Chief Executive Officer\\nYeah, Kristian, I'm thinking of the numbers we're largely done, but not completely. Eighty percent, 90% done.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYep, with the exiting.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean we'll be hiring people throughout the year. So -- but in terms of the people who are exiting, they're largely exited by now that largely happened within the first quarter.\\nSterling Auty -- J.P. Morgan -- Analyst\\nUnderstood. Thank you.\\nOperator\\nWe have no further questions. I'd like to turn the call back over to Jim Heppelmann for closing remarks.\\nJim Heppelmann -- Chief Executive Officer\\nOK. Well, thank you, all. There's a lot of good questions and, you know, I think good answers because the business is performing very well right now. ARR is doing well.\\nBookings are doing well. Free cash flow is doing well. You know, I think we executed -- through good times and bad, we executed through the changes we made over the last quarter, and we're set up to do pretty well for the balance of the year. So, we're very confident and, you know, look forward to talking to you all in 90 days if we don't happen to cross pass with you sooner in an investor event or what have you.\\nSo, thanks a lot for joining us and have a good evening.\\nKristian Talvitie -- Chief Financial Officer\\nThanks, everyone.\\u00a0\\nOperator\\n[Operator signoff]\\nDuration: 59 minutes\\nCall participants:\\nMatthew Shimao -- Head of Investor Relations\\nJim Heppelmann -- Chief Executive Officer\\nKristian Talvitie -- Chief Financial Officer\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nYun Kim -- Loop Capital -- Analyst\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nKen Wong -- Guggenheim Securities -- Analyst\\nMatt Broome -- Mizuho Securities -- Analyst\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nSaket Kalia -- Barclays -- Analyst\\nJoe Vruwink -- Robert W. Baird and Company\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nSterling Auty -- J.P. Morgan -- Analyst\\nMore PTC analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, ladies and gentlemen, and welcome to ASUR's First Quarter 2020 Results Conference Call. My name is Kathy and I'll be your operator.\\n[Operator Instructions]\\nNow I would like to turn this call over to Mr. Adolfo Castro, Chief Executive Officer. Please go ahead, sir.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and good morning everyone. Thank you for joining us on the conference call to discuss ASUR's first quarter financial and operating results. Before starting the call, I would like to express my hope that you and your families are healthy and safe in these uncertain times. As a reminder, please note that certain statements made during the course of our discussion today may constitute forward-looking statements which are based on our current management expectations and beliefs and are subject to a number of risk and uncertainties that could cause active results to differ materially, including factors that may be beyond our company's control including the impact from COVID-19. For an explanation of these risks, please refer to our filings with the US Securities and Exchange Commission and the Mexican Stock Exchange.\\nOverall, our first quarter results were good. The year began in solid footing before we started to see the impact of COVID-19 pandemic in the second half of March. It resulted in the disruption of global travel industry. Importantly, in the end of the first quarter we had healthy balance sheet which I will come back and discuss in more detail later in my presentation. I'm going to start today's presentation with some comments regarding COVID-19 and the impact on the industry, on our business, and the steps we are taking to mitigate this disruption to the best we can in this rapidly changing environment. From an industry perspective, since mid-March, many governments have issued flight restrictions in an effort to mitigate the spread of COVID-19 virus. In turn, capacity has been severely reduced and very few people are booking flights as most are in some form in lock down around the world and not traveling. With respect to our airports, the situation varies by country and could be subject to change depending upon how fast or slow the pandemic is brought under control. Colombia has been the most active and we've suspended operations at all six of our airports since the third week of March with domestic flights suspended until April 27 in accordance with the published decree and most recently extended to up to May 11.\\nInternational travels have been suspended through May 13. By contrast, in our airports in Puerto Rico and Mexico remain open, although there's significant reduced flights and passenger traffic. As a result, total passenger traffic declined sharply in the second half of March, down nearly 69% year over year between March 16 and March 31. By country, we show the margin decline in Colombia around 77%, followed by Puerto Rico down 73% and Mexico with 63% decrease [Indecipherable]. Additionally starting in mid-March, some of the airlines as well as some tenants that operate in our airports began asking for assistance either through discounts on payments owed to ASUR or by extension by payment which resulted in a higher accounts receivables in March in Mexico and Colombia, up 54% and 78% year-over-year. We are having ongoing commercial discussions with these companies with respect to their contracts.\\nMoving next to action we have taken, starting with health and safety. Following the guidelines of relevant health agencies, we have implemented health and safety protocols for both our airport employees and passengers travelling through our airports. For example, protective gear such as wearing masks is required for airport staff. We have also stepped up disinfectants and sanitization practices, once again in accordance with the guidelines of local health authorities. Lastly, where possible, we have also implemented remote working points.\\nMoving next to ensuring continuity of our business. We have introduced cost reduction initiatives across our airports. The impact of these initiatives however is not expected to be significant vis-a-vis the potential decline in passenger traffic at the majority of the cost structure is different, except for concession fees and technical assistance in Mexico which are biannual cost. We are prepared to take additional step, if needed, to respond to the evolving business environment. Now, let me talk about our financial situation. We entered this quarter in a position of strength with strong liquidity and very low principal payments required through year end. Additionally we believe the company has sufficient liquidity to meet its obligations and continue operating in the normal course of business. Our cash position ended at MXN7.8 billion which was up from MXN6.2 billion at the year-end 2019. And subsequent to the quarter end, as we further strengthen our financial positions as our subsidiary in Puerto Rico drew down an additional $10 million of its committed line of credit. The line of credit [Indecipherable] support for the capex projects we have under construction, Apelian airport in Puerto Rico.\\nWe closed the quarter with total debt of MXN15.3 billion. Although 11% high than the year-end 2019, this was due to the conversion effect from the depreciation of the peso to the dollar. As a reminder, the majority of our debt, 54% is denominated in the US dollars which is at our subsidiary in Puerto Rico. 26% of total debt was denominated in Mexican pesos and 20% in Colombian pesos. We have principal payments of only MXN432 million coming due over the next three quarters. This represents less than 3% of ASUR's total debt. With respect to that ratios, net debt to last 12 months EBITDA stood at 0.7 times at the close of first quarter '20. You can see the interest coverage ratio by country in the table we have included in the annual release this quarter.\\nNow, stepping back for more, since we began operations over 20 years ago, we have successfully navigated through many very significant challenges. From the 9/11 event in 2001 to [Indecipherable] into 2005 and 2008 and 2009 business financial crisis, H1 and H2 and the bankruptcy of 50% of airlines in Mexico which cut planes capacity in Mexico by more than half. Following each of these events, passenger traffic recovered, although recovery time varied from 13 months to 26 months and then continued to grow. Between 2000 and 2019, annual passenger traffic increased the compound annual growth rate of 6.6%, up from slightly over 10 million to historical high to over 34 million last January. We believe the COVID-19 pandemic is unique in that sense it is global event and with a broad disruption in travel and economies worldwide and could change the way of travelling in the future while a vaccine or a cure is found. Summing up this section, we have a strong balance sheet, we have generated years of consistent profitability and we exercise prudent capital management. In the sense we believe that we cannot be very prepared for an event of this magnitude, but of course given its great uncertainty on the final effects in the worldwide economy and that travel will be [Indecipherable].\\nNow turning to our first quarter results, more details can be found in the press release issued last evening. Like I mentioned this part of my presentation, let me spend with the effects of the business in late March. We believe we had solid results in the first quarter 2020. Total passenger traffic was down in most of the airports, which leads to a total passenger decrease of slightly 6% YoverY. This was primarily due to the fallout from COVID-19 and the impact of the global travel industry beginning in the second half of March. Our airports in all three countries experienced total passengers decline from a low of nearly 3% in Colombia to a high 8% in Mexico. Puerto Rico passenger traffic was down 4%. All three countries reported declines in both domestic and international traffic.\\nMoving next to the P&L highlights, revenues ex construction were relatively unchanged at 4% increase in revenues from non-aeronautical services was offset by a 3% decline in aeronautical revenues. Commercial revenues per passenger increased 11% year over year, reaching MXN116.3. This was driven by solid performance across the region. Mexico posted a good performance with an increase of 11% on a per passenger basis benefiting from the currency peso devaluation and regulated revenues. Puerto Rico posted 7% increase per passenger benefiting from peso depreciation and finally Colombia saw a 33% increase on a per passenger basis, reflecting the 43 new stores opened over the last year and currency depreciation. The main drivers were ground transportation and car rentals.\\nMoving on to profitability, reported consolidated EBITDA increased 3% from the same period over the prior year. Both periods benefited from insurance recoveries related to the Hurricane Maria. In the first quarter '20, it amounted nearly MXN124 million while last year the amount was dragging over MXN41 million. Excluding these recoveries, consolidated EBITDA was essentially flat year-over-year at MXN2.7 billion. Ex-IFRIC 12 and without taking into account insurance recoveries in both quarters, adjusted EBITDA margin increased 20 basis points to 66.7% this quarter.\\nA few comments about capital allocation. Capital expenditures were MXN353 million in the quarter. Of these, nearly MXN58 million was allocated in Mexico due to the terminal expansion of Merida airport. For the full year, and as we have discussed before, our non-prevalent plan in Mexico calls for investment of approximately MXN5.3 billion for the full year. At the current time, there are no changes to the planned continuation of the foreigners tax relief of the second one we have at Cancun airport and the beginning of the first expansion at the Merida. Our plans call for a conclusion of Phase 1 of the Merida terminal expansion and typically the second phase this year. Nevertheless, due to the COVID-19 health crisis, you may see some disruption in the construction process, attributable to stay-at-home, the combination and we have informed the government about this situation. In Puerto Rico we have made investments of MXN114 million this quarter, mainly from the connection with some major maintenance referred tax relief. Finally, capex in Colombia amounted to MXN1 million related to maintenance. Last year we concluded our committed capex was at MXN20 million. And going forward, we only expect to incur a major maintenance capex in Colombia.\\nNext, our Annual General Meeting from yesterday, shareholders approved an ordinary net cash dividend of MXN8.1 per share to be paid, subject to the Board's approval on or after May 11, 2021 in a single installment.\\nIn conclusion, we are proactively responding to the developing situation. No one can control the virus or even the economic fallout. But we can control how we react to the crisis. I am optimistic about the prospects for the future both navigating through the current crisis and in the long term recovery. I believe that we are well positioned with a healthy balance sheet. We had a solid first quarter results. We believe in the strategies that we are executing.\\nThis ends my prepared remarks. Kathy, please open the lines for questions.\\nQuestions and Answers:\\nOperator\\n[Operator Instructions]\\nWe'll go first to Alejandro Zamacona of Credit Suisse.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nThank you Adolfo, thanks for the call. Two questions from our side. The first one is on the aeronautical maximum tariff. So, considering that airlines have been negotiating with most of airports and in some cases some fees have not been charging. What could we expect for maximum tariffs in the short-term meaning the second quarter and in the immediate term, meaning year end 2020? Could we still expect tariffs to be close to the maximum level?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro, hi, good morning. Well, basically what we are seeing today is a very reduced demand. So we believe that there is no effect if we try to reduce our fees for the month of April or the month of May. So we have maintained our tariffs and we believe that we can comply with -- we have to maintain compliance toward the year end.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you. And my second question is on the non-aeronautical business. Same thing in the same context, what could we expect in the short term for commercial revenues per passenger? Have you grant any rent payments facility to payments or any deferrals? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nMost of our contracts, as you may know, they have to pay higher of the minimum guarantee payment per passenger or a percentage of sales. So if we do not have passengers, we will not have to pay rent. So it's made automatically. So in that sense, we are not reducing or adjusting the contracts.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you Adolfo.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nWe will now take a question from Fernando Sanchez of Bradesco BBI.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nHi, good morning and thanks for taking my question. My question is light of the likelihood of the GDP contraction beyond 5% I just wanted to ask if you have had the opportunity to discuss with the authorities the possibility of delaying the 2021 and the key mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. Well as you are aware, the contract has a clause that says that the maximum tariff can be reviewed in the case of Mexico in an external way. When on the Mexican GDP drops by more than 5% in a year and that's happened in fact on track. Of course with the current circumstance and the current expectations from analysts, it is possible that the Mexican GDP will drop by more than 5% this year. So in that sense, we will be we -- and the possibility of review our maximum time in an external rate. That's for next year, but not this year.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nOkay. Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nAnd now, we'll take a question from Carlos Peyrelongue of Bank of America.\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nThank you. Good morning Adolfo. Thank you for the call. On the something I couldn't hear well because of the connection but can you comment as to whether the dividend will be kept or there is the possibility of cutting the dividend until we have more sense about passenger traffic? That would be the first question. And the second would be related to cash burn, if you could give us an idea of what your cash burn is on a quarterly basis, just to get a sense of compare that primarily to your strong cash position. Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYes, of course. In the case of the dividends, yesterday we held Annual Shareholders Meeting, they have sadly approved the dividend that it was proposed MXN8.1 per share. But it was -- this was subject to the approval from the Board to the moment of the payment that's from May 11, 2021. So the Board will have to approve when this dividend will be paid. In the case of the cash burn, what I said to you during the initiative months, is that our currency structure is basically fit. The only variable pieces are the technical assistance fee and the concession fees we paid to the government. So we are working and just to remember the case of Mexico is 5% as well as in Puerto Rico, and in the case of Colombia its' 19%. So this of course will reduce -- our passenger traffic is reduced and our income gets reduced. The remaining is basically, of course, we are taking measures to try to reduce as much as we can, all the expenses in the companies. But as I said, at the end, in the overall picture, the cost reduction will not be significant in comparison with reduction in the revenues of the company.\\nOperator\\nAnd we'll run to our next question, and that will come from Andressa Varotto of UBS.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much for taking my question. So my question is if have plans to negotiate with the government postponement of the mandatory capital is this possible? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nCould you repeat the question? I couldn't hear you.\\nAndressa Varotto -- UBS -- Analyst\\nYes. So my question is if you plan to negotiate with government the postponement of mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said before, in accordance with the contract, we do not have that possibility this year. But of course, with the given standards [Phonetic] and as I said it in my initial remarks, during an expansion situation and that expansion situation is that some companies have stopped operations [Indecipherable] and that it was reactivated later on, but there was a decree from the Mexican government that also named the steel and glass that is produced in the country will be used for the project. So in that sense, at the moment it's almost impossible for us to expand our 10-year buildings without these material. So we have this situation to the government. So for the moment, what we see is that we will see some disruption in our construction process for some months and then we will have to talk about these with the government. That's what I can share with you for the moment on this respect.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nOur next question will come from Stephen Trent of Citi.\\nStephen Trent -- Citi -- Analyst\\nGood morning, Adolfo and thanks very much for taking my question. Hope that you and your family are well. Just one quick one for me, I know that it seems that Mexico apparently has not been that active in likely offering any assistance to the corporate sector. What are you hearing from Colombia? Kind of any indications from them with respect to whether aviation industry will get some sort of relief?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nSteve, thank you for your question. So in the case of Colombia in comparison with Mexico they have been more active in the measures that they have been taking. As I said here in the report they were very [Indecipherable] basically closing or sorting down everything as from March 23. And that can be seen in terms of results. In the case of Spain and the active they have in comparison with active cases we have in Mexico. So their curve is decreasing or at least flattening while the Mexican curve is still increasing. In terms of what they have said for our industry, we have been closed since March 23 and they have issued decrees in that respect. Maybe this week, there was a new announcement from the President expanding the process of shutting down everything. As I said in my remarks, for the case of domestic aviation that will be close up to May 11 and in the case of international up to May 30. It is important to remember that in the case of Colombia, 85% of aviation is domestic and 15% is international. That's what we know as of today. Of course all of these may change depending on how fast or how slow they can control the virus in their country.\\nStephen Trent -- Citi -- Analyst\\nThank you very much Adolfo. Apologies I couldn't hear all of your remarks. But no indication at this point for example that Columbia's planning a kind of tax relief for aviation or something along those lines offering kind of financial support.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nWell we have not heard anything above that yet.\\nStephen Trent -- Citi -- Analyst\\nOkay. Appreciate that. I'll let someone ask a question. Thanks Adolfo.\\nOperator\\nAnd next we will go to Gabriel Himelfarb of Deutsche Bank.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nHi, good morning, thanks for the call. I have two questions. The first one is concerning about account receivables. Can you give us like a number or approximate number about what's the total of the sales coming from airlines and in specific from Interjet and American Airlines and my second question is do you think you could obtain some waivers in opex sorry capex your current MDP in Mexico and could you will be able to extend the life of the concession in Colombia?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. In terms of the account receivables you can see those in our report, revenue increase in the case of Mexico and Colombia, most of the increase is coming from the land industry. I do not have the details of American Airlines and Interjet you are requesting. In terms of the capex, as I said before, we have informed the government about this current situation. We don't know if they are going to react in that respect. But of course it's going to be almost impossible for us to construct and expand our buildings with that material. So more or less what I say to you.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nOkay, thank you.\\nOperator\\nAnd now we will go to Ruben Lopez of Santander.\\nRuben Lopez -- Santander -- Analyst\\nHi Adolfo, thanks for the call. My question is on commercial revenues. Sorry if you commented on these. But I understanding Cancun operating in just one terminal. So I want to confirm you how are your operations there in Cancun and what are the implications on commercial operations? Are there any penalties with the tenants? What are negotiations here? That's the first one. And the second one is related with the same topic. When we see commercial revenues and we kind of try to compare current levels versus what would be the fixed amount or the fixed part of the minimum payment. I mean can you give us any sense of the guidance here? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nOkay. As you have said, yes, in the case of Cancun, we have closed two terminals and we are just operating today in terminal 4. So all the operations of airport have been concentrated there in order to reduce on one side the expenses and of course on the other side be better prepared in the case of these reduced demand. All the stores are working in the case of terminal 4. So terminal 4 is operating as it was before the event. As I said before, most of the contracts, the financial contracts we have with the tenants are related to a minimum guarantee payment passenger. So once again, they do not have, let's talk about one of the deals that is closed. So if they do not have passenger traffic in terminal 2, they almost have to pay the rent. Of course when they operate in terminal 4 their operations will be in the accordance with the amount of passengers we have in that facility. So I would say terminal 4 is operating normally.\\nRuben Lopez -- Santander -- Analyst\\nThank you. And when you compare, sorry, the current level of commercial revenues versus what would be the minimum payment from the contract, can you give us any idea on that?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said, minimum payment -- the contract is on a per passenger basis.\\nRuben Lopez -- Santander -- Analyst\\nPerfect, thank you.\\nOperator\\n[Operator Instructions]\\nAnd we will now go to Jorge Larocco of Morgan Stanley.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nHi Adolfo, good morning. Thank you for the questions. It's two questions, actually a pretty general question, I was just wondering if you could provide more color on what are the main initiatives regarding our cost reduction efforts. How are those working down, your payment reductions on paid leave of absence, maintenance cost, utility costs, etc. and how are those playing out so far? Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThe main initiatives of course are related to in the case of Cancun in the terms of amounts. So we these key terminals closed, we are not burning the same amount of energy as if they were open. Also in the case of Cancun, we are in the process to shut down and one of the runway because today in accordance with the [Indecipherable] it's not needed. So, that runway will be turned off in terms of light at night also reducing their energy we will have to pay. And in terms of some other measures we are taking, adjusting some of the contracts of nature or mainly maintenance in the case of the buildings are closed and to try as much as possible to reduce operating cost and expenses. But I once again at the end, most of our cost is fixed. So if we apply the cost structure of the company, the most important lines are personnel and utility costs as we have said so. In the case of personnel, we are maintaining the personnel for the event or the crisis and in the case utilities, we are trying, as much as we can to try to reduce that.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nThanks so much Adolfo. Stay safe and have a good day.\\nOperator\\nAnd with that, that does concludes the question and answer portion of today's conference call. I would like to turn the call back over to Mr. Castro for closing remarks.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and thank you again for participating in our fourth quarter results conference call. On behalf of ASUR, we wish you good day and until we meet, be safe. Good bye.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 34 minutes\\nCall participants:\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nAndressa Varotto -- UBS -- Analyst\\nStephen Trent -- Citi -- Analyst\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nRuben Lopez -- Santander -- Analyst\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nMore ASR analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nHello, and welcome to the Globus Medical fourth quarter and full year 2021 earnings call. [Operator instructions] I will now turn the call over to Brian Kearns, senior vice president of business development and investor relations. Mr. Kearns, please go ahead.\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nThank you, Chris, and thank you, everyone, for joining us today. Joining today's call from Globus Medical will be Dave Demski, president, and CEO; Dan Scavilla, executive vice president and president of Ortho; and Keith Pfeil, senior vice president, and chief financial officer. This review is being made available via webcast accessible through the investor relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements.\\nOur Form 10-K for the 2021 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP.\\nWe believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available on the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Dave Demski, our president, and CEO. \\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Brian, and good afternoon, everyone. Globus finished an outstanding 2021 with a strong fourth quarter performance. Revenue for the year was a record $958 million, an increase of 21% over 2020 or $169 million in growth. To put that in perspective, our growth dollars alone would have ranked us in the top 10 spine companies in the world.\\nRevenue in 2021 was 22% higher than 2019, an outstanding performance in itself, given the disruption caused by COVID but magnified further by a recent independent research report showing that each of the other top 6 spine companies actually had sales declines over that same time period. We achieved record sales and growth while maintaining industry-leading profitability, generating a record $2.04 in non-GAAP EPS, a 42% increase over 2020, and adjusted EBITDA of 34.6% even as we invested heavily in INR, trauma, and competitive recruiting. Revenue for the quarter was $250 million, up 7% over 4Q '20 as COVID-related headwinds remained strong throughout the quarter. Non-GAAP EPS was $0.49 per share, a 16% decrease compared to the artificially high 4Q '20.\\nNot only were business travel and surgeon education activities severely curtailed last year, several other nonoperational factors, as Keith will expound upon in his remarks, also impacted the decline. Adjusted EBITDA in the fourth quarter was a strong 34%. Enabling technology continues to gain momentum, producing a record $25 million in revenue for Q4, an increase of 40% over 4Q '20. For the full year, enabling technology revenue was $81 million, an outstanding 100% increase over 2020.\\nThe clinical superiority of ExcelsiusGPS is the primary factor driving this growing momentum. Robotic utilization, which is the number of cases performed per installed robot, was at an all-time high in 2021. And nearly 30,000 procedures have been completed using ExcelsiusGPS technology since launch. Our spinal implant business continues to experience the flywheel effect of an increasing number of robots being sold combined with increasing utilization of each robot.\\nOur U.S. spine business grew by 3% in Q4 as COVID-related shutdowns had a significant impact throughout the quarter. We saw this trend continue into January, but all signs point to a rebound commencing late in Q1. For the full year, the U.S.\\nspine business grew by 18% as we continued to take significant market share. Robotics pull-through, coupled with contributions from recent product introductions and competitive recruiting, were all factors driving growth. Our international spine implant business grew by 9% in the quarter, a remarkable result in light of COVID impacts and an ongoing drag from Japan. Due to the impact of strategic moves we made in Japan last year, we expect to see continued declines there through the first half of 2022 with growth to follow off a reset baseline.\\nThis should result in accelerated overall international growth in the second half of this year. Trauma revenue was up 32% in the fourth quarter and 39% for the full year. Competitive recruiting and new product launches are driving growth. The Anthem Mini Frag system was launched on a limited basis in Q4 with excellent feedback from surgeon users.\\nWe are proceeding to full launch in Q1 and have a series of impactful product launches planned for the first half of 2022. The clients have launched the Excelsius 3D imaging system on a limited basis later this quarter with a full launch following in late Q2 or early Q3. There is tremendous anticipation and excitement about this technology among surgeons, and we already have double-digit orders signed. The Excelsius ecosystem, Globus Medical's unique combination of robotics, imaging, and freehand navigation that provides a seamless, scalable, and unmatched clinical experience for surgeons is about to become a reality.\\nI'm extremely proud of our team's performance in 2021, record growth and profitability, exciting, clinically impactful new technology introductions, and an unmatched focus on providing value to surgeons and their patients. Thank you for a great year. I will now turn the call over to Keith.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you, Dave, and good afternoon to everyone joining us for today's call. Globus capped off a record 2021 with a robust Q4 performance despite ongoing COVID-related disruptions and shutdowns. For the full year, 2021 revenue was $958.1 million, growing 21.4% as reported. On a day-adjusted basis, sales grew by 22.1%, with two fewer selling days in the U.S.\\nand international. Net income was $149.2 million, resulting in fully diluted earnings per share of $1.44. Non-GAAP net income was $211.4 million, generating a record $2.04 of fully diluted non-GAAP earnings per share. Adjusted EBITDA was 34.6% for the year, and we generated a record $219.4 million of free cash flow for the full year.\\nQ4 '21 revenue was $250 million, growing 7.1% as reported and 8.5% on a day-adjusted basis with one less selling day in the U.S. and international compared to the prior-year quarter. Net income was $15.1 million, and non-GAAP net income was $51.1 million. Our Q4 diluted -- fully diluted earnings per share was $0.14, while our fully diluted non-GAAP earnings per share was $0.49.\\nAdjusted EBITDA was 34.1%, and we generated $59.2 million of free cash flow for the quarter. Taking a deeper dive into sales. Q4 U.S. revenue was $213 million, 7.2% higher compared to Q4 of 2020 driven by our INR and U.S.\\nspine businesses. International revenue for Q4 was $37.1 million, growing 6.8% over the prior-year quarter led by growth in spinal implants despite lingering COVID impacts and the impact of our strategic changes in Japan as Dave mentioned earlier. On a constant currency basis, international revenue grew by 8.7%. Q4 gross profit was 75.3% versus 73.9% in the prior-year quarter.\\nThe 140 basis point improvement was driven primarily by nonrepeating inventory reserves in the prior-year quarter and was consistent with our expectations noted in our Q4 2020 earnings commentary. Full year 2021 gross profit was 75%, compared to 72.4% in the prior year. The increase in full year gross profit is primarily the result of lower inventory reserves and operational and supply chain efficiencies, partially offset by sales mix. Looking ahead to 2022, we project a mid-70s gross profit rate.\\nResearch and development expenses in Q4 were $51 million or 20.4% of sales, compared to $15.2 million or 6.5% of sales in the prior-year quarter. The increased spending is primarily reflective of in-process research and development acquired during the quarter. Adjusting for these costs, Q4 2021 research and development expense was $16.7 million or 6.7% of revenue, in line with the prior-year quarter as a percentage of sales, but $1.5 million higher driven by incremental investments in headcount across our spine, INR, and trauma businesses. Our full year 2021 research and development expenses were $97.3 million or 10.2% of sales, compared to $84.5 million or 10.7% of sales in the prior year.\\nAdjusting for the acquisitions made in both periods, research and development expenses were $63 million or 6.6% of sales in 2021, compared to $60.1 million or 7.6% of sales in 2020. The increase in spending is reflective of our continued investment in research and development to foster future growth and is consistent with comments made earlier in the year. We expect our R&D expenses to be approximately 7% of sales in 2022. SG&A expenses in the fourth quarter were $106.6 million or 42.6% of sales, compared to $92 million or 39.4% of sales in the prior-year quarter.\\nThe resulting increase is reflective of higher sales compensation and benefit costs as well as increased travel and training expenses driven by the resumption of normalized travel levels following the COVID-19 impacts experienced in the prior year. Full year SG&A expenses were $408.1 million or 42.6% of sales, compared to $354.8 million or 45% of sales in the prior year. The resulting decrease as a percentage of sales is reflective of leverage on fixed costs as a result of the higher volumes when comparing against the COVID impact in 2020. The income tax rate for the quarter was 23.8%, compared to 14.9% in Q4 of 2020 with the resulting increase driven primarily by lower tax benefits associated with stock option exercises.\\nOur full year 2021 income tax rate was 17.3%, slightly lower than the 18.8% in 2020 driven primarily by the nonrecurring tax treatment related to a 2020 acquisition, partially offset by lower tax benefits associated with stock option exercises. Looking ahead to 2022, we expect our effective tax rate to be approximately 20% for the full year, which assumes no significant changes in the current U.S. tax policy. Fourth quarter net income was $15.1 million, and non-GAAP net income was $51.1 million.\\nQ4 diluted earnings per share was $0.14, and non-GAAP diluted earnings per share were $0.49, compared to $0.58 in the prior-year quarter. The quarter-over-quarter decrease is driven by more normalized levels of travel, trainings, and meetings noted above or noted earlier as well as nonoperational items, primarily a higher tax rate as previously mentioned, higher stock compensation expense, and lower interest income. Looking ahead to 2022, we are expecting a mid-30s adjusted EBITDA rate. Full year diluted earnings per share were $1.44, and non-GAAP diluted earnings per share were $2.04, reflecting a 42.2% increase over 2020 primarily related to higher sales volumes following the 2020 impact of COVID-19, partially offset by approximately $0.09 of nonoperating headwinds related to a higher share count and lower interest income.\\nQ4 adjusted EBITDA was 34.1%, compared to 36.2% in the prior-year quarter. Full year 2021 adjusted EBITDA was 34.6%, compared to 29.4% in 2020. Net cash provided by operating activities were $76.3 million for the fourth quarter and a record $276.3 million for the full year 2021. Free cash flow was $59.2 million for the fourth quarter and a record $219.4 million for the full year 2021.\\nThe company remains debt free. At this time, the company is establishing full year 2022 guidance. We are projecting full year 2022 sales guidance of $1.025 billion, representing 7% growth versus 2021. We are guiding to a full year fully diluted non-GAAP earnings per share of $2.10, representing 3% growth versus 2021.\\nI note that the 2022 guidance includes approximately $0.10 of nonoperating headwinds, including higher shares worth $0.04, a higher tax rate worth $0.03, and higher stock compensation expense worth $0.03. Adjusting for these nonoperational factors, our 2022 guidance would have been $2.20 or 7.8% higher than 2021. Overall, we view this guidance as appropriately conservative and reflective of the current operating environment around COVID and inflation-related impacts. Our 2021 results represent our teamwork, our commitment, and our focus on execution.\\nWe continue to differentiate ourselves in the marketplace. And it is a testament of the hard work and dedication of each of our Globus employees. We remain excited for the future as we continue on our mission of improving patient care. Operator, we will now open the call for questions.\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] Our first question comes from Matt Miksic of Credit Suisse. Your line is open.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks so much for taking the questions and congrats on a really strong finish to a pretty amazing year, given the circumstances. I wanted to follow up on some of the comments around EPS guidance, in particular. As you pointed out, there are some items that ex those items, up 7% to 8%.\\nCan you talk a little bit about where in your guidance you're contemplating things that some of the other companies in the space have talked about like rising input costs, staffing challenges, labor costs, freight, etc., things that generally are driving operating costs up a little bit? Maybe give us a sense of how those figure into your guidance? And I have one quick follow-up.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks. This is Keith speaking. So we projected our guidance at $2.10. And as we look at the year, we see inflation as a market event.\\nEveryone is experiencing it, and we have it baked in our numbers. But when you step back and look at the $2.04 and the $2.10, I commented on the $0.10 of the nonoperating headwinds. But the other things that are impacting the business as we think about getting back to more normalized levels of spend are really the travel and the trainings that go along with the surgeons and [Inaudible] that we provide. That's worth going into the next year likely an $0.08 headwind.\\nAnd then one of the things that we commented on earlier in the year was our continued investment into R&D. As you look into next year, we're seeing roughly I would say, call it, $0.04 of additional investment in R&D. When you look at those things together, coupled with the inflation, we're landing at about $2.10.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And can you just maybe just elaborate a little bit on the spend or R&D and sort of the expectations for returns in terms of growth or programs that you're investing in?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nSo we're continuing to invest heavily in our spine business and as well as our robotic businesses. We talked about that in Q1 of our earnings call earlier in the year, and really all sign points to us continuing to do that. Dave talked earlier about some of the benefits that we're seeing for robotic technologies. We continue to invest in that and really grow for the future.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And then just one quick follow-up I had was on the environment for robots and spending in capital and equipment in general. Some of the other, again, companies in the space have talked about a fairly strong year for equipment, a strong year for robots. Any sense of whether this is something that needs to sort of take a breather or catch up here in 2022? Or whether orders and demand and pipeline for new deals would indicate just continued strength into 2022?\\nDave Demski -- President and Chief Executive Officer\\nYeah. Matt, this is Dave. No, it's very strong. I don't see anything laying off.\\nIn our case, in particular, it's been accelerating. I think the demand for Excelsius has been strong, and it's becoming more and more common. The narrative has changed from why robotics to which robot. And I think we're clearly establishing our lead there.\\nAnd then as I mentioned, there's a lot of enthusiasm over our Excelsius 3D system, which is going to launch later this quarter. We've had every surgeon we show that to seems like they want one. So I don't see it backing off at all.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks and congrats.\\nDave Demski -- President and Chief Executive Officer\\nThank you.\\nOperator\\nThank you. Our next question comes from Matt Taylor of UBS. Your line is open.\\nMatt Taylor -- UBS -- Analyst\\nExcuse me. Hi, guys. Thanks for taking the question. So I wanted to ask the first one about margins longer term.\\nMaybe just talk about the difference between what you're doing this year with some of the investments and obviously, headwinds year over year from spending back to normal and inflation, and how we should think about margins longer term? Would you start to get more leverage at some point? And what would the inflection point for that be?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. It's a good question. But as I look at where we're at and where we're going, our goal is to always maintain a mid-70s GP. But as we look longer term and look at our EBITDA rates, we're always looking to be in that mid-30s range.\\nWe could toggle our investments in various parts of our business to really achieve that, but we're investing now to drive growth -- to drive top-line growth for the future. And as we get that growth, that's going to create more fixed cost leverage in our P&L. So I think by doing that, investing for growth today helps project the margins going forward. I feel that we're going to work to try to stay in that range.\\nDave Demski -- President and Chief Executive Officer\\nYeah. I can add a little bit maybe to that, Matt. In the spine business, I don't think you'll see much greater improvement in our margins there, but we have a lot of operating leverage in front of us in the orthopedic side of the business and the capital side. Those are both fairly nascent businesses for us, and we're funding it with spine.\\nBut once we start to hit some volume numbers there, I think those businesses will definitely expand.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Can I ask a follow-up on the robotics strength? I mean, you talked in the past about getting pull-through on these placements, and obviously had a great year in 2021 with enabling tech. I guess are you still seeing the same kind of trends? And could that bode well for pull-through implants in '22?\\nDave Demski -- President and Chief Executive Officer\\nYes. It does. We're seeing that generally the same kinds of trends. And as a company, we're focusing on really going back to that installed base and seeing we can get more users to utilize the technology once it's placed in the hospital.\\nAnd that's a big focus for us in 2022.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Thank you, guys. Thanks so much.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And next, we have Shagun Singh of RBC. Your line is open.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGreat. Thank you for taking the question. I guess my first one is on Excelsius 3D imaging system. Can you talk to us about the delay? Why is there a delay in the launch? And then just elaborate on your go-to-market strategy.\\nAre you targeting the replacement opportunity or greenfield? You're obviously going after a major competitor. So just any color there would be helpful. And then on the recon robotics, do you still plan to launch that in the second half? And then I have a quick follow-up.\\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Shagun. I'll try to knock those off one by one. In terms of the delay, it's just taking longer than we thought. It's nothing significant in terms of the technology hurdle to get over.\\nThere's just a lot to do to get that over the line. So I wish we were a bit earlier but very confident we can get it done this quarter. Go-to-market. I think initially, we're going to be targeting our installed base of Excelsius users.\\nThose are -- there's a high demand among them. It's going to make those procedures much more efficient and much easier for them to do. And then from there, we'll be branching out to target more of that free-hand navigation market that you alluded to earlier. And then I apologize, I forgot the last part of your question.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nI was just wondering if you plan to launch the recon robotics platform in the second half of '22 like you had previously indicated?\\nDave Demski -- President and Chief Executive Officer\\nNo. That's been delayed as well. We're going to be -- early '23 is the target for that.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGot it. And then just as a follow-up, I was wondering if you could talk about trends that you're seeing on the procedure volume side in Q1, so in January and February. And spine typically has a high pain burden, so procedures come back quickly. So do you expect the recovery to come in Q1? Or do you expect a longer tail given staffing shortages? Thanks for taking the question.\\nDave Demski -- President and Chief Executive Officer\\nSure. Yes, January was really bad, but we've already started to see it turning in February. The last three weeks have all been progressively higher. Not back to where we want it to be, but definitely, I think we've hit bottom.\\nWe're going in the right direction. And I'm not going to try to predict what's going to happen with COVID though. That's proven to be frivolous for everyone, but it's encouraging where we are right now.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nThank you.\\nOperator\\nThank you. And next, we have Matthew O'Brien of Piper Sandler. Your line is open.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat. Thanks for taking the questions. I guess, Dave, just for starters on the top-line guidance. This time last year, you guided about $35 million below The Street.\\nWe end up doing well above what you initially guided and actually what The Street was modeling. And this time, you're guiding about $25 million below The Street. I know January was soft, and maybe Excelsius 3D has pushed a little bit in terms of the contribution. But are there other factors that we should be thinking about? I don't know if it's a rep hiring perspective or a robot perspective that gives you a little bit more caution versus kind of where The Street was modeling things?\\nDave Demski -- President and Chief Executive Officer\\nThanks, Matt. I'm sorry we don't pay that much attention to The Street. We look internally to our own forecast, and we always want to be appropriately conservative going into a year. I feel really confident in the business.\\nThe U.S. spine business has been just cranking away. The robotic momentum is there. We're going to have 3D out this year.\\nJapan is going to turn around in the second half. So I feel really good about the business. We just have taken a very conservative approach over the years when we give guidance, and we're doing that again.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nOK. Fair enough. And then the follow-up is on acquisitions. Sorry if I cut somebody off there, but there's been some talk about you guys doing a scale acquisition.\\nI'm curious if you have any thoughts about the need for scale in spine. And then if not, there's some pretty interesting assets still in the spine space, but more on the pain management side of things. Are those higher on the list in terms of things that you potentially are looking at from a acquisition perspective?\\nDave Demski -- President and Chief Executive Officer\\nNo. It's actually a bit different. We're more active in terms of growing the business through BD and on the orthopedic side of the business. I think we're really strong in spine, and there's really nothing in spine that's of interest to us at the moment.\\nWe're more focused on growing the other piece of our business, which is smaller. There's nothing, I would say, transformative in our sights right now. But we are looking at several modest-sized deals as been our history in the past.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat.\\nDave Demski -- President and Chief Executive Officer\\nDid that answer your question?\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nYep. That's perfect. Thank you.\\nOperator\\nThank you. Next, we have David Saxon of Needham. Your line is open.\\nDavid Saxon -- Needham and Company -- Analyst\\nYeah. Hi, guys. Good afternoon, and thanks for taking the questions. Maybe one on enabling tech.\\nI mean, it doubled this year, and you've really built out the enabling tech platform with hub and 3D, etc. How should we think about those launches kind of starting to ramp? And could '22 be another double?\\nDave Demski -- President and Chief Executive Officer\\nYeah. I think as I said, we're going to get some -- a few units out this quarter and kind of a soft launch, if you will, with the full launch starting in probably end of Q2, it might be into Q3 and then strong in the second half of this year. I don't want to comment on the double. It's -- we don't really drill into the components of our business.\\nI can tell you that we're really excited about what we're seeing from our technology, from the adoption of our technology and not only what's right in front of us, but some things we have coming after that.\\nDavid Saxon -- Needham and Company -- Analyst\\nOK. Got it. And then maybe on trauma, kind of how close are you to having a full portfolio there? And then in terms of growth, 32% in the quarter. Is that sustainable in '22? Thanks for taking the questions.\\nDave Demski -- President and Chief Executive Officer\\nSure. The bag in trauma is by the second half of this year, I think full is kind of interesting term. We're going to have enough in our bag to be a full-line player and be able to compete with the major companies by the end of this year. And is that growth rate sustainable? Yes, I think that's certainly achievable in 2022.\\nDavid Saxon -- Needham and Company -- Analyst\\nGreat. Thank you.\\nOperator\\nThank you. Next, we have Craig Bijou of Bank of America. Your line is open.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nHey, guys. Thanks for taking the questions. Maybe a follow-up on top-line guidance and to the extent that you guys are willing to share. I mean, how to think about the contributions from each of the businesses? I know generally, you've been reluctant to share that info.\\nBut in terms of the composition of the guidance, how do we think about that incremental revenue coming in? Where is it coming from and to what extent?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. As Dave said earlier, we're not going to get a ton into the parts and pieces. But what I will say is if you look at the business, whether by musculoskeletal and INR or you look U.S. versus international, the parts and pieces of our business we continue to feel extremely positive about as we look into 2022 and beyond.\\nWe're investing in our business. We're driving investment for the future, and we feel that we'll see that turn out to us taking share and driving sales growth. I alluded to my earlier prepared comments that our guidance is appropriately conservative, but there's nothing that I sit here and feel that we have kind of an ongoing issue that I would be concerned about our ability to grow across our business, like I said, whether it's U.S., international or musculoskeletal versus INR.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGot it. Thanks, Keith. That's helpful. And then, Dave, I think you alluded to it, but I wanted to ask more specifically how to think about some of the new product rollouts? Obviously, you have 3D coming out and launching this year.\\nBut from a new product perspective, is it -- do you have a number of launches coming this year on the spine side? Do you have a number coming on the INR side? Just maybe a little bit more perspective of what to expect during the year.\\nDave Demski -- President and Chief Executive Officer\\nSure. Thanks, Craig. I think we've been pretty clear that it's a big one coming with 3D followed by our hub [Inaudible] offering. I think spine, we are typically 10 to 12 launches a year, and that's currently our target going into 2022.\\nTrauma is probably the real bright spot. There is a number of products that we were working on for a while, they're going to hit the early part of this year and through this year. So -- and then our orthopedics business actually has some launches as well. So that's kind of who we are and who we're going to be.\\nAnd it's -- the number one focus of the company is to drive great technology.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGreat. Thanks for taking the questions, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. Next, we have Ryan Zimmerman of BTIG. Your line is open.\\nRyan Zimmerman -- BTIG -- Analyst\\nAll right. Thanks for taking my questions and congrats on a great year. Just want to follow up on a couple of questions. Dave, when we think about U.S.\\nSpine performance kind of relative to the market, you look at some of the larger players, they were down a bit in the fourth quarter. Some of the smaller players we saw were up double digits. Obviously, a few major players still yet to report next week. But I guess I'm kind of curious if you can kind of talk about the U.S.\\nperformance, that growth this fourth quarter relative to the market, and kind of where you think you're tracking relative to that level? And if you could kind of give us color on what you think that level was just given the dynamics in the fourth quarter through the quarter would be helpful.\\nDave Demski -- President and Chief Executive Officer\\nThanks, Ryan. It's really challenging to figure out where we are, given COVID. So from the early returns of some of the folks who we have reported, again, we're taking significant share. I can't speak to the smaller guys who have reported or how that impacts us.\\nAnd I don't really have a feel for the overall market. I know it was heavily impacted by COVID so likely down versus prior year overall. But that's more of just a guess and kind of where we landed versus some of our earlier trends. Our business is strong.\\nI can tell you that. We haven't lost significant pieces of business in the U.S. And we continue to see growth in the recent product introductions, and we continue to sell robots and drive pull-through from that. So it's strong.\\nI just -- I can't really see the overall market, and it's really hard to figure out what's going on given what's happening with COVID.\\nRyan Zimmerman -- BTIG -- Analyst\\nOK. Just two follow-ups for me. One, we've heard some of the larger capital equipment companies have obviously called out chips as being a gating factor to sales or median demand in 2022. One, want to see if there's any concern there around chips for the Excelsius platform or for 3D and whether that could gate sales? And then I'll just ask the other -- sneak in a quick follow-up, too.\\nThe Japan distributor dynamics, how much of a lift should we expect when that distributor dynamic clears in the second half of 2022 on the international business? Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. In terms of chips, I would just -- I would extend that to all supply chain. So it's not just chips, it's all components are challenging. It hasn't cost us revenue now, but it's certainly on our radar and making our life really hard.\\nSo it's a risk that's out there for 2022. I'll let Keith maybe handle the international question.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nAs it relates to Japan and the distributor dynamic, as we look ahead, we finished 2021, I think international grew by about 11%. We've historically said that we believe that the international business can grow mid-to-high teens. I would expect us to be able to get back to that on an annual basis. So you would expect the second half of the year to accelerate ahead of that to potentially balance -- to get closer to that 15 by the end of this year.\\nRyan Zimmerman -- BTIG -- Analyst\\nThanks, Kieth. Thanks, Dave. Appreciate it.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. Next, we have Kyle Rose of Canaccord. Your line is open.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nGreat. Thank you for taking the questions. I wanted to start on enabling. I mean, look, you put up a good quarter in enabling.\\nI guess a tough backdrop, particularly without the imaging platform. Maybe just help us understand kind of where that stands from a utilization perspective into your customer base. You're talking about the really good utilization there is continuing to see strong pull through. Can you just kind of level set maybe how many of your customers might have it or on a percentage basis or on an absolute basis? Just trying to really understand where we are in the uptake and the adoption within the historical core Globus customer base.\\nDave Demski -- President and Chief Executive Officer\\nYes, Kyle. To be honest, I don't feel comfortable sharing that information from a competitive standpoint.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nTotally fair. I had to try. I also wanted to touch on the orthopedic side of the business. I mean, it's been a couple of years since you acquired the StelKast business.\\nI think earlier in the call, you talked about the fact that the recon robot is going to come in '23. Where do you stand just from an implant perspective? Do you have the right implants there? Do you need to make different investments from an M&A perspective, technologies, distribution? Just help us understand what you need to do on that total joints business before the recon robot comes next year. Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. We do not have the implant portfolio we need to really make a strong outing. So we are working on that, have been working on that, and expect to roll some products out this year. I don't see us filling the gaps in our product portfolio with acquisitions in terms of hips and knees in particular.\\nI do think there's opportunity for scale there. So that's not off the table because we are very small right now. And then the extremities is an interesting segment for us as well. It's a fast-growing segment.\\nSo that's an area where we've taken a look at a few things. Does that help with your question?\\nKyle Rose -- Canaccord Genuity -- Analyst\\nYes. Thank you very much.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. And next, we have Samuel Brodovsky of Truist. Your line is open.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nHi. Thank you for taking the questions. Just a first quick one on U.S. Spine.\\nJust would be curious to hear about the portion of growth in the U.S. coming from robotic-specific instrumentation versus where you're seeing potential share gain with other parts of the portfolio?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nYes. Thanks for the question. In terms of breaking it out, we typically don't break out the parts and pieces of where the growth is coming from. What I would say is that as you look at our U.S.\\nSpine business, it's really a combination of what we always talked about: new product innovation, our competitive recruiting, and the pull-through from implants. Those three continue to propel the business from a growth perspective, and we see that continuing as we enter 2022.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nGreat. That's helpful. And then when thinking about 3D and going to customers with it, in terms of any competitive trialing, are you seeing it being trialed against other more novel imaging technologies on the market? Or is it typically being compared to the large competitor out there? Thanks.\\nDave Demski -- President and Chief Executive Officer\\nInteresting question. I assume it's -- we don't really trial against it, but we have customers looking at our technology. And I think their interest just probably lines up with the market share of the other imaging systems in the market, particularly ones that are utilized more in spine. I'm sure that some of the more innovative ones are getting a look, but we don't hear that much about them.\\nSo it's not disproportionately, maybe I could answer it that way.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nThanks.\\nOperator\\nThank you. [Operator instructions] Our next question comes from Steven Lichtman of Oppenheimer. Your line is open.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nThank you. Hi, guys. I wanted to ask you first on trauma. Where do you think you stand now in terms of coverage of procedures in terms of your product portfolio? And also from a sales force perspective, I'd just love to get an update on where you feel you are overall in terms of being able to go at the market.\\nDan Scavilla -- Executive Vice President and President of Ortho\\nSteven, it's Dan Scavilla. So again, it's always the evolving and expanding story. We have about 14 family products out there now. I think with that, we're saying we would cover 50% to 60% of the market.\\nCertainly, plan, as David said, to launch several more this year to cover that further. I believe and through what I'm saying, we're at a point where we're able to get into some significant facilities and support their needs for the most common procedures. And with that that's the main driver of growth to us. So we'll continue to expand the product line and fill that out over time, but we're in a good spot now.\\nWith that is the competitive recruiting that's been accelerating for us. So again, we're small, and we have a lot of spaces to fill. But the traction that has been occurring really through 2021 is very promising. And I do feel bullish as we are -- from what I've seen so far in the first quarter of 2022 that that will continue.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nGreat. Thanks, Dan. Keith, just a follow-up on gross margin. I apologize if you mentioned this, but just relative to 2021, given the inflation commentary, should we assume gross margin down? Or are there some offsets that can keep it relatively flat to maybe -- or even up in '22?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. We project the mid-70s GP. I think it's fair to assume that we are seeing inflation just like everybody else, but we're also growing. And it's obviously getting us some leverage in our cost structure.\\nSo as I think about 2022, mid-70s is kind of where I see it. I wouldn't project upside.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nOK. Got it. Thanks, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And we now have Jason Wittes of Loop Capital. Your line is open.\\nJason Wittes -- Loop Capital -- Analyst\\nHi. Thanks for taking the questions. Just two follow-ups, one on the guidance and one on trauma. But -- so first off, your guidance, I think the way you described it, especially relating to product launches, kind of assumes a strong second half versus the first half.\\nSo related to that, one, are we assuming that -- I know we can't predict COVID, but COVID pretty much works its way throughout the year? And then secondly, related to that, in the first quarter, I'm not sure how to read your comment that January was very weak. It bounced back. Should this be a normalized first quarter? Or are we -- is it going to be a little weaker relative to last year because of the COVID impact and launches? Thanks.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. Dave commented that January was weak, but we were starting to see some bounce back in February. Will it all bounce back in the same quarter versus having some bleed through into Q2? We don't necessarily know. But I think your earlier comment about some of the launches and a strong second half, I think that's directionally correct.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. And then I don't know if you can comment on this, but you did mention that you had -- it sounds like a record year in terms of sales force hires. In the past, you've kind of given us an indication of how large you've been able to grow your sales force percentage-wise. Can you give us any kind of indication on that in terms of what 2021 look like? And it sounds like 2022, you're optimistic that you can do -- go at a similar run rate?\\nDave Demski -- President and Chief Executive Officer\\nYeah. '21 was not a record year for us. I think we had one really strong quarter, but we've had years that were better. That's a renewed emphasis on it.\\nI can tell you the pipeline right now is extremely strong. So we're coming out of the gate strong. But last year was a good year. It just wasn't our best.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. Thanks a lot. Appreciate it all.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\n[Operator signoff]\\nDuration: 45 minutes\\nCall participants:\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nDave Demski -- President and Chief Executive Officer\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nMatt Miksic -- Credit Suisse -- Analyst\\nMatt Taylor -- UBS -- Analyst\\nShagun Singh -- RBC Capital Markets -- Analyst\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nDavid Saxon -- Needham and Company -- Analyst\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nRyan Zimmerman -- BTIG -- Analyst\\nKyle Rose -- Canaccord Genuity -- Analyst\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nDan Scavilla -- Executive Vice President and President of Ortho\\nJason Wittes -- Loop Capital -- Analyst\\nMore GMED analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4006,\n        \"samples\": [\n          \"2022-08-11 07:30:00\",\n          \"2021-03-18 08:00:00\",\n          \"2021-08-09 11:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 771,\n        \"samples\": [\n          \"2022-07-12\",\n          \"2020-10-22\",\n          \"2022-06-10\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Clean_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10031,\n        \"samples\": [\n          \"I'd now like to turn the call over to Matt Shimao, PTC's head of investor relations. Please go ahead. Matthew Shimao -- Head of Investor Relations Hello. Thank you, Julian, and welcome to PTC's results call for Q1 of fiscal '22. On the call today are Jim Heppelmann, chief executive officer; and Kristian Talvitie, chief financial officer. During this call, PTC will make forward-looking statements, including guidance on future operating results. Because such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in PTC's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission, as well as in today's press release. The forward-looking statements, including guidance provided during today's call are valid only as of today's date, January 26, 2022, and PTC assumes no obligation to update these forward-looking statements. During the call, PTC will also discuss non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures can be found in today's press release made available on our website. With that, I'd like to turn the call over to PTC's chief executive officer, Jim Heppelmann. Jim Heppelmann -- Chief Executive Officer Thanks, Matt. Good afternoon, everyone, and thank you for joining us. Turning to Slide 3, I'm pleased to share that PTC delivered another strong financial performance in fiscal Q1. We executed very well, building on the momentum we saw in Q4. To simplify things, please note that throughout my prepared commentary, I will only discuss growth rates in constant currency. ARR came in at $1.507 billion, which was better than the $1.5 billion we had guided to at the recent Investor Day. That represents 16% growth, 11% of which was organic. Adjusted free cash flow was also strong at $145 million, which was up 20% year over year and better than the $140 million expectation we said at the Investor Day. We're off to a very strong start in fiscal 2022. Turning to Slide 4. Of particular note was our bookings strength. Bookings were up double digits organically and high teens overall against the very strong COVID bounce back quarter we saw in Q1 of fiscal '21 when bookings grew more than 30% over the prior year. To put it in perspective, given the tough comparison against Q1 of last year, we had planned bookings to actually be down slightly, inclusive of Arena. So this performance was more than 20% above plan. I know that some analysts and investors had voice concerned that the restructuring work we did in late Q4 and throughout Q1 would distract us, but obviously, we didn't see that. The strength was broad-based across direct sales and resellers and was achieved with no megadeals. Rockwell came in ahead of their part of our plan, too, which was great to see and suggest my concerns of them being distracted and may prove overstated. Arena contributed the inorganic element of bookings growth, with another strong bookings quarter, coming in above plan as well. With the Arena acquisition getting round tripped here in Q2, Arena becomes part of the organic results going forward and their low 20s growth rate will then add another tailwind to the organic results. Arena has been a great acquisition. Bookings growth was particularly strong in PLM, and in both Europe and Americas. From a macro perspective, global PMIs remain an expansion territory, while digital transformation and SaaS continue to grow in importance as secular drivers. The interest in digital transformation in SaaS has been driving strong bookings for what is very sticky software, which when layered into a recurring revenue model that is atypical of industry peers, has allowed PTC to deliver performance in excess of market growth rates. This happened right through the pandemic, especially in the large core business that represents about 70% of our ARR, and we fully expect it to continue going forward. These factors gave us confidence to raise the lower end of our ARR guidance range, which at the new midpoint basically means we've rolled our Q1 beat forward. Now let's take a look at the ARR performance by geography on Slide 5 before turning to business units. In Q1, we saw a strong ARR performance across all geographies. Our ARR growth in the Americas was 19%. All product segments grew with key growth drivers being the acquired Arena contribution and the velocity business unit overall, layered on top of another strong quarter in the core CAD and PLM business. In Europe, our ARR growth was 13%. We saw strong results across the board in Europe, with the strongest drivers of the growth being our digital thread growth and core businesses. Europe has the largest mix of channel versus direct and the resellers continue to perform well. Our ARR growth in APAC was 14%, with growth primarily driven by our digital thread core business. Next, let's take a look at the ARR performance of our various business units, starting with the digital thread group on Slide 6. In our largest product segment, digital thread core, we delivered yet another double-digit performance in Q1 with 11% growth. Within this, CAD and PLM, both grew double digits, with strong growth across all three geographies. This is the 17th consecutive quarter of double-digit ARR growth in the core business. And as we roll out our more aggressive SaaS strategy, I expect we'll see many more. In the digital thread growth, which is IoT and AR, we saw ARR growth of about 14%, consistent across both elements. This was in line with our plan and the mid-teens near-term growth expectation we set at the recent Investor Day. While this level of growth remains accretive to company growth, we continue to expect an acceleration of growth into the 20s as we get into the back half of the year. The biggest driver of growth in Q1 was from expansions, especially in Europe and APAC. We believe market conditions in IoT are improving, and we like the way the pipeline for our new DPM offering is developing through both PTC and Rockwell channels. For AR, we continue to see a tremendous level of interest, but the market remains nascent. Perhaps most importantly, the formation of the digital thread business unit at the start of FY '22 has driven important initiatives to increase our focus on cross-selling of IoT and AR into the core CAD and PLM customer base. FSG had a great Q1 with 6% ARR growth. The expansion deal we recently announced with the U.S. Air Force, both increases and extends this key relationship for up to five more years. Contracts like this demonstrate the value that our customers are realizing from Servigistics and other FSG products such as retail PLM and ALM. You may remember, I noted at our Investor Day that having FSG grow in the mid-single digits rather than flat would be a helpful upside growth driver. So I'm pleased to see FSG post another strong quarter. Let me run through a couple of quick customer anecdotes to give you a sense for our digital thread customers and how they rely on us. On Slide 7, MAN Energy Solutions is the world's top provider of large-bore engines in turbomachinery for the maritime and energy industries. The company manufactures complex parts in nearly every engine they make must meet unique customer requirements. Before implementing Creo, they relied on manual outdated processes that slowed design and production. With Creo, they've been able to transition from 2D to a full 3D model-based approach. Creo's broad range of tool path automation capabilities enable them to save time in the programming of the tool pass used to machine the large complex engine parts, greatly increasing efficiency in transitioning from design to production. Turning to Slide 8. You may have noticed we announced a deal with -- we announced that the German company, Scheffler, has expanded its relationship with PTC, and I'd like to share a bit of the back story. Scheffler has been a longtime Creo customer and has successfully deployed Windchill within engineering. But back in 2017, one of our PLM competitors announced a large PLM deal with Scheffler that appeared to cap PTC's expansion opportunity. But that system didn't ultimately stick as Scheffler has now decided to consolidate on PTC systems with Windchill being the backbone and is broadly deploying our solutions in their standard out-of-the-box fashion so that Scheffler can participate in the full power of our digital thread portfolio. I'm very excited about this collaboration and the further expansion that Scheffler is exploring with our IoT and AR offerings. On Slide 9, you'll see how IMA Group, our global business that delivers packaging machines, services, and solutions to a wide variety of industries, was looking for a way to expand their control room offering to help their customers improve overall equipment effectiveness and reduce downtime. As longtime users of PTC's Creo and Windchill, IMA decided that ThingWorx was the ideal IoT solution for their initiative and that Kepware could provide connectivity not only to their machines, but to the other vendors' machines deployed alongside them. IMA has successfully launched new revenue streams by enabling 24/7 monitoring of customer production lines and improved OEE by up to 16%. The Vuforia integrated with ThingWorx is the platform of choice for the U.S. Air Force training initiatives. Slide 10 highlights the work that PTC partner, Vectrona has done with the U.S. Air Force. With finite training resources and limited capacity, the U.S. Air Force set out to incorporate augmented reality into their maintenance and munitions training. Vectrona using Vuforia Studio worked with the U.S. Air Force to create immersive 3D AR experiences for phones, tablets, and the HoloLens 2 that are designed to accelerate learning, improve work performance and facilitate remote training. The improved training shows better engagement and information retention with continuous and repeatable task training available regardless of the system or aircraft type. Turning to Slide 11, the velocity business ARR growth in Q1 was more than 650% due to the inclusion of Arena and 53% organically, which would be Onshape. If you were to add Arena's pre-acquisition results into the prior year to get a better pro forma comparison, then you'd have the velocity business unit growing at 28% in Q1. That 28% is a mix of Onshape growing at 53% and the larger Arena business growing in the low 20s. Growth of both Onshape and Arena is multiple times higher than market rates, clearly demonstrating that industrial companies see the benefits of SaaS. We continue to ramp investments to expand technology leadership and to broaden the geographic presence of our velocity businesses. On Slide 12, Beta Technologies, a leading developer of next-generation electric aircraft for the cargo and logistics market, sought a cloud-native product development platform where everyone would be working with one single source of truth without the workflow restrictions of traditional file-based design systems. Beta turned to Onshape because of how it enables real-time collaboration, allowing the engineering team to work from any location while streamlining their communications during the design process. To profile Arena customer, Potrero Medical, on Slide 13, is a predictive health company developing the next generation of medical devices, leveraging smart sensors and artificial intelligence. Potrero needed a scalable quality management system to support its growing product development and compliance needs, including satisfying FDA audit requirements. Arena was the right solution, offering a cloud-native QMS with a quick implementation, leading to ECO cycle time reduction of 30% and nonconformance improvement of 20%. As a final topic, I'd like to give you a quick update on our SaaS acceleration initiative on Slide 14. We've made tremendous progress in the past 90 days since we announced the more aggressive strategy. We've launched our SaaS program management office, which was modeled after the very successful approach we used to drive our subscription transition several years back. Our field organizations transition to the new two-in-a-box customer success organization model without missing a beat. We converged our cloud and tech support organizations with product development to deploy the DevOps type of approach you see in virtually all SaaS companies. We've made good progress advancing our offerings, especially the Windchill multi-tenant version, which will go into production shortly this quarter, and we made good progress preparing the SaaS conversion offerings that will power the hundreds of lifts and shifts that will happen in the coming quarters and years. We have more work to do, but we're certainly up and running. The time for SaaS has arrived in our industry and PTC is very well positioned. We're already the SaaS leader in our space with continued strong SaaS growth in Windchill and FSG and high levels of growth in our cloud-native velocity business unit. Sharing the Atlas SaaS platform, we have a dual strategy to win with Onshape and Arena powering a new agile product development approach, while we transition our digital thread portfolio and existing customer base to SaaS to elevate the platform strategies that so many larger companies have. To wrap up on Slide 15, I'm pleased with PTC's position and the opportunity that lies ahead. Q1 gave us a strong start to what we expect to be our fifth consecutive year of double-digit ARR growth. Our portfolio of products is unique and compelling and obviously aligns well to customer demand. Our results have been consistently strong for many quarters, but we're poised to accelerate growth as the SaaS tailwind blows harder in coming quarters and as we gain more momentum with our IoT and AR initiatives in the back half of the year. We're poised to drive higher levels of profitability, too, following the organizational changes we've already implemented and as our start-up businesses continue to mature up their J curves. The company has never been in a better position to create shareholder value. With that, I'll turn it over to Kristian for more details on the financial results. Kristian Talvitie -- Chief Financial Officer Thanks, Jim, and good afternoon, everyone. Before I review our results, I'd like to note that I'll be discussing non-GAAP results and guidance, and growth rate references will be in both constant currency and as-reported rates. So turning to Slide 17, we delivered constant currency ARR of $1.507 billion, which is 16% growth year over year and slightly exceeded our Q1 guidance of $1.5 billion. On an organic constant currency basis, this is 11% growth. FX was an approximate $11 million headwind in Q1, so our as reported ARR was $1.496 billion. Our SaaS products in both the digital thread and velocity business units saw a continued strong growth in Q1, with growth rates similar to what we discussed at our recent Investor Day. This is in combination with continued strong growth of our software-only sales. As of Q1, our SaaS portfolio is now 15% of our total ARR on a constant currency basis. Q1 free cash flow of $134 million grew 21% year over year and includes $11 million in restructuring and other related payments. Adjusted free cash flow was $145 million and was slightly ahead of the $140 million we discussed at our Investor Day. Q1 revenue of $458 million increased 7% year over year. As we've discussed previously, revenue is impacted by ASC 606, so we do not believe that revenue growth rates are indicative of our underlying business performance but would rather guide you to ARR as the best metric to understand our top-line performance and cash collection. FX only impacted revenue by about $1 million in Q1. So our revenue on a constant currency basis was $459 million. Q1 non-GAAP operating margin of 35%, compared to 36% in Q1 of 2021. While this is a strong result, it's still worth pointing out that because revenue was impacted by ASC 606, other derivative metrics such as gross margin, operating margin, and EPS are all also impacted. Suffice it to say that our COGS and opex came in in line with our expectations in Q1, and we continue to maintain good discipline on our operating expense structure. I would like to point out that our GAAP results reflect a gain of $9.8 million related to our investment in Matterport. And we're also slightly reducing the range for expected P&L charges from approximately $45 million to $50 million, down to $40 million to $45 million for the full year. And coincidentally, we're also reducing the range of expected cash payments for the restructuring and other from what was previously $50 million to $55 million, down to $45 million to $50 million for the full year. For guidance purposes, we will continue to show $50 million as the cash payments and the adjusted free cash flow reconciliation. But as payments come in lower, then we would just expect actual free cash flow to come in higher. There's no change to the $450 million adjusted free cash flow target. Moving to Slide 18, I'll begin with our balance sheet. We ended Q1 with cash and cash equivalents of $296 million. In addition, at the end of Q1, we had medium-term investments of $87 million, primarily related to our investment in Matterport. Our gross debt was $1.45 billion with an aggregate interest rate of about 3.2%. In Q1, we used $120 million of cash to repurchase shares. We also had an additional $5 million of repurchases, which settled early in Q2. For the remainder of fiscal '22, we will focus on delevering and looking forward to FY '23 in an ongoing go-forward basis, assuming our debt-to-EBITDA ratio is below three times, we will continue to target to return approximately 50% of our free cash flow to shareholders via share repurchases. Turning to Slide 19. We post a data table to our IR website that has our financial statements, as well as ARR detail by segment. In that file, we share both constant currency and as-reported ARR. As a reminder, when we calculate constant currency, we use our current year plan FX rates and restate history to the same rates. So here, for example, on this slide, you can see our Q1 constant currency ARR of $1.507 billion and the actual as reported ARR of $1.496 billion. This is important to remember in the context of our guidance because we provide guidance at the planned rate. We believe this is the best way to evaluate the top-line performance of our business because it removes FX fluctuations from the analysis, positive or negative. With that, I'll move on to guidance on Slide 20. As Jim mentioned, we're raising the low end of our full year constant currency ARR guidance by $10 million. The new range is now $1.625 billion to $1.660 billion. This essentially reflects rolling our Q1 overperformance through the remainder of the year. We're now expecting constant currency ARR growth of 11% to 13% in fiscal '22. It's worth pointing out that based on FX rates at the end of Q1, we would expect a $13 million headwind against that full year ARR guidance. For Q2, we're setting constant currency ARR guidance of $1.540 billion to $1.550 billion. This is 12% organic constant currency growth at the midpoint. On an as-reported basis, the FX impact we're calculating based on the FX rates at the end of Q1 is a $12 million headwind in Q2 compared to the constant currency guidance. Moving to free cash flow. We're maintaining our full year free cash flow target of $400 million. This includes approximately $50 million of restructuring and acquisition-related payments. The majority of these payments are related to the reorganization we announced in Q1 with some residual payments primarily related to our Seaport move for which we took the accounting charge in prior periods. So our adjusted free cash flow target for fiscal '22 remains $450 million. Fiscal Q2 adjusted free cash flow is expected to be approximately $155 million. We expect to make approximately $20 million in restructuring and other related payments in Q2, bringing our free cash flow to approximately $135 million. Moving to revenue. We're also taking the low end of the full year revenue guidance up by $20 million. This reflects both the strength in software and strength in the professional services business that we saw in Q1 and the related forecasts for the full year. So for fiscal '22, our net revenue guidance range is $1.870 billion to $1.975 billion. The year-over-year growth rate range is now 3% to 9%. Our ASC 606 makes revenue very difficult to predict for on-premise subscription companies, hence the wide range. Note that revenue variability has -- this is from 606, has no impact on ARR or its related cash generation as we continue to primarily bill customers annually upfront regardless of term length. We continue to expect more than 60% of our annual free cash flow generation to occur in the first half of the year. Collections are stronger in the first half, and we expect expenses to increase as we ramp hiring in our SaaS investments throughout the year. We're wrapping up on Slide 21 with the free cash flow model that we use and went into some depth on at our recent Investor Day that you can see here. I know many of you use model free cash flow using the indirect method. However, given the complexities related to revenue recognition due to 606, this is difficult to do. The model we show here has proven quite effective. The table shows fiscal '21 actuals compared to the model we shared at Investor Day compared to our current guidance. Let me take you through the model focusing on the non-GAAP column on the right and starting at the top. First, we're showing the midpoint of our as reported ARR guidance of $1.630 billion, which is different from the constant currency guidance that we gave due to the $13 million FX headwind and is also $5 million lower than what we showed at the Investor Day. We use it as reported here because it's a better reflection of the cash we expect to generate. You can also see that we have increased the perpetual license revenue forecast slightly and also the professional services revenue increase that we mentioned earlier. COGS is slightly higher, reflecting the increased costs to deliver the incremental professional services revenue and the rest of the assumptions remain the same, and we still end up with our target adjusted free cash flow of $450 million. Obviously, this is a model based on assumptions such as the midpoint of the ARR range, the impact of FX, the pace of hiring, etc. So if some of those variables change, which they invariably will, the model will have to be adjusted accordingly. And as I mentioned earlier, if cash payments related to the restructuring coming at the low end of the range, we would see a flip from the restructuring line to the free cash flow line, but the adjusted free cash flow target would remain unchanged. But as we sit here today, we think this is a reasonable view of how we expect the year to shape up. So with that, I'll turn the call over to the operator, and we can begin Q&A. Questions & Answers: Your first question will come from Andrew Obin from Bank of America. Please go ahead. Your line is open. Andrew Obin -- Bank of America Merrill Lynch -- Analyst Hi, yes. Good afternoon. Jim Heppelmann -- Chief Executive Officer Hello, Andrew. Andrew Obin -- Bank of America Merrill Lynch -- Analyst Just a bigger picture question. I apologize, I missed the first couple of minutes. You know, we hear a lot about supply chain constraints. And frankly, we're hearing that this might extend the run-in terms of PMI expansion. So what are you hearing in terms of sort of as you have conversations about PLM and in terms of adoption? What kind of conversations are you having with your customers? And do customers have awareness of sort of supply chains being gummed up for longer? And are you seeing this having any discernible impact on what kind of conversations you're having with people? Jim Heppelmann -- Chief Executive Officer Andrew, it's Jim. No, actually, it's not really a frequent topic in our conversations because -- well, first of all, since you said you missed the first minute, one of the things I pointed out is that our bookings came in very, very strong, and I explained about 20% higher than planned. So we had a very, very strong bookings quarter. And notable in that was PLM, although, frankly, the strength was broad-based. I think the key thing to remember is that PLM is really associated with preparing product data in engineering that will then subsequently be used in manufacturing and perhaps in aftermarket service. And it's collecting data from supply chain partners and so forth. But production problems in a supply chain don't necessarily impede the collaboration during the engineering and the preparation for production process. So I think people are saying like, maybe I can't get chips to complete the product, but that doesn't mean I should stop designing the next one because if it does, then I'll fall behind. So I think that our view would be that the product development process has largely been unaffected by the supply chain process. Now some other things, we talked about how perhaps COVID had an impact on IoT, perhaps the supply chain a little bit, although I think muted compared to COVID. So to me, the supply chain thing is a fairly small factor in our results. We just see very little correlation between what's happening out there with supply chain problems and what's happening with our pipeline and frankly, with our bookings. Jim Heppelmann -- Chief Executive Officer Hey, Yun. Yun Kim -- Loop Capital -- Analyst Thank you. Hi, Jim. Can you just talk about the IoT business, you know, in terms of the large deal activity? What kind of trends are you seeing there? Obviously, you are expecting that business to accelerate in the back half -- second half of the year. If you can talk about whether that confidence is coming from the, you know, improvement in the large deal activity? Or is it just the overall volume of the activity around IoT? And then also, if you can just comment around deal size activity around the AR business as well. Thanks. Jim Heppelmann -- Chief Executive Officer Yeah. I think deal sizes are sort of unchanged from previous trends. If you think -- what are we looking at when we project forward how IoT and AR will perform. Well, we're looking at the bookings, let me say, at the pipeline that will drive bookings, and for IoT and AR was quite strong. We're looking at the backlog. Last year, bookings actually had improved over the prior year. And bookings that went into backlog or -- I'm sorry, what we call deferred ARR, were quite high. We were well ahead of our deferred planned number as we actually did last year. So you could imagine we've got more, and if you want to call it, backlog waiting for us. And then what other initiatives are we doing? So for example, our DPM launch, I think, will be materially positive for our IoT results. It will drive bigger deals. It will drive better value propositions. It's really software that's ready to turn on and get value from as opposed to a platform. And then the other thing is, Troy Richardson talked at our Investor Day about organizing better for cross-sell. And I think if we look backwards, maybe we had pivoted too much toward new logos, which are great. I mean, new logos are a wonderful thing. But we probably have low-hanging fruit yet to pick within our installed base of CAD and PLM accounts. So I think it's really this combination of a strong-looking pipeline, good-looking trends, awaiting us in the deferred backlog and then these other initiatives kicking into place, DPM and cross-sell that I think will all be very helpful as we proceed through the year. And again, I want to remind everybody, we set the expectation that the two handle would materialize in the back half of the year and that you wouldn't see it in Q1 and Q2. So we sort of feel like this was as we had predicted just mid-December a couple of weeks ago. Jason Celino -- KeyBanc Capital Markets -- Analyst Hey. Hi, Jim. Hi, Kristian. Jim Heppelmann -- Chief Executive Officer Hi, Jason. Jason Celino -- KeyBanc Capital Markets -- Analyst So one question on maybe the SaaS Windchill, you know, launch. It seems like it's coming along, you know, nicely, and we could see something maybe go GA this quarter. Have you had a chance to maybe, you know, discuss this with customers? How is the pipeline shaping? Or is it maybe better to think that the pipeline might start to form once we do go live? Jim Heppelmann -- Chief Executive Officer No, we have, for sure, started talking about it with customers. I mean, ramping up that process. We've got to educate a lot of people and they, in turn, have to educate customers. But we've certainly made some progress, and I can tell you the customer interest is actually quite high. You should know that actually, customers were pushing us a little bit to get going with such initiatives -- so I feel like the demand is there. And in fact, again, just reflecting on what we told you, that business has been growing about 30%. And Kristian mentioned we posted another quarter just like that, without us really invoking the new strategy yet. So there's lots of demand. We're just looking for a model where we can promote the demand because we like the margin profile better. And that's what's coming into place here in Q2. Adam Borg -- Stifel Financial Corp. -- Analyst Great. Thanks so much. And maybe just two quick ones. Just on the Scheffler win that you announced yesterday and highlighted on the call earlier. One of the things I thought was really interesting in the press release was this opportunity around some more vertical-specific or market-specific solutions targeting either automotive or industrial companies. So maybe, Jim, if you could just talk about that. And maybe just as a quick follow-up, just maybe for Kristian. Any way you could talk about this transition, it's great to get the early feedback on the SaaSification efforts, but any way to comment on, you know, how much this has contributed to bookings or the pipeline, at least qualitatively? Thanks so much. Jim Heppelmann -- Chief Executive Officer Yeah. I'll get the first part of the question. Kristian, you can take the second part. Yeah. So Scheffler is a great account. And as I mentioned back in 2017, it appeared they were going in a different direction, and now they've decided to come back into the fold. And honestly, they did that for two main reasons. One is that they really want off-the-shelf technology. The other competitor had told them this low-code, no-code story, and they tried that out and decided that's not really what they want. They don't want to develop their own solutions. They want to deploy standard out-of-the-box software that all works together. And then they want to engage in partnerships with the vendor, in this case, PTC to talk about how those solutions should evolve to be more and more powerful to meet their needs. So yeah, I'm very excited. I'm in the middle of that relationship myself. And yes, what's going to come out of that is technology that fits better and better, for example, for the automotive supply chain, which is a place where we have a lot of customers. So it's a great win or win back, maybe I should say, and a great partnership going forward that's going to produce a lot more business for us in years to come. And sorry, the second part of the question was around the transition to SaaS and how that's manifesting itself in terms of pipeline and activity? Is that right, just making sure I got that right. Adam Borg -- Stifel Financial Corp. -- Analyst Exactly. Any way to qualitatively comment from, you know, either bookings or a pipeline perspective? Jim Heppelmann -- Chief Executive Officer Yeah. Well, remember, I mean, the bookings that we just reported were for Q1, and Q1 is really when we actually just announced the acceleration of it. So I would say there's actually a limited impact in the actual bookings result here in Q1. That said, as I mentioned, we continue to see strong demand for the SaaS properties that we have. That's both in velocity and the digital thread. And so those products continue to grow at a rate higher than our software-only products. And now as the program is pushing ahead, we expect to see demand and pipeline generate, especially with the new Windchill launch coming out here and the program continuing to pick up speed internally. Kristian Talvitie -- Chief Financial Officer Maybe, Adam, I could just add. We launched this phase 3 strategy 90 days ago on the earnings call. And there's nothing we've seen since that makes us any less bullish than we were back then. I mean it looks like a really nice opportunity for PTC, and we're pushing forward ahead as aggressively as we can because we'd like to bring that very promising upside growth driver, you know, closer in. So it has a bigger impact on '23 and '24 and so forth than it would otherwise have had. Jay Vleeschhouwer -- Griffin Securities -- Analyst Thank you. Hello. Hi, Jim. Hi, Kristian. A couple of things. With regard to the strength you noted for PLM, at your partner conference six months ago, back in the summer, management presented to the channel, your concept that PLM was no longer just an engineering vault that it was becoming memorial, what you call, multisystem, multidiscipline concept. And the question is, to what extent is that broader, more diverse view of PLM a current part of new business or in the pipeline for new business as compared to the more conventional historical way of thinking about PLM? By our calculation, we are already the second-largest brand by revenue in PLM, and maybe talk about what some of the drivers are to that? And then just a quick clarification you referred earlier to cross-sell. At the Analyst Meeting last month, in the slide deck, you referred to cross-sell 10 times and relatedly account-based selling. PTC is often over the years, talked about cross-sell, but maybe talk about what's different this time in terms of resources and programs across your various segments and your new customer segmentation model. Jim Heppelmann -- Chief Executive Officer Yeah. Well, on your first question, Jay, you know, you are always very pressy on, you've been watching this industry for a long time. When we say multisystem, multidiscipline, what we're really talking about is an enterprise system. And so what's happened in the last couple of years is PLM has graduated from being an engineering data management system to being an enterprise system that contains the system of record for the product definition. And so if you're in manufacturing, well, you need to know the product definition. If you're in procurement, you need to know the product definition. If you're all on an installation or a support call, you probably need to know the product definition. So definitely what's happened is that the enterprise deployments of Windchill are multiple times larger than the engineering deployments of Windchill. So something that's been driving growth for some years now is that the new deals we're taking are more and more frequently enterprise deals and they're larger. You may remember, last quarter, I told you we took the largest deal we had taken to date from a med device company. And the second thing that's happening is, we're circling back to those companies who had deployed the engineering solution like say, Scheffler, and we're upselling them to the enterprise solution and turning that into a much bigger opportunity for us. So definitely, that's a real thing, and it's been driving the momentum we've seen in Windchill for years. And frankly, there's a lot of it out ahead of us even before we start talking about SaaS. The upsell from a departmental solution to an enterprise solution is a driver, taking that whole enterprise solution to SaaS is a whole another growth driver that's on top of that and sort of orthogonal to it. And then on the account-based selling, there's two ways to look at that. Cross-selling into your accounts is a great thing. You have established relationships. It's much easier to sell another product to an existing customer than to sell a new product to a new customer or a first product to a new customer. At the same time, we like new logos. So it's really always about the balance of how much do you invest in new logos pursuits versus how much do you invest in selling more to the companies who know and trust you. And I think perhaps with IoT and AR, we realized we had over pivoted toward new logo, which is just generally speaking, less productive selling, you might imagine. And so the reason we formed this digital thread group, which brought CAD and PLM and IoT and AR together under Troy Richardson, was to really lubricate how these products work together and how we position them together and to be able to start anywhere and sell up and down that chain. So it's a good strategy. It's one that we -- it's a muscle we've developed well over the years. We really built the Windchill business, largely by cross-selling to the Creo base. And I think this is going to be something that will help us a lot to kind of get the right balance of new logo pursuits in cross-sell. Ken Wong -- Guggenheim Securities -- Analyst Thank you so much for taking my question. Jim or Kristian, I wanted to perhaps dive into the double-digit organic bookings growth. You know, I couldn't help and notice you guys also had a very large Servigistics expansion deal with the Air Force. I mean how much of that was already in expectations? Or did you get some boost there from timing shifts or anything of that nature? Jim Heppelmann -- Chief Executive Officer Yeah. Let me tell you, none of that actually contributed to the double-digit growth because that was a Q4 deal. You know, we released it when we had approval to release it, and I commented on it because it was, you know, an important customer and so forth. And let me say that deal, again, that was closed in Q4, both represented five years of extension, but also about a 50% growth in a ramp that happens over -- I think it's three years. So it roughly goes from a $10 million run rate to a $15 million run rate over three years and stays there for a couple more. That's what the contract contemplates. So some of that will come into ARR in Q4 of this year, but the bookings actually were in Q4 last year. So that strength -- the strength we saw in Q1 was exclusive of that Air Force deal, which just means it was really great strength. So anyway, it was hard to pin down where the strength comes from because it came from CAD. It came from PLM. The IoT number was actually pretty decent. It didn't all go into ARR. And then, of course, the velocity numbers and the FSG numbers. So it was broad-based in all geographies and really in all product lines. Jim Heppelmann -- Chief Executive Officer Hello, Matt. Matt Broome -- Mizuho Securities -- Analyst Thanks, man. So Jim, I mean, I guess, just on that -- sorry, just deal that I can just mention. Given the importance of supply chain management right now, are you seeing like ramping demand to the solution elsewhere? And sort of following on from that, is there a chance that FSG ARR could actually accelerate on the back of that demand beyond the sort of the mid-single-digit level and actually become sort of more strategic in a way? Jim Heppelmann -- Chief Executive Officer Yeah. I mean that's one of the points, Matt, that I brought up at the recent Investor Day is that we've generally modeled FSG to be roughly flat, flat about plus 1% to 2%. But it's actually been performing. I think last year, Kristian, wasn't up 7%, FSG. It was up 6% here again in Q1. So yes, we're overperforming and Servigistics is one of the key drivers. And then the second one probably is retail PLM, which has also been doing fairly well. So definitely, there's some -- I think we'll be conservative and leave the FSG sort of guidance where it is in the near term, but I do like overperforming it because it's a growth driver. The FSG business is about the same size as the IoT and AR business. So every point of growth we get there is pretty meaningful. Matt Swanson -- RBC Capital Markets -- Analyst Yeah. Thanks. This is Matt Swanson on for Matt. I'll kind of follow up on a piece of both Adam and Jay's questions. So looking at the Scheffler announcement, I think the thing I was really interested in was the idea around standardization and the idea around end-to-end. So could you talk a little bit about your customers' desire around standardization? And clearly, this product road map has really expanded your TAM, but I think one of the upside areas something we -- you know, maybe the holy grail of the transition would be more competitive displacements. And I'm just curious if you're starting to hear, you know, any early or more talk around that because you're building something so differentiated. Jim Heppelmann -- Chief Executive Officer Yeah. I mean, for sure. So the standard thing, I think maybe over the last couple of years, industrial companies have realized that they should be using software, not developing it. And so we saw this in our IoT business, and it's been why we've been heading up the stack with solutions like DPM is, customers would like to buy the software and use it, not buy some kind of a platform and create it because they just don't really know how to create it if I'm frank. So Scheffler had gone down the path of kind of like I said, low-code sort of environments and came back to standard products. And then the end-to-end thing, for sure, the CAD data that's created in Creo and managed in Windchill gets used, for example, in augmented reality, manufacturing, and service instructions much later and in a different part of the company if it's all well managed. And that connectivity from IoT, well, let's say, from CAD to PLM to IoT to AR is what we call the digital thread. And so we actually see so much interest in this that we kind of organized around that principle. Let's stop presenting these products as kind of independent things and let's shine the light on how well they work together in an end-to-end solution. And by the way, how they're all ready to go. That this is something that turn on and use. And that's really what one Scheffler over, but I can tell you, Scheffler is not unique at all. And it's really -- we're organizing to respond to that. SaaS is helpful, by the way, because if you want a lot of technology working end to end, it'd be better not to ship at all to the customer side because it gets complicated. The customer would like to just use it, not set it all up and care and feed for it on-premise. Saket Kalia -- Barclays -- Analyst OK, great. Hey, guys. Thanks for taking my question here. Hi, Jim. Hey, Jim, maybe -- hey, Kristian. Jim, maybe for you, it was great to hear the PLM strength this quarter in bookings. With other companies that have done shifts like this, there's always a risk, I guess, of customers behaving differently, right, whether that's slowing purchases to see what's coming or maybe pulling forward purchases before something new comes out. Now just to be clear, it doesn't sound like that happened here. But can you just stress test that for us a little bit? And what you sort of look at to sort of manage what is, you know, more choices for our customer to make. Does that make sense? Jim Heppelmann -- Chief Executive Officer Yeah. Are you referring -- just let me clarify, are you referring to like SaaS choices being new choices or more broad -- Saket Kalia -- Barclays -- Analyst Yeah, that's right, yeah, Windchill. No, Windchill specifically. Jim Heppelmann -- Chief Executive Officer Yeah. So keep in mind, Saket, we have been selling Windchill as SaaS for some time. Remember, the phase 1, phase 2, phase 3 thing. So since phase 1, we've been selling Windchill, and we showed you, it's got a three-year growth CAGR of 30% in SaaS. So the customer demand is strong. It's just -- on the PTC side, we need to pivot to multi-tenant because in the single-tenant model we just don't have the profitability we like. So the demand is strong. The customers are buying it. Kristian mentioned we had another strong quarter. So it really is, we'd like to meet that demand with a solution that's more efficient for us to operate on behalf of the customer. And that's what phase 3 multitenant really is all about. Now when it becomes more efficient for us, we can then lean in on the promotion and marketing of it, because we haven't really done that. So we've been servicing demand, not driving it. And with phase 3, we think there's an opportunity to drive demand and, you know, the preliminary data we've seen this quarter suggest customers are very responsive, both to buying new systems that way, but also to lifting and shifting the previous systems they bought and giving them to us to operate and serve back to them in a SaaS model. Joe Vruwink -- Robert W. Baird and Company Great. Hi, everyone. Just to go back to bookings, does the strength this quarter absent mega deals suggest anything about either the demand environments or maybe just the health of your mid-market and SMB customers? And looking ahead, are there going to be certain things you think about or track when contemplating, you know, the probability of more mega deals or maybe the larger ARR contributors for PTC, maybe, you know, being a bit more represented in future bookings? Jim Heppelmann -- Chief Executive Officer Kristian, let me again take a stab at that and maybe you'll find things to add. So I think if you look at the bookings, again, they were phenomenal, and it's hard to pin down. It wasn't one geography. It wasn't one product. It was all geographies, all products. So I think it tells us that the end market is very healthy. And I would say, for two different reasons. On one hand, the PMIs are in good shape. That's helpful. On the other hand, the interest they have in the digital thread, digital transformation story, and the interest they have in SaaS is secular. That interest is not related to the PMIs, it's kind of independent of them. And so I think that we're just in a very healthy situation where industrial companies are leaning in on trying to get more digital. They see PTC as having a fairly unique and compelling portfolio, and they're interested in engaging and trying to make their companies more efficient. I can tell you, at Scheffler, for example, it's one of the top initiatives in the company is to get more digital. And as it relates to the whole product life cycle, the partners PTC. And we see that kind of phenomenon happening in a lot of places in the industrial world. So I think it's just good, strong, secular and as well macro-environment out there right now. But I'll remind you that we've had good performance even when the macro environment wasn't so strong. So all things being equal, I like the strong macro. But we're 17 quarters in with double-digit growth in the core business, and there were a lot of bad macro quarters over the course of those 17. So I think it really is the secular driver. Kristian, anything? Kristian Talvitie -- Chief Financial Officer Yeah. I mean I agree with all that. I mean, actually, just on the big deal dynamic, you know, what we used to call mega deals. We haven't -- I think we've had four in the past four years. Jim Heppelmann -- Chief Executive Officer Yeah. Well, keep in mind, perpetual drove bigger upfront purchases and subscription or SaaS tends not to. Kristian Talvitie -- Chief Financial Officer Yeah, which is my point that we've been seeing good strong bookings performance and bookings growth, you know, even with the absence of what used to be a fairly regular occurrence back in the perpetual days, like we really don't see a lot of those. Jim Heppelmann -- Chief Executive Officer Yeah, it's a good healthy business. OK. Next question. Blair Abernethy -- Rosenblatt Securities -- Analyst Thanks very much. Guys, just maybe a quick question on -- around partnerships, in particular. I wonder if you could just give us a little deeper dive into how things are going with Rockwell and as well on the simulation side with Ansys? Jim Heppelmann -- Chief Executive Officer Yeah. So the state of the partner economy is good and, you know, Microsoft, I could put on that list, is also strong. With Rockwell, you'll remember in the past quarters, I had said we should take a bit of a conservative posture as it relates to what Rockwell would contribute to PTC's numbers here in fiscal '22. And we did that because Rockwell had made a big acquisition. You know, Rockwell never completely agreed with me on that. Their own public commentary kind of indicated they didn't worry too much about that. And in Q1, they were right. So we're pleased to see that Rockwell's contribution was solid in Q1 and starting to feel pretty good about the year. I'll tell you one thing is this DPM solution appears to be a very good fit with Rockwell. And in fact, their Calypso alarm is probably lined up to be our strongest partner in promoting DPM. So we're very happy with that. Calypso has a long-term relationship with PTC that even predates their acquisition by Rockwell. So great alignment around DPM. Again, DPM is a high-value up-to-stack solution that drives bigger deal sizes, and we think will be a very sticky solution. So lots of optimism around that. With Ansys, we continue to differentiate now with best-in-class simulation. So whereas simulation some years back would have been viewed as a soft spot for PTC. Now it's a strength. If we're competing against Autodesk or Siemens or Dassault, nobody is going to have a better simulation story than PTC because nobody has a better simulation story than Ansys, and Ansys products are built into PTC products. So that's been going well. And then, of course, with Microsoft, that partnership is performing well and poised to get a lot bigger because as we bring more stuff aggressively to SaaS, a whole lot of that is going to land on Azure. So I think all three partnerships are alive and well and as important as ever and helping us achieve the kind of results that we're achieving. Sterling Auty -- J.P. Morgan -- Analyst Yeah. Thanks. Hi, guys. Just wondering if you could characterize with the headcount changes that you pointed out are necessary to facilitate the acceleration to SaaS. Where are you in that process? What's left to go? And kind of what's the time frame that you expect to complete that over? Jim Heppelmann -- Chief Executive Officer Yeah, Kristian, I'm thinking of the numbers we're largely done, but not completely. Eighty percent, 90% done. Kristian Talvitie -- Chief Financial Officer Yep, with the exiting. Jim Heppelmann -- Chief Executive Officer Yeah. I mean we'll be hiring people throughout the year. So -- but in terms of the people who are exiting, they're largely exited by now that largely happened within the first quarter. Sterling Auty -- J.P. Morgan -- Analyst Understood. Thank you. Jim Heppelmann -- Chief Executive Officer OK. Well, thank you, all. There's a lot of good questions and, you know, I think good answers because the business is performing very well right now. ARR is doing well. Bookings are doing well. Free cash flow is doing well. You know, I think we executed -- through good times and bad, we executed through the changes we made over the last quarter, and we're set up to do pretty well for the balance of the year. So, we're very confident and, you know, look forward to talking to you all in 90 days if we don't happen to cross pass with you sooner in an investor event or what have you. So, thanks a lot for joining us and have a good evening. Kristian Talvitie -- Chief Financial Officer Thanks, everyone. Duration: 59 minutes Call participants: Matthew Shimao -- Head of Investor Relations Jim Heppelmann -- Chief Executive Officer Kristian Talvitie -- Chief Financial Officer Andrew Obin -- Bank of America Merrill Lynch -- Analyst Yun Kim -- Loop Capital -- Analyst Jason Celino -- KeyBanc Capital Markets -- Analyst Adam Borg -- Stifel Financial Corp. -- Analyst Jay Vleeschhouwer -- Griffin Securities -- Analyst Ken Wong -- Guggenheim Securities -- Analyst Matt Broome -- Mizuho Securities -- Analyst Matt Swanson -- RBC Capital Markets -- Analyst Saket Kalia -- Barclays -- Analyst Joe Vruwink -- Robert W. Baird and Company Blair Abernethy -- Rosenblatt Securities -- Analyst Sterling Auty -- J.P. Morgan -- Analyst More PTC analysis All earnings call transcripts\",\n          \"[Operator Instructions] Now I would like to turn this call over to Mr. Adolfo Castro, Chief Executive Officer. Please go ahead, sir. Adolfo Castro Rivas -- Chief Executive Officer Thank you Kathy and good morning everyone. Thank you for joining us on the conference call to discuss ASUR's first quarter financial and operating results. Before starting the call, I would like to express my hope that you and your families are healthy and safe in these uncertain times. As a reminder, please note that certain statements made during the course of our discussion today may constitute forward-looking statements which are based on our current management expectations and beliefs and are subject to a number of risk and uncertainties that could cause active results to differ materially, including factors that may be beyond our company's control including the impact from COVID-19. For an explanation of these risks, please refer to our filings with the US Securities and Exchange Commission and the Mexican Stock Exchange. Overall, our first quarter results were good. The year began in solid footing before we started to see the impact of COVID-19 pandemic in the second half of March. It resulted in the disruption of global travel industry. Importantly, in the end of the first quarter we had healthy balance sheet which I will come back and discuss in more detail later in my presentation. I'm going to start today's presentation with some comments regarding COVID-19 and the impact on the industry, on our business, and the steps we are taking to mitigate this disruption to the best we can in this rapidly changing environment. From an industry perspective, since mid-March, many governments have issued flight restrictions in an effort to mitigate the spread of COVID-19 virus. In turn, capacity has been severely reduced and very few people are booking flights as most are in some form in lock down around the world and not traveling. With respect to our airports, the situation varies by country and could be subject to change depending upon how fast or slow the pandemic is brought under control. Colombia has been the most active and we've suspended operations at all six of our airports since the third week of March with domestic flights suspended until April 27 in accordance with the published decree and most recently extended to up to May 11. International travels have been suspended through May 13. By contrast, in our airports in Puerto Rico and Mexico remain open, although there's significant reduced flights and passenger traffic. As a result, total passenger traffic declined sharply in the second half of March, down nearly 69% year over year between March 16 and March 31. By country, we show the margin decline in Colombia around 77%, followed by Puerto Rico down 73% and Mexico with 63% decrease [Indecipherable]. Additionally starting in mid-March, some of the airlines as well as some tenants that operate in our airports began asking for assistance either through discounts on payments owed to ASUR or by extension by payment which resulted in a higher accounts receivables in March in Mexico and Colombia, up 54% and 78% year-over-year. We are having ongoing commercial discussions with these companies with respect to their contracts. Moving next to action we have taken, starting with health and safety. Following the guidelines of relevant health agencies, we have implemented health and safety protocols for both our airport employees and passengers travelling through our airports. For example, protective gear such as wearing masks is required for airport staff. We have also stepped up disinfectants and sanitization practices, once again in accordance with the guidelines of local health authorities. Lastly, where possible, we have also implemented remote working points. Moving next to ensuring continuity of our business. We have introduced cost reduction initiatives across our airports. The impact of these initiatives however is not expected to be significant vis-a-vis the potential decline in passenger traffic at the majority of the cost structure is different, except for concession fees and technical assistance in Mexico which are biannual cost. We are prepared to take additional step, if needed, to respond to the evolving business environment. Now, let me talk about our financial situation. We entered this quarter in a position of strength with strong liquidity and very low principal payments required through year end. Additionally we believe the company has sufficient liquidity to meet its obligations and continue operating in the normal course of business. Our cash position ended at MXN7.8 billion which was up from MXN6.2 billion at the year-end 2019. And subsequent to the quarter end, as we further strengthen our financial positions as our subsidiary in Puerto Rico drew down an additional $10 million of its committed line of credit. The line of credit [Indecipherable] support for the capex projects we have under construction, Apelian airport in Puerto Rico. We closed the quarter with total debt of MXN15.3 billion. Although 11% high than the year-end 2019, this was due to the conversion effect from the depreciation of the peso to the dollar. As a reminder, the majority of our debt, 54% is denominated in the US dollars which is at our subsidiary in Puerto Rico. 26% of total debt was denominated in Mexican pesos and 20% in Colombian pesos. We have principal payments of only MXN432 million coming due over the next three quarters. This represents less than 3% of ASUR's total debt. With respect to that ratios, net debt to last 12 months EBITDA stood at 0.7 times at the close of first quarter '20. You can see the interest coverage ratio by country in the table we have included in the annual release this quarter. Now, stepping back for more, since we began operations over 20 years ago, we have successfully navigated through many very significant challenges. From the 9/11 event in 2001 to [Indecipherable] into 2005 and 2008 and 2009 business financial crisis, H1 and H2 and the bankruptcy of 50% of airlines in Mexico which cut planes capacity in Mexico by more than half. Following each of these events, passenger traffic recovered, although recovery time varied from 13 months to 26 months and then continued to grow. Between 2000 and 2019, annual passenger traffic increased the compound annual growth rate of 6.6%, up from slightly over 10 million to historical high to over 34 million last January. We believe the COVID-19 pandemic is unique in that sense it is global event and with a broad disruption in travel and economies worldwide and could change the way of travelling in the future while a vaccine or a cure is found. Summing up this section, we have a strong balance sheet, we have generated years of consistent profitability and we exercise prudent capital management. In the sense we believe that we cannot be very prepared for an event of this magnitude, but of course given its great uncertainty on the final effects in the worldwide economy and that travel will be [Indecipherable]. Now turning to our first quarter results, more details can be found in the press release issued last evening. Like I mentioned this part of my presentation, let me spend with the effects of the business in late March. We believe we had solid results in the first quarter 2020. Total passenger traffic was down in most of the airports, which leads to a total passenger decrease of slightly 6% YoverY. This was primarily due to the fallout from COVID-19 and the impact of the global travel industry beginning in the second half of March. Our airports in all three countries experienced total passengers decline from a low of nearly 3% in Colombia to a high 8% in Mexico. Puerto Rico passenger traffic was down 4%. All three countries reported declines in both domestic and international traffic. Moving next to the P&L highlights, revenues ex construction were relatively unchanged at 4% increase in revenues from non-aeronautical services was offset by a 3% decline in aeronautical revenues. Commercial revenues per passenger increased 11% year over year, reaching MXN116.3. This was driven by solid performance across the region. Mexico posted a good performance with an increase of 11% on a per passenger basis benefiting from the currency peso devaluation and regulated revenues. Puerto Rico posted 7% increase per passenger benefiting from peso depreciation and finally Colombia saw a 33% increase on a per passenger basis, reflecting the 43 new stores opened over the last year and currency depreciation. The main drivers were ground transportation and car rentals. Moving on to profitability, reported consolidated EBITDA increased 3% from the same period over the prior year. Both periods benefited from insurance recoveries related to the Hurricane Maria. In the first quarter '20, it amounted nearly MXN124 million while last year the amount was dragging over MXN41 million. Excluding these recoveries, consolidated EBITDA was essentially flat year-over-year at MXN2.7 billion. Ex-IFRIC 12 and without taking into account insurance recoveries in both quarters, adjusted EBITDA margin increased 20 basis points to 66.7% this quarter. A few comments about capital allocation. Capital expenditures were MXN353 million in the quarter. Of these, nearly MXN58 million was allocated in Mexico due to the terminal expansion of Merida airport. For the full year, and as we have discussed before, our non-prevalent plan in Mexico calls for investment of approximately MXN5.3 billion for the full year. At the current time, there are no changes to the planned continuation of the foreigners tax relief of the second one we have at Cancun airport and the beginning of the first expansion at the Merida. Our plans call for a conclusion of Phase 1 of the Merida terminal expansion and typically the second phase this year. Nevertheless, due to the COVID-19 health crisis, you may see some disruption in the construction process, attributable to stay-at-home, the combination and we have informed the government about this situation. In Puerto Rico we have made investments of MXN114 million this quarter, mainly from the connection with some major maintenance referred tax relief. Finally, capex in Colombia amounted to MXN1 million related to maintenance. Last year we concluded our committed capex was at MXN20 million. And going forward, we only expect to incur a major maintenance capex in Colombia. Next, our Annual General Meeting from yesterday, shareholders approved an ordinary net cash dividend of MXN8.1 per share to be paid, subject to the Board's approval on or after May 11, 2021 in a single installment. In conclusion, we are proactively responding to the developing situation. No one can control the virus or even the economic fallout. But we can control how we react to the crisis. I am optimistic about the prospects for the future both navigating through the current crisis and in the long term recovery. I believe that we are well positioned with a healthy balance sheet. We had a solid first quarter results. We believe in the strategies that we are executing. This ends my prepared remarks. Kathy, please open the lines for questions. We'll go first to Alejandro Zamacona of Credit Suisse. Alejandro Zamacona -- Credit Suisse -- Analyst Thank you Adolfo, thanks for the call. Two questions from our side. The first one is on the aeronautical maximum tariff. So, considering that airlines have been negotiating with most of airports and in some cases some fees have not been charging. What could we expect for maximum tariffs in the short-term meaning the second quarter and in the immediate term, meaning year end 2020? Could we still expect tariffs to be close to the maximum level? Adolfo Castro Rivas -- Chief Executive Officer Alejandro, hi, good morning. Well, basically what we are seeing today is a very reduced demand. So we believe that there is no effect if we try to reduce our fees for the month of April or the month of May. So we have maintained our tariffs and we believe that we can comply with -- we have to maintain compliance toward the year end. Alejandro Zamacona -- Credit Suisse -- Analyst Okay, thank you. And my second question is on the non-aeronautical business. Same thing in the same context, what could we expect in the short term for commercial revenues per passenger? Have you grant any rent payments facility to payments or any deferrals? Thank you. Adolfo Castro Rivas -- Chief Executive Officer Most of our contracts, as you may know, they have to pay higher of the minimum guarantee payment per passenger or a percentage of sales. So if we do not have passengers, we will not have to pay rent. So it's made automatically. So in that sense, we are not reducing or adjusting the contracts. Alejandro Zamacona -- Credit Suisse -- Analyst Okay, thank you Adolfo. Adolfo Castro Rivas -- Chief Executive Officer You're welcome. Fernando Sanchez -- Bradesco BBI -- Analyst Hi, good morning and thanks for taking my question. My question is light of the likelihood of the GDP contraction beyond 5% I just wanted to ask if you have had the opportunity to discuss with the authorities the possibility of delaying the 2021 and the key mandatory capex? Adolfo Castro Rivas -- Chief Executive Officer Hi, good morning. Well as you are aware, the contract has a clause that says that the maximum tariff can be reviewed in the case of Mexico in an external way. When on the Mexican GDP drops by more than 5% in a year and that's happened in fact on track. Of course with the current circumstance and the current expectations from analysts, it is possible that the Mexican GDP will drop by more than 5% this year. So in that sense, we will be we -- and the possibility of review our maximum time in an external rate. That's for next year, but not this year. Fernando Sanchez -- Bradesco BBI -- Analyst Okay. Thank you very much. Adolfo Castro Rivas -- Chief Executive Officer You're welcome. Carlos Peyrelongue -- Bank of America -- Analyst Thank you. Good morning Adolfo. Thank you for the call. On the something I couldn't hear well because of the connection but can you comment as to whether the dividend will be kept or there is the possibility of cutting the dividend until we have more sense about passenger traffic? That would be the first question. And the second would be related to cash burn, if you could give us an idea of what your cash burn is on a quarterly basis, just to get a sense of compare that primarily to your strong cash position. Thank you. Adolfo Castro Rivas -- Chief Executive Officer Yes, of course. In the case of the dividends, yesterday we held Annual Shareholders Meeting, they have sadly approved the dividend that it was proposed MXN8.1 per share. But it was -- this was subject to the approval from the Board to the moment of the payment that's from May 11, 2021. So the Board will have to approve when this dividend will be paid. In the case of the cash burn, what I said to you during the initiative months, is that our currency structure is basically fit. The only variable pieces are the technical assistance fee and the concession fees we paid to the government. So we are working and just to remember the case of Mexico is 5% as well as in Puerto Rico, and in the case of Colombia its' 19%. So this of course will reduce -- our passenger traffic is reduced and our income gets reduced. The remaining is basically, of course, we are taking measures to try to reduce as much as we can, all the expenses in the companies. But as I said, at the end, in the overall picture, the cost reduction will not be significant in comparison with reduction in the revenues of the company. Andressa Varotto -- UBS -- Analyst Thank you very much for taking my question. So my question is if have plans to negotiate with the government postponement of the mandatory capital is this possible? Thank you. Adolfo Castro Rivas -- Chief Executive Officer Could you repeat the question? I couldn't hear you. Andressa Varotto -- UBS -- Analyst Yes. So my question is if you plan to negotiate with government the postponement of mandatory capex? Adolfo Castro Rivas -- Chief Executive Officer As I said before, in accordance with the contract, we do not have that possibility this year. But of course, with the given standards [Phonetic] and as I said it in my initial remarks, during an expansion situation and that expansion situation is that some companies have stopped operations [Indecipherable] and that it was reactivated later on, but there was a decree from the Mexican government that also named the steel and glass that is produced in the country will be used for the project. So in that sense, at the moment it's almost impossible for us to expand our 10-year buildings without these material. So we have this situation to the government. So for the moment, what we see is that we will see some disruption in our construction process for some months and then we will have to talk about these with the government. That's what I can share with you for the moment on this respect. Andressa Varotto -- UBS -- Analyst Thank you very much. Adolfo Castro Rivas -- Chief Executive Officer You're welcome. Stephen Trent -- Citi -- Analyst Good morning, Adolfo and thanks very much for taking my question. Hope that you and your family are well. Just one quick one for me, I know that it seems that Mexico apparently has not been that active in likely offering any assistance to the corporate sector. What are you hearing from Colombia? Kind of any indications from them with respect to whether aviation industry will get some sort of relief? Adolfo Castro Rivas -- Chief Executive Officer Steve, thank you for your question. So in the case of Colombia in comparison with Mexico they have been more active in the measures that they have been taking. As I said here in the report they were very [Indecipherable] basically closing or sorting down everything as from March 23. And that can be seen in terms of results. In the case of Spain and the active they have in comparison with active cases we have in Mexico. So their curve is decreasing or at least flattening while the Mexican curve is still increasing. In terms of what they have said for our industry, we have been closed since March 23 and they have issued decrees in that respect. Maybe this week, there was a new announcement from the President expanding the process of shutting down everything. As I said in my remarks, for the case of domestic aviation that will be close up to May 11 and in the case of international up to May 30. It is important to remember that in the case of Colombia, 85% of aviation is domestic and 15% is international. That's what we know as of today. Of course all of these may change depending on how fast or how slow they can control the virus in their country. Stephen Trent -- Citi -- Analyst Thank you very much Adolfo. Apologies I couldn't hear all of your remarks. But no indication at this point for example that Columbia's planning a kind of tax relief for aviation or something along those lines offering kind of financial support. Adolfo Castro Rivas -- Chief Executive Officer Well we have not heard anything above that yet. Stephen Trent -- Citi -- Analyst Okay. Appreciate that. I'll let someone ask a question. Thanks Adolfo. Gabriel Himelfarb -- Deutsche Bank -- Analyst Hi, good morning, thanks for the call. I have two questions. The first one is concerning about account receivables. Can you give us like a number or approximate number about what's the total of the sales coming from airlines and in specific from Interjet and American Airlines and my second question is do you think you could obtain some waivers in opex sorry capex your current MDP in Mexico and could you will be able to extend the life of the concession in Colombia? Adolfo Castro Rivas -- Chief Executive Officer Hi, good morning. In terms of the account receivables you can see those in our report, revenue increase in the case of Mexico and Colombia, most of the increase is coming from the land industry. I do not have the details of American Airlines and Interjet you are requesting. In terms of the capex, as I said before, we have informed the government about this current situation. We don't know if they are going to react in that respect. But of course it's going to be almost impossible for us to construct and expand our buildings with that material. So more or less what I say to you. Gabriel Himelfarb -- Deutsche Bank -- Analyst Okay, thank you. Ruben Lopez -- Santander -- Analyst Hi Adolfo, thanks for the call. My question is on commercial revenues. Sorry if you commented on these. But I understanding Cancun operating in just one terminal. So I want to confirm you how are your operations there in Cancun and what are the implications on commercial operations? Are there any penalties with the tenants? What are negotiations here? That's the first one. And the second one is related with the same topic. When we see commercial revenues and we kind of try to compare current levels versus what would be the fixed amount or the fixed part of the minimum payment. I mean can you give us any sense of the guidance here? Thank you. Adolfo Castro Rivas -- Chief Executive Officer Okay. As you have said, yes, in the case of Cancun, we have closed two terminals and we are just operating today in terminal 4. So all the operations of airport have been concentrated there in order to reduce on one side the expenses and of course on the other side be better prepared in the case of these reduced demand. All the stores are working in the case of terminal 4. So terminal 4 is operating as it was before the event. As I said before, most of the contracts, the financial contracts we have with the tenants are related to a minimum guarantee payment passenger. So once again, they do not have, let's talk about one of the deals that is closed. So if they do not have passenger traffic in terminal 2, they almost have to pay the rent. Of course when they operate in terminal 4 their operations will be in the accordance with the amount of passengers we have in that facility. So I would say terminal 4 is operating normally. Ruben Lopez -- Santander -- Analyst Thank you. And when you compare, sorry, the current level of commercial revenues versus what would be the minimum payment from the contract, can you give us any idea on that? Adolfo Castro Rivas -- Chief Executive Officer As I said, minimum payment -- the contract is on a per passenger basis. Ruben Lopez -- Santander -- Analyst Perfect, thank you. And we will now go to Jorge Larocco of Morgan Stanley. Jorge Larocco -- Morgan Stanley. -- Analyst Hi Adolfo, good morning. Thank you for the questions. It's two questions, actually a pretty general question, I was just wondering if you could provide more color on what are the main initiatives regarding our cost reduction efforts. How are those working down, your payment reductions on paid leave of absence, maintenance cost, utility costs, etc. and how are those playing out so far? Thank you very much. Adolfo Castro Rivas -- Chief Executive Officer The main initiatives of course are related to in the case of Cancun in the terms of amounts. So we these key terminals closed, we are not burning the same amount of energy as if they were open. Also in the case of Cancun, we are in the process to shut down and one of the runway because today in accordance with the [Indecipherable] it's not needed. So, that runway will be turned off in terms of light at night also reducing their energy we will have to pay. And in terms of some other measures we are taking, adjusting some of the contracts of nature or mainly maintenance in the case of the buildings are closed and to try as much as possible to reduce operating cost and expenses. But I once again at the end, most of our cost is fixed. So if we apply the cost structure of the company, the most important lines are personnel and utility costs as we have said so. In the case of personnel, we are maintaining the personnel for the event or the crisis and in the case utilities, we are trying, as much as we can to try to reduce that. Jorge Larocco -- Morgan Stanley. -- Analyst Thanks so much Adolfo. Stay safe and have a good day. Adolfo Castro Rivas -- Chief Executive Officer Thank you Kathy and thank you again for participating in our fourth quarter results conference call. On behalf of ASUR, we wish you good day and until we meet, be safe. Good bye. Duration: 34 minutes Call participants: Adolfo Castro Rivas -- Chief Executive Officer Alejandro Zamacona -- Credit Suisse -- Analyst Fernando Sanchez -- Bradesco BBI -- Analyst Carlos Peyrelongue -- Bank of America -- Analyst Andressa Varotto -- UBS -- Analyst Stephen Trent -- Citi -- Analyst Gabriel Himelfarb -- Deutsche Bank -- Analyst Ruben Lopez -- Santander -- Analyst Jorge Larocco -- Morgan Stanley. -- Analyst More ASR analysis All earnings call transcripts\",\n          \"Brian Kearns -- Senior Vice President of Business Development and Investor Relations Thank you, Chris, and thank you, everyone, for joining us today. Joining today's call from Globus Medical will be Dave Demski, president, and CEO; Dan Scavilla, executive vice president and president of Ortho; and Keith Pfeil, senior vice president, and chief financial officer. This review is being made available via webcast accessible through the investor relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. Our Form 10-K for the 2021 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available on the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Dave Demski, our president, and CEO. Dave Demski -- President and Chief Executive Officer Well, thank you, Brian, and good afternoon, everyone. Globus finished an outstanding 2021 with a strong fourth quarter performance. Revenue for the year was a record $958 million, an increase of 21% over 2020 or $169 million in growth. To put that in perspective, our growth dollars alone would have ranked us in the top 10 spine companies in the world. Revenue in 2021 was 22% higher than 2019, an outstanding performance in itself, given the disruption caused by COVID but magnified further by a recent independent research report showing that each of the other top 6 spine companies actually had sales declines over that same time period. We achieved record sales and growth while maintaining industry-leading profitability, generating a record $2.04 in non-GAAP EPS, a 42% increase over 2020, and adjusted EBITDA of 34.6% even as we invested heavily in INR, trauma, and competitive recruiting. Revenue for the quarter was $250 million, up 7% over 4Q '20 as COVID-related headwinds remained strong throughout the quarter. Non-GAAP EPS was $0.49 per share, a 16% decrease compared to the artificially high 4Q '20. Not only were business travel and surgeon education activities severely curtailed last year, several other nonoperational factors, as Keith will expound upon in his remarks, also impacted the decline. Adjusted EBITDA in the fourth quarter was a strong 34%. Enabling technology continues to gain momentum, producing a record $25 million in revenue for Q4, an increase of 40% over 4Q '20. For the full year, enabling technology revenue was $81 million, an outstanding 100% increase over 2020. The clinical superiority of ExcelsiusGPS is the primary factor driving this growing momentum. Robotic utilization, which is the number of cases performed per installed robot, was at an all-time high in 2021. And nearly 30,000 procedures have been completed using ExcelsiusGPS technology since launch. Our spinal implant business continues to experience the flywheel effect of an increasing number of robots being sold combined with increasing utilization of each robot. Our U.S. spine business grew by 3% in Q4 as COVID-related shutdowns had a significant impact throughout the quarter. We saw this trend continue into January, but all signs point to a rebound commencing late in Q1. For the full year, the U.S. spine business grew by 18% as we continued to take significant market share. Robotics pull-through, coupled with contributions from recent product introductions and competitive recruiting, were all factors driving growth. Our international spine implant business grew by 9% in the quarter, a remarkable result in light of COVID impacts and an ongoing drag from Japan. Due to the impact of strategic moves we made in Japan last year, we expect to see continued declines there through the first half of 2022 with growth to follow off a reset baseline. This should result in accelerated overall international growth in the second half of this year. Trauma revenue was up 32% in the fourth quarter and 39% for the full year. Competitive recruiting and new product launches are driving growth. The Anthem Mini Frag system was launched on a limited basis in Q4 with excellent feedback from surgeon users. We are proceeding to full launch in Q1 and have a series of impactful product launches planned for the first half of 2022. The clients have launched the Excelsius 3D imaging system on a limited basis later this quarter with a full launch following in late Q2 or early Q3. There is tremendous anticipation and excitement about this technology among surgeons, and we already have double-digit orders signed. The Excelsius ecosystem, Globus Medical's unique combination of robotics, imaging, and freehand navigation that provides a seamless, scalable, and unmatched clinical experience for surgeons is about to become a reality. I'm extremely proud of our team's performance in 2021, record growth and profitability, exciting, clinically impactful new technology introductions, and an unmatched focus on providing value to surgeons and their patients. Thank you for a great year. I will now turn the call over to Keith. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you, Dave, and good afternoon to everyone joining us for today's call. Globus capped off a record 2021 with a robust Q4 performance despite ongoing COVID-related disruptions and shutdowns. For the full year, 2021 revenue was $958.1 million, growing 21.4% as reported. On a day-adjusted basis, sales grew by 22.1%, with two fewer selling days in the U.S. and international. Net income was $149.2 million, resulting in fully diluted earnings per share of $1.44. Non-GAAP net income was $211.4 million, generating a record $2.04 of fully diluted non-GAAP earnings per share. Adjusted EBITDA was 34.6% for the year, and we generated a record $219.4 million of free cash flow for the full year. Q4 '21 revenue was $250 million, growing 7.1% as reported and 8.5% on a day-adjusted basis with one less selling day in the U.S. and international compared to the prior-year quarter. Net income was $15.1 million, and non-GAAP net income was $51.1 million. Our Q4 diluted -- fully diluted earnings per share was $0.14, while our fully diluted non-GAAP earnings per share was $0.49. Adjusted EBITDA was 34.1%, and we generated $59.2 million of free cash flow for the quarter. Taking a deeper dive into sales. Q4 U.S. revenue was $213 million, 7.2% higher compared to Q4 of 2020 driven by our INR and U.S. spine businesses. International revenue for Q4 was $37.1 million, growing 6.8% over the prior-year quarter led by growth in spinal implants despite lingering COVID impacts and the impact of our strategic changes in Japan as Dave mentioned earlier. On a constant currency basis, international revenue grew by 8.7%. Q4 gross profit was 75.3% versus 73.9% in the prior-year quarter. The 140 basis point improvement was driven primarily by nonrepeating inventory reserves in the prior-year quarter and was consistent with our expectations noted in our Q4 2020 earnings commentary. Full year 2021 gross profit was 75%, compared to 72.4% in the prior year. The increase in full year gross profit is primarily the result of lower inventory reserves and operational and supply chain efficiencies, partially offset by sales mix. Looking ahead to 2022, we project a mid-70s gross profit rate. Research and development expenses in Q4 were $51 million or 20.4% of sales, compared to $15.2 million or 6.5% of sales in the prior-year quarter. The increased spending is primarily reflective of in-process research and development acquired during the quarter. Adjusting for these costs, Q4 2021 research and development expense was $16.7 million or 6.7% of revenue, in line with the prior-year quarter as a percentage of sales, but $1.5 million higher driven by incremental investments in headcount across our spine, INR, and trauma businesses. Our full year 2021 research and development expenses were $97.3 million or 10.2% of sales, compared to $84.5 million or 10.7% of sales in the prior year. Adjusting for the acquisitions made in both periods, research and development expenses were $63 million or 6.6% of sales in 2021, compared to $60.1 million or 7.6% of sales in 2020. The increase in spending is reflective of our continued investment in research and development to foster future growth and is consistent with comments made earlier in the year. We expect our R&D expenses to be approximately 7% of sales in 2022. SG&A expenses in the fourth quarter were $106.6 million or 42.6% of sales, compared to $92 million or 39.4% of sales in the prior-year quarter. The resulting increase is reflective of higher sales compensation and benefit costs as well as increased travel and training expenses driven by the resumption of normalized travel levels following the COVID-19 impacts experienced in the prior year. Full year SG&A expenses were $408.1 million or 42.6% of sales, compared to $354.8 million or 45% of sales in the prior year. The resulting decrease as a percentage of sales is reflective of leverage on fixed costs as a result of the higher volumes when comparing against the COVID impact in 2020. The income tax rate for the quarter was 23.8%, compared to 14.9% in Q4 of 2020 with the resulting increase driven primarily by lower tax benefits associated with stock option exercises. Our full year 2021 income tax rate was 17.3%, slightly lower than the 18.8% in 2020 driven primarily by the nonrecurring tax treatment related to a 2020 acquisition, partially offset by lower tax benefits associated with stock option exercises. Looking ahead to 2022, we expect our effective tax rate to be approximately 20% for the full year, which assumes no significant changes in the current U.S. tax policy. Fourth quarter net income was $15.1 million, and non-GAAP net income was $51.1 million. Q4 diluted earnings per share was $0.14, and non-GAAP diluted earnings per share were $0.49, compared to $0.58 in the prior-year quarter. The quarter-over-quarter decrease is driven by more normalized levels of travel, trainings, and meetings noted above or noted earlier as well as nonoperational items, primarily a higher tax rate as previously mentioned, higher stock compensation expense, and lower interest income. Looking ahead to 2022, we are expecting a mid-30s adjusted EBITDA rate. Full year diluted earnings per share were $1.44, and non-GAAP diluted earnings per share were $2.04, reflecting a 42.2% increase over 2020 primarily related to higher sales volumes following the 2020 impact of COVID-19, partially offset by approximately $0.09 of nonoperating headwinds related to a higher share count and lower interest income. Q4 adjusted EBITDA was 34.1%, compared to 36.2% in the prior-year quarter. Full year 2021 adjusted EBITDA was 34.6%, compared to 29.4% in 2020. Net cash provided by operating activities were $76.3 million for the fourth quarter and a record $276.3 million for the full year 2021. Free cash flow was $59.2 million for the fourth quarter and a record $219.4 million for the full year 2021. The company remains debt free. At this time, the company is establishing full year 2022 guidance. We are projecting full year 2022 sales guidance of $1.025 billion, representing 7% growth versus 2021. We are guiding to a full year fully diluted non-GAAP earnings per share of $2.10, representing 3% growth versus 2021. I note that the 2022 guidance includes approximately $0.10 of nonoperating headwinds, including higher shares worth $0.04, a higher tax rate worth $0.03, and higher stock compensation expense worth $0.03. Adjusting for these nonoperational factors, our 2022 guidance would have been $2.20 or 7.8% higher than 2021. Overall, we view this guidance as appropriately conservative and reflective of the current operating environment around COVID and inflation-related impacts. Our 2021 results represent our teamwork, our commitment, and our focus on execution. We continue to differentiate ourselves in the marketplace. And it is a testament of the hard work and dedication of each of our Globus employees. We remain excited for the future as we continue on our mission of improving patient care. Operator, we will now open the call for questions. Questions & Answers: Matt Miksic -- Credit Suisse -- Analyst Great. Thanks so much for taking the questions and congrats on a really strong finish to a pretty amazing year, given the circumstances. I wanted to follow up on some of the comments around EPS guidance, in particular. As you pointed out, there are some items that ex those items, up 7% to 8%. Can you talk a little bit about where in your guidance you're contemplating things that some of the other companies in the space have talked about like rising input costs, staffing challenges, labor costs, freight, etc., things that generally are driving operating costs up a little bit? Maybe give us a sense of how those figure into your guidance? And I have one quick follow-up. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks. This is Keith speaking. So we projected our guidance at $2.10. And as we look at the year, we see inflation as a market event. Everyone is experiencing it, and we have it baked in our numbers. But when you step back and look at the $2.04 and the $2.10, I commented on the $0.10 of the nonoperating headwinds. But the other things that are impacting the business as we think about getting back to more normalized levels of spend are really the travel and the trainings that go along with the surgeons and [Inaudible] that we provide. That's worth going into the next year likely an $0.08 headwind. And then one of the things that we commented on earlier in the year was our continued investment into R&D. As you look into next year, we're seeing roughly I would say, call it, $0.04 of additional investment in R&D. When you look at those things together, coupled with the inflation, we're landing at about $2.10. Matt Miksic -- Credit Suisse -- Analyst OK. And can you just maybe just elaborate a little bit on the spend or R&D and sort of the expectations for returns in terms of growth or programs that you're investing in? Keith Pfeil -- Senior Vice President and Chief Financial Officer So we're continuing to invest heavily in our spine business and as well as our robotic businesses. We talked about that in Q1 of our earnings call earlier in the year, and really all sign points to us continuing to do that. Dave talked earlier about some of the benefits that we're seeing for robotic technologies. We continue to invest in that and really grow for the future. Matt Miksic -- Credit Suisse -- Analyst OK. And then just one quick follow-up I had was on the environment for robots and spending in capital and equipment in general. Some of the other, again, companies in the space have talked about a fairly strong year for equipment, a strong year for robots. Any sense of whether this is something that needs to sort of take a breather or catch up here in 2022? Or whether orders and demand and pipeline for new deals would indicate just continued strength into 2022? Dave Demski -- President and Chief Executive Officer Yeah. Matt, this is Dave. No, it's very strong. I don't see anything laying off. In our case, in particular, it's been accelerating. I think the demand for Excelsius has been strong, and it's becoming more and more common. The narrative has changed from why robotics to which robot. And I think we're clearly establishing our lead there. And then as I mentioned, there's a lot of enthusiasm over our Excelsius 3D system, which is going to launch later this quarter. We've had every surgeon we show that to seems like they want one. So I don't see it backing off at all. Matt Miksic -- Credit Suisse -- Analyst Great. Thanks and congrats. Dave Demski -- President and Chief Executive Officer Thank you. Matt Taylor -- UBS -- Analyst Excuse me. Hi, guys. Thanks for taking the question. So I wanted to ask the first one about margins longer term. Maybe just talk about the difference between what you're doing this year with some of the investments and obviously, headwinds year over year from spending back to normal and inflation, and how we should think about margins longer term? Would you start to get more leverage at some point? And what would the inflection point for that be? Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. It's a good question. But as I look at where we're at and where we're going, our goal is to always maintain a mid-70s GP. But as we look longer term and look at our EBITDA rates, we're always looking to be in that mid-30s range. We could toggle our investments in various parts of our business to really achieve that, but we're investing now to drive growth -- to drive top-line growth for the future. And as we get that growth, that's going to create more fixed cost leverage in our P&L. So I think by doing that, investing for growth today helps project the margins going forward. I feel that we're going to work to try to stay in that range. Dave Demski -- President and Chief Executive Officer Yeah. I can add a little bit maybe to that, Matt. In the spine business, I don't think you'll see much greater improvement in our margins there, but we have a lot of operating leverage in front of us in the orthopedic side of the business and the capital side. Those are both fairly nascent businesses for us, and we're funding it with spine. But once we start to hit some volume numbers there, I think those businesses will definitely expand. Matt Taylor -- UBS -- Analyst Great. Can I ask a follow-up on the robotics strength? I mean, you talked in the past about getting pull-through on these placements, and obviously had a great year in 2021 with enabling tech. I guess are you still seeing the same kind of trends? And could that bode well for pull-through implants in '22? Dave Demski -- President and Chief Executive Officer Yes. It does. We're seeing that generally the same kinds of trends. And as a company, we're focusing on really going back to that installed base and seeing we can get more users to utilize the technology once it's placed in the hospital. And that's a big focus for us in 2022. Matt Taylor -- UBS -- Analyst Great. Thank you, guys. Thanks so much. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you. Shagun Singh -- RBC Capital Markets -- Analyst Great. Thank you for taking the question. I guess my first one is on Excelsius 3D imaging system. Can you talk to us about the delay? Why is there a delay in the launch? And then just elaborate on your go-to-market strategy. Are you targeting the replacement opportunity or greenfield? You're obviously going after a major competitor. So just any color there would be helpful. And then on the recon robotics, do you still plan to launch that in the second half? And then I have a quick follow-up. Dave Demski -- President and Chief Executive Officer Well, thank you, Shagun. I'll try to knock those off one by one. In terms of the delay, it's just taking longer than we thought. It's nothing significant in terms of the technology hurdle to get over. There's just a lot to do to get that over the line. So I wish we were a bit earlier but very confident we can get it done this quarter. Go-to-market. I think initially, we're going to be targeting our installed base of Excelsius users. Those are -- there's a high demand among them. It's going to make those procedures much more efficient and much easier for them to do. And then from there, we'll be branching out to target more of that free-hand navigation market that you alluded to earlier. And then I apologize, I forgot the last part of your question. Shagun Singh -- RBC Capital Markets -- Analyst I was just wondering if you plan to launch the recon robotics platform in the second half of '22 like you had previously indicated? Dave Demski -- President and Chief Executive Officer No. That's been delayed as well. We're going to be -- early '23 is the target for that. Shagun Singh -- RBC Capital Markets -- Analyst Got it. And then just as a follow-up, I was wondering if you could talk about trends that you're seeing on the procedure volume side in Q1, so in January and February. And spine typically has a high pain burden, so procedures come back quickly. So do you expect the recovery to come in Q1? Or do you expect a longer tail given staffing shortages? Thanks for taking the question. Dave Demski -- President and Chief Executive Officer Sure. Yes, January was really bad, but we've already started to see it turning in February. The last three weeks have all been progressively higher. Not back to where we want it to be, but definitely, I think we've hit bottom. We're going in the right direction. And I'm not going to try to predict what's going to happen with COVID though. That's proven to be frivolous for everyone, but it's encouraging where we are right now. Shagun Singh -- RBC Capital Markets -- Analyst Thank you. Matthew O'Brien -- Piper Sandler -- Analyst Great. Thanks for taking the questions. I guess, Dave, just for starters on the top-line guidance. This time last year, you guided about $35 million below The Street. We end up doing well above what you initially guided and actually what The Street was modeling. And this time, you're guiding about $25 million below The Street. I know January was soft, and maybe Excelsius 3D has pushed a little bit in terms of the contribution. But are there other factors that we should be thinking about? I don't know if it's a rep hiring perspective or a robot perspective that gives you a little bit more caution versus kind of where The Street was modeling things? Dave Demski -- President and Chief Executive Officer Thanks, Matt. I'm sorry we don't pay that much attention to The Street. We look internally to our own forecast, and we always want to be appropriately conservative going into a year. I feel really confident in the business. The U.S. spine business has been just cranking away. The robotic momentum is there. We're going to have 3D out this year. Japan is going to turn around in the second half. So I feel really good about the business. We just have taken a very conservative approach over the years when we give guidance, and we're doing that again. Matthew O'Brien -- Piper Sandler -- Analyst OK. Fair enough. And then the follow-up is on acquisitions. Sorry if I cut somebody off there, but there's been some talk about you guys doing a scale acquisition. I'm curious if you have any thoughts about the need for scale in spine. And then if not, there's some pretty interesting assets still in the spine space, but more on the pain management side of things. Are those higher on the list in terms of things that you potentially are looking at from a acquisition perspective? Dave Demski -- President and Chief Executive Officer No. It's actually a bit different. We're more active in terms of growing the business through BD and on the orthopedic side of the business. I think we're really strong in spine, and there's really nothing in spine that's of interest to us at the moment. We're more focused on growing the other piece of our business, which is smaller. There's nothing, I would say, transformative in our sights right now. But we are looking at several modest-sized deals as been our history in the past. Matthew O'Brien -- Piper Sandler -- Analyst Great. Dave Demski -- President and Chief Executive Officer Did that answer your question? Matthew O'Brien -- Piper Sandler -- Analyst Yep. That's perfect. Thank you. David Saxon -- Needham and Company -- Analyst Yeah. Hi, guys. Good afternoon, and thanks for taking the questions. Maybe one on enabling tech. I mean, it doubled this year, and you've really built out the enabling tech platform with hub and 3D, etc. How should we think about those launches kind of starting to ramp? And could '22 be another double? Dave Demski -- President and Chief Executive Officer Yeah. I think as I said, we're going to get some -- a few units out this quarter and kind of a soft launch, if you will, with the full launch starting in probably end of Q2, it might be into Q3 and then strong in the second half of this year. I don't want to comment on the double. It's -- we don't really drill into the components of our business. I can tell you that we're really excited about what we're seeing from our technology, from the adoption of our technology and not only what's right in front of us, but some things we have coming after that. David Saxon -- Needham and Company -- Analyst OK. Got it. And then maybe on trauma, kind of how close are you to having a full portfolio there? And then in terms of growth, 32% in the quarter. Is that sustainable in '22? Thanks for taking the questions. Dave Demski -- President and Chief Executive Officer Sure. The bag in trauma is by the second half of this year, I think full is kind of interesting term. We're going to have enough in our bag to be a full-line player and be able to compete with the major companies by the end of this year. And is that growth rate sustainable? Yes, I think that's certainly achievable in 2022. David Saxon -- Needham and Company -- Analyst Great. Thank you. Craig Bijou -- Bank of America Merrill Lynch -- Analyst Hey, guys. Thanks for taking the questions. Maybe a follow-up on top-line guidance and to the extent that you guys are willing to share. I mean, how to think about the contributions from each of the businesses? I know generally, you've been reluctant to share that info. But in terms of the composition of the guidance, how do we think about that incremental revenue coming in? Where is it coming from and to what extent? Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. As Dave said earlier, we're not going to get a ton into the parts and pieces. But what I will say is if you look at the business, whether by musculoskeletal and INR or you look U.S. versus international, the parts and pieces of our business we continue to feel extremely positive about as we look into 2022 and beyond. We're investing in our business. We're driving investment for the future, and we feel that we'll see that turn out to us taking share and driving sales growth. I alluded to my earlier prepared comments that our guidance is appropriately conservative, but there's nothing that I sit here and feel that we have kind of an ongoing issue that I would be concerned about our ability to grow across our business, like I said, whether it's U.S., international or musculoskeletal versus INR. Craig Bijou -- Bank of America Merrill Lynch -- Analyst Got it. Thanks, Keith. That's helpful. And then, Dave, I think you alluded to it, but I wanted to ask more specifically how to think about some of the new product rollouts? Obviously, you have 3D coming out and launching this year. But from a new product perspective, is it -- do you have a number of launches coming this year on the spine side? Do you have a number coming on the INR side? Just maybe a little bit more perspective of what to expect during the year. Dave Demski -- President and Chief Executive Officer Sure. Thanks, Craig. I think we've been pretty clear that it's a big one coming with 3D followed by our hub [Inaudible] offering. I think spine, we are typically 10 to 12 launches a year, and that's currently our target going into 2022. Trauma is probably the real bright spot. There is a number of products that we were working on for a while, they're going to hit the early part of this year and through this year. So -- and then our orthopedics business actually has some launches as well. So that's kind of who we are and who we're going to be. And it's -- the number one focus of the company is to drive great technology. Craig Bijou -- Bank of America Merrill Lynch -- Analyst Great. Thanks for taking the questions, guys. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you. Ryan Zimmerman -- BTIG -- Analyst All right. Thanks for taking my questions and congrats on a great year. Just want to follow up on a couple of questions. Dave, when we think about U.S. Spine performance kind of relative to the market, you look at some of the larger players, they were down a bit in the fourth quarter. Some of the smaller players we saw were up double digits. Obviously, a few major players still yet to report next week. But I guess I'm kind of curious if you can kind of talk about the U.S. performance, that growth this fourth quarter relative to the market, and kind of where you think you're tracking relative to that level? And if you could kind of give us color on what you think that level was just given the dynamics in the fourth quarter through the quarter would be helpful. Dave Demski -- President and Chief Executive Officer Thanks, Ryan. It's really challenging to figure out where we are, given COVID. So from the early returns of some of the folks who we have reported, again, we're taking significant share. I can't speak to the smaller guys who have reported or how that impacts us. And I don't really have a feel for the overall market. I know it was heavily impacted by COVID so likely down versus prior year overall. But that's more of just a guess and kind of where we landed versus some of our earlier trends. Our business is strong. I can tell you that. We haven't lost significant pieces of business in the U.S. And we continue to see growth in the recent product introductions, and we continue to sell robots and drive pull-through from that. So it's strong. I just -- I can't really see the overall market, and it's really hard to figure out what's going on given what's happening with COVID. Ryan Zimmerman -- BTIG -- Analyst OK. Just two follow-ups for me. One, we've heard some of the larger capital equipment companies have obviously called out chips as being a gating factor to sales or median demand in 2022. One, want to see if there's any concern there around chips for the Excelsius platform or for 3D and whether that could gate sales? And then I'll just ask the other -- sneak in a quick follow-up, too. The Japan distributor dynamics, how much of a lift should we expect when that distributor dynamic clears in the second half of 2022 on the international business? Thank you. Dave Demski -- President and Chief Executive Officer Sure. In terms of chips, I would just -- I would extend that to all supply chain. So it's not just chips, it's all components are challenging. It hasn't cost us revenue now, but it's certainly on our radar and making our life really hard. So it's a risk that's out there for 2022. I'll let Keith maybe handle the international question. Keith Pfeil -- Senior Vice President and Chief Financial Officer As it relates to Japan and the distributor dynamic, as we look ahead, we finished 2021, I think international grew by about 11%. We've historically said that we believe that the international business can grow mid-to-high teens. I would expect us to be able to get back to that on an annual basis. So you would expect the second half of the year to accelerate ahead of that to potentially balance -- to get closer to that 15 by the end of this year. Ryan Zimmerman -- BTIG -- Analyst Thanks, Kieth. Thanks, Dave. Appreciate it. Dave Demski -- President and Chief Executive Officer Sure. Kyle Rose -- Canaccord Genuity -- Analyst Great. Thank you for taking the questions. I wanted to start on enabling. I mean, look, you put up a good quarter in enabling. I guess a tough backdrop, particularly without the imaging platform. Maybe just help us understand kind of where that stands from a utilization perspective into your customer base. You're talking about the really good utilization there is continuing to see strong pull through. Can you just kind of level set maybe how many of your customers might have it or on a percentage basis or on an absolute basis? Just trying to really understand where we are in the uptake and the adoption within the historical core Globus customer base. Dave Demski -- President and Chief Executive Officer Yes, Kyle. To be honest, I don't feel comfortable sharing that information from a competitive standpoint. Kyle Rose -- Canaccord Genuity -- Analyst Totally fair. I had to try. I also wanted to touch on the orthopedic side of the business. I mean, it's been a couple of years since you acquired the StelKast business. I think earlier in the call, you talked about the fact that the recon robot is going to come in '23. Where do you stand just from an implant perspective? Do you have the right implants there? Do you need to make different investments from an M&A perspective, technologies, distribution? Just help us understand what you need to do on that total joints business before the recon robot comes next year. Thank you. Dave Demski -- President and Chief Executive Officer Sure. We do not have the implant portfolio we need to really make a strong outing. So we are working on that, have been working on that, and expect to roll some products out this year. I don't see us filling the gaps in our product portfolio with acquisitions in terms of hips and knees in particular. I do think there's opportunity for scale there. So that's not off the table because we are very small right now. And then the extremities is an interesting segment for us as well. It's a fast-growing segment. So that's an area where we've taken a look at a few things. Does that help with your question? Kyle Rose -- Canaccord Genuity -- Analyst Yes. Thank you very much. Dave Demski -- President and Chief Executive Officer Sure. Samuel Brodovsky -- Truist Securities -- Analyst Hi. Thank you for taking the questions. Just a first quick one on U.S. Spine. Just would be curious to hear about the portion of growth in the U.S. coming from robotic-specific instrumentation versus where you're seeing potential share gain with other parts of the portfolio? Keith Pfeil -- Senior Vice President and Chief Financial Officer Yes. Thanks for the question. In terms of breaking it out, we typically don't break out the parts and pieces of where the growth is coming from. What I would say is that as you look at our U.S. Spine business, it's really a combination of what we always talked about: new product innovation, our competitive recruiting, and the pull-through from implants. Those three continue to propel the business from a growth perspective, and we see that continuing as we enter 2022. Samuel Brodovsky -- Truist Securities -- Analyst Great. That's helpful. And then when thinking about 3D and going to customers with it, in terms of any competitive trialing, are you seeing it being trialed against other more novel imaging technologies on the market? Or is it typically being compared to the large competitor out there? Thanks. Dave Demski -- President and Chief Executive Officer Interesting question. I assume it's -- we don't really trial against it, but we have customers looking at our technology. And I think their interest just probably lines up with the market share of the other imaging systems in the market, particularly ones that are utilized more in spine. I'm sure that some of the more innovative ones are getting a look, but we don't hear that much about them. So it's not disproportionately, maybe I could answer it that way. Samuel Brodovsky -- Truist Securities -- Analyst Thanks. Steven Lichtman -- Oppenheimer and Company -- Analyst Thank you. Hi, guys. I wanted to ask you first on trauma. Where do you think you stand now in terms of coverage of procedures in terms of your product portfolio? And also from a sales force perspective, I'd just love to get an update on where you feel you are overall in terms of being able to go at the market. Dan Scavilla -- Executive Vice President and President of Ortho Steven, it's Dan Scavilla. So again, it's always the evolving and expanding story. We have about 14 family products out there now. I think with that, we're saying we would cover 50% to 60% of the market. Certainly, plan, as David said, to launch several more this year to cover that further. I believe and through what I'm saying, we're at a point where we're able to get into some significant facilities and support their needs for the most common procedures. And with that that's the main driver of growth to us. So we'll continue to expand the product line and fill that out over time, but we're in a good spot now. With that is the competitive recruiting that's been accelerating for us. So again, we're small, and we have a lot of spaces to fill. But the traction that has been occurring really through 2021 is very promising. And I do feel bullish as we are -- from what I've seen so far in the first quarter of 2022 that that will continue. Steven Lichtman -- Oppenheimer and Company -- Analyst Great. Thanks, Dan. Keith, just a follow-up on gross margin. I apologize if you mentioned this, but just relative to 2021, given the inflation commentary, should we assume gross margin down? Or are there some offsets that can keep it relatively flat to maybe -- or even up in '22? Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. We project the mid-70s GP. I think it's fair to assume that we are seeing inflation just like everybody else, but we're also growing. And it's obviously getting us some leverage in our cost structure. So as I think about 2022, mid-70s is kind of where I see it. I wouldn't project upside. Steven Lichtman -- Oppenheimer and Company -- Analyst OK. Got it. Thanks, guys. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you. Jason Wittes -- Loop Capital -- Analyst Hi. Thanks for taking the questions. Just two follow-ups, one on the guidance and one on trauma. But -- so first off, your guidance, I think the way you described it, especially relating to product launches, kind of assumes a strong second half versus the first half. So related to that, one, are we assuming that -- I know we can't predict COVID, but COVID pretty much works its way throughout the year? And then secondly, related to that, in the first quarter, I'm not sure how to read your comment that January was very weak. It bounced back. Should this be a normalized first quarter? Or are we -- is it going to be a little weaker relative to last year because of the COVID impact and launches? Thanks. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. Dave commented that January was weak, but we were starting to see some bounce back in February. Will it all bounce back in the same quarter versus having some bleed through into Q2? We don't necessarily know. But I think your earlier comment about some of the launches and a strong second half, I think that's directionally correct. Jason Wittes -- Loop Capital -- Analyst OK. And then I don't know if you can comment on this, but you did mention that you had -- it sounds like a record year in terms of sales force hires. In the past, you've kind of given us an indication of how large you've been able to grow your sales force percentage-wise. Can you give us any kind of indication on that in terms of what 2021 look like? And it sounds like 2022, you're optimistic that you can do -- go at a similar run rate? Dave Demski -- President and Chief Executive Officer Yeah. '21 was not a record year for us. I think we had one really strong quarter, but we've had years that were better. That's a renewed emphasis on it. I can tell you the pipeline right now is extremely strong. So we're coming out of the gate strong. But last year was a good year. It just wasn't our best. Jason Wittes -- Loop Capital -- Analyst OK. Thanks a lot. Appreciate it all. Dave Demski -- President and Chief Executive Officer Sure. Duration: 45 minutes Call participants: Brian Kearns -- Senior Vice President of Business Development and Investor Relations Dave Demski -- President and Chief Executive Officer Keith Pfeil -- Senior Vice President and Chief Financial Officer Matt Miksic -- Credit Suisse -- Analyst Matt Taylor -- UBS -- Analyst Shagun Singh -- RBC Capital Markets -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst David Saxon -- Needham and Company -- Analyst Craig Bijou -- Bank of America Merrill Lynch -- Analyst Ryan Zimmerman -- BTIG -- Analyst Kyle Rose -- Canaccord Genuity -- Analyst Samuel Brodovsky -- Truist Securities -- Analyst Steven Lichtman -- Oppenheimer and Company -- Analyst Dan Scavilla -- Executive Vice President and President of Ortho Jason Wittes -- Loop Capital -- Analyst More GMED analysis All earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2535,\n        \"min\": 571,\n        \"max\": 32540,\n        \"num_unique_values\": 6023,\n        \"samples\": [\n          8055,\n          8114,\n          14273\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker_clean\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"AVB\",\n          \"THRM\",\n          \"ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08086309609059458,\n        \"min\": -0.6091428484235492,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 9985,\n        \"samples\": [\n          0.0115302149459788,\n          0.1053023227425508,\n          -0.0781132122800544\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 22
        }
      ],
      "source": [
        "df_analysis=pd.read_csv(\"/content/drive/MyDrive/Earnings call prediction/cleaned_stock_price_reaction.csv\")\n",
        "df_analysis.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 23,
      "metadata": {
        "id": "8ioyN99unPEw",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "87a2e9ed-ebd3-4f4c-bc2e-110514990dfb"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "(10913, 11)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['date', 'exchange', 'q', 'ticker', 'transcript', 'Timestamp',\n",
              "       'Date_only', 'Clean_Text', 'word_count', 'ticker_clean',\n",
              "       'Price_change'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 23
        }
      ],
      "source": [
        "print(df_analysis.shape)\n",
        "df_analysis.columns"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 24,
      "metadata": {
        "id": "t0EntZ3Hnae7",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 335
        },
        "outputId": "c377b0b3-3d19-4396-87cf-8df6d6dbe074"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "count    10913.000000\n",
              "mean        -0.000077\n",
              "std          0.080863\n",
              "min         -0.609143\n",
              "25%         -0.038139\n",
              "50%         -0.000344\n",
              "75%          0.037409\n",
              "max          0.715686\n",
              "Name: Price_change, dtype: float64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Price_change</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>count</th>\n",
              "      <td>10913.000000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>mean</th>\n",
              "      <td>-0.000077</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>std</th>\n",
              "      <td>0.080863</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>min</th>\n",
              "      <td>-0.609143</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25%</th>\n",
              "      <td>-0.038139</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>50%</th>\n",
              "      <td>-0.000344</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>75%</th>\n",
              "      <td>0.037409</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>max</th>\n",
              "      <td>0.715686</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div><br><label><b>dtype:</b> float64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 24
        }
      ],
      "source": [
        "df_analysis['Price_change'].describe()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 25,
      "metadata": {
        "id": "JxAudB0xn6Rb",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "117086ac-1160-44ce-aad0-d371e0ad1872"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "No. of Earning calls resulting extreme gain : 883\n",
            "No. of Earning calls resulting extreme loss : 862\n"
          ]
        }
      ],
      "source": [
        "extreme_gain_count=df_analysis[df_analysis[\"Price_change\"]>0.1].shape[0]\n",
        "extreme_loss_count=df_analysis[df_analysis[\"Price_change\"]<-0.1].shape[0]\n",
        "print(f\"No. of Earning calls resulting extreme gain : {extreme_gain_count}\")\n",
        "print(f\"No. of Earning calls resulting extreme loss : {extreme_loss_count}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 26,
      "metadata": {
        "id": "1Y1jm2ckqK5l"
      },
      "outputs": [],
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import seaborn as sns"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 27,
      "metadata": {
        "id": "IeN0RDxbqQ8Y",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 570
        },
        "outputId": "3b36af6d-88bf-4556-8cde-531a6cdaf530"
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1200x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ],
      "source": [
        "CURRENT_THRESHOLD = 0.10\n",
        "LOWER_THRESHOLD = 0.05\n",
        "\n",
        "plt.figure(figsize=(12,6))\n",
        "sns.histplot(df_analysis[\"Price_change\"],bins=100,kde=True,edgecolor=\"none\",color=\"skyblue\",alpha=0.7)\n",
        "plt.axvline(CURRENT_THRESHOLD,color=\"red\",linestyle=\"--\",linewidth=2,label=f\"+{CURRENT_THRESHOLD*100:.0f}% Threshold (10%)\")\n",
        "plt.axvline(-CURRENT_THRESHOLD,color=\"red\",linestyle=\"--\",linewidth=2,label=f\"-{CURRENT_THRESHOLD*100:.0f}% Threshold (10%)\")\n",
        "\n",
        "plt.axvline(LOWER_THRESHOLD,color=\"green\",linestyle=\":\",linewidth=1,label=f\"+{LOWER_THRESHOLD*100:.0f}% Test Threshold (5%)\")\n",
        "plt.axvline(-LOWER_THRESHOLD,color=\"green\",linestyle=\":\",linewidth=1,label=f\"-{LOWER_THRESHOLD*100:.0f}% Test Threshold (5%)\")\n",
        "\n",
        "plt.title(\"Distribution of Price change day0 open to day 1 close\",fontsize=16)\n",
        "plt.xlabel(\"Price_change (in decimal)\",fontsize=12)\n",
        "plt.ylabel(\"Frequency\",fontsize=12)\n",
        "plt.grid(axis=\"y\",alpha=0.5)\n",
        "plt.legend()\n",
        "plt.show()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 28,
      "metadata": {
        "id": "rfYBvmR6Y2-a",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "736d8be9-c2a3-4131-9f72-1284b1cdcbec"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Target_Class column created\n"
          ]
        }
      ],
      "source": [
        "THRESHOLD=0.05\n",
        "conditions=[(df_analysis[\"Price_change\"]>=THRESHOLD), (df_analysis[\"Price_change\"]<=-THRESHOLD)]\n",
        "values=[\"Gain\",\"Loss\"]\n",
        "df_analysis[\"Target_Class\"]=np.select(condlist=conditions,choicelist=values,default=\"Neutral\")\n",
        "print(\"Target_Class column created\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 29,
      "metadata": {
        "id": "75eKJ98_aLdf",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "2584e0d4-e9f8-45f9-84ca-d90bc5a3627f"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "class_distribution_counts are Target_Class\n",
            "Neutral    6621\n",
            "Loss       2186\n",
            "Gain       2106\n",
            "Name: count, dtype: int64\n",
            "Class distribution percentage are Target_Class\n",
            "Neutral    60.670760%\n",
            "Loss       20.031156%\n",
            "Gain       19.298085%\n",
            "Name: count, dtype: object\n"
          ]
        }
      ],
      "source": [
        "class_distribution_counts=df_analysis['Target_Class'].value_counts()\n",
        "class_distribution_percent=class_distribution_counts.apply(lambda x:f\"{(x/class_distribution_counts.sum())*100:2f}%\")\n",
        "print(f\"class_distribution_counts are {class_distribution_counts}\")\n",
        "print(f\"Class distribution percentage are {class_distribution_percent}\")"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "dpdi2MjEcShg"
      },
      "source": [
        "# **4 Feature Engineering**"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "H0whx68RdZ-A"
      },
      "source": [
        "**Temporal Features**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 30,
      "metadata": {
        "id": "YcHKXEyrcmFv"
      },
      "outputs": [],
      "source": [
        "df_analysis['Date_only']=pd.to_datetime(df_analysis[\"Date_only\"])\n",
        "df_analysis[\"DateOfWeek\"]=df_analysis[\"Date_only\"].dt.day_of_week\n",
        "df_analysis[\"Month\"]=df_analysis[\"Date_only\"].dt.month\n",
        "df_analysis[\"Quarter\"]=df_analysis[\"Date_only\"].dt.quarter"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "sV8psN1T0tCa"
      },
      "source": [
        "**bold text**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 31,
      "metadata": {
        "id": "646uLoOidkel",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "ec85d2f5-f024-462d-d068-e9675ef0d5fa"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting category_encoders\n",
            "  Downloading category_encoders-2.9.0-py3-none-any.whl.metadata (7.9 kB)\n",
            "Requirement already satisfied: numpy>=1.14.0 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (2.0.2)\n",
            "Requirement already satisfied: pandas>=1.0.5 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (2.2.2)\n",
            "Collecting patsy>=0.5.1 (from category_encoders)\n",
            "  Downloading patsy-1.0.2-py2.py3-none-any.whl.metadata (3.6 kB)\n",
            "Requirement already satisfied: scikit-learn>=1.6.0 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (1.6.1)\n",
            "Requirement already satisfied: scipy>=1.0.0 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (1.16.3)\n",
            "Collecting statsmodels>=0.9.0 (from category_encoders)\n",
            "  Downloading statsmodels-0.14.6-cp312-cp312-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl.metadata (9.5 kB)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.0.5->category_encoders) (2.9.0.post0)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.0.5->category_encoders) (2025.2)\n",
            "Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.0.5->category_encoders) (2025.2)\n",
            "Requirement already satisfied: joblib>=1.2.0 in /usr/local/lib/python3.12/dist-packages (from scikit-learn>=1.6.0->category_encoders) (1.5.2)\n",
            "Requirement already satisfied: threadpoolctl>=3.1.0 in /usr/local/lib/python3.12/dist-packages (from scikit-learn>=1.6.0->category_encoders) (3.6.0)\n",
            "Requirement already satisfied: packaging>=21.3 in /usr/local/lib/python3.12/dist-packages (from statsmodels>=0.9.0->category_encoders) (25.0)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.12/dist-packages (from python-dateutil>=2.8.2->pandas>=1.0.5->category_encoders) (1.17.0)\n",
            "Downloading category_encoders-2.9.0-py3-none-any.whl (85 kB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m85.9/85.9 kB\u001b[0m \u001b[31m4.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading patsy-1.0.2-py2.py3-none-any.whl (233 kB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m233.3/233.3 kB\u001b[0m \u001b[31m13.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading statsmodels-0.14.6-cp312-cp312-manylinux2014_x86_64.manylinux_2_17_x86_64.manylinux_2_28_x86_64.whl (10.3 MB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m10.3/10.3 MB\u001b[0m \u001b[31m144.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: patsy, statsmodels, category_encoders\n",
            "Successfully installed category_encoders-2.9.0 patsy-1.0.2 statsmodels-0.14.6\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript            Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel...  2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta...  2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc...  2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon...  2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel...  2019-08-07 08:30:00   \n",
              "\n",
              "   Date_only                                         Clean_Text  word_count  \\\n",
              "0 2020-08-27  At this time, I would like to turn the confere...        5623   \n",
              "1 2020-07-30  Brian G. Harris -- Senior Vice President and C...        4755   \n",
              "2 2019-10-23  Tina Correia -- Vice President, Investor Relat...        8917   \n",
              "3 2019-11-06  Joining us today are BBSIs President and CEO, ...        8286   \n",
              "4 2019-08-07  I would now like to turn the conference over t...        4611   \n",
              "\n",
              "  ticker_clean  Price_change Target_Class  DateOfWeek  Month  Quarter  \\\n",
              "0         BILI      0.035078      Neutral           3      8        3   \n",
              "1          GFF      0.116154         Gain           3      7        3   \n",
              "2         LRCX      0.142022         Gain           2     10        4   \n",
              "3         BBSI      0.029891      Neutral           2     11        4   \n",
              "4         CSTE      0.249623         Gain           2      8        3   \n",
              "\n",
              "   Target_gain_flag  Ticker_gain_prob  Target_loss_flag  Ticker_loss_prob  \n",
              "0                 0          0.137200                 0          0.221243  \n",
              "1                 1          0.212841                 0          0.218602  \n",
              "2                 1          0.264048                 0          0.182879  \n",
              "3                 0          0.212841                 0          0.188007  \n",
              "4                 1          0.255781                 0          0.205784  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-97c6add2-6b2c-4bcf-8d72-32ff2b082588\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>Clean_Text</th>\n",
              "      <th>word_count</th>\n",
              "      <th>ticker_clean</th>\n",
              "      <th>Price_change</th>\n",
              "      <th>Target_Class</th>\n",
              "      <th>DateOfWeek</th>\n",
              "      <th>Month</th>\n",
              "      <th>Quarter</th>\n",
              "      <th>Target_gain_flag</th>\n",
              "      <th>Ticker_gain_prob</th>\n",
              "      <th>Target_loss_flag</th>\n",
              "      <th>Ticker_loss_prob</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>At this time, I would like to turn the confere...</td>\n",
              "      <td>5623</td>\n",
              "      <td>BILI</td>\n",
              "      <td>0.035078</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>3</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0</td>\n",
              "      <td>0.137200</td>\n",
              "      <td>0</td>\n",
              "      <td>0.221243</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>Brian G. Harris -- Senior Vice President and C...</td>\n",
              "      <td>4755</td>\n",
              "      <td>GFF</td>\n",
              "      <td>0.116154</td>\n",
              "      <td>Gain</td>\n",
              "      <td>3</td>\n",
              "      <td>7</td>\n",
              "      <td>3</td>\n",
              "      <td>1</td>\n",
              "      <td>0.212841</td>\n",
              "      <td>0</td>\n",
              "      <td>0.218602</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>Tina Correia -- Vice President, Investor Relat...</td>\n",
              "      <td>8917</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>0.142022</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>10</td>\n",
              "      <td>4</td>\n",
              "      <td>1</td>\n",
              "      <td>0.264048</td>\n",
              "      <td>0</td>\n",
              "      <td>0.182879</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>Joining us today are BBSIs President and CEO, ...</td>\n",
              "      <td>8286</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>0.029891</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>2</td>\n",
              "      <td>11</td>\n",
              "      <td>4</td>\n",
              "      <td>0</td>\n",
              "      <td>0.212841</td>\n",
              "      <td>0</td>\n",
              "      <td>0.188007</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>I would now like to turn the conference over t...</td>\n",
              "      <td>4611</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>0.249623</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>1</td>\n",
              "      <td>0.255781</td>\n",
              "      <td>0</td>\n",
              "      <td>0.205784</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-97c6add2-6b2c-4bcf-8d72-32ff2b082588')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-97c6add2-6b2c-4bcf-8d72-32ff2b082588 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-97c6add2-6b2c-4bcf-8d72-32ff2b082588');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-7918d8d4-dd53-426d-a80f-8b49783c215c\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-7918d8d4-dd53-426d-a80f-8b49783c215c')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-7918d8d4-dd53-426d-a80f-8b49783c215c button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_analysis",
              "summary": "{\n  \"name\": \"df_analysis\",\n  \"rows\": 10913,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4311,\n        \"samples\": [\n          \"Jul 8, 2021, 11:00 a.m. ET\",\n          \"Feb 13, 2020, 9:00 a.m. ET\",\n          \"May 18, 2022, 9:00 a.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"NYSE: AVB\",\n          \"NASDAQ: THRM\",\n          \"NASDAQ: ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q4\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"AVB\",\n          \"THRM\",\n          \"ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10031,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nGood afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the PTC's 2022 first quarter conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open for questions.\\nI'd now like to turn the call over to Matt Shimao, PTC's head of investor relations. Please go ahead.\\nMatthew Shimao -- Head of Investor Relations\\nHello. Thank you, Julian, and welcome to PTC's results call for Q1 of fiscal '22. On the call today are Jim Heppelmann, chief executive officer; and Kristian Talvitie, chief financial officer. During this call, PTC will make forward-looking statements, including guidance on future operating results.\\nBecause such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in PTC's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission, as well as in today's press release. The forward-looking statements, including guidance provided during today's call are valid only as of today's date, January 26, 2022, and PTC assumes no obligation to update these forward-looking statements.\\nDuring the call, PTC will also discuss non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures can be found in today's press release made available on our website. With that, I'd like to turn the call over to PTC's chief executive officer, Jim Heppelmann.\\u00a0 \\nJim Heppelmann -- Chief Executive Officer\\nThanks, Matt. Good afternoon, everyone, and thank you for joining us. Turning to Slide 3, I'm pleased to share that PTC delivered another strong financial performance in fiscal Q1. We executed very well, building on the momentum we saw in Q4.\\nTo simplify things, please note that throughout my prepared commentary, I will only discuss growth rates in constant currency. ARR came in at $1.507 billion, which was better than the $1.5 billion we had guided to at the recent Investor Day. That represents 16% growth, 11% of which was organic. Adjusted free cash flow was also strong at $145 million, which was up 20% year over year and better than the $140 million expectation we said at the Investor Day.\\nWe're off to a very strong start in fiscal 2022. Turning to Slide 4. Of particular note was our bookings strength. Bookings were up double digits organically and high teens overall against the very strong COVID bounce back quarter we saw in Q1 of fiscal '21 when bookings grew more than 30% over the prior year.\\nTo put it in perspective, given the tough comparison against Q1 of last year, we had planned bookings to actually be down slightly, inclusive of Arena. So this performance was more than 20% above plan. I know that some analysts and investors had voice concerned that the restructuring work we did in late Q4 and throughout Q1 would distract us, but obviously, we didn't see that. The strength was broad-based across direct sales and resellers and was achieved with no megadeals.\\nRockwell came in ahead of their part of our plan, too, which was great to see and suggest my concerns of them being distracted and may prove overstated. Arena contributed the inorganic element of bookings growth, with another strong bookings quarter, coming in above plan as well. With the Arena acquisition getting round tripped here in Q2, Arena becomes part of the organic results going forward and their low 20s growth rate will then add another tailwind to the organic results. Arena has been a great acquisition.\\nBookings growth was particularly strong in PLM, and in both Europe and Americas. From a macro perspective, global PMIs remain an expansion territory, while digital transformation and SaaS continue to grow in importance as secular drivers. The interest in digital transformation in SaaS has been driving strong bookings for what is very sticky software, which when layered into a recurring revenue model that is atypical of industry peers, has allowed PTC to deliver performance in excess of market growth rates. This happened right through the pandemic, especially in the large core business that represents about 70% of our ARR, and we fully expect it to continue going forward.\\nThese factors gave us confidence to raise the lower end of our ARR guidance range, which at the new midpoint basically means we've rolled our Q1 beat forward. Now let's take a look at the ARR performance by geography on Slide 5 before turning to business units. In Q1, we saw a strong ARR performance across all geographies. Our ARR growth in the Americas was 19%.\\nAll product segments grew with key growth drivers being the acquired Arena contribution and the velocity business unit overall, layered on top of another strong quarter in the core CAD and PLM business. In Europe, our ARR growth was 13%. We saw strong results across the board in Europe, with the strongest drivers of the growth being our digital thread growth and core businesses. Europe has the largest mix of channel versus direct and the resellers continue to perform well.\\nOur ARR growth in APAC was 14%, with growth primarily driven by our digital thread core business. Next, let's take a look at the ARR performance of our various business units, starting with the digital thread group on Slide 6. In our largest product segment, digital thread core, we delivered yet another double-digit performance in Q1 with 11% growth. Within this, CAD and PLM, both grew double digits, with strong growth across all three geographies.\\nThis is the 17th consecutive quarter of double-digit ARR growth in the core business. And as we roll out our more aggressive SaaS strategy, I expect we'll see many more. In the digital thread growth, which is IoT and AR, we saw ARR growth of about 14%, consistent across both elements. This was in line with our plan and the mid-teens near-term growth expectation we set at the recent Investor Day.\\nWhile this level of growth remains accretive to company growth, we continue to expect an acceleration of growth into the 20s as we get into the back half of the year. The biggest driver of growth in Q1 was from expansions, especially in Europe and APAC. We believe market conditions in IoT are improving, and we like the way the pipeline for our new DPM offering is developing through both PTC and Rockwell channels. For AR, we continue to see a tremendous level of interest, but the market remains nascent.\\nPerhaps most importantly, the formation of the digital thread business unit at the start of FY '22 has driven important initiatives to increase our focus on cross-selling of IoT and AR into the core CAD and PLM customer base. FSG had a great Q1 with 6% ARR growth. The expansion deal we recently announced with the U.S. Air Force, both increases and extends this key relationship for up to five more years.\\nContracts like this demonstrate the value that our customers are realizing from Servigistics and other FSG products such as retail PLM and ALM. You may remember, I noted at our Investor Day that having FSG grow in the mid-single digits rather than flat would be a helpful upside growth driver. So I'm pleased to see FSG post another strong quarter. Let me run through a couple of quick customer anecdotes to give you a sense for our digital thread customers and how they rely on us.\\nOn Slide 7, MAN Energy Solutions is the world's top provider of large-bore engines in turbomachinery for the maritime and energy industries. The company manufactures complex parts in nearly every engine they make must meet unique customer requirements. Before implementing Creo, they relied on manual outdated processes that slowed design and production. With Creo, they've been able to transition from 2D to a full 3D model-based approach.\\nCreo's broad range of tool path automation capabilities enable them to save time in the programming of the tool pass used to machine the large complex engine parts, greatly increasing efficiency in transitioning from design to production. Turning to Slide 8. You may have noticed we announced a deal with -- we announced that the German company, Scheffler, has expanded its relationship with PTC, and I'd like to share a bit of the back story. Scheffler has been a longtime Creo customer and has successfully deployed Windchill within engineering.\\nBut back in 2017, one of our PLM competitors announced a large PLM deal with Scheffler that appeared to cap PTC's expansion opportunity. But that system didn't ultimately stick as Scheffler has now decided to consolidate on PTC systems with Windchill being the backbone and is broadly deploying our solutions in their standard out-of-the-box fashion so that Scheffler can participate in the full power of our digital thread portfolio. I'm very excited about this collaboration and the further expansion that Scheffler is exploring with our IoT and AR offerings. On Slide 9, you'll see how IMA Group, our global business that delivers packaging machines, services, and solutions to a wide variety of industries, was looking for a way to expand their control room offering to help their customers improve overall equipment effectiveness and reduce downtime.\\nAs longtime users of PTC's Creo and Windchill, IMA decided that ThingWorx was the ideal IoT solution for their initiative and that Kepware could provide connectivity not only to their machines, but to the other vendors' machines deployed alongside them. IMA has successfully launched new revenue streams by enabling 24/7 monitoring of customer production lines and improved OEE by up to 16%. The Vuforia integrated with ThingWorx is the platform of choice for the U.S. Air Force training initiatives.\\nSlide 10 highlights the work that PTC partner, Vectrona has done with the U.S. Air Force. With finite training resources and limited capacity, the U.S. Air Force set out to incorporate augmented reality into their maintenance and munitions training.\\nVectrona using Vuforia Studio worked with the U.S. Air Force to create immersive 3D AR experiences for phones, tablets, and the HoloLens 2 that are designed to accelerate learning, improve work performance and facilitate remote training. The improved training shows better engagement and information retention with continuous and repeatable task training available regardless of the system or aircraft type. Turning to Slide 11, the velocity business ARR growth in Q1 was more than 650% due to the inclusion of Arena and 53% organically, which would be Onshape.\\nIf you were to add Arena's pre-acquisition results into the prior year to get a better pro forma comparison, then you'd have the velocity business unit growing at 28% in Q1. That 28% is a mix of Onshape growing at 53% and the larger Arena business growing in the low 20s. Growth of both Onshape and Arena is multiple times higher than market rates, clearly demonstrating that industrial companies see the benefits of SaaS. We continue to ramp investments to expand technology leadership and to broaden the geographic presence of our velocity businesses.\\nOn Slide 12, Beta Technologies, a leading developer of next-generation electric aircraft for the cargo and logistics market, sought a cloud-native product development platform where everyone would be working with one single source of truth without the workflow restrictions of traditional file-based design systems. Beta turned to Onshape because of how it enables real-time collaboration, allowing the engineering team to work from any location while streamlining their communications during the design process. To profile Arena customer, Potrero Medical, on Slide 13, is a predictive health company developing the next generation of medical devices, leveraging smart sensors and artificial intelligence. Potrero needed a scalable quality management system to support its growing product development and compliance needs, including satisfying FDA audit requirements.\\nArena was the right solution, offering a cloud-native QMS with a quick implementation, leading to ECO cycle time reduction of 30% and nonconformance improvement of 20%. As a final topic, I'd like to give you a quick update on our SaaS acceleration initiative on Slide 14. We've made tremendous progress in the past 90 days since we announced the more aggressive strategy. We've launched our SaaS program management office, which was modeled after the very successful approach we used to drive our subscription transition several years back.\\nOur field organizations transition to the new two-in-a-box customer success organization model without missing a beat. We converged our cloud and tech support organizations with product development to deploy the DevOps type of approach you see in virtually all SaaS companies. We've made good progress advancing our offerings, especially the Windchill multi-tenant version, which will go into production shortly this quarter, and we made good progress preparing the SaaS conversion offerings that will power the hundreds of lifts and shifts that will happen in the coming quarters and years. We have more work to do, but we're certainly up and running.\\nThe time for SaaS has arrived in our industry and PTC is very well positioned. We're already the SaaS leader in our space with continued strong SaaS growth in Windchill and FSG and high levels of growth in our cloud-native velocity business unit. Sharing the Atlas SaaS platform, we have a dual strategy to win with Onshape and Arena powering a new agile product development approach, while we transition our digital thread portfolio and existing customer base to SaaS to elevate the platform strategies that so many larger companies have. To wrap up on Slide 15, I'm pleased with PTC's position and the opportunity that lies ahead.\\nQ1 gave us a strong start to what we expect to be our fifth consecutive year of double-digit ARR growth. Our portfolio of products is unique and compelling and obviously aligns well to customer demand. Our results have been consistently strong for many quarters, but we're poised to accelerate growth as the SaaS tailwind blows harder in coming quarters and as we gain more momentum with our IoT and AR initiatives in the back half of the year. We're poised to drive higher levels of profitability, too, following the organizational changes we've already implemented and as our start-up businesses continue to mature up their J curves.\\nThe company has never been in a better position to create shareholder value. With that, I'll turn it over to Kristian for more details on the financial results.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nThanks, Jim, and good afternoon, everyone. Before I review our results, I'd like to note that I'll be discussing non-GAAP results and guidance, and growth rate references will be in both constant currency and as-reported rates. So turning to Slide 17, we delivered constant currency ARR of $1.507 billion, which is 16% growth year over year and slightly exceeded our Q1 guidance of $1.5 billion. On an organic constant currency basis, this is 11% growth.\\nFX was an approximate $11 million headwind in Q1, so our as reported ARR was $1.496 billion. Our SaaS products in both the digital thread and velocity business units saw a continued strong growth in Q1, with growth rates similar to what we discussed at our recent Investor Day. This is in combination with continued strong growth of our software-only sales. As of Q1, our SaaS portfolio is now 15% of our total ARR on a constant currency basis.\\nQ1 free cash flow of $134 million grew 21% year over year and includes $11 million in restructuring and other related payments. Adjusted free cash flow was $145 million and was slightly ahead of the $140 million we discussed at our Investor Day. Q1 revenue of $458 million increased 7% year over year. As we've discussed previously, revenue is impacted by ASC 606, so we do not believe that revenue growth rates are indicative of our underlying business performance but would rather guide you to ARR as the best metric to understand our top-line performance and cash collection.\\nFX only impacted revenue by about $1 million in Q1. So our revenue on a constant currency basis was $459 million. Q1 non-GAAP operating margin of 35%, compared to 36% in Q1 of 2021. While this is a strong result, it's still worth pointing out that because revenue was impacted by ASC 606, other derivative metrics such as gross margin, operating margin, and EPS are all also impacted.\\nSuffice it to say that our COGS and opex came in in line with our expectations in Q1, and we continue to maintain good discipline on our operating expense structure. I would like to point out that our GAAP results reflect a gain of $9.8 million related to our investment in Matterport. And we're also slightly reducing the range for expected P&L charges from approximately $45 million to $50 million, down to $40 million to $45 million for the full year. And coincidentally, we're also reducing the range of expected cash payments for the restructuring and other from what was previously $50 million to $55 million, down to $45 million to $50 million for the full year.\\nFor guidance purposes, we will continue to show $50 million as the cash payments and the adjusted free cash flow reconciliation. But as payments come in lower, then we would just expect actual free cash flow to come in higher. There's no change to the $450 million adjusted free cash flow target. Moving to Slide 18, I'll begin with our balance sheet.\\nWe ended Q1 with cash and cash equivalents of $296 million. In addition, at the end of Q1, we had medium-term investments of $87 million, primarily related to our investment in Matterport. Our gross debt was $1.45 billion with an aggregate interest rate of about 3.2%. In Q1, we used $120 million of cash to repurchase shares.\\nWe also had an additional $5 million of repurchases, which settled early in Q2. For the remainder of fiscal '22, we will focus on delevering and looking forward to FY '23 in an ongoing go-forward basis, assuming our debt-to-EBITDA ratio is below three times, we will continue to target to return approximately 50% of our free cash flow to shareholders via share repurchases. Turning to Slide 19. We post a data table to our IR website that has our financial statements, as well as ARR detail by segment.\\nIn that file, we share both constant currency and as-reported ARR. As a reminder, when we calculate constant currency, we use our current year plan FX rates and restate history to the same rates. So here, for example, on this slide, you can see our Q1 constant currency ARR of $1.507 billion and the actual as reported ARR of $1.496 billion. This is important to remember in the context of our guidance because we provide guidance at the planned rate.\\nWe believe this is the best way to evaluate the top-line performance of our business because it removes FX fluctuations from the analysis, positive or negative. With that, I'll move on to guidance on Slide 20. As Jim mentioned, we're raising the low end of our full year constant currency ARR guidance by $10 million. The new range is now $1.625 billion to $1.660 billion.\\nThis essentially reflects rolling our Q1 overperformance through the remainder of the year. We're now expecting constant currency ARR growth of 11% to 13% in fiscal '22. It's worth pointing out that based on FX rates at the end of Q1, we would expect a $13 million headwind against that full year ARR guidance. For Q2, we're setting constant currency ARR guidance of $1.540 billion to $1.550 billion.\\nThis is 12% organic constant currency growth at the midpoint. On an as-reported basis, the FX impact we're calculating based on the FX rates at the end of Q1 is a $12 million headwind in Q2 compared to the constant currency guidance. Moving to free cash flow. We're maintaining our full year free cash flow target of $400 million.\\nThis includes approximately $50 million of restructuring and acquisition-related payments. The majority of these payments are related to the reorganization we announced in Q1 with some residual payments primarily related to our Seaport move for which we took the accounting charge in prior periods. So our adjusted free cash flow target for fiscal '22 remains $450 million. Fiscal Q2 adjusted free cash flow is expected to be approximately $155 million.\\nWe expect to make approximately $20 million in restructuring and other related payments in Q2, bringing our free cash flow to approximately $135 million. Moving to revenue. We're also taking the low end of the full year revenue guidance up by $20 million. This reflects both the strength in software and strength in the professional services business that we saw in Q1 and the related forecasts for the full year.\\nSo for fiscal '22, our net revenue guidance range is $1.870 billion to $1.975 billion. The year-over-year growth rate range is now 3% to 9%. Our ASC 606 makes revenue very difficult to predict for on-premise subscription companies, hence the wide range. Note that revenue variability has -- this is from 606, has no impact on ARR or its related cash generation as we continue to primarily bill customers annually upfront regardless of term length.\\nWe continue to expect more than 60% of our annual free cash flow generation to occur in the first half of the year. Collections are stronger in the first half, and we expect expenses to increase as we ramp hiring in our SaaS investments throughout the year. We're wrapping up on Slide 21 with the free cash flow model that we use and went into some depth on at our recent Investor Day that you can see here. I know many of you use model free cash flow using the indirect method.\\nHowever, given the complexities related to revenue recognition due to 606, this is difficult to do. The model we show here has proven quite effective. The table shows fiscal '21 actuals compared to the model we shared at Investor Day compared to our current guidance. Let me take you through the model focusing on the non-GAAP column on the right and starting at the top.\\nFirst, we're showing the midpoint of our as reported ARR guidance of $1.630 billion, which is different from the constant currency guidance that we gave due to the $13 million FX headwind and is also $5 million lower than what we showed at the Investor Day. We use it as reported here because it's a better reflection of the cash we expect to generate. You can also see that we have increased the perpetual license revenue forecast slightly and also the professional services revenue increase that we mentioned earlier. COGS is slightly higher, reflecting the increased costs to deliver the incremental professional services revenue and the rest of the assumptions remain the same, and we still end up with our target adjusted free cash flow of $450 million.\\nObviously, this is a model based on assumptions such as the midpoint of the ARR range, the impact of FX, the pace of hiring, etc. So if some of those variables change, which they invariably will, the model will have to be adjusted accordingly. And as I mentioned earlier, if cash payments related to the restructuring coming at the low end of the range, we would see a flip from the restructuring line to the free cash flow line, but the adjusted free cash flow target would remain unchanged. But as we sit here today, we think this is a reasonable view of how we expect the year to shape up.\\nSo with that, I'll turn the call over to the operator, and we can begin Q&A.\\u00a0\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] We ask the analysts to please limit themselves to one question only. If you have any additional questions, please return to the queue. Thank you.\\nYour first question will come from Andrew Obin from Bank of America. Please go ahead. Your line is open.\\u00a0\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nHi, yes. Good afternoon.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Andrew.\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nJust a bigger picture question. I apologize, I missed the first couple of minutes. You know, we hear a lot about supply chain constraints. And frankly, we're hearing that this might extend the run-in terms of PMI expansion.\\nSo what are you hearing in terms of sort of as you have conversations about PLM and in terms of adoption? What kind of conversations are you having with your customers? And do customers have awareness of sort of supply chains being gummed up for longer? And are you seeing this having any discernible impact on what kind of conversations you're having with people?\\nJim Heppelmann -- Chief Executive Officer\\nAndrew, it's Jim. No, actually, it's not really a frequent topic in our conversations because -- well, first of all, since you said you missed the first minute, one of the things I pointed out is that our bookings came in very, very strong, and I explained about 20% higher than planned. So we had a very, very strong bookings quarter. And notable in that was PLM, although, frankly, the strength was broad-based.\\nI think the key thing to remember is that PLM is really associated with preparing product data in engineering that will then subsequently be used in manufacturing and perhaps in aftermarket service. And it's collecting data from supply chain partners and so forth. But production problems in a supply chain don't necessarily impede the collaboration during the engineering and the preparation for production process. So I think people are saying like, maybe I can't get chips to complete the product, but that doesn't mean I should stop designing the next one because if it does, then I'll fall behind.\\nSo I think that our view would be that the product development process has largely been unaffected by the supply chain process. Now some other things, we talked about how perhaps COVID had an impact on IoT, perhaps the supply chain a little bit, although I think muted compared to COVID. So to me, the supply chain thing is a fairly small factor in our results. We just see very little correlation between what's happening out there with supply chain problems and what's happening with our pipeline and frankly, with our bookings.\\nOperator\\nYour next question comes from Yun Kim from Loop Capital. Please go ahead. Your line is open.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nHey, Yun.\\nYun Kim -- Loop Capital -- Analyst\\nThank you. Hi, Jim. Can you just talk about the IoT business, you know, in terms of the large deal activity? What kind of trends are you seeing there? Obviously, you are expecting that business to accelerate in the back half -- second half of the year. If you can talk about whether that confidence is coming from the, you know, improvement in the large deal activity? Or is it just the overall volume of the activity around IoT? And then also, if you can just comment around deal size activity around the AR business as well.\\nThanks.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I think deal sizes are sort of unchanged from previous trends. If you think -- what are we looking at when we project forward how IoT and AR will perform. Well, we're looking at the bookings, let me say, at the pipeline that will drive bookings, and for IoT and AR was quite strong.\\nWe're looking at the backlog. Last year, bookings actually had improved over the prior year. And bookings that went into backlog or -- I'm sorry, what we call deferred ARR, were quite high. We were well ahead of our deferred planned number as we actually did last year.\\nSo you could imagine we've got more, and if you want to call it, backlog waiting for us. And then what other initiatives are we doing? So for example, our DPM launch, I think, will be materially positive for our IoT results. It will drive bigger deals. It will drive better value propositions.\\nIt's really software that's ready to turn on and get value from as opposed to a platform. And then the other thing is, Troy Richardson talked at our Investor Day about organizing better for cross-sell. And I think if we look backwards, maybe we had pivoted too much toward new logos, which are great. I mean, new logos are a wonderful thing.\\nBut we probably have low-hanging fruit yet to pick within our installed base of CAD and PLM accounts. So I think it's really this combination of a strong-looking pipeline, good-looking trends, awaiting us in the deferred backlog and then these other initiatives kicking into place, DPM and cross-sell that I think will all be very helpful as we proceed through the year. And again, I want to remind everybody, we set the expectation that the two handle would materialize in the back half of the year and that you wouldn't see it in Q1 and Q2. So we sort of feel like this was as we had predicted just mid-December a couple of weeks ago.\\nOperator\\nYour next question comes from Jason Celino from KeyBanc Capital Markets. Please go ahead. Your line is open.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nHey. Hi, Jim. Hi, Kristian.\\nJim Heppelmann -- Chief Executive Officer\\nHi, Jason.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nSo one question on maybe the SaaS Windchill, you know, launch. It seems like it's coming along, you know, nicely, and we could see something maybe go GA this quarter. Have you had a chance to maybe, you know, discuss this with customers? How is the pipeline shaping? Or is it maybe better to think that the pipeline might start to form once we do go live?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nNo, we have, for sure, started talking about it with customers. I mean, ramping up that process. We've got to educate a lot of people and they, in turn, have to educate customers. But we've certainly made some progress, and I can tell you the customer interest is actually quite high.\\nYou should know that actually, customers were pushing us a little bit to get going with such initiatives -- so I feel like the demand is there. And in fact, again, just reflecting on what we told you, that business has been growing about 30%. And Kristian mentioned we posted another quarter just like that, without us really invoking the new strategy yet. So there's lots of demand.\\nWe're just looking for a model where we can promote the demand because we like the margin profile better. And that's what's coming into place here in Q2.\\nOperator\\nYour next question comes from Adam Borg from Stifel. Please go ahead. Your line is open.\\u00a0\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nGreat. Thanks so much. And maybe just two quick ones. Just on the Scheffler win that you announced yesterday and highlighted on the call earlier.\\nOne of the things I thought was really interesting in the press release was this opportunity around some more vertical-specific or market-specific solutions targeting either automotive or industrial companies. So maybe, Jim, if you could just talk about that. And maybe just as a quick follow-up, just maybe for Kristian. Any way you could talk about this transition, it's great to get the early feedback on the SaaSification efforts, but any way to comment on, you know, how much this has contributed to bookings or the pipeline, at least qualitatively? Thanks so much.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I'll get the first part of the question. Kristian, you can take the second part. Yeah.\\nSo Scheffler is a great account. And as I mentioned back in 2017, it appeared they were going in a different direction, and now they've decided to come back into the fold. And honestly, they did that for two main reasons. One is that they really want off-the-shelf technology.\\nThe other competitor had told them this low-code, no-code story, and they tried that out and decided that's not really what they want. They don't want to develop their own solutions. They want to deploy standard out-of-the-box software that all works together. And then they want to engage in partnerships with the vendor, in this case, PTC to talk about how those solutions should evolve to be more and more powerful to meet their needs.\\nSo yeah, I'm very excited. I'm in the middle of that relationship myself. And yes, what's going to come out of that is technology that fits better and better, for example, for the automotive supply chain, which is a place where we have a lot of customers. So it's a great win or win back, maybe I should say, and a great partnership going forward that's going to produce a lot more business for us in years to come.\\nAnd sorry, the second part of the question was around the transition to SaaS and how that's manifesting itself in terms of pipeline and activity? Is that right, just making sure I got that right.\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nExactly. Any way to qualitatively comment from, you know, either bookings or a pipeline perspective?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, remember, I mean, the bookings that we just reported were for Q1, and Q1 is really when we actually just announced the acceleration of it. So I would say there's actually a limited impact in the actual bookings result here in Q1. That said, as I mentioned, we continue to see strong demand for the SaaS properties that we have.\\nThat's both in velocity and the digital thread. And so those products continue to grow at a rate higher than our software-only products. And now as the program is pushing ahead, we expect to see demand and pipeline generate, especially with the new Windchill launch coming out here and the program continuing to pick up speed internally.\\nKristian Talvitie -- Chief Financial Officer\\nMaybe, Adam, I could just add. We launched this phase 3 strategy 90 days ago on the earnings call. And there's nothing we've seen since that makes us any less bullish than we were back then. I mean it looks like a really nice opportunity for PTC, and we're pushing forward ahead as aggressively as we can because we'd like to bring that very promising upside growth driver, you know, closer in.\\nSo it has a bigger impact on '23 and '24 and so forth than it would otherwise have had.\\u00a0\\nOperator\\nYour next question comes from Jay Vleeschhouwer from Griffin Securities. Please go ahead. Your line is open.\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nThank you. Hello. Hi, Jim. Hi, Kristian.\\nA couple of things. With regard to the strength you noted for PLM, at your partner conference six months ago, back in the summer, management presented to the channel, your concept that PLM was no longer just an engineering vault that it was becoming memorial, what you call, multisystem, multidiscipline concept. And the question is, to what extent is that broader, more diverse view of PLM a current part of new business or in the pipeline for new business as compared to the more conventional historical way of thinking about PLM? By our calculation, we are already the second-largest brand by revenue in PLM, and maybe talk about what some of the drivers are to that? And then just a quick clarification you referred earlier to cross-sell. At the Analyst Meeting last month, in the slide deck, you referred to cross-sell 10 times and relatedly account-based selling.\\nPTC is often over the years, talked about cross-sell, but maybe talk about what's different this time in terms of resources and programs across your various segments and your new customer segmentation model.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, on your first question, Jay, you know, you are always very pressy on, you've been watching this industry for a long time. When we say multisystem, multidiscipline, what we're really talking about is an enterprise system. And so what's happened in the last couple of years is PLM has graduated from being an engineering data management system to being an enterprise system that contains the system of record for the product definition.\\nAnd so if you're in manufacturing, well, you need to know the product definition. If you're in procurement, you need to know the product definition. If you're all on an installation or a support call, you probably need to know the product definition. So definitely what's happened is that the enterprise deployments of Windchill are multiple times larger than the engineering deployments of Windchill.\\nSo something that's been driving growth for some years now is that the new deals we're taking are more and more frequently enterprise deals and they're larger. You may remember, last quarter, I told you we took the largest deal we had taken to date from a med device company. And the second thing that's happening is, we're circling back to those companies who had deployed the engineering solution like say, Scheffler, and we're upselling them to the enterprise solution and turning that into a much bigger opportunity for us. So definitely, that's a real thing, and it's been driving the momentum we've seen in Windchill for years.\\nAnd frankly, there's a lot of it out ahead of us even before we start talking about SaaS. The upsell from a departmental solution to an enterprise solution is a driver, taking that whole enterprise solution to SaaS is a whole another growth driver that's on top of that and sort of orthogonal to it. And then on the account-based selling, there's two ways to look at that. Cross-selling into your accounts is a great thing.\\nYou have established relationships. It's much easier to sell another product to an existing customer than to sell a new product to a new customer or a first product to a new customer. At the same time, we like new logos. So it's really always about the balance of how much do you invest in new logos pursuits versus how much do you invest in selling more to the companies who know and trust you.\\nAnd I think perhaps with IoT and AR, we realized we had over pivoted toward new logo, which is just generally speaking, less productive selling, you might imagine. And so the reason we formed this digital thread group, which brought CAD and PLM and IoT and AR together under Troy Richardson, was to really lubricate how these products work together and how we position them together and to be able to start anywhere and sell up and down that chain. So it's a good strategy. It's one that we -- it's a muscle we've developed well over the years.\\nWe really built the Windchill business, largely by cross-selling to the Creo base. And I think this is going to be something that will help us a lot to kind of get the right balance of new logo pursuits in cross-sell.\\nOperator\\nYour next question comes from Ken Wong from Guggenheim Securities. Please go ahead. Your line is open.\\u00a0\\nKen Wong -- Guggenheim Securities -- Analyst\\nThank you so much for taking my question. Jim or Kristian, I wanted to perhaps dive into the double-digit organic bookings growth. You know, I couldn't help and notice you guys also had a very large Servigistics expansion deal with the Air Force. I mean how much of that was already in expectations? Or did you get some boost there from timing shifts or anything of that nature?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Let me tell you, none of that actually contributed to the double-digit growth because that was a Q4 deal. You know, we released it when we had approval to release it, and I commented on it because it was, you know, an important customer and so forth. And let me say that deal, again, that was closed in Q4, both represented five years of extension, but also about a 50% growth in a ramp that happens over -- I think it's three years.\\nSo it roughly goes from a $10 million run rate to a $15 million run rate over three years and stays there for a couple more. That's what the contract contemplates. So some of that will come into ARR in Q4 of this year, but the bookings actually were in Q4 last year. So that strength -- the strength we saw in Q1 was exclusive of that Air Force deal, which just means it was really great strength.\\nSo anyway, it was hard to pin down where the strength comes from because it came from CAD. It came from PLM. The IoT number was actually pretty decent. It didn't all go into ARR.\\nAnd then, of course, the velocity numbers and the FSG numbers. So it was broad-based in all geographies and really in all product lines.\\nOperator\\nYour next question comes from Matt Broome from Mizuho Securities. Please go ahead. Your line is open.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Matt.\\nMatt Broome -- Mizuho Securities -- Analyst\\nThanks, man. So Jim, I mean, I guess, just on that -- sorry, just deal that I can just mention. Given the importance of supply chain management right now, are you seeing like ramping demand to the solution elsewhere? And sort of following on from that, is there a chance that FSG ARR could actually accelerate on the back of that demand beyond the sort of the mid-single-digit level and actually become sort of more strategic in a way?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean that's one of the points, Matt, that I brought up at the recent Investor Day is that we've generally modeled FSG to be roughly flat, flat about plus 1% to 2%. But it's actually been performing. I think last year, Kristian, wasn't up 7%, FSG.\\nIt was up 6% here again in Q1. So yes, we're overperforming and Servigistics is one of the key drivers. And then the second one probably is retail PLM, which has also been doing fairly well. So definitely, there's some -- I think we'll be conservative and leave the FSG sort of guidance where it is in the near term, but I do like overperforming it because it's a growth driver.\\nThe FSG business is about the same size as the IoT and AR business. So every point of growth we get there is pretty meaningful.\\nOperator\\nYour next question comes from Matt Hedberg from RBC Capital Markets. Please go ahead. Your line is open.\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nYeah. Thanks. This is Matt Swanson on for Matt. I'll kind of follow up on a piece of both Adam and Jay's questions.\\nSo looking at the Scheffler announcement, I think the thing I was really interested in was the idea around standardization and the idea around end-to-end. So could you talk a little bit about your customers' desire around standardization? And clearly, this product road map has really expanded your TAM, but I think one of the upside areas something we -- you know, maybe the holy grail of the transition would be more competitive displacements. And I'm just curious if you're starting to hear, you know, any early or more talk around that because you're building something so differentiated.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean, for sure. So the standard thing, I think maybe over the last couple of years, industrial companies have realized that they should be using software, not developing it. And so we saw this in our IoT business, and it's been why we've been heading up the stack with solutions like DPM is, customers would like to buy the software and use it, not buy some kind of a platform and create it because they just don't really know how to create it if I'm frank.\\nSo Scheffler had gone down the path of kind of like I said, low-code sort of environments and came back to standard products. And then the end-to-end thing, for sure, the CAD data that's created in Creo and managed in Windchill gets used, for example, in augmented reality, manufacturing, and service instructions much later and in a different part of the company if it's all well managed. And that connectivity from IoT, well, let's say, from CAD to PLM to IoT to AR is what we call the digital thread. And so we actually see so much interest in this that we kind of organized around that principle.\\nLet's stop presenting these products as kind of independent things and let's shine the light on how well they work together in an end-to-end solution. And by the way, how they're all ready to go. That this is something that turn on and use. And that's really what one Scheffler over, but I can tell you, Scheffler is not unique at all.\\nAnd it's really -- we're organizing to respond to that. SaaS is helpful, by the way, because if you want a lot of technology working end to end, it'd be better not to ship at all to the customer side because it gets complicated. The customer would like to just use it, not set it all up and care and feed for it on-premise.\\nOperator\\nYour next question comes from Saket Kalia from Barclays Capital. Please go ahead. Your line is open.\\nSaket Kalia -- Barclays -- Analyst\\nOK, great. Hey, guys. Thanks for taking my question here. Hi, Jim.\\nHey, Jim, maybe -- hey, Kristian. Jim, maybe for you, it was great to hear the PLM strength this quarter in bookings. With other companies that have done shifts like this, there's always a risk, I guess, of customers behaving differently, right, whether that's slowing purchases to see what's coming or maybe pulling forward purchases before something new comes out. Now just to be clear, it doesn't sound like that happened here.\\nBut can you just stress test that for us a little bit? And what you sort of look at to sort of manage what is, you know, more choices for our customer to make. Does that make sense?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Are you referring -- just let me clarify, are you referring to like SaaS choices being new choices or more broad --\\u00a0\\nSaket Kalia -- Barclays -- Analyst\\nYeah, that's right, yeah, Windchill. No, Windchill specifically.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So keep in mind, Saket, we have been selling Windchill as SaaS for some time. Remember, the phase 1, phase 2, phase 3 thing. So since phase 1, we've been selling Windchill, and we showed you, it's got a three-year growth CAGR of 30% in SaaS.\\nSo the customer demand is strong. It's just -- on the PTC side, we need to pivot to multi-tenant because in the single-tenant model we just don't have the profitability we like. So the demand is strong. The customers are buying it.\\nKristian mentioned we had another strong quarter. So it really is, we'd like to meet that demand with a solution that's more efficient for us to operate on behalf of the customer. And that's what phase 3 multitenant really is all about. Now when it becomes more efficient for us, we can then lean in on the promotion and marketing of it, because we haven't really done that.\\nSo we've been servicing demand, not driving it. And with phase 3, we think there's an opportunity to drive demand and, you know, the preliminary data we've seen this quarter suggest customers are very responsive, both to buying new systems that way, but also to lifting and shifting the previous systems they bought and giving them to us to operate and serve back to them in a SaaS model.\\nOperator\\nYour next question comes from Joe Vruwink from Baird. Please go ahead. Your line is open.\\nJoe Vruwink -- Robert W. Baird and Company\\nGreat. Hi, everyone. Just to go back to bookings, does the strength this quarter absent mega deals suggest anything about either the demand environments or maybe just the health of your mid-market and SMB customers? And looking ahead, are there going to be certain things you think about or track when contemplating, you know, the probability of more mega deals or maybe the larger ARR contributors for PTC, maybe, you know, being a bit more represented in future bookings?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nKristian, let me again take a stab at that and maybe you'll find things to add. So I think if you look at the bookings, again, they were phenomenal, and it's hard to pin down. It wasn't one geography. It wasn't one product.\\nIt was all geographies, all products. So I think it tells us that the end market is very healthy. And I would say, for two different reasons. On one hand, the PMIs are in good shape.\\nThat's helpful. On the other hand, the interest they have in the digital thread, digital transformation story, and the interest they have in SaaS is secular. That interest is not related to the PMIs, it's kind of independent of them. And so I think that we're just in a very healthy situation where industrial companies are leaning in on trying to get more digital.\\nThey see PTC as having a fairly unique and compelling portfolio, and they're interested in engaging and trying to make their companies more efficient. I can tell you, at Scheffler, for example, it's one of the top initiatives in the company is to get more digital. And as it relates to the whole product life cycle, the partners PTC. And we see that kind of phenomenon happening in a lot of places in the industrial world.\\nSo I think it's just good, strong, secular and as well macro-environment out there right now. But I'll remind you that we've had good performance even when the macro environment wasn't so strong. So all things being equal, I like the strong macro. But we're 17 quarters in with double-digit growth in the core business, and there were a lot of bad macro quarters over the course of those 17.\\nSo I think it really is the secular driver. Kristian, anything?\\nKristian Talvitie -- Chief Financial Officer\\nYeah. I mean I agree with all that. I mean, actually, just on the big deal dynamic, you know, what we used to call mega deals. We haven't -- I think we've had four in the past four years.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, keep in mind, perpetual drove bigger upfront purchases and subscription or SaaS tends not to.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYeah, which is my point that we've been seeing good strong bookings performance and bookings growth, you know, even with the absence of what used to be a fairly regular occurrence back in the perpetual days, like we really don't see a lot of those.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah, it's a good healthy business. OK. Next question.\\nOperator\\nYour next question comes from Blair Abernethy from Rosenblatt Securities. Please go ahead. Your line is open.\\u00a0\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nThanks very much. Guys, just maybe a quick question on -- around partnerships, in particular. I wonder if you could just give us a little deeper dive into how things are going with Rockwell and as well on the simulation side with Ansys?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So the state of the partner economy is good and, you know, Microsoft, I could put on that list, is also strong. With Rockwell, you'll remember in the past quarters, I had said we should take a bit of a conservative posture as it relates to what Rockwell would contribute to PTC's numbers here in fiscal '22. And we did that because Rockwell had made a big acquisition.\\nYou know, Rockwell never completely agreed with me on that. Their own public commentary kind of indicated they didn't worry too much about that. And in Q1, they were right. So we're pleased to see that Rockwell's contribution was solid in Q1 and starting to feel pretty good about the year.\\nI'll tell you one thing is this DPM solution appears to be a very good fit with Rockwell. And in fact, their Calypso alarm is probably lined up to be our strongest partner in promoting DPM. So we're very happy with that. Calypso has a long-term relationship with PTC that even predates their acquisition by Rockwell.\\nSo great alignment around DPM. Again, DPM is a high-value up-to-stack solution that drives bigger deal sizes, and we think will be a very sticky solution. So lots of optimism around that. With Ansys, we continue to differentiate now with best-in-class simulation.\\nSo whereas simulation some years back would have been viewed as a soft spot for PTC. Now it's a strength. If we're competing against Autodesk or Siemens or Dassault, nobody is going to have a better simulation story than PTC because nobody has a better simulation story than Ansys, and Ansys products are built into PTC products. So that's been going well.\\nAnd then, of course, with Microsoft, that partnership is performing well and poised to get a lot bigger because as we bring more stuff aggressively to SaaS, a whole lot of that is going to land on Azure. So I think all three partnerships are alive and well and as important as ever and helping us achieve the kind of results that we're achieving.\\u00a0\\nOperator\\nYour last question comes from Sterling Auty from J.P. Morgan. Please go ahead. Your line is open.\\nSterling Auty -- J.P. Morgan -- Analyst\\nYeah. Thanks. Hi, guys. Just wondering if you could characterize with the headcount changes that you pointed out are necessary to facilitate the acceleration to SaaS.\\nWhere are you in that process? What's left to go? And kind of what's the time frame that you expect to complete that over?\\nJim Heppelmann -- Chief Executive Officer\\nYeah, Kristian, I'm thinking of the numbers we're largely done, but not completely. Eighty percent, 90% done.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYep, with the exiting.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean we'll be hiring people throughout the year. So -- but in terms of the people who are exiting, they're largely exited by now that largely happened within the first quarter.\\nSterling Auty -- J.P. Morgan -- Analyst\\nUnderstood. Thank you.\\nOperator\\nWe have no further questions. I'd like to turn the call back over to Jim Heppelmann for closing remarks.\\nJim Heppelmann -- Chief Executive Officer\\nOK. Well, thank you, all. There's a lot of good questions and, you know, I think good answers because the business is performing very well right now. ARR is doing well.\\nBookings are doing well. Free cash flow is doing well. You know, I think we executed -- through good times and bad, we executed through the changes we made over the last quarter, and we're set up to do pretty well for the balance of the year. So, we're very confident and, you know, look forward to talking to you all in 90 days if we don't happen to cross pass with you sooner in an investor event or what have you.\\nSo, thanks a lot for joining us and have a good evening.\\nKristian Talvitie -- Chief Financial Officer\\nThanks, everyone.\\u00a0\\nOperator\\n[Operator signoff]\\nDuration: 59 minutes\\nCall participants:\\nMatthew Shimao -- Head of Investor Relations\\nJim Heppelmann -- Chief Executive Officer\\nKristian Talvitie -- Chief Financial Officer\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nYun Kim -- Loop Capital -- Analyst\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nKen Wong -- Guggenheim Securities -- Analyst\\nMatt Broome -- Mizuho Securities -- Analyst\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nSaket Kalia -- Barclays -- Analyst\\nJoe Vruwink -- Robert W. Baird and Company\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nSterling Auty -- J.P. Morgan -- Analyst\\nMore PTC analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, ladies and gentlemen, and welcome to ASUR's First Quarter 2020 Results Conference Call. My name is Kathy and I'll be your operator.\\n[Operator Instructions]\\nNow I would like to turn this call over to Mr. Adolfo Castro, Chief Executive Officer. Please go ahead, sir.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and good morning everyone. Thank you for joining us on the conference call to discuss ASUR's first quarter financial and operating results. Before starting the call, I would like to express my hope that you and your families are healthy and safe in these uncertain times. As a reminder, please note that certain statements made during the course of our discussion today may constitute forward-looking statements which are based on our current management expectations and beliefs and are subject to a number of risk and uncertainties that could cause active results to differ materially, including factors that may be beyond our company's control including the impact from COVID-19. For an explanation of these risks, please refer to our filings with the US Securities and Exchange Commission and the Mexican Stock Exchange.\\nOverall, our first quarter results were good. The year began in solid footing before we started to see the impact of COVID-19 pandemic in the second half of March. It resulted in the disruption of global travel industry. Importantly, in the end of the first quarter we had healthy balance sheet which I will come back and discuss in more detail later in my presentation. I'm going to start today's presentation with some comments regarding COVID-19 and the impact on the industry, on our business, and the steps we are taking to mitigate this disruption to the best we can in this rapidly changing environment. From an industry perspective, since mid-March, many governments have issued flight restrictions in an effort to mitigate the spread of COVID-19 virus. In turn, capacity has been severely reduced and very few people are booking flights as most are in some form in lock down around the world and not traveling. With respect to our airports, the situation varies by country and could be subject to change depending upon how fast or slow the pandemic is brought under control. Colombia has been the most active and we've suspended operations at all six of our airports since the third week of March with domestic flights suspended until April 27 in accordance with the published decree and most recently extended to up to May 11.\\nInternational travels have been suspended through May 13. By contrast, in our airports in Puerto Rico and Mexico remain open, although there's significant reduced flights and passenger traffic. As a result, total passenger traffic declined sharply in the second half of March, down nearly 69% year over year between March 16 and March 31. By country, we show the margin decline in Colombia around 77%, followed by Puerto Rico down 73% and Mexico with 63% decrease [Indecipherable]. Additionally starting in mid-March, some of the airlines as well as some tenants that operate in our airports began asking for assistance either through discounts on payments owed to ASUR or by extension by payment which resulted in a higher accounts receivables in March in Mexico and Colombia, up 54% and 78% year-over-year. We are having ongoing commercial discussions with these companies with respect to their contracts.\\nMoving next to action we have taken, starting with health and safety. Following the guidelines of relevant health agencies, we have implemented health and safety protocols for both our airport employees and passengers travelling through our airports. For example, protective gear such as wearing masks is required for airport staff. We have also stepped up disinfectants and sanitization practices, once again in accordance with the guidelines of local health authorities. Lastly, where possible, we have also implemented remote working points.\\nMoving next to ensuring continuity of our business. We have introduced cost reduction initiatives across our airports. The impact of these initiatives however is not expected to be significant vis-a-vis the potential decline in passenger traffic at the majority of the cost structure is different, except for concession fees and technical assistance in Mexico which are biannual cost. We are prepared to take additional step, if needed, to respond to the evolving business environment. Now, let me talk about our financial situation. We entered this quarter in a position of strength with strong liquidity and very low principal payments required through year end. Additionally we believe the company has sufficient liquidity to meet its obligations and continue operating in the normal course of business. Our cash position ended at MXN7.8 billion which was up from MXN6.2 billion at the year-end 2019. And subsequent to the quarter end, as we further strengthen our financial positions as our subsidiary in Puerto Rico drew down an additional $10 million of its committed line of credit. The line of credit [Indecipherable] support for the capex projects we have under construction, Apelian airport in Puerto Rico.\\nWe closed the quarter with total debt of MXN15.3 billion. Although 11% high than the year-end 2019, this was due to the conversion effect from the depreciation of the peso to the dollar. As a reminder, the majority of our debt, 54% is denominated in the US dollars which is at our subsidiary in Puerto Rico. 26% of total debt was denominated in Mexican pesos and 20% in Colombian pesos. We have principal payments of only MXN432 million coming due over the next three quarters. This represents less than 3% of ASUR's total debt. With respect to that ratios, net debt to last 12 months EBITDA stood at 0.7 times at the close of first quarter '20. You can see the interest coverage ratio by country in the table we have included in the annual release this quarter.\\nNow, stepping back for more, since we began operations over 20 years ago, we have successfully navigated through many very significant challenges. From the 9/11 event in 2001 to [Indecipherable] into 2005 and 2008 and 2009 business financial crisis, H1 and H2 and the bankruptcy of 50% of airlines in Mexico which cut planes capacity in Mexico by more than half. Following each of these events, passenger traffic recovered, although recovery time varied from 13 months to 26 months and then continued to grow. Between 2000 and 2019, annual passenger traffic increased the compound annual growth rate of 6.6%, up from slightly over 10 million to historical high to over 34 million last January. We believe the COVID-19 pandemic is unique in that sense it is global event and with a broad disruption in travel and economies worldwide and could change the way of travelling in the future while a vaccine or a cure is found. Summing up this section, we have a strong balance sheet, we have generated years of consistent profitability and we exercise prudent capital management. In the sense we believe that we cannot be very prepared for an event of this magnitude, but of course given its great uncertainty on the final effects in the worldwide economy and that travel will be [Indecipherable].\\nNow turning to our first quarter results, more details can be found in the press release issued last evening. Like I mentioned this part of my presentation, let me spend with the effects of the business in late March. We believe we had solid results in the first quarter 2020. Total passenger traffic was down in most of the airports, which leads to a total passenger decrease of slightly 6% YoverY. This was primarily due to the fallout from COVID-19 and the impact of the global travel industry beginning in the second half of March. Our airports in all three countries experienced total passengers decline from a low of nearly 3% in Colombia to a high 8% in Mexico. Puerto Rico passenger traffic was down 4%. All three countries reported declines in both domestic and international traffic.\\nMoving next to the P&L highlights, revenues ex construction were relatively unchanged at 4% increase in revenues from non-aeronautical services was offset by a 3% decline in aeronautical revenues. Commercial revenues per passenger increased 11% year over year, reaching MXN116.3. This was driven by solid performance across the region. Mexico posted a good performance with an increase of 11% on a per passenger basis benefiting from the currency peso devaluation and regulated revenues. Puerto Rico posted 7% increase per passenger benefiting from peso depreciation and finally Colombia saw a 33% increase on a per passenger basis, reflecting the 43 new stores opened over the last year and currency depreciation. The main drivers were ground transportation and car rentals.\\nMoving on to profitability, reported consolidated EBITDA increased 3% from the same period over the prior year. Both periods benefited from insurance recoveries related to the Hurricane Maria. In the first quarter '20, it amounted nearly MXN124 million while last year the amount was dragging over MXN41 million. Excluding these recoveries, consolidated EBITDA was essentially flat year-over-year at MXN2.7 billion. Ex-IFRIC 12 and without taking into account insurance recoveries in both quarters, adjusted EBITDA margin increased 20 basis points to 66.7% this quarter.\\nA few comments about capital allocation. Capital expenditures were MXN353 million in the quarter. Of these, nearly MXN58 million was allocated in Mexico due to the terminal expansion of Merida airport. For the full year, and as we have discussed before, our non-prevalent plan in Mexico calls for investment of approximately MXN5.3 billion for the full year. At the current time, there are no changes to the planned continuation of the foreigners tax relief of the second one we have at Cancun airport and the beginning of the first expansion at the Merida. Our plans call for a conclusion of Phase 1 of the Merida terminal expansion and typically the second phase this year. Nevertheless, due to the COVID-19 health crisis, you may see some disruption in the construction process, attributable to stay-at-home, the combination and we have informed the government about this situation. In Puerto Rico we have made investments of MXN114 million this quarter, mainly from the connection with some major maintenance referred tax relief. Finally, capex in Colombia amounted to MXN1 million related to maintenance. Last year we concluded our committed capex was at MXN20 million. And going forward, we only expect to incur a major maintenance capex in Colombia.\\nNext, our Annual General Meeting from yesterday, shareholders approved an ordinary net cash dividend of MXN8.1 per share to be paid, subject to the Board's approval on or after May 11, 2021 in a single installment.\\nIn conclusion, we are proactively responding to the developing situation. No one can control the virus or even the economic fallout. But we can control how we react to the crisis. I am optimistic about the prospects for the future both navigating through the current crisis and in the long term recovery. I believe that we are well positioned with a healthy balance sheet. We had a solid first quarter results. We believe in the strategies that we are executing.\\nThis ends my prepared remarks. Kathy, please open the lines for questions.\\nQuestions and Answers:\\nOperator\\n[Operator Instructions]\\nWe'll go first to Alejandro Zamacona of Credit Suisse.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nThank you Adolfo, thanks for the call. Two questions from our side. The first one is on the aeronautical maximum tariff. So, considering that airlines have been negotiating with most of airports and in some cases some fees have not been charging. What could we expect for maximum tariffs in the short-term meaning the second quarter and in the immediate term, meaning year end 2020? Could we still expect tariffs to be close to the maximum level?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro, hi, good morning. Well, basically what we are seeing today is a very reduced demand. So we believe that there is no effect if we try to reduce our fees for the month of April or the month of May. So we have maintained our tariffs and we believe that we can comply with -- we have to maintain compliance toward the year end.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you. And my second question is on the non-aeronautical business. Same thing in the same context, what could we expect in the short term for commercial revenues per passenger? Have you grant any rent payments facility to payments or any deferrals? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nMost of our contracts, as you may know, they have to pay higher of the minimum guarantee payment per passenger or a percentage of sales. So if we do not have passengers, we will not have to pay rent. So it's made automatically. So in that sense, we are not reducing or adjusting the contracts.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you Adolfo.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nWe will now take a question from Fernando Sanchez of Bradesco BBI.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nHi, good morning and thanks for taking my question. My question is light of the likelihood of the GDP contraction beyond 5% I just wanted to ask if you have had the opportunity to discuss with the authorities the possibility of delaying the 2021 and the key mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. Well as you are aware, the contract has a clause that says that the maximum tariff can be reviewed in the case of Mexico in an external way. When on the Mexican GDP drops by more than 5% in a year and that's happened in fact on track. Of course with the current circumstance and the current expectations from analysts, it is possible that the Mexican GDP will drop by more than 5% this year. So in that sense, we will be we -- and the possibility of review our maximum time in an external rate. That's for next year, but not this year.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nOkay. Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nAnd now, we'll take a question from Carlos Peyrelongue of Bank of America.\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nThank you. Good morning Adolfo. Thank you for the call. On the something I couldn't hear well because of the connection but can you comment as to whether the dividend will be kept or there is the possibility of cutting the dividend until we have more sense about passenger traffic? That would be the first question. And the second would be related to cash burn, if you could give us an idea of what your cash burn is on a quarterly basis, just to get a sense of compare that primarily to your strong cash position. Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYes, of course. In the case of the dividends, yesterday we held Annual Shareholders Meeting, they have sadly approved the dividend that it was proposed MXN8.1 per share. But it was -- this was subject to the approval from the Board to the moment of the payment that's from May 11, 2021. So the Board will have to approve when this dividend will be paid. In the case of the cash burn, what I said to you during the initiative months, is that our currency structure is basically fit. The only variable pieces are the technical assistance fee and the concession fees we paid to the government. So we are working and just to remember the case of Mexico is 5% as well as in Puerto Rico, and in the case of Colombia its' 19%. So this of course will reduce -- our passenger traffic is reduced and our income gets reduced. The remaining is basically, of course, we are taking measures to try to reduce as much as we can, all the expenses in the companies. But as I said, at the end, in the overall picture, the cost reduction will not be significant in comparison with reduction in the revenues of the company.\\nOperator\\nAnd we'll run to our next question, and that will come from Andressa Varotto of UBS.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much for taking my question. So my question is if have plans to negotiate with the government postponement of the mandatory capital is this possible? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nCould you repeat the question? I couldn't hear you.\\nAndressa Varotto -- UBS -- Analyst\\nYes. So my question is if you plan to negotiate with government the postponement of mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said before, in accordance with the contract, we do not have that possibility this year. But of course, with the given standards [Phonetic] and as I said it in my initial remarks, during an expansion situation and that expansion situation is that some companies have stopped operations [Indecipherable] and that it was reactivated later on, but there was a decree from the Mexican government that also named the steel and glass that is produced in the country will be used for the project. So in that sense, at the moment it's almost impossible for us to expand our 10-year buildings without these material. So we have this situation to the government. So for the moment, what we see is that we will see some disruption in our construction process for some months and then we will have to talk about these with the government. That's what I can share with you for the moment on this respect.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nOur next question will come from Stephen Trent of Citi.\\nStephen Trent -- Citi -- Analyst\\nGood morning, Adolfo and thanks very much for taking my question. Hope that you and your family are well. Just one quick one for me, I know that it seems that Mexico apparently has not been that active in likely offering any assistance to the corporate sector. What are you hearing from Colombia? Kind of any indications from them with respect to whether aviation industry will get some sort of relief?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nSteve, thank you for your question. So in the case of Colombia in comparison with Mexico they have been more active in the measures that they have been taking. As I said here in the report they were very [Indecipherable] basically closing or sorting down everything as from March 23. And that can be seen in terms of results. In the case of Spain and the active they have in comparison with active cases we have in Mexico. So their curve is decreasing or at least flattening while the Mexican curve is still increasing. In terms of what they have said for our industry, we have been closed since March 23 and they have issued decrees in that respect. Maybe this week, there was a new announcement from the President expanding the process of shutting down everything. As I said in my remarks, for the case of domestic aviation that will be close up to May 11 and in the case of international up to May 30. It is important to remember that in the case of Colombia, 85% of aviation is domestic and 15% is international. That's what we know as of today. Of course all of these may change depending on how fast or how slow they can control the virus in their country.\\nStephen Trent -- Citi -- Analyst\\nThank you very much Adolfo. Apologies I couldn't hear all of your remarks. But no indication at this point for example that Columbia's planning a kind of tax relief for aviation or something along those lines offering kind of financial support.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nWell we have not heard anything above that yet.\\nStephen Trent -- Citi -- Analyst\\nOkay. Appreciate that. I'll let someone ask a question. Thanks Adolfo.\\nOperator\\nAnd next we will go to Gabriel Himelfarb of Deutsche Bank.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nHi, good morning, thanks for the call. I have two questions. The first one is concerning about account receivables. Can you give us like a number or approximate number about what's the total of the sales coming from airlines and in specific from Interjet and American Airlines and my second question is do you think you could obtain some waivers in opex sorry capex your current MDP in Mexico and could you will be able to extend the life of the concession in Colombia?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. In terms of the account receivables you can see those in our report, revenue increase in the case of Mexico and Colombia, most of the increase is coming from the land industry. I do not have the details of American Airlines and Interjet you are requesting. In terms of the capex, as I said before, we have informed the government about this current situation. We don't know if they are going to react in that respect. But of course it's going to be almost impossible for us to construct and expand our buildings with that material. So more or less what I say to you.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nOkay, thank you.\\nOperator\\nAnd now we will go to Ruben Lopez of Santander.\\nRuben Lopez -- Santander -- Analyst\\nHi Adolfo, thanks for the call. My question is on commercial revenues. Sorry if you commented on these. But I understanding Cancun operating in just one terminal. So I want to confirm you how are your operations there in Cancun and what are the implications on commercial operations? Are there any penalties with the tenants? What are negotiations here? That's the first one. And the second one is related with the same topic. When we see commercial revenues and we kind of try to compare current levels versus what would be the fixed amount or the fixed part of the minimum payment. I mean can you give us any sense of the guidance here? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nOkay. As you have said, yes, in the case of Cancun, we have closed two terminals and we are just operating today in terminal 4. So all the operations of airport have been concentrated there in order to reduce on one side the expenses and of course on the other side be better prepared in the case of these reduced demand. All the stores are working in the case of terminal 4. So terminal 4 is operating as it was before the event. As I said before, most of the contracts, the financial contracts we have with the tenants are related to a minimum guarantee payment passenger. So once again, they do not have, let's talk about one of the deals that is closed. So if they do not have passenger traffic in terminal 2, they almost have to pay the rent. Of course when they operate in terminal 4 their operations will be in the accordance with the amount of passengers we have in that facility. So I would say terminal 4 is operating normally.\\nRuben Lopez -- Santander -- Analyst\\nThank you. And when you compare, sorry, the current level of commercial revenues versus what would be the minimum payment from the contract, can you give us any idea on that?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said, minimum payment -- the contract is on a per passenger basis.\\nRuben Lopez -- Santander -- Analyst\\nPerfect, thank you.\\nOperator\\n[Operator Instructions]\\nAnd we will now go to Jorge Larocco of Morgan Stanley.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nHi Adolfo, good morning. Thank you for the questions. It's two questions, actually a pretty general question, I was just wondering if you could provide more color on what are the main initiatives regarding our cost reduction efforts. How are those working down, your payment reductions on paid leave of absence, maintenance cost, utility costs, etc. and how are those playing out so far? Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThe main initiatives of course are related to in the case of Cancun in the terms of amounts. So we these key terminals closed, we are not burning the same amount of energy as if they were open. Also in the case of Cancun, we are in the process to shut down and one of the runway because today in accordance with the [Indecipherable] it's not needed. So, that runway will be turned off in terms of light at night also reducing their energy we will have to pay. And in terms of some other measures we are taking, adjusting some of the contracts of nature or mainly maintenance in the case of the buildings are closed and to try as much as possible to reduce operating cost and expenses. But I once again at the end, most of our cost is fixed. So if we apply the cost structure of the company, the most important lines are personnel and utility costs as we have said so. In the case of personnel, we are maintaining the personnel for the event or the crisis and in the case utilities, we are trying, as much as we can to try to reduce that.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nThanks so much Adolfo. Stay safe and have a good day.\\nOperator\\nAnd with that, that does concludes the question and answer portion of today's conference call. I would like to turn the call back over to Mr. Castro for closing remarks.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and thank you again for participating in our fourth quarter results conference call. On behalf of ASUR, we wish you good day and until we meet, be safe. Good bye.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 34 minutes\\nCall participants:\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nAndressa Varotto -- UBS -- Analyst\\nStephen Trent -- Citi -- Analyst\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nRuben Lopez -- Santander -- Analyst\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nMore ASR analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nHello, and welcome to the Globus Medical fourth quarter and full year 2021 earnings call. [Operator instructions] I will now turn the call over to Brian Kearns, senior vice president of business development and investor relations. Mr. Kearns, please go ahead.\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nThank you, Chris, and thank you, everyone, for joining us today. Joining today's call from Globus Medical will be Dave Demski, president, and CEO; Dan Scavilla, executive vice president and president of Ortho; and Keith Pfeil, senior vice president, and chief financial officer. This review is being made available via webcast accessible through the investor relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements.\\nOur Form 10-K for the 2021 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP.\\nWe believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available on the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Dave Demski, our president, and CEO. \\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Brian, and good afternoon, everyone. Globus finished an outstanding 2021 with a strong fourth quarter performance. Revenue for the year was a record $958 million, an increase of 21% over 2020 or $169 million in growth. To put that in perspective, our growth dollars alone would have ranked us in the top 10 spine companies in the world.\\nRevenue in 2021 was 22% higher than 2019, an outstanding performance in itself, given the disruption caused by COVID but magnified further by a recent independent research report showing that each of the other top 6 spine companies actually had sales declines over that same time period. We achieved record sales and growth while maintaining industry-leading profitability, generating a record $2.04 in non-GAAP EPS, a 42% increase over 2020, and adjusted EBITDA of 34.6% even as we invested heavily in INR, trauma, and competitive recruiting. Revenue for the quarter was $250 million, up 7% over 4Q '20 as COVID-related headwinds remained strong throughout the quarter. Non-GAAP EPS was $0.49 per share, a 16% decrease compared to the artificially high 4Q '20.\\nNot only were business travel and surgeon education activities severely curtailed last year, several other nonoperational factors, as Keith will expound upon in his remarks, also impacted the decline. Adjusted EBITDA in the fourth quarter was a strong 34%. Enabling technology continues to gain momentum, producing a record $25 million in revenue for Q4, an increase of 40% over 4Q '20. For the full year, enabling technology revenue was $81 million, an outstanding 100% increase over 2020.\\nThe clinical superiority of ExcelsiusGPS is the primary factor driving this growing momentum. Robotic utilization, which is the number of cases performed per installed robot, was at an all-time high in 2021. And nearly 30,000 procedures have been completed using ExcelsiusGPS technology since launch. Our spinal implant business continues to experience the flywheel effect of an increasing number of robots being sold combined with increasing utilization of each robot.\\nOur U.S. spine business grew by 3% in Q4 as COVID-related shutdowns had a significant impact throughout the quarter. We saw this trend continue into January, but all signs point to a rebound commencing late in Q1. For the full year, the U.S.\\nspine business grew by 18% as we continued to take significant market share. Robotics pull-through, coupled with contributions from recent product introductions and competitive recruiting, were all factors driving growth. Our international spine implant business grew by 9% in the quarter, a remarkable result in light of COVID impacts and an ongoing drag from Japan. Due to the impact of strategic moves we made in Japan last year, we expect to see continued declines there through the first half of 2022 with growth to follow off a reset baseline.\\nThis should result in accelerated overall international growth in the second half of this year. Trauma revenue was up 32% in the fourth quarter and 39% for the full year. Competitive recruiting and new product launches are driving growth. The Anthem Mini Frag system was launched on a limited basis in Q4 with excellent feedback from surgeon users.\\nWe are proceeding to full launch in Q1 and have a series of impactful product launches planned for the first half of 2022. The clients have launched the Excelsius 3D imaging system on a limited basis later this quarter with a full launch following in late Q2 or early Q3. There is tremendous anticipation and excitement about this technology among surgeons, and we already have double-digit orders signed. The Excelsius ecosystem, Globus Medical's unique combination of robotics, imaging, and freehand navigation that provides a seamless, scalable, and unmatched clinical experience for surgeons is about to become a reality.\\nI'm extremely proud of our team's performance in 2021, record growth and profitability, exciting, clinically impactful new technology introductions, and an unmatched focus on providing value to surgeons and their patients. Thank you for a great year. I will now turn the call over to Keith.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you, Dave, and good afternoon to everyone joining us for today's call. Globus capped off a record 2021 with a robust Q4 performance despite ongoing COVID-related disruptions and shutdowns. For the full year, 2021 revenue was $958.1 million, growing 21.4% as reported. On a day-adjusted basis, sales grew by 22.1%, with two fewer selling days in the U.S.\\nand international. Net income was $149.2 million, resulting in fully diluted earnings per share of $1.44. Non-GAAP net income was $211.4 million, generating a record $2.04 of fully diluted non-GAAP earnings per share. Adjusted EBITDA was 34.6% for the year, and we generated a record $219.4 million of free cash flow for the full year.\\nQ4 '21 revenue was $250 million, growing 7.1% as reported and 8.5% on a day-adjusted basis with one less selling day in the U.S. and international compared to the prior-year quarter. Net income was $15.1 million, and non-GAAP net income was $51.1 million. Our Q4 diluted -- fully diluted earnings per share was $0.14, while our fully diluted non-GAAP earnings per share was $0.49.\\nAdjusted EBITDA was 34.1%, and we generated $59.2 million of free cash flow for the quarter. Taking a deeper dive into sales. Q4 U.S. revenue was $213 million, 7.2% higher compared to Q4 of 2020 driven by our INR and U.S.\\nspine businesses. International revenue for Q4 was $37.1 million, growing 6.8% over the prior-year quarter led by growth in spinal implants despite lingering COVID impacts and the impact of our strategic changes in Japan as Dave mentioned earlier. On a constant currency basis, international revenue grew by 8.7%. Q4 gross profit was 75.3% versus 73.9% in the prior-year quarter.\\nThe 140 basis point improvement was driven primarily by nonrepeating inventory reserves in the prior-year quarter and was consistent with our expectations noted in our Q4 2020 earnings commentary. Full year 2021 gross profit was 75%, compared to 72.4% in the prior year. The increase in full year gross profit is primarily the result of lower inventory reserves and operational and supply chain efficiencies, partially offset by sales mix. Looking ahead to 2022, we project a mid-70s gross profit rate.\\nResearch and development expenses in Q4 were $51 million or 20.4% of sales, compared to $15.2 million or 6.5% of sales in the prior-year quarter. The increased spending is primarily reflective of in-process research and development acquired during the quarter. Adjusting for these costs, Q4 2021 research and development expense was $16.7 million or 6.7% of revenue, in line with the prior-year quarter as a percentage of sales, but $1.5 million higher driven by incremental investments in headcount across our spine, INR, and trauma businesses. Our full year 2021 research and development expenses were $97.3 million or 10.2% of sales, compared to $84.5 million or 10.7% of sales in the prior year.\\nAdjusting for the acquisitions made in both periods, research and development expenses were $63 million or 6.6% of sales in 2021, compared to $60.1 million or 7.6% of sales in 2020. The increase in spending is reflective of our continued investment in research and development to foster future growth and is consistent with comments made earlier in the year. We expect our R&D expenses to be approximately 7% of sales in 2022. SG&A expenses in the fourth quarter were $106.6 million or 42.6% of sales, compared to $92 million or 39.4% of sales in the prior-year quarter.\\nThe resulting increase is reflective of higher sales compensation and benefit costs as well as increased travel and training expenses driven by the resumption of normalized travel levels following the COVID-19 impacts experienced in the prior year. Full year SG&A expenses were $408.1 million or 42.6% of sales, compared to $354.8 million or 45% of sales in the prior year. The resulting decrease as a percentage of sales is reflective of leverage on fixed costs as a result of the higher volumes when comparing against the COVID impact in 2020. The income tax rate for the quarter was 23.8%, compared to 14.9% in Q4 of 2020 with the resulting increase driven primarily by lower tax benefits associated with stock option exercises.\\nOur full year 2021 income tax rate was 17.3%, slightly lower than the 18.8% in 2020 driven primarily by the nonrecurring tax treatment related to a 2020 acquisition, partially offset by lower tax benefits associated with stock option exercises. Looking ahead to 2022, we expect our effective tax rate to be approximately 20% for the full year, which assumes no significant changes in the current U.S. tax policy. Fourth quarter net income was $15.1 million, and non-GAAP net income was $51.1 million.\\nQ4 diluted earnings per share was $0.14, and non-GAAP diluted earnings per share were $0.49, compared to $0.58 in the prior-year quarter. The quarter-over-quarter decrease is driven by more normalized levels of travel, trainings, and meetings noted above or noted earlier as well as nonoperational items, primarily a higher tax rate as previously mentioned, higher stock compensation expense, and lower interest income. Looking ahead to 2022, we are expecting a mid-30s adjusted EBITDA rate. Full year diluted earnings per share were $1.44, and non-GAAP diluted earnings per share were $2.04, reflecting a 42.2% increase over 2020 primarily related to higher sales volumes following the 2020 impact of COVID-19, partially offset by approximately $0.09 of nonoperating headwinds related to a higher share count and lower interest income.\\nQ4 adjusted EBITDA was 34.1%, compared to 36.2% in the prior-year quarter. Full year 2021 adjusted EBITDA was 34.6%, compared to 29.4% in 2020. Net cash provided by operating activities were $76.3 million for the fourth quarter and a record $276.3 million for the full year 2021. Free cash flow was $59.2 million for the fourth quarter and a record $219.4 million for the full year 2021.\\nThe company remains debt free. At this time, the company is establishing full year 2022 guidance. We are projecting full year 2022 sales guidance of $1.025 billion, representing 7% growth versus 2021. We are guiding to a full year fully diluted non-GAAP earnings per share of $2.10, representing 3% growth versus 2021.\\nI note that the 2022 guidance includes approximately $0.10 of nonoperating headwinds, including higher shares worth $0.04, a higher tax rate worth $0.03, and higher stock compensation expense worth $0.03. Adjusting for these nonoperational factors, our 2022 guidance would have been $2.20 or 7.8% higher than 2021. Overall, we view this guidance as appropriately conservative and reflective of the current operating environment around COVID and inflation-related impacts. Our 2021 results represent our teamwork, our commitment, and our focus on execution.\\nWe continue to differentiate ourselves in the marketplace. And it is a testament of the hard work and dedication of each of our Globus employees. We remain excited for the future as we continue on our mission of improving patient care. Operator, we will now open the call for questions.\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] Our first question comes from Matt Miksic of Credit Suisse. Your line is open.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks so much for taking the questions and congrats on a really strong finish to a pretty amazing year, given the circumstances. I wanted to follow up on some of the comments around EPS guidance, in particular. As you pointed out, there are some items that ex those items, up 7% to 8%.\\nCan you talk a little bit about where in your guidance you're contemplating things that some of the other companies in the space have talked about like rising input costs, staffing challenges, labor costs, freight, etc., things that generally are driving operating costs up a little bit? Maybe give us a sense of how those figure into your guidance? And I have one quick follow-up.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks. This is Keith speaking. So we projected our guidance at $2.10. And as we look at the year, we see inflation as a market event.\\nEveryone is experiencing it, and we have it baked in our numbers. But when you step back and look at the $2.04 and the $2.10, I commented on the $0.10 of the nonoperating headwinds. But the other things that are impacting the business as we think about getting back to more normalized levels of spend are really the travel and the trainings that go along with the surgeons and [Inaudible] that we provide. That's worth going into the next year likely an $0.08 headwind.\\nAnd then one of the things that we commented on earlier in the year was our continued investment into R&D. As you look into next year, we're seeing roughly I would say, call it, $0.04 of additional investment in R&D. When you look at those things together, coupled with the inflation, we're landing at about $2.10.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And can you just maybe just elaborate a little bit on the spend or R&D and sort of the expectations for returns in terms of growth or programs that you're investing in?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nSo we're continuing to invest heavily in our spine business and as well as our robotic businesses. We talked about that in Q1 of our earnings call earlier in the year, and really all sign points to us continuing to do that. Dave talked earlier about some of the benefits that we're seeing for robotic technologies. We continue to invest in that and really grow for the future.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And then just one quick follow-up I had was on the environment for robots and spending in capital and equipment in general. Some of the other, again, companies in the space have talked about a fairly strong year for equipment, a strong year for robots. Any sense of whether this is something that needs to sort of take a breather or catch up here in 2022? Or whether orders and demand and pipeline for new deals would indicate just continued strength into 2022?\\nDave Demski -- President and Chief Executive Officer\\nYeah. Matt, this is Dave. No, it's very strong. I don't see anything laying off.\\nIn our case, in particular, it's been accelerating. I think the demand for Excelsius has been strong, and it's becoming more and more common. The narrative has changed from why robotics to which robot. And I think we're clearly establishing our lead there.\\nAnd then as I mentioned, there's a lot of enthusiasm over our Excelsius 3D system, which is going to launch later this quarter. We've had every surgeon we show that to seems like they want one. So I don't see it backing off at all.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks and congrats.\\nDave Demski -- President and Chief Executive Officer\\nThank you.\\nOperator\\nThank you. Our next question comes from Matt Taylor of UBS. Your line is open.\\nMatt Taylor -- UBS -- Analyst\\nExcuse me. Hi, guys. Thanks for taking the question. So I wanted to ask the first one about margins longer term.\\nMaybe just talk about the difference between what you're doing this year with some of the investments and obviously, headwinds year over year from spending back to normal and inflation, and how we should think about margins longer term? Would you start to get more leverage at some point? And what would the inflection point for that be?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. It's a good question. But as I look at where we're at and where we're going, our goal is to always maintain a mid-70s GP. But as we look longer term and look at our EBITDA rates, we're always looking to be in that mid-30s range.\\nWe could toggle our investments in various parts of our business to really achieve that, but we're investing now to drive growth -- to drive top-line growth for the future. And as we get that growth, that's going to create more fixed cost leverage in our P&L. So I think by doing that, investing for growth today helps project the margins going forward. I feel that we're going to work to try to stay in that range.\\nDave Demski -- President and Chief Executive Officer\\nYeah. I can add a little bit maybe to that, Matt. In the spine business, I don't think you'll see much greater improvement in our margins there, but we have a lot of operating leverage in front of us in the orthopedic side of the business and the capital side. Those are both fairly nascent businesses for us, and we're funding it with spine.\\nBut once we start to hit some volume numbers there, I think those businesses will definitely expand.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Can I ask a follow-up on the robotics strength? I mean, you talked in the past about getting pull-through on these placements, and obviously had a great year in 2021 with enabling tech. I guess are you still seeing the same kind of trends? And could that bode well for pull-through implants in '22?\\nDave Demski -- President and Chief Executive Officer\\nYes. It does. We're seeing that generally the same kinds of trends. And as a company, we're focusing on really going back to that installed base and seeing we can get more users to utilize the technology once it's placed in the hospital.\\nAnd that's a big focus for us in 2022.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Thank you, guys. Thanks so much.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And next, we have Shagun Singh of RBC. Your line is open.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGreat. Thank you for taking the question. I guess my first one is on Excelsius 3D imaging system. Can you talk to us about the delay? Why is there a delay in the launch? And then just elaborate on your go-to-market strategy.\\nAre you targeting the replacement opportunity or greenfield? You're obviously going after a major competitor. So just any color there would be helpful. And then on the recon robotics, do you still plan to launch that in the second half? And then I have a quick follow-up.\\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Shagun. I'll try to knock those off one by one. In terms of the delay, it's just taking longer than we thought. It's nothing significant in terms of the technology hurdle to get over.\\nThere's just a lot to do to get that over the line. So I wish we were a bit earlier but very confident we can get it done this quarter. Go-to-market. I think initially, we're going to be targeting our installed base of Excelsius users.\\nThose are -- there's a high demand among them. It's going to make those procedures much more efficient and much easier for them to do. And then from there, we'll be branching out to target more of that free-hand navigation market that you alluded to earlier. And then I apologize, I forgot the last part of your question.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nI was just wondering if you plan to launch the recon robotics platform in the second half of '22 like you had previously indicated?\\nDave Demski -- President and Chief Executive Officer\\nNo. That's been delayed as well. We're going to be -- early '23 is the target for that.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGot it. And then just as a follow-up, I was wondering if you could talk about trends that you're seeing on the procedure volume side in Q1, so in January and February. And spine typically has a high pain burden, so procedures come back quickly. So do you expect the recovery to come in Q1? Or do you expect a longer tail given staffing shortages? Thanks for taking the question.\\nDave Demski -- President and Chief Executive Officer\\nSure. Yes, January was really bad, but we've already started to see it turning in February. The last three weeks have all been progressively higher. Not back to where we want it to be, but definitely, I think we've hit bottom.\\nWe're going in the right direction. And I'm not going to try to predict what's going to happen with COVID though. That's proven to be frivolous for everyone, but it's encouraging where we are right now.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nThank you.\\nOperator\\nThank you. And next, we have Matthew O'Brien of Piper Sandler. Your line is open.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat. Thanks for taking the questions. I guess, Dave, just for starters on the top-line guidance. This time last year, you guided about $35 million below The Street.\\nWe end up doing well above what you initially guided and actually what The Street was modeling. And this time, you're guiding about $25 million below The Street. I know January was soft, and maybe Excelsius 3D has pushed a little bit in terms of the contribution. But are there other factors that we should be thinking about? I don't know if it's a rep hiring perspective or a robot perspective that gives you a little bit more caution versus kind of where The Street was modeling things?\\nDave Demski -- President and Chief Executive Officer\\nThanks, Matt. I'm sorry we don't pay that much attention to The Street. We look internally to our own forecast, and we always want to be appropriately conservative going into a year. I feel really confident in the business.\\nThe U.S. spine business has been just cranking away. The robotic momentum is there. We're going to have 3D out this year.\\nJapan is going to turn around in the second half. So I feel really good about the business. We just have taken a very conservative approach over the years when we give guidance, and we're doing that again.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nOK. Fair enough. And then the follow-up is on acquisitions. Sorry if I cut somebody off there, but there's been some talk about you guys doing a scale acquisition.\\nI'm curious if you have any thoughts about the need for scale in spine. And then if not, there's some pretty interesting assets still in the spine space, but more on the pain management side of things. Are those higher on the list in terms of things that you potentially are looking at from a acquisition perspective?\\nDave Demski -- President and Chief Executive Officer\\nNo. It's actually a bit different. We're more active in terms of growing the business through BD and on the orthopedic side of the business. I think we're really strong in spine, and there's really nothing in spine that's of interest to us at the moment.\\nWe're more focused on growing the other piece of our business, which is smaller. There's nothing, I would say, transformative in our sights right now. But we are looking at several modest-sized deals as been our history in the past.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat.\\nDave Demski -- President and Chief Executive Officer\\nDid that answer your question?\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nYep. That's perfect. Thank you.\\nOperator\\nThank you. Next, we have David Saxon of Needham. Your line is open.\\nDavid Saxon -- Needham and Company -- Analyst\\nYeah. Hi, guys. Good afternoon, and thanks for taking the questions. Maybe one on enabling tech.\\nI mean, it doubled this year, and you've really built out the enabling tech platform with hub and 3D, etc. How should we think about those launches kind of starting to ramp? And could '22 be another double?\\nDave Demski -- President and Chief Executive Officer\\nYeah. I think as I said, we're going to get some -- a few units out this quarter and kind of a soft launch, if you will, with the full launch starting in probably end of Q2, it might be into Q3 and then strong in the second half of this year. I don't want to comment on the double. It's -- we don't really drill into the components of our business.\\nI can tell you that we're really excited about what we're seeing from our technology, from the adoption of our technology and not only what's right in front of us, but some things we have coming after that.\\nDavid Saxon -- Needham and Company -- Analyst\\nOK. Got it. And then maybe on trauma, kind of how close are you to having a full portfolio there? And then in terms of growth, 32% in the quarter. Is that sustainable in '22? Thanks for taking the questions.\\nDave Demski -- President and Chief Executive Officer\\nSure. The bag in trauma is by the second half of this year, I think full is kind of interesting term. We're going to have enough in our bag to be a full-line player and be able to compete with the major companies by the end of this year. And is that growth rate sustainable? Yes, I think that's certainly achievable in 2022.\\nDavid Saxon -- Needham and Company -- Analyst\\nGreat. Thank you.\\nOperator\\nThank you. Next, we have Craig Bijou of Bank of America. Your line is open.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nHey, guys. Thanks for taking the questions. Maybe a follow-up on top-line guidance and to the extent that you guys are willing to share. I mean, how to think about the contributions from each of the businesses? I know generally, you've been reluctant to share that info.\\nBut in terms of the composition of the guidance, how do we think about that incremental revenue coming in? Where is it coming from and to what extent?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. As Dave said earlier, we're not going to get a ton into the parts and pieces. But what I will say is if you look at the business, whether by musculoskeletal and INR or you look U.S. versus international, the parts and pieces of our business we continue to feel extremely positive about as we look into 2022 and beyond.\\nWe're investing in our business. We're driving investment for the future, and we feel that we'll see that turn out to us taking share and driving sales growth. I alluded to my earlier prepared comments that our guidance is appropriately conservative, but there's nothing that I sit here and feel that we have kind of an ongoing issue that I would be concerned about our ability to grow across our business, like I said, whether it's U.S., international or musculoskeletal versus INR.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGot it. Thanks, Keith. That's helpful. And then, Dave, I think you alluded to it, but I wanted to ask more specifically how to think about some of the new product rollouts? Obviously, you have 3D coming out and launching this year.\\nBut from a new product perspective, is it -- do you have a number of launches coming this year on the spine side? Do you have a number coming on the INR side? Just maybe a little bit more perspective of what to expect during the year.\\nDave Demski -- President and Chief Executive Officer\\nSure. Thanks, Craig. I think we've been pretty clear that it's a big one coming with 3D followed by our hub [Inaudible] offering. I think spine, we are typically 10 to 12 launches a year, and that's currently our target going into 2022.\\nTrauma is probably the real bright spot. There is a number of products that we were working on for a while, they're going to hit the early part of this year and through this year. So -- and then our orthopedics business actually has some launches as well. So that's kind of who we are and who we're going to be.\\nAnd it's -- the number one focus of the company is to drive great technology.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGreat. Thanks for taking the questions, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. Next, we have Ryan Zimmerman of BTIG. Your line is open.\\nRyan Zimmerman -- BTIG -- Analyst\\nAll right. Thanks for taking my questions and congrats on a great year. Just want to follow up on a couple of questions. Dave, when we think about U.S.\\nSpine performance kind of relative to the market, you look at some of the larger players, they were down a bit in the fourth quarter. Some of the smaller players we saw were up double digits. Obviously, a few major players still yet to report next week. But I guess I'm kind of curious if you can kind of talk about the U.S.\\nperformance, that growth this fourth quarter relative to the market, and kind of where you think you're tracking relative to that level? And if you could kind of give us color on what you think that level was just given the dynamics in the fourth quarter through the quarter would be helpful.\\nDave Demski -- President and Chief Executive Officer\\nThanks, Ryan. It's really challenging to figure out where we are, given COVID. So from the early returns of some of the folks who we have reported, again, we're taking significant share. I can't speak to the smaller guys who have reported or how that impacts us.\\nAnd I don't really have a feel for the overall market. I know it was heavily impacted by COVID so likely down versus prior year overall. But that's more of just a guess and kind of where we landed versus some of our earlier trends. Our business is strong.\\nI can tell you that. We haven't lost significant pieces of business in the U.S. And we continue to see growth in the recent product introductions, and we continue to sell robots and drive pull-through from that. So it's strong.\\nI just -- I can't really see the overall market, and it's really hard to figure out what's going on given what's happening with COVID.\\nRyan Zimmerman -- BTIG -- Analyst\\nOK. Just two follow-ups for me. One, we've heard some of the larger capital equipment companies have obviously called out chips as being a gating factor to sales or median demand in 2022. One, want to see if there's any concern there around chips for the Excelsius platform or for 3D and whether that could gate sales? And then I'll just ask the other -- sneak in a quick follow-up, too.\\nThe Japan distributor dynamics, how much of a lift should we expect when that distributor dynamic clears in the second half of 2022 on the international business? Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. In terms of chips, I would just -- I would extend that to all supply chain. So it's not just chips, it's all components are challenging. It hasn't cost us revenue now, but it's certainly on our radar and making our life really hard.\\nSo it's a risk that's out there for 2022. I'll let Keith maybe handle the international question.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nAs it relates to Japan and the distributor dynamic, as we look ahead, we finished 2021, I think international grew by about 11%. We've historically said that we believe that the international business can grow mid-to-high teens. I would expect us to be able to get back to that on an annual basis. So you would expect the second half of the year to accelerate ahead of that to potentially balance -- to get closer to that 15 by the end of this year.\\nRyan Zimmerman -- BTIG -- Analyst\\nThanks, Kieth. Thanks, Dave. Appreciate it.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. Next, we have Kyle Rose of Canaccord. Your line is open.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nGreat. Thank you for taking the questions. I wanted to start on enabling. I mean, look, you put up a good quarter in enabling.\\nI guess a tough backdrop, particularly without the imaging platform. Maybe just help us understand kind of where that stands from a utilization perspective into your customer base. You're talking about the really good utilization there is continuing to see strong pull through. Can you just kind of level set maybe how many of your customers might have it or on a percentage basis or on an absolute basis? Just trying to really understand where we are in the uptake and the adoption within the historical core Globus customer base.\\nDave Demski -- President and Chief Executive Officer\\nYes, Kyle. To be honest, I don't feel comfortable sharing that information from a competitive standpoint.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nTotally fair. I had to try. I also wanted to touch on the orthopedic side of the business. I mean, it's been a couple of years since you acquired the StelKast business.\\nI think earlier in the call, you talked about the fact that the recon robot is going to come in '23. Where do you stand just from an implant perspective? Do you have the right implants there? Do you need to make different investments from an M&A perspective, technologies, distribution? Just help us understand what you need to do on that total joints business before the recon robot comes next year. Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. We do not have the implant portfolio we need to really make a strong outing. So we are working on that, have been working on that, and expect to roll some products out this year. I don't see us filling the gaps in our product portfolio with acquisitions in terms of hips and knees in particular.\\nI do think there's opportunity for scale there. So that's not off the table because we are very small right now. And then the extremities is an interesting segment for us as well. It's a fast-growing segment.\\nSo that's an area where we've taken a look at a few things. Does that help with your question?\\nKyle Rose -- Canaccord Genuity -- Analyst\\nYes. Thank you very much.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. And next, we have Samuel Brodovsky of Truist. Your line is open.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nHi. Thank you for taking the questions. Just a first quick one on U.S. Spine.\\nJust would be curious to hear about the portion of growth in the U.S. coming from robotic-specific instrumentation versus where you're seeing potential share gain with other parts of the portfolio?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nYes. Thanks for the question. In terms of breaking it out, we typically don't break out the parts and pieces of where the growth is coming from. What I would say is that as you look at our U.S.\\nSpine business, it's really a combination of what we always talked about: new product innovation, our competitive recruiting, and the pull-through from implants. Those three continue to propel the business from a growth perspective, and we see that continuing as we enter 2022.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nGreat. That's helpful. And then when thinking about 3D and going to customers with it, in terms of any competitive trialing, are you seeing it being trialed against other more novel imaging technologies on the market? Or is it typically being compared to the large competitor out there? Thanks.\\nDave Demski -- President and Chief Executive Officer\\nInteresting question. I assume it's -- we don't really trial against it, but we have customers looking at our technology. And I think their interest just probably lines up with the market share of the other imaging systems in the market, particularly ones that are utilized more in spine. I'm sure that some of the more innovative ones are getting a look, but we don't hear that much about them.\\nSo it's not disproportionately, maybe I could answer it that way.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nThanks.\\nOperator\\nThank you. [Operator instructions] Our next question comes from Steven Lichtman of Oppenheimer. Your line is open.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nThank you. Hi, guys. I wanted to ask you first on trauma. Where do you think you stand now in terms of coverage of procedures in terms of your product portfolio? And also from a sales force perspective, I'd just love to get an update on where you feel you are overall in terms of being able to go at the market.\\nDan Scavilla -- Executive Vice President and President of Ortho\\nSteven, it's Dan Scavilla. So again, it's always the evolving and expanding story. We have about 14 family products out there now. I think with that, we're saying we would cover 50% to 60% of the market.\\nCertainly, plan, as David said, to launch several more this year to cover that further. I believe and through what I'm saying, we're at a point where we're able to get into some significant facilities and support their needs for the most common procedures. And with that that's the main driver of growth to us. So we'll continue to expand the product line and fill that out over time, but we're in a good spot now.\\nWith that is the competitive recruiting that's been accelerating for us. So again, we're small, and we have a lot of spaces to fill. But the traction that has been occurring really through 2021 is very promising. And I do feel bullish as we are -- from what I've seen so far in the first quarter of 2022 that that will continue.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nGreat. Thanks, Dan. Keith, just a follow-up on gross margin. I apologize if you mentioned this, but just relative to 2021, given the inflation commentary, should we assume gross margin down? Or are there some offsets that can keep it relatively flat to maybe -- or even up in '22?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. We project the mid-70s GP. I think it's fair to assume that we are seeing inflation just like everybody else, but we're also growing. And it's obviously getting us some leverage in our cost structure.\\nSo as I think about 2022, mid-70s is kind of where I see it. I wouldn't project upside.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nOK. Got it. Thanks, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And we now have Jason Wittes of Loop Capital. Your line is open.\\nJason Wittes -- Loop Capital -- Analyst\\nHi. Thanks for taking the questions. Just two follow-ups, one on the guidance and one on trauma. But -- so first off, your guidance, I think the way you described it, especially relating to product launches, kind of assumes a strong second half versus the first half.\\nSo related to that, one, are we assuming that -- I know we can't predict COVID, but COVID pretty much works its way throughout the year? And then secondly, related to that, in the first quarter, I'm not sure how to read your comment that January was very weak. It bounced back. Should this be a normalized first quarter? Or are we -- is it going to be a little weaker relative to last year because of the COVID impact and launches? Thanks.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. Dave commented that January was weak, but we were starting to see some bounce back in February. Will it all bounce back in the same quarter versus having some bleed through into Q2? We don't necessarily know. But I think your earlier comment about some of the launches and a strong second half, I think that's directionally correct.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. And then I don't know if you can comment on this, but you did mention that you had -- it sounds like a record year in terms of sales force hires. In the past, you've kind of given us an indication of how large you've been able to grow your sales force percentage-wise. Can you give us any kind of indication on that in terms of what 2021 look like? And it sounds like 2022, you're optimistic that you can do -- go at a similar run rate?\\nDave Demski -- President and Chief Executive Officer\\nYeah. '21 was not a record year for us. I think we had one really strong quarter, but we've had years that were better. That's a renewed emphasis on it.\\nI can tell you the pipeline right now is extremely strong. So we're coming out of the gate strong. But last year was a good year. It just wasn't our best.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. Thanks a lot. Appreciate it all.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\n[Operator signoff]\\nDuration: 45 minutes\\nCall participants:\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nDave Demski -- President and Chief Executive Officer\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nMatt Miksic -- Credit Suisse -- Analyst\\nMatt Taylor -- UBS -- Analyst\\nShagun Singh -- RBC Capital Markets -- Analyst\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nDavid Saxon -- Needham and Company -- Analyst\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nRyan Zimmerman -- BTIG -- Analyst\\nKyle Rose -- Canaccord Genuity -- Analyst\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nDan Scavilla -- Executive Vice President and President of Ortho\\nJason Wittes -- Loop Capital -- Analyst\\nMore GMED analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4006,\n        \"samples\": [\n          \"2022-08-11 07:30:00\",\n          \"2021-03-18 08:00:00\",\n          \"2021-08-09 11:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 00:00:00\",\n        \"max\": \"2023-02-23 00:00:00\",\n        \"num_unique_values\": 771,\n        \"samples\": [\n          \"2022-07-12 00:00:00\",\n          \"2020-10-22 00:00:00\",\n          \"2022-06-10 00:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Clean_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10031,\n        \"samples\": [\n          \"I'd now like to turn the call over to Matt Shimao, PTC's head of investor relations. Please go ahead. Matthew Shimao -- Head of Investor Relations Hello. Thank you, Julian, and welcome to PTC's results call for Q1 of fiscal '22. On the call today are Jim Heppelmann, chief executive officer; and Kristian Talvitie, chief financial officer. During this call, PTC will make forward-looking statements, including guidance on future operating results. Because such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in PTC's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission, as well as in today's press release. The forward-looking statements, including guidance provided during today's call are valid only as of today's date, January 26, 2022, and PTC assumes no obligation to update these forward-looking statements. During the call, PTC will also discuss non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures can be found in today's press release made available on our website. With that, I'd like to turn the call over to PTC's chief executive officer, Jim Heppelmann. Jim Heppelmann -- Chief Executive Officer Thanks, Matt. Good afternoon, everyone, and thank you for joining us. Turning to Slide 3, I'm pleased to share that PTC delivered another strong financial performance in fiscal Q1. We executed very well, building on the momentum we saw in Q4. To simplify things, please note that throughout my prepared commentary, I will only discuss growth rates in constant currency. ARR came in at $1.507 billion, which was better than the $1.5 billion we had guided to at the recent Investor Day. That represents 16% growth, 11% of which was organic. Adjusted free cash flow was also strong at $145 million, which was up 20% year over year and better than the $140 million expectation we said at the Investor Day. We're off to a very strong start in fiscal 2022. Turning to Slide 4. Of particular note was our bookings strength. Bookings were up double digits organically and high teens overall against the very strong COVID bounce back quarter we saw in Q1 of fiscal '21 when bookings grew more than 30% over the prior year. To put it in perspective, given the tough comparison against Q1 of last year, we had planned bookings to actually be down slightly, inclusive of Arena. So this performance was more than 20% above plan. I know that some analysts and investors had voice concerned that the restructuring work we did in late Q4 and throughout Q1 would distract us, but obviously, we didn't see that. The strength was broad-based across direct sales and resellers and was achieved with no megadeals. Rockwell came in ahead of their part of our plan, too, which was great to see and suggest my concerns of them being distracted and may prove overstated. Arena contributed the inorganic element of bookings growth, with another strong bookings quarter, coming in above plan as well. With the Arena acquisition getting round tripped here in Q2, Arena becomes part of the organic results going forward and their low 20s growth rate will then add another tailwind to the organic results. Arena has been a great acquisition. Bookings growth was particularly strong in PLM, and in both Europe and Americas. From a macro perspective, global PMIs remain an expansion territory, while digital transformation and SaaS continue to grow in importance as secular drivers. The interest in digital transformation in SaaS has been driving strong bookings for what is very sticky software, which when layered into a recurring revenue model that is atypical of industry peers, has allowed PTC to deliver performance in excess of market growth rates. This happened right through the pandemic, especially in the large core business that represents about 70% of our ARR, and we fully expect it to continue going forward. These factors gave us confidence to raise the lower end of our ARR guidance range, which at the new midpoint basically means we've rolled our Q1 beat forward. Now let's take a look at the ARR performance by geography on Slide 5 before turning to business units. In Q1, we saw a strong ARR performance across all geographies. Our ARR growth in the Americas was 19%. All product segments grew with key growth drivers being the acquired Arena contribution and the velocity business unit overall, layered on top of another strong quarter in the core CAD and PLM business. In Europe, our ARR growth was 13%. We saw strong results across the board in Europe, with the strongest drivers of the growth being our digital thread growth and core businesses. Europe has the largest mix of channel versus direct and the resellers continue to perform well. Our ARR growth in APAC was 14%, with growth primarily driven by our digital thread core business. Next, let's take a look at the ARR performance of our various business units, starting with the digital thread group on Slide 6. In our largest product segment, digital thread core, we delivered yet another double-digit performance in Q1 with 11% growth. Within this, CAD and PLM, both grew double digits, with strong growth across all three geographies. This is the 17th consecutive quarter of double-digit ARR growth in the core business. And as we roll out our more aggressive SaaS strategy, I expect we'll see many more. In the digital thread growth, which is IoT and AR, we saw ARR growth of about 14%, consistent across both elements. This was in line with our plan and the mid-teens near-term growth expectation we set at the recent Investor Day. While this level of growth remains accretive to company growth, we continue to expect an acceleration of growth into the 20s as we get into the back half of the year. The biggest driver of growth in Q1 was from expansions, especially in Europe and APAC. We believe market conditions in IoT are improving, and we like the way the pipeline for our new DPM offering is developing through both PTC and Rockwell channels. For AR, we continue to see a tremendous level of interest, but the market remains nascent. Perhaps most importantly, the formation of the digital thread business unit at the start of FY '22 has driven important initiatives to increase our focus on cross-selling of IoT and AR into the core CAD and PLM customer base. FSG had a great Q1 with 6% ARR growth. The expansion deal we recently announced with the U.S. Air Force, both increases and extends this key relationship for up to five more years. Contracts like this demonstrate the value that our customers are realizing from Servigistics and other FSG products such as retail PLM and ALM. You may remember, I noted at our Investor Day that having FSG grow in the mid-single digits rather than flat would be a helpful upside growth driver. So I'm pleased to see FSG post another strong quarter. Let me run through a couple of quick customer anecdotes to give you a sense for our digital thread customers and how they rely on us. On Slide 7, MAN Energy Solutions is the world's top provider of large-bore engines in turbomachinery for the maritime and energy industries. The company manufactures complex parts in nearly every engine they make must meet unique customer requirements. Before implementing Creo, they relied on manual outdated processes that slowed design and production. With Creo, they've been able to transition from 2D to a full 3D model-based approach. Creo's broad range of tool path automation capabilities enable them to save time in the programming of the tool pass used to machine the large complex engine parts, greatly increasing efficiency in transitioning from design to production. Turning to Slide 8. You may have noticed we announced a deal with -- we announced that the German company, Scheffler, has expanded its relationship with PTC, and I'd like to share a bit of the back story. Scheffler has been a longtime Creo customer and has successfully deployed Windchill within engineering. But back in 2017, one of our PLM competitors announced a large PLM deal with Scheffler that appeared to cap PTC's expansion opportunity. But that system didn't ultimately stick as Scheffler has now decided to consolidate on PTC systems with Windchill being the backbone and is broadly deploying our solutions in their standard out-of-the-box fashion so that Scheffler can participate in the full power of our digital thread portfolio. I'm very excited about this collaboration and the further expansion that Scheffler is exploring with our IoT and AR offerings. On Slide 9, you'll see how IMA Group, our global business that delivers packaging machines, services, and solutions to a wide variety of industries, was looking for a way to expand their control room offering to help their customers improve overall equipment effectiveness and reduce downtime. As longtime users of PTC's Creo and Windchill, IMA decided that ThingWorx was the ideal IoT solution for their initiative and that Kepware could provide connectivity not only to their machines, but to the other vendors' machines deployed alongside them. IMA has successfully launched new revenue streams by enabling 24/7 monitoring of customer production lines and improved OEE by up to 16%. The Vuforia integrated with ThingWorx is the platform of choice for the U.S. Air Force training initiatives. Slide 10 highlights the work that PTC partner, Vectrona has done with the U.S. Air Force. With finite training resources and limited capacity, the U.S. Air Force set out to incorporate augmented reality into their maintenance and munitions training. Vectrona using Vuforia Studio worked with the U.S. Air Force to create immersive 3D AR experiences for phones, tablets, and the HoloLens 2 that are designed to accelerate learning, improve work performance and facilitate remote training. The improved training shows better engagement and information retention with continuous and repeatable task training available regardless of the system or aircraft type. Turning to Slide 11, the velocity business ARR growth in Q1 was more than 650% due to the inclusion of Arena and 53% organically, which would be Onshape. If you were to add Arena's pre-acquisition results into the prior year to get a better pro forma comparison, then you'd have the velocity business unit growing at 28% in Q1. That 28% is a mix of Onshape growing at 53% and the larger Arena business growing in the low 20s. Growth of both Onshape and Arena is multiple times higher than market rates, clearly demonstrating that industrial companies see the benefits of SaaS. We continue to ramp investments to expand technology leadership and to broaden the geographic presence of our velocity businesses. On Slide 12, Beta Technologies, a leading developer of next-generation electric aircraft for the cargo and logistics market, sought a cloud-native product development platform where everyone would be working with one single source of truth without the workflow restrictions of traditional file-based design systems. Beta turned to Onshape because of how it enables real-time collaboration, allowing the engineering team to work from any location while streamlining their communications during the design process. To profile Arena customer, Potrero Medical, on Slide 13, is a predictive health company developing the next generation of medical devices, leveraging smart sensors and artificial intelligence. Potrero needed a scalable quality management system to support its growing product development and compliance needs, including satisfying FDA audit requirements. Arena was the right solution, offering a cloud-native QMS with a quick implementation, leading to ECO cycle time reduction of 30% and nonconformance improvement of 20%. As a final topic, I'd like to give you a quick update on our SaaS acceleration initiative on Slide 14. We've made tremendous progress in the past 90 days since we announced the more aggressive strategy. We've launched our SaaS program management office, which was modeled after the very successful approach we used to drive our subscription transition several years back. Our field organizations transition to the new two-in-a-box customer success organization model without missing a beat. We converged our cloud and tech support organizations with product development to deploy the DevOps type of approach you see in virtually all SaaS companies. We've made good progress advancing our offerings, especially the Windchill multi-tenant version, which will go into production shortly this quarter, and we made good progress preparing the SaaS conversion offerings that will power the hundreds of lifts and shifts that will happen in the coming quarters and years. We have more work to do, but we're certainly up and running. The time for SaaS has arrived in our industry and PTC is very well positioned. We're already the SaaS leader in our space with continued strong SaaS growth in Windchill and FSG and high levels of growth in our cloud-native velocity business unit. Sharing the Atlas SaaS platform, we have a dual strategy to win with Onshape and Arena powering a new agile product development approach, while we transition our digital thread portfolio and existing customer base to SaaS to elevate the platform strategies that so many larger companies have. To wrap up on Slide 15, I'm pleased with PTC's position and the opportunity that lies ahead. Q1 gave us a strong start to what we expect to be our fifth consecutive year of double-digit ARR growth. Our portfolio of products is unique and compelling and obviously aligns well to customer demand. Our results have been consistently strong for many quarters, but we're poised to accelerate growth as the SaaS tailwind blows harder in coming quarters and as we gain more momentum with our IoT and AR initiatives in the back half of the year. We're poised to drive higher levels of profitability, too, following the organizational changes we've already implemented and as our start-up businesses continue to mature up their J curves. The company has never been in a better position to create shareholder value. With that, I'll turn it over to Kristian for more details on the financial results. Kristian Talvitie -- Chief Financial Officer Thanks, Jim, and good afternoon, everyone. Before I review our results, I'd like to note that I'll be discussing non-GAAP results and guidance, and growth rate references will be in both constant currency and as-reported rates. So turning to Slide 17, we delivered constant currency ARR of $1.507 billion, which is 16% growth year over year and slightly exceeded our Q1 guidance of $1.5 billion. On an organic constant currency basis, this is 11% growth. FX was an approximate $11 million headwind in Q1, so our as reported ARR was $1.496 billion. Our SaaS products in both the digital thread and velocity business units saw a continued strong growth in Q1, with growth rates similar to what we discussed at our recent Investor Day. This is in combination with continued strong growth of our software-only sales. As of Q1, our SaaS portfolio is now 15% of our total ARR on a constant currency basis. Q1 free cash flow of $134 million grew 21% year over year and includes $11 million in restructuring and other related payments. Adjusted free cash flow was $145 million and was slightly ahead of the $140 million we discussed at our Investor Day. Q1 revenue of $458 million increased 7% year over year. As we've discussed previously, revenue is impacted by ASC 606, so we do not believe that revenue growth rates are indicative of our underlying business performance but would rather guide you to ARR as the best metric to understand our top-line performance and cash collection. FX only impacted revenue by about $1 million in Q1. So our revenue on a constant currency basis was $459 million. Q1 non-GAAP operating margin of 35%, compared to 36% in Q1 of 2021. While this is a strong result, it's still worth pointing out that because revenue was impacted by ASC 606, other derivative metrics such as gross margin, operating margin, and EPS are all also impacted. Suffice it to say that our COGS and opex came in in line with our expectations in Q1, and we continue to maintain good discipline on our operating expense structure. I would like to point out that our GAAP results reflect a gain of $9.8 million related to our investment in Matterport. And we're also slightly reducing the range for expected P&L charges from approximately $45 million to $50 million, down to $40 million to $45 million for the full year. And coincidentally, we're also reducing the range of expected cash payments for the restructuring and other from what was previously $50 million to $55 million, down to $45 million to $50 million for the full year. For guidance purposes, we will continue to show $50 million as the cash payments and the adjusted free cash flow reconciliation. But as payments come in lower, then we would just expect actual free cash flow to come in higher. There's no change to the $450 million adjusted free cash flow target. Moving to Slide 18, I'll begin with our balance sheet. We ended Q1 with cash and cash equivalents of $296 million. In addition, at the end of Q1, we had medium-term investments of $87 million, primarily related to our investment in Matterport. Our gross debt was $1.45 billion with an aggregate interest rate of about 3.2%. In Q1, we used $120 million of cash to repurchase shares. We also had an additional $5 million of repurchases, which settled early in Q2. For the remainder of fiscal '22, we will focus on delevering and looking forward to FY '23 in an ongoing go-forward basis, assuming our debt-to-EBITDA ratio is below three times, we will continue to target to return approximately 50% of our free cash flow to shareholders via share repurchases. Turning to Slide 19. We post a data table to our IR website that has our financial statements, as well as ARR detail by segment. In that file, we share both constant currency and as-reported ARR. As a reminder, when we calculate constant currency, we use our current year plan FX rates and restate history to the same rates. So here, for example, on this slide, you can see our Q1 constant currency ARR of $1.507 billion and the actual as reported ARR of $1.496 billion. This is important to remember in the context of our guidance because we provide guidance at the planned rate. We believe this is the best way to evaluate the top-line performance of our business because it removes FX fluctuations from the analysis, positive or negative. With that, I'll move on to guidance on Slide 20. As Jim mentioned, we're raising the low end of our full year constant currency ARR guidance by $10 million. The new range is now $1.625 billion to $1.660 billion. This essentially reflects rolling our Q1 overperformance through the remainder of the year. We're now expecting constant currency ARR growth of 11% to 13% in fiscal '22. It's worth pointing out that based on FX rates at the end of Q1, we would expect a $13 million headwind against that full year ARR guidance. For Q2, we're setting constant currency ARR guidance of $1.540 billion to $1.550 billion. This is 12% organic constant currency growth at the midpoint. On an as-reported basis, the FX impact we're calculating based on the FX rates at the end of Q1 is a $12 million headwind in Q2 compared to the constant currency guidance. Moving to free cash flow. We're maintaining our full year free cash flow target of $400 million. This includes approximately $50 million of restructuring and acquisition-related payments. The majority of these payments are related to the reorganization we announced in Q1 with some residual payments primarily related to our Seaport move for which we took the accounting charge in prior periods. So our adjusted free cash flow target for fiscal '22 remains $450 million. Fiscal Q2 adjusted free cash flow is expected to be approximately $155 million. We expect to make approximately $20 million in restructuring and other related payments in Q2, bringing our free cash flow to approximately $135 million. Moving to revenue. We're also taking the low end of the full year revenue guidance up by $20 million. This reflects both the strength in software and strength in the professional services business that we saw in Q1 and the related forecasts for the full year. So for fiscal '22, our net revenue guidance range is $1.870 billion to $1.975 billion. The year-over-year growth rate range is now 3% to 9%. Our ASC 606 makes revenue very difficult to predict for on-premise subscription companies, hence the wide range. Note that revenue variability has -- this is from 606, has no impact on ARR or its related cash generation as we continue to primarily bill customers annually upfront regardless of term length. We continue to expect more than 60% of our annual free cash flow generation to occur in the first half of the year. Collections are stronger in the first half, and we expect expenses to increase as we ramp hiring in our SaaS investments throughout the year. We're wrapping up on Slide 21 with the free cash flow model that we use and went into some depth on at our recent Investor Day that you can see here. I know many of you use model free cash flow using the indirect method. However, given the complexities related to revenue recognition due to 606, this is difficult to do. The model we show here has proven quite effective. The table shows fiscal '21 actuals compared to the model we shared at Investor Day compared to our current guidance. Let me take you through the model focusing on the non-GAAP column on the right and starting at the top. First, we're showing the midpoint of our as reported ARR guidance of $1.630 billion, which is different from the constant currency guidance that we gave due to the $13 million FX headwind and is also $5 million lower than what we showed at the Investor Day. We use it as reported here because it's a better reflection of the cash we expect to generate. You can also see that we have increased the perpetual license revenue forecast slightly and also the professional services revenue increase that we mentioned earlier. COGS is slightly higher, reflecting the increased costs to deliver the incremental professional services revenue and the rest of the assumptions remain the same, and we still end up with our target adjusted free cash flow of $450 million. Obviously, this is a model based on assumptions such as the midpoint of the ARR range, the impact of FX, the pace of hiring, etc. So if some of those variables change, which they invariably will, the model will have to be adjusted accordingly. And as I mentioned earlier, if cash payments related to the restructuring coming at the low end of the range, we would see a flip from the restructuring line to the free cash flow line, but the adjusted free cash flow target would remain unchanged. But as we sit here today, we think this is a reasonable view of how we expect the year to shape up. So with that, I'll turn the call over to the operator, and we can begin Q&A. Questions & Answers: Your first question will come from Andrew Obin from Bank of America. Please go ahead. Your line is open. Andrew Obin -- Bank of America Merrill Lynch -- Analyst Hi, yes. Good afternoon. Jim Heppelmann -- Chief Executive Officer Hello, Andrew. Andrew Obin -- Bank of America Merrill Lynch -- Analyst Just a bigger picture question. I apologize, I missed the first couple of minutes. You know, we hear a lot about supply chain constraints. And frankly, we're hearing that this might extend the run-in terms of PMI expansion. So what are you hearing in terms of sort of as you have conversations about PLM and in terms of adoption? What kind of conversations are you having with your customers? And do customers have awareness of sort of supply chains being gummed up for longer? And are you seeing this having any discernible impact on what kind of conversations you're having with people? Jim Heppelmann -- Chief Executive Officer Andrew, it's Jim. No, actually, it's not really a frequent topic in our conversations because -- well, first of all, since you said you missed the first minute, one of the things I pointed out is that our bookings came in very, very strong, and I explained about 20% higher than planned. So we had a very, very strong bookings quarter. And notable in that was PLM, although, frankly, the strength was broad-based. I think the key thing to remember is that PLM is really associated with preparing product data in engineering that will then subsequently be used in manufacturing and perhaps in aftermarket service. And it's collecting data from supply chain partners and so forth. But production problems in a supply chain don't necessarily impede the collaboration during the engineering and the preparation for production process. So I think people are saying like, maybe I can't get chips to complete the product, but that doesn't mean I should stop designing the next one because if it does, then I'll fall behind. So I think that our view would be that the product development process has largely been unaffected by the supply chain process. Now some other things, we talked about how perhaps COVID had an impact on IoT, perhaps the supply chain a little bit, although I think muted compared to COVID. So to me, the supply chain thing is a fairly small factor in our results. We just see very little correlation between what's happening out there with supply chain problems and what's happening with our pipeline and frankly, with our bookings. Jim Heppelmann -- Chief Executive Officer Hey, Yun. Yun Kim -- Loop Capital -- Analyst Thank you. Hi, Jim. Can you just talk about the IoT business, you know, in terms of the large deal activity? What kind of trends are you seeing there? Obviously, you are expecting that business to accelerate in the back half -- second half of the year. If you can talk about whether that confidence is coming from the, you know, improvement in the large deal activity? Or is it just the overall volume of the activity around IoT? And then also, if you can just comment around deal size activity around the AR business as well. Thanks. Jim Heppelmann -- Chief Executive Officer Yeah. I think deal sizes are sort of unchanged from previous trends. If you think -- what are we looking at when we project forward how IoT and AR will perform. Well, we're looking at the bookings, let me say, at the pipeline that will drive bookings, and for IoT and AR was quite strong. We're looking at the backlog. Last year, bookings actually had improved over the prior year. And bookings that went into backlog or -- I'm sorry, what we call deferred ARR, were quite high. We were well ahead of our deferred planned number as we actually did last year. So you could imagine we've got more, and if you want to call it, backlog waiting for us. And then what other initiatives are we doing? So for example, our DPM launch, I think, will be materially positive for our IoT results. It will drive bigger deals. It will drive better value propositions. It's really software that's ready to turn on and get value from as opposed to a platform. And then the other thing is, Troy Richardson talked at our Investor Day about organizing better for cross-sell. And I think if we look backwards, maybe we had pivoted too much toward new logos, which are great. I mean, new logos are a wonderful thing. But we probably have low-hanging fruit yet to pick within our installed base of CAD and PLM accounts. So I think it's really this combination of a strong-looking pipeline, good-looking trends, awaiting us in the deferred backlog and then these other initiatives kicking into place, DPM and cross-sell that I think will all be very helpful as we proceed through the year. And again, I want to remind everybody, we set the expectation that the two handle would materialize in the back half of the year and that you wouldn't see it in Q1 and Q2. So we sort of feel like this was as we had predicted just mid-December a couple of weeks ago. Jason Celino -- KeyBanc Capital Markets -- Analyst Hey. Hi, Jim. Hi, Kristian. Jim Heppelmann -- Chief Executive Officer Hi, Jason. Jason Celino -- KeyBanc Capital Markets -- Analyst So one question on maybe the SaaS Windchill, you know, launch. It seems like it's coming along, you know, nicely, and we could see something maybe go GA this quarter. Have you had a chance to maybe, you know, discuss this with customers? How is the pipeline shaping? Or is it maybe better to think that the pipeline might start to form once we do go live? Jim Heppelmann -- Chief Executive Officer No, we have, for sure, started talking about it with customers. I mean, ramping up that process. We've got to educate a lot of people and they, in turn, have to educate customers. But we've certainly made some progress, and I can tell you the customer interest is actually quite high. You should know that actually, customers were pushing us a little bit to get going with such initiatives -- so I feel like the demand is there. And in fact, again, just reflecting on what we told you, that business has been growing about 30%. And Kristian mentioned we posted another quarter just like that, without us really invoking the new strategy yet. So there's lots of demand. We're just looking for a model where we can promote the demand because we like the margin profile better. And that's what's coming into place here in Q2. Adam Borg -- Stifel Financial Corp. -- Analyst Great. Thanks so much. And maybe just two quick ones. Just on the Scheffler win that you announced yesterday and highlighted on the call earlier. One of the things I thought was really interesting in the press release was this opportunity around some more vertical-specific or market-specific solutions targeting either automotive or industrial companies. So maybe, Jim, if you could just talk about that. And maybe just as a quick follow-up, just maybe for Kristian. Any way you could talk about this transition, it's great to get the early feedback on the SaaSification efforts, but any way to comment on, you know, how much this has contributed to bookings or the pipeline, at least qualitatively? Thanks so much. Jim Heppelmann -- Chief Executive Officer Yeah. I'll get the first part of the question. Kristian, you can take the second part. Yeah. So Scheffler is a great account. And as I mentioned back in 2017, it appeared they were going in a different direction, and now they've decided to come back into the fold. And honestly, they did that for two main reasons. One is that they really want off-the-shelf technology. The other competitor had told them this low-code, no-code story, and they tried that out and decided that's not really what they want. They don't want to develop their own solutions. They want to deploy standard out-of-the-box software that all works together. And then they want to engage in partnerships with the vendor, in this case, PTC to talk about how those solutions should evolve to be more and more powerful to meet their needs. So yeah, I'm very excited. I'm in the middle of that relationship myself. And yes, what's going to come out of that is technology that fits better and better, for example, for the automotive supply chain, which is a place where we have a lot of customers. So it's a great win or win back, maybe I should say, and a great partnership going forward that's going to produce a lot more business for us in years to come. And sorry, the second part of the question was around the transition to SaaS and how that's manifesting itself in terms of pipeline and activity? Is that right, just making sure I got that right. Adam Borg -- Stifel Financial Corp. -- Analyst Exactly. Any way to qualitatively comment from, you know, either bookings or a pipeline perspective? Jim Heppelmann -- Chief Executive Officer Yeah. Well, remember, I mean, the bookings that we just reported were for Q1, and Q1 is really when we actually just announced the acceleration of it. So I would say there's actually a limited impact in the actual bookings result here in Q1. That said, as I mentioned, we continue to see strong demand for the SaaS properties that we have. That's both in velocity and the digital thread. And so those products continue to grow at a rate higher than our software-only products. And now as the program is pushing ahead, we expect to see demand and pipeline generate, especially with the new Windchill launch coming out here and the program continuing to pick up speed internally. Kristian Talvitie -- Chief Financial Officer Maybe, Adam, I could just add. We launched this phase 3 strategy 90 days ago on the earnings call. And there's nothing we've seen since that makes us any less bullish than we were back then. I mean it looks like a really nice opportunity for PTC, and we're pushing forward ahead as aggressively as we can because we'd like to bring that very promising upside growth driver, you know, closer in. So it has a bigger impact on '23 and '24 and so forth than it would otherwise have had. Jay Vleeschhouwer -- Griffin Securities -- Analyst Thank you. Hello. Hi, Jim. Hi, Kristian. A couple of things. With regard to the strength you noted for PLM, at your partner conference six months ago, back in the summer, management presented to the channel, your concept that PLM was no longer just an engineering vault that it was becoming memorial, what you call, multisystem, multidiscipline concept. And the question is, to what extent is that broader, more diverse view of PLM a current part of new business or in the pipeline for new business as compared to the more conventional historical way of thinking about PLM? By our calculation, we are already the second-largest brand by revenue in PLM, and maybe talk about what some of the drivers are to that? And then just a quick clarification you referred earlier to cross-sell. At the Analyst Meeting last month, in the slide deck, you referred to cross-sell 10 times and relatedly account-based selling. PTC is often over the years, talked about cross-sell, but maybe talk about what's different this time in terms of resources and programs across your various segments and your new customer segmentation model. Jim Heppelmann -- Chief Executive Officer Yeah. Well, on your first question, Jay, you know, you are always very pressy on, you've been watching this industry for a long time. When we say multisystem, multidiscipline, what we're really talking about is an enterprise system. And so what's happened in the last couple of years is PLM has graduated from being an engineering data management system to being an enterprise system that contains the system of record for the product definition. And so if you're in manufacturing, well, you need to know the product definition. If you're in procurement, you need to know the product definition. If you're all on an installation or a support call, you probably need to know the product definition. So definitely what's happened is that the enterprise deployments of Windchill are multiple times larger than the engineering deployments of Windchill. So something that's been driving growth for some years now is that the new deals we're taking are more and more frequently enterprise deals and they're larger. You may remember, last quarter, I told you we took the largest deal we had taken to date from a med device company. And the second thing that's happening is, we're circling back to those companies who had deployed the engineering solution like say, Scheffler, and we're upselling them to the enterprise solution and turning that into a much bigger opportunity for us. So definitely, that's a real thing, and it's been driving the momentum we've seen in Windchill for years. And frankly, there's a lot of it out ahead of us even before we start talking about SaaS. The upsell from a departmental solution to an enterprise solution is a driver, taking that whole enterprise solution to SaaS is a whole another growth driver that's on top of that and sort of orthogonal to it. And then on the account-based selling, there's two ways to look at that. Cross-selling into your accounts is a great thing. You have established relationships. It's much easier to sell another product to an existing customer than to sell a new product to a new customer or a first product to a new customer. At the same time, we like new logos. So it's really always about the balance of how much do you invest in new logos pursuits versus how much do you invest in selling more to the companies who know and trust you. And I think perhaps with IoT and AR, we realized we had over pivoted toward new logo, which is just generally speaking, less productive selling, you might imagine. And so the reason we formed this digital thread group, which brought CAD and PLM and IoT and AR together under Troy Richardson, was to really lubricate how these products work together and how we position them together and to be able to start anywhere and sell up and down that chain. So it's a good strategy. It's one that we -- it's a muscle we've developed well over the years. We really built the Windchill business, largely by cross-selling to the Creo base. And I think this is going to be something that will help us a lot to kind of get the right balance of new logo pursuits in cross-sell. Ken Wong -- Guggenheim Securities -- Analyst Thank you so much for taking my question. Jim or Kristian, I wanted to perhaps dive into the double-digit organic bookings growth. You know, I couldn't help and notice you guys also had a very large Servigistics expansion deal with the Air Force. I mean how much of that was already in expectations? Or did you get some boost there from timing shifts or anything of that nature? Jim Heppelmann -- Chief Executive Officer Yeah. Let me tell you, none of that actually contributed to the double-digit growth because that was a Q4 deal. You know, we released it when we had approval to release it, and I commented on it because it was, you know, an important customer and so forth. And let me say that deal, again, that was closed in Q4, both represented five years of extension, but also about a 50% growth in a ramp that happens over -- I think it's three years. So it roughly goes from a $10 million run rate to a $15 million run rate over three years and stays there for a couple more. That's what the contract contemplates. So some of that will come into ARR in Q4 of this year, but the bookings actually were in Q4 last year. So that strength -- the strength we saw in Q1 was exclusive of that Air Force deal, which just means it was really great strength. So anyway, it was hard to pin down where the strength comes from because it came from CAD. It came from PLM. The IoT number was actually pretty decent. It didn't all go into ARR. And then, of course, the velocity numbers and the FSG numbers. So it was broad-based in all geographies and really in all product lines. Jim Heppelmann -- Chief Executive Officer Hello, Matt. Matt Broome -- Mizuho Securities -- Analyst Thanks, man. So Jim, I mean, I guess, just on that -- sorry, just deal that I can just mention. Given the importance of supply chain management right now, are you seeing like ramping demand to the solution elsewhere? And sort of following on from that, is there a chance that FSG ARR could actually accelerate on the back of that demand beyond the sort of the mid-single-digit level and actually become sort of more strategic in a way? Jim Heppelmann -- Chief Executive Officer Yeah. I mean that's one of the points, Matt, that I brought up at the recent Investor Day is that we've generally modeled FSG to be roughly flat, flat about plus 1% to 2%. But it's actually been performing. I think last year, Kristian, wasn't up 7%, FSG. It was up 6% here again in Q1. So yes, we're overperforming and Servigistics is one of the key drivers. And then the second one probably is retail PLM, which has also been doing fairly well. So definitely, there's some -- I think we'll be conservative and leave the FSG sort of guidance where it is in the near term, but I do like overperforming it because it's a growth driver. The FSG business is about the same size as the IoT and AR business. So every point of growth we get there is pretty meaningful. Matt Swanson -- RBC Capital Markets -- Analyst Yeah. Thanks. This is Matt Swanson on for Matt. I'll kind of follow up on a piece of both Adam and Jay's questions. So looking at the Scheffler announcement, I think the thing I was really interested in was the idea around standardization and the idea around end-to-end. So could you talk a little bit about your customers' desire around standardization? And clearly, this product road map has really expanded your TAM, but I think one of the upside areas something we -- you know, maybe the holy grail of the transition would be more competitive displacements. And I'm just curious if you're starting to hear, you know, any early or more talk around that because you're building something so differentiated. Jim Heppelmann -- Chief Executive Officer Yeah. I mean, for sure. So the standard thing, I think maybe over the last couple of years, industrial companies have realized that they should be using software, not developing it. And so we saw this in our IoT business, and it's been why we've been heading up the stack with solutions like DPM is, customers would like to buy the software and use it, not buy some kind of a platform and create it because they just don't really know how to create it if I'm frank. So Scheffler had gone down the path of kind of like I said, low-code sort of environments and came back to standard products. And then the end-to-end thing, for sure, the CAD data that's created in Creo and managed in Windchill gets used, for example, in augmented reality, manufacturing, and service instructions much later and in a different part of the company if it's all well managed. And that connectivity from IoT, well, let's say, from CAD to PLM to IoT to AR is what we call the digital thread. And so we actually see so much interest in this that we kind of organized around that principle. Let's stop presenting these products as kind of independent things and let's shine the light on how well they work together in an end-to-end solution. And by the way, how they're all ready to go. That this is something that turn on and use. And that's really what one Scheffler over, but I can tell you, Scheffler is not unique at all. And it's really -- we're organizing to respond to that. SaaS is helpful, by the way, because if you want a lot of technology working end to end, it'd be better not to ship at all to the customer side because it gets complicated. The customer would like to just use it, not set it all up and care and feed for it on-premise. Saket Kalia -- Barclays -- Analyst OK, great. Hey, guys. Thanks for taking my question here. Hi, Jim. Hey, Jim, maybe -- hey, Kristian. Jim, maybe for you, it was great to hear the PLM strength this quarter in bookings. With other companies that have done shifts like this, there's always a risk, I guess, of customers behaving differently, right, whether that's slowing purchases to see what's coming or maybe pulling forward purchases before something new comes out. Now just to be clear, it doesn't sound like that happened here. But can you just stress test that for us a little bit? And what you sort of look at to sort of manage what is, you know, more choices for our customer to make. Does that make sense? Jim Heppelmann -- Chief Executive Officer Yeah. Are you referring -- just let me clarify, are you referring to like SaaS choices being new choices or more broad -- Saket Kalia -- Barclays -- Analyst Yeah, that's right, yeah, Windchill. No, Windchill specifically. Jim Heppelmann -- Chief Executive Officer Yeah. So keep in mind, Saket, we have been selling Windchill as SaaS for some time. Remember, the phase 1, phase 2, phase 3 thing. So since phase 1, we've been selling Windchill, and we showed you, it's got a three-year growth CAGR of 30% in SaaS. So the customer demand is strong. It's just -- on the PTC side, we need to pivot to multi-tenant because in the single-tenant model we just don't have the profitability we like. So the demand is strong. The customers are buying it. Kristian mentioned we had another strong quarter. So it really is, we'd like to meet that demand with a solution that's more efficient for us to operate on behalf of the customer. And that's what phase 3 multitenant really is all about. Now when it becomes more efficient for us, we can then lean in on the promotion and marketing of it, because we haven't really done that. So we've been servicing demand, not driving it. And with phase 3, we think there's an opportunity to drive demand and, you know, the preliminary data we've seen this quarter suggest customers are very responsive, both to buying new systems that way, but also to lifting and shifting the previous systems they bought and giving them to us to operate and serve back to them in a SaaS model. Joe Vruwink -- Robert W. Baird and Company Great. Hi, everyone. Just to go back to bookings, does the strength this quarter absent mega deals suggest anything about either the demand environments or maybe just the health of your mid-market and SMB customers? And looking ahead, are there going to be certain things you think about or track when contemplating, you know, the probability of more mega deals or maybe the larger ARR contributors for PTC, maybe, you know, being a bit more represented in future bookings? Jim Heppelmann -- Chief Executive Officer Kristian, let me again take a stab at that and maybe you'll find things to add. So I think if you look at the bookings, again, they were phenomenal, and it's hard to pin down. It wasn't one geography. It wasn't one product. It was all geographies, all products. So I think it tells us that the end market is very healthy. And I would say, for two different reasons. On one hand, the PMIs are in good shape. That's helpful. On the other hand, the interest they have in the digital thread, digital transformation story, and the interest they have in SaaS is secular. That interest is not related to the PMIs, it's kind of independent of them. And so I think that we're just in a very healthy situation where industrial companies are leaning in on trying to get more digital. They see PTC as having a fairly unique and compelling portfolio, and they're interested in engaging and trying to make their companies more efficient. I can tell you, at Scheffler, for example, it's one of the top initiatives in the company is to get more digital. And as it relates to the whole product life cycle, the partners PTC. And we see that kind of phenomenon happening in a lot of places in the industrial world. So I think it's just good, strong, secular and as well macro-environment out there right now. But I'll remind you that we've had good performance even when the macro environment wasn't so strong. So all things being equal, I like the strong macro. But we're 17 quarters in with double-digit growth in the core business, and there were a lot of bad macro quarters over the course of those 17. So I think it really is the secular driver. Kristian, anything? Kristian Talvitie -- Chief Financial Officer Yeah. I mean I agree with all that. I mean, actually, just on the big deal dynamic, you know, what we used to call mega deals. We haven't -- I think we've had four in the past four years. Jim Heppelmann -- Chief Executive Officer Yeah. Well, keep in mind, perpetual drove bigger upfront purchases and subscription or SaaS tends not to. Kristian Talvitie -- Chief Financial Officer Yeah, which is my point that we've been seeing good strong bookings performance and bookings growth, you know, even with the absence of what used to be a fairly regular occurrence back in the perpetual days, like we really don't see a lot of those. Jim Heppelmann -- Chief Executive Officer Yeah, it's a good healthy business. OK. Next question. Blair Abernethy -- Rosenblatt Securities -- Analyst Thanks very much. Guys, just maybe a quick question on -- around partnerships, in particular. I wonder if you could just give us a little deeper dive into how things are going with Rockwell and as well on the simulation side with Ansys? Jim Heppelmann -- Chief Executive Officer Yeah. So the state of the partner economy is good and, you know, Microsoft, I could put on that list, is also strong. With Rockwell, you'll remember in the past quarters, I had said we should take a bit of a conservative posture as it relates to what Rockwell would contribute to PTC's numbers here in fiscal '22. And we did that because Rockwell had made a big acquisition. You know, Rockwell never completely agreed with me on that. Their own public commentary kind of indicated they didn't worry too much about that. And in Q1, they were right. So we're pleased to see that Rockwell's contribution was solid in Q1 and starting to feel pretty good about the year. I'll tell you one thing is this DPM solution appears to be a very good fit with Rockwell. And in fact, their Calypso alarm is probably lined up to be our strongest partner in promoting DPM. So we're very happy with that. Calypso has a long-term relationship with PTC that even predates their acquisition by Rockwell. So great alignment around DPM. Again, DPM is a high-value up-to-stack solution that drives bigger deal sizes, and we think will be a very sticky solution. So lots of optimism around that. With Ansys, we continue to differentiate now with best-in-class simulation. So whereas simulation some years back would have been viewed as a soft spot for PTC. Now it's a strength. If we're competing against Autodesk or Siemens or Dassault, nobody is going to have a better simulation story than PTC because nobody has a better simulation story than Ansys, and Ansys products are built into PTC products. So that's been going well. And then, of course, with Microsoft, that partnership is performing well and poised to get a lot bigger because as we bring more stuff aggressively to SaaS, a whole lot of that is going to land on Azure. So I think all three partnerships are alive and well and as important as ever and helping us achieve the kind of results that we're achieving. Sterling Auty -- J.P. Morgan -- Analyst Yeah. Thanks. Hi, guys. Just wondering if you could characterize with the headcount changes that you pointed out are necessary to facilitate the acceleration to SaaS. Where are you in that process? What's left to go? And kind of what's the time frame that you expect to complete that over? Jim Heppelmann -- Chief Executive Officer Yeah, Kristian, I'm thinking of the numbers we're largely done, but not completely. Eighty percent, 90% done. Kristian Talvitie -- Chief Financial Officer Yep, with the exiting. Jim Heppelmann -- Chief Executive Officer Yeah. I mean we'll be hiring people throughout the year. So -- but in terms of the people who are exiting, they're largely exited by now that largely happened within the first quarter. Sterling Auty -- J.P. Morgan -- Analyst Understood. Thank you. Jim Heppelmann -- Chief Executive Officer OK. Well, thank you, all. There's a lot of good questions and, you know, I think good answers because the business is performing very well right now. ARR is doing well. Bookings are doing well. Free cash flow is doing well. You know, I think we executed -- through good times and bad, we executed through the changes we made over the last quarter, and we're set up to do pretty well for the balance of the year. So, we're very confident and, you know, look forward to talking to you all in 90 days if we don't happen to cross pass with you sooner in an investor event or what have you. So, thanks a lot for joining us and have a good evening. Kristian Talvitie -- Chief Financial Officer Thanks, everyone. Duration: 59 minutes Call participants: Matthew Shimao -- Head of Investor Relations Jim Heppelmann -- Chief Executive Officer Kristian Talvitie -- Chief Financial Officer Andrew Obin -- Bank of America Merrill Lynch -- Analyst Yun Kim -- Loop Capital -- Analyst Jason Celino -- KeyBanc Capital Markets -- Analyst Adam Borg -- Stifel Financial Corp. -- Analyst Jay Vleeschhouwer -- Griffin Securities -- Analyst Ken Wong -- Guggenheim Securities -- Analyst Matt Broome -- Mizuho Securities -- Analyst Matt Swanson -- RBC Capital Markets -- Analyst Saket Kalia -- Barclays -- Analyst Joe Vruwink -- Robert W. Baird and Company Blair Abernethy -- Rosenblatt Securities -- Analyst Sterling Auty -- J.P. Morgan -- Analyst More PTC analysis All earnings call transcripts\",\n          \"[Operator Instructions] Now I would like to turn this call over to Mr. Adolfo Castro, Chief Executive Officer. Please go ahead, sir. Adolfo Castro Rivas -- Chief Executive Officer Thank you Kathy and good morning everyone. Thank you for joining us on the conference call to discuss ASUR's first quarter financial and operating results. Before starting the call, I would like to express my hope that you and your families are healthy and safe in these uncertain times. As a reminder, please note that certain statements made during the course of our discussion today may constitute forward-looking statements which are based on our current management expectations and beliefs and are subject to a number of risk and uncertainties that could cause active results to differ materially, including factors that may be beyond our company's control including the impact from COVID-19. For an explanation of these risks, please refer to our filings with the US Securities and Exchange Commission and the Mexican Stock Exchange. Overall, our first quarter results were good. The year began in solid footing before we started to see the impact of COVID-19 pandemic in the second half of March. It resulted in the disruption of global travel industry. Importantly, in the end of the first quarter we had healthy balance sheet which I will come back and discuss in more detail later in my presentation. I'm going to start today's presentation with some comments regarding COVID-19 and the impact on the industry, on our business, and the steps we are taking to mitigate this disruption to the best we can in this rapidly changing environment. From an industry perspective, since mid-March, many governments have issued flight restrictions in an effort to mitigate the spread of COVID-19 virus. In turn, capacity has been severely reduced and very few people are booking flights as most are in some form in lock down around the world and not traveling. With respect to our airports, the situation varies by country and could be subject to change depending upon how fast or slow the pandemic is brought under control. Colombia has been the most active and we've suspended operations at all six of our airports since the third week of March with domestic flights suspended until April 27 in accordance with the published decree and most recently extended to up to May 11. International travels have been suspended through May 13. By contrast, in our airports in Puerto Rico and Mexico remain open, although there's significant reduced flights and passenger traffic. As a result, total passenger traffic declined sharply in the second half of March, down nearly 69% year over year between March 16 and March 31. By country, we show the margin decline in Colombia around 77%, followed by Puerto Rico down 73% and Mexico with 63% decrease [Indecipherable]. Additionally starting in mid-March, some of the airlines as well as some tenants that operate in our airports began asking for assistance either through discounts on payments owed to ASUR or by extension by payment which resulted in a higher accounts receivables in March in Mexico and Colombia, up 54% and 78% year-over-year. We are having ongoing commercial discussions with these companies with respect to their contracts. Moving next to action we have taken, starting with health and safety. Following the guidelines of relevant health agencies, we have implemented health and safety protocols for both our airport employees and passengers travelling through our airports. For example, protective gear such as wearing masks is required for airport staff. We have also stepped up disinfectants and sanitization practices, once again in accordance with the guidelines of local health authorities. Lastly, where possible, we have also implemented remote working points. Moving next to ensuring continuity of our business. We have introduced cost reduction initiatives across our airports. The impact of these initiatives however is not expected to be significant vis-a-vis the potential decline in passenger traffic at the majority of the cost structure is different, except for concession fees and technical assistance in Mexico which are biannual cost. We are prepared to take additional step, if needed, to respond to the evolving business environment. Now, let me talk about our financial situation. We entered this quarter in a position of strength with strong liquidity and very low principal payments required through year end. Additionally we believe the company has sufficient liquidity to meet its obligations and continue operating in the normal course of business. Our cash position ended at MXN7.8 billion which was up from MXN6.2 billion at the year-end 2019. And subsequent to the quarter end, as we further strengthen our financial positions as our subsidiary in Puerto Rico drew down an additional $10 million of its committed line of credit. The line of credit [Indecipherable] support for the capex projects we have under construction, Apelian airport in Puerto Rico. We closed the quarter with total debt of MXN15.3 billion. Although 11% high than the year-end 2019, this was due to the conversion effect from the depreciation of the peso to the dollar. As a reminder, the majority of our debt, 54% is denominated in the US dollars which is at our subsidiary in Puerto Rico. 26% of total debt was denominated in Mexican pesos and 20% in Colombian pesos. We have principal payments of only MXN432 million coming due over the next three quarters. This represents less than 3% of ASUR's total debt. With respect to that ratios, net debt to last 12 months EBITDA stood at 0.7 times at the close of first quarter '20. You can see the interest coverage ratio by country in the table we have included in the annual release this quarter. Now, stepping back for more, since we began operations over 20 years ago, we have successfully navigated through many very significant challenges. From the 9/11 event in 2001 to [Indecipherable] into 2005 and 2008 and 2009 business financial crisis, H1 and H2 and the bankruptcy of 50% of airlines in Mexico which cut planes capacity in Mexico by more than half. Following each of these events, passenger traffic recovered, although recovery time varied from 13 months to 26 months and then continued to grow. Between 2000 and 2019, annual passenger traffic increased the compound annual growth rate of 6.6%, up from slightly over 10 million to historical high to over 34 million last January. We believe the COVID-19 pandemic is unique in that sense it is global event and with a broad disruption in travel and economies worldwide and could change the way of travelling in the future while a vaccine or a cure is found. Summing up this section, we have a strong balance sheet, we have generated years of consistent profitability and we exercise prudent capital management. In the sense we believe that we cannot be very prepared for an event of this magnitude, but of course given its great uncertainty on the final effects in the worldwide economy and that travel will be [Indecipherable]. Now turning to our first quarter results, more details can be found in the press release issued last evening. Like I mentioned this part of my presentation, let me spend with the effects of the business in late March. We believe we had solid results in the first quarter 2020. Total passenger traffic was down in most of the airports, which leads to a total passenger decrease of slightly 6% YoverY. This was primarily due to the fallout from COVID-19 and the impact of the global travel industry beginning in the second half of March. Our airports in all three countries experienced total passengers decline from a low of nearly 3% in Colombia to a high 8% in Mexico. Puerto Rico passenger traffic was down 4%. All three countries reported declines in both domestic and international traffic. Moving next to the P&L highlights, revenues ex construction were relatively unchanged at 4% increase in revenues from non-aeronautical services was offset by a 3% decline in aeronautical revenues. Commercial revenues per passenger increased 11% year over year, reaching MXN116.3. This was driven by solid performance across the region. Mexico posted a good performance with an increase of 11% on a per passenger basis benefiting from the currency peso devaluation and regulated revenues. Puerto Rico posted 7% increase per passenger benefiting from peso depreciation and finally Colombia saw a 33% increase on a per passenger basis, reflecting the 43 new stores opened over the last year and currency depreciation. The main drivers were ground transportation and car rentals. Moving on to profitability, reported consolidated EBITDA increased 3% from the same period over the prior year. Both periods benefited from insurance recoveries related to the Hurricane Maria. In the first quarter '20, it amounted nearly MXN124 million while last year the amount was dragging over MXN41 million. Excluding these recoveries, consolidated EBITDA was essentially flat year-over-year at MXN2.7 billion. Ex-IFRIC 12 and without taking into account insurance recoveries in both quarters, adjusted EBITDA margin increased 20 basis points to 66.7% this quarter. A few comments about capital allocation. Capital expenditures were MXN353 million in the quarter. Of these, nearly MXN58 million was allocated in Mexico due to the terminal expansion of Merida airport. For the full year, and as we have discussed before, our non-prevalent plan in Mexico calls for investment of approximately MXN5.3 billion for the full year. At the current time, there are no changes to the planned continuation of the foreigners tax relief of the second one we have at Cancun airport and the beginning of the first expansion at the Merida. Our plans call for a conclusion of Phase 1 of the Merida terminal expansion and typically the second phase this year. Nevertheless, due to the COVID-19 health crisis, you may see some disruption in the construction process, attributable to stay-at-home, the combination and we have informed the government about this situation. In Puerto Rico we have made investments of MXN114 million this quarter, mainly from the connection with some major maintenance referred tax relief. Finally, capex in Colombia amounted to MXN1 million related to maintenance. Last year we concluded our committed capex was at MXN20 million. And going forward, we only expect to incur a major maintenance capex in Colombia. Next, our Annual General Meeting from yesterday, shareholders approved an ordinary net cash dividend of MXN8.1 per share to be paid, subject to the Board's approval on or after May 11, 2021 in a single installment. In conclusion, we are proactively responding to the developing situation. No one can control the virus or even the economic fallout. But we can control how we react to the crisis. I am optimistic about the prospects for the future both navigating through the current crisis and in the long term recovery. I believe that we are well positioned with a healthy balance sheet. We had a solid first quarter results. We believe in the strategies that we are executing. This ends my prepared remarks. Kathy, please open the lines for questions. We'll go first to Alejandro Zamacona of Credit Suisse. Alejandro Zamacona -- Credit Suisse -- Analyst Thank you Adolfo, thanks for the call. Two questions from our side. The first one is on the aeronautical maximum tariff. So, considering that airlines have been negotiating with most of airports and in some cases some fees have not been charging. What could we expect for maximum tariffs in the short-term meaning the second quarter and in the immediate term, meaning year end 2020? Could we still expect tariffs to be close to the maximum level? Adolfo Castro Rivas -- Chief Executive Officer Alejandro, hi, good morning. Well, basically what we are seeing today is a very reduced demand. So we believe that there is no effect if we try to reduce our fees for the month of April or the month of May. So we have maintained our tariffs and we believe that we can comply with -- we have to maintain compliance toward the year end. Alejandro Zamacona -- Credit Suisse -- Analyst Okay, thank you. And my second question is on the non-aeronautical business. Same thing in the same context, what could we expect in the short term for commercial revenues per passenger? Have you grant any rent payments facility to payments or any deferrals? Thank you. Adolfo Castro Rivas -- Chief Executive Officer Most of our contracts, as you may know, they have to pay higher of the minimum guarantee payment per passenger or a percentage of sales. So if we do not have passengers, we will not have to pay rent. So it's made automatically. So in that sense, we are not reducing or adjusting the contracts. Alejandro Zamacona -- Credit Suisse -- Analyst Okay, thank you Adolfo. Adolfo Castro Rivas -- Chief Executive Officer You're welcome. Fernando Sanchez -- Bradesco BBI -- Analyst Hi, good morning and thanks for taking my question. My question is light of the likelihood of the GDP contraction beyond 5% I just wanted to ask if you have had the opportunity to discuss with the authorities the possibility of delaying the 2021 and the key mandatory capex? Adolfo Castro Rivas -- Chief Executive Officer Hi, good morning. Well as you are aware, the contract has a clause that says that the maximum tariff can be reviewed in the case of Mexico in an external way. When on the Mexican GDP drops by more than 5% in a year and that's happened in fact on track. Of course with the current circumstance and the current expectations from analysts, it is possible that the Mexican GDP will drop by more than 5% this year. So in that sense, we will be we -- and the possibility of review our maximum time in an external rate. That's for next year, but not this year. Fernando Sanchez -- Bradesco BBI -- Analyst Okay. Thank you very much. Adolfo Castro Rivas -- Chief Executive Officer You're welcome. Carlos Peyrelongue -- Bank of America -- Analyst Thank you. Good morning Adolfo. Thank you for the call. On the something I couldn't hear well because of the connection but can you comment as to whether the dividend will be kept or there is the possibility of cutting the dividend until we have more sense about passenger traffic? That would be the first question. And the second would be related to cash burn, if you could give us an idea of what your cash burn is on a quarterly basis, just to get a sense of compare that primarily to your strong cash position. Thank you. Adolfo Castro Rivas -- Chief Executive Officer Yes, of course. In the case of the dividends, yesterday we held Annual Shareholders Meeting, they have sadly approved the dividend that it was proposed MXN8.1 per share. But it was -- this was subject to the approval from the Board to the moment of the payment that's from May 11, 2021. So the Board will have to approve when this dividend will be paid. In the case of the cash burn, what I said to you during the initiative months, is that our currency structure is basically fit. The only variable pieces are the technical assistance fee and the concession fees we paid to the government. So we are working and just to remember the case of Mexico is 5% as well as in Puerto Rico, and in the case of Colombia its' 19%. So this of course will reduce -- our passenger traffic is reduced and our income gets reduced. The remaining is basically, of course, we are taking measures to try to reduce as much as we can, all the expenses in the companies. But as I said, at the end, in the overall picture, the cost reduction will not be significant in comparison with reduction in the revenues of the company. Andressa Varotto -- UBS -- Analyst Thank you very much for taking my question. So my question is if have plans to negotiate with the government postponement of the mandatory capital is this possible? Thank you. Adolfo Castro Rivas -- Chief Executive Officer Could you repeat the question? I couldn't hear you. Andressa Varotto -- UBS -- Analyst Yes. So my question is if you plan to negotiate with government the postponement of mandatory capex? Adolfo Castro Rivas -- Chief Executive Officer As I said before, in accordance with the contract, we do not have that possibility this year. But of course, with the given standards [Phonetic] and as I said it in my initial remarks, during an expansion situation and that expansion situation is that some companies have stopped operations [Indecipherable] and that it was reactivated later on, but there was a decree from the Mexican government that also named the steel and glass that is produced in the country will be used for the project. So in that sense, at the moment it's almost impossible for us to expand our 10-year buildings without these material. So we have this situation to the government. So for the moment, what we see is that we will see some disruption in our construction process for some months and then we will have to talk about these with the government. That's what I can share with you for the moment on this respect. Andressa Varotto -- UBS -- Analyst Thank you very much. Adolfo Castro Rivas -- Chief Executive Officer You're welcome. Stephen Trent -- Citi -- Analyst Good morning, Adolfo and thanks very much for taking my question. Hope that you and your family are well. Just one quick one for me, I know that it seems that Mexico apparently has not been that active in likely offering any assistance to the corporate sector. What are you hearing from Colombia? Kind of any indications from them with respect to whether aviation industry will get some sort of relief? Adolfo Castro Rivas -- Chief Executive Officer Steve, thank you for your question. So in the case of Colombia in comparison with Mexico they have been more active in the measures that they have been taking. As I said here in the report they were very [Indecipherable] basically closing or sorting down everything as from March 23. And that can be seen in terms of results. In the case of Spain and the active they have in comparison with active cases we have in Mexico. So their curve is decreasing or at least flattening while the Mexican curve is still increasing. In terms of what they have said for our industry, we have been closed since March 23 and they have issued decrees in that respect. Maybe this week, there was a new announcement from the President expanding the process of shutting down everything. As I said in my remarks, for the case of domestic aviation that will be close up to May 11 and in the case of international up to May 30. It is important to remember that in the case of Colombia, 85% of aviation is domestic and 15% is international. That's what we know as of today. Of course all of these may change depending on how fast or how slow they can control the virus in their country. Stephen Trent -- Citi -- Analyst Thank you very much Adolfo. Apologies I couldn't hear all of your remarks. But no indication at this point for example that Columbia's planning a kind of tax relief for aviation or something along those lines offering kind of financial support. Adolfo Castro Rivas -- Chief Executive Officer Well we have not heard anything above that yet. Stephen Trent -- Citi -- Analyst Okay. Appreciate that. I'll let someone ask a question. Thanks Adolfo. Gabriel Himelfarb -- Deutsche Bank -- Analyst Hi, good morning, thanks for the call. I have two questions. The first one is concerning about account receivables. Can you give us like a number or approximate number about what's the total of the sales coming from airlines and in specific from Interjet and American Airlines and my second question is do you think you could obtain some waivers in opex sorry capex your current MDP in Mexico and could you will be able to extend the life of the concession in Colombia? Adolfo Castro Rivas -- Chief Executive Officer Hi, good morning. In terms of the account receivables you can see those in our report, revenue increase in the case of Mexico and Colombia, most of the increase is coming from the land industry. I do not have the details of American Airlines and Interjet you are requesting. In terms of the capex, as I said before, we have informed the government about this current situation. We don't know if they are going to react in that respect. But of course it's going to be almost impossible for us to construct and expand our buildings with that material. So more or less what I say to you. Gabriel Himelfarb -- Deutsche Bank -- Analyst Okay, thank you. Ruben Lopez -- Santander -- Analyst Hi Adolfo, thanks for the call. My question is on commercial revenues. Sorry if you commented on these. But I understanding Cancun operating in just one terminal. So I want to confirm you how are your operations there in Cancun and what are the implications on commercial operations? Are there any penalties with the tenants? What are negotiations here? That's the first one. And the second one is related with the same topic. When we see commercial revenues and we kind of try to compare current levels versus what would be the fixed amount or the fixed part of the minimum payment. I mean can you give us any sense of the guidance here? Thank you. Adolfo Castro Rivas -- Chief Executive Officer Okay. As you have said, yes, in the case of Cancun, we have closed two terminals and we are just operating today in terminal 4. So all the operations of airport have been concentrated there in order to reduce on one side the expenses and of course on the other side be better prepared in the case of these reduced demand. All the stores are working in the case of terminal 4. So terminal 4 is operating as it was before the event. As I said before, most of the contracts, the financial contracts we have with the tenants are related to a minimum guarantee payment passenger. So once again, they do not have, let's talk about one of the deals that is closed. So if they do not have passenger traffic in terminal 2, they almost have to pay the rent. Of course when they operate in terminal 4 their operations will be in the accordance with the amount of passengers we have in that facility. So I would say terminal 4 is operating normally. Ruben Lopez -- Santander -- Analyst Thank you. And when you compare, sorry, the current level of commercial revenues versus what would be the minimum payment from the contract, can you give us any idea on that? Adolfo Castro Rivas -- Chief Executive Officer As I said, minimum payment -- the contract is on a per passenger basis. Ruben Lopez -- Santander -- Analyst Perfect, thank you. And we will now go to Jorge Larocco of Morgan Stanley. Jorge Larocco -- Morgan Stanley. -- Analyst Hi Adolfo, good morning. Thank you for the questions. It's two questions, actually a pretty general question, I was just wondering if you could provide more color on what are the main initiatives regarding our cost reduction efforts. How are those working down, your payment reductions on paid leave of absence, maintenance cost, utility costs, etc. and how are those playing out so far? Thank you very much. Adolfo Castro Rivas -- Chief Executive Officer The main initiatives of course are related to in the case of Cancun in the terms of amounts. So we these key terminals closed, we are not burning the same amount of energy as if they were open. Also in the case of Cancun, we are in the process to shut down and one of the runway because today in accordance with the [Indecipherable] it's not needed. So, that runway will be turned off in terms of light at night also reducing their energy we will have to pay. And in terms of some other measures we are taking, adjusting some of the contracts of nature or mainly maintenance in the case of the buildings are closed and to try as much as possible to reduce operating cost and expenses. But I once again at the end, most of our cost is fixed. So if we apply the cost structure of the company, the most important lines are personnel and utility costs as we have said so. In the case of personnel, we are maintaining the personnel for the event or the crisis and in the case utilities, we are trying, as much as we can to try to reduce that. Jorge Larocco -- Morgan Stanley. -- Analyst Thanks so much Adolfo. Stay safe and have a good day. Adolfo Castro Rivas -- Chief Executive Officer Thank you Kathy and thank you again for participating in our fourth quarter results conference call. On behalf of ASUR, we wish you good day and until we meet, be safe. Good bye. Duration: 34 minutes Call participants: Adolfo Castro Rivas -- Chief Executive Officer Alejandro Zamacona -- Credit Suisse -- Analyst Fernando Sanchez -- Bradesco BBI -- Analyst Carlos Peyrelongue -- Bank of America -- Analyst Andressa Varotto -- UBS -- Analyst Stephen Trent -- Citi -- Analyst Gabriel Himelfarb -- Deutsche Bank -- Analyst Ruben Lopez -- Santander -- Analyst Jorge Larocco -- Morgan Stanley. -- Analyst More ASR analysis All earnings call transcripts\",\n          \"Brian Kearns -- Senior Vice President of Business Development and Investor Relations Thank you, Chris, and thank you, everyone, for joining us today. Joining today's call from Globus Medical will be Dave Demski, president, and CEO; Dan Scavilla, executive vice president and president of Ortho; and Keith Pfeil, senior vice president, and chief financial officer. This review is being made available via webcast accessible through the investor relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. Our Form 10-K for the 2021 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available on the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Dave Demski, our president, and CEO. Dave Demski -- President and Chief Executive Officer Well, thank you, Brian, and good afternoon, everyone. Globus finished an outstanding 2021 with a strong fourth quarter performance. Revenue for the year was a record $958 million, an increase of 21% over 2020 or $169 million in growth. To put that in perspective, our growth dollars alone would have ranked us in the top 10 spine companies in the world. Revenue in 2021 was 22% higher than 2019, an outstanding performance in itself, given the disruption caused by COVID but magnified further by a recent independent research report showing that each of the other top 6 spine companies actually had sales declines over that same time period. We achieved record sales and growth while maintaining industry-leading profitability, generating a record $2.04 in non-GAAP EPS, a 42% increase over 2020, and adjusted EBITDA of 34.6% even as we invested heavily in INR, trauma, and competitive recruiting. Revenue for the quarter was $250 million, up 7% over 4Q '20 as COVID-related headwinds remained strong throughout the quarter. Non-GAAP EPS was $0.49 per share, a 16% decrease compared to the artificially high 4Q '20. Not only were business travel and surgeon education activities severely curtailed last year, several other nonoperational factors, as Keith will expound upon in his remarks, also impacted the decline. Adjusted EBITDA in the fourth quarter was a strong 34%. Enabling technology continues to gain momentum, producing a record $25 million in revenue for Q4, an increase of 40% over 4Q '20. For the full year, enabling technology revenue was $81 million, an outstanding 100% increase over 2020. The clinical superiority of ExcelsiusGPS is the primary factor driving this growing momentum. Robotic utilization, which is the number of cases performed per installed robot, was at an all-time high in 2021. And nearly 30,000 procedures have been completed using ExcelsiusGPS technology since launch. Our spinal implant business continues to experience the flywheel effect of an increasing number of robots being sold combined with increasing utilization of each robot. Our U.S. spine business grew by 3% in Q4 as COVID-related shutdowns had a significant impact throughout the quarter. We saw this trend continue into January, but all signs point to a rebound commencing late in Q1. For the full year, the U.S. spine business grew by 18% as we continued to take significant market share. Robotics pull-through, coupled with contributions from recent product introductions and competitive recruiting, were all factors driving growth. Our international spine implant business grew by 9% in the quarter, a remarkable result in light of COVID impacts and an ongoing drag from Japan. Due to the impact of strategic moves we made in Japan last year, we expect to see continued declines there through the first half of 2022 with growth to follow off a reset baseline. This should result in accelerated overall international growth in the second half of this year. Trauma revenue was up 32% in the fourth quarter and 39% for the full year. Competitive recruiting and new product launches are driving growth. The Anthem Mini Frag system was launched on a limited basis in Q4 with excellent feedback from surgeon users. We are proceeding to full launch in Q1 and have a series of impactful product launches planned for the first half of 2022. The clients have launched the Excelsius 3D imaging system on a limited basis later this quarter with a full launch following in late Q2 or early Q3. There is tremendous anticipation and excitement about this technology among surgeons, and we already have double-digit orders signed. The Excelsius ecosystem, Globus Medical's unique combination of robotics, imaging, and freehand navigation that provides a seamless, scalable, and unmatched clinical experience for surgeons is about to become a reality. I'm extremely proud of our team's performance in 2021, record growth and profitability, exciting, clinically impactful new technology introductions, and an unmatched focus on providing value to surgeons and their patients. Thank you for a great year. I will now turn the call over to Keith. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you, Dave, and good afternoon to everyone joining us for today's call. Globus capped off a record 2021 with a robust Q4 performance despite ongoing COVID-related disruptions and shutdowns. For the full year, 2021 revenue was $958.1 million, growing 21.4% as reported. On a day-adjusted basis, sales grew by 22.1%, with two fewer selling days in the U.S. and international. Net income was $149.2 million, resulting in fully diluted earnings per share of $1.44. Non-GAAP net income was $211.4 million, generating a record $2.04 of fully diluted non-GAAP earnings per share. Adjusted EBITDA was 34.6% for the year, and we generated a record $219.4 million of free cash flow for the full year. Q4 '21 revenue was $250 million, growing 7.1% as reported and 8.5% on a day-adjusted basis with one less selling day in the U.S. and international compared to the prior-year quarter. Net income was $15.1 million, and non-GAAP net income was $51.1 million. Our Q4 diluted -- fully diluted earnings per share was $0.14, while our fully diluted non-GAAP earnings per share was $0.49. Adjusted EBITDA was 34.1%, and we generated $59.2 million of free cash flow for the quarter. Taking a deeper dive into sales. Q4 U.S. revenue was $213 million, 7.2% higher compared to Q4 of 2020 driven by our INR and U.S. spine businesses. International revenue for Q4 was $37.1 million, growing 6.8% over the prior-year quarter led by growth in spinal implants despite lingering COVID impacts and the impact of our strategic changes in Japan as Dave mentioned earlier. On a constant currency basis, international revenue grew by 8.7%. Q4 gross profit was 75.3% versus 73.9% in the prior-year quarter. The 140 basis point improvement was driven primarily by nonrepeating inventory reserves in the prior-year quarter and was consistent with our expectations noted in our Q4 2020 earnings commentary. Full year 2021 gross profit was 75%, compared to 72.4% in the prior year. The increase in full year gross profit is primarily the result of lower inventory reserves and operational and supply chain efficiencies, partially offset by sales mix. Looking ahead to 2022, we project a mid-70s gross profit rate. Research and development expenses in Q4 were $51 million or 20.4% of sales, compared to $15.2 million or 6.5% of sales in the prior-year quarter. The increased spending is primarily reflective of in-process research and development acquired during the quarter. Adjusting for these costs, Q4 2021 research and development expense was $16.7 million or 6.7% of revenue, in line with the prior-year quarter as a percentage of sales, but $1.5 million higher driven by incremental investments in headcount across our spine, INR, and trauma businesses. Our full year 2021 research and development expenses were $97.3 million or 10.2% of sales, compared to $84.5 million or 10.7% of sales in the prior year. Adjusting for the acquisitions made in both periods, research and development expenses were $63 million or 6.6% of sales in 2021, compared to $60.1 million or 7.6% of sales in 2020. The increase in spending is reflective of our continued investment in research and development to foster future growth and is consistent with comments made earlier in the year. We expect our R&D expenses to be approximately 7% of sales in 2022. SG&A expenses in the fourth quarter were $106.6 million or 42.6% of sales, compared to $92 million or 39.4% of sales in the prior-year quarter. The resulting increase is reflective of higher sales compensation and benefit costs as well as increased travel and training expenses driven by the resumption of normalized travel levels following the COVID-19 impacts experienced in the prior year. Full year SG&A expenses were $408.1 million or 42.6% of sales, compared to $354.8 million or 45% of sales in the prior year. The resulting decrease as a percentage of sales is reflective of leverage on fixed costs as a result of the higher volumes when comparing against the COVID impact in 2020. The income tax rate for the quarter was 23.8%, compared to 14.9% in Q4 of 2020 with the resulting increase driven primarily by lower tax benefits associated with stock option exercises. Our full year 2021 income tax rate was 17.3%, slightly lower than the 18.8% in 2020 driven primarily by the nonrecurring tax treatment related to a 2020 acquisition, partially offset by lower tax benefits associated with stock option exercises. Looking ahead to 2022, we expect our effective tax rate to be approximately 20% for the full year, which assumes no significant changes in the current U.S. tax policy. Fourth quarter net income was $15.1 million, and non-GAAP net income was $51.1 million. Q4 diluted earnings per share was $0.14, and non-GAAP diluted earnings per share were $0.49, compared to $0.58 in the prior-year quarter. The quarter-over-quarter decrease is driven by more normalized levels of travel, trainings, and meetings noted above or noted earlier as well as nonoperational items, primarily a higher tax rate as previously mentioned, higher stock compensation expense, and lower interest income. Looking ahead to 2022, we are expecting a mid-30s adjusted EBITDA rate. Full year diluted earnings per share were $1.44, and non-GAAP diluted earnings per share were $2.04, reflecting a 42.2% increase over 2020 primarily related to higher sales volumes following the 2020 impact of COVID-19, partially offset by approximately $0.09 of nonoperating headwinds related to a higher share count and lower interest income. Q4 adjusted EBITDA was 34.1%, compared to 36.2% in the prior-year quarter. Full year 2021 adjusted EBITDA was 34.6%, compared to 29.4% in 2020. Net cash provided by operating activities were $76.3 million for the fourth quarter and a record $276.3 million for the full year 2021. Free cash flow was $59.2 million for the fourth quarter and a record $219.4 million for the full year 2021. The company remains debt free. At this time, the company is establishing full year 2022 guidance. We are projecting full year 2022 sales guidance of $1.025 billion, representing 7% growth versus 2021. We are guiding to a full year fully diluted non-GAAP earnings per share of $2.10, representing 3% growth versus 2021. I note that the 2022 guidance includes approximately $0.10 of nonoperating headwinds, including higher shares worth $0.04, a higher tax rate worth $0.03, and higher stock compensation expense worth $0.03. Adjusting for these nonoperational factors, our 2022 guidance would have been $2.20 or 7.8% higher than 2021. Overall, we view this guidance as appropriately conservative and reflective of the current operating environment around COVID and inflation-related impacts. Our 2021 results represent our teamwork, our commitment, and our focus on execution. We continue to differentiate ourselves in the marketplace. And it is a testament of the hard work and dedication of each of our Globus employees. We remain excited for the future as we continue on our mission of improving patient care. Operator, we will now open the call for questions. Questions & Answers: Matt Miksic -- Credit Suisse -- Analyst Great. Thanks so much for taking the questions and congrats on a really strong finish to a pretty amazing year, given the circumstances. I wanted to follow up on some of the comments around EPS guidance, in particular. As you pointed out, there are some items that ex those items, up 7% to 8%. Can you talk a little bit about where in your guidance you're contemplating things that some of the other companies in the space have talked about like rising input costs, staffing challenges, labor costs, freight, etc., things that generally are driving operating costs up a little bit? Maybe give us a sense of how those figure into your guidance? And I have one quick follow-up. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks. This is Keith speaking. So we projected our guidance at $2.10. And as we look at the year, we see inflation as a market event. Everyone is experiencing it, and we have it baked in our numbers. But when you step back and look at the $2.04 and the $2.10, I commented on the $0.10 of the nonoperating headwinds. But the other things that are impacting the business as we think about getting back to more normalized levels of spend are really the travel and the trainings that go along with the surgeons and [Inaudible] that we provide. That's worth going into the next year likely an $0.08 headwind. And then one of the things that we commented on earlier in the year was our continued investment into R&D. As you look into next year, we're seeing roughly I would say, call it, $0.04 of additional investment in R&D. When you look at those things together, coupled with the inflation, we're landing at about $2.10. Matt Miksic -- Credit Suisse -- Analyst OK. And can you just maybe just elaborate a little bit on the spend or R&D and sort of the expectations for returns in terms of growth or programs that you're investing in? Keith Pfeil -- Senior Vice President and Chief Financial Officer So we're continuing to invest heavily in our spine business and as well as our robotic businesses. We talked about that in Q1 of our earnings call earlier in the year, and really all sign points to us continuing to do that. Dave talked earlier about some of the benefits that we're seeing for robotic technologies. We continue to invest in that and really grow for the future. Matt Miksic -- Credit Suisse -- Analyst OK. And then just one quick follow-up I had was on the environment for robots and spending in capital and equipment in general. Some of the other, again, companies in the space have talked about a fairly strong year for equipment, a strong year for robots. Any sense of whether this is something that needs to sort of take a breather or catch up here in 2022? Or whether orders and demand and pipeline for new deals would indicate just continued strength into 2022? Dave Demski -- President and Chief Executive Officer Yeah. Matt, this is Dave. No, it's very strong. I don't see anything laying off. In our case, in particular, it's been accelerating. I think the demand for Excelsius has been strong, and it's becoming more and more common. The narrative has changed from why robotics to which robot. And I think we're clearly establishing our lead there. And then as I mentioned, there's a lot of enthusiasm over our Excelsius 3D system, which is going to launch later this quarter. We've had every surgeon we show that to seems like they want one. So I don't see it backing off at all. Matt Miksic -- Credit Suisse -- Analyst Great. Thanks and congrats. Dave Demski -- President and Chief Executive Officer Thank you. Matt Taylor -- UBS -- Analyst Excuse me. Hi, guys. Thanks for taking the question. So I wanted to ask the first one about margins longer term. Maybe just talk about the difference between what you're doing this year with some of the investments and obviously, headwinds year over year from spending back to normal and inflation, and how we should think about margins longer term? Would you start to get more leverage at some point? And what would the inflection point for that be? Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. It's a good question. But as I look at where we're at and where we're going, our goal is to always maintain a mid-70s GP. But as we look longer term and look at our EBITDA rates, we're always looking to be in that mid-30s range. We could toggle our investments in various parts of our business to really achieve that, but we're investing now to drive growth -- to drive top-line growth for the future. And as we get that growth, that's going to create more fixed cost leverage in our P&L. So I think by doing that, investing for growth today helps project the margins going forward. I feel that we're going to work to try to stay in that range. Dave Demski -- President and Chief Executive Officer Yeah. I can add a little bit maybe to that, Matt. In the spine business, I don't think you'll see much greater improvement in our margins there, but we have a lot of operating leverage in front of us in the orthopedic side of the business and the capital side. Those are both fairly nascent businesses for us, and we're funding it with spine. But once we start to hit some volume numbers there, I think those businesses will definitely expand. Matt Taylor -- UBS -- Analyst Great. Can I ask a follow-up on the robotics strength? I mean, you talked in the past about getting pull-through on these placements, and obviously had a great year in 2021 with enabling tech. I guess are you still seeing the same kind of trends? And could that bode well for pull-through implants in '22? Dave Demski -- President and Chief Executive Officer Yes. It does. We're seeing that generally the same kinds of trends. And as a company, we're focusing on really going back to that installed base and seeing we can get more users to utilize the technology once it's placed in the hospital. And that's a big focus for us in 2022. Matt Taylor -- UBS -- Analyst Great. Thank you, guys. Thanks so much. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you. Shagun Singh -- RBC Capital Markets -- Analyst Great. Thank you for taking the question. I guess my first one is on Excelsius 3D imaging system. Can you talk to us about the delay? Why is there a delay in the launch? And then just elaborate on your go-to-market strategy. Are you targeting the replacement opportunity or greenfield? You're obviously going after a major competitor. So just any color there would be helpful. And then on the recon robotics, do you still plan to launch that in the second half? And then I have a quick follow-up. Dave Demski -- President and Chief Executive Officer Well, thank you, Shagun. I'll try to knock those off one by one. In terms of the delay, it's just taking longer than we thought. It's nothing significant in terms of the technology hurdle to get over. There's just a lot to do to get that over the line. So I wish we were a bit earlier but very confident we can get it done this quarter. Go-to-market. I think initially, we're going to be targeting our installed base of Excelsius users. Those are -- there's a high demand among them. It's going to make those procedures much more efficient and much easier for them to do. And then from there, we'll be branching out to target more of that free-hand navigation market that you alluded to earlier. And then I apologize, I forgot the last part of your question. Shagun Singh -- RBC Capital Markets -- Analyst I was just wondering if you plan to launch the recon robotics platform in the second half of '22 like you had previously indicated? Dave Demski -- President and Chief Executive Officer No. That's been delayed as well. We're going to be -- early '23 is the target for that. Shagun Singh -- RBC Capital Markets -- Analyst Got it. And then just as a follow-up, I was wondering if you could talk about trends that you're seeing on the procedure volume side in Q1, so in January and February. And spine typically has a high pain burden, so procedures come back quickly. So do you expect the recovery to come in Q1? Or do you expect a longer tail given staffing shortages? Thanks for taking the question. Dave Demski -- President and Chief Executive Officer Sure. Yes, January was really bad, but we've already started to see it turning in February. The last three weeks have all been progressively higher. Not back to where we want it to be, but definitely, I think we've hit bottom. We're going in the right direction. And I'm not going to try to predict what's going to happen with COVID though. That's proven to be frivolous for everyone, but it's encouraging where we are right now. Shagun Singh -- RBC Capital Markets -- Analyst Thank you. Matthew O'Brien -- Piper Sandler -- Analyst Great. Thanks for taking the questions. I guess, Dave, just for starters on the top-line guidance. This time last year, you guided about $35 million below The Street. We end up doing well above what you initially guided and actually what The Street was modeling. And this time, you're guiding about $25 million below The Street. I know January was soft, and maybe Excelsius 3D has pushed a little bit in terms of the contribution. But are there other factors that we should be thinking about? I don't know if it's a rep hiring perspective or a robot perspective that gives you a little bit more caution versus kind of where The Street was modeling things? Dave Demski -- President and Chief Executive Officer Thanks, Matt. I'm sorry we don't pay that much attention to The Street. We look internally to our own forecast, and we always want to be appropriately conservative going into a year. I feel really confident in the business. The U.S. spine business has been just cranking away. The robotic momentum is there. We're going to have 3D out this year. Japan is going to turn around in the second half. So I feel really good about the business. We just have taken a very conservative approach over the years when we give guidance, and we're doing that again. Matthew O'Brien -- Piper Sandler -- Analyst OK. Fair enough. And then the follow-up is on acquisitions. Sorry if I cut somebody off there, but there's been some talk about you guys doing a scale acquisition. I'm curious if you have any thoughts about the need for scale in spine. And then if not, there's some pretty interesting assets still in the spine space, but more on the pain management side of things. Are those higher on the list in terms of things that you potentially are looking at from a acquisition perspective? Dave Demski -- President and Chief Executive Officer No. It's actually a bit different. We're more active in terms of growing the business through BD and on the orthopedic side of the business. I think we're really strong in spine, and there's really nothing in spine that's of interest to us at the moment. We're more focused on growing the other piece of our business, which is smaller. There's nothing, I would say, transformative in our sights right now. But we are looking at several modest-sized deals as been our history in the past. Matthew O'Brien -- Piper Sandler -- Analyst Great. Dave Demski -- President and Chief Executive Officer Did that answer your question? Matthew O'Brien -- Piper Sandler -- Analyst Yep. That's perfect. Thank you. David Saxon -- Needham and Company -- Analyst Yeah. Hi, guys. Good afternoon, and thanks for taking the questions. Maybe one on enabling tech. I mean, it doubled this year, and you've really built out the enabling tech platform with hub and 3D, etc. How should we think about those launches kind of starting to ramp? And could '22 be another double? Dave Demski -- President and Chief Executive Officer Yeah. I think as I said, we're going to get some -- a few units out this quarter and kind of a soft launch, if you will, with the full launch starting in probably end of Q2, it might be into Q3 and then strong in the second half of this year. I don't want to comment on the double. It's -- we don't really drill into the components of our business. I can tell you that we're really excited about what we're seeing from our technology, from the adoption of our technology and not only what's right in front of us, but some things we have coming after that. David Saxon -- Needham and Company -- Analyst OK. Got it. And then maybe on trauma, kind of how close are you to having a full portfolio there? And then in terms of growth, 32% in the quarter. Is that sustainable in '22? Thanks for taking the questions. Dave Demski -- President and Chief Executive Officer Sure. The bag in trauma is by the second half of this year, I think full is kind of interesting term. We're going to have enough in our bag to be a full-line player and be able to compete with the major companies by the end of this year. And is that growth rate sustainable? Yes, I think that's certainly achievable in 2022. David Saxon -- Needham and Company -- Analyst Great. Thank you. Craig Bijou -- Bank of America Merrill Lynch -- Analyst Hey, guys. Thanks for taking the questions. Maybe a follow-up on top-line guidance and to the extent that you guys are willing to share. I mean, how to think about the contributions from each of the businesses? I know generally, you've been reluctant to share that info. But in terms of the composition of the guidance, how do we think about that incremental revenue coming in? Where is it coming from and to what extent? Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. As Dave said earlier, we're not going to get a ton into the parts and pieces. But what I will say is if you look at the business, whether by musculoskeletal and INR or you look U.S. versus international, the parts and pieces of our business we continue to feel extremely positive about as we look into 2022 and beyond. We're investing in our business. We're driving investment for the future, and we feel that we'll see that turn out to us taking share and driving sales growth. I alluded to my earlier prepared comments that our guidance is appropriately conservative, but there's nothing that I sit here and feel that we have kind of an ongoing issue that I would be concerned about our ability to grow across our business, like I said, whether it's U.S., international or musculoskeletal versus INR. Craig Bijou -- Bank of America Merrill Lynch -- Analyst Got it. Thanks, Keith. That's helpful. And then, Dave, I think you alluded to it, but I wanted to ask more specifically how to think about some of the new product rollouts? Obviously, you have 3D coming out and launching this year. But from a new product perspective, is it -- do you have a number of launches coming this year on the spine side? Do you have a number coming on the INR side? Just maybe a little bit more perspective of what to expect during the year. Dave Demski -- President and Chief Executive Officer Sure. Thanks, Craig. I think we've been pretty clear that it's a big one coming with 3D followed by our hub [Inaudible] offering. I think spine, we are typically 10 to 12 launches a year, and that's currently our target going into 2022. Trauma is probably the real bright spot. There is a number of products that we were working on for a while, they're going to hit the early part of this year and through this year. So -- and then our orthopedics business actually has some launches as well. So that's kind of who we are and who we're going to be. And it's -- the number one focus of the company is to drive great technology. Craig Bijou -- Bank of America Merrill Lynch -- Analyst Great. Thanks for taking the questions, guys. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you. Ryan Zimmerman -- BTIG -- Analyst All right. Thanks for taking my questions and congrats on a great year. Just want to follow up on a couple of questions. Dave, when we think about U.S. Spine performance kind of relative to the market, you look at some of the larger players, they were down a bit in the fourth quarter. Some of the smaller players we saw were up double digits. Obviously, a few major players still yet to report next week. But I guess I'm kind of curious if you can kind of talk about the U.S. performance, that growth this fourth quarter relative to the market, and kind of where you think you're tracking relative to that level? And if you could kind of give us color on what you think that level was just given the dynamics in the fourth quarter through the quarter would be helpful. Dave Demski -- President and Chief Executive Officer Thanks, Ryan. It's really challenging to figure out where we are, given COVID. So from the early returns of some of the folks who we have reported, again, we're taking significant share. I can't speak to the smaller guys who have reported or how that impacts us. And I don't really have a feel for the overall market. I know it was heavily impacted by COVID so likely down versus prior year overall. But that's more of just a guess and kind of where we landed versus some of our earlier trends. Our business is strong. I can tell you that. We haven't lost significant pieces of business in the U.S. And we continue to see growth in the recent product introductions, and we continue to sell robots and drive pull-through from that. So it's strong. I just -- I can't really see the overall market, and it's really hard to figure out what's going on given what's happening with COVID. Ryan Zimmerman -- BTIG -- Analyst OK. Just two follow-ups for me. One, we've heard some of the larger capital equipment companies have obviously called out chips as being a gating factor to sales or median demand in 2022. One, want to see if there's any concern there around chips for the Excelsius platform or for 3D and whether that could gate sales? And then I'll just ask the other -- sneak in a quick follow-up, too. The Japan distributor dynamics, how much of a lift should we expect when that distributor dynamic clears in the second half of 2022 on the international business? Thank you. Dave Demski -- President and Chief Executive Officer Sure. In terms of chips, I would just -- I would extend that to all supply chain. So it's not just chips, it's all components are challenging. It hasn't cost us revenue now, but it's certainly on our radar and making our life really hard. So it's a risk that's out there for 2022. I'll let Keith maybe handle the international question. Keith Pfeil -- Senior Vice President and Chief Financial Officer As it relates to Japan and the distributor dynamic, as we look ahead, we finished 2021, I think international grew by about 11%. We've historically said that we believe that the international business can grow mid-to-high teens. I would expect us to be able to get back to that on an annual basis. So you would expect the second half of the year to accelerate ahead of that to potentially balance -- to get closer to that 15 by the end of this year. Ryan Zimmerman -- BTIG -- Analyst Thanks, Kieth. Thanks, Dave. Appreciate it. Dave Demski -- President and Chief Executive Officer Sure. Kyle Rose -- Canaccord Genuity -- Analyst Great. Thank you for taking the questions. I wanted to start on enabling. I mean, look, you put up a good quarter in enabling. I guess a tough backdrop, particularly without the imaging platform. Maybe just help us understand kind of where that stands from a utilization perspective into your customer base. You're talking about the really good utilization there is continuing to see strong pull through. Can you just kind of level set maybe how many of your customers might have it or on a percentage basis or on an absolute basis? Just trying to really understand where we are in the uptake and the adoption within the historical core Globus customer base. Dave Demski -- President and Chief Executive Officer Yes, Kyle. To be honest, I don't feel comfortable sharing that information from a competitive standpoint. Kyle Rose -- Canaccord Genuity -- Analyst Totally fair. I had to try. I also wanted to touch on the orthopedic side of the business. I mean, it's been a couple of years since you acquired the StelKast business. I think earlier in the call, you talked about the fact that the recon robot is going to come in '23. Where do you stand just from an implant perspective? Do you have the right implants there? Do you need to make different investments from an M&A perspective, technologies, distribution? Just help us understand what you need to do on that total joints business before the recon robot comes next year. Thank you. Dave Demski -- President and Chief Executive Officer Sure. We do not have the implant portfolio we need to really make a strong outing. So we are working on that, have been working on that, and expect to roll some products out this year. I don't see us filling the gaps in our product portfolio with acquisitions in terms of hips and knees in particular. I do think there's opportunity for scale there. So that's not off the table because we are very small right now. And then the extremities is an interesting segment for us as well. It's a fast-growing segment. So that's an area where we've taken a look at a few things. Does that help with your question? Kyle Rose -- Canaccord Genuity -- Analyst Yes. Thank you very much. Dave Demski -- President and Chief Executive Officer Sure. Samuel Brodovsky -- Truist Securities -- Analyst Hi. Thank you for taking the questions. Just a first quick one on U.S. Spine. Just would be curious to hear about the portion of growth in the U.S. coming from robotic-specific instrumentation versus where you're seeing potential share gain with other parts of the portfolio? Keith Pfeil -- Senior Vice President and Chief Financial Officer Yes. Thanks for the question. In terms of breaking it out, we typically don't break out the parts and pieces of where the growth is coming from. What I would say is that as you look at our U.S. Spine business, it's really a combination of what we always talked about: new product innovation, our competitive recruiting, and the pull-through from implants. Those three continue to propel the business from a growth perspective, and we see that continuing as we enter 2022. Samuel Brodovsky -- Truist Securities -- Analyst Great. That's helpful. And then when thinking about 3D and going to customers with it, in terms of any competitive trialing, are you seeing it being trialed against other more novel imaging technologies on the market? Or is it typically being compared to the large competitor out there? Thanks. Dave Demski -- President and Chief Executive Officer Interesting question. I assume it's -- we don't really trial against it, but we have customers looking at our technology. And I think their interest just probably lines up with the market share of the other imaging systems in the market, particularly ones that are utilized more in spine. I'm sure that some of the more innovative ones are getting a look, but we don't hear that much about them. So it's not disproportionately, maybe I could answer it that way. Samuel Brodovsky -- Truist Securities -- Analyst Thanks. Steven Lichtman -- Oppenheimer and Company -- Analyst Thank you. Hi, guys. I wanted to ask you first on trauma. Where do you think you stand now in terms of coverage of procedures in terms of your product portfolio? And also from a sales force perspective, I'd just love to get an update on where you feel you are overall in terms of being able to go at the market. Dan Scavilla -- Executive Vice President and President of Ortho Steven, it's Dan Scavilla. So again, it's always the evolving and expanding story. We have about 14 family products out there now. I think with that, we're saying we would cover 50% to 60% of the market. Certainly, plan, as David said, to launch several more this year to cover that further. I believe and through what I'm saying, we're at a point where we're able to get into some significant facilities and support their needs for the most common procedures. And with that that's the main driver of growth to us. So we'll continue to expand the product line and fill that out over time, but we're in a good spot now. With that is the competitive recruiting that's been accelerating for us. So again, we're small, and we have a lot of spaces to fill. But the traction that has been occurring really through 2021 is very promising. And I do feel bullish as we are -- from what I've seen so far in the first quarter of 2022 that that will continue. Steven Lichtman -- Oppenheimer and Company -- Analyst Great. Thanks, Dan. Keith, just a follow-up on gross margin. I apologize if you mentioned this, but just relative to 2021, given the inflation commentary, should we assume gross margin down? Or are there some offsets that can keep it relatively flat to maybe -- or even up in '22? Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. We project the mid-70s GP. I think it's fair to assume that we are seeing inflation just like everybody else, but we're also growing. And it's obviously getting us some leverage in our cost structure. So as I think about 2022, mid-70s is kind of where I see it. I wouldn't project upside. Steven Lichtman -- Oppenheimer and Company -- Analyst OK. Got it. Thanks, guys. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you. Jason Wittes -- Loop Capital -- Analyst Hi. Thanks for taking the questions. Just two follow-ups, one on the guidance and one on trauma. But -- so first off, your guidance, I think the way you described it, especially relating to product launches, kind of assumes a strong second half versus the first half. So related to that, one, are we assuming that -- I know we can't predict COVID, but COVID pretty much works its way throughout the year? And then secondly, related to that, in the first quarter, I'm not sure how to read your comment that January was very weak. It bounced back. Should this be a normalized first quarter? Or are we -- is it going to be a little weaker relative to last year because of the COVID impact and launches? Thanks. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. Dave commented that January was weak, but we were starting to see some bounce back in February. Will it all bounce back in the same quarter versus having some bleed through into Q2? We don't necessarily know. But I think your earlier comment about some of the launches and a strong second half, I think that's directionally correct. Jason Wittes -- Loop Capital -- Analyst OK. And then I don't know if you can comment on this, but you did mention that you had -- it sounds like a record year in terms of sales force hires. In the past, you've kind of given us an indication of how large you've been able to grow your sales force percentage-wise. Can you give us any kind of indication on that in terms of what 2021 look like? And it sounds like 2022, you're optimistic that you can do -- go at a similar run rate? Dave Demski -- President and Chief Executive Officer Yeah. '21 was not a record year for us. I think we had one really strong quarter, but we've had years that were better. That's a renewed emphasis on it. I can tell you the pipeline right now is extremely strong. So we're coming out of the gate strong. But last year was a good year. It just wasn't our best. Jason Wittes -- Loop Capital -- Analyst OK. Thanks a lot. Appreciate it all. Dave Demski -- President and Chief Executive Officer Sure. Duration: 45 minutes Call participants: Brian Kearns -- Senior Vice President of Business Development and Investor Relations Dave Demski -- President and Chief Executive Officer Keith Pfeil -- Senior Vice President and Chief Financial Officer Matt Miksic -- Credit Suisse -- Analyst Matt Taylor -- UBS -- Analyst Shagun Singh -- RBC Capital Markets -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst David Saxon -- Needham and Company -- Analyst Craig Bijou -- Bank of America Merrill Lynch -- Analyst Ryan Zimmerman -- BTIG -- Analyst Kyle Rose -- Canaccord Genuity -- Analyst Samuel Brodovsky -- Truist Securities -- Analyst Steven Lichtman -- Oppenheimer and Company -- Analyst Dan Scavilla -- Executive Vice President and President of Ortho Jason Wittes -- Loop Capital -- Analyst More GMED analysis All earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2535,\n        \"min\": 571,\n        \"max\": 32540,\n        \"num_unique_values\": 6023,\n        \"samples\": [\n          8055,\n          8114,\n          14273\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker_clean\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"AVB\",\n          \"THRM\",\n          \"ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08086309609059458,\n        \"min\": -0.6091428484235492,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 9985,\n        \"samples\": [\n          0.0115302149459788,\n          0.1053023227425508,\n          -0.0781132122800544\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Target_Class\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Neutral\",\n          \"Gain\",\n          \"Loss\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"DateOfWeek\",\n      \"properties\": {\n        \"dtype\": \"int32\",\n        \"num_unique_values\": 7,\n        \"samples\": [\n          3,\n          2,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Month\",\n      \"properties\": {\n        \"dtype\": \"int32\",\n        \"num_unique_values\": 12,\n        \"samples\": [\n          12,\n          5,\n          8\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Quarter\",\n      \"properties\": {\n        \"dtype\": \"int32\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          4,\n          2,\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Target_gain_flag\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 1,\n        \"num_unique_values\": 2,\n        \"samples\": [\n          1,\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Ticker_gain_prob\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.050861298714432415,\n        \"min\": 0.07254027229556778,\n        \"max\": 0.6145290734110492,\n        \"num_unique_values\": 96,\n        \"samples\": [\n          0.32191697721115614,\n          0.1799954783009513\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Target_loss_flag\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 1,\n        \"num_unique_values\": 2,\n        \"samples\": [\n          1,\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Ticker_loss_prob\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.05845408745944301,\n        \"min\": 0.002959409262484645,\n        \"max\": 0.6360831434700265,\n        \"num_unique_values\": 96,\n        \"samples\": [\n          0.2926491076860506,\n          0.312513854371121\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 31
        }
      ],
      "source": [
        "!pip install category_encoders\n",
        "from category_encoders import TargetEncoder\n",
        "\n",
        "df_analysis[\"Target_gain_flag\"]=(df_analysis[\"Target_Class\"]==\"Gain\").astype(int)\n",
        "encoder=TargetEncoder(cols=[\"ticker_clean\"])\n",
        "df_analysis[\"Ticker_gain_prob\"]=encoder.fit_transform(df_analysis[\"ticker_clean\"],df_analysis[\"Target_gain_flag\"])\n",
        "\n",
        "df_analysis[\"Target_loss_flag\"]=(df_analysis[\"Target_Class\"]==\"Loss\").astype(int)\n",
        "encoder=TargetEncoder(cols=[\"ticker_clean\"])\n",
        "df_analysis[\"Ticker_loss_prob\"]=encoder.fit_transform(df_analysis[\"ticker_clean\"],df_analysis[\"Target_loss_flag\"])\n",
        "df_analysis.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 32,
      "metadata": {
        "id": "zFQvAHjVhMGC",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 660
        },
        "outputId": "836c7704-2772-4450-dc0f-b1d0e83c7ccf"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript            Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel...  2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta...  2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc...  2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon...  2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel...  2019-08-07 08:30:00   \n",
              "\n",
              "   Date_only                                         Clean_Text  word_count  \\\n",
              "0 2020-08-27  At this time, I would like to turn the confere...        5623   \n",
              "1 2020-07-30  Brian G. Harris -- Senior Vice President and C...        4755   \n",
              "2 2019-10-23  Tina Correia -- Vice President, Investor Relat...        8917   \n",
              "3 2019-11-06  Joining us today are BBSIs President and CEO, ...        8286   \n",
              "4 2019-08-07  I would now like to turn the conference over t...        4611   \n",
              "\n",
              "   Price_change Target_Class  DateOfWeek  Month  Quarter  Ticker_gain_prob  \\\n",
              "0      0.035078      Neutral           3      8        3          0.137200   \n",
              "1      0.116154         Gain           3      7        3          0.212841   \n",
              "2      0.142022         Gain           2     10        4          0.264048   \n",
              "3      0.029891      Neutral           2     11        4          0.212841   \n",
              "4      0.249623         Gain           2      8        3          0.255781   \n",
              "\n",
              "   Ticker_loss_prob  \n",
              "0          0.221243  \n",
              "1          0.218602  \n",
              "2          0.182879  \n",
              "3          0.188007  \n",
              "4          0.205784  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-eeb48732-a3a9-4a99-9398-15858904f439\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>Clean_Text</th>\n",
              "      <th>word_count</th>\n",
              "      <th>Price_change</th>\n",
              "      <th>Target_Class</th>\n",
              "      <th>DateOfWeek</th>\n",
              "      <th>Month</th>\n",
              "      <th>Quarter</th>\n",
              "      <th>Ticker_gain_prob</th>\n",
              "      <th>Ticker_loss_prob</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>At this time, I would like to turn the confere...</td>\n",
              "      <td>5623</td>\n",
              "      <td>0.035078</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>3</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.137200</td>\n",
              "      <td>0.221243</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>Brian G. Harris -- Senior Vice President and C...</td>\n",
              "      <td>4755</td>\n",
              "      <td>0.116154</td>\n",
              "      <td>Gain</td>\n",
              "      <td>3</td>\n",
              "      <td>7</td>\n",
              "      <td>3</td>\n",
              "      <td>0.212841</td>\n",
              "      <td>0.218602</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>Tina Correia -- Vice President, Investor Relat...</td>\n",
              "      <td>8917</td>\n",
              "      <td>0.142022</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>10</td>\n",
              "      <td>4</td>\n",
              "      <td>0.264048</td>\n",
              "      <td>0.182879</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>Joining us today are BBSIs President and CEO, ...</td>\n",
              "      <td>8286</td>\n",
              "      <td>0.029891</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>2</td>\n",
              "      <td>11</td>\n",
              "      <td>4</td>\n",
              "      <td>0.212841</td>\n",
              "      <td>0.188007</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>I would now like to turn the conference over t...</td>\n",
              "      <td>4611</td>\n",
              "      <td>0.249623</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.255781</td>\n",
              "      <td>0.205784</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-eeb48732-a3a9-4a99-9398-15858904f439')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-eeb48732-a3a9-4a99-9398-15858904f439 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-eeb48732-a3a9-4a99-9398-15858904f439');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-06020f98-79ef-4fc8-abdf-5749a00ffcc0\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-06020f98-79ef-4fc8-abdf-5749a00ffcc0')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-06020f98-79ef-4fc8-abdf-5749a00ffcc0 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_analysis",
              "summary": "{\n  \"name\": \"df_analysis\",\n  \"rows\": 10913,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4311,\n        \"samples\": [\n          \"Jul 8, 2021, 11:00 a.m. ET\",\n          \"Feb 13, 2020, 9:00 a.m. ET\",\n          \"May 18, 2022, 9:00 a.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"NYSE: AVB\",\n          \"NASDAQ: THRM\",\n          \"NASDAQ: ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q4\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"AVB\",\n          \"THRM\",\n          \"ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10031,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nGood afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the PTC's 2022 first quarter conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open for questions.\\nI'd now like to turn the call over to Matt Shimao, PTC's head of investor relations. Please go ahead.\\nMatthew Shimao -- Head of Investor Relations\\nHello. Thank you, Julian, and welcome to PTC's results call for Q1 of fiscal '22. On the call today are Jim Heppelmann, chief executive officer; and Kristian Talvitie, chief financial officer. During this call, PTC will make forward-looking statements, including guidance on future operating results.\\nBecause such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in PTC's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission, as well as in today's press release. The forward-looking statements, including guidance provided during today's call are valid only as of today's date, January 26, 2022, and PTC assumes no obligation to update these forward-looking statements.\\nDuring the call, PTC will also discuss non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures can be found in today's press release made available on our website. With that, I'd like to turn the call over to PTC's chief executive officer, Jim Heppelmann.\\u00a0 \\nJim Heppelmann -- Chief Executive Officer\\nThanks, Matt. Good afternoon, everyone, and thank you for joining us. Turning to Slide 3, I'm pleased to share that PTC delivered another strong financial performance in fiscal Q1. We executed very well, building on the momentum we saw in Q4.\\nTo simplify things, please note that throughout my prepared commentary, I will only discuss growth rates in constant currency. ARR came in at $1.507 billion, which was better than the $1.5 billion we had guided to at the recent Investor Day. That represents 16% growth, 11% of which was organic. Adjusted free cash flow was also strong at $145 million, which was up 20% year over year and better than the $140 million expectation we said at the Investor Day.\\nWe're off to a very strong start in fiscal 2022. Turning to Slide 4. Of particular note was our bookings strength. Bookings were up double digits organically and high teens overall against the very strong COVID bounce back quarter we saw in Q1 of fiscal '21 when bookings grew more than 30% over the prior year.\\nTo put it in perspective, given the tough comparison against Q1 of last year, we had planned bookings to actually be down slightly, inclusive of Arena. So this performance was more than 20% above plan. I know that some analysts and investors had voice concerned that the restructuring work we did in late Q4 and throughout Q1 would distract us, but obviously, we didn't see that. The strength was broad-based across direct sales and resellers and was achieved with no megadeals.\\nRockwell came in ahead of their part of our plan, too, which was great to see and suggest my concerns of them being distracted and may prove overstated. Arena contributed the inorganic element of bookings growth, with another strong bookings quarter, coming in above plan as well. With the Arena acquisition getting round tripped here in Q2, Arena becomes part of the organic results going forward and their low 20s growth rate will then add another tailwind to the organic results. Arena has been a great acquisition.\\nBookings growth was particularly strong in PLM, and in both Europe and Americas. From a macro perspective, global PMIs remain an expansion territory, while digital transformation and SaaS continue to grow in importance as secular drivers. The interest in digital transformation in SaaS has been driving strong bookings for what is very sticky software, which when layered into a recurring revenue model that is atypical of industry peers, has allowed PTC to deliver performance in excess of market growth rates. This happened right through the pandemic, especially in the large core business that represents about 70% of our ARR, and we fully expect it to continue going forward.\\nThese factors gave us confidence to raise the lower end of our ARR guidance range, which at the new midpoint basically means we've rolled our Q1 beat forward. Now let's take a look at the ARR performance by geography on Slide 5 before turning to business units. In Q1, we saw a strong ARR performance across all geographies. Our ARR growth in the Americas was 19%.\\nAll product segments grew with key growth drivers being the acquired Arena contribution and the velocity business unit overall, layered on top of another strong quarter in the core CAD and PLM business. In Europe, our ARR growth was 13%. We saw strong results across the board in Europe, with the strongest drivers of the growth being our digital thread growth and core businesses. Europe has the largest mix of channel versus direct and the resellers continue to perform well.\\nOur ARR growth in APAC was 14%, with growth primarily driven by our digital thread core business. Next, let's take a look at the ARR performance of our various business units, starting with the digital thread group on Slide 6. In our largest product segment, digital thread core, we delivered yet another double-digit performance in Q1 with 11% growth. Within this, CAD and PLM, both grew double digits, with strong growth across all three geographies.\\nThis is the 17th consecutive quarter of double-digit ARR growth in the core business. And as we roll out our more aggressive SaaS strategy, I expect we'll see many more. In the digital thread growth, which is IoT and AR, we saw ARR growth of about 14%, consistent across both elements. This was in line with our plan and the mid-teens near-term growth expectation we set at the recent Investor Day.\\nWhile this level of growth remains accretive to company growth, we continue to expect an acceleration of growth into the 20s as we get into the back half of the year. The biggest driver of growth in Q1 was from expansions, especially in Europe and APAC. We believe market conditions in IoT are improving, and we like the way the pipeline for our new DPM offering is developing through both PTC and Rockwell channels. For AR, we continue to see a tremendous level of interest, but the market remains nascent.\\nPerhaps most importantly, the formation of the digital thread business unit at the start of FY '22 has driven important initiatives to increase our focus on cross-selling of IoT and AR into the core CAD and PLM customer base. FSG had a great Q1 with 6% ARR growth. The expansion deal we recently announced with the U.S. Air Force, both increases and extends this key relationship for up to five more years.\\nContracts like this demonstrate the value that our customers are realizing from Servigistics and other FSG products such as retail PLM and ALM. You may remember, I noted at our Investor Day that having FSG grow in the mid-single digits rather than flat would be a helpful upside growth driver. So I'm pleased to see FSG post another strong quarter. Let me run through a couple of quick customer anecdotes to give you a sense for our digital thread customers and how they rely on us.\\nOn Slide 7, MAN Energy Solutions is the world's top provider of large-bore engines in turbomachinery for the maritime and energy industries. The company manufactures complex parts in nearly every engine they make must meet unique customer requirements. Before implementing Creo, they relied on manual outdated processes that slowed design and production. With Creo, they've been able to transition from 2D to a full 3D model-based approach.\\nCreo's broad range of tool path automation capabilities enable them to save time in the programming of the tool pass used to machine the large complex engine parts, greatly increasing efficiency in transitioning from design to production. Turning to Slide 8. You may have noticed we announced a deal with -- we announced that the German company, Scheffler, has expanded its relationship with PTC, and I'd like to share a bit of the back story. Scheffler has been a longtime Creo customer and has successfully deployed Windchill within engineering.\\nBut back in 2017, one of our PLM competitors announced a large PLM deal with Scheffler that appeared to cap PTC's expansion opportunity. But that system didn't ultimately stick as Scheffler has now decided to consolidate on PTC systems with Windchill being the backbone and is broadly deploying our solutions in their standard out-of-the-box fashion so that Scheffler can participate in the full power of our digital thread portfolio. I'm very excited about this collaboration and the further expansion that Scheffler is exploring with our IoT and AR offerings. On Slide 9, you'll see how IMA Group, our global business that delivers packaging machines, services, and solutions to a wide variety of industries, was looking for a way to expand their control room offering to help their customers improve overall equipment effectiveness and reduce downtime.\\nAs longtime users of PTC's Creo and Windchill, IMA decided that ThingWorx was the ideal IoT solution for their initiative and that Kepware could provide connectivity not only to their machines, but to the other vendors' machines deployed alongside them. IMA has successfully launched new revenue streams by enabling 24/7 monitoring of customer production lines and improved OEE by up to 16%. The Vuforia integrated with ThingWorx is the platform of choice for the U.S. Air Force training initiatives.\\nSlide 10 highlights the work that PTC partner, Vectrona has done with the U.S. Air Force. With finite training resources and limited capacity, the U.S. Air Force set out to incorporate augmented reality into their maintenance and munitions training.\\nVectrona using Vuforia Studio worked with the U.S. Air Force to create immersive 3D AR experiences for phones, tablets, and the HoloLens 2 that are designed to accelerate learning, improve work performance and facilitate remote training. The improved training shows better engagement and information retention with continuous and repeatable task training available regardless of the system or aircraft type. Turning to Slide 11, the velocity business ARR growth in Q1 was more than 650% due to the inclusion of Arena and 53% organically, which would be Onshape.\\nIf you were to add Arena's pre-acquisition results into the prior year to get a better pro forma comparison, then you'd have the velocity business unit growing at 28% in Q1. That 28% is a mix of Onshape growing at 53% and the larger Arena business growing in the low 20s. Growth of both Onshape and Arena is multiple times higher than market rates, clearly demonstrating that industrial companies see the benefits of SaaS. We continue to ramp investments to expand technology leadership and to broaden the geographic presence of our velocity businesses.\\nOn Slide 12, Beta Technologies, a leading developer of next-generation electric aircraft for the cargo and logistics market, sought a cloud-native product development platform where everyone would be working with one single source of truth without the workflow restrictions of traditional file-based design systems. Beta turned to Onshape because of how it enables real-time collaboration, allowing the engineering team to work from any location while streamlining their communications during the design process. To profile Arena customer, Potrero Medical, on Slide 13, is a predictive health company developing the next generation of medical devices, leveraging smart sensors and artificial intelligence. Potrero needed a scalable quality management system to support its growing product development and compliance needs, including satisfying FDA audit requirements.\\nArena was the right solution, offering a cloud-native QMS with a quick implementation, leading to ECO cycle time reduction of 30% and nonconformance improvement of 20%. As a final topic, I'd like to give you a quick update on our SaaS acceleration initiative on Slide 14. We've made tremendous progress in the past 90 days since we announced the more aggressive strategy. We've launched our SaaS program management office, which was modeled after the very successful approach we used to drive our subscription transition several years back.\\nOur field organizations transition to the new two-in-a-box customer success organization model without missing a beat. We converged our cloud and tech support organizations with product development to deploy the DevOps type of approach you see in virtually all SaaS companies. We've made good progress advancing our offerings, especially the Windchill multi-tenant version, which will go into production shortly this quarter, and we made good progress preparing the SaaS conversion offerings that will power the hundreds of lifts and shifts that will happen in the coming quarters and years. We have more work to do, but we're certainly up and running.\\nThe time for SaaS has arrived in our industry and PTC is very well positioned. We're already the SaaS leader in our space with continued strong SaaS growth in Windchill and FSG and high levels of growth in our cloud-native velocity business unit. Sharing the Atlas SaaS platform, we have a dual strategy to win with Onshape and Arena powering a new agile product development approach, while we transition our digital thread portfolio and existing customer base to SaaS to elevate the platform strategies that so many larger companies have. To wrap up on Slide 15, I'm pleased with PTC's position and the opportunity that lies ahead.\\nQ1 gave us a strong start to what we expect to be our fifth consecutive year of double-digit ARR growth. Our portfolio of products is unique and compelling and obviously aligns well to customer demand. Our results have been consistently strong for many quarters, but we're poised to accelerate growth as the SaaS tailwind blows harder in coming quarters and as we gain more momentum with our IoT and AR initiatives in the back half of the year. We're poised to drive higher levels of profitability, too, following the organizational changes we've already implemented and as our start-up businesses continue to mature up their J curves.\\nThe company has never been in a better position to create shareholder value. With that, I'll turn it over to Kristian for more details on the financial results.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nThanks, Jim, and good afternoon, everyone. Before I review our results, I'd like to note that I'll be discussing non-GAAP results and guidance, and growth rate references will be in both constant currency and as-reported rates. So turning to Slide 17, we delivered constant currency ARR of $1.507 billion, which is 16% growth year over year and slightly exceeded our Q1 guidance of $1.5 billion. On an organic constant currency basis, this is 11% growth.\\nFX was an approximate $11 million headwind in Q1, so our as reported ARR was $1.496 billion. Our SaaS products in both the digital thread and velocity business units saw a continued strong growth in Q1, with growth rates similar to what we discussed at our recent Investor Day. This is in combination with continued strong growth of our software-only sales. As of Q1, our SaaS portfolio is now 15% of our total ARR on a constant currency basis.\\nQ1 free cash flow of $134 million grew 21% year over year and includes $11 million in restructuring and other related payments. Adjusted free cash flow was $145 million and was slightly ahead of the $140 million we discussed at our Investor Day. Q1 revenue of $458 million increased 7% year over year. As we've discussed previously, revenue is impacted by ASC 606, so we do not believe that revenue growth rates are indicative of our underlying business performance but would rather guide you to ARR as the best metric to understand our top-line performance and cash collection.\\nFX only impacted revenue by about $1 million in Q1. So our revenue on a constant currency basis was $459 million. Q1 non-GAAP operating margin of 35%, compared to 36% in Q1 of 2021. While this is a strong result, it's still worth pointing out that because revenue was impacted by ASC 606, other derivative metrics such as gross margin, operating margin, and EPS are all also impacted.\\nSuffice it to say that our COGS and opex came in in line with our expectations in Q1, and we continue to maintain good discipline on our operating expense structure. I would like to point out that our GAAP results reflect a gain of $9.8 million related to our investment in Matterport. And we're also slightly reducing the range for expected P&L charges from approximately $45 million to $50 million, down to $40 million to $45 million for the full year. And coincidentally, we're also reducing the range of expected cash payments for the restructuring and other from what was previously $50 million to $55 million, down to $45 million to $50 million for the full year.\\nFor guidance purposes, we will continue to show $50 million as the cash payments and the adjusted free cash flow reconciliation. But as payments come in lower, then we would just expect actual free cash flow to come in higher. There's no change to the $450 million adjusted free cash flow target. Moving to Slide 18, I'll begin with our balance sheet.\\nWe ended Q1 with cash and cash equivalents of $296 million. In addition, at the end of Q1, we had medium-term investments of $87 million, primarily related to our investment in Matterport. Our gross debt was $1.45 billion with an aggregate interest rate of about 3.2%. In Q1, we used $120 million of cash to repurchase shares.\\nWe also had an additional $5 million of repurchases, which settled early in Q2. For the remainder of fiscal '22, we will focus on delevering and looking forward to FY '23 in an ongoing go-forward basis, assuming our debt-to-EBITDA ratio is below three times, we will continue to target to return approximately 50% of our free cash flow to shareholders via share repurchases. Turning to Slide 19. We post a data table to our IR website that has our financial statements, as well as ARR detail by segment.\\nIn that file, we share both constant currency and as-reported ARR. As a reminder, when we calculate constant currency, we use our current year plan FX rates and restate history to the same rates. So here, for example, on this slide, you can see our Q1 constant currency ARR of $1.507 billion and the actual as reported ARR of $1.496 billion. This is important to remember in the context of our guidance because we provide guidance at the planned rate.\\nWe believe this is the best way to evaluate the top-line performance of our business because it removes FX fluctuations from the analysis, positive or negative. With that, I'll move on to guidance on Slide 20. As Jim mentioned, we're raising the low end of our full year constant currency ARR guidance by $10 million. The new range is now $1.625 billion to $1.660 billion.\\nThis essentially reflects rolling our Q1 overperformance through the remainder of the year. We're now expecting constant currency ARR growth of 11% to 13% in fiscal '22. It's worth pointing out that based on FX rates at the end of Q1, we would expect a $13 million headwind against that full year ARR guidance. For Q2, we're setting constant currency ARR guidance of $1.540 billion to $1.550 billion.\\nThis is 12% organic constant currency growth at the midpoint. On an as-reported basis, the FX impact we're calculating based on the FX rates at the end of Q1 is a $12 million headwind in Q2 compared to the constant currency guidance. Moving to free cash flow. We're maintaining our full year free cash flow target of $400 million.\\nThis includes approximately $50 million of restructuring and acquisition-related payments. The majority of these payments are related to the reorganization we announced in Q1 with some residual payments primarily related to our Seaport move for which we took the accounting charge in prior periods. So our adjusted free cash flow target for fiscal '22 remains $450 million. Fiscal Q2 adjusted free cash flow is expected to be approximately $155 million.\\nWe expect to make approximately $20 million in restructuring and other related payments in Q2, bringing our free cash flow to approximately $135 million. Moving to revenue. We're also taking the low end of the full year revenue guidance up by $20 million. This reflects both the strength in software and strength in the professional services business that we saw in Q1 and the related forecasts for the full year.\\nSo for fiscal '22, our net revenue guidance range is $1.870 billion to $1.975 billion. The year-over-year growth rate range is now 3% to 9%. Our ASC 606 makes revenue very difficult to predict for on-premise subscription companies, hence the wide range. Note that revenue variability has -- this is from 606, has no impact on ARR or its related cash generation as we continue to primarily bill customers annually upfront regardless of term length.\\nWe continue to expect more than 60% of our annual free cash flow generation to occur in the first half of the year. Collections are stronger in the first half, and we expect expenses to increase as we ramp hiring in our SaaS investments throughout the year. We're wrapping up on Slide 21 with the free cash flow model that we use and went into some depth on at our recent Investor Day that you can see here. I know many of you use model free cash flow using the indirect method.\\nHowever, given the complexities related to revenue recognition due to 606, this is difficult to do. The model we show here has proven quite effective. The table shows fiscal '21 actuals compared to the model we shared at Investor Day compared to our current guidance. Let me take you through the model focusing on the non-GAAP column on the right and starting at the top.\\nFirst, we're showing the midpoint of our as reported ARR guidance of $1.630 billion, which is different from the constant currency guidance that we gave due to the $13 million FX headwind and is also $5 million lower than what we showed at the Investor Day. We use it as reported here because it's a better reflection of the cash we expect to generate. You can also see that we have increased the perpetual license revenue forecast slightly and also the professional services revenue increase that we mentioned earlier. COGS is slightly higher, reflecting the increased costs to deliver the incremental professional services revenue and the rest of the assumptions remain the same, and we still end up with our target adjusted free cash flow of $450 million.\\nObviously, this is a model based on assumptions such as the midpoint of the ARR range, the impact of FX, the pace of hiring, etc. So if some of those variables change, which they invariably will, the model will have to be adjusted accordingly. And as I mentioned earlier, if cash payments related to the restructuring coming at the low end of the range, we would see a flip from the restructuring line to the free cash flow line, but the adjusted free cash flow target would remain unchanged. But as we sit here today, we think this is a reasonable view of how we expect the year to shape up.\\nSo with that, I'll turn the call over to the operator, and we can begin Q&A.\\u00a0\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] We ask the analysts to please limit themselves to one question only. If you have any additional questions, please return to the queue. Thank you.\\nYour first question will come from Andrew Obin from Bank of America. Please go ahead. Your line is open.\\u00a0\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nHi, yes. Good afternoon.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Andrew.\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nJust a bigger picture question. I apologize, I missed the first couple of minutes. You know, we hear a lot about supply chain constraints. And frankly, we're hearing that this might extend the run-in terms of PMI expansion.\\nSo what are you hearing in terms of sort of as you have conversations about PLM and in terms of adoption? What kind of conversations are you having with your customers? And do customers have awareness of sort of supply chains being gummed up for longer? And are you seeing this having any discernible impact on what kind of conversations you're having with people?\\nJim Heppelmann -- Chief Executive Officer\\nAndrew, it's Jim. No, actually, it's not really a frequent topic in our conversations because -- well, first of all, since you said you missed the first minute, one of the things I pointed out is that our bookings came in very, very strong, and I explained about 20% higher than planned. So we had a very, very strong bookings quarter. And notable in that was PLM, although, frankly, the strength was broad-based.\\nI think the key thing to remember is that PLM is really associated with preparing product data in engineering that will then subsequently be used in manufacturing and perhaps in aftermarket service. And it's collecting data from supply chain partners and so forth. But production problems in a supply chain don't necessarily impede the collaboration during the engineering and the preparation for production process. So I think people are saying like, maybe I can't get chips to complete the product, but that doesn't mean I should stop designing the next one because if it does, then I'll fall behind.\\nSo I think that our view would be that the product development process has largely been unaffected by the supply chain process. Now some other things, we talked about how perhaps COVID had an impact on IoT, perhaps the supply chain a little bit, although I think muted compared to COVID. So to me, the supply chain thing is a fairly small factor in our results. We just see very little correlation between what's happening out there with supply chain problems and what's happening with our pipeline and frankly, with our bookings.\\nOperator\\nYour next question comes from Yun Kim from Loop Capital. Please go ahead. Your line is open.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nHey, Yun.\\nYun Kim -- Loop Capital -- Analyst\\nThank you. Hi, Jim. Can you just talk about the IoT business, you know, in terms of the large deal activity? What kind of trends are you seeing there? Obviously, you are expecting that business to accelerate in the back half -- second half of the year. If you can talk about whether that confidence is coming from the, you know, improvement in the large deal activity? Or is it just the overall volume of the activity around IoT? And then also, if you can just comment around deal size activity around the AR business as well.\\nThanks.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I think deal sizes are sort of unchanged from previous trends. If you think -- what are we looking at when we project forward how IoT and AR will perform. Well, we're looking at the bookings, let me say, at the pipeline that will drive bookings, and for IoT and AR was quite strong.\\nWe're looking at the backlog. Last year, bookings actually had improved over the prior year. And bookings that went into backlog or -- I'm sorry, what we call deferred ARR, were quite high. We were well ahead of our deferred planned number as we actually did last year.\\nSo you could imagine we've got more, and if you want to call it, backlog waiting for us. And then what other initiatives are we doing? So for example, our DPM launch, I think, will be materially positive for our IoT results. It will drive bigger deals. It will drive better value propositions.\\nIt's really software that's ready to turn on and get value from as opposed to a platform. And then the other thing is, Troy Richardson talked at our Investor Day about organizing better for cross-sell. And I think if we look backwards, maybe we had pivoted too much toward new logos, which are great. I mean, new logos are a wonderful thing.\\nBut we probably have low-hanging fruit yet to pick within our installed base of CAD and PLM accounts. So I think it's really this combination of a strong-looking pipeline, good-looking trends, awaiting us in the deferred backlog and then these other initiatives kicking into place, DPM and cross-sell that I think will all be very helpful as we proceed through the year. And again, I want to remind everybody, we set the expectation that the two handle would materialize in the back half of the year and that you wouldn't see it in Q1 and Q2. So we sort of feel like this was as we had predicted just mid-December a couple of weeks ago.\\nOperator\\nYour next question comes from Jason Celino from KeyBanc Capital Markets. Please go ahead. Your line is open.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nHey. Hi, Jim. Hi, Kristian.\\nJim Heppelmann -- Chief Executive Officer\\nHi, Jason.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nSo one question on maybe the SaaS Windchill, you know, launch. It seems like it's coming along, you know, nicely, and we could see something maybe go GA this quarter. Have you had a chance to maybe, you know, discuss this with customers? How is the pipeline shaping? Or is it maybe better to think that the pipeline might start to form once we do go live?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nNo, we have, for sure, started talking about it with customers. I mean, ramping up that process. We've got to educate a lot of people and they, in turn, have to educate customers. But we've certainly made some progress, and I can tell you the customer interest is actually quite high.\\nYou should know that actually, customers were pushing us a little bit to get going with such initiatives -- so I feel like the demand is there. And in fact, again, just reflecting on what we told you, that business has been growing about 30%. And Kristian mentioned we posted another quarter just like that, without us really invoking the new strategy yet. So there's lots of demand.\\nWe're just looking for a model where we can promote the demand because we like the margin profile better. And that's what's coming into place here in Q2.\\nOperator\\nYour next question comes from Adam Borg from Stifel. Please go ahead. Your line is open.\\u00a0\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nGreat. Thanks so much. And maybe just two quick ones. Just on the Scheffler win that you announced yesterday and highlighted on the call earlier.\\nOne of the things I thought was really interesting in the press release was this opportunity around some more vertical-specific or market-specific solutions targeting either automotive or industrial companies. So maybe, Jim, if you could just talk about that. And maybe just as a quick follow-up, just maybe for Kristian. Any way you could talk about this transition, it's great to get the early feedback on the SaaSification efforts, but any way to comment on, you know, how much this has contributed to bookings or the pipeline, at least qualitatively? Thanks so much.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I'll get the first part of the question. Kristian, you can take the second part. Yeah.\\nSo Scheffler is a great account. And as I mentioned back in 2017, it appeared they were going in a different direction, and now they've decided to come back into the fold. And honestly, they did that for two main reasons. One is that they really want off-the-shelf technology.\\nThe other competitor had told them this low-code, no-code story, and they tried that out and decided that's not really what they want. They don't want to develop their own solutions. They want to deploy standard out-of-the-box software that all works together. And then they want to engage in partnerships with the vendor, in this case, PTC to talk about how those solutions should evolve to be more and more powerful to meet their needs.\\nSo yeah, I'm very excited. I'm in the middle of that relationship myself. And yes, what's going to come out of that is technology that fits better and better, for example, for the automotive supply chain, which is a place where we have a lot of customers. So it's a great win or win back, maybe I should say, and a great partnership going forward that's going to produce a lot more business for us in years to come.\\nAnd sorry, the second part of the question was around the transition to SaaS and how that's manifesting itself in terms of pipeline and activity? Is that right, just making sure I got that right.\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nExactly. Any way to qualitatively comment from, you know, either bookings or a pipeline perspective?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, remember, I mean, the bookings that we just reported were for Q1, and Q1 is really when we actually just announced the acceleration of it. So I would say there's actually a limited impact in the actual bookings result here in Q1. That said, as I mentioned, we continue to see strong demand for the SaaS properties that we have.\\nThat's both in velocity and the digital thread. And so those products continue to grow at a rate higher than our software-only products. And now as the program is pushing ahead, we expect to see demand and pipeline generate, especially with the new Windchill launch coming out here and the program continuing to pick up speed internally.\\nKristian Talvitie -- Chief Financial Officer\\nMaybe, Adam, I could just add. We launched this phase 3 strategy 90 days ago on the earnings call. And there's nothing we've seen since that makes us any less bullish than we were back then. I mean it looks like a really nice opportunity for PTC, and we're pushing forward ahead as aggressively as we can because we'd like to bring that very promising upside growth driver, you know, closer in.\\nSo it has a bigger impact on '23 and '24 and so forth than it would otherwise have had.\\u00a0\\nOperator\\nYour next question comes from Jay Vleeschhouwer from Griffin Securities. Please go ahead. Your line is open.\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nThank you. Hello. Hi, Jim. Hi, Kristian.\\nA couple of things. With regard to the strength you noted for PLM, at your partner conference six months ago, back in the summer, management presented to the channel, your concept that PLM was no longer just an engineering vault that it was becoming memorial, what you call, multisystem, multidiscipline concept. And the question is, to what extent is that broader, more diverse view of PLM a current part of new business or in the pipeline for new business as compared to the more conventional historical way of thinking about PLM? By our calculation, we are already the second-largest brand by revenue in PLM, and maybe talk about what some of the drivers are to that? And then just a quick clarification you referred earlier to cross-sell. At the Analyst Meeting last month, in the slide deck, you referred to cross-sell 10 times and relatedly account-based selling.\\nPTC is often over the years, talked about cross-sell, but maybe talk about what's different this time in terms of resources and programs across your various segments and your new customer segmentation model.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, on your first question, Jay, you know, you are always very pressy on, you've been watching this industry for a long time. When we say multisystem, multidiscipline, what we're really talking about is an enterprise system. And so what's happened in the last couple of years is PLM has graduated from being an engineering data management system to being an enterprise system that contains the system of record for the product definition.\\nAnd so if you're in manufacturing, well, you need to know the product definition. If you're in procurement, you need to know the product definition. If you're all on an installation or a support call, you probably need to know the product definition. So definitely what's happened is that the enterprise deployments of Windchill are multiple times larger than the engineering deployments of Windchill.\\nSo something that's been driving growth for some years now is that the new deals we're taking are more and more frequently enterprise deals and they're larger. You may remember, last quarter, I told you we took the largest deal we had taken to date from a med device company. And the second thing that's happening is, we're circling back to those companies who had deployed the engineering solution like say, Scheffler, and we're upselling them to the enterprise solution and turning that into a much bigger opportunity for us. So definitely, that's a real thing, and it's been driving the momentum we've seen in Windchill for years.\\nAnd frankly, there's a lot of it out ahead of us even before we start talking about SaaS. The upsell from a departmental solution to an enterprise solution is a driver, taking that whole enterprise solution to SaaS is a whole another growth driver that's on top of that and sort of orthogonal to it. And then on the account-based selling, there's two ways to look at that. Cross-selling into your accounts is a great thing.\\nYou have established relationships. It's much easier to sell another product to an existing customer than to sell a new product to a new customer or a first product to a new customer. At the same time, we like new logos. So it's really always about the balance of how much do you invest in new logos pursuits versus how much do you invest in selling more to the companies who know and trust you.\\nAnd I think perhaps with IoT and AR, we realized we had over pivoted toward new logo, which is just generally speaking, less productive selling, you might imagine. And so the reason we formed this digital thread group, which brought CAD and PLM and IoT and AR together under Troy Richardson, was to really lubricate how these products work together and how we position them together and to be able to start anywhere and sell up and down that chain. So it's a good strategy. It's one that we -- it's a muscle we've developed well over the years.\\nWe really built the Windchill business, largely by cross-selling to the Creo base. And I think this is going to be something that will help us a lot to kind of get the right balance of new logo pursuits in cross-sell.\\nOperator\\nYour next question comes from Ken Wong from Guggenheim Securities. Please go ahead. Your line is open.\\u00a0\\nKen Wong -- Guggenheim Securities -- Analyst\\nThank you so much for taking my question. Jim or Kristian, I wanted to perhaps dive into the double-digit organic bookings growth. You know, I couldn't help and notice you guys also had a very large Servigistics expansion deal with the Air Force. I mean how much of that was already in expectations? Or did you get some boost there from timing shifts or anything of that nature?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Let me tell you, none of that actually contributed to the double-digit growth because that was a Q4 deal. You know, we released it when we had approval to release it, and I commented on it because it was, you know, an important customer and so forth. And let me say that deal, again, that was closed in Q4, both represented five years of extension, but also about a 50% growth in a ramp that happens over -- I think it's three years.\\nSo it roughly goes from a $10 million run rate to a $15 million run rate over three years and stays there for a couple more. That's what the contract contemplates. So some of that will come into ARR in Q4 of this year, but the bookings actually were in Q4 last year. So that strength -- the strength we saw in Q1 was exclusive of that Air Force deal, which just means it was really great strength.\\nSo anyway, it was hard to pin down where the strength comes from because it came from CAD. It came from PLM. The IoT number was actually pretty decent. It didn't all go into ARR.\\nAnd then, of course, the velocity numbers and the FSG numbers. So it was broad-based in all geographies and really in all product lines.\\nOperator\\nYour next question comes from Matt Broome from Mizuho Securities. Please go ahead. Your line is open.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Matt.\\nMatt Broome -- Mizuho Securities -- Analyst\\nThanks, man. So Jim, I mean, I guess, just on that -- sorry, just deal that I can just mention. Given the importance of supply chain management right now, are you seeing like ramping demand to the solution elsewhere? And sort of following on from that, is there a chance that FSG ARR could actually accelerate on the back of that demand beyond the sort of the mid-single-digit level and actually become sort of more strategic in a way?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean that's one of the points, Matt, that I brought up at the recent Investor Day is that we've generally modeled FSG to be roughly flat, flat about plus 1% to 2%. But it's actually been performing. I think last year, Kristian, wasn't up 7%, FSG.\\nIt was up 6% here again in Q1. So yes, we're overperforming and Servigistics is one of the key drivers. And then the second one probably is retail PLM, which has also been doing fairly well. So definitely, there's some -- I think we'll be conservative and leave the FSG sort of guidance where it is in the near term, but I do like overperforming it because it's a growth driver.\\nThe FSG business is about the same size as the IoT and AR business. So every point of growth we get there is pretty meaningful.\\nOperator\\nYour next question comes from Matt Hedberg from RBC Capital Markets. Please go ahead. Your line is open.\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nYeah. Thanks. This is Matt Swanson on for Matt. I'll kind of follow up on a piece of both Adam and Jay's questions.\\nSo looking at the Scheffler announcement, I think the thing I was really interested in was the idea around standardization and the idea around end-to-end. So could you talk a little bit about your customers' desire around standardization? And clearly, this product road map has really expanded your TAM, but I think one of the upside areas something we -- you know, maybe the holy grail of the transition would be more competitive displacements. And I'm just curious if you're starting to hear, you know, any early or more talk around that because you're building something so differentiated.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean, for sure. So the standard thing, I think maybe over the last couple of years, industrial companies have realized that they should be using software, not developing it. And so we saw this in our IoT business, and it's been why we've been heading up the stack with solutions like DPM is, customers would like to buy the software and use it, not buy some kind of a platform and create it because they just don't really know how to create it if I'm frank.\\nSo Scheffler had gone down the path of kind of like I said, low-code sort of environments and came back to standard products. And then the end-to-end thing, for sure, the CAD data that's created in Creo and managed in Windchill gets used, for example, in augmented reality, manufacturing, and service instructions much later and in a different part of the company if it's all well managed. And that connectivity from IoT, well, let's say, from CAD to PLM to IoT to AR is what we call the digital thread. And so we actually see so much interest in this that we kind of organized around that principle.\\nLet's stop presenting these products as kind of independent things and let's shine the light on how well they work together in an end-to-end solution. And by the way, how they're all ready to go. That this is something that turn on and use. And that's really what one Scheffler over, but I can tell you, Scheffler is not unique at all.\\nAnd it's really -- we're organizing to respond to that. SaaS is helpful, by the way, because if you want a lot of technology working end to end, it'd be better not to ship at all to the customer side because it gets complicated. The customer would like to just use it, not set it all up and care and feed for it on-premise.\\nOperator\\nYour next question comes from Saket Kalia from Barclays Capital. Please go ahead. Your line is open.\\nSaket Kalia -- Barclays -- Analyst\\nOK, great. Hey, guys. Thanks for taking my question here. Hi, Jim.\\nHey, Jim, maybe -- hey, Kristian. Jim, maybe for you, it was great to hear the PLM strength this quarter in bookings. With other companies that have done shifts like this, there's always a risk, I guess, of customers behaving differently, right, whether that's slowing purchases to see what's coming or maybe pulling forward purchases before something new comes out. Now just to be clear, it doesn't sound like that happened here.\\nBut can you just stress test that for us a little bit? And what you sort of look at to sort of manage what is, you know, more choices for our customer to make. Does that make sense?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Are you referring -- just let me clarify, are you referring to like SaaS choices being new choices or more broad --\\u00a0\\nSaket Kalia -- Barclays -- Analyst\\nYeah, that's right, yeah, Windchill. No, Windchill specifically.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So keep in mind, Saket, we have been selling Windchill as SaaS for some time. Remember, the phase 1, phase 2, phase 3 thing. So since phase 1, we've been selling Windchill, and we showed you, it's got a three-year growth CAGR of 30% in SaaS.\\nSo the customer demand is strong. It's just -- on the PTC side, we need to pivot to multi-tenant because in the single-tenant model we just don't have the profitability we like. So the demand is strong. The customers are buying it.\\nKristian mentioned we had another strong quarter. So it really is, we'd like to meet that demand with a solution that's more efficient for us to operate on behalf of the customer. And that's what phase 3 multitenant really is all about. Now when it becomes more efficient for us, we can then lean in on the promotion and marketing of it, because we haven't really done that.\\nSo we've been servicing demand, not driving it. And with phase 3, we think there's an opportunity to drive demand and, you know, the preliminary data we've seen this quarter suggest customers are very responsive, both to buying new systems that way, but also to lifting and shifting the previous systems they bought and giving them to us to operate and serve back to them in a SaaS model.\\nOperator\\nYour next question comes from Joe Vruwink from Baird. Please go ahead. Your line is open.\\nJoe Vruwink -- Robert W. Baird and Company\\nGreat. Hi, everyone. Just to go back to bookings, does the strength this quarter absent mega deals suggest anything about either the demand environments or maybe just the health of your mid-market and SMB customers? And looking ahead, are there going to be certain things you think about or track when contemplating, you know, the probability of more mega deals or maybe the larger ARR contributors for PTC, maybe, you know, being a bit more represented in future bookings?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nKristian, let me again take a stab at that and maybe you'll find things to add. So I think if you look at the bookings, again, they were phenomenal, and it's hard to pin down. It wasn't one geography. It wasn't one product.\\nIt was all geographies, all products. So I think it tells us that the end market is very healthy. And I would say, for two different reasons. On one hand, the PMIs are in good shape.\\nThat's helpful. On the other hand, the interest they have in the digital thread, digital transformation story, and the interest they have in SaaS is secular. That interest is not related to the PMIs, it's kind of independent of them. And so I think that we're just in a very healthy situation where industrial companies are leaning in on trying to get more digital.\\nThey see PTC as having a fairly unique and compelling portfolio, and they're interested in engaging and trying to make their companies more efficient. I can tell you, at Scheffler, for example, it's one of the top initiatives in the company is to get more digital. And as it relates to the whole product life cycle, the partners PTC. And we see that kind of phenomenon happening in a lot of places in the industrial world.\\nSo I think it's just good, strong, secular and as well macro-environment out there right now. But I'll remind you that we've had good performance even when the macro environment wasn't so strong. So all things being equal, I like the strong macro. But we're 17 quarters in with double-digit growth in the core business, and there were a lot of bad macro quarters over the course of those 17.\\nSo I think it really is the secular driver. Kristian, anything?\\nKristian Talvitie -- Chief Financial Officer\\nYeah. I mean I agree with all that. I mean, actually, just on the big deal dynamic, you know, what we used to call mega deals. We haven't -- I think we've had four in the past four years.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, keep in mind, perpetual drove bigger upfront purchases and subscription or SaaS tends not to.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYeah, which is my point that we've been seeing good strong bookings performance and bookings growth, you know, even with the absence of what used to be a fairly regular occurrence back in the perpetual days, like we really don't see a lot of those.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah, it's a good healthy business. OK. Next question.\\nOperator\\nYour next question comes from Blair Abernethy from Rosenblatt Securities. Please go ahead. Your line is open.\\u00a0\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nThanks very much. Guys, just maybe a quick question on -- around partnerships, in particular. I wonder if you could just give us a little deeper dive into how things are going with Rockwell and as well on the simulation side with Ansys?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So the state of the partner economy is good and, you know, Microsoft, I could put on that list, is also strong. With Rockwell, you'll remember in the past quarters, I had said we should take a bit of a conservative posture as it relates to what Rockwell would contribute to PTC's numbers here in fiscal '22. And we did that because Rockwell had made a big acquisition.\\nYou know, Rockwell never completely agreed with me on that. Their own public commentary kind of indicated they didn't worry too much about that. And in Q1, they were right. So we're pleased to see that Rockwell's contribution was solid in Q1 and starting to feel pretty good about the year.\\nI'll tell you one thing is this DPM solution appears to be a very good fit with Rockwell. And in fact, their Calypso alarm is probably lined up to be our strongest partner in promoting DPM. So we're very happy with that. Calypso has a long-term relationship with PTC that even predates their acquisition by Rockwell.\\nSo great alignment around DPM. Again, DPM is a high-value up-to-stack solution that drives bigger deal sizes, and we think will be a very sticky solution. So lots of optimism around that. With Ansys, we continue to differentiate now with best-in-class simulation.\\nSo whereas simulation some years back would have been viewed as a soft spot for PTC. Now it's a strength. If we're competing against Autodesk or Siemens or Dassault, nobody is going to have a better simulation story than PTC because nobody has a better simulation story than Ansys, and Ansys products are built into PTC products. So that's been going well.\\nAnd then, of course, with Microsoft, that partnership is performing well and poised to get a lot bigger because as we bring more stuff aggressively to SaaS, a whole lot of that is going to land on Azure. So I think all three partnerships are alive and well and as important as ever and helping us achieve the kind of results that we're achieving.\\u00a0\\nOperator\\nYour last question comes from Sterling Auty from J.P. Morgan. Please go ahead. Your line is open.\\nSterling Auty -- J.P. Morgan -- Analyst\\nYeah. Thanks. Hi, guys. Just wondering if you could characterize with the headcount changes that you pointed out are necessary to facilitate the acceleration to SaaS.\\nWhere are you in that process? What's left to go? And kind of what's the time frame that you expect to complete that over?\\nJim Heppelmann -- Chief Executive Officer\\nYeah, Kristian, I'm thinking of the numbers we're largely done, but not completely. Eighty percent, 90% done.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYep, with the exiting.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean we'll be hiring people throughout the year. So -- but in terms of the people who are exiting, they're largely exited by now that largely happened within the first quarter.\\nSterling Auty -- J.P. Morgan -- Analyst\\nUnderstood. Thank you.\\nOperator\\nWe have no further questions. I'd like to turn the call back over to Jim Heppelmann for closing remarks.\\nJim Heppelmann -- Chief Executive Officer\\nOK. Well, thank you, all. There's a lot of good questions and, you know, I think good answers because the business is performing very well right now. ARR is doing well.\\nBookings are doing well. Free cash flow is doing well. You know, I think we executed -- through good times and bad, we executed through the changes we made over the last quarter, and we're set up to do pretty well for the balance of the year. So, we're very confident and, you know, look forward to talking to you all in 90 days if we don't happen to cross pass with you sooner in an investor event or what have you.\\nSo, thanks a lot for joining us and have a good evening.\\nKristian Talvitie -- Chief Financial Officer\\nThanks, everyone.\\u00a0\\nOperator\\n[Operator signoff]\\nDuration: 59 minutes\\nCall participants:\\nMatthew Shimao -- Head of Investor Relations\\nJim Heppelmann -- Chief Executive Officer\\nKristian Talvitie -- Chief Financial Officer\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nYun Kim -- Loop Capital -- Analyst\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nKen Wong -- Guggenheim Securities -- Analyst\\nMatt Broome -- Mizuho Securities -- Analyst\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nSaket Kalia -- Barclays -- Analyst\\nJoe Vruwink -- Robert W. Baird and Company\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nSterling Auty -- J.P. Morgan -- Analyst\\nMore PTC analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, ladies and gentlemen, and welcome to ASUR's First Quarter 2020 Results Conference Call. My name is Kathy and I'll be your operator.\\n[Operator Instructions]\\nNow I would like to turn this call over to Mr. Adolfo Castro, Chief Executive Officer. Please go ahead, sir.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and good morning everyone. Thank you for joining us on the conference call to discuss ASUR's first quarter financial and operating results. Before starting the call, I would like to express my hope that you and your families are healthy and safe in these uncertain times. As a reminder, please note that certain statements made during the course of our discussion today may constitute forward-looking statements which are based on our current management expectations and beliefs and are subject to a number of risk and uncertainties that could cause active results to differ materially, including factors that may be beyond our company's control including the impact from COVID-19. For an explanation of these risks, please refer to our filings with the US Securities and Exchange Commission and the Mexican Stock Exchange.\\nOverall, our first quarter results were good. The year began in solid footing before we started to see the impact of COVID-19 pandemic in the second half of March. It resulted in the disruption of global travel industry. Importantly, in the end of the first quarter we had healthy balance sheet which I will come back and discuss in more detail later in my presentation. I'm going to start today's presentation with some comments regarding COVID-19 and the impact on the industry, on our business, and the steps we are taking to mitigate this disruption to the best we can in this rapidly changing environment. From an industry perspective, since mid-March, many governments have issued flight restrictions in an effort to mitigate the spread of COVID-19 virus. In turn, capacity has been severely reduced and very few people are booking flights as most are in some form in lock down around the world and not traveling. With respect to our airports, the situation varies by country and could be subject to change depending upon how fast or slow the pandemic is brought under control. Colombia has been the most active and we've suspended operations at all six of our airports since the third week of March with domestic flights suspended until April 27 in accordance with the published decree and most recently extended to up to May 11.\\nInternational travels have been suspended through May 13. By contrast, in our airports in Puerto Rico and Mexico remain open, although there's significant reduced flights and passenger traffic. As a result, total passenger traffic declined sharply in the second half of March, down nearly 69% year over year between March 16 and March 31. By country, we show the margin decline in Colombia around 77%, followed by Puerto Rico down 73% and Mexico with 63% decrease [Indecipherable]. Additionally starting in mid-March, some of the airlines as well as some tenants that operate in our airports began asking for assistance either through discounts on payments owed to ASUR or by extension by payment which resulted in a higher accounts receivables in March in Mexico and Colombia, up 54% and 78% year-over-year. We are having ongoing commercial discussions with these companies with respect to their contracts.\\nMoving next to action we have taken, starting with health and safety. Following the guidelines of relevant health agencies, we have implemented health and safety protocols for both our airport employees and passengers travelling through our airports. For example, protective gear such as wearing masks is required for airport staff. We have also stepped up disinfectants and sanitization practices, once again in accordance with the guidelines of local health authorities. Lastly, where possible, we have also implemented remote working points.\\nMoving next to ensuring continuity of our business. We have introduced cost reduction initiatives across our airports. The impact of these initiatives however is not expected to be significant vis-a-vis the potential decline in passenger traffic at the majority of the cost structure is different, except for concession fees and technical assistance in Mexico which are biannual cost. We are prepared to take additional step, if needed, to respond to the evolving business environment. Now, let me talk about our financial situation. We entered this quarter in a position of strength with strong liquidity and very low principal payments required through year end. Additionally we believe the company has sufficient liquidity to meet its obligations and continue operating in the normal course of business. Our cash position ended at MXN7.8 billion which was up from MXN6.2 billion at the year-end 2019. And subsequent to the quarter end, as we further strengthen our financial positions as our subsidiary in Puerto Rico drew down an additional $10 million of its committed line of credit. The line of credit [Indecipherable] support for the capex projects we have under construction, Apelian airport in Puerto Rico.\\nWe closed the quarter with total debt of MXN15.3 billion. Although 11% high than the year-end 2019, this was due to the conversion effect from the depreciation of the peso to the dollar. As a reminder, the majority of our debt, 54% is denominated in the US dollars which is at our subsidiary in Puerto Rico. 26% of total debt was denominated in Mexican pesos and 20% in Colombian pesos. We have principal payments of only MXN432 million coming due over the next three quarters. This represents less than 3% of ASUR's total debt. With respect to that ratios, net debt to last 12 months EBITDA stood at 0.7 times at the close of first quarter '20. You can see the interest coverage ratio by country in the table we have included in the annual release this quarter.\\nNow, stepping back for more, since we began operations over 20 years ago, we have successfully navigated through many very significant challenges. From the 9/11 event in 2001 to [Indecipherable] into 2005 and 2008 and 2009 business financial crisis, H1 and H2 and the bankruptcy of 50% of airlines in Mexico which cut planes capacity in Mexico by more than half. Following each of these events, passenger traffic recovered, although recovery time varied from 13 months to 26 months and then continued to grow. Between 2000 and 2019, annual passenger traffic increased the compound annual growth rate of 6.6%, up from slightly over 10 million to historical high to over 34 million last January. We believe the COVID-19 pandemic is unique in that sense it is global event and with a broad disruption in travel and economies worldwide and could change the way of travelling in the future while a vaccine or a cure is found. Summing up this section, we have a strong balance sheet, we have generated years of consistent profitability and we exercise prudent capital management. In the sense we believe that we cannot be very prepared for an event of this magnitude, but of course given its great uncertainty on the final effects in the worldwide economy and that travel will be [Indecipherable].\\nNow turning to our first quarter results, more details can be found in the press release issued last evening. Like I mentioned this part of my presentation, let me spend with the effects of the business in late March. We believe we had solid results in the first quarter 2020. Total passenger traffic was down in most of the airports, which leads to a total passenger decrease of slightly 6% YoverY. This was primarily due to the fallout from COVID-19 and the impact of the global travel industry beginning in the second half of March. Our airports in all three countries experienced total passengers decline from a low of nearly 3% in Colombia to a high 8% in Mexico. Puerto Rico passenger traffic was down 4%. All three countries reported declines in both domestic and international traffic.\\nMoving next to the P&L highlights, revenues ex construction were relatively unchanged at 4% increase in revenues from non-aeronautical services was offset by a 3% decline in aeronautical revenues. Commercial revenues per passenger increased 11% year over year, reaching MXN116.3. This was driven by solid performance across the region. Mexico posted a good performance with an increase of 11% on a per passenger basis benefiting from the currency peso devaluation and regulated revenues. Puerto Rico posted 7% increase per passenger benefiting from peso depreciation and finally Colombia saw a 33% increase on a per passenger basis, reflecting the 43 new stores opened over the last year and currency depreciation. The main drivers were ground transportation and car rentals.\\nMoving on to profitability, reported consolidated EBITDA increased 3% from the same period over the prior year. Both periods benefited from insurance recoveries related to the Hurricane Maria. In the first quarter '20, it amounted nearly MXN124 million while last year the amount was dragging over MXN41 million. Excluding these recoveries, consolidated EBITDA was essentially flat year-over-year at MXN2.7 billion. Ex-IFRIC 12 and without taking into account insurance recoveries in both quarters, adjusted EBITDA margin increased 20 basis points to 66.7% this quarter.\\nA few comments about capital allocation. Capital expenditures were MXN353 million in the quarter. Of these, nearly MXN58 million was allocated in Mexico due to the terminal expansion of Merida airport. For the full year, and as we have discussed before, our non-prevalent plan in Mexico calls for investment of approximately MXN5.3 billion for the full year. At the current time, there are no changes to the planned continuation of the foreigners tax relief of the second one we have at Cancun airport and the beginning of the first expansion at the Merida. Our plans call for a conclusion of Phase 1 of the Merida terminal expansion and typically the second phase this year. Nevertheless, due to the COVID-19 health crisis, you may see some disruption in the construction process, attributable to stay-at-home, the combination and we have informed the government about this situation. In Puerto Rico we have made investments of MXN114 million this quarter, mainly from the connection with some major maintenance referred tax relief. Finally, capex in Colombia amounted to MXN1 million related to maintenance. Last year we concluded our committed capex was at MXN20 million. And going forward, we only expect to incur a major maintenance capex in Colombia.\\nNext, our Annual General Meeting from yesterday, shareholders approved an ordinary net cash dividend of MXN8.1 per share to be paid, subject to the Board's approval on or after May 11, 2021 in a single installment.\\nIn conclusion, we are proactively responding to the developing situation. No one can control the virus or even the economic fallout. But we can control how we react to the crisis. I am optimistic about the prospects for the future both navigating through the current crisis and in the long term recovery. I believe that we are well positioned with a healthy balance sheet. We had a solid first quarter results. We believe in the strategies that we are executing.\\nThis ends my prepared remarks. Kathy, please open the lines for questions.\\nQuestions and Answers:\\nOperator\\n[Operator Instructions]\\nWe'll go first to Alejandro Zamacona of Credit Suisse.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nThank you Adolfo, thanks for the call. Two questions from our side. The first one is on the aeronautical maximum tariff. So, considering that airlines have been negotiating with most of airports and in some cases some fees have not been charging. What could we expect for maximum tariffs in the short-term meaning the second quarter and in the immediate term, meaning year end 2020? Could we still expect tariffs to be close to the maximum level?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro, hi, good morning. Well, basically what we are seeing today is a very reduced demand. So we believe that there is no effect if we try to reduce our fees for the month of April or the month of May. So we have maintained our tariffs and we believe that we can comply with -- we have to maintain compliance toward the year end.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you. And my second question is on the non-aeronautical business. Same thing in the same context, what could we expect in the short term for commercial revenues per passenger? Have you grant any rent payments facility to payments or any deferrals? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nMost of our contracts, as you may know, they have to pay higher of the minimum guarantee payment per passenger or a percentage of sales. So if we do not have passengers, we will not have to pay rent. So it's made automatically. So in that sense, we are not reducing or adjusting the contracts.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you Adolfo.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nWe will now take a question from Fernando Sanchez of Bradesco BBI.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nHi, good morning and thanks for taking my question. My question is light of the likelihood of the GDP contraction beyond 5% I just wanted to ask if you have had the opportunity to discuss with the authorities the possibility of delaying the 2021 and the key mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. Well as you are aware, the contract has a clause that says that the maximum tariff can be reviewed in the case of Mexico in an external way. When on the Mexican GDP drops by more than 5% in a year and that's happened in fact on track. Of course with the current circumstance and the current expectations from analysts, it is possible that the Mexican GDP will drop by more than 5% this year. So in that sense, we will be we -- and the possibility of review our maximum time in an external rate. That's for next year, but not this year.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nOkay. Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nAnd now, we'll take a question from Carlos Peyrelongue of Bank of America.\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nThank you. Good morning Adolfo. Thank you for the call. On the something I couldn't hear well because of the connection but can you comment as to whether the dividend will be kept or there is the possibility of cutting the dividend until we have more sense about passenger traffic? That would be the first question. And the second would be related to cash burn, if you could give us an idea of what your cash burn is on a quarterly basis, just to get a sense of compare that primarily to your strong cash position. Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYes, of course. In the case of the dividends, yesterday we held Annual Shareholders Meeting, they have sadly approved the dividend that it was proposed MXN8.1 per share. But it was -- this was subject to the approval from the Board to the moment of the payment that's from May 11, 2021. So the Board will have to approve when this dividend will be paid. In the case of the cash burn, what I said to you during the initiative months, is that our currency structure is basically fit. The only variable pieces are the technical assistance fee and the concession fees we paid to the government. So we are working and just to remember the case of Mexico is 5% as well as in Puerto Rico, and in the case of Colombia its' 19%. So this of course will reduce -- our passenger traffic is reduced and our income gets reduced. The remaining is basically, of course, we are taking measures to try to reduce as much as we can, all the expenses in the companies. But as I said, at the end, in the overall picture, the cost reduction will not be significant in comparison with reduction in the revenues of the company.\\nOperator\\nAnd we'll run to our next question, and that will come from Andressa Varotto of UBS.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much for taking my question. So my question is if have plans to negotiate with the government postponement of the mandatory capital is this possible? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nCould you repeat the question? I couldn't hear you.\\nAndressa Varotto -- UBS -- Analyst\\nYes. So my question is if you plan to negotiate with government the postponement of mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said before, in accordance with the contract, we do not have that possibility this year. But of course, with the given standards [Phonetic] and as I said it in my initial remarks, during an expansion situation and that expansion situation is that some companies have stopped operations [Indecipherable] and that it was reactivated later on, but there was a decree from the Mexican government that also named the steel and glass that is produced in the country will be used for the project. So in that sense, at the moment it's almost impossible for us to expand our 10-year buildings without these material. So we have this situation to the government. So for the moment, what we see is that we will see some disruption in our construction process for some months and then we will have to talk about these with the government. That's what I can share with you for the moment on this respect.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nOur next question will come from Stephen Trent of Citi.\\nStephen Trent -- Citi -- Analyst\\nGood morning, Adolfo and thanks very much for taking my question. Hope that you and your family are well. Just one quick one for me, I know that it seems that Mexico apparently has not been that active in likely offering any assistance to the corporate sector. What are you hearing from Colombia? Kind of any indications from them with respect to whether aviation industry will get some sort of relief?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nSteve, thank you for your question. So in the case of Colombia in comparison with Mexico they have been more active in the measures that they have been taking. As I said here in the report they were very [Indecipherable] basically closing or sorting down everything as from March 23. And that can be seen in terms of results. In the case of Spain and the active they have in comparison with active cases we have in Mexico. So their curve is decreasing or at least flattening while the Mexican curve is still increasing. In terms of what they have said for our industry, we have been closed since March 23 and they have issued decrees in that respect. Maybe this week, there was a new announcement from the President expanding the process of shutting down everything. As I said in my remarks, for the case of domestic aviation that will be close up to May 11 and in the case of international up to May 30. It is important to remember that in the case of Colombia, 85% of aviation is domestic and 15% is international. That's what we know as of today. Of course all of these may change depending on how fast or how slow they can control the virus in their country.\\nStephen Trent -- Citi -- Analyst\\nThank you very much Adolfo. Apologies I couldn't hear all of your remarks. But no indication at this point for example that Columbia's planning a kind of tax relief for aviation or something along those lines offering kind of financial support.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nWell we have not heard anything above that yet.\\nStephen Trent -- Citi -- Analyst\\nOkay. Appreciate that. I'll let someone ask a question. Thanks Adolfo.\\nOperator\\nAnd next we will go to Gabriel Himelfarb of Deutsche Bank.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nHi, good morning, thanks for the call. I have two questions. The first one is concerning about account receivables. Can you give us like a number or approximate number about what's the total of the sales coming from airlines and in specific from Interjet and American Airlines and my second question is do you think you could obtain some waivers in opex sorry capex your current MDP in Mexico and could you will be able to extend the life of the concession in Colombia?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. In terms of the account receivables you can see those in our report, revenue increase in the case of Mexico and Colombia, most of the increase is coming from the land industry. I do not have the details of American Airlines and Interjet you are requesting. In terms of the capex, as I said before, we have informed the government about this current situation. We don't know if they are going to react in that respect. But of course it's going to be almost impossible for us to construct and expand our buildings with that material. So more or less what I say to you.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nOkay, thank you.\\nOperator\\nAnd now we will go to Ruben Lopez of Santander.\\nRuben Lopez -- Santander -- Analyst\\nHi Adolfo, thanks for the call. My question is on commercial revenues. Sorry if you commented on these. But I understanding Cancun operating in just one terminal. So I want to confirm you how are your operations there in Cancun and what are the implications on commercial operations? Are there any penalties with the tenants? What are negotiations here? That's the first one. And the second one is related with the same topic. When we see commercial revenues and we kind of try to compare current levels versus what would be the fixed amount or the fixed part of the minimum payment. I mean can you give us any sense of the guidance here? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nOkay. As you have said, yes, in the case of Cancun, we have closed two terminals and we are just operating today in terminal 4. So all the operations of airport have been concentrated there in order to reduce on one side the expenses and of course on the other side be better prepared in the case of these reduced demand. All the stores are working in the case of terminal 4. So terminal 4 is operating as it was before the event. As I said before, most of the contracts, the financial contracts we have with the tenants are related to a minimum guarantee payment passenger. So once again, they do not have, let's talk about one of the deals that is closed. So if they do not have passenger traffic in terminal 2, they almost have to pay the rent. Of course when they operate in terminal 4 their operations will be in the accordance with the amount of passengers we have in that facility. So I would say terminal 4 is operating normally.\\nRuben Lopez -- Santander -- Analyst\\nThank you. And when you compare, sorry, the current level of commercial revenues versus what would be the minimum payment from the contract, can you give us any idea on that?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said, minimum payment -- the contract is on a per passenger basis.\\nRuben Lopez -- Santander -- Analyst\\nPerfect, thank you.\\nOperator\\n[Operator Instructions]\\nAnd we will now go to Jorge Larocco of Morgan Stanley.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nHi Adolfo, good morning. Thank you for the questions. It's two questions, actually a pretty general question, I was just wondering if you could provide more color on what are the main initiatives regarding our cost reduction efforts. How are those working down, your payment reductions on paid leave of absence, maintenance cost, utility costs, etc. and how are those playing out so far? Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThe main initiatives of course are related to in the case of Cancun in the terms of amounts. So we these key terminals closed, we are not burning the same amount of energy as if they were open. Also in the case of Cancun, we are in the process to shut down and one of the runway because today in accordance with the [Indecipherable] it's not needed. So, that runway will be turned off in terms of light at night also reducing their energy we will have to pay. And in terms of some other measures we are taking, adjusting some of the contracts of nature or mainly maintenance in the case of the buildings are closed and to try as much as possible to reduce operating cost and expenses. But I once again at the end, most of our cost is fixed. So if we apply the cost structure of the company, the most important lines are personnel and utility costs as we have said so. In the case of personnel, we are maintaining the personnel for the event or the crisis and in the case utilities, we are trying, as much as we can to try to reduce that.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nThanks so much Adolfo. Stay safe and have a good day.\\nOperator\\nAnd with that, that does concludes the question and answer portion of today's conference call. I would like to turn the call back over to Mr. Castro for closing remarks.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and thank you again for participating in our fourth quarter results conference call. On behalf of ASUR, we wish you good day and until we meet, be safe. Good bye.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 34 minutes\\nCall participants:\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nAndressa Varotto -- UBS -- Analyst\\nStephen Trent -- Citi -- Analyst\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nRuben Lopez -- Santander -- Analyst\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nMore ASR analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nHello, and welcome to the Globus Medical fourth quarter and full year 2021 earnings call. [Operator instructions] I will now turn the call over to Brian Kearns, senior vice president of business development and investor relations. Mr. Kearns, please go ahead.\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nThank you, Chris, and thank you, everyone, for joining us today. Joining today's call from Globus Medical will be Dave Demski, president, and CEO; Dan Scavilla, executive vice president and president of Ortho; and Keith Pfeil, senior vice president, and chief financial officer. This review is being made available via webcast accessible through the investor relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements.\\nOur Form 10-K for the 2021 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP.\\nWe believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available on the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Dave Demski, our president, and CEO. \\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Brian, and good afternoon, everyone. Globus finished an outstanding 2021 with a strong fourth quarter performance. Revenue for the year was a record $958 million, an increase of 21% over 2020 or $169 million in growth. To put that in perspective, our growth dollars alone would have ranked us in the top 10 spine companies in the world.\\nRevenue in 2021 was 22% higher than 2019, an outstanding performance in itself, given the disruption caused by COVID but magnified further by a recent independent research report showing that each of the other top 6 spine companies actually had sales declines over that same time period. We achieved record sales and growth while maintaining industry-leading profitability, generating a record $2.04 in non-GAAP EPS, a 42% increase over 2020, and adjusted EBITDA of 34.6% even as we invested heavily in INR, trauma, and competitive recruiting. Revenue for the quarter was $250 million, up 7% over 4Q '20 as COVID-related headwinds remained strong throughout the quarter. Non-GAAP EPS was $0.49 per share, a 16% decrease compared to the artificially high 4Q '20.\\nNot only were business travel and surgeon education activities severely curtailed last year, several other nonoperational factors, as Keith will expound upon in his remarks, also impacted the decline. Adjusted EBITDA in the fourth quarter was a strong 34%. Enabling technology continues to gain momentum, producing a record $25 million in revenue for Q4, an increase of 40% over 4Q '20. For the full year, enabling technology revenue was $81 million, an outstanding 100% increase over 2020.\\nThe clinical superiority of ExcelsiusGPS is the primary factor driving this growing momentum. Robotic utilization, which is the number of cases performed per installed robot, was at an all-time high in 2021. And nearly 30,000 procedures have been completed using ExcelsiusGPS technology since launch. Our spinal implant business continues to experience the flywheel effect of an increasing number of robots being sold combined with increasing utilization of each robot.\\nOur U.S. spine business grew by 3% in Q4 as COVID-related shutdowns had a significant impact throughout the quarter. We saw this trend continue into January, but all signs point to a rebound commencing late in Q1. For the full year, the U.S.\\nspine business grew by 18% as we continued to take significant market share. Robotics pull-through, coupled with contributions from recent product introductions and competitive recruiting, were all factors driving growth. Our international spine implant business grew by 9% in the quarter, a remarkable result in light of COVID impacts and an ongoing drag from Japan. Due to the impact of strategic moves we made in Japan last year, we expect to see continued declines there through the first half of 2022 with growth to follow off a reset baseline.\\nThis should result in accelerated overall international growth in the second half of this year. Trauma revenue was up 32% in the fourth quarter and 39% for the full year. Competitive recruiting and new product launches are driving growth. The Anthem Mini Frag system was launched on a limited basis in Q4 with excellent feedback from surgeon users.\\nWe are proceeding to full launch in Q1 and have a series of impactful product launches planned for the first half of 2022. The clients have launched the Excelsius 3D imaging system on a limited basis later this quarter with a full launch following in late Q2 or early Q3. There is tremendous anticipation and excitement about this technology among surgeons, and we already have double-digit orders signed. The Excelsius ecosystem, Globus Medical's unique combination of robotics, imaging, and freehand navigation that provides a seamless, scalable, and unmatched clinical experience for surgeons is about to become a reality.\\nI'm extremely proud of our team's performance in 2021, record growth and profitability, exciting, clinically impactful new technology introductions, and an unmatched focus on providing value to surgeons and their patients. Thank you for a great year. I will now turn the call over to Keith.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you, Dave, and good afternoon to everyone joining us for today's call. Globus capped off a record 2021 with a robust Q4 performance despite ongoing COVID-related disruptions and shutdowns. For the full year, 2021 revenue was $958.1 million, growing 21.4% as reported. On a day-adjusted basis, sales grew by 22.1%, with two fewer selling days in the U.S.\\nand international. Net income was $149.2 million, resulting in fully diluted earnings per share of $1.44. Non-GAAP net income was $211.4 million, generating a record $2.04 of fully diluted non-GAAP earnings per share. Adjusted EBITDA was 34.6% for the year, and we generated a record $219.4 million of free cash flow for the full year.\\nQ4 '21 revenue was $250 million, growing 7.1% as reported and 8.5% on a day-adjusted basis with one less selling day in the U.S. and international compared to the prior-year quarter. Net income was $15.1 million, and non-GAAP net income was $51.1 million. Our Q4 diluted -- fully diluted earnings per share was $0.14, while our fully diluted non-GAAP earnings per share was $0.49.\\nAdjusted EBITDA was 34.1%, and we generated $59.2 million of free cash flow for the quarter. Taking a deeper dive into sales. Q4 U.S. revenue was $213 million, 7.2% higher compared to Q4 of 2020 driven by our INR and U.S.\\nspine businesses. International revenue for Q4 was $37.1 million, growing 6.8% over the prior-year quarter led by growth in spinal implants despite lingering COVID impacts and the impact of our strategic changes in Japan as Dave mentioned earlier. On a constant currency basis, international revenue grew by 8.7%. Q4 gross profit was 75.3% versus 73.9% in the prior-year quarter.\\nThe 140 basis point improvement was driven primarily by nonrepeating inventory reserves in the prior-year quarter and was consistent with our expectations noted in our Q4 2020 earnings commentary. Full year 2021 gross profit was 75%, compared to 72.4% in the prior year. The increase in full year gross profit is primarily the result of lower inventory reserves and operational and supply chain efficiencies, partially offset by sales mix. Looking ahead to 2022, we project a mid-70s gross profit rate.\\nResearch and development expenses in Q4 were $51 million or 20.4% of sales, compared to $15.2 million or 6.5% of sales in the prior-year quarter. The increased spending is primarily reflective of in-process research and development acquired during the quarter. Adjusting for these costs, Q4 2021 research and development expense was $16.7 million or 6.7% of revenue, in line with the prior-year quarter as a percentage of sales, but $1.5 million higher driven by incremental investments in headcount across our spine, INR, and trauma businesses. Our full year 2021 research and development expenses were $97.3 million or 10.2% of sales, compared to $84.5 million or 10.7% of sales in the prior year.\\nAdjusting for the acquisitions made in both periods, research and development expenses were $63 million or 6.6% of sales in 2021, compared to $60.1 million or 7.6% of sales in 2020. The increase in spending is reflective of our continued investment in research and development to foster future growth and is consistent with comments made earlier in the year. We expect our R&D expenses to be approximately 7% of sales in 2022. SG&A expenses in the fourth quarter were $106.6 million or 42.6% of sales, compared to $92 million or 39.4% of sales in the prior-year quarter.\\nThe resulting increase is reflective of higher sales compensation and benefit costs as well as increased travel and training expenses driven by the resumption of normalized travel levels following the COVID-19 impacts experienced in the prior year. Full year SG&A expenses were $408.1 million or 42.6% of sales, compared to $354.8 million or 45% of sales in the prior year. The resulting decrease as a percentage of sales is reflective of leverage on fixed costs as a result of the higher volumes when comparing against the COVID impact in 2020. The income tax rate for the quarter was 23.8%, compared to 14.9% in Q4 of 2020 with the resulting increase driven primarily by lower tax benefits associated with stock option exercises.\\nOur full year 2021 income tax rate was 17.3%, slightly lower than the 18.8% in 2020 driven primarily by the nonrecurring tax treatment related to a 2020 acquisition, partially offset by lower tax benefits associated with stock option exercises. Looking ahead to 2022, we expect our effective tax rate to be approximately 20% for the full year, which assumes no significant changes in the current U.S. tax policy. Fourth quarter net income was $15.1 million, and non-GAAP net income was $51.1 million.\\nQ4 diluted earnings per share was $0.14, and non-GAAP diluted earnings per share were $0.49, compared to $0.58 in the prior-year quarter. The quarter-over-quarter decrease is driven by more normalized levels of travel, trainings, and meetings noted above or noted earlier as well as nonoperational items, primarily a higher tax rate as previously mentioned, higher stock compensation expense, and lower interest income. Looking ahead to 2022, we are expecting a mid-30s adjusted EBITDA rate. Full year diluted earnings per share were $1.44, and non-GAAP diluted earnings per share were $2.04, reflecting a 42.2% increase over 2020 primarily related to higher sales volumes following the 2020 impact of COVID-19, partially offset by approximately $0.09 of nonoperating headwinds related to a higher share count and lower interest income.\\nQ4 adjusted EBITDA was 34.1%, compared to 36.2% in the prior-year quarter. Full year 2021 adjusted EBITDA was 34.6%, compared to 29.4% in 2020. Net cash provided by operating activities were $76.3 million for the fourth quarter and a record $276.3 million for the full year 2021. Free cash flow was $59.2 million for the fourth quarter and a record $219.4 million for the full year 2021.\\nThe company remains debt free. At this time, the company is establishing full year 2022 guidance. We are projecting full year 2022 sales guidance of $1.025 billion, representing 7% growth versus 2021. We are guiding to a full year fully diluted non-GAAP earnings per share of $2.10, representing 3% growth versus 2021.\\nI note that the 2022 guidance includes approximately $0.10 of nonoperating headwinds, including higher shares worth $0.04, a higher tax rate worth $0.03, and higher stock compensation expense worth $0.03. Adjusting for these nonoperational factors, our 2022 guidance would have been $2.20 or 7.8% higher than 2021. Overall, we view this guidance as appropriately conservative and reflective of the current operating environment around COVID and inflation-related impacts. Our 2021 results represent our teamwork, our commitment, and our focus on execution.\\nWe continue to differentiate ourselves in the marketplace. And it is a testament of the hard work and dedication of each of our Globus employees. We remain excited for the future as we continue on our mission of improving patient care. Operator, we will now open the call for questions.\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] Our first question comes from Matt Miksic of Credit Suisse. Your line is open.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks so much for taking the questions and congrats on a really strong finish to a pretty amazing year, given the circumstances. I wanted to follow up on some of the comments around EPS guidance, in particular. As you pointed out, there are some items that ex those items, up 7% to 8%.\\nCan you talk a little bit about where in your guidance you're contemplating things that some of the other companies in the space have talked about like rising input costs, staffing challenges, labor costs, freight, etc., things that generally are driving operating costs up a little bit? Maybe give us a sense of how those figure into your guidance? And I have one quick follow-up.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks. This is Keith speaking. So we projected our guidance at $2.10. And as we look at the year, we see inflation as a market event.\\nEveryone is experiencing it, and we have it baked in our numbers. But when you step back and look at the $2.04 and the $2.10, I commented on the $0.10 of the nonoperating headwinds. But the other things that are impacting the business as we think about getting back to more normalized levels of spend are really the travel and the trainings that go along with the surgeons and [Inaudible] that we provide. That's worth going into the next year likely an $0.08 headwind.\\nAnd then one of the things that we commented on earlier in the year was our continued investment into R&D. As you look into next year, we're seeing roughly I would say, call it, $0.04 of additional investment in R&D. When you look at those things together, coupled with the inflation, we're landing at about $2.10.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And can you just maybe just elaborate a little bit on the spend or R&D and sort of the expectations for returns in terms of growth or programs that you're investing in?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nSo we're continuing to invest heavily in our spine business and as well as our robotic businesses. We talked about that in Q1 of our earnings call earlier in the year, and really all sign points to us continuing to do that. Dave talked earlier about some of the benefits that we're seeing for robotic technologies. We continue to invest in that and really grow for the future.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And then just one quick follow-up I had was on the environment for robots and spending in capital and equipment in general. Some of the other, again, companies in the space have talked about a fairly strong year for equipment, a strong year for robots. Any sense of whether this is something that needs to sort of take a breather or catch up here in 2022? Or whether orders and demand and pipeline for new deals would indicate just continued strength into 2022?\\nDave Demski -- President and Chief Executive Officer\\nYeah. Matt, this is Dave. No, it's very strong. I don't see anything laying off.\\nIn our case, in particular, it's been accelerating. I think the demand for Excelsius has been strong, and it's becoming more and more common. The narrative has changed from why robotics to which robot. And I think we're clearly establishing our lead there.\\nAnd then as I mentioned, there's a lot of enthusiasm over our Excelsius 3D system, which is going to launch later this quarter. We've had every surgeon we show that to seems like they want one. So I don't see it backing off at all.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks and congrats.\\nDave Demski -- President and Chief Executive Officer\\nThank you.\\nOperator\\nThank you. Our next question comes from Matt Taylor of UBS. Your line is open.\\nMatt Taylor -- UBS -- Analyst\\nExcuse me. Hi, guys. Thanks for taking the question. So I wanted to ask the first one about margins longer term.\\nMaybe just talk about the difference between what you're doing this year with some of the investments and obviously, headwinds year over year from spending back to normal and inflation, and how we should think about margins longer term? Would you start to get more leverage at some point? And what would the inflection point for that be?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. It's a good question. But as I look at where we're at and where we're going, our goal is to always maintain a mid-70s GP. But as we look longer term and look at our EBITDA rates, we're always looking to be in that mid-30s range.\\nWe could toggle our investments in various parts of our business to really achieve that, but we're investing now to drive growth -- to drive top-line growth for the future. And as we get that growth, that's going to create more fixed cost leverage in our P&L. So I think by doing that, investing for growth today helps project the margins going forward. I feel that we're going to work to try to stay in that range.\\nDave Demski -- President and Chief Executive Officer\\nYeah. I can add a little bit maybe to that, Matt. In the spine business, I don't think you'll see much greater improvement in our margins there, but we have a lot of operating leverage in front of us in the orthopedic side of the business and the capital side. Those are both fairly nascent businesses for us, and we're funding it with spine.\\nBut once we start to hit some volume numbers there, I think those businesses will definitely expand.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Can I ask a follow-up on the robotics strength? I mean, you talked in the past about getting pull-through on these placements, and obviously had a great year in 2021 with enabling tech. I guess are you still seeing the same kind of trends? And could that bode well for pull-through implants in '22?\\nDave Demski -- President and Chief Executive Officer\\nYes. It does. We're seeing that generally the same kinds of trends. And as a company, we're focusing on really going back to that installed base and seeing we can get more users to utilize the technology once it's placed in the hospital.\\nAnd that's a big focus for us in 2022.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Thank you, guys. Thanks so much.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And next, we have Shagun Singh of RBC. Your line is open.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGreat. Thank you for taking the question. I guess my first one is on Excelsius 3D imaging system. Can you talk to us about the delay? Why is there a delay in the launch? And then just elaborate on your go-to-market strategy.\\nAre you targeting the replacement opportunity or greenfield? You're obviously going after a major competitor. So just any color there would be helpful. And then on the recon robotics, do you still plan to launch that in the second half? And then I have a quick follow-up.\\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Shagun. I'll try to knock those off one by one. In terms of the delay, it's just taking longer than we thought. It's nothing significant in terms of the technology hurdle to get over.\\nThere's just a lot to do to get that over the line. So I wish we were a bit earlier but very confident we can get it done this quarter. Go-to-market. I think initially, we're going to be targeting our installed base of Excelsius users.\\nThose are -- there's a high demand among them. It's going to make those procedures much more efficient and much easier for them to do. And then from there, we'll be branching out to target more of that free-hand navigation market that you alluded to earlier. And then I apologize, I forgot the last part of your question.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nI was just wondering if you plan to launch the recon robotics platform in the second half of '22 like you had previously indicated?\\nDave Demski -- President and Chief Executive Officer\\nNo. That's been delayed as well. We're going to be -- early '23 is the target for that.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGot it. And then just as a follow-up, I was wondering if you could talk about trends that you're seeing on the procedure volume side in Q1, so in January and February. And spine typically has a high pain burden, so procedures come back quickly. So do you expect the recovery to come in Q1? Or do you expect a longer tail given staffing shortages? Thanks for taking the question.\\nDave Demski -- President and Chief Executive Officer\\nSure. Yes, January was really bad, but we've already started to see it turning in February. The last three weeks have all been progressively higher. Not back to where we want it to be, but definitely, I think we've hit bottom.\\nWe're going in the right direction. And I'm not going to try to predict what's going to happen with COVID though. That's proven to be frivolous for everyone, but it's encouraging where we are right now.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nThank you.\\nOperator\\nThank you. And next, we have Matthew O'Brien of Piper Sandler. Your line is open.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat. Thanks for taking the questions. I guess, Dave, just for starters on the top-line guidance. This time last year, you guided about $35 million below The Street.\\nWe end up doing well above what you initially guided and actually what The Street was modeling. And this time, you're guiding about $25 million below The Street. I know January was soft, and maybe Excelsius 3D has pushed a little bit in terms of the contribution. But are there other factors that we should be thinking about? I don't know if it's a rep hiring perspective or a robot perspective that gives you a little bit more caution versus kind of where The Street was modeling things?\\nDave Demski -- President and Chief Executive Officer\\nThanks, Matt. I'm sorry we don't pay that much attention to The Street. We look internally to our own forecast, and we always want to be appropriately conservative going into a year. I feel really confident in the business.\\nThe U.S. spine business has been just cranking away. The robotic momentum is there. We're going to have 3D out this year.\\nJapan is going to turn around in the second half. So I feel really good about the business. We just have taken a very conservative approach over the years when we give guidance, and we're doing that again.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nOK. Fair enough. And then the follow-up is on acquisitions. Sorry if I cut somebody off there, but there's been some talk about you guys doing a scale acquisition.\\nI'm curious if you have any thoughts about the need for scale in spine. And then if not, there's some pretty interesting assets still in the spine space, but more on the pain management side of things. Are those higher on the list in terms of things that you potentially are looking at from a acquisition perspective?\\nDave Demski -- President and Chief Executive Officer\\nNo. It's actually a bit different. We're more active in terms of growing the business through BD and on the orthopedic side of the business. I think we're really strong in spine, and there's really nothing in spine that's of interest to us at the moment.\\nWe're more focused on growing the other piece of our business, which is smaller. There's nothing, I would say, transformative in our sights right now. But we are looking at several modest-sized deals as been our history in the past.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat.\\nDave Demski -- President and Chief Executive Officer\\nDid that answer your question?\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nYep. That's perfect. Thank you.\\nOperator\\nThank you. Next, we have David Saxon of Needham. Your line is open.\\nDavid Saxon -- Needham and Company -- Analyst\\nYeah. Hi, guys. Good afternoon, and thanks for taking the questions. Maybe one on enabling tech.\\nI mean, it doubled this year, and you've really built out the enabling tech platform with hub and 3D, etc. How should we think about those launches kind of starting to ramp? And could '22 be another double?\\nDave Demski -- President and Chief Executive Officer\\nYeah. I think as I said, we're going to get some -- a few units out this quarter and kind of a soft launch, if you will, with the full launch starting in probably end of Q2, it might be into Q3 and then strong in the second half of this year. I don't want to comment on the double. It's -- we don't really drill into the components of our business.\\nI can tell you that we're really excited about what we're seeing from our technology, from the adoption of our technology and not only what's right in front of us, but some things we have coming after that.\\nDavid Saxon -- Needham and Company -- Analyst\\nOK. Got it. And then maybe on trauma, kind of how close are you to having a full portfolio there? And then in terms of growth, 32% in the quarter. Is that sustainable in '22? Thanks for taking the questions.\\nDave Demski -- President and Chief Executive Officer\\nSure. The bag in trauma is by the second half of this year, I think full is kind of interesting term. We're going to have enough in our bag to be a full-line player and be able to compete with the major companies by the end of this year. And is that growth rate sustainable? Yes, I think that's certainly achievable in 2022.\\nDavid Saxon -- Needham and Company -- Analyst\\nGreat. Thank you.\\nOperator\\nThank you. Next, we have Craig Bijou of Bank of America. Your line is open.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nHey, guys. Thanks for taking the questions. Maybe a follow-up on top-line guidance and to the extent that you guys are willing to share. I mean, how to think about the contributions from each of the businesses? I know generally, you've been reluctant to share that info.\\nBut in terms of the composition of the guidance, how do we think about that incremental revenue coming in? Where is it coming from and to what extent?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. As Dave said earlier, we're not going to get a ton into the parts and pieces. But what I will say is if you look at the business, whether by musculoskeletal and INR or you look U.S. versus international, the parts and pieces of our business we continue to feel extremely positive about as we look into 2022 and beyond.\\nWe're investing in our business. We're driving investment for the future, and we feel that we'll see that turn out to us taking share and driving sales growth. I alluded to my earlier prepared comments that our guidance is appropriately conservative, but there's nothing that I sit here and feel that we have kind of an ongoing issue that I would be concerned about our ability to grow across our business, like I said, whether it's U.S., international or musculoskeletal versus INR.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGot it. Thanks, Keith. That's helpful. And then, Dave, I think you alluded to it, but I wanted to ask more specifically how to think about some of the new product rollouts? Obviously, you have 3D coming out and launching this year.\\nBut from a new product perspective, is it -- do you have a number of launches coming this year on the spine side? Do you have a number coming on the INR side? Just maybe a little bit more perspective of what to expect during the year.\\nDave Demski -- President and Chief Executive Officer\\nSure. Thanks, Craig. I think we've been pretty clear that it's a big one coming with 3D followed by our hub [Inaudible] offering. I think spine, we are typically 10 to 12 launches a year, and that's currently our target going into 2022.\\nTrauma is probably the real bright spot. There is a number of products that we were working on for a while, they're going to hit the early part of this year and through this year. So -- and then our orthopedics business actually has some launches as well. So that's kind of who we are and who we're going to be.\\nAnd it's -- the number one focus of the company is to drive great technology.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGreat. Thanks for taking the questions, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. Next, we have Ryan Zimmerman of BTIG. Your line is open.\\nRyan Zimmerman -- BTIG -- Analyst\\nAll right. Thanks for taking my questions and congrats on a great year. Just want to follow up on a couple of questions. Dave, when we think about U.S.\\nSpine performance kind of relative to the market, you look at some of the larger players, they were down a bit in the fourth quarter. Some of the smaller players we saw were up double digits. Obviously, a few major players still yet to report next week. But I guess I'm kind of curious if you can kind of talk about the U.S.\\nperformance, that growth this fourth quarter relative to the market, and kind of where you think you're tracking relative to that level? And if you could kind of give us color on what you think that level was just given the dynamics in the fourth quarter through the quarter would be helpful.\\nDave Demski -- President and Chief Executive Officer\\nThanks, Ryan. It's really challenging to figure out where we are, given COVID. So from the early returns of some of the folks who we have reported, again, we're taking significant share. I can't speak to the smaller guys who have reported or how that impacts us.\\nAnd I don't really have a feel for the overall market. I know it was heavily impacted by COVID so likely down versus prior year overall. But that's more of just a guess and kind of where we landed versus some of our earlier trends. Our business is strong.\\nI can tell you that. We haven't lost significant pieces of business in the U.S. And we continue to see growth in the recent product introductions, and we continue to sell robots and drive pull-through from that. So it's strong.\\nI just -- I can't really see the overall market, and it's really hard to figure out what's going on given what's happening with COVID.\\nRyan Zimmerman -- BTIG -- Analyst\\nOK. Just two follow-ups for me. One, we've heard some of the larger capital equipment companies have obviously called out chips as being a gating factor to sales or median demand in 2022. One, want to see if there's any concern there around chips for the Excelsius platform or for 3D and whether that could gate sales? And then I'll just ask the other -- sneak in a quick follow-up, too.\\nThe Japan distributor dynamics, how much of a lift should we expect when that distributor dynamic clears in the second half of 2022 on the international business? Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. In terms of chips, I would just -- I would extend that to all supply chain. So it's not just chips, it's all components are challenging. It hasn't cost us revenue now, but it's certainly on our radar and making our life really hard.\\nSo it's a risk that's out there for 2022. I'll let Keith maybe handle the international question.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nAs it relates to Japan and the distributor dynamic, as we look ahead, we finished 2021, I think international grew by about 11%. We've historically said that we believe that the international business can grow mid-to-high teens. I would expect us to be able to get back to that on an annual basis. So you would expect the second half of the year to accelerate ahead of that to potentially balance -- to get closer to that 15 by the end of this year.\\nRyan Zimmerman -- BTIG -- Analyst\\nThanks, Kieth. Thanks, Dave. Appreciate it.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. Next, we have Kyle Rose of Canaccord. Your line is open.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nGreat. Thank you for taking the questions. I wanted to start on enabling. I mean, look, you put up a good quarter in enabling.\\nI guess a tough backdrop, particularly without the imaging platform. Maybe just help us understand kind of where that stands from a utilization perspective into your customer base. You're talking about the really good utilization there is continuing to see strong pull through. Can you just kind of level set maybe how many of your customers might have it or on a percentage basis or on an absolute basis? Just trying to really understand where we are in the uptake and the adoption within the historical core Globus customer base.\\nDave Demski -- President and Chief Executive Officer\\nYes, Kyle. To be honest, I don't feel comfortable sharing that information from a competitive standpoint.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nTotally fair. I had to try. I also wanted to touch on the orthopedic side of the business. I mean, it's been a couple of years since you acquired the StelKast business.\\nI think earlier in the call, you talked about the fact that the recon robot is going to come in '23. Where do you stand just from an implant perspective? Do you have the right implants there? Do you need to make different investments from an M&A perspective, technologies, distribution? Just help us understand what you need to do on that total joints business before the recon robot comes next year. Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. We do not have the implant portfolio we need to really make a strong outing. So we are working on that, have been working on that, and expect to roll some products out this year. I don't see us filling the gaps in our product portfolio with acquisitions in terms of hips and knees in particular.\\nI do think there's opportunity for scale there. So that's not off the table because we are very small right now. And then the extremities is an interesting segment for us as well. It's a fast-growing segment.\\nSo that's an area where we've taken a look at a few things. Does that help with your question?\\nKyle Rose -- Canaccord Genuity -- Analyst\\nYes. Thank you very much.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. And next, we have Samuel Brodovsky of Truist. Your line is open.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nHi. Thank you for taking the questions. Just a first quick one on U.S. Spine.\\nJust would be curious to hear about the portion of growth in the U.S. coming from robotic-specific instrumentation versus where you're seeing potential share gain with other parts of the portfolio?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nYes. Thanks for the question. In terms of breaking it out, we typically don't break out the parts and pieces of where the growth is coming from. What I would say is that as you look at our U.S.\\nSpine business, it's really a combination of what we always talked about: new product innovation, our competitive recruiting, and the pull-through from implants. Those three continue to propel the business from a growth perspective, and we see that continuing as we enter 2022.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nGreat. That's helpful. And then when thinking about 3D and going to customers with it, in terms of any competitive trialing, are you seeing it being trialed against other more novel imaging technologies on the market? Or is it typically being compared to the large competitor out there? Thanks.\\nDave Demski -- President and Chief Executive Officer\\nInteresting question. I assume it's -- we don't really trial against it, but we have customers looking at our technology. And I think their interest just probably lines up with the market share of the other imaging systems in the market, particularly ones that are utilized more in spine. I'm sure that some of the more innovative ones are getting a look, but we don't hear that much about them.\\nSo it's not disproportionately, maybe I could answer it that way.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nThanks.\\nOperator\\nThank you. [Operator instructions] Our next question comes from Steven Lichtman of Oppenheimer. Your line is open.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nThank you. Hi, guys. I wanted to ask you first on trauma. Where do you think you stand now in terms of coverage of procedures in terms of your product portfolio? And also from a sales force perspective, I'd just love to get an update on where you feel you are overall in terms of being able to go at the market.\\nDan Scavilla -- Executive Vice President and President of Ortho\\nSteven, it's Dan Scavilla. So again, it's always the evolving and expanding story. We have about 14 family products out there now. I think with that, we're saying we would cover 50% to 60% of the market.\\nCertainly, plan, as David said, to launch several more this year to cover that further. I believe and through what I'm saying, we're at a point where we're able to get into some significant facilities and support their needs for the most common procedures. And with that that's the main driver of growth to us. So we'll continue to expand the product line and fill that out over time, but we're in a good spot now.\\nWith that is the competitive recruiting that's been accelerating for us. So again, we're small, and we have a lot of spaces to fill. But the traction that has been occurring really through 2021 is very promising. And I do feel bullish as we are -- from what I've seen so far in the first quarter of 2022 that that will continue.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nGreat. Thanks, Dan. Keith, just a follow-up on gross margin. I apologize if you mentioned this, but just relative to 2021, given the inflation commentary, should we assume gross margin down? Or are there some offsets that can keep it relatively flat to maybe -- or even up in '22?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. We project the mid-70s GP. I think it's fair to assume that we are seeing inflation just like everybody else, but we're also growing. And it's obviously getting us some leverage in our cost structure.\\nSo as I think about 2022, mid-70s is kind of where I see it. I wouldn't project upside.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nOK. Got it. Thanks, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And we now have Jason Wittes of Loop Capital. Your line is open.\\nJason Wittes -- Loop Capital -- Analyst\\nHi. Thanks for taking the questions. Just two follow-ups, one on the guidance and one on trauma. But -- so first off, your guidance, I think the way you described it, especially relating to product launches, kind of assumes a strong second half versus the first half.\\nSo related to that, one, are we assuming that -- I know we can't predict COVID, but COVID pretty much works its way throughout the year? And then secondly, related to that, in the first quarter, I'm not sure how to read your comment that January was very weak. It bounced back. Should this be a normalized first quarter? Or are we -- is it going to be a little weaker relative to last year because of the COVID impact and launches? Thanks.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. Dave commented that January was weak, but we were starting to see some bounce back in February. Will it all bounce back in the same quarter versus having some bleed through into Q2? We don't necessarily know. But I think your earlier comment about some of the launches and a strong second half, I think that's directionally correct.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. And then I don't know if you can comment on this, but you did mention that you had -- it sounds like a record year in terms of sales force hires. In the past, you've kind of given us an indication of how large you've been able to grow your sales force percentage-wise. Can you give us any kind of indication on that in terms of what 2021 look like? And it sounds like 2022, you're optimistic that you can do -- go at a similar run rate?\\nDave Demski -- President and Chief Executive Officer\\nYeah. '21 was not a record year for us. I think we had one really strong quarter, but we've had years that were better. That's a renewed emphasis on it.\\nI can tell you the pipeline right now is extremely strong. So we're coming out of the gate strong. But last year was a good year. It just wasn't our best.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. Thanks a lot. Appreciate it all.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\n[Operator signoff]\\nDuration: 45 minutes\\nCall participants:\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nDave Demski -- President and Chief Executive Officer\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nMatt Miksic -- Credit Suisse -- Analyst\\nMatt Taylor -- UBS -- Analyst\\nShagun Singh -- RBC Capital Markets -- Analyst\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nDavid Saxon -- Needham and Company -- Analyst\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nRyan Zimmerman -- BTIG -- Analyst\\nKyle Rose -- Canaccord Genuity -- Analyst\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nDan Scavilla -- Executive Vice President and President of Ortho\\nJason Wittes -- Loop Capital -- Analyst\\nMore GMED analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4006,\n        \"samples\": [\n          \"2022-08-11 07:30:00\",\n          \"2021-03-18 08:00:00\",\n          \"2021-08-09 11:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2019-04-11 00:00:00\",\n        \"max\": \"2023-02-23 00:00:00\",\n        \"num_unique_values\": 771,\n        \"samples\": [\n          \"2022-07-12 00:00:00\",\n          \"2020-10-22 00:00:00\",\n          \"2022-06-10 00:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Clean_Text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10031,\n        \"samples\": [\n          \"I'd now like to turn the call over to Matt Shimao, PTC's head of investor relations. Please go ahead. Matthew Shimao -- Head of Investor Relations Hello. Thank you, Julian, and welcome to PTC's results call for Q1 of fiscal '22. On the call today are Jim Heppelmann, chief executive officer; and Kristian Talvitie, chief financial officer. During this call, PTC will make forward-looking statements, including guidance on future operating results. Because such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in PTC's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission, as well as in today's press release. The forward-looking statements, including guidance provided during today's call are valid only as of today's date, January 26, 2022, and PTC assumes no obligation to update these forward-looking statements. During the call, PTC will also discuss non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures can be found in today's press release made available on our website. With that, I'd like to turn the call over to PTC's chief executive officer, Jim Heppelmann. Jim Heppelmann -- Chief Executive Officer Thanks, Matt. Good afternoon, everyone, and thank you for joining us. Turning to Slide 3, I'm pleased to share that PTC delivered another strong financial performance in fiscal Q1. We executed very well, building on the momentum we saw in Q4. To simplify things, please note that throughout my prepared commentary, I will only discuss growth rates in constant currency. ARR came in at $1.507 billion, which was better than the $1.5 billion we had guided to at the recent Investor Day. That represents 16% growth, 11% of which was organic. Adjusted free cash flow was also strong at $145 million, which was up 20% year over year and better than the $140 million expectation we said at the Investor Day. We're off to a very strong start in fiscal 2022. Turning to Slide 4. Of particular note was our bookings strength. Bookings were up double digits organically and high teens overall against the very strong COVID bounce back quarter we saw in Q1 of fiscal '21 when bookings grew more than 30% over the prior year. To put it in perspective, given the tough comparison against Q1 of last year, we had planned bookings to actually be down slightly, inclusive of Arena. So this performance was more than 20% above plan. I know that some analysts and investors had voice concerned that the restructuring work we did in late Q4 and throughout Q1 would distract us, but obviously, we didn't see that. The strength was broad-based across direct sales and resellers and was achieved with no megadeals. Rockwell came in ahead of their part of our plan, too, which was great to see and suggest my concerns of them being distracted and may prove overstated. Arena contributed the inorganic element of bookings growth, with another strong bookings quarter, coming in above plan as well. With the Arena acquisition getting round tripped here in Q2, Arena becomes part of the organic results going forward and their low 20s growth rate will then add another tailwind to the organic results. Arena has been a great acquisition. Bookings growth was particularly strong in PLM, and in both Europe and Americas. From a macro perspective, global PMIs remain an expansion territory, while digital transformation and SaaS continue to grow in importance as secular drivers. The interest in digital transformation in SaaS has been driving strong bookings for what is very sticky software, which when layered into a recurring revenue model that is atypical of industry peers, has allowed PTC to deliver performance in excess of market growth rates. This happened right through the pandemic, especially in the large core business that represents about 70% of our ARR, and we fully expect it to continue going forward. These factors gave us confidence to raise the lower end of our ARR guidance range, which at the new midpoint basically means we've rolled our Q1 beat forward. Now let's take a look at the ARR performance by geography on Slide 5 before turning to business units. In Q1, we saw a strong ARR performance across all geographies. Our ARR growth in the Americas was 19%. All product segments grew with key growth drivers being the acquired Arena contribution and the velocity business unit overall, layered on top of another strong quarter in the core CAD and PLM business. In Europe, our ARR growth was 13%. We saw strong results across the board in Europe, with the strongest drivers of the growth being our digital thread growth and core businesses. Europe has the largest mix of channel versus direct and the resellers continue to perform well. Our ARR growth in APAC was 14%, with growth primarily driven by our digital thread core business. Next, let's take a look at the ARR performance of our various business units, starting with the digital thread group on Slide 6. In our largest product segment, digital thread core, we delivered yet another double-digit performance in Q1 with 11% growth. Within this, CAD and PLM, both grew double digits, with strong growth across all three geographies. This is the 17th consecutive quarter of double-digit ARR growth in the core business. And as we roll out our more aggressive SaaS strategy, I expect we'll see many more. In the digital thread growth, which is IoT and AR, we saw ARR growth of about 14%, consistent across both elements. This was in line with our plan and the mid-teens near-term growth expectation we set at the recent Investor Day. While this level of growth remains accretive to company growth, we continue to expect an acceleration of growth into the 20s as we get into the back half of the year. The biggest driver of growth in Q1 was from expansions, especially in Europe and APAC. We believe market conditions in IoT are improving, and we like the way the pipeline for our new DPM offering is developing through both PTC and Rockwell channels. For AR, we continue to see a tremendous level of interest, but the market remains nascent. Perhaps most importantly, the formation of the digital thread business unit at the start of FY '22 has driven important initiatives to increase our focus on cross-selling of IoT and AR into the core CAD and PLM customer base. FSG had a great Q1 with 6% ARR growth. The expansion deal we recently announced with the U.S. Air Force, both increases and extends this key relationship for up to five more years. Contracts like this demonstrate the value that our customers are realizing from Servigistics and other FSG products such as retail PLM and ALM. You may remember, I noted at our Investor Day that having FSG grow in the mid-single digits rather than flat would be a helpful upside growth driver. So I'm pleased to see FSG post another strong quarter. Let me run through a couple of quick customer anecdotes to give you a sense for our digital thread customers and how they rely on us. On Slide 7, MAN Energy Solutions is the world's top provider of large-bore engines in turbomachinery for the maritime and energy industries. The company manufactures complex parts in nearly every engine they make must meet unique customer requirements. Before implementing Creo, they relied on manual outdated processes that slowed design and production. With Creo, they've been able to transition from 2D to a full 3D model-based approach. Creo's broad range of tool path automation capabilities enable them to save time in the programming of the tool pass used to machine the large complex engine parts, greatly increasing efficiency in transitioning from design to production. Turning to Slide 8. You may have noticed we announced a deal with -- we announced that the German company, Scheffler, has expanded its relationship with PTC, and I'd like to share a bit of the back story. Scheffler has been a longtime Creo customer and has successfully deployed Windchill within engineering. But back in 2017, one of our PLM competitors announced a large PLM deal with Scheffler that appeared to cap PTC's expansion opportunity. But that system didn't ultimately stick as Scheffler has now decided to consolidate on PTC systems with Windchill being the backbone and is broadly deploying our solutions in their standard out-of-the-box fashion so that Scheffler can participate in the full power of our digital thread portfolio. I'm very excited about this collaboration and the further expansion that Scheffler is exploring with our IoT and AR offerings. On Slide 9, you'll see how IMA Group, our global business that delivers packaging machines, services, and solutions to a wide variety of industries, was looking for a way to expand their control room offering to help their customers improve overall equipment effectiveness and reduce downtime. As longtime users of PTC's Creo and Windchill, IMA decided that ThingWorx was the ideal IoT solution for their initiative and that Kepware could provide connectivity not only to their machines, but to the other vendors' machines deployed alongside them. IMA has successfully launched new revenue streams by enabling 24/7 monitoring of customer production lines and improved OEE by up to 16%. The Vuforia integrated with ThingWorx is the platform of choice for the U.S. Air Force training initiatives. Slide 10 highlights the work that PTC partner, Vectrona has done with the U.S. Air Force. With finite training resources and limited capacity, the U.S. Air Force set out to incorporate augmented reality into their maintenance and munitions training. Vectrona using Vuforia Studio worked with the U.S. Air Force to create immersive 3D AR experiences for phones, tablets, and the HoloLens 2 that are designed to accelerate learning, improve work performance and facilitate remote training. The improved training shows better engagement and information retention with continuous and repeatable task training available regardless of the system or aircraft type. Turning to Slide 11, the velocity business ARR growth in Q1 was more than 650% due to the inclusion of Arena and 53% organically, which would be Onshape. If you were to add Arena's pre-acquisition results into the prior year to get a better pro forma comparison, then you'd have the velocity business unit growing at 28% in Q1. That 28% is a mix of Onshape growing at 53% and the larger Arena business growing in the low 20s. Growth of both Onshape and Arena is multiple times higher than market rates, clearly demonstrating that industrial companies see the benefits of SaaS. We continue to ramp investments to expand technology leadership and to broaden the geographic presence of our velocity businesses. On Slide 12, Beta Technologies, a leading developer of next-generation electric aircraft for the cargo and logistics market, sought a cloud-native product development platform where everyone would be working with one single source of truth without the workflow restrictions of traditional file-based design systems. Beta turned to Onshape because of how it enables real-time collaboration, allowing the engineering team to work from any location while streamlining their communications during the design process. To profile Arena customer, Potrero Medical, on Slide 13, is a predictive health company developing the next generation of medical devices, leveraging smart sensors and artificial intelligence. Potrero needed a scalable quality management system to support its growing product development and compliance needs, including satisfying FDA audit requirements. Arena was the right solution, offering a cloud-native QMS with a quick implementation, leading to ECO cycle time reduction of 30% and nonconformance improvement of 20%. As a final topic, I'd like to give you a quick update on our SaaS acceleration initiative on Slide 14. We've made tremendous progress in the past 90 days since we announced the more aggressive strategy. We've launched our SaaS program management office, which was modeled after the very successful approach we used to drive our subscription transition several years back. Our field organizations transition to the new two-in-a-box customer success organization model without missing a beat. We converged our cloud and tech support organizations with product development to deploy the DevOps type of approach you see in virtually all SaaS companies. We've made good progress advancing our offerings, especially the Windchill multi-tenant version, which will go into production shortly this quarter, and we made good progress preparing the SaaS conversion offerings that will power the hundreds of lifts and shifts that will happen in the coming quarters and years. We have more work to do, but we're certainly up and running. The time for SaaS has arrived in our industry and PTC is very well positioned. We're already the SaaS leader in our space with continued strong SaaS growth in Windchill and FSG and high levels of growth in our cloud-native velocity business unit. Sharing the Atlas SaaS platform, we have a dual strategy to win with Onshape and Arena powering a new agile product development approach, while we transition our digital thread portfolio and existing customer base to SaaS to elevate the platform strategies that so many larger companies have. To wrap up on Slide 15, I'm pleased with PTC's position and the opportunity that lies ahead. Q1 gave us a strong start to what we expect to be our fifth consecutive year of double-digit ARR growth. Our portfolio of products is unique and compelling and obviously aligns well to customer demand. Our results have been consistently strong for many quarters, but we're poised to accelerate growth as the SaaS tailwind blows harder in coming quarters and as we gain more momentum with our IoT and AR initiatives in the back half of the year. We're poised to drive higher levels of profitability, too, following the organizational changes we've already implemented and as our start-up businesses continue to mature up their J curves. The company has never been in a better position to create shareholder value. With that, I'll turn it over to Kristian for more details on the financial results. Kristian Talvitie -- Chief Financial Officer Thanks, Jim, and good afternoon, everyone. Before I review our results, I'd like to note that I'll be discussing non-GAAP results and guidance, and growth rate references will be in both constant currency and as-reported rates. So turning to Slide 17, we delivered constant currency ARR of $1.507 billion, which is 16% growth year over year and slightly exceeded our Q1 guidance of $1.5 billion. On an organic constant currency basis, this is 11% growth. FX was an approximate $11 million headwind in Q1, so our as reported ARR was $1.496 billion. Our SaaS products in both the digital thread and velocity business units saw a continued strong growth in Q1, with growth rates similar to what we discussed at our recent Investor Day. This is in combination with continued strong growth of our software-only sales. As of Q1, our SaaS portfolio is now 15% of our total ARR on a constant currency basis. Q1 free cash flow of $134 million grew 21% year over year and includes $11 million in restructuring and other related payments. Adjusted free cash flow was $145 million and was slightly ahead of the $140 million we discussed at our Investor Day. Q1 revenue of $458 million increased 7% year over year. As we've discussed previously, revenue is impacted by ASC 606, so we do not believe that revenue growth rates are indicative of our underlying business performance but would rather guide you to ARR as the best metric to understand our top-line performance and cash collection. FX only impacted revenue by about $1 million in Q1. So our revenue on a constant currency basis was $459 million. Q1 non-GAAP operating margin of 35%, compared to 36% in Q1 of 2021. While this is a strong result, it's still worth pointing out that because revenue was impacted by ASC 606, other derivative metrics such as gross margin, operating margin, and EPS are all also impacted. Suffice it to say that our COGS and opex came in in line with our expectations in Q1, and we continue to maintain good discipline on our operating expense structure. I would like to point out that our GAAP results reflect a gain of $9.8 million related to our investment in Matterport. And we're also slightly reducing the range for expected P&L charges from approximately $45 million to $50 million, down to $40 million to $45 million for the full year. And coincidentally, we're also reducing the range of expected cash payments for the restructuring and other from what was previously $50 million to $55 million, down to $45 million to $50 million for the full year. For guidance purposes, we will continue to show $50 million as the cash payments and the adjusted free cash flow reconciliation. But as payments come in lower, then we would just expect actual free cash flow to come in higher. There's no change to the $450 million adjusted free cash flow target. Moving to Slide 18, I'll begin with our balance sheet. We ended Q1 with cash and cash equivalents of $296 million. In addition, at the end of Q1, we had medium-term investments of $87 million, primarily related to our investment in Matterport. Our gross debt was $1.45 billion with an aggregate interest rate of about 3.2%. In Q1, we used $120 million of cash to repurchase shares. We also had an additional $5 million of repurchases, which settled early in Q2. For the remainder of fiscal '22, we will focus on delevering and looking forward to FY '23 in an ongoing go-forward basis, assuming our debt-to-EBITDA ratio is below three times, we will continue to target to return approximately 50% of our free cash flow to shareholders via share repurchases. Turning to Slide 19. We post a data table to our IR website that has our financial statements, as well as ARR detail by segment. In that file, we share both constant currency and as-reported ARR. As a reminder, when we calculate constant currency, we use our current year plan FX rates and restate history to the same rates. So here, for example, on this slide, you can see our Q1 constant currency ARR of $1.507 billion and the actual as reported ARR of $1.496 billion. This is important to remember in the context of our guidance because we provide guidance at the planned rate. We believe this is the best way to evaluate the top-line performance of our business because it removes FX fluctuations from the analysis, positive or negative. With that, I'll move on to guidance on Slide 20. As Jim mentioned, we're raising the low end of our full year constant currency ARR guidance by $10 million. The new range is now $1.625 billion to $1.660 billion. This essentially reflects rolling our Q1 overperformance through the remainder of the year. We're now expecting constant currency ARR growth of 11% to 13% in fiscal '22. It's worth pointing out that based on FX rates at the end of Q1, we would expect a $13 million headwind against that full year ARR guidance. For Q2, we're setting constant currency ARR guidance of $1.540 billion to $1.550 billion. This is 12% organic constant currency growth at the midpoint. On an as-reported basis, the FX impact we're calculating based on the FX rates at the end of Q1 is a $12 million headwind in Q2 compared to the constant currency guidance. Moving to free cash flow. We're maintaining our full year free cash flow target of $400 million. This includes approximately $50 million of restructuring and acquisition-related payments. The majority of these payments are related to the reorganization we announced in Q1 with some residual payments primarily related to our Seaport move for which we took the accounting charge in prior periods. So our adjusted free cash flow target for fiscal '22 remains $450 million. Fiscal Q2 adjusted free cash flow is expected to be approximately $155 million. We expect to make approximately $20 million in restructuring and other related payments in Q2, bringing our free cash flow to approximately $135 million. Moving to revenue. We're also taking the low end of the full year revenue guidance up by $20 million. This reflects both the strength in software and strength in the professional services business that we saw in Q1 and the related forecasts for the full year. So for fiscal '22, our net revenue guidance range is $1.870 billion to $1.975 billion. The year-over-year growth rate range is now 3% to 9%. Our ASC 606 makes revenue very difficult to predict for on-premise subscription companies, hence the wide range. Note that revenue variability has -- this is from 606, has no impact on ARR or its related cash generation as we continue to primarily bill customers annually upfront regardless of term length. We continue to expect more than 60% of our annual free cash flow generation to occur in the first half of the year. Collections are stronger in the first half, and we expect expenses to increase as we ramp hiring in our SaaS investments throughout the year. We're wrapping up on Slide 21 with the free cash flow model that we use and went into some depth on at our recent Investor Day that you can see here. I know many of you use model free cash flow using the indirect method. However, given the complexities related to revenue recognition due to 606, this is difficult to do. The model we show here has proven quite effective. The table shows fiscal '21 actuals compared to the model we shared at Investor Day compared to our current guidance. Let me take you through the model focusing on the non-GAAP column on the right and starting at the top. First, we're showing the midpoint of our as reported ARR guidance of $1.630 billion, which is different from the constant currency guidance that we gave due to the $13 million FX headwind and is also $5 million lower than what we showed at the Investor Day. We use it as reported here because it's a better reflection of the cash we expect to generate. You can also see that we have increased the perpetual license revenue forecast slightly and also the professional services revenue increase that we mentioned earlier. COGS is slightly higher, reflecting the increased costs to deliver the incremental professional services revenue and the rest of the assumptions remain the same, and we still end up with our target adjusted free cash flow of $450 million. Obviously, this is a model based on assumptions such as the midpoint of the ARR range, the impact of FX, the pace of hiring, etc. So if some of those variables change, which they invariably will, the model will have to be adjusted accordingly. And as I mentioned earlier, if cash payments related to the restructuring coming at the low end of the range, we would see a flip from the restructuring line to the free cash flow line, but the adjusted free cash flow target would remain unchanged. But as we sit here today, we think this is a reasonable view of how we expect the year to shape up. So with that, I'll turn the call over to the operator, and we can begin Q&A. Questions & Answers: Your first question will come from Andrew Obin from Bank of America. Please go ahead. Your line is open. Andrew Obin -- Bank of America Merrill Lynch -- Analyst Hi, yes. Good afternoon. Jim Heppelmann -- Chief Executive Officer Hello, Andrew. Andrew Obin -- Bank of America Merrill Lynch -- Analyst Just a bigger picture question. I apologize, I missed the first couple of minutes. You know, we hear a lot about supply chain constraints. And frankly, we're hearing that this might extend the run-in terms of PMI expansion. So what are you hearing in terms of sort of as you have conversations about PLM and in terms of adoption? What kind of conversations are you having with your customers? And do customers have awareness of sort of supply chains being gummed up for longer? And are you seeing this having any discernible impact on what kind of conversations you're having with people? Jim Heppelmann -- Chief Executive Officer Andrew, it's Jim. No, actually, it's not really a frequent topic in our conversations because -- well, first of all, since you said you missed the first minute, one of the things I pointed out is that our bookings came in very, very strong, and I explained about 20% higher than planned. So we had a very, very strong bookings quarter. And notable in that was PLM, although, frankly, the strength was broad-based. I think the key thing to remember is that PLM is really associated with preparing product data in engineering that will then subsequently be used in manufacturing and perhaps in aftermarket service. And it's collecting data from supply chain partners and so forth. But production problems in a supply chain don't necessarily impede the collaboration during the engineering and the preparation for production process. So I think people are saying like, maybe I can't get chips to complete the product, but that doesn't mean I should stop designing the next one because if it does, then I'll fall behind. So I think that our view would be that the product development process has largely been unaffected by the supply chain process. Now some other things, we talked about how perhaps COVID had an impact on IoT, perhaps the supply chain a little bit, although I think muted compared to COVID. So to me, the supply chain thing is a fairly small factor in our results. We just see very little correlation between what's happening out there with supply chain problems and what's happening with our pipeline and frankly, with our bookings. Jim Heppelmann -- Chief Executive Officer Hey, Yun. Yun Kim -- Loop Capital -- Analyst Thank you. Hi, Jim. Can you just talk about the IoT business, you know, in terms of the large deal activity? What kind of trends are you seeing there? Obviously, you are expecting that business to accelerate in the back half -- second half of the year. If you can talk about whether that confidence is coming from the, you know, improvement in the large deal activity? Or is it just the overall volume of the activity around IoT? And then also, if you can just comment around deal size activity around the AR business as well. Thanks. Jim Heppelmann -- Chief Executive Officer Yeah. I think deal sizes are sort of unchanged from previous trends. If you think -- what are we looking at when we project forward how IoT and AR will perform. Well, we're looking at the bookings, let me say, at the pipeline that will drive bookings, and for IoT and AR was quite strong. We're looking at the backlog. Last year, bookings actually had improved over the prior year. And bookings that went into backlog or -- I'm sorry, what we call deferred ARR, were quite high. We were well ahead of our deferred planned number as we actually did last year. So you could imagine we've got more, and if you want to call it, backlog waiting for us. And then what other initiatives are we doing? So for example, our DPM launch, I think, will be materially positive for our IoT results. It will drive bigger deals. It will drive better value propositions. It's really software that's ready to turn on and get value from as opposed to a platform. And then the other thing is, Troy Richardson talked at our Investor Day about organizing better for cross-sell. And I think if we look backwards, maybe we had pivoted too much toward new logos, which are great. I mean, new logos are a wonderful thing. But we probably have low-hanging fruit yet to pick within our installed base of CAD and PLM accounts. So I think it's really this combination of a strong-looking pipeline, good-looking trends, awaiting us in the deferred backlog and then these other initiatives kicking into place, DPM and cross-sell that I think will all be very helpful as we proceed through the year. And again, I want to remind everybody, we set the expectation that the two handle would materialize in the back half of the year and that you wouldn't see it in Q1 and Q2. So we sort of feel like this was as we had predicted just mid-December a couple of weeks ago. Jason Celino -- KeyBanc Capital Markets -- Analyst Hey. Hi, Jim. Hi, Kristian. Jim Heppelmann -- Chief Executive Officer Hi, Jason. Jason Celino -- KeyBanc Capital Markets -- Analyst So one question on maybe the SaaS Windchill, you know, launch. It seems like it's coming along, you know, nicely, and we could see something maybe go GA this quarter. Have you had a chance to maybe, you know, discuss this with customers? How is the pipeline shaping? Or is it maybe better to think that the pipeline might start to form once we do go live? Jim Heppelmann -- Chief Executive Officer No, we have, for sure, started talking about it with customers. I mean, ramping up that process. We've got to educate a lot of people and they, in turn, have to educate customers. But we've certainly made some progress, and I can tell you the customer interest is actually quite high. You should know that actually, customers were pushing us a little bit to get going with such initiatives -- so I feel like the demand is there. And in fact, again, just reflecting on what we told you, that business has been growing about 30%. And Kristian mentioned we posted another quarter just like that, without us really invoking the new strategy yet. So there's lots of demand. We're just looking for a model where we can promote the demand because we like the margin profile better. And that's what's coming into place here in Q2. Adam Borg -- Stifel Financial Corp. -- Analyst Great. Thanks so much. And maybe just two quick ones. Just on the Scheffler win that you announced yesterday and highlighted on the call earlier. One of the things I thought was really interesting in the press release was this opportunity around some more vertical-specific or market-specific solutions targeting either automotive or industrial companies. So maybe, Jim, if you could just talk about that. And maybe just as a quick follow-up, just maybe for Kristian. Any way you could talk about this transition, it's great to get the early feedback on the SaaSification efforts, but any way to comment on, you know, how much this has contributed to bookings or the pipeline, at least qualitatively? Thanks so much. Jim Heppelmann -- Chief Executive Officer Yeah. I'll get the first part of the question. Kristian, you can take the second part. Yeah. So Scheffler is a great account. And as I mentioned back in 2017, it appeared they were going in a different direction, and now they've decided to come back into the fold. And honestly, they did that for two main reasons. One is that they really want off-the-shelf technology. The other competitor had told them this low-code, no-code story, and they tried that out and decided that's not really what they want. They don't want to develop their own solutions. They want to deploy standard out-of-the-box software that all works together. And then they want to engage in partnerships with the vendor, in this case, PTC to talk about how those solutions should evolve to be more and more powerful to meet their needs. So yeah, I'm very excited. I'm in the middle of that relationship myself. And yes, what's going to come out of that is technology that fits better and better, for example, for the automotive supply chain, which is a place where we have a lot of customers. So it's a great win or win back, maybe I should say, and a great partnership going forward that's going to produce a lot more business for us in years to come. And sorry, the second part of the question was around the transition to SaaS and how that's manifesting itself in terms of pipeline and activity? Is that right, just making sure I got that right. Adam Borg -- Stifel Financial Corp. -- Analyst Exactly. Any way to qualitatively comment from, you know, either bookings or a pipeline perspective? Jim Heppelmann -- Chief Executive Officer Yeah. Well, remember, I mean, the bookings that we just reported were for Q1, and Q1 is really when we actually just announced the acceleration of it. So I would say there's actually a limited impact in the actual bookings result here in Q1. That said, as I mentioned, we continue to see strong demand for the SaaS properties that we have. That's both in velocity and the digital thread. And so those products continue to grow at a rate higher than our software-only products. And now as the program is pushing ahead, we expect to see demand and pipeline generate, especially with the new Windchill launch coming out here and the program continuing to pick up speed internally. Kristian Talvitie -- Chief Financial Officer Maybe, Adam, I could just add. We launched this phase 3 strategy 90 days ago on the earnings call. And there's nothing we've seen since that makes us any less bullish than we were back then. I mean it looks like a really nice opportunity for PTC, and we're pushing forward ahead as aggressively as we can because we'd like to bring that very promising upside growth driver, you know, closer in. So it has a bigger impact on '23 and '24 and so forth than it would otherwise have had. Jay Vleeschhouwer -- Griffin Securities -- Analyst Thank you. Hello. Hi, Jim. Hi, Kristian. A couple of things. With regard to the strength you noted for PLM, at your partner conference six months ago, back in the summer, management presented to the channel, your concept that PLM was no longer just an engineering vault that it was becoming memorial, what you call, multisystem, multidiscipline concept. And the question is, to what extent is that broader, more diverse view of PLM a current part of new business or in the pipeline for new business as compared to the more conventional historical way of thinking about PLM? By our calculation, we are already the second-largest brand by revenue in PLM, and maybe talk about what some of the drivers are to that? And then just a quick clarification you referred earlier to cross-sell. At the Analyst Meeting last month, in the slide deck, you referred to cross-sell 10 times and relatedly account-based selling. PTC is often over the years, talked about cross-sell, but maybe talk about what's different this time in terms of resources and programs across your various segments and your new customer segmentation model. Jim Heppelmann -- Chief Executive Officer Yeah. Well, on your first question, Jay, you know, you are always very pressy on, you've been watching this industry for a long time. When we say multisystem, multidiscipline, what we're really talking about is an enterprise system. And so what's happened in the last couple of years is PLM has graduated from being an engineering data management system to being an enterprise system that contains the system of record for the product definition. And so if you're in manufacturing, well, you need to know the product definition. If you're in procurement, you need to know the product definition. If you're all on an installation or a support call, you probably need to know the product definition. So definitely what's happened is that the enterprise deployments of Windchill are multiple times larger than the engineering deployments of Windchill. So something that's been driving growth for some years now is that the new deals we're taking are more and more frequently enterprise deals and they're larger. You may remember, last quarter, I told you we took the largest deal we had taken to date from a med device company. And the second thing that's happening is, we're circling back to those companies who had deployed the engineering solution like say, Scheffler, and we're upselling them to the enterprise solution and turning that into a much bigger opportunity for us. So definitely, that's a real thing, and it's been driving the momentum we've seen in Windchill for years. And frankly, there's a lot of it out ahead of us even before we start talking about SaaS. The upsell from a departmental solution to an enterprise solution is a driver, taking that whole enterprise solution to SaaS is a whole another growth driver that's on top of that and sort of orthogonal to it. And then on the account-based selling, there's two ways to look at that. Cross-selling into your accounts is a great thing. You have established relationships. It's much easier to sell another product to an existing customer than to sell a new product to a new customer or a first product to a new customer. At the same time, we like new logos. So it's really always about the balance of how much do you invest in new logos pursuits versus how much do you invest in selling more to the companies who know and trust you. And I think perhaps with IoT and AR, we realized we had over pivoted toward new logo, which is just generally speaking, less productive selling, you might imagine. And so the reason we formed this digital thread group, which brought CAD and PLM and IoT and AR together under Troy Richardson, was to really lubricate how these products work together and how we position them together and to be able to start anywhere and sell up and down that chain. So it's a good strategy. It's one that we -- it's a muscle we've developed well over the years. We really built the Windchill business, largely by cross-selling to the Creo base. And I think this is going to be something that will help us a lot to kind of get the right balance of new logo pursuits in cross-sell. Ken Wong -- Guggenheim Securities -- Analyst Thank you so much for taking my question. Jim or Kristian, I wanted to perhaps dive into the double-digit organic bookings growth. You know, I couldn't help and notice you guys also had a very large Servigistics expansion deal with the Air Force. I mean how much of that was already in expectations? Or did you get some boost there from timing shifts or anything of that nature? Jim Heppelmann -- Chief Executive Officer Yeah. Let me tell you, none of that actually contributed to the double-digit growth because that was a Q4 deal. You know, we released it when we had approval to release it, and I commented on it because it was, you know, an important customer and so forth. And let me say that deal, again, that was closed in Q4, both represented five years of extension, but also about a 50% growth in a ramp that happens over -- I think it's three years. So it roughly goes from a $10 million run rate to a $15 million run rate over three years and stays there for a couple more. That's what the contract contemplates. So some of that will come into ARR in Q4 of this year, but the bookings actually were in Q4 last year. So that strength -- the strength we saw in Q1 was exclusive of that Air Force deal, which just means it was really great strength. So anyway, it was hard to pin down where the strength comes from because it came from CAD. It came from PLM. The IoT number was actually pretty decent. It didn't all go into ARR. And then, of course, the velocity numbers and the FSG numbers. So it was broad-based in all geographies and really in all product lines. Jim Heppelmann -- Chief Executive Officer Hello, Matt. Matt Broome -- Mizuho Securities -- Analyst Thanks, man. So Jim, I mean, I guess, just on that -- sorry, just deal that I can just mention. Given the importance of supply chain management right now, are you seeing like ramping demand to the solution elsewhere? And sort of following on from that, is there a chance that FSG ARR could actually accelerate on the back of that demand beyond the sort of the mid-single-digit level and actually become sort of more strategic in a way? Jim Heppelmann -- Chief Executive Officer Yeah. I mean that's one of the points, Matt, that I brought up at the recent Investor Day is that we've generally modeled FSG to be roughly flat, flat about plus 1% to 2%. But it's actually been performing. I think last year, Kristian, wasn't up 7%, FSG. It was up 6% here again in Q1. So yes, we're overperforming and Servigistics is one of the key drivers. And then the second one probably is retail PLM, which has also been doing fairly well. So definitely, there's some -- I think we'll be conservative and leave the FSG sort of guidance where it is in the near term, but I do like overperforming it because it's a growth driver. The FSG business is about the same size as the IoT and AR business. So every point of growth we get there is pretty meaningful. Matt Swanson -- RBC Capital Markets -- Analyst Yeah. Thanks. This is Matt Swanson on for Matt. I'll kind of follow up on a piece of both Adam and Jay's questions. So looking at the Scheffler announcement, I think the thing I was really interested in was the idea around standardization and the idea around end-to-end. So could you talk a little bit about your customers' desire around standardization? And clearly, this product road map has really expanded your TAM, but I think one of the upside areas something we -- you know, maybe the holy grail of the transition would be more competitive displacements. And I'm just curious if you're starting to hear, you know, any early or more talk around that because you're building something so differentiated. Jim Heppelmann -- Chief Executive Officer Yeah. I mean, for sure. So the standard thing, I think maybe over the last couple of years, industrial companies have realized that they should be using software, not developing it. And so we saw this in our IoT business, and it's been why we've been heading up the stack with solutions like DPM is, customers would like to buy the software and use it, not buy some kind of a platform and create it because they just don't really know how to create it if I'm frank. So Scheffler had gone down the path of kind of like I said, low-code sort of environments and came back to standard products. And then the end-to-end thing, for sure, the CAD data that's created in Creo and managed in Windchill gets used, for example, in augmented reality, manufacturing, and service instructions much later and in a different part of the company if it's all well managed. And that connectivity from IoT, well, let's say, from CAD to PLM to IoT to AR is what we call the digital thread. And so we actually see so much interest in this that we kind of organized around that principle. Let's stop presenting these products as kind of independent things and let's shine the light on how well they work together in an end-to-end solution. And by the way, how they're all ready to go. That this is something that turn on and use. And that's really what one Scheffler over, but I can tell you, Scheffler is not unique at all. And it's really -- we're organizing to respond to that. SaaS is helpful, by the way, because if you want a lot of technology working end to end, it'd be better not to ship at all to the customer side because it gets complicated. The customer would like to just use it, not set it all up and care and feed for it on-premise. Saket Kalia -- Barclays -- Analyst OK, great. Hey, guys. Thanks for taking my question here. Hi, Jim. Hey, Jim, maybe -- hey, Kristian. Jim, maybe for you, it was great to hear the PLM strength this quarter in bookings. With other companies that have done shifts like this, there's always a risk, I guess, of customers behaving differently, right, whether that's slowing purchases to see what's coming or maybe pulling forward purchases before something new comes out. Now just to be clear, it doesn't sound like that happened here. But can you just stress test that for us a little bit? And what you sort of look at to sort of manage what is, you know, more choices for our customer to make. Does that make sense? Jim Heppelmann -- Chief Executive Officer Yeah. Are you referring -- just let me clarify, are you referring to like SaaS choices being new choices or more broad -- Saket Kalia -- Barclays -- Analyst Yeah, that's right, yeah, Windchill. No, Windchill specifically. Jim Heppelmann -- Chief Executive Officer Yeah. So keep in mind, Saket, we have been selling Windchill as SaaS for some time. Remember, the phase 1, phase 2, phase 3 thing. So since phase 1, we've been selling Windchill, and we showed you, it's got a three-year growth CAGR of 30% in SaaS. So the customer demand is strong. It's just -- on the PTC side, we need to pivot to multi-tenant because in the single-tenant model we just don't have the profitability we like. So the demand is strong. The customers are buying it. Kristian mentioned we had another strong quarter. So it really is, we'd like to meet that demand with a solution that's more efficient for us to operate on behalf of the customer. And that's what phase 3 multitenant really is all about. Now when it becomes more efficient for us, we can then lean in on the promotion and marketing of it, because we haven't really done that. So we've been servicing demand, not driving it. And with phase 3, we think there's an opportunity to drive demand and, you know, the preliminary data we've seen this quarter suggest customers are very responsive, both to buying new systems that way, but also to lifting and shifting the previous systems they bought and giving them to us to operate and serve back to them in a SaaS model. Joe Vruwink -- Robert W. Baird and Company Great. Hi, everyone. Just to go back to bookings, does the strength this quarter absent mega deals suggest anything about either the demand environments or maybe just the health of your mid-market and SMB customers? And looking ahead, are there going to be certain things you think about or track when contemplating, you know, the probability of more mega deals or maybe the larger ARR contributors for PTC, maybe, you know, being a bit more represented in future bookings? Jim Heppelmann -- Chief Executive Officer Kristian, let me again take a stab at that and maybe you'll find things to add. So I think if you look at the bookings, again, they were phenomenal, and it's hard to pin down. It wasn't one geography. It wasn't one product. It was all geographies, all products. So I think it tells us that the end market is very healthy. And I would say, for two different reasons. On one hand, the PMIs are in good shape. That's helpful. On the other hand, the interest they have in the digital thread, digital transformation story, and the interest they have in SaaS is secular. That interest is not related to the PMIs, it's kind of independent of them. And so I think that we're just in a very healthy situation where industrial companies are leaning in on trying to get more digital. They see PTC as having a fairly unique and compelling portfolio, and they're interested in engaging and trying to make their companies more efficient. I can tell you, at Scheffler, for example, it's one of the top initiatives in the company is to get more digital. And as it relates to the whole product life cycle, the partners PTC. And we see that kind of phenomenon happening in a lot of places in the industrial world. So I think it's just good, strong, secular and as well macro-environment out there right now. But I'll remind you that we've had good performance even when the macro environment wasn't so strong. So all things being equal, I like the strong macro. But we're 17 quarters in with double-digit growth in the core business, and there were a lot of bad macro quarters over the course of those 17. So I think it really is the secular driver. Kristian, anything? Kristian Talvitie -- Chief Financial Officer Yeah. I mean I agree with all that. I mean, actually, just on the big deal dynamic, you know, what we used to call mega deals. We haven't -- I think we've had four in the past four years. Jim Heppelmann -- Chief Executive Officer Yeah. Well, keep in mind, perpetual drove bigger upfront purchases and subscription or SaaS tends not to. Kristian Talvitie -- Chief Financial Officer Yeah, which is my point that we've been seeing good strong bookings performance and bookings growth, you know, even with the absence of what used to be a fairly regular occurrence back in the perpetual days, like we really don't see a lot of those. Jim Heppelmann -- Chief Executive Officer Yeah, it's a good healthy business. OK. Next question. Blair Abernethy -- Rosenblatt Securities -- Analyst Thanks very much. Guys, just maybe a quick question on -- around partnerships, in particular. I wonder if you could just give us a little deeper dive into how things are going with Rockwell and as well on the simulation side with Ansys? Jim Heppelmann -- Chief Executive Officer Yeah. So the state of the partner economy is good and, you know, Microsoft, I could put on that list, is also strong. With Rockwell, you'll remember in the past quarters, I had said we should take a bit of a conservative posture as it relates to what Rockwell would contribute to PTC's numbers here in fiscal '22. And we did that because Rockwell had made a big acquisition. You know, Rockwell never completely agreed with me on that. Their own public commentary kind of indicated they didn't worry too much about that. And in Q1, they were right. So we're pleased to see that Rockwell's contribution was solid in Q1 and starting to feel pretty good about the year. I'll tell you one thing is this DPM solution appears to be a very good fit with Rockwell. And in fact, their Calypso alarm is probably lined up to be our strongest partner in promoting DPM. So we're very happy with that. Calypso has a long-term relationship with PTC that even predates their acquisition by Rockwell. So great alignment around DPM. Again, DPM is a high-value up-to-stack solution that drives bigger deal sizes, and we think will be a very sticky solution. So lots of optimism around that. With Ansys, we continue to differentiate now with best-in-class simulation. So whereas simulation some years back would have been viewed as a soft spot for PTC. Now it's a strength. If we're competing against Autodesk or Siemens or Dassault, nobody is going to have a better simulation story than PTC because nobody has a better simulation story than Ansys, and Ansys products are built into PTC products. So that's been going well. And then, of course, with Microsoft, that partnership is performing well and poised to get a lot bigger because as we bring more stuff aggressively to SaaS, a whole lot of that is going to land on Azure. So I think all three partnerships are alive and well and as important as ever and helping us achieve the kind of results that we're achieving. Sterling Auty -- J.P. Morgan -- Analyst Yeah. Thanks. Hi, guys. Just wondering if you could characterize with the headcount changes that you pointed out are necessary to facilitate the acceleration to SaaS. Where are you in that process? What's left to go? And kind of what's the time frame that you expect to complete that over? Jim Heppelmann -- Chief Executive Officer Yeah, Kristian, I'm thinking of the numbers we're largely done, but not completely. Eighty percent, 90% done. Kristian Talvitie -- Chief Financial Officer Yep, with the exiting. Jim Heppelmann -- Chief Executive Officer Yeah. I mean we'll be hiring people throughout the year. So -- but in terms of the people who are exiting, they're largely exited by now that largely happened within the first quarter. Sterling Auty -- J.P. Morgan -- Analyst Understood. Thank you. Jim Heppelmann -- Chief Executive Officer OK. Well, thank you, all. There's a lot of good questions and, you know, I think good answers because the business is performing very well right now. ARR is doing well. Bookings are doing well. Free cash flow is doing well. You know, I think we executed -- through good times and bad, we executed through the changes we made over the last quarter, and we're set up to do pretty well for the balance of the year. So, we're very confident and, you know, look forward to talking to you all in 90 days if we don't happen to cross pass with you sooner in an investor event or what have you. So, thanks a lot for joining us and have a good evening. Kristian Talvitie -- Chief Financial Officer Thanks, everyone. Duration: 59 minutes Call participants: Matthew Shimao -- Head of Investor Relations Jim Heppelmann -- Chief Executive Officer Kristian Talvitie -- Chief Financial Officer Andrew Obin -- Bank of America Merrill Lynch -- Analyst Yun Kim -- Loop Capital -- Analyst Jason Celino -- KeyBanc Capital Markets -- Analyst Adam Borg -- Stifel Financial Corp. -- Analyst Jay Vleeschhouwer -- Griffin Securities -- Analyst Ken Wong -- Guggenheim Securities -- Analyst Matt Broome -- Mizuho Securities -- Analyst Matt Swanson -- RBC Capital Markets -- Analyst Saket Kalia -- Barclays -- Analyst Joe Vruwink -- Robert W. Baird and Company Blair Abernethy -- Rosenblatt Securities -- Analyst Sterling Auty -- J.P. Morgan -- Analyst More PTC analysis All earnings call transcripts\",\n          \"[Operator Instructions] Now I would like to turn this call over to Mr. Adolfo Castro, Chief Executive Officer. Please go ahead, sir. Adolfo Castro Rivas -- Chief Executive Officer Thank you Kathy and good morning everyone. Thank you for joining us on the conference call to discuss ASUR's first quarter financial and operating results. Before starting the call, I would like to express my hope that you and your families are healthy and safe in these uncertain times. As a reminder, please note that certain statements made during the course of our discussion today may constitute forward-looking statements which are based on our current management expectations and beliefs and are subject to a number of risk and uncertainties that could cause active results to differ materially, including factors that may be beyond our company's control including the impact from COVID-19. For an explanation of these risks, please refer to our filings with the US Securities and Exchange Commission and the Mexican Stock Exchange. Overall, our first quarter results were good. The year began in solid footing before we started to see the impact of COVID-19 pandemic in the second half of March. It resulted in the disruption of global travel industry. Importantly, in the end of the first quarter we had healthy balance sheet which I will come back and discuss in more detail later in my presentation. I'm going to start today's presentation with some comments regarding COVID-19 and the impact on the industry, on our business, and the steps we are taking to mitigate this disruption to the best we can in this rapidly changing environment. From an industry perspective, since mid-March, many governments have issued flight restrictions in an effort to mitigate the spread of COVID-19 virus. In turn, capacity has been severely reduced and very few people are booking flights as most are in some form in lock down around the world and not traveling. With respect to our airports, the situation varies by country and could be subject to change depending upon how fast or slow the pandemic is brought under control. Colombia has been the most active and we've suspended operations at all six of our airports since the third week of March with domestic flights suspended until April 27 in accordance with the published decree and most recently extended to up to May 11. International travels have been suspended through May 13. By contrast, in our airports in Puerto Rico and Mexico remain open, although there's significant reduced flights and passenger traffic. As a result, total passenger traffic declined sharply in the second half of March, down nearly 69% year over year between March 16 and March 31. By country, we show the margin decline in Colombia around 77%, followed by Puerto Rico down 73% and Mexico with 63% decrease [Indecipherable]. Additionally starting in mid-March, some of the airlines as well as some tenants that operate in our airports began asking for assistance either through discounts on payments owed to ASUR or by extension by payment which resulted in a higher accounts receivables in March in Mexico and Colombia, up 54% and 78% year-over-year. We are having ongoing commercial discussions with these companies with respect to their contracts. Moving next to action we have taken, starting with health and safety. Following the guidelines of relevant health agencies, we have implemented health and safety protocols for both our airport employees and passengers travelling through our airports. For example, protective gear such as wearing masks is required for airport staff. We have also stepped up disinfectants and sanitization practices, once again in accordance with the guidelines of local health authorities. Lastly, where possible, we have also implemented remote working points. Moving next to ensuring continuity of our business. We have introduced cost reduction initiatives across our airports. The impact of these initiatives however is not expected to be significant vis-a-vis the potential decline in passenger traffic at the majority of the cost structure is different, except for concession fees and technical assistance in Mexico which are biannual cost. We are prepared to take additional step, if needed, to respond to the evolving business environment. Now, let me talk about our financial situation. We entered this quarter in a position of strength with strong liquidity and very low principal payments required through year end. Additionally we believe the company has sufficient liquidity to meet its obligations and continue operating in the normal course of business. Our cash position ended at MXN7.8 billion which was up from MXN6.2 billion at the year-end 2019. And subsequent to the quarter end, as we further strengthen our financial positions as our subsidiary in Puerto Rico drew down an additional $10 million of its committed line of credit. The line of credit [Indecipherable] support for the capex projects we have under construction, Apelian airport in Puerto Rico. We closed the quarter with total debt of MXN15.3 billion. Although 11% high than the year-end 2019, this was due to the conversion effect from the depreciation of the peso to the dollar. As a reminder, the majority of our debt, 54% is denominated in the US dollars which is at our subsidiary in Puerto Rico. 26% of total debt was denominated in Mexican pesos and 20% in Colombian pesos. We have principal payments of only MXN432 million coming due over the next three quarters. This represents less than 3% of ASUR's total debt. With respect to that ratios, net debt to last 12 months EBITDA stood at 0.7 times at the close of first quarter '20. You can see the interest coverage ratio by country in the table we have included in the annual release this quarter. Now, stepping back for more, since we began operations over 20 years ago, we have successfully navigated through many very significant challenges. From the 9/11 event in 2001 to [Indecipherable] into 2005 and 2008 and 2009 business financial crisis, H1 and H2 and the bankruptcy of 50% of airlines in Mexico which cut planes capacity in Mexico by more than half. Following each of these events, passenger traffic recovered, although recovery time varied from 13 months to 26 months and then continued to grow. Between 2000 and 2019, annual passenger traffic increased the compound annual growth rate of 6.6%, up from slightly over 10 million to historical high to over 34 million last January. We believe the COVID-19 pandemic is unique in that sense it is global event and with a broad disruption in travel and economies worldwide and could change the way of travelling in the future while a vaccine or a cure is found. Summing up this section, we have a strong balance sheet, we have generated years of consistent profitability and we exercise prudent capital management. In the sense we believe that we cannot be very prepared for an event of this magnitude, but of course given its great uncertainty on the final effects in the worldwide economy and that travel will be [Indecipherable]. Now turning to our first quarter results, more details can be found in the press release issued last evening. Like I mentioned this part of my presentation, let me spend with the effects of the business in late March. We believe we had solid results in the first quarter 2020. Total passenger traffic was down in most of the airports, which leads to a total passenger decrease of slightly 6% YoverY. This was primarily due to the fallout from COVID-19 and the impact of the global travel industry beginning in the second half of March. Our airports in all three countries experienced total passengers decline from a low of nearly 3% in Colombia to a high 8% in Mexico. Puerto Rico passenger traffic was down 4%. All three countries reported declines in both domestic and international traffic. Moving next to the P&L highlights, revenues ex construction were relatively unchanged at 4% increase in revenues from non-aeronautical services was offset by a 3% decline in aeronautical revenues. Commercial revenues per passenger increased 11% year over year, reaching MXN116.3. This was driven by solid performance across the region. Mexico posted a good performance with an increase of 11% on a per passenger basis benefiting from the currency peso devaluation and regulated revenues. Puerto Rico posted 7% increase per passenger benefiting from peso depreciation and finally Colombia saw a 33% increase on a per passenger basis, reflecting the 43 new stores opened over the last year and currency depreciation. The main drivers were ground transportation and car rentals. Moving on to profitability, reported consolidated EBITDA increased 3% from the same period over the prior year. Both periods benefited from insurance recoveries related to the Hurricane Maria. In the first quarter '20, it amounted nearly MXN124 million while last year the amount was dragging over MXN41 million. Excluding these recoveries, consolidated EBITDA was essentially flat year-over-year at MXN2.7 billion. Ex-IFRIC 12 and without taking into account insurance recoveries in both quarters, adjusted EBITDA margin increased 20 basis points to 66.7% this quarter. A few comments about capital allocation. Capital expenditures were MXN353 million in the quarter. Of these, nearly MXN58 million was allocated in Mexico due to the terminal expansion of Merida airport. For the full year, and as we have discussed before, our non-prevalent plan in Mexico calls for investment of approximately MXN5.3 billion for the full year. At the current time, there are no changes to the planned continuation of the foreigners tax relief of the second one we have at Cancun airport and the beginning of the first expansion at the Merida. Our plans call for a conclusion of Phase 1 of the Merida terminal expansion and typically the second phase this year. Nevertheless, due to the COVID-19 health crisis, you may see some disruption in the construction process, attributable to stay-at-home, the combination and we have informed the government about this situation. In Puerto Rico we have made investments of MXN114 million this quarter, mainly from the connection with some major maintenance referred tax relief. Finally, capex in Colombia amounted to MXN1 million related to maintenance. Last year we concluded our committed capex was at MXN20 million. And going forward, we only expect to incur a major maintenance capex in Colombia. Next, our Annual General Meeting from yesterday, shareholders approved an ordinary net cash dividend of MXN8.1 per share to be paid, subject to the Board's approval on or after May 11, 2021 in a single installment. In conclusion, we are proactively responding to the developing situation. No one can control the virus or even the economic fallout. But we can control how we react to the crisis. I am optimistic about the prospects for the future both navigating through the current crisis and in the long term recovery. I believe that we are well positioned with a healthy balance sheet. We had a solid first quarter results. We believe in the strategies that we are executing. This ends my prepared remarks. Kathy, please open the lines for questions. We'll go first to Alejandro Zamacona of Credit Suisse. Alejandro Zamacona -- Credit Suisse -- Analyst Thank you Adolfo, thanks for the call. Two questions from our side. The first one is on the aeronautical maximum tariff. So, considering that airlines have been negotiating with most of airports and in some cases some fees have not been charging. What could we expect for maximum tariffs in the short-term meaning the second quarter and in the immediate term, meaning year end 2020? Could we still expect tariffs to be close to the maximum level? Adolfo Castro Rivas -- Chief Executive Officer Alejandro, hi, good morning. Well, basically what we are seeing today is a very reduced demand. So we believe that there is no effect if we try to reduce our fees for the month of April or the month of May. So we have maintained our tariffs and we believe that we can comply with -- we have to maintain compliance toward the year end. Alejandro Zamacona -- Credit Suisse -- Analyst Okay, thank you. And my second question is on the non-aeronautical business. Same thing in the same context, what could we expect in the short term for commercial revenues per passenger? Have you grant any rent payments facility to payments or any deferrals? Thank you. Adolfo Castro Rivas -- Chief Executive Officer Most of our contracts, as you may know, they have to pay higher of the minimum guarantee payment per passenger or a percentage of sales. So if we do not have passengers, we will not have to pay rent. So it's made automatically. So in that sense, we are not reducing or adjusting the contracts. Alejandro Zamacona -- Credit Suisse -- Analyst Okay, thank you Adolfo. Adolfo Castro Rivas -- Chief Executive Officer You're welcome. Fernando Sanchez -- Bradesco BBI -- Analyst Hi, good morning and thanks for taking my question. My question is light of the likelihood of the GDP contraction beyond 5% I just wanted to ask if you have had the opportunity to discuss with the authorities the possibility of delaying the 2021 and the key mandatory capex? Adolfo Castro Rivas -- Chief Executive Officer Hi, good morning. Well as you are aware, the contract has a clause that says that the maximum tariff can be reviewed in the case of Mexico in an external way. When on the Mexican GDP drops by more than 5% in a year and that's happened in fact on track. Of course with the current circumstance and the current expectations from analysts, it is possible that the Mexican GDP will drop by more than 5% this year. So in that sense, we will be we -- and the possibility of review our maximum time in an external rate. That's for next year, but not this year. Fernando Sanchez -- Bradesco BBI -- Analyst Okay. Thank you very much. Adolfo Castro Rivas -- Chief Executive Officer You're welcome. Carlos Peyrelongue -- Bank of America -- Analyst Thank you. Good morning Adolfo. Thank you for the call. On the something I couldn't hear well because of the connection but can you comment as to whether the dividend will be kept or there is the possibility of cutting the dividend until we have more sense about passenger traffic? That would be the first question. And the second would be related to cash burn, if you could give us an idea of what your cash burn is on a quarterly basis, just to get a sense of compare that primarily to your strong cash position. Thank you. Adolfo Castro Rivas -- Chief Executive Officer Yes, of course. In the case of the dividends, yesterday we held Annual Shareholders Meeting, they have sadly approved the dividend that it was proposed MXN8.1 per share. But it was -- this was subject to the approval from the Board to the moment of the payment that's from May 11, 2021. So the Board will have to approve when this dividend will be paid. In the case of the cash burn, what I said to you during the initiative months, is that our currency structure is basically fit. The only variable pieces are the technical assistance fee and the concession fees we paid to the government. So we are working and just to remember the case of Mexico is 5% as well as in Puerto Rico, and in the case of Colombia its' 19%. So this of course will reduce -- our passenger traffic is reduced and our income gets reduced. The remaining is basically, of course, we are taking measures to try to reduce as much as we can, all the expenses in the companies. But as I said, at the end, in the overall picture, the cost reduction will not be significant in comparison with reduction in the revenues of the company. Andressa Varotto -- UBS -- Analyst Thank you very much for taking my question. So my question is if have plans to negotiate with the government postponement of the mandatory capital is this possible? Thank you. Adolfo Castro Rivas -- Chief Executive Officer Could you repeat the question? I couldn't hear you. Andressa Varotto -- UBS -- Analyst Yes. So my question is if you plan to negotiate with government the postponement of mandatory capex? Adolfo Castro Rivas -- Chief Executive Officer As I said before, in accordance with the contract, we do not have that possibility this year. But of course, with the given standards [Phonetic] and as I said it in my initial remarks, during an expansion situation and that expansion situation is that some companies have stopped operations [Indecipherable] and that it was reactivated later on, but there was a decree from the Mexican government that also named the steel and glass that is produced in the country will be used for the project. So in that sense, at the moment it's almost impossible for us to expand our 10-year buildings without these material. So we have this situation to the government. So for the moment, what we see is that we will see some disruption in our construction process for some months and then we will have to talk about these with the government. That's what I can share with you for the moment on this respect. Andressa Varotto -- UBS -- Analyst Thank you very much. Adolfo Castro Rivas -- Chief Executive Officer You're welcome. Stephen Trent -- Citi -- Analyst Good morning, Adolfo and thanks very much for taking my question. Hope that you and your family are well. Just one quick one for me, I know that it seems that Mexico apparently has not been that active in likely offering any assistance to the corporate sector. What are you hearing from Colombia? Kind of any indications from them with respect to whether aviation industry will get some sort of relief? Adolfo Castro Rivas -- Chief Executive Officer Steve, thank you for your question. So in the case of Colombia in comparison with Mexico they have been more active in the measures that they have been taking. As I said here in the report they were very [Indecipherable] basically closing or sorting down everything as from March 23. And that can be seen in terms of results. In the case of Spain and the active they have in comparison with active cases we have in Mexico. So their curve is decreasing or at least flattening while the Mexican curve is still increasing. In terms of what they have said for our industry, we have been closed since March 23 and they have issued decrees in that respect. Maybe this week, there was a new announcement from the President expanding the process of shutting down everything. As I said in my remarks, for the case of domestic aviation that will be close up to May 11 and in the case of international up to May 30. It is important to remember that in the case of Colombia, 85% of aviation is domestic and 15% is international. That's what we know as of today. Of course all of these may change depending on how fast or how slow they can control the virus in their country. Stephen Trent -- Citi -- Analyst Thank you very much Adolfo. Apologies I couldn't hear all of your remarks. But no indication at this point for example that Columbia's planning a kind of tax relief for aviation or something along those lines offering kind of financial support. Adolfo Castro Rivas -- Chief Executive Officer Well we have not heard anything above that yet. Stephen Trent -- Citi -- Analyst Okay. Appreciate that. I'll let someone ask a question. Thanks Adolfo. Gabriel Himelfarb -- Deutsche Bank -- Analyst Hi, good morning, thanks for the call. I have two questions. The first one is concerning about account receivables. Can you give us like a number or approximate number about what's the total of the sales coming from airlines and in specific from Interjet and American Airlines and my second question is do you think you could obtain some waivers in opex sorry capex your current MDP in Mexico and could you will be able to extend the life of the concession in Colombia? Adolfo Castro Rivas -- Chief Executive Officer Hi, good morning. In terms of the account receivables you can see those in our report, revenue increase in the case of Mexico and Colombia, most of the increase is coming from the land industry. I do not have the details of American Airlines and Interjet you are requesting. In terms of the capex, as I said before, we have informed the government about this current situation. We don't know if they are going to react in that respect. But of course it's going to be almost impossible for us to construct and expand our buildings with that material. So more or less what I say to you. Gabriel Himelfarb -- Deutsche Bank -- Analyst Okay, thank you. Ruben Lopez -- Santander -- Analyst Hi Adolfo, thanks for the call. My question is on commercial revenues. Sorry if you commented on these. But I understanding Cancun operating in just one terminal. So I want to confirm you how are your operations there in Cancun and what are the implications on commercial operations? Are there any penalties with the tenants? What are negotiations here? That's the first one. And the second one is related with the same topic. When we see commercial revenues and we kind of try to compare current levels versus what would be the fixed amount or the fixed part of the minimum payment. I mean can you give us any sense of the guidance here? Thank you. Adolfo Castro Rivas -- Chief Executive Officer Okay. As you have said, yes, in the case of Cancun, we have closed two terminals and we are just operating today in terminal 4. So all the operations of airport have been concentrated there in order to reduce on one side the expenses and of course on the other side be better prepared in the case of these reduced demand. All the stores are working in the case of terminal 4. So terminal 4 is operating as it was before the event. As I said before, most of the contracts, the financial contracts we have with the tenants are related to a minimum guarantee payment passenger. So once again, they do not have, let's talk about one of the deals that is closed. So if they do not have passenger traffic in terminal 2, they almost have to pay the rent. Of course when they operate in terminal 4 their operations will be in the accordance with the amount of passengers we have in that facility. So I would say terminal 4 is operating normally. Ruben Lopez -- Santander -- Analyst Thank you. And when you compare, sorry, the current level of commercial revenues versus what would be the minimum payment from the contract, can you give us any idea on that? Adolfo Castro Rivas -- Chief Executive Officer As I said, minimum payment -- the contract is on a per passenger basis. Ruben Lopez -- Santander -- Analyst Perfect, thank you. And we will now go to Jorge Larocco of Morgan Stanley. Jorge Larocco -- Morgan Stanley. -- Analyst Hi Adolfo, good morning. Thank you for the questions. It's two questions, actually a pretty general question, I was just wondering if you could provide more color on what are the main initiatives regarding our cost reduction efforts. How are those working down, your payment reductions on paid leave of absence, maintenance cost, utility costs, etc. and how are those playing out so far? Thank you very much. Adolfo Castro Rivas -- Chief Executive Officer The main initiatives of course are related to in the case of Cancun in the terms of amounts. So we these key terminals closed, we are not burning the same amount of energy as if they were open. Also in the case of Cancun, we are in the process to shut down and one of the runway because today in accordance with the [Indecipherable] it's not needed. So, that runway will be turned off in terms of light at night also reducing their energy we will have to pay. And in terms of some other measures we are taking, adjusting some of the contracts of nature or mainly maintenance in the case of the buildings are closed and to try as much as possible to reduce operating cost and expenses. But I once again at the end, most of our cost is fixed. So if we apply the cost structure of the company, the most important lines are personnel and utility costs as we have said so. In the case of personnel, we are maintaining the personnel for the event or the crisis and in the case utilities, we are trying, as much as we can to try to reduce that. Jorge Larocco -- Morgan Stanley. -- Analyst Thanks so much Adolfo. Stay safe and have a good day. Adolfo Castro Rivas -- Chief Executive Officer Thank you Kathy and thank you again for participating in our fourth quarter results conference call. On behalf of ASUR, we wish you good day and until we meet, be safe. Good bye. Duration: 34 minutes Call participants: Adolfo Castro Rivas -- Chief Executive Officer Alejandro Zamacona -- Credit Suisse -- Analyst Fernando Sanchez -- Bradesco BBI -- Analyst Carlos Peyrelongue -- Bank of America -- Analyst Andressa Varotto -- UBS -- Analyst Stephen Trent -- Citi -- Analyst Gabriel Himelfarb -- Deutsche Bank -- Analyst Ruben Lopez -- Santander -- Analyst Jorge Larocco -- Morgan Stanley. -- Analyst More ASR analysis All earnings call transcripts\",\n          \"Brian Kearns -- Senior Vice President of Business Development and Investor Relations Thank you, Chris, and thank you, everyone, for joining us today. Joining today's call from Globus Medical will be Dave Demski, president, and CEO; Dan Scavilla, executive vice president and president of Ortho; and Keith Pfeil, senior vice president, and chief financial officer. This review is being made available via webcast accessible through the investor relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. Our Form 10-K for the 2021 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available on the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Dave Demski, our president, and CEO. Dave Demski -- President and Chief Executive Officer Well, thank you, Brian, and good afternoon, everyone. Globus finished an outstanding 2021 with a strong fourth quarter performance. Revenue for the year was a record $958 million, an increase of 21% over 2020 or $169 million in growth. To put that in perspective, our growth dollars alone would have ranked us in the top 10 spine companies in the world. Revenue in 2021 was 22% higher than 2019, an outstanding performance in itself, given the disruption caused by COVID but magnified further by a recent independent research report showing that each of the other top 6 spine companies actually had sales declines over that same time period. We achieved record sales and growth while maintaining industry-leading profitability, generating a record $2.04 in non-GAAP EPS, a 42% increase over 2020, and adjusted EBITDA of 34.6% even as we invested heavily in INR, trauma, and competitive recruiting. Revenue for the quarter was $250 million, up 7% over 4Q '20 as COVID-related headwinds remained strong throughout the quarter. Non-GAAP EPS was $0.49 per share, a 16% decrease compared to the artificially high 4Q '20. Not only were business travel and surgeon education activities severely curtailed last year, several other nonoperational factors, as Keith will expound upon in his remarks, also impacted the decline. Adjusted EBITDA in the fourth quarter was a strong 34%. Enabling technology continues to gain momentum, producing a record $25 million in revenue for Q4, an increase of 40% over 4Q '20. For the full year, enabling technology revenue was $81 million, an outstanding 100% increase over 2020. The clinical superiority of ExcelsiusGPS is the primary factor driving this growing momentum. Robotic utilization, which is the number of cases performed per installed robot, was at an all-time high in 2021. And nearly 30,000 procedures have been completed using ExcelsiusGPS technology since launch. Our spinal implant business continues to experience the flywheel effect of an increasing number of robots being sold combined with increasing utilization of each robot. Our U.S. spine business grew by 3% in Q4 as COVID-related shutdowns had a significant impact throughout the quarter. We saw this trend continue into January, but all signs point to a rebound commencing late in Q1. For the full year, the U.S. spine business grew by 18% as we continued to take significant market share. Robotics pull-through, coupled with contributions from recent product introductions and competitive recruiting, were all factors driving growth. Our international spine implant business grew by 9% in the quarter, a remarkable result in light of COVID impacts and an ongoing drag from Japan. Due to the impact of strategic moves we made in Japan last year, we expect to see continued declines there through the first half of 2022 with growth to follow off a reset baseline. This should result in accelerated overall international growth in the second half of this year. Trauma revenue was up 32% in the fourth quarter and 39% for the full year. Competitive recruiting and new product launches are driving growth. The Anthem Mini Frag system was launched on a limited basis in Q4 with excellent feedback from surgeon users. We are proceeding to full launch in Q1 and have a series of impactful product launches planned for the first half of 2022. The clients have launched the Excelsius 3D imaging system on a limited basis later this quarter with a full launch following in late Q2 or early Q3. There is tremendous anticipation and excitement about this technology among surgeons, and we already have double-digit orders signed. The Excelsius ecosystem, Globus Medical's unique combination of robotics, imaging, and freehand navigation that provides a seamless, scalable, and unmatched clinical experience for surgeons is about to become a reality. I'm extremely proud of our team's performance in 2021, record growth and profitability, exciting, clinically impactful new technology introductions, and an unmatched focus on providing value to surgeons and their patients. Thank you for a great year. I will now turn the call over to Keith. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you, Dave, and good afternoon to everyone joining us for today's call. Globus capped off a record 2021 with a robust Q4 performance despite ongoing COVID-related disruptions and shutdowns. For the full year, 2021 revenue was $958.1 million, growing 21.4% as reported. On a day-adjusted basis, sales grew by 22.1%, with two fewer selling days in the U.S. and international. Net income was $149.2 million, resulting in fully diluted earnings per share of $1.44. Non-GAAP net income was $211.4 million, generating a record $2.04 of fully diluted non-GAAP earnings per share. Adjusted EBITDA was 34.6% for the year, and we generated a record $219.4 million of free cash flow for the full year. Q4 '21 revenue was $250 million, growing 7.1% as reported and 8.5% on a day-adjusted basis with one less selling day in the U.S. and international compared to the prior-year quarter. Net income was $15.1 million, and non-GAAP net income was $51.1 million. Our Q4 diluted -- fully diluted earnings per share was $0.14, while our fully diluted non-GAAP earnings per share was $0.49. Adjusted EBITDA was 34.1%, and we generated $59.2 million of free cash flow for the quarter. Taking a deeper dive into sales. Q4 U.S. revenue was $213 million, 7.2% higher compared to Q4 of 2020 driven by our INR and U.S. spine businesses. International revenue for Q4 was $37.1 million, growing 6.8% over the prior-year quarter led by growth in spinal implants despite lingering COVID impacts and the impact of our strategic changes in Japan as Dave mentioned earlier. On a constant currency basis, international revenue grew by 8.7%. Q4 gross profit was 75.3% versus 73.9% in the prior-year quarter. The 140 basis point improvement was driven primarily by nonrepeating inventory reserves in the prior-year quarter and was consistent with our expectations noted in our Q4 2020 earnings commentary. Full year 2021 gross profit was 75%, compared to 72.4% in the prior year. The increase in full year gross profit is primarily the result of lower inventory reserves and operational and supply chain efficiencies, partially offset by sales mix. Looking ahead to 2022, we project a mid-70s gross profit rate. Research and development expenses in Q4 were $51 million or 20.4% of sales, compared to $15.2 million or 6.5% of sales in the prior-year quarter. The increased spending is primarily reflective of in-process research and development acquired during the quarter. Adjusting for these costs, Q4 2021 research and development expense was $16.7 million or 6.7% of revenue, in line with the prior-year quarter as a percentage of sales, but $1.5 million higher driven by incremental investments in headcount across our spine, INR, and trauma businesses. Our full year 2021 research and development expenses were $97.3 million or 10.2% of sales, compared to $84.5 million or 10.7% of sales in the prior year. Adjusting for the acquisitions made in both periods, research and development expenses were $63 million or 6.6% of sales in 2021, compared to $60.1 million or 7.6% of sales in 2020. The increase in spending is reflective of our continued investment in research and development to foster future growth and is consistent with comments made earlier in the year. We expect our R&D expenses to be approximately 7% of sales in 2022. SG&A expenses in the fourth quarter were $106.6 million or 42.6% of sales, compared to $92 million or 39.4% of sales in the prior-year quarter. The resulting increase is reflective of higher sales compensation and benefit costs as well as increased travel and training expenses driven by the resumption of normalized travel levels following the COVID-19 impacts experienced in the prior year. Full year SG&A expenses were $408.1 million or 42.6% of sales, compared to $354.8 million or 45% of sales in the prior year. The resulting decrease as a percentage of sales is reflective of leverage on fixed costs as a result of the higher volumes when comparing against the COVID impact in 2020. The income tax rate for the quarter was 23.8%, compared to 14.9% in Q4 of 2020 with the resulting increase driven primarily by lower tax benefits associated with stock option exercises. Our full year 2021 income tax rate was 17.3%, slightly lower than the 18.8% in 2020 driven primarily by the nonrecurring tax treatment related to a 2020 acquisition, partially offset by lower tax benefits associated with stock option exercises. Looking ahead to 2022, we expect our effective tax rate to be approximately 20% for the full year, which assumes no significant changes in the current U.S. tax policy. Fourth quarter net income was $15.1 million, and non-GAAP net income was $51.1 million. Q4 diluted earnings per share was $0.14, and non-GAAP diluted earnings per share were $0.49, compared to $0.58 in the prior-year quarter. The quarter-over-quarter decrease is driven by more normalized levels of travel, trainings, and meetings noted above or noted earlier as well as nonoperational items, primarily a higher tax rate as previously mentioned, higher stock compensation expense, and lower interest income. Looking ahead to 2022, we are expecting a mid-30s adjusted EBITDA rate. Full year diluted earnings per share were $1.44, and non-GAAP diluted earnings per share were $2.04, reflecting a 42.2% increase over 2020 primarily related to higher sales volumes following the 2020 impact of COVID-19, partially offset by approximately $0.09 of nonoperating headwinds related to a higher share count and lower interest income. Q4 adjusted EBITDA was 34.1%, compared to 36.2% in the prior-year quarter. Full year 2021 adjusted EBITDA was 34.6%, compared to 29.4% in 2020. Net cash provided by operating activities were $76.3 million for the fourth quarter and a record $276.3 million for the full year 2021. Free cash flow was $59.2 million for the fourth quarter and a record $219.4 million for the full year 2021. The company remains debt free. At this time, the company is establishing full year 2022 guidance. We are projecting full year 2022 sales guidance of $1.025 billion, representing 7% growth versus 2021. We are guiding to a full year fully diluted non-GAAP earnings per share of $2.10, representing 3% growth versus 2021. I note that the 2022 guidance includes approximately $0.10 of nonoperating headwinds, including higher shares worth $0.04, a higher tax rate worth $0.03, and higher stock compensation expense worth $0.03. Adjusting for these nonoperational factors, our 2022 guidance would have been $2.20 or 7.8% higher than 2021. Overall, we view this guidance as appropriately conservative and reflective of the current operating environment around COVID and inflation-related impacts. Our 2021 results represent our teamwork, our commitment, and our focus on execution. We continue to differentiate ourselves in the marketplace. And it is a testament of the hard work and dedication of each of our Globus employees. We remain excited for the future as we continue on our mission of improving patient care. Operator, we will now open the call for questions. Questions & Answers: Matt Miksic -- Credit Suisse -- Analyst Great. Thanks so much for taking the questions and congrats on a really strong finish to a pretty amazing year, given the circumstances. I wanted to follow up on some of the comments around EPS guidance, in particular. As you pointed out, there are some items that ex those items, up 7% to 8%. Can you talk a little bit about where in your guidance you're contemplating things that some of the other companies in the space have talked about like rising input costs, staffing challenges, labor costs, freight, etc., things that generally are driving operating costs up a little bit? Maybe give us a sense of how those figure into your guidance? And I have one quick follow-up. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks. This is Keith speaking. So we projected our guidance at $2.10. And as we look at the year, we see inflation as a market event. Everyone is experiencing it, and we have it baked in our numbers. But when you step back and look at the $2.04 and the $2.10, I commented on the $0.10 of the nonoperating headwinds. But the other things that are impacting the business as we think about getting back to more normalized levels of spend are really the travel and the trainings that go along with the surgeons and [Inaudible] that we provide. That's worth going into the next year likely an $0.08 headwind. And then one of the things that we commented on earlier in the year was our continued investment into R&D. As you look into next year, we're seeing roughly I would say, call it, $0.04 of additional investment in R&D. When you look at those things together, coupled with the inflation, we're landing at about $2.10. Matt Miksic -- Credit Suisse -- Analyst OK. And can you just maybe just elaborate a little bit on the spend or R&D and sort of the expectations for returns in terms of growth or programs that you're investing in? Keith Pfeil -- Senior Vice President and Chief Financial Officer So we're continuing to invest heavily in our spine business and as well as our robotic businesses. We talked about that in Q1 of our earnings call earlier in the year, and really all sign points to us continuing to do that. Dave talked earlier about some of the benefits that we're seeing for robotic technologies. We continue to invest in that and really grow for the future. Matt Miksic -- Credit Suisse -- Analyst OK. And then just one quick follow-up I had was on the environment for robots and spending in capital and equipment in general. Some of the other, again, companies in the space have talked about a fairly strong year for equipment, a strong year for robots. Any sense of whether this is something that needs to sort of take a breather or catch up here in 2022? Or whether orders and demand and pipeline for new deals would indicate just continued strength into 2022? Dave Demski -- President and Chief Executive Officer Yeah. Matt, this is Dave. No, it's very strong. I don't see anything laying off. In our case, in particular, it's been accelerating. I think the demand for Excelsius has been strong, and it's becoming more and more common. The narrative has changed from why robotics to which robot. And I think we're clearly establishing our lead there. And then as I mentioned, there's a lot of enthusiasm over our Excelsius 3D system, which is going to launch later this quarter. We've had every surgeon we show that to seems like they want one. So I don't see it backing off at all. Matt Miksic -- Credit Suisse -- Analyst Great. Thanks and congrats. Dave Demski -- President and Chief Executive Officer Thank you. Matt Taylor -- UBS -- Analyst Excuse me. Hi, guys. Thanks for taking the question. So I wanted to ask the first one about margins longer term. Maybe just talk about the difference between what you're doing this year with some of the investments and obviously, headwinds year over year from spending back to normal and inflation, and how we should think about margins longer term? Would you start to get more leverage at some point? And what would the inflection point for that be? Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. It's a good question. But as I look at where we're at and where we're going, our goal is to always maintain a mid-70s GP. But as we look longer term and look at our EBITDA rates, we're always looking to be in that mid-30s range. We could toggle our investments in various parts of our business to really achieve that, but we're investing now to drive growth -- to drive top-line growth for the future. And as we get that growth, that's going to create more fixed cost leverage in our P&L. So I think by doing that, investing for growth today helps project the margins going forward. I feel that we're going to work to try to stay in that range. Dave Demski -- President and Chief Executive Officer Yeah. I can add a little bit maybe to that, Matt. In the spine business, I don't think you'll see much greater improvement in our margins there, but we have a lot of operating leverage in front of us in the orthopedic side of the business and the capital side. Those are both fairly nascent businesses for us, and we're funding it with spine. But once we start to hit some volume numbers there, I think those businesses will definitely expand. Matt Taylor -- UBS -- Analyst Great. Can I ask a follow-up on the robotics strength? I mean, you talked in the past about getting pull-through on these placements, and obviously had a great year in 2021 with enabling tech. I guess are you still seeing the same kind of trends? And could that bode well for pull-through implants in '22? Dave Demski -- President and Chief Executive Officer Yes. It does. We're seeing that generally the same kinds of trends. And as a company, we're focusing on really going back to that installed base and seeing we can get more users to utilize the technology once it's placed in the hospital. And that's a big focus for us in 2022. Matt Taylor -- UBS -- Analyst Great. Thank you, guys. Thanks so much. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you. Shagun Singh -- RBC Capital Markets -- Analyst Great. Thank you for taking the question. I guess my first one is on Excelsius 3D imaging system. Can you talk to us about the delay? Why is there a delay in the launch? And then just elaborate on your go-to-market strategy. Are you targeting the replacement opportunity or greenfield? You're obviously going after a major competitor. So just any color there would be helpful. And then on the recon robotics, do you still plan to launch that in the second half? And then I have a quick follow-up. Dave Demski -- President and Chief Executive Officer Well, thank you, Shagun. I'll try to knock those off one by one. In terms of the delay, it's just taking longer than we thought. It's nothing significant in terms of the technology hurdle to get over. There's just a lot to do to get that over the line. So I wish we were a bit earlier but very confident we can get it done this quarter. Go-to-market. I think initially, we're going to be targeting our installed base of Excelsius users. Those are -- there's a high demand among them. It's going to make those procedures much more efficient and much easier for them to do. And then from there, we'll be branching out to target more of that free-hand navigation market that you alluded to earlier. And then I apologize, I forgot the last part of your question. Shagun Singh -- RBC Capital Markets -- Analyst I was just wondering if you plan to launch the recon robotics platform in the second half of '22 like you had previously indicated? Dave Demski -- President and Chief Executive Officer No. That's been delayed as well. We're going to be -- early '23 is the target for that. Shagun Singh -- RBC Capital Markets -- Analyst Got it. And then just as a follow-up, I was wondering if you could talk about trends that you're seeing on the procedure volume side in Q1, so in January and February. And spine typically has a high pain burden, so procedures come back quickly. So do you expect the recovery to come in Q1? Or do you expect a longer tail given staffing shortages? Thanks for taking the question. Dave Demski -- President and Chief Executive Officer Sure. Yes, January was really bad, but we've already started to see it turning in February. The last three weeks have all been progressively higher. Not back to where we want it to be, but definitely, I think we've hit bottom. We're going in the right direction. And I'm not going to try to predict what's going to happen with COVID though. That's proven to be frivolous for everyone, but it's encouraging where we are right now. Shagun Singh -- RBC Capital Markets -- Analyst Thank you. Matthew O'Brien -- Piper Sandler -- Analyst Great. Thanks for taking the questions. I guess, Dave, just for starters on the top-line guidance. This time last year, you guided about $35 million below The Street. We end up doing well above what you initially guided and actually what The Street was modeling. And this time, you're guiding about $25 million below The Street. I know January was soft, and maybe Excelsius 3D has pushed a little bit in terms of the contribution. But are there other factors that we should be thinking about? I don't know if it's a rep hiring perspective or a robot perspective that gives you a little bit more caution versus kind of where The Street was modeling things? Dave Demski -- President and Chief Executive Officer Thanks, Matt. I'm sorry we don't pay that much attention to The Street. We look internally to our own forecast, and we always want to be appropriately conservative going into a year. I feel really confident in the business. The U.S. spine business has been just cranking away. The robotic momentum is there. We're going to have 3D out this year. Japan is going to turn around in the second half. So I feel really good about the business. We just have taken a very conservative approach over the years when we give guidance, and we're doing that again. Matthew O'Brien -- Piper Sandler -- Analyst OK. Fair enough. And then the follow-up is on acquisitions. Sorry if I cut somebody off there, but there's been some talk about you guys doing a scale acquisition. I'm curious if you have any thoughts about the need for scale in spine. And then if not, there's some pretty interesting assets still in the spine space, but more on the pain management side of things. Are those higher on the list in terms of things that you potentially are looking at from a acquisition perspective? Dave Demski -- President and Chief Executive Officer No. It's actually a bit different. We're more active in terms of growing the business through BD and on the orthopedic side of the business. I think we're really strong in spine, and there's really nothing in spine that's of interest to us at the moment. We're more focused on growing the other piece of our business, which is smaller. There's nothing, I would say, transformative in our sights right now. But we are looking at several modest-sized deals as been our history in the past. Matthew O'Brien -- Piper Sandler -- Analyst Great. Dave Demski -- President and Chief Executive Officer Did that answer your question? Matthew O'Brien -- Piper Sandler -- Analyst Yep. That's perfect. Thank you. David Saxon -- Needham and Company -- Analyst Yeah. Hi, guys. Good afternoon, and thanks for taking the questions. Maybe one on enabling tech. I mean, it doubled this year, and you've really built out the enabling tech platform with hub and 3D, etc. How should we think about those launches kind of starting to ramp? And could '22 be another double? Dave Demski -- President and Chief Executive Officer Yeah. I think as I said, we're going to get some -- a few units out this quarter and kind of a soft launch, if you will, with the full launch starting in probably end of Q2, it might be into Q3 and then strong in the second half of this year. I don't want to comment on the double. It's -- we don't really drill into the components of our business. I can tell you that we're really excited about what we're seeing from our technology, from the adoption of our technology and not only what's right in front of us, but some things we have coming after that. David Saxon -- Needham and Company -- Analyst OK. Got it. And then maybe on trauma, kind of how close are you to having a full portfolio there? And then in terms of growth, 32% in the quarter. Is that sustainable in '22? Thanks for taking the questions. Dave Demski -- President and Chief Executive Officer Sure. The bag in trauma is by the second half of this year, I think full is kind of interesting term. We're going to have enough in our bag to be a full-line player and be able to compete with the major companies by the end of this year. And is that growth rate sustainable? Yes, I think that's certainly achievable in 2022. David Saxon -- Needham and Company -- Analyst Great. Thank you. Craig Bijou -- Bank of America Merrill Lynch -- Analyst Hey, guys. Thanks for taking the questions. Maybe a follow-up on top-line guidance and to the extent that you guys are willing to share. I mean, how to think about the contributions from each of the businesses? I know generally, you've been reluctant to share that info. But in terms of the composition of the guidance, how do we think about that incremental revenue coming in? Where is it coming from and to what extent? Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. As Dave said earlier, we're not going to get a ton into the parts and pieces. But what I will say is if you look at the business, whether by musculoskeletal and INR or you look U.S. versus international, the parts and pieces of our business we continue to feel extremely positive about as we look into 2022 and beyond. We're investing in our business. We're driving investment for the future, and we feel that we'll see that turn out to us taking share and driving sales growth. I alluded to my earlier prepared comments that our guidance is appropriately conservative, but there's nothing that I sit here and feel that we have kind of an ongoing issue that I would be concerned about our ability to grow across our business, like I said, whether it's U.S., international or musculoskeletal versus INR. Craig Bijou -- Bank of America Merrill Lynch -- Analyst Got it. Thanks, Keith. That's helpful. And then, Dave, I think you alluded to it, but I wanted to ask more specifically how to think about some of the new product rollouts? Obviously, you have 3D coming out and launching this year. But from a new product perspective, is it -- do you have a number of launches coming this year on the spine side? Do you have a number coming on the INR side? Just maybe a little bit more perspective of what to expect during the year. Dave Demski -- President and Chief Executive Officer Sure. Thanks, Craig. I think we've been pretty clear that it's a big one coming with 3D followed by our hub [Inaudible] offering. I think spine, we are typically 10 to 12 launches a year, and that's currently our target going into 2022. Trauma is probably the real bright spot. There is a number of products that we were working on for a while, they're going to hit the early part of this year and through this year. So -- and then our orthopedics business actually has some launches as well. So that's kind of who we are and who we're going to be. And it's -- the number one focus of the company is to drive great technology. Craig Bijou -- Bank of America Merrill Lynch -- Analyst Great. Thanks for taking the questions, guys. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you. Ryan Zimmerman -- BTIG -- Analyst All right. Thanks for taking my questions and congrats on a great year. Just want to follow up on a couple of questions. Dave, when we think about U.S. Spine performance kind of relative to the market, you look at some of the larger players, they were down a bit in the fourth quarter. Some of the smaller players we saw were up double digits. Obviously, a few major players still yet to report next week. But I guess I'm kind of curious if you can kind of talk about the U.S. performance, that growth this fourth quarter relative to the market, and kind of where you think you're tracking relative to that level? And if you could kind of give us color on what you think that level was just given the dynamics in the fourth quarter through the quarter would be helpful. Dave Demski -- President and Chief Executive Officer Thanks, Ryan. It's really challenging to figure out where we are, given COVID. So from the early returns of some of the folks who we have reported, again, we're taking significant share. I can't speak to the smaller guys who have reported or how that impacts us. And I don't really have a feel for the overall market. I know it was heavily impacted by COVID so likely down versus prior year overall. But that's more of just a guess and kind of where we landed versus some of our earlier trends. Our business is strong. I can tell you that. We haven't lost significant pieces of business in the U.S. And we continue to see growth in the recent product introductions, and we continue to sell robots and drive pull-through from that. So it's strong. I just -- I can't really see the overall market, and it's really hard to figure out what's going on given what's happening with COVID. Ryan Zimmerman -- BTIG -- Analyst OK. Just two follow-ups for me. One, we've heard some of the larger capital equipment companies have obviously called out chips as being a gating factor to sales or median demand in 2022. One, want to see if there's any concern there around chips for the Excelsius platform or for 3D and whether that could gate sales? And then I'll just ask the other -- sneak in a quick follow-up, too. The Japan distributor dynamics, how much of a lift should we expect when that distributor dynamic clears in the second half of 2022 on the international business? Thank you. Dave Demski -- President and Chief Executive Officer Sure. In terms of chips, I would just -- I would extend that to all supply chain. So it's not just chips, it's all components are challenging. It hasn't cost us revenue now, but it's certainly on our radar and making our life really hard. So it's a risk that's out there for 2022. I'll let Keith maybe handle the international question. Keith Pfeil -- Senior Vice President and Chief Financial Officer As it relates to Japan and the distributor dynamic, as we look ahead, we finished 2021, I think international grew by about 11%. We've historically said that we believe that the international business can grow mid-to-high teens. I would expect us to be able to get back to that on an annual basis. So you would expect the second half of the year to accelerate ahead of that to potentially balance -- to get closer to that 15 by the end of this year. Ryan Zimmerman -- BTIG -- Analyst Thanks, Kieth. Thanks, Dave. Appreciate it. Dave Demski -- President and Chief Executive Officer Sure. Kyle Rose -- Canaccord Genuity -- Analyst Great. Thank you for taking the questions. I wanted to start on enabling. I mean, look, you put up a good quarter in enabling. I guess a tough backdrop, particularly without the imaging platform. Maybe just help us understand kind of where that stands from a utilization perspective into your customer base. You're talking about the really good utilization there is continuing to see strong pull through. Can you just kind of level set maybe how many of your customers might have it or on a percentage basis or on an absolute basis? Just trying to really understand where we are in the uptake and the adoption within the historical core Globus customer base. Dave Demski -- President and Chief Executive Officer Yes, Kyle. To be honest, I don't feel comfortable sharing that information from a competitive standpoint. Kyle Rose -- Canaccord Genuity -- Analyst Totally fair. I had to try. I also wanted to touch on the orthopedic side of the business. I mean, it's been a couple of years since you acquired the StelKast business. I think earlier in the call, you talked about the fact that the recon robot is going to come in '23. Where do you stand just from an implant perspective? Do you have the right implants there? Do you need to make different investments from an M&A perspective, technologies, distribution? Just help us understand what you need to do on that total joints business before the recon robot comes next year. Thank you. Dave Demski -- President and Chief Executive Officer Sure. We do not have the implant portfolio we need to really make a strong outing. So we are working on that, have been working on that, and expect to roll some products out this year. I don't see us filling the gaps in our product portfolio with acquisitions in terms of hips and knees in particular. I do think there's opportunity for scale there. So that's not off the table because we are very small right now. And then the extremities is an interesting segment for us as well. It's a fast-growing segment. So that's an area where we've taken a look at a few things. Does that help with your question? Kyle Rose -- Canaccord Genuity -- Analyst Yes. Thank you very much. Dave Demski -- President and Chief Executive Officer Sure. Samuel Brodovsky -- Truist Securities -- Analyst Hi. Thank you for taking the questions. Just a first quick one on U.S. Spine. Just would be curious to hear about the portion of growth in the U.S. coming from robotic-specific instrumentation versus where you're seeing potential share gain with other parts of the portfolio? Keith Pfeil -- Senior Vice President and Chief Financial Officer Yes. Thanks for the question. In terms of breaking it out, we typically don't break out the parts and pieces of where the growth is coming from. What I would say is that as you look at our U.S. Spine business, it's really a combination of what we always talked about: new product innovation, our competitive recruiting, and the pull-through from implants. Those three continue to propel the business from a growth perspective, and we see that continuing as we enter 2022. Samuel Brodovsky -- Truist Securities -- Analyst Great. That's helpful. And then when thinking about 3D and going to customers with it, in terms of any competitive trialing, are you seeing it being trialed against other more novel imaging technologies on the market? Or is it typically being compared to the large competitor out there? Thanks. Dave Demski -- President and Chief Executive Officer Interesting question. I assume it's -- we don't really trial against it, but we have customers looking at our technology. And I think their interest just probably lines up with the market share of the other imaging systems in the market, particularly ones that are utilized more in spine. I'm sure that some of the more innovative ones are getting a look, but we don't hear that much about them. So it's not disproportionately, maybe I could answer it that way. Samuel Brodovsky -- Truist Securities -- Analyst Thanks. Steven Lichtman -- Oppenheimer and Company -- Analyst Thank you. Hi, guys. I wanted to ask you first on trauma. Where do you think you stand now in terms of coverage of procedures in terms of your product portfolio? And also from a sales force perspective, I'd just love to get an update on where you feel you are overall in terms of being able to go at the market. Dan Scavilla -- Executive Vice President and President of Ortho Steven, it's Dan Scavilla. So again, it's always the evolving and expanding story. We have about 14 family products out there now. I think with that, we're saying we would cover 50% to 60% of the market. Certainly, plan, as David said, to launch several more this year to cover that further. I believe and through what I'm saying, we're at a point where we're able to get into some significant facilities and support their needs for the most common procedures. And with that that's the main driver of growth to us. So we'll continue to expand the product line and fill that out over time, but we're in a good spot now. With that is the competitive recruiting that's been accelerating for us. So again, we're small, and we have a lot of spaces to fill. But the traction that has been occurring really through 2021 is very promising. And I do feel bullish as we are -- from what I've seen so far in the first quarter of 2022 that that will continue. Steven Lichtman -- Oppenheimer and Company -- Analyst Great. Thanks, Dan. Keith, just a follow-up on gross margin. I apologize if you mentioned this, but just relative to 2021, given the inflation commentary, should we assume gross margin down? Or are there some offsets that can keep it relatively flat to maybe -- or even up in '22? Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. We project the mid-70s GP. I think it's fair to assume that we are seeing inflation just like everybody else, but we're also growing. And it's obviously getting us some leverage in our cost structure. So as I think about 2022, mid-70s is kind of where I see it. I wouldn't project upside. Steven Lichtman -- Oppenheimer and Company -- Analyst OK. Got it. Thanks, guys. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thank you. Jason Wittes -- Loop Capital -- Analyst Hi. Thanks for taking the questions. Just two follow-ups, one on the guidance and one on trauma. But -- so first off, your guidance, I think the way you described it, especially relating to product launches, kind of assumes a strong second half versus the first half. So related to that, one, are we assuming that -- I know we can't predict COVID, but COVID pretty much works its way throughout the year? And then secondly, related to that, in the first quarter, I'm not sure how to read your comment that January was very weak. It bounced back. Should this be a normalized first quarter? Or are we -- is it going to be a little weaker relative to last year because of the COVID impact and launches? Thanks. Keith Pfeil -- Senior Vice President and Chief Financial Officer Thanks for the question. Dave commented that January was weak, but we were starting to see some bounce back in February. Will it all bounce back in the same quarter versus having some bleed through into Q2? We don't necessarily know. But I think your earlier comment about some of the launches and a strong second half, I think that's directionally correct. Jason Wittes -- Loop Capital -- Analyst OK. And then I don't know if you can comment on this, but you did mention that you had -- it sounds like a record year in terms of sales force hires. In the past, you've kind of given us an indication of how large you've been able to grow your sales force percentage-wise. Can you give us any kind of indication on that in terms of what 2021 look like? And it sounds like 2022, you're optimistic that you can do -- go at a similar run rate? Dave Demski -- President and Chief Executive Officer Yeah. '21 was not a record year for us. I think we had one really strong quarter, but we've had years that were better. That's a renewed emphasis on it. I can tell you the pipeline right now is extremely strong. So we're coming out of the gate strong. But last year was a good year. It just wasn't our best. Jason Wittes -- Loop Capital -- Analyst OK. Thanks a lot. Appreciate it all. Dave Demski -- President and Chief Executive Officer Sure. Duration: 45 minutes Call participants: Brian Kearns -- Senior Vice President of Business Development and Investor Relations Dave Demski -- President and Chief Executive Officer Keith Pfeil -- Senior Vice President and Chief Financial Officer Matt Miksic -- Credit Suisse -- Analyst Matt Taylor -- UBS -- Analyst Shagun Singh -- RBC Capital Markets -- Analyst Matthew O'Brien -- Piper Sandler -- Analyst David Saxon -- Needham and Company -- Analyst Craig Bijou -- Bank of America Merrill Lynch -- Analyst Ryan Zimmerman -- BTIG -- Analyst Kyle Rose -- Canaccord Genuity -- Analyst Samuel Brodovsky -- Truist Securities -- Analyst Steven Lichtman -- Oppenheimer and Company -- Analyst Dan Scavilla -- Executive Vice President and President of Ortho Jason Wittes -- Loop Capital -- Analyst More GMED analysis All earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2535,\n        \"min\": 571,\n        \"max\": 32540,\n        \"num_unique_values\": 6023,\n        \"samples\": [\n          8055,\n          8114,\n          14273\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08086309609059458,\n        \"min\": -0.6091428484235492,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 9985,\n        \"samples\": [\n          0.0115302149459788,\n          0.1053023227425508,\n          -0.0781132122800544\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Target_Class\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Neutral\",\n          \"Gain\",\n          \"Loss\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"DateOfWeek\",\n      \"properties\": {\n        \"dtype\": \"int32\",\n        \"num_unique_values\": 7,\n        \"samples\": [\n          3,\n          2,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Month\",\n      \"properties\": {\n        \"dtype\": \"int32\",\n        \"num_unique_values\": 12,\n        \"samples\": [\n          12,\n          5,\n          8\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Quarter\",\n      \"properties\": {\n        \"dtype\": \"int32\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          4,\n          2,\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Ticker_gain_prob\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.050861298714432415,\n        \"min\": 0.07254027229556778,\n        \"max\": 0.6145290734110492,\n        \"num_unique_values\": 96,\n        \"samples\": [\n          0.32191697721115614,\n          0.1799954783009513,\n          0.3176372756886915\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Ticker_loss_prob\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.05845408745944301,\n        \"min\": 0.002959409262484645,\n        \"max\": 0.6360831434700265,\n        \"num_unique_values\": 96,\n        \"samples\": [\n          0.2926491076860506,\n          0.312513854371121,\n          0.2925641097616779\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 32
        }
      ],
      "source": [
        "df_analysis.drop(columns=[\"Target_gain_flag\",\"Target_loss_flag\",\"ticker_clean\"],inplace=True)\n",
        "df_analysis.head(5)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 33,
      "metadata": {
        "id": "WIc_YdaNotVA"
      },
      "outputs": [],
      "source": [
        "path=\"/content/drive/MyDrive/Earnings call prediction/final_dataframe_after_FE.csv\"\n",
        "df_analysis.to_csv(path)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "adUtpKgg0iJo"
      },
      "source": [
        "**Sentiment scores**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 34,
      "metadata": {
        "id": "ELUs2zvf0dDG"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "import numpy as np"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 36,
      "metadata": {
        "id": "K5Jt4NFj0VFP"
      },
      "outputs": [],
      "source": [
        "df_analysis=pd.read_csv(\"/content/drive/MyDrive/Earnings call prediction/final_dataframe_after_FE.csv\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 37,
      "metadata": {
        "id": "u0E71rE-ltm_",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000,
          "referenced_widgets": [
            "1e916467ea9c46df95fd5432db8e5a3c",
            "b4ab73df06874f8e8f141df478dca1a4",
            "d9e82e1b057a4f14acf2bff1be63f254",
            "c1543499b6374ca8af4c6c2fc9b1df53",
            "28e34e84cefe42dabf45d2a3c1e7960b",
            "5a47cbee9e324981bc885fb7b5ca6d75",
            "4f2b76167aa44152ad065e7cf15638d2",
            "da3a157002ed4a8e8dc4d6a8e63d1b9a",
            "d30cf355dffb4326a88fb18cc764f08e",
            "b06341f319714661999b42984f457271",
            "1245e336cd924ce3b16c9f8f040ecb7d",
            "9b6ca5cdf4d44e4fb7901ef83c5d37dc",
            "8b74c463b9c74eb9b2f3fe777c23666c",
            "51c8838e3f814b9c942c252d9191b831",
            "09210b5f6536496d952fecec581ab3a0",
            "88eb3c7cd9b240a5843579063c4f1bd9",
            "238cc8a03c9b4f39837817d5f4b73f93",
            "ca73fbe064fb496b915193426739a873",
            "687aa65a31de4bf5938fd3ff8c75e7be",
            "c1d862b91d69491a958271916aa82b73",
            "e0f0e442877f443aafd467d695ff3bd3",
            "82ec97d145784d14a72ae9e4ef76e534",
            "6dce441defcf4fa780dd4e3739ecf244",
            "0bd17fae0284401eae37748396590b7b",
            "3a6f605a97ad4e14811cf78cc0d41279",
            "9fa7b89297c24216af645fca14090226",
            "c40a29aabbac4b88a8f0184caf9e47fc",
            "d671941626df4552ab8912eef0d76865",
            "dcb19d7562774b928d9d0159781ace02",
            "ba0e17df241c48b7a606c131b72515f0",
            "3c7c6999d41d437f8c0a22c473a255f6",
            "4c1af1fbcf6642e7b74cc0e6085dc7c0",
            "b843a5df882b48b08f68182ff706760d",
            "87ad63da3e044409bcead4e419cf5577",
            "b9df23a020944383a814a3b95a6642bb",
            "7ccf48edfd9e41c383f63edda8c263a2",
            "c8f9cbf1173c48409f14d6e2f5783005",
            "a625a19f30a0466fa31e7f132f88feb9",
            "5ffeef791d5940dabff21692cc4f3088",
            "663251685016407585321b94bd893b84",
            "017f513534b74e6497337e362810e875",
            "0146282e2a704392888a3f90d384226c",
            "4c40cea38fb74d519131fb9645b8feb7",
            "5531ddb12edc4217a63044e40720f2fa",
            "8d3d92d2603f487faeaa58fc2fd4ffbb",
            "cb4bc34d6e1c415a80772a5f7e10dd77",
            "e2ccec58564d4c9b902e186f20d55edf",
            "2360eb056f03475189770a36fdce01ae",
            "daea8b423d7043a9aff41011b74ad4ac",
            "d0cb2e97fcc242c4aedaec67f9dcd33d",
            "04e86e3168a94836ab7b82813bcb0fb2",
            "fdc15608dc2d4543a31bfc392cbd18c6",
            "552cd187f03847fdbb44173da249e3dc",
            "752171ef0f3f4afdbe4b72a46f8c6dae",
            "ebf8e21c8762438f8434043bd951e8f4",
            "debb28da914449fabc6c43e02b53bc24",
            "892cd66911654ad08fe5749f1ba74742",
            "4354fa94254b4df0ae663a0280ab48fc",
            "f0bd4608e03d45c39d57edfdd19a95b4",
            "a3317a1b4379499c816abd485b6fe7d0",
            "ae89e18e776546e2bd32a24bd766ad3d",
            "7d8ead4119bc40a282a47904cc07b76d",
            "9f427394bfae4484a0238150e7c759b9",
            "8affe1811fd943088ccb365829dceb1c",
            "b659a16035394b2fb4383f420cd80688",
            "52754a2a974746cc9cd0d793912c3829",
            "b36baef6c5c54d99ae333257319558c1",
            "8bbc14cfd6174873ac5e43864d6bc70e",
            "54dc24ff48d643f1a7d0c202cd7894f7",
            "220b2487a6fb4229a8d8bc8dc0c96aaa",
            "2ad49dea9a3d4a45afdb9d4b2ab25e06",
            "1fbe0825a0094dd985fe2e800d665cde",
            "a3957abbef004d73ba015ffbad018f56",
            "acd8b14cbc874101bc4cefc985ae56fa",
            "691ab1b3142e486b9e83fdf025649bc1",
            "8a366e4d03394123a4ff1a573d64d313",
            "2a2f9287cf924940915a2c39d97d8c4f"
          ]
        },
        "outputId": "7edd9050-1b46-4297-a1fc-de8b55e003ef"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: transformers in /usr/local/lib/python3.12/dist-packages (4.57.3)\n",
            "Requirement already satisfied: torch in /usr/local/lib/python3.12/dist-packages (2.9.0+cpu)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.12/dist-packages (4.67.1)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.12/dist-packages (from transformers) (3.20.0)\n",
            "Requirement already satisfied: huggingface-hub<1.0,>=0.34.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.36.0)\n",
            "Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.12/dist-packages (from transformers) (2.0.2)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (25.0)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.12/dist-packages (from transformers) (6.0.3)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.12/dist-packages (from transformers) (2025.11.3)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.12/dist-packages (from transformers) (2.32.4)\n",
            "Requirement already satisfied: tokenizers<=0.23.0,>=0.22.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.22.1)\n",
            "Requirement already satisfied: safetensors>=0.4.3 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.7.0)\n",
            "Requirement already satisfied: typing-extensions>=4.10.0 in /usr/local/lib/python3.12/dist-packages (from torch) (4.15.0)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.12/dist-packages (from torch) (75.2.0)\n",
            "Requirement already satisfied: sympy>=1.13.3 in /usr/local/lib/python3.12/dist-packages (from torch) (1.14.0)\n",
            "Requirement already satisfied: networkx>=2.5.1 in /usr/local/lib/python3.12/dist-packages (from torch) (3.6.1)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.12/dist-packages (from torch) (3.1.6)\n",
            "Requirement already satisfied: fsspec>=0.8.5 in /usr/local/lib/python3.12/dist-packages (from torch) (2025.12.0)\n",
            "Requirement already satisfied: hf-xet<2.0.0,>=1.1.3 in /usr/local/lib/python3.12/dist-packages (from huggingface-hub<1.0,>=0.34.0->transformers) (1.2.0)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.12/dist-packages (from sympy>=1.13.3->torch) (1.3.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.12/dist-packages (from jinja2->torch) (3.0.3)\n",
            "Requirement already satisfied: charset_normalizer<4,>=2 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (3.4.4)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (3.11)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (2.5.0)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (2025.11.12)\n",
            "Looking in links: https://storage.googleapis.com/libtpu-releases/index.html\n",
            "Requirement already satisfied: torch==2.9.0 in /usr/local/lib/python3.12/dist-packages (2.9.0+cpu)\n",
            "Requirement already satisfied: torch_xla==2.9.0 in /usr/local/lib/python3.12/dist-packages (from torch_xla[tpu]==2.9.0) (2.9.0)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (3.20.0)\n",
            "Requirement already satisfied: typing-extensions>=4.10.0 in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (4.15.0)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (75.2.0)\n",
            "Requirement already satisfied: sympy>=1.13.3 in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (1.14.0)\n",
            "Requirement already satisfied: networkx>=2.5.1 in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (3.6.1)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (3.1.6)\n",
            "Requirement already satisfied: fsspec>=0.8.5 in /usr/local/lib/python3.12/dist-packages (from torch==2.9.0) (2025.12.0)\n",
            "Requirement already satisfied: absl-py>=1.0.0 in /usr/local/lib/python3.12/dist-packages (from torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (1.4.0)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.12/dist-packages (from torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (2.0.2)\n",
            "Requirement already satisfied: pyyaml in /usr/local/lib/python3.12/dist-packages (from torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (6.0.3)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.12/dist-packages (from torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (2.32.4)\n",
            "Collecting libtpu==0.0.21 (from torch_xla[tpu]==2.9.0)\n",
            "  Downloading libtpu-0.0.21-cp312-cp312-manylinux_2_31_x86_64.whl.metadata (1.0 kB)\n",
            "Requirement already satisfied: tpu-info in /usr/local/lib/python3.12/dist-packages (from torch_xla[tpu]==2.9.0) (0.2.2)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.12/dist-packages (from sympy>=1.13.3->torch==2.9.0) (1.3.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.12/dist-packages (from jinja2->torch==2.9.0) (3.0.3)\n",
            "Requirement already satisfied: charset_normalizer<4,>=2 in /usr/local/lib/python3.12/dist-packages (from requests->torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (3.4.4)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.12/dist-packages (from requests->torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (3.11)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.12/dist-packages (from requests->torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (2.5.0)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.12/dist-packages (from requests->torch_xla==2.9.0->torch_xla[tpu]==2.9.0) (2025.11.12)\n",
            "Requirement already satisfied: grpcio>=1.65.5 in /usr/local/lib/python3.12/dist-packages (from tpu-info->torch_xla[tpu]==2.9.0) (1.76.0)\n",
            "Requirement already satisfied: protobuf in /usr/local/lib/python3.12/dist-packages (from tpu-info->torch_xla[tpu]==2.9.0) (6.33.2)\n",
            "Requirement already satisfied: rich in /usr/local/lib/python3.12/dist-packages (from tpu-info->torch_xla[tpu]==2.9.0) (14.2.0)\n",
            "Requirement already satisfied: markdown-it-py>=2.2.0 in /usr/local/lib/python3.12/dist-packages (from rich->tpu-info->torch_xla[tpu]==2.9.0) (4.0.0)\n",
            "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /usr/local/lib/python3.12/dist-packages (from rich->tpu-info->torch_xla[tpu]==2.9.0) (2.19.2)\n",
            "Requirement already satisfied: mdurl~=0.1 in /usr/local/lib/python3.12/dist-packages (from markdown-it-py>=2.2.0->rich->tpu-info->torch_xla[tpu]==2.9.0) (0.1.2)\n",
            "Downloading libtpu-0.0.21-cp312-cp312-manylinux_2_31_x86_64.whl (149.8 MB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m149.8/149.8 MB\u001b[0m \u001b[31m2.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: libtpu\n",
            "  Attempting uninstall: libtpu\n",
            "    Found existing installation: libtpu 0.0.17\n",
            "    Uninstalling libtpu-0.0.17:\n",
            "      Successfully uninstalled libtpu-0.0.17\n",
            "Successfully installed libtpu-0.0.21\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/tmp/ipython-input-3842202340.py:5: DeprecationWarning: Use torch_xla.device instead\n",
            "  device = xm.xla_device()\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "TPU device connected: xla:0\n",
            "\n",
            "Example computation on TPU: tensor([[ 0.3355, -1.4628, -3.2610],\n",
            "        [-1.4656,  0.3196, -2.8766],\n",
            "        [ 0.8667, -1.5060,  0.7125]], device='xla:0')\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.12/dist-packages/jax/_src/cloud_tpu_init.py:86: UserWarning: Transparent hugepages are not enabled. TPU runtime startup and shutdown time should be significantly improved on TPU v5e and newer. If not already set, you may need to enable transparent hugepages in your VM image (sudo sh -c \"echo always > /sys/kernel/mm/transparent_hugepage/enabled\")\n",
            "  warnings.warn(\n",
            "/usr/local/lib/python3.12/dist-packages/huggingface_hub/utils/_auth.py:94: UserWarning: \n",
            "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
            "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
            "You will be able to reuse this secret in all of your notebooks.\n",
            "Please note that authentication is recommended but still optional to access public models or datasets.\n",
            "  warnings.warn(\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config.json:   0%|          | 0.00/758 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "1e916467ea9c46df95fd5432db8e5a3c"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "pytorch_model.bin:   0%|          | 0.00/438M [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "9b6ca5cdf4d44e4fb7901ef83c5d37dc"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "tokenizer_config.json:   0%|          | 0.00/252 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "6dce441defcf4fa780dd4e3739ecf244"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "model.safetensors:   0%|          | 0.00/438M [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "87ad63da3e044409bcead4e419cf5577"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "vocab.txt: 0.00B [00:00, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "8d3d92d2603f487faeaa58fc2fd4ffbb"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "special_tokens_map.json:   0%|          | 0.00/112 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "debb28da914449fabc6c43e02b53bc24"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Device set to use xla:0\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Starting inference on 10913 rows...\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.12/dist-packages/transformers/pipelines/text_classification.py:111: UserWarning: `return_all_scores` is now deprecated,  if want a similar functionality use `top_k=None` instead of `return_all_scores=True` or `top_k=1` instead of `return_all_scores=False`.\n",
            "  warnings.warn(\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "  0%|          | 0/342 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "b36baef6c5c54d99ae333257319558c1"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Success! FinBERT scores added.\n"
          ]
        }
      ],
      "source": [
        "!pip install transformers torch tqdm\n",
        "! pip install torch==2.9.0 'torch_xla[tpu]==2.9.0' -f https://storage.googleapis.com/libtpu-releases/index.html\n",
        "import torch_xla.core.xla_model as xm\n",
        "import torch\n",
        "device = xm.xla_device()\n",
        "print(\"TPU device connected:\", device)\n",
        "t1 = torch.randn(3, 3, device=device)\n",
        "t2 = torch.randn(3, 3, device=device)\n",
        "print(\"\\nExample computation on TPU:\", t1 + t2)\n",
        "\n",
        "import torch\n",
        "from transformers import pipeline\n",
        "from tqdm.auto import tqdm\n",
        "import pandas as pd\n",
        "\n",
        "classifier = pipeline(\"text-classification\", model=\"ProsusAI/finbert\", return_all_scores=True, device=device)\n",
        "\n",
        "# Preparing Data\n",
        "texts = df_analysis['Clean_Text'].astype(str).tolist()\n",
        "batch_size = 32\n",
        "results = []\n",
        "\n",
        "print(f\"Starting inference on {len(texts)} rows...\")\n",
        "for i in tqdm(range(0, len(texts), batch_size)):\n",
        "  batch = texts[i : i + batch_size]\n",
        "  batch_results = classifier(batch, truncation=True, max_length=512)\n",
        "  results.extend(batch_results)\n",
        "\n",
        "# Parsing Results into Columns. FinBERT outputs a list of dictionaries. Mapping them to columns\n",
        "pos_scores = []\n",
        "neg_scores = []\n",
        "neu_scores = []\n",
        "\n",
        "for row_result in results:\n",
        "  scores_dict = {item['label']: item['score'] for item in row_result}\n",
        "  pos_scores.append(scores_dict.get('positive', 0))\n",
        "  neg_scores.append(scores_dict.get('negative', 0))\n",
        "  neu_scores.append(scores_dict.get('neutral', 0))\n",
        "\n",
        "#Adding to DataFrame\n",
        "df_analysis['FinBERT_Positive'] = pos_scores\n",
        "df_analysis['FinBERT_Negative'] = neg_scores\n",
        "df_analysis['FinBERT_Neutral'] = neu_scores\n",
        "\n",
        "df_analysis.drop(columns=['Clean_Text'], inplace=True)\n",
        "\n",
        "print(\"Success! FinBERT scores added.\")"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_analysis.head(5)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 677
        },
        "id": "Ncg3LMKGH8xw",
        "outputId": "c2fbf23e-e6b6-4b05-bb28-35d3a6db3ce2"
      },
      "execution_count": 38,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   Unnamed: 0                        date      exchange        q ticker  \\\n",
              "0           0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1           1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2           2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3           3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4           4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript            Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel...  2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta...  2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc...  2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon...  2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel...  2019-08-07 08:30:00   \n",
              "\n",
              "    Date_only  word_count  Price_change Target_Class  DateOfWeek  Month  \\\n",
              "0  2020-08-27        5623      0.035078      Neutral           3      8   \n",
              "1  2020-07-30        4755      0.116154         Gain           3      7   \n",
              "2  2019-10-23        8917      0.142022         Gain           2     10   \n",
              "3  2019-11-06        8286      0.029891      Neutral           2     11   \n",
              "4  2019-08-07        4611      0.249623         Gain           2      8   \n",
              "\n",
              "   Quarter  Ticker_gain_prob  Ticker_loss_prob  FinBERT_Positive  \\\n",
              "0        3          0.137200          0.221243          0.146988   \n",
              "1        3          0.212841          0.218602          0.910005   \n",
              "2        4          0.264048          0.182879          0.878131   \n",
              "3        4          0.212841          0.188007          0.727205   \n",
              "4        3          0.255781          0.205784          0.755221   \n",
              "\n",
              "   FinBERT_Negative  FinBERT_Neutral  \n",
              "0          0.012653         0.840358  \n",
              "1          0.010605         0.079389  \n",
              "2          0.012376         0.109493  \n",
              "3          0.122016         0.150779  \n",
              "4          0.136653         0.108126  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-2513e6ff-47c7-4151-b759-b9c67b51d85f\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Unnamed: 0</th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>word_count</th>\n",
              "      <th>Price_change</th>\n",
              "      <th>Target_Class</th>\n",
              "      <th>DateOfWeek</th>\n",
              "      <th>Month</th>\n",
              "      <th>Quarter</th>\n",
              "      <th>Ticker_gain_prob</th>\n",
              "      <th>Ticker_loss_prob</th>\n",
              "      <th>FinBERT_Positive</th>\n",
              "      <th>FinBERT_Negative</th>\n",
              "      <th>FinBERT_Neutral</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>0</td>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>5623</td>\n",
              "      <td>0.035078</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>3</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.137200</td>\n",
              "      <td>0.221243</td>\n",
              "      <td>0.146988</td>\n",
              "      <td>0.012653</td>\n",
              "      <td>0.840358</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>1</td>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>4755</td>\n",
              "      <td>0.116154</td>\n",
              "      <td>Gain</td>\n",
              "      <td>3</td>\n",
              "      <td>7</td>\n",
              "      <td>3</td>\n",
              "      <td>0.212841</td>\n",
              "      <td>0.218602</td>\n",
              "      <td>0.910005</td>\n",
              "      <td>0.010605</td>\n",
              "      <td>0.079389</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>2</td>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>8917</td>\n",
              "      <td>0.142022</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>10</td>\n",
              "      <td>4</td>\n",
              "      <td>0.264048</td>\n",
              "      <td>0.182879</td>\n",
              "      <td>0.878131</td>\n",
              "      <td>0.012376</td>\n",
              "      <td>0.109493</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>3</td>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>8286</td>\n",
              "      <td>0.029891</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>2</td>\n",
              "      <td>11</td>\n",
              "      <td>4</td>\n",
              "      <td>0.212841</td>\n",
              "      <td>0.188007</td>\n",
              "      <td>0.727205</td>\n",
              "      <td>0.122016</td>\n",
              "      <td>0.150779</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>4</td>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>4611</td>\n",
              "      <td>0.249623</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.255781</td>\n",
              "      <td>0.205784</td>\n",
              "      <td>0.755221</td>\n",
              "      <td>0.136653</td>\n",
              "      <td>0.108126</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-2513e6ff-47c7-4151-b759-b9c67b51d85f')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-2513e6ff-47c7-4151-b759-b9c67b51d85f button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-2513e6ff-47c7-4151-b759-b9c67b51d85f');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-fd44e448-b45e-4789-9746-5e72399cc643\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-fd44e448-b45e-4789-9746-5e72399cc643')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-fd44e448-b45e-4789-9746-5e72399cc643 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_analysis",
              "summary": "{\n  \"name\": \"df_analysis\",\n  \"rows\": 10913,\n  \"fields\": [\n    {\n      \"column\": \"Unnamed: 0\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3150,\n        \"min\": 0,\n        \"max\": 10912,\n        \"num_unique_values\": 10913,\n        \"samples\": [\n          4830,\n          5082,\n          5012\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4311,\n        \"samples\": [\n          \"Jul 8, 2021, 11:00 a.m. ET\",\n          \"Feb 13, 2020, 9:00 a.m. ET\",\n          \"May 18, 2022, 9:00 a.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"NYSE: AVB\",\n          \"NASDAQ: THRM\",\n          \"NASDAQ: ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q4\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"AVB\",\n          \"THRM\",\n          \"ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10031,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nGood afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the PTC's 2022 first quarter conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open for questions.\\nI'd now like to turn the call over to Matt Shimao, PTC's head of investor relations. Please go ahead.\\nMatthew Shimao -- Head of Investor Relations\\nHello. Thank you, Julian, and welcome to PTC's results call for Q1 of fiscal '22. On the call today are Jim Heppelmann, chief executive officer; and Kristian Talvitie, chief financial officer. During this call, PTC will make forward-looking statements, including guidance on future operating results.\\nBecause such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in PTC's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission, as well as in today's press release. The forward-looking statements, including guidance provided during today's call are valid only as of today's date, January 26, 2022, and PTC assumes no obligation to update these forward-looking statements.\\nDuring the call, PTC will also discuss non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures can be found in today's press release made available on our website. With that, I'd like to turn the call over to PTC's chief executive officer, Jim Heppelmann.\\u00a0 \\nJim Heppelmann -- Chief Executive Officer\\nThanks, Matt. Good afternoon, everyone, and thank you for joining us. Turning to Slide 3, I'm pleased to share that PTC delivered another strong financial performance in fiscal Q1. We executed very well, building on the momentum we saw in Q4.\\nTo simplify things, please note that throughout my prepared commentary, I will only discuss growth rates in constant currency. ARR came in at $1.507 billion, which was better than the $1.5 billion we had guided to at the recent Investor Day. That represents 16% growth, 11% of which was organic. Adjusted free cash flow was also strong at $145 million, which was up 20% year over year and better than the $140 million expectation we said at the Investor Day.\\nWe're off to a very strong start in fiscal 2022. Turning to Slide 4. Of particular note was our bookings strength. Bookings were up double digits organically and high teens overall against the very strong COVID bounce back quarter we saw in Q1 of fiscal '21 when bookings grew more than 30% over the prior year.\\nTo put it in perspective, given the tough comparison against Q1 of last year, we had planned bookings to actually be down slightly, inclusive of Arena. So this performance was more than 20% above plan. I know that some analysts and investors had voice concerned that the restructuring work we did in late Q4 and throughout Q1 would distract us, but obviously, we didn't see that. The strength was broad-based across direct sales and resellers and was achieved with no megadeals.\\nRockwell came in ahead of their part of our plan, too, which was great to see and suggest my concerns of them being distracted and may prove overstated. Arena contributed the inorganic element of bookings growth, with another strong bookings quarter, coming in above plan as well. With the Arena acquisition getting round tripped here in Q2, Arena becomes part of the organic results going forward and their low 20s growth rate will then add another tailwind to the organic results. Arena has been a great acquisition.\\nBookings growth was particularly strong in PLM, and in both Europe and Americas. From a macro perspective, global PMIs remain an expansion territory, while digital transformation and SaaS continue to grow in importance as secular drivers. The interest in digital transformation in SaaS has been driving strong bookings for what is very sticky software, which when layered into a recurring revenue model that is atypical of industry peers, has allowed PTC to deliver performance in excess of market growth rates. This happened right through the pandemic, especially in the large core business that represents about 70% of our ARR, and we fully expect it to continue going forward.\\nThese factors gave us confidence to raise the lower end of our ARR guidance range, which at the new midpoint basically means we've rolled our Q1 beat forward. Now let's take a look at the ARR performance by geography on Slide 5 before turning to business units. In Q1, we saw a strong ARR performance across all geographies. Our ARR growth in the Americas was 19%.\\nAll product segments grew with key growth drivers being the acquired Arena contribution and the velocity business unit overall, layered on top of another strong quarter in the core CAD and PLM business. In Europe, our ARR growth was 13%. We saw strong results across the board in Europe, with the strongest drivers of the growth being our digital thread growth and core businesses. Europe has the largest mix of channel versus direct and the resellers continue to perform well.\\nOur ARR growth in APAC was 14%, with growth primarily driven by our digital thread core business. Next, let's take a look at the ARR performance of our various business units, starting with the digital thread group on Slide 6. In our largest product segment, digital thread core, we delivered yet another double-digit performance in Q1 with 11% growth. Within this, CAD and PLM, both grew double digits, with strong growth across all three geographies.\\nThis is the 17th consecutive quarter of double-digit ARR growth in the core business. And as we roll out our more aggressive SaaS strategy, I expect we'll see many more. In the digital thread growth, which is IoT and AR, we saw ARR growth of about 14%, consistent across both elements. This was in line with our plan and the mid-teens near-term growth expectation we set at the recent Investor Day.\\nWhile this level of growth remains accretive to company growth, we continue to expect an acceleration of growth into the 20s as we get into the back half of the year. The biggest driver of growth in Q1 was from expansions, especially in Europe and APAC. We believe market conditions in IoT are improving, and we like the way the pipeline for our new DPM offering is developing through both PTC and Rockwell channels. For AR, we continue to see a tremendous level of interest, but the market remains nascent.\\nPerhaps most importantly, the formation of the digital thread business unit at the start of FY '22 has driven important initiatives to increase our focus on cross-selling of IoT and AR into the core CAD and PLM customer base. FSG had a great Q1 with 6% ARR growth. The expansion deal we recently announced with the U.S. Air Force, both increases and extends this key relationship for up to five more years.\\nContracts like this demonstrate the value that our customers are realizing from Servigistics and other FSG products such as retail PLM and ALM. You may remember, I noted at our Investor Day that having FSG grow in the mid-single digits rather than flat would be a helpful upside growth driver. So I'm pleased to see FSG post another strong quarter. Let me run through a couple of quick customer anecdotes to give you a sense for our digital thread customers and how they rely on us.\\nOn Slide 7, MAN Energy Solutions is the world's top provider of large-bore engines in turbomachinery for the maritime and energy industries. The company manufactures complex parts in nearly every engine they make must meet unique customer requirements. Before implementing Creo, they relied on manual outdated processes that slowed design and production. With Creo, they've been able to transition from 2D to a full 3D model-based approach.\\nCreo's broad range of tool path automation capabilities enable them to save time in the programming of the tool pass used to machine the large complex engine parts, greatly increasing efficiency in transitioning from design to production. Turning to Slide 8. You may have noticed we announced a deal with -- we announced that the German company, Scheffler, has expanded its relationship with PTC, and I'd like to share a bit of the back story. Scheffler has been a longtime Creo customer and has successfully deployed Windchill within engineering.\\nBut back in 2017, one of our PLM competitors announced a large PLM deal with Scheffler that appeared to cap PTC's expansion opportunity. But that system didn't ultimately stick as Scheffler has now decided to consolidate on PTC systems with Windchill being the backbone and is broadly deploying our solutions in their standard out-of-the-box fashion so that Scheffler can participate in the full power of our digital thread portfolio. I'm very excited about this collaboration and the further expansion that Scheffler is exploring with our IoT and AR offerings. On Slide 9, you'll see how IMA Group, our global business that delivers packaging machines, services, and solutions to a wide variety of industries, was looking for a way to expand their control room offering to help their customers improve overall equipment effectiveness and reduce downtime.\\nAs longtime users of PTC's Creo and Windchill, IMA decided that ThingWorx was the ideal IoT solution for their initiative and that Kepware could provide connectivity not only to their machines, but to the other vendors' machines deployed alongside them. IMA has successfully launched new revenue streams by enabling 24/7 monitoring of customer production lines and improved OEE by up to 16%. The Vuforia integrated with ThingWorx is the platform of choice for the U.S. Air Force training initiatives.\\nSlide 10 highlights the work that PTC partner, Vectrona has done with the U.S. Air Force. With finite training resources and limited capacity, the U.S. Air Force set out to incorporate augmented reality into their maintenance and munitions training.\\nVectrona using Vuforia Studio worked with the U.S. Air Force to create immersive 3D AR experiences for phones, tablets, and the HoloLens 2 that are designed to accelerate learning, improve work performance and facilitate remote training. The improved training shows better engagement and information retention with continuous and repeatable task training available regardless of the system or aircraft type. Turning to Slide 11, the velocity business ARR growth in Q1 was more than 650% due to the inclusion of Arena and 53% organically, which would be Onshape.\\nIf you were to add Arena's pre-acquisition results into the prior year to get a better pro forma comparison, then you'd have the velocity business unit growing at 28% in Q1. That 28% is a mix of Onshape growing at 53% and the larger Arena business growing in the low 20s. Growth of both Onshape and Arena is multiple times higher than market rates, clearly demonstrating that industrial companies see the benefits of SaaS. We continue to ramp investments to expand technology leadership and to broaden the geographic presence of our velocity businesses.\\nOn Slide 12, Beta Technologies, a leading developer of next-generation electric aircraft for the cargo and logistics market, sought a cloud-native product development platform where everyone would be working with one single source of truth without the workflow restrictions of traditional file-based design systems. Beta turned to Onshape because of how it enables real-time collaboration, allowing the engineering team to work from any location while streamlining their communications during the design process. To profile Arena customer, Potrero Medical, on Slide 13, is a predictive health company developing the next generation of medical devices, leveraging smart sensors and artificial intelligence. Potrero needed a scalable quality management system to support its growing product development and compliance needs, including satisfying FDA audit requirements.\\nArena was the right solution, offering a cloud-native QMS with a quick implementation, leading to ECO cycle time reduction of 30% and nonconformance improvement of 20%. As a final topic, I'd like to give you a quick update on our SaaS acceleration initiative on Slide 14. We've made tremendous progress in the past 90 days since we announced the more aggressive strategy. We've launched our SaaS program management office, which was modeled after the very successful approach we used to drive our subscription transition several years back.\\nOur field organizations transition to the new two-in-a-box customer success organization model without missing a beat. We converged our cloud and tech support organizations with product development to deploy the DevOps type of approach you see in virtually all SaaS companies. We've made good progress advancing our offerings, especially the Windchill multi-tenant version, which will go into production shortly this quarter, and we made good progress preparing the SaaS conversion offerings that will power the hundreds of lifts and shifts that will happen in the coming quarters and years. We have more work to do, but we're certainly up and running.\\nThe time for SaaS has arrived in our industry and PTC is very well positioned. We're already the SaaS leader in our space with continued strong SaaS growth in Windchill and FSG and high levels of growth in our cloud-native velocity business unit. Sharing the Atlas SaaS platform, we have a dual strategy to win with Onshape and Arena powering a new agile product development approach, while we transition our digital thread portfolio and existing customer base to SaaS to elevate the platform strategies that so many larger companies have. To wrap up on Slide 15, I'm pleased with PTC's position and the opportunity that lies ahead.\\nQ1 gave us a strong start to what we expect to be our fifth consecutive year of double-digit ARR growth. Our portfolio of products is unique and compelling and obviously aligns well to customer demand. Our results have been consistently strong for many quarters, but we're poised to accelerate growth as the SaaS tailwind blows harder in coming quarters and as we gain more momentum with our IoT and AR initiatives in the back half of the year. We're poised to drive higher levels of profitability, too, following the organizational changes we've already implemented and as our start-up businesses continue to mature up their J curves.\\nThe company has never been in a better position to create shareholder value. With that, I'll turn it over to Kristian for more details on the financial results.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nThanks, Jim, and good afternoon, everyone. Before I review our results, I'd like to note that I'll be discussing non-GAAP results and guidance, and growth rate references will be in both constant currency and as-reported rates. So turning to Slide 17, we delivered constant currency ARR of $1.507 billion, which is 16% growth year over year and slightly exceeded our Q1 guidance of $1.5 billion. On an organic constant currency basis, this is 11% growth.\\nFX was an approximate $11 million headwind in Q1, so our as reported ARR was $1.496 billion. Our SaaS products in both the digital thread and velocity business units saw a continued strong growth in Q1, with growth rates similar to what we discussed at our recent Investor Day. This is in combination with continued strong growth of our software-only sales. As of Q1, our SaaS portfolio is now 15% of our total ARR on a constant currency basis.\\nQ1 free cash flow of $134 million grew 21% year over year and includes $11 million in restructuring and other related payments. Adjusted free cash flow was $145 million and was slightly ahead of the $140 million we discussed at our Investor Day. Q1 revenue of $458 million increased 7% year over year. As we've discussed previously, revenue is impacted by ASC 606, so we do not believe that revenue growth rates are indicative of our underlying business performance but would rather guide you to ARR as the best metric to understand our top-line performance and cash collection.\\nFX only impacted revenue by about $1 million in Q1. So our revenue on a constant currency basis was $459 million. Q1 non-GAAP operating margin of 35%, compared to 36% in Q1 of 2021. While this is a strong result, it's still worth pointing out that because revenue was impacted by ASC 606, other derivative metrics such as gross margin, operating margin, and EPS are all also impacted.\\nSuffice it to say that our COGS and opex came in in line with our expectations in Q1, and we continue to maintain good discipline on our operating expense structure. I would like to point out that our GAAP results reflect a gain of $9.8 million related to our investment in Matterport. And we're also slightly reducing the range for expected P&L charges from approximately $45 million to $50 million, down to $40 million to $45 million for the full year. And coincidentally, we're also reducing the range of expected cash payments for the restructuring and other from what was previously $50 million to $55 million, down to $45 million to $50 million for the full year.\\nFor guidance purposes, we will continue to show $50 million as the cash payments and the adjusted free cash flow reconciliation. But as payments come in lower, then we would just expect actual free cash flow to come in higher. There's no change to the $450 million adjusted free cash flow target. Moving to Slide 18, I'll begin with our balance sheet.\\nWe ended Q1 with cash and cash equivalents of $296 million. In addition, at the end of Q1, we had medium-term investments of $87 million, primarily related to our investment in Matterport. Our gross debt was $1.45 billion with an aggregate interest rate of about 3.2%. In Q1, we used $120 million of cash to repurchase shares.\\nWe also had an additional $5 million of repurchases, which settled early in Q2. For the remainder of fiscal '22, we will focus on delevering and looking forward to FY '23 in an ongoing go-forward basis, assuming our debt-to-EBITDA ratio is below three times, we will continue to target to return approximately 50% of our free cash flow to shareholders via share repurchases. Turning to Slide 19. We post a data table to our IR website that has our financial statements, as well as ARR detail by segment.\\nIn that file, we share both constant currency and as-reported ARR. As a reminder, when we calculate constant currency, we use our current year plan FX rates and restate history to the same rates. So here, for example, on this slide, you can see our Q1 constant currency ARR of $1.507 billion and the actual as reported ARR of $1.496 billion. This is important to remember in the context of our guidance because we provide guidance at the planned rate.\\nWe believe this is the best way to evaluate the top-line performance of our business because it removes FX fluctuations from the analysis, positive or negative. With that, I'll move on to guidance on Slide 20. As Jim mentioned, we're raising the low end of our full year constant currency ARR guidance by $10 million. The new range is now $1.625 billion to $1.660 billion.\\nThis essentially reflects rolling our Q1 overperformance through the remainder of the year. We're now expecting constant currency ARR growth of 11% to 13% in fiscal '22. It's worth pointing out that based on FX rates at the end of Q1, we would expect a $13 million headwind against that full year ARR guidance. For Q2, we're setting constant currency ARR guidance of $1.540 billion to $1.550 billion.\\nThis is 12% organic constant currency growth at the midpoint. On an as-reported basis, the FX impact we're calculating based on the FX rates at the end of Q1 is a $12 million headwind in Q2 compared to the constant currency guidance. Moving to free cash flow. We're maintaining our full year free cash flow target of $400 million.\\nThis includes approximately $50 million of restructuring and acquisition-related payments. The majority of these payments are related to the reorganization we announced in Q1 with some residual payments primarily related to our Seaport move for which we took the accounting charge in prior periods. So our adjusted free cash flow target for fiscal '22 remains $450 million. Fiscal Q2 adjusted free cash flow is expected to be approximately $155 million.\\nWe expect to make approximately $20 million in restructuring and other related payments in Q2, bringing our free cash flow to approximately $135 million. Moving to revenue. We're also taking the low end of the full year revenue guidance up by $20 million. This reflects both the strength in software and strength in the professional services business that we saw in Q1 and the related forecasts for the full year.\\nSo for fiscal '22, our net revenue guidance range is $1.870 billion to $1.975 billion. The year-over-year growth rate range is now 3% to 9%. Our ASC 606 makes revenue very difficult to predict for on-premise subscription companies, hence the wide range. Note that revenue variability has -- this is from 606, has no impact on ARR or its related cash generation as we continue to primarily bill customers annually upfront regardless of term length.\\nWe continue to expect more than 60% of our annual free cash flow generation to occur in the first half of the year. Collections are stronger in the first half, and we expect expenses to increase as we ramp hiring in our SaaS investments throughout the year. We're wrapping up on Slide 21 with the free cash flow model that we use and went into some depth on at our recent Investor Day that you can see here. I know many of you use model free cash flow using the indirect method.\\nHowever, given the complexities related to revenue recognition due to 606, this is difficult to do. The model we show here has proven quite effective. The table shows fiscal '21 actuals compared to the model we shared at Investor Day compared to our current guidance. Let me take you through the model focusing on the non-GAAP column on the right and starting at the top.\\nFirst, we're showing the midpoint of our as reported ARR guidance of $1.630 billion, which is different from the constant currency guidance that we gave due to the $13 million FX headwind and is also $5 million lower than what we showed at the Investor Day. We use it as reported here because it's a better reflection of the cash we expect to generate. You can also see that we have increased the perpetual license revenue forecast slightly and also the professional services revenue increase that we mentioned earlier. COGS is slightly higher, reflecting the increased costs to deliver the incremental professional services revenue and the rest of the assumptions remain the same, and we still end up with our target adjusted free cash flow of $450 million.\\nObviously, this is a model based on assumptions such as the midpoint of the ARR range, the impact of FX, the pace of hiring, etc. So if some of those variables change, which they invariably will, the model will have to be adjusted accordingly. And as I mentioned earlier, if cash payments related to the restructuring coming at the low end of the range, we would see a flip from the restructuring line to the free cash flow line, but the adjusted free cash flow target would remain unchanged. But as we sit here today, we think this is a reasonable view of how we expect the year to shape up.\\nSo with that, I'll turn the call over to the operator, and we can begin Q&A.\\u00a0\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] We ask the analysts to please limit themselves to one question only. If you have any additional questions, please return to the queue. Thank you.\\nYour first question will come from Andrew Obin from Bank of America. Please go ahead. Your line is open.\\u00a0\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nHi, yes. Good afternoon.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Andrew.\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nJust a bigger picture question. I apologize, I missed the first couple of minutes. You know, we hear a lot about supply chain constraints. And frankly, we're hearing that this might extend the run-in terms of PMI expansion.\\nSo what are you hearing in terms of sort of as you have conversations about PLM and in terms of adoption? What kind of conversations are you having with your customers? And do customers have awareness of sort of supply chains being gummed up for longer? And are you seeing this having any discernible impact on what kind of conversations you're having with people?\\nJim Heppelmann -- Chief Executive Officer\\nAndrew, it's Jim. No, actually, it's not really a frequent topic in our conversations because -- well, first of all, since you said you missed the first minute, one of the things I pointed out is that our bookings came in very, very strong, and I explained about 20% higher than planned. So we had a very, very strong bookings quarter. And notable in that was PLM, although, frankly, the strength was broad-based.\\nI think the key thing to remember is that PLM is really associated with preparing product data in engineering that will then subsequently be used in manufacturing and perhaps in aftermarket service. And it's collecting data from supply chain partners and so forth. But production problems in a supply chain don't necessarily impede the collaboration during the engineering and the preparation for production process. So I think people are saying like, maybe I can't get chips to complete the product, but that doesn't mean I should stop designing the next one because if it does, then I'll fall behind.\\nSo I think that our view would be that the product development process has largely been unaffected by the supply chain process. Now some other things, we talked about how perhaps COVID had an impact on IoT, perhaps the supply chain a little bit, although I think muted compared to COVID. So to me, the supply chain thing is a fairly small factor in our results. We just see very little correlation between what's happening out there with supply chain problems and what's happening with our pipeline and frankly, with our bookings.\\nOperator\\nYour next question comes from Yun Kim from Loop Capital. Please go ahead. Your line is open.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nHey, Yun.\\nYun Kim -- Loop Capital -- Analyst\\nThank you. Hi, Jim. Can you just talk about the IoT business, you know, in terms of the large deal activity? What kind of trends are you seeing there? Obviously, you are expecting that business to accelerate in the back half -- second half of the year. If you can talk about whether that confidence is coming from the, you know, improvement in the large deal activity? Or is it just the overall volume of the activity around IoT? And then also, if you can just comment around deal size activity around the AR business as well.\\nThanks.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I think deal sizes are sort of unchanged from previous trends. If you think -- what are we looking at when we project forward how IoT and AR will perform. Well, we're looking at the bookings, let me say, at the pipeline that will drive bookings, and for IoT and AR was quite strong.\\nWe're looking at the backlog. Last year, bookings actually had improved over the prior year. And bookings that went into backlog or -- I'm sorry, what we call deferred ARR, were quite high. We were well ahead of our deferred planned number as we actually did last year.\\nSo you could imagine we've got more, and if you want to call it, backlog waiting for us. And then what other initiatives are we doing? So for example, our DPM launch, I think, will be materially positive for our IoT results. It will drive bigger deals. It will drive better value propositions.\\nIt's really software that's ready to turn on and get value from as opposed to a platform. And then the other thing is, Troy Richardson talked at our Investor Day about organizing better for cross-sell. And I think if we look backwards, maybe we had pivoted too much toward new logos, which are great. I mean, new logos are a wonderful thing.\\nBut we probably have low-hanging fruit yet to pick within our installed base of CAD and PLM accounts. So I think it's really this combination of a strong-looking pipeline, good-looking trends, awaiting us in the deferred backlog and then these other initiatives kicking into place, DPM and cross-sell that I think will all be very helpful as we proceed through the year. And again, I want to remind everybody, we set the expectation that the two handle would materialize in the back half of the year and that you wouldn't see it in Q1 and Q2. So we sort of feel like this was as we had predicted just mid-December a couple of weeks ago.\\nOperator\\nYour next question comes from Jason Celino from KeyBanc Capital Markets. Please go ahead. Your line is open.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nHey. Hi, Jim. Hi, Kristian.\\nJim Heppelmann -- Chief Executive Officer\\nHi, Jason.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nSo one question on maybe the SaaS Windchill, you know, launch. It seems like it's coming along, you know, nicely, and we could see something maybe go GA this quarter. Have you had a chance to maybe, you know, discuss this with customers? How is the pipeline shaping? Or is it maybe better to think that the pipeline might start to form once we do go live?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nNo, we have, for sure, started talking about it with customers. I mean, ramping up that process. We've got to educate a lot of people and they, in turn, have to educate customers. But we've certainly made some progress, and I can tell you the customer interest is actually quite high.\\nYou should know that actually, customers were pushing us a little bit to get going with such initiatives -- so I feel like the demand is there. And in fact, again, just reflecting on what we told you, that business has been growing about 30%. And Kristian mentioned we posted another quarter just like that, without us really invoking the new strategy yet. So there's lots of demand.\\nWe're just looking for a model where we can promote the demand because we like the margin profile better. And that's what's coming into place here in Q2.\\nOperator\\nYour next question comes from Adam Borg from Stifel. Please go ahead. Your line is open.\\u00a0\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nGreat. Thanks so much. And maybe just two quick ones. Just on the Scheffler win that you announced yesterday and highlighted on the call earlier.\\nOne of the things I thought was really interesting in the press release was this opportunity around some more vertical-specific or market-specific solutions targeting either automotive or industrial companies. So maybe, Jim, if you could just talk about that. And maybe just as a quick follow-up, just maybe for Kristian. Any way you could talk about this transition, it's great to get the early feedback on the SaaSification efforts, but any way to comment on, you know, how much this has contributed to bookings or the pipeline, at least qualitatively? Thanks so much.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I'll get the first part of the question. Kristian, you can take the second part. Yeah.\\nSo Scheffler is a great account. And as I mentioned back in 2017, it appeared they were going in a different direction, and now they've decided to come back into the fold. And honestly, they did that for two main reasons. One is that they really want off-the-shelf technology.\\nThe other competitor had told them this low-code, no-code story, and they tried that out and decided that's not really what they want. They don't want to develop their own solutions. They want to deploy standard out-of-the-box software that all works together. And then they want to engage in partnerships with the vendor, in this case, PTC to talk about how those solutions should evolve to be more and more powerful to meet their needs.\\nSo yeah, I'm very excited. I'm in the middle of that relationship myself. And yes, what's going to come out of that is technology that fits better and better, for example, for the automotive supply chain, which is a place where we have a lot of customers. So it's a great win or win back, maybe I should say, and a great partnership going forward that's going to produce a lot more business for us in years to come.\\nAnd sorry, the second part of the question was around the transition to SaaS and how that's manifesting itself in terms of pipeline and activity? Is that right, just making sure I got that right.\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nExactly. Any way to qualitatively comment from, you know, either bookings or a pipeline perspective?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, remember, I mean, the bookings that we just reported were for Q1, and Q1 is really when we actually just announced the acceleration of it. So I would say there's actually a limited impact in the actual bookings result here in Q1. That said, as I mentioned, we continue to see strong demand for the SaaS properties that we have.\\nThat's both in velocity and the digital thread. And so those products continue to grow at a rate higher than our software-only products. And now as the program is pushing ahead, we expect to see demand and pipeline generate, especially with the new Windchill launch coming out here and the program continuing to pick up speed internally.\\nKristian Talvitie -- Chief Financial Officer\\nMaybe, Adam, I could just add. We launched this phase 3 strategy 90 days ago on the earnings call. And there's nothing we've seen since that makes us any less bullish than we were back then. I mean it looks like a really nice opportunity for PTC, and we're pushing forward ahead as aggressively as we can because we'd like to bring that very promising upside growth driver, you know, closer in.\\nSo it has a bigger impact on '23 and '24 and so forth than it would otherwise have had.\\u00a0\\nOperator\\nYour next question comes from Jay Vleeschhouwer from Griffin Securities. Please go ahead. Your line is open.\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nThank you. Hello. Hi, Jim. Hi, Kristian.\\nA couple of things. With regard to the strength you noted for PLM, at your partner conference six months ago, back in the summer, management presented to the channel, your concept that PLM was no longer just an engineering vault that it was becoming memorial, what you call, multisystem, multidiscipline concept. And the question is, to what extent is that broader, more diverse view of PLM a current part of new business or in the pipeline for new business as compared to the more conventional historical way of thinking about PLM? By our calculation, we are already the second-largest brand by revenue in PLM, and maybe talk about what some of the drivers are to that? And then just a quick clarification you referred earlier to cross-sell. At the Analyst Meeting last month, in the slide deck, you referred to cross-sell 10 times and relatedly account-based selling.\\nPTC is often over the years, talked about cross-sell, but maybe talk about what's different this time in terms of resources and programs across your various segments and your new customer segmentation model.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, on your first question, Jay, you know, you are always very pressy on, you've been watching this industry for a long time. When we say multisystem, multidiscipline, what we're really talking about is an enterprise system. And so what's happened in the last couple of years is PLM has graduated from being an engineering data management system to being an enterprise system that contains the system of record for the product definition.\\nAnd so if you're in manufacturing, well, you need to know the product definition. If you're in procurement, you need to know the product definition. If you're all on an installation or a support call, you probably need to know the product definition. So definitely what's happened is that the enterprise deployments of Windchill are multiple times larger than the engineering deployments of Windchill.\\nSo something that's been driving growth for some years now is that the new deals we're taking are more and more frequently enterprise deals and they're larger. You may remember, last quarter, I told you we took the largest deal we had taken to date from a med device company. And the second thing that's happening is, we're circling back to those companies who had deployed the engineering solution like say, Scheffler, and we're upselling them to the enterprise solution and turning that into a much bigger opportunity for us. So definitely, that's a real thing, and it's been driving the momentum we've seen in Windchill for years.\\nAnd frankly, there's a lot of it out ahead of us even before we start talking about SaaS. The upsell from a departmental solution to an enterprise solution is a driver, taking that whole enterprise solution to SaaS is a whole another growth driver that's on top of that and sort of orthogonal to it. And then on the account-based selling, there's two ways to look at that. Cross-selling into your accounts is a great thing.\\nYou have established relationships. It's much easier to sell another product to an existing customer than to sell a new product to a new customer or a first product to a new customer. At the same time, we like new logos. So it's really always about the balance of how much do you invest in new logos pursuits versus how much do you invest in selling more to the companies who know and trust you.\\nAnd I think perhaps with IoT and AR, we realized we had over pivoted toward new logo, which is just generally speaking, less productive selling, you might imagine. And so the reason we formed this digital thread group, which brought CAD and PLM and IoT and AR together under Troy Richardson, was to really lubricate how these products work together and how we position them together and to be able to start anywhere and sell up and down that chain. So it's a good strategy. It's one that we -- it's a muscle we've developed well over the years.\\nWe really built the Windchill business, largely by cross-selling to the Creo base. And I think this is going to be something that will help us a lot to kind of get the right balance of new logo pursuits in cross-sell.\\nOperator\\nYour next question comes from Ken Wong from Guggenheim Securities. Please go ahead. Your line is open.\\u00a0\\nKen Wong -- Guggenheim Securities -- Analyst\\nThank you so much for taking my question. Jim or Kristian, I wanted to perhaps dive into the double-digit organic bookings growth. You know, I couldn't help and notice you guys also had a very large Servigistics expansion deal with the Air Force. I mean how much of that was already in expectations? Or did you get some boost there from timing shifts or anything of that nature?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Let me tell you, none of that actually contributed to the double-digit growth because that was a Q4 deal. You know, we released it when we had approval to release it, and I commented on it because it was, you know, an important customer and so forth. And let me say that deal, again, that was closed in Q4, both represented five years of extension, but also about a 50% growth in a ramp that happens over -- I think it's three years.\\nSo it roughly goes from a $10 million run rate to a $15 million run rate over three years and stays there for a couple more. That's what the contract contemplates. So some of that will come into ARR in Q4 of this year, but the bookings actually were in Q4 last year. So that strength -- the strength we saw in Q1 was exclusive of that Air Force deal, which just means it was really great strength.\\nSo anyway, it was hard to pin down where the strength comes from because it came from CAD. It came from PLM. The IoT number was actually pretty decent. It didn't all go into ARR.\\nAnd then, of course, the velocity numbers and the FSG numbers. So it was broad-based in all geographies and really in all product lines.\\nOperator\\nYour next question comes from Matt Broome from Mizuho Securities. Please go ahead. Your line is open.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Matt.\\nMatt Broome -- Mizuho Securities -- Analyst\\nThanks, man. So Jim, I mean, I guess, just on that -- sorry, just deal that I can just mention. Given the importance of supply chain management right now, are you seeing like ramping demand to the solution elsewhere? And sort of following on from that, is there a chance that FSG ARR could actually accelerate on the back of that demand beyond the sort of the mid-single-digit level and actually become sort of more strategic in a way?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean that's one of the points, Matt, that I brought up at the recent Investor Day is that we've generally modeled FSG to be roughly flat, flat about plus 1% to 2%. But it's actually been performing. I think last year, Kristian, wasn't up 7%, FSG.\\nIt was up 6% here again in Q1. So yes, we're overperforming and Servigistics is one of the key drivers. And then the second one probably is retail PLM, which has also been doing fairly well. So definitely, there's some -- I think we'll be conservative and leave the FSG sort of guidance where it is in the near term, but I do like overperforming it because it's a growth driver.\\nThe FSG business is about the same size as the IoT and AR business. So every point of growth we get there is pretty meaningful.\\nOperator\\nYour next question comes from Matt Hedberg from RBC Capital Markets. Please go ahead. Your line is open.\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nYeah. Thanks. This is Matt Swanson on for Matt. I'll kind of follow up on a piece of both Adam and Jay's questions.\\nSo looking at the Scheffler announcement, I think the thing I was really interested in was the idea around standardization and the idea around end-to-end. So could you talk a little bit about your customers' desire around standardization? And clearly, this product road map has really expanded your TAM, but I think one of the upside areas something we -- you know, maybe the holy grail of the transition would be more competitive displacements. And I'm just curious if you're starting to hear, you know, any early or more talk around that because you're building something so differentiated.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean, for sure. So the standard thing, I think maybe over the last couple of years, industrial companies have realized that they should be using software, not developing it. And so we saw this in our IoT business, and it's been why we've been heading up the stack with solutions like DPM is, customers would like to buy the software and use it, not buy some kind of a platform and create it because they just don't really know how to create it if I'm frank.\\nSo Scheffler had gone down the path of kind of like I said, low-code sort of environments and came back to standard products. And then the end-to-end thing, for sure, the CAD data that's created in Creo and managed in Windchill gets used, for example, in augmented reality, manufacturing, and service instructions much later and in a different part of the company if it's all well managed. And that connectivity from IoT, well, let's say, from CAD to PLM to IoT to AR is what we call the digital thread. And so we actually see so much interest in this that we kind of organized around that principle.\\nLet's stop presenting these products as kind of independent things and let's shine the light on how well they work together in an end-to-end solution. And by the way, how they're all ready to go. That this is something that turn on and use. And that's really what one Scheffler over, but I can tell you, Scheffler is not unique at all.\\nAnd it's really -- we're organizing to respond to that. SaaS is helpful, by the way, because if you want a lot of technology working end to end, it'd be better not to ship at all to the customer side because it gets complicated. The customer would like to just use it, not set it all up and care and feed for it on-premise.\\nOperator\\nYour next question comes from Saket Kalia from Barclays Capital. Please go ahead. Your line is open.\\nSaket Kalia -- Barclays -- Analyst\\nOK, great. Hey, guys. Thanks for taking my question here. Hi, Jim.\\nHey, Jim, maybe -- hey, Kristian. Jim, maybe for you, it was great to hear the PLM strength this quarter in bookings. With other companies that have done shifts like this, there's always a risk, I guess, of customers behaving differently, right, whether that's slowing purchases to see what's coming or maybe pulling forward purchases before something new comes out. Now just to be clear, it doesn't sound like that happened here.\\nBut can you just stress test that for us a little bit? And what you sort of look at to sort of manage what is, you know, more choices for our customer to make. Does that make sense?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Are you referring -- just let me clarify, are you referring to like SaaS choices being new choices or more broad --\\u00a0\\nSaket Kalia -- Barclays -- Analyst\\nYeah, that's right, yeah, Windchill. No, Windchill specifically.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So keep in mind, Saket, we have been selling Windchill as SaaS for some time. Remember, the phase 1, phase 2, phase 3 thing. So since phase 1, we've been selling Windchill, and we showed you, it's got a three-year growth CAGR of 30% in SaaS.\\nSo the customer demand is strong. It's just -- on the PTC side, we need to pivot to multi-tenant because in the single-tenant model we just don't have the profitability we like. So the demand is strong. The customers are buying it.\\nKristian mentioned we had another strong quarter. So it really is, we'd like to meet that demand with a solution that's more efficient for us to operate on behalf of the customer. And that's what phase 3 multitenant really is all about. Now when it becomes more efficient for us, we can then lean in on the promotion and marketing of it, because we haven't really done that.\\nSo we've been servicing demand, not driving it. And with phase 3, we think there's an opportunity to drive demand and, you know, the preliminary data we've seen this quarter suggest customers are very responsive, both to buying new systems that way, but also to lifting and shifting the previous systems they bought and giving them to us to operate and serve back to them in a SaaS model.\\nOperator\\nYour next question comes from Joe Vruwink from Baird. Please go ahead. Your line is open.\\nJoe Vruwink -- Robert W. Baird and Company\\nGreat. Hi, everyone. Just to go back to bookings, does the strength this quarter absent mega deals suggest anything about either the demand environments or maybe just the health of your mid-market and SMB customers? And looking ahead, are there going to be certain things you think about or track when contemplating, you know, the probability of more mega deals or maybe the larger ARR contributors for PTC, maybe, you know, being a bit more represented in future bookings?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nKristian, let me again take a stab at that and maybe you'll find things to add. So I think if you look at the bookings, again, they were phenomenal, and it's hard to pin down. It wasn't one geography. It wasn't one product.\\nIt was all geographies, all products. So I think it tells us that the end market is very healthy. And I would say, for two different reasons. On one hand, the PMIs are in good shape.\\nThat's helpful. On the other hand, the interest they have in the digital thread, digital transformation story, and the interest they have in SaaS is secular. That interest is not related to the PMIs, it's kind of independent of them. And so I think that we're just in a very healthy situation where industrial companies are leaning in on trying to get more digital.\\nThey see PTC as having a fairly unique and compelling portfolio, and they're interested in engaging and trying to make their companies more efficient. I can tell you, at Scheffler, for example, it's one of the top initiatives in the company is to get more digital. And as it relates to the whole product life cycle, the partners PTC. And we see that kind of phenomenon happening in a lot of places in the industrial world.\\nSo I think it's just good, strong, secular and as well macro-environment out there right now. But I'll remind you that we've had good performance even when the macro environment wasn't so strong. So all things being equal, I like the strong macro. But we're 17 quarters in with double-digit growth in the core business, and there were a lot of bad macro quarters over the course of those 17.\\nSo I think it really is the secular driver. Kristian, anything?\\nKristian Talvitie -- Chief Financial Officer\\nYeah. I mean I agree with all that. I mean, actually, just on the big deal dynamic, you know, what we used to call mega deals. We haven't -- I think we've had four in the past four years.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, keep in mind, perpetual drove bigger upfront purchases and subscription or SaaS tends not to.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYeah, which is my point that we've been seeing good strong bookings performance and bookings growth, you know, even with the absence of what used to be a fairly regular occurrence back in the perpetual days, like we really don't see a lot of those.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah, it's a good healthy business. OK. Next question.\\nOperator\\nYour next question comes from Blair Abernethy from Rosenblatt Securities. Please go ahead. Your line is open.\\u00a0\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nThanks very much. Guys, just maybe a quick question on -- around partnerships, in particular. I wonder if you could just give us a little deeper dive into how things are going with Rockwell and as well on the simulation side with Ansys?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So the state of the partner economy is good and, you know, Microsoft, I could put on that list, is also strong. With Rockwell, you'll remember in the past quarters, I had said we should take a bit of a conservative posture as it relates to what Rockwell would contribute to PTC's numbers here in fiscal '22. And we did that because Rockwell had made a big acquisition.\\nYou know, Rockwell never completely agreed with me on that. Their own public commentary kind of indicated they didn't worry too much about that. And in Q1, they were right. So we're pleased to see that Rockwell's contribution was solid in Q1 and starting to feel pretty good about the year.\\nI'll tell you one thing is this DPM solution appears to be a very good fit with Rockwell. And in fact, their Calypso alarm is probably lined up to be our strongest partner in promoting DPM. So we're very happy with that. Calypso has a long-term relationship with PTC that even predates their acquisition by Rockwell.\\nSo great alignment around DPM. Again, DPM is a high-value up-to-stack solution that drives bigger deal sizes, and we think will be a very sticky solution. So lots of optimism around that. With Ansys, we continue to differentiate now with best-in-class simulation.\\nSo whereas simulation some years back would have been viewed as a soft spot for PTC. Now it's a strength. If we're competing against Autodesk or Siemens or Dassault, nobody is going to have a better simulation story than PTC because nobody has a better simulation story than Ansys, and Ansys products are built into PTC products. So that's been going well.\\nAnd then, of course, with Microsoft, that partnership is performing well and poised to get a lot bigger because as we bring more stuff aggressively to SaaS, a whole lot of that is going to land on Azure. So I think all three partnerships are alive and well and as important as ever and helping us achieve the kind of results that we're achieving.\\u00a0\\nOperator\\nYour last question comes from Sterling Auty from J.P. Morgan. Please go ahead. Your line is open.\\nSterling Auty -- J.P. Morgan -- Analyst\\nYeah. Thanks. Hi, guys. Just wondering if you could characterize with the headcount changes that you pointed out are necessary to facilitate the acceleration to SaaS.\\nWhere are you in that process? What's left to go? And kind of what's the time frame that you expect to complete that over?\\nJim Heppelmann -- Chief Executive Officer\\nYeah, Kristian, I'm thinking of the numbers we're largely done, but not completely. Eighty percent, 90% done.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYep, with the exiting.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean we'll be hiring people throughout the year. So -- but in terms of the people who are exiting, they're largely exited by now that largely happened within the first quarter.\\nSterling Auty -- J.P. Morgan -- Analyst\\nUnderstood. Thank you.\\nOperator\\nWe have no further questions. I'd like to turn the call back over to Jim Heppelmann for closing remarks.\\nJim Heppelmann -- Chief Executive Officer\\nOK. Well, thank you, all. There's a lot of good questions and, you know, I think good answers because the business is performing very well right now. ARR is doing well.\\nBookings are doing well. Free cash flow is doing well. You know, I think we executed -- through good times and bad, we executed through the changes we made over the last quarter, and we're set up to do pretty well for the balance of the year. So, we're very confident and, you know, look forward to talking to you all in 90 days if we don't happen to cross pass with you sooner in an investor event or what have you.\\nSo, thanks a lot for joining us and have a good evening.\\nKristian Talvitie -- Chief Financial Officer\\nThanks, everyone.\\u00a0\\nOperator\\n[Operator signoff]\\nDuration: 59 minutes\\nCall participants:\\nMatthew Shimao -- Head of Investor Relations\\nJim Heppelmann -- Chief Executive Officer\\nKristian Talvitie -- Chief Financial Officer\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nYun Kim -- Loop Capital -- Analyst\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nKen Wong -- Guggenheim Securities -- Analyst\\nMatt Broome -- Mizuho Securities -- Analyst\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nSaket Kalia -- Barclays -- Analyst\\nJoe Vruwink -- Robert W. Baird and Company\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nSterling Auty -- J.P. Morgan -- Analyst\\nMore PTC analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, ladies and gentlemen, and welcome to ASUR's First Quarter 2020 Results Conference Call. My name is Kathy and I'll be your operator.\\n[Operator Instructions]\\nNow I would like to turn this call over to Mr. Adolfo Castro, Chief Executive Officer. Please go ahead, sir.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and good morning everyone. Thank you for joining us on the conference call to discuss ASUR's first quarter financial and operating results. Before starting the call, I would like to express my hope that you and your families are healthy and safe in these uncertain times. As a reminder, please note that certain statements made during the course of our discussion today may constitute forward-looking statements which are based on our current management expectations and beliefs and are subject to a number of risk and uncertainties that could cause active results to differ materially, including factors that may be beyond our company's control including the impact from COVID-19. For an explanation of these risks, please refer to our filings with the US Securities and Exchange Commission and the Mexican Stock Exchange.\\nOverall, our first quarter results were good. The year began in solid footing before we started to see the impact of COVID-19 pandemic in the second half of March. It resulted in the disruption of global travel industry. Importantly, in the end of the first quarter we had healthy balance sheet which I will come back and discuss in more detail later in my presentation. I'm going to start today's presentation with some comments regarding COVID-19 and the impact on the industry, on our business, and the steps we are taking to mitigate this disruption to the best we can in this rapidly changing environment. From an industry perspective, since mid-March, many governments have issued flight restrictions in an effort to mitigate the spread of COVID-19 virus. In turn, capacity has been severely reduced and very few people are booking flights as most are in some form in lock down around the world and not traveling. With respect to our airports, the situation varies by country and could be subject to change depending upon how fast or slow the pandemic is brought under control. Colombia has been the most active and we've suspended operations at all six of our airports since the third week of March with domestic flights suspended until April 27 in accordance with the published decree and most recently extended to up to May 11.\\nInternational travels have been suspended through May 13. By contrast, in our airports in Puerto Rico and Mexico remain open, although there's significant reduced flights and passenger traffic. As a result, total passenger traffic declined sharply in the second half of March, down nearly 69% year over year between March 16 and March 31. By country, we show the margin decline in Colombia around 77%, followed by Puerto Rico down 73% and Mexico with 63% decrease [Indecipherable]. Additionally starting in mid-March, some of the airlines as well as some tenants that operate in our airports began asking for assistance either through discounts on payments owed to ASUR or by extension by payment which resulted in a higher accounts receivables in March in Mexico and Colombia, up 54% and 78% year-over-year. We are having ongoing commercial discussions with these companies with respect to their contracts.\\nMoving next to action we have taken, starting with health and safety. Following the guidelines of relevant health agencies, we have implemented health and safety protocols for both our airport employees and passengers travelling through our airports. For example, protective gear such as wearing masks is required for airport staff. We have also stepped up disinfectants and sanitization practices, once again in accordance with the guidelines of local health authorities. Lastly, where possible, we have also implemented remote working points.\\nMoving next to ensuring continuity of our business. We have introduced cost reduction initiatives across our airports. The impact of these initiatives however is not expected to be significant vis-a-vis the potential decline in passenger traffic at the majority of the cost structure is different, except for concession fees and technical assistance in Mexico which are biannual cost. We are prepared to take additional step, if needed, to respond to the evolving business environment. Now, let me talk about our financial situation. We entered this quarter in a position of strength with strong liquidity and very low principal payments required through year end. Additionally we believe the company has sufficient liquidity to meet its obligations and continue operating in the normal course of business. Our cash position ended at MXN7.8 billion which was up from MXN6.2 billion at the year-end 2019. And subsequent to the quarter end, as we further strengthen our financial positions as our subsidiary in Puerto Rico drew down an additional $10 million of its committed line of credit. The line of credit [Indecipherable] support for the capex projects we have under construction, Apelian airport in Puerto Rico.\\nWe closed the quarter with total debt of MXN15.3 billion. Although 11% high than the year-end 2019, this was due to the conversion effect from the depreciation of the peso to the dollar. As a reminder, the majority of our debt, 54% is denominated in the US dollars which is at our subsidiary in Puerto Rico. 26% of total debt was denominated in Mexican pesos and 20% in Colombian pesos. We have principal payments of only MXN432 million coming due over the next three quarters. This represents less than 3% of ASUR's total debt. With respect to that ratios, net debt to last 12 months EBITDA stood at 0.7 times at the close of first quarter '20. You can see the interest coverage ratio by country in the table we have included in the annual release this quarter.\\nNow, stepping back for more, since we began operations over 20 years ago, we have successfully navigated through many very significant challenges. From the 9/11 event in 2001 to [Indecipherable] into 2005 and 2008 and 2009 business financial crisis, H1 and H2 and the bankruptcy of 50% of airlines in Mexico which cut planes capacity in Mexico by more than half. Following each of these events, passenger traffic recovered, although recovery time varied from 13 months to 26 months and then continued to grow. Between 2000 and 2019, annual passenger traffic increased the compound annual growth rate of 6.6%, up from slightly over 10 million to historical high to over 34 million last January. We believe the COVID-19 pandemic is unique in that sense it is global event and with a broad disruption in travel and economies worldwide and could change the way of travelling in the future while a vaccine or a cure is found. Summing up this section, we have a strong balance sheet, we have generated years of consistent profitability and we exercise prudent capital management. In the sense we believe that we cannot be very prepared for an event of this magnitude, but of course given its great uncertainty on the final effects in the worldwide economy and that travel will be [Indecipherable].\\nNow turning to our first quarter results, more details can be found in the press release issued last evening. Like I mentioned this part of my presentation, let me spend with the effects of the business in late March. We believe we had solid results in the first quarter 2020. Total passenger traffic was down in most of the airports, which leads to a total passenger decrease of slightly 6% YoverY. This was primarily due to the fallout from COVID-19 and the impact of the global travel industry beginning in the second half of March. Our airports in all three countries experienced total passengers decline from a low of nearly 3% in Colombia to a high 8% in Mexico. Puerto Rico passenger traffic was down 4%. All three countries reported declines in both domestic and international traffic.\\nMoving next to the P&L highlights, revenues ex construction were relatively unchanged at 4% increase in revenues from non-aeronautical services was offset by a 3% decline in aeronautical revenues. Commercial revenues per passenger increased 11% year over year, reaching MXN116.3. This was driven by solid performance across the region. Mexico posted a good performance with an increase of 11% on a per passenger basis benefiting from the currency peso devaluation and regulated revenues. Puerto Rico posted 7% increase per passenger benefiting from peso depreciation and finally Colombia saw a 33% increase on a per passenger basis, reflecting the 43 new stores opened over the last year and currency depreciation. The main drivers were ground transportation and car rentals.\\nMoving on to profitability, reported consolidated EBITDA increased 3% from the same period over the prior year. Both periods benefited from insurance recoveries related to the Hurricane Maria. In the first quarter '20, it amounted nearly MXN124 million while last year the amount was dragging over MXN41 million. Excluding these recoveries, consolidated EBITDA was essentially flat year-over-year at MXN2.7 billion. Ex-IFRIC 12 and without taking into account insurance recoveries in both quarters, adjusted EBITDA margin increased 20 basis points to 66.7% this quarter.\\nA few comments about capital allocation. Capital expenditures were MXN353 million in the quarter. Of these, nearly MXN58 million was allocated in Mexico due to the terminal expansion of Merida airport. For the full year, and as we have discussed before, our non-prevalent plan in Mexico calls for investment of approximately MXN5.3 billion for the full year. At the current time, there are no changes to the planned continuation of the foreigners tax relief of the second one we have at Cancun airport and the beginning of the first expansion at the Merida. Our plans call for a conclusion of Phase 1 of the Merida terminal expansion and typically the second phase this year. Nevertheless, due to the COVID-19 health crisis, you may see some disruption in the construction process, attributable to stay-at-home, the combination and we have informed the government about this situation. In Puerto Rico we have made investments of MXN114 million this quarter, mainly from the connection with some major maintenance referred tax relief. Finally, capex in Colombia amounted to MXN1 million related to maintenance. Last year we concluded our committed capex was at MXN20 million. And going forward, we only expect to incur a major maintenance capex in Colombia.\\nNext, our Annual General Meeting from yesterday, shareholders approved an ordinary net cash dividend of MXN8.1 per share to be paid, subject to the Board's approval on or after May 11, 2021 in a single installment.\\nIn conclusion, we are proactively responding to the developing situation. No one can control the virus or even the economic fallout. But we can control how we react to the crisis. I am optimistic about the prospects for the future both navigating through the current crisis and in the long term recovery. I believe that we are well positioned with a healthy balance sheet. We had a solid first quarter results. We believe in the strategies that we are executing.\\nThis ends my prepared remarks. Kathy, please open the lines for questions.\\nQuestions and Answers:\\nOperator\\n[Operator Instructions]\\nWe'll go first to Alejandro Zamacona of Credit Suisse.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nThank you Adolfo, thanks for the call. Two questions from our side. The first one is on the aeronautical maximum tariff. So, considering that airlines have been negotiating with most of airports and in some cases some fees have not been charging. What could we expect for maximum tariffs in the short-term meaning the second quarter and in the immediate term, meaning year end 2020? Could we still expect tariffs to be close to the maximum level?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro, hi, good morning. Well, basically what we are seeing today is a very reduced demand. So we believe that there is no effect if we try to reduce our fees for the month of April or the month of May. So we have maintained our tariffs and we believe that we can comply with -- we have to maintain compliance toward the year end.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you. And my second question is on the non-aeronautical business. Same thing in the same context, what could we expect in the short term for commercial revenues per passenger? Have you grant any rent payments facility to payments or any deferrals? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nMost of our contracts, as you may know, they have to pay higher of the minimum guarantee payment per passenger or a percentage of sales. So if we do not have passengers, we will not have to pay rent. So it's made automatically. So in that sense, we are not reducing or adjusting the contracts.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you Adolfo.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nWe will now take a question from Fernando Sanchez of Bradesco BBI.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nHi, good morning and thanks for taking my question. My question is light of the likelihood of the GDP contraction beyond 5% I just wanted to ask if you have had the opportunity to discuss with the authorities the possibility of delaying the 2021 and the key mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. Well as you are aware, the contract has a clause that says that the maximum tariff can be reviewed in the case of Mexico in an external way. When on the Mexican GDP drops by more than 5% in a year and that's happened in fact on track. Of course with the current circumstance and the current expectations from analysts, it is possible that the Mexican GDP will drop by more than 5% this year. So in that sense, we will be we -- and the possibility of review our maximum time in an external rate. That's for next year, but not this year.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nOkay. Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nAnd now, we'll take a question from Carlos Peyrelongue of Bank of America.\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nThank you. Good morning Adolfo. Thank you for the call. On the something I couldn't hear well because of the connection but can you comment as to whether the dividend will be kept or there is the possibility of cutting the dividend until we have more sense about passenger traffic? That would be the first question. And the second would be related to cash burn, if you could give us an idea of what your cash burn is on a quarterly basis, just to get a sense of compare that primarily to your strong cash position. Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYes, of course. In the case of the dividends, yesterday we held Annual Shareholders Meeting, they have sadly approved the dividend that it was proposed MXN8.1 per share. But it was -- this was subject to the approval from the Board to the moment of the payment that's from May 11, 2021. So the Board will have to approve when this dividend will be paid. In the case of the cash burn, what I said to you during the initiative months, is that our currency structure is basically fit. The only variable pieces are the technical assistance fee and the concession fees we paid to the government. So we are working and just to remember the case of Mexico is 5% as well as in Puerto Rico, and in the case of Colombia its' 19%. So this of course will reduce -- our passenger traffic is reduced and our income gets reduced. The remaining is basically, of course, we are taking measures to try to reduce as much as we can, all the expenses in the companies. But as I said, at the end, in the overall picture, the cost reduction will not be significant in comparison with reduction in the revenues of the company.\\nOperator\\nAnd we'll run to our next question, and that will come from Andressa Varotto of UBS.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much for taking my question. So my question is if have plans to negotiate with the government postponement of the mandatory capital is this possible? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nCould you repeat the question? I couldn't hear you.\\nAndressa Varotto -- UBS -- Analyst\\nYes. So my question is if you plan to negotiate with government the postponement of mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said before, in accordance with the contract, we do not have that possibility this year. But of course, with the given standards [Phonetic] and as I said it in my initial remarks, during an expansion situation and that expansion situation is that some companies have stopped operations [Indecipherable] and that it was reactivated later on, but there was a decree from the Mexican government that also named the steel and glass that is produced in the country will be used for the project. So in that sense, at the moment it's almost impossible for us to expand our 10-year buildings without these material. So we have this situation to the government. So for the moment, what we see is that we will see some disruption in our construction process for some months and then we will have to talk about these with the government. That's what I can share with you for the moment on this respect.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nOur next question will come from Stephen Trent of Citi.\\nStephen Trent -- Citi -- Analyst\\nGood morning, Adolfo and thanks very much for taking my question. Hope that you and your family are well. Just one quick one for me, I know that it seems that Mexico apparently has not been that active in likely offering any assistance to the corporate sector. What are you hearing from Colombia? Kind of any indications from them with respect to whether aviation industry will get some sort of relief?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nSteve, thank you for your question. So in the case of Colombia in comparison with Mexico they have been more active in the measures that they have been taking. As I said here in the report they were very [Indecipherable] basically closing or sorting down everything as from March 23. And that can be seen in terms of results. In the case of Spain and the active they have in comparison with active cases we have in Mexico. So their curve is decreasing or at least flattening while the Mexican curve is still increasing. In terms of what they have said for our industry, we have been closed since March 23 and they have issued decrees in that respect. Maybe this week, there was a new announcement from the President expanding the process of shutting down everything. As I said in my remarks, for the case of domestic aviation that will be close up to May 11 and in the case of international up to May 30. It is important to remember that in the case of Colombia, 85% of aviation is domestic and 15% is international. That's what we know as of today. Of course all of these may change depending on how fast or how slow they can control the virus in their country.\\nStephen Trent -- Citi -- Analyst\\nThank you very much Adolfo. Apologies I couldn't hear all of your remarks. But no indication at this point for example that Columbia's planning a kind of tax relief for aviation or something along those lines offering kind of financial support.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nWell we have not heard anything above that yet.\\nStephen Trent -- Citi -- Analyst\\nOkay. Appreciate that. I'll let someone ask a question. Thanks Adolfo.\\nOperator\\nAnd next we will go to Gabriel Himelfarb of Deutsche Bank.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nHi, good morning, thanks for the call. I have two questions. The first one is concerning about account receivables. Can you give us like a number or approximate number about what's the total of the sales coming from airlines and in specific from Interjet and American Airlines and my second question is do you think you could obtain some waivers in opex sorry capex your current MDP in Mexico and could you will be able to extend the life of the concession in Colombia?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. In terms of the account receivables you can see those in our report, revenue increase in the case of Mexico and Colombia, most of the increase is coming from the land industry. I do not have the details of American Airlines and Interjet you are requesting. In terms of the capex, as I said before, we have informed the government about this current situation. We don't know if they are going to react in that respect. But of course it's going to be almost impossible for us to construct and expand our buildings with that material. So more or less what I say to you.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nOkay, thank you.\\nOperator\\nAnd now we will go to Ruben Lopez of Santander.\\nRuben Lopez -- Santander -- Analyst\\nHi Adolfo, thanks for the call. My question is on commercial revenues. Sorry if you commented on these. But I understanding Cancun operating in just one terminal. So I want to confirm you how are your operations there in Cancun and what are the implications on commercial operations? Are there any penalties with the tenants? What are negotiations here? That's the first one. And the second one is related with the same topic. When we see commercial revenues and we kind of try to compare current levels versus what would be the fixed amount or the fixed part of the minimum payment. I mean can you give us any sense of the guidance here? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nOkay. As you have said, yes, in the case of Cancun, we have closed two terminals and we are just operating today in terminal 4. So all the operations of airport have been concentrated there in order to reduce on one side the expenses and of course on the other side be better prepared in the case of these reduced demand. All the stores are working in the case of terminal 4. So terminal 4 is operating as it was before the event. As I said before, most of the contracts, the financial contracts we have with the tenants are related to a minimum guarantee payment passenger. So once again, they do not have, let's talk about one of the deals that is closed. So if they do not have passenger traffic in terminal 2, they almost have to pay the rent. Of course when they operate in terminal 4 their operations will be in the accordance with the amount of passengers we have in that facility. So I would say terminal 4 is operating normally.\\nRuben Lopez -- Santander -- Analyst\\nThank you. And when you compare, sorry, the current level of commercial revenues versus what would be the minimum payment from the contract, can you give us any idea on that?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said, minimum payment -- the contract is on a per passenger basis.\\nRuben Lopez -- Santander -- Analyst\\nPerfect, thank you.\\nOperator\\n[Operator Instructions]\\nAnd we will now go to Jorge Larocco of Morgan Stanley.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nHi Adolfo, good morning. Thank you for the questions. It's two questions, actually a pretty general question, I was just wondering if you could provide more color on what are the main initiatives regarding our cost reduction efforts. How are those working down, your payment reductions on paid leave of absence, maintenance cost, utility costs, etc. and how are those playing out so far? Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThe main initiatives of course are related to in the case of Cancun in the terms of amounts. So we these key terminals closed, we are not burning the same amount of energy as if they were open. Also in the case of Cancun, we are in the process to shut down and one of the runway because today in accordance with the [Indecipherable] it's not needed. So, that runway will be turned off in terms of light at night also reducing their energy we will have to pay. And in terms of some other measures we are taking, adjusting some of the contracts of nature or mainly maintenance in the case of the buildings are closed and to try as much as possible to reduce operating cost and expenses. But I once again at the end, most of our cost is fixed. So if we apply the cost structure of the company, the most important lines are personnel and utility costs as we have said so. In the case of personnel, we are maintaining the personnel for the event or the crisis and in the case utilities, we are trying, as much as we can to try to reduce that.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nThanks so much Adolfo. Stay safe and have a good day.\\nOperator\\nAnd with that, that does concludes the question and answer portion of today's conference call. I would like to turn the call back over to Mr. Castro for closing remarks.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and thank you again for participating in our fourth quarter results conference call. On behalf of ASUR, we wish you good day and until we meet, be safe. Good bye.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 34 minutes\\nCall participants:\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nAndressa Varotto -- UBS -- Analyst\\nStephen Trent -- Citi -- Analyst\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nRuben Lopez -- Santander -- Analyst\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nMore ASR analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nHello, and welcome to the Globus Medical fourth quarter and full year 2021 earnings call. [Operator instructions] I will now turn the call over to Brian Kearns, senior vice president of business development and investor relations. Mr. Kearns, please go ahead.\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nThank you, Chris, and thank you, everyone, for joining us today. Joining today's call from Globus Medical will be Dave Demski, president, and CEO; Dan Scavilla, executive vice president and president of Ortho; and Keith Pfeil, senior vice president, and chief financial officer. This review is being made available via webcast accessible through the investor relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements.\\nOur Form 10-K for the 2021 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP.\\nWe believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available on the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Dave Demski, our president, and CEO. \\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Brian, and good afternoon, everyone. Globus finished an outstanding 2021 with a strong fourth quarter performance. Revenue for the year was a record $958 million, an increase of 21% over 2020 or $169 million in growth. To put that in perspective, our growth dollars alone would have ranked us in the top 10 spine companies in the world.\\nRevenue in 2021 was 22% higher than 2019, an outstanding performance in itself, given the disruption caused by COVID but magnified further by a recent independent research report showing that each of the other top 6 spine companies actually had sales declines over that same time period. We achieved record sales and growth while maintaining industry-leading profitability, generating a record $2.04 in non-GAAP EPS, a 42% increase over 2020, and adjusted EBITDA of 34.6% even as we invested heavily in INR, trauma, and competitive recruiting. Revenue for the quarter was $250 million, up 7% over 4Q '20 as COVID-related headwinds remained strong throughout the quarter. Non-GAAP EPS was $0.49 per share, a 16% decrease compared to the artificially high 4Q '20.\\nNot only were business travel and surgeon education activities severely curtailed last year, several other nonoperational factors, as Keith will expound upon in his remarks, also impacted the decline. Adjusted EBITDA in the fourth quarter was a strong 34%. Enabling technology continues to gain momentum, producing a record $25 million in revenue for Q4, an increase of 40% over 4Q '20. For the full year, enabling technology revenue was $81 million, an outstanding 100% increase over 2020.\\nThe clinical superiority of ExcelsiusGPS is the primary factor driving this growing momentum. Robotic utilization, which is the number of cases performed per installed robot, was at an all-time high in 2021. And nearly 30,000 procedures have been completed using ExcelsiusGPS technology since launch. Our spinal implant business continues to experience the flywheel effect of an increasing number of robots being sold combined with increasing utilization of each robot.\\nOur U.S. spine business grew by 3% in Q4 as COVID-related shutdowns had a significant impact throughout the quarter. We saw this trend continue into January, but all signs point to a rebound commencing late in Q1. For the full year, the U.S.\\nspine business grew by 18% as we continued to take significant market share. Robotics pull-through, coupled with contributions from recent product introductions and competitive recruiting, were all factors driving growth. Our international spine implant business grew by 9% in the quarter, a remarkable result in light of COVID impacts and an ongoing drag from Japan. Due to the impact of strategic moves we made in Japan last year, we expect to see continued declines there through the first half of 2022 with growth to follow off a reset baseline.\\nThis should result in accelerated overall international growth in the second half of this year. Trauma revenue was up 32% in the fourth quarter and 39% for the full year. Competitive recruiting and new product launches are driving growth. The Anthem Mini Frag system was launched on a limited basis in Q4 with excellent feedback from surgeon users.\\nWe are proceeding to full launch in Q1 and have a series of impactful product launches planned for the first half of 2022. The clients have launched the Excelsius 3D imaging system on a limited basis later this quarter with a full launch following in late Q2 or early Q3. There is tremendous anticipation and excitement about this technology among surgeons, and we already have double-digit orders signed. The Excelsius ecosystem, Globus Medical's unique combination of robotics, imaging, and freehand navigation that provides a seamless, scalable, and unmatched clinical experience for surgeons is about to become a reality.\\nI'm extremely proud of our team's performance in 2021, record growth and profitability, exciting, clinically impactful new technology introductions, and an unmatched focus on providing value to surgeons and their patients. Thank you for a great year. I will now turn the call over to Keith.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you, Dave, and good afternoon to everyone joining us for today's call. Globus capped off a record 2021 with a robust Q4 performance despite ongoing COVID-related disruptions and shutdowns. For the full year, 2021 revenue was $958.1 million, growing 21.4% as reported. On a day-adjusted basis, sales grew by 22.1%, with two fewer selling days in the U.S.\\nand international. Net income was $149.2 million, resulting in fully diluted earnings per share of $1.44. Non-GAAP net income was $211.4 million, generating a record $2.04 of fully diluted non-GAAP earnings per share. Adjusted EBITDA was 34.6% for the year, and we generated a record $219.4 million of free cash flow for the full year.\\nQ4 '21 revenue was $250 million, growing 7.1% as reported and 8.5% on a day-adjusted basis with one less selling day in the U.S. and international compared to the prior-year quarter. Net income was $15.1 million, and non-GAAP net income was $51.1 million. Our Q4 diluted -- fully diluted earnings per share was $0.14, while our fully diluted non-GAAP earnings per share was $0.49.\\nAdjusted EBITDA was 34.1%, and we generated $59.2 million of free cash flow for the quarter. Taking a deeper dive into sales. Q4 U.S. revenue was $213 million, 7.2% higher compared to Q4 of 2020 driven by our INR and U.S.\\nspine businesses. International revenue for Q4 was $37.1 million, growing 6.8% over the prior-year quarter led by growth in spinal implants despite lingering COVID impacts and the impact of our strategic changes in Japan as Dave mentioned earlier. On a constant currency basis, international revenue grew by 8.7%. Q4 gross profit was 75.3% versus 73.9% in the prior-year quarter.\\nThe 140 basis point improvement was driven primarily by nonrepeating inventory reserves in the prior-year quarter and was consistent with our expectations noted in our Q4 2020 earnings commentary. Full year 2021 gross profit was 75%, compared to 72.4% in the prior year. The increase in full year gross profit is primarily the result of lower inventory reserves and operational and supply chain efficiencies, partially offset by sales mix. Looking ahead to 2022, we project a mid-70s gross profit rate.\\nResearch and development expenses in Q4 were $51 million or 20.4% of sales, compared to $15.2 million or 6.5% of sales in the prior-year quarter. The increased spending is primarily reflective of in-process research and development acquired during the quarter. Adjusting for these costs, Q4 2021 research and development expense was $16.7 million or 6.7% of revenue, in line with the prior-year quarter as a percentage of sales, but $1.5 million higher driven by incremental investments in headcount across our spine, INR, and trauma businesses. Our full year 2021 research and development expenses were $97.3 million or 10.2% of sales, compared to $84.5 million or 10.7% of sales in the prior year.\\nAdjusting for the acquisitions made in both periods, research and development expenses were $63 million or 6.6% of sales in 2021, compared to $60.1 million or 7.6% of sales in 2020. The increase in spending is reflective of our continued investment in research and development to foster future growth and is consistent with comments made earlier in the year. We expect our R&D expenses to be approximately 7% of sales in 2022. SG&A expenses in the fourth quarter were $106.6 million or 42.6% of sales, compared to $92 million or 39.4% of sales in the prior-year quarter.\\nThe resulting increase is reflective of higher sales compensation and benefit costs as well as increased travel and training expenses driven by the resumption of normalized travel levels following the COVID-19 impacts experienced in the prior year. Full year SG&A expenses were $408.1 million or 42.6% of sales, compared to $354.8 million or 45% of sales in the prior year. The resulting decrease as a percentage of sales is reflective of leverage on fixed costs as a result of the higher volumes when comparing against the COVID impact in 2020. The income tax rate for the quarter was 23.8%, compared to 14.9% in Q4 of 2020 with the resulting increase driven primarily by lower tax benefits associated with stock option exercises.\\nOur full year 2021 income tax rate was 17.3%, slightly lower than the 18.8% in 2020 driven primarily by the nonrecurring tax treatment related to a 2020 acquisition, partially offset by lower tax benefits associated with stock option exercises. Looking ahead to 2022, we expect our effective tax rate to be approximately 20% for the full year, which assumes no significant changes in the current U.S. tax policy. Fourth quarter net income was $15.1 million, and non-GAAP net income was $51.1 million.\\nQ4 diluted earnings per share was $0.14, and non-GAAP diluted earnings per share were $0.49, compared to $0.58 in the prior-year quarter. The quarter-over-quarter decrease is driven by more normalized levels of travel, trainings, and meetings noted above or noted earlier as well as nonoperational items, primarily a higher tax rate as previously mentioned, higher stock compensation expense, and lower interest income. Looking ahead to 2022, we are expecting a mid-30s adjusted EBITDA rate. Full year diluted earnings per share were $1.44, and non-GAAP diluted earnings per share were $2.04, reflecting a 42.2% increase over 2020 primarily related to higher sales volumes following the 2020 impact of COVID-19, partially offset by approximately $0.09 of nonoperating headwinds related to a higher share count and lower interest income.\\nQ4 adjusted EBITDA was 34.1%, compared to 36.2% in the prior-year quarter. Full year 2021 adjusted EBITDA was 34.6%, compared to 29.4% in 2020. Net cash provided by operating activities were $76.3 million for the fourth quarter and a record $276.3 million for the full year 2021. Free cash flow was $59.2 million for the fourth quarter and a record $219.4 million for the full year 2021.\\nThe company remains debt free. At this time, the company is establishing full year 2022 guidance. We are projecting full year 2022 sales guidance of $1.025 billion, representing 7% growth versus 2021. We are guiding to a full year fully diluted non-GAAP earnings per share of $2.10, representing 3% growth versus 2021.\\nI note that the 2022 guidance includes approximately $0.10 of nonoperating headwinds, including higher shares worth $0.04, a higher tax rate worth $0.03, and higher stock compensation expense worth $0.03. Adjusting for these nonoperational factors, our 2022 guidance would have been $2.20 or 7.8% higher than 2021. Overall, we view this guidance as appropriately conservative and reflective of the current operating environment around COVID and inflation-related impacts. Our 2021 results represent our teamwork, our commitment, and our focus on execution.\\nWe continue to differentiate ourselves in the marketplace. And it is a testament of the hard work and dedication of each of our Globus employees. We remain excited for the future as we continue on our mission of improving patient care. Operator, we will now open the call for questions.\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] Our first question comes from Matt Miksic of Credit Suisse. Your line is open.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks so much for taking the questions and congrats on a really strong finish to a pretty amazing year, given the circumstances. I wanted to follow up on some of the comments around EPS guidance, in particular. As you pointed out, there are some items that ex those items, up 7% to 8%.\\nCan you talk a little bit about where in your guidance you're contemplating things that some of the other companies in the space have talked about like rising input costs, staffing challenges, labor costs, freight, etc., things that generally are driving operating costs up a little bit? Maybe give us a sense of how those figure into your guidance? And I have one quick follow-up.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks. This is Keith speaking. So we projected our guidance at $2.10. And as we look at the year, we see inflation as a market event.\\nEveryone is experiencing it, and we have it baked in our numbers. But when you step back and look at the $2.04 and the $2.10, I commented on the $0.10 of the nonoperating headwinds. But the other things that are impacting the business as we think about getting back to more normalized levels of spend are really the travel and the trainings that go along with the surgeons and [Inaudible] that we provide. That's worth going into the next year likely an $0.08 headwind.\\nAnd then one of the things that we commented on earlier in the year was our continued investment into R&D. As you look into next year, we're seeing roughly I would say, call it, $0.04 of additional investment in R&D. When you look at those things together, coupled with the inflation, we're landing at about $2.10.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And can you just maybe just elaborate a little bit on the spend or R&D and sort of the expectations for returns in terms of growth or programs that you're investing in?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nSo we're continuing to invest heavily in our spine business and as well as our robotic businesses. We talked about that in Q1 of our earnings call earlier in the year, and really all sign points to us continuing to do that. Dave talked earlier about some of the benefits that we're seeing for robotic technologies. We continue to invest in that and really grow for the future.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And then just one quick follow-up I had was on the environment for robots and spending in capital and equipment in general. Some of the other, again, companies in the space have talked about a fairly strong year for equipment, a strong year for robots. Any sense of whether this is something that needs to sort of take a breather or catch up here in 2022? Or whether orders and demand and pipeline for new deals would indicate just continued strength into 2022?\\nDave Demski -- President and Chief Executive Officer\\nYeah. Matt, this is Dave. No, it's very strong. I don't see anything laying off.\\nIn our case, in particular, it's been accelerating. I think the demand for Excelsius has been strong, and it's becoming more and more common. The narrative has changed from why robotics to which robot. And I think we're clearly establishing our lead there.\\nAnd then as I mentioned, there's a lot of enthusiasm over our Excelsius 3D system, which is going to launch later this quarter. We've had every surgeon we show that to seems like they want one. So I don't see it backing off at all.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks and congrats.\\nDave Demski -- President and Chief Executive Officer\\nThank you.\\nOperator\\nThank you. Our next question comes from Matt Taylor of UBS. Your line is open.\\nMatt Taylor -- UBS -- Analyst\\nExcuse me. Hi, guys. Thanks for taking the question. So I wanted to ask the first one about margins longer term.\\nMaybe just talk about the difference between what you're doing this year with some of the investments and obviously, headwinds year over year from spending back to normal and inflation, and how we should think about margins longer term? Would you start to get more leverage at some point? And what would the inflection point for that be?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. It's a good question. But as I look at where we're at and where we're going, our goal is to always maintain a mid-70s GP. But as we look longer term and look at our EBITDA rates, we're always looking to be in that mid-30s range.\\nWe could toggle our investments in various parts of our business to really achieve that, but we're investing now to drive growth -- to drive top-line growth for the future. And as we get that growth, that's going to create more fixed cost leverage in our P&L. So I think by doing that, investing for growth today helps project the margins going forward. I feel that we're going to work to try to stay in that range.\\nDave Demski -- President and Chief Executive Officer\\nYeah. I can add a little bit maybe to that, Matt. In the spine business, I don't think you'll see much greater improvement in our margins there, but we have a lot of operating leverage in front of us in the orthopedic side of the business and the capital side. Those are both fairly nascent businesses for us, and we're funding it with spine.\\nBut once we start to hit some volume numbers there, I think those businesses will definitely expand.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Can I ask a follow-up on the robotics strength? I mean, you talked in the past about getting pull-through on these placements, and obviously had a great year in 2021 with enabling tech. I guess are you still seeing the same kind of trends? And could that bode well for pull-through implants in '22?\\nDave Demski -- President and Chief Executive Officer\\nYes. It does. We're seeing that generally the same kinds of trends. And as a company, we're focusing on really going back to that installed base and seeing we can get more users to utilize the technology once it's placed in the hospital.\\nAnd that's a big focus for us in 2022.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Thank you, guys. Thanks so much.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And next, we have Shagun Singh of RBC. Your line is open.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGreat. Thank you for taking the question. I guess my first one is on Excelsius 3D imaging system. Can you talk to us about the delay? Why is there a delay in the launch? And then just elaborate on your go-to-market strategy.\\nAre you targeting the replacement opportunity or greenfield? You're obviously going after a major competitor. So just any color there would be helpful. And then on the recon robotics, do you still plan to launch that in the second half? And then I have a quick follow-up.\\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Shagun. I'll try to knock those off one by one. In terms of the delay, it's just taking longer than we thought. It's nothing significant in terms of the technology hurdle to get over.\\nThere's just a lot to do to get that over the line. So I wish we were a bit earlier but very confident we can get it done this quarter. Go-to-market. I think initially, we're going to be targeting our installed base of Excelsius users.\\nThose are -- there's a high demand among them. It's going to make those procedures much more efficient and much easier for them to do. And then from there, we'll be branching out to target more of that free-hand navigation market that you alluded to earlier. And then I apologize, I forgot the last part of your question.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nI was just wondering if you plan to launch the recon robotics platform in the second half of '22 like you had previously indicated?\\nDave Demski -- President and Chief Executive Officer\\nNo. That's been delayed as well. We're going to be -- early '23 is the target for that.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGot it. And then just as a follow-up, I was wondering if you could talk about trends that you're seeing on the procedure volume side in Q1, so in January and February. And spine typically has a high pain burden, so procedures come back quickly. So do you expect the recovery to come in Q1? Or do you expect a longer tail given staffing shortages? Thanks for taking the question.\\nDave Demski -- President and Chief Executive Officer\\nSure. Yes, January was really bad, but we've already started to see it turning in February. The last three weeks have all been progressively higher. Not back to where we want it to be, but definitely, I think we've hit bottom.\\nWe're going in the right direction. And I'm not going to try to predict what's going to happen with COVID though. That's proven to be frivolous for everyone, but it's encouraging where we are right now.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nThank you.\\nOperator\\nThank you. And next, we have Matthew O'Brien of Piper Sandler. Your line is open.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat. Thanks for taking the questions. I guess, Dave, just for starters on the top-line guidance. This time last year, you guided about $35 million below The Street.\\nWe end up doing well above what you initially guided and actually what The Street was modeling. And this time, you're guiding about $25 million below The Street. I know January was soft, and maybe Excelsius 3D has pushed a little bit in terms of the contribution. But are there other factors that we should be thinking about? I don't know if it's a rep hiring perspective or a robot perspective that gives you a little bit more caution versus kind of where The Street was modeling things?\\nDave Demski -- President and Chief Executive Officer\\nThanks, Matt. I'm sorry we don't pay that much attention to The Street. We look internally to our own forecast, and we always want to be appropriately conservative going into a year. I feel really confident in the business.\\nThe U.S. spine business has been just cranking away. The robotic momentum is there. We're going to have 3D out this year.\\nJapan is going to turn around in the second half. So I feel really good about the business. We just have taken a very conservative approach over the years when we give guidance, and we're doing that again.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nOK. Fair enough. And then the follow-up is on acquisitions. Sorry if I cut somebody off there, but there's been some talk about you guys doing a scale acquisition.\\nI'm curious if you have any thoughts about the need for scale in spine. And then if not, there's some pretty interesting assets still in the spine space, but more on the pain management side of things. Are those higher on the list in terms of things that you potentially are looking at from a acquisition perspective?\\nDave Demski -- President and Chief Executive Officer\\nNo. It's actually a bit different. We're more active in terms of growing the business through BD and on the orthopedic side of the business. I think we're really strong in spine, and there's really nothing in spine that's of interest to us at the moment.\\nWe're more focused on growing the other piece of our business, which is smaller. There's nothing, I would say, transformative in our sights right now. But we are looking at several modest-sized deals as been our history in the past.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat.\\nDave Demski -- President and Chief Executive Officer\\nDid that answer your question?\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nYep. That's perfect. Thank you.\\nOperator\\nThank you. Next, we have David Saxon of Needham. Your line is open.\\nDavid Saxon -- Needham and Company -- Analyst\\nYeah. Hi, guys. Good afternoon, and thanks for taking the questions. Maybe one on enabling tech.\\nI mean, it doubled this year, and you've really built out the enabling tech platform with hub and 3D, etc. How should we think about those launches kind of starting to ramp? And could '22 be another double?\\nDave Demski -- President and Chief Executive Officer\\nYeah. I think as I said, we're going to get some -- a few units out this quarter and kind of a soft launch, if you will, with the full launch starting in probably end of Q2, it might be into Q3 and then strong in the second half of this year. I don't want to comment on the double. It's -- we don't really drill into the components of our business.\\nI can tell you that we're really excited about what we're seeing from our technology, from the adoption of our technology and not only what's right in front of us, but some things we have coming after that.\\nDavid Saxon -- Needham and Company -- Analyst\\nOK. Got it. And then maybe on trauma, kind of how close are you to having a full portfolio there? And then in terms of growth, 32% in the quarter. Is that sustainable in '22? Thanks for taking the questions.\\nDave Demski -- President and Chief Executive Officer\\nSure. The bag in trauma is by the second half of this year, I think full is kind of interesting term. We're going to have enough in our bag to be a full-line player and be able to compete with the major companies by the end of this year. And is that growth rate sustainable? Yes, I think that's certainly achievable in 2022.\\nDavid Saxon -- Needham and Company -- Analyst\\nGreat. Thank you.\\nOperator\\nThank you. Next, we have Craig Bijou of Bank of America. Your line is open.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nHey, guys. Thanks for taking the questions. Maybe a follow-up on top-line guidance and to the extent that you guys are willing to share. I mean, how to think about the contributions from each of the businesses? I know generally, you've been reluctant to share that info.\\nBut in terms of the composition of the guidance, how do we think about that incremental revenue coming in? Where is it coming from and to what extent?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. As Dave said earlier, we're not going to get a ton into the parts and pieces. But what I will say is if you look at the business, whether by musculoskeletal and INR or you look U.S. versus international, the parts and pieces of our business we continue to feel extremely positive about as we look into 2022 and beyond.\\nWe're investing in our business. We're driving investment for the future, and we feel that we'll see that turn out to us taking share and driving sales growth. I alluded to my earlier prepared comments that our guidance is appropriately conservative, but there's nothing that I sit here and feel that we have kind of an ongoing issue that I would be concerned about our ability to grow across our business, like I said, whether it's U.S., international or musculoskeletal versus INR.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGot it. Thanks, Keith. That's helpful. And then, Dave, I think you alluded to it, but I wanted to ask more specifically how to think about some of the new product rollouts? Obviously, you have 3D coming out and launching this year.\\nBut from a new product perspective, is it -- do you have a number of launches coming this year on the spine side? Do you have a number coming on the INR side? Just maybe a little bit more perspective of what to expect during the year.\\nDave Demski -- President and Chief Executive Officer\\nSure. Thanks, Craig. I think we've been pretty clear that it's a big one coming with 3D followed by our hub [Inaudible] offering. I think spine, we are typically 10 to 12 launches a year, and that's currently our target going into 2022.\\nTrauma is probably the real bright spot. There is a number of products that we were working on for a while, they're going to hit the early part of this year and through this year. So -- and then our orthopedics business actually has some launches as well. So that's kind of who we are and who we're going to be.\\nAnd it's -- the number one focus of the company is to drive great technology.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGreat. Thanks for taking the questions, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. Next, we have Ryan Zimmerman of BTIG. Your line is open.\\nRyan Zimmerman -- BTIG -- Analyst\\nAll right. Thanks for taking my questions and congrats on a great year. Just want to follow up on a couple of questions. Dave, when we think about U.S.\\nSpine performance kind of relative to the market, you look at some of the larger players, they were down a bit in the fourth quarter. Some of the smaller players we saw were up double digits. Obviously, a few major players still yet to report next week. But I guess I'm kind of curious if you can kind of talk about the U.S.\\nperformance, that growth this fourth quarter relative to the market, and kind of where you think you're tracking relative to that level? And if you could kind of give us color on what you think that level was just given the dynamics in the fourth quarter through the quarter would be helpful.\\nDave Demski -- President and Chief Executive Officer\\nThanks, Ryan. It's really challenging to figure out where we are, given COVID. So from the early returns of some of the folks who we have reported, again, we're taking significant share. I can't speak to the smaller guys who have reported or how that impacts us.\\nAnd I don't really have a feel for the overall market. I know it was heavily impacted by COVID so likely down versus prior year overall. But that's more of just a guess and kind of where we landed versus some of our earlier trends. Our business is strong.\\nI can tell you that. We haven't lost significant pieces of business in the U.S. And we continue to see growth in the recent product introductions, and we continue to sell robots and drive pull-through from that. So it's strong.\\nI just -- I can't really see the overall market, and it's really hard to figure out what's going on given what's happening with COVID.\\nRyan Zimmerman -- BTIG -- Analyst\\nOK. Just two follow-ups for me. One, we've heard some of the larger capital equipment companies have obviously called out chips as being a gating factor to sales or median demand in 2022. One, want to see if there's any concern there around chips for the Excelsius platform or for 3D and whether that could gate sales? And then I'll just ask the other -- sneak in a quick follow-up, too.\\nThe Japan distributor dynamics, how much of a lift should we expect when that distributor dynamic clears in the second half of 2022 on the international business? Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. In terms of chips, I would just -- I would extend that to all supply chain. So it's not just chips, it's all components are challenging. It hasn't cost us revenue now, but it's certainly on our radar and making our life really hard.\\nSo it's a risk that's out there for 2022. I'll let Keith maybe handle the international question.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nAs it relates to Japan and the distributor dynamic, as we look ahead, we finished 2021, I think international grew by about 11%. We've historically said that we believe that the international business can grow mid-to-high teens. I would expect us to be able to get back to that on an annual basis. So you would expect the second half of the year to accelerate ahead of that to potentially balance -- to get closer to that 15 by the end of this year.\\nRyan Zimmerman -- BTIG -- Analyst\\nThanks, Kieth. Thanks, Dave. Appreciate it.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. Next, we have Kyle Rose of Canaccord. Your line is open.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nGreat. Thank you for taking the questions. I wanted to start on enabling. I mean, look, you put up a good quarter in enabling.\\nI guess a tough backdrop, particularly without the imaging platform. Maybe just help us understand kind of where that stands from a utilization perspective into your customer base. You're talking about the really good utilization there is continuing to see strong pull through. Can you just kind of level set maybe how many of your customers might have it or on a percentage basis or on an absolute basis? Just trying to really understand where we are in the uptake and the adoption within the historical core Globus customer base.\\nDave Demski -- President and Chief Executive Officer\\nYes, Kyle. To be honest, I don't feel comfortable sharing that information from a competitive standpoint.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nTotally fair. I had to try. I also wanted to touch on the orthopedic side of the business. I mean, it's been a couple of years since you acquired the StelKast business.\\nI think earlier in the call, you talked about the fact that the recon robot is going to come in '23. Where do you stand just from an implant perspective? Do you have the right implants there? Do you need to make different investments from an M&A perspective, technologies, distribution? Just help us understand what you need to do on that total joints business before the recon robot comes next year. Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. We do not have the implant portfolio we need to really make a strong outing. So we are working on that, have been working on that, and expect to roll some products out this year. I don't see us filling the gaps in our product portfolio with acquisitions in terms of hips and knees in particular.\\nI do think there's opportunity for scale there. So that's not off the table because we are very small right now. And then the extremities is an interesting segment for us as well. It's a fast-growing segment.\\nSo that's an area where we've taken a look at a few things. Does that help with your question?\\nKyle Rose -- Canaccord Genuity -- Analyst\\nYes. Thank you very much.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. And next, we have Samuel Brodovsky of Truist. Your line is open.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nHi. Thank you for taking the questions. Just a first quick one on U.S. Spine.\\nJust would be curious to hear about the portion of growth in the U.S. coming from robotic-specific instrumentation versus where you're seeing potential share gain with other parts of the portfolio?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nYes. Thanks for the question. In terms of breaking it out, we typically don't break out the parts and pieces of where the growth is coming from. What I would say is that as you look at our U.S.\\nSpine business, it's really a combination of what we always talked about: new product innovation, our competitive recruiting, and the pull-through from implants. Those three continue to propel the business from a growth perspective, and we see that continuing as we enter 2022.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nGreat. That's helpful. And then when thinking about 3D and going to customers with it, in terms of any competitive trialing, are you seeing it being trialed against other more novel imaging technologies on the market? Or is it typically being compared to the large competitor out there? Thanks.\\nDave Demski -- President and Chief Executive Officer\\nInteresting question. I assume it's -- we don't really trial against it, but we have customers looking at our technology. And I think their interest just probably lines up with the market share of the other imaging systems in the market, particularly ones that are utilized more in spine. I'm sure that some of the more innovative ones are getting a look, but we don't hear that much about them.\\nSo it's not disproportionately, maybe I could answer it that way.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nThanks.\\nOperator\\nThank you. [Operator instructions] Our next question comes from Steven Lichtman of Oppenheimer. Your line is open.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nThank you. Hi, guys. I wanted to ask you first on trauma. Where do you think you stand now in terms of coverage of procedures in terms of your product portfolio? And also from a sales force perspective, I'd just love to get an update on where you feel you are overall in terms of being able to go at the market.\\nDan Scavilla -- Executive Vice President and President of Ortho\\nSteven, it's Dan Scavilla. So again, it's always the evolving and expanding story. We have about 14 family products out there now. I think with that, we're saying we would cover 50% to 60% of the market.\\nCertainly, plan, as David said, to launch several more this year to cover that further. I believe and through what I'm saying, we're at a point where we're able to get into some significant facilities and support their needs for the most common procedures. And with that that's the main driver of growth to us. So we'll continue to expand the product line and fill that out over time, but we're in a good spot now.\\nWith that is the competitive recruiting that's been accelerating for us. So again, we're small, and we have a lot of spaces to fill. But the traction that has been occurring really through 2021 is very promising. And I do feel bullish as we are -- from what I've seen so far in the first quarter of 2022 that that will continue.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nGreat. Thanks, Dan. Keith, just a follow-up on gross margin. I apologize if you mentioned this, but just relative to 2021, given the inflation commentary, should we assume gross margin down? Or are there some offsets that can keep it relatively flat to maybe -- or even up in '22?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. We project the mid-70s GP. I think it's fair to assume that we are seeing inflation just like everybody else, but we're also growing. And it's obviously getting us some leverage in our cost structure.\\nSo as I think about 2022, mid-70s is kind of where I see it. I wouldn't project upside.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nOK. Got it. Thanks, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And we now have Jason Wittes of Loop Capital. Your line is open.\\nJason Wittes -- Loop Capital -- Analyst\\nHi. Thanks for taking the questions. Just two follow-ups, one on the guidance and one on trauma. But -- so first off, your guidance, I think the way you described it, especially relating to product launches, kind of assumes a strong second half versus the first half.\\nSo related to that, one, are we assuming that -- I know we can't predict COVID, but COVID pretty much works its way throughout the year? And then secondly, related to that, in the first quarter, I'm not sure how to read your comment that January was very weak. It bounced back. Should this be a normalized first quarter? Or are we -- is it going to be a little weaker relative to last year because of the COVID impact and launches? Thanks.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. Dave commented that January was weak, but we were starting to see some bounce back in February. Will it all bounce back in the same quarter versus having some bleed through into Q2? We don't necessarily know. But I think your earlier comment about some of the launches and a strong second half, I think that's directionally correct.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. And then I don't know if you can comment on this, but you did mention that you had -- it sounds like a record year in terms of sales force hires. In the past, you've kind of given us an indication of how large you've been able to grow your sales force percentage-wise. Can you give us any kind of indication on that in terms of what 2021 look like? And it sounds like 2022, you're optimistic that you can do -- go at a similar run rate?\\nDave Demski -- President and Chief Executive Officer\\nYeah. '21 was not a record year for us. I think we had one really strong quarter, but we've had years that were better. That's a renewed emphasis on it.\\nI can tell you the pipeline right now is extremely strong. So we're coming out of the gate strong. But last year was a good year. It just wasn't our best.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. Thanks a lot. Appreciate it all.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\n[Operator signoff]\\nDuration: 45 minutes\\nCall participants:\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nDave Demski -- President and Chief Executive Officer\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nMatt Miksic -- Credit Suisse -- Analyst\\nMatt Taylor -- UBS -- Analyst\\nShagun Singh -- RBC Capital Markets -- Analyst\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nDavid Saxon -- Needham and Company -- Analyst\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nRyan Zimmerman -- BTIG -- Analyst\\nKyle Rose -- Canaccord Genuity -- Analyst\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nDan Scavilla -- Executive Vice President and President of Ortho\\nJason Wittes -- Loop Capital -- Analyst\\nMore GMED analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4006,\n        \"samples\": [\n          \"2022-08-11 07:30:00\",\n          \"2021-03-18 08:00:00\",\n          \"2021-08-09 11:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 771,\n        \"samples\": [\n          \"2022-07-12\",\n          \"2020-10-22\",\n          \"2022-06-10\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2535,\n        \"min\": 571,\n        \"max\": 32540,\n        \"num_unique_values\": 6023,\n        \"samples\": [\n          8055,\n          8114,\n          14273\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08086309609059458,\n        \"min\": -0.6091428484235492,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 9985,\n        \"samples\": [\n          0.0115302149459788,\n          0.1053023227425508,\n          -0.0781132122800544\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Target_Class\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Neutral\",\n          \"Gain\",\n          \"Loss\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"DateOfWeek\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 0,\n        \"max\": 6,\n        \"num_unique_values\": 7,\n        \"samples\": [\n          3,\n          2,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Month\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3,\n        \"min\": 1,\n        \"max\": 12,\n        \"num_unique_values\": 12,\n        \"samples\": [\n          12,\n          5,\n          8\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Quarter\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 1,\n        \"max\": 4,\n        \"num_unique_values\": 4,\n        \"samples\": [\n          4,\n          2,\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Ticker_gain_prob\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.05086129871443242,\n        \"min\": 0.0725402722955677,\n        \"max\": 0.6145290734110492,\n        \"num_unique_values\": 96,\n        \"samples\": [\n          0.3219169772111561,\n          0.1799954783009513,\n          0.3176372756886915\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Ticker_loss_prob\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.05845408745944302,\n        \"min\": 0.0029594092624846,\n        \"max\": 0.6360831434700265,\n        \"num_unique_values\": 96,\n        \"samples\": [\n          0.2926491076860506,\n          0.312513854371121,\n          0.2925641097616779\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Positive\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.31461293934408074,\n        \"min\": 0.008341541513800621,\n        \"max\": 0.9573535919189453,\n        \"num_unique_values\": 10002,\n        \"samples\": [\n          0.9299212098121643,\n          0.026290403679013252,\n          0.04736625775694847\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Negative\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.15365381668059275,\n        \"min\": 0.007326572202146053,\n        \"max\": 0.9723434448242188,\n        \"num_unique_values\": 10004,\n        \"samples\": [\n          0.02593323402106762,\n          0.013618996366858482,\n          0.026145340874791145\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Neutral\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.32946208504390717,\n        \"min\": 0.016457758843898773,\n        \"max\": 0.9523656368255615,\n        \"num_unique_values\": 9990,\n        \"samples\": [\n          0.7056020498275757,\n          0.1328488439321518,\n          0.09590130299329758\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 38
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_analysis.columns"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ceNBpJirLzrN",
        "outputId": "5f4acb5e-e780-4547-b93d-68e8ff096452"
      },
      "execution_count": 39,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['Unnamed: 0', 'date', 'exchange', 'q', 'ticker', 'transcript',\n",
              "       'Timestamp', 'Date_only', 'word_count', 'Price_change', 'Target_Class',\n",
              "       'DateOfWeek', 'Month', 'Quarter', 'Ticker_gain_prob',\n",
              "       'Ticker_loss_prob', 'FinBERT_Positive', 'FinBERT_Negative',\n",
              "       'FinBERT_Neutral'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 39
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_analysis.drop(columns=['Unnamed: 0',\"Ticker_gain_prob\",\"Ticker_loss_prob\"],inplace=True)\n",
        "df_analysis.head(5)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 660
        },
        "id": "lXWIMM4eMiz4",
        "outputId": "9012d95f-122a-4682-f57b-b8705c49d541"
      },
      "execution_count": 40,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript            Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel...  2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta...  2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc...  2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon...  2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel...  2019-08-07 08:30:00   \n",
              "\n",
              "    Date_only  word_count  Price_change Target_Class  DateOfWeek  Month  \\\n",
              "0  2020-08-27        5623      0.035078      Neutral           3      8   \n",
              "1  2020-07-30        4755      0.116154         Gain           3      7   \n",
              "2  2019-10-23        8917      0.142022         Gain           2     10   \n",
              "3  2019-11-06        8286      0.029891      Neutral           2     11   \n",
              "4  2019-08-07        4611      0.249623         Gain           2      8   \n",
              "\n",
              "   Quarter  FinBERT_Positive  FinBERT_Negative  FinBERT_Neutral  \n",
              "0        3          0.146988          0.012653         0.840358  \n",
              "1        3          0.910005          0.010605         0.079389  \n",
              "2        4          0.878131          0.012376         0.109493  \n",
              "3        4          0.727205          0.122016         0.150779  \n",
              "4        3          0.755221          0.136653         0.108126  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-b840636c-1eff-4232-ac90-9d8ed10a2166\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>word_count</th>\n",
              "      <th>Price_change</th>\n",
              "      <th>Target_Class</th>\n",
              "      <th>DateOfWeek</th>\n",
              "      <th>Month</th>\n",
              "      <th>Quarter</th>\n",
              "      <th>FinBERT_Positive</th>\n",
              "      <th>FinBERT_Negative</th>\n",
              "      <th>FinBERT_Neutral</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>5623</td>\n",
              "      <td>0.035078</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>3</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.146988</td>\n",
              "      <td>0.012653</td>\n",
              "      <td>0.840358</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>4755</td>\n",
              "      <td>0.116154</td>\n",
              "      <td>Gain</td>\n",
              "      <td>3</td>\n",
              "      <td>7</td>\n",
              "      <td>3</td>\n",
              "      <td>0.910005</td>\n",
              "      <td>0.010605</td>\n",
              "      <td>0.079389</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>8917</td>\n",
              "      <td>0.142022</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>10</td>\n",
              "      <td>4</td>\n",
              "      <td>0.878131</td>\n",
              "      <td>0.012376</td>\n",
              "      <td>0.109493</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>8286</td>\n",
              "      <td>0.029891</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>2</td>\n",
              "      <td>11</td>\n",
              "      <td>4</td>\n",
              "      <td>0.727205</td>\n",
              "      <td>0.122016</td>\n",
              "      <td>0.150779</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>4611</td>\n",
              "      <td>0.249623</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.755221</td>\n",
              "      <td>0.136653</td>\n",
              "      <td>0.108126</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-b840636c-1eff-4232-ac90-9d8ed10a2166')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-b840636c-1eff-4232-ac90-9d8ed10a2166 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-b840636c-1eff-4232-ac90-9d8ed10a2166');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-84584157-b2ec-473c-90f1-8823c4374af9\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-84584157-b2ec-473c-90f1-8823c4374af9')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-84584157-b2ec-473c-90f1-8823c4374af9 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_analysis",
              "summary": "{\n  \"name\": \"df_analysis\",\n  \"rows\": 10913,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4311,\n        \"samples\": [\n          \"Jul 8, 2021, 11:00 a.m. ET\",\n          \"Feb 13, 2020, 9:00 a.m. ET\",\n          \"May 18, 2022, 9:00 a.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"NYSE: AVB\",\n          \"NASDAQ: THRM\",\n          \"NASDAQ: ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q4\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"AVB\",\n          \"THRM\",\n          \"ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10031,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nGood afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the PTC's 2022 first quarter conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open for questions.\\nI'd now like to turn the call over to Matt Shimao, PTC's head of investor relations. Please go ahead.\\nMatthew Shimao -- Head of Investor Relations\\nHello. Thank you, Julian, and welcome to PTC's results call for Q1 of fiscal '22. On the call today are Jim Heppelmann, chief executive officer; and Kristian Talvitie, chief financial officer. During this call, PTC will make forward-looking statements, including guidance on future operating results.\\nBecause such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in PTC's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission, as well as in today's press release. The forward-looking statements, including guidance provided during today's call are valid only as of today's date, January 26, 2022, and PTC assumes no obligation to update these forward-looking statements.\\nDuring the call, PTC will also discuss non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures can be found in today's press release made available on our website. With that, I'd like to turn the call over to PTC's chief executive officer, Jim Heppelmann.\\u00a0 \\nJim Heppelmann -- Chief Executive Officer\\nThanks, Matt. Good afternoon, everyone, and thank you for joining us. Turning to Slide 3, I'm pleased to share that PTC delivered another strong financial performance in fiscal Q1. We executed very well, building on the momentum we saw in Q4.\\nTo simplify things, please note that throughout my prepared commentary, I will only discuss growth rates in constant currency. ARR came in at $1.507 billion, which was better than the $1.5 billion we had guided to at the recent Investor Day. That represents 16% growth, 11% of which was organic. Adjusted free cash flow was also strong at $145 million, which was up 20% year over year and better than the $140 million expectation we said at the Investor Day.\\nWe're off to a very strong start in fiscal 2022. Turning to Slide 4. Of particular note was our bookings strength. Bookings were up double digits organically and high teens overall against the very strong COVID bounce back quarter we saw in Q1 of fiscal '21 when bookings grew more than 30% over the prior year.\\nTo put it in perspective, given the tough comparison against Q1 of last year, we had planned bookings to actually be down slightly, inclusive of Arena. So this performance was more than 20% above plan. I know that some analysts and investors had voice concerned that the restructuring work we did in late Q4 and throughout Q1 would distract us, but obviously, we didn't see that. The strength was broad-based across direct sales and resellers and was achieved with no megadeals.\\nRockwell came in ahead of their part of our plan, too, which was great to see and suggest my concerns of them being distracted and may prove overstated. Arena contributed the inorganic element of bookings growth, with another strong bookings quarter, coming in above plan as well. With the Arena acquisition getting round tripped here in Q2, Arena becomes part of the organic results going forward and their low 20s growth rate will then add another tailwind to the organic results. Arena has been a great acquisition.\\nBookings growth was particularly strong in PLM, and in both Europe and Americas. From a macro perspective, global PMIs remain an expansion territory, while digital transformation and SaaS continue to grow in importance as secular drivers. The interest in digital transformation in SaaS has been driving strong bookings for what is very sticky software, which when layered into a recurring revenue model that is atypical of industry peers, has allowed PTC to deliver performance in excess of market growth rates. This happened right through the pandemic, especially in the large core business that represents about 70% of our ARR, and we fully expect it to continue going forward.\\nThese factors gave us confidence to raise the lower end of our ARR guidance range, which at the new midpoint basically means we've rolled our Q1 beat forward. Now let's take a look at the ARR performance by geography on Slide 5 before turning to business units. In Q1, we saw a strong ARR performance across all geographies. Our ARR growth in the Americas was 19%.\\nAll product segments grew with key growth drivers being the acquired Arena contribution and the velocity business unit overall, layered on top of another strong quarter in the core CAD and PLM business. In Europe, our ARR growth was 13%. We saw strong results across the board in Europe, with the strongest drivers of the growth being our digital thread growth and core businesses. Europe has the largest mix of channel versus direct and the resellers continue to perform well.\\nOur ARR growth in APAC was 14%, with growth primarily driven by our digital thread core business. Next, let's take a look at the ARR performance of our various business units, starting with the digital thread group on Slide 6. In our largest product segment, digital thread core, we delivered yet another double-digit performance in Q1 with 11% growth. Within this, CAD and PLM, both grew double digits, with strong growth across all three geographies.\\nThis is the 17th consecutive quarter of double-digit ARR growth in the core business. And as we roll out our more aggressive SaaS strategy, I expect we'll see many more. In the digital thread growth, which is IoT and AR, we saw ARR growth of about 14%, consistent across both elements. This was in line with our plan and the mid-teens near-term growth expectation we set at the recent Investor Day.\\nWhile this level of growth remains accretive to company growth, we continue to expect an acceleration of growth into the 20s as we get into the back half of the year. The biggest driver of growth in Q1 was from expansions, especially in Europe and APAC. We believe market conditions in IoT are improving, and we like the way the pipeline for our new DPM offering is developing through both PTC and Rockwell channels. For AR, we continue to see a tremendous level of interest, but the market remains nascent.\\nPerhaps most importantly, the formation of the digital thread business unit at the start of FY '22 has driven important initiatives to increase our focus on cross-selling of IoT and AR into the core CAD and PLM customer base. FSG had a great Q1 with 6% ARR growth. The expansion deal we recently announced with the U.S. Air Force, both increases and extends this key relationship for up to five more years.\\nContracts like this demonstrate the value that our customers are realizing from Servigistics and other FSG products such as retail PLM and ALM. You may remember, I noted at our Investor Day that having FSG grow in the mid-single digits rather than flat would be a helpful upside growth driver. So I'm pleased to see FSG post another strong quarter. Let me run through a couple of quick customer anecdotes to give you a sense for our digital thread customers and how they rely on us.\\nOn Slide 7, MAN Energy Solutions is the world's top provider of large-bore engines in turbomachinery for the maritime and energy industries. The company manufactures complex parts in nearly every engine they make must meet unique customer requirements. Before implementing Creo, they relied on manual outdated processes that slowed design and production. With Creo, they've been able to transition from 2D to a full 3D model-based approach.\\nCreo's broad range of tool path automation capabilities enable them to save time in the programming of the tool pass used to machine the large complex engine parts, greatly increasing efficiency in transitioning from design to production. Turning to Slide 8. You may have noticed we announced a deal with -- we announced that the German company, Scheffler, has expanded its relationship with PTC, and I'd like to share a bit of the back story. Scheffler has been a longtime Creo customer and has successfully deployed Windchill within engineering.\\nBut back in 2017, one of our PLM competitors announced a large PLM deal with Scheffler that appeared to cap PTC's expansion opportunity. But that system didn't ultimately stick as Scheffler has now decided to consolidate on PTC systems with Windchill being the backbone and is broadly deploying our solutions in their standard out-of-the-box fashion so that Scheffler can participate in the full power of our digital thread portfolio. I'm very excited about this collaboration and the further expansion that Scheffler is exploring with our IoT and AR offerings. On Slide 9, you'll see how IMA Group, our global business that delivers packaging machines, services, and solutions to a wide variety of industries, was looking for a way to expand their control room offering to help their customers improve overall equipment effectiveness and reduce downtime.\\nAs longtime users of PTC's Creo and Windchill, IMA decided that ThingWorx was the ideal IoT solution for their initiative and that Kepware could provide connectivity not only to their machines, but to the other vendors' machines deployed alongside them. IMA has successfully launched new revenue streams by enabling 24/7 monitoring of customer production lines and improved OEE by up to 16%. The Vuforia integrated with ThingWorx is the platform of choice for the U.S. Air Force training initiatives.\\nSlide 10 highlights the work that PTC partner, Vectrona has done with the U.S. Air Force. With finite training resources and limited capacity, the U.S. Air Force set out to incorporate augmented reality into their maintenance and munitions training.\\nVectrona using Vuforia Studio worked with the U.S. Air Force to create immersive 3D AR experiences for phones, tablets, and the HoloLens 2 that are designed to accelerate learning, improve work performance and facilitate remote training. The improved training shows better engagement and information retention with continuous and repeatable task training available regardless of the system or aircraft type. Turning to Slide 11, the velocity business ARR growth in Q1 was more than 650% due to the inclusion of Arena and 53% organically, which would be Onshape.\\nIf you were to add Arena's pre-acquisition results into the prior year to get a better pro forma comparison, then you'd have the velocity business unit growing at 28% in Q1. That 28% is a mix of Onshape growing at 53% and the larger Arena business growing in the low 20s. Growth of both Onshape and Arena is multiple times higher than market rates, clearly demonstrating that industrial companies see the benefits of SaaS. We continue to ramp investments to expand technology leadership and to broaden the geographic presence of our velocity businesses.\\nOn Slide 12, Beta Technologies, a leading developer of next-generation electric aircraft for the cargo and logistics market, sought a cloud-native product development platform where everyone would be working with one single source of truth without the workflow restrictions of traditional file-based design systems. Beta turned to Onshape because of how it enables real-time collaboration, allowing the engineering team to work from any location while streamlining their communications during the design process. To profile Arena customer, Potrero Medical, on Slide 13, is a predictive health company developing the next generation of medical devices, leveraging smart sensors and artificial intelligence. Potrero needed a scalable quality management system to support its growing product development and compliance needs, including satisfying FDA audit requirements.\\nArena was the right solution, offering a cloud-native QMS with a quick implementation, leading to ECO cycle time reduction of 30% and nonconformance improvement of 20%. As a final topic, I'd like to give you a quick update on our SaaS acceleration initiative on Slide 14. We've made tremendous progress in the past 90 days since we announced the more aggressive strategy. We've launched our SaaS program management office, which was modeled after the very successful approach we used to drive our subscription transition several years back.\\nOur field organizations transition to the new two-in-a-box customer success organization model without missing a beat. We converged our cloud and tech support organizations with product development to deploy the DevOps type of approach you see in virtually all SaaS companies. We've made good progress advancing our offerings, especially the Windchill multi-tenant version, which will go into production shortly this quarter, and we made good progress preparing the SaaS conversion offerings that will power the hundreds of lifts and shifts that will happen in the coming quarters and years. We have more work to do, but we're certainly up and running.\\nThe time for SaaS has arrived in our industry and PTC is very well positioned. We're already the SaaS leader in our space with continued strong SaaS growth in Windchill and FSG and high levels of growth in our cloud-native velocity business unit. Sharing the Atlas SaaS platform, we have a dual strategy to win with Onshape and Arena powering a new agile product development approach, while we transition our digital thread portfolio and existing customer base to SaaS to elevate the platform strategies that so many larger companies have. To wrap up on Slide 15, I'm pleased with PTC's position and the opportunity that lies ahead.\\nQ1 gave us a strong start to what we expect to be our fifth consecutive year of double-digit ARR growth. Our portfolio of products is unique and compelling and obviously aligns well to customer demand. Our results have been consistently strong for many quarters, but we're poised to accelerate growth as the SaaS tailwind blows harder in coming quarters and as we gain more momentum with our IoT and AR initiatives in the back half of the year. We're poised to drive higher levels of profitability, too, following the organizational changes we've already implemented and as our start-up businesses continue to mature up their J curves.\\nThe company has never been in a better position to create shareholder value. With that, I'll turn it over to Kristian for more details on the financial results.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nThanks, Jim, and good afternoon, everyone. Before I review our results, I'd like to note that I'll be discussing non-GAAP results and guidance, and growth rate references will be in both constant currency and as-reported rates. So turning to Slide 17, we delivered constant currency ARR of $1.507 billion, which is 16% growth year over year and slightly exceeded our Q1 guidance of $1.5 billion. On an organic constant currency basis, this is 11% growth.\\nFX was an approximate $11 million headwind in Q1, so our as reported ARR was $1.496 billion. Our SaaS products in both the digital thread and velocity business units saw a continued strong growth in Q1, with growth rates similar to what we discussed at our recent Investor Day. This is in combination with continued strong growth of our software-only sales. As of Q1, our SaaS portfolio is now 15% of our total ARR on a constant currency basis.\\nQ1 free cash flow of $134 million grew 21% year over year and includes $11 million in restructuring and other related payments. Adjusted free cash flow was $145 million and was slightly ahead of the $140 million we discussed at our Investor Day. Q1 revenue of $458 million increased 7% year over year. As we've discussed previously, revenue is impacted by ASC 606, so we do not believe that revenue growth rates are indicative of our underlying business performance but would rather guide you to ARR as the best metric to understand our top-line performance and cash collection.\\nFX only impacted revenue by about $1 million in Q1. So our revenue on a constant currency basis was $459 million. Q1 non-GAAP operating margin of 35%, compared to 36% in Q1 of 2021. While this is a strong result, it's still worth pointing out that because revenue was impacted by ASC 606, other derivative metrics such as gross margin, operating margin, and EPS are all also impacted.\\nSuffice it to say that our COGS and opex came in in line with our expectations in Q1, and we continue to maintain good discipline on our operating expense structure. I would like to point out that our GAAP results reflect a gain of $9.8 million related to our investment in Matterport. And we're also slightly reducing the range for expected P&L charges from approximately $45 million to $50 million, down to $40 million to $45 million for the full year. And coincidentally, we're also reducing the range of expected cash payments for the restructuring and other from what was previously $50 million to $55 million, down to $45 million to $50 million for the full year.\\nFor guidance purposes, we will continue to show $50 million as the cash payments and the adjusted free cash flow reconciliation. But as payments come in lower, then we would just expect actual free cash flow to come in higher. There's no change to the $450 million adjusted free cash flow target. Moving to Slide 18, I'll begin with our balance sheet.\\nWe ended Q1 with cash and cash equivalents of $296 million. In addition, at the end of Q1, we had medium-term investments of $87 million, primarily related to our investment in Matterport. Our gross debt was $1.45 billion with an aggregate interest rate of about 3.2%. In Q1, we used $120 million of cash to repurchase shares.\\nWe also had an additional $5 million of repurchases, which settled early in Q2. For the remainder of fiscal '22, we will focus on delevering and looking forward to FY '23 in an ongoing go-forward basis, assuming our debt-to-EBITDA ratio is below three times, we will continue to target to return approximately 50% of our free cash flow to shareholders via share repurchases. Turning to Slide 19. We post a data table to our IR website that has our financial statements, as well as ARR detail by segment.\\nIn that file, we share both constant currency and as-reported ARR. As a reminder, when we calculate constant currency, we use our current year plan FX rates and restate history to the same rates. So here, for example, on this slide, you can see our Q1 constant currency ARR of $1.507 billion and the actual as reported ARR of $1.496 billion. This is important to remember in the context of our guidance because we provide guidance at the planned rate.\\nWe believe this is the best way to evaluate the top-line performance of our business because it removes FX fluctuations from the analysis, positive or negative. With that, I'll move on to guidance on Slide 20. As Jim mentioned, we're raising the low end of our full year constant currency ARR guidance by $10 million. The new range is now $1.625 billion to $1.660 billion.\\nThis essentially reflects rolling our Q1 overperformance through the remainder of the year. We're now expecting constant currency ARR growth of 11% to 13% in fiscal '22. It's worth pointing out that based on FX rates at the end of Q1, we would expect a $13 million headwind against that full year ARR guidance. For Q2, we're setting constant currency ARR guidance of $1.540 billion to $1.550 billion.\\nThis is 12% organic constant currency growth at the midpoint. On an as-reported basis, the FX impact we're calculating based on the FX rates at the end of Q1 is a $12 million headwind in Q2 compared to the constant currency guidance. Moving to free cash flow. We're maintaining our full year free cash flow target of $400 million.\\nThis includes approximately $50 million of restructuring and acquisition-related payments. The majority of these payments are related to the reorganization we announced in Q1 with some residual payments primarily related to our Seaport move for which we took the accounting charge in prior periods. So our adjusted free cash flow target for fiscal '22 remains $450 million. Fiscal Q2 adjusted free cash flow is expected to be approximately $155 million.\\nWe expect to make approximately $20 million in restructuring and other related payments in Q2, bringing our free cash flow to approximately $135 million. Moving to revenue. We're also taking the low end of the full year revenue guidance up by $20 million. This reflects both the strength in software and strength in the professional services business that we saw in Q1 and the related forecasts for the full year.\\nSo for fiscal '22, our net revenue guidance range is $1.870 billion to $1.975 billion. The year-over-year growth rate range is now 3% to 9%. Our ASC 606 makes revenue very difficult to predict for on-premise subscription companies, hence the wide range. Note that revenue variability has -- this is from 606, has no impact on ARR or its related cash generation as we continue to primarily bill customers annually upfront regardless of term length.\\nWe continue to expect more than 60% of our annual free cash flow generation to occur in the first half of the year. Collections are stronger in the first half, and we expect expenses to increase as we ramp hiring in our SaaS investments throughout the year. We're wrapping up on Slide 21 with the free cash flow model that we use and went into some depth on at our recent Investor Day that you can see here. I know many of you use model free cash flow using the indirect method.\\nHowever, given the complexities related to revenue recognition due to 606, this is difficult to do. The model we show here has proven quite effective. The table shows fiscal '21 actuals compared to the model we shared at Investor Day compared to our current guidance. Let me take you through the model focusing on the non-GAAP column on the right and starting at the top.\\nFirst, we're showing the midpoint of our as reported ARR guidance of $1.630 billion, which is different from the constant currency guidance that we gave due to the $13 million FX headwind and is also $5 million lower than what we showed at the Investor Day. We use it as reported here because it's a better reflection of the cash we expect to generate. You can also see that we have increased the perpetual license revenue forecast slightly and also the professional services revenue increase that we mentioned earlier. COGS is slightly higher, reflecting the increased costs to deliver the incremental professional services revenue and the rest of the assumptions remain the same, and we still end up with our target adjusted free cash flow of $450 million.\\nObviously, this is a model based on assumptions such as the midpoint of the ARR range, the impact of FX, the pace of hiring, etc. So if some of those variables change, which they invariably will, the model will have to be adjusted accordingly. And as I mentioned earlier, if cash payments related to the restructuring coming at the low end of the range, we would see a flip from the restructuring line to the free cash flow line, but the adjusted free cash flow target would remain unchanged. But as we sit here today, we think this is a reasonable view of how we expect the year to shape up.\\nSo with that, I'll turn the call over to the operator, and we can begin Q&A.\\u00a0\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] We ask the analysts to please limit themselves to one question only. If you have any additional questions, please return to the queue. Thank you.\\nYour first question will come from Andrew Obin from Bank of America. Please go ahead. Your line is open.\\u00a0\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nHi, yes. Good afternoon.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Andrew.\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nJust a bigger picture question. I apologize, I missed the first couple of minutes. You know, we hear a lot about supply chain constraints. And frankly, we're hearing that this might extend the run-in terms of PMI expansion.\\nSo what are you hearing in terms of sort of as you have conversations about PLM and in terms of adoption? What kind of conversations are you having with your customers? And do customers have awareness of sort of supply chains being gummed up for longer? And are you seeing this having any discernible impact on what kind of conversations you're having with people?\\nJim Heppelmann -- Chief Executive Officer\\nAndrew, it's Jim. No, actually, it's not really a frequent topic in our conversations because -- well, first of all, since you said you missed the first minute, one of the things I pointed out is that our bookings came in very, very strong, and I explained about 20% higher than planned. So we had a very, very strong bookings quarter. And notable in that was PLM, although, frankly, the strength was broad-based.\\nI think the key thing to remember is that PLM is really associated with preparing product data in engineering that will then subsequently be used in manufacturing and perhaps in aftermarket service. And it's collecting data from supply chain partners and so forth. But production problems in a supply chain don't necessarily impede the collaboration during the engineering and the preparation for production process. So I think people are saying like, maybe I can't get chips to complete the product, but that doesn't mean I should stop designing the next one because if it does, then I'll fall behind.\\nSo I think that our view would be that the product development process has largely been unaffected by the supply chain process. Now some other things, we talked about how perhaps COVID had an impact on IoT, perhaps the supply chain a little bit, although I think muted compared to COVID. So to me, the supply chain thing is a fairly small factor in our results. We just see very little correlation between what's happening out there with supply chain problems and what's happening with our pipeline and frankly, with our bookings.\\nOperator\\nYour next question comes from Yun Kim from Loop Capital. Please go ahead. Your line is open.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nHey, Yun.\\nYun Kim -- Loop Capital -- Analyst\\nThank you. Hi, Jim. Can you just talk about the IoT business, you know, in terms of the large deal activity? What kind of trends are you seeing there? Obviously, you are expecting that business to accelerate in the back half -- second half of the year. If you can talk about whether that confidence is coming from the, you know, improvement in the large deal activity? Or is it just the overall volume of the activity around IoT? And then also, if you can just comment around deal size activity around the AR business as well.\\nThanks.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I think deal sizes are sort of unchanged from previous trends. If you think -- what are we looking at when we project forward how IoT and AR will perform. Well, we're looking at the bookings, let me say, at the pipeline that will drive bookings, and for IoT and AR was quite strong.\\nWe're looking at the backlog. Last year, bookings actually had improved over the prior year. And bookings that went into backlog or -- I'm sorry, what we call deferred ARR, were quite high. We were well ahead of our deferred planned number as we actually did last year.\\nSo you could imagine we've got more, and if you want to call it, backlog waiting for us. And then what other initiatives are we doing? So for example, our DPM launch, I think, will be materially positive for our IoT results. It will drive bigger deals. It will drive better value propositions.\\nIt's really software that's ready to turn on and get value from as opposed to a platform. And then the other thing is, Troy Richardson talked at our Investor Day about organizing better for cross-sell. And I think if we look backwards, maybe we had pivoted too much toward new logos, which are great. I mean, new logos are a wonderful thing.\\nBut we probably have low-hanging fruit yet to pick within our installed base of CAD and PLM accounts. So I think it's really this combination of a strong-looking pipeline, good-looking trends, awaiting us in the deferred backlog and then these other initiatives kicking into place, DPM and cross-sell that I think will all be very helpful as we proceed through the year. And again, I want to remind everybody, we set the expectation that the two handle would materialize in the back half of the year and that you wouldn't see it in Q1 and Q2. So we sort of feel like this was as we had predicted just mid-December a couple of weeks ago.\\nOperator\\nYour next question comes from Jason Celino from KeyBanc Capital Markets. Please go ahead. Your line is open.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nHey. Hi, Jim. Hi, Kristian.\\nJim Heppelmann -- Chief Executive Officer\\nHi, Jason.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nSo one question on maybe the SaaS Windchill, you know, launch. It seems like it's coming along, you know, nicely, and we could see something maybe go GA this quarter. Have you had a chance to maybe, you know, discuss this with customers? How is the pipeline shaping? Or is it maybe better to think that the pipeline might start to form once we do go live?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nNo, we have, for sure, started talking about it with customers. I mean, ramping up that process. We've got to educate a lot of people and they, in turn, have to educate customers. But we've certainly made some progress, and I can tell you the customer interest is actually quite high.\\nYou should know that actually, customers were pushing us a little bit to get going with such initiatives -- so I feel like the demand is there. And in fact, again, just reflecting on what we told you, that business has been growing about 30%. And Kristian mentioned we posted another quarter just like that, without us really invoking the new strategy yet. So there's lots of demand.\\nWe're just looking for a model where we can promote the demand because we like the margin profile better. And that's what's coming into place here in Q2.\\nOperator\\nYour next question comes from Adam Borg from Stifel. Please go ahead. Your line is open.\\u00a0\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nGreat. Thanks so much. And maybe just two quick ones. Just on the Scheffler win that you announced yesterday and highlighted on the call earlier.\\nOne of the things I thought was really interesting in the press release was this opportunity around some more vertical-specific or market-specific solutions targeting either automotive or industrial companies. So maybe, Jim, if you could just talk about that. And maybe just as a quick follow-up, just maybe for Kristian. Any way you could talk about this transition, it's great to get the early feedback on the SaaSification efforts, but any way to comment on, you know, how much this has contributed to bookings or the pipeline, at least qualitatively? Thanks so much.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I'll get the first part of the question. Kristian, you can take the second part. Yeah.\\nSo Scheffler is a great account. And as I mentioned back in 2017, it appeared they were going in a different direction, and now they've decided to come back into the fold. And honestly, they did that for two main reasons. One is that they really want off-the-shelf technology.\\nThe other competitor had told them this low-code, no-code story, and they tried that out and decided that's not really what they want. They don't want to develop their own solutions. They want to deploy standard out-of-the-box software that all works together. And then they want to engage in partnerships with the vendor, in this case, PTC to talk about how those solutions should evolve to be more and more powerful to meet their needs.\\nSo yeah, I'm very excited. I'm in the middle of that relationship myself. And yes, what's going to come out of that is technology that fits better and better, for example, for the automotive supply chain, which is a place where we have a lot of customers. So it's a great win or win back, maybe I should say, and a great partnership going forward that's going to produce a lot more business for us in years to come.\\nAnd sorry, the second part of the question was around the transition to SaaS and how that's manifesting itself in terms of pipeline and activity? Is that right, just making sure I got that right.\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nExactly. Any way to qualitatively comment from, you know, either bookings or a pipeline perspective?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, remember, I mean, the bookings that we just reported were for Q1, and Q1 is really when we actually just announced the acceleration of it. So I would say there's actually a limited impact in the actual bookings result here in Q1. That said, as I mentioned, we continue to see strong demand for the SaaS properties that we have.\\nThat's both in velocity and the digital thread. And so those products continue to grow at a rate higher than our software-only products. And now as the program is pushing ahead, we expect to see demand and pipeline generate, especially with the new Windchill launch coming out here and the program continuing to pick up speed internally.\\nKristian Talvitie -- Chief Financial Officer\\nMaybe, Adam, I could just add. We launched this phase 3 strategy 90 days ago on the earnings call. And there's nothing we've seen since that makes us any less bullish than we were back then. I mean it looks like a really nice opportunity for PTC, and we're pushing forward ahead as aggressively as we can because we'd like to bring that very promising upside growth driver, you know, closer in.\\nSo it has a bigger impact on '23 and '24 and so forth than it would otherwise have had.\\u00a0\\nOperator\\nYour next question comes from Jay Vleeschhouwer from Griffin Securities. Please go ahead. Your line is open.\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nThank you. Hello. Hi, Jim. Hi, Kristian.\\nA couple of things. With regard to the strength you noted for PLM, at your partner conference six months ago, back in the summer, management presented to the channel, your concept that PLM was no longer just an engineering vault that it was becoming memorial, what you call, multisystem, multidiscipline concept. And the question is, to what extent is that broader, more diverse view of PLM a current part of new business or in the pipeline for new business as compared to the more conventional historical way of thinking about PLM? By our calculation, we are already the second-largest brand by revenue in PLM, and maybe talk about what some of the drivers are to that? And then just a quick clarification you referred earlier to cross-sell. At the Analyst Meeting last month, in the slide deck, you referred to cross-sell 10 times and relatedly account-based selling.\\nPTC is often over the years, talked about cross-sell, but maybe talk about what's different this time in terms of resources and programs across your various segments and your new customer segmentation model.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, on your first question, Jay, you know, you are always very pressy on, you've been watching this industry for a long time. When we say multisystem, multidiscipline, what we're really talking about is an enterprise system. And so what's happened in the last couple of years is PLM has graduated from being an engineering data management system to being an enterprise system that contains the system of record for the product definition.\\nAnd so if you're in manufacturing, well, you need to know the product definition. If you're in procurement, you need to know the product definition. If you're all on an installation or a support call, you probably need to know the product definition. So definitely what's happened is that the enterprise deployments of Windchill are multiple times larger than the engineering deployments of Windchill.\\nSo something that's been driving growth for some years now is that the new deals we're taking are more and more frequently enterprise deals and they're larger. You may remember, last quarter, I told you we took the largest deal we had taken to date from a med device company. And the second thing that's happening is, we're circling back to those companies who had deployed the engineering solution like say, Scheffler, and we're upselling them to the enterprise solution and turning that into a much bigger opportunity for us. So definitely, that's a real thing, and it's been driving the momentum we've seen in Windchill for years.\\nAnd frankly, there's a lot of it out ahead of us even before we start talking about SaaS. The upsell from a departmental solution to an enterprise solution is a driver, taking that whole enterprise solution to SaaS is a whole another growth driver that's on top of that and sort of orthogonal to it. And then on the account-based selling, there's two ways to look at that. Cross-selling into your accounts is a great thing.\\nYou have established relationships. It's much easier to sell another product to an existing customer than to sell a new product to a new customer or a first product to a new customer. At the same time, we like new logos. So it's really always about the balance of how much do you invest in new logos pursuits versus how much do you invest in selling more to the companies who know and trust you.\\nAnd I think perhaps with IoT and AR, we realized we had over pivoted toward new logo, which is just generally speaking, less productive selling, you might imagine. And so the reason we formed this digital thread group, which brought CAD and PLM and IoT and AR together under Troy Richardson, was to really lubricate how these products work together and how we position them together and to be able to start anywhere and sell up and down that chain. So it's a good strategy. It's one that we -- it's a muscle we've developed well over the years.\\nWe really built the Windchill business, largely by cross-selling to the Creo base. And I think this is going to be something that will help us a lot to kind of get the right balance of new logo pursuits in cross-sell.\\nOperator\\nYour next question comes from Ken Wong from Guggenheim Securities. Please go ahead. Your line is open.\\u00a0\\nKen Wong -- Guggenheim Securities -- Analyst\\nThank you so much for taking my question. Jim or Kristian, I wanted to perhaps dive into the double-digit organic bookings growth. You know, I couldn't help and notice you guys also had a very large Servigistics expansion deal with the Air Force. I mean how much of that was already in expectations? Or did you get some boost there from timing shifts or anything of that nature?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Let me tell you, none of that actually contributed to the double-digit growth because that was a Q4 deal. You know, we released it when we had approval to release it, and I commented on it because it was, you know, an important customer and so forth. And let me say that deal, again, that was closed in Q4, both represented five years of extension, but also about a 50% growth in a ramp that happens over -- I think it's three years.\\nSo it roughly goes from a $10 million run rate to a $15 million run rate over three years and stays there for a couple more. That's what the contract contemplates. So some of that will come into ARR in Q4 of this year, but the bookings actually were in Q4 last year. So that strength -- the strength we saw in Q1 was exclusive of that Air Force deal, which just means it was really great strength.\\nSo anyway, it was hard to pin down where the strength comes from because it came from CAD. It came from PLM. The IoT number was actually pretty decent. It didn't all go into ARR.\\nAnd then, of course, the velocity numbers and the FSG numbers. So it was broad-based in all geographies and really in all product lines.\\nOperator\\nYour next question comes from Matt Broome from Mizuho Securities. Please go ahead. Your line is open.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Matt.\\nMatt Broome -- Mizuho Securities -- Analyst\\nThanks, man. So Jim, I mean, I guess, just on that -- sorry, just deal that I can just mention. Given the importance of supply chain management right now, are you seeing like ramping demand to the solution elsewhere? And sort of following on from that, is there a chance that FSG ARR could actually accelerate on the back of that demand beyond the sort of the mid-single-digit level and actually become sort of more strategic in a way?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean that's one of the points, Matt, that I brought up at the recent Investor Day is that we've generally modeled FSG to be roughly flat, flat about plus 1% to 2%. But it's actually been performing. I think last year, Kristian, wasn't up 7%, FSG.\\nIt was up 6% here again in Q1. So yes, we're overperforming and Servigistics is one of the key drivers. And then the second one probably is retail PLM, which has also been doing fairly well. So definitely, there's some -- I think we'll be conservative and leave the FSG sort of guidance where it is in the near term, but I do like overperforming it because it's a growth driver.\\nThe FSG business is about the same size as the IoT and AR business. So every point of growth we get there is pretty meaningful.\\nOperator\\nYour next question comes from Matt Hedberg from RBC Capital Markets. Please go ahead. Your line is open.\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nYeah. Thanks. This is Matt Swanson on for Matt. I'll kind of follow up on a piece of both Adam and Jay's questions.\\nSo looking at the Scheffler announcement, I think the thing I was really interested in was the idea around standardization and the idea around end-to-end. So could you talk a little bit about your customers' desire around standardization? And clearly, this product road map has really expanded your TAM, but I think one of the upside areas something we -- you know, maybe the holy grail of the transition would be more competitive displacements. And I'm just curious if you're starting to hear, you know, any early or more talk around that because you're building something so differentiated.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean, for sure. So the standard thing, I think maybe over the last couple of years, industrial companies have realized that they should be using software, not developing it. And so we saw this in our IoT business, and it's been why we've been heading up the stack with solutions like DPM is, customers would like to buy the software and use it, not buy some kind of a platform and create it because they just don't really know how to create it if I'm frank.\\nSo Scheffler had gone down the path of kind of like I said, low-code sort of environments and came back to standard products. And then the end-to-end thing, for sure, the CAD data that's created in Creo and managed in Windchill gets used, for example, in augmented reality, manufacturing, and service instructions much later and in a different part of the company if it's all well managed. And that connectivity from IoT, well, let's say, from CAD to PLM to IoT to AR is what we call the digital thread. And so we actually see so much interest in this that we kind of organized around that principle.\\nLet's stop presenting these products as kind of independent things and let's shine the light on how well they work together in an end-to-end solution. And by the way, how they're all ready to go. That this is something that turn on and use. And that's really what one Scheffler over, but I can tell you, Scheffler is not unique at all.\\nAnd it's really -- we're organizing to respond to that. SaaS is helpful, by the way, because if you want a lot of technology working end to end, it'd be better not to ship at all to the customer side because it gets complicated. The customer would like to just use it, not set it all up and care and feed for it on-premise.\\nOperator\\nYour next question comes from Saket Kalia from Barclays Capital. Please go ahead. Your line is open.\\nSaket Kalia -- Barclays -- Analyst\\nOK, great. Hey, guys. Thanks for taking my question here. Hi, Jim.\\nHey, Jim, maybe -- hey, Kristian. Jim, maybe for you, it was great to hear the PLM strength this quarter in bookings. With other companies that have done shifts like this, there's always a risk, I guess, of customers behaving differently, right, whether that's slowing purchases to see what's coming or maybe pulling forward purchases before something new comes out. Now just to be clear, it doesn't sound like that happened here.\\nBut can you just stress test that for us a little bit? And what you sort of look at to sort of manage what is, you know, more choices for our customer to make. Does that make sense?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Are you referring -- just let me clarify, are you referring to like SaaS choices being new choices or more broad --\\u00a0\\nSaket Kalia -- Barclays -- Analyst\\nYeah, that's right, yeah, Windchill. No, Windchill specifically.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So keep in mind, Saket, we have been selling Windchill as SaaS for some time. Remember, the phase 1, phase 2, phase 3 thing. So since phase 1, we've been selling Windchill, and we showed you, it's got a three-year growth CAGR of 30% in SaaS.\\nSo the customer demand is strong. It's just -- on the PTC side, we need to pivot to multi-tenant because in the single-tenant model we just don't have the profitability we like. So the demand is strong. The customers are buying it.\\nKristian mentioned we had another strong quarter. So it really is, we'd like to meet that demand with a solution that's more efficient for us to operate on behalf of the customer. And that's what phase 3 multitenant really is all about. Now when it becomes more efficient for us, we can then lean in on the promotion and marketing of it, because we haven't really done that.\\nSo we've been servicing demand, not driving it. And with phase 3, we think there's an opportunity to drive demand and, you know, the preliminary data we've seen this quarter suggest customers are very responsive, both to buying new systems that way, but also to lifting and shifting the previous systems they bought and giving them to us to operate and serve back to them in a SaaS model.\\nOperator\\nYour next question comes from Joe Vruwink from Baird. Please go ahead. Your line is open.\\nJoe Vruwink -- Robert W. Baird and Company\\nGreat. Hi, everyone. Just to go back to bookings, does the strength this quarter absent mega deals suggest anything about either the demand environments or maybe just the health of your mid-market and SMB customers? And looking ahead, are there going to be certain things you think about or track when contemplating, you know, the probability of more mega deals or maybe the larger ARR contributors for PTC, maybe, you know, being a bit more represented in future bookings?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nKristian, let me again take a stab at that and maybe you'll find things to add. So I think if you look at the bookings, again, they were phenomenal, and it's hard to pin down. It wasn't one geography. It wasn't one product.\\nIt was all geographies, all products. So I think it tells us that the end market is very healthy. And I would say, for two different reasons. On one hand, the PMIs are in good shape.\\nThat's helpful. On the other hand, the interest they have in the digital thread, digital transformation story, and the interest they have in SaaS is secular. That interest is not related to the PMIs, it's kind of independent of them. And so I think that we're just in a very healthy situation where industrial companies are leaning in on trying to get more digital.\\nThey see PTC as having a fairly unique and compelling portfolio, and they're interested in engaging and trying to make their companies more efficient. I can tell you, at Scheffler, for example, it's one of the top initiatives in the company is to get more digital. And as it relates to the whole product life cycle, the partners PTC. And we see that kind of phenomenon happening in a lot of places in the industrial world.\\nSo I think it's just good, strong, secular and as well macro-environment out there right now. But I'll remind you that we've had good performance even when the macro environment wasn't so strong. So all things being equal, I like the strong macro. But we're 17 quarters in with double-digit growth in the core business, and there were a lot of bad macro quarters over the course of those 17.\\nSo I think it really is the secular driver. Kristian, anything?\\nKristian Talvitie -- Chief Financial Officer\\nYeah. I mean I agree with all that. I mean, actually, just on the big deal dynamic, you know, what we used to call mega deals. We haven't -- I think we've had four in the past four years.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, keep in mind, perpetual drove bigger upfront purchases and subscription or SaaS tends not to.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYeah, which is my point that we've been seeing good strong bookings performance and bookings growth, you know, even with the absence of what used to be a fairly regular occurrence back in the perpetual days, like we really don't see a lot of those.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah, it's a good healthy business. OK. Next question.\\nOperator\\nYour next question comes from Blair Abernethy from Rosenblatt Securities. Please go ahead. Your line is open.\\u00a0\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nThanks very much. Guys, just maybe a quick question on -- around partnerships, in particular. I wonder if you could just give us a little deeper dive into how things are going with Rockwell and as well on the simulation side with Ansys?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So the state of the partner economy is good and, you know, Microsoft, I could put on that list, is also strong. With Rockwell, you'll remember in the past quarters, I had said we should take a bit of a conservative posture as it relates to what Rockwell would contribute to PTC's numbers here in fiscal '22. And we did that because Rockwell had made a big acquisition.\\nYou know, Rockwell never completely agreed with me on that. Their own public commentary kind of indicated they didn't worry too much about that. And in Q1, they were right. So we're pleased to see that Rockwell's contribution was solid in Q1 and starting to feel pretty good about the year.\\nI'll tell you one thing is this DPM solution appears to be a very good fit with Rockwell. And in fact, their Calypso alarm is probably lined up to be our strongest partner in promoting DPM. So we're very happy with that. Calypso has a long-term relationship with PTC that even predates their acquisition by Rockwell.\\nSo great alignment around DPM. Again, DPM is a high-value up-to-stack solution that drives bigger deal sizes, and we think will be a very sticky solution. So lots of optimism around that. With Ansys, we continue to differentiate now with best-in-class simulation.\\nSo whereas simulation some years back would have been viewed as a soft spot for PTC. Now it's a strength. If we're competing against Autodesk or Siemens or Dassault, nobody is going to have a better simulation story than PTC because nobody has a better simulation story than Ansys, and Ansys products are built into PTC products. So that's been going well.\\nAnd then, of course, with Microsoft, that partnership is performing well and poised to get a lot bigger because as we bring more stuff aggressively to SaaS, a whole lot of that is going to land on Azure. So I think all three partnerships are alive and well and as important as ever and helping us achieve the kind of results that we're achieving.\\u00a0\\nOperator\\nYour last question comes from Sterling Auty from J.P. Morgan. Please go ahead. Your line is open.\\nSterling Auty -- J.P. Morgan -- Analyst\\nYeah. Thanks. Hi, guys. Just wondering if you could characterize with the headcount changes that you pointed out are necessary to facilitate the acceleration to SaaS.\\nWhere are you in that process? What's left to go? And kind of what's the time frame that you expect to complete that over?\\nJim Heppelmann -- Chief Executive Officer\\nYeah, Kristian, I'm thinking of the numbers we're largely done, but not completely. Eighty percent, 90% done.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYep, with the exiting.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean we'll be hiring people throughout the year. So -- but in terms of the people who are exiting, they're largely exited by now that largely happened within the first quarter.\\nSterling Auty -- J.P. Morgan -- Analyst\\nUnderstood. Thank you.\\nOperator\\nWe have no further questions. I'd like to turn the call back over to Jim Heppelmann for closing remarks.\\nJim Heppelmann -- Chief Executive Officer\\nOK. Well, thank you, all. There's a lot of good questions and, you know, I think good answers because the business is performing very well right now. ARR is doing well.\\nBookings are doing well. Free cash flow is doing well. You know, I think we executed -- through good times and bad, we executed through the changes we made over the last quarter, and we're set up to do pretty well for the balance of the year. So, we're very confident and, you know, look forward to talking to you all in 90 days if we don't happen to cross pass with you sooner in an investor event or what have you.\\nSo, thanks a lot for joining us and have a good evening.\\nKristian Talvitie -- Chief Financial Officer\\nThanks, everyone.\\u00a0\\nOperator\\n[Operator signoff]\\nDuration: 59 minutes\\nCall participants:\\nMatthew Shimao -- Head of Investor Relations\\nJim Heppelmann -- Chief Executive Officer\\nKristian Talvitie -- Chief Financial Officer\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nYun Kim -- Loop Capital -- Analyst\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nKen Wong -- Guggenheim Securities -- Analyst\\nMatt Broome -- Mizuho Securities -- Analyst\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nSaket Kalia -- Barclays -- Analyst\\nJoe Vruwink -- Robert W. Baird and Company\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nSterling Auty -- J.P. Morgan -- Analyst\\nMore PTC analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, ladies and gentlemen, and welcome to ASUR's First Quarter 2020 Results Conference Call. My name is Kathy and I'll be your operator.\\n[Operator Instructions]\\nNow I would like to turn this call over to Mr. Adolfo Castro, Chief Executive Officer. Please go ahead, sir.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and good morning everyone. Thank you for joining us on the conference call to discuss ASUR's first quarter financial and operating results. Before starting the call, I would like to express my hope that you and your families are healthy and safe in these uncertain times. As a reminder, please note that certain statements made during the course of our discussion today may constitute forward-looking statements which are based on our current management expectations and beliefs and are subject to a number of risk and uncertainties that could cause active results to differ materially, including factors that may be beyond our company's control including the impact from COVID-19. For an explanation of these risks, please refer to our filings with the US Securities and Exchange Commission and the Mexican Stock Exchange.\\nOverall, our first quarter results were good. The year began in solid footing before we started to see the impact of COVID-19 pandemic in the second half of March. It resulted in the disruption of global travel industry. Importantly, in the end of the first quarter we had healthy balance sheet which I will come back and discuss in more detail later in my presentation. I'm going to start today's presentation with some comments regarding COVID-19 and the impact on the industry, on our business, and the steps we are taking to mitigate this disruption to the best we can in this rapidly changing environment. From an industry perspective, since mid-March, many governments have issued flight restrictions in an effort to mitigate the spread of COVID-19 virus. In turn, capacity has been severely reduced and very few people are booking flights as most are in some form in lock down around the world and not traveling. With respect to our airports, the situation varies by country and could be subject to change depending upon how fast or slow the pandemic is brought under control. Colombia has been the most active and we've suspended operations at all six of our airports since the third week of March with domestic flights suspended until April 27 in accordance with the published decree and most recently extended to up to May 11.\\nInternational travels have been suspended through May 13. By contrast, in our airports in Puerto Rico and Mexico remain open, although there's significant reduced flights and passenger traffic. As a result, total passenger traffic declined sharply in the second half of March, down nearly 69% year over year between March 16 and March 31. By country, we show the margin decline in Colombia around 77%, followed by Puerto Rico down 73% and Mexico with 63% decrease [Indecipherable]. Additionally starting in mid-March, some of the airlines as well as some tenants that operate in our airports began asking for assistance either through discounts on payments owed to ASUR or by extension by payment which resulted in a higher accounts receivables in March in Mexico and Colombia, up 54% and 78% year-over-year. We are having ongoing commercial discussions with these companies with respect to their contracts.\\nMoving next to action we have taken, starting with health and safety. Following the guidelines of relevant health agencies, we have implemented health and safety protocols for both our airport employees and passengers travelling through our airports. For example, protective gear such as wearing masks is required for airport staff. We have also stepped up disinfectants and sanitization practices, once again in accordance with the guidelines of local health authorities. Lastly, where possible, we have also implemented remote working points.\\nMoving next to ensuring continuity of our business. We have introduced cost reduction initiatives across our airports. The impact of these initiatives however is not expected to be significant vis-a-vis the potential decline in passenger traffic at the majority of the cost structure is different, except for concession fees and technical assistance in Mexico which are biannual cost. We are prepared to take additional step, if needed, to respond to the evolving business environment. Now, let me talk about our financial situation. We entered this quarter in a position of strength with strong liquidity and very low principal payments required through year end. Additionally we believe the company has sufficient liquidity to meet its obligations and continue operating in the normal course of business. Our cash position ended at MXN7.8 billion which was up from MXN6.2 billion at the year-end 2019. And subsequent to the quarter end, as we further strengthen our financial positions as our subsidiary in Puerto Rico drew down an additional $10 million of its committed line of credit. The line of credit [Indecipherable] support for the capex projects we have under construction, Apelian airport in Puerto Rico.\\nWe closed the quarter with total debt of MXN15.3 billion. Although 11% high than the year-end 2019, this was due to the conversion effect from the depreciation of the peso to the dollar. As a reminder, the majority of our debt, 54% is denominated in the US dollars which is at our subsidiary in Puerto Rico. 26% of total debt was denominated in Mexican pesos and 20% in Colombian pesos. We have principal payments of only MXN432 million coming due over the next three quarters. This represents less than 3% of ASUR's total debt. With respect to that ratios, net debt to last 12 months EBITDA stood at 0.7 times at the close of first quarter '20. You can see the interest coverage ratio by country in the table we have included in the annual release this quarter.\\nNow, stepping back for more, since we began operations over 20 years ago, we have successfully navigated through many very significant challenges. From the 9/11 event in 2001 to [Indecipherable] into 2005 and 2008 and 2009 business financial crisis, H1 and H2 and the bankruptcy of 50% of airlines in Mexico which cut planes capacity in Mexico by more than half. Following each of these events, passenger traffic recovered, although recovery time varied from 13 months to 26 months and then continued to grow. Between 2000 and 2019, annual passenger traffic increased the compound annual growth rate of 6.6%, up from slightly over 10 million to historical high to over 34 million last January. We believe the COVID-19 pandemic is unique in that sense it is global event and with a broad disruption in travel and economies worldwide and could change the way of travelling in the future while a vaccine or a cure is found. Summing up this section, we have a strong balance sheet, we have generated years of consistent profitability and we exercise prudent capital management. In the sense we believe that we cannot be very prepared for an event of this magnitude, but of course given its great uncertainty on the final effects in the worldwide economy and that travel will be [Indecipherable].\\nNow turning to our first quarter results, more details can be found in the press release issued last evening. Like I mentioned this part of my presentation, let me spend with the effects of the business in late March. We believe we had solid results in the first quarter 2020. Total passenger traffic was down in most of the airports, which leads to a total passenger decrease of slightly 6% YoverY. This was primarily due to the fallout from COVID-19 and the impact of the global travel industry beginning in the second half of March. Our airports in all three countries experienced total passengers decline from a low of nearly 3% in Colombia to a high 8% in Mexico. Puerto Rico passenger traffic was down 4%. All three countries reported declines in both domestic and international traffic.\\nMoving next to the P&L highlights, revenues ex construction were relatively unchanged at 4% increase in revenues from non-aeronautical services was offset by a 3% decline in aeronautical revenues. Commercial revenues per passenger increased 11% year over year, reaching MXN116.3. This was driven by solid performance across the region. Mexico posted a good performance with an increase of 11% on a per passenger basis benefiting from the currency peso devaluation and regulated revenues. Puerto Rico posted 7% increase per passenger benefiting from peso depreciation and finally Colombia saw a 33% increase on a per passenger basis, reflecting the 43 new stores opened over the last year and currency depreciation. The main drivers were ground transportation and car rentals.\\nMoving on to profitability, reported consolidated EBITDA increased 3% from the same period over the prior year. Both periods benefited from insurance recoveries related to the Hurricane Maria. In the first quarter '20, it amounted nearly MXN124 million while last year the amount was dragging over MXN41 million. Excluding these recoveries, consolidated EBITDA was essentially flat year-over-year at MXN2.7 billion. Ex-IFRIC 12 and without taking into account insurance recoveries in both quarters, adjusted EBITDA margin increased 20 basis points to 66.7% this quarter.\\nA few comments about capital allocation. Capital expenditures were MXN353 million in the quarter. Of these, nearly MXN58 million was allocated in Mexico due to the terminal expansion of Merida airport. For the full year, and as we have discussed before, our non-prevalent plan in Mexico calls for investment of approximately MXN5.3 billion for the full year. At the current time, there are no changes to the planned continuation of the foreigners tax relief of the second one we have at Cancun airport and the beginning of the first expansion at the Merida. Our plans call for a conclusion of Phase 1 of the Merida terminal expansion and typically the second phase this year. Nevertheless, due to the COVID-19 health crisis, you may see some disruption in the construction process, attributable to stay-at-home, the combination and we have informed the government about this situation. In Puerto Rico we have made investments of MXN114 million this quarter, mainly from the connection with some major maintenance referred tax relief. Finally, capex in Colombia amounted to MXN1 million related to maintenance. Last year we concluded our committed capex was at MXN20 million. And going forward, we only expect to incur a major maintenance capex in Colombia.\\nNext, our Annual General Meeting from yesterday, shareholders approved an ordinary net cash dividend of MXN8.1 per share to be paid, subject to the Board's approval on or after May 11, 2021 in a single installment.\\nIn conclusion, we are proactively responding to the developing situation. No one can control the virus or even the economic fallout. But we can control how we react to the crisis. I am optimistic about the prospects for the future both navigating through the current crisis and in the long term recovery. I believe that we are well positioned with a healthy balance sheet. We had a solid first quarter results. We believe in the strategies that we are executing.\\nThis ends my prepared remarks. Kathy, please open the lines for questions.\\nQuestions and Answers:\\nOperator\\n[Operator Instructions]\\nWe'll go first to Alejandro Zamacona of Credit Suisse.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nThank you Adolfo, thanks for the call. Two questions from our side. The first one is on the aeronautical maximum tariff. So, considering that airlines have been negotiating with most of airports and in some cases some fees have not been charging. What could we expect for maximum tariffs in the short-term meaning the second quarter and in the immediate term, meaning year end 2020? Could we still expect tariffs to be close to the maximum level?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro, hi, good morning. Well, basically what we are seeing today is a very reduced demand. So we believe that there is no effect if we try to reduce our fees for the month of April or the month of May. So we have maintained our tariffs and we believe that we can comply with -- we have to maintain compliance toward the year end.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you. And my second question is on the non-aeronautical business. Same thing in the same context, what could we expect in the short term for commercial revenues per passenger? Have you grant any rent payments facility to payments or any deferrals? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nMost of our contracts, as you may know, they have to pay higher of the minimum guarantee payment per passenger or a percentage of sales. So if we do not have passengers, we will not have to pay rent. So it's made automatically. So in that sense, we are not reducing or adjusting the contracts.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you Adolfo.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nWe will now take a question from Fernando Sanchez of Bradesco BBI.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nHi, good morning and thanks for taking my question. My question is light of the likelihood of the GDP contraction beyond 5% I just wanted to ask if you have had the opportunity to discuss with the authorities the possibility of delaying the 2021 and the key mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. Well as you are aware, the contract has a clause that says that the maximum tariff can be reviewed in the case of Mexico in an external way. When on the Mexican GDP drops by more than 5% in a year and that's happened in fact on track. Of course with the current circumstance and the current expectations from analysts, it is possible that the Mexican GDP will drop by more than 5% this year. So in that sense, we will be we -- and the possibility of review our maximum time in an external rate. That's for next year, but not this year.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nOkay. Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nAnd now, we'll take a question from Carlos Peyrelongue of Bank of America.\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nThank you. Good morning Adolfo. Thank you for the call. On the something I couldn't hear well because of the connection but can you comment as to whether the dividend will be kept or there is the possibility of cutting the dividend until we have more sense about passenger traffic? That would be the first question. And the second would be related to cash burn, if you could give us an idea of what your cash burn is on a quarterly basis, just to get a sense of compare that primarily to your strong cash position. Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYes, of course. In the case of the dividends, yesterday we held Annual Shareholders Meeting, they have sadly approved the dividend that it was proposed MXN8.1 per share. But it was -- this was subject to the approval from the Board to the moment of the payment that's from May 11, 2021. So the Board will have to approve when this dividend will be paid. In the case of the cash burn, what I said to you during the initiative months, is that our currency structure is basically fit. The only variable pieces are the technical assistance fee and the concession fees we paid to the government. So we are working and just to remember the case of Mexico is 5% as well as in Puerto Rico, and in the case of Colombia its' 19%. So this of course will reduce -- our passenger traffic is reduced and our income gets reduced. The remaining is basically, of course, we are taking measures to try to reduce as much as we can, all the expenses in the companies. But as I said, at the end, in the overall picture, the cost reduction will not be significant in comparison with reduction in the revenues of the company.\\nOperator\\nAnd we'll run to our next question, and that will come from Andressa Varotto of UBS.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much for taking my question. So my question is if have plans to negotiate with the government postponement of the mandatory capital is this possible? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nCould you repeat the question? I couldn't hear you.\\nAndressa Varotto -- UBS -- Analyst\\nYes. So my question is if you plan to negotiate with government the postponement of mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said before, in accordance with the contract, we do not have that possibility this year. But of course, with the given standards [Phonetic] and as I said it in my initial remarks, during an expansion situation and that expansion situation is that some companies have stopped operations [Indecipherable] and that it was reactivated later on, but there was a decree from the Mexican government that also named the steel and glass that is produced in the country will be used for the project. So in that sense, at the moment it's almost impossible for us to expand our 10-year buildings without these material. So we have this situation to the government. So for the moment, what we see is that we will see some disruption in our construction process for some months and then we will have to talk about these with the government. That's what I can share with you for the moment on this respect.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nOur next question will come from Stephen Trent of Citi.\\nStephen Trent -- Citi -- Analyst\\nGood morning, Adolfo and thanks very much for taking my question. Hope that you and your family are well. Just one quick one for me, I know that it seems that Mexico apparently has not been that active in likely offering any assistance to the corporate sector. What are you hearing from Colombia? Kind of any indications from them with respect to whether aviation industry will get some sort of relief?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nSteve, thank you for your question. So in the case of Colombia in comparison with Mexico they have been more active in the measures that they have been taking. As I said here in the report they were very [Indecipherable] basically closing or sorting down everything as from March 23. And that can be seen in terms of results. In the case of Spain and the active they have in comparison with active cases we have in Mexico. So their curve is decreasing or at least flattening while the Mexican curve is still increasing. In terms of what they have said for our industry, we have been closed since March 23 and they have issued decrees in that respect. Maybe this week, there was a new announcement from the President expanding the process of shutting down everything. As I said in my remarks, for the case of domestic aviation that will be close up to May 11 and in the case of international up to May 30. It is important to remember that in the case of Colombia, 85% of aviation is domestic and 15% is international. That's what we know as of today. Of course all of these may change depending on how fast or how slow they can control the virus in their country.\\nStephen Trent -- Citi -- Analyst\\nThank you very much Adolfo. Apologies I couldn't hear all of your remarks. But no indication at this point for example that Columbia's planning a kind of tax relief for aviation or something along those lines offering kind of financial support.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nWell we have not heard anything above that yet.\\nStephen Trent -- Citi -- Analyst\\nOkay. Appreciate that. I'll let someone ask a question. Thanks Adolfo.\\nOperator\\nAnd next we will go to Gabriel Himelfarb of Deutsche Bank.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nHi, good morning, thanks for the call. I have two questions. The first one is concerning about account receivables. Can you give us like a number or approximate number about what's the total of the sales coming from airlines and in specific from Interjet and American Airlines and my second question is do you think you could obtain some waivers in opex sorry capex your current MDP in Mexico and could you will be able to extend the life of the concession in Colombia?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. In terms of the account receivables you can see those in our report, revenue increase in the case of Mexico and Colombia, most of the increase is coming from the land industry. I do not have the details of American Airlines and Interjet you are requesting. In terms of the capex, as I said before, we have informed the government about this current situation. We don't know if they are going to react in that respect. But of course it's going to be almost impossible for us to construct and expand our buildings with that material. So more or less what I say to you.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nOkay, thank you.\\nOperator\\nAnd now we will go to Ruben Lopez of Santander.\\nRuben Lopez -- Santander -- Analyst\\nHi Adolfo, thanks for the call. My question is on commercial revenues. Sorry if you commented on these. But I understanding Cancun operating in just one terminal. So I want to confirm you how are your operations there in Cancun and what are the implications on commercial operations? Are there any penalties with the tenants? What are negotiations here? That's the first one. And the second one is related with the same topic. When we see commercial revenues and we kind of try to compare current levels versus what would be the fixed amount or the fixed part of the minimum payment. I mean can you give us any sense of the guidance here? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nOkay. As you have said, yes, in the case of Cancun, we have closed two terminals and we are just operating today in terminal 4. So all the operations of airport have been concentrated there in order to reduce on one side the expenses and of course on the other side be better prepared in the case of these reduced demand. All the stores are working in the case of terminal 4. So terminal 4 is operating as it was before the event. As I said before, most of the contracts, the financial contracts we have with the tenants are related to a minimum guarantee payment passenger. So once again, they do not have, let's talk about one of the deals that is closed. So if they do not have passenger traffic in terminal 2, they almost have to pay the rent. Of course when they operate in terminal 4 their operations will be in the accordance with the amount of passengers we have in that facility. So I would say terminal 4 is operating normally.\\nRuben Lopez -- Santander -- Analyst\\nThank you. And when you compare, sorry, the current level of commercial revenues versus what would be the minimum payment from the contract, can you give us any idea on that?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said, minimum payment -- the contract is on a per passenger basis.\\nRuben Lopez -- Santander -- Analyst\\nPerfect, thank you.\\nOperator\\n[Operator Instructions]\\nAnd we will now go to Jorge Larocco of Morgan Stanley.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nHi Adolfo, good morning. Thank you for the questions. It's two questions, actually a pretty general question, I was just wondering if you could provide more color on what are the main initiatives regarding our cost reduction efforts. How are those working down, your payment reductions on paid leave of absence, maintenance cost, utility costs, etc. and how are those playing out so far? Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThe main initiatives of course are related to in the case of Cancun in the terms of amounts. So we these key terminals closed, we are not burning the same amount of energy as if they were open. Also in the case of Cancun, we are in the process to shut down and one of the runway because today in accordance with the [Indecipherable] it's not needed. So, that runway will be turned off in terms of light at night also reducing their energy we will have to pay. And in terms of some other measures we are taking, adjusting some of the contracts of nature or mainly maintenance in the case of the buildings are closed and to try as much as possible to reduce operating cost and expenses. But I once again at the end, most of our cost is fixed. So if we apply the cost structure of the company, the most important lines are personnel and utility costs as we have said so. In the case of personnel, we are maintaining the personnel for the event or the crisis and in the case utilities, we are trying, as much as we can to try to reduce that.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nThanks so much Adolfo. Stay safe and have a good day.\\nOperator\\nAnd with that, that does concludes the question and answer portion of today's conference call. I would like to turn the call back over to Mr. Castro for closing remarks.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and thank you again for participating in our fourth quarter results conference call. On behalf of ASUR, we wish you good day and until we meet, be safe. Good bye.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 34 minutes\\nCall participants:\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nAndressa Varotto -- UBS -- Analyst\\nStephen Trent -- Citi -- Analyst\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nRuben Lopez -- Santander -- Analyst\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nMore ASR analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nHello, and welcome to the Globus Medical fourth quarter and full year 2021 earnings call. [Operator instructions] I will now turn the call over to Brian Kearns, senior vice president of business development and investor relations. Mr. Kearns, please go ahead.\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nThank you, Chris, and thank you, everyone, for joining us today. Joining today's call from Globus Medical will be Dave Demski, president, and CEO; Dan Scavilla, executive vice president and president of Ortho; and Keith Pfeil, senior vice president, and chief financial officer. This review is being made available via webcast accessible through the investor relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements.\\nOur Form 10-K for the 2021 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP.\\nWe believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available on the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Dave Demski, our president, and CEO. \\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Brian, and good afternoon, everyone. Globus finished an outstanding 2021 with a strong fourth quarter performance. Revenue for the year was a record $958 million, an increase of 21% over 2020 or $169 million in growth. To put that in perspective, our growth dollars alone would have ranked us in the top 10 spine companies in the world.\\nRevenue in 2021 was 22% higher than 2019, an outstanding performance in itself, given the disruption caused by COVID but magnified further by a recent independent research report showing that each of the other top 6 spine companies actually had sales declines over that same time period. We achieved record sales and growth while maintaining industry-leading profitability, generating a record $2.04 in non-GAAP EPS, a 42% increase over 2020, and adjusted EBITDA of 34.6% even as we invested heavily in INR, trauma, and competitive recruiting. Revenue for the quarter was $250 million, up 7% over 4Q '20 as COVID-related headwinds remained strong throughout the quarter. Non-GAAP EPS was $0.49 per share, a 16% decrease compared to the artificially high 4Q '20.\\nNot only were business travel and surgeon education activities severely curtailed last year, several other nonoperational factors, as Keith will expound upon in his remarks, also impacted the decline. Adjusted EBITDA in the fourth quarter was a strong 34%. Enabling technology continues to gain momentum, producing a record $25 million in revenue for Q4, an increase of 40% over 4Q '20. For the full year, enabling technology revenue was $81 million, an outstanding 100% increase over 2020.\\nThe clinical superiority of ExcelsiusGPS is the primary factor driving this growing momentum. Robotic utilization, which is the number of cases performed per installed robot, was at an all-time high in 2021. And nearly 30,000 procedures have been completed using ExcelsiusGPS technology since launch. Our spinal implant business continues to experience the flywheel effect of an increasing number of robots being sold combined with increasing utilization of each robot.\\nOur U.S. spine business grew by 3% in Q4 as COVID-related shutdowns had a significant impact throughout the quarter. We saw this trend continue into January, but all signs point to a rebound commencing late in Q1. For the full year, the U.S.\\nspine business grew by 18% as we continued to take significant market share. Robotics pull-through, coupled with contributions from recent product introductions and competitive recruiting, were all factors driving growth. Our international spine implant business grew by 9% in the quarter, a remarkable result in light of COVID impacts and an ongoing drag from Japan. Due to the impact of strategic moves we made in Japan last year, we expect to see continued declines there through the first half of 2022 with growth to follow off a reset baseline.\\nThis should result in accelerated overall international growth in the second half of this year. Trauma revenue was up 32% in the fourth quarter and 39% for the full year. Competitive recruiting and new product launches are driving growth. The Anthem Mini Frag system was launched on a limited basis in Q4 with excellent feedback from surgeon users.\\nWe are proceeding to full launch in Q1 and have a series of impactful product launches planned for the first half of 2022. The clients have launched the Excelsius 3D imaging system on a limited basis later this quarter with a full launch following in late Q2 or early Q3. There is tremendous anticipation and excitement about this technology among surgeons, and we already have double-digit orders signed. The Excelsius ecosystem, Globus Medical's unique combination of robotics, imaging, and freehand navigation that provides a seamless, scalable, and unmatched clinical experience for surgeons is about to become a reality.\\nI'm extremely proud of our team's performance in 2021, record growth and profitability, exciting, clinically impactful new technology introductions, and an unmatched focus on providing value to surgeons and their patients. Thank you for a great year. I will now turn the call over to Keith.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you, Dave, and good afternoon to everyone joining us for today's call. Globus capped off a record 2021 with a robust Q4 performance despite ongoing COVID-related disruptions and shutdowns. For the full year, 2021 revenue was $958.1 million, growing 21.4% as reported. On a day-adjusted basis, sales grew by 22.1%, with two fewer selling days in the U.S.\\nand international. Net income was $149.2 million, resulting in fully diluted earnings per share of $1.44. Non-GAAP net income was $211.4 million, generating a record $2.04 of fully diluted non-GAAP earnings per share. Adjusted EBITDA was 34.6% for the year, and we generated a record $219.4 million of free cash flow for the full year.\\nQ4 '21 revenue was $250 million, growing 7.1% as reported and 8.5% on a day-adjusted basis with one less selling day in the U.S. and international compared to the prior-year quarter. Net income was $15.1 million, and non-GAAP net income was $51.1 million. Our Q4 diluted -- fully diluted earnings per share was $0.14, while our fully diluted non-GAAP earnings per share was $0.49.\\nAdjusted EBITDA was 34.1%, and we generated $59.2 million of free cash flow for the quarter. Taking a deeper dive into sales. Q4 U.S. revenue was $213 million, 7.2% higher compared to Q4 of 2020 driven by our INR and U.S.\\nspine businesses. International revenue for Q4 was $37.1 million, growing 6.8% over the prior-year quarter led by growth in spinal implants despite lingering COVID impacts and the impact of our strategic changes in Japan as Dave mentioned earlier. On a constant currency basis, international revenue grew by 8.7%. Q4 gross profit was 75.3% versus 73.9% in the prior-year quarter.\\nThe 140 basis point improvement was driven primarily by nonrepeating inventory reserves in the prior-year quarter and was consistent with our expectations noted in our Q4 2020 earnings commentary. Full year 2021 gross profit was 75%, compared to 72.4% in the prior year. The increase in full year gross profit is primarily the result of lower inventory reserves and operational and supply chain efficiencies, partially offset by sales mix. Looking ahead to 2022, we project a mid-70s gross profit rate.\\nResearch and development expenses in Q4 were $51 million or 20.4% of sales, compared to $15.2 million or 6.5% of sales in the prior-year quarter. The increased spending is primarily reflective of in-process research and development acquired during the quarter. Adjusting for these costs, Q4 2021 research and development expense was $16.7 million or 6.7% of revenue, in line with the prior-year quarter as a percentage of sales, but $1.5 million higher driven by incremental investments in headcount across our spine, INR, and trauma businesses. Our full year 2021 research and development expenses were $97.3 million or 10.2% of sales, compared to $84.5 million or 10.7% of sales in the prior year.\\nAdjusting for the acquisitions made in both periods, research and development expenses were $63 million or 6.6% of sales in 2021, compared to $60.1 million or 7.6% of sales in 2020. The increase in spending is reflective of our continued investment in research and development to foster future growth and is consistent with comments made earlier in the year. We expect our R&D expenses to be approximately 7% of sales in 2022. SG&A expenses in the fourth quarter were $106.6 million or 42.6% of sales, compared to $92 million or 39.4% of sales in the prior-year quarter.\\nThe resulting increase is reflective of higher sales compensation and benefit costs as well as increased travel and training expenses driven by the resumption of normalized travel levels following the COVID-19 impacts experienced in the prior year. Full year SG&A expenses were $408.1 million or 42.6% of sales, compared to $354.8 million or 45% of sales in the prior year. The resulting decrease as a percentage of sales is reflective of leverage on fixed costs as a result of the higher volumes when comparing against the COVID impact in 2020. The income tax rate for the quarter was 23.8%, compared to 14.9% in Q4 of 2020 with the resulting increase driven primarily by lower tax benefits associated with stock option exercises.\\nOur full year 2021 income tax rate was 17.3%, slightly lower than the 18.8% in 2020 driven primarily by the nonrecurring tax treatment related to a 2020 acquisition, partially offset by lower tax benefits associated with stock option exercises. Looking ahead to 2022, we expect our effective tax rate to be approximately 20% for the full year, which assumes no significant changes in the current U.S. tax policy. Fourth quarter net income was $15.1 million, and non-GAAP net income was $51.1 million.\\nQ4 diluted earnings per share was $0.14, and non-GAAP diluted earnings per share were $0.49, compared to $0.58 in the prior-year quarter. The quarter-over-quarter decrease is driven by more normalized levels of travel, trainings, and meetings noted above or noted earlier as well as nonoperational items, primarily a higher tax rate as previously mentioned, higher stock compensation expense, and lower interest income. Looking ahead to 2022, we are expecting a mid-30s adjusted EBITDA rate. Full year diluted earnings per share were $1.44, and non-GAAP diluted earnings per share were $2.04, reflecting a 42.2% increase over 2020 primarily related to higher sales volumes following the 2020 impact of COVID-19, partially offset by approximately $0.09 of nonoperating headwinds related to a higher share count and lower interest income.\\nQ4 adjusted EBITDA was 34.1%, compared to 36.2% in the prior-year quarter. Full year 2021 adjusted EBITDA was 34.6%, compared to 29.4% in 2020. Net cash provided by operating activities were $76.3 million for the fourth quarter and a record $276.3 million for the full year 2021. Free cash flow was $59.2 million for the fourth quarter and a record $219.4 million for the full year 2021.\\nThe company remains debt free. At this time, the company is establishing full year 2022 guidance. We are projecting full year 2022 sales guidance of $1.025 billion, representing 7% growth versus 2021. We are guiding to a full year fully diluted non-GAAP earnings per share of $2.10, representing 3% growth versus 2021.\\nI note that the 2022 guidance includes approximately $0.10 of nonoperating headwinds, including higher shares worth $0.04, a higher tax rate worth $0.03, and higher stock compensation expense worth $0.03. Adjusting for these nonoperational factors, our 2022 guidance would have been $2.20 or 7.8% higher than 2021. Overall, we view this guidance as appropriately conservative and reflective of the current operating environment around COVID and inflation-related impacts. Our 2021 results represent our teamwork, our commitment, and our focus on execution.\\nWe continue to differentiate ourselves in the marketplace. And it is a testament of the hard work and dedication of each of our Globus employees. We remain excited for the future as we continue on our mission of improving patient care. Operator, we will now open the call for questions.\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] Our first question comes from Matt Miksic of Credit Suisse. Your line is open.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks so much for taking the questions and congrats on a really strong finish to a pretty amazing year, given the circumstances. I wanted to follow up on some of the comments around EPS guidance, in particular. As you pointed out, there are some items that ex those items, up 7% to 8%.\\nCan you talk a little bit about where in your guidance you're contemplating things that some of the other companies in the space have talked about like rising input costs, staffing challenges, labor costs, freight, etc., things that generally are driving operating costs up a little bit? Maybe give us a sense of how those figure into your guidance? And I have one quick follow-up.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks. This is Keith speaking. So we projected our guidance at $2.10. And as we look at the year, we see inflation as a market event.\\nEveryone is experiencing it, and we have it baked in our numbers. But when you step back and look at the $2.04 and the $2.10, I commented on the $0.10 of the nonoperating headwinds. But the other things that are impacting the business as we think about getting back to more normalized levels of spend are really the travel and the trainings that go along with the surgeons and [Inaudible] that we provide. That's worth going into the next year likely an $0.08 headwind.\\nAnd then one of the things that we commented on earlier in the year was our continued investment into R&D. As you look into next year, we're seeing roughly I would say, call it, $0.04 of additional investment in R&D. When you look at those things together, coupled with the inflation, we're landing at about $2.10.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And can you just maybe just elaborate a little bit on the spend or R&D and sort of the expectations for returns in terms of growth or programs that you're investing in?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nSo we're continuing to invest heavily in our spine business and as well as our robotic businesses. We talked about that in Q1 of our earnings call earlier in the year, and really all sign points to us continuing to do that. Dave talked earlier about some of the benefits that we're seeing for robotic technologies. We continue to invest in that and really grow for the future.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And then just one quick follow-up I had was on the environment for robots and spending in capital and equipment in general. Some of the other, again, companies in the space have talked about a fairly strong year for equipment, a strong year for robots. Any sense of whether this is something that needs to sort of take a breather or catch up here in 2022? Or whether orders and demand and pipeline for new deals would indicate just continued strength into 2022?\\nDave Demski -- President and Chief Executive Officer\\nYeah. Matt, this is Dave. No, it's very strong. I don't see anything laying off.\\nIn our case, in particular, it's been accelerating. I think the demand for Excelsius has been strong, and it's becoming more and more common. The narrative has changed from why robotics to which robot. And I think we're clearly establishing our lead there.\\nAnd then as I mentioned, there's a lot of enthusiasm over our Excelsius 3D system, which is going to launch later this quarter. We've had every surgeon we show that to seems like they want one. So I don't see it backing off at all.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks and congrats.\\nDave Demski -- President and Chief Executive Officer\\nThank you.\\nOperator\\nThank you. Our next question comes from Matt Taylor of UBS. Your line is open.\\nMatt Taylor -- UBS -- Analyst\\nExcuse me. Hi, guys. Thanks for taking the question. So I wanted to ask the first one about margins longer term.\\nMaybe just talk about the difference between what you're doing this year with some of the investments and obviously, headwinds year over year from spending back to normal and inflation, and how we should think about margins longer term? Would you start to get more leverage at some point? And what would the inflection point for that be?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. It's a good question. But as I look at where we're at and where we're going, our goal is to always maintain a mid-70s GP. But as we look longer term and look at our EBITDA rates, we're always looking to be in that mid-30s range.\\nWe could toggle our investments in various parts of our business to really achieve that, but we're investing now to drive growth -- to drive top-line growth for the future. And as we get that growth, that's going to create more fixed cost leverage in our P&L. So I think by doing that, investing for growth today helps project the margins going forward. I feel that we're going to work to try to stay in that range.\\nDave Demski -- President and Chief Executive Officer\\nYeah. I can add a little bit maybe to that, Matt. In the spine business, I don't think you'll see much greater improvement in our margins there, but we have a lot of operating leverage in front of us in the orthopedic side of the business and the capital side. Those are both fairly nascent businesses for us, and we're funding it with spine.\\nBut once we start to hit some volume numbers there, I think those businesses will definitely expand.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Can I ask a follow-up on the robotics strength? I mean, you talked in the past about getting pull-through on these placements, and obviously had a great year in 2021 with enabling tech. I guess are you still seeing the same kind of trends? And could that bode well for pull-through implants in '22?\\nDave Demski -- President and Chief Executive Officer\\nYes. It does. We're seeing that generally the same kinds of trends. And as a company, we're focusing on really going back to that installed base and seeing we can get more users to utilize the technology once it's placed in the hospital.\\nAnd that's a big focus for us in 2022.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Thank you, guys. Thanks so much.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And next, we have Shagun Singh of RBC. Your line is open.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGreat. Thank you for taking the question. I guess my first one is on Excelsius 3D imaging system. Can you talk to us about the delay? Why is there a delay in the launch? And then just elaborate on your go-to-market strategy.\\nAre you targeting the replacement opportunity or greenfield? You're obviously going after a major competitor. So just any color there would be helpful. And then on the recon robotics, do you still plan to launch that in the second half? And then I have a quick follow-up.\\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Shagun. I'll try to knock those off one by one. In terms of the delay, it's just taking longer than we thought. It's nothing significant in terms of the technology hurdle to get over.\\nThere's just a lot to do to get that over the line. So I wish we were a bit earlier but very confident we can get it done this quarter. Go-to-market. I think initially, we're going to be targeting our installed base of Excelsius users.\\nThose are -- there's a high demand among them. It's going to make those procedures much more efficient and much easier for them to do. And then from there, we'll be branching out to target more of that free-hand navigation market that you alluded to earlier. And then I apologize, I forgot the last part of your question.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nI was just wondering if you plan to launch the recon robotics platform in the second half of '22 like you had previously indicated?\\nDave Demski -- President and Chief Executive Officer\\nNo. That's been delayed as well. We're going to be -- early '23 is the target for that.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGot it. And then just as a follow-up, I was wondering if you could talk about trends that you're seeing on the procedure volume side in Q1, so in January and February. And spine typically has a high pain burden, so procedures come back quickly. So do you expect the recovery to come in Q1? Or do you expect a longer tail given staffing shortages? Thanks for taking the question.\\nDave Demski -- President and Chief Executive Officer\\nSure. Yes, January was really bad, but we've already started to see it turning in February. The last three weeks have all been progressively higher. Not back to where we want it to be, but definitely, I think we've hit bottom.\\nWe're going in the right direction. And I'm not going to try to predict what's going to happen with COVID though. That's proven to be frivolous for everyone, but it's encouraging where we are right now.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nThank you.\\nOperator\\nThank you. And next, we have Matthew O'Brien of Piper Sandler. Your line is open.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat. Thanks for taking the questions. I guess, Dave, just for starters on the top-line guidance. This time last year, you guided about $35 million below The Street.\\nWe end up doing well above what you initially guided and actually what The Street was modeling. And this time, you're guiding about $25 million below The Street. I know January was soft, and maybe Excelsius 3D has pushed a little bit in terms of the contribution. But are there other factors that we should be thinking about? I don't know if it's a rep hiring perspective or a robot perspective that gives you a little bit more caution versus kind of where The Street was modeling things?\\nDave Demski -- President and Chief Executive Officer\\nThanks, Matt. I'm sorry we don't pay that much attention to The Street. We look internally to our own forecast, and we always want to be appropriately conservative going into a year. I feel really confident in the business.\\nThe U.S. spine business has been just cranking away. The robotic momentum is there. We're going to have 3D out this year.\\nJapan is going to turn around in the second half. So I feel really good about the business. We just have taken a very conservative approach over the years when we give guidance, and we're doing that again.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nOK. Fair enough. And then the follow-up is on acquisitions. Sorry if I cut somebody off there, but there's been some talk about you guys doing a scale acquisition.\\nI'm curious if you have any thoughts about the need for scale in spine. And then if not, there's some pretty interesting assets still in the spine space, but more on the pain management side of things. Are those higher on the list in terms of things that you potentially are looking at from a acquisition perspective?\\nDave Demski -- President and Chief Executive Officer\\nNo. It's actually a bit different. We're more active in terms of growing the business through BD and on the orthopedic side of the business. I think we're really strong in spine, and there's really nothing in spine that's of interest to us at the moment.\\nWe're more focused on growing the other piece of our business, which is smaller. There's nothing, I would say, transformative in our sights right now. But we are looking at several modest-sized deals as been our history in the past.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat.\\nDave Demski -- President and Chief Executive Officer\\nDid that answer your question?\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nYep. That's perfect. Thank you.\\nOperator\\nThank you. Next, we have David Saxon of Needham. Your line is open.\\nDavid Saxon -- Needham and Company -- Analyst\\nYeah. Hi, guys. Good afternoon, and thanks for taking the questions. Maybe one on enabling tech.\\nI mean, it doubled this year, and you've really built out the enabling tech platform with hub and 3D, etc. How should we think about those launches kind of starting to ramp? And could '22 be another double?\\nDave Demski -- President and Chief Executive Officer\\nYeah. I think as I said, we're going to get some -- a few units out this quarter and kind of a soft launch, if you will, with the full launch starting in probably end of Q2, it might be into Q3 and then strong in the second half of this year. I don't want to comment on the double. It's -- we don't really drill into the components of our business.\\nI can tell you that we're really excited about what we're seeing from our technology, from the adoption of our technology and not only what's right in front of us, but some things we have coming after that.\\nDavid Saxon -- Needham and Company -- Analyst\\nOK. Got it. And then maybe on trauma, kind of how close are you to having a full portfolio there? And then in terms of growth, 32% in the quarter. Is that sustainable in '22? Thanks for taking the questions.\\nDave Demski -- President and Chief Executive Officer\\nSure. The bag in trauma is by the second half of this year, I think full is kind of interesting term. We're going to have enough in our bag to be a full-line player and be able to compete with the major companies by the end of this year. And is that growth rate sustainable? Yes, I think that's certainly achievable in 2022.\\nDavid Saxon -- Needham and Company -- Analyst\\nGreat. Thank you.\\nOperator\\nThank you. Next, we have Craig Bijou of Bank of America. Your line is open.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nHey, guys. Thanks for taking the questions. Maybe a follow-up on top-line guidance and to the extent that you guys are willing to share. I mean, how to think about the contributions from each of the businesses? I know generally, you've been reluctant to share that info.\\nBut in terms of the composition of the guidance, how do we think about that incremental revenue coming in? Where is it coming from and to what extent?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. As Dave said earlier, we're not going to get a ton into the parts and pieces. But what I will say is if you look at the business, whether by musculoskeletal and INR or you look U.S. versus international, the parts and pieces of our business we continue to feel extremely positive about as we look into 2022 and beyond.\\nWe're investing in our business. We're driving investment for the future, and we feel that we'll see that turn out to us taking share and driving sales growth. I alluded to my earlier prepared comments that our guidance is appropriately conservative, but there's nothing that I sit here and feel that we have kind of an ongoing issue that I would be concerned about our ability to grow across our business, like I said, whether it's U.S., international or musculoskeletal versus INR.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGot it. Thanks, Keith. That's helpful. And then, Dave, I think you alluded to it, but I wanted to ask more specifically how to think about some of the new product rollouts? Obviously, you have 3D coming out and launching this year.\\nBut from a new product perspective, is it -- do you have a number of launches coming this year on the spine side? Do you have a number coming on the INR side? Just maybe a little bit more perspective of what to expect during the year.\\nDave Demski -- President and Chief Executive Officer\\nSure. Thanks, Craig. I think we've been pretty clear that it's a big one coming with 3D followed by our hub [Inaudible] offering. I think spine, we are typically 10 to 12 launches a year, and that's currently our target going into 2022.\\nTrauma is probably the real bright spot. There is a number of products that we were working on for a while, they're going to hit the early part of this year and through this year. So -- and then our orthopedics business actually has some launches as well. So that's kind of who we are and who we're going to be.\\nAnd it's -- the number one focus of the company is to drive great technology.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGreat. Thanks for taking the questions, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. Next, we have Ryan Zimmerman of BTIG. Your line is open.\\nRyan Zimmerman -- BTIG -- Analyst\\nAll right. Thanks for taking my questions and congrats on a great year. Just want to follow up on a couple of questions. Dave, when we think about U.S.\\nSpine performance kind of relative to the market, you look at some of the larger players, they were down a bit in the fourth quarter. Some of the smaller players we saw were up double digits. Obviously, a few major players still yet to report next week. But I guess I'm kind of curious if you can kind of talk about the U.S.\\nperformance, that growth this fourth quarter relative to the market, and kind of where you think you're tracking relative to that level? And if you could kind of give us color on what you think that level was just given the dynamics in the fourth quarter through the quarter would be helpful.\\nDave Demski -- President and Chief Executive Officer\\nThanks, Ryan. It's really challenging to figure out where we are, given COVID. So from the early returns of some of the folks who we have reported, again, we're taking significant share. I can't speak to the smaller guys who have reported or how that impacts us.\\nAnd I don't really have a feel for the overall market. I know it was heavily impacted by COVID so likely down versus prior year overall. But that's more of just a guess and kind of where we landed versus some of our earlier trends. Our business is strong.\\nI can tell you that. We haven't lost significant pieces of business in the U.S. And we continue to see growth in the recent product introductions, and we continue to sell robots and drive pull-through from that. So it's strong.\\nI just -- I can't really see the overall market, and it's really hard to figure out what's going on given what's happening with COVID.\\nRyan Zimmerman -- BTIG -- Analyst\\nOK. Just two follow-ups for me. One, we've heard some of the larger capital equipment companies have obviously called out chips as being a gating factor to sales or median demand in 2022. One, want to see if there's any concern there around chips for the Excelsius platform or for 3D and whether that could gate sales? And then I'll just ask the other -- sneak in a quick follow-up, too.\\nThe Japan distributor dynamics, how much of a lift should we expect when that distributor dynamic clears in the second half of 2022 on the international business? Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. In terms of chips, I would just -- I would extend that to all supply chain. So it's not just chips, it's all components are challenging. It hasn't cost us revenue now, but it's certainly on our radar and making our life really hard.\\nSo it's a risk that's out there for 2022. I'll let Keith maybe handle the international question.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nAs it relates to Japan and the distributor dynamic, as we look ahead, we finished 2021, I think international grew by about 11%. We've historically said that we believe that the international business can grow mid-to-high teens. I would expect us to be able to get back to that on an annual basis. So you would expect the second half of the year to accelerate ahead of that to potentially balance -- to get closer to that 15 by the end of this year.\\nRyan Zimmerman -- BTIG -- Analyst\\nThanks, Kieth. Thanks, Dave. Appreciate it.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. Next, we have Kyle Rose of Canaccord. Your line is open.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nGreat. Thank you for taking the questions. I wanted to start on enabling. I mean, look, you put up a good quarter in enabling.\\nI guess a tough backdrop, particularly without the imaging platform. Maybe just help us understand kind of where that stands from a utilization perspective into your customer base. You're talking about the really good utilization there is continuing to see strong pull through. Can you just kind of level set maybe how many of your customers might have it or on a percentage basis or on an absolute basis? Just trying to really understand where we are in the uptake and the adoption within the historical core Globus customer base.\\nDave Demski -- President and Chief Executive Officer\\nYes, Kyle. To be honest, I don't feel comfortable sharing that information from a competitive standpoint.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nTotally fair. I had to try. I also wanted to touch on the orthopedic side of the business. I mean, it's been a couple of years since you acquired the StelKast business.\\nI think earlier in the call, you talked about the fact that the recon robot is going to come in '23. Where do you stand just from an implant perspective? Do you have the right implants there? Do you need to make different investments from an M&A perspective, technologies, distribution? Just help us understand what you need to do on that total joints business before the recon robot comes next year. Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. We do not have the implant portfolio we need to really make a strong outing. So we are working on that, have been working on that, and expect to roll some products out this year. I don't see us filling the gaps in our product portfolio with acquisitions in terms of hips and knees in particular.\\nI do think there's opportunity for scale there. So that's not off the table because we are very small right now. And then the extremities is an interesting segment for us as well. It's a fast-growing segment.\\nSo that's an area where we've taken a look at a few things. Does that help with your question?\\nKyle Rose -- Canaccord Genuity -- Analyst\\nYes. Thank you very much.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. And next, we have Samuel Brodovsky of Truist. Your line is open.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nHi. Thank you for taking the questions. Just a first quick one on U.S. Spine.\\nJust would be curious to hear about the portion of growth in the U.S. coming from robotic-specific instrumentation versus where you're seeing potential share gain with other parts of the portfolio?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nYes. Thanks for the question. In terms of breaking it out, we typically don't break out the parts and pieces of where the growth is coming from. What I would say is that as you look at our U.S.\\nSpine business, it's really a combination of what we always talked about: new product innovation, our competitive recruiting, and the pull-through from implants. Those three continue to propel the business from a growth perspective, and we see that continuing as we enter 2022.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nGreat. That's helpful. And then when thinking about 3D and going to customers with it, in terms of any competitive trialing, are you seeing it being trialed against other more novel imaging technologies on the market? Or is it typically being compared to the large competitor out there? Thanks.\\nDave Demski -- President and Chief Executive Officer\\nInteresting question. I assume it's -- we don't really trial against it, but we have customers looking at our technology. And I think their interest just probably lines up with the market share of the other imaging systems in the market, particularly ones that are utilized more in spine. I'm sure that some of the more innovative ones are getting a look, but we don't hear that much about them.\\nSo it's not disproportionately, maybe I could answer it that way.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nThanks.\\nOperator\\nThank you. [Operator instructions] Our next question comes from Steven Lichtman of Oppenheimer. Your line is open.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nThank you. Hi, guys. I wanted to ask you first on trauma. Where do you think you stand now in terms of coverage of procedures in terms of your product portfolio? And also from a sales force perspective, I'd just love to get an update on where you feel you are overall in terms of being able to go at the market.\\nDan Scavilla -- Executive Vice President and President of Ortho\\nSteven, it's Dan Scavilla. So again, it's always the evolving and expanding story. We have about 14 family products out there now. I think with that, we're saying we would cover 50% to 60% of the market.\\nCertainly, plan, as David said, to launch several more this year to cover that further. I believe and through what I'm saying, we're at a point where we're able to get into some significant facilities and support their needs for the most common procedures. And with that that's the main driver of growth to us. So we'll continue to expand the product line and fill that out over time, but we're in a good spot now.\\nWith that is the competitive recruiting that's been accelerating for us. So again, we're small, and we have a lot of spaces to fill. But the traction that has been occurring really through 2021 is very promising. And I do feel bullish as we are -- from what I've seen so far in the first quarter of 2022 that that will continue.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nGreat. Thanks, Dan. Keith, just a follow-up on gross margin. I apologize if you mentioned this, but just relative to 2021, given the inflation commentary, should we assume gross margin down? Or are there some offsets that can keep it relatively flat to maybe -- or even up in '22?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. We project the mid-70s GP. I think it's fair to assume that we are seeing inflation just like everybody else, but we're also growing. And it's obviously getting us some leverage in our cost structure.\\nSo as I think about 2022, mid-70s is kind of where I see it. I wouldn't project upside.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nOK. Got it. Thanks, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And we now have Jason Wittes of Loop Capital. Your line is open.\\nJason Wittes -- Loop Capital -- Analyst\\nHi. Thanks for taking the questions. Just two follow-ups, one on the guidance and one on trauma. But -- so first off, your guidance, I think the way you described it, especially relating to product launches, kind of assumes a strong second half versus the first half.\\nSo related to that, one, are we assuming that -- I know we can't predict COVID, but COVID pretty much works its way throughout the year? And then secondly, related to that, in the first quarter, I'm not sure how to read your comment that January was very weak. It bounced back. Should this be a normalized first quarter? Or are we -- is it going to be a little weaker relative to last year because of the COVID impact and launches? Thanks.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. Dave commented that January was weak, but we were starting to see some bounce back in February. Will it all bounce back in the same quarter versus having some bleed through into Q2? We don't necessarily know. But I think your earlier comment about some of the launches and a strong second half, I think that's directionally correct.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. And then I don't know if you can comment on this, but you did mention that you had -- it sounds like a record year in terms of sales force hires. In the past, you've kind of given us an indication of how large you've been able to grow your sales force percentage-wise. Can you give us any kind of indication on that in terms of what 2021 look like? And it sounds like 2022, you're optimistic that you can do -- go at a similar run rate?\\nDave Demski -- President and Chief Executive Officer\\nYeah. '21 was not a record year for us. I think we had one really strong quarter, but we've had years that were better. That's a renewed emphasis on it.\\nI can tell you the pipeline right now is extremely strong. So we're coming out of the gate strong. But last year was a good year. It just wasn't our best.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. Thanks a lot. Appreciate it all.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\n[Operator signoff]\\nDuration: 45 minutes\\nCall participants:\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nDave Demski -- President and Chief Executive Officer\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nMatt Miksic -- Credit Suisse -- Analyst\\nMatt Taylor -- UBS -- Analyst\\nShagun Singh -- RBC Capital Markets -- Analyst\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nDavid Saxon -- Needham and Company -- Analyst\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nRyan Zimmerman -- BTIG -- Analyst\\nKyle Rose -- Canaccord Genuity -- Analyst\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nDan Scavilla -- Executive Vice President and President of Ortho\\nJason Wittes -- Loop Capital -- Analyst\\nMore GMED analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4006,\n        \"samples\": [\n          \"2022-08-11 07:30:00\",\n          \"2021-03-18 08:00:00\",\n          \"2021-08-09 11:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 771,\n        \"samples\": [\n          \"2022-07-12\",\n          \"2020-10-22\",\n          \"2022-06-10\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2535,\n        \"min\": 571,\n        \"max\": 32540,\n        \"num_unique_values\": 6023,\n        \"samples\": [\n          8055,\n          8114,\n          14273\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08086309609059458,\n        \"min\": -0.6091428484235492,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 9985,\n        \"samples\": [\n          0.0115302149459788,\n          0.1053023227425508,\n          -0.0781132122800544\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Target_Class\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Neutral\",\n          \"Gain\",\n          \"Loss\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"DateOfWeek\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 0,\n        \"max\": 6,\n        \"num_unique_values\": 7,\n        \"samples\": [\n          3,\n          2,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Month\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3,\n        \"min\": 1,\n        \"max\": 12,\n        \"num_unique_values\": 12,\n        \"samples\": [\n          12,\n          5,\n          8\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Quarter\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 1,\n        \"max\": 4,\n        \"num_unique_values\": 4,\n        \"samples\": [\n          4,\n          2,\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Positive\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.31461293934408074,\n        \"min\": 0.008341541513800621,\n        \"max\": 0.9573535919189453,\n        \"num_unique_values\": 10002,\n        \"samples\": [\n          0.9299212098121643,\n          0.026290403679013252,\n          0.04736625775694847\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Negative\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.15365381668059275,\n        \"min\": 0.007326572202146053,\n        \"max\": 0.9723434448242188,\n        \"num_unique_values\": 10004,\n        \"samples\": [\n          0.02593323402106762,\n          0.013618996366858482,\n          0.026145340874791145\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Neutral\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.32946208504390717,\n        \"min\": 0.016457758843898773,\n        \"max\": 0.9523656368255615,\n        \"num_unique_values\": 9990,\n        \"samples\": [\n          0.7056020498275757,\n          0.1328488439321518,\n          0.09590130299329758\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 40
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def clean_ticker(ticker_str):\n",
        "  t=str(ticker_str).upper().strip()\n",
        "  if \":\" in t:    #if ticker is NASDAQ:AAPL\n",
        "    t=t.split(\":\")[1].strip()\n",
        "  t=t.replace(\"$\",\"\")\n",
        "  return t\n",
        "df_analysis[\"ticker_clean\"]=df_analysis['ticker'].apply(clean_ticker)\n",
        "print(f\"unique tickers: {df_analysis[\"ticker_clean\"].unique().tolist()}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "lyo2cj_XOCJi",
        "outputId": "4a497047-23bf-48a8-f1da-09765d5295e3"
      },
      "execution_count": 41,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "unique tickers: ['BILI', 'GFF', 'LRCX', 'BBSI', 'CSTE', 'GDOT', 'KAR', 'EPAC', 'ABM', 'SGHC', 'SJM', 'URBN', 'HESM', 'SPOK', 'TSM', 'GNW', 'WPP', 'DXCM', 'EME', 'EEFT', 'ARAY', 'ZBRA', 'ROST', 'STZ', 'NET', 'HZO', 'LZB', 'USPH', 'MRNA', 'MELI', 'CDNS', 'VIV', 'NTCT', 'U', 'RUSHA', 'DTM', 'VCEL', 'MSTR', 'CSIQ', 'AAPL', 'CENT', 'FLNT', 'ACLS', 'GEO', 'DFIN', 'GOTU', 'MT', 'SHOP', 'EL', 'LGIH', 'EBS', 'REGN', 'EAF', 'META', 'HRB', 'STRS', 'TTE', 'FCNCA', 'OTIS', 'DHI', 'HLT', 'TLRY', 'ALGN', 'F', 'ADNT', 'PPG', 'AL', 'MKL', 'INBK', 'LILAK', 'SXC', 'CNI', 'BX', 'CMC', 'GNRC', 'BABA', 'OPRX', 'MOD', 'LAMR', 'TRV', 'LOPE', 'OCFT', 'HUN', 'TGT', 'SBSW', 'DB', 'MRCY', 'AI', 'FCN', 'PSMT', 'LITE', 'HCAT', 'KO', 'CMLS', 'OOMA', 'MVIS', 'BJRI', 'AGNC', 'TTWO', 'AMZN', 'IMOS', 'ROKU', 'CGEN', 'ONTO', 'MNKD', 'HR', 'CLF', 'SITM', 'OLED', 'COHR', 'ABR', 'WGO', 'APAM', 'CASH', 'MSA', 'GPI', 'CYD', 'ZEUS', 'WFC', 'NGD', 'PRI', 'CB', 'ANET', 'ARRY', 'SEER', 'KMB', 'GPRO', 'VVV', 'SNAP', 'OKTA', 'NUE', 'DIS', 'MED', 'UNM', 'CRTO', 'CCK', 'PODD', 'SPOT', 'PAYS', 'APPS', 'CHDN', 'VIRT', 'SYK', 'IHG', 'SE', 'AMWL', 'IRS', 'SIRI', 'EQIX', 'CARS', 'CACI', 'FOSL', 'GOGO', 'SABR', 'SDGR', 'HGV', 'TWO', 'MAX', 'LULU', 'CWBHF', 'TGNA', 'OGI', 'CF', 'CCO', 'RTX', 'TSLA', 'PLNT', 'PFGC', 'PLD', 'KMX', 'QRVO', 'BNGO', 'NSA', 'DOV', 'SBRA', 'PRGO', 'BZUN', 'CRVL', 'MTSI', 'PBYI', 'UPS', 'ETSY', 'SCL', 'ESS', 'INTC', 'LLY', 'CBT', 'EGRX', 'VUZI', 'SBH', 'FOXF', 'NKE', 'ACM', 'AON', 'PBR', 'CDXS', 'CVLG', 'LBTYA', 'CVGW', 'PINS', 'PAG', 'SUI', 'PTC', 'IBM', 'PM', 'MODG', 'KOS', 'ERIE', 'SYF', 'LVS', 'ICUI', 'MAN', 'XGN', 'OMC', 'NOW', 'VLO', 'MASI', 'EOG', 'PLTR', 'C', 'BOX', 'BCRX', 'BLND', 'USB', 'MNST', 'GRPN', 'PKE', 'WIX', 'XPO', 'BAC', 'JOUT', 'SNDL', 'BALL', 'IDXX', 'LX', 'BWXT', 'CHD', 'GOOGL', 'MAIN', 'RC', 'PCH', 'NVO', 'MSCI', 'GERN', 'TNDM', 'FRO', 'CHE', 'GWW', 'OCFC', 'KEX', 'MAT', 'TCEHY', 'NDAQ', 'NAVI', 'ARGX', 'ATHM', 'NMIH', 'MSM', 'K', 'FSM', 'DOMO', 'CLX', 'GVA', 'KWR', 'COST', 'ANGI', 'CSGP', 'REYN', 'UAA', 'TRMK', 'BFH', 'GTY', 'ESE', 'CNA', 'BP', 'GEOS', 'BZH', 'ENB', 'ISRG', 'TTD', 'RDWR', 'BUD', 'OII', 'UBER', 'STAG', 'HLX', 'CLDT', 'BCS', 'ADM', 'CLFD', 'SO', 'ADPT', 'ING', 'ATI', 'VNET', 'OCGN', 'GEF', 'REX', 'APO', 'TXT', 'GEL', 'IT', 'TENB', 'HMC', 'SIFY', 'JCI', 'EEX', 'GE', 'HCA', 'FTHM', 'GSHD', 'RACE', 'TREX', 'ILPT', 'ORGO', 'PTON', 'ATOM', 'FROG', 'GFI', 'ONTF', 'HST', 'SWBI', 'AAP', 'LILA', 'NVDA', 'CNX', 'SNY', 'EVC', 'AIR', 'TK', 'EZPW', 'CCEP', 'GIS', 'CBRL', 'MIDD', 'CORT', 'ORCL', 'LOW', 'FCEL', 'INCY', 'NOC', 'DLB', 'NYT', 'OCSL', 'PGNY', 'ALNY', 'MGPI', 'ICL', 'UCTT', 'WMS', 'CLNE', 'MTZ', 'NOK', 'COTY', 'CC', 'CHKP', 'ACMR', 'EXPI', 'NGVT', 'HLIT', 'UEIC', 'ACEL', 'NJR', 'KTB', 'SPB', 'RERE', 'T', 'NKTR', 'LFUS', 'CRWD', 'DCOM', 'MCD', 'NIO', 'HIMX', 'AVT', 'TXRH', 'UL', 'TX', 'LASR', 'PNC', 'WM', 'DOCU', 'AQN', 'DOW', 'FANG', 'AR', 'MTDR', 'SCHL', 'CYRX', 'UPWK', 'PTEN', 'BB', 'MTH', 'SWKS', 'AMSC', 'RKT', 'GCO', 'AER', 'GRWG', 'WPC', 'AIT', 'SBAC', 'EGBN', 'IPG', 'SSRM', 'HD', 'TCOM', 'ALE', 'CVNA', 'HNI', 'RLX', 'KRC', 'IR', 'HAS', 'KR', 'GBDC', 'PLAY', 'KEY', 'BIO', 'SITC', 'RRC', 'OTEX', 'ALL', 'TMCI', 'ZVIA', 'SLM', 'BMRN', 'HL', 'AMBC', 'AMRC', 'ECL', 'TRMB', 'RY', 'RDN', 'PLAB', 'NVT', 'EXTR', 'ALV', 'SFBS', 'INTU', 'DAR', 'EQNR', 'EXEL', 'CLB', 'OZK', 'CYH', 'ASR', 'AMRX', 'HUBS', 'MRVL', 'JBL', 'TILE', 'GS', 'CTSH', 'GAIN', 'NVCR', 'FUTU', 'AEM', 'A', 'MGRC', 'INO', 'AVB', 'CXW', 'NWN', 'MMM', 'STX', 'BAX', 'AGIO', 'LMT', 'FSLY', 'TIGO', 'LCII', 'STNG', 'RITM', 'NEE', 'DGICA', 'NEO', 'CHCT', 'TSE', 'LII', 'LGND', 'BYND', 'GLNG', 'CINF', 'IMXI', 'TFC', 'SPNS', 'PCYO', 'RGS', 'PBI', 'ALKS', 'VOD', 'CPS', 'JBSS', 'SYY', 'MLCO', 'NTR', 'GOLD', 'JLL', 'NDLS', 'MTCH', 'JNJ', 'CVS', 'UPLD', 'CAH', 'FHB', 'DQ', 'UHAL', 'HSY', 'LAD', 'CANG', 'EQX', 'PHG', 'PANW', 'FIBK', 'NEM', 'IIPR', 'CMTL', 'VECO', 'FDS', 'BJ', 'DT', 'FIVE', 'FE', 'RUN', 'ASML', 'SBS', 'NFLX', 'FLGT', 'TBI', 'FRPT', 'VST', 'RF', 'CRIS', 'UNH', 'ZS', 'ITW', 'OIS', 'AVGO', 'VNOM', 'DAL', 'CLAR', 'GD', 'OPRA', 'SXT', 'OI', 'GL', 'QDEL', 'XXII', 'AMTB', 'SSD', 'AMRN', 'LOVE', 'WYNN', 'BNED', 'AAOI', 'QTRX', 'KAI', 'NWSA', 'MESA', 'JG', 'DPZ', 'XP', 'MGNI', 'AXP', 'CCRN', 'CRC', 'TXN', 'TMUS', 'MO', 'WPRT', 'PAC', 'LEN', 'BLK', 'EM', 'MEI', 'NBR', 'CMG', 'SQNS', 'CIGI', 'ETD', 'CNS', 'ALLE', 'FTV', 'TTSH', 'PATK', 'CARR', 'BDSX', 'JAZZ', 'SF', 'HII', 'HAL', 'KNDI', 'SU', 'INSG', 'GSK', 'HSBC', 'NCLH', 'AMD', 'MPC', 'WDAY', 'LPLA', 'DSGX', 'SPG', 'TISI', 'TSEM', 'NTGR', 'WRLD', 'VIPS', 'MSGS', 'BLDP', 'VIAV', 'AEIS', 'VERU', 'DVN', 'BIRD', 'WSM', 'AMPL', 'DKNG', 'LQDT', 'TRUP', 'AIRG', 'LCTX', 'ACIW', 'TXMD', 'DG', 'KPTI', 'CVEO', 'MYRG', 'BLMN', 'EXLS', 'PDM', 'ESI', 'FNF', 'INMB', 'RELY', 'DUK', 'ICE', 'BIOX', 'ET', 'MKTX', 'SON', 'VERX', 'EIG', 'CCL', 'XRAY', 'HIW', 'SHEN', 'BG', 'GBX', 'BKR', 'GATX', 'BMBL', 'EVLO', 'CIM', 'WSBC', 'JELD', 'BOOM', 'CHRS', 'SSSS', 'AROC', 'FUN', 'AWK', 'HDB', 'SKYW', 'G', 'CMP', 'EGO', 'NXPI', 'VZ', 'PSTG', 'RPAY', 'MAC', 'FOUR', 'GLOB', 'ASC', 'OXM', 'PDD', 'SMSI', 'PACB', 'EXK', 'DBX', 'MSI', 'TDS', 'JAGX', 'GM', 'LMAT', 'FCPT', 'LSTR', 'COMP', 'HCC', 'PRTS', 'DVA', 'STM', 'NXST', 'ACGL', 'BIIB', 'SPCE', 'TLYS', 'ANF', 'STNE', 'OHI', 'CDNA', 'TELA', 'IPHA', 'HAE', 'SBLK', 'WDFC', 'FOLD', 'NTST', 'SERA', 'LRN', 'TT', 'SGU', 'SCI', 'CNR', 'OGE', 'AHCO', 'IRM', 'MUR', 'BCH', 'FLR', 'ST', 'SIG', 'RDHL', 'EBAY', 'PHR', 'VNO', 'MDU', 'TEX', 'FPI', 'DAC', 'SONY', 'LAW', 'WRB', 'ENR', 'WB', 'VSH', 'GKOS', 'AGCO', 'PEN', 'PAA', 'JPM', 'NX', 'PLUG', 'AMAT', 'PRLB', 'JACK', 'GDRX', 'WST', 'UNFI', 'ENPH', 'SM', 'LYTS', 'DASTY', 'SLG', 'SNEX', 'EH', 'AXTI', 'DBRG', 'PERI', 'NRP', 'RMD', 'VITL', 'AXTA', 'JMIA', 'ALK', 'HUBB', 'LIND', 'COO', 'VOYA', 'LOB', 'ABT', 'VRSK', 'HPQ', 'LXP', 'BDC', 'APPN', 'LNG', 'MKC', 'PGR', 'SNOW', 'RBLX', 'ON', 'TCBI', 'CTRN', 'VFF', 'APEI', 'ULTA', 'EPAM', 'AX', 'FWONA', 'VRSN', 'AYI', 'OSPN', 'ARMK', 'IPGP', 'HQY', 'ALSN', 'AVD', 'SPH', 'OMCL', 'CTS', 'OPK', 'AZN', 'PR', 'GPRE', 'IPI', 'BEP', 'WEN', 'MTB', 'TW', 'APOG', 'ASIX', 'GES', 'L', 'AMGN', 'CRMD', 'MANH', 'SND', 'AMT', 'STN', 'KALU', 'QSR', 'KOP', 'WOR', 'MCK', 'IQV', 'CVX', 'PCG', 'FC', 'E', 'IONS', 'URI', 'ALGM', 'EVER', 'RNG', 'BNR', 'STIM', 'AMBA', 'MPLX', 'RMR', 'TEAM', 'OTTR', 'BIDU', 'EW', 'VRA', 'LNC', 'HBM', 'CWT', 'CARG', 'ALLY', 'SRPT', 'DLR', 'RRGB', 'LAND', 'KMI', 'AJG', 'DBI', 'ADSK', 'MDT', 'BYSI', 'TTC', 'MPWR', 'CGNX', 'RIG', 'IQ', 'VRNS', 'MYGN', 'DRH', 'WPM', 'VERI', 'SSYS', 'CPT', 'WMT', 'HRZN', 'BA', 'CAAS', 'BSX', 'SLP', 'PARR', 'SHW', 'LDI', 'LBRT', 'AXL', 'TWLO', 'EXAS', 'TRUE', 'AMG', 'COP', 'PAR', 'HUYA', 'HRI', 'NTLA', 'NPO', 'HON', 'BEN', 'UTZ', 'GMED', 'LUV', 'BCPC', 'NLY', 'ALT', 'NTES', 'SNV', 'ESRT', 'SEDG', 'ENTG', 'ATUS', 'EA', 'WAL', 'TFII', 'GLW', 'DECK', 'HELE', 'NBN', 'CWEN', 'DDOG', 'VALE', 'RS', 'RRR', 'WAT', 'SONO', 'CROX', 'MATX', 'JBLU', 'HOLX', 'CSGS', 'BOH', 'TDG', 'SKT', 'NOAH', 'WSO', 'CHTR', 'CBZ', 'OXY', 'CODI', 'H', 'CL', 'TASK', 'AUDC', 'DHC', 'RCL', 'GTN', 'CNP', 'JD', 'GLPI', 'ESLT', 'RBA', 'MCO', 'CHWY', 'CME', 'ZM', 'IDCC', 'ARCO', 'RM', 'TMO', 'ESTC', 'TPH', 'MBUU', 'WHD', 'DKL', 'CPRX', 'LIN', 'XHR', 'IVR', 'NTNX', 'XERS', 'CTAS', 'FNV', 'SFM', 'ABNB', 'NDSN', 'SIMO', 'MTRN', 'BBBY', 'POOL', 'BCO', 'QCOM', 'MCHP', 'HTGC', 'PETS', 'TEF', 'ADCT', 'LECO', 'AN', 'FSLR', 'LOCO', 'ZUMZ', 'ACN', 'SBGI', 'SAM', 'UTL', 'LEA', 'SQM', 'FIVN', 'KLAC', 'DOX', 'CYBR', 'ICHR', 'DLTR', 'MFA', 'D', 'TRN', 'NVGS', 'ALB', 'MOH', 'MGM', 'APG', 'AUPH', 'GHG', 'TIGR', 'RL', 'ORLY', 'CNO', 'EHTH', 'ZD', 'CAG', 'TDC', 'FLEX', 'AZO', 'YEXT', 'PNR', 'BRC', 'VEON', 'WDC', 'LSPD', 'ZTS', 'IBKR', 'WELL', 'CNDT', 'GEVO', 'ICLR', 'NBIX', 'HOPE', 'DKS', 'BHE', 'APA', 'CLPT', 'GILD', 'CUBE', 'GME', 'STAA', 'LSCC', 'PMT', 'IRBT', 'TRGP', 'FOXA', 'AHH', 'CE', 'FN', 'COHU', 'SSP', 'VMI', 'TECH', 'LH', 'PRGS', 'PPL', 'AFIB', 'GDS', 'CRUS', 'IMAX', 'URGN', 'HBAN', 'TITN', 'WEX', 'V', 'WVE', 'YETI', 'LMND', 'VRE', 'AXGN', 'EXPE', 'CM', 'POWL', 'ASPN', 'IOSP', 'MDB', 'ENS', 'SMP', 'OKE', 'CPB', 'ENSG', 'ACCO', 'BFAM', 'BMY', 'JJSF', 'IDT', 'CLS', 'COF', 'GCI', 'KBR', 'COIN', 'VICI', 'ERJ', 'NOV', 'BR', 'FGEN', 'TRIP', 'CRI', 'BRKR', 'AGYS', 'DCI', 'ROG', 'TTEC', 'VFC', 'NNBR', 'TWST', 'XPEV', 'QFIN', 'LNN', 'ECVT', 'GBCI', 'LW', 'PFE', 'LYFT', 'NSC', 'MTX', 'DAO', 'DDD', 'BBY', 'FCX', 'AXSM', 'CASY', 'ELF', 'PEP', 'SBUX', 'CRON', 'MNSO', 'FDP', 'MA', 'AFL', 'MEDP', 'HTH', 'PG', 'ARCC', 'CAE', 'RVLV', 'ASO', 'ARCB', 'ARWR', 'PWR', 'PHM', 'DHT', 'STWD', 'TNET', 'MOS', 'GTLS', 'CACC', 'PSO', 'CFLT', 'ASTE', 'AAL', 'CMA', 'HRMY', 'SAFE', 'BDN', 'EPD', 'BKNG', 'BRY', 'DGX', 'ORA', 'VNT', 'ABBV', 'NRG', 'DVAX', 'MRCC', 'PYPL', 'RCI', 'TJX', 'DLTH', 'CABO', 'FATE', 'LE', 'SII', 'GNSS', 'PENN', 'RMNI', 'WWW', 'KOPN', 'PAYX', 'ABEV', 'MMC', 'DRI', 'VSTA', 'EVH', 'CCI', 'XYL', 'AA', 'SMG', 'NVS', 'KEYS', 'MMS', 'TSN', 'UNP', 'COLM', 'BWA', 'WTFC', 'IEP', 'TBBK', 'HRL', 'GOCO', 'MGNX', 'WSC', 'EPM', 'BMO', 'SLAB', 'YUM', 'KMPR', 'ESPR', 'RHP', 'JAMF', 'CRS', 'ANDE', 'NATR', 'HSTM', 'TDOC', 'VRTX', 'AMC', 'EXP', 'RH', 'BBDC', 'ARLP', 'HOOD', 'BDX', 'CEVA', 'ADP', 'CBOE', 'CNC', 'IRT', 'TD', 'SUN', 'CFG', 'LFST', 'PSX', 'EVCM', 'PEG', 'ALDX', 'MITK', 'AIV', 'DOC', 'WLK', 'BEDU', 'SSTK', 'ODFL', 'WING', 'PLXS', 'AKAM', 'DXC', 'INMD', 'YOU', 'TPR', 'AOS', 'QLYS', 'KBH', 'ADC', 'PRCT', 'SLGN', 'MTN', 'AGEN', 'CRNT', 'NTRS', 'CW', 'RGP', 'LEVI', 'VEEV', 'ZENV', 'PRU', 'CAMT', 'CRH', 'KTOS', 'ACB', 'OMI', 'FLXS', 'FTCI', 'ELAN', 'CWAN', 'QGEN', 'RBBN', 'NEU', 'CRM', 'HAIN', 'NMFC', 'AVAV', 'YQ', 'GSL', 'SIGI', 'HUBG', 'DV', 'HLNE', 'BELFB', 'PII', 'NTB', 'XOM', 'SLB', 'WEC', 'CCAP', 'JKHY', 'IEX', 'PAYC', 'NWE', 'ATO', 'BZ', 'HY', 'TECK', 'ABUS', 'MITT', 'DAN', 'MAR', 'HUM', 'FDX', 'MDLZ', 'SEE', 'TRU', 'THRM', 'GGB', 'PBF', 'W', 'SPGI', 'CSCO', 'KSS', 'TEVA', 'ENVA', 'CZR', 'EYE', 'VREX', 'AEO', 'VTR', 'BRBR', 'EPR', 'LI', 'ABCL', 'PLYM', 'LUNG', 'BBVA', 'ABG', 'PNW', 'USNA', 'CTVA', 'GPN', 'AQST', 'HSIC', 'MRK', 'LPSN', 'HBI', 'CUBI', 'HOG', 'EWBC', 'UNF', 'VSAT', 'SRDX', 'JKS', 'CHH', 'ARR', 'UXIN', 'AHT', 'SAP', 'MGY', 'GNL', 'EAT', 'SNN', 'ADAP', 'AIG', 'CALA', 'DSP', 'IBEX', 'PCRX', 'BILL', 'ACI', 'INNV', 'RARE', 'EVTC', 'BXMT', 'QIWI', 'MTW', 'FRME', 'TTI', 'GIII', 'FINV', 'YI', 'BAP', 'NCNO', 'CBRE', 'JRVR', 'DLX', 'NIU', 'FFIV', 'CRMT', 'NNN', 'CVBF', 'ALRS', 'AVO', 'REKR', 'SNA', 'ATRO', 'HPE', 'SHG', 'SNBR', 'EXR', 'MSFT', 'KRT', 'ROCK', 'AMWD', 'UAL', 'CENX', 'SUZ', 'PRAA', 'GLPG', 'KN', 'NOMD', 'CMCM', 'FSS', 'CX', 'FITB', 'AFG', 'KVHI', 'TXG', 'CSTM', 'UFI', 'FSV', 'SVC', 'LAZ', 'AZZ', 'RJF', 'AIN', 'ELV', 'RUSHB', 'COMM', 'CPNG', 'ZION', 'SEM', 'COLB', 'PAAS', 'CDLX', 'IAC', 'BMA', 'EBR', 'CMRE', 'RIO', 'CHEF', 'MRVI', 'ODC', 'HE', 'BHF', 'CELH', 'SGC', 'SNCR', 'CERS', 'HALO', 'UTHR', 'CP', 'PAGS', 'RPM', 'LKQ', 'KRG', 'FIGS', 'GHM', 'REVG', 'CSX', 'OVV', 'GFL', 'PDS', 'MCRB', 'RYN', 'MTD', 'CRK', 'CTO', 'INGR', 'ADI', 'SMWB', 'BAK', 'ITGR', 'ULCC', 'TRI', 'AVNT', 'WNC', 'PFBC', 'AKBA', 'LCUT', 'AFYA', 'TIPT', 'TER', 'JHX', 'TPC', 'SATS', 'KMT', 'WES', 'FAF', 'BHC', 'LAKE', 'MHO', 'SCOR', 'RYAM', 'PBA', 'AVDL', 'MQ', 'FTI', 'UIS', 'STKL', 'SNX', 'TEL', 'BCE', 'TFX', 'SMCI', 'HAYW', 'UVSP', 'FORR', 'SOPH', 'KODK', 'AZTA', 'CMCSA', 'YELP', 'BXP', 'RGEN', 'BC', 'CYTK', 'INN', 'CSWC', 'SFIX', 'ALGT']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_analysis.head(5)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 660
        },
        "id": "2E4BpGg2OWKs",
        "outputId": "ff966e67-3d2c-4ca2-b2ad-bdef6f66ac0e"
      },
      "execution_count": 42,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                         date      exchange        q ticker  \\\n",
              "0  Aug 27, 2020, 9:00 p.m. ET  NASDAQ: BILI  2020-Q2   BILI   \n",
              "1  Jul 30, 2020, 4:30 p.m. ET     NYSE: GFF  2020-Q3    GFF   \n",
              "2  Oct 23, 2019, 5:00 p.m. ET  NASDAQ: LRCX  2020-Q1   LRCX   \n",
              "3  Nov 6, 2019, 12:00 p.m. ET  NASDAQ: BBSI  2019-Q3   BBSI   \n",
              "4   Aug 7, 2019, 8:30 a.m. ET  NASDAQ: CSTE  2019-Q2   CSTE   \n",
              "\n",
              "                                          transcript            Timestamp  \\\n",
              "0  Prepared Remarks:\\nOperator\\nGood day, and wel...  2020-08-27 21:00:00   \n",
              "1  Prepared Remarks:\\nOperator\\nThank you for sta...  2020-07-30 16:30:00   \n",
              "2  Prepared Remarks:\\nOperator\\nGood day and welc...  2019-10-23 17:00:00   \n",
              "3  Prepared Remarks:\\nOperator\\nGood day, everyon...  2019-11-06 12:00:00   \n",
              "4  Prepared Remarks:\\nOperator\\nGreetings and wel...  2019-08-07 08:30:00   \n",
              "\n",
              "    Date_only  word_count  Price_change Target_Class  DateOfWeek  Month  \\\n",
              "0  2020-08-27        5623      0.035078      Neutral           3      8   \n",
              "1  2020-07-30        4755      0.116154         Gain           3      7   \n",
              "2  2019-10-23        8917      0.142022         Gain           2     10   \n",
              "3  2019-11-06        8286      0.029891      Neutral           2     11   \n",
              "4  2019-08-07        4611      0.249623         Gain           2      8   \n",
              "\n",
              "   Quarter  FinBERT_Positive  FinBERT_Negative  FinBERT_Neutral ticker_clean  \n",
              "0        3          0.146988          0.012653         0.840358         BILI  \n",
              "1        3          0.910005          0.010605         0.079389          GFF  \n",
              "2        4          0.878131          0.012376         0.109493         LRCX  \n",
              "3        4          0.727205          0.122016         0.150779         BBSI  \n",
              "4        3          0.755221          0.136653         0.108126         CSTE  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-448dca7c-826e-4308-a1a9-740063fec47d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>date</th>\n",
              "      <th>exchange</th>\n",
              "      <th>q</th>\n",
              "      <th>ticker</th>\n",
              "      <th>transcript</th>\n",
              "      <th>Timestamp</th>\n",
              "      <th>Date_only</th>\n",
              "      <th>word_count</th>\n",
              "      <th>Price_change</th>\n",
              "      <th>Target_Class</th>\n",
              "      <th>DateOfWeek</th>\n",
              "      <th>Month</th>\n",
              "      <th>Quarter</th>\n",
              "      <th>FinBERT_Positive</th>\n",
              "      <th>FinBERT_Negative</th>\n",
              "      <th>FinBERT_Neutral</th>\n",
              "      <th>ticker_clean</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Aug 27, 2020, 9:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BILI</td>\n",
              "      <td>2020-Q2</td>\n",
              "      <td>BILI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, and wel...</td>\n",
              "      <td>2020-08-27 21:00:00</td>\n",
              "      <td>2020-08-27</td>\n",
              "      <td>5623</td>\n",
              "      <td>0.035078</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>3</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.146988</td>\n",
              "      <td>0.012653</td>\n",
              "      <td>0.840358</td>\n",
              "      <td>BILI</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Jul 30, 2020, 4:30 p.m. ET</td>\n",
              "      <td>NYSE: GFF</td>\n",
              "      <td>2020-Q3</td>\n",
              "      <td>GFF</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nThank you for sta...</td>\n",
              "      <td>2020-07-30 16:30:00</td>\n",
              "      <td>2020-07-30</td>\n",
              "      <td>4755</td>\n",
              "      <td>0.116154</td>\n",
              "      <td>Gain</td>\n",
              "      <td>3</td>\n",
              "      <td>7</td>\n",
              "      <td>3</td>\n",
              "      <td>0.910005</td>\n",
              "      <td>0.010605</td>\n",
              "      <td>0.079389</td>\n",
              "      <td>GFF</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Oct 23, 2019, 5:00 p.m. ET</td>\n",
              "      <td>NASDAQ: LRCX</td>\n",
              "      <td>2020-Q1</td>\n",
              "      <td>LRCX</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day and welc...</td>\n",
              "      <td>2019-10-23 17:00:00</td>\n",
              "      <td>2019-10-23</td>\n",
              "      <td>8917</td>\n",
              "      <td>0.142022</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>10</td>\n",
              "      <td>4</td>\n",
              "      <td>0.878131</td>\n",
              "      <td>0.012376</td>\n",
              "      <td>0.109493</td>\n",
              "      <td>LRCX</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Nov 6, 2019, 12:00 p.m. ET</td>\n",
              "      <td>NASDAQ: BBSI</td>\n",
              "      <td>2019-Q3</td>\n",
              "      <td>BBSI</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGood day, everyon...</td>\n",
              "      <td>2019-11-06 12:00:00</td>\n",
              "      <td>2019-11-06</td>\n",
              "      <td>8286</td>\n",
              "      <td>0.029891</td>\n",
              "      <td>Neutral</td>\n",
              "      <td>2</td>\n",
              "      <td>11</td>\n",
              "      <td>4</td>\n",
              "      <td>0.727205</td>\n",
              "      <td>0.122016</td>\n",
              "      <td>0.150779</td>\n",
              "      <td>BBSI</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Aug 7, 2019, 8:30 a.m. ET</td>\n",
              "      <td>NASDAQ: CSTE</td>\n",
              "      <td>2019-Q2</td>\n",
              "      <td>CSTE</td>\n",
              "      <td>Prepared Remarks:\\nOperator\\nGreetings and wel...</td>\n",
              "      <td>2019-08-07 08:30:00</td>\n",
              "      <td>2019-08-07</td>\n",
              "      <td>4611</td>\n",
              "      <td>0.249623</td>\n",
              "      <td>Gain</td>\n",
              "      <td>2</td>\n",
              "      <td>8</td>\n",
              "      <td>3</td>\n",
              "      <td>0.755221</td>\n",
              "      <td>0.136653</td>\n",
              "      <td>0.108126</td>\n",
              "      <td>CSTE</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-448dca7c-826e-4308-a1a9-740063fec47d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-448dca7c-826e-4308-a1a9-740063fec47d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-448dca7c-826e-4308-a1a9-740063fec47d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-cdbf802d-c320-4e4c-8b4f-a2dc80bf7731\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-cdbf802d-c320-4e4c-8b4f-a2dc80bf7731')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-cdbf802d-c320-4e4c-8b4f-a2dc80bf7731 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_analysis",
              "summary": "{\n  \"name\": \"df_analysis\",\n  \"rows\": 10913,\n  \"fields\": [\n    {\n      \"column\": \"date\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4311,\n        \"samples\": [\n          \"Jul 8, 2021, 11:00 a.m. ET\",\n          \"Feb 13, 2020, 9:00 a.m. ET\",\n          \"May 18, 2022, 9:00 a.m. ET\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"exchange\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"NYSE: AVB\",\n          \"NASDAQ: THRM\",\n          \"NASDAQ: ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"q\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"2020-Q2\",\n          \"2021-Q2\",\n          \"2021-Q4\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"AVB\",\n          \"THRM\",\n          \"ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"transcript\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 10031,\n        \"samples\": [\n          \"Prepared Remarks:\\nOperator\\nGood afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the PTC's 2022 first quarter conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open for questions.\\nI'd now like to turn the call over to Matt Shimao, PTC's head of investor relations. Please go ahead.\\nMatthew Shimao -- Head of Investor Relations\\nHello. Thank you, Julian, and welcome to PTC's results call for Q1 of fiscal '22. On the call today are Jim Heppelmann, chief executive officer; and Kristian Talvitie, chief financial officer. During this call, PTC will make forward-looking statements, including guidance on future operating results.\\nBecause such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in PTC's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission, as well as in today's press release. The forward-looking statements, including guidance provided during today's call are valid only as of today's date, January 26, 2022, and PTC assumes no obligation to update these forward-looking statements.\\nDuring the call, PTC will also discuss non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures can be found in today's press release made available on our website. With that, I'd like to turn the call over to PTC's chief executive officer, Jim Heppelmann.\\u00a0 \\nJim Heppelmann -- Chief Executive Officer\\nThanks, Matt. Good afternoon, everyone, and thank you for joining us. Turning to Slide 3, I'm pleased to share that PTC delivered another strong financial performance in fiscal Q1. We executed very well, building on the momentum we saw in Q4.\\nTo simplify things, please note that throughout my prepared commentary, I will only discuss growth rates in constant currency. ARR came in at $1.507 billion, which was better than the $1.5 billion we had guided to at the recent Investor Day. That represents 16% growth, 11% of which was organic. Adjusted free cash flow was also strong at $145 million, which was up 20% year over year and better than the $140 million expectation we said at the Investor Day.\\nWe're off to a very strong start in fiscal 2022. Turning to Slide 4. Of particular note was our bookings strength. Bookings were up double digits organically and high teens overall against the very strong COVID bounce back quarter we saw in Q1 of fiscal '21 when bookings grew more than 30% over the prior year.\\nTo put it in perspective, given the tough comparison against Q1 of last year, we had planned bookings to actually be down slightly, inclusive of Arena. So this performance was more than 20% above plan. I know that some analysts and investors had voice concerned that the restructuring work we did in late Q4 and throughout Q1 would distract us, but obviously, we didn't see that. The strength was broad-based across direct sales and resellers and was achieved with no megadeals.\\nRockwell came in ahead of their part of our plan, too, which was great to see and suggest my concerns of them being distracted and may prove overstated. Arena contributed the inorganic element of bookings growth, with another strong bookings quarter, coming in above plan as well. With the Arena acquisition getting round tripped here in Q2, Arena becomes part of the organic results going forward and their low 20s growth rate will then add another tailwind to the organic results. Arena has been a great acquisition.\\nBookings growth was particularly strong in PLM, and in both Europe and Americas. From a macro perspective, global PMIs remain an expansion territory, while digital transformation and SaaS continue to grow in importance as secular drivers. The interest in digital transformation in SaaS has been driving strong bookings for what is very sticky software, which when layered into a recurring revenue model that is atypical of industry peers, has allowed PTC to deliver performance in excess of market growth rates. This happened right through the pandemic, especially in the large core business that represents about 70% of our ARR, and we fully expect it to continue going forward.\\nThese factors gave us confidence to raise the lower end of our ARR guidance range, which at the new midpoint basically means we've rolled our Q1 beat forward. Now let's take a look at the ARR performance by geography on Slide 5 before turning to business units. In Q1, we saw a strong ARR performance across all geographies. Our ARR growth in the Americas was 19%.\\nAll product segments grew with key growth drivers being the acquired Arena contribution and the velocity business unit overall, layered on top of another strong quarter in the core CAD and PLM business. In Europe, our ARR growth was 13%. We saw strong results across the board in Europe, with the strongest drivers of the growth being our digital thread growth and core businesses. Europe has the largest mix of channel versus direct and the resellers continue to perform well.\\nOur ARR growth in APAC was 14%, with growth primarily driven by our digital thread core business. Next, let's take a look at the ARR performance of our various business units, starting with the digital thread group on Slide 6. In our largest product segment, digital thread core, we delivered yet another double-digit performance in Q1 with 11% growth. Within this, CAD and PLM, both grew double digits, with strong growth across all three geographies.\\nThis is the 17th consecutive quarter of double-digit ARR growth in the core business. And as we roll out our more aggressive SaaS strategy, I expect we'll see many more. In the digital thread growth, which is IoT and AR, we saw ARR growth of about 14%, consistent across both elements. This was in line with our plan and the mid-teens near-term growth expectation we set at the recent Investor Day.\\nWhile this level of growth remains accretive to company growth, we continue to expect an acceleration of growth into the 20s as we get into the back half of the year. The biggest driver of growth in Q1 was from expansions, especially in Europe and APAC. We believe market conditions in IoT are improving, and we like the way the pipeline for our new DPM offering is developing through both PTC and Rockwell channels. For AR, we continue to see a tremendous level of interest, but the market remains nascent.\\nPerhaps most importantly, the formation of the digital thread business unit at the start of FY '22 has driven important initiatives to increase our focus on cross-selling of IoT and AR into the core CAD and PLM customer base. FSG had a great Q1 with 6% ARR growth. The expansion deal we recently announced with the U.S. Air Force, both increases and extends this key relationship for up to five more years.\\nContracts like this demonstrate the value that our customers are realizing from Servigistics and other FSG products such as retail PLM and ALM. You may remember, I noted at our Investor Day that having FSG grow in the mid-single digits rather than flat would be a helpful upside growth driver. So I'm pleased to see FSG post another strong quarter. Let me run through a couple of quick customer anecdotes to give you a sense for our digital thread customers and how they rely on us.\\nOn Slide 7, MAN Energy Solutions is the world's top provider of large-bore engines in turbomachinery for the maritime and energy industries. The company manufactures complex parts in nearly every engine they make must meet unique customer requirements. Before implementing Creo, they relied on manual outdated processes that slowed design and production. With Creo, they've been able to transition from 2D to a full 3D model-based approach.\\nCreo's broad range of tool path automation capabilities enable them to save time in the programming of the tool pass used to machine the large complex engine parts, greatly increasing efficiency in transitioning from design to production. Turning to Slide 8. You may have noticed we announced a deal with -- we announced that the German company, Scheffler, has expanded its relationship with PTC, and I'd like to share a bit of the back story. Scheffler has been a longtime Creo customer and has successfully deployed Windchill within engineering.\\nBut back in 2017, one of our PLM competitors announced a large PLM deal with Scheffler that appeared to cap PTC's expansion opportunity. But that system didn't ultimately stick as Scheffler has now decided to consolidate on PTC systems with Windchill being the backbone and is broadly deploying our solutions in their standard out-of-the-box fashion so that Scheffler can participate in the full power of our digital thread portfolio. I'm very excited about this collaboration and the further expansion that Scheffler is exploring with our IoT and AR offerings. On Slide 9, you'll see how IMA Group, our global business that delivers packaging machines, services, and solutions to a wide variety of industries, was looking for a way to expand their control room offering to help their customers improve overall equipment effectiveness and reduce downtime.\\nAs longtime users of PTC's Creo and Windchill, IMA decided that ThingWorx was the ideal IoT solution for their initiative and that Kepware could provide connectivity not only to their machines, but to the other vendors' machines deployed alongside them. IMA has successfully launched new revenue streams by enabling 24/7 monitoring of customer production lines and improved OEE by up to 16%. The Vuforia integrated with ThingWorx is the platform of choice for the U.S. Air Force training initiatives.\\nSlide 10 highlights the work that PTC partner, Vectrona has done with the U.S. Air Force. With finite training resources and limited capacity, the U.S. Air Force set out to incorporate augmented reality into their maintenance and munitions training.\\nVectrona using Vuforia Studio worked with the U.S. Air Force to create immersive 3D AR experiences for phones, tablets, and the HoloLens 2 that are designed to accelerate learning, improve work performance and facilitate remote training. The improved training shows better engagement and information retention with continuous and repeatable task training available regardless of the system or aircraft type. Turning to Slide 11, the velocity business ARR growth in Q1 was more than 650% due to the inclusion of Arena and 53% organically, which would be Onshape.\\nIf you were to add Arena's pre-acquisition results into the prior year to get a better pro forma comparison, then you'd have the velocity business unit growing at 28% in Q1. That 28% is a mix of Onshape growing at 53% and the larger Arena business growing in the low 20s. Growth of both Onshape and Arena is multiple times higher than market rates, clearly demonstrating that industrial companies see the benefits of SaaS. We continue to ramp investments to expand technology leadership and to broaden the geographic presence of our velocity businesses.\\nOn Slide 12, Beta Technologies, a leading developer of next-generation electric aircraft for the cargo and logistics market, sought a cloud-native product development platform where everyone would be working with one single source of truth without the workflow restrictions of traditional file-based design systems. Beta turned to Onshape because of how it enables real-time collaboration, allowing the engineering team to work from any location while streamlining their communications during the design process. To profile Arena customer, Potrero Medical, on Slide 13, is a predictive health company developing the next generation of medical devices, leveraging smart sensors and artificial intelligence. Potrero needed a scalable quality management system to support its growing product development and compliance needs, including satisfying FDA audit requirements.\\nArena was the right solution, offering a cloud-native QMS with a quick implementation, leading to ECO cycle time reduction of 30% and nonconformance improvement of 20%. As a final topic, I'd like to give you a quick update on our SaaS acceleration initiative on Slide 14. We've made tremendous progress in the past 90 days since we announced the more aggressive strategy. We've launched our SaaS program management office, which was modeled after the very successful approach we used to drive our subscription transition several years back.\\nOur field organizations transition to the new two-in-a-box customer success organization model without missing a beat. We converged our cloud and tech support organizations with product development to deploy the DevOps type of approach you see in virtually all SaaS companies. We've made good progress advancing our offerings, especially the Windchill multi-tenant version, which will go into production shortly this quarter, and we made good progress preparing the SaaS conversion offerings that will power the hundreds of lifts and shifts that will happen in the coming quarters and years. We have more work to do, but we're certainly up and running.\\nThe time for SaaS has arrived in our industry and PTC is very well positioned. We're already the SaaS leader in our space with continued strong SaaS growth in Windchill and FSG and high levels of growth in our cloud-native velocity business unit. Sharing the Atlas SaaS platform, we have a dual strategy to win with Onshape and Arena powering a new agile product development approach, while we transition our digital thread portfolio and existing customer base to SaaS to elevate the platform strategies that so many larger companies have. To wrap up on Slide 15, I'm pleased with PTC's position and the opportunity that lies ahead.\\nQ1 gave us a strong start to what we expect to be our fifth consecutive year of double-digit ARR growth. Our portfolio of products is unique and compelling and obviously aligns well to customer demand. Our results have been consistently strong for many quarters, but we're poised to accelerate growth as the SaaS tailwind blows harder in coming quarters and as we gain more momentum with our IoT and AR initiatives in the back half of the year. We're poised to drive higher levels of profitability, too, following the organizational changes we've already implemented and as our start-up businesses continue to mature up their J curves.\\nThe company has never been in a better position to create shareholder value. With that, I'll turn it over to Kristian for more details on the financial results.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nThanks, Jim, and good afternoon, everyone. Before I review our results, I'd like to note that I'll be discussing non-GAAP results and guidance, and growth rate references will be in both constant currency and as-reported rates. So turning to Slide 17, we delivered constant currency ARR of $1.507 billion, which is 16% growth year over year and slightly exceeded our Q1 guidance of $1.5 billion. On an organic constant currency basis, this is 11% growth.\\nFX was an approximate $11 million headwind in Q1, so our as reported ARR was $1.496 billion. Our SaaS products in both the digital thread and velocity business units saw a continued strong growth in Q1, with growth rates similar to what we discussed at our recent Investor Day. This is in combination with continued strong growth of our software-only sales. As of Q1, our SaaS portfolio is now 15% of our total ARR on a constant currency basis.\\nQ1 free cash flow of $134 million grew 21% year over year and includes $11 million in restructuring and other related payments. Adjusted free cash flow was $145 million and was slightly ahead of the $140 million we discussed at our Investor Day. Q1 revenue of $458 million increased 7% year over year. As we've discussed previously, revenue is impacted by ASC 606, so we do not believe that revenue growth rates are indicative of our underlying business performance but would rather guide you to ARR as the best metric to understand our top-line performance and cash collection.\\nFX only impacted revenue by about $1 million in Q1. So our revenue on a constant currency basis was $459 million. Q1 non-GAAP operating margin of 35%, compared to 36% in Q1 of 2021. While this is a strong result, it's still worth pointing out that because revenue was impacted by ASC 606, other derivative metrics such as gross margin, operating margin, and EPS are all also impacted.\\nSuffice it to say that our COGS and opex came in in line with our expectations in Q1, and we continue to maintain good discipline on our operating expense structure. I would like to point out that our GAAP results reflect a gain of $9.8 million related to our investment in Matterport. And we're also slightly reducing the range for expected P&L charges from approximately $45 million to $50 million, down to $40 million to $45 million for the full year. And coincidentally, we're also reducing the range of expected cash payments for the restructuring and other from what was previously $50 million to $55 million, down to $45 million to $50 million for the full year.\\nFor guidance purposes, we will continue to show $50 million as the cash payments and the adjusted free cash flow reconciliation. But as payments come in lower, then we would just expect actual free cash flow to come in higher. There's no change to the $450 million adjusted free cash flow target. Moving to Slide 18, I'll begin with our balance sheet.\\nWe ended Q1 with cash and cash equivalents of $296 million. In addition, at the end of Q1, we had medium-term investments of $87 million, primarily related to our investment in Matterport. Our gross debt was $1.45 billion with an aggregate interest rate of about 3.2%. In Q1, we used $120 million of cash to repurchase shares.\\nWe also had an additional $5 million of repurchases, which settled early in Q2. For the remainder of fiscal '22, we will focus on delevering and looking forward to FY '23 in an ongoing go-forward basis, assuming our debt-to-EBITDA ratio is below three times, we will continue to target to return approximately 50% of our free cash flow to shareholders via share repurchases. Turning to Slide 19. We post a data table to our IR website that has our financial statements, as well as ARR detail by segment.\\nIn that file, we share both constant currency and as-reported ARR. As a reminder, when we calculate constant currency, we use our current year plan FX rates and restate history to the same rates. So here, for example, on this slide, you can see our Q1 constant currency ARR of $1.507 billion and the actual as reported ARR of $1.496 billion. This is important to remember in the context of our guidance because we provide guidance at the planned rate.\\nWe believe this is the best way to evaluate the top-line performance of our business because it removes FX fluctuations from the analysis, positive or negative. With that, I'll move on to guidance on Slide 20. As Jim mentioned, we're raising the low end of our full year constant currency ARR guidance by $10 million. The new range is now $1.625 billion to $1.660 billion.\\nThis essentially reflects rolling our Q1 overperformance through the remainder of the year. We're now expecting constant currency ARR growth of 11% to 13% in fiscal '22. It's worth pointing out that based on FX rates at the end of Q1, we would expect a $13 million headwind against that full year ARR guidance. For Q2, we're setting constant currency ARR guidance of $1.540 billion to $1.550 billion.\\nThis is 12% organic constant currency growth at the midpoint. On an as-reported basis, the FX impact we're calculating based on the FX rates at the end of Q1 is a $12 million headwind in Q2 compared to the constant currency guidance. Moving to free cash flow. We're maintaining our full year free cash flow target of $400 million.\\nThis includes approximately $50 million of restructuring and acquisition-related payments. The majority of these payments are related to the reorganization we announced in Q1 with some residual payments primarily related to our Seaport move for which we took the accounting charge in prior periods. So our adjusted free cash flow target for fiscal '22 remains $450 million. Fiscal Q2 adjusted free cash flow is expected to be approximately $155 million.\\nWe expect to make approximately $20 million in restructuring and other related payments in Q2, bringing our free cash flow to approximately $135 million. Moving to revenue. We're also taking the low end of the full year revenue guidance up by $20 million. This reflects both the strength in software and strength in the professional services business that we saw in Q1 and the related forecasts for the full year.\\nSo for fiscal '22, our net revenue guidance range is $1.870 billion to $1.975 billion. The year-over-year growth rate range is now 3% to 9%. Our ASC 606 makes revenue very difficult to predict for on-premise subscription companies, hence the wide range. Note that revenue variability has -- this is from 606, has no impact on ARR or its related cash generation as we continue to primarily bill customers annually upfront regardless of term length.\\nWe continue to expect more than 60% of our annual free cash flow generation to occur in the first half of the year. Collections are stronger in the first half, and we expect expenses to increase as we ramp hiring in our SaaS investments throughout the year. We're wrapping up on Slide 21 with the free cash flow model that we use and went into some depth on at our recent Investor Day that you can see here. I know many of you use model free cash flow using the indirect method.\\nHowever, given the complexities related to revenue recognition due to 606, this is difficult to do. The model we show here has proven quite effective. The table shows fiscal '21 actuals compared to the model we shared at Investor Day compared to our current guidance. Let me take you through the model focusing on the non-GAAP column on the right and starting at the top.\\nFirst, we're showing the midpoint of our as reported ARR guidance of $1.630 billion, which is different from the constant currency guidance that we gave due to the $13 million FX headwind and is also $5 million lower than what we showed at the Investor Day. We use it as reported here because it's a better reflection of the cash we expect to generate. You can also see that we have increased the perpetual license revenue forecast slightly and also the professional services revenue increase that we mentioned earlier. COGS is slightly higher, reflecting the increased costs to deliver the incremental professional services revenue and the rest of the assumptions remain the same, and we still end up with our target adjusted free cash flow of $450 million.\\nObviously, this is a model based on assumptions such as the midpoint of the ARR range, the impact of FX, the pace of hiring, etc. So if some of those variables change, which they invariably will, the model will have to be adjusted accordingly. And as I mentioned earlier, if cash payments related to the restructuring coming at the low end of the range, we would see a flip from the restructuring line to the free cash flow line, but the adjusted free cash flow target would remain unchanged. But as we sit here today, we think this is a reasonable view of how we expect the year to shape up.\\nSo with that, I'll turn the call over to the operator, and we can begin Q&A.\\u00a0\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] We ask the analysts to please limit themselves to one question only. If you have any additional questions, please return to the queue. Thank you.\\nYour first question will come from Andrew Obin from Bank of America. Please go ahead. Your line is open.\\u00a0\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nHi, yes. Good afternoon.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Andrew.\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nJust a bigger picture question. I apologize, I missed the first couple of minutes. You know, we hear a lot about supply chain constraints. And frankly, we're hearing that this might extend the run-in terms of PMI expansion.\\nSo what are you hearing in terms of sort of as you have conversations about PLM and in terms of adoption? What kind of conversations are you having with your customers? And do customers have awareness of sort of supply chains being gummed up for longer? And are you seeing this having any discernible impact on what kind of conversations you're having with people?\\nJim Heppelmann -- Chief Executive Officer\\nAndrew, it's Jim. No, actually, it's not really a frequent topic in our conversations because -- well, first of all, since you said you missed the first minute, one of the things I pointed out is that our bookings came in very, very strong, and I explained about 20% higher than planned. So we had a very, very strong bookings quarter. And notable in that was PLM, although, frankly, the strength was broad-based.\\nI think the key thing to remember is that PLM is really associated with preparing product data in engineering that will then subsequently be used in manufacturing and perhaps in aftermarket service. And it's collecting data from supply chain partners and so forth. But production problems in a supply chain don't necessarily impede the collaboration during the engineering and the preparation for production process. So I think people are saying like, maybe I can't get chips to complete the product, but that doesn't mean I should stop designing the next one because if it does, then I'll fall behind.\\nSo I think that our view would be that the product development process has largely been unaffected by the supply chain process. Now some other things, we talked about how perhaps COVID had an impact on IoT, perhaps the supply chain a little bit, although I think muted compared to COVID. So to me, the supply chain thing is a fairly small factor in our results. We just see very little correlation between what's happening out there with supply chain problems and what's happening with our pipeline and frankly, with our bookings.\\nOperator\\nYour next question comes from Yun Kim from Loop Capital. Please go ahead. Your line is open.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nHey, Yun.\\nYun Kim -- Loop Capital -- Analyst\\nThank you. Hi, Jim. Can you just talk about the IoT business, you know, in terms of the large deal activity? What kind of trends are you seeing there? Obviously, you are expecting that business to accelerate in the back half -- second half of the year. If you can talk about whether that confidence is coming from the, you know, improvement in the large deal activity? Or is it just the overall volume of the activity around IoT? And then also, if you can just comment around deal size activity around the AR business as well.\\nThanks.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I think deal sizes are sort of unchanged from previous trends. If you think -- what are we looking at when we project forward how IoT and AR will perform. Well, we're looking at the bookings, let me say, at the pipeline that will drive bookings, and for IoT and AR was quite strong.\\nWe're looking at the backlog. Last year, bookings actually had improved over the prior year. And bookings that went into backlog or -- I'm sorry, what we call deferred ARR, were quite high. We were well ahead of our deferred planned number as we actually did last year.\\nSo you could imagine we've got more, and if you want to call it, backlog waiting for us. And then what other initiatives are we doing? So for example, our DPM launch, I think, will be materially positive for our IoT results. It will drive bigger deals. It will drive better value propositions.\\nIt's really software that's ready to turn on and get value from as opposed to a platform. And then the other thing is, Troy Richardson talked at our Investor Day about organizing better for cross-sell. And I think if we look backwards, maybe we had pivoted too much toward new logos, which are great. I mean, new logos are a wonderful thing.\\nBut we probably have low-hanging fruit yet to pick within our installed base of CAD and PLM accounts. So I think it's really this combination of a strong-looking pipeline, good-looking trends, awaiting us in the deferred backlog and then these other initiatives kicking into place, DPM and cross-sell that I think will all be very helpful as we proceed through the year. And again, I want to remind everybody, we set the expectation that the two handle would materialize in the back half of the year and that you wouldn't see it in Q1 and Q2. So we sort of feel like this was as we had predicted just mid-December a couple of weeks ago.\\nOperator\\nYour next question comes from Jason Celino from KeyBanc Capital Markets. Please go ahead. Your line is open.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nHey. Hi, Jim. Hi, Kristian.\\nJim Heppelmann -- Chief Executive Officer\\nHi, Jason.\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nSo one question on maybe the SaaS Windchill, you know, launch. It seems like it's coming along, you know, nicely, and we could see something maybe go GA this quarter. Have you had a chance to maybe, you know, discuss this with customers? How is the pipeline shaping? Or is it maybe better to think that the pipeline might start to form once we do go live?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nNo, we have, for sure, started talking about it with customers. I mean, ramping up that process. We've got to educate a lot of people and they, in turn, have to educate customers. But we've certainly made some progress, and I can tell you the customer interest is actually quite high.\\nYou should know that actually, customers were pushing us a little bit to get going with such initiatives -- so I feel like the demand is there. And in fact, again, just reflecting on what we told you, that business has been growing about 30%. And Kristian mentioned we posted another quarter just like that, without us really invoking the new strategy yet. So there's lots of demand.\\nWe're just looking for a model where we can promote the demand because we like the margin profile better. And that's what's coming into place here in Q2.\\nOperator\\nYour next question comes from Adam Borg from Stifel. Please go ahead. Your line is open.\\u00a0\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nGreat. Thanks so much. And maybe just two quick ones. Just on the Scheffler win that you announced yesterday and highlighted on the call earlier.\\nOne of the things I thought was really interesting in the press release was this opportunity around some more vertical-specific or market-specific solutions targeting either automotive or industrial companies. So maybe, Jim, if you could just talk about that. And maybe just as a quick follow-up, just maybe for Kristian. Any way you could talk about this transition, it's great to get the early feedback on the SaaSification efforts, but any way to comment on, you know, how much this has contributed to bookings or the pipeline, at least qualitatively? Thanks so much.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I'll get the first part of the question. Kristian, you can take the second part. Yeah.\\nSo Scheffler is a great account. And as I mentioned back in 2017, it appeared they were going in a different direction, and now they've decided to come back into the fold. And honestly, they did that for two main reasons. One is that they really want off-the-shelf technology.\\nThe other competitor had told them this low-code, no-code story, and they tried that out and decided that's not really what they want. They don't want to develop their own solutions. They want to deploy standard out-of-the-box software that all works together. And then they want to engage in partnerships with the vendor, in this case, PTC to talk about how those solutions should evolve to be more and more powerful to meet their needs.\\nSo yeah, I'm very excited. I'm in the middle of that relationship myself. And yes, what's going to come out of that is technology that fits better and better, for example, for the automotive supply chain, which is a place where we have a lot of customers. So it's a great win or win back, maybe I should say, and a great partnership going forward that's going to produce a lot more business for us in years to come.\\nAnd sorry, the second part of the question was around the transition to SaaS and how that's manifesting itself in terms of pipeline and activity? Is that right, just making sure I got that right.\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nExactly. Any way to qualitatively comment from, you know, either bookings or a pipeline perspective?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, remember, I mean, the bookings that we just reported were for Q1, and Q1 is really when we actually just announced the acceleration of it. So I would say there's actually a limited impact in the actual bookings result here in Q1. That said, as I mentioned, we continue to see strong demand for the SaaS properties that we have.\\nThat's both in velocity and the digital thread. And so those products continue to grow at a rate higher than our software-only products. And now as the program is pushing ahead, we expect to see demand and pipeline generate, especially with the new Windchill launch coming out here and the program continuing to pick up speed internally.\\nKristian Talvitie -- Chief Financial Officer\\nMaybe, Adam, I could just add. We launched this phase 3 strategy 90 days ago on the earnings call. And there's nothing we've seen since that makes us any less bullish than we were back then. I mean it looks like a really nice opportunity for PTC, and we're pushing forward ahead as aggressively as we can because we'd like to bring that very promising upside growth driver, you know, closer in.\\nSo it has a bigger impact on '23 and '24 and so forth than it would otherwise have had.\\u00a0\\nOperator\\nYour next question comes from Jay Vleeschhouwer from Griffin Securities. Please go ahead. Your line is open.\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nThank you. Hello. Hi, Jim. Hi, Kristian.\\nA couple of things. With regard to the strength you noted for PLM, at your partner conference six months ago, back in the summer, management presented to the channel, your concept that PLM was no longer just an engineering vault that it was becoming memorial, what you call, multisystem, multidiscipline concept. And the question is, to what extent is that broader, more diverse view of PLM a current part of new business or in the pipeline for new business as compared to the more conventional historical way of thinking about PLM? By our calculation, we are already the second-largest brand by revenue in PLM, and maybe talk about what some of the drivers are to that? And then just a quick clarification you referred earlier to cross-sell. At the Analyst Meeting last month, in the slide deck, you referred to cross-sell 10 times and relatedly account-based selling.\\nPTC is often over the years, talked about cross-sell, but maybe talk about what's different this time in terms of resources and programs across your various segments and your new customer segmentation model.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, on your first question, Jay, you know, you are always very pressy on, you've been watching this industry for a long time. When we say multisystem, multidiscipline, what we're really talking about is an enterprise system. And so what's happened in the last couple of years is PLM has graduated from being an engineering data management system to being an enterprise system that contains the system of record for the product definition.\\nAnd so if you're in manufacturing, well, you need to know the product definition. If you're in procurement, you need to know the product definition. If you're all on an installation or a support call, you probably need to know the product definition. So definitely what's happened is that the enterprise deployments of Windchill are multiple times larger than the engineering deployments of Windchill.\\nSo something that's been driving growth for some years now is that the new deals we're taking are more and more frequently enterprise deals and they're larger. You may remember, last quarter, I told you we took the largest deal we had taken to date from a med device company. And the second thing that's happening is, we're circling back to those companies who had deployed the engineering solution like say, Scheffler, and we're upselling them to the enterprise solution and turning that into a much bigger opportunity for us. So definitely, that's a real thing, and it's been driving the momentum we've seen in Windchill for years.\\nAnd frankly, there's a lot of it out ahead of us even before we start talking about SaaS. The upsell from a departmental solution to an enterprise solution is a driver, taking that whole enterprise solution to SaaS is a whole another growth driver that's on top of that and sort of orthogonal to it. And then on the account-based selling, there's two ways to look at that. Cross-selling into your accounts is a great thing.\\nYou have established relationships. It's much easier to sell another product to an existing customer than to sell a new product to a new customer or a first product to a new customer. At the same time, we like new logos. So it's really always about the balance of how much do you invest in new logos pursuits versus how much do you invest in selling more to the companies who know and trust you.\\nAnd I think perhaps with IoT and AR, we realized we had over pivoted toward new logo, which is just generally speaking, less productive selling, you might imagine. And so the reason we formed this digital thread group, which brought CAD and PLM and IoT and AR together under Troy Richardson, was to really lubricate how these products work together and how we position them together and to be able to start anywhere and sell up and down that chain. So it's a good strategy. It's one that we -- it's a muscle we've developed well over the years.\\nWe really built the Windchill business, largely by cross-selling to the Creo base. And I think this is going to be something that will help us a lot to kind of get the right balance of new logo pursuits in cross-sell.\\nOperator\\nYour next question comes from Ken Wong from Guggenheim Securities. Please go ahead. Your line is open.\\u00a0\\nKen Wong -- Guggenheim Securities -- Analyst\\nThank you so much for taking my question. Jim or Kristian, I wanted to perhaps dive into the double-digit organic bookings growth. You know, I couldn't help and notice you guys also had a very large Servigistics expansion deal with the Air Force. I mean how much of that was already in expectations? Or did you get some boost there from timing shifts or anything of that nature?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Let me tell you, none of that actually contributed to the double-digit growth because that was a Q4 deal. You know, we released it when we had approval to release it, and I commented on it because it was, you know, an important customer and so forth. And let me say that deal, again, that was closed in Q4, both represented five years of extension, but also about a 50% growth in a ramp that happens over -- I think it's three years.\\nSo it roughly goes from a $10 million run rate to a $15 million run rate over three years and stays there for a couple more. That's what the contract contemplates. So some of that will come into ARR in Q4 of this year, but the bookings actually were in Q4 last year. So that strength -- the strength we saw in Q1 was exclusive of that Air Force deal, which just means it was really great strength.\\nSo anyway, it was hard to pin down where the strength comes from because it came from CAD. It came from PLM. The IoT number was actually pretty decent. It didn't all go into ARR.\\nAnd then, of course, the velocity numbers and the FSG numbers. So it was broad-based in all geographies and really in all product lines.\\nOperator\\nYour next question comes from Matt Broome from Mizuho Securities. Please go ahead. Your line is open.\\nJim Heppelmann -- Chief Executive Officer\\nHello, Matt.\\nMatt Broome -- Mizuho Securities -- Analyst\\nThanks, man. So Jim, I mean, I guess, just on that -- sorry, just deal that I can just mention. Given the importance of supply chain management right now, are you seeing like ramping demand to the solution elsewhere? And sort of following on from that, is there a chance that FSG ARR could actually accelerate on the back of that demand beyond the sort of the mid-single-digit level and actually become sort of more strategic in a way?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean that's one of the points, Matt, that I brought up at the recent Investor Day is that we've generally modeled FSG to be roughly flat, flat about plus 1% to 2%. But it's actually been performing. I think last year, Kristian, wasn't up 7%, FSG.\\nIt was up 6% here again in Q1. So yes, we're overperforming and Servigistics is one of the key drivers. And then the second one probably is retail PLM, which has also been doing fairly well. So definitely, there's some -- I think we'll be conservative and leave the FSG sort of guidance where it is in the near term, but I do like overperforming it because it's a growth driver.\\nThe FSG business is about the same size as the IoT and AR business. So every point of growth we get there is pretty meaningful.\\nOperator\\nYour next question comes from Matt Hedberg from RBC Capital Markets. Please go ahead. Your line is open.\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nYeah. Thanks. This is Matt Swanson on for Matt. I'll kind of follow up on a piece of both Adam and Jay's questions.\\nSo looking at the Scheffler announcement, I think the thing I was really interested in was the idea around standardization and the idea around end-to-end. So could you talk a little bit about your customers' desire around standardization? And clearly, this product road map has really expanded your TAM, but I think one of the upside areas something we -- you know, maybe the holy grail of the transition would be more competitive displacements. And I'm just curious if you're starting to hear, you know, any early or more talk around that because you're building something so differentiated.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean, for sure. So the standard thing, I think maybe over the last couple of years, industrial companies have realized that they should be using software, not developing it. And so we saw this in our IoT business, and it's been why we've been heading up the stack with solutions like DPM is, customers would like to buy the software and use it, not buy some kind of a platform and create it because they just don't really know how to create it if I'm frank.\\nSo Scheffler had gone down the path of kind of like I said, low-code sort of environments and came back to standard products. And then the end-to-end thing, for sure, the CAD data that's created in Creo and managed in Windchill gets used, for example, in augmented reality, manufacturing, and service instructions much later and in a different part of the company if it's all well managed. And that connectivity from IoT, well, let's say, from CAD to PLM to IoT to AR is what we call the digital thread. And so we actually see so much interest in this that we kind of organized around that principle.\\nLet's stop presenting these products as kind of independent things and let's shine the light on how well they work together in an end-to-end solution. And by the way, how they're all ready to go. That this is something that turn on and use. And that's really what one Scheffler over, but I can tell you, Scheffler is not unique at all.\\nAnd it's really -- we're organizing to respond to that. SaaS is helpful, by the way, because if you want a lot of technology working end to end, it'd be better not to ship at all to the customer side because it gets complicated. The customer would like to just use it, not set it all up and care and feed for it on-premise.\\nOperator\\nYour next question comes from Saket Kalia from Barclays Capital. Please go ahead. Your line is open.\\nSaket Kalia -- Barclays -- Analyst\\nOK, great. Hey, guys. Thanks for taking my question here. Hi, Jim.\\nHey, Jim, maybe -- hey, Kristian. Jim, maybe for you, it was great to hear the PLM strength this quarter in bookings. With other companies that have done shifts like this, there's always a risk, I guess, of customers behaving differently, right, whether that's slowing purchases to see what's coming or maybe pulling forward purchases before something new comes out. Now just to be clear, it doesn't sound like that happened here.\\nBut can you just stress test that for us a little bit? And what you sort of look at to sort of manage what is, you know, more choices for our customer to make. Does that make sense?\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Are you referring -- just let me clarify, are you referring to like SaaS choices being new choices or more broad --\\u00a0\\nSaket Kalia -- Barclays -- Analyst\\nYeah, that's right, yeah, Windchill. No, Windchill specifically.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So keep in mind, Saket, we have been selling Windchill as SaaS for some time. Remember, the phase 1, phase 2, phase 3 thing. So since phase 1, we've been selling Windchill, and we showed you, it's got a three-year growth CAGR of 30% in SaaS.\\nSo the customer demand is strong. It's just -- on the PTC side, we need to pivot to multi-tenant because in the single-tenant model we just don't have the profitability we like. So the demand is strong. The customers are buying it.\\nKristian mentioned we had another strong quarter. So it really is, we'd like to meet that demand with a solution that's more efficient for us to operate on behalf of the customer. And that's what phase 3 multitenant really is all about. Now when it becomes more efficient for us, we can then lean in on the promotion and marketing of it, because we haven't really done that.\\nSo we've been servicing demand, not driving it. And with phase 3, we think there's an opportunity to drive demand and, you know, the preliminary data we've seen this quarter suggest customers are very responsive, both to buying new systems that way, but also to lifting and shifting the previous systems they bought and giving them to us to operate and serve back to them in a SaaS model.\\nOperator\\nYour next question comes from Joe Vruwink from Baird. Please go ahead. Your line is open.\\nJoe Vruwink -- Robert W. Baird and Company\\nGreat. Hi, everyone. Just to go back to bookings, does the strength this quarter absent mega deals suggest anything about either the demand environments or maybe just the health of your mid-market and SMB customers? And looking ahead, are there going to be certain things you think about or track when contemplating, you know, the probability of more mega deals or maybe the larger ARR contributors for PTC, maybe, you know, being a bit more represented in future bookings?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nKristian, let me again take a stab at that and maybe you'll find things to add. So I think if you look at the bookings, again, they were phenomenal, and it's hard to pin down. It wasn't one geography. It wasn't one product.\\nIt was all geographies, all products. So I think it tells us that the end market is very healthy. And I would say, for two different reasons. On one hand, the PMIs are in good shape.\\nThat's helpful. On the other hand, the interest they have in the digital thread, digital transformation story, and the interest they have in SaaS is secular. That interest is not related to the PMIs, it's kind of independent of them. And so I think that we're just in a very healthy situation where industrial companies are leaning in on trying to get more digital.\\nThey see PTC as having a fairly unique and compelling portfolio, and they're interested in engaging and trying to make their companies more efficient. I can tell you, at Scheffler, for example, it's one of the top initiatives in the company is to get more digital. And as it relates to the whole product life cycle, the partners PTC. And we see that kind of phenomenon happening in a lot of places in the industrial world.\\nSo I think it's just good, strong, secular and as well macro-environment out there right now. But I'll remind you that we've had good performance even when the macro environment wasn't so strong. So all things being equal, I like the strong macro. But we're 17 quarters in with double-digit growth in the core business, and there were a lot of bad macro quarters over the course of those 17.\\nSo I think it really is the secular driver. Kristian, anything?\\nKristian Talvitie -- Chief Financial Officer\\nYeah. I mean I agree with all that. I mean, actually, just on the big deal dynamic, you know, what we used to call mega deals. We haven't -- I think we've had four in the past four years.\\nJim Heppelmann -- Chief Executive Officer\\nYeah. Well, keep in mind, perpetual drove bigger upfront purchases and subscription or SaaS tends not to.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYeah, which is my point that we've been seeing good strong bookings performance and bookings growth, you know, even with the absence of what used to be a fairly regular occurrence back in the perpetual days, like we really don't see a lot of those.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah, it's a good healthy business. OK. Next question.\\nOperator\\nYour next question comes from Blair Abernethy from Rosenblatt Securities. Please go ahead. Your line is open.\\u00a0\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nThanks very much. Guys, just maybe a quick question on -- around partnerships, in particular. I wonder if you could just give us a little deeper dive into how things are going with Rockwell and as well on the simulation side with Ansys?\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. So the state of the partner economy is good and, you know, Microsoft, I could put on that list, is also strong. With Rockwell, you'll remember in the past quarters, I had said we should take a bit of a conservative posture as it relates to what Rockwell would contribute to PTC's numbers here in fiscal '22. And we did that because Rockwell had made a big acquisition.\\nYou know, Rockwell never completely agreed with me on that. Their own public commentary kind of indicated they didn't worry too much about that. And in Q1, they were right. So we're pleased to see that Rockwell's contribution was solid in Q1 and starting to feel pretty good about the year.\\nI'll tell you one thing is this DPM solution appears to be a very good fit with Rockwell. And in fact, their Calypso alarm is probably lined up to be our strongest partner in promoting DPM. So we're very happy with that. Calypso has a long-term relationship with PTC that even predates their acquisition by Rockwell.\\nSo great alignment around DPM. Again, DPM is a high-value up-to-stack solution that drives bigger deal sizes, and we think will be a very sticky solution. So lots of optimism around that. With Ansys, we continue to differentiate now with best-in-class simulation.\\nSo whereas simulation some years back would have been viewed as a soft spot for PTC. Now it's a strength. If we're competing against Autodesk or Siemens or Dassault, nobody is going to have a better simulation story than PTC because nobody has a better simulation story than Ansys, and Ansys products are built into PTC products. So that's been going well.\\nAnd then, of course, with Microsoft, that partnership is performing well and poised to get a lot bigger because as we bring more stuff aggressively to SaaS, a whole lot of that is going to land on Azure. So I think all three partnerships are alive and well and as important as ever and helping us achieve the kind of results that we're achieving.\\u00a0\\nOperator\\nYour last question comes from Sterling Auty from J.P. Morgan. Please go ahead. Your line is open.\\nSterling Auty -- J.P. Morgan -- Analyst\\nYeah. Thanks. Hi, guys. Just wondering if you could characterize with the headcount changes that you pointed out are necessary to facilitate the acceleration to SaaS.\\nWhere are you in that process? What's left to go? And kind of what's the time frame that you expect to complete that over?\\nJim Heppelmann -- Chief Executive Officer\\nYeah, Kristian, I'm thinking of the numbers we're largely done, but not completely. Eighty percent, 90% done.\\u00a0\\nKristian Talvitie -- Chief Financial Officer\\nYep, with the exiting.\\u00a0\\nJim Heppelmann -- Chief Executive Officer\\nYeah. I mean we'll be hiring people throughout the year. So -- but in terms of the people who are exiting, they're largely exited by now that largely happened within the first quarter.\\nSterling Auty -- J.P. Morgan -- Analyst\\nUnderstood. Thank you.\\nOperator\\nWe have no further questions. I'd like to turn the call back over to Jim Heppelmann for closing remarks.\\nJim Heppelmann -- Chief Executive Officer\\nOK. Well, thank you, all. There's a lot of good questions and, you know, I think good answers because the business is performing very well right now. ARR is doing well.\\nBookings are doing well. Free cash flow is doing well. You know, I think we executed -- through good times and bad, we executed through the changes we made over the last quarter, and we're set up to do pretty well for the balance of the year. So, we're very confident and, you know, look forward to talking to you all in 90 days if we don't happen to cross pass with you sooner in an investor event or what have you.\\nSo, thanks a lot for joining us and have a good evening.\\nKristian Talvitie -- Chief Financial Officer\\nThanks, everyone.\\u00a0\\nOperator\\n[Operator signoff]\\nDuration: 59 minutes\\nCall participants:\\nMatthew Shimao -- Head of Investor Relations\\nJim Heppelmann -- Chief Executive Officer\\nKristian Talvitie -- Chief Financial Officer\\nAndrew Obin -- Bank of America Merrill Lynch -- Analyst\\nYun Kim -- Loop Capital -- Analyst\\nJason Celino -- KeyBanc Capital Markets -- Analyst\\nAdam Borg -- Stifel Financial Corp. -- Analyst\\nJay Vleeschhouwer -- Griffin Securities -- Analyst\\nKen Wong -- Guggenheim Securities -- Analyst\\nMatt Broome -- Mizuho Securities -- Analyst\\nMatt Swanson -- RBC Capital Markets -- Analyst\\nSaket Kalia -- Barclays -- Analyst\\nJoe Vruwink -- Robert W. Baird and Company\\nBlair Abernethy -- Rosenblatt Securities -- Analyst\\nSterling Auty -- J.P. Morgan -- Analyst\\nMore PTC analysis\\nAll earnings call transcripts\",\n          \"Prepared Remarks:\\nOperator\\nGood day, ladies and gentlemen, and welcome to ASUR's First Quarter 2020 Results Conference Call. My name is Kathy and I'll be your operator.\\n[Operator Instructions]\\nNow I would like to turn this call over to Mr. Adolfo Castro, Chief Executive Officer. Please go ahead, sir.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and good morning everyone. Thank you for joining us on the conference call to discuss ASUR's first quarter financial and operating results. Before starting the call, I would like to express my hope that you and your families are healthy and safe in these uncertain times. As a reminder, please note that certain statements made during the course of our discussion today may constitute forward-looking statements which are based on our current management expectations and beliefs and are subject to a number of risk and uncertainties that could cause active results to differ materially, including factors that may be beyond our company's control including the impact from COVID-19. For an explanation of these risks, please refer to our filings with the US Securities and Exchange Commission and the Mexican Stock Exchange.\\nOverall, our first quarter results were good. The year began in solid footing before we started to see the impact of COVID-19 pandemic in the second half of March. It resulted in the disruption of global travel industry. Importantly, in the end of the first quarter we had healthy balance sheet which I will come back and discuss in more detail later in my presentation. I'm going to start today's presentation with some comments regarding COVID-19 and the impact on the industry, on our business, and the steps we are taking to mitigate this disruption to the best we can in this rapidly changing environment. From an industry perspective, since mid-March, many governments have issued flight restrictions in an effort to mitigate the spread of COVID-19 virus. In turn, capacity has been severely reduced and very few people are booking flights as most are in some form in lock down around the world and not traveling. With respect to our airports, the situation varies by country and could be subject to change depending upon how fast or slow the pandemic is brought under control. Colombia has been the most active and we've suspended operations at all six of our airports since the third week of March with domestic flights suspended until April 27 in accordance with the published decree and most recently extended to up to May 11.\\nInternational travels have been suspended through May 13. By contrast, in our airports in Puerto Rico and Mexico remain open, although there's significant reduced flights and passenger traffic. As a result, total passenger traffic declined sharply in the second half of March, down nearly 69% year over year between March 16 and March 31. By country, we show the margin decline in Colombia around 77%, followed by Puerto Rico down 73% and Mexico with 63% decrease [Indecipherable]. Additionally starting in mid-March, some of the airlines as well as some tenants that operate in our airports began asking for assistance either through discounts on payments owed to ASUR or by extension by payment which resulted in a higher accounts receivables in March in Mexico and Colombia, up 54% and 78% year-over-year. We are having ongoing commercial discussions with these companies with respect to their contracts.\\nMoving next to action we have taken, starting with health and safety. Following the guidelines of relevant health agencies, we have implemented health and safety protocols for both our airport employees and passengers travelling through our airports. For example, protective gear such as wearing masks is required for airport staff. We have also stepped up disinfectants and sanitization practices, once again in accordance with the guidelines of local health authorities. Lastly, where possible, we have also implemented remote working points.\\nMoving next to ensuring continuity of our business. We have introduced cost reduction initiatives across our airports. The impact of these initiatives however is not expected to be significant vis-a-vis the potential decline in passenger traffic at the majority of the cost structure is different, except for concession fees and technical assistance in Mexico which are biannual cost. We are prepared to take additional step, if needed, to respond to the evolving business environment. Now, let me talk about our financial situation. We entered this quarter in a position of strength with strong liquidity and very low principal payments required through year end. Additionally we believe the company has sufficient liquidity to meet its obligations and continue operating in the normal course of business. Our cash position ended at MXN7.8 billion which was up from MXN6.2 billion at the year-end 2019. And subsequent to the quarter end, as we further strengthen our financial positions as our subsidiary in Puerto Rico drew down an additional $10 million of its committed line of credit. The line of credit [Indecipherable] support for the capex projects we have under construction, Apelian airport in Puerto Rico.\\nWe closed the quarter with total debt of MXN15.3 billion. Although 11% high than the year-end 2019, this was due to the conversion effect from the depreciation of the peso to the dollar. As a reminder, the majority of our debt, 54% is denominated in the US dollars which is at our subsidiary in Puerto Rico. 26% of total debt was denominated in Mexican pesos and 20% in Colombian pesos. We have principal payments of only MXN432 million coming due over the next three quarters. This represents less than 3% of ASUR's total debt. With respect to that ratios, net debt to last 12 months EBITDA stood at 0.7 times at the close of first quarter '20. You can see the interest coverage ratio by country in the table we have included in the annual release this quarter.\\nNow, stepping back for more, since we began operations over 20 years ago, we have successfully navigated through many very significant challenges. From the 9/11 event in 2001 to [Indecipherable] into 2005 and 2008 and 2009 business financial crisis, H1 and H2 and the bankruptcy of 50% of airlines in Mexico which cut planes capacity in Mexico by more than half. Following each of these events, passenger traffic recovered, although recovery time varied from 13 months to 26 months and then continued to grow. Between 2000 and 2019, annual passenger traffic increased the compound annual growth rate of 6.6%, up from slightly over 10 million to historical high to over 34 million last January. We believe the COVID-19 pandemic is unique in that sense it is global event and with a broad disruption in travel and economies worldwide and could change the way of travelling in the future while a vaccine or a cure is found. Summing up this section, we have a strong balance sheet, we have generated years of consistent profitability and we exercise prudent capital management. In the sense we believe that we cannot be very prepared for an event of this magnitude, but of course given its great uncertainty on the final effects in the worldwide economy and that travel will be [Indecipherable].\\nNow turning to our first quarter results, more details can be found in the press release issued last evening. Like I mentioned this part of my presentation, let me spend with the effects of the business in late March. We believe we had solid results in the first quarter 2020. Total passenger traffic was down in most of the airports, which leads to a total passenger decrease of slightly 6% YoverY. This was primarily due to the fallout from COVID-19 and the impact of the global travel industry beginning in the second half of March. Our airports in all three countries experienced total passengers decline from a low of nearly 3% in Colombia to a high 8% in Mexico. Puerto Rico passenger traffic was down 4%. All three countries reported declines in both domestic and international traffic.\\nMoving next to the P&L highlights, revenues ex construction were relatively unchanged at 4% increase in revenues from non-aeronautical services was offset by a 3% decline in aeronautical revenues. Commercial revenues per passenger increased 11% year over year, reaching MXN116.3. This was driven by solid performance across the region. Mexico posted a good performance with an increase of 11% on a per passenger basis benefiting from the currency peso devaluation and regulated revenues. Puerto Rico posted 7% increase per passenger benefiting from peso depreciation and finally Colombia saw a 33% increase on a per passenger basis, reflecting the 43 new stores opened over the last year and currency depreciation. The main drivers were ground transportation and car rentals.\\nMoving on to profitability, reported consolidated EBITDA increased 3% from the same period over the prior year. Both periods benefited from insurance recoveries related to the Hurricane Maria. In the first quarter '20, it amounted nearly MXN124 million while last year the amount was dragging over MXN41 million. Excluding these recoveries, consolidated EBITDA was essentially flat year-over-year at MXN2.7 billion. Ex-IFRIC 12 and without taking into account insurance recoveries in both quarters, adjusted EBITDA margin increased 20 basis points to 66.7% this quarter.\\nA few comments about capital allocation. Capital expenditures were MXN353 million in the quarter. Of these, nearly MXN58 million was allocated in Mexico due to the terminal expansion of Merida airport. For the full year, and as we have discussed before, our non-prevalent plan in Mexico calls for investment of approximately MXN5.3 billion for the full year. At the current time, there are no changes to the planned continuation of the foreigners tax relief of the second one we have at Cancun airport and the beginning of the first expansion at the Merida. Our plans call for a conclusion of Phase 1 of the Merida terminal expansion and typically the second phase this year. Nevertheless, due to the COVID-19 health crisis, you may see some disruption in the construction process, attributable to stay-at-home, the combination and we have informed the government about this situation. In Puerto Rico we have made investments of MXN114 million this quarter, mainly from the connection with some major maintenance referred tax relief. Finally, capex in Colombia amounted to MXN1 million related to maintenance. Last year we concluded our committed capex was at MXN20 million. And going forward, we only expect to incur a major maintenance capex in Colombia.\\nNext, our Annual General Meeting from yesterday, shareholders approved an ordinary net cash dividend of MXN8.1 per share to be paid, subject to the Board's approval on or after May 11, 2021 in a single installment.\\nIn conclusion, we are proactively responding to the developing situation. No one can control the virus or even the economic fallout. But we can control how we react to the crisis. I am optimistic about the prospects for the future both navigating through the current crisis and in the long term recovery. I believe that we are well positioned with a healthy balance sheet. We had a solid first quarter results. We believe in the strategies that we are executing.\\nThis ends my prepared remarks. Kathy, please open the lines for questions.\\nQuestions and Answers:\\nOperator\\n[Operator Instructions]\\nWe'll go first to Alejandro Zamacona of Credit Suisse.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nThank you Adolfo, thanks for the call. Two questions from our side. The first one is on the aeronautical maximum tariff. So, considering that airlines have been negotiating with most of airports and in some cases some fees have not been charging. What could we expect for maximum tariffs in the short-term meaning the second quarter and in the immediate term, meaning year end 2020? Could we still expect tariffs to be close to the maximum level?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro, hi, good morning. Well, basically what we are seeing today is a very reduced demand. So we believe that there is no effect if we try to reduce our fees for the month of April or the month of May. So we have maintained our tariffs and we believe that we can comply with -- we have to maintain compliance toward the year end.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you. And my second question is on the non-aeronautical business. Same thing in the same context, what could we expect in the short term for commercial revenues per passenger? Have you grant any rent payments facility to payments or any deferrals? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nMost of our contracts, as you may know, they have to pay higher of the minimum guarantee payment per passenger or a percentage of sales. So if we do not have passengers, we will not have to pay rent. So it's made automatically. So in that sense, we are not reducing or adjusting the contracts.\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nOkay, thank you Adolfo.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nWe will now take a question from Fernando Sanchez of Bradesco BBI.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nHi, good morning and thanks for taking my question. My question is light of the likelihood of the GDP contraction beyond 5% I just wanted to ask if you have had the opportunity to discuss with the authorities the possibility of delaying the 2021 and the key mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. Well as you are aware, the contract has a clause that says that the maximum tariff can be reviewed in the case of Mexico in an external way. When on the Mexican GDP drops by more than 5% in a year and that's happened in fact on track. Of course with the current circumstance and the current expectations from analysts, it is possible that the Mexican GDP will drop by more than 5% this year. So in that sense, we will be we -- and the possibility of review our maximum time in an external rate. That's for next year, but not this year.\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nOkay. Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nAnd now, we'll take a question from Carlos Peyrelongue of Bank of America.\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nThank you. Good morning Adolfo. Thank you for the call. On the something I couldn't hear well because of the connection but can you comment as to whether the dividend will be kept or there is the possibility of cutting the dividend until we have more sense about passenger traffic? That would be the first question. And the second would be related to cash burn, if you could give us an idea of what your cash burn is on a quarterly basis, just to get a sense of compare that primarily to your strong cash position. Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYes, of course. In the case of the dividends, yesterday we held Annual Shareholders Meeting, they have sadly approved the dividend that it was proposed MXN8.1 per share. But it was -- this was subject to the approval from the Board to the moment of the payment that's from May 11, 2021. So the Board will have to approve when this dividend will be paid. In the case of the cash burn, what I said to you during the initiative months, is that our currency structure is basically fit. The only variable pieces are the technical assistance fee and the concession fees we paid to the government. So we are working and just to remember the case of Mexico is 5% as well as in Puerto Rico, and in the case of Colombia its' 19%. So this of course will reduce -- our passenger traffic is reduced and our income gets reduced. The remaining is basically, of course, we are taking measures to try to reduce as much as we can, all the expenses in the companies. But as I said, at the end, in the overall picture, the cost reduction will not be significant in comparison with reduction in the revenues of the company.\\nOperator\\nAnd we'll run to our next question, and that will come from Andressa Varotto of UBS.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much for taking my question. So my question is if have plans to negotiate with the government postponement of the mandatory capital is this possible? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nCould you repeat the question? I couldn't hear you.\\nAndressa Varotto -- UBS -- Analyst\\nYes. So my question is if you plan to negotiate with government the postponement of mandatory capex?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said before, in accordance with the contract, we do not have that possibility this year. But of course, with the given standards [Phonetic] and as I said it in my initial remarks, during an expansion situation and that expansion situation is that some companies have stopped operations [Indecipherable] and that it was reactivated later on, but there was a decree from the Mexican government that also named the steel and glass that is produced in the country will be used for the project. So in that sense, at the moment it's almost impossible for us to expand our 10-year buildings without these material. So we have this situation to the government. So for the moment, what we see is that we will see some disruption in our construction process for some months and then we will have to talk about these with the government. That's what I can share with you for the moment on this respect.\\nAndressa Varotto -- UBS -- Analyst\\nThank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nYou're welcome.\\nOperator\\nOur next question will come from Stephen Trent of Citi.\\nStephen Trent -- Citi -- Analyst\\nGood morning, Adolfo and thanks very much for taking my question. Hope that you and your family are well. Just one quick one for me, I know that it seems that Mexico apparently has not been that active in likely offering any assistance to the corporate sector. What are you hearing from Colombia? Kind of any indications from them with respect to whether aviation industry will get some sort of relief?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nSteve, thank you for your question. So in the case of Colombia in comparison with Mexico they have been more active in the measures that they have been taking. As I said here in the report they were very [Indecipherable] basically closing or sorting down everything as from March 23. And that can be seen in terms of results. In the case of Spain and the active they have in comparison with active cases we have in Mexico. So their curve is decreasing or at least flattening while the Mexican curve is still increasing. In terms of what they have said for our industry, we have been closed since March 23 and they have issued decrees in that respect. Maybe this week, there was a new announcement from the President expanding the process of shutting down everything. As I said in my remarks, for the case of domestic aviation that will be close up to May 11 and in the case of international up to May 30. It is important to remember that in the case of Colombia, 85% of aviation is domestic and 15% is international. That's what we know as of today. Of course all of these may change depending on how fast or how slow they can control the virus in their country.\\nStephen Trent -- Citi -- Analyst\\nThank you very much Adolfo. Apologies I couldn't hear all of your remarks. But no indication at this point for example that Columbia's planning a kind of tax relief for aviation or something along those lines offering kind of financial support.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nWell we have not heard anything above that yet.\\nStephen Trent -- Citi -- Analyst\\nOkay. Appreciate that. I'll let someone ask a question. Thanks Adolfo.\\nOperator\\nAnd next we will go to Gabriel Himelfarb of Deutsche Bank.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nHi, good morning, thanks for the call. I have two questions. The first one is concerning about account receivables. Can you give us like a number or approximate number about what's the total of the sales coming from airlines and in specific from Interjet and American Airlines and my second question is do you think you could obtain some waivers in opex sorry capex your current MDP in Mexico and could you will be able to extend the life of the concession in Colombia?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nHi, good morning. In terms of the account receivables you can see those in our report, revenue increase in the case of Mexico and Colombia, most of the increase is coming from the land industry. I do not have the details of American Airlines and Interjet you are requesting. In terms of the capex, as I said before, we have informed the government about this current situation. We don't know if they are going to react in that respect. But of course it's going to be almost impossible for us to construct and expand our buildings with that material. So more or less what I say to you.\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nOkay, thank you.\\nOperator\\nAnd now we will go to Ruben Lopez of Santander.\\nRuben Lopez -- Santander -- Analyst\\nHi Adolfo, thanks for the call. My question is on commercial revenues. Sorry if you commented on these. But I understanding Cancun operating in just one terminal. So I want to confirm you how are your operations there in Cancun and what are the implications on commercial operations? Are there any penalties with the tenants? What are negotiations here? That's the first one. And the second one is related with the same topic. When we see commercial revenues and we kind of try to compare current levels versus what would be the fixed amount or the fixed part of the minimum payment. I mean can you give us any sense of the guidance here? Thank you.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nOkay. As you have said, yes, in the case of Cancun, we have closed two terminals and we are just operating today in terminal 4. So all the operations of airport have been concentrated there in order to reduce on one side the expenses and of course on the other side be better prepared in the case of these reduced demand. All the stores are working in the case of terminal 4. So terminal 4 is operating as it was before the event. As I said before, most of the contracts, the financial contracts we have with the tenants are related to a minimum guarantee payment passenger. So once again, they do not have, let's talk about one of the deals that is closed. So if they do not have passenger traffic in terminal 2, they almost have to pay the rent. Of course when they operate in terminal 4 their operations will be in the accordance with the amount of passengers we have in that facility. So I would say terminal 4 is operating normally.\\nRuben Lopez -- Santander -- Analyst\\nThank you. And when you compare, sorry, the current level of commercial revenues versus what would be the minimum payment from the contract, can you give us any idea on that?\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAs I said, minimum payment -- the contract is on a per passenger basis.\\nRuben Lopez -- Santander -- Analyst\\nPerfect, thank you.\\nOperator\\n[Operator Instructions]\\nAnd we will now go to Jorge Larocco of Morgan Stanley.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nHi Adolfo, good morning. Thank you for the questions. It's two questions, actually a pretty general question, I was just wondering if you could provide more color on what are the main initiatives regarding our cost reduction efforts. How are those working down, your payment reductions on paid leave of absence, maintenance cost, utility costs, etc. and how are those playing out so far? Thank you very much.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThe main initiatives of course are related to in the case of Cancun in the terms of amounts. So we these key terminals closed, we are not burning the same amount of energy as if they were open. Also in the case of Cancun, we are in the process to shut down and one of the runway because today in accordance with the [Indecipherable] it's not needed. So, that runway will be turned off in terms of light at night also reducing their energy we will have to pay. And in terms of some other measures we are taking, adjusting some of the contracts of nature or mainly maintenance in the case of the buildings are closed and to try as much as possible to reduce operating cost and expenses. But I once again at the end, most of our cost is fixed. So if we apply the cost structure of the company, the most important lines are personnel and utility costs as we have said so. In the case of personnel, we are maintaining the personnel for the event or the crisis and in the case utilities, we are trying, as much as we can to try to reduce that.\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nThanks so much Adolfo. Stay safe and have a good day.\\nOperator\\nAnd with that, that does concludes the question and answer portion of today's conference call. I would like to turn the call back over to Mr. Castro for closing remarks.\\nAdolfo Castro Rivas -- Chief Executive Officer\\nThank you Kathy and thank you again for participating in our fourth quarter results conference call. On behalf of ASUR, we wish you good day and until we meet, be safe. Good bye.\\nOperator\\n[Operator Closing Remarks]\\nDuration: 34 minutes\\nCall participants:\\nAdolfo Castro Rivas -- Chief Executive Officer\\nAlejandro Zamacona -- Credit Suisse -- Analyst\\nFernando Sanchez -- Bradesco BBI -- Analyst\\nCarlos Peyrelongue -- Bank of America -- Analyst\\nAndressa Varotto -- UBS -- Analyst\\nStephen Trent -- Citi -- Analyst\\nGabriel Himelfarb -- Deutsche Bank -- Analyst\\nRuben Lopez -- Santander -- Analyst\\nJorge Larocco -- Morgan Stanley. -- Analyst\\nMore ASR analysis\\nAll earnings call transcripts\\n\\n\\n\\n\\n\",\n          \"Prepared Remarks:\\nOperator\\nHello, and welcome to the Globus Medical fourth quarter and full year 2021 earnings call. [Operator instructions] I will now turn the call over to Brian Kearns, senior vice president of business development and investor relations. Mr. Kearns, please go ahead.\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nThank you, Chris, and thank you, everyone, for joining us today. Joining today's call from Globus Medical will be Dave Demski, president, and CEO; Dan Scavilla, executive vice president and president of Ortho; and Keith Pfeil, senior vice president, and chief financial officer. This review is being made available via webcast accessible through the investor relations section of the Globus Medical website at www.globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements.\\nOur Form 10-K for the 2021 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today. Our SEC filings, including the 10-K, are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP.\\nWe believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are available on the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Dave Demski, our president, and CEO. \\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Brian, and good afternoon, everyone. Globus finished an outstanding 2021 with a strong fourth quarter performance. Revenue for the year was a record $958 million, an increase of 21% over 2020 or $169 million in growth. To put that in perspective, our growth dollars alone would have ranked us in the top 10 spine companies in the world.\\nRevenue in 2021 was 22% higher than 2019, an outstanding performance in itself, given the disruption caused by COVID but magnified further by a recent independent research report showing that each of the other top 6 spine companies actually had sales declines over that same time period. We achieved record sales and growth while maintaining industry-leading profitability, generating a record $2.04 in non-GAAP EPS, a 42% increase over 2020, and adjusted EBITDA of 34.6% even as we invested heavily in INR, trauma, and competitive recruiting. Revenue for the quarter was $250 million, up 7% over 4Q '20 as COVID-related headwinds remained strong throughout the quarter. Non-GAAP EPS was $0.49 per share, a 16% decrease compared to the artificially high 4Q '20.\\nNot only were business travel and surgeon education activities severely curtailed last year, several other nonoperational factors, as Keith will expound upon in his remarks, also impacted the decline. Adjusted EBITDA in the fourth quarter was a strong 34%. Enabling technology continues to gain momentum, producing a record $25 million in revenue for Q4, an increase of 40% over 4Q '20. For the full year, enabling technology revenue was $81 million, an outstanding 100% increase over 2020.\\nThe clinical superiority of ExcelsiusGPS is the primary factor driving this growing momentum. Robotic utilization, which is the number of cases performed per installed robot, was at an all-time high in 2021. And nearly 30,000 procedures have been completed using ExcelsiusGPS technology since launch. Our spinal implant business continues to experience the flywheel effect of an increasing number of robots being sold combined with increasing utilization of each robot.\\nOur U.S. spine business grew by 3% in Q4 as COVID-related shutdowns had a significant impact throughout the quarter. We saw this trend continue into January, but all signs point to a rebound commencing late in Q1. For the full year, the U.S.\\nspine business grew by 18% as we continued to take significant market share. Robotics pull-through, coupled with contributions from recent product introductions and competitive recruiting, were all factors driving growth. Our international spine implant business grew by 9% in the quarter, a remarkable result in light of COVID impacts and an ongoing drag from Japan. Due to the impact of strategic moves we made in Japan last year, we expect to see continued declines there through the first half of 2022 with growth to follow off a reset baseline.\\nThis should result in accelerated overall international growth in the second half of this year. Trauma revenue was up 32% in the fourth quarter and 39% for the full year. Competitive recruiting and new product launches are driving growth. The Anthem Mini Frag system was launched on a limited basis in Q4 with excellent feedback from surgeon users.\\nWe are proceeding to full launch in Q1 and have a series of impactful product launches planned for the first half of 2022. The clients have launched the Excelsius 3D imaging system on a limited basis later this quarter with a full launch following in late Q2 or early Q3. There is tremendous anticipation and excitement about this technology among surgeons, and we already have double-digit orders signed. The Excelsius ecosystem, Globus Medical's unique combination of robotics, imaging, and freehand navigation that provides a seamless, scalable, and unmatched clinical experience for surgeons is about to become a reality.\\nI'm extremely proud of our team's performance in 2021, record growth and profitability, exciting, clinically impactful new technology introductions, and an unmatched focus on providing value to surgeons and their patients. Thank you for a great year. I will now turn the call over to Keith.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you, Dave, and good afternoon to everyone joining us for today's call. Globus capped off a record 2021 with a robust Q4 performance despite ongoing COVID-related disruptions and shutdowns. For the full year, 2021 revenue was $958.1 million, growing 21.4% as reported. On a day-adjusted basis, sales grew by 22.1%, with two fewer selling days in the U.S.\\nand international. Net income was $149.2 million, resulting in fully diluted earnings per share of $1.44. Non-GAAP net income was $211.4 million, generating a record $2.04 of fully diluted non-GAAP earnings per share. Adjusted EBITDA was 34.6% for the year, and we generated a record $219.4 million of free cash flow for the full year.\\nQ4 '21 revenue was $250 million, growing 7.1% as reported and 8.5% on a day-adjusted basis with one less selling day in the U.S. and international compared to the prior-year quarter. Net income was $15.1 million, and non-GAAP net income was $51.1 million. Our Q4 diluted -- fully diluted earnings per share was $0.14, while our fully diluted non-GAAP earnings per share was $0.49.\\nAdjusted EBITDA was 34.1%, and we generated $59.2 million of free cash flow for the quarter. Taking a deeper dive into sales. Q4 U.S. revenue was $213 million, 7.2% higher compared to Q4 of 2020 driven by our INR and U.S.\\nspine businesses. International revenue for Q4 was $37.1 million, growing 6.8% over the prior-year quarter led by growth in spinal implants despite lingering COVID impacts and the impact of our strategic changes in Japan as Dave mentioned earlier. On a constant currency basis, international revenue grew by 8.7%. Q4 gross profit was 75.3% versus 73.9% in the prior-year quarter.\\nThe 140 basis point improvement was driven primarily by nonrepeating inventory reserves in the prior-year quarter and was consistent with our expectations noted in our Q4 2020 earnings commentary. Full year 2021 gross profit was 75%, compared to 72.4% in the prior year. The increase in full year gross profit is primarily the result of lower inventory reserves and operational and supply chain efficiencies, partially offset by sales mix. Looking ahead to 2022, we project a mid-70s gross profit rate.\\nResearch and development expenses in Q4 were $51 million or 20.4% of sales, compared to $15.2 million or 6.5% of sales in the prior-year quarter. The increased spending is primarily reflective of in-process research and development acquired during the quarter. Adjusting for these costs, Q4 2021 research and development expense was $16.7 million or 6.7% of revenue, in line with the prior-year quarter as a percentage of sales, but $1.5 million higher driven by incremental investments in headcount across our spine, INR, and trauma businesses. Our full year 2021 research and development expenses were $97.3 million or 10.2% of sales, compared to $84.5 million or 10.7% of sales in the prior year.\\nAdjusting for the acquisitions made in both periods, research and development expenses were $63 million or 6.6% of sales in 2021, compared to $60.1 million or 7.6% of sales in 2020. The increase in spending is reflective of our continued investment in research and development to foster future growth and is consistent with comments made earlier in the year. We expect our R&D expenses to be approximately 7% of sales in 2022. SG&A expenses in the fourth quarter were $106.6 million or 42.6% of sales, compared to $92 million or 39.4% of sales in the prior-year quarter.\\nThe resulting increase is reflective of higher sales compensation and benefit costs as well as increased travel and training expenses driven by the resumption of normalized travel levels following the COVID-19 impacts experienced in the prior year. Full year SG&A expenses were $408.1 million or 42.6% of sales, compared to $354.8 million or 45% of sales in the prior year. The resulting decrease as a percentage of sales is reflective of leverage on fixed costs as a result of the higher volumes when comparing against the COVID impact in 2020. The income tax rate for the quarter was 23.8%, compared to 14.9% in Q4 of 2020 with the resulting increase driven primarily by lower tax benefits associated with stock option exercises.\\nOur full year 2021 income tax rate was 17.3%, slightly lower than the 18.8% in 2020 driven primarily by the nonrecurring tax treatment related to a 2020 acquisition, partially offset by lower tax benefits associated with stock option exercises. Looking ahead to 2022, we expect our effective tax rate to be approximately 20% for the full year, which assumes no significant changes in the current U.S. tax policy. Fourth quarter net income was $15.1 million, and non-GAAP net income was $51.1 million.\\nQ4 diluted earnings per share was $0.14, and non-GAAP diluted earnings per share were $0.49, compared to $0.58 in the prior-year quarter. The quarter-over-quarter decrease is driven by more normalized levels of travel, trainings, and meetings noted above or noted earlier as well as nonoperational items, primarily a higher tax rate as previously mentioned, higher stock compensation expense, and lower interest income. Looking ahead to 2022, we are expecting a mid-30s adjusted EBITDA rate. Full year diluted earnings per share were $1.44, and non-GAAP diluted earnings per share were $2.04, reflecting a 42.2% increase over 2020 primarily related to higher sales volumes following the 2020 impact of COVID-19, partially offset by approximately $0.09 of nonoperating headwinds related to a higher share count and lower interest income.\\nQ4 adjusted EBITDA was 34.1%, compared to 36.2% in the prior-year quarter. Full year 2021 adjusted EBITDA was 34.6%, compared to 29.4% in 2020. Net cash provided by operating activities were $76.3 million for the fourth quarter and a record $276.3 million for the full year 2021. Free cash flow was $59.2 million for the fourth quarter and a record $219.4 million for the full year 2021.\\nThe company remains debt free. At this time, the company is establishing full year 2022 guidance. We are projecting full year 2022 sales guidance of $1.025 billion, representing 7% growth versus 2021. We are guiding to a full year fully diluted non-GAAP earnings per share of $2.10, representing 3% growth versus 2021.\\nI note that the 2022 guidance includes approximately $0.10 of nonoperating headwinds, including higher shares worth $0.04, a higher tax rate worth $0.03, and higher stock compensation expense worth $0.03. Adjusting for these nonoperational factors, our 2022 guidance would have been $2.20 or 7.8% higher than 2021. Overall, we view this guidance as appropriately conservative and reflective of the current operating environment around COVID and inflation-related impacts. Our 2021 results represent our teamwork, our commitment, and our focus on execution.\\nWe continue to differentiate ourselves in the marketplace. And it is a testament of the hard work and dedication of each of our Globus employees. We remain excited for the future as we continue on our mission of improving patient care. Operator, we will now open the call for questions.\\nQuestions & Answers:\\nOperator\\nThank you. [Operator instructions] Our first question comes from Matt Miksic of Credit Suisse. Your line is open.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks so much for taking the questions and congrats on a really strong finish to a pretty amazing year, given the circumstances. I wanted to follow up on some of the comments around EPS guidance, in particular. As you pointed out, there are some items that ex those items, up 7% to 8%.\\nCan you talk a little bit about where in your guidance you're contemplating things that some of the other companies in the space have talked about like rising input costs, staffing challenges, labor costs, freight, etc., things that generally are driving operating costs up a little bit? Maybe give us a sense of how those figure into your guidance? And I have one quick follow-up.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks. This is Keith speaking. So we projected our guidance at $2.10. And as we look at the year, we see inflation as a market event.\\nEveryone is experiencing it, and we have it baked in our numbers. But when you step back and look at the $2.04 and the $2.10, I commented on the $0.10 of the nonoperating headwinds. But the other things that are impacting the business as we think about getting back to more normalized levels of spend are really the travel and the trainings that go along with the surgeons and [Inaudible] that we provide. That's worth going into the next year likely an $0.08 headwind.\\nAnd then one of the things that we commented on earlier in the year was our continued investment into R&D. As you look into next year, we're seeing roughly I would say, call it, $0.04 of additional investment in R&D. When you look at those things together, coupled with the inflation, we're landing at about $2.10.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And can you just maybe just elaborate a little bit on the spend or R&D and sort of the expectations for returns in terms of growth or programs that you're investing in?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nSo we're continuing to invest heavily in our spine business and as well as our robotic businesses. We talked about that in Q1 of our earnings call earlier in the year, and really all sign points to us continuing to do that. Dave talked earlier about some of the benefits that we're seeing for robotic technologies. We continue to invest in that and really grow for the future.\\nMatt Miksic -- Credit Suisse -- Analyst\\nOK. And then just one quick follow-up I had was on the environment for robots and spending in capital and equipment in general. Some of the other, again, companies in the space have talked about a fairly strong year for equipment, a strong year for robots. Any sense of whether this is something that needs to sort of take a breather or catch up here in 2022? Or whether orders and demand and pipeline for new deals would indicate just continued strength into 2022?\\nDave Demski -- President and Chief Executive Officer\\nYeah. Matt, this is Dave. No, it's very strong. I don't see anything laying off.\\nIn our case, in particular, it's been accelerating. I think the demand for Excelsius has been strong, and it's becoming more and more common. The narrative has changed from why robotics to which robot. And I think we're clearly establishing our lead there.\\nAnd then as I mentioned, there's a lot of enthusiasm over our Excelsius 3D system, which is going to launch later this quarter. We've had every surgeon we show that to seems like they want one. So I don't see it backing off at all.\\nMatt Miksic -- Credit Suisse -- Analyst\\nGreat. Thanks and congrats.\\nDave Demski -- President and Chief Executive Officer\\nThank you.\\nOperator\\nThank you. Our next question comes from Matt Taylor of UBS. Your line is open.\\nMatt Taylor -- UBS -- Analyst\\nExcuse me. Hi, guys. Thanks for taking the question. So I wanted to ask the first one about margins longer term.\\nMaybe just talk about the difference between what you're doing this year with some of the investments and obviously, headwinds year over year from spending back to normal and inflation, and how we should think about margins longer term? Would you start to get more leverage at some point? And what would the inflection point for that be?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. It's a good question. But as I look at where we're at and where we're going, our goal is to always maintain a mid-70s GP. But as we look longer term and look at our EBITDA rates, we're always looking to be in that mid-30s range.\\nWe could toggle our investments in various parts of our business to really achieve that, but we're investing now to drive growth -- to drive top-line growth for the future. And as we get that growth, that's going to create more fixed cost leverage in our P&L. So I think by doing that, investing for growth today helps project the margins going forward. I feel that we're going to work to try to stay in that range.\\nDave Demski -- President and Chief Executive Officer\\nYeah. I can add a little bit maybe to that, Matt. In the spine business, I don't think you'll see much greater improvement in our margins there, but we have a lot of operating leverage in front of us in the orthopedic side of the business and the capital side. Those are both fairly nascent businesses for us, and we're funding it with spine.\\nBut once we start to hit some volume numbers there, I think those businesses will definitely expand.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Can I ask a follow-up on the robotics strength? I mean, you talked in the past about getting pull-through on these placements, and obviously had a great year in 2021 with enabling tech. I guess are you still seeing the same kind of trends? And could that bode well for pull-through implants in '22?\\nDave Demski -- President and Chief Executive Officer\\nYes. It does. We're seeing that generally the same kinds of trends. And as a company, we're focusing on really going back to that installed base and seeing we can get more users to utilize the technology once it's placed in the hospital.\\nAnd that's a big focus for us in 2022.\\nMatt Taylor -- UBS -- Analyst\\nGreat. Thank you, guys. Thanks so much.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And next, we have Shagun Singh of RBC. Your line is open.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGreat. Thank you for taking the question. I guess my first one is on Excelsius 3D imaging system. Can you talk to us about the delay? Why is there a delay in the launch? And then just elaborate on your go-to-market strategy.\\nAre you targeting the replacement opportunity or greenfield? You're obviously going after a major competitor. So just any color there would be helpful. And then on the recon robotics, do you still plan to launch that in the second half? And then I have a quick follow-up.\\nDave Demski -- President and Chief Executive Officer\\nWell, thank you, Shagun. I'll try to knock those off one by one. In terms of the delay, it's just taking longer than we thought. It's nothing significant in terms of the technology hurdle to get over.\\nThere's just a lot to do to get that over the line. So I wish we were a bit earlier but very confident we can get it done this quarter. Go-to-market. I think initially, we're going to be targeting our installed base of Excelsius users.\\nThose are -- there's a high demand among them. It's going to make those procedures much more efficient and much easier for them to do. And then from there, we'll be branching out to target more of that free-hand navigation market that you alluded to earlier. And then I apologize, I forgot the last part of your question.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nI was just wondering if you plan to launch the recon robotics platform in the second half of '22 like you had previously indicated?\\nDave Demski -- President and Chief Executive Officer\\nNo. That's been delayed as well. We're going to be -- early '23 is the target for that.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nGot it. And then just as a follow-up, I was wondering if you could talk about trends that you're seeing on the procedure volume side in Q1, so in January and February. And spine typically has a high pain burden, so procedures come back quickly. So do you expect the recovery to come in Q1? Or do you expect a longer tail given staffing shortages? Thanks for taking the question.\\nDave Demski -- President and Chief Executive Officer\\nSure. Yes, January was really bad, but we've already started to see it turning in February. The last three weeks have all been progressively higher. Not back to where we want it to be, but definitely, I think we've hit bottom.\\nWe're going in the right direction. And I'm not going to try to predict what's going to happen with COVID though. That's proven to be frivolous for everyone, but it's encouraging where we are right now.\\nShagun Singh -- RBC Capital Markets -- Analyst\\nThank you.\\nOperator\\nThank you. And next, we have Matthew O'Brien of Piper Sandler. Your line is open.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat. Thanks for taking the questions. I guess, Dave, just for starters on the top-line guidance. This time last year, you guided about $35 million below The Street.\\nWe end up doing well above what you initially guided and actually what The Street was modeling. And this time, you're guiding about $25 million below The Street. I know January was soft, and maybe Excelsius 3D has pushed a little bit in terms of the contribution. But are there other factors that we should be thinking about? I don't know if it's a rep hiring perspective or a robot perspective that gives you a little bit more caution versus kind of where The Street was modeling things?\\nDave Demski -- President and Chief Executive Officer\\nThanks, Matt. I'm sorry we don't pay that much attention to The Street. We look internally to our own forecast, and we always want to be appropriately conservative going into a year. I feel really confident in the business.\\nThe U.S. spine business has been just cranking away. The robotic momentum is there. We're going to have 3D out this year.\\nJapan is going to turn around in the second half. So I feel really good about the business. We just have taken a very conservative approach over the years when we give guidance, and we're doing that again.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nOK. Fair enough. And then the follow-up is on acquisitions. Sorry if I cut somebody off there, but there's been some talk about you guys doing a scale acquisition.\\nI'm curious if you have any thoughts about the need for scale in spine. And then if not, there's some pretty interesting assets still in the spine space, but more on the pain management side of things. Are those higher on the list in terms of things that you potentially are looking at from a acquisition perspective?\\nDave Demski -- President and Chief Executive Officer\\nNo. It's actually a bit different. We're more active in terms of growing the business through BD and on the orthopedic side of the business. I think we're really strong in spine, and there's really nothing in spine that's of interest to us at the moment.\\nWe're more focused on growing the other piece of our business, which is smaller. There's nothing, I would say, transformative in our sights right now. But we are looking at several modest-sized deals as been our history in the past.\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nGreat.\\nDave Demski -- President and Chief Executive Officer\\nDid that answer your question?\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nYep. That's perfect. Thank you.\\nOperator\\nThank you. Next, we have David Saxon of Needham. Your line is open.\\nDavid Saxon -- Needham and Company -- Analyst\\nYeah. Hi, guys. Good afternoon, and thanks for taking the questions. Maybe one on enabling tech.\\nI mean, it doubled this year, and you've really built out the enabling tech platform with hub and 3D, etc. How should we think about those launches kind of starting to ramp? And could '22 be another double?\\nDave Demski -- President and Chief Executive Officer\\nYeah. I think as I said, we're going to get some -- a few units out this quarter and kind of a soft launch, if you will, with the full launch starting in probably end of Q2, it might be into Q3 and then strong in the second half of this year. I don't want to comment on the double. It's -- we don't really drill into the components of our business.\\nI can tell you that we're really excited about what we're seeing from our technology, from the adoption of our technology and not only what's right in front of us, but some things we have coming after that.\\nDavid Saxon -- Needham and Company -- Analyst\\nOK. Got it. And then maybe on trauma, kind of how close are you to having a full portfolio there? And then in terms of growth, 32% in the quarter. Is that sustainable in '22? Thanks for taking the questions.\\nDave Demski -- President and Chief Executive Officer\\nSure. The bag in trauma is by the second half of this year, I think full is kind of interesting term. We're going to have enough in our bag to be a full-line player and be able to compete with the major companies by the end of this year. And is that growth rate sustainable? Yes, I think that's certainly achievable in 2022.\\nDavid Saxon -- Needham and Company -- Analyst\\nGreat. Thank you.\\nOperator\\nThank you. Next, we have Craig Bijou of Bank of America. Your line is open.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nHey, guys. Thanks for taking the questions. Maybe a follow-up on top-line guidance and to the extent that you guys are willing to share. I mean, how to think about the contributions from each of the businesses? I know generally, you've been reluctant to share that info.\\nBut in terms of the composition of the guidance, how do we think about that incremental revenue coming in? Where is it coming from and to what extent?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. As Dave said earlier, we're not going to get a ton into the parts and pieces. But what I will say is if you look at the business, whether by musculoskeletal and INR or you look U.S. versus international, the parts and pieces of our business we continue to feel extremely positive about as we look into 2022 and beyond.\\nWe're investing in our business. We're driving investment for the future, and we feel that we'll see that turn out to us taking share and driving sales growth. I alluded to my earlier prepared comments that our guidance is appropriately conservative, but there's nothing that I sit here and feel that we have kind of an ongoing issue that I would be concerned about our ability to grow across our business, like I said, whether it's U.S., international or musculoskeletal versus INR.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGot it. Thanks, Keith. That's helpful. And then, Dave, I think you alluded to it, but I wanted to ask more specifically how to think about some of the new product rollouts? Obviously, you have 3D coming out and launching this year.\\nBut from a new product perspective, is it -- do you have a number of launches coming this year on the spine side? Do you have a number coming on the INR side? Just maybe a little bit more perspective of what to expect during the year.\\nDave Demski -- President and Chief Executive Officer\\nSure. Thanks, Craig. I think we've been pretty clear that it's a big one coming with 3D followed by our hub [Inaudible] offering. I think spine, we are typically 10 to 12 launches a year, and that's currently our target going into 2022.\\nTrauma is probably the real bright spot. There is a number of products that we were working on for a while, they're going to hit the early part of this year and through this year. So -- and then our orthopedics business actually has some launches as well. So that's kind of who we are and who we're going to be.\\nAnd it's -- the number one focus of the company is to drive great technology.\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nGreat. Thanks for taking the questions, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. Next, we have Ryan Zimmerman of BTIG. Your line is open.\\nRyan Zimmerman -- BTIG -- Analyst\\nAll right. Thanks for taking my questions and congrats on a great year. Just want to follow up on a couple of questions. Dave, when we think about U.S.\\nSpine performance kind of relative to the market, you look at some of the larger players, they were down a bit in the fourth quarter. Some of the smaller players we saw were up double digits. Obviously, a few major players still yet to report next week. But I guess I'm kind of curious if you can kind of talk about the U.S.\\nperformance, that growth this fourth quarter relative to the market, and kind of where you think you're tracking relative to that level? And if you could kind of give us color on what you think that level was just given the dynamics in the fourth quarter through the quarter would be helpful.\\nDave Demski -- President and Chief Executive Officer\\nThanks, Ryan. It's really challenging to figure out where we are, given COVID. So from the early returns of some of the folks who we have reported, again, we're taking significant share. I can't speak to the smaller guys who have reported or how that impacts us.\\nAnd I don't really have a feel for the overall market. I know it was heavily impacted by COVID so likely down versus prior year overall. But that's more of just a guess and kind of where we landed versus some of our earlier trends. Our business is strong.\\nI can tell you that. We haven't lost significant pieces of business in the U.S. And we continue to see growth in the recent product introductions, and we continue to sell robots and drive pull-through from that. So it's strong.\\nI just -- I can't really see the overall market, and it's really hard to figure out what's going on given what's happening with COVID.\\nRyan Zimmerman -- BTIG -- Analyst\\nOK. Just two follow-ups for me. One, we've heard some of the larger capital equipment companies have obviously called out chips as being a gating factor to sales or median demand in 2022. One, want to see if there's any concern there around chips for the Excelsius platform or for 3D and whether that could gate sales? And then I'll just ask the other -- sneak in a quick follow-up, too.\\nThe Japan distributor dynamics, how much of a lift should we expect when that distributor dynamic clears in the second half of 2022 on the international business? Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. In terms of chips, I would just -- I would extend that to all supply chain. So it's not just chips, it's all components are challenging. It hasn't cost us revenue now, but it's certainly on our radar and making our life really hard.\\nSo it's a risk that's out there for 2022. I'll let Keith maybe handle the international question.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nAs it relates to Japan and the distributor dynamic, as we look ahead, we finished 2021, I think international grew by about 11%. We've historically said that we believe that the international business can grow mid-to-high teens. I would expect us to be able to get back to that on an annual basis. So you would expect the second half of the year to accelerate ahead of that to potentially balance -- to get closer to that 15 by the end of this year.\\nRyan Zimmerman -- BTIG -- Analyst\\nThanks, Kieth. Thanks, Dave. Appreciate it.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. Next, we have Kyle Rose of Canaccord. Your line is open.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nGreat. Thank you for taking the questions. I wanted to start on enabling. I mean, look, you put up a good quarter in enabling.\\nI guess a tough backdrop, particularly without the imaging platform. Maybe just help us understand kind of where that stands from a utilization perspective into your customer base. You're talking about the really good utilization there is continuing to see strong pull through. Can you just kind of level set maybe how many of your customers might have it or on a percentage basis or on an absolute basis? Just trying to really understand where we are in the uptake and the adoption within the historical core Globus customer base.\\nDave Demski -- President and Chief Executive Officer\\nYes, Kyle. To be honest, I don't feel comfortable sharing that information from a competitive standpoint.\\nKyle Rose -- Canaccord Genuity -- Analyst\\nTotally fair. I had to try. I also wanted to touch on the orthopedic side of the business. I mean, it's been a couple of years since you acquired the StelKast business.\\nI think earlier in the call, you talked about the fact that the recon robot is going to come in '23. Where do you stand just from an implant perspective? Do you have the right implants there? Do you need to make different investments from an M&A perspective, technologies, distribution? Just help us understand what you need to do on that total joints business before the recon robot comes next year. Thank you.\\nDave Demski -- President and Chief Executive Officer\\nSure. We do not have the implant portfolio we need to really make a strong outing. So we are working on that, have been working on that, and expect to roll some products out this year. I don't see us filling the gaps in our product portfolio with acquisitions in terms of hips and knees in particular.\\nI do think there's opportunity for scale there. So that's not off the table because we are very small right now. And then the extremities is an interesting segment for us as well. It's a fast-growing segment.\\nSo that's an area where we've taken a look at a few things. Does that help with your question?\\nKyle Rose -- Canaccord Genuity -- Analyst\\nYes. Thank you very much.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\nThank you. And next, we have Samuel Brodovsky of Truist. Your line is open.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nHi. Thank you for taking the questions. Just a first quick one on U.S. Spine.\\nJust would be curious to hear about the portion of growth in the U.S. coming from robotic-specific instrumentation versus where you're seeing potential share gain with other parts of the portfolio?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nYes. Thanks for the question. In terms of breaking it out, we typically don't break out the parts and pieces of where the growth is coming from. What I would say is that as you look at our U.S.\\nSpine business, it's really a combination of what we always talked about: new product innovation, our competitive recruiting, and the pull-through from implants. Those three continue to propel the business from a growth perspective, and we see that continuing as we enter 2022.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nGreat. That's helpful. And then when thinking about 3D and going to customers with it, in terms of any competitive trialing, are you seeing it being trialed against other more novel imaging technologies on the market? Or is it typically being compared to the large competitor out there? Thanks.\\nDave Demski -- President and Chief Executive Officer\\nInteresting question. I assume it's -- we don't really trial against it, but we have customers looking at our technology. And I think their interest just probably lines up with the market share of the other imaging systems in the market, particularly ones that are utilized more in spine. I'm sure that some of the more innovative ones are getting a look, but we don't hear that much about them.\\nSo it's not disproportionately, maybe I could answer it that way.\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nThanks.\\nOperator\\nThank you. [Operator instructions] Our next question comes from Steven Lichtman of Oppenheimer. Your line is open.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nThank you. Hi, guys. I wanted to ask you first on trauma. Where do you think you stand now in terms of coverage of procedures in terms of your product portfolio? And also from a sales force perspective, I'd just love to get an update on where you feel you are overall in terms of being able to go at the market.\\nDan Scavilla -- Executive Vice President and President of Ortho\\nSteven, it's Dan Scavilla. So again, it's always the evolving and expanding story. We have about 14 family products out there now. I think with that, we're saying we would cover 50% to 60% of the market.\\nCertainly, plan, as David said, to launch several more this year to cover that further. I believe and through what I'm saying, we're at a point where we're able to get into some significant facilities and support their needs for the most common procedures. And with that that's the main driver of growth to us. So we'll continue to expand the product line and fill that out over time, but we're in a good spot now.\\nWith that is the competitive recruiting that's been accelerating for us. So again, we're small, and we have a lot of spaces to fill. But the traction that has been occurring really through 2021 is very promising. And I do feel bullish as we are -- from what I've seen so far in the first quarter of 2022 that that will continue.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nGreat. Thanks, Dan. Keith, just a follow-up on gross margin. I apologize if you mentioned this, but just relative to 2021, given the inflation commentary, should we assume gross margin down? Or are there some offsets that can keep it relatively flat to maybe -- or even up in '22?\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. We project the mid-70s GP. I think it's fair to assume that we are seeing inflation just like everybody else, but we're also growing. And it's obviously getting us some leverage in our cost structure.\\nSo as I think about 2022, mid-70s is kind of where I see it. I wouldn't project upside.\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nOK. Got it. Thanks, guys.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThank you.\\nOperator\\nThank you. And we now have Jason Wittes of Loop Capital. Your line is open.\\nJason Wittes -- Loop Capital -- Analyst\\nHi. Thanks for taking the questions. Just two follow-ups, one on the guidance and one on trauma. But -- so first off, your guidance, I think the way you described it, especially relating to product launches, kind of assumes a strong second half versus the first half.\\nSo related to that, one, are we assuming that -- I know we can't predict COVID, but COVID pretty much works its way throughout the year? And then secondly, related to that, in the first quarter, I'm not sure how to read your comment that January was very weak. It bounced back. Should this be a normalized first quarter? Or are we -- is it going to be a little weaker relative to last year because of the COVID impact and launches? Thanks.\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nThanks for the question. Dave commented that January was weak, but we were starting to see some bounce back in February. Will it all bounce back in the same quarter versus having some bleed through into Q2? We don't necessarily know. But I think your earlier comment about some of the launches and a strong second half, I think that's directionally correct.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. And then I don't know if you can comment on this, but you did mention that you had -- it sounds like a record year in terms of sales force hires. In the past, you've kind of given us an indication of how large you've been able to grow your sales force percentage-wise. Can you give us any kind of indication on that in terms of what 2021 look like? And it sounds like 2022, you're optimistic that you can do -- go at a similar run rate?\\nDave Demski -- President and Chief Executive Officer\\nYeah. '21 was not a record year for us. I think we had one really strong quarter, but we've had years that were better. That's a renewed emphasis on it.\\nI can tell you the pipeline right now is extremely strong. So we're coming out of the gate strong. But last year was a good year. It just wasn't our best.\\nJason Wittes -- Loop Capital -- Analyst\\nOK. Thanks a lot. Appreciate it all.\\nDave Demski -- President and Chief Executive Officer\\nSure.\\nOperator\\n[Operator signoff]\\nDuration: 45 minutes\\nCall participants:\\nBrian Kearns -- Senior Vice President of Business Development and Investor Relations\\nDave Demski -- President and Chief Executive Officer\\nKeith Pfeil -- Senior Vice President and Chief Financial Officer\\nMatt Miksic -- Credit Suisse -- Analyst\\nMatt Taylor -- UBS -- Analyst\\nShagun Singh -- RBC Capital Markets -- Analyst\\nMatthew O'Brien -- Piper Sandler -- Analyst\\nDavid Saxon -- Needham and Company -- Analyst\\nCraig Bijou -- Bank of America Merrill Lynch -- Analyst\\nRyan Zimmerman -- BTIG -- Analyst\\nKyle Rose -- Canaccord Genuity -- Analyst\\nSamuel Brodovsky -- Truist Securities -- Analyst\\nSteven Lichtman -- Oppenheimer and Company -- Analyst\\nDan Scavilla -- Executive Vice President and President of Ortho\\nJason Wittes -- Loop Capital -- Analyst\\nMore GMED analysis\\nAll earnings call transcripts\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 4006,\n        \"samples\": [\n          \"2022-08-11 07:30:00\",\n          \"2021-03-18 08:00:00\",\n          \"2021-08-09 11:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Date_only\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 771,\n        \"samples\": [\n          \"2022-07-12\",\n          \"2020-10-22\",\n          \"2022-06-10\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"word_count\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2535,\n        \"min\": 571,\n        \"max\": 32540,\n        \"num_unique_values\": 6023,\n        \"samples\": [\n          8055,\n          8114,\n          14273\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Price_change\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.08086309609059458,\n        \"min\": -0.6091428484235492,\n        \"max\": 0.7156863065922738,\n        \"num_unique_values\": 9985,\n        \"samples\": [\n          0.0115302149459788,\n          0.1053023227425508,\n          -0.0781132122800544\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Target_Class\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"Neutral\",\n          \"Gain\",\n          \"Loss\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"DateOfWeek\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 0,\n        \"max\": 6,\n        \"num_unique_values\": 7,\n        \"samples\": [\n          3,\n          2,\n          4\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Month\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3,\n        \"min\": 1,\n        \"max\": 12,\n        \"num_unique_values\": 12,\n        \"samples\": [\n          12,\n          5,\n          8\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Quarter\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 1,\n        \"max\": 4,\n        \"num_unique_values\": 4,\n        \"samples\": [\n          4,\n          2,\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Positive\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.31461293934408074,\n        \"min\": 0.008341541513800621,\n        \"max\": 0.9573535919189453,\n        \"num_unique_values\": 10002,\n        \"samples\": [\n          0.9299212098121643,\n          0.026290403679013252,\n          0.04736625775694847\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Negative\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.15365381668059275,\n        \"min\": 0.007326572202146053,\n        \"max\": 0.9723434448242188,\n        \"num_unique_values\": 10004,\n        \"samples\": [\n          0.02593323402106762,\n          0.013618996366858482,\n          0.026145340874791145\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"FinBERT_Neutral\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.32946208504390717,\n        \"min\": 0.016457758843898773,\n        \"max\": 0.9523656368255615,\n        \"num_unique_values\": 9990,\n        \"samples\": [\n          0.7056020498275757,\n          0.1328488439321518,\n          0.09590130299329758\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"ticker_clean\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1520,\n        \"samples\": [\n          \"AVB\",\n          \"THRM\",\n          \"ULCC\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 42
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_analysis.columns"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "0VTl8qy3Oiue",
        "outputId": "df168424-e510-4c3b-b70b-6529b75a049b"
      },
      "execution_count": 43,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['date', 'exchange', 'q', 'ticker', 'transcript', 'Timestamp',\n",
              "       'Date_only', 'word_count', 'Price_change', 'Target_Class', 'DateOfWeek',\n",
              "       'Month', 'Quarter', 'FinBERT_Positive', 'FinBERT_Negative',\n",
              "       'FinBERT_Neutral', 'ticker_clean'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 43
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "path=\"/content/drive/MyDrive/Earnings call prediction/Dataframe_after_finbert.csv\"\n",
        "df_analysis.to_csv(path,index=False)"
      ],
      "metadata": {
        "id": "Yp7ZmVH0O4-L"
      },
      "execution_count": 46,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.model_selection import train_test_split, TimeSeriesSplit\n",
        "df_analysis = df_analysis.sort_values(by='Date_only').reset_index(drop=True)\n",
        "cols_to_drop = [\n",
        "    \"Target_Class\",\n",
        "    \"Price_change\",\n",
        "    \"Date_only\",\n",
        "    \"date\",\n",
        "    \"Timestamp\",\n",
        "    \"transcript\",\n",
        "    \"exchange\",\n",
        "    \"q\",\n",
        "    \"ticker\",\n",
        "    \"word_count\"\n",
        "]\n",
        "\n",
        "X = df_analysis.drop(columns=[c for c in cols_to_drop if c in df_analysis.columns])\n",
        "y = df_analysis[\"Target_Class\"]\n",
        "\n",
        "test_size = 0.3\n",
        "split_index = int(len(df_analysis) * (1 - test_size))\n",
        "\n",
        "X_train = X.iloc[:split_index]\n",
        "X_test = X.iloc[split_index:]\n",
        "y_train = y.iloc[:split_index]\n",
        "y_test = y.iloc[split_index:]\n",
        "\n",
        "print(f\"Training data size: {len(X_train)}\")\n",
        "print(f\"Test data size: {len(X_test)}\")\n",
        "print(\"\\nFinal Features in X_train:\", X_train.columns.tolist())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "S_2de7oMPQww",
        "outputId": "3269148d-ab4a-4ac4-d8f2-264987e11de0"
      },
      "execution_count": 47,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Training data size: 7639\n",
            "Test data size: 3274\n",
            "\n",
            "Final Features in X_train: ['DateOfWeek', 'Month', 'Quarter', 'FinBERT_Positive', 'FinBERT_Negative', 'FinBERT_Neutral', 'ticker_clean']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "train_df = pd.concat([X_train, y_train], axis=1)\n",
        "test_df = pd.concat([X_test, y_test], axis=1)\n",
        "train_path=\"/content/drive/MyDrive/Earnings call prediction/train_dataset.csv\"\n",
        "test_path=\"/content/drive/MyDrive/Earnings call prediction/test_dataset.csv\"\n",
        "train_df.to_csv(train_path, index=False)\n",
        "test_df.to_csv(test_path, index=False)\n",
        "\n",
        "print(\"Train and Test datasets saved successfully!\")\n",
        "print(f\"Train shape: {train_df.shape}\")\n",
        "print(f\"Test shape: {test_df.shape}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "nwMH1tG1QsSK",
        "outputId": "caf4bd2c-1de5-48de-8945-a696d061c216"
      },
      "execution_count": 49,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Train and Test datasets saved successfully!\n",
            "Train shape: (7639, 8)\n",
            "Test shape: (3274, 8)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install category_encoders\n",
        "from category_encoders import TargetEncoder\n",
        "\n",
        "gain_encoder = TargetEncoder(cols=['ticker_clean'])\n",
        "loss_encoder = TargetEncoder(cols=['ticker_clean'])\n",
        "\n",
        "y_train_gain = (y_train == 'Gain').astype(int)\n",
        "y_train_loss = (y_train == 'Loss').astype(int)\n",
        "\n",
        "# FITTING on X_train, TRANSFORM X_train\n",
        "X_train['Ticker_Gain_Prob'] = gain_encoder.fit_transform(X_train['ticker_clean'], y_train_gain)\n",
        "X_train['Ticker_Loss_Prob'] = loss_encoder.fit_transform(X_train['ticker_clean'], y_train_loss)\n",
        "\n",
        "# TRANSFORM X_test\n",
        "X_test['Ticker_Gain_Prob'] = gain_encoder.transform(X_test['ticker_clean'])\n",
        "X_test['Ticker_Loss_Prob'] = loss_encoder.transform(X_test['ticker_clean'])\n",
        "\n",
        "X_train.drop(columns=['ticker_clean'], inplace=True)\n",
        "X_test.drop(columns=['ticker_clean'], inplace=True)\n",
        "\n",
        "print(\"Target Encoding done correctly! No data leakage.\")\n",
        "print(\"X_train columns:\", X_train.columns.tolist())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "wYjMXRmeKmcW",
        "outputId": "f09194b6-432d-4236-f8b5-8dccb21363f0"
      },
      "execution_count": 50,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: category_encoders in /usr/local/lib/python3.12/dist-packages (2.9.0)\n",
            "Requirement already satisfied: numpy>=1.14.0 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (2.0.2)\n",
            "Requirement already satisfied: pandas>=1.0.5 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (2.2.2)\n",
            "Requirement already satisfied: patsy>=0.5.1 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (1.0.2)\n",
            "Requirement already satisfied: scikit-learn>=1.6.0 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (1.6.1)\n",
            "Requirement already satisfied: scipy>=1.0.0 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (1.16.3)\n",
            "Requirement already satisfied: statsmodels>=0.9.0 in /usr/local/lib/python3.12/dist-packages (from category_encoders) (0.14.6)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.0.5->category_encoders) (2.9.0.post0)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.0.5->category_encoders) (2025.2)\n",
            "Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.12/dist-packages (from pandas>=1.0.5->category_encoders) (2025.2)\n",
            "Requirement already satisfied: joblib>=1.2.0 in /usr/local/lib/python3.12/dist-packages (from scikit-learn>=1.6.0->category_encoders) (1.5.2)\n",
            "Requirement already satisfied: threadpoolctl>=3.1.0 in /usr/local/lib/python3.12/dist-packages (from scikit-learn>=1.6.0->category_encoders) (3.6.0)\n",
            "Requirement already satisfied: packaging>=21.3 in /usr/local/lib/python3.12/dist-packages (from statsmodels>=0.9.0->category_encoders) (25.0)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.12/dist-packages (from python-dateutil>=2.8.2->pandas>=1.0.5->category_encoders) (1.17.0)\n",
            "Target Encoding done correctly! No data leakage.\n",
            "X_train columns: ['DateOfWeek', 'Month', 'Quarter', 'FinBERT_Positive', 'FinBERT_Negative', 'FinBERT_Neutral', 'Ticker_Gain_Prob', 'Ticker_Loss_Prob']\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/tmp/ipython-input-2961120192.py:11: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  X_train['Ticker_Gain_Prob'] = gain_encoder.fit_transform(X_train['ticker_clean'], y_train_gain)\n",
            "/tmp/ipython-input-2961120192.py:12: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  X_train['Ticker_Loss_Prob'] = loss_encoder.fit_transform(X_train['ticker_clean'], y_train_loss)\n",
            "/tmp/ipython-input-2961120192.py:15: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  X_test['Ticker_Gain_Prob'] = gain_encoder.transform(X_test['ticker_clean'])\n",
            "/tmp/ipython-input-2961120192.py:16: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  X_test['Ticker_Loss_Prob'] = loss_encoder.transform(X_test['ticker_clean'])\n",
            "/tmp/ipython-input-2961120192.py:18: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  X_train.drop(columns=['ticker_clean'], inplace=True)\n",
            "/tmp/ipython-input-2961120192.py:19: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  X_test.drop(columns=['ticker_clean'], inplace=True)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **5.Feature Scaling**"
      ],
      "metadata": {
        "id": "24bQFuu8TVP1"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.preprocessing import StandardScaler\n",
        "import joblib\n",
        "\n",
        "scaler = StandardScaler()\n",
        "\n",
        "# Fitting on Train, Transforming Train\n",
        "X_train_scaled = scaler.fit_transform(X_train)\n",
        "# Transforming Test\n",
        "X_test_scaled = scaler.transform(X_test)\n",
        "\n",
        "X_train_scaled = pd.DataFrame(X_train_scaled, columns=X_train.columns)\n",
        "X_test_scaled = pd.DataFrame(X_test_scaled, columns=X_test.columns)\n",
        "print(\"Data Scaling Complete.\")\n",
        "\n",
        "# SAVING THE COMPONENTS for Streamlit ---\n",
        "# Save Encoders\n",
        "joblib.dump(gain_encoder, 'ticker_gain_encoder.joblib')\n",
        "joblib.dump(loss_encoder, 'ticker_loss_encoder.joblib')\n",
        "# Save Scaler (\n",
        "joblib.dump(scaler, 'standard_scaler.joblib')\n",
        "\n",
        "print(\"Encoders and Scaler saved to .joblib files.\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GfclUf4XS6gO",
        "outputId": "203a4e82-9fa6-4f77-e428-9d312ed0a0a7"
      },
      "execution_count": 51,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Data Scaling Complete.\n",
            "Encoders and Scaler saved to .joblib files.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "train_final_df=X_train_scaled.copy()\n",
        "test_final_df=X_test_scaled.copy()\n",
        "\n",
        "# Adding the Target column to them to save\n",
        "train_final_df['Target_Class'] = y_train.reset_index(drop=True)\n",
        "test_final_df['Target_Class'] = y_test.reset_index(drop=True)\n",
        "\n",
        "train_final_df.to_csv(\"/content/drive/MyDrive/Earnings call prediction/train_scaled_ready.csv\", index=False)\n",
        "test_final_df.to_csv(\"/content/drive/MyDrive/Earnings call prediction/test_scaled_ready.csv\", index=False)\n",
        "\n",
        "print(\"Scaled data saved! You are safe to start Hyperparameter Tuning.\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "sDmZVUMQVJQh",
        "outputId": "bc2c9734-112d-48ab-a465-75dd5b0b5027"
      },
      "execution_count": 53,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Scaled data saved! You are safe to start Hyperparameter Tuning.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **6 Model Training**"
      ],
      "metadata": {
        "id": "dIMxcka3W9zQ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install xgboost\n",
        "from sklearn.preprocessing import LabelEncoder\n",
        "from sklearn.model_selection import RandomizedSearchCV\n",
        "from xgboost import XGBClassifier\n",
        "import joblib\n",
        "\n",
        "# Encoding Target Labels (Gain/Loss/Neutral -> 0/1/2)\n",
        "le = LabelEncoder()\n",
        "y_train_encoded = le.fit_transform(y_train)\n",
        "y_test_encoded = le.transform(y_test)\n",
        "\n",
        "# Saving the Label Encoder for streamlit\n",
        "joblib.dump(le, 'target_label_encoder.joblib')\n",
        "print(\"Target Labels encoded and encoder saved.\")\n",
        "\n",
        "tscv = TimeSeriesSplit(n_splits=5)\n",
        "# Hyperparameter Grid\n",
        "param_grid = {\n",
        "    'n_estimators': [100, 200, 300],\n",
        "    'learning_rate': [0.01, 0.05, 0.1, 0.2],\n",
        "    'max_depth': [3, 4, 5, 6, 8],\n",
        "    'min_child_weight': [1, 3, 5, 7],\n",
        "    'subsample': [0.6, 0.8, 1.0],\n",
        "    'colsample_bytree': [0.6, 0.8, 1.0],\n",
        "    'gamma': [0, 0.1, 0.2]\n",
        "}\n",
        "\n",
        "# Initializing the Model\n",
        "xgb = XGBClassifier(\n",
        "    objective='multi:softprob',\n",
        "    num_class=3,\n",
        "    random_state=42,\n",
        "    eval_metric='mlogloss'\n",
        ")\n",
        "\n",
        "#Randomized Search\n",
        "random_search = RandomizedSearchCV(\n",
        "    estimator=xgb,\n",
        "    param_distributions=param_grid,\n",
        "    n_iter=50,\n",
        "    scoring='f1_weighted',\n",
        "    cv=tscv,\n",
        "    verbose=1,\n",
        "    random_state=42,\n",
        "    n_jobs=-1\n",
        ")\n",
        "\n",
        "print(\"Starting Hyperparameter Tuning...\")\n",
        "random_search.fit(X_train_scaled, y_train_encoded)\n",
        "\n",
        "print(\"\\nTuning Complete!\")\n",
        "print(f\"Best Parameters: {random_search.best_params_}\")\n",
        "print(f\"Best Weighted F1-Score: {random_search.best_score_:.4f}\")\n",
        "\n",
        "# Saving the Best Model\n",
        "best_model = random_search.best_estimator_\n",
        "joblib.dump(best_model, 'final_xgb_model.joblib')\n",
        "print(\"Best model saved as 'final_xgb_model.joblib'\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "IWQJ2fC0UwIL",
        "outputId": "3670b0e2-a262-45be-ed87-68bfa5d70242"
      },
      "execution_count": 54,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting xgboost\n",
            "  Downloading xgboost-3.1.2-py3-none-manylinux_2_28_x86_64.whl.metadata (2.1 kB)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.12/dist-packages (from xgboost) (2.0.2)\n",
            "Collecting nvidia-nccl-cu12 (from xgboost)\n",
            "  Downloading nvidia_nccl_cu12-2.28.9-py3-none-manylinux_2_18_x86_64.whl.metadata (2.0 kB)\n",
            "Requirement already satisfied: scipy in /usr/local/lib/python3.12/dist-packages (from xgboost) (1.16.3)\n",
            "Downloading xgboost-3.1.2-py3-none-manylinux_2_28_x86_64.whl (115.9 MB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m115.9/115.9 MB\u001b[0m \u001b[31m5.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_nccl_cu12-2.28.9-py3-none-manylinux_2_18_x86_64.whl (296.8 MB)\n",
            "\u001b[2K   \u001b[90m\u001b[0m \u001b[32m296.8/296.8 MB\u001b[0m \u001b[31m1.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: nvidia-nccl-cu12, xgboost\n",
            "Successfully installed nvidia-nccl-cu12-2.28.9 xgboost-3.1.2\n",
            "Target Labels encoded and encoder saved.\n",
            "Starting Hyperparameter Tuning...\n",
            "Fitting 5 folds for each of 50 candidates, totalling 250 fits\n",
            "\n",
            "Tuning Complete!\n",
            "Best Parameters: {'subsample': 0.8, 'n_estimators': 100, 'min_child_weight': 5, 'max_depth': 4, 'learning_rate': 0.05, 'gamma': 0, 'colsample_bytree': 1.0}\n",
            "Best Weighted F1-Score: 0.6936\n",
            "Best model saved as 'final_xgb_model.joblib'\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "X_train_scaled.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "qNkoCUpIYopL",
        "outputId": "c957c2ae-accc-465e-a8b5-3f2f7b54284e"
      },
      "execution_count": 55,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(7639, 8)"
            ]
          },
          "metadata": {},
          "execution_count": 55
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **7 Model Testing and Evaluation**"
      ],
      "metadata": {
        "id": "hzQhNlzJZLek"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.metrics import classification_report, confusion_matrix\n",
        "import seaborn as sns\n",
        "import matplotlib.pyplot as plt\n",
        "\n",
        "y_pred = best_model.predict(X_test_scaled)\n",
        "# Converting numerical predictions back to labels (0/1/2 -> Gain/Loss/Neutral)\n",
        "y_test_decoded = le.inverse_transform(y_test_encoded)\n",
        "y_pred_decoded = le.inverse_transform(y_pred)\n",
        "\n",
        "print(\"\\n--- FINAL CLASSIFICATION REPORT ---\")\n",
        "print(classification_report(y_test_decoded, y_pred_decoded))\n",
        "\n",
        "cm = confusion_matrix(y_test_decoded, y_pred_decoded, labels=['Gain', 'Loss', 'Neutral'])\n",
        "plt.figure(figsize=(8, 6))\n",
        "sns.heatmap(cm, annot=True, fmt='d', cmap='Blues',\n",
        "            xticklabels=['Gain', 'Loss', 'Neutral'],\n",
        "            yticklabels=['Gain', 'Loss', 'Neutral'])\n",
        "plt.xlabel('Predicted')\n",
        "plt.ylabel('Actual')\n",
        "plt.title('Confusion Matrix')\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 772
        },
        "id": "XPBQAgjhZJ6V",
        "outputId": "5db37347-0a08-4e61-a70d-489ee62d52e7"
      },
      "execution_count": 56,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "--- FINAL CLASSIFICATION REPORT ---\n",
            "              precision    recall  f1-score   support\n",
            "\n",
            "        Gain       0.31      0.20      0.24       738\n",
            "        Loss       0.35      0.26      0.30       805\n",
            "     Neutral       0.61      0.78      0.68      1731\n",
            "\n",
            "    accuracy                           0.52      3274\n",
            "   macro avg       0.42      0.41      0.41      3274\n",
            "weighted avg       0.48      0.52      0.49      3274\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 800x600 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **8 Feature Importance**"
      ],
      "metadata": {
        "id": "dvj7Tn_3fk3v"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import matplotlib.pyplot as plt\n",
        "import seaborn as sns\n",
        "importances = best_model.feature_importances_\n",
        "\n",
        "# Mapping scores to column names\n",
        "feature_names = X_train.columns\n",
        "feature_importance_df = pd.DataFrame({\n",
        "    'Feature': feature_names,\n",
        "    'Importance': importances\n",
        "}).sort_values(by='Importance', ascending=False)\n",
        "\n",
        "# Visualize\n",
        "plt.figure(figsize=(10, 6))\n",
        "sns.barplot(x='Importance', y='Feature', data=feature_importance_df.head(10), palette='viridis')\n",
        "plt.title('Top 10 Most Important Features for Predicting Stock Movement')\n",
        "plt.xlabel('Importance Score')\n",
        "plt.ylabel('Feature Name')\n",
        "plt.show()\n",
        "\n",
        "# Printing the raw data\n",
        "print(feature_importance_df.head(10))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 827
        },
        "id": "f7y3LBsFaZui",
        "outputId": "0839e66f-4773-44ea-829d-3ead44558295"
      },
      "execution_count": 57,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/tmp/ipython-input-895659390.py:15: FutureWarning: \n",
            "\n",
            "Passing `palette` without assigning `hue` is deprecated and will be removed in v0.14.0. Assign the `y` variable to `hue` and set `legend=False` for the same effect.\n",
            "\n",
            "  sns.barplot(x='Importance', y='Feature', data=feature_importance_df.head(10), palette='viridis')\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "            Feature  Importance\n",
            "6  Ticker_Gain_Prob    0.411073\n",
            "7  Ticker_Loss_Prob    0.371030\n",
            "1             Month    0.056265\n",
            "3  FinBERT_Positive    0.044843\n",
            "5   FinBERT_Neutral    0.043177\n",
            "4  FinBERT_Negative    0.042573\n",
            "0        DateOfWeek    0.031039\n",
            "2           Quarter    0.000000\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **10 Threshold Tuning**"
      ],
      "metadata": {
        "id": "J83DSxaTgIU3"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "import matplotlib.pyplot as plt\n",
        "from sklearn.metrics import precision_score, recall_score\n",
        "\n",
        "# Getting Probabilities instead of Class Labels\n",
        "# This returns an array with 3 columns: [Prob_Gain, Prob_Loss, Prob_Neutral]\n",
        "y_probs = best_model.predict_proba(X_test_scaled)\n",
        "\n",
        "print(f\"Class Order: {le.classes_}\")\n",
        "gain_index = np.where(le.classes_ == 'Gain')[0][0]\n",
        "\n",
        "# Testing Thresholds from 0.3 to 0.9\n",
        "thresholds = np.arange(0.3, 0.95, 0.05)\n",
        "precisions = []\n",
        "recalls = []\n",
        "\n",
        "# Ground truth for Gain (Binary: 1 if Gain, 0 if Loss/Neutral)\n",
        "y_test_gain_binary = (y_test_decoded == 'Gain').astype(int)\n",
        "\n",
        "for t in thresholds:\n",
        "    # If Prob_Gain > t, predict 1, else 0\n",
        "    custom_preds = (y_probs[:, gain_index] >= t).astype(int)\n",
        "    # Calculating scores\n",
        "    if np.sum(custom_preds) > 0: # Avoid division by zero\n",
        "        p = precision_score(y_test_gain_binary, custom_preds)\n",
        "        r = recall_score(y_test_gain_binary, custom_preds)\n",
        "    else:\n",
        "        p = 1.0\n",
        "        r = 0.0\n",
        "\n",
        "    precisions.append(p)\n",
        "    recalls.append(r)\n",
        "\n",
        "# Plotting the Trade-off of Precision and Recall\n",
        "plt.figure(figsize=(10, 6))\n",
        "plt.plot(thresholds, precisions, label='Precision (Win Rate)', marker='o', color='green')\n",
        "plt.plot(thresholds, recalls, label='Recall (Opportunity Capture)', marker='x', color='blue')\n",
        "plt.title('Impact of Confidence Threshold on Trading Performance')\n",
        "plt.xlabel('Probability Threshold required to predict \"Gain\"')\n",
        "plt.ylabel('Score')\n",
        "plt.legend()\n",
        "plt.grid(True)\n",
        "plt.show()\n",
        "\n",
        "\n",
        "for t, p, r in zip(thresholds, precisions, recalls):\n",
        "    print(f\"Threshold: {t:.2f} | Precision: {p:.2f} | Recall: {r:.2f}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 807
        },
        "id": "_AkZs_Q5bXR5",
        "outputId": "ff099a59-3224-4b0a-b397-13981bb7ffdb"
      },
      "execution_count": 58,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Class Order: ['Gain' 'Loss' 'Neutral']\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Threshold: 0.30 | Precision: 0.28 | Recall: 0.34\n",
            "Threshold: 0.35 | Precision: 0.29 | Recall: 0.27\n",
            "Threshold: 0.40 | Precision: 0.29 | Recall: 0.22\n",
            "Threshold: 0.45 | Precision: 0.30 | Recall: 0.19\n",
            "Threshold: 0.50 | Precision: 0.31 | Recall: 0.15\n",
            "Threshold: 0.55 | Precision: 0.32 | Recall: 0.11\n",
            "Threshold: 0.60 | Precision: 0.32 | Recall: 0.09\n",
            "Threshold: 0.65 | Precision: 0.34 | Recall: 0.07\n",
            "Threshold: 0.70 | Precision: 0.36 | Recall: 0.06\n",
            "Threshold: 0.75 | Precision: 0.36 | Recall: 0.05\n",
            "Threshold: 0.80 | Precision: 0.30 | Recall: 0.03\n",
            "Threshold: 0.85 | Precision: 0.26 | Recall: 0.01\n",
            "Threshold: 0.90 | Precision: 1.00 | Recall: 0.00\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "loss_index = np.where(le.classes_ == 'Loss')[0][0]\n",
        "\n",
        "# Testing Thresholds from 0.3 to 0.9\n",
        "thresholds = np.arange(0.3, 0.95, 0.05)\n",
        "precisions = []\n",
        "recalls = []\n",
        "\n",
        "# Ground truth for Gain (Binary: 1 if Gain, 0 if Loss/Neutral)\n",
        "y_test_loss_binary = (y_test_decoded == 'Loss').astype(int)\n",
        "\n",
        "for t in thresholds:\n",
        "    # If Prob_Gain > t, predict 1, else 0\n",
        "    custom_preds = (y_probs[:, loss_index] >= t).astype(int)\n",
        "    # Calculating scores\n",
        "    if np.sum(custom_preds) > 0: # Avoid division by zero\n",
        "        p = precision_score(y_test_loss_binary, custom_preds)\n",
        "        r = recall_score(y_test_loss_binary, custom_preds)\n",
        "    else:\n",
        "        p = 1.0\n",
        "        r = 0.0\n",
        "\n",
        "    precisions.append(p)\n",
        "    recalls.append(r)\n",
        "\n",
        "# Plotting the Trade-off of Precision and Recall\n",
        "plt.figure(figsize=(10, 6))\n",
        "plt.plot(thresholds, precisions, label='Precision (Win Rate)', marker='o', color='green')\n",
        "plt.plot(thresholds, recalls, label='Recall (Opportunity Capture)', marker='x', color='blue')\n",
        "plt.title('Impact of Confidence Threshold on Trading Performance')\n",
        "plt.xlabel('Probability Threshold required to predict \"Loss\"')\n",
        "plt.ylabel('Score')\n",
        "plt.legend()\n",
        "plt.grid(True)\n",
        "plt.show()\n",
        "\n",
        "\n",
        "for t, p, r in zip(thresholds, precisions, recalls):\n",
        "    print(f\"Threshold: {t:.2f} | Precision: {p:.2f} | Recall: {r:.2f}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 790
        },
        "id": "fa9hRAJn1iyn",
        "outputId": "b16bcf3c-32f2-4d09-e7c4-6a6894e9c507"
      },
      "execution_count": 61,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Threshold: 0.30 | Precision: 0.33 | Recall: 0.40\n",
            "Threshold: 0.35 | Precision: 0.32 | Recall: 0.33\n",
            "Threshold: 0.40 | Precision: 0.34 | Recall: 0.28\n",
            "Threshold: 0.45 | Precision: 0.35 | Recall: 0.21\n",
            "Threshold: 0.50 | Precision: 0.34 | Recall: 0.16\n",
            "Threshold: 0.55 | Precision: 0.34 | Recall: 0.12\n",
            "Threshold: 0.60 | Precision: 0.37 | Recall: 0.10\n",
            "Threshold: 0.65 | Precision: 0.38 | Recall: 0.08\n",
            "Threshold: 0.70 | Precision: 0.37 | Recall: 0.06\n",
            "Threshold: 0.75 | Precision: 0.42 | Recall: 0.05\n",
            "Threshold: 0.80 | Precision: 0.43 | Recall: 0.03\n",
            "Threshold: 0.85 | Precision: 0.41 | Recall: 0.02\n",
            "Threshold: 0.90 | Precision: 1.00 | Recall: 0.00\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "**Download Files and get versions for Streamlit**"
      ],
      "metadata": {
        "id": "610EFqXNfRVo"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import zipfile\n",
        "from IPython.display import FileLink\n",
        "\n",
        "files_to_download = [\n",
        "    'final_xgb_model.joblib',\n",
        "    'standard_scaler.joblib',\n",
        "    'target_label_encoder.joblib',\n",
        "    'ticker_gain_encoder.joblib',\n",
        "    'ticker_loss_encoder.joblib',\n",
        "    'cleaned_stock_data.csv'\n",
        "]\n",
        "\n",
        "zip_filename = 'project_artifacts.zip'\n",
        "\n",
        "print(f\"Zipping {len(files_to_download)} files into '{zip_filename}'...\")\n",
        "missing_files = []\n",
        "\n",
        "with zipfile.ZipFile(zip_filename, 'w') as zipf:\n",
        "    for file in files_to_download:\n",
        "        if os.path.exists(file):\n",
        "            zipf.write(file)\n",
        "            print(f\"  - Added: {file}\")\n",
        "        else:\n",
        "            missing_files.append(file)\n",
        "            print(f\"Warning: '{file}' not found. Did you save it?\")\n",
        "\n",
        "if len(missing_files) == len(files_to_download):\n",
        "    print(\"\\nError: No files found to zip. Please re-run the saving steps.\")\n",
        "else:\n",
        "    print(f\"\\nZip file created: {zip_filename}\")\n",
        "    try:\n",
        "        from google.colab import files\n",
        "        files.download(zip_filename)\n",
        "        print(\"Downloading via Google Colab...\")\n",
        "    except ImportError:\n",
        "        print(\"Kaggle Detected. Click the link below to download:\")\n",
        "        display(FileLink(zip_filename))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 191
        },
        "id": "CwAC5ix5eNGa",
        "outputId": "aade8552-6946-4185-b4bf-44583b3917be"
      },
      "execution_count": 59,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Zipping 6 files into 'project_artifacts.zip'...\n",
            "  - Added: final_xgb_model.joblib\n",
            "  - Added: standard_scaler.joblib\n",
            "  - Added: target_label_encoder.joblib\n",
            "  - Added: ticker_gain_encoder.joblib\n",
            "  - Added: ticker_loss_encoder.joblib\n",
            "Warning: 'cleaned_stock_data.csv' not found. Did you save it?\n",
            "\n",
            "Zip file created: project_artifacts.zip\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "\n",
              "    async function download(id, filename, size) {\n",
              "      if (!google.colab.kernel.accessAllowed) {\n",
              "        return;\n",
              "      }\n",
              "      const div = document.createElement('div');\n",
              "      const label = document.createElement('label');\n",
              "      label.textContent = `Downloading \"${filename}\": `;\n",
              "      div.appendChild(label);\n",
              "      const progress = document.createElement('progress');\n",
              "      progress.max = size;\n",
              "      div.appendChild(progress);\n",
              "      document.body.appendChild(div);\n",
              "\n",
              "      const buffers = [];\n",
              "      let downloaded = 0;\n",
              "\n",
              "      const channel = await google.colab.kernel.comms.open(id);\n",
              "      // Send a message to notify the kernel that we're ready.\n",
              "      channel.send({})\n",
              "\n",
              "      for await (const message of channel.messages) {\n",
              "        // Send a message to notify the kernel that we're ready.\n",
              "        channel.send({})\n",
              "        if (message.buffers) {\n",
              "          for (const buffer of message.buffers) {\n",
              "            buffers.push(buffer);\n",
              "            downloaded += buffer.byteLength;\n",
              "            progress.value = downloaded;\n",
              "          }\n",
              "        }\n",
              "      }\n",
              "      const blob = new Blob(buffers, {type: 'application/binary'});\n",
              "      const a = document.createElement('a');\n",
              "      a.href = window.URL.createObjectURL(blob);\n",
              "      a.download = filename;\n",
              "      div.appendChild(a);\n",
              "      a.click();\n",
              "      div.remove();\n",
              "    }\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "download(\"download_daf34195-5a2e-4f4e-89a4-e514aa7e2b64\", \"project_artifacts.zip\", 659599)"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Downloading via Google Colab...\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import xgboost\n",
        "import sklearn\n",
        "import joblib\n",
        "print(f\"XGBoost Version: {xgboost.__version__}\")\n",
        "print(f\"Scikit-Learn Version: {sklearn.__version__}\")\n",
        "print(f\"Joblib Version: {joblib.__version__}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "xvToeIZOaEtp",
        "outputId": "3f5c05d1-9137-4ccc-9c15-7153b9a42d4a"
      },
      "execution_count": 60,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "XGBoost Version: 3.1.2\n",
            "Scikit-Learn Version: 1.6.1\n",
            "Joblib Version: 1.5.2\n"
          ]
        }
      ]
    }
  ],
  "metadata": {
    "accelerator": "TPU",
    "colab": {
      "gpuType": "V5E1",
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}